<SEC-DOCUMENT>0001280776-22-000017.txt : 20220804
<SEC-HEADER>0001280776-22-000017.hdr.sgml : 20220804
<ACCEPTANCE-DATETIME>20220804070152
ACCESSION NUMBER:		0001280776-22-000017
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220804
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNIC, INC.
		CENTRAL INDEX KEY:			0001280776
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562358443
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36201
		FILM NUMBER:		221134581

	BUSINESS ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036
		BUSINESS PHONE:		(332) 255-9818

	MAIL ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VITAL THERAPIES INC
		DATE OF NAME CHANGE:	20040219
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vtl-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:87493b76-11b9-4c9e-8fb7-f973ce8e577c,g:e8a78576-a7c5-4c0a-9fc2-78dfa0931d1d,d:132a36b84ae14363889a7cabe57a8d6f--><html xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vtl="http://vitaltherapies.com/20220630" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vtl-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80L2ZyYWc6ODJhOWQwZTkyYjM5NDFjMTkzYmMzNTZiMDE5MTBkY2UvdGFibGU6Njg4ODAwMDFlNDMzNGU1NTg2Mzc4YmZlOTM2ZDMxNDUvdGFibGVyYW5nZTo2ODg4MDAwMWU0MzM0ZTU1ODYzNzhiZmU5MzZkMzE0NV8yLTEtMS0xLTI2ODkx_40aa48bf-a443-47e9-9185-e39b088b5df8">2022</ix:nonNumeric><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80L2ZyYWc6ODJhOWQwZTkyYjM5NDFjMTkzYmMzNTZiMDE5MTBkY2UvdGFibGU6Njg4ODAwMDFlNDMzNGU1NTg2Mzc4YmZlOTM2ZDMxNDUvdGFibGVyYW5nZTo2ODg4MDAwMWU0MzM0ZTU1ODYzNzhiZmU5MzZkMzE0NV8zLTEtMS0xLTI2ODkx_9853189f-4a07-4242-9e16-11c0db11382e">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80L2ZyYWc6ODJhOWQwZTkyYjM5NDFjMTkzYmMzNTZiMDE5MTBkY2UvdGFibGU6Njg4ODAwMDFlNDMzNGU1NTg2Mzc4YmZlOTM2ZDMxNDUvdGFibGVyYW5nZTo2ODg4MDAwMWU0MzM0ZTU1ODYzNzhiZmU5MzZkMzE0NV80LTEtMS0xLTI2ODkx_12830e5b-1fbd-4005-9339-4e2ea2754006">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80L2ZyYWc6ODJhOWQwZTkyYjM5NDFjMTkzYmMzNTZiMDE5MTBkY2UvdGV4dHJlZ2lvbjo4MmE5ZDBlOTJiMzk0MWMxOTNiYzM1NmIwMTkxMGRjZV8zOA_3aa42a89-3535-4e0c-bec7-ba9546a8974a">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80L2ZyYWc6ODJhOWQwZTkyYjM5NDFjMTkzYmMzNTZiMDE5MTBkY2UvdGV4dHJlZ2lvbjo4MmE5ZDBlOTJiMzk0MWMxOTNiYzM1NmIwMTkxMGRjZV82Nw_bf772137-75e4-4275-ad47-489e3abcace7">0001280776</ix:nonNumeric><ix:nonNumeric contextRef="ifd8c52afb34d445d83af15ec3dbddf0b_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDU2MA_257586a5-1545-4cd3-af1d-02cb0660d644">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfMjE5OTAyMzI1NjI5MA_3d8ceb1b-3c21-469b-880e-2ea581b8f112">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfMjE5OTAyMzI1NjI5MA_f85fe492-0c02-4937-8946-c1829a42d290">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i4afb1db82db3489ca373a267e6b8630c_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI1Mzg0_7a7a7119-e170-4cdf-8081-4d8911387b29">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vtl-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id01675085b9d47cfa6a56a99e63d5f56_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0947672575364c46afe56198033d6c85_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4fb55fd2ef8427d80a634661f1773b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e90af7dc9ef4a6c9069acdbb42eae07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i383623f0307f4b9d96b57d1489b5600c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a7559d9f82448c8987eae81fa4ec3ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic96897f104fb48d78ee6473de6c83c97_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9608caccfcbc4563859345eaa9991b07_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i076950ee40df42d89a5d26ba9bf6795d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i465c366ef51f4b189565cac81dffddbe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75532eaec46d443bbf4be7aca9794114_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i495588de7e354f81b29f181b399ebdba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf34bda03a394ba8a77214d6b3305235_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i121e4a3cffdb4f6fbed73a792bf1b69e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i961bd468dc6e4b2085750c3208bb55f3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f74c7f405464d128cc5abb31ca4304c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a5095123e1441ce8ab5b195e2a7381e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i290eaed6709c4900870088935dc57a9c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia63039ccf15b40d4b5364ae7c9bf408a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02e09f06bafe421b9a79431f6587dd3f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aa74dec5d9242b787918ed1421800d6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85c7a5aa8a4246d0b7f7f081825bb773_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba1820fc164b4f9bac61e09fc44afa8b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5159f770ea0f4a9497673433e3e78293_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3074803226e47ebb7c58a8d15c07885_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10c1446033584b39a0f7674b22567b72_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24615a42f1564951b37f6e0d11cdb4d2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6c3453adbd4c6dafb2f21387665bff_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3b20273750b4a70831e7df55a20101e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bbd2fff93de403e844b1b5d38504e4c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i640e715a3f0c4def9b0d868c1d6092b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d857c13ffa547129b4b709b775b0c0c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3b3eff571ab4389b83a686f38bf0009_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2320639dc1b945fb806ec94ec779e328_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a4772f1271c40e191e770ac6d61d1dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72df3680356349e7bfa91bda10e3f3f7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2fb388e8881440ea3a00a25cd305aca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id83cbae3a80f4486b48792aefcc6aa84_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i819b55b7eb0b41cb872b2a55a28511a4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i302f3eed4b894be3bfb581b012217fa7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:A4SCRoyaltySettlementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia25252f765c54d26893666d4b8a4b6d1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:A4SCRoyaltySettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cff2d4dae0141d7a9400429428808cb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:A4SCRoyaltySettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06b0939acbbd4016a2017d08bbc14611_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id40c3cee4b0a4933a0d3743284b8b9bb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6038f471ebd492dacb91545b0bd1204_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib888b4c6dea340ddac2a5f3d0444fb01_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e6c3ba533a04a6d9765af14c3539988_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie94d2d5ea505442cbfb5b9f4af2174cb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i273c8f6ffe2d4bae939069532f577216_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf514b4446b646f2969c39b9e0c88824_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2addead69d9548889d3828a4cf706290_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d825e45e7c948c9b4d93eb5be9afd4c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7d44abdaa9d4db2a3c8a5442cead68d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f57bfb4d140406a809324570a0730bb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5539c23cb2e040f787397c935b00dc96_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d116a4fcc3e4f2aab94d415e3453a5a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2540362a6b449a9988c08de956ec7c7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>vtl:employee</xbrli:measure></xbrli:unit><xbrli:unit id="program"><xbrli:measure>vtl:program</xbrli:measure></xbrli:unit><xbrli:context id="id28377b56621409b831d879cd0e930a4_D20140417-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-04-17</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd8c52afb34d445d83af15ec3dbddf0b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad392238f03492fb9409e9edf57a05e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e8992acd92c4178a465c433d46d5797_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8745b84aae60434e9b96daf94cfac93a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>vtl:lease</xbrli:measure></xbrli:unit><xbrli:context id="i58796c8360524abb862423e11c8db6ad_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcfd1b5059be473ca463b8dfc127debf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8851c67679bf4084b6bf5354695ad9d2_I20200407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfa9e23428124c2486f4015b0a2d6c95_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0900a41bd91a4900bd798f3276eb85bb_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic0596eac93474ba595e10a41ccb463c3_D20160501-20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-01</xbrli:startDate><xbrli:endDate>2016-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic822612a93bf4322a15f67ee66c0e1ea_I20190412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ac3802756644803be0171f1cae2cca5_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtl:ImmunicAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e183777c2784361bb1f6d43969d764e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtl:ImmunicAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if619c407624b4922b1afa2e57a9ff01a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0e026c775ec49f9861b7f0d7ef051f1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf678ced37ba47f7910be49d8d28b9e7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf2a21a1b3143b9a9bb2e50c90d5ad2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01049530b3a04055a71bdcbd2ddb098f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91585558cbe34e778b4f5fbf7b1c8daa_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8722bc2bc004244be18e6327d5c0084_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i848040a12f93446e94b293d803e3ba3e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i900fc28b42424c17b00cd3ca859d30a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd253af90c7049ba9afdf7bd8778d934_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee4d595729674eff99b3ca2ca86c0b7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e62c8bbfe554143bcfccd623eef0f68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee62d52d680b41dba637ae523465d27e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fcb0abe6f0749babe8150c967988400_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9a91903ca2a4ad0b30d85fb1a845075_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8557ddef2d144928039c8fb2320084e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib934db459d0f41d6983debfc2a9bb490_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i655d008592954266b8c505297b7e326a_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if084565ea6544630b40bf38bc6aa362c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5357132f62b84045b8592c18e2fa2958_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="i84614fc2f3a34f45abbfe8caa4cc2f8c_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaab1b036d9dc44e98547c47688f3775e_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b29f09bbaba4becbebde67f5b01a643_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31e27d1c40d042c8a3fc68107417bf24_I20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77bff47627ab4656a7df6dfe32e589aa_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f1bda4b5eb14655844a6f52d4e19aeb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42f6581040da46739944cde97b521f6f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc9159032004498fb16925e81f722e24_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5fb46bdccd14b0bb258e8b0caf6b17a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if73baf845ed84292a90be900622c8546_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a7be395eedf4ec7b90be1d1cc54a7f4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a36d78c3a1d41aabc3bc530c7149510_D20210425-20210425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-25</xbrli:startDate><xbrli:endDate>2021-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4759bb9bc5548028846f27721d451dd_I20210425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic41959aa4a854ce99c1ae76d7e539c7b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3846e4b177145349132e464e8ead06e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a60641c12434b9d9746366fd13f9c6a_D20210425-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-25</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i331baf434b944eed8f84aac672fd3fba_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4743858c51494178bb0a0087929cf1ca_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78621ec446654b619edd9f1c7ddbbfdb_D20200101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i241a45995e6d46d2b52b33a2b6d06c7f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f6c4820198d4fcbbd17c0e25cf2af03_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4afb1db82db3489ca373a267e6b8630c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1175a630abb249cba6da4df17900b2f3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic25815c038244077a908eacfe7cdb746_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c548edb791d48468aecdf5a3211e335_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e20fcc653c40a39665c834b098509d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93a9137d93f44392b7470a9982635184_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa2a1c898f234b2da41f85403f50c9d6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie44b429d3b05430ea58a4793c8c7b0ed_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d31dbd295f24c42bfabd2db4c4c9f38_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc512c7aab944fc485311bf9c02ff970_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a4ddd497fd542b9b3fd027648d47f75_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e71423082664f22b47833b74742032b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2bea17fde984023989bd83f8d7409d3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647b4b4c351941fe967436ca5d55ac90_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d7bda77d8e54df095211d496fde1e19_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i780a02233b614aad8fc86df96172eeb7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6be40b2c9d674c08af4179c7ed347d3e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbabe7452d5d43f6b73995f3e391e6b8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26a9bf6e1992474bbccdbdce509a8df2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd13b02f4a346ca9385ff8f54ab0d4c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23ce68a8dc964e0992d506ff2d9b8074_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib42e39df400b422a95c9c1d1cd93fae5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12cdbd33c3434c698ad8b49490ad01ef_I20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i679e236a84ee4593a0aed89cb7edadf1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic40354f16dc842a1a88ac97efa9f06d6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb4ae9a6beec4eae8fa5eb08ddd32a03_D20210415-20210415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-15</xbrli:startDate><xbrli:endDate>2021-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if42ab5585116465fbf465ea6f59165fe_D20210515-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-15</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaabe57dcd0314a53bb5425c2259aeed2_D20210101-20210514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a5888f9828e4ffcb2ca6bbe78a31e05_D20220315-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-15</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie57caaa75a5a464083b4f824217dc1e7_D20220315-20220315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-15</xbrli:startDate><xbrli:endDate>2022-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdfa66f7711347ab96273868fd75f343_D20220706-20220706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-06</xbrli:startDate><xbrli:endDate>2022-07-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8de1a675bd3646b6b25adee3e85cab4c_D20220706-20220706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:OptionsVestingInOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-06</xbrli:startDate><xbrli:endDate>2022-07-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib73002cd7def4d70a33e0dbcb20c34ff_D20220706-20220706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:OptionsVestingInThreeYearsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-06</xbrli:startDate><xbrli:endDate>2022-07-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i132a36b84ae14363889a7cabe57a8d6f_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF84Mw_b9b9078b-f4de-45b3-9aee-6cc34686e302">10-Q</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MWZkNzUwNDhlNTE5NDg5N2JiM2U1MzJmZmMyZGQxZmUvdGFibGVyYW5nZToxZmQ3NTA0OGU1MTk0ODk3YmIzZTUzMmZmYzJkZDFmZV8wLTAtMS0xLTI2ODkx_f7bb5ad4-7e87-471d-a653-e7c9c42c4bcd">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8xMzI_5dbaa63e-e0ac-4e68-be24-bc8c7bf2475e">June 30, 2022</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6YWJjYjIwNzE1YzJjNGY4NmExNzA2MDg0ODU0YTI2NmQvdGFibGVyYW5nZTphYmNiMjA3MTVjMmM0Zjg2YTE3MDYwODQ4NTRhMjY2ZF8wLTAtMS0xLTI2ODkx_684bfa34-1ca4-40f6-8c1f-5431700ba44a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8yNDA_4c77572d-6d5b-4d71-b78d-94bc598cd7a7">001-36201</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8yNDU_682b2489-097a-4019-bacb-7644eca81649">Immunic, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.654%"><tr><td style="width:1.0%"></td><td style="width:46.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MzQ2M2E1M2FjYjY3NGJkYjllZmJkYTNhNDgzOWVhOGUvdGFibGVyYW5nZTozNDYzYTUzYWNiNjc0YmRiOWVmYmRhM2E0ODM5ZWE4ZV8wLTAtMS0xLTI2ODkx_d88aff92-0561-4694-884d-31d5e38c2a52">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MzQ2M2E1M2FjYjY3NGJkYjllZmJkYTNhNDgzOWVhOGUvdGFibGVyYW5nZTozNDYzYTUzYWNiNjc0YmRiOWVmYmRhM2E0ODM5ZWE4ZV8wLTItMS0xLTI2ODkx_225e6e45-b3d9-46a4-9953-4911967d8334">56-2358443</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MzQ2M2E1M2FjYjY3NGJkYjllZmJkYTNhNDgzOWVhOGUvdGFibGVyYW5nZTozNDYzYTUzYWNiNjc0YmRiOWVmYmRhM2E0ODM5ZWE4ZV8zLTAtMS0xLTI2ODkx_05fcf09a-f103-4b34-b845-48da1d7bf025">1200 Avenue of the Americas</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MzQ2M2E1M2FjYjY3NGJkYjllZmJkYTNhNDgzOWVhOGUvdGFibGVyYW5nZTozNDYzYTUzYWNiNjc0YmRiOWVmYmRhM2E0ODM5ZWE4ZV80LTAtMS0xLTI2ODkx_892217c4-556d-4d26-a006-382ae57693c1">Suite 200</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MzQ2M2E1M2FjYjY3NGJkYjllZmJkYTNhNDgzOWVhOGUvdGFibGVyYW5nZTozNDYzYTUzYWNiNjc0YmRiOWVmYmRhM2E0ODM5ZWE4ZV81LTAtMS0xLTI2ODkx_b1a5c2c3-ecb4-430c-b460-7fe33409a0bc">New York,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MzQ2M2E1M2FjYjY3NGJkYjllZmJkYTNhNDgzOWVhOGUvdGFibGVyYW5nZTozNDYzYTUzYWNiNjc0YmRiOWVmYmRhM2E0ODM5ZWE4ZV81LTEtMS0xLTI2ODkx_47b8e44f-0a24-4229-ac3c-78425d6e0943">NY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MzQ2M2E1M2FjYjY3NGJkYjllZmJkYTNhNDgzOWVhOGUvdGFibGVyYW5nZTozNDYzYTUzYWNiNjc0YmRiOWVmYmRhM2E0ODM5ZWE4ZV81LTItMS0xLTI2ODkx_6b5a56f7-a79f-44a0-94d7-57af845a0a1f">10036</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8xOTY0_f73a0be9-faaf-45c4-8e6b-bee81a2c7997">332</ix:nonNumeric>) <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8xOTY1_7bb51ab7-37cc-4b21-a436-c042251ad2c7">255-9818</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.976%"><tr><td style="width:1.0%"></td><td style="width:35.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6NThkNTMyOWE2OTVlNGRjNGIzYjVlYTQ0MTQxZTRkNjcvdGFibGVyYW5nZTo1OGQ1MzI5YTY5NWU0ZGM0YjNiNWVhNDQxNDFlNGQ2N18xLTAtMS0xLTI2ODkx_e3363439-1c6c-4d48-bc93-636d6327ba80">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6NThkNTMyOWE2OTVlNGRjNGIzYjVlYTQ0MTQxZTRkNjcvdGFibGVyYW5nZTo1OGQ1MzI5YTY5NWU0ZGM0YjNiNWVhNDQxNDFlNGQ2N18xLTEtMS0xLTI2ODkx_ca7424f3-4cc9-4947-959a-400bff7a363b">IMUX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6NThkNTMyOWE2OTVlNGRjNGIzYjVlYTQ0MTQxZTRkNjcvdGFibGVyYW5nZTo1OGQ1MzI5YTY5NWU0ZGM0YjNiNWVhNDQxNDFlNGQ2N18xLTItMS0xLTI2ODkx_f8a88980-b1af-4171-abde-5e9814f3bd37">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF83ODk_cd406666-cb51-4ca7-a6e1-d0522d6b19ae">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8xMTI2_080f5b96-a1c6-4443-bdb7-a2f009a55666">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6NGU1MTBmZTcwNzczNDRjZWFiYjgwNTc0YjRjN2YzYTgvdGFibGVyYW5nZTo0ZTUxMGZlNzA3NzM0NGNlYWJiODA1NzRiNGM3ZjNhOF8yLTAtMS0xLTI2ODkx_49fef7e4-7510-4254-bb23-7dca25e74ae9">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6NGU1MTBmZTcwNzczNDRjZWFiYjgwNTc0YjRjN2YzYTgvdGFibGVyYW5nZTo0ZTUxMGZlNzA3NzM0NGNlYWJiODA1NzRiNGM3ZjNhOF8yLTMtMS0xLTI2ODkx_ce9a1484-d27b-42ce-adc2-7e36d54f7b25">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6NGU1MTBmZTcwNzczNDRjZWFiYjgwNTc0YjRjN2YzYTgvdGFibGVyYW5nZTo0ZTUxMGZlNzA3NzM0NGNlYWJiODA1NzRiNGM3ZjNhOF80LTMtMS0xLTI2ODkx_0e1cce1a-06b2-4342-b227-421a720f1ef9">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8xODcw_671a65e7-f18d-4ab6-bc58-c69318b5e030">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July 31, 2022, <ix:nonFraction unitRef="shares" contextRef="id01675085b9d47cfa6a56a99e63d5f56_I20220731" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8xOTAw_4ef60ff0-2c9c-46a2-aa2f-52777848254d">30,564,995</ix:nonFraction> shares of common stock, $0.0001 par value, were outstanding.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i132a36b84ae14363889a7cabe57a8d6f_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMMUNIC, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page&#160;No.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_10">PART I - FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_10">Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_10">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_13">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_13">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_16">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_19">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_25">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_28">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_61">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_61">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_73">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_73">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_76">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_76">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_79">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_82">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_82">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_85">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_85">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_88">Unregistered Sales of Equity Securities</a> and Use of Proceeds</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_88">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_91">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_88">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_94">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_94">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_97">Other Information </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_97">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_100">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i132a36b84ae14363889a7cabe57a8d6f_100">37</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i132a36b84ae14363889a7cabe57a8d6f_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:73.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNC0xLTEtMS0yNjg5MQ_bd879333-9035-43cd-8287-4af5297a2b08">88,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNC0zLTEtMS0yNjg5MQ_ca27a4d6-f1a5-4859-822c-91be1577f595">86,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNS0xLTEtMS0yNjg5MQ_c7bf18e2-201a-445f-952e-722c5a691664">16,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNS0zLTEtMS0yNjg5MQ_912e30a1-9ecd-41dc-99d0-464d30569ea9">18,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNi0xLTEtMS0yNjg5MQ_d4573743-295b-4d80-a0cf-4a700aaf3d7a">104,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNi0zLTEtMS0yNjg5MQ_edf659e2-7d8d-4add-b18e-c85e44aa0eba">104,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNy0xLTEtMS0yNjg5MQ_a2f9d841-3863-4053-afad-beffa76cfa3e">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNy0zLTEtMS0yNjg5MQ_eb840058-e6b7-4919-912d-b270e81195f0">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfOC0xLTEtMS0yNjg5MQ_fbb13026-855a-4372-9057-4d83c64f8a81">32,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfOC0zLTEtMS0yNjg5MQ_a20534d1-5f7f-4d86-84ff-1fb99cfa322f">32,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfOS0xLTEtMS0yNjg5MQ_c273cb5d-7389-4ca5-a840-a617b6c88f1d">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfOS0zLTEtMS0yNjg5MQ_ea5c98a7-f018-476e-8669-4b4b2537643f">948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTAtMS0xLTEtMjY4OTE_8a7998ee-e79a-4618-9a7b-f8e61af0b484">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTAtMy0xLTEtMjY4OTE_98a7d291-228c-4165-ba48-4dd44fc4255e">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTEtMS0xLTEtMjY4OTE_270ca0bc-b3b7-4198-b63d-ca0c62748c01">138,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTEtMy0xLTEtMjY4OTE_f384b8c3-fd83-465a-94d3-6ae59113b2b2">139,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTQtMS0xLTEtMjY4OTE_543f72cc-1977-471f-b608-68605287becd">4,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTQtMy0xLTEtMjY4OTE_53ca381d-8eea-485b-b826-23fc097aa2cb">3,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTUtMS0xLTEtMjY4OTE_2314997f-a00a-48b4-a746-5e24699e3e08">5,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTUtMy0xLTEtMjY4OTE_c196e74f-b4dc-45d2-ac32-7c48d3757588">7,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTYtMS0xLTEtMjY4OTE_4b6a2579-5188-49b7-b7b5-f67f05c7fd08">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTYtMy0xLTEtMjY4OTE_e5b58f54-bf07-49e4-9b67-2dcf1e41ab53">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTctMS0xLTEtMjY4OTE_9b21b5b6-3995-4fc5-b415-45cbc20e9993">10,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTctMy0xLTEtMjY4OTE_d2a1c57a-b2bb-41de-a24a-206f10b6d5c5">11,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTktMS0xLTEtMjY4OTE_43a30272-5559-4b1e-ae75-0419f7a4d358">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTktMy0xLTEtMjY4OTE_1d1c3fa0-caaa-469d-b8d8-db53233ad9e8">584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjAtMS0xLTEtMjY4OTE_dabcf1de-3e76-416a-9b64-0f0fa501cc5d">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjAtMy0xLTEtMjY4OTE_fd2c344e-7883-458f-91fc-9f96db291e64">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjEtMS0xLTEtMjY4OTE_6d758824-5c0b-43b5-b321-3d15007ffec8">10,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjEtMy0xLTEtMjY4OTE_aadf5e52-e9b3-4895-9836-7a6a782551a2">11,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjItMS0xLTEtMjY4OTE_3f2f2460-b623-42db-b639-bd7743caf685"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjItMy0xLTEtMjY4OTE_918d878b-8e4f-47a0-92eb-82b0525db712"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzEx_20bce812-22ca-4ce1-bc5f-5582fc293970"><ix:nonFraction unitRef="usdPerShare" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzEx_ec28c54e-8b0a-49b8-b94e-fbf06885a171">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzAx_0d1a0723-f818-4d96-b263-a3a5310145c8"><ix:nonFraction unitRef="shares" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzAx_3ee5b529-538c-46f8-b1d9-17883cea98ec">20,000,000</ix:nonFraction></ix:nonFraction> authorized and <ix:nonFraction unitRef="shares" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzE2_0eea3ce3-3947-49dc-ad20-6898c5d853dd"><ix:nonFraction unitRef="shares" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzE2_15eb8202-6e79-4a62-83a9-e5673ea9248b"><ix:nonFraction unitRef="shares" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzE2_4d4efef0-51ea-4d03-960a-ec8d43380969"><ix:nonFraction unitRef="shares" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzE2_7ef31782-feb5-4e19-a1e0-63f9d4a98849">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of June 30, 2022 and December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMS0xLTEtMjY4OTE_32205f7d-9163-4738-b95f-3608f388cae3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMy0xLTEtMjY4OTE_bfc29858-8de9-44cd-95f7-8b087d394ea8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1NzQx_4f8f7905-c31a-49f3-9666-77079730d68c"><ix:nonFraction unitRef="usdPerShare" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1NzQx_fba6a383-0ed6-4e0a-b2a0-53fba0e87694">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1NzU1_5a5a147e-7a28-4930-860f-14e2173d537f"><ix:nonFraction unitRef="shares" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1NzU1_7f8ff03c-d2bf-424b-8954-f1c14a47eedc">130,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1NzY4_4063f0c7-692d-4f4d-a680-7cbbbeb87800"><ix:nonFraction unitRef="shares" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1NzY4_8fa408a7-8c06-4a20-b2cd-20bfb0590190">30,564,995</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1Nzgx_0d33ae19-d5dc-412e-ae98-08ec305fc4b6"><ix:nonFraction unitRef="shares" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1Nzgx_3e1a864d-f080-428a-90cd-7d646932bb1a">26,335,418</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June 30, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMS0xLTEtMjY4OTE_a6ab8f48-1e7e-46bb-a779-86323a4c9f4c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMy0xLTEtMjY4OTE_cb085ce4-4ea4-4210-95eb-dde15ac7fb99">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjYtMS0xLTEtMjY4OTE_07f431de-52ed-4809-9912-9f822409bb94">368,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjYtMy0xLTEtMjY4OTE_0787ef0c-0404-4ffb-a1a5-bac438c20b3d">324,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjctMS0xLTEtMjY4OTE_7f45fc2f-f715-47f9-b475-9b1808d592fa">660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjctMy0xLTEtMjY4OTE_e2383212-c631-4037-a57d-df4042a6a4e9">252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjgtMS0xLTEtMjY4OTE_d33fd4d6-fd59-45d0-ab54-f0a17ba4b461">239,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjgtMy0xLTEtMjY4OTE_fc4cb686-134b-42d3-b839-484afbd87b62">196,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjktMS0xLTEtMjY4OTE_897aed52-c7f6-4d29-b945-71be980dd7c9">127,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjktMy0xLTEtMjY4OTE_071242b8-800a-4da8-a0d4-131c184b2e18">127,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMzAtMS0xLTEtMjY4OTE_cc1da695-89d3-45a0-88dd-b304b7f0e02c">138,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMzAtMy0xLTEtMjY4OTE_baafb126-e355-4f6c-bbfb-8b18fc50a904">139,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i132a36b84ae14363889a7cabe57a8d6f_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:49.696%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>&#160;Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMy01LTEtMS0yNjg5MQ_0aa69ffc-002c-4153-8a5f-cd12754a0c3b">16,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMy03LTEtMS0yNjg5MQ_96f9b648-c4d8-4558-aaca-cf8764a22dc6">15,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMy05LTEtMS0yNjg5MQ_ba6a8ca9-1e3b-49e6-a5be-100e92dbffff">33,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMy0xMS0xLTEtMjY4OTE_8af10435-9faf-4804-a158-0a307a32ebd4">27,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNC01LTEtMS0yNjg5MQ_defaf8a9-0623-42f8-bb33-07013cce4105">4,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNC03LTEtMS0yNjg5MQ_6ded3e4f-d958-4a08-b820-79cd1ac38768">3,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNC05LTEtMS0yNjg5MQ_cb852271-750d-4b36-8e60-f9b7427e0612">8,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNC0xMS0xLTEtMjY4OTE_6132896a-ba1c-47ba-bbdc-6015a3900832">7,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4SC royalty settlement (see Note 4)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" name="vtl:RoyaltySettlementAgreementSalesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNS01LTEtMS0yNjg5MQ_7471402d-809d-463d-8c9f-0c78c29eabdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" name="vtl:RoyaltySettlementAgreementSalesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNS03LTEtMS0yNjg5MQ_fb6eaecd-0b81-4502-b12e-20348ad1d1f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="vtl:RoyaltySettlementAgreementSalesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNS05LTEtMS0yNjg5MQ_f4ac1ebf-3945-4453-8c8a-49a6c3b1fc54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="vtl:RoyaltySettlementAgreementSalesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNS0xMS0xLTEtMjY4OTE_828ad43c-951a-4b1e-bc89-8207d371d501">17,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNi01LTEtMS0yNjg5MQ_0db05a11-1285-46da-828d-3335ccd19d72">20,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNi03LTEtMS0yNjg5MQ_d2efae9e-2cae-43d7-930c-ff3aff5c4cf1">19,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNi05LTEtMS0yNjg5MQ_b4b37645-7bf3-45a0-bb38-4adab347d6ab">42,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNi0xMS0xLTEtMjY4OTE_c0215ee0-6c61-48e2-b922-c4be9930ea6d">51,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNy01LTEtMS0yNjg5MQ_c6a2d3a8-b66f-4b09-80ca-bd44b825a6a2">20,610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNy03LTEtMS0yNjg5MQ_42fe0b1f-be4c-4ddb-9792-ab8e18c4a477">19,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNy05LTEtMS0yNjg5MQ_0941012d-49dd-4b24-b262-638e4b9c33d4">42,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNy0xMS0xLTEtMjY4OTE_fdc51c0b-7360-4274-b996-6dea7a9cd216">51,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfOS01LTEtMS0yNjg5MQ_b4c24d22-1317-464e-a24b-00047ecf954f">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfOS03LTEtMS0yNjg5MQ_f402a81b-72c9-4a14-9e61-0f088b3d34e6">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfOS05LTEtMS0yNjg5MQ_38429236-abc4-4853-bbd8-b191acd39cc4">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfOS0xMS0xLTEtMjY4OTE_c6f7bfca-963c-4896-977c-fb83a585824d">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other  income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTAtNS0xLTEtMjY4OTE_11294bb8-aa5e-4955-a950-f93c04e7197d">1,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTAtNy0xLTEtMjY4OTE_be97899e-1754-40f9-8b92-9fcf231f8220">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTAtOS0xLTEtMjY4OTE_60d138db-dd70-45d8-ac4d-eedffedec71c">777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTAtMTEtMS0xLTI2ODkx_e9935ce6-68f7-4ced-974b-6d5d0e0177d5">952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTEtNS0xLTEtMjY4OTE_b2fdefe1-ff2c-43e0-8513-9d34fd5abd7a">1,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTEtNy0xLTEtMjY4OTE_6e338c71-011b-4a97-99e1-99d65201585b">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTEtOS0xLTEtMjY4OTE_4575d626-d4b0-44d1-82e3-9e4debde9929">664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTEtMTEtMS0xLTI2ODkx_5bd93d92-07d7-425f-bf74-bb0c870086a8">911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTItNS0xLTEtMjY4OTE_50493c7f-721a-46a0-82c5-1667ef067e93">21,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTItNy0xLTEtMjY4OTE_86df4c1f-637a-4814-bba5-a2559c7b088c">17,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTItOS0xLTEtMjY4OTE_63fbca6a-13bc-4cd9-8dd3-93bcb4a14925">42,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTItMTEtMS0xLTI2ODkx_f6853c51-63c9-4149-824d-32ee2010972a">52,468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtNS0xLTEtMjY4OTE_63b07437-8fa1-4afd-b85a-ad767be69549"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtNS0xLTEtMjY4OTE_6eb7bb64-2a12-4de2-a2a6-a01bd917647c">0.72</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtNy0xLTEtMjY4OTE_6c323fc5-5677-4ac4-85a1-9925b9f5431e"><ix:nonFraction unitRef="usdPerShare" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtNy0xLTEtMjY4OTE_f552c187-5d93-4638-a411-81b1d89bab9d">0.82</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtOS0xLTEtMjY4OTE_dec0d4ec-e4ae-4e92-8f08-f093b2a7b4fe"><ix:nonFraction unitRef="usdPerShare" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtOS0xLTEtMjY4OTE_fcda81a0-1c7c-4e47-b63c-17240954c0b5">1.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtMTEtMS0xLTI2ODkx_1591700f-2cc5-4eab-8324-a6bac1097b02"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtMTEtMS0xLTI2ODkx_168f3726-ec6f-42c8-be8c-d09704871803">2.44</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtNS0xLTEtMjY4OTE_a6f0d533-b7e3-44f6-963d-0feae7428a2a"><ix:nonFraction unitRef="shares" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtNS0xLTEtMjY4OTE_c7497a37-72f2-4223-8900-cf5c5bb55405">30,248,767</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtNy0xLTEtMjY4OTE_3eb704bc-efde-4fb3-b958-0192f9ff24a2"><ix:nonFraction unitRef="shares" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtNy0xLTEtMjY4OTE_e4f3b232-31e8-4912-9512-7290c0b75aec">21,749,439</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtOS0xLTEtMjY4OTE_10e5c688-845a-487e-85b7-ac791f99e551"><ix:nonFraction unitRef="shares" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtOS0xLTEtMjY4OTE_3d27df15-ddee-4bf3-97a4-8338d6bfc5c1">28,686,910</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtMTEtMS0xLTI2ODkx_19d8eff1-a120-450e-ac32-4bfa39544bb2"><ix:nonFraction unitRef="shares" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtMTEtMS0xLTI2ODkx_8ea30a61-8d1b-4dda-bf51-e8bd18b29f23">21,463,656</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i132a36b84ae14363889a7cabe57a8d6f_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:55.298%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>&#160;Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfMi01LTEtMS0yNjg5MQ_74231f36-fd54-44e9-9fe6-30fb95d83618">21,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfMi03LTEtMS0yNjg5MQ_3c3b9785-2ecb-4dc2-bcee-1c1f5fe13dc1">17,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfMi05LTEtMS0yNjg5MQ_63fbca6a-13bc-4cd9-8dd3-93bcb4a14925">42,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfMi0xMS0xLTEtMjY4OTE_f6853c51-63c9-4149-824d-32ee2010972a">52,468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNC01LTEtMS0yNjg5MQ_2979ba31-8cd2-454d-adbc-622be6ed24a6">350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNC03LTEtMS0yNjg5MQ_f01ed116-277f-43c6-9b55-90368c3de4f1">277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNC05LTEtMS0yNjg5MQ_f3f979ea-4a3a-4ef6-bf6a-38e0c711c340">408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNC0xMS0xLTEtMjY4OTE_3963de4d-68ad-4288-9257-e426942bfe60">2,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNi01LTEtMS0yNjg5MQ_a4322b0c-8a9e-46b1-ba7f-d13f4ae75153">22,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNi03LTEtMS0yNjg5MQ_03971c50-9f5a-4b87-bfd3-cb6140180570">18,211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNi05LTEtMS0yNjg5MQ_c79d4f63-472a-4bfd-8020-4abe4cbcebde">43,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNi0xMS0xLTEtMjY4OTE_e7503f6b-65dc-4645-b373-0d110d14fd17">49,754</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i132a36b84ae14363889a7cabe57a8d6f_19"></div><hr style="page-break-after:always"/><div style="min-height:36.72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:232%">IMMUNIC, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:232%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.920%"><tr><td style="width:1.0%"></td><td style="width:43.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4fb55fd2ef8427d80a634661f1773b2_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMy0xLTEtMS0yNjg5MQ_15930644-8c6b-4377-9b01-d51f21651c13">26,335,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4fb55fd2ef8427d80a634661f1773b2_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMy0zLTEtMS0yNjg5MQ_e63a752f-77fb-4be6-b501-dafc7834ae1e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e90af7dc9ef4a6c9069acdbb42eae07_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMy01LTEtMS0yNjg5MQ_4fe6e0e5-7950-4cb5-8712-5b7267309c8a">324,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i383623f0307f4b9d96b57d1489b5600c_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMy03LTEtMS0yNjg5MQ_619e13f0-3410-4e0f-ac36-5fec0a60e7bd">252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a7559d9f82448c8987eae81fa4ec3ac_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMy05LTEtMS0yNjg5MQ_6956c5aa-98be-4cd2-8180-b29ade32350d">196,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMy0xMS0xLTEtMjY4OTE_e0356510-92b4-4048-b3ad-cc9bbe4bb3f8">127,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic96897f104fb48d78ee6473de6c83c97_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNC05LTEtMS0yNjg5MQ_a3653cd7-b099-4bfb-8420-082e80126f50">20,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9608caccfcbc4563859345eaa9991b07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNC0xMS0xLTEtMjY4OTE_4d41b4cf-1a5f-40c5-b50c-fbe8532a9043">20,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076950ee40df42d89a5d26ba9bf6795d_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNS01LTEtMS0yNjg5MQ_20d28773-c5d5-4d7f-97ee-d02542380fb9">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9608caccfcbc4563859345eaa9991b07_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNS0xMS0xLTEtMjY4OTE_693a7d01-cb74-44a2-800e-e5ecfdcdec33">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i465c366ef51f4b189565cac81dffddbe_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNi03LTEtMS0yNjg5MQ_08799999-2061-4547-9df0-1282ac4ddc04">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9608caccfcbc4563859345eaa9991b07_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNi0xMS0xLTEtMjY4OTE_08e32058-f0af-49f3-bb08-1b29497d9e38">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued in connection with the Company's stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75532eaec46d443bbf4be7aca9794114_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNy0xLTEtMS0yNjg5MQ_5f02fb9c-09eb-47b8-bbc0-30135e1ab7fb">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076950ee40df42d89a5d26ba9bf6795d_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNy01LTEtMS0yNjg5MQ_deeb3450-bea0-4a52-81d6-1c364c792556">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9608caccfcbc4563859345eaa9991b07_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNy0xMS0xLTEtMjY4OTE_cd03095d-0844-4b4d-a2d2-5c14f301e809">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - at the market Sales Agreement net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i9608caccfcbc4563859345eaa9991b07_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOC0wLTEtMS0yNzUxMy90ZXh0cmVnaW9uOjJjYzczNmY0Mzk1YjQzNjQ4MDA3OGFhYTRhYmUyOWE5XzIxOTkwMjMyNTU2NDY_4618ace1-4b76-437b-907d-f23097216e73">918</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i495588de7e354f81b29f181b399ebdba_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOC0xLTEtMS0yNjg5MQ_22df07db-b466-4ed7-a646-4d571e4aebc7">2,904,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf34bda03a394ba8a77214d6b3305235_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOC01LTEtMS0yNjg5MQ_4f299f8b-76c7-4b3f-9c68-b54f9e9814a2">29,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i121e4a3cffdb4f6fbed73a792bf1b69e_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOC0xMS0xLTEtMjY4OTE_40f1b5d4-1a22-4322-850c-454aeaba80f1">29,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i961bd468dc6e4b2085750c3208bb55f3_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOS0xLTEtMS0yNjg5MQ_bd5939a1-2baa-48c9-96ff-15e838893694">29,240,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961bd468dc6e4b2085750c3208bb55f3_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOS0zLTEtMS0yNjg5MQ_e4fff4dc-9de1-40a3-90ae-988e7ca865dd">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f74c7f405464d128cc5abb31ca4304c_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOS01LTEtMS0yNjg5MQ_5d584515-926e-4d27-890b-2fbbd5b3fe27">355,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a5095123e1441ce8ab5b195e2a7381e_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOS03LTEtMS0yNjg5MQ_c3d49943-cabe-4ade-90ce-4ea69548b3dc">310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i290eaed6709c4900870088935dc57a9c_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOS05LTEtMS0yNjg5MQ_880b1c6a-eb19-4037-8055-0b85b4cea2bd">217,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63039ccf15b40d4b5364ae7c9bf408a_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOS0xMS0xLTEtMjY4OTE_bf548ee5-7c72-4068-afad-9671c296faa9">137,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02e09f06bafe421b9a79431f6587dd3f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTAtOS0xLTEtMjY4OTE_8c23aef7-b3d8-4312-88eb-8ce9d7b26e25">21,901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTAtMTEtMS0xLTI2ODkx_9aee1a3f-48ae-4150-8814-9fc8a9c89755">21,901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aa74dec5d9242b787918ed1421800d6_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTEtNS0xLTEtMjY4OTE_91d6268c-ad32-49e2-a2d4-c36097ee11f4">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTEtMTEtMS0xLTI2ODkx_f173240a-1148-4cd0-ad40-25d064700f05">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85c7a5aa8a4246d0b7f7f081825bb773_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTItNy0xLTEtMjY4OTE_914308bf-a52a-4af4-ac7c-000bfe389974">350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTItMTEtMS0xLTI2ODkx_a177e7d3-a22e-4435-b055-ef8bb19c9429">350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued in connection with the Company's Employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba1820fc164b4f9bac61e09fc44afa8b_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtMS0xLTEtMjgxNDY_c7173d65-78cf-47e1-82e8-bf69ea15a116">24,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aa74dec5d9242b787918ed1421800d6_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtNS0xLTEtMjgxNTM_97470b8c-ac5b-4649-a391-fcdbb392f235">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtMTEtMS0xLTI3NTE4_4a9dd3f8-1ea2-487e-814f-ee2cd6159fba">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - at the market Sales Agreement net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTQtMC0xLTEtMjc1MTgvdGV4dHJlZ2lvbjphM2EzN2QyNjEyYTM0M2UyOWQxMDAxOGEzMGJiODI1M18yMTk5MDIzMjU1NjQ2_3680df10-010f-4024-aa63-64c8d8d02a9b">308</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5159f770ea0f4a9497673433e3e78293_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTQtMS0xLTEtMjc1MTg_331a4f47-9ae3-4bdd-97a8-4e1a2b1f05c8">1,300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3074803226e47ebb7c58a8d15c07885_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTQtNS0xLTEtMjc1MTg_245028eb-cfd9-4218-8f55-2cfefeba861f">9,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c1446033584b39a0f7674b22567b72_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTQtMTEtMS0xLTI3NTE4_23fb185e-4e4b-41b3-a427-0659e88d097f">9,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i24615a42f1564951b37f6e0d11cdb4d2_I20220630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtMS0xLTEtMjY4OTE_22476513-75b1-4c75-a891-6b7af10907ec">30,564,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24615a42f1564951b37f6e0d11cdb4d2_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtMy0xLTEtMjY4OTE_c61fac6a-0814-499c-959c-a2ff8b64e5d3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6c3453adbd4c6dafb2f21387665bff_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtNS0xLTEtMjY4OTE_c305d945-7284-47ed-a3dd-7cb57e169a56">368,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3b20273750b4a70831e7df55a20101e_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtNy0xLTEtMjY4OTE_da8f4c05-1f48-4144-9a20-8321bca6bc31">660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bbd2fff93de403e844b1b5d38504e4c_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtOS0xLTEtMjY4OTE_6f227bfc-2681-4801-84e0-638bac14ed2f">239,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtMTEtMS0xLTI2ODkx_15cc3c05-2f48-43fc-9113-cd9e4f9c9337">127,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36.72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.920%"><tr><td style="width:1.0%"></td><td style="width:42.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i640e715a3f0c4def9b0d868c1d6092b8_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMy0xLTEtMS0yNjg5MQ_fe3f06af-bcca-4c8c-aa41-2aa1937f56df">21,168,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i640e715a3f0c4def9b0d868c1d6092b8_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMy0zLTEtMS0yNjg5MQ_939c280c-6a1d-456b-bc81-54824f566094">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d857c13ffa547129b4b709b775b0c0c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMy01LTEtMS0yNjg5MQ_3c2ec1cf-e675-4c3f-9d50-1be670318f48">266,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3b3eff571ab4389b83a686f38bf0009_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMy03LTEtMS0yNjg5MQ_41f88346-83f5-457d-ad22-12fbf5f5ec00">4,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2320639dc1b945fb806ec94ec779e328_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMy05LTEtMS0yNjg5MQ_6cae2d52-9e52-4b51-8a5a-1f1c4492dc8a">103,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4772f1271c40e191e770ac6d61d1dd_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMy0xMS0xLTEtMjY4OTE_320cd7fd-a80b-40bc-8489-d6a879f926fb">158,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72df3680356349e7bfa91bda10e3f3f7_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNC05LTEtMS0yNjg5MQ_188ee169-1ff2-4623-81fc-d6aabece0fec">34,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2fb388e8881440ea3a00a25cd305aca_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNC0xMS0xLTEtMjY4OTE_d471e966-544b-4a1c-8738-fd3d2c9805dd">34,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83cbae3a80f4486b48792aefcc6aa84_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNS01LTEtMS0yNjg5MQ_8ab77705-8ec8-45d8-b92c-69116735e8a5">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2fb388e8881440ea3a00a25cd305aca_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNS0xMS0xLTEtMjY4OTE_539baacf-0135-44d9-948c-11cbf6799614">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i819b55b7eb0b41cb872b2a55a28511a4_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNi03LTEtMS0yNjg5MQ_3d865b0a-d50b-4271-b3dd-07dc424f8366">2,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2fb388e8881440ea3a00a25cd305aca_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNi0xMS0xLTEtMjY4OTE_5369b198-9823-4d95-9b10-e14f3ef7b584">2,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the 4SC royalty settlement (see Note 4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i302f3eed4b894be3bfb581b012217fa7_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNy0xLTEtMS0yNjg5MQ_a1fb32d5-8aa5-4221-b32e-b176c33b4b0c">581,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25252f765c54d26893666d4b8a4b6d1_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNy01LTEtMS0yNjg5MQ_12e0b5f1-a51e-4636-8462-f2becdcbe48c">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cff2d4dae0141d7a9400429428808cb_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNy0xMS0xLTEtMjY4OTE_d6c5deea-0a99-4f5e-b789-7772f94238b5">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06b0939acbbd4016a2017d08bbc14611_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOC0xLTEtMS0yNjg5MQ_4de025d3-cc90-42bd-8f0c-d218f8b48c2b">21,749,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06b0939acbbd4016a2017d08bbc14611_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOC0zLTEtMS0yNjg5MQ_d59a638e-a9d9-434f-8fd0-4331dee7518f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id40c3cee4b0a4933a0d3743284b8b9bb_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOC01LTEtMS0yNjg5MQ_cbb2255d-a0b1-461c-b8f4-547598f18de9">277,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6038f471ebd492dacb91545b0bd1204_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOC03LTEtMS0yNjg5MQ_ec23a61f-2ec8-4928-9914-9db59a093a47">1,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib888b4c6dea340ddac2a5f3d0444fb01_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOC05LTEtMS0yNjg5MQ_a970d7a7-4018-49d0-b616-545f2d09e4e1">138,462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6c3ba533a04a6d9765af14c3539988_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOC0xMS0xLTEtMjY4OTE_19e5284e-ecf6-4b31-bedf-db5c11b14ffd">137,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie94d2d5ea505442cbfb5b9f4af2174cb_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOS05LTEtMS0yNjg5MQ_ace902bd-f1ce-43b8-a787-2698d1eee2cd">17,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOS0xMS0xLTEtMjY4OTE_1dc28fcd-a15a-4f49-b7e0-c158b8f14f80">17,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i273c8f6ffe2d4bae939069532f577216_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTAtNS0xLTEtMjY4OTE_cbacb169-eafd-4688-b523-d8dd590940e7">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTAtMTEtMS0xLTI2ODkx_5c783625-63bd-41b0-923b-a28e7b2e7369">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf514b4446b646f2969c39b9e0c88824_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTEtNy0xLTEtMjY4OTE_867bec99-922f-4fce-a08a-c31ca40b6d6f">277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTEtMTEtMS0xLTI2ODkx_b322d121-6bc8-4b9e-8855-cf128f429b2e">277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2addead69d9548889d3828a4cf706290_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTUtMS0xLTEtMjY4OTE_1196cadb-bf5f-4f01-a015-c00bd4824fa3">21,749,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2addead69d9548889d3828a4cf706290_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTUtMy0xLTEtMjY4OTE_2270fd7f-92ab-46de-8161-b267764daf4e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d825e45e7c948c9b4d93eb5be9afd4c_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTUtNS0xLTEtMjY4OTE_b393b33c-3953-43eb-893a-37f093a3f65b">278,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7d44abdaa9d4db2a3c8a5442cead68d_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTUtNy0xLTEtMjY4OTE_475d7231-e9e8-4625-971c-f95bc245a2d1">1,398</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f57bfb4d140406a809324570a0730bb_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTUtOS0xLTEtMjY4OTE_92ae5415-45d9-4d6f-b4c6-4a0c191a890f">156,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5539c23cb2e040f787397c935b00dc96_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTUtMTEtMS0xLTI2ODkx_528dd36d-16d8-4f16-ac38-9e3c1793fb11">120,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i132a36b84ae14363889a7cabe57a8d6f_25"></div><hr style="page-break-after:always"/><div style="min-height:27.36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.622%"><tr><td style="width:1.0%"></td><td style="width:79.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>&#160;Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMy0xLTEtMS0yNjg5MQ_cebea2fd-346d-4c21-85ca-b34056d523de">42,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMy0zLTEtMS0yNjg5MQ_ef3a85e0-44b7-4129-a6cd-6ad783e66690">52,468</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfNS0xLTEtMS0yNjg5MQ_b2d16554-b497-47dd-ac7f-9049e588f5dc">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfNS0zLTEtMS0yNjg5MQ_71417ca8-4ae0-4df0-bbbe-b61875c4bb5d">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign currency  loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfNi0xLTEtMS0yNjg5MQ_c34deac2-93d1-4179-90b8-76360ef5060e">2,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfNi0zLTEtMS0yNjg5MQ_23bdfc14-347c-4c59-a6ce-8a5faacd6a40">1,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfOC0xLTEtMS0yNjg5MQ_cc8d0aa7-1053-498f-9bfd-2d7aad797abf">4,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfOC0zLTEtMS0yNjg5MQ_3fd42570-67a3-43b8-b31f-5a6e795cb3b7">3,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock issued in connection with the 4SC royalty settlement (see Note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfOS0xLTEtMS0yNjg5MQ_365fb296-8a1d-484f-9136-434f58b26799">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfOS0zLTEtMS0yNjg5MQ_c7d65fb7-1a99-4328-bfc9-93a11dd99ca0">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTEtMS0xLTEtMjY4OTE_f95de18e-189a-4981-a373-b9eb7f24eb19">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTEtMy0xLTEtMjY4OTE_d26f32f0-a483-4dd2-ae83-4f6810bdc0b1">8,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTItMS0xLTEtMjY4OTE_a73ea7bb-9c74-471c-9cbc-33bdb9937ee2">826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTItMy0xLTEtMjY4OTE_7a0103e6-d4f2-4602-8f6e-79085320cac1">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTMtMS0xLTEtMjY4OTE_ca82c266-7f2d-4691-8fa7-845c03547ffb">861</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTMtMy0xLTEtMjY4OTE_e5d68902-b07e-403a-b64c-adeb0c7c5f30">2,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTQtMS0xLTEtMjY4OTE_1527a637-8af5-465a-8a99-2a0a68408867">114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTQtMy0xLTEtMjY4OTE_10fa1cc3-12ac-4143-86b1-d9bdaebcc37b">3,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTUtMS0xLTEtMjY4OTE_38170463-1a6e-4b00-b4b0-2b13fb8b06ed">36,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTUtMy0xLTEtMjY4OTE_4ca87b94-2f99-40a3-8de7-271bbf9fac50">41,953</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjAtMS0xLTEtMjY4OTE_5b51b9ed-d82b-4395-ae9e-a0cc13a482cd">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjAtMy0xLTEtMjY4OTE_b0ea85ff-00ed-4519-812d-62495891c2bc">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjItMS0xLTEtMjY4OTE_c7280b28-aacd-4244-b6ed-c15ac39382ac">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjItMy0xLTEtMjY4OTE_424d7d99-0044-4e4f-bdde-f75eb0023c4a">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock through At The Market Sales Agreement, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d116a4fcc3e4f2aab94d415e3453a5a_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjUtMS0xLTEtMjY4OTE_8e2064cc-efc1-4251-a1e2-252e96190f67">39,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2540362a6b449a9988c08de956ec7c7_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjUtMy0xLTEtMjY4OTE_db883da0-6462-4e16-8153-2be1c78f009b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjYtMS0xLTEtMjY4OTE_25f13236-9c81-4dd0-ac48-3afea52a202c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjYtMy0xLTEtMjY4OTE_ef45393b-a6c6-44b8-b71c-d9c1e600d9b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from shares issued in connection with the Company's employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjctMS0xLTEtMjY4OTE_69f75e2e-548b-479d-824f-b7b3a532360b">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjctMy0xLTEtMjY4OTE_88d4266d-98ec-44fc-9ad9-6481186a1009">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjgtMS0xLTEtMjY4OTE_ea62d408-a9ea-4d58-a2a4-d492a0ee6966">39,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjgtMy0xLTEtMjY4OTE_c2ecbea4-26dc-47ae-8a50-e578deef0a55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjktMS0xLTEtMjY4OTE_34d576bc-db2e-4290-8a39-0095130c2692">2,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjktMy0xLTEtMjY4OTE_274bb238-4687-4af0-b877-30e702ab83a4">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzAtMS0xLTEtMjY4OTE_324ce4a6-4b68-465f-a7e4-7e7bbb50946a">1,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzAtMy0xLTEtMjY4OTE_e40901c9-3644-48b2-b960-4e15a3b04919">40,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzEtMS0xLTEtMjY4OTE_534db2ca-60dc-4a42-83cd-5c1be8180570">86,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4772f1271c40e191e770ac6d61d1dd_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzEtMy0xLTEtMjY4OTE_b156185a-ebda-4564-90a4-cc5c1040353f">127,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzItMS0xLTEtMjY4OTE_5879065b-bed3-4247-8f8a-80c5c0a4ba29">88,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5539c23cb2e040f787397c935b00dc96_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzItMy0xLTEtMjY4OTE_26e0ff28-c851-4108-8c4d-4e9ddb86ef01">87,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock issued in connection with the 4SC royalty settlement (see Note 4)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzctMS0xLTEtMjY4OTE_85afcadd-3618-4a77-8b87-9be56ead524a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzctMy0xLTEtMjY4OTE_3151f312-0142-435e-b2a2-87a7744039ec">8,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of use asset obtained in exchange for lease obligation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzgtMS0xLTEtMjY4OTE_85ff23eb-c965-427b-98fe-06533e90b7ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzgtMy0xLTEtMjY4OTE_eebec66e-bd2e-4109-8f1b-7f854a1a6972">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:27.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i132a36b84ae14363889a7cabe57a8d6f_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfNTQ5OQ_962abe5c-bef1-4aaf-bee6-2169133e6d16" continuedAt="ic0838fee35a547eabcabea69037f4cfc" escape="true">Description of Business and Basis of Financial Statements</ix:nonNumeric></span></div><ix:continuation id="ic0838fee35a547eabcabea69037f4cfc" continuedAt="i92a31a618daf48c59f32ed8c385f9abf"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic, Inc. ("Immunic" or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#228;felfing near Munich, Germany.  The Company currently has approximately <ix:nonFraction unitRef="employee" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-1" name="dei:EntityNumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfMjE5OTAyMzI3MjI3NQ_6e9f8a80-f46a-41c5-a726-c455679393a6">60</ix:nonFraction> employees.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is currently pursuing <ix:nonFraction unitRef="program" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="vtl:NumberOfDevelopmentProgramsPursued" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfNTQ5NzU1ODIzMTQ1_821d71f4-5c0f-4e7c-a1a7-1ef25b072ea6">three</ix:nonFraction> development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;); the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (&#8220;ROR&#947;t&#8221;), an immune cell-specific isoform of ROR&#947;; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. These product candidates are being developed to address diseases such as multiple sclerosis ("MS"), psoriasis and gastrointestinal diseases. In addition to these large markets, these products are also being developed to address certain rare diseases with high unmet medical needs, such as primary sclerosing cholangitis (&#8220;PSC&#8221;), as well as metastatic castration-resistant prostate cancer (&#8220;mCRPC&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and the inability to obtain on acceptable terms, if at all, additional funding to complete the development and commercialization of the Company's three development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfNTQ5NzU1ODMwNjM3_4f039848-a8dd-4180-a0ad-d0de2fb811d9">239.6</ix:nonFraction> million as of June 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfNTQ5NzU1ODI0Nzc0_78b8267b-36f6-4f0d-a18e-3b30a453a601">196.9</ix:nonFraction> million as of December 31, 2021.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the preclinical and clinical development of its product candidates and adds personnel necessary to advance its clinical pipeline of product candidates.  Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through June 30, 2022, Immunic has raised net cash of approximately $<ix:nonFraction unitRef="usd" contextRef="id28377b56621409b831d879cd0e930a4_D20140417-20220630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfNTQ5NzU1ODMwNDcx_c3fec4cf-bc97-4071-94a7-3f6e77efeae7">299.1</ix:nonFraction> million from private and public offerings of preferred and common stock. As of June 30, 2022, the Company had cash and cash equivalents of approximately $<ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfNTQ5NzU1ODMwNjE3_bbfb9f63-0f4c-41bc-915c-ece7121e061c">88.1</ix:nonFraction> million.  With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfNTUwMw_00f03956-d8e9-4208-bc8e-e7fd692ee583" continuedAt="ie92b9d32d8214726aba5fa273103a3e8" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Research GmbH (which both began operations in 2016) and Immunic Australia Pty Ltd. (which began operations in 2018).  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. </span></div></ix:nonNumeric></ix:continuation><div style="padding-left:24.75pt"><span><br/></span></div><div style="padding-left:24.75pt"><span><br/></span></div><div style="padding-left:24.75pt"><span><br/></span></div><div style="padding-left:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i92a31a618daf48c59f32ed8c385f9abf" continuedAt="i9658e03dc36f4f438c5195ea5254d4e3"><ix:continuation id="ie92b9d32d8214726aba5fa273103a3e8" continuedAt="ibc606bf7287d446e9bf7ea0e9dee04f3">Unaudited Interim Financial Information</ix:continuation></ix:continuation></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9658e03dc36f4f438c5195ea5254d4e3"><ix:continuation id="ibc606bf7287d446e9bf7ea0e9dee04f3">Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed on February 24, 2022. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</ix:continuation></ix:continuation> </span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDE_1f3e53ce-079e-4ed3-ad5e-61a3a9f8d3b4" continuedAt="i2d4d5ed772274d9591b723d1859e1ba9" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i2d4d5ed772274d9591b723d1859e1ba9" continuedAt="iab86d4434e6d4e089d871b419cfcc955"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MjA_afbde2c7-1188-4aea-9f23-012e74a1da49" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDM_ac3ea99a-d3f2-4d5c-b852-e8da8b320f24" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG and Immunic Research GmbH&#8217;s operations are located in Germany with the Euro being their functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDQ_4fd27a2b-0aa2-4a48-8c1f-8b0c477a8af4" continuedAt="ib138a24f20504a1daea900635a0893ee" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib138a24f20504a1daea900635a0893ee">Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iab86d4434e6d4e089d871b419cfcc955" continuedAt="ia872ce9b2d874ea08dc2284646d3b1c1"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTM_4bb33025-46b7-434f-8735-ceda152215b3" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDI_d309e193-b673-4b7f-ad90-7496e1f8852d" continuedAt="i5b0dea397dec4391bef5cc064f808f75" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5b0dea397dec4391bef5cc064f808f75">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDU2MA_257586a5-1545-4cd3-af1d-02cb0660d644">three</span> to <ix:nonNumeric contextRef="i3ad392238f03492fb9409e9edf57a05e_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDU2Ng_f9e52995-18da-40b7-90e2-456c96a1570f">thirteen years</ix:nonNumeric>.</ix:continuation> Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDU5NQ_7948bb51-6bac-4126-8005-2d0ec1b3d67e">20,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDYwMg_d8ad37fa-1bf1-4392-8824-e168085c19db">15,000</ix:nonFraction> for the three months ended June 30, 2022 and 2021, respectively. Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDY5NQ_c8fc5053-4eb5-487d-a447-b5f130a3bf81">41,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDcwMg_670f98c8-63e5-43d4-a7b8-143822bbb9e5">29,000</ix:nonFraction> for the six months ended June 30, 2022 and 2021, respectively</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTY_c5b96dad-3287-46c5-9b04-a412390af8c0" continuedAt="i965706b1b0314e36b4d5ac980f394bf1" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i965706b1b0314e36b4d5ac980f394bf1">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTExMg_58a0132b-78e1-489f-b7f2-b4a4bbc7ab1c"><ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTExMg_803476e9-f223-4a65-ae56-998644e45b36"><ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTExMg_b197de6b-6824-4cb0-9376-fbbe59584cbe"><ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTExMg_d988873f-6345-4d65-b3e3-87eaf22197db">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment losses during the three and six months ended June 30, 2022 and 2021.</span></div><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDU_229e8a65-3fea-45ee-8158-8be814747f82" continuedAt="i9a672ead276042b0b11576035dc32fe7" escape="true"><div style="margin-top:12pt;padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">When conducting the Company&#8217;s interim goodwill impairment assessment, we considered the Company&#8217;s history of reported losses and negative cash flows from operating activities, along with the downturn in macroeconomic conditions and the broader mid-cap and micro-cap equity markets in 2022. Given the relatively short period of time between the commencement of the downturn in macroeconomic and general equity market conditions as of June 30, 2022, management believes that the recent reduction in prices of our common stock, consistent with the broader market, is not other-than-temporary and not indicative of any fundamental change in the value or prospects of the underlying business as of the measurement date.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia872ce9b2d874ea08dc2284646d3b1c1" continuedAt="i3cc485b6c58046f89fde2a8ad96d7587"><ix:continuation id="i9a672ead276042b0b11576035dc32fe7"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As another data point, the Company also performed a quantitative goodwill impairment analysis comparing the estimated fair value of the Company&#8217;s reporting unit to its carrying or book value as of the current period presented herein. In performing the quantitative analysis, the Company compared the fair value of the reporting unit to its carrying or book value to determine if the fair value of the reporting unit exceeded its carrying value as of the testing date, in which case the standard indicates that goodwill would not be impaired, and no further testing is required. The fair value of a reporting unit refers to the price that would be received to sell the reporting unit as a whole in an orderly transaction between market participants at the measurement date. Quoted market prices in active markets are considered to be the best evidence of fair value and should be used as the basis for fair value measurement, if available. When using quoted market prices to estimate the fair value of a reporting unit, we consider all available evidence. In certain circumstances, such as a distressed market, it may be appropriate to consider recent trends in the Company&#8217;s stock price, instead of a single day&#8217;s stock price in evaluating fair value. In these circumstances, averages over relatively short periods of time are used to determine representative market values.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the qualitative analysis and other data points described above,  the Company concluded that goodwill was not &#8220;more likely than not&#8221; impaired as of June 30, 2022.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described above, we have significant goodwill recorded on our consolidated balance sheets. We will continue to evaluate the recoverability of the carrying amount of goodwill on an ongoing basis. There can be no assurance that the outcome of such reviews in the future will not result in substantial impairment charges. Impairment assessment inherently involves judgment as to assumptions about expected future cash flows and the impact of market conditions on those assumptions. Future events and changing market conditions may impact our assumptions as to prices, costs, holding periods or other factors that may result in changes in our estimates of future cash flows. Although we believe the assumptions we used in testing for impairment are reasonable, significant changes in any one of our assumptions could produce a significantly different result. The  closing stock prices for our common stock subsequent to June 30, 2022, consistent with the broader market, have continued to trend downward. If the decline in our stock price persists throughout the three month period ending September 30, 2022, we will perform an interim goodwill impairment assessment as of September 30, 2022, consistent with the methodology and approach described above.</span></div></ix:continuation><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTQ_57004986-499f-4aa5-a881-0e35c4adafb0" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC, COVID-19, and PSC.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDg_d921faac-ba05-4f4c-86e7-e3894de82617" continuedAt="ibf0a00164f4a4e748c10ce67ba601c0f" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3cc485b6c58046f89fde2a8ad96d7587" continuedAt="i5ed1cb1f8197415eab8d9343eb8f40ec"><ix:continuation id="ibf0a00164f4a4e748c10ce67ba601c0f"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div></ix:continuation><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc0OTk_3edc16d1-f6c8-43db-aab6-176c38303d27" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDk_1249641e-1964-4b59-9863-e524c62e8698" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTA_6a8338cc-7710-421f-9b31-d3029c9369d3" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than <ix:nonNumeric contextRef="i9e8992acd92c4178a465c433d46d5797_I20220630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTQ5NzU1ODU1ODA1_89919aae-2535-445e-a8ea-c412cbd5d19b">12</ix:nonNumeric> months and up to <ix:nonNumeric contextRef="i8745b84aae60434e9b96daf94cfac93a_I20220630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTQ5NzU1ODU1ODE5_33426e25-5854-45ad-a6fa-84fa8693880f">60</ix:nonNumeric> months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="lease" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="vtl:LesseeOperatingLeasesNumberOfExistingLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTQ5NzU1ODU1OTgy_60d39a03-8f8b-4109-b907-33a38e46d704">two</ix:nonFraction> existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's <ix:nonFraction unitRef="lease" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="vtl:LesseeOperatingLeasesNumberOfExistingLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTQ5NzU1ODU2MjQy_60d39a03-8f8b-4109-b907-33a38e46d704">two</ix:nonFraction> leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:18pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:18pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5ed1cb1f8197415eab8d9343eb8f40ec"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTc_e1c724e7-b021-4e31-b080-c95129154fb4" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDA_6d167f63-97c5-44c1-9544-6f0c7c255de5" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of June 30, 2022 and 2021, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTg_68b75c04-543e-42f7-bd7d-02033f9a25c6" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTE_e7187c53-85de-48dd-9659-6f15e0ee5ae6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:73.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58796c8360524abb862423e11c8db6ad_D20220101-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RhYmxlOjM3ZWY4MjM5OThjMzRlZDM5ZjI5ZWVmMDNjMWY2NmZlL3RhYmxlcmFuZ2U6MzdlZjgyMzk5OGMzNGVkMzlmMjllZWYwM2MxZjY2ZmVfMi0xLTEtMS0yNjg5MQ_6835d07b-052a-4b3c-9a89-7d221d096c08">3,713,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcfd1b5059be473ca463b8dfc127debf_D20210101-20210630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RhYmxlOjM3ZWY4MjM5OThjMzRlZDM5ZjI5ZWVmMDNjMWY2NmZlL3RhYmxlcmFuZ2U6MzdlZjgyMzk5OGMzNGVkMzlmMjllZWYwM2MxZjY2ZmVfMi0zLTEtMS0yNjg5MQ_c758d0f6-ddb7-40f9-bb53-1c193bd73895">2,064,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTI_f5e43c53-69a0-4541-b55a-64eeab6768e1" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i132a36b84ae14363889a7cabe57a8d6f_37"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfNTM4_3318b1fe-a08a-473c-867f-2ea34a5c7fc9" continuedAt="i18dd125222894080bff84fb5b93dccbc" escape="true">Balance Sheet Details</ix:nonNumeric></span></div><ix:continuation id="i18dd125222894080bff84fb5b93dccbc"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets and Prepaid Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfNTMw_d72b4075-a7fa-493c-8554-fa89e120f250" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:74.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.255%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="vtl:PrepaidClinicalAndRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfMi0xLTEtMS0yNjg5MQ_ca2518fb-b037-4d11-97bc-d7e707777bd4">11,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="vtl:PrepaidClinicalAndRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfMi0zLTEtMS0yNjg5MQ_45da4d32-fd3c-433a-aecb-25722617dcd5">14,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfMy0xLTEtMS0yNjg5MQ_f98a2192-35bb-4a8a-b448-31d91f0516b5">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfMy0zLTEtMS0yNjg5MQ_f83e8d65-97a8-442c-935c-e80b34db7b8f">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="vtl:ResearchAndDevelopmentTaxIncentiveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfNC0xLTEtMS0yNjg5MQ_fcdd4bce-b141-4e8b-bb0b-972abc299741">2,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="vtl:ResearchAndDevelopmentTaxIncentiveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfNC0zLTEtMS0yNjg5MQ_c6cc20fb-404d-4cda-92f7-f59dd0969a1b">1,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfNS0xLTEtMS0yNjg5MQ_eafde641-6d2f-4c4f-83c0-bbd2209ee8ec">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfNS0zLTEtMS0yNjg5MQ_761d7ffa-2ef7-40dd-be95-577487f4eb91">1,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfNi0xLTEtMS0yNjg5MQ_9305e114-db05-40b0-8b54-91908c73f26b">16,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfNi0zLTEtMS0yNjg5MQ_b65abbd9-87f5-4d28-8609-82d1f0637522">18,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfNTM2_cf85d761-54c1-4919-8c74-5a8c7cabde5c" continuedAt="i0cde473e36aa45efb21bea7f92cd1171" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="vtl:ClinicalCostsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfMi0xLTEtMS0yNjg5MQ_ef0e4d76-a41f-42a9-b278-8b0a53960d5d">3,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="vtl:ClinicalCostsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfMi0zLTEtMS0yNjg5MQ_ea8fd2a8-f4ec-4abd-b644-f5b78c21f651">3,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="vtl:LegalAndAuditCostsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfMy0xLTEtMS0yNjg5MQ_de2d15d1-3515-47dd-ae1d-79aed2ee893c">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="vtl:LegalAndAuditCostsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfMy0zLTEtMS0yNjg5MQ_e8e24719-bf38-4ed7-94d2-ab258617be05">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfNS0xLTEtMS0yNjg5MQ_9aedb22c-d30b-4261-8cab-b600a4dfe4a1">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfNS0zLTEtMS0yNjg5MQ_27634cdb-1d7e-418f-8d93-b887ce186583">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfNi0xLTEtMS0yNjg5MQ_d30e3b43-9fa8-4ccc-b171-8190a31e93f6">4,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfNi0zLTEtMS0yNjg5MQ_3adf575e-399b-4ac3-990c-5e44dd664ad0">3,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:continuation id="i0cde473e36aa45efb21bea7f92cd1171"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="vtl:AccruedClinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfMi0xLTEtMS0yNjg5MQ_41c4f2db-4b8e-49f4-a8bf-99db385166a4">4,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="vtl:AccruedClinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfMi0zLTEtMS0yNjg5MQ_29f28932-129f-45d7-ab9d-91794ad24abb">6,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="vtl:AccruedLegalAndAuditCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfMy0xLTEtMS0yNjg5MQ_89a3c795-867d-472e-83a0-d1a0ff1cffe3">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="vtl:AccruedLegalAndAuditCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfMy0zLTEtMS0yNjg5MQ_04a479f8-1feb-422d-94c6-8a0d2cd5e063">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="vtl:AccruedCompensationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfNC0xLTEtMS0yNjg5MQ_9fd86827-dd64-4e7e-a8ae-214eaee11ab1">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="vtl:AccruedCompensationCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfNC0zLTEtMS0yNjg5MQ_4c4d8ac5-c196-421d-a8ad-b661cec0d63a">674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfNS0xLTEtMS0yNjg5MQ_d155158f-7741-4746-8d15-f0d398c4b926">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfNS0zLTEtMS0yNjg5MQ_b1322f93-b0b9-4f15-8e17-b9df90efbd8c">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfNi0xLTEtMS0yNjg5MQ_60241f9a-eb7a-4c72-b50c-b50d09170f3f">5,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfNi0zLTEtMS0yNjg5MQ_f029f953-29ca-4e92-bc71-8b550fee7fa3">7,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfMjE5OTAyMzI1NjI5MA_3d8ceb1b-3c21-469b-880e-2ea581b8f112"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfMjE5OTAyMzI1NjI5MA_f85fe492-0c02-4937-8946-c1829a42d290">Other Current Liabilities</span></span></span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfNTMx_50b91b42-7122-49d3-9461-335064082d3c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.740%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjc0YTM1YjBiYTFmODQ3MDRiZDkyYTQ0ZDY1MWI2NWM1L3RhYmxlcmFuZ2U6NzRhMzViMGJhMWY4NDcwNGJkOTJhNDRkNjUxYjY1YzVfMi0xLTEtMS0yNjg5MQ_9e735579-b915-4062-8364-61adf8434ce4">366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjc0YTM1YjBiYTFmODQ3MDRiZDkyYTQ0ZDY1MWI2NWM1L3RhYmxlcmFuZ2U6NzRhMzViMGJhMWY4NDcwNGJkOTJhNDRkNjUxYjY1YzVfMi0zLTEtMS0yNjg5MQ_f102a985-4940-44d7-ba23-4ad521a06276">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjc0YTM1YjBiYTFmODQ3MDRiZDkyYTQ0ZDY1MWI2NWM1L3RhYmxlcmFuZ2U6NzRhMzViMGJhMWY4NDcwNGJkOTJhNDRkNjUxYjY1YzVfNC0xLTEtMS0yNjg5MQ_212ab774-774c-4eb9-8a35-8dbde4cbfc4f">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjc0YTM1YjBiYTFmODQ3MDRiZDkyYTQ0ZDY1MWI2NWM1L3RhYmxlcmFuZ2U6NzRhMzViMGJhMWY4NDcwNGJkOTJhNDRkNjUxYjY1YzVfNC0zLTEtMS0yNjg5MQ_9c497109-d22a-4045-8af0-e89473750786">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjc0YTM1YjBiYTFmODQ3MDRiZDkyYTQ0ZDY1MWI2NWM1L3RhYmxlcmFuZ2U6NzRhMzViMGJhMWY4NDcwNGJkOTJhNDRkNjUxYjY1YzVfNS0xLTEtMS0yNjg5MQ_79ee9b5d-989a-492a-8f48-8e13c59b83a6">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjc0YTM1YjBiYTFmODQ3MDRiZDkyYTQ0ZDY1MWI2NWM1L3RhYmxlcmFuZ2U6NzRhMzViMGJhMWY4NDcwNGJkOTJhNDRkNjUxYjY1YzVfNS0zLTEtMS0yNjg5MQ_4d1c92a3-66fa-4d9b-af42-810aa30ea8ca">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i132a36b84ae14363889a7cabe57a8d6f_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTEyOQ_04a5f7a4-63f6-4ddc-ab10-af535e6215a1" continuedAt="i468562e9cc124a999b56c4aee5046563" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i468562e9cc124a999b56c4aee5046563" continuedAt="i0a71358372e04bfb908747e634db410b"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on April 30, 2023 for the New York City office and on June 30, 2025 for the Gr&#228;felfing, Germany office.  These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease has renewal options, but they were not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a <ix:nonNumeric contextRef="i8851c67679bf4084b6bf5354695ad9d2_I20200407" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfMjE5OTAyMzI3MDExOA_606ba24b-e6b9-4e81-82af-a43a6d566db3">five year</ix:nonNumeric> lease for its facility in Gr&#228;felfing, Germany. On March 1, 2021, the Company added additional lease space at the Gr&#228;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a <ix:nonNumeric contextRef="idfa9e23428124c2486f4015b0a2d6c95_D20220101-20220630" name="vtl:LesseeOperatingLeaseRentHolidayPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfMjE5OTAyMzI3MDExOQ_7a75b61e-284f-42ec-8aa7-09a47a650a47">six month</ix:nonNumeric> rent holiday at the beginning of the lease.  There were net additions to right of use assets of $<ix:nonFraction unitRef="usd" contextRef="i0900a41bd91a4900bd798f3276eb85bb_D20210301-20210331" decimals="-3" name="vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODIyNDc5_1a252324-a339-4f26-90e0-91c8f8d39b0d">435,000</ix:nonFraction> as a result of signing for additional lease space at the Gr&#228;felfing, Germany office in March 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be <ix:nonFraction unitRef="number" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="2" name="vtl:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODIyODIz_7524421f-4310-45ba-a4e3-b28262d458c9">6</ix:nonFraction>%, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $<ix:nonFraction unitRef="usd" contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfMjMwOA_b28d10c7-3e13-4e13-a7fd-8ff4b19cd784">136,000</ix:nonFraction> and <ix:nonFraction unitRef="usd" contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfMjMxNQ_f418b2d8-14c8-40f7-87d1-4163745538dd">145,000</ix:nonFraction> for the three months ended June 30, 2022 and 2021, respectively and $<ix:nonFraction unitRef="usd" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfMjM4Ng_4248006b-73e9-4ec2-9b93-9c7895ca0457">266,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfMjM5Mw_2cd57965-c27d-46b6-9fd3-f9384d5794ad">239,000</ix:nonFraction> for the six months ended June 30, 2022 and 2021, respectively.  Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTEzNQ_9196074b-b41a-4722-96f3-275d02fd39bc" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of June 30, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:85.106%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfMC0yLTEtMS0yNjg5MQ_0347d81f-0b46-407f-a240-47336fff56e1">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfMS0yLTEtMS0yNjg5MQ_93c48846-18e2-454b-86d8-9739163cf0c0">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfMi0yLTEtMS0yNjg5MQ_43abf3fc-067c-4305-b9d7-8dc49766a1b7">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfMy0yLTEtMS0yNjg5MQ_535f8281-2497-40a7-a181-290251f43ce4">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfNC0yLTEtMS0yNjg5MQ_3ac8aff5-390c-453e-b981-9687edbb7984">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfNS0yLTEtMS0yNjg5MQ_57926198-8930-4097-9540-2b27c4201b77">829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfNi0yLTEtMS0yNjg5MQ_bc100f58-8b14-49e5-a8d6-af87dc0c9d6d">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfNy0yLTEtMS0yNjg5MQ_5f2d3dac-75bc-4826-83a3-54894ea40b12">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company has non-cancelable contractual obligations under certain agreements related to its development programs for vidofludimus calcium, IMU-935 and IMU-856 totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-5" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfMjE5OTAyMzI3MDU4Ng_35082021-1370-49ba-9e74-051a07611085">2.6</ix:nonFraction>&#160;million, all of which is expected to be paid in the next twelve months.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, the Company entered into a purchase agreement (the &#8220;Agreement&#8221;) with 4SC AG, whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to <ix:nonFraction unitRef="number" contextRef="ic0596eac93474ba595e10a41ccb463c3_D20160501-20160531" decimals="3" name="vtl:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODI1NzM2_df758eeb-f257-4f54-a28b-53fdf3574eb8">4.4</ix:nonFraction>% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing <ix:nonFraction unitRef="shares" contextRef="ic822612a93bf4322a15f67ee66c0e1ea_I20190412" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODI1OTU1_ebb51acc-279b-4487-b30b-601853d0b0e0">120,070</ix:nonFraction> shares of the Company&#8217;s common stock, immediately following the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0a71358372e04bfb908747e634db410b"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transaction, to 4SC AG while keeping Tranche III in effect. Approximately $<ix:nonFraction unitRef="usd" contextRef="ic822612a93bf4322a15f67ee66c0e1ea_I20190412" decimals="-5" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODI2MDk3_926eeb1f-e706-4b2b-ab30-211e5fb80f3b">1.5</ix:nonFraction> million of expense was recorded as a result of the issuance of these shares on April 12, 2019. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, Immunic AG and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the <ix:nonFraction unitRef="number" contextRef="i0ac3802756644803be0171f1cae2cca5_D20210331-20210331" decimals="3" name="vtl:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODI2MzM2_fbd9f822-42fe-4745-a6f9-68231232f31b">4.4</ix:nonFraction>% royalty on net sales for $<ix:nonFraction unitRef="usd" contextRef="i0ac3802756644803be0171f1cae2cca5_D20210331-20210331" decimals="-4" name="vtl:RoyaltySettlementAgreementSalesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODI2MzY1_374df1f8-f1ba-41e5-bf74-efab675dac41">17.25</ix:nonFraction>&#160;million (Tranche III of the Agreement). The payment was made <ix:nonFraction unitRef="number" contextRef="i6e183777c2784361bb1f6d43969d764e_I20210331" decimals="INF" name="vtl:RoyaltySettlementAgreementCashPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODI2NDIy_bb2e26b2-b24c-4fd7-8f61-be842e44d3eb">50</ix:nonFraction>% in cash and <ix:nonFraction unitRef="number" contextRef="i6e183777c2784361bb1f6d43969d764e_I20210331" decimals="INF" name="vtl:RoyaltySettlementAgreementSharesPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODI2NDM4_48dd3d90-9496-4aee-a5ea-dbc59fb48633">50</ix:nonFraction>% in shares of Immunic&#8217;s common stock (the &#8220;Shares&#8221;). Pursuant to the Agreement, the Company filed a resale shelf registration statement on Form S-3 covering the resale of the Shares. With the execution of the Agreement, no further payment obligations remain between Immunic AG and 4SC AG.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div></ix:continuation><div id="i132a36b84ae14363889a7cabe57a8d6f_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RleHRyZWdpb246NTQyZDBiODBhMGMyNGU2Yjk0MGNjMWZhNWJjYzU2MGJfODY2_89da85dd-ba8e-4c97-8615-6f4bf33cee93" continuedAt="i0f21036b6f234c6e8cc0837b5ef9076d" escape="true">Fair Value</ix:nonNumeric></span></div><ix:continuation id="i0f21036b6f234c6e8cc0837b5ef9076d" continuedAt="ibac34e8a825a45d9ad7f37f4c7c6401d"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RleHRyZWdpb246NTQyZDBiODBhMGMyNGU2Yjk0MGNjMWZhNWJjYzU2MGJfODY1_46211e67-c1d3-4933-b287-84714b8a672f" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if619c407624b4922b1afa2e57a9ff01a_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfMy0xLTEtMS0yNjg5MQ_f286d260-279b-452a-9404-a44c7a21732c">63,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e026c775ec49f9861b7f0d7ef051f1_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfMy0zLTEtMS0yNjg5MQ_76703a2d-ead2-4dc7-904a-bae615050ffc">63,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf678ced37ba47f7910be49d8d28b9e7_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfMy01LTEtMS0yNjg5MQ_78c22210-bf2f-440a-ac0d-5c4b9937e2fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bf2a21a1b3143b9a9bb2e50c90d5ad2_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfMy03LTEtMS0yNjg5MQ_cd5e0772-ebe4-412f-90d5-850ee1e494f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01049530b3a04055a71bdcbd2ddb098f_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfNC0xLTEtMS0yNjg5MQ_448a2e37-f9cf-4f57-a77d-7f1f7011454d">63,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91585558cbe34e778b4f5fbf7b1c8daa_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfNC0zLTEtMS0yNjg5MQ_c62f459b-8edb-4c41-a457-105f3691561d">63,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8722bc2bc004244be18e6327d5c0084_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfNC01LTEtMS0yNjg5MQ_dbaf61aa-7120-45c9-9d80-cbc781ce0186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848040a12f93446e94b293d803e3ba3e_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfNC03LTEtMS0yNjg5MQ_4461615e-0e39-475c-bf27-509c13566eb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i900fc28b42424c17b00cd3ca859d30a1_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfMy0xLTEtMS0yNjg5MQ_3b7f7b42-5ce7-43e9-8657-67b24dc3c249">31,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd253af90c7049ba9afdf7bd8778d934_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfMy0zLTEtMS0yNjg5MQ_be8e9fcd-ecdc-45c3-8a77-ffeeb3f1decb">31,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4d595729674eff99b3ca2ca86c0b7e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfMy01LTEtMS0yNjg5MQ_cf8b7835-7198-4914-9c4d-65225adca713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e62c8bbfe554143bcfccd623eef0f68_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfMy03LTEtMS0yNjg5MQ_4677d250-ec12-4269-92d3-526f9c5d7f0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee62d52d680b41dba637ae523465d27e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfNC0xLTEtMS0yNjg5MQ_0caa509b-0e01-4b65-a9a6-354484fe9614">31,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fcb0abe6f0749babe8150c967988400_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfNC0zLTEtMS0yNjg5MQ_31dc69b2-1393-4afe-9bb1-4f0e16f0fde1">31,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9a91903ca2a4ad0b30d85fb1a845075_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfNC01LTEtMS0yNjg5MQ_bb3995c1-33e8-40ed-866f-7c6695c67d98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8557ddef2d144928039c8fb2320084e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfNC03LTEtMS0yNjg5MQ_223ecc1d-3551-44fb-9f59-8bcb3b3ac0f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds, which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibac34e8a825a45d9ad7f37f4c7c6401d">The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i132a36b84ae14363889a7cabe57a8d6f_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNjc3Mw_7c896d89-1324-49df-a5e6-840fd05feba9" continuedAt="i19a30ecc8b8d4d938f56d17ff6291533" escape="true">Common Stock</ix:nonNumeric></span></div><ix:continuation id="i19a30ecc8b8d4d938f56d17ff6291533" continuedAt="i5a114bc6c1fe44899a1018da6c6643a8"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $<ix:nonFraction unitRef="usd" contextRef="ib934db459d0f41d6983debfc2a9bb490_I20201130" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTQ5NzU1ODI0Mzgy_a2f120db-804b-4eec-bb4e-bc4bcc02782f">250.0</ix:nonFraction>&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of July 31, 2022, there is $<ix:nonFraction unitRef="usd" contextRef="i655d008592954266b8c505297b7e326a_I20220731" decimals="-5" name="vtl:ShelfRegistrationStatementAmountRemaining" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTQ5NzU1ODI0NTU1_77d257b6-1afc-41df-8a44-ffbfbe831db5">75.0</ix:nonFraction>&#160;million remaining on this shelf registration statement </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="if084565ea6544630b40bf38bc6aa362c_I20201231" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTQ5NzU1ODI0NzUx_454e223d-e8f9-4b1e-944b-095092d539c6">50.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon <ix:nonFraction unitRef="d" contextRef="i5357132f62b84045b8592c18e2fa2958_I20220630" decimals="INF" name="vtl:ShelfRegistrationTerminationPriorWrittenNotice" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NTcyNQ_b42a3b6b-5114-4103-93bf-55f531b750a1">ten</ix:nonFraction> days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i84614fc2f3a34f45abbfe8caa4cc2f8c_I20220731" decimals="-5" name="vtl:SaleOfStockRemainingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTQ5NzU1ODI1Njg0_e0cee319-e3db-4747-9229-849a77e229c2">8.4</ix:nonFraction>&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="iaab1b036d9dc44e98547c47688f3775e_I20220510" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTQ5NzU1ODI1ODc4_80880fa4-8602-4ab7-97e7-48d71d055217">80.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon <ix:nonFraction unitRef="d" contextRef="i2b29f09bbaba4becbebde67f5b01a643_I20220630" decimals="INF" name="vtl:ShelfRegistrationTerminationPriorWrittenNotice" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NTc0NA_21020bd6-b18a-4d4c-838c-c70c7c608c3f">ten</ix:nonFraction> days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i31e27d1c40d042c8a3fc68107417bf24_I20220505" decimals="-5" name="vtl:SaleOfStockRemainingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTQ5NzU1ODI2Nzg2_66ad3d43-cecb-4863-97df-b4b010244a3e">80.0</ix:nonFraction>&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company has agreed to pay SVB Leerink a commission equal to <ix:nonFraction unitRef="number" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="3" name="vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTQ5NzU1ODI2OTAw_2a1985bb-7b9a-4717-a816-e2acd04dc897">3.0</ix:nonFraction>% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended June 30, 2022, the Company raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i77bff47627ab4656a7df6dfe32e589aa_D20220401-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDU1NQ_146214a2-8c59-4831-96f9-380fe11dc9dd">10.3</ix:nonFraction>&#160;million pursuant to the December 2020 ATM through the sale of <ix:nonFraction unitRef="shares" contextRef="i77bff47627ab4656a7df6dfe32e589aa_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDU3MA_755d1206-f316-4c08-b2f1-2bb12d44a394">1,300,000</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i77bff47627ab4656a7df6dfe32e589aa_D20220401-20220630" decimals="2" name="vtl:SharesIssuedWeightedAverageSharePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDU4MQ_561a61b4-0828-447a-a339-47fb3c9714c7">7.90</ix:nonFraction> per share. The net proceeds from the December 2020 ATM were $<ix:nonFraction unitRef="usd" contextRef="i77bff47627ab4656a7df6dfe32e589aa_D20220401-20220630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDU4OA_fae2400c-09ae-4e07-b3a8-e211722d30d8">10.0</ix:nonFraction>&#160;million after deducting underwriter commissions of $<ix:nonFraction unitRef="usd" contextRef="i77bff47627ab4656a7df6dfe32e589aa_D20220401-20220630" decimals="-5" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDYwMw_11205a78-cf95-4fed-a80d-015a01ffaa2c">0.3</ix:nonFraction>&#160;million.  In the six months ended June 30, 2022, the Company raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i0f1bda4b5eb14655844a6f52d4e19aeb_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDYxNw_6996505d-125c-475a-82da-ec08aa0f8553">40.9</ix:nonFraction>&#160;million pursuant to the December 2020 ATM through the sale of <ix:nonFraction unitRef="shares" contextRef="i0f1bda4b5eb14655844a6f52d4e19aeb_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDYzMg_24b71785-ae60-4e29-a4dd-82c45c9e1fba">4,204,113</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0f1bda4b5eb14655844a6f52d4e19aeb_D20220101-20220630" decimals="2" name="vtl:SharesIssuedWeightedAverageSharePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDY0Mw_5fdf3af4-fc7a-4dca-a9b4-119243ad8eaa">9.72</ix:nonFraction> per share. The net proceeds from the December 2020 ATM were $<ix:nonFraction unitRef="usd" contextRef="i0f1bda4b5eb14655844a6f52d4e19aeb_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDY1MA_d32db5f2-20da-4d63-b0ba-0809abed05ff">39.6</ix:nonFraction>&#160;million after deducting underwriter commissions of $<ix:nonFraction unitRef="usd" contextRef="i0f1bda4b5eb14655844a6f52d4e19aeb_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDY2NQ_44a21f95-82f1-4868-8e32-658b5041f973">1.2</ix:nonFraction>&#160;million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any ATM activity during the three or six months ended June 30, 2021.</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Common Stock</span></div><div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue <ix:nonFraction unitRef="shares" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTg1NA_5062a8c3-a5c6-483c-a41f-ed17dff783dc">130,000,000</ix:nonFraction> shares of common stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTg5NA_1978b503-4ab5-4256-9549-5546ad053006">0.0001</ix:nonFraction> per share. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through June 30, 2022, <ix:nonFraction unitRef="usdPerShare" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNjM1Ng_25f0efe1-6058-4b2d-82cc-d82ca99d534c"><ix:nonFraction unitRef="usdPerShare" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNjM1Ng_9e3aac0a-3c39-4172-ad5b-ad88bc819aaf">no</ix:nonFraction></ix:nonFraction> cash dividends had been declared or paid.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5a114bc6c1fe44899a1018da6c6643a8"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNjUxOA_a6e94bc1-c0e7-4d52-8fe8-b948c3a04651">20</ix:nonFraction> million shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNjUzMQ_e902a588-ac98-4706-bfe4-aa05a379f7a4">0.0001</ix:nonFraction> par value preferred stock, having rights and preferences to be set by the Board of Directors. <ix:nonFraction unitRef="shares" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNjYyMQ_096d6cf3-3f57-408f-b1d3-bd7e2b1ca6bc">No</ix:nonFraction> preferred shares were outstanding as of June 30, 2022.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNjc4MQ_5cfc076f-af8a-448c-b97a-a71f19c04809" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at June 30, 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;2021 Employee Stock Purchase Plan    </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42f6581040da46739944cde97b521f6f_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RhYmxlOmEyNDE4ZWRmNzM3NjRjNzliNzU3MzY3NTAyN2QxZmEyL3RhYmxlcmFuZ2U6YTI0MThlZGY3Mzc2NGM3OWI3NTczNjc1MDI3ZDFmYTJfMi0xLTEtMS0yNjg5MQ_ae17a6db-faeb-4ca9-a39d-33a3027a01a9">162,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc9159032004498fb16925e81f722e24_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RhYmxlOmEyNDE4ZWRmNzM3NjRjNzliNzU3MzY3NTAyN2QxZmEyL3RhYmxlcmFuZ2U6YTI0MThlZGY3Mzc2NGM3OWI3NTczNjc1MDI3ZDFmYTJfMy0xLTEtMS0yNjg5MQ_1685c470-b0fa-4dd3-adc1-358d587e5a7b">3,713,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5fb46bdccd14b0bb258e8b0caf6b17a_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RhYmxlOmEyNDE4ZWRmNzM3NjRjNzliNzU3MzY3NTAyN2QxZmEyL3RhYmxlcmFuZ2U6YTI0MThlZGY3Mzc2NGM3OWI3NTczNjc1MDI3ZDFmYTJfNS0xLTEtMS0yNjg5MQ_5d6f8c14-c864-45da-9d2b-6c7d8fb81ee2">43,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if73baf845ed84292a90be900622c8546_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RhYmxlOmEyNDE4ZWRmNzM3NjRjNzliNzU3MzY3NTAyN2QxZmEyL3RhYmxlcmFuZ2U6YTI0MThlZGY3Mzc2NGM3OWI3NTczNjc1MDI3ZDFmYTJfNi0xLTEtMS0yNjg5MQ_281c0510-aa10-4e80-9e13-4885b2501041">46,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a7be395eedf4ec7b90be1d1cc54a7f4_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RhYmxlOmEyNDE4ZWRmNzM3NjRjNzliNzU3MzY3NTAyN2QxZmEyL3RhYmxlcmFuZ2U6YTI0MThlZGY3Mzc2NGM3OWI3NTczNjc1MDI3ZDFmYTJfNy0xLTEtMS0yNjg5MQ_6bf91979-8e55-4928-88b5-772fe3167141">267,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RhYmxlOmEyNDE4ZWRmNzM3NjRjNzliNzU3MzY3NTAyN2QxZmEyL3RhYmxlcmFuZ2U6YTI0MThlZGY3Mzc2NGM3OWI3NTczNjc1MDI3ZDFmYTJfOC0xLTEtMS0yNjg5MQ_9852e8ad-afd6-4991-b25b-3b6d69c40572">4,232,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_49"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTk5NQ_3ac3509b-b39e-4ed8-8370-9d9809724bb3" continuedAt="i6827ba1c26284e5d96ed0c7a9150b09c" escape="true">Stock-Based Compensation Plans</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i6827ba1c26284e5d96ed0c7a9150b09c" continuedAt="i1d71f67a4495409ca600296c3df688ad"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of <ix:nonFraction unitRef="number" contextRef="i7a36d78c3a1d41aabc3bc530c7149510_D20210425-20210425" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODIxNjU0_f50bf778-6448-4c1a-b36d-3f6c8f7d28d5">15</ix:nonFraction>% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#8217;s common stock. The purchase price of the stock is the lesser of (i) <ix:nonFraction unitRef="number" contextRef="i7a36d78c3a1d41aabc3bc530c7149510_D20210425-20210425" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODIxODY3_ee108844-fc69-438e-9808-2ddcf71cf378">85</ix:nonFraction>% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is <ix:nonFraction unitRef="shares" contextRef="id4759bb9bc5548028846f27721d451dd_I20210425" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODIyMDc3_92991f44-08b6-41b4-98d2-e58ab683a668">200,000</ix:nonFraction> shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">     </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued  <ix:nonFraction unitRef="shares" contextRef="ic41959aa4a854ce99c1ae76d7e539c7b_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfMzI5ODUzNDkwNzQ2OA_396b25c6-5426-43e2-b6c4-7f55010115a0"><ix:nonFraction unitRef="shares" contextRef="ie3846e4b177145349132e464e8ead06e_D20220401-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfMzI5ODUzNDkwNzQ2OA_642d8a3a-8c5e-4f9a-bdf0-c1f756bb664c">24,612</ix:nonFraction></ix:nonFraction> shares under the ESPP for the three and six months ended June 30, 2022 and <ix:nonFraction unitRef="shares" contextRef="i7a60641c12434b9d9746366fd13f9c6a_D20210425-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfMzI5ODUzNDkwNzQ3Ng_54221b62-4642-4b08-b9e6-2f52c1f58e84">37,370</ix:nonFraction> shares life to date.   The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ie3846e4b177145349132e464e8ead06e_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfMzI5ODUzNDkwNzQ4NA_ee072828-5251-44d1-afbb-d908bfa684b7">25,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic41959aa4a854ce99c1ae76d7e539c7b_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfMzI5ODUzNDkwNzQ5Mw_ca91d6ae-375d-418f-b368-409e8ac78b9c">53,000</ix:nonFraction> of expense related to the ESPP during the three and six months ended June 30, 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of <ix:nonFraction unitRef="shares" contextRef="i331baf434b944eed8f84aac672fd3fba_I20190731" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI0MzA5_1d788d4e-462e-4f99-9b7b-bffa293e33b3">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to <ix:nonFraction unitRef="number" contextRef="i4743858c51494178bb0a0087929cf1ca_D20190701-20190731" decimals="INF" name="vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI0NDg2_f313fca1-c32b-4d27-8757-2f55f0d22658">4</ix:nonFraction>% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable increase of <ix:nonFraction unitRef="shares" contextRef="i4743858c51494178bb0a0087929cf1ca_D20190701-20190731" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI0NTc3_725f8c8e-53df-41ce-b489-5e3087a7978c">4,900,000</ix:nonFraction> shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2022 by a total of <ix:nonFraction unitRef="shares" contextRef="i78621ec446654b619edd9f1c7ddbbfdb_D20200101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI0NzM2_5229a578-ff8c-4c9e-8966-2d59961b546e">2,481,195</ix:nonFraction> shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than <ix:nonNumeric contextRef="i241a45995e6d46d2b52b33a2b6d06c7f_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI1MTcy_a7e9e3fd-5506-4be4-a212-6c3627dbc9d1">ten years</ix:nonNumeric>. Incentive stock options granted to employees typically vest over <ix:nonNumeric contextRef="i9f6c4820198d4fcbbd17c0e25cf2af03_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI1MjQy_fad3faf4-d502-4c7e-9fbf-971939cfe43d">four years</ix:nonNumeric>. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI1Mzg0_7a7a7119-e170-4cdf-8081-4d8911387b29">three</span> or <ix:nonNumeric contextRef="i1175a630abb249cba6da4df17900b2f3_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI1Mzkx_b53d43fe-8fb8-4fcc-8105-b7529bffaf2a">four years</ix:nonNumeric>. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1d71f67a4495409ca600296c3df688ad" continuedAt="i1b9fe31f2fce43df92e0daafeb112a04"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTk5Ng_f9427e69-27b8-435b-804a-69880631eb22" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the six months ended June 30, 2022 and 2021, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:52.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic25815c038244077a908eacfe7cdb746_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfMS0xLTEtMS0yNjg5MQ_1fd14178-b2b5-4aab-8c72-539b80fd78fb">2,157,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic25815c038244077a908eacfe7cdb746_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfMS0zLTEtMS0yNjg5MQ_e8886b0d-a2ed-45da-8794-3f3c457018f1">13.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfMi0xLTEtMS0yNjg5MQ_06a57ade-4dfc-43ab-a8f7-4fe152a3da90">1,702,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfMi0zLTEtMS0yNjg5MQ_554d3806-60c2-40cf-8beb-5129530b1d31">9.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfMy0xLTEtMS0yNjg5MQ_e2536700-5958-436c-9611-176ddec6b222">852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfMy0zLTEtMS0yNjg5MQ_d5e5007b-6cbe-4d8e-8029-aac8464cd1c3">5.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNC0xLTEtMS0yNjg5MQ_e475887b-b6bf-4e82-8d42-51723aeda02f">145,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNC0zLTEtMS0yNjg5MQ_54ff622f-455e-42db-864d-84fbecfa8ecd">11.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNS0xLTEtMS0yNjg5MQ_f9afa761-5cbc-4f7a-a843-ac14750f1a2f">3,713,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNS0zLTEtMS0yNjg5MQ_c714d448-2c2b-44d9-8546-ec0035eab9d5">11.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNS01LTEtMS0yNjg5MQ_43c2da5f-fee7-4014-9082-b2635d9bccba">8.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNS03LTEtMS0yNjg5MQ_6a3b9b70-9ba4-437d-ad43-69080572d258">23,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNi0xLTEtMS0yNjg5MQ_32439ec1-add8-42c0-a13d-c271f4366a5c">3,713,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNi0zLTEtMS0yNjg5MQ_45f4a336-7759-4e1c-93b0-02a198fd296d">11.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNi01LTEtMS0yNjg5MQ_48473d87-1977-4c86-8dc0-cc5006f00845">8.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNi03LTEtMS0yNjg5MQ_4429ae96-c487-4cf8-8a10-a83f04133f93">23,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNy0xLTEtMS0yNjg5MQ_8b9c34ae-f015-4de4-ac05-8c4dbf3f0aa6">1,127,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNy0zLTEtMS0yNjg5MQ_1cf6af1f-402a-47e2-a3a5-07f3d17dc162">13.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNy01LTEtMS0yNjg5MQ_2706486f-23c8-4c66-a779-204afa16089d">8.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNy03LTEtMS0yNjg5MQ_57e3f7c1-fd2f-4b86-a38b-c3d49859d073">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:52.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0e20fcc653c40a39665c834b098509d_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfMS0xLTEtMS0yNjg5MQ_c1d1ed41-c805-4c52-b9c0-91e28454c2e9">1,117,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib0e20fcc653c40a39665c834b098509d_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfMS0zLTEtMS0yNjg5MQ_7af22a58-d533-4975-b65a-b6d5879d0b1b">12.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfMi0xLTEtMS0yNjg5MQ_d92918a1-13a9-4be1-891c-ab43b97ed6cf">961,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfMi0zLTEtMS0yNjg5MQ_55890bd4-bd7a-4276-b9c2-938357143d3f">15.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfMy0xLTEtMS0yNjg5MQ_f3ac54fd-3650-46a7-ad6f-544fe6a70123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfMy0zLTEtMS0yNjg5MQ_c9f98428-81d6-4996-8d20-6b4b2a8dfb5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNC0xLTEtMS0yNjg5MQ_5f5706a4-d7fe-4e26-ad9e-72e820b21ded">13,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNC0zLTEtMS0yNjg5MQ_e290fa04-0548-471d-b7b5-83ef2e2c18cd">12.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNS0xLTEtMS0yNjg5MQ_d8621fd6-0dd8-41cc-9bb1-108f112c086d">2,064,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNS0zLTEtMS0yNjg5MQ_f04cce76-2ff2-4e7a-b2a6-8418af1bdd67">14.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNS01LTEtMS0yNjg5MQ_b471dc66-9e06-4218-85fd-168efac32485">9.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNS03LTEtMS0yNjg5MQ_c786deb4-4ebe-4a7e-9d7b-e3f2b12fe579">411,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNi0xLTEtMS0yNjg5MQ_1437df00-5195-411e-a6e2-8ea2e62005f5">2,064,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNi0zLTEtMS0yNjg5MQ_04ad025f-3c34-4902-83ef-211175e5b219">14.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNi01LTEtMS0yNjg5MQ_2494949e-9223-487f-ab2c-667d68081ec4">9.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNi03LTEtMS0yNjg5MQ_b1157d22-9462-4ebc-b799-396e1da863a2">411,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNy0xLTEtMS0yNjg5MQ_80505e88-b139-4151-bd19-6ecc0fa0e902">462,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNy0zLTEtMS0yNjg5MQ_86453c9b-4e20-45d2-ab5c-62f3bd6e3fc8">13.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNy01LTEtMS0yNjg5MQ_2704e05c-dd30-43bf-ab40-bc3661457359">8.65</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNy03LTEtMS0yNjg5MQ_a1bd3c3f-4c41-45f6-9cb5-3681b25027a6">227,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be <ix:nonFraction unitRef="number" contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODM0MDE5_4f3f2eeb-a824-4d69-ba31-7936fffbe9e4">zero</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1b9fe31f2fce43df92e0daafeb112a04"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the six months ended June 30, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ie44b429d3b05430ea58a4793c8c7b0ed_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfMzI5ODUzNDkwNzQ1Mw_42130e7d-0a65-4072-9c4b-b08996660562">7.25</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i5d31dbd295f24c42bfabd2db4c4c9f38_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfMzI5ODUzNDkwNzQ2MA_079e339c-dc71-441c-8f9d-3f1f18d07e8c">11.36</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTk5Nw_43f27d30-a0e6-4637-8a8d-dcbd9cf71d3e" continuedAt="ibab64933aa2c4cf7839e16ca6921fcfe" escape="true">The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</ix:nonNumeric></span><ix:continuation id="ibab64933aa2c4cf7839e16ca6921fcfe"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six  Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie44b429d3b05430ea58a4793c8c7b0ed_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfMi0xLTEtMS0yNjg5MQ_285acef3-bc35-4fe2-ae26-437a2889943a">1.95</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d31dbd295f24c42bfabd2db4c4c9f38_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfMi0yLTEtMS0yNjg5MQ_82948537-291f-4eb5-a080-e6a17d46e680">0.88</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie44b429d3b05430ea58a4793c8c7b0ed_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfMy0xLTEtMS0yNjg5MQ_db63fc10-afb0-4187-af49-8472bdb6c1a6">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d31dbd295f24c42bfabd2db4c4c9f38_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfMy0yLTEtMS0yNjg5MQ_f939c8f8-b715-412c-a11b-cf41e02b0ec5">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie44b429d3b05430ea58a4793c8c7b0ed_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfNC0xLTEtMS0yNjg5MQ_ad750ffa-1015-4e97-9488-1b9bbc517baf">97.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d31dbd295f24c42bfabd2db4c4c9f38_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfNC0yLTEtMS0yNjg5MQ_bfd009fb-6fac-4107-8bea-08a543f0666c">92.3</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie44b429d3b05430ea58a4793c8c7b0ed_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfNS0xLTEtMS0yNjg5MQ_964de7d3-37ad-4af7-999b-307010d0fc8a">6.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5d31dbd295f24c42bfabd2db4c4c9f38_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfNS0yLTEtMS0yNjg5MQ_84b9aa46-bb36-4ee9-8dc8-fec3e3c93541">5.94</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTk5OA_085e6cc2-b383-428c-bcda-6093e7755868" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>&#160;Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc512c7aab944fc485311bf9c02ff970_D20220401-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMi01LTEtMS0yNjg5MQ_d79e5b34-251c-48a7-8d3f-b271ae1f80f8">765,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a4ddd497fd542b9b3fd027648d47f75_D20210401-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMi03LTEtMS0yNjg5MQ_67f444f7-c515-418a-8841-be641efbb4f4">492,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e71423082664f22b47833b74742032b_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMi05LTEtMS0yNjg5MQ_ed4a80f2-eade-4891-bcb7-2b34b55dcc67">1,561,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2bea17fde984023989bd83f8d7409d3_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMi0xMS0xLTEtMjY4OTE_d13d1d29-42b1-431a-b9ab-43456afc6806">823,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i647b4b4c351941fe967436ca5d55ac90_D20220401-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMy01LTEtMS0yNjg5MQ_f94233a2-96be-49be-9bdf-f600620a55dd">1,297,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d7bda77d8e54df095211d496fde1e19_D20210401-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMy03LTEtMS0yNjg5MQ_5ddda92b-2577-4460-ae5f-69791b2d5fcc">1,015,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780a02233b614aad8fc86df96172eeb7_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMy05LTEtMS0yNjg5MQ_21577fa0-fc30-4fb6-be73-38088c4725d0">2,570,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6be40b2c9d674c08af4179c7ed347d3e_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMy0xMS0xLTEtMjY4OTE_89836af6-06af-4a96-b363-47d9ecbe6031">2,263,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbabe7452d5d43f6b73995f3e391e6b8_D20220401-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfNC01LTEtMS0yNjg5MQ_51baa32b-021e-4188-8853-e4238ef1d79e">2,062,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a9bf6e1992474bbccdbdce509a8df2_D20210401-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfNC03LTEtMS0yNjg5MQ_969b5866-4b04-4b86-b94d-1c3d54c38070">1,507,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd13b02f4a346ca9385ff8f54ab0d4c_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfNC05LTEtMS0yNjg5MQ_fed53e81-fdca-44c6-9418-c825af4620b2">4,131,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23ce68a8dc964e0992d506ff2d9b8074_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfNC0xMS0xLTEtMjY4OTE_6a8eb5df-33b0-40ef-9e63-bac83e4efb41">3,086,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNDgwNA_bc39d115-ab44-4a7c-ae2b-11b7a86231d8">19.4</ix:nonFraction> million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNDkyNw_cfc0cbb8-ac86-4c34-9046-df7179c0f8f0">3.06</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital Therapies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital&#8217;s 2012 Stock Option Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain <ix:nonFraction unitRef="shares" contextRef="ib42e39df400b422a95c9c1d1cd93fae5_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODM2NDI4_14f072f0-77ce-49d5-b357-68624b89267b">43,311</ix:nonFraction> shares available for grant under the 2014 Plan as of June 30, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Vital&#8217;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan <ix:nonFraction unitRef="shares" contextRef="i12cdbd33c3434c698ad8b49490ad01ef_I20170930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODM2NjUy_3e0fc136-1a65-4c50-bd4d-b6096518b363">46,250</ix:nonFraction> shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i679e236a84ee4593a0aed89cb7edadf1_D20210101-20210331" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODM2OTQy_9ffcc378-de89-49a6-9b12-7cde7987d08c"><ix:nonFraction unitRef="usd" contextRef="ic40354f16dc842a1a88ac97efa9f06d6_D20220101-20220331" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODM2OTQy_e1f54d93-7966-49df-8afc-8d45d4c688a7">No</ix:nonFraction></ix:nonFraction> expense was recorded for the plans assumed from Vital during the three and six months ended June 30, 2022 and 2021, respectively.</span></div></ix:continuation><div style="margin-top:17.6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_55"></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81NS9mcmFnOmFmODAzNzI1YWZiZDQ4ZWFhODVjZjNjMTBlY2M0OWQyL3RleHRyZWdpb246YWY4MDM3MjVhZmJkNDhlYWE4NWNmM2MxMGVjYzQ5ZDJfMTEyMg_0362fff9-8ec8-4a03-a6fa-2b88d99428c5" continuedAt="ida90be0bc5cc4df9bbdd51e336d1fc80" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="ida90be0bc5cc4df9bbdd51e336d1fc80"><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the current Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020, which was subsequently extended to April 15, 2021. On April 15, 2021, the Company and Dr. Nash entered into an addendum (the &#8220;Addendum&#8221;) to extend the term of the Executive Chairman Agreement to April 15, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Addendum, the Company made a one-time award to Dr. Nash of an option to purchase <ix:nonFraction unitRef="shares" contextRef="ibb4ae9a6beec4eae8fa5eb08ddd32a03_D20210415-20210415" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81NS9mcmFnOmFmODAzNzI1YWZiZDQ4ZWFhODVjZjNjMTBlY2M0OWQyL3RleHRyZWdpb246YWY4MDM3MjVhZmJkNDhlYWE4NWNmM2MxMGVjYzQ5ZDJfMzI5ODUzNDg5MDMyNQ_6b8a895f-6632-4779-80da-88e391f7bc8f">90,000</ix:nonFraction> shares of Company common stock, which vests monthly commencing on May 15, 2021, and to increase Dr. Nash&#8217;s monthly base salary to $<ix:nonFraction unitRef="usd" contextRef="if42ab5585116465fbf465ea6f59165fe_D20210515-20211231" decimals="0" name="vtl:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81NS9mcmFnOmFmODAzNzI1YWZiZDQ4ZWFhODVjZjNjMTBlY2M0OWQyL3RleHRyZWdpb246YWY4MDM3MjVhZmJkNDhlYWE4NWNmM2MxMGVjYzQ5ZDJfMzI5ODUzNDg5MDM1MA_73689642-084b-409a-af8b-0d64351cdcf5">27,960</ix:nonFraction> from $<ix:nonFraction unitRef="usd" contextRef="iaabe57dcd0314a53bb5425c2259aeed2_D20210101-20210514" decimals="0" name="vtl:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81NS9mcmFnOmFmODAzNzI1YWZiZDQ4ZWFhODVjZjNjMTBlY2M0OWQyL3RleHRyZWdpb246YWY4MDM3MjVhZmJkNDhlYWE4NWNmM2MxMGVjYzQ5ZDJfMzI5ODUzNDg5MDM1OQ_4fb8f9d2-931c-429b-8bee-347aec89e2ac">25,417</ix:nonFraction>. Effective March 15, 2022, the Company extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $<ix:nonFraction unitRef="usd" contextRef="i9a5888f9828e4ffcb2ca6bbe78a31e05_D20220315-20221231" decimals="0" name="vtl:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81NS9mcmFnOmFmODAzNzI1YWZiZDQ4ZWFhODVjZjNjMTBlY2M0OWQyL3RleHRyZWdpb246YWY4MDM3MjVhZmJkNDhlYWE4NWNmM2MxMGVjYzQ5ZDJfMzI5ODUzNDg5MDMzMw_08387a5f-0727-487b-abff-cb9e811ccaa4">29,358</ix:nonFraction> per month (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). In connection with this extension, the Company made a one-time award to Dr. Nash of an option to purchase <ix:nonFraction unitRef="shares" contextRef="ie57caaa75a5a464083b4f824217dc1e7_D20220315-20220315" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81NS9mcmFnOmFmODAzNzI1YWZiZDQ4ZWFhODVjZjNjMTBlY2M0OWQyL3RleHRyZWdpb246YWY4MDM3MjVhZmJkNDhlYWE4NWNmM2MxMGVjYzQ5ZDJfMzI5ODUzNDg5MDM0Mg_12bcee7f-4a39-4e82-ba08-3dbe7923eaed">75,000</ix:nonFraction> shares of the Company&#8217;s common stock, which vests monthly commencing on April 10, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other terms of the Executive Chairman Agreement remain the same.</span></div></ix:continuation><div id="i132a36b84ae14363889a7cabe57a8d6f_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81OC9mcmFnOmI0ZmMwYjVhNzdkZjQyYmVhNTk4MGZiMDFjZThlMzUzL3RleHRyZWdpb246YjRmYzBiNWE3N2RmNDJiZWE1OTgwZmIwMWNlOGUzNTNfODc2_02060a9e-d65b-4c6f-8fd1-aa45ea06b48f" continuedAt="i0815a85465644a0788d763cb6db7881a" escape="true">Subsequent Events </ix:nonNumeric></span></div><ix:continuation id="i0815a85465644a0788d763cb6db7881a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Board of Directors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2022, the Company announced the appointment of Monika Maria T&#246;rns&#233;n as a member of the Board of Directors of the Company, effective as of July 5, 2022. As a Class III director, Ms. T&#246;rns&#233;n&#8217;s term lasts until the Company&#8217;s 2023 annual meeting of stockholders.  Ms. T&#246;rns&#233;n is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Ms. T&#246;rns&#233;n and any other persons pursuant to which she was selected as a director.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with her appointment as director, Ms. T&#246;rns&#233;n was granted a long-term equity incentive grant in the form of an option to purchase a total of <ix:nonFraction unitRef="shares" contextRef="ifdfa66f7711347ab96273868fd75f343_D20220706-20220706" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81OC9mcmFnOmI0ZmMwYjVhNzdkZjQyYmVhNTk4MGZiMDFjZThlMzUzL3RleHRyZWdpb246YjRmYzBiNWE3N2RmNDJiZWE1OTgwZmIwMWNlOGUzNTNfMzI5ODUzNDg5OTM5MQ_2c81e3d1-1ae7-45a8-92a1-1204174c96fd">30,000</ix:nonFraction> shares of the Company&#8217;s common stock, with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifdfa66f7711347ab96273868fd75f343_D20220706-20220706" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81OC9mcmFnOmI0ZmMwYjVhNzdkZjQyYmVhNTk4MGZiMDFjZThlMzUzL3RleHRyZWdpb246YjRmYzBiNWE3N2RmNDJiZWE1OTgwZmIwMWNlOGUzNTNfMzI5ODUzNDg5OTM5OQ_2ead954c-fbf5-49f2-be54-c62b85bb5ad5">4.30</ix:nonFraction> per share, which is equal to the closing price of the Company's common stock on The Nasdaq Stock Market on the date of grant, July 8, 2022. The option to purchase <ix:nonFraction unitRef="shares" contextRef="i8de1a675bd3646b6b25adee3e85cab4c_D20220706-20220706" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81OC9mcmFnOmI0ZmMwYjVhNzdkZjQyYmVhNTk4MGZiMDFjZThlMzUzL3RleHRyZWdpb246YjRmYzBiNWE3N2RmNDJiZWE1OTgwZmIwMWNlOGUzNTNfMzI5ODUzNDg5OTQwNg_e4c9180d-0f4f-4c76-a11c-66440db5843d">10,000</ix:nonFraction> shares vests in monthly increments over a period of <ix:nonNumeric contextRef="i8de1a675bd3646b6b25adee3e85cab4c_D20220706-20220706" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81OC9mcmFnOmI0ZmMwYjVhNzdkZjQyYmVhNTk4MGZiMDFjZThlMzUzL3RleHRyZWdpb246YjRmYzBiNWE3N2RmNDJiZWE1OTgwZmIwMWNlOGUzNTNfMjE5OTAyMzI3MTY2NQ_4daf3a2a-5844-480c-9047-486314e2de6f">one year</ix:nonNumeric> from the grant date, and the option to purchase <ix:nonFraction unitRef="shares" contextRef="ib73002cd7def4d70a33e0dbcb20c34ff_D20220706-20220706" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81OC9mcmFnOmI0ZmMwYjVhNzdkZjQyYmVhNTk4MGZiMDFjZThlMzUzL3RleHRyZWdpb246YjRmYzBiNWE3N2RmNDJiZWE1OTgwZmIwMWNlOGUzNTNfMzI5ODUzNDg5OTQxNA_8393dafc-e4bf-4c7a-861c-401b80b64ade">20,000</ix:nonFraction> shares vests in monthly increments over a period of <ix:nonNumeric contextRef="ib73002cd7def4d70a33e0dbcb20c34ff_D20220706-20220706" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81OC9mcmFnOmI0ZmMwYjVhNzdkZjQyYmVhNTk4MGZiMDFjZThlMzUzL3RleHRyZWdpb246YjRmYzBiNWE3N2RmNDJiZWE1OTgwZmIwMWNlOGUzNTNfMjE5OTAyMzI3MTY4Mw_bdaa3d93-4ad5-4677-9b4f-56e5528fa313">three years</ix:nonNumeric> from the grant date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Ms. T&#246;rns&#233;n and the Company entered into the Company&#8217;s standard form of indemnification agreement for directors and executive officers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently, the Company also announced that current Class III director, Jan Van den Bossche, resigned from the Board. The Board accepted Mr. Van den Bossche&#8217;s resignation effective July 5, 2022. Mr. Van den Bossche&#8217;s decision to resign did not result from any disagreement with the Company on any matter relating to Company operations, policies or practices.</span></div></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited interim condensed consolidated financial statements and notes thereto included in Item&#160;1 &#8220;Financial Statements&#8221; in this Quarterly Report on Form 10-Q (the "Quarterly Report") and the audited Consolidated Financial Statements in our Annual Report on Form 10-K. filed with the Securities and Exchange Commission ("SEC"), on February 24, 2022. As used in this report, unless the context suggests otherwise, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221; or &#8220;Immunic&#8221; refer to Immunic, Inc. and its subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to historical information, this Quarterly Report includes forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to certain risks and uncertainties, many of which are beyond our control. Such statements include, but are not limited to, statements preceded by, followed by or that otherwise include the words, &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; or similar expressions and the negatives of those terms.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements discuss matters that are not historical facts. Our forward-looking statements involve assumptions that, if they ever materialize or prove correct, could cause our results to differ materially from those expressed or implied by such forward-looking statements. In this Quarterly Report, for example, we make forward-looking statements, among others, regarding potential strategic options; financial estimates and projections; and the sufficiency of our capital resources to fund our operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The inclusion of any forward-looking statements in this Quarterly Report should not be regarded as a representation that any of our plans will be achieved. Our actual results may differ from those anticipated in our forward-looking statements as a result of various factors, including those noted below under the caption &#8220;Part II, Item 1A-Risk Factors,&#8221; and the differences may be material. These risk factors include, but are not limited to statements relating to our three development programs and the targeted diseases; the potential for vidofludimus calcium, IMU-935 and IMU-856 to safely and effectively target diseases; the nature, strategy and focus of the Company; expectations regarding our capitalization and financial resources; the development and commercial potential of any product candidates of the Company; and our ability to retain certain personnel important to our ongoing operations and to maintain effective internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our forward-looking statements reflect the good faith judgment of our management, these statements are based only on facts and factors currently known by us. As a result, stockholders are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update such statements to reflect events or circumstances after the date hereof, except as required by law.</span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic, Inc. ("Immunic," &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. We are headquartered in New York City with our main operations in Gr&#228;felfing near Munich, Germany. We currently have approximately 60 employees.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently pursuing three development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;); the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (&#8220;ROR&#947;t&#8221;), an immune cell-specific isoform of ROR&#947;; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. These product candidates are being developed to address diseases such as multiple sclerosis ("MS"), psoriasis and gastrointestinal diseases. In addition to these large markets, these products are also being developed to address certain rare diseases with high unmet medical needs, such as primary sclerosing cholangitis (&#8220;PSC&#8221;), as well as metastatic castration-resistant prostate cancer (&#8220;mCRPC&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the potential indications, clinical targets and clinical development status of our three product candidates:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><img src="vtl-20220630_g1.jpg" alt="vtl-20220630_g1.jpg" style="height:208px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our most advanced drug candidate, vidofludimus calcium (IMU-838), targets DHODH, a key enzyme in the intracellular metabolism of immune cells in the body. In the third quarter of 2020, we reported positive results from our Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (&#8220;RRMS&#8221;), achieving both primary and key secondary endpoints with high statistical significance. The first patient in our Phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis (&#8220;RMS&#8221;), comprising twin studies evaluating efficacy, safety, and tolerability of vidofludimus </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">calcium versus placebo, was enrolled in November 2021. The first patient in our supportive Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (&#8220;PMS&#8221;) was enrolled in September 2021. We have carefully analyzed the impact that current events in Ukraine and Russia may have on our ongoing clinical programs. Based on this assessment, our current goal is to report data from the interim analysis of the CALLIPER trial in the second half of 2023 and to read-out top-line data at the end of 2024. Moreover, the read-out of the first of the ENSURE trials is currently targeted for end of 2025. Although we currently believe that each of these goals is achievable, they are each dependent on numerous factors which are not under our direct control and can be difficult to predict. We plan to periodically review this assessment and provide updates of material changes as appropriate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2021, we reported positive top-line data from an investigator-sponsored Phase 2 proof-of-concept clinical trial of vidofludimus calcium in primary sclerosing cholangitis which was conducted in collaboration with the Mayo Clinic. Also, in the first quarter of 2021, we announced that vidofludimus calcium showed evidence of clinical activity in our Phase 2 CALVID-1 trial in hospitalized patients with moderate coronavirus disease 2019 ("COVID-19"). Top-line results of our Phase 2 CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe ulcerative colitis (&#8220;UC&#8221;) were reported in June 2022, showing an interaction with chronic concurrent steroid use and, therefore, missing the trial&#8217;s primary endpoint. We announced that our development programs in the inflammatory bowel disease (&#8220;IBD&#8221;) indications will not be continued without a partner. Additional antiviral-directed development activities remain ongoing through preclinical research examining the potential to treat a broad set of viral indications with vidofludimus calcium and other DHODH inhibitors and further antiviral molecules. Immunic is exploring several options to support further development of our antiviral portfolio, including a potential spin-off into a new or existing company and potential licensing transactions. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If approved, we believe that vidofludimus calcium has the potential to be a best-in-class DHODH inhibitor in RMS. Importantly, vidofludimus calcium has an attractive pharmacokinetic, safety and tolerability profile and has already been exposed to more than 1,100 human subjects and patients in either of the drug&#8217;s formulations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our second drug candidate, IMU-935, is a highly potent and selective inverse agonist of a transcription factor called ROR&#947;t. We believe that the nuclear receptor ROR&#947;t is a main driver for the differentiation of T-helper 17 (&#8220;Th17&#8221;) cells and the release of cytokines involved in various inflammatory and autoimmune diseases. We believe this target is an attractive alternative to approved antibodies as acting on interleukin-23 (&#8220;IL-23&#8221;), the IL-17 receptor and IL-17. We have observed strong cytokine inhibition targeting both Th1 and Th17 responses in preclinical testing, as well as indications of activity in animal models for psoriasis, graft versus host disease, MS and IBD. Preclinical experiments indicated that, while leading to a potent inhibition of Th17 differentiation and inhibition of cytokine secretion, IMU-935 did not affect thymocyte maturation, one of the important physiological functions of ROR&#947;t that should be maintained. Based on these preclinical data and the selectivity of the effect maintaining important physiological functions while providing the desired anti-Th17 effect, we believe that IMU-935 has potential to be a best-in-class therapy for various autoimmune diseases. The final portion of a Phase 1 clinical trial exploring safety, pharmacodynamics and pharmacokinetics of IMU-935 in psoriasis patients is currently ongoing and we expect initial results to be available in the fourth quarter of 2022. An exploratory Phase 1 trial investigating the drug-drug interaction (&#8220;DDI&#8221;) potential of IMU-935 was completed in the second quarter of 2022. Additionally, IMU-935 has been shown in preclinical models to target an established mechanism of treatment resistance to androgen receptor therapy, making it a potential treatment option for patients with resistant CRPC. A Phase 1 clinical trial exploring safety and tolerability of increasing doses of IMU-935 to establish the maximum tolerated dose and the recommended Phase 2 dose is currently ongoing in patients with mCRPC.   </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our third program, IMU-856, which we believe to be novel, is an orally available small molecule modulator that targets a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. We have not yet disclosed the molecular target for IMU-856 to the public. Based on preclinical data, we believe this compound may represent a new treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function and bowel wall architecture in patients suffering from gastrointestinal diseases such as celiac disease, IBD, irritable bowel syndrome with diarrhea and other intestinal barrier function associated diseases. We believe that, because IMU-856 has been shown in preclinical investigations to avoid suppression of immune cells, it may therefore have the potential to maintain immune surveillance for patients during therapy, an important advantage versus chronic treatment with potentially immunosuppressive medications. A Phase 1 clinical trial exploring safety, pharmacodynamics and pharmacokinetics of IMU-856 in healthy human subjects and celiac disease patients is currently ongoing. Unblinded safety data from the single and multiple ascending dose parts in healthy human subjects are expected to be available in the third quarter of 2022.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to lead most of our research and development activities from our Gr&#228;felfing, Germany location, where dedicated scientific, regulatory, clinical and medical teams conduct their activities. Due to these teams' key relationships with local and international service providers, we anticipate that this will result in timely, cost-effective execution of our development programs. In addition, we are using our subsidiary in Melbourne, Australia to expedite the early clinical trials for IMU-935 and IMU-856. We also conduct preclinical work in Halle/Saale, Germany through a collaboration with the Fraunhofer Institute.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of our clinical trials to meet their endpoints, failure to obtain regulatory approval and failure to obtain needed additional funding on acceptable terms, if at all, to complete the development and commercialization of our three development programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since our inception in 2016. We have an accumulated deficit of approximately $239.6 million as of June 30, 2022 and  $196.9 million as of December 31, 2021. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the preclinical and clinical development of our product candidates and add personnel necessary to advance our clinical pipeline of product candidates.  We expect that our operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through June 30, 2022, we have raised net cash of approximately $299.1 million  from private and public offerings of preferred and common stock. As of June 30, 2022, we had cash and cash equivalents of approximately $88.1 million. With these funds, we expect to be able to fund our operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:102%">Phase 1 Clinical Trial of IMU-935 in Healthy Human Subjects and Moderate-to-Severe Psoriasis Patients</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, we provided an update on our IMU-935 program, including new preclinical and clinical data. The main result from preclinical investigations was that IMU-935 inhibits cytokine production (thought to be a pre-condition for its use in immunological and autoimmune diseases) while maintaining the known and required physiological functions of maturing T lymphocytes. In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mouse cell differentiation and maturation assays, IMU-935 was observed to selectively inhibit ROR&#947;t-dependent gene expression during Th17 differentiation without affecting either ROR&#947;t-dependent gene regulation relevant to thymocyte development, or the viability of these cells. In third-party research, impairment of thymocyte development has been shown to be associated with serious safety issues, including, among others, T cell malfunction and potential lymphoma formation. We believe that IMU-935's observed selectivity may enable it to inhibit both the generation of Th17 cells and the production of IL-17 cytokines that are responsible for the development of autoimmune diseases, without impairing thymocyte development, which is associated with the potential risk of lymphoma seen with other, third-party ROR&#947;t programs.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, we provided an update on the preclinical and clinical development of IMU-935, announcing that:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unblinded data from the single ascending dose part of the ongoing Phase 1 clinical trial of a new powder-in-capsule formulation of IMU-935, in which healthy human subjects were treated with 100 mg, 200 mg, 300 mg and 400 mg of this new formulation or placebo, found these single ascending daily doses of IMU-935 to be safe and well-tolerated, and no maximum tolerated dose was reached. No serious adverse events occurred. A dose-proportional pharmacokinetic profile was observed across the investigated dose range.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unblinded data from the multiple ascending dose part of the ongoing Phase 1 clinical trial, in which healthy human subjects were dosed for 14 days with 150 mg either once or twice daily doses of IMU-935 or placebo, found these multiple ascending doses of IMU-935 to be safe and well-tolerated, and no maximum tolerated dose was reached. Treatment emergent adverse events were generally mild in severity, with moderate treatment emergent adverse events reported in one of eleven IMU-935 treated subjects, compared with one of four subjects on placebo. No serious adverse events were reported. No dose-dependent changes in laboratory values (including no effects on liver enzymes or in hematological parameters), vital signs or in electrocardiographic evaluations were found. Pharmacokinetic analysis showed that stable steady-state plasma concentrations were achieved within the first week of dosing with an accumulation factor for IMU-935 allowing predictable trough levels during daily dosing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Based on the favorable safety and tolerability data observed in healthy human subjects, our Phase 1 clinical trial of IMU-935 was expanded in October 2021 to include a third portion, part C, in which moderate-to-severe psoriasis patients are randomized to 28-day treatment of IMU-935 or placebo. Planned assessments include safety, tolerability, pharmacokinetic and pharmacodynamic markers, as well as skin evaluations. Part C is ongoing in Australia, New Zealand and Bulgaria.  Initial results are expected to be available in the fourth quarter of 2022.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In previous preclinical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> data, it was shown that IMU-935 selectively inhibits Th17 differentiation and IL-17 production, whereas ROR&#947;t was unaffected by IMU-935 during thymocyte maturation and, therefore, does not harm normal thymocyte maturation. Data from acute and chronic treatment of mice corroborated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that IMU-935 is the first molecule observed to impact neither thymus size, thymocyte numbers, nor the maturation status of thymocytes, in contrast to two other known inhibitors of ROR&#947;t.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMU-935 Composition-of-Matter Patents Granted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, we received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for patent application 16/644581, entitled, &#8220;IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation&#8221;. We also received notice of allowance of patent application EP18762111.5 in Europe, and notice of grant of patent application 2018330633 in Australia. All three patents cover composition-of-matter of IMU-935 and related formulations, and are expected to provide protection into at least 2038, without accounting for potential Patent Term Extension ("PTE") in the United States or Supplementary Protection Certificates ("SPC") in Europe, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Exploratory Phase 1 DDI Study of IMU-935</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">An exploratory Phase 1 study was completed in 15 evaluable healthy human subjects to assess the DDI potential of IMU-935. No relevant signals for DDI potential were observed and treatment was safe and well-tolerated.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Update on Phase 1 Clinical Trial of IMU-935 in mCRPC &#8211; Initial Safety Data Available</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The first two dose cohorts of the phase 1 clinical trial of IMU-935 in mCRPC have been fully recruited, with 6 patients enrolled in the 300 mg cohort and 6 patients in the 600 mg cohort. Of these patients, all have completed the 28-day dose limiting toxicity (&#8220;DLT&#8221;) observation period. The third, 900 mg cohort will be started after analysis of the cohort 2 data of the DLT observation period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Initial safety data available so far show a promising safety profile of IMU-935 in mCRPC, with only benign adverse events and no dose limiting toxicities. We plan to provide a more comprehensive update on safety and also on potential signs of anti-tumor activity of IMU-935 in this trial as soon as data from the planned dose expansion part are available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The phase 1 clinical trial of IMU-935 in mCRPC is structured in two portions: a dose-escalation part and an optional expansion part. A total of between 18 and 24 patients are planned to be enrolled in the dose-escalation part at three dose levels, 300 mg, 600 mg and 900 mg of daily IMU-935, to be given for three cycles of 28 days each. At each of the three dose levels a safety analysis after 28 days and an interim analysis after three months of treatment will be performed. The main analysis for this trial is planned after the last patient has received six months of study treatment. The primary objective is to evaluate the safety and tolerability of increasing doses of IMU-935 to establish the maximum tolerated dose and the recommended phase 2 dose. The trial will also evaluate the anti-tumor activity of IMU-935 by means of prostate-specific antigen (&#8220;PSA&#8221;) levels, circulating tumor cell (&#8220;CTC&#8221;) numbers, and radiographic response assessments of tumor progression. Patients who receive a benefit from IMU-935 will have the option to continue treatment until progression. Following completion of all dose-escalation cohorts, an expansion cohort at one or two therapeutically active dose levels with up to 18 additional patients may be performed to support selection of a recommended phase 2 dose. The trial&#8217;s Principal Investigator is Johann Sebastian de Bono, M.D., Ph.D., Regius Professor of Cancer Research and Professor in Experimental Cancer Medicine, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, London.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Start of Patient Cohorts in Phase 1 Clinical Trial of IMU-856 in Celiac Disease</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2022, we announced the start of the patient cohorts in our ongoing Phase 1 clinical trial of IMU-856 in patients with celiac disease. Part C is structured as a 28-day, double-blind, placebo-controlled trial designed to assess the safety and tolerability of IMU-856 in patients with celiac disease during periods of gluten-free diet and gluten challenge. Approximately 42 patients are planned to be enrolled in two consecutive cohorts with IMU-856 given once-daily over 28 days. Secondary objectives include pharmacokinetics and disease markers, including those evaluating gastrointestinal architecture and inflammation. Approximately 10 sites in Australia and New Zealand are expected to participate in Part C.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Publication of Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in RRMS in Peer Reviewed Journal</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2022, we announced that data from our Phase 2 EMPhASIS trial of vidofludimus calcium in patients with RRMS has been published in the peer reviewed journal, Annals of Clinical and Translational Neurology. The paper, authored by coordinating investigator, Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, is entitled, &#8220;Safety and efficacy of vidofludimus calcium, a selective dihydroorotate dehydrogenase inhibitor, in relapsing-remitting multiple sclerosis (EMPhASIS): a double-blind, randomized, placebo-controlled Phase 2 trial.&#8221;</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Update on the Use of Steroids in the Phase 2 EMPhASIS Trial in RRMS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on the observed interaction between vidofludimus calcium and chronic steroid use in the CALDOSE-1 trial in ulcerative colitis patients, we performed a post-hoc analysis of our Phase 2 EMPhASIS data in RRMS patients to explore the potential influence of steroids on these study results. As anticipated, steroid use was rare and among those RRMS patients who received any steroids, the majority received only short steroid courses following relapse events or acute neurological events. Only four patients received any steroids for reasons other than relapse (COVID-19 infection, eczema, acute bronchitis, and contact urticaria, one patient each). Most patients only had one single short course of steroids, and only nine patients had two or more steroid courses. The average duration of steroid treatment in this RRMS trial was 4.4 days with a maximum duration of 10 days. This indicates to us that steroids are rarely used in MS patients and mostly for a very short duration. In conclusion, comparing patients who received at least one dose of corticosteroids with those who did not, we do not see any difference in clinical parameters or any evidence that the rare, short-term use of steroids in RRMS patients has any influence on the effectiveness of vidofludimus calcium in this patient population.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2022, we reported top-line data from our Phase 2 CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe ulcerative colitis (&#8220;UC&#8221;). The trial did not achieve the primary endpoint of clinical remission for the pooled 30 and 45 mg/day active dose groups of vidofludimus calcium versus placebo at week 10. In addition, no meaningful differences were observed between the three active dose groups for the overall intent-to-treat patient population (10 mg/day: 14.9%, 30 mg/day: 10.6%, 45 mg/day: 13.6%, placebo: 12.5%) or for the trial&#8217;s other secondary endpoints, including symptomatic remission, or endoscopic healing.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in this trial was observed to be safe and well-tolerated. No new safety signals were observed. As compared to placebo, there were no increased rates of infections and infestations, no elevated rates of liver events or liver enzyme elevations, and no elevated rates for changes in hematology-related laboratory variables. The most common adverse events in this trial were anemia (15/263 patients, 5.7%), headache (9/263 patients, 3.4%) and COVID-19 (7/263 patients, 2.7%). Most adverse events were generally mild in severity.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common for the design of clinical trials in UC, the use of oral systemic corticosteroids (&#8804;20 mg/day prednisolone equivalent) was allowed in CALDOSE-1 in patients who had been treated with corticosteroids for at least four weeks before randomization. Doses of corticosteroids were required to be kept constant throughout the induction phase (weaning was not allowed in this phase of the trial), and the distribution of patients using corticosteroids was equal throughout all treatment groups. Surprisingly, CALDOSE-1 data suggest a previously unknown treatment interference between the efficacy of vidofludimus calcium and the concurrent use of corticosteroids in the UC patient population. More specifically, the non-steroid patient population showed an 11.4% advantage in clinical remission for vidofludimus calcium over placebo (pooled vidofludimus calcium treatment groups at week 10: 14.7%, placebo: 3.3%). Such a difference in clinical remission between active treatment and placebo would traditionally be considered as confirming therapeutic activity. In contrast, patients </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">concomitantly taking vidofludimus calcium and corticosteroids during induction treatment had a lower rate of clinical remission at week 10 (11.5%) than placebo patients (20.6%) and also lower than the group of vidofludimus calcium monotherapy without concurrent use of steroids (14.7%). This treatment interference between vidofludimus calcium and corticosteroids was not expected by currently available preclinical or clinical data.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on these results, we announced that our development programs in the IBD indications will not be continued without a partner.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investigator-Sponsored Phase 2 IONIC Trial in Moderate-to-Severe COVID-19 is Closing Down</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 23, 2022, sponsor and lead site, University Hospitals Coventry and Warwickshire NHS Trust, London, United Kingdom, informed us that the investigator-sponsored Phase 2 IONIC trial for the treatment of patients with moderate-to-severe COVID-19 is being closed down. Recruitment for the trial ended on May 20, 2022 and the last patient follow-up is due on September 21, 2022.  The trial was a prospective, randomized, parallel-group, open-label Phase 2b trial, designed to evaluate efficacy and safety of vidofludimus calcium in combination with the neuraminidase inhibitor, Oseltamivir (Tamiflu&#9415;), in approximately 120 adult patients with moderate-to-severe COVID-19.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in Board of Directors</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 6, 2022, we announced the appointment of Monika Maria T&#246;rns&#233;n as a member of our Board of Directors, effective as of July 5, 2022. As a Class III director, Ms. T&#246;rns&#233;n&#8217;s term lasts until the Company&#8217;s 2023 annual meeting of stockholders. Concurrently, we also announced that current Class III director, Jan Van den Bossche, resigned from the Board. The Board accepted Mr. Van den Bossche&#8217;s resignation effective July 5, 2022. Mr. Van den Bossche&#8217;s decision to resign did not result from any disagreement with the Company on any matter relating to Company operations, policies or practices.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the current Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020, which was subsequently extended to April 15, 2021. On April 15, 2021, the Company and Dr. Nash entered into an addendum (the &#8220;Addendum&#8221;) to extend the term of the Executive Chairman Agreement to April 15, 2022.  In connection with the Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 90,000 shares of Company common stock, which vests monthly commencing on May 15, 2021, and to increase Dr. Nash&#8217;s monthly base salary to $27,960 from $25,417. Effective March 15, 2022, the Company extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $29,358 per month (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). In connection with this extension, the Company made a one-time award to Dr. Nash of an option to purchase 75,000 shares of the Company&#8217;s common stock, which vests monthly commencing on April 10, 2022.  All other terms of the Executive Chairman Agreement remain the same.</span></div><div><span><br/></span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates or achieving market acceptance and commercial success for any product that does receive regulatory approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with our research activities, including our product discovery efforts and the development of our product candidates. Our research and development expenses include: </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses and milestone payments incurred under arrangements with third parties, such as CROs, contract manufacturing organizations, collaborations with partners, consultants, and our scientific advisors; and</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">internal personnel expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used in future research and development activities are capitalized as prepaid expenses and expensed when the service has been performed or when the goods have been received.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in March 2016, we have spent a total of approximately $177.3 million in research and development expenses through June 30, 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, IMU-935 and IMU-856. We have spent the majority of our research and development resources on vidofludimus calcium, our lead development program for clinical trials in MS, UC, COVID-19 and PSC.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Immunic AG received a grant of up to approximately $730,000 from the German Federal Ministry of Education and Research, in support of the InnoMuNiCH (Innovations through Munich-Nippon Cooperation in Healthcare) project.  The grant funds will be used to fund a three-year research project relating to autoimmune diseases by us and our three project partners.  Since the inception of the grant, we have recorded $457,000 of income in total of which $100,000 and $178,000 of which were recorded in 2022 and 2021, respectively, and were classified in Other Income in the accompanying consolidated statement of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses are expected to increase in the foreseeable future as we continue to conduct ongoing regulatory and development activities, initiate new preclinical and clinical trials and build our pipeline of product candidates. The process of conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving regulatory approval for any of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful development of product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to the development and regulatory success of each product candidate, and ongoing assessments as to each product candidate&#8217;s commercial potential.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel expenses, professional fees for legal, accounting, tax and business consulting services, insurance premiums and stock-based compensation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our money market funds and bank accounts which are a portion of our cash and cash equivalents balance. Our interest income has not been significant due to low interest rates earned on invested balances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of a research and development tax incentive related to clinical trials performed in Australia and foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June 30, 2022 and 2021 </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses for the three months ended June 30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4SC royalty settlement (see Note 4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,610)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,170)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,440)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,291)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,527)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,901)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,934)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,967)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses increased by $0.8 million during the three months ended June 30, 2022, as compared to the three months ended June 30, 2021. The increase reflects (i) a $1.5 million increase in external development costs related to the Phase 3 program of vidofludimus calcium in relapsing multiple sclerosis, (ii) a $0.9 million increase in external development costs related to the Phase 2 trial of vidofludimus calcium in progressive multiple sclerosis, (iii) a $1.2 million increase in external development costs related to the clinical studies of IMU-935, (iv) a $0.7 million increase in personnel expense in research and development, $0.3 million of which is related to non-cash stock compensation expense and the remainder of which is related to an increase in headcount, and (v) $0.4 million related to increased costs across numerous categories.  The increases were partially offset by (i) a $1.4 million decrease in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in COVID-19, (ii) a decrease of $1.3 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in ulcerative colitis, (iii) a decrease of $0.5 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in relapsing-remitting multiple sclerosis, and (iv) a decrease of $0.7 million across numerous categories.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $0.6 million during the three months ended June 30, 2022, as compared to the three months ended June 30, 2021. The increase was primarily due to a $0.6 million increase in personnel expense in general and administrative, $0.3 million of which is related to non-cash stock compensation expense and the remainder of which is related to an increase of headcount. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income decreased by $2.5 million during the three months ended June 30, 2022, as compared to the three months ended June 30, 2021. The decrease was primarily attributable to (i) a $2.3 million increase in the loss on an intercompany loan between Immunic, Inc. and Immunic AG as a result of changes in currency exchange rates, (ii) a $0.2 million foreign exchange loss in the second quarter of 2022 on an intercompany loan between Immunic AG and Immunic Australia Pty Ltd.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comparison of the Six Months Ended June 30, 2022 and 2021 </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses for the six months ended June 30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4SC royalty settlement (see Note 4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,512)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,045)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,557)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,512&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(664)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(911)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,709)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,468)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,759&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses increased by $6.7 million during the six months ended June 30, 2022, as compared to the six months ended June 30, 2021. The increase reflects (i) a $5.4 million increase in external development costs related to the Phase 3 program of vidofludimus calcium in relapsing multiple sclerosis, (ii) a $2.9 million increase in external development costs related to the Phase 2 trial of vidofludimus calcium in progressive multiple sclerosis, (iii) a $3.1 million increase in external development costs related to the clinical studies of IMU-935, (iv) a $1.8 million increase in personnel expense in research and development, $0.7 million of which is related to non-cash stock compensation expense and the remainder of which is related to an increase in headcount, (v) a $0.5 million increase in external development costs related to the Phase 1 clinical trial of IMU-856, and (vi) $0.2 million related to increased costs across numerous categories.  The increases were partially offset by (i) a $3.1 million decrease in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in COVID-19, (ii) a decrease of $2.0 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in ulcerative colitis, (iii) a decrease of $1.2 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in relapsing-remitting multiple sclerosis, and (iv) a decrease of $0.9 million in external development costs across numerous categories.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $1.0 million during the six months ended June 30, 2022, as compared to the six months ended June 30, 2021. The increase was primarily due to (i) a $0.9 million increase in personnel expense in general and administrative, $0.3 million of which is related to non-cash stock compensation expense and the remainder of which is related to an increase in headcount, and (ii) a $0.1 million increase across numerous categories. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, Immunic AG and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.25 million (Tranche III of the Agreement). The payment was made 50% in cash and 50% in shares of Immunic&#8217;s common stock.  No further payment obligations remain between Immunic and 4SC AG.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense decreased by $0.2 million during the six months ended June 30, 2022, as compared to the six months ended June 30, 2021. The decrease was primarily attributable to (i) a $0.3 million increase in research and development tax incentives for clinical trials in Australia as a result of increased spending on clinical trials in Australia, and (ii) a $0.2 million foreign exchange gain in the first two quarters of 2022 on an intercompany loan between Immunic AG and Immunic Australia Pty Ltd.   The increase was partially offset by a $0.3 million increase in the loss on an intercompany loan between Immunic, Inc. and Immunic AG.</span></div><div><span><br/></span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since our inception in 2016.  We have an accumulated deficit of approximately $239.6 million at June 30, 2022 and $196.9 million as of December 31, 2021.  Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the preclinical and clinical development of our product candidates and add personnel necessary to operate as a company with an advanced clinical pipeline of product candidates. To the extent additional funds are necessary to meet long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of indebtedness, additional equity financings or a combination of these potential sources of funds, although we can provide no assurance that these sources of funding will be available on reasonable terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through July 31, 2022, we have raised net cash of approximately $299.1 million from private and public offerings of preferred and common stock. As of June 30, 2022, we had cash and cash equivalents of approximately $88.1 million.  With these funds, we expect to be able to fund our operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we filed a shelf registration statement on Form S-3 (the "2020 Shelf Registration Statement").   The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0 million of common stock that may be issued and sold under an at-the-market sales agreement with SVB Leerink as agent. We have used and intend to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 31, 2022, $8.4 million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0 million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. We intend to use the net proceeds from the offering to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 31, 2022, $80.0 million in capacity remains under the April 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended June 30, 2022, we raised gross proceeds of $10.3&#160;million pursuant to the December 2020 ATM through the sale of 1,300,000 shares of common stock at a weighted average price of $7.90 per share. The net proceeds from the December 2020 ATM were $10.0&#160;million after deducting underwriter commissions of $0.3&#160;million.  In the six months ended June 30, 2022, we raised gross proceeds of $40.9&#160;million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6&#160;million after deducting underwriter commissions of $1.2&#160;million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any ATM activity during the three or six months ended June 30, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Capital Requirements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we have not generated any revenue from product sales and we do not know when, or if, we will generate any revenue from product sales. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize any of our product candidates. At the same time, we expect our expenses to increase as we continue the ongoing research, development, manufacture and clinical trials of, and seek regulatory approval for, our product candidates. We expect to incur additional costs associated with operating as a public company. In addition, subject to obtaining regulatory approval of any of our product candidates, we anticipate that we will need substantial additional funding in connection with our continuing operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future expenses and capital requirements are difficult to forecast and will depend on many factors, including, but not limited to:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and structure of any strategic options and transactions, if any;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and outcome of any future litigation;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expenses, including salaries, benefits, stock-based compensation expense and other compensation expenses related to retention and termination of personnel;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of research and development and ongoing clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of future regulatory submissions;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of developing and validating the manufacturing processes for any potential product candidates;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of any commercialization activities, including reimbursement, marketing, sales and distribution costs;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish new collaborations, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of any future product candidates we pursue;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved with being a public company;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents, including litigation costs and the outcome of such litigation; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount from the sales of, or royalties on, any future products.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of stock offerings, debt financings, strategic alliances, collaborations and licensing arrangements. We do not expect to achieve revenue from product sales prior to the use of the net proceeds from our public and private offerings to date. We do not have any committed external source of funds. Additional funds may not be available on acceptable terms, if at all. To the extent that we raise additional capital through the sale of equity securities, the ownership interest of our stockholders will be diluted and it may be on terms that are not favorable to us or our stockholders. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt or other terms that are not favorable to us or our stockholders. If we raise additional funds through collaborations and licensing arrangements with third parties, we would expect to relinquish substantial rights to our technologies or our future products, or grant licenses on terms that may not be favorable to us. If we were to complete a merger, we may relinquish all control over the organization and could experience detrimental tax effects.  If we are unable to raise adequate funds, we may have to liquidate some or all of our assets. Any of these factors could harm our operating results and could result in substantial declines in the trading price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we had cash and cash equivalents of approximately $88.1 million. </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the six months ended June 30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, operating activities used $36.4 million of cash. The use of cash primarily resulted from (i) our net loss of $42.7 million adjusted for non-cash charges of $6.3 million related to $2.1 million for an unrealized foreign currency loss and $4.2 million related to stock-based compensation and depreciation and amortization while our net change in operating assets and liabilities remained flat. Changes in our operating assets and liabilities during the six months ended June 30, 2022 consisted primarily of (i) a $0.1 million increase in our other current assets and prepaid expenses  partially offset by an decrease of $0.1 million in our other current liabilities.   </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, operating activities used $42.0 million of cash. The use of cash primarily resulted from (i) our net loss of $52.5 million adjusted for non-cash charges of $8.6 million related to common stock issued for the 4SC AG transaction, $1.9 million for an unrealized foreign currency loss, $3.1 million related to stock-based compensation and depreciation and amortization as well as a $3.1 million net increase in our operating assets and liabilities. Changes in our operating assets and liabilities during the six months ended June 30, 2021 consisted primarily of (i) an increase of $8.6 million in other current assets and prepaid expenses, partially offset by an increase of $5.5 million in our other current liabilities </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $40,000 and $28,000 during the six months ended June 30, 2022, and 2021, respectively, which was related to the purchase of property and equipment.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $39.7 million during the six months ended June 30, 2022 consisting primarily of net cash proceeds from the sale of common stock under our ATM facility. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no cash based financing activities during the six months ended June 30, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through June 30, 2022, we have not entered into and did not have any relationships with unconsolidated entities or financial collaborations, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purpose.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of June 30, 2022:</span></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:84.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we have non-cancelable contractual obligations under certain agreements related to our development programs vidofludimus calcium, IMU-935 and IMU-856 totaling approximately $2.6 million, all of which is expected to be paid in the next twelve months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements are prepared in conformity with U.S. GAAP. The preparation of our unaudited condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. We have reviewed these critical accounting policies and related disclosures with the Audit Committee of our Board.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first six months of 2022, there were no significant changes in our critical accounting policies or in the methodology used for estimates. Our significant accounting policies are described in more detail in (i) Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report and (ii) our audited consolidated financial statements for the years ended December 31, 2021 and 2020 filed in our Annual Report on Form 10-K on February 24, 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_73"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Sensitivity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash and cash equivalents of $88.1 million as of June 30, 2022, which were held for working capital purposes. We do not enter into investments for trading or speculative purposes. We do not believe that we have any material exposure to changes in the fair value of these investments as a result of changes in interest rates due to their short-term nature. However, $23.9 million of these funds are held in German bank accounts that were earning no interest as of July 31, 2022.  Decreases or increases in interest rates, however, will reduce or increase future investment income, respectively, to the extent we have funds available for investment.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary research and development operations are conducted in our facilities in Germany. We have entered and may continue to enter into international agreements, primarily related to our clinical studies. Accordingly, we have exposure to foreign currency exchange rates and fluctuations between the U.S. dollar and foreign currencies, primarily the euro and the Australian dollar, which could adversely affect our financial results, including income and losses as well as assets and liabilities. To date, we have not entered into, and do not have any current plans to enter into, any foreign currency hedging transactions or derivative financial transactions. Our exposure to foreign currency risk will fluctuate in future periods as our research and clinical development activities in Europe and Australia change. We currently maintain a significant amount of our assets outside of the U.S.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of our foreign subsidiaries are the applicable local currencies. Accordingly, the effects of exchange rate fluctuations on the net assets of these operations are accounted for as translation gains or losses in accumulated other comprehensive income (loss) within stockholders&#8217; equity.  Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). Our German subsidiaries are currently a significant portion of our business and, accordingly, a change of 10% in the currency exchange rates, primarily the euro, could have a material impact on their financial position or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although operating in local currencies may limit the impact of currency rate fluctuations on the results of operations of our German and Australian subsidiaries, rate fluctuations may impact the consolidated financial position as the assets and liabilities of our foreign operations are translated into U.S. dollars in preparing our condensed consolidated balance sheets. As of June 30, 2022, our German and Australian subsidiaries had net current assets (defined as current assets less current liabilities), subject to foreign currency translation risk, of $30.6 million. A decrease of approximately $3.1 million in net current assets would result as of June 30, 2022, from a hypothetical 10% adverse change in quoted foreign currency exchange rates, primarily due to the euro.  In addition, a 10% change in the foreign currency exchange rates for the six months ended June 30, 2022, would have impacted our net loss by approximately $3.5 million, primarily due to the euro.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i132a36b84ae14363889a7cabe57a8d6f_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-bottom:8.85pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Principal Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15 (e)) under the Securities Exchange Act of 1934 ("the Exchange Act"), as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and our Principal Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that the information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:0.2pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting that occurred during the six months ended June 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_79"></div><div><span><br/></span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II - OTHER INFORMATION</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any litigation, nor are we aware of any pending or threatened litigation against us, that we believe would materially affect our business, operating results, financial condition or cash flows. Our industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. It is not uncommon for lawsuits to be filed alleging lack of process or breach of fiduciary duties by directors, and we may face such suits in the future. As a result, in the future, we may be involved in various legal proceedings from time to time.</span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;Risk Factors</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials could be delayed or suspended, and costs would increase, as a result of the military action by Russia in the Ukraine.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2022, Russia invaded Ukraine. As a result, the United States and other countries imposed economic and other sanctions on Russia and could impose further sanctions, which may disrupt international commerce and damage the global economy. The continuing conflict may impair our ability to recruit patients in Ukraine, Russia and Belarus for current and upcoming clinical trials, which could result in delays of our trials and additional recruitment costs.  Although we are making efforts to compensate for our temporary stop of patient recruitment in Ukraine, Russia and Belarus, seeking activation of other countries and additional sites in currently participating countries, the broader or longer-term consequences of this conflict or the sanctions imposed to date or in the future could adversely affect clinical trials we are currently conducting or are planning to conduct in this region by delaying or preventing their completion and increasing our costs. Alternative sites to fully and timely compensate for delays in our clinical trial activities in Ukraine, Russia and Belarus may not be available or may not fully compensate for a lack of enrollment in Ukraine, Russia and Belarus. Although the route, length and impact of this continuing conflict are highly unpredictable, vendors, investigators or clinical trial sites in Ukraine, Russia and Belarus could suspend or terminate any trials being conducted, and patients could be forced to discontinue further study participation or to evacuate or voluntarily choose to relocate far from clinical trial sites, making them unavailable for further dosing or necessary follow-up. If our clinical trials are materially interrupted or otherwise negatively impacted, we may have insufficient data to support regulatory approvals of vidofludimus calcium, and any commercialization may be delayed, which could limit our potential revenue and hurt the competitive position of any products we may successfully develop.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Uncertainty in global economic conditions could negatively affect our business, results of operations and financial condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have significant goodwill recorded on our consolidated balance sheets as of December 31, 2021. We will continue to evaluate the recoverability of the carrying amount of our goodwill on an ongoing basis, and we may incur substantial impairment charges, which would adversely affect our consolidated financial results. There can be no assurance that the outcome of such reviews in the future will not result in substantial impairment charges. Impairment assessment inherently involves judgment as to assumptions about expected future cash flows and the impact of market conditions on those assumptions. Future events and changing market conditions may impact our assumptions as to prices, costs, holding periods or other factors that may result in changes in our estimates of future cash flows. Although we believe the assumptions we used in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing for impairment are reasonable, significant changes in any one of our assumptions could produce a significantly different result.</span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_91"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_94"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Other Information</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i132a36b84ae14363889a7cabe57a8d6f_100"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBITS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-1.htm">Amended and Restated Articles of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-2.htm">Third Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000837/e618652_ex4-2.htm">2019 Omnibus Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 20, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;4.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit4211111.htm">Description of Registrant's Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-1.htm">Sales Agreement, dated July 17, 2019, between Immunic, Inc. and SVB Leerink LLC.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-2.htm">Option and License Agreement, dated September 27, 2018, between Immunic AG and Daiichi Sankyo Company, Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-3.htm">Asset Purchase Agreement, dated May 13, 2016, between Immunic AG and 4SC AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-4.htm">Form of Indemnification Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-5.htm">Employment Agreement between Dr. Daniel Vitt and Immunic AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex10-1.htm">Addendum to Service Agreement between Immunic AG and Dr. Daniel Vitt.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-6.htm">Employment Agreement between Dr. Manfred Groeppel and Immunic AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex10-2.htm">Addendum to Service Agreement between Immunic AG and Dr. Manfred Groeppel.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000499/e619564_ex10-2.htm">Employment Agreement dated April 17, 2020, between Immunic, Inc. and Duane Nash.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380521000513/e620493_ex10-1.htm">Second Addendum to Employment Agreement dated October 15, 2020, between Immunic, Inc. and Duane Nash.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 19, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000519/e619576_ex10-1.htm">Placement Agency Agreement, dated April 23, 2020, between Immunic, Inc. and Roth Capital Partners, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2020</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000519/e619576_ex10-2.htm">Form of Securities Purchase Agreement, dated April 23, 2020, between Immunic, Inc. and the investors party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000688/e619697_ex10-1.htm">Placement Agency Agreement, dated June 10, 2020, between Immunic, Inc.  and the Roth Partners, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 12, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000688/e619697_ex10-2.htm">Form of Securities Purchase Agreement, dated June 10, 2020, between Immunic, Inc. and the investors party thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 12, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000975/e619841_ex1-1.htm">Underwriting Agreement, dated August 4, 2020, by and between Immunic, Inc. and SVB Leerink LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520001296/e620006_ex10-1.htm">Finance Contract, dated October 19, 2020, between Immunic, Inc., Immunic AG and European Investment Bank</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520001296/e620006_ex10-2.htm">Form of Guarantee Agreement between Immunic, Inc., Immunic AG and European Investment Bank.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000002/e620187_ex10-1.htm">Sales Agreement, dated December 29, 2020 between Immunic, Inc. and SVB Leerink LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 4, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520001425/e620080_ex10-1.htm">Amendment Letter, dated November 11, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 13, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380521000441/e620436_ex10-1.htm">Settlement Agreement, dated March 31, 2021, between Immunic AG and 4SC AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000513/e620493_ex10-1.htm">Addendum No. 2 to Employment Agreement dated April 15, 2021 between Immunic, Inc. and Duane Nash</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 15, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-1.htm">Second Addendum to Service Agreement between Immunic AG and Dr. Daniel Vitt</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-2.htm">Second Addendum, dated June 10, 2021 to Service Agreement between Immunic AG and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-3.htm">Employment Agreement, dated June 10, 2021 between Immunic, Inc. and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-4.htm">Employment Agreement, dated June 10, 2021 between Immunic, Inc. and Glenn Whaley</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521001043/e620806_ex1-1.htm">Underwriting Agreement, dated July 15, 2021, by and between Immunic, Inc. and Piper Sandler &amp; Co</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521001455/e621010_ex10-1.htm">Employment Agreement, dated October 14, 2021, between Immunic, Inc. and Patrick Walsh</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 14, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380522000023/e621200_ex10-1.htm">Third Addendum, dated January 5, 2022, to Service Agreement between Immunic AG and Dr. Daniel Vitt</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 10, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380522000023/e621200_ex10-2.htm">Third Addendum, dated January 5, 2022, to Service Agreement between Immunic AG and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 10, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380522000023/e621200_ex10-3.htm">Third Addendum, dated January 5, 2022, to Service Agreement between Immunic AG and Dr. Hella Kohlhof</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 10, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380522000504/e621458_ex10-1.htm">Addendum No. 3 to Employment Agreement, dated March 15, 2022, between Immunic, Inc. and Duane Nash</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380522000711/e621604_ex10-1.htm">Sales Agreement dated as of May 2, 2022, between SVB Securities LLC and Immunic, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-063022xexhibit311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-063022xexhibit312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-063022xexhibit321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-063022xexhibit322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex99-3.htm">Employment Agreement, dated September 4, 2019, between Immunic, Inc. and Dr. Andreas Muehler.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex99-2.htm">Addendum, dated September 4, 2019, to Service Agreement between Immunic AG and Dr. Andreas Muehler.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex99-4.htm">Addendum, dated September 4, 2019, to Service Agreement between Immunic AG and Dr. Hella Kohlhof.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex99-2.htm">Second Addendum, dated June 10, 2021, to Service Agreement between Immunic AG and Dr. Hella Kohlhof</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Database.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with Item&#160;601(b)(32)(ii) of Regulation S-K and SEC Release No.&#160;33-8238 and 34-47986, Final Rule: Management&#8217;s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i132a36b84ae14363889a7cabe57a8d6f_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August&#160;4, 2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ Daniel Vitt                                 </span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         &#160;&#160;&#160;&#160;Daniel Vitt</span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         &#160;&#160;&#160;&#160;Chief Executive Officer and President</span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>exhibit4211111.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib07b0c34c0984a91b355a37f56ae2561_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DESCRIPTION OF CAPITAL STOCK </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our authorized capital stock consists of 130,000,000 shares of common stock, par value $0.0001 per share, and 20,000,000 shares of preferred stock, par value $0.0001 per share.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following description of our common stock summarizes its material terms and provisions, but it is not complete. For the complete terms of our common stock, please refer to our certificate of incorporation and our bylaws that are incorporated by reference into the Annual Report on Form 10-K of which this exhibit is a part.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Common Stock</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2020, there were 21,168,240 shares of common stock outstanding. The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors, and as a consequence, minority stockholders will not be able to elect directors on the basis of their votes alone.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to preferences that may be applicable to any then outstanding shares of preferred stock, holders of common stock are entitled to receive ratably such dividends as may be declared by the board of directors out of funds legally available therefor. In the event of a liquidation, dissolution or winding up of us, holders of the common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any then outstanding shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to our common stock. All outstanding shares of common stock are fully paid and non-assessable. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any of our outstanding preferred stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Listing</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;IMUX.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Transfer Agent and Registrar</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transfer agent and registrar for our common stock is American Stock Transfer &#38; Trust Company, LLC (&#8220;AST&#8221;). The transfer agent and registrar&#8217;s address is 6201 15th Avenue, Brooklyn, New York 11219.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Dividends</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have not declared any cash dividends on our common stock since inception and we do not anticipate paying any cash dividends on our common stock in the foreseeable future.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Possible Anti-Takeover Effects of Delaware Law and our Charter Documents</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could make the following transactions more difficult&#58; an acquisition of us by means of a tender offer, an acquisition of us by means of a proxy contest or otherwise, or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interest, including transactions which provide for payment of a premium over the market price for our shares.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delaware Anti-Takeover Statute</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to Section 203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), an anti-takeover statute. In general, Section 203 of the DGCL prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the time the person became an interested stockholder, unless the business combination or the acquisition of shares that resulted in a stockholder becoming an interested stockholder is approved in a prescribed manner. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns (or within three years prior to the determination of interested stockholder status did own) 15% or more of a corporation&#8217;s voting stock. The existence of this provision would be expected to have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by our stockholders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Undesignated Preferred Stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ability of our board of directors, without action by the stockholders, to issue up to 20,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to effect a change in control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Requirements for Advance Notification of Stockholder Nominations and Proposals.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Elimination of Stockholder Action by Written Consent.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Staggered Board.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Removal of Directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote in the election of directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stockholders Not Entitled to Cumulative Voting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Authorized but Unissued Shares</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our authorized but unissued shares of common stock and preferred stock will be available for future issuance without stockholder approval. We may use additional shares for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions and as employee compensation. The existence of authorized but unissued shares of undesignated preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">obligations, our board of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer, stockholder or stockholder group. The rights of holders of our common stock described above will be subject to, and may be adversely affected by, the rights of any preferred stock that we may designate and issue in the future. The issuance of shares of undesignated preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Director Liability</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our bylaws limit the extent to which our directors are personally liable to us and our stockholders, to the fullest extent permitted by the DGCL. The inclusion of this provision in our bylaws may reduce the likelihood of derivative litigation against directors and may discourage or deter stockholders or management from bringing a lawsuit against directors for breach of their duty of care.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interest.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>imux-063022xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9d74027677514f6c84f2af0300b46b22_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Vitt, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>imux-063022xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i21d1457728354d44b277f2a12c4adb94_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Glenn Whaley, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>imux-063022xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i78b988f113e549c49de209e450b41004_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Daniel Vitt, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that to his knowledge&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>imux-063022xexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie0dec2275614484e820afb97f487c301_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Glenn Whaley, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that to his knowledge&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 4, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial  Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>vtl-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:87493b76-11b9-4c9e-8fb7-f973ce8e577c,g:e8a78576-a7c5-4c0a-9fc2-78dfa0931d1d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vtl="http://vitaltherapies.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://vitaltherapies.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://vitaltherapies.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofCashFlows" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows">
        <link:definition>1007008 - Statement - Condensed Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatements" roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements">
        <link:definition>2101101 - Disclosure - Description of Business and Basis of Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatementsDetails" roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails">
        <link:definition>2402401 - Disclosure - Description of Business and Basis of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetails" roleURI="http://vitaltherapies.com/role/BalanceSheetDetails">
        <link:definition>2108103 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsTables" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsTables">
        <link:definition>2309302 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail">
        <link:definition>2410404 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccountsPayableDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail">
        <link:definition>2411405 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccruedExpensesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail">
        <link:definition>2412406 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail">
        <link:definition>2413407 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://vitaltherapies.com/role/CommitmentsandContingencies">
        <link:definition>2114104 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesTables">
        <link:definition>2315303 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2416408 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails">
        <link:definition>2417409 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1">
        <link:definition>2417409 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://vitaltherapies.com/role/FairValue">
        <link:definition>2118105 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://vitaltherapies.com/role/FairValueTables">
        <link:definition>2319304 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2420410 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://vitaltherapies.com/role/CommonStock">
        <link:definition>2121106 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockTables" roleURI="http://vitaltherapies.com/role/CommonStockTables">
        <link:definition>2322305 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockShelfRegistrationStatementDetails" roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails">
        <link:definition>2423411 - Disclosure - Common Stock - Shelf Registration Statement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockCommonStockDetails" roleURI="http://vitaltherapies.com/role/CommonStockCommonStockDetails">
        <link:definition>2424412 - Disclosure - Common Stock - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockPreferredStockDetails" roleURI="http://vitaltherapies.com/role/CommonStockPreferredStockDetails">
        <link:definition>2425413 - Disclosure - Common Stock - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockSharesReservedforFutureIssuanceDetails" roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails">
        <link:definition>2426414 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlans" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlans">
        <link:definition>2127107 - Disclosure - Stock-Based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansTables" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansTables">
        <link:definition>2328306 - Disclosure - Stock-Based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails">
        <link:definition>2429415 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansSummaryofStockOptionActivityDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails">
        <link:definition>2430416 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail">
        <link:definition>2431417 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails">
        <link:definition>2432418 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://vitaltherapies.com/role/RelatedPartyTransactions">
        <link:definition>2133108 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>2434419 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://vitaltherapies.com/role/SubsequentEvents">
        <link:definition>2135109 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://vitaltherapies.com/role/SubsequentEventsDetails">
        <link:definition>2436420 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vtl_SalaryCostsMonthlyBaseSalary" abstract="false" name="SalaryCostsMonthlyBaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_RoyaltySettlementAgreementSharesPaymentPercent" abstract="false" name="RoyaltySettlementAgreementSharesPaymentPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ClinicalCostsPayableCurrent" abstract="false" name="ClinicalCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_PrepaidClinicalAndRelatedCostsCurrent" abstract="false" name="PrepaidClinicalAndRelatedCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_DuaneNashMDJDMBAMember" abstract="true" name="DuaneNashMDJDMBAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ShelfRegistrationTerminationPriorWrittenNotice" abstract="false" name="ShelfRegistrationTerminationPriorWrittenNotice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_TwoThousandFourteenEquityIncentivePlanMember" abstract="true" name="TwoThousandFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_May2022ATMMember" abstract="true" name="May2022ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ExecutiveChairmanAgreementMember" abstract="true" name="ExecutiveChairmanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ResearchAndDevelopmentTaxIncentiveCurrent" abstract="false" name="ResearchAndDevelopmentTaxIncentiveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" abstract="false" name="MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_EmployeeStockOptionsforFutureGrantMember" abstract="true" name="EmployeeStockOptionsforFutureGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" abstract="false" name="ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_AccruedLegalAndAuditCostsCurrent" abstract="false" name="AccruedLegalAndAuditCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ShelfRegistrationStatementAmountRemaining" abstract="false" name="ShelfRegistrationStatementAmountRemaining" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ImmunicAGMember" abstract="true" name="ImmunicAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_NewYorkCityMember" abstract="true" name="NewYorkCityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_A2017InducementEquityIncentivePlanMember" abstract="true" name="A2017InducementEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_OperatingAndVariableLeasesCost" abstract="false" name="OperatingAndVariableLeasesCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_A2019OmnibusEquityIncentivePlanMember" abstract="true" name="A2019OmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_A2021EmployeeStockPurchasePlanMember" abstract="true" name="A2021EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_RoyaltySettlementAgreementCashPaymentPercent" abstract="false" name="RoyaltySettlementAgreementCashPaymentPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_OptionsVestingInOneYearMember" abstract="true" name="OptionsVestingInOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_OperatingLeaseIncrementalBorrowingRate" abstract="false" name="OperatingLeaseIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_A4SCRoyaltySettlementMember" abstract="true" name="A4SCRoyaltySettlementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_GrafelfingGermanyMember" abstract="true" name="GrafelfingGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" abstract="false" name="AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_AccruedClinicalCostsCurrent" abstract="false" name="AccruedClinicalCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_AccruedCompensationCurrent" abstract="false" name="AccruedCompensationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_December2020ATMMember" abstract="true" name="December2020ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_OptionsVestingInThreeYearsMember" abstract="true" name="OptionsVestingInThreeYearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_LesseeOperatingLeasesNumberOfExistingLeases" abstract="false" name="LesseeOperatingLeasesNumberOfExistingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_NumberOfDevelopmentProgramsPursued" abstract="false" name="NumberOfDevelopmentProgramsPursued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_SharesIssuedWeightedAverageSharePricePerShare" abstract="false" name="SharesIssuedWeightedAverageSharePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vtl_RoyaltySettlementAgreementSalesNet" abstract="false" name="RoyaltySettlementAgreementSalesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_SaleOfStockRemainingCapacity" abstract="false" name="SaleOfStockRemainingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_LesseeOperatingLeaseRentHolidayPeriod" abstract="false" name="LesseeOperatingLeaseRentHolidayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_IncentiveEmployeeStockOptionMember" abstract="true" name="IncentiveEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_LegalAndAuditCostsPayableCurrent" abstract="false" name="LegalAndAuditCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_NonStatutoryEmployeeStockOptionMember" abstract="true" name="NonStatutoryEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>vtl-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:87493b76-11b9-4c9e-8fb7-f973ce8e577c,g:e8a78576-a7c5-4c0a-9fc2-78dfa0931d1d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtl-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_be3f133b-b845-42b0-943d-4deb6b260d66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b3e43d39-a1c8-4774-b248-f22e5df59827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_be3f133b-b845-42b0-943d-4deb6b260d66" xlink:to="loc_us-gaap_StockholdersEquity_b3e43d39-a1c8-4774-b248-f22e5df59827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e8cc31dd-6133-4217-a209-afb84f49bbd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_be3f133b-b845-42b0-943d-4deb6b260d66" xlink:to="loc_us-gaap_Liabilities_e8cc31dd-6133-4217-a209-afb84f49bbd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a0637faf-e126-42c9-b7f1-ba45245a66d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_be3f133b-b845-42b0-943d-4deb6b260d66" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a0637faf-e126-42c9-b7f1-ba45245a66d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2f063817-46f4-46d4-b1cb-99b59289c2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b9760a65-b4e0-4620-819e-9c26c1d029fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2f063817-46f4-46d4-b1cb-99b59289c2fa" xlink:to="loc_us-gaap_LiabilitiesCurrent_b9760a65-b4e0-4620-819e-9c26c1d029fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_bed23f18-edee-4580-afbb-8ddcda7808a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2f063817-46f4-46d4-b1cb-99b59289c2fa" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_bed23f18-edee-4580-afbb-8ddcda7808a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7f6744dc-a8cd-4148-ae3e-76d377e463cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8cb7a3e0-d229-4221-bc10-58d49053ebd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7f6744dc-a8cd-4148-ae3e-76d377e463cd" xlink:to="loc_us-gaap_PreferredStockValue_8cb7a3e0-d229-4221-bc10-58d49053ebd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ba4d7963-7740-4904-b745-8a54534666c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7f6744dc-a8cd-4148-ae3e-76d377e463cd" xlink:to="loc_us-gaap_CommonStockValue_ba4d7963-7740-4904-b745-8a54534666c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a4092aae-a0f8-41e9-969c-35e1a1b875b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7f6744dc-a8cd-4148-ae3e-76d377e463cd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a4092aae-a0f8-41e9-969c-35e1a1b875b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e5214a8c-6924-4847-ac9c-c6fe8d797f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7f6744dc-a8cd-4148-ae3e-76d377e463cd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e5214a8c-6924-4847-ac9c-c6fe8d797f84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2714ae29-f0b7-459b-ba7d-1049f60a8cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7f6744dc-a8cd-4148-ae3e-76d377e463cd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2714ae29-f0b7-459b-ba7d-1049f60a8cc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_402651fc-89fe-4d6e-98d0-287192c511ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e67b187c-d874-4bce-9aa3-7d35ac60ae05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_402651fc-89fe-4d6e-98d0-287192c511ac" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e67b187c-d874-4bce-9aa3-7d35ac60ae05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f3b41a1a-4079-40a4-a54b-874d3985cdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_402651fc-89fe-4d6e-98d0-287192c511ac" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f3b41a1a-4079-40a4-a54b-874d3985cdf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b4b8f928-003f-4326-850a-00461db9fb95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0e2e8ac0-e1d9-485e-bf76-975be552d6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b4b8f928-003f-4326-850a-00461db9fb95" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0e2e8ac0-e1d9-485e-bf76-975be552d6cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b6603064-c60f-470e-af14-9e44b20482f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b4b8f928-003f-4326-850a-00461db9fb95" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b6603064-c60f-470e-af14-9e44b20482f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_99317a5d-c758-4b1f-8480-4ef8a1388b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b4b8f928-003f-4326-850a-00461db9fb95" xlink:to="loc_us-gaap_AccountsPayableCurrent_99317a5d-c758-4b1f-8480-4ef8a1388b99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_784b3617-8c9c-4605-a8ac-4e1149989815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_45a9b093-57d2-4a9e-a886-5699740d810f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_784b3617-8c9c-4605-a8ac-4e1149989815" xlink:to="loc_us-gaap_AssetsCurrent_45a9b093-57d2-4a9e-a886-5699740d810f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6561bf92-c459-4c62-92f4-09dccd089747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_784b3617-8c9c-4605-a8ac-4e1149989815" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6561bf92-c459-4c62-92f4-09dccd089747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_da6d205b-e952-4e6b-8368-01ea59bfa53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_784b3617-8c9c-4605-a8ac-4e1149989815" xlink:to="loc_us-gaap_Goodwill_da6d205b-e952-4e6b-8368-01ea59bfa53b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c904f26-4749-45ff-8830-9edca61e43c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_784b3617-8c9c-4605-a8ac-4e1149989815" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c904f26-4749-45ff-8830-9edca61e43c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8093443b-da4c-4aaf-bad5-3a5a59278ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_784b3617-8c9c-4605-a8ac-4e1149989815" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8093443b-da4c-4aaf-bad5-3a5a59278ce6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c0a5c39a-515a-4392-9717-86944160dede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e8389f22-c1f0-47a2-a35a-06b919cddc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_c0a5c39a-515a-4392-9717-86944160dede" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e8389f22-c1f0-47a2-a35a-06b919cddc3d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="vtl-20220630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_05fbb5cf-edf0-4f83-bb66-83976d5066af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11753e38-5b2c-471b-a062-d1820e413ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_05fbb5cf-edf0-4f83-bb66-83976d5066af" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11753e38-5b2c-471b-a062-d1820e413ed6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_25fb3a96-daed-4665-bb2e-b72a6b7f8322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_05fbb5cf-edf0-4f83-bb66-83976d5066af" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_25fb3a96-daed-4665-bb2e-b72a6b7f8322" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSalesNet_0e265ae6-c32a-42dc-a9fb-c8aef05c1265" xlink:href="vtl-20220630.xsd#vtl_RoyaltySettlementAgreementSalesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_05fbb5cf-edf0-4f83-bb66-83976d5066af" xlink:to="loc_vtl_RoyaltySettlementAgreementSalesNet_0e265ae6-c32a-42dc-a9fb-c8aef05c1265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0fd152a2-309f-488f-a3d2-7ebd28675d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fee59339-c090-423a-be90-92e4b7916319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0fd152a2-309f-488f-a3d2-7ebd28675d26" xlink:to="loc_us-gaap_OperatingExpenses_fee59339-c090-423a-be90-92e4b7916319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c6346754-d40b-46da-9f5f-d36db1d94c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b762a1ea-91d4-4641-ab63-47154651ae76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c6346754-d40b-46da-9f5f-d36db1d94c5b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b762a1ea-91d4-4641-ab63-47154651ae76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cd230e37-17ac-4235-8d1b-950d41a5c871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c6346754-d40b-46da-9f5f-d36db1d94c5b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cd230e37-17ac-4235-8d1b-950d41a5c871" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_75ddc61a-19ae-4ea5-bbe5-5f5e3c99f5de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_12419d0f-6a94-4b48-9b6d-c157a8b153ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_75ddc61a-19ae-4ea5-bbe5-5f5e3c99f5de" xlink:to="loc_us-gaap_OperatingIncomeLoss_12419d0f-6a94-4b48-9b6d-c157a8b153ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c773c19d-4bb7-4ecf-8264-c3e89067ca02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_75ddc61a-19ae-4ea5-bbe5-5f5e3c99f5de" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c773c19d-4bb7-4ecf-8264-c3e89067ca02" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="vtl-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f3940078-1c44-4108-a1b2-33377bfeba61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9c464273-0789-4f14-8378-2181d84e2a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f3940078-1c44-4108-a1b2-33377bfeba61" xlink:to="loc_us-gaap_NetIncomeLoss_9c464273-0789-4f14-8378-2181d84e2a35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_feab100e-5124-447a-ba96-ae5f6098afe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f3940078-1c44-4108-a1b2-33377bfeba61" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_feab100e-5124-447a-ba96-ae5f6098afe6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="vtl-20220630.xsd#CondensedConsolidatedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8683723c-5f4e-4602-a1b6-a1ca29780ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7550bb2-741a-4373-9700-63862b915afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8683723c-5f4e-4602-a1b6-a1ca29780ebc" xlink:to="loc_us-gaap_NetIncomeLoss_c7550bb2-741a-4373-9700-63862b915afa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2b393967-47bc-4d94-b193-1988c7200231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8683723c-5f4e-4602-a1b6-a1ca29780ebc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2b393967-47bc-4d94-b193-1988c7200231" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f3f08bf1-58fd-404f-9e8c-5ca70efbe618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8683723c-5f4e-4602-a1b6-a1ca29780ebc" xlink:to="loc_us-gaap_ShareBasedCompensation_f3f08bf1-58fd-404f-9e8c-5ca70efbe618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cd437e90-b3b1-40fa-b8bc-67063deef63e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8683723c-5f4e-4602-a1b6-a1ca29780ebc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cd437e90-b3b1-40fa-b8bc-67063deef63e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b438e72a-ac78-4321-bef0-f1216290e349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8683723c-5f4e-4602-a1b6-a1ca29780ebc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b438e72a-ac78-4321-bef0-f1216290e349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_27b47aa0-8525-46e6-95d2-280ed5d2cfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8683723c-5f4e-4602-a1b6-a1ca29780ebc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_27b47aa0-8525-46e6-95d2-280ed5d2cfb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ab088079-a22d-4445-a420-e0783f6ae8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8683723c-5f4e-4602-a1b6-a1ca29780ebc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ab088079-a22d-4445-a420-e0783f6ae8f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8039b945-5fe7-4f79-85ad-9466bb55dde5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8683723c-5f4e-4602-a1b6-a1ca29780ebc" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8039b945-5fe7-4f79-85ad-9466bb55dde5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_546dd9af-402b-409d-b2dc-4c612d093aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8683723c-5f4e-4602-a1b6-a1ca29780ebc" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_546dd9af-402b-409d-b2dc-4c612d093aee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd56818a-99e3-4efd-9154-22eb7a73d0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28f097ac-3da2-4fa0-a7e7-ac7991f6825f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd56818a-99e3-4efd-9154-22eb7a73d0e5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28f097ac-3da2-4fa0-a7e7-ac7991f6825f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_76346168-316c-4d93-871d-5a1b1297c4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd56818a-99e3-4efd-9154-22eb7a73d0e5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_76346168-316c-4d93-871d-5a1b1297c4fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0885f51c-520a-4378-8102-c7a2dedccbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd56818a-99e3-4efd-9154-22eb7a73d0e5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0885f51c-520a-4378-8102-c7a2dedccbf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a9b9995-fb29-41e8-8653-df9d28aa3e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd56818a-99e3-4efd-9154-22eb7a73d0e5" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a9b9995-fb29-41e8-8653-df9d28aa3e29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_050ad743-8190-4377-a746-7037a74a1bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_24b09e64-d39e-4093-815d-48f570ae755c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_050ad743-8190-4377-a746-7037a74a1bd4" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_24b09e64-d39e-4093-815d-48f570ae755c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_9eaf16b2-3373-4089-b290-4a6ec6f9c520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_050ad743-8190-4377-a746-7037a74a1bd4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_9eaf16b2-3373-4089-b290-4a6ec6f9c520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3a1b3410-46f9-436d-a3dd-1ca7e8a64754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_050ad743-8190-4377-a746-7037a74a1bd4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3a1b3410-46f9-436d-a3dd-1ca7e8a64754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52faf6ff-14fe-40e0-8cfd-2db07f599c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fa1c6389-b616-4954-9318-2fc3ebe7d9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52faf6ff-14fe-40e0-8cfd-2db07f599c91" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fa1c6389-b616-4954-9318-2fc3ebe7d9ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="simple" xlink:href="vtl-20220630.xsd#BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78d216a7-a2db-457a-a08d-4c422a1d9eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_f075965c-0655-49fd-8b05-16b58c62fa0d" xlink:href="vtl-20220630.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78d216a7-a2db-457a-a08d-4c422a1d9eef" xlink:to="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_f075965c-0655-49fd-8b05-16b58c62fa0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_19e8913f-2dff-4047-ab37-e2293e78b3b2" xlink:href="vtl-20220630.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78d216a7-a2db-457a-a08d-4c422a1d9eef" xlink:to="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_19e8913f-2dff-4047-ab37-e2293e78b3b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_91378dc5-7903-40eb-a38c-60b273f9107c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78d216a7-a2db-457a-a08d-4c422a1d9eef" xlink:to="loc_us-gaap_OtherAssetsCurrent_91378dc5-7903-40eb-a38c-60b273f9107c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_872f5f83-cb99-438a-8a51-15754ca051f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78d216a7-a2db-457a-a08d-4c422a1d9eef" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_872f5f83-cb99-438a-8a51-15754ca051f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="vtl-20220630.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_63cfb64d-036b-41c3-a941-9b203c1262b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent_04f76552-2129-4acd-b49b-d936b2ab7143" xlink:href="vtl-20220630.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_63cfb64d-036b-41c3-a941-9b203c1262b4" xlink:to="loc_vtl_ClinicalCostsPayableCurrent_04f76552-2129-4acd-b49b-d936b2ab7143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent_a7648484-dbfc-4840-bcf2-686957843296" xlink:href="vtl-20220630.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_63cfb64d-036b-41c3-a941-9b203c1262b4" xlink:to="loc_vtl_LegalAndAuditCostsPayableCurrent_a7648484-dbfc-4840-bcf2-686957843296" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_ea9c3362-3ece-4eba-834f-35dc184bfc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_63cfb64d-036b-41c3-a941-9b203c1262b4" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_ea9c3362-3ece-4eba-834f-35dc184bfc6e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="vtl-20220630.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7fc1d74b-a9aa-4869-8558-25ef111731f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f907df74-e03c-4268-946b-47546ced4ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7fc1d74b-a9aa-4869-8558-25ef111731f0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f907df74-e03c-4268-946b-47546ced4ed6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent_5890c5db-a0ef-4baf-a778-f19f3d77cf36" xlink:href="vtl-20220630.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7fc1d74b-a9aa-4869-8558-25ef111731f0" xlink:to="loc_vtl_AccruedClinicalCostsCurrent_5890c5db-a0ef-4baf-a778-f19f3d77cf36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent_91331e11-210a-4ed4-a859-0f32331540a0" xlink:href="vtl-20220630.xsd#vtl_AccruedCompensationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7fc1d74b-a9aa-4869-8558-25ef111731f0" xlink:to="loc_vtl_AccruedCompensationCurrent_91331e11-210a-4ed4-a859-0f32331540a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent_0291464f-c412-44ac-aa5f-c6cd312ad74b" xlink:href="vtl-20220630.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7fc1d74b-a9aa-4869-8558-25ef111731f0" xlink:to="loc_vtl_AccruedLegalAndAuditCostsCurrent_0291464f-c412-44ac-aa5f-c6cd312ad74b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="vtl-20220630.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_04316fe6-f940-43ca-96f7-710361740882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_f495dd9d-a490-4c9c-ba1d-b40633f0a500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_04316fe6-f940-43ca-96f7-710361740882" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_f495dd9d-a490-4c9c-ba1d-b40633f0a500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0495319a-e27b-452d-a33a-010fa8e20499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_04316fe6-f940-43ca-96f7-710361740882" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0495319a-e27b-452d-a33a-010fa8e20499" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_48e3ac9f-a877-4916-9808-7ded67df1c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_09555021-4d73-40a8-a2c3-0c1c3a0ecc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_48e3ac9f-a877-4916-9808-7ded67df1c4f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_09555021-4d73-40a8-a2c3-0c1c3a0ecc74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0510a16f-088b-435f-a4da-416553423c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_48e3ac9f-a877-4916-9808-7ded67df1c4f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0510a16f-088b-435f-a4da-416553423c6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1f088753-b249-42be-916e-f815d8e581e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_48e3ac9f-a877-4916-9808-7ded67df1c4f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1f088753-b249-42be-916e-f815d8e581e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_17b427d9-ab8c-4a1f-b739-8e5a53c9b8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_48e3ac9f-a877-4916-9808-7ded67df1c4f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_17b427d9-ab8c-4a1f-b739-8e5a53c9b8a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8ea0ae61-d60e-4714-aae8-eb4b5d2c3d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_48e3ac9f-a877-4916-9808-7ded67df1c4f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8ea0ae61-d60e-4714-aae8-eb4b5d2c3d5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_19f82cd0-bc86-4d13-992e-62559c360b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_17f76159-9837-4b0f-b3f1-296fada699be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_19f82cd0-bc86-4d13-992e-62559c360b21" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_17f76159-9837-4b0f-b3f1-296fada699be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3c283539-6b86-4da8-8ffd-02adbf5498c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_19f82cd0-bc86-4d13-992e-62559c360b21" xlink:to="loc_us-gaap_OperatingLeaseLiability_3c283539-6b86-4da8-8ffd-02adbf5498c8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>vtl-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:87493b76-11b9-4c9e-8fb7-f973ce8e577c,g:e8a78576-a7c5-4c0a-9fc2-78dfa0931d1d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vtl-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i42c1e1e6672947d88c54bf4a326eb7c5_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d5d70e95-afc9-4fc4-a28d-5785a1b33be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5d70e95-afc9-4fc4-a28d-5785a1b33be9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c43cedef-4441-4bcc-9a68-8a9dc041f08d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_SharesOutstanding_c43cedef-4441-4bcc-9a68-8a9dc041f08d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_533089da-9d72-480d-8ef1-5f99370aca1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_StockholdersEquity_533089da-9d72-480d-8ef1-5f99370aca1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_da910301-c194-43a5-9e43-63c32d484fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_NetIncomeLoss_da910301-c194-43a5-9e43-63c32d484fe3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_93cccb0a-aa00-4e08-bbdb-2f17b16ea6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_93cccb0a-aa00-4e08-bbdb-2f17b16ea6b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_83a875a0-83a7-4f88-a7ff-c52c722e0d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_83a875a0-83a7-4f88-a7ff-c52c722e0d0f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8485e33f-e058-401c-8ac5-b1e3174129b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8485e33f-e058-401c-8ac5-b1e3174129b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3e8fc6ac-ae77-4332-a94e-76dc7f133c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3e8fc6ac-ae77-4332-a94e-76dc7f133c83" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3faf6230-3a7b-43cc-8c1b-ed311cf8fbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_60217859-7322-4607-8dad-8e306f47b5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_77a81b21-cdf7-4511-ab93-1291677bd29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d5d70e95-afc9-4fc4-a28d-5785a1b33be9" xlink:to="loc_us-gaap_StatementTable_77a81b21-cdf7-4511-ab93-1291677bd29e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f4af31b6-cc36-4480-80bb-eed5b44255a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_77a81b21-cdf7-4511-ab93-1291677bd29e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f4af31b6-cc36-4480-80bb-eed5b44255a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f4af31b6-cc36-4480-80bb-eed5b44255a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4af31b6-cc36-4480-80bb-eed5b44255a5" xlink:to="loc_us-gaap_EquityComponentDomain_f4af31b6-cc36-4480-80bb-eed5b44255a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f271e067-cf45-4dcb-a492-abf02c1f2a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4af31b6-cc36-4480-80bb-eed5b44255a5" xlink:to="loc_us-gaap_EquityComponentDomain_f271e067-cf45-4dcb-a492-abf02c1f2a01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cffb0b85-25d3-4926-9946-b34be1c1c84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f271e067-cf45-4dcb-a492-abf02c1f2a01" xlink:to="loc_us-gaap_CommonStockMember_cffb0b85-25d3-4926-9946-b34be1c1c84e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_83d68093-7c89-4c0b-8de1-1e2dfbfd030b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f271e067-cf45-4dcb-a492-abf02c1f2a01" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_83d68093-7c89-4c0b-8de1-1e2dfbfd030b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c58a0d5d-d2f9-4757-9276-c52e96c10f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f271e067-cf45-4dcb-a492-abf02c1f2a01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c58a0d5d-d2f9-4757-9276-c52e96c10f4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6fb499b3-bb56-4bc8-aa7a-387112143065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f271e067-cf45-4dcb-a492-abf02c1f2a01" xlink:to="loc_us-gaap_RetainedEarningsMember_6fb499b3-bb56-4bc8-aa7a-387112143065" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2a81ce49-a3c6-458c-9481-cf22bb427c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_77a81b21-cdf7-4511-ab93-1291677bd29e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2a81ce49-a3c6-458c-9481-cf22bb427c45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a81ce49-a3c6-458c-9481-cf22bb427c45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2a81ce49-a3c6-458c-9481-cf22bb427c45" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a81ce49-a3c6-458c-9481-cf22bb427c45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_258e24ed-ffa6-445d-8e13-f33b658207dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2a81ce49-a3c6-458c-9481-cf22bb427c45" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_258e24ed-ffa6-445d-8e13-f33b658207dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PublicOfferingMember_53a01e42-0eb9-40c0-b82f-1b4e0a39dbf1" xlink:href="vtl-20220630.xsd#vtl_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_258e24ed-ffa6-445d-8e13-f33b658207dc" xlink:to="loc_vtl_PublicOfferingMember_53a01e42-0eb9-40c0-b82f-1b4e0a39dbf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A4SCRoyaltySettlementMember_03b54cf1-38fa-47c6-9651-cd22f227e64b" xlink:href="vtl-20220630.xsd#vtl_A4SCRoyaltySettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_258e24ed-ffa6-445d-8e13-f33b658207dc" xlink:to="loc_vtl_A4SCRoyaltySettlementMember_03b54cf1-38fa-47c6-9651-cd22f227e64b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="vtl-20220630.xsd#CondensedConsolidatedStatementofCashFlows"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="extended" id="i6d21533a240941a090f1b65231c4cc05_CondensedConsolidatedStatementofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ac78fce-a4c3-4455-9c76-769b8ddb3bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ac78fce-a4c3-4455-9c76-769b8ddb3bff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c1e066ba-5ff2-4d9d-8297-ecddd7dffd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ac78fce-a4c3-4455-9c76-769b8ddb3bff" xlink:to="loc_us-gaap_NetIncomeLoss_c1e066ba-5ff2-4d9d-8297-ecddd7dffd79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d55479b-b669-425d-98ae-0639eff5f595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ac78fce-a4c3-4455-9c76-769b8ddb3bff" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d55479b-b669-425d-98ae-0639eff5f595" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_988d618d-6d13-4288-9488-a184358c4be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d55479b-b669-425d-98ae-0639eff5f595" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_988d618d-6d13-4288-9488-a184358c4be7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d6116fa7-704e-449b-b7a7-30cfb8ce77e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d55479b-b669-425d-98ae-0639eff5f595" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d6116fa7-704e-449b-b7a7-30cfb8ce77e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7e2a99fc-c316-47de-96fd-57fe1703fe23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d55479b-b669-425d-98ae-0639eff5f595" xlink:to="loc_us-gaap_ShareBasedCompensation_7e2a99fc-c316-47de-96fd-57fe1703fe23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_94c2874b-c61b-45b9-a22a-53c31a44833a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d55479b-b669-425d-98ae-0639eff5f595" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_94c2874b-c61b-45b9-a22a-53c31a44833a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_523be5ba-ff7a-466f-9597-0775c2f63cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d55479b-b669-425d-98ae-0639eff5f595" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_523be5ba-ff7a-466f-9597-0775c2f63cc3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ab1840db-4a6c-4987-915c-b5b174fba36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_523be5ba-ff7a-466f-9597-0775c2f63cc3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ab1840db-4a6c-4987-915c-b5b174fba36b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ae9c8b65-530c-4164-85cf-b85176dec2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_523be5ba-ff7a-466f-9597-0775c2f63cc3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ae9c8b65-530c-4164-85cf-b85176dec2ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_37b3f97f-3e5e-4120-9e75-fc7212a3d756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_523be5ba-ff7a-466f-9597-0775c2f63cc3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_37b3f97f-3e5e-4120-9e75-fc7212a3d756" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a40eb15d-e6c9-4894-b4e9-625366331ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_523be5ba-ff7a-466f-9597-0775c2f63cc3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a40eb15d-e6c9-4894-b4e9-625366331ef0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de593d21-8441-405e-b49c-6281236e1dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ac78fce-a4c3-4455-9c76-769b8ddb3bff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de593d21-8441-405e-b49c-6281236e1dcc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_32fc7897-2f05-4873-85b9-a446b842ee4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_32fc7897-2f05-4873-85b9-a446b842ee4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c8d20740-aa02-4a46-805e-e7ffdc8897d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_32fc7897-2f05-4873-85b9-a446b842ee4c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c8d20740-aa02-4a46-805e-e7ffdc8897d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bf0e22d7-e9e6-44df-a1a8-625044f52b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_32fc7897-2f05-4873-85b9-a446b842ee4c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bf0e22d7-e9e6-44df-a1a8-625044f52b30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ebd4ad43-d7f3-4ac4-b418-09c91481402c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ebd4ad43-d7f3-4ac4-b418-09c91481402c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c8c21655-278a-4612-bd58-49dbd8ea495a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ebd4ad43-d7f3-4ac4-b418-09c91481402c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c8c21655-278a-4612-bd58-49dbd8ea495a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_159d26e4-3e41-4a5e-9d4b-32dbb1f54975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ebd4ad43-d7f3-4ac4-b418-09c91481402c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_159d26e4-3e41-4a5e-9d4b-32dbb1f54975" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_44b655ff-970b-4884-9718-08c81e752509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ebd4ad43-d7f3-4ac4-b418-09c91481402c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_44b655ff-970b-4884-9718-08c81e752509" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_12768781-dc12-4be8-9720-369f28dce4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ebd4ad43-d7f3-4ac4-b418-09c91481402c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_12768781-dc12-4be8-9720-369f28dce4bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecbb6741-9885-4f9c-a756-6d65117a39b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecbb6741-9885-4f9c-a756-6d65117a39b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e9964814-afb0-4138-9fe0-6fe12db52bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e9964814-afb0-4138-9fe0-6fe12db52bd2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f2e8123e-6570-43c7-9837-61d15a8e96ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f2e8123e-6570-43c7-9837-61d15a8e96ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7285e308-7453-4ef2-8ab5-16bd83fe800e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_81133000-7538-4e89-8ccb-13feb9837fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_81133000-7538-4e89-8ccb-13feb9837fff" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_37183d33-d671-41e5-bda5-d6f7c099434d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_81133000-7538-4e89-8ccb-13feb9837fff" xlink:to="loc_us-gaap_StockIssued1_37183d33-d671-41e5-bda5-d6f7c099434d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_09bc96ed-8871-4e02-b76c-e39818d7b56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_81133000-7538-4e89-8ccb-13feb9837fff" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_09bc96ed-8871-4e02-b76c-e39818d7b56c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_91906bee-1d85-4a61-8e30-a19c904e4623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_StatementTable_91906bee-1d85-4a61-8e30-a19c904e4623" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bd08ff82-e81a-424b-b5e6-3465bfc2495b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_91906bee-1d85-4a61-8e30-a19c904e4623" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bd08ff82-e81a-424b-b5e6-3465bfc2495b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bd08ff82-e81a-424b-b5e6-3465bfc2495b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bd08ff82-e81a-424b-b5e6-3465bfc2495b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bd08ff82-e81a-424b-b5e6-3465bfc2495b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df1e4af5-38ae-4c67-948f-478a143078b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bd08ff82-e81a-424b-b5e6-3465bfc2495b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df1e4af5-38ae-4c67-948f-478a143078b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PublicOfferingMember_33b2ab30-fa4f-409f-b9ad-dbb4366f865d" xlink:href="vtl-20220630.xsd#vtl_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df1e4af5-38ae-4c67-948f-478a143078b5" xlink:to="loc_vtl_PublicOfferingMember_33b2ab30-fa4f-409f-b9ad-dbb4366f865d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i3b4d9e1ed3f34676a93d1468b10ed724_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f4b9537-5f78-4654-9900-eb6a20f39a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0c959b6c-f19b-4d5d-8729-dc84e15c90a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f4b9537-5f78-4654-9900-eb6a20f39a99" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0c959b6c-f19b-4d5d-8729-dc84e15c90a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3f2059c0-2292-4422-ae4e-d63e666fbe4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f4b9537-5f78-4654-9900-eb6a20f39a99" xlink:to="loc_us-gaap_Depreciation_3f2059c0-2292-4422-ae4e-d63e666fbe4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_ea0e7a50-cb45-4240-a983-ae576cf2735d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f4b9537-5f78-4654-9900-eb6a20f39a99" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_ea0e7a50-cb45-4240-a983-ae576cf2735d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_59331a66-8da1-4cc9-8e1f-335fec04b5af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f4b9537-5f78-4654-9900-eb6a20f39a99" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_59331a66-8da1-4cc9-8e1f-335fec04b5af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_1095c7db-a1c4-469a-8f88-e096fcef0eae" xlink:href="vtl-20220630.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f4b9537-5f78-4654-9900-eb6a20f39a99" xlink:to="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_1095c7db-a1c4-469a-8f88-e096fcef0eae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fd00e4d-50ca-424c-8d85-a2ba192f7ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f4b9537-5f78-4654-9900-eb6a20f39a99" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fd00e4d-50ca-424c-8d85-a2ba192f7ecd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9465d8ad-671f-4e5f-b9d3-5922efc7908e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fd00e4d-50ca-424c-8d85-a2ba192f7ecd" xlink:to="loc_srt_RangeAxis_9465d8ad-671f-4e5f-b9d3-5922efc7908e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9465d8ad-671f-4e5f-b9d3-5922efc7908e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9465d8ad-671f-4e5f-b9d3-5922efc7908e" xlink:to="loc_srt_RangeMember_9465d8ad-671f-4e5f-b9d3-5922efc7908e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7d2f2560-1b0e-42d5-b88e-e5a327142f2c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9465d8ad-671f-4e5f-b9d3-5922efc7908e" xlink:to="loc_srt_RangeMember_7d2f2560-1b0e-42d5-b88e-e5a327142f2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e7b9ae38-1171-4128-81f7-1a3cfac27651" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7d2f2560-1b0e-42d5-b88e-e5a327142f2c" xlink:to="loc_srt_MinimumMember_e7b9ae38-1171-4128-81f7-1a3cfac27651" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_136da454-22f6-4a3f-9cd0-7c5485193b89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7d2f2560-1b0e-42d5-b88e-e5a327142f2c" xlink:to="loc_srt_MaximumMember_136da454-22f6-4a3f-9cd0-7c5485193b89" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended" id="i83b3cf4b436147a191b37b08da4ebf90_SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d2a738d6-e134-42ff-8bf2-87b4204857bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a8b0f94a-cd7e-49ea-a440-d062760713e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d2a738d6-e134-42ff-8bf2-87b4204857bc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a8b0f94a-cd7e-49ea-a440-d062760713e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d860a446-d0c5-4a30-b80a-5b884411292c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d2a738d6-e134-42ff-8bf2-87b4204857bc" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d860a446-d0c5-4a30-b80a-5b884411292c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1461e2c3-4483-443d-a1ee-82efd7999e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d860a446-d0c5-4a30-b80a-5b884411292c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1461e2c3-4483-443d-a1ee-82efd7999e80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1461e2c3-4483-443d-a1ee-82efd7999e80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1461e2c3-4483-443d-a1ee-82efd7999e80" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1461e2c3-4483-443d-a1ee-82efd7999e80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e14649fe-6561-4063-a4e9-94c690953db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1461e2c3-4483-443d-a1ee-82efd7999e80" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e14649fe-6561-4063-a4e9-94c690953db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_bf5da9fc-9bdd-4ec4-9ff6-675a0ce94e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e14649fe-6561-4063-a4e9-94c690953db3" xlink:to="loc_us-gaap_StockOptionMember_bf5da9fc-9bdd-4ec4-9ff6-675a0ce94e00" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="ie805d94060b54a268e2ab2e2f9ac69e9_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_80dcdacf-2d50-4b69-9c84-d8e15e6d4c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_80dcdacf-2d50-4b69-9c84-d8e15e6d4c9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseRentHolidayPeriod_c4aa3c87-44fb-420a-9f0f-ac2df334969c" xlink:href="vtl-20220630.xsd#vtl_LesseeOperatingLeaseRentHolidayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_LesseeOperatingLeaseRentHolidayPeriod_c4aa3c87-44fb-420a-9f0f-ac2df334969c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_15324f9d-e8d8-4ed9-bc24-e3e1da9cf31f" xlink:href="vtl-20220630.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_15324f9d-e8d8-4ed9-bc24-e3e1da9cf31f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate_bf6540f1-5223-4455-a598-f6e0e01f6597" xlink:href="vtl-20220630.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_OperatingLeaseIncrementalBorrowingRate_bf6540f1-5223-4455-a598-f6e0e01f6597" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost_17ba6ed1-6e2f-4a1b-a453-22cfdf6e48e2" xlink:href="vtl-20220630.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_OperatingAndVariableLeasesCost_17ba6ed1-6e2f-4a1b-a453-22cfdf6e48e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_19bb5809-f2dd-43fc-90d2-7f020ed36e8c" xlink:href="vtl-20220630.xsd#vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_19bb5809-f2dd-43fc-90d2-7f020ed36e8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7e77fcd8-a2ff-44ec-9c8d-e588c8a0ab37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_us-gaap_CommonStockSharesIssued_7e77fcd8-a2ff-44ec-9c8d-e588c8a0ab37" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bd01afd1-c844-440c-b51d-394bc215d440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_us-gaap_CommonStockValue_bd01afd1-c844-440c-b51d-394bc215d440" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSalesNet_f02b625d-d559-488c-8be0-0f63f0863a3e" xlink:href="vtl-20220630.xsd#vtl_RoyaltySettlementAgreementSalesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_RoyaltySettlementAgreementSalesNet_f02b625d-d559-488c-8be0-0f63f0863a3e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementCashPaymentPercent_2b26aa96-3926-4247-be7d-e3234218421d" xlink:href="vtl-20220630.xsd#vtl_RoyaltySettlementAgreementCashPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_RoyaltySettlementAgreementCashPaymentPercent_2b26aa96-3926-4247-be7d-e3234218421d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSharesPaymentPercent_03393cbf-0733-47f3-8dc3-a48dff8450ca" xlink:href="vtl-20220630.xsd#vtl_RoyaltySettlementAgreementSharesPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_RoyaltySettlementAgreementSharesPaymentPercent_03393cbf-0733-47f3-8dc3-a48dff8450ca" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_8ea3873a-1984-4b4f-a6cb-cb92234f5933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_us-gaap_ContractualObligation_8ea3873a-1984-4b4f-a6cb-cb92234f5933" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fd497d69-8bac-40a3-beb3-b32af505fb32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_us-gaap_LossContingenciesTable_fd497d69-8bac-40a3-beb3-b32af505fb32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4dc2ab40-7735-438b-b480-2e165275b32a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fd497d69-8bac-40a3-beb3-b32af505fb32" xlink:to="loc_srt_StatementGeographicalAxis_4dc2ab40-7735-438b-b480-2e165275b32a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4dc2ab40-7735-438b-b480-2e165275b32a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4dc2ab40-7735-438b-b480-2e165275b32a" xlink:to="loc_srt_SegmentGeographicalDomain_4dc2ab40-7735-438b-b480-2e165275b32a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dd65fab1-6e2f-4561-8c5c-d74fd567d07e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4dc2ab40-7735-438b-b480-2e165275b32a" xlink:to="loc_srt_SegmentGeographicalDomain_dd65fab1-6e2f-4561-8c5c-d74fd567d07e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember_5c85c266-4981-4399-adaf-7f3b0e1649a7" xlink:href="vtl-20220630.xsd#vtl_GrafelfingGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_dd65fab1-6e2f-4561-8c5c-d74fd567d07e" xlink:to="loc_vtl_GrafelfingGermanyMember_5c85c266-4981-4399-adaf-7f3b0e1649a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember_bd70daba-a083-4910-9b61-5347ecbd7431" xlink:href="vtl-20220630.xsd#vtl_NewYorkCityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_dd65fab1-6e2f-4561-8c5c-d74fd567d07e" xlink:to="loc_vtl_NewYorkCityMember_bd70daba-a083-4910-9b61-5347ecbd7431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b02fd5ed-ef87-4d5a-84df-62bb3ab0806f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fd497d69-8bac-40a3-beb3-b32af505fb32" xlink:to="loc_dei_LegalEntityAxis_b02fd5ed-ef87-4d5a-84df-62bb3ab0806f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b02fd5ed-ef87-4d5a-84df-62bb3ab0806f_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_b02fd5ed-ef87-4d5a-84df-62bb3ab0806f" xlink:to="loc_dei_EntityDomain_b02fd5ed-ef87-4d5a-84df-62bb3ab0806f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e8ce4928-057d-4ffc-b023-79d7e78f5a1a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_b02fd5ed-ef87-4d5a-84df-62bb3ab0806f" xlink:to="loc_dei_EntityDomain_e8ce4928-057d-4ffc-b023-79d7e78f5a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ImmunicAGMember_f50ebf97-9394-4db4-ae23-12ae8bd9d860" xlink:href="vtl-20220630.xsd#vtl_ImmunicAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e8ce4928-057d-4ffc-b023-79d7e78f5a1a" xlink:to="loc_vtl_ImmunicAGMember_f50ebf97-9394-4db4-ae23-12ae8bd9d860" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i361b383c9b4d471889099dbdb8241c32_FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_247faf67-0081-4ef1-9d32-963bf8479797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d93cf111-e78e-4364-9129-1a070800c871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_247faf67-0081-4ef1-9d32-963bf8479797" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d93cf111-e78e-4364-9129-1a070800c871" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ba548033-e781-483f-940d-88841901c6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d93cf111-e78e-4364-9129-1a070800c871" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ba548033-e781-483f-940d-88841901c6c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49216c19-77b4-4e95-8997-8f332a1cecf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_247faf67-0081-4ef1-9d32-963bf8479797" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49216c19-77b4-4e95-8997-8f332a1cecf0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_46a5059a-bf98-40ef-a6b5-2a5481330e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49216c19-77b4-4e95-8997-8f332a1cecf0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_46a5059a-bf98-40ef-a6b5-2a5481330e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46a5059a-bf98-40ef-a6b5-2a5481330e77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_46a5059a-bf98-40ef-a6b5-2a5481330e77" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_46a5059a-bf98-40ef-a6b5-2a5481330e77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7aaaca42-6040-4c88-90cf-f98bfea4d0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_46a5059a-bf98-40ef-a6b5-2a5481330e77" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7aaaca42-6040-4c88-90cf-f98bfea4d0fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a9b52550-6487-46e8-898b-a3b6c1fd92d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7aaaca42-6040-4c88-90cf-f98bfea4d0fe" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a9b52550-6487-46e8-898b-a3b6c1fd92d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_41811d75-b92a-4953-a82d-4f7db925a19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7aaaca42-6040-4c88-90cf-f98bfea4d0fe" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_41811d75-b92a-4953-a82d-4f7db925a19a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2ee747ef-90bb-425f-b8a0-17ade9b7ba9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7aaaca42-6040-4c88-90cf-f98bfea4d0fe" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2ee747ef-90bb-425f-b8a0-17ade9b7ba9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bf53a74c-f31c-46e0-830d-aa47c7a69e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49216c19-77b4-4e95-8997-8f332a1cecf0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bf53a74c-f31c-46e0-830d-aa47c7a69e9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bf53a74c-f31c-46e0-830d-aa47c7a69e9f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bf53a74c-f31c-46e0-830d-aa47c7a69e9f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bf53a74c-f31c-46e0-830d-aa47c7a69e9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5536a68e-8e98-4c90-b381-a492dedd9fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bf53a74c-f31c-46e0-830d-aa47c7a69e9f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5536a68e-8e98-4c90-b381-a492dedd9fcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e509a2dc-14a6-408e-9e2c-04729928aa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5536a68e-8e98-4c90-b381-a492dedd9fcb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e509a2dc-14a6-408e-9e2c-04729928aa4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_b8897586-0c54-4531-87e0-8db38963d26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49216c19-77b4-4e95-8997-8f332a1cecf0" xlink:to="loc_us-gaap_InvestmentTypeAxis_b8897586-0c54-4531-87e0-8db38963d26a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b8897586-0c54-4531-87e0-8db38963d26a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_b8897586-0c54-4531-87e0-8db38963d26a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b8897586-0c54-4531-87e0-8db38963d26a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7b131bbc-682d-45e7-85f3-6cf9eb27e358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_b8897586-0c54-4531-87e0-8db38963d26a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7b131bbc-682d-45e7-85f3-6cf9eb27e358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d5ee7b45-e2d0-4b4e-9d37-474cad860baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7b131bbc-682d-45e7-85f3-6cf9eb27e358" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d5ee7b45-e2d0-4b4e-9d37-474cad860baf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommonStockShelfRegistrationStatementDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="extended" id="i6531ac228b63410bb0168f57cfbec387_CommonStockShelfRegistrationStatementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_9af11654-4392-4066-856f-a370b5426d09" xlink:href="vtl-20220630.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_9af11654-4392-4066-856f-a370b5426d09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining_949dd3f2-6f78-4f41-8ff8-e4aac83c8309" xlink:href="vtl-20220630.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_vtl_ShelfRegistrationStatementAmountRemaining_949dd3f2-6f78-4f41-8ff8-e4aac83c8309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_9068a954-a7b1-443b-999d-cf6745d68d0d" xlink:href="vtl-20220630.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_9068a954-a7b1-443b-999d-cf6745d68d0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity_930feaaa-ea60-40e5-8a5c-e97bde4bf3f9" xlink:href="vtl-20220630.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_vtl_SaleOfStockRemainingCapacity_930feaaa-ea60-40e5-8a5c-e97bde4bf3f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_d7e98388-59b4-4da5-bf6a-42e3f2a5186f" xlink:href="vtl-20220630.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_d7e98388-59b4-4da5-bf6a-42e3f2a5186f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59c96251-d7a1-4bbd-b738-1c2178b49a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59c96251-d7a1-4bbd-b738-1c2178b49a22" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8b24ba53-a618-491e-984f-6ca03f2d9d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8b24ba53-a618-491e-984f-6ca03f2d9d17" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_3c0dda0a-edf2-4655-8f0b-ef6127b6dc62" xlink:href="vtl-20220630.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_3c0dda0a-edf2-4655-8f0b-ef6127b6dc62" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a3f4ee19-45e3-47ce-890a-d6537486ce78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a3f4ee19-45e3-47ce-890a-d6537486ce78" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_13f72180-a759-4769-8a9e-530ede086fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_us-gaap_PaymentsForCommissions_13f72180-a759-4769-8a9e-530ede086fb7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_522a9029-4f0c-40cb-a81a-5f49210bf036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_522a9029-4f0c-40cb-a81a-5f49210bf036" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_28f5e82a-f5c6-4d26-8c3e-a8dfc7d88489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_522a9029-4f0c-40cb-a81a-5f49210bf036" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_28f5e82a-f5c6-4d26-8c3e-a8dfc7d88489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28f5e82a-f5c6-4d26-8c3e-a8dfc7d88489_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_28f5e82a-f5c6-4d26-8c3e-a8dfc7d88489" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28f5e82a-f5c6-4d26-8c3e-a8dfc7d88489_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e60ef5-3a6a-49c0-b7df-72a09dbfc250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_28f5e82a-f5c6-4d26-8c3e-a8dfc7d88489" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e60ef5-3a6a-49c0-b7df-72a09dbfc250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember_49d7d2a6-ab5e-47dc-b905-74109c565417" xlink:href="vtl-20220630.xsd#vtl_December2020ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e60ef5-3a6a-49c0-b7df-72a09dbfc250" xlink:to="loc_vtl_December2020ATMMember_49d7d2a6-ab5e-47dc-b905-74109c565417" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember_d05519c6-d639-45ef-97c2-520979ae7fe0" xlink:href="vtl-20220630.xsd#vtl_May2022ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e60ef5-3a6a-49c0-b7df-72a09dbfc250" xlink:to="loc_vtl_May2022ATMMember_d05519c6-d639-45ef-97c2-520979ae7fe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_56e25a64-f5c7-416b-8f3c-0f35a394dfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_522a9029-4f0c-40cb-a81a-5f49210bf036" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_56e25a64-f5c7-416b-8f3c-0f35a394dfbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_56e25a64-f5c7-416b-8f3c-0f35a394dfbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_56e25a64-f5c7-416b-8f3c-0f35a394dfbc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_56e25a64-f5c7-416b-8f3c-0f35a394dfbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_61a4d76d-9413-441f-a592-74bd3679786c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_56e25a64-f5c7-416b-8f3c-0f35a394dfbc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_61a4d76d-9413-441f-a592-74bd3679786c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_acd0db41-7926-4836-9fcc-7000aa70018e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_61a4d76d-9413-441f-a592-74bd3679786c" xlink:to="loc_us-gaap_SubsequentEventMember_acd0db41-7926-4836-9fcc-7000aa70018e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommonStockSharesReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="extended" id="id63f950bd015495bb325d87aa9fa28c6_CommonStockSharesReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c4050a75-4c71-4fea-9579-f4b2b0464939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f8277ba0-0e37-43fe-b260-e2ca6dabc39d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4050a75-4c71-4fea-9579-f4b2b0464939" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f8277ba0-0e37-43fe-b260-e2ca6dabc39d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bf5b0491-7e64-42d0-b854-df217f7fd625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4050a75-4c71-4fea-9579-f4b2b0464939" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bf5b0491-7e64-42d0-b854-df217f7fd625" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_accdd2bd-20ac-45a4-b9e0-b92e2446b610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bf5b0491-7e64-42d0-b854-df217f7fd625" xlink:to="loc_us-gaap_PlanNameAxis_accdd2bd-20ac-45a4-b9e0-b92e2446b610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_accdd2bd-20ac-45a4-b9e0-b92e2446b610_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_accdd2bd-20ac-45a4-b9e0-b92e2446b610" xlink:to="loc_us-gaap_PlanNameDomain_accdd2bd-20ac-45a4-b9e0-b92e2446b610_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_25feaba7-f5fe-45d9-baa2-d04f5cb7fb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_accdd2bd-20ac-45a4-b9e0-b92e2446b610" xlink:to="loc_us-gaap_PlanNameDomain_25feaba7-f5fe-45d9-baa2-d04f5cb7fb73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_4a57c5ab-7f49-4a42-b33e-28db81145145" xlink:href="vtl-20220630.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_25feaba7-f5fe-45d9-baa2-d04f5cb7fb73" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_4a57c5ab-7f49-4a42-b33e-28db81145145" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_abdf45e7-0b17-4059-ae95-d23fa920aaaf" xlink:href="vtl-20220630.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_25feaba7-f5fe-45d9-baa2-d04f5cb7fb73" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_abdf45e7-0b17-4059-ae95-d23fa920aaaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_47c48cee-6357-4229-a135-bbb0526d3898" xlink:href="vtl-20220630.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_25feaba7-f5fe-45d9-baa2-d04f5cb7fb73" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_47c48cee-6357-4229-a135-bbb0526d3898" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a6bfcfe5-3d82-420b-88f7-58bac62f8e30" xlink:href="vtl-20220630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_25feaba7-f5fe-45d9-baa2-d04f5cb7fb73" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a6bfcfe5-3d82-420b-88f7-58bac62f8e30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5bf43bcb-ed1a-475e-9937-999d469301f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bf5b0491-7e64-42d0-b854-df217f7fd625" xlink:to="loc_us-gaap_AwardTypeAxis_5bf43bcb-ed1a-475e-9937-999d469301f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5bf43bcb-ed1a-475e-9937-999d469301f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5bf43bcb-ed1a-475e-9937-999d469301f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5bf43bcb-ed1a-475e-9937-999d469301f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2c01b3-c225-4734-8b86-55cdd9a7a6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5bf43bcb-ed1a-475e-9937-999d469301f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2c01b3-c225-4734-8b86-55cdd9a7a6b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c531c9ad-69a0-4c77-a547-0e286fbab3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2c01b3-c225-4734-8b86-55cdd9a7a6b3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c531c9ad-69a0-4c77-a547-0e286fbab3d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember_a429c026-ffed-4ca7-ae8b-37d2b4324ce4" xlink:href="vtl-20220630.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2c01b3-c225-4734-8b86-55cdd9a7a6b3" xlink:to="loc_vtl_EmployeeStockOptionsforFutureGrantMember_a429c026-ffed-4ca7-ae8b-37d2b4324ce4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#StockBasedCompensationPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="extended" id="i3970ebe57fd9401eadf428a9b3c0ead7_StockBasedCompensationPlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_817b1945-82f5-4e5b-a81c-5698ae2b42a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_817b1945-82f5-4e5b-a81c-5698ae2b42a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2f5a691b-8ba0-49fc-a57a-8eaa76db1a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2f5a691b-8ba0-49fc-a57a-8eaa76db1a8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_acf16f97-7b87-4b3d-99fe-0bf7d2a7f6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_acf16f97-7b87-4b3d-99fe-0bf7d2a7f6e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_76c354ca-7c1f-4a77-a731-dfbdde2434db" xlink:href="vtl-20220630.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_76c354ca-7c1f-4a77-a731-dfbdde2434db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e82a2d28-fa34-4016-b150-d51021ede734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e82a2d28-fa34-4016-b150-d51021ede734" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fc147a05-e089-4862-a228-50c366f185c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fc147a05-e089-4862-a228-50c366f185c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9c58a7be-6b7f-4400-a686-6b515d32415a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9c58a7be-6b7f-4400-a686-6b515d32415a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2a152eb5-698d-47eb-a021-cce7cf106c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2a152eb5-698d-47eb-a021-cce7cf106c39" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1e6f0ca1-8e68-4ae7-bacb-cff32056d74c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1e6f0ca1-8e68-4ae7-bacb-cff32056d74c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35391e2c-3de8-4e15-81d5-a4a3d1475536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35391e2c-3de8-4e15-81d5-a4a3d1475536" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af468119-7c2b-4053-8a06-0e5808544757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af468119-7c2b-4053-8a06-0e5808544757" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ae479d4c-d938-45d4-b38e-860573b93a50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ae479d4c-d938-45d4-b38e-860573b93a50" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7152bf6-dc86-4686-a44a-cd65ab4819cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7152bf6-dc86-4686-a44a-cd65ab4819cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_603ba655-2794-4fa0-975c-33341059e7fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7152bf6-dc86-4686-a44a-cd65ab4819cf" xlink:to="loc_srt_RangeAxis_603ba655-2794-4fa0-975c-33341059e7fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_603ba655-2794-4fa0-975c-33341059e7fe_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_603ba655-2794-4fa0-975c-33341059e7fe" xlink:to="loc_srt_RangeMember_603ba655-2794-4fa0-975c-33341059e7fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_72b38536-1739-4601-8d30-68a99166c924" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_603ba655-2794-4fa0-975c-33341059e7fe" xlink:to="loc_srt_RangeMember_72b38536-1739-4601-8d30-68a99166c924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_081ae49b-079c-4c3d-a2d2-14a1aeabc864" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_72b38536-1739-4601-8d30-68a99166c924" xlink:to="loc_srt_MinimumMember_081ae49b-079c-4c3d-a2d2-14a1aeabc864" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2d46b5e3-2fca-4972-a152-8d890efcc21b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_72b38536-1739-4601-8d30-68a99166c924" xlink:to="loc_srt_MaximumMember_2d46b5e3-2fca-4972-a152-8d890efcc21b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9ec5cc0b-6767-43f0-9685-510fbcc1d042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7152bf6-dc86-4686-a44a-cd65ab4819cf" xlink:to="loc_us-gaap_AwardTypeAxis_9ec5cc0b-6767-43f0-9685-510fbcc1d042" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ec5cc0b-6767-43f0-9685-510fbcc1d042_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9ec5cc0b-6767-43f0-9685-510fbcc1d042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ec5cc0b-6767-43f0-9685-510fbcc1d042_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e23ad26-4752-435d-862a-f8600422a328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9ec5cc0b-6767-43f0-9685-510fbcc1d042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e23ad26-4752-435d-862a-f8600422a328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember_2ccffcd2-5c3f-48ee-a853-a201c037f7b4" xlink:href="vtl-20220630.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e23ad26-4752-435d-862a-f8600422a328" xlink:to="loc_vtl_IncentiveEmployeeStockOptionMember_2ccffcd2-5c3f-48ee-a853-a201c037f7b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember_48d57c8d-ed42-47a9-82d0-29bdf1e42937" xlink:href="vtl-20220630.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e23ad26-4752-435d-862a-f8600422a328" xlink:to="loc_vtl_NonStatutoryEmployeeStockOptionMember_48d57c8d-ed42-47a9-82d0-29bdf1e42937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2f3d0531-71e4-4530-a63e-ad4a5e4c6d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7152bf6-dc86-4686-a44a-cd65ab4819cf" xlink:to="loc_us-gaap_PlanNameAxis_2f3d0531-71e4-4530-a63e-ad4a5e4c6d55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2f3d0531-71e4-4530-a63e-ad4a5e4c6d55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2f3d0531-71e4-4530-a63e-ad4a5e4c6d55" xlink:to="loc_us-gaap_PlanNameDomain_2f3d0531-71e4-4530-a63e-ad4a5e4c6d55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7edda3e0-2cf1-4c4a-9326-b8a1d26c0ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2f3d0531-71e4-4530-a63e-ad4a5e4c6d55" xlink:to="loc_us-gaap_PlanNameDomain_7edda3e0-2cf1-4c4a-9326-b8a1d26c0ce3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_aa686e2c-1ba0-4c96-a401-9dd71fe6d6ed" xlink:href="vtl-20220630.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7edda3e0-2cf1-4c4a-9326-b8a1d26c0ce3" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_aa686e2c-1ba0-4c96-a401-9dd71fe6d6ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_ded58c75-933f-473a-8984-7d63373a0586" xlink:href="vtl-20220630.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7edda3e0-2cf1-4c4a-9326-b8a1d26c0ce3" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_ded58c75-933f-473a-8984-7d63373a0586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_fe8d3d6e-b751-4073-91fa-fcfd4931407d" xlink:href="vtl-20220630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtl_A2019OmnibusEquityIncentivePlanMember_ded58c75-933f-473a-8984-7d63373a0586" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_fe8d3d6e-b751-4073-91fa-fcfd4931407d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_9711e216-1a25-4a05-9d9e-6cc85f69e96f" xlink:href="vtl-20220630.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7edda3e0-2cf1-4c4a-9326-b8a1d26c0ce3" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_9711e216-1a25-4a05-9d9e-6cc85f69e96f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_0671851a-ff7c-420c-b35a-e41f32ea571d" xlink:href="vtl-20220630.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7edda3e0-2cf1-4c4a-9326-b8a1d26c0ce3" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_0671851a-ff7c-420c-b35a-e41f32ea571d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#StockBasedCompensationPlansSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="extended" id="i0c1b1ebf894c44bf9fcbcd30d01799df_StockBasedCompensationPlansSummaryofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2f13ac7-ee30-436e-9971-1bb472e0d187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2f13ac7-ee30-436e-9971-1bb472e0d187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9c828fb5-6174-4f1d-b15d-6f476bbd7511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2f13ac7-ee30-436e-9971-1bb472e0d187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9c828fb5-6174-4f1d-b15d-6f476bbd7511" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7b41f171-0de9-4dc6-913f-ddaf931115d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2f13ac7-ee30-436e-9971-1bb472e0d187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7b41f171-0de9-4dc6-913f-ddaf931115d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_623d1d9f-c8a8-4c08-922d-711b56907189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2f13ac7-ee30-436e-9971-1bb472e0d187" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_623d1d9f-c8a8-4c08-922d-711b56907189" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_157e4908-77cc-49ca-bf04-6db93159fa81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2f13ac7-ee30-436e-9971-1bb472e0d187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_157e4908-77cc-49ca-bf04-6db93159fa81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6baefb0b-da6b-4e52-8ea6-ebbb366d6383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_570e9a0c-6bb9-4e2b-b6cf-7b928739e065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_570e9a0c-6bb9-4e2b-b6cf-7b928739e065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_498a6d7a-459a-4da2-b89b-66b793e18ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_498a6d7a-459a-4da2-b89b-66b793e18ba0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d011f73-f712-4595-a806-8a37bb119c90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d011f73-f712-4595-a806-8a37bb119c90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1906cec6-37d6-4fde-b268-6048775a38a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d011f73-f712-4595-a806-8a37bb119c90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1906cec6-37d6-4fde-b268-6048775a38a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c6779bd1-20c5-4a76-adbd-5be2fb8e6cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d011f73-f712-4595-a806-8a37bb119c90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c6779bd1-20c5-4a76-adbd-5be2fb8e6cff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c16e42f2-4e31-4c83-8044-61ef8fca79a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d011f73-f712-4595-a806-8a37bb119c90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c16e42f2-4e31-4c83-8044-61ef8fca79a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1d118551-b4b7-4175-98ba-ba6af6234796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d011f73-f712-4595-a806-8a37bb119c90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1d118551-b4b7-4175-98ba-ba6af6234796" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fc579097-58c9-4d87-8594-af31d9e1d9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0de81bd8-5da0-48bb-8330-5051bceed9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0de81bd8-5da0-48bb-8330-5051bceed9fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6cceea48-3d20-4b83-976d-e08a6f208f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6cceea48-3d20-4b83-976d-e08a6f208f72" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d9df3e18-a29b-4c53-9d70-1b868e455c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d9df3e18-a29b-4c53-9d70-1b868e455c44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a28a2bf6-a16c-4566-8018-8abbf1c54199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a28a2bf6-a16c-4566-8018-8abbf1c54199" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7702e387-890a-4fa9-b0ff-eea88f6b3d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7702e387-890a-4fa9-b0ff-eea88f6b3d0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3828052d-b794-4fe3-8610-d7f9317f5a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3828052d-b794-4fe3-8610-d7f9317f5a1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d3e04170-b91d-458f-8918-0e809410afc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d3e04170-b91d-458f-8918-0e809410afc8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9539eb02-3cda-425b-bee6-d850301de915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9539eb02-3cda-425b-bee6-d850301de915" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_201afd88-1419-4b12-b361-afb93795cb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_201afd88-1419-4b12-b361-afb93795cb75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6bfa0baa-cee4-48eb-af55-65865a9f4ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_201afd88-1419-4b12-b361-afb93795cb75" xlink:to="loc_us-gaap_PlanNameAxis_6bfa0baa-cee4-48eb-af55-65865a9f4ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6bfa0baa-cee4-48eb-af55-65865a9f4ba9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6bfa0baa-cee4-48eb-af55-65865a9f4ba9" xlink:to="loc_us-gaap_PlanNameDomain_6bfa0baa-cee4-48eb-af55-65865a9f4ba9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6f81a901-c707-40c2-96f6-4042c6a3896b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6bfa0baa-cee4-48eb-af55-65865a9f4ba9" xlink:to="loc_us-gaap_PlanNameDomain_6f81a901-c707-40c2-96f6-4042c6a3896b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_62e983d7-12e6-48b1-a0b7-39c8069a3ee0" xlink:href="vtl-20220630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6f81a901-c707-40c2-96f6-4042c6a3896b" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_62e983d7-12e6-48b1-a0b7-39c8069a3ee0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5124764c-1bcd-40b4-a44c-0cd30f851a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_201afd88-1419-4b12-b361-afb93795cb75" xlink:to="loc_us-gaap_AwardTypeAxis_5124764c-1bcd-40b4-a44c-0cd30f851a9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5124764c-1bcd-40b4-a44c-0cd30f851a9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5124764c-1bcd-40b4-a44c-0cd30f851a9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5124764c-1bcd-40b4-a44c-0cd30f851a9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5548ca6e-5488-4e16-8493-32927ffaa884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5124764c-1bcd-40b4-a44c-0cd30f851a9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5548ca6e-5488-4e16-8493-32927ffaa884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e80983a4-4af4-4e37-82ee-e68e248a4635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5548ca6e-5488-4e16-8493-32927ffaa884" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e80983a4-4af4-4e37-82ee-e68e248a4635" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="simple" xlink:href="vtl-20220630.xsd#StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="extended" id="ie9105705c20f4187876f63f39323595f_StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec7de2df-c024-4603-b779-986d4cdac727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f00cfe04-069c-418c-93ae-f8bf841de77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec7de2df-c024-4603-b779-986d4cdac727" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f00cfe04-069c-418c-93ae-f8bf841de77c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c16f894a-8ea6-4383-aa3a-df59718d0287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec7de2df-c024-4603-b779-986d4cdac727" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c16f894a-8ea6-4383-aa3a-df59718d0287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_65b9c948-628f-429e-b1d5-4922c9512821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec7de2df-c024-4603-b779-986d4cdac727" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_65b9c948-628f-429e-b1d5-4922c9512821" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_38d7fa55-2d89-4549-b6a4-38d41b311494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec7de2df-c024-4603-b779-986d4cdac727" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_38d7fa55-2d89-4549-b6a4-38d41b311494" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_62721170-c2ef-4f39-b377-d3e0a8251179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec7de2df-c024-4603-b779-986d4cdac727" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_62721170-c2ef-4f39-b377-d3e0a8251179" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677f6813-008c-4873-92a5-e8308017a1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec7de2df-c024-4603-b779-986d4cdac727" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677f6813-008c-4873-92a5-e8308017a1b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ef1a186e-de7a-41a9-9a6c-46513cec2a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677f6813-008c-4873-92a5-e8308017a1b5" xlink:to="loc_us-gaap_PlanNameAxis_ef1a186e-de7a-41a9-9a6c-46513cec2a19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ef1a186e-de7a-41a9-9a6c-46513cec2a19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ef1a186e-de7a-41a9-9a6c-46513cec2a19" xlink:to="loc_us-gaap_PlanNameDomain_ef1a186e-de7a-41a9-9a6c-46513cec2a19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cc310457-ca23-479b-aa86-25c5b8a4c90f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ef1a186e-de7a-41a9-9a6c-46513cec2a19" xlink:to="loc_us-gaap_PlanNameDomain_cc310457-ca23-479b-aa86-25c5b8a4c90f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_455908c7-864a-4b02-8bc9-97cb397b44cb" xlink:href="vtl-20220630.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cc310457-ca23-479b-aa86-25c5b8a4c90f" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_455908c7-864a-4b02-8bc9-97cb397b44cb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="extended" id="i240b9dadf729432790fc26b3c80c6dc9_StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_155f3cb7-2259-42b7-ba4a-a5f9bbc06133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fb7d8fe8-cf21-477b-8a4d-335b55e5d023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_155f3cb7-2259-42b7-ba4a-a5f9bbc06133" xlink:to="loc_us-gaap_ShareBasedCompensation_fb7d8fe8-cf21-477b-8a4d-335b55e5d023" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce362177-d263-452b-b7fb-7214fb69d1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_155f3cb7-2259-42b7-ba4a-a5f9bbc06133" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce362177-d263-452b-b7fb-7214fb69d1d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_c7c7ddeb-361a-4430-abfc-ad1fb038f451" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce362177-d263-452b-b7fb-7214fb69d1d2" xlink:to="loc_srt_TitleOfIndividualAxis_c7c7ddeb-361a-4430-abfc-ad1fb038f451" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c7c7ddeb-361a-4430-abfc-ad1fb038f451_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_c7c7ddeb-361a-4430-abfc-ad1fb038f451" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c7c7ddeb-361a-4430-abfc-ad1fb038f451_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e35bcc3b-cda0-454f-bd1e-6b2bd44bafeb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_c7c7ddeb-361a-4430-abfc-ad1fb038f451" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e35bcc3b-cda0-454f-bd1e-6b2bd44bafeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember_57cbf2a0-6ea8-4e24-b9d7-b29c104a01e4" xlink:href="vtl-20220630.xsd#vtl_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e35bcc3b-cda0-454f-bd1e-6b2bd44bafeb" xlink:to="loc_vtl_EmployeeMember_57cbf2a0-6ea8-4e24-b9d7-b29c104a01e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b7e0f4d8-97ec-47f9-b62d-9d35f26d025b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce362177-d263-452b-b7fb-7214fb69d1d2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b7e0f4d8-97ec-47f9-b62d-9d35f26d025b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b7e0f4d8-97ec-47f9-b62d-9d35f26d025b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b7e0f4d8-97ec-47f9-b62d-9d35f26d025b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b7e0f4d8-97ec-47f9-b62d-9d35f26d025b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7c1025e6-1119-41ff-aec2-12c3761e3711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b7e0f4d8-97ec-47f9-b62d-9d35f26d025b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7c1025e6-1119-41ff-aec2-12c3761e3711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_54e3e641-4152-492f-948a-9b5e765284c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7c1025e6-1119-41ff-aec2-12c3761e3711" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_54e3e641-4152-492f-948a-9b5e765284c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_870d96a4-a718-4e7e-acf8-94496e8b5fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7c1025e6-1119-41ff-aec2-12c3761e3711" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_870d96a4-a718-4e7e-acf8-94496e8b5fe1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="ib13d03ae844b4e6887d486c661ca3b73_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_81765962-3ed8-4d87-9fbb-aaf4936ff4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_123ae7c9-ed66-4718-8045-5f7d3edd7c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_81765962-3ed8-4d87-9fbb-aaf4936ff4d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_123ae7c9-ed66-4718-8045-5f7d3edd7c2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary_8b6b3983-5c2c-4c07-b483-72bc1bef30b1" xlink:href="vtl-20220630.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_81765962-3ed8-4d87-9fbb-aaf4936ff4d2" xlink:to="loc_vtl_SalaryCostsMonthlyBaseSalary_8b6b3983-5c2c-4c07-b483-72bc1bef30b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_81765962-3ed8-4d87-9fbb-aaf4936ff4d2" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b522cf5d-3d6a-4440-bbf7-d2cb6a2d55e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b522cf5d-3d6a-4440-bbf7-d2cb6a2d55e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b522cf5d-3d6a-4440-bbf7-d2cb6a2d55e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b522cf5d-3d6a-4440-bbf7-d2cb6a2d55e0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b522cf5d-3d6a-4440-bbf7-d2cb6a2d55e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d690c9d1-e595-45aa-bdc8-5c684e71878e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b522cf5d-3d6a-4440-bbf7-d2cb6a2d55e0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d690c9d1-e595-45aa-bdc8-5c684e71878e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember_3b260766-65b7-46e3-b2c7-20f486dd6cfa" xlink:href="vtl-20220630.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d690c9d1-e595-45aa-bdc8-5c684e71878e" xlink:to="loc_vtl_ExecutiveChairmanAgreementMember_3b260766-65b7-46e3-b2c7-20f486dd6cfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01722550-3a8a-48aa-8045-b71a936fa62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01722550-3a8a-48aa-8045-b71a936fa62a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_01722550-3a8a-48aa-8045-b71a936fa62a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01722550-3a8a-48aa-8045-b71a936fa62a" xlink:to="loc_us-gaap_RelatedPartyDomain_01722550-3a8a-48aa-8045-b71a936fa62a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cb176a77-a79f-4e27-a17d-0549d48bb827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01722550-3a8a-48aa-8045-b71a936fa62a" xlink:to="loc_us-gaap_RelatedPartyDomain_cb176a77-a79f-4e27-a17d-0549d48bb827" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_be4edff3-4d20-472c-94e7-32060725e4ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cb176a77-a79f-4e27-a17d-0549d48bb827" xlink:to="loc_srt_AffiliatedEntityMember_be4edff3-4d20-472c-94e7-32060725e4ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_93354bc8-becc-4d81-b8ba-37541978f8a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:to="loc_srt_CounterpartyNameAxis_93354bc8-becc-4d81-b8ba-37541978f8a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93354bc8-becc-4d81-b8ba-37541978f8a2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_93354bc8-becc-4d81-b8ba-37541978f8a2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93354bc8-becc-4d81-b8ba-37541978f8a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45501ebd-402a-4abe-b1e0-441cc572ce8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_93354bc8-becc-4d81-b8ba-37541978f8a2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45501ebd-402a-4abe-b1e0-441cc572ce8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember_e316fddf-e8ff-4d3d-9622-d3bb32887330" xlink:href="vtl-20220630.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45501ebd-402a-4abe-b1e0-441cc572ce8f" xlink:to="loc_vtl_DuaneNashMDJDMBAMember_e316fddf-e8ff-4d3d-9622-d3bb32887330" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_8eef9e29-d764-433d-a663-35588b06cd8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:to="loc_srt_TitleOfIndividualAxis_8eef9e29-d764-433d-a663-35588b06cd8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8eef9e29-d764-433d-a663-35588b06cd8c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_8eef9e29-d764-433d-a663-35588b06cd8c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8eef9e29-d764-433d-a663-35588b06cd8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e532f279-e38f-4c65-ba0d-1349754fc1d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_8eef9e29-d764-433d-a663-35588b06cd8c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e532f279-e38f-4c65-ba0d-1349754fc1d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_de782ace-e60a-44c3-bdd7-59b73a640e0b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e532f279-e38f-4c65-ba0d-1349754fc1d7" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_de782ace-e60a-44c3-bdd7-59b73a640e0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9fd538d2-f79a-4c7e-8299-91fa2e8027fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:to="loc_srt_StatementScenarioAxis_9fd538d2-f79a-4c7e-8299-91fa2e8027fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9fd538d2-f79a-4c7e-8299-91fa2e8027fb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_9fd538d2-f79a-4c7e-8299-91fa2e8027fb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9fd538d2-f79a-4c7e-8299-91fa2e8027fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_55afaa38-1f19-4097-af1d-027967aac9e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_9fd538d2-f79a-4c7e-8299-91fa2e8027fb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_55afaa38-1f19-4097-af1d-027967aac9e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ec841f72-2613-4694-93b6-5aea8dc38940" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_55afaa38-1f19-4097-af1d-027967aac9e5" xlink:to="loc_srt_ScenarioForecastMember_ec841f72-2613-4694-93b6-5aea8dc38940" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SubsequentEventsDetails" xlink:type="extended" id="i7cf2d10f719e494b90a4419405b1c5e3_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_d4648fc0-7fb2-4882-bdd9-f08b2a268fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c799df02-a326-4576-a93d-6a9adee4fc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d4648fc0-7fb2-4882-bdd9-f08b2a268fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c799df02-a326-4576-a93d-6a9adee4fc4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eccf8bf6-4e8f-4384-9e53-d48d60d7c694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d4648fc0-7fb2-4882-bdd9-f08b2a268fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eccf8bf6-4e8f-4384-9e53-d48d60d7c694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c056671b-9d0d-4136-abd1-5344115df44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_d4648fc0-7fb2-4882-bdd9-f08b2a268fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c056671b-9d0d-4136-abd1-5344115df44a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_3eb67910-4831-4162-a339-1f5adc510c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_d4648fc0-7fb2-4882-bdd9-f08b2a268fe2" xlink:to="loc_us-gaap_SubsequentEventTable_3eb67910-4831-4162-a339-1f5adc510c5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fcb2d880-e0e7-445a-8b19-9643b98641c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3eb67910-4831-4162-a339-1f5adc510c5d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fcb2d880-e0e7-445a-8b19-9643b98641c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fcb2d880-e0e7-445a-8b19-9643b98641c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fcb2d880-e0e7-445a-8b19-9643b98641c6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fcb2d880-e0e7-445a-8b19-9643b98641c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7a58d7a1-96c3-4811-9601-76feaca830e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fcb2d880-e0e7-445a-8b19-9643b98641c6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7a58d7a1-96c3-4811-9601-76feaca830e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f61546f9-9cb6-4317-85d3-d64069c6fb55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7a58d7a1-96c3-4811-9601-76feaca830e7" xlink:to="loc_us-gaap_SubsequentEventMember_f61546f9-9cb6-4317-85d3-d64069c6fb55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5c4cafea-8ed7-4da0-a6fd-bfb625d5368a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3eb67910-4831-4162-a339-1f5adc510c5d" xlink:to="loc_us-gaap_AwardTypeAxis_5c4cafea-8ed7-4da0-a6fd-bfb625d5368a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c4cafea-8ed7-4da0-a6fd-bfb625d5368a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5c4cafea-8ed7-4da0-a6fd-bfb625d5368a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c4cafea-8ed7-4da0-a6fd-bfb625d5368a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc74d13f-b6c7-4146-8bee-2353d89ac418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5c4cafea-8ed7-4da0-a6fd-bfb625d5368a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc74d13f-b6c7-4146-8bee-2353d89ac418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OptionsVestingInOneYearMember_06485432-f83c-4510-bc98-a5e5d89b355a" xlink:href="vtl-20220630.xsd#vtl_OptionsVestingInOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc74d13f-b6c7-4146-8bee-2353d89ac418" xlink:to="loc_vtl_OptionsVestingInOneYearMember_06485432-f83c-4510-bc98-a5e5d89b355a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OptionsVestingInThreeYearsMember_41272462-33e7-478d-a604-d4f43559cfa6" xlink:href="vtl-20220630.xsd#vtl_OptionsVestingInThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc74d13f-b6c7-4146-8bee-2353d89ac418" xlink:to="loc_vtl_OptionsVestingInThreeYearsMember_41272462-33e7-478d-a604-d4f43559cfa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b7981788-135a-46be-a5bb-fcf24a051745" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3eb67910-4831-4162-a339-1f5adc510c5d" xlink:to="loc_srt_TitleOfIndividualAxis_b7981788-135a-46be-a5bb-fcf24a051745" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b7981788-135a-46be-a5bb-fcf24a051745_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_b7981788-135a-46be-a5bb-fcf24a051745" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b7981788-135a-46be-a5bb-fcf24a051745_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85ba407e-7705-4c62-b422-fa59a37ddfe9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_b7981788-135a-46be-a5bb-fcf24a051745" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85ba407e-7705-4c62-b422-fa59a37ddfe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_4854ae90-7477-4b57-8fdc-ac5f1acdfb70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85ba407e-7705-4c62-b422-fa59a37ddfe9" xlink:to="loc_srt_DirectorMember_4854ae90-7477-4b57-8fdc-ac5f1acdfb70" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>vtl-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:87493b76-11b9-4c9e-8fb7-f973ce8e577c,g:e8a78576-a7c5-4c0a-9fc2-78dfa0931d1d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c511a9a-1e22-43d4-ba55-5e262a3a4b9e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c2aa63b8-7aa0-4b4d-9924-7bd788c0a6ff_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b822e8d5-15c7-4d89-85ea-46c88140aee6_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation and Presentation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_b663b6b6-c685-4f50-a1d1-032f61ed50f8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_42b7ef78-72d8-462a-8c3b-9a2a7a3f716f_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_592c741e-60fd-40f8-a671-9287d0ae31f8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1faec90c-f2d3-463f-8cfd-412804b069d9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8ccb0f42-421f-4460-814f-4147197fad3d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_2ace2f71-9e72-4815-80f0-53098764774f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9ef02393-b18d-4e4e-a5db-256168ecfd3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2e65fef9-039d-4837-a6ac-473d4dae7c1f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3c712cd6-b015-45cd-ab71-351f1ea11216_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_3ad227de-8434-4ea6-b0d5-0a7e15dfe2cb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3580f51b-269e-4093-9ba2-50171a5f9b4a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6196a8a3-5d66-4857-abb2-f127bbfea6b5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_33ce54c8-1672-4db3-b9e4-411480408759_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ab47bd16-a2ab-4b57-85b3-b14477e3fb60_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_f1910942-dd86-422f-a642-115fb9009ea0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OptionsVestingInOneYearMember_2a4b1699-6e75-4257-bc7c-7f02dad5e0a6_terseLabel_en-US" xlink:label="lab_vtl_OptionsVestingInOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Vesting In One Year</link:label>
    <link:label id="lab_vtl_OptionsVestingInOneYearMember_label_en-US" xlink:label="lab_vtl_OptionsVestingInOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Vesting In One Year [Member]</link:label>
    <link:label id="lab_vtl_OptionsVestingInOneYearMember_documentation_en-US" xlink:label="lab_vtl_OptionsVestingInOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Vesting In One Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OptionsVestingInOneYearMember" xlink:href="vtl-20220630.xsd#vtl_OptionsVestingInOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OptionsVestingInOneYearMember" xlink:to="lab_vtl_OptionsVestingInOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_cf5c37fb-11de-4107-b385-eac6ad74241e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, cash dividends paid (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_40257137-3227-4f6c-9119-b3d771a841f3_terseLabel_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical costs</link:label>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_label_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_documentation_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent" xlink:href="vtl-20220630.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ClinicalCostsPayableCurrent" xlink:to="lab_vtl_ClinicalCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_cce46052-62f7-4705-9a72-dae80450eb3a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_61788f04-38b9-46ca-a7fc-2f922717cb88_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 130,000,000 shares authorized and 30,564,995 and 26,335,418 shares issued and outstanding as of June 30, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_b3f719f4-ab05-40fb-b222-26aeb6031d2d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_999f77e7-8c32-454c-acf3-24fefcfe29e0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_de06f754-180a-4a24-8634-dfc580b9c66d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ae438825-7c4e-4821-8965-046e2971df1c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_c9f3582a-bd2f-44fa-932a-84348131039f_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6a40ffe0-a1f1-4ed4-abf5-884f77c76415_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_747695ad-9daf-422e-8299-c077ef32040b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2f550473-de53-49e4-aa0b-5c66696092b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5b59016f-6d9a-4a9b-9f28-e5e9a565bda3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4049ebe-898f-44a5-b3d4-aebe32ebf026_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_8f9461cd-b4da-424e-98f4-d6e867545e01_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_a6328627-286d-49b2-b039-fbb8fdf20b20_terseLabel_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:href="vtl-20220630.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:to="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_59d2793a-c4ba-4a02-acf7-ee43b3f04d0a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9c9451e8-c471-417b-b0c8-78789dcac131_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1af7767f-153d-48f4-ab24-1641caad7a10_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c878f70e-fdde-4ad5-b155-03eaa9384487_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_May2022ATMMember_588b629f-21f1-454e-beab-aeddfc6c2739_terseLabel_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM</link:label>
    <link:label id="lab_vtl_May2022ATMMember_label_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM [Member]</link:label>
    <link:label id="lab_vtl_May2022ATMMember_documentation_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember" xlink:href="vtl-20220630.xsd#vtl_May2022ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_May2022ATMMember" xlink:to="lab_vtl_May2022ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_31e7de5d-ae9a-47b3-ba45-b39c6f793925_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_f14d257a-5e75-4bb5-8cb4-0fda35cf487f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_6b776040-7267-4b6e-a3a6-143becf5352c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_13cf1f38-6c50-4959-9852-61c3928ed2c5_terseLabel_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="vtl-20220630.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_578eadef-2dde-4b1b-a95b-4c9b41c396b2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fe9e1566-5262-4c5a-a8ba-8f695ef30592_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_badeb1bf-54df-41da-b8d0-86d8749202c1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_04d71821-6971-4e3f-9861-706e417cc74d_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b5b7f9db-864c-478c-84a8-55d445783c47_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock ( in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_ef03f883-1578-424c-90f9-2969be47db6c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_64f81bb9-e2bd-4446-8e25-f14a2298f42b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c276a4de-69eb-4f45-bad3-7ae0c5f8d719_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_33cd8802-c7c4-4c75-8756-b3f5b1da9f77_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_35d28dca-d137-4489-810d-0312c7bf8184_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b5eb0a0e-6dfb-45cb-8ec1-941275b92f3f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_a56f4689-0cdb-4c4b-aa23-fd25b81a69f3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_16efbb9b-26df-4cc3-a9fe-13a3c60b74b0_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_44e23aa9-bca6-4693-8e14-8198b907aa38_terseLabel_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement</link:label>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_label_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement [Member]</link:label>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_documentation_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember" xlink:href="vtl-20220630.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ExecutiveChairmanAgreementMember" xlink:to="lab_vtl_ExecutiveChairmanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_299b712e-f311-4df8-8b6f-693fa5ce3ee2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_417e56dc-e962-4430-a7c8-7d062759923a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_48cf32d1-6335-4b3a-b07f-5bb3437e750e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EmployeeMember_96831a47-80f0-4684-a042-a56c52dedb2d_terseLabel_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_vtl_EmployeeMember_label_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_vtl_EmployeeMember_documentation_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember" xlink:href="vtl-20220630.xsd#vtl_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EmployeeMember" xlink:to="lab_vtl_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_fd7f3165-2fc0-4dcd-a2e4-d84d8832bfff_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ImmunicAGMember_ed9a51cd-8ec4-4823-90a1-d05c0a06e89b_terseLabel_en-US" xlink:label="lab_vtl_ImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic AG</link:label>
    <link:label id="lab_vtl_ImmunicAGMember_label_en-US" xlink:label="lab_vtl_ImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic AG [Member]</link:label>
    <link:label id="lab_vtl_ImmunicAGMember_documentation_en-US" xlink:label="lab_vtl_ImmunicAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunic AG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ImmunicAGMember" xlink:href="vtl-20220630.xsd#vtl_ImmunicAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ImmunicAGMember" xlink:to="lab_vtl_ImmunicAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_6aa4067c-753b-46cb-83cc-d1dc68307c36_terseLabel_en-US" xlink:label="lab_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreement, royalties as percent of aggregated net sales (as a percent)</link:label>
    <link:label id="lab_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_label_en-US" xlink:label="lab_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales</link:label>
    <link:label id="lab_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_documentation_en-US" xlink:label="lab_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:href="vtl-20220630.xsd#vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:to="lab_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_2615c2ab-2bd9-4e40-87b6-153f3345bc82_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_242d80f9-0d94-46d9-adce-c34096e1e406_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f4143da8-d84f-406b-a2b9-7be52d260433_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4caa644f-d3ae-4fb0-a5ad-e9f2d8c1cee2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_b0eaffff-8c8a-4e40-8273-fa3c69d65082_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_33b85cbc-b6a8-42e9-b468-dce0db27271c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_1f105265-5035-43a5-ae29-17b75f588cc4_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of existing leases</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:href="vtl-20220630.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:to="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_07cb3b37-60d6-4118-8944-9c48cd54e1e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_620a12fe-7c18-43e4-a2c3-abc05849e036_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_6569ba2e-7dbb-4ba0-81d1-3ba8738bea00_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability, current, statement of financial position</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_25a6a734-f84f-4624-b0a4-8a6f7c92668d_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2c0b27a1-78d7-4dfe-8809-9ca41c1ebbd3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_RoyaltySettlementAgreementSalesNet_912d305f-3b01-4e74-8d0f-2bc194fb4a3c_terseLabel_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementSalesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC royalty settlement (see Note 4)</link:label>
    <link:label id="lab_vtl_RoyaltySettlementAgreementSalesNet_label_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementSalesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Sales Net</link:label>
    <link:label id="lab_vtl_RoyaltySettlementAgreementSalesNet_documentation_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementSalesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Sales Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSalesNet" xlink:href="vtl-20220630.xsd#vtl_RoyaltySettlementAgreementSalesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_RoyaltySettlementAgreementSalesNet" xlink:to="lab_vtl_RoyaltySettlementAgreementSalesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_4979e6f3-cd5c-4f92-9786-899aa8c02a58_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d8b9802b-82d2-45bb-9a20-32b593bbe49b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_f69e7946-8ca0-476d-b916-929d28bbcdd3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_8578ddab-faa8-46b3-83ef-d75e7a1e96e5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_55bdd239-49e5-4cb5-9cf1-f42c6a9f60b5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_bfc8cd62-c48c-405e-bebd-168fac245ff5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_95929081-2e8f-4ca0-82ea-f7864d8d3b24_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_4bac3371-762e-4c0a-8d64-d27e7447ec8c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_44e6f5c6-4ab2-49b3-82c4-9ba037659108_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_04775d6e-e5db-482c-b744-c82fa8684504_terseLabel_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember" xlink:href="vtl-20220630.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2017InducementEquityIncentivePlanMember" xlink:to="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b7f44dfc-1674-4f7a-85c7-c3bd87db6395_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4003a598-ef07-46ac-a88f-9ad4698eeb1f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_acc7c08e-63cd-45ad-b16e-e9c1aae72151_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_a1be84cc-0e56-4f7c-b64f-266ca0cc43c0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ab00aadc-5883-4e12-a2a8-b0dd9f47a75d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCommissions_a2843fa7-e59a-48ac-b1dd-fdf6d774e9bb_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter commissions</link:label>
    <link:label id="lab_us-gaap_PaymentsForCommissions_label_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCommissions" xlink:to="lab_us-gaap_PaymentsForCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ac6925a9-6e44-46df-8951-c191da3070af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_GrafelfingGermanyMember_44920a51-ce58-4b42-a36a-94fe10c56b9b_terseLabel_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany</link:label>
    <link:label id="lab_vtl_GrafelfingGermanyMember_label_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany [Member]</link:label>
    <link:label id="lab_vtl_GrafelfingGermanyMember_documentation_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember" xlink:href="vtl-20220630.xsd#vtl_GrafelfingGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_GrafelfingGermanyMember" xlink:to="lab_vtl_GrafelfingGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ca022fa9-2828-43bc-9d87-d4f93a251725_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b585fddc-d95a-453a-95f8-4a34bd1b177b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a3c9ed0d-7ce9-48ea-8523-47f0652ad548_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c061a8f3-c8a3-414c-ae81-9062ab23240a_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_abed8c41-3fa4-4e93-abc2-c44544ce34e6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_bf107049-3b88-4dc8-a0af-12df24a92035_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6eecdcac-dbef-4008-be62-1f19f03d5442_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_f38562e0-0222-48dc-a570-d32007531cb7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ec3515a9-82eb-4dbb-82a1-7c91c155df72_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A4SCRoyaltySettlementMember_c8c0ed83-1eb0-49d2-8a64-2af91ef88bfa_terseLabel_en-US" xlink:label="lab_vtl_A4SCRoyaltySettlementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC Royalty Settlement</link:label>
    <link:label id="lab_vtl_A4SCRoyaltySettlementMember_label_en-US" xlink:label="lab_vtl_A4SCRoyaltySettlementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC Royalty Settlement [Member]</link:label>
    <link:label id="lab_vtl_A4SCRoyaltySettlementMember_documentation_en-US" xlink:label="lab_vtl_A4SCRoyaltySettlementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4SC Royalty Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A4SCRoyaltySettlementMember" xlink:href="vtl-20220630.xsd#vtl_A4SCRoyaltySettlementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A4SCRoyaltySettlementMember" xlink:to="lab_vtl_A4SCRoyaltySettlementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_2dc6d3a4-fe64-46ab-9e3c-208753038d69_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_66d3752a-f742-48aa-b9cc-a4201e94ae7b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_02bd8538-a127-4307-afe1-2793a7a1cc06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_dc4b59ce-add3-4979-adc7-a367c1d2e7ce_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f99d7d67-c234-4094-aa79-b227be6a9892_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_7223050b-e2f2-4783-b0ef-fb3b0e3d5ff8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contributions per employee (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_a3909ea3-9f1b-4d9d-8cdd-1ab66399b283_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8f6516e6-1053-4e61-88b1-c49baed65ac9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_52bb50a0-5662-4bb0-afa0-60f888e6cf18_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7eb71eeb-9bb4-461c-93c0-0d9c6a0c6790_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9cf65d9e-eee8-44ef-93cf-f4e3ac454383_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4f123760-61a7-480f-b0a3-ca8d1b722408_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e686f0b-0dda-417d-84c0-298a85acb85b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_9ff62df4-b6b0-4754-a4bc-574ff92a63a1_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfDevelopmentProgramsPursued_b944cc4d-b043-4845-979c-d1c789a301b2_terseLabel_en-US" xlink:label="lab_vtl_NumberOfDevelopmentProgramsPursued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of development programs</link:label>
    <link:label id="lab_vtl_NumberOfDevelopmentProgramsPursued_label_en-US" xlink:label="lab_vtl_NumberOfDevelopmentProgramsPursued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs Pursued</link:label>
    <link:label id="lab_vtl_NumberOfDevelopmentProgramsPursued_documentation_en-US" xlink:label="lab_vtl_NumberOfDevelopmentProgramsPursued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs Pursued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentProgramsPursued" xlink:href="vtl-20220630.xsd#vtl_NumberOfDevelopmentProgramsPursued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfDevelopmentProgramsPursued" xlink:to="lab_vtl_NumberOfDevelopmentProgramsPursued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_3590fcbe-51c2-4ea9-a9f8-9c6bfc2aac8f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a04c0336-38d4-4a1c-9ec6-3c826b60dc40_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_51a8b127-85f0-4a17-bda4-5a21a101ba43_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_a3a42cc3-dc0e-414a-b721-f4856d26ce70_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f37deef5-723d-44eb-aeab-8fe3635ba650_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab0cf37c-14df-4d33-bf77-1bb4c210efc8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_afd60610-8824-4c07-aeba-3971301828d0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_55e30aa2-9b10-4fc7-819e-c04205482d8a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1b7c203e-f9ba-4d77-b100-826f86cdc4eb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_15db78ee-761d-445e-bacb-ea7f4d1328fc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_958faf8c-d454-4492-8efd-92cc2a53ad96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_bdba0c52-9c27-4327-b962-018ab427ec3e_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_cd90e5f4-088b-404f-a765-2a8d6f568055_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_7f520741-4ea4-4b12-8f5e-f6f6297e97e3_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_be7d5dac-7246-4f57-8730-fdd43d9e67d1_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d53a37a2-8441-43cd-827a-9e9567d413aa_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_c28d0237-2156-4d43-b69e-581fa1d3659f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_c3009621-affa-4b8d-ad03-7949fe5aecf9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock issued in connection with the 4SC royalty settlement (see Note 4)</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_bea3dc81-90c6-41c7-900f-70f7788019df_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_200fee09-1963-4b5d-be4d-de245d931411_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, cash dividends declared (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_9a01e399-99ff-41fa-b340-2db07a4a81e3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_c627ec33-8c1d-4461-a854-05c01ca7c2d8_terseLabel_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal and audit costs</link:label>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_label_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent" xlink:href="vtl-20220630.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedLegalAndAuditCostsCurrent" xlink:to="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_670d8983-5656-4822-89b4-011195335151_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:href="vtl-20220630.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_December2020ATMMember_e7872f41-3386-4b34-b2b0-143487a17c96_terseLabel_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM</link:label>
    <link:label id="lab_vtl_December2020ATMMember_label_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM [Member]</link:label>
    <link:label id="lab_vtl_December2020ATMMember_documentation_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember" xlink:href="vtl-20220630.xsd#vtl_December2020ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_December2020ATMMember" xlink:to="lab_vtl_December2020ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_f081dbd5-cc32-4c78-a7d6-e77fd160f9b4_terseLabel_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical and related costs</link:label>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_label_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_documentation_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:href="vtl-20220630.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:to="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_44d01fc1-50a6-4312-9b5b-f33e3c4b07bf_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_596da080-806f-402f-a539-3dc4f70160f3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_01c94c2d-0f6d-461d-b4ac-763e8a219ab7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_dac8abed-94b0-430c-8a98-d4e9dd7a2165_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_d050a2e8-c1cd-403e-a68e-c5bef067677c_terseLabel_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="vtl-20220630.xsd#vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_86fc870c-827f-4eba-9bac-06ec39c23d21_terseLabel_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (as a percent)</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_label_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_documentation_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:href="vtl-20220630.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:to="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_11a9dd80-a771-4237-b735-4378aee0d8a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_3588cde3-4c58-425e-9079-7f2df742571b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b4f61a60-b526-473e-9611-209caf5dcc8d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_85a37c90-abf1-43eb-8af5-4c907611ae3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_16a926a1-d817-4eee-bccf-7fdd474a8b19_terseLabel_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock (in USD per share)</link:label>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_label_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Weighted Average Share Price Per Share</link:label>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_documentation_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Weighted Average Share Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:href="vtl-20220630.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:to="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c16fa3de-50d6-4050-9f71-29341c49fc70_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedCompensationCurrent_f37316a8-b93e-4ac6-9e1e-f9615eb970bf_terseLabel_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_vtl_AccruedCompensationCurrent_label_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:label id="lab_vtl_AccruedCompensationCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent" xlink:href="vtl-20220630.xsd#vtl_AccruedCompensationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedCompensationCurrent" xlink:to="lab_vtl_AccruedCompensationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_90650889-f443-4477-b8f6-cd4690e65317_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_f3a40b44-c587-48f4-a114-f9f75c38920e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b33d2caa-cfc4-48b6-8cc2-d000406868d5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NewYorkCityMember_4a26441d-3e54-40a2-bd0f-8df92156adae_terseLabel_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City</link:label>
    <link:label id="lab_vtl_NewYorkCityMember_label_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City [Member]</link:label>
    <link:label id="lab_vtl_NewYorkCityMember_documentation_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember" xlink:href="vtl-20220630.xsd#vtl_NewYorkCityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NewYorkCityMember" xlink:to="lab_vtl_NewYorkCityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_ee934eb2-9ce2-4783-b6d6-51291eda9a4c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_02030063-fc23-49b2-9019-fe0e9d7217a6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_f1a2f414-d9f1-4b5b-9194-22eed324bc02_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_51f7570e-a1b6-4033-9fbe-a1200a0ad767_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PV of obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_67ce36eb-d9f0-4e60-9299-81e037efcd2f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_fc8bfc4f-48d0-4882-9099-94aabca642ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c8b25271-472e-4622-89ce-0306bad10ddf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_230c7318-4080-4136-9af0-a62510c9dac1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a32ed12e-f090-44de-94fa-6c9a9e58bf25_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_be481404-36e9-4760-a069-e37b4e48c47e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_aa5baaa8-66e1-460a-9c15-1ea0e8683b85_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e5d04194-83e8-49c1-90e7-238598b82e55_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_7571124f-b08a-47d2-9227-12a4374d02b1_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bcb8931b-301e-469a-a2c6-e7b6aa8eea1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_17352943-e542-4b19-884e-00d5502daed1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_21a05130-1265-4a07-ba52-2cadf8104138_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ac1fe2d7-be71-48d2-a26b-eae39dd0b97b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_41c21f67-3f07-40ec-bf6d-1cc2aa983e9d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_25672b78-a8c8-489a-9329-8a5fc487532a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e2a99e4a-e0a1-4c16-9f36-1b2d7c4ffe3e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6b430ddf-22f1-4411-82d0-df9cc7c6bcf8_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_587d7c29-ae00-4e05-be49-78844d6840f6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_af8050c2-68d7-43a5-a24b-abf47b5ea212_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ac0db122-15bb-48cc-a85f-b0c8375b7e50_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_366ff88c-5a10-474b-86a7-c977d5cc3139_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityNumberOfEmployees_4f17a8a0-f28a-475f-816b-e13c9ad9a3df_terseLabel_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_dei_EntityNumberOfEmployees_label_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Number of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_80c9c05b-2b55-4528-b07c-b5985590664f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_dca680ac-f607-411f-9ba3-a3233de2c1d4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c3f490eb-f1d4-47df-a7c6-0fe8413844ba_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d22f2496-d3c1-4e08-ae02-863f53faf455_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_2c1878cc-9103-4534-82c1-c83e802c6e3d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_cf71e0c6-6df1-42c9-bfb5-f541a221806b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6d360dcf-76e4-4ad7-aafc-764f72ce2709_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf29b173-2603-4089-a11a-454c94268516_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f860202-9aa3-4e90-9d37-d3b455765bb8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_30930eb2-6ae3-4353-860a-fb83a874dbae_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which compensation cost will be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d1e996cb-1d68-4814-a035-cf5a639f0f1d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_9bf20ead-3134-4bb6-af49-4decea3ac467_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission, percent of gross proceeds from sale of common stock (as a percent)</link:label>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_label_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:href="vtl-20220630.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:to="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_efcac656-f94a-4b27-9930-2e1313a7c7ff_terseLabel_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and variable lease costs</link:label>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_label_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_documentation_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost" xlink:href="vtl-20220630.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OperatingAndVariableLeasesCost" xlink:to="lab_vtl_OperatingAndVariableLeasesCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ec17c914-f73b-48ca-9087-cafce5fc447b_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_58231eb9-7541-4898-831c-affadaf84327_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b32d9683-b9d0-4306-80b5-e7d4435bcb6d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 4)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_9b8c43a7-b2c0-4dd6-aa3d-8cff8d997f50_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6d4074e0-55cd-4ccd-8fcd-eeed5ed14496_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5c705b3d-12bb-41df-8b89-357f6ae04123_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fc66dfb4-2b29-44d3-aacf-5eff00c46408_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ca59acf6-36a5-4c41-a7ff-1d66ca5673fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b14723ef-5739-4eae-9b67-a2df239842e7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_5fb6e47c-3a0b-4e4b-ae45-caebad54ef61_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_ee519f6a-de44-470a-a46d-5f7d23a257e9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_caa2587e-9389-4825-acfb-285b17bf1538_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock issued in connection with the 4SC royalty settlement (see Note 4)</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_09896b04-04d0-45d6-acf4-9035968d36a9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of June 30, 2022 and December 31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_aa5a7b45-5765-4119-848a-29c33f7f022c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_e78923f4-9274-446e-903b-a8ed709c4b38_terseLabel_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian research and development tax incentive</link:label>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_label_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive, Current</link:label>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_documentation_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:href="vtl-20220630.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:to="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_dd5c0a21-41be-41c1-b2bd-73b21a1a5a68_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf registration statement, amount remaining</link:label>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_label_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement, Amount Remaining</link:label>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement, Amount Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining" xlink:href="vtl-20220630.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationStatementAmountRemaining" xlink:to="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_12dcd77c-36a4-4fe3-bd77-fa0e12586e8f_terseLabel_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options available for future grant:</link:label>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_label_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_documentation_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:href="vtl-20220630.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:to="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_661b11a9-aea1-43ad-ae29-67cd2fa05efe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_899e8d17-9063-4ce4-9d57-e58cf707a494_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e9c77c63-f9da-412c-8c88-007f4c8c3833_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_c254ba70-b4b0-4ac2-9b61-c073542d8459_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:href="vtl-20220630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:to="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_39a4e98e-acce-4526-b517-74dbb191627c_terseLabel_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical and related costs</link:label>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_label_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent" xlink:href="vtl-20220630.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedClinicalCostsCurrent" xlink:to="lab_vtl_AccruedClinicalCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c8028705-a441-4184-8db8-29d3b3f26561_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_e7db0ae7-836d-42cd-a714-bad57755b816_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_f1fd2dd7-da16-43eb-9fe4-38fee58bd151_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_1348e41e-7b34-43e8-a59b-fc09cd5f748e_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf registration, termination, prior written notice</link:label>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_label_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, Termination, Prior Written Notice</link:label>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, Termination, Prior Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:href="vtl-20220630.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:to="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_3d044e92-d84c-4481-929c-d43bc1c00960_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_65115b37-01c8-460c-819f-23df64d14792_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OptionsVestingInThreeYearsMember_ecfa5d7e-fa7a-4542-8ef5-285e564f5dc5_terseLabel_en-US" xlink:label="lab_vtl_OptionsVestingInThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Vesting In Three Years</link:label>
    <link:label id="lab_vtl_OptionsVestingInThreeYearsMember_label_en-US" xlink:label="lab_vtl_OptionsVestingInThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Vesting In Three Years [Member]</link:label>
    <link:label id="lab_vtl_OptionsVestingInThreeYearsMember_documentation_en-US" xlink:label="lab_vtl_OptionsVestingInThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Vesting In Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OptionsVestingInThreeYearsMember" xlink:href="vtl-20220630.xsd#vtl_OptionsVestingInThreeYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OptionsVestingInThreeYearsMember" xlink:to="lab_vtl_OptionsVestingInThreeYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c46381bc-eb58-4516-9a66-90db81692102_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_5ac9ec2f-643f-4146-a73a-80fe14c9868b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_2deb38e9-7a82-4775-88eb-2e0a3a2bea82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets and Prepaid Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5d746691-be0e-4d37-be6a-f7cce6937488_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_924ce7b8-dba4-4fb7-9c8d-21b7b801092c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_RoyaltySettlementAgreementCashPaymentPercent_fc301b73-a9ed-4f10-96c1-8eb6bbd98324_terseLabel_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementCashPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty settlement agreement, cash payment (as a percent)</link:label>
    <link:label id="lab_vtl_RoyaltySettlementAgreementCashPaymentPercent_label_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementCashPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Cash Payment, Percent</link:label>
    <link:label id="lab_vtl_RoyaltySettlementAgreementCashPaymentPercent_documentation_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementCashPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Cash Payment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementCashPaymentPercent" xlink:href="vtl-20220630.xsd#vtl_RoyaltySettlementAgreementCashPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_RoyaltySettlementAgreementCashPaymentPercent" xlink:to="lab_vtl_RoyaltySettlementAgreementCashPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7e9343af-54d1-48ff-8f1a-db357baf436f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_d1a035ba-c5aa-467b-b3db-3a4303c9413d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_79f69cd1-951d-4570-98c6-435286055cc6_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_ce10b97e-ba8c-4cb6-8166-69da561c88fd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4d4fc16d-d83a-44f1-9b2d-f40649bb0c76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72272c05-8be3-4c07-9025-920086560426_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_2be87208-266a-424e-b842-dd39ca639ad5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_daeb71e9-8349-4fc1-9f7a-4f5012149e3b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5b059be5-6dc0-4f36-a590-7ff89590c168_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b7f90429-85f4-4fdb-ac00-16b04865dc6f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_97d49637-4bde-41a4-a2f6-ddcc1b1989d6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign currency loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_c5e74538-4777-4d8c-bc33-d8ce07d47e89_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued in connection with the Company's employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8210a477-18da-427a-864a-fc2112a6e055_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b92c89ba-a3f0-475b-b71b-e0e059710679_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f46b5a2-4332-4b28-8728-6a1d813f12f0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_43dc4c0a-b99f-43e8-bfad-9f1a6375de2e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6c131b4c-ef37-4219-8db6-59654eaff813_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_11952ab8-34ed-48f7-9032-41aa514f5006_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0562ee86-0b3f-4fba-a87c-3727365f5358_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_85ba9ac4-8a88-4047-9a55-1c6699a6b6db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c2d28c6a-deb2-4b01-913e-eae8da1d4194_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6b0f032a-7fe1-4610-83cd-824b5d64712d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c8f45019-fe01-470f-b5ec-01cb9257c6f0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ce8afc7b-0053-4ae7-b5ad-9e6b80c47aba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_17e34e21-5f89-4720-b4bf-4d0a9ee2ebad_terseLabel_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-statutory options</link:label>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_label_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember" xlink:href="vtl-20220630.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NonStatutoryEmployeeStockOptionMember" xlink:to="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_33d8dfd7-57bf-46e8-b753-2f03917c26e1_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_eebff424-b461-4bd0-a0bc-a8117b2d0910_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_874c279c-717b-4f4c-b357-ee86c7b94150_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_954390f8-1d47-4ef6-922b-93fcb9463d64_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_926d83d9-4c1a-41be-982b-d14ae5945adb_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_edaea70a-dd67-457b-a6f7-96d6cff387aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4270512d-5a38-4189-9598-d81fdc019ecc_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_0d06f583-a7ca-4242-aa33-aacc93dcf24e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_9dfba029-2581-4126-a5dc-4fdce649d65a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3701b3b9-e623-4db3-80c7-8449b26864a0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PublicOfferingMember_6cdcd459-d43e-4c4c-83ae-98d521f62c57_terseLabel_en-US" xlink:label="lab_vtl_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_vtl_PublicOfferingMember_label_en-US" xlink:label="lab_vtl_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_vtl_PublicOfferingMember_documentation_en-US" xlink:label="lab_vtl_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PublicOfferingMember" xlink:href="vtl-20220630.xsd#vtl_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PublicOfferingMember" xlink:to="lab_vtl_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a944e823-d8af-4887-915c-ca48204fa872_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_9edc04f4-989b-40ca-9b89-8a91b4fd01d8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_fbbbd4c8-5a79-4277-b1fa-c85c115a01bc_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VAT receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_e3b8a6b7-7be4-4f2e-bdef-06c2ab2e9907_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_812b0406-11f9-4b9d-8c28-ff3a81da44ea_terseLabel_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember" xlink:href="vtl-20220630.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2021EmployeeStockPurchasePlanMember" xlink:to="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a7d4d34f-1887-470d-afdc-0606a99b20a3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_e8de3d01-b074-478f-a79a-b492e4357abc_terseLabel_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock options</link:label>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_label_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember" xlink:href="vtl-20220630.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_IncentiveEmployeeStockOptionMember" xlink:to="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_701885ab-3df1-49a9-8fff-dcf6428ff8f8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeaseRentHolidayPeriod_d18ff2c9-2d93-4f90-9b33-b91fbd7084b7_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent holiday period (in months)</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseRentHolidayPeriod_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Holiday Period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseRentHolidayPeriod_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Holiday Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseRentHolidayPeriod" xlink:href="vtl-20220630.xsd#vtl_LesseeOperatingLeaseRentHolidayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeaseRentHolidayPeriod" xlink:to="lab_vtl_LesseeOperatingLeaseRentHolidayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_10af4650-16b5-492f-addb-0380c2d766c5_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_465e219f-8a30-42a0-b05b-babbb487d007_terseLabel_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA</link:label>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_label_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA [Member]</link:label>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_documentation_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember" xlink:href="vtl-20220630.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_DuaneNashMDJDMBAMember" xlink:to="lab_vtl_DuaneNashMDJDMBAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_735e06b2-5d50-4a9b-bb26-219a9111d3fc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Operating Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_fc405800-b2f4-4157-aaef-9b9af9804ea9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8be45109-f260-46fe-8bcd-726fa2b3f4e3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_7e6d22bd-4cd2-468b-8ec3-136b71acf85c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ff8092a7-b7cd-4740-8940-8c14226f994c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3db143b9-d4b4-4d0b-808f-c2da4528196a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_289c2471-97de-49dd-973e-f7d7f87276a1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_a72ba641-3fed-490d-ac4e-2ce41b17e7b2_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_69b5b68e-b693-4acd-8714-e0b181618c9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d4c99385-7ac7-430a-bc59-41849d04d967_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d2bf88eb-7e80-4231-9d92-042b4edfd6e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_59390f70-0b0a-459a-abbc-5bf354880e88_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_37aa5a17-bf50-4397-b142-74c4f6b0be47_terseLabel_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, remaining capacity</link:label>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_label_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Capacity</link:label>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_documentation_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity" xlink:href="vtl-20220630.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SaleOfStockRemainingCapacity" xlink:to="lab_vtl_SaleOfStockRemainingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_416d1147-71fe-4d53-8844-5403924e8c57_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_14f6670e-b114-4657-b0f1-83d8709e483d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4d2ea197-4277-43b7-a3e5-034fadff9682_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_df104b4a-ae8c-4259-8e61-04050359f0fd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0fc4144b-81e5-4920-93c9-4c2a501cfbb4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2a43721a-9cdd-4404-b78b-eaa33457c888_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of the stock, at discount from market price at purchase date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3e5ffe4d-fa7f-413e-b0f7-f085ef57ceb1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a0d5199b-106c-40e3-88fd-40e65085a92c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bf00c0f3-718a-474f-8475-25adf686cbc1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_07d891a2-58f3-403d-b17d-52472869a2b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f31b0093-b58e-469e-a3fc-d8c04c2916b1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_c08c8a19-e477-4da3-9ac5-9f7279aef069_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9b17e211-c2aa-441a-8fc9-cd421d6c4251_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_283d6061-4499-45cc-af9d-e7893047dca4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0c8db0f2-8ed0-4ca0-beb3-ee433b668f80_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1f0262fc-9ab7-4e78-a6d4-f6b12c5d4894_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_efc91476-2917-4f3a-8847-ea3b2810a464_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_982c1a75-8f1d-4866-8b61-c44ffeef7d77_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_52c73a9a-a352-4f6d-9993-48d2541768a8_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f21bf95b-4c50-4d97-8e0e-d6705410f7f9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_26cd4dbc-2349-4e50-8021-9f58ba67b49b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_833b7a09-c665-408c-81be-575d5d01463c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_6f7864ad-8a29-4294-bac7-721371eecf0f_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_ea53adc7-30c3-4ebe-8b04-a99e94084e4b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_c55b0daa-00a8-40ea-aca9-1cc4e1b1481f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_8a53ac8e-963f-417c-aafe-e95cce2a00a2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_1bf22cd3-0767-479b-8c36-3c953d8afc07_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_label_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:href="vtl-20220630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:to="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1a59e0da-98dc-4a87-83c0-2dfda69cf2ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_020ba4a6-22b0-4368-b571-c6c79e50d2cf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5a2c97b9-900d-46db-a4d8-22511ebcf861_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_65be3e7d-1f5c-4d3d-928b-1b329e2f3244_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted-Average Exercise Price, Ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dec0b35c-da1a-4777-9130-374dc9600021_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_70125929-3ea9-485e-ada7-d27a6c26c041_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_eec0849e-6cbd-4827-9c91-0f547fcff8ea_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_13a3554e-1c7e-4a2a-bdd5-1ca853efd86f_terseLabel_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal and audit costs</link:label>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_label_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_documentation_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent" xlink:href="vtl-20220630.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LegalAndAuditCostsPayableCurrent" xlink:to="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2e4a69a1-1dd3-4e50-a8b8-94aa6e2810b5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_3d5a7136-423d-4463-84d7-eda069a8193c_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2b3f7b06-456e-4a61-bf9a-f9b1ab1775a6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d6b05373-a992-4264-8244-17af6d27d2cd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9bf5283a-1d17-4dd3-9fc2-8527cb325485_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7796e940-b7e0-40df-aa92-dc2360abdaf2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_c08dac1a-606c-40f5-bd6a-1734b0e5f95d_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d7063b23-77c7-43d4-9675-665b5c4b0be4_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_RoyaltySettlementAgreementSharesPaymentPercent_c5ac0dfa-c6f7-4464-b637-30bdeb4e9ca8_terseLabel_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementSharesPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty settlement agreement, shares payment (as a percent)</link:label>
    <link:label id="lab_vtl_RoyaltySettlementAgreementSharesPaymentPercent_label_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementSharesPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Shares Payment, Percent</link:label>
    <link:label id="lab_vtl_RoyaltySettlementAgreementSharesPaymentPercent_documentation_en-US" xlink:label="lab_vtl_RoyaltySettlementAgreementSharesPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Settlement Agreement, Shares Payment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSharesPaymentPercent" xlink:href="vtl-20220630.xsd#vtl_RoyaltySettlementAgreementSharesPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_RoyaltySettlementAgreementSharesPaymentPercent" xlink:to="lab_vtl_RoyaltySettlementAgreementSharesPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_fa19b4f0-3767-44f8-a7ac-f12e7935d16d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d36730ae-4231-4a1b-b04e-bc739054d36b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_c8c6ebcd-0b49-4fd1-9a30-ade3a8d002da_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_ec4fd184-5fcd-4be9-a36f-e172ac9aa973_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_23d4c6ae-2773-40bc-a725-6f1c5a7f1be2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5626c0cf-c9ab-4bf9-97c2-ef5337a6e797_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_eead1a93-f9ab-4703-bd97-69cfbcb6c3e8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_569cadf3-9500-4ac5-87d4-b7e3ffca5adc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6af2273c-0bdf-4114-8684-4dd9e80d8dd6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a297359f-6f6f-4cac-875b-1c79b4e9715b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6a95a6a0-4ab6-48bb-be85-356bd9746ed7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in period, weighted-average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f6c9a0e9-1553-4c8b-8d11-ba898bf92512_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Weighted-Average Exercise Price, Ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_09699b7d-25a0-4c86-8004-c9840152f7ef_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2a2bef4f-2c3d-4ec0-8cd3-389dd35ab1d4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_33342f9d-39b3-4cf9-9640-d0323fda0300_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9e7cf1c5-b18a-49f3-a868-21e03ea74d1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c7bd898c-bf7b-49d0-9e59-08ca4a8b7352_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_21a7e1f5-7045-4311-a515-11d10c86c43d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_fd04be78-1c12-4756-8bdb-de5869a32ff5_terseLabel_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate on operating leases (as a percent)</link:label>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_label_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:href="vtl-20220630.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:to="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_568645c8-ffb1-42b3-82a9-a4cad74fca3c_terseLabel_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base salary</link:label>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_label_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary Costs, Monthly Base Salary</link:label>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_documentation_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary Costs, Monthly Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary" xlink:href="vtl-20220630.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SalaryCostsMonthlyBaseSalary" xlink:to="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1e12febc-a774-425e-998a-56ed2da2fbc6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued and/or Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_44080677-901c-432b-98fd-e682c01bab2a_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of use asset obtained in exchange for lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8488a457-2e4b-41e4-988c-d7135a172655_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_cf2191e6-5d66-4feb-910a-440963c4c840_terseLabel_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price of securities under shelf registration</link:label>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_label_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_documentation_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:href="vtl-20220630.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:to="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_abe12623-181c-4130-8701-8affa0ada40a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_c55ee3b6-33bc-414c-affd-a916a9976d08_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Basis of Financial Statements</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_a0a2b6c3-c51f-4244-b164-2d993ff738ed_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>vtl-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:87493b76-11b9-4c9e-8fb7-f973ce8e577c,g:e8a78576-a7c5-4c0a-9fc2-78dfa0931d1d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vitaltherapies.com/role/CoverPage" xlink:type="simple" xlink:href="vtl-20220630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b4dbe49c-80ef-4d63-a8c5-1e5bd37e0008" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_DocumentType_b4dbe49c-80ef-4d63-a8c5-1e5bd37e0008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_86342590-8493-434e-840b-f129293f46ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_DocumentQuarterlyReport_86342590-8493-434e-840b-f129293f46ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c0784a98-e1d7-4a30-91a5-f1f94b677a60" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_DocumentPeriodEndDate_c0784a98-e1d7-4a30-91a5-f1f94b677a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4fa515ed-f625-4e7f-a042-0f1e1fa74eb2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_DocumentTransitionReport_4fa515ed-f625-4e7f-a042-0f1e1fa74eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9e4f50b3-192d-400b-a22b-d21ae29ce355" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityFileNumber_9e4f50b3-192d-400b-a22b-d21ae29ce355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_674bd2d2-b4ed-49de-80a9-dc47dc4bc366" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityRegistrantName_674bd2d2-b4ed-49de-80a9-dc47dc4bc366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_aa8e2a10-f5e3-4792-a79f-3aa87c0d7dda" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityIncorporationStateCountryCode_aa8e2a10-f5e3-4792-a79f-3aa87c0d7dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_cfbcc3c3-c756-42d9-90af-3ece2f5a1274" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityTaxIdentificationNumber_cfbcc3c3-c756-42d9-90af-3ece2f5a1274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_18e085b8-d1e2-4e11-845c-4ccb2020121e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityAddressAddressLine1_18e085b8-d1e2-4e11-845c-4ccb2020121e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_04f0c875-a34b-4f42-acac-da0d21a4fd35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityAddressAddressLine2_04f0c875-a34b-4f42-acac-da0d21a4fd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5796fab2-32ea-4722-84f8-59a433c625bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityAddressCityOrTown_5796fab2-32ea-4722-84f8-59a433c625bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_88012930-ba74-44a4-8752-d2bb49d6f0fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityAddressStateOrProvince_88012930-ba74-44a4-8752-d2bb49d6f0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_270963f3-db4e-4530-8ada-1ca80b200b3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityAddressPostalZipCode_270963f3-db4e-4530-8ada-1ca80b200b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_08745886-5a8c-4870-90a5-b7cd736dbc2e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_CityAreaCode_08745886-5a8c-4870-90a5-b7cd736dbc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5e3c257e-168c-4cd0-b4d4-636c56aa4168" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_LocalPhoneNumber_5e3c257e-168c-4cd0-b4d4-636c56aa4168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_19934655-a6c9-4b31-acbe-457dc9ae28c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_Security12bTitle_19934655-a6c9-4b31-acbe-457dc9ae28c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8f44987d-9c76-4473-8062-7e4dbb9d7fc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_TradingSymbol_8f44987d-9c76-4473-8062-7e4dbb9d7fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_35b00b34-f794-4500-816b-e644794b61b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_SecurityExchangeName_35b00b34-f794-4500-816b-e644794b61b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7127c302-898c-4209-be85-ad4ef49e5684" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityCurrentReportingStatus_7127c302-898c-4209-be85-ad4ef49e5684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4a1b3f54-6025-487d-bb80-2915c2ac0c3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityInteractiveDataCurrent_4a1b3f54-6025-487d-bb80-2915c2ac0c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_18c5a7be-f35d-483a-9064-bb86d0d43552" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityFilerCategory_18c5a7be-f35d-483a-9064-bb86d0d43552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_94945efa-bbff-49a8-ae38-8d3729ff2b05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntitySmallBusiness_94945efa-bbff-49a8-ae38-8d3729ff2b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2b58aa7e-d9f9-4877-b9fc-3acf11910c9a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityEmergingGrowthCompany_2b58aa7e-d9f9-4877-b9fc-3acf11910c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_655eb39b-3fe9-427a-b42d-311ddf1e820e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityShellCompany_655eb39b-3fe9-427a-b42d-311ddf1e820e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_aad80a42-d130-4354-ab57-a7259da6d7e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_aad80a42-d130-4354-ab57-a7259da6d7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_46282e39-b13f-445e-86fe-4fe93492ba0f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_DocumentFiscalYearFocus_46282e39-b13f-445e-86fe-4fe93492ba0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_19aba665-3e49-4710-9953-0cfd13f9d758" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_DocumentFiscalPeriodFocus_19aba665-3e49-4710-9953-0cfd13f9d758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_aca823ac-2f85-4e25-8524-cfd832157792" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_AmendmentFlag_aca823ac-2f85-4e25-8524-cfd832157792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_cbcc8415-9a81-4079-b29a-c48c7df7428c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_CurrentFiscalYearEndDate_cbcc8415-9a81-4079-b29a-c48c7df7428c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3a69b654-72c0-4be7-989a-066d069e1e31" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_78d6ccc3-9e64-46db-b08b-f6dc359f33ed" xlink:to="loc_dei_EntityCentralIndexKey_3a69b654-72c0-4be7-989a-066d069e1e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtl-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_13a52ec8-b5ed-4100-8dea-a9c4bd6595f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_267e20d6-b467-4592-a84c-b67d1fef17e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13a52ec8-b5ed-4100-8dea-a9c4bd6595f9" xlink:to="loc_us-gaap_AssetsAbstract_267e20d6-b467-4592-a84c-b67d1fef17e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ed11f0e2-823d-4241-9dfa-85e79da44ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_267e20d6-b467-4592-a84c-b67d1fef17e0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ed11f0e2-823d-4241-9dfa-85e79da44ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1ba13da3-85a6-46c3-bd3d-7545408841ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ed11f0e2-823d-4241-9dfa-85e79da44ea2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1ba13da3-85a6-46c3-bd3d-7545408841ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e40d39e6-9ad0-4258-85bc-d93bde42b7af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ed11f0e2-823d-4241-9dfa-85e79da44ea2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e40d39e6-9ad0-4258-85bc-d93bde42b7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3c16e7f2-8e7d-4808-b25a-ff158651b73a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ed11f0e2-823d-4241-9dfa-85e79da44ea2" xlink:to="loc_us-gaap_AssetsCurrent_3c16e7f2-8e7d-4808-b25a-ff158651b73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_633724cd-903e-4bc8-9e9d-ce0ede96db19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_267e20d6-b467-4592-a84c-b67d1fef17e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_633724cd-903e-4bc8-9e9d-ce0ede96db19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f6e2aa1b-7d89-46c8-9d1b-2337fbc939de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_267e20d6-b467-4592-a84c-b67d1fef17e0" xlink:to="loc_us-gaap_Goodwill_f6e2aa1b-7d89-46c8-9d1b-2337fbc939de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c654282-952e-4caf-b428-12b9b2e0f2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_267e20d6-b467-4592-a84c-b67d1fef17e0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c654282-952e-4caf-b428-12b9b2e0f2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_94e1cfc9-8a0e-415d-9129-3b6cc3f0faa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_267e20d6-b467-4592-a84c-b67d1fef17e0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_94e1cfc9-8a0e-415d-9129-3b6cc3f0faa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_54b4ba1c-7cba-4ef6-af35-42a5fb8ccb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_267e20d6-b467-4592-a84c-b67d1fef17e0" xlink:to="loc_us-gaap_Assets_54b4ba1c-7cba-4ef6-af35-42a5fb8ccb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_034d3ae3-ed40-447b-8d80-453cb6a7750d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_13a52ec8-b5ed-4100-8dea-a9c4bd6595f9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_034d3ae3-ed40-447b-8d80-453cb6a7750d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5a531d2f-38f9-49df-9555-7fdf342017f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_034d3ae3-ed40-447b-8d80-453cb6a7750d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5a531d2f-38f9-49df-9555-7fdf342017f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_eccb4767-9383-4cc2-abcd-068028a052b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5a531d2f-38f9-49df-9555-7fdf342017f1" xlink:to="loc_us-gaap_AccountsPayableCurrent_eccb4767-9383-4cc2-abcd-068028a052b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_84aa0abf-45e8-4ff3-becc-f982d59f42e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5a531d2f-38f9-49df-9555-7fdf342017f1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_84aa0abf-45e8-4ff3-becc-f982d59f42e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2daab70d-82f8-41df-a1b5-d0dbe6ff600c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5a531d2f-38f9-49df-9555-7fdf342017f1" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2daab70d-82f8-41df-a1b5-d0dbe6ff600c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7216b84a-f222-4592-b29e-ee3d936616ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5a531d2f-38f9-49df-9555-7fdf342017f1" xlink:to="loc_us-gaap_LiabilitiesCurrent_7216b84a-f222-4592-b29e-ee3d936616ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_224458ff-d0a2-44ea-83f6-8c0f36ec2719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_034d3ae3-ed40-447b-8d80-453cb6a7750d" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_224458ff-d0a2-44ea-83f6-8c0f36ec2719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_44b5e62d-ea83-4ff1-a313-e4301b36aaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_224458ff-d0a2-44ea-83f6-8c0f36ec2719" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_44b5e62d-ea83-4ff1-a313-e4301b36aaf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_8e0dd3ca-5667-4c44-80b5-2203d9d13370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_224458ff-d0a2-44ea-83f6-8c0f36ec2719" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_8e0dd3ca-5667-4c44-80b5-2203d9d13370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7934c5d9-b0d4-4b35-9c32-874f4c99f3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_034d3ae3-ed40-447b-8d80-453cb6a7750d" xlink:to="loc_us-gaap_Liabilities_7934c5d9-b0d4-4b35-9c32-874f4c99f3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_acc20a78-d2be-44b4-83eb-a0d360d5de5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_034d3ae3-ed40-447b-8d80-453cb6a7750d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_acc20a78-d2be-44b4-83eb-a0d360d5de5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a8f70f72-ac70-405f-9e1a-496f664a0ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_034d3ae3-ed40-447b-8d80-453cb6a7750d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a8f70f72-ac70-405f-9e1a-496f664a0ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ca06ca19-40a6-4d84-a802-1de2f6300e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a8f70f72-ac70-405f-9e1a-496f664a0ab1" xlink:to="loc_us-gaap_PreferredStockValue_ca06ca19-40a6-4d84-a802-1de2f6300e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_16bef3c3-b8a2-4e6c-a6c4-e241e4bdf8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a8f70f72-ac70-405f-9e1a-496f664a0ab1" xlink:to="loc_us-gaap_CommonStockValue_16bef3c3-b8a2-4e6c-a6c4-e241e4bdf8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_96ea17dd-0031-4fb1-b86e-a7552295373e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a8f70f72-ac70-405f-9e1a-496f664a0ab1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_96ea17dd-0031-4fb1-b86e-a7552295373e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_649f692e-d2e1-4b8b-9ad3-c5e1dca6bb03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a8f70f72-ac70-405f-9e1a-496f664a0ab1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_649f692e-d2e1-4b8b-9ad3-c5e1dca6bb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aa7a1bce-4cee-40fc-bca9-7faf96508fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a8f70f72-ac70-405f-9e1a-496f664a0ab1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aa7a1bce-4cee-40fc-bca9-7faf96508fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e34ce918-ccad-481e-8e22-04bf3f0ef08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a8f70f72-ac70-405f-9e1a-496f664a0ab1" xlink:to="loc_us-gaap_StockholdersEquity_e34ce918-ccad-481e-8e22-04bf3f0ef08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8af3de1a-7d46-47ea-863a-a02c57c25c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_034d3ae3-ed40-447b-8d80-453cb6a7750d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8af3de1a-7d46-47ea-863a-a02c57c25c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vtl-20220630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6195de72-efdb-425f-b428-d3444efd7738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29ef50a4-ccf8-4a32-b59c-0f414869309a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6195de72-efdb-425f-b428-d3444efd7738" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29ef50a4-ccf8-4a32-b59c-0f414869309a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2c5fca89-de60-4ed3-a753-1c163e2d8c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6195de72-efdb-425f-b428-d3444efd7738" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2c5fca89-de60-4ed3-a753-1c163e2d8c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5292993d-b4e2-448a-9f9e-a35dda5aa518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6195de72-efdb-425f-b428-d3444efd7738" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5292993d-b4e2-448a-9f9e-a35dda5aa518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_45c314df-008b-4e5d-b067-94c5159b23ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6195de72-efdb-425f-b428-d3444efd7738" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_45c314df-008b-4e5d-b067-94c5159b23ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f95eeb20-3176-48df-a7cb-ca2e66d7bd93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6195de72-efdb-425f-b428-d3444efd7738" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f95eeb20-3176-48df-a7cb-ca2e66d7bd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_de29ad08-b929-488e-acb5-98c6f18f6cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6195de72-efdb-425f-b428-d3444efd7738" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_de29ad08-b929-488e-acb5-98c6f18f6cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_9da7f9bc-f7ae-4d89-9189-98eb2c9e9e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6195de72-efdb-425f-b428-d3444efd7738" xlink:to="loc_us-gaap_CommonStockSharesIssued_9da7f9bc-f7ae-4d89-9189-98eb2c9e9e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_da9d5384-4047-4ebd-839b-e72ced49c6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6195de72-efdb-425f-b428-d3444efd7738" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_da9d5384-4047-4ebd-839b-e72ced49c6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="vtl-20220630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d4b2cc1f-efe8-409d-9705-46b5e248203c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_129dd745-8b97-4870-88dd-a5ca3134b48a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4b2cc1f-efe8-409d-9705-46b5e248203c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_129dd745-8b97-4870-88dd-a5ca3134b48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_93b8e54b-7cce-489b-86c3-7f639974f770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_129dd745-8b97-4870-88dd-a5ca3134b48a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_93b8e54b-7cce-489b-86c3-7f639974f770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9b6e73f3-f9e9-4335-b9c1-b0a8a9184399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_129dd745-8b97-4870-88dd-a5ca3134b48a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9b6e73f3-f9e9-4335-b9c1-b0a8a9184399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSalesNet_e801ac5c-7a16-4110-84b3-43a538ca6fb6" xlink:href="vtl-20220630.xsd#vtl_RoyaltySettlementAgreementSalesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_129dd745-8b97-4870-88dd-a5ca3134b48a" xlink:to="loc_vtl_RoyaltySettlementAgreementSalesNet_e801ac5c-7a16-4110-84b3-43a538ca6fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_63a2e9e4-f858-4bac-b337-76994c4b9374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_129dd745-8b97-4870-88dd-a5ca3134b48a" xlink:to="loc_us-gaap_OperatingExpenses_63a2e9e4-f858-4bac-b337-76994c4b9374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a592693e-3e31-4c14-9d79-ed451d8b3d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4b2cc1f-efe8-409d-9705-46b5e248203c" xlink:to="loc_us-gaap_OperatingIncomeLoss_a592693e-3e31-4c14-9d79-ed451d8b3d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ae209ca8-3128-4f8d-84cc-1a56e818c220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4b2cc1f-efe8-409d-9705-46b5e248203c" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ae209ca8-3128-4f8d-84cc-1a56e818c220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a34898ab-4415-498a-ab9c-d642d8bc0bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ae209ca8-3128-4f8d-84cc-1a56e818c220" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a34898ab-4415-498a-ab9c-d642d8bc0bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_51578fdf-9e90-43d3-aa66-6f84cc764777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ae209ca8-3128-4f8d-84cc-1a56e818c220" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_51578fdf-9e90-43d3-aa66-6f84cc764777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a50abb85-c051-4d35-acb5-040eca01925e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ae209ca8-3128-4f8d-84cc-1a56e818c220" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a50abb85-c051-4d35-acb5-040eca01925e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0238d7a8-9f49-4b33-8355-7d86cd1168b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4b2cc1f-efe8-409d-9705-46b5e248203c" xlink:to="loc_us-gaap_NetIncomeLoss_0238d7a8-9f49-4b33-8355-7d86cd1168b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b7e8f678-69a9-47d2-81e3-36b84c5a35f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4b2cc1f-efe8-409d-9705-46b5e248203c" xlink:to="loc_us-gaap_EarningsPerShareBasic_b7e8f678-69a9-47d2-81e3-36b84c5a35f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_95472b6e-7f12-422d-b17c-b54477581086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4b2cc1f-efe8-409d-9705-46b5e248203c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_95472b6e-7f12-422d-b17c-b54477581086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fcb57e15-c0c5-43b8-a9bf-bc72b4947a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4b2cc1f-efe8-409d-9705-46b5e248203c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fcb57e15-c0c5-43b8-a9bf-bc72b4947a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2a12eed8-80f1-4bed-935e-863eb518d4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d4b2cc1f-efe8-409d-9705-46b5e248203c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2a12eed8-80f1-4bed-935e-863eb518d4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="vtl-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e3e18bc6-0227-4089-b777-b8edc3d742e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a4128e2-8039-490b-8cd1-3cd5359f9dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e3e18bc6-0227-4089-b777-b8edc3d742e8" xlink:to="loc_us-gaap_NetIncomeLoss_1a4128e2-8039-490b-8cd1-3cd5359f9dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_4928909f-eca3-4b5e-80e2-c407cb6e30ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e3e18bc6-0227-4089-b777-b8edc3d742e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_4928909f-eca3-4b5e-80e2-c407cb6e30ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9dd44cb4-8011-497f-9134-de2b6da6d289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_4928909f-eca3-4b5e-80e2-c407cb6e30ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_9dd44cb4-8011-497f-9134-de2b6da6d289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2e59af58-9493-4708-9ac3-bcd977d57f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e3e18bc6-0227-4089-b777-b8edc3d742e8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2e59af58-9493-4708-9ac3-bcd977d57f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vtl-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b879c2bc-1cb3-4538-b701-21b8f5dea7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_77a81b21-cdf7-4511-ab93-1291677bd29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b879c2bc-1cb3-4538-b701-21b8f5dea7e3" xlink:to="loc_us-gaap_StatementTable_77a81b21-cdf7-4511-ab93-1291677bd29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f4af31b6-cc36-4480-80bb-eed5b44255a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77a81b21-cdf7-4511-ab93-1291677bd29e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f4af31b6-cc36-4480-80bb-eed5b44255a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f271e067-cf45-4dcb-a492-abf02c1f2a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4af31b6-cc36-4480-80bb-eed5b44255a5" xlink:to="loc_us-gaap_EquityComponentDomain_f271e067-cf45-4dcb-a492-abf02c1f2a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cffb0b85-25d3-4926-9946-b34be1c1c84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f271e067-cf45-4dcb-a492-abf02c1f2a01" xlink:to="loc_us-gaap_CommonStockMember_cffb0b85-25d3-4926-9946-b34be1c1c84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_83d68093-7c89-4c0b-8de1-1e2dfbfd030b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f271e067-cf45-4dcb-a492-abf02c1f2a01" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_83d68093-7c89-4c0b-8de1-1e2dfbfd030b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c58a0d5d-d2f9-4757-9276-c52e96c10f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f271e067-cf45-4dcb-a492-abf02c1f2a01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c58a0d5d-d2f9-4757-9276-c52e96c10f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6fb499b3-bb56-4bc8-aa7a-387112143065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f271e067-cf45-4dcb-a492-abf02c1f2a01" xlink:to="loc_us-gaap_RetainedEarningsMember_6fb499b3-bb56-4bc8-aa7a-387112143065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2a81ce49-a3c6-458c-9481-cf22bb427c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77a81b21-cdf7-4511-ab93-1291677bd29e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2a81ce49-a3c6-458c-9481-cf22bb427c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_258e24ed-ffa6-445d-8e13-f33b658207dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2a81ce49-a3c6-458c-9481-cf22bb427c45" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_258e24ed-ffa6-445d-8e13-f33b658207dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PublicOfferingMember_53a01e42-0eb9-40c0-b82f-1b4e0a39dbf1" xlink:href="vtl-20220630.xsd#vtl_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_258e24ed-ffa6-445d-8e13-f33b658207dc" xlink:to="loc_vtl_PublicOfferingMember_53a01e42-0eb9-40c0-b82f-1b4e0a39dbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A4SCRoyaltySettlementMember_03b54cf1-38fa-47c6-9651-cd22f227e64b" xlink:href="vtl-20220630.xsd#vtl_A4SCRoyaltySettlementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_258e24ed-ffa6-445d-8e13-f33b658207dc" xlink:to="loc_vtl_A4SCRoyaltySettlementMember_03b54cf1-38fa-47c6-9651-cd22f227e64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d5d70e95-afc9-4fc4-a28d-5785a1b33be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77a81b21-cdf7-4511-ab93-1291677bd29e" xlink:to="loc_us-gaap_StatementLineItems_d5d70e95-afc9-4fc4-a28d-5785a1b33be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5d70e95-afc9-4fc4-a28d-5785a1b33be9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c43cedef-4441-4bcc-9a68-8a9dc041f08d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_SharesOutstanding_c43cedef-4441-4bcc-9a68-8a9dc041f08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_533089da-9d72-480d-8ef1-5f99370aca1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_StockholdersEquity_533089da-9d72-480d-8ef1-5f99370aca1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_da910301-c194-43a5-9e43-63c32d484fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_NetIncomeLoss_da910301-c194-43a5-9e43-63c32d484fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_93cccb0a-aa00-4e08-bbdb-2f17b16ea6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_93cccb0a-aa00-4e08-bbdb-2f17b16ea6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_83a875a0-83a7-4f88-a7ff-c52c722e0d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_83a875a0-83a7-4f88-a7ff-c52c722e0d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8485e33f-e058-401c-8ac5-b1e3174129b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8485e33f-e058-401c-8ac5-b1e3174129b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3e8fc6ac-ae77-4332-a94e-76dc7f133c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3e8fc6ac-ae77-4332-a94e-76dc7f133c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3faf6230-3a7b-43cc-8c1b-ed311cf8fbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_SharesOutstanding_3faf6230-3a7b-43cc-8c1b-ed311cf8fbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_60217859-7322-4607-8dad-8e306f47b5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_50f3c940-73f3-44e6-90ad-55878c4c6c53" xlink:to="loc_us-gaap_StockholdersEquity_60217859-7322-4607-8dad-8e306f47b5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="vtl-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_32f1ce11-a4e4-43a4-bd16-38f155c0132e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f28f1a86-a236-4ead-a61a-998417c051c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_32f1ce11-a4e4-43a4-bd16-38f155c0132e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f28f1a86-a236-4ead-a61a-998417c051c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="vtl-20220630.xsd#CondensedConsolidatedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e36534ca-0037-487a-b7b6-4d0c8711e952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_91906bee-1d85-4a61-8e30-a19c904e4623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e36534ca-0037-487a-b7b6-4d0c8711e952" xlink:to="loc_us-gaap_StatementTable_91906bee-1d85-4a61-8e30-a19c904e4623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bd08ff82-e81a-424b-b5e6-3465bfc2495b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_91906bee-1d85-4a61-8e30-a19c904e4623" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bd08ff82-e81a-424b-b5e6-3465bfc2495b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df1e4af5-38ae-4c67-948f-478a143078b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bd08ff82-e81a-424b-b5e6-3465bfc2495b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df1e4af5-38ae-4c67-948f-478a143078b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PublicOfferingMember_33b2ab30-fa4f-409f-b9ad-dbb4366f865d" xlink:href="vtl-20220630.xsd#vtl_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df1e4af5-38ae-4c67-948f-478a143078b5" xlink:to="loc_vtl_PublicOfferingMember_33b2ab30-fa4f-409f-b9ad-dbb4366f865d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_91906bee-1d85-4a61-8e30-a19c904e4623" xlink:to="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ac78fce-a4c3-4455-9c76-769b8ddb3bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ac78fce-a4c3-4455-9c76-769b8ddb3bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c1e066ba-5ff2-4d9d-8297-ecddd7dffd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ac78fce-a4c3-4455-9c76-769b8ddb3bff" xlink:to="loc_us-gaap_NetIncomeLoss_c1e066ba-5ff2-4d9d-8297-ecddd7dffd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d55479b-b669-425d-98ae-0639eff5f595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ac78fce-a4c3-4455-9c76-769b8ddb3bff" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d55479b-b669-425d-98ae-0639eff5f595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_988d618d-6d13-4288-9488-a184358c4be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d55479b-b669-425d-98ae-0639eff5f595" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_988d618d-6d13-4288-9488-a184358c4be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d6116fa7-704e-449b-b7a7-30cfb8ce77e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d55479b-b669-425d-98ae-0639eff5f595" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_d6116fa7-704e-449b-b7a7-30cfb8ce77e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7e2a99fc-c316-47de-96fd-57fe1703fe23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d55479b-b669-425d-98ae-0639eff5f595" xlink:to="loc_us-gaap_ShareBasedCompensation_7e2a99fc-c316-47de-96fd-57fe1703fe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_94c2874b-c61b-45b9-a22a-53c31a44833a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d55479b-b669-425d-98ae-0639eff5f595" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_94c2874b-c61b-45b9-a22a-53c31a44833a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_523be5ba-ff7a-466f-9597-0775c2f63cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d55479b-b669-425d-98ae-0639eff5f595" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_523be5ba-ff7a-466f-9597-0775c2f63cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ab1840db-4a6c-4987-915c-b5b174fba36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_523be5ba-ff7a-466f-9597-0775c2f63cc3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ab1840db-4a6c-4987-915c-b5b174fba36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ae9c8b65-530c-4164-85cf-b85176dec2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_523be5ba-ff7a-466f-9597-0775c2f63cc3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ae9c8b65-530c-4164-85cf-b85176dec2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_37b3f97f-3e5e-4120-9e75-fc7212a3d756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_523be5ba-ff7a-466f-9597-0775c2f63cc3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_37b3f97f-3e5e-4120-9e75-fc7212a3d756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a40eb15d-e6c9-4894-b4e9-625366331ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_523be5ba-ff7a-466f-9597-0775c2f63cc3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a40eb15d-e6c9-4894-b4e9-625366331ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de593d21-8441-405e-b49c-6281236e1dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5ac78fce-a4c3-4455-9c76-769b8ddb3bff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_de593d21-8441-405e-b49c-6281236e1dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_32fc7897-2f05-4873-85b9-a446b842ee4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_32fc7897-2f05-4873-85b9-a446b842ee4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c8d20740-aa02-4a46-805e-e7ffdc8897d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_32fc7897-2f05-4873-85b9-a446b842ee4c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c8d20740-aa02-4a46-805e-e7ffdc8897d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bf0e22d7-e9e6-44df-a1a8-625044f52b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_32fc7897-2f05-4873-85b9-a446b842ee4c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bf0e22d7-e9e6-44df-a1a8-625044f52b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ebd4ad43-d7f3-4ac4-b418-09c91481402c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ebd4ad43-d7f3-4ac4-b418-09c91481402c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c8c21655-278a-4612-bd58-49dbd8ea495a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ebd4ad43-d7f3-4ac4-b418-09c91481402c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c8c21655-278a-4612-bd58-49dbd8ea495a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_159d26e4-3e41-4a5e-9d4b-32dbb1f54975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ebd4ad43-d7f3-4ac4-b418-09c91481402c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_159d26e4-3e41-4a5e-9d4b-32dbb1f54975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_44b655ff-970b-4884-9718-08c81e752509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ebd4ad43-d7f3-4ac4-b418-09c91481402c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_44b655ff-970b-4884-9718-08c81e752509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_12768781-dc12-4be8-9720-369f28dce4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ebd4ad43-d7f3-4ac4-b418-09c91481402c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_12768781-dc12-4be8-9720-369f28dce4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecbb6741-9885-4f9c-a756-6d65117a39b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecbb6741-9885-4f9c-a756-6d65117a39b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e9964814-afb0-4138-9fe0-6fe12db52bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e9964814-afb0-4138-9fe0-6fe12db52bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f2e8123e-6570-43c7-9837-61d15a8e96ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f2e8123e-6570-43c7-9837-61d15a8e96ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7285e308-7453-4ef2-8ab5-16bd83fe800e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7285e308-7453-4ef2-8ab5-16bd83fe800e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_81133000-7538-4e89-8ccb-13feb9837fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fa13315-b489-41e6-8879-442f66657e57" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_81133000-7538-4e89-8ccb-13feb9837fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_37183d33-d671-41e5-bda5-d6f7c099434d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_81133000-7538-4e89-8ccb-13feb9837fff" xlink:to="loc_us-gaap_StockIssued1_37183d33-d671-41e5-bda5-d6f7c099434d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_09bc96ed-8871-4e02-b76c-e39818d7b56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_81133000-7538-4e89-8ccb-13feb9837fff" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_09bc96ed-8871-4e02-b76c-e39818d7b56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="simple" xlink:href="vtl-20220630.xsd#DescriptionofBusinessandBasisofFinancialStatements"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_acc569d5-68f4-48db-8c87-9b670c8a6e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_31c9deab-a28a-4668-ab45-2666a4289d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_acc569d5-68f4-48db-8c87-9b670c8a6e0f" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_31c9deab-a28a-4668-ab45-2666a4289d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#DescriptionofBusinessandBasisofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1bb46acd-8f76-4668-ba51-1f0c3cc55d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_16744dd0-83c3-444b-82f6-e04c37a13b65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bb46acd-8f76-4668-ba51-1f0c3cc55d2e" xlink:to="loc_dei_EntityNumberOfEmployees_16744dd0-83c3-444b-82f6-e04c37a13b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentProgramsPursued_37a14b87-a2f6-4642-8ba0-12d1860059fb" xlink:href="vtl-20220630.xsd#vtl_NumberOfDevelopmentProgramsPursued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bb46acd-8f76-4668-ba51-1f0c3cc55d2e" xlink:to="loc_vtl_NumberOfDevelopmentProgramsPursued_37a14b87-a2f6-4642-8ba0-12d1860059fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f5323d7a-931a-46b7-8e89-2b677aa2d91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bb46acd-8f76-4668-ba51-1f0c3cc55d2e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f5323d7a-931a-46b7-8e89-2b677aa2d91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_9cb6c3ce-f6ae-45fd-a061-71bfe599f1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bb46acd-8f76-4668-ba51-1f0c3cc55d2e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_9cb6c3ce-f6ae-45fd-a061-71bfe599f1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43189fd9-3f48-42d7-9ef5-bd8c9f154954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bb46acd-8f76-4668-ba51-1f0c3cc55d2e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43189fd9-3f48-42d7-9ef5-bd8c9f154954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vtl-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_79b195ee-782e-4702-95b4-533eac41d4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c17b5d96-b3b3-4d43-b849-a3b395342d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79b195ee-782e-4702-95b4-533eac41d4c8" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_c17b5d96-b3b3-4d43-b849-a3b395342d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vtl-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_df65e8f7-1e7a-4bee-9a0e-92d2949e5d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_df65e8f7-1e7a-4bee-9a0e-92d2949e5d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_d35e0cfe-da17-41d2-899a-ffb9ae70ce90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_UseOfEstimates_d35e0cfe-da17-41d2-899a-ffb9ae70ce90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d96be9c8-245b-4af5-a8ca-7f2fcec2cfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d96be9c8-245b-4af5-a8ca-7f2fcec2cfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_413a24c5-9ede-462a-b4e3-2e8985240115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_413a24c5-9ede-462a-b4e3-2e8985240115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_027342d9-425e-4349-b7fd-326612abbeea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_027342d9-425e-4349-b7fd-326612abbeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c10d5543-a563-401c-896a-e31d2fc21103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c10d5543-a563-401c-896a-e31d2fc21103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3386015c-3d31-4e85-b7df-139924f70882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_3386015c-3d31-4e85-b7df-139924f70882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_8233886e-9488-4cff-81bc-514832b833e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_8233886e-9488-4cff-81bc-514832b833e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0e41d0b2-0d0f-4ec5-925b-cbfdec771fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0e41d0b2-0d0f-4ec5-925b-cbfdec771fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_fd83264f-ba63-48a2-b3c3-ff7c61dcde7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_fd83264f-ba63-48a2-b3c3-ff7c61dcde7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_75ae4f4e-c50a-411b-af1b-91bd64ca0a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_75ae4f4e-c50a-411b-af1b-91bd64ca0a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d59d4dd1-2426-4cb7-bee4-e75958bd25ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d59d4dd1-2426-4cb7-bee4-e75958bd25ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_9ae1c2bf-eb9a-4a77-b3ab-5a51dc565aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_9ae1c2bf-eb9a-4a77-b3ab-5a51dc565aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5fd3b912-a992-4adf-9683-83e6583a936d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5fd3b912-a992-4adf-9683-83e6583a936d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_2d329b86-69a9-4802-9879-c29f3f057442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_2d329b86-69a9-4802-9879-c29f3f057442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_b30b65d8-402f-4109-8911-17362f255423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_b30b65d8-402f-4109-8911-17362f255423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3a1fec08-f96c-4723-a5af-62c94bb77189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97fbe19d-3746-42fc-b6ad-56821cddb676" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3a1fec08-f96c-4723-a5af-62c94bb77189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="vtl-20220630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0e1041d0-01b7-4b46-bf60-bed737e26d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d7759450-e63b-4954-90d3-7d01a7ac51c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e1041d0-01b7-4b46-bf60-bed737e26d80" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d7759450-e63b-4954-90d3-7d01a7ac51c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5af88eaa-0ea9-465e-a7f7-250ed0cdd892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fd00e4d-50ca-424c-8d85-a2ba192f7ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5af88eaa-0ea9-465e-a7f7-250ed0cdd892" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fd00e4d-50ca-424c-8d85-a2ba192f7ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9465d8ad-671f-4e5f-b9d3-5922efc7908e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fd00e4d-50ca-424c-8d85-a2ba192f7ecd" xlink:to="loc_srt_RangeAxis_9465d8ad-671f-4e5f-b9d3-5922efc7908e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7d2f2560-1b0e-42d5-b88e-e5a327142f2c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9465d8ad-671f-4e5f-b9d3-5922efc7908e" xlink:to="loc_srt_RangeMember_7d2f2560-1b0e-42d5-b88e-e5a327142f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e7b9ae38-1171-4128-81f7-1a3cfac27651" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7d2f2560-1b0e-42d5-b88e-e5a327142f2c" xlink:to="loc_srt_MinimumMember_e7b9ae38-1171-4128-81f7-1a3cfac27651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_136da454-22f6-4a3f-9cd0-7c5485193b89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7d2f2560-1b0e-42d5-b88e-e5a327142f2c" xlink:to="loc_srt_MaximumMember_136da454-22f6-4a3f-9cd0-7c5485193b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f4b9537-5f78-4654-9900-eb6a20f39a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9fd00e4d-50ca-424c-8d85-a2ba192f7ecd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f4b9537-5f78-4654-9900-eb6a20f39a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0c959b6c-f19b-4d5d-8729-dc84e15c90a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f4b9537-5f78-4654-9900-eb6a20f39a99" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0c959b6c-f19b-4d5d-8729-dc84e15c90a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3f2059c0-2292-4422-ae4e-d63e666fbe4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f4b9537-5f78-4654-9900-eb6a20f39a99" xlink:to="loc_us-gaap_Depreciation_3f2059c0-2292-4422-ae4e-d63e666fbe4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_ea0e7a50-cb45-4240-a983-ae576cf2735d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f4b9537-5f78-4654-9900-eb6a20f39a99" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_ea0e7a50-cb45-4240-a983-ae576cf2735d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_59331a66-8da1-4cc9-8e1f-335fec04b5af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f4b9537-5f78-4654-9900-eb6a20f39a99" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_59331a66-8da1-4cc9-8e1f-335fec04b5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_1095c7db-a1c4-469a-8f88-e096fcef0eae" xlink:href="vtl-20220630.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2f4b9537-5f78-4654-9900-eb6a20f39a99" xlink:to="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_1095c7db-a1c4-469a-8f88-e096fcef0eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e68825c5-eb04-4de0-8857-f30cd0a8991a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d860a446-d0c5-4a30-b80a-5b884411292c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e68825c5-eb04-4de0-8857-f30cd0a8991a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d860a446-d0c5-4a30-b80a-5b884411292c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1461e2c3-4483-443d-a1ee-82efd7999e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d860a446-d0c5-4a30-b80a-5b884411292c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1461e2c3-4483-443d-a1ee-82efd7999e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e14649fe-6561-4063-a4e9-94c690953db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1461e2c3-4483-443d-a1ee-82efd7999e80" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e14649fe-6561-4063-a4e9-94c690953db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_bf5da9fc-9bdd-4ec4-9ff6-675a0ce94e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e14649fe-6561-4063-a4e9-94c690953db3" xlink:to="loc_us-gaap_StockOptionMember_bf5da9fc-9bdd-4ec4-9ff6-675a0ce94e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d2a738d6-e134-42ff-8bf2-87b4204857bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d860a446-d0c5-4a30-b80a-5b884411292c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d2a738d6-e134-42ff-8bf2-87b4204857bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a8b0f94a-cd7e-49ea-a440-d062760713e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d2a738d6-e134-42ff-8bf2-87b4204857bc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a8b0f94a-cd7e-49ea-a440-d062760713e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#BalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c013f2cf-444d-4ddd-9478-e37f12f79d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5698c32f-b3ab-42b4-8dbc-fc9823b90bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c013f2cf-444d-4ddd-9478-e37f12f79d4c" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5698c32f-b3ab-42b4-8dbc-fc9823b90bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsTables" xlink:type="simple" xlink:href="vtl-20220630.xsd#BalanceSheetDetailsTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a007c073-d3ab-408b-b3b3-fd0060cd523f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_7a7688e9-c932-401e-953a-b8795b96b687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a007c073-d3ab-408b-b3b3-fd0060cd523f" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_7a7688e9-c932-401e-953a-b8795b96b687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_8622886e-bb50-4187-82ab-0ac8b11b1f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a007c073-d3ab-408b-b3b3-fd0060cd523f" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_8622886e-bb50-4187-82ab-0ac8b11b1f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_e58d3996-20ac-4171-a549-1310e220882a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a007c073-d3ab-408b-b3b3-fd0060cd523f" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_e58d3996-20ac-4171-a549-1310e220882a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="simple" xlink:href="vtl-20220630.xsd#BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9ad7f11-fe44-4528-92bf-049ee7ee45cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_f37d7cab-8beb-4aea-838b-e88f00bc4d8f" xlink:href="vtl-20220630.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9ad7f11-fe44-4528-92bf-049ee7ee45cb" xlink:to="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_f37d7cab-8beb-4aea-838b-e88f00bc4d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_84e96a98-095a-4fb7-9c75-dc83ceebb819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9ad7f11-fe44-4528-92bf-049ee7ee45cb" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_84e96a98-095a-4fb7-9c75-dc83ceebb819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_87a4d900-bc05-4cf6-9f16-ef2720616e45" xlink:href="vtl-20220630.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9ad7f11-fe44-4528-92bf-049ee7ee45cb" xlink:to="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_87a4d900-bc05-4cf6-9f16-ef2720616e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_edf8b27a-1e5b-47f0-8e51-63316a53cdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9ad7f11-fe44-4528-92bf-049ee7ee45cb" xlink:to="loc_us-gaap_OtherAssetsCurrent_edf8b27a-1e5b-47f0-8e51-63316a53cdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_900c4f54-d6e2-47b0-862e-220326b12b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9ad7f11-fe44-4528-92bf-049ee7ee45cb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_900c4f54-d6e2-47b0-862e-220326b12b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="vtl-20220630.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a96015ea-543c-4874-855c-5b1ff8b6e108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent_68aff73c-cb07-4129-8d6b-416cf3b12834" xlink:href="vtl-20220630.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a96015ea-543c-4874-855c-5b1ff8b6e108" xlink:to="loc_vtl_ClinicalCostsPayableCurrent_68aff73c-cb07-4129-8d6b-416cf3b12834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent_a218e157-817b-4116-a97b-bdcf8a7f1eb7" xlink:href="vtl-20220630.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a96015ea-543c-4874-855c-5b1ff8b6e108" xlink:to="loc_vtl_LegalAndAuditCostsPayableCurrent_a218e157-817b-4116-a97b-bdcf8a7f1eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_29be8cd3-1474-4b57-ae89-0c4dba2b3125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a96015ea-543c-4874-855c-5b1ff8b6e108" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_29be8cd3-1474-4b57-ae89-0c4dba2b3125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3af2c395-8237-4cd7-9530-75f3d86b9a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a96015ea-543c-4874-855c-5b1ff8b6e108" xlink:to="loc_us-gaap_AccountsPayableCurrent_3af2c395-8237-4cd7-9530-75f3d86b9a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="vtl-20220630.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22327a16-8acf-43d0-8106-16a2d311b56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent_115e0736-00eb-4c59-8705-839be67998a3" xlink:href="vtl-20220630.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22327a16-8acf-43d0-8106-16a2d311b56a" xlink:to="loc_vtl_AccruedClinicalCostsCurrent_115e0736-00eb-4c59-8705-839be67998a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent_83d67db2-7be7-4fac-a5b6-956db890cc67" xlink:href="vtl-20220630.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22327a16-8acf-43d0-8106-16a2d311b56a" xlink:to="loc_vtl_AccruedLegalAndAuditCostsCurrent_83d67db2-7be7-4fac-a5b6-956db890cc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent_6261b880-9cca-4bbd-9a18-dac670f57bae" xlink:href="vtl-20220630.xsd#vtl_AccruedCompensationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22327a16-8acf-43d0-8106-16a2d311b56a" xlink:to="loc_vtl_AccruedCompensationCurrent_6261b880-9cca-4bbd-9a18-dac670f57bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7e696781-1e1d-43f8-913e-469e531a689d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22327a16-8acf-43d0-8106-16a2d311b56a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7e696781-1e1d-43f8-913e-469e531a689d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_908ecbea-2073-4f58-9262-b7ce2ee200a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_22327a16-8acf-43d0-8106-16a2d311b56a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_908ecbea-2073-4f58-9262-b7ce2ee200a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="vtl-20220630.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97aed251-809d-4b37-991b-b79164fa9242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_38bc4a4c-e084-48b8-a463-47c66690d0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97aed251-809d-4b37-991b-b79164fa9242" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_38bc4a4c-e084-48b8-a463-47c66690d0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_14c6164e-9bdd-43e9-a0ee-0e6e21d7e6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97aed251-809d-4b37-991b-b79164fa9242" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_14c6164e-9bdd-43e9-a0ee-0e6e21d7e6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_da989439-c320-4017-8351-2ca3fc8cb91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97aed251-809d-4b37-991b-b79164fa9242" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_da989439-c320-4017-8351-2ca3fc8cb91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_ba9ecd30-5d3a-4acf-a04b-e9cd085c7108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97aed251-809d-4b37-991b-b79164fa9242" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_ba9ecd30-5d3a-4acf-a04b-e9cd085c7108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d095e16f-93f5-4ba6-a7db-0421fe1c38f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dd024152-2f70-41ba-9464-47f083c0ec12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d095e16f-93f5-4ba6-a7db-0421fe1c38f3" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dd024152-2f70-41ba-9464-47f083c0ec12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_512fa59e-83c6-44fc-a3d6-9f604e1f8f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8e0c3f4d-ba84-4582-acb8-4aeca704af55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_512fa59e-83c6-44fc-a3d6-9f604e1f8f1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8e0c3f4d-ba84-4582-acb8-4aeca704af55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5df076a0-2ce5-433f-9270-4f30f7c8de2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fd497d69-8bac-40a3-beb3-b32af505fb32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5df076a0-2ce5-433f-9270-4f30f7c8de2e" xlink:to="loc_us-gaap_LossContingenciesTable_fd497d69-8bac-40a3-beb3-b32af505fb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4dc2ab40-7735-438b-b480-2e165275b32a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fd497d69-8bac-40a3-beb3-b32af505fb32" xlink:to="loc_srt_StatementGeographicalAxis_4dc2ab40-7735-438b-b480-2e165275b32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dd65fab1-6e2f-4561-8c5c-d74fd567d07e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4dc2ab40-7735-438b-b480-2e165275b32a" xlink:to="loc_srt_SegmentGeographicalDomain_dd65fab1-6e2f-4561-8c5c-d74fd567d07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember_5c85c266-4981-4399-adaf-7f3b0e1649a7" xlink:href="vtl-20220630.xsd#vtl_GrafelfingGermanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_dd65fab1-6e2f-4561-8c5c-d74fd567d07e" xlink:to="loc_vtl_GrafelfingGermanyMember_5c85c266-4981-4399-adaf-7f3b0e1649a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember_bd70daba-a083-4910-9b61-5347ecbd7431" xlink:href="vtl-20220630.xsd#vtl_NewYorkCityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_dd65fab1-6e2f-4561-8c5c-d74fd567d07e" xlink:to="loc_vtl_NewYorkCityMember_bd70daba-a083-4910-9b61-5347ecbd7431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b02fd5ed-ef87-4d5a-84df-62bb3ab0806f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fd497d69-8bac-40a3-beb3-b32af505fb32" xlink:to="loc_dei_LegalEntityAxis_b02fd5ed-ef87-4d5a-84df-62bb3ab0806f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e8ce4928-057d-4ffc-b023-79d7e78f5a1a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_b02fd5ed-ef87-4d5a-84df-62bb3ab0806f" xlink:to="loc_dei_EntityDomain_e8ce4928-057d-4ffc-b023-79d7e78f5a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ImmunicAGMember_f50ebf97-9394-4db4-ae23-12ae8bd9d860" xlink:href="vtl-20220630.xsd#vtl_ImmunicAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e8ce4928-057d-4ffc-b023-79d7e78f5a1a" xlink:to="loc_vtl_ImmunicAGMember_f50ebf97-9394-4db4-ae23-12ae8bd9d860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fd497d69-8bac-40a3-beb3-b32af505fb32" xlink:to="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_80dcdacf-2d50-4b69-9c84-d8e15e6d4c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_80dcdacf-2d50-4b69-9c84-d8e15e6d4c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseRentHolidayPeriod_c4aa3c87-44fb-420a-9f0f-ac2df334969c" xlink:href="vtl-20220630.xsd#vtl_LesseeOperatingLeaseRentHolidayPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_LesseeOperatingLeaseRentHolidayPeriod_c4aa3c87-44fb-420a-9f0f-ac2df334969c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_15324f9d-e8d8-4ed9-bc24-e3e1da9cf31f" xlink:href="vtl-20220630.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_15324f9d-e8d8-4ed9-bc24-e3e1da9cf31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate_bf6540f1-5223-4455-a598-f6e0e01f6597" xlink:href="vtl-20220630.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_OperatingLeaseIncrementalBorrowingRate_bf6540f1-5223-4455-a598-f6e0e01f6597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost_17ba6ed1-6e2f-4a1b-a453-22cfdf6e48e2" xlink:href="vtl-20220630.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_OperatingAndVariableLeasesCost_17ba6ed1-6e2f-4a1b-a453-22cfdf6e48e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_19bb5809-f2dd-43fc-90d2-7f020ed36e8c" xlink:href="vtl-20220630.xsd#vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales_19bb5809-f2dd-43fc-90d2-7f020ed36e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7e77fcd8-a2ff-44ec-9c8d-e588c8a0ab37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_us-gaap_CommonStockSharesIssued_7e77fcd8-a2ff-44ec-9c8d-e588c8a0ab37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bd01afd1-c844-440c-b51d-394bc215d440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_us-gaap_CommonStockValue_bd01afd1-c844-440c-b51d-394bc215d440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSalesNet_f02b625d-d559-488c-8be0-0f63f0863a3e" xlink:href="vtl-20220630.xsd#vtl_RoyaltySettlementAgreementSalesNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_RoyaltySettlementAgreementSalesNet_f02b625d-d559-488c-8be0-0f63f0863a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementCashPaymentPercent_2b26aa96-3926-4247-be7d-e3234218421d" xlink:href="vtl-20220630.xsd#vtl_RoyaltySettlementAgreementCashPaymentPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_RoyaltySettlementAgreementCashPaymentPercent_2b26aa96-3926-4247-be7d-e3234218421d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RoyaltySettlementAgreementSharesPaymentPercent_03393cbf-0733-47f3-8dc3-a48dff8450ca" xlink:href="vtl-20220630.xsd#vtl_RoyaltySettlementAgreementSharesPaymentPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_vtl_RoyaltySettlementAgreementSharesPaymentPercent_03393cbf-0733-47f3-8dc3-a48dff8450ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_8ea3873a-1984-4b4f-a6cb-cb92234f5933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_893f7dc9-22fa-476d-9454-308fe530fad1" xlink:to="loc_us-gaap_ContractualObligation_8ea3873a-1984-4b4f-a6cb-cb92234f5933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f0638e4-190b-4de8-9b60-4d8b91859353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_55cd4bc0-d5c4-41a4-9550-6c6210a2bbca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f0638e4-190b-4de8-9b60-4d8b91859353" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_55cd4bc0-d5c4-41a4-9550-6c6210a2bbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0a6aa6a9-8431-4d11-b2f9-81cd208a2601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f0638e4-190b-4de8-9b60-4d8b91859353" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0a6aa6a9-8431-4d11-b2f9-81cd208a2601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_45e5e97a-2db5-4743-8dbb-467c6d0fdefc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f0638e4-190b-4de8-9b60-4d8b91859353" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_45e5e97a-2db5-4743-8dbb-467c6d0fdefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_69360f5c-eeb1-4fb5-93f7-b7f418797676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f0638e4-190b-4de8-9b60-4d8b91859353" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_69360f5c-eeb1-4fb5-93f7-b7f418797676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c9e1a8a7-13c3-4b44-972b-d504f999cd58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f0638e4-190b-4de8-9b60-4d8b91859353" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c9e1a8a7-13c3-4b44-972b-d504f999cd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2566eb0d-84a0-4443-b84b-6dd4b4f2e117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f0638e4-190b-4de8-9b60-4d8b91859353" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2566eb0d-84a0-4443-b84b-6dd4b4f2e117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6df6c8c6-cc81-43d0-b65c-2ee882edec87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f0638e4-190b-4de8-9b60-4d8b91859353" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6df6c8c6-cc81-43d0-b65c-2ee882edec87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fa99f6c6-1094-49a3-9a56-4358dcb428ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f0638e4-190b-4de8-9b60-4d8b91859353" xlink:to="loc_us-gaap_OperatingLeaseLiability_fa99f6c6-1094-49a3-9a56-4358dcb428ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValue" xlink:type="simple" xlink:href="vtl-20220630.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_98b7f8c9-5f74-4f77-a9d6-64120dabec42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_08a6c803-e080-448e-a8b9-82662c62d61f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_98b7f8c9-5f74-4f77-a9d6-64120dabec42" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_08a6c803-e080-448e-a8b9-82662c62d61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueTables" xlink:type="simple" xlink:href="vtl-20220630.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c22d4253-a22c-42d0-b7a4-69a5c215a01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a3b05925-054c-45bd-809f-902c74beb06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c22d4253-a22c-42d0-b7a4-69a5c215a01d" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a3b05925-054c-45bd-809f-902c74beb06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_112c143b-2456-4c91-862c-c5fe39127cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49216c19-77b4-4e95-8997-8f332a1cecf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_112c143b-2456-4c91-862c-c5fe39127cfc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49216c19-77b4-4e95-8997-8f332a1cecf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_46a5059a-bf98-40ef-a6b5-2a5481330e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49216c19-77b4-4e95-8997-8f332a1cecf0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_46a5059a-bf98-40ef-a6b5-2a5481330e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7aaaca42-6040-4c88-90cf-f98bfea4d0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_46a5059a-bf98-40ef-a6b5-2a5481330e77" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7aaaca42-6040-4c88-90cf-f98bfea4d0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a9b52550-6487-46e8-898b-a3b6c1fd92d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7aaaca42-6040-4c88-90cf-f98bfea4d0fe" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a9b52550-6487-46e8-898b-a3b6c1fd92d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_41811d75-b92a-4953-a82d-4f7db925a19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7aaaca42-6040-4c88-90cf-f98bfea4d0fe" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_41811d75-b92a-4953-a82d-4f7db925a19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2ee747ef-90bb-425f-b8a0-17ade9b7ba9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7aaaca42-6040-4c88-90cf-f98bfea4d0fe" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2ee747ef-90bb-425f-b8a0-17ade9b7ba9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bf53a74c-f31c-46e0-830d-aa47c7a69e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49216c19-77b4-4e95-8997-8f332a1cecf0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bf53a74c-f31c-46e0-830d-aa47c7a69e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5536a68e-8e98-4c90-b381-a492dedd9fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_bf53a74c-f31c-46e0-830d-aa47c7a69e9f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5536a68e-8e98-4c90-b381-a492dedd9fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e509a2dc-14a6-408e-9e2c-04729928aa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5536a68e-8e98-4c90-b381-a492dedd9fcb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e509a2dc-14a6-408e-9e2c-04729928aa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_b8897586-0c54-4531-87e0-8db38963d26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49216c19-77b4-4e95-8997-8f332a1cecf0" xlink:to="loc_us-gaap_InvestmentTypeAxis_b8897586-0c54-4531-87e0-8db38963d26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7b131bbc-682d-45e7-85f3-6cf9eb27e358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_b8897586-0c54-4531-87e0-8db38963d26a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7b131bbc-682d-45e7-85f3-6cf9eb27e358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d5ee7b45-e2d0-4b4e-9d37-474cad860baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7b131bbc-682d-45e7-85f3-6cf9eb27e358" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d5ee7b45-e2d0-4b4e-9d37-474cad860baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_247faf67-0081-4ef1-9d32-963bf8479797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_49216c19-77b4-4e95-8997-8f332a1cecf0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_247faf67-0081-4ef1-9d32-963bf8479797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d93cf111-e78e-4364-9129-1a070800c871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_247faf67-0081-4ef1-9d32-963bf8479797" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d93cf111-e78e-4364-9129-1a070800c871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ba548033-e781-483f-940d-88841901c6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d93cf111-e78e-4364-9129-1a070800c871" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ba548033-e781-483f-940d-88841901c6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStock" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e6f600b4-2f40-41aa-b244-f5925b64ea07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bf1290df-4374-453d-be23-56d5b3156b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e6f600b4-2f40-41aa-b244-f5925b64ea07" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bf1290df-4374-453d-be23-56d5b3156b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockTables" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommonStockTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7085f56e-59ba-4913-a785-81c4917f035e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_0e905f82-a759-4d0e-91bf-62127df7a882" xlink:href="vtl-20220630.xsd#vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7085f56e-59ba-4913-a785-81c4917f035e" xlink:to="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_0e905f82-a759-4d0e-91bf-62127df7a882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommonStockShelfRegistrationStatementDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1052b254-941e-4ddd-b2b2-163a1c2dd12a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_522a9029-4f0c-40cb-a81a-5f49210bf036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1052b254-941e-4ddd-b2b2-163a1c2dd12a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_522a9029-4f0c-40cb-a81a-5f49210bf036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_28f5e82a-f5c6-4d26-8c3e-a8dfc7d88489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_522a9029-4f0c-40cb-a81a-5f49210bf036" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_28f5e82a-f5c6-4d26-8c3e-a8dfc7d88489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e60ef5-3a6a-49c0-b7df-72a09dbfc250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_28f5e82a-f5c6-4d26-8c3e-a8dfc7d88489" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e60ef5-3a6a-49c0-b7df-72a09dbfc250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember_49d7d2a6-ab5e-47dc-b905-74109c565417" xlink:href="vtl-20220630.xsd#vtl_December2020ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e60ef5-3a6a-49c0-b7df-72a09dbfc250" xlink:to="loc_vtl_December2020ATMMember_49d7d2a6-ab5e-47dc-b905-74109c565417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember_d05519c6-d639-45ef-97c2-520979ae7fe0" xlink:href="vtl-20220630.xsd#vtl_May2022ATMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6e60ef5-3a6a-49c0-b7df-72a09dbfc250" xlink:to="loc_vtl_May2022ATMMember_d05519c6-d639-45ef-97c2-520979ae7fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_56e25a64-f5c7-416b-8f3c-0f35a394dfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_522a9029-4f0c-40cb-a81a-5f49210bf036" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_56e25a64-f5c7-416b-8f3c-0f35a394dfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_61a4d76d-9413-441f-a592-74bd3679786c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_56e25a64-f5c7-416b-8f3c-0f35a394dfbc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_61a4d76d-9413-441f-a592-74bd3679786c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_acd0db41-7926-4836-9fcc-7000aa70018e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_61a4d76d-9413-441f-a592-74bd3679786c" xlink:to="loc_us-gaap_SubsequentEventMember_acd0db41-7926-4836-9fcc-7000aa70018e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_522a9029-4f0c-40cb-a81a-5f49210bf036" xlink:to="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_9af11654-4392-4066-856f-a370b5426d09" xlink:href="vtl-20220630.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_9af11654-4392-4066-856f-a370b5426d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining_949dd3f2-6f78-4f41-8ff8-e4aac83c8309" xlink:href="vtl-20220630.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_vtl_ShelfRegistrationStatementAmountRemaining_949dd3f2-6f78-4f41-8ff8-e4aac83c8309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_9068a954-a7b1-443b-999d-cf6745d68d0d" xlink:href="vtl-20220630.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_9068a954-a7b1-443b-999d-cf6745d68d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity_930feaaa-ea60-40e5-8a5c-e97bde4bf3f9" xlink:href="vtl-20220630.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_vtl_SaleOfStockRemainingCapacity_930feaaa-ea60-40e5-8a5c-e97bde4bf3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_d7e98388-59b4-4da5-bf6a-42e3f2a5186f" xlink:href="vtl-20220630.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_d7e98388-59b4-4da5-bf6a-42e3f2a5186f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59c96251-d7a1-4bbd-b738-1c2178b49a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_59c96251-d7a1-4bbd-b738-1c2178b49a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8b24ba53-a618-491e-984f-6ca03f2d9d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8b24ba53-a618-491e-984f-6ca03f2d9d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_3c0dda0a-edf2-4655-8f0b-ef6127b6dc62" xlink:href="vtl-20220630.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_3c0dda0a-edf2-4655-8f0b-ef6127b6dc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a3f4ee19-45e3-47ce-890a-d6537486ce78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a3f4ee19-45e3-47ce-890a-d6537486ce78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_13f72180-a759-4769-8a9e-530ede086fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b76b2a74-d09c-48de-851a-25f2e95a6b5f" xlink:to="loc_us-gaap_PaymentsForCommissions_13f72180-a759-4769-8a9e-530ede086fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockCommonStockDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommonStockCommonStockDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f62a2224-8243-450c-84bf-a6da198e5032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e08d666c-a3ff-472b-9304-48f42ee106a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f62a2224-8243-450c-84bf-a6da198e5032" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e08d666c-a3ff-472b-9304-48f42ee106a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_952fe051-0761-4c02-9f2b-b004f1bb6ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f62a2224-8243-450c-84bf-a6da198e5032" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_952fe051-0761-4c02-9f2b-b004f1bb6ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_92e7058e-0ac4-42db-ac7f-57aeb2914f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f62a2224-8243-450c-84bf-a6da198e5032" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_92e7058e-0ac4-42db-ac7f-57aeb2914f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1ee711fc-a2b5-40db-9e49-47627d38fb54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f62a2224-8243-450c-84bf-a6da198e5032" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_1ee711fc-a2b5-40db-9e49-47627d38fb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockPreferredStockDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommonStockPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f2d1cfb5-6806-4269-a8f5-7d588b672103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_64ad53b3-53cd-4481-ad29-be75feeec727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f2d1cfb5-6806-4269-a8f5-7d588b672103" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_64ad53b3-53cd-4481-ad29-be75feeec727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_397f1e49-be42-44c9-9a50-1bbe71920ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f2d1cfb5-6806-4269-a8f5-7d588b672103" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_397f1e49-be42-44c9-9a50-1bbe71920ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e86f395c-be18-4cb5-9e69-d15a3e2c342c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f2d1cfb5-6806-4269-a8f5-7d588b672103" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e86f395c-be18-4cb5-9e69-d15a3e2c342c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#CommonStockSharesReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e22fb97e-e00e-47d8-90a5-e432331ad0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bf5b0491-7e64-42d0-b854-df217f7fd625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e22fb97e-e00e-47d8-90a5-e432331ad0ba" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bf5b0491-7e64-42d0-b854-df217f7fd625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_accdd2bd-20ac-45a4-b9e0-b92e2446b610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bf5b0491-7e64-42d0-b854-df217f7fd625" xlink:to="loc_us-gaap_PlanNameAxis_accdd2bd-20ac-45a4-b9e0-b92e2446b610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_25feaba7-f5fe-45d9-baa2-d04f5cb7fb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_accdd2bd-20ac-45a4-b9e0-b92e2446b610" xlink:to="loc_us-gaap_PlanNameDomain_25feaba7-f5fe-45d9-baa2-d04f5cb7fb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_4a57c5ab-7f49-4a42-b33e-28db81145145" xlink:href="vtl-20220630.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_25feaba7-f5fe-45d9-baa2-d04f5cb7fb73" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_4a57c5ab-7f49-4a42-b33e-28db81145145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_abdf45e7-0b17-4059-ae95-d23fa920aaaf" xlink:href="vtl-20220630.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_25feaba7-f5fe-45d9-baa2-d04f5cb7fb73" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_abdf45e7-0b17-4059-ae95-d23fa920aaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_47c48cee-6357-4229-a135-bbb0526d3898" xlink:href="vtl-20220630.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_25feaba7-f5fe-45d9-baa2-d04f5cb7fb73" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_47c48cee-6357-4229-a135-bbb0526d3898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a6bfcfe5-3d82-420b-88f7-58bac62f8e30" xlink:href="vtl-20220630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_25feaba7-f5fe-45d9-baa2-d04f5cb7fb73" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a6bfcfe5-3d82-420b-88f7-58bac62f8e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5bf43bcb-ed1a-475e-9937-999d469301f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bf5b0491-7e64-42d0-b854-df217f7fd625" xlink:to="loc_us-gaap_AwardTypeAxis_5bf43bcb-ed1a-475e-9937-999d469301f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2c01b3-c225-4734-8b86-55cdd9a7a6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5bf43bcb-ed1a-475e-9937-999d469301f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2c01b3-c225-4734-8b86-55cdd9a7a6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c531c9ad-69a0-4c77-a547-0e286fbab3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2c01b3-c225-4734-8b86-55cdd9a7a6b3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c531c9ad-69a0-4c77-a547-0e286fbab3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember_a429c026-ffed-4ca7-ae8b-37d2b4324ce4" xlink:href="vtl-20220630.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4e2c01b3-c225-4734-8b86-55cdd9a7a6b3" xlink:to="loc_vtl_EmployeeStockOptionsforFutureGrantMember_a429c026-ffed-4ca7-ae8b-37d2b4324ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c4050a75-4c71-4fea-9579-f4b2b0464939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bf5b0491-7e64-42d0-b854-df217f7fd625" xlink:to="loc_us-gaap_ClassOfStockLineItems_c4050a75-4c71-4fea-9579-f4b2b0464939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f8277ba0-0e37-43fe-b260-e2ca6dabc39d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4050a75-4c71-4fea-9579-f4b2b0464939" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f8277ba0-0e37-43fe-b260-e2ca6dabc39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="vtl-20220630.xsd#StockBasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d008d3cb-d5d3-4306-b002-659d02ffeae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_00669d08-a293-4d52-95d3-2a71ef2ca8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d008d3cb-d5d3-4306-b002-659d02ffeae9" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_00669d08-a293-4d52-95d3-2a71ef2ca8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="vtl-20220630.xsd#StockBasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1695698-81cd-464c-a889-1aa3f4b2d61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c659269f-d248-4169-b9e4-849273309961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1695698-81cd-464c-a889-1aa3f4b2d61b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c659269f-d248-4169-b9e4-849273309961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_80c0d793-9a6c-403b-b1a5-eee655912486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1695698-81cd-464c-a889-1aa3f4b2d61b" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_80c0d793-9a6c-403b-b1a5-eee655912486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_64d030d2-9881-4ff7-ab35-fd64d9077cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1695698-81cd-464c-a889-1aa3f4b2d61b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_64d030d2-9881-4ff7-ab35-fd64d9077cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#StockBasedCompensationPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3977332c-52a0-4f03-81a8-40c4d4b13885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7152bf6-dc86-4686-a44a-cd65ab4819cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3977332c-52a0-4f03-81a8-40c4d4b13885" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7152bf6-dc86-4686-a44a-cd65ab4819cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_603ba655-2794-4fa0-975c-33341059e7fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7152bf6-dc86-4686-a44a-cd65ab4819cf" xlink:to="loc_srt_RangeAxis_603ba655-2794-4fa0-975c-33341059e7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_72b38536-1739-4601-8d30-68a99166c924" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_603ba655-2794-4fa0-975c-33341059e7fe" xlink:to="loc_srt_RangeMember_72b38536-1739-4601-8d30-68a99166c924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_081ae49b-079c-4c3d-a2d2-14a1aeabc864" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_72b38536-1739-4601-8d30-68a99166c924" xlink:to="loc_srt_MinimumMember_081ae49b-079c-4c3d-a2d2-14a1aeabc864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2d46b5e3-2fca-4972-a152-8d890efcc21b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_72b38536-1739-4601-8d30-68a99166c924" xlink:to="loc_srt_MaximumMember_2d46b5e3-2fca-4972-a152-8d890efcc21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9ec5cc0b-6767-43f0-9685-510fbcc1d042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7152bf6-dc86-4686-a44a-cd65ab4819cf" xlink:to="loc_us-gaap_AwardTypeAxis_9ec5cc0b-6767-43f0-9685-510fbcc1d042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e23ad26-4752-435d-862a-f8600422a328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9ec5cc0b-6767-43f0-9685-510fbcc1d042" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e23ad26-4752-435d-862a-f8600422a328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember_2ccffcd2-5c3f-48ee-a853-a201c037f7b4" xlink:href="vtl-20220630.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e23ad26-4752-435d-862a-f8600422a328" xlink:to="loc_vtl_IncentiveEmployeeStockOptionMember_2ccffcd2-5c3f-48ee-a853-a201c037f7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember_48d57c8d-ed42-47a9-82d0-29bdf1e42937" xlink:href="vtl-20220630.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5e23ad26-4752-435d-862a-f8600422a328" xlink:to="loc_vtl_NonStatutoryEmployeeStockOptionMember_48d57c8d-ed42-47a9-82d0-29bdf1e42937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2f3d0531-71e4-4530-a63e-ad4a5e4c6d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7152bf6-dc86-4686-a44a-cd65ab4819cf" xlink:to="loc_us-gaap_PlanNameAxis_2f3d0531-71e4-4530-a63e-ad4a5e4c6d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7edda3e0-2cf1-4c4a-9326-b8a1d26c0ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2f3d0531-71e4-4530-a63e-ad4a5e4c6d55" xlink:to="loc_us-gaap_PlanNameDomain_7edda3e0-2cf1-4c4a-9326-b8a1d26c0ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_aa686e2c-1ba0-4c96-a401-9dd71fe6d6ed" xlink:href="vtl-20220630.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7edda3e0-2cf1-4c4a-9326-b8a1d26c0ce3" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_aa686e2c-1ba0-4c96-a401-9dd71fe6d6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_ded58c75-933f-473a-8984-7d63373a0586" xlink:href="vtl-20220630.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7edda3e0-2cf1-4c4a-9326-b8a1d26c0ce3" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_ded58c75-933f-473a-8984-7d63373a0586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_fe8d3d6e-b751-4073-91fa-fcfd4931407d" xlink:href="vtl-20220630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtl_A2019OmnibusEquityIncentivePlanMember_ded58c75-933f-473a-8984-7d63373a0586" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_fe8d3d6e-b751-4073-91fa-fcfd4931407d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_9711e216-1a25-4a05-9d9e-6cc85f69e96f" xlink:href="vtl-20220630.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7edda3e0-2cf1-4c4a-9326-b8a1d26c0ce3" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_9711e216-1a25-4a05-9d9e-6cc85f69e96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_0671851a-ff7c-420c-b35a-e41f32ea571d" xlink:href="vtl-20220630.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7edda3e0-2cf1-4c4a-9326-b8a1d26c0ce3" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_0671851a-ff7c-420c-b35a-e41f32ea571d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7152bf6-dc86-4686-a44a-cd65ab4819cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_817b1945-82f5-4e5b-a81c-5698ae2b42a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_817b1945-82f5-4e5b-a81c-5698ae2b42a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2f5a691b-8ba0-49fc-a57a-8eaa76db1a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_2f5a691b-8ba0-49fc-a57a-8eaa76db1a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_acf16f97-7b87-4b3d-99fe-0bf7d2a7f6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_acf16f97-7b87-4b3d-99fe-0bf7d2a7f6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_76c354ca-7c1f-4a77-a731-dfbdde2434db" xlink:href="vtl-20220630.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_76c354ca-7c1f-4a77-a731-dfbdde2434db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e82a2d28-fa34-4016-b150-d51021ede734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e82a2d28-fa34-4016-b150-d51021ede734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fc147a05-e089-4862-a228-50c366f185c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fc147a05-e089-4862-a228-50c366f185c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9c58a7be-6b7f-4400-a686-6b515d32415a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9c58a7be-6b7f-4400-a686-6b515d32415a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2a152eb5-698d-47eb-a021-cce7cf106c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2a152eb5-698d-47eb-a021-cce7cf106c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1e6f0ca1-8e68-4ae7-bacb-cff32056d74c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1e6f0ca1-8e68-4ae7-bacb-cff32056d74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35391e2c-3de8-4e15-81d5-a4a3d1475536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35391e2c-3de8-4e15-81d5-a4a3d1475536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af468119-7c2b-4053-8a06-0e5808544757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_af468119-7c2b-4053-8a06-0e5808544757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ae479d4c-d938-45d4-b38e-860573b93a50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb606e63-bdcf-4cdf-ac6b-dd40979e8a42" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ae479d4c-d938-45d4-b38e-860573b93a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#StockBasedCompensationPlansSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_403c0c32-45a7-4694-ae79-cd1bf82f31a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_201afd88-1419-4b12-b361-afb93795cb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_403c0c32-45a7-4694-ae79-cd1bf82f31a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_201afd88-1419-4b12-b361-afb93795cb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6bfa0baa-cee4-48eb-af55-65865a9f4ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_201afd88-1419-4b12-b361-afb93795cb75" xlink:to="loc_us-gaap_PlanNameAxis_6bfa0baa-cee4-48eb-af55-65865a9f4ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6f81a901-c707-40c2-96f6-4042c6a3896b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6bfa0baa-cee4-48eb-af55-65865a9f4ba9" xlink:to="loc_us-gaap_PlanNameDomain_6f81a901-c707-40c2-96f6-4042c6a3896b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_62e983d7-12e6-48b1-a0b7-39c8069a3ee0" xlink:href="vtl-20220630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6f81a901-c707-40c2-96f6-4042c6a3896b" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_62e983d7-12e6-48b1-a0b7-39c8069a3ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5124764c-1bcd-40b4-a44c-0cd30f851a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_201afd88-1419-4b12-b361-afb93795cb75" xlink:to="loc_us-gaap_AwardTypeAxis_5124764c-1bcd-40b4-a44c-0cd30f851a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5548ca6e-5488-4e16-8493-32927ffaa884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5124764c-1bcd-40b4-a44c-0cd30f851a9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5548ca6e-5488-4e16-8493-32927ffaa884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e80983a4-4af4-4e37-82ee-e68e248a4635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5548ca6e-5488-4e16-8493-32927ffaa884" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e80983a4-4af4-4e37-82ee-e68e248a4635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_201afd88-1419-4b12-b361-afb93795cb75" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2f13ac7-ee30-436e-9971-1bb472e0d187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2f13ac7-ee30-436e-9971-1bb472e0d187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9c828fb5-6174-4f1d-b15d-6f476bbd7511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2f13ac7-ee30-436e-9971-1bb472e0d187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9c828fb5-6174-4f1d-b15d-6f476bbd7511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7b41f171-0de9-4dc6-913f-ddaf931115d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2f13ac7-ee30-436e-9971-1bb472e0d187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7b41f171-0de9-4dc6-913f-ddaf931115d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_623d1d9f-c8a8-4c08-922d-711b56907189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2f13ac7-ee30-436e-9971-1bb472e0d187" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_623d1d9f-c8a8-4c08-922d-711b56907189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_157e4908-77cc-49ca-bf04-6db93159fa81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2f13ac7-ee30-436e-9971-1bb472e0d187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_157e4908-77cc-49ca-bf04-6db93159fa81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6baefb0b-da6b-4e52-8ea6-ebbb366d6383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d2f13ac7-ee30-436e-9971-1bb472e0d187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6baefb0b-da6b-4e52-8ea6-ebbb366d6383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_570e9a0c-6bb9-4e2b-b6cf-7b928739e065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_570e9a0c-6bb9-4e2b-b6cf-7b928739e065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_498a6d7a-459a-4da2-b89b-66b793e18ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_498a6d7a-459a-4da2-b89b-66b793e18ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d011f73-f712-4595-a806-8a37bb119c90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d011f73-f712-4595-a806-8a37bb119c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1906cec6-37d6-4fde-b268-6048775a38a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d011f73-f712-4595-a806-8a37bb119c90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1906cec6-37d6-4fde-b268-6048775a38a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c6779bd1-20c5-4a76-adbd-5be2fb8e6cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d011f73-f712-4595-a806-8a37bb119c90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c6779bd1-20c5-4a76-adbd-5be2fb8e6cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c16e42f2-4e31-4c83-8044-61ef8fca79a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d011f73-f712-4595-a806-8a37bb119c90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c16e42f2-4e31-4c83-8044-61ef8fca79a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1d118551-b4b7-4175-98ba-ba6af6234796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d011f73-f712-4595-a806-8a37bb119c90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1d118551-b4b7-4175-98ba-ba6af6234796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fc579097-58c9-4d87-8594-af31d9e1d9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d011f73-f712-4595-a806-8a37bb119c90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fc579097-58c9-4d87-8594-af31d9e1d9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0de81bd8-5da0-48bb-8330-5051bceed9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0de81bd8-5da0-48bb-8330-5051bceed9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6cceea48-3d20-4b83-976d-e08a6f208f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6cceea48-3d20-4b83-976d-e08a6f208f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc611280-adfc-4cab-8ae9-f742533b220c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d9df3e18-a29b-4c53-9d70-1b868e455c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d9df3e18-a29b-4c53-9d70-1b868e455c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a28a2bf6-a16c-4566-8018-8abbf1c54199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a28a2bf6-a16c-4566-8018-8abbf1c54199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7702e387-890a-4fa9-b0ff-eea88f6b3d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7702e387-890a-4fa9-b0ff-eea88f6b3d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3828052d-b794-4fe3-8610-d7f9317f5a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3828052d-b794-4fe3-8610-d7f9317f5a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d3e04170-b91d-458f-8918-0e809410afc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d3e04170-b91d-458f-8918-0e809410afc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9539eb02-3cda-425b-bee6-d850301de915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f5ce9901-c9b4-4de5-a312-4391a5c7aeea" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9539eb02-3cda-425b-bee6-d850301de915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="simple" xlink:href="vtl-20220630.xsd#StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11be886d-2831-46ec-8481-337f16561da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677f6813-008c-4873-92a5-e8308017a1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11be886d-2831-46ec-8481-337f16561da8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677f6813-008c-4873-92a5-e8308017a1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ef1a186e-de7a-41a9-9a6c-46513cec2a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677f6813-008c-4873-92a5-e8308017a1b5" xlink:to="loc_us-gaap_PlanNameAxis_ef1a186e-de7a-41a9-9a6c-46513cec2a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cc310457-ca23-479b-aa86-25c5b8a4c90f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ef1a186e-de7a-41a9-9a6c-46513cec2a19" xlink:to="loc_us-gaap_PlanNameDomain_cc310457-ca23-479b-aa86-25c5b8a4c90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_455908c7-864a-4b02-8bc9-97cb397b44cb" xlink:href="vtl-20220630.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cc310457-ca23-479b-aa86-25c5b8a4c90f" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_455908c7-864a-4b02-8bc9-97cb397b44cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec7de2df-c024-4603-b779-986d4cdac727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_677f6813-008c-4873-92a5-e8308017a1b5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec7de2df-c024-4603-b779-986d4cdac727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f00cfe04-069c-418c-93ae-f8bf841de77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec7de2df-c024-4603-b779-986d4cdac727" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f00cfe04-069c-418c-93ae-f8bf841de77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c16f894a-8ea6-4383-aa3a-df59718d0287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec7de2df-c024-4603-b779-986d4cdac727" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c16f894a-8ea6-4383-aa3a-df59718d0287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_65b9c948-628f-429e-b1d5-4922c9512821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec7de2df-c024-4603-b779-986d4cdac727" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_65b9c948-628f-429e-b1d5-4922c9512821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_38d7fa55-2d89-4549-b6a4-38d41b311494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec7de2df-c024-4603-b779-986d4cdac727" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_38d7fa55-2d89-4549-b6a4-38d41b311494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_62721170-c2ef-4f39-b377-d3e0a8251179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec7de2df-c024-4603-b779-986d4cdac727" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_62721170-c2ef-4f39-b377-d3e0a8251179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_80526c3e-06e6-4c1b-81dc-7fe9c4bfb892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce362177-d263-452b-b7fb-7214fb69d1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_80526c3e-06e6-4c1b-81dc-7fe9c4bfb892" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce362177-d263-452b-b7fb-7214fb69d1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_c7c7ddeb-361a-4430-abfc-ad1fb038f451" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce362177-d263-452b-b7fb-7214fb69d1d2" xlink:to="loc_srt_TitleOfIndividualAxis_c7c7ddeb-361a-4430-abfc-ad1fb038f451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e35bcc3b-cda0-454f-bd1e-6b2bd44bafeb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_c7c7ddeb-361a-4430-abfc-ad1fb038f451" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e35bcc3b-cda0-454f-bd1e-6b2bd44bafeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember_57cbf2a0-6ea8-4e24-b9d7-b29c104a01e4" xlink:href="vtl-20220630.xsd#vtl_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e35bcc3b-cda0-454f-bd1e-6b2bd44bafeb" xlink:to="loc_vtl_EmployeeMember_57cbf2a0-6ea8-4e24-b9d7-b29c104a01e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b7e0f4d8-97ec-47f9-b62d-9d35f26d025b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce362177-d263-452b-b7fb-7214fb69d1d2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b7e0f4d8-97ec-47f9-b62d-9d35f26d025b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7c1025e6-1119-41ff-aec2-12c3761e3711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b7e0f4d8-97ec-47f9-b62d-9d35f26d025b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7c1025e6-1119-41ff-aec2-12c3761e3711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_54e3e641-4152-492f-948a-9b5e765284c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7c1025e6-1119-41ff-aec2-12c3761e3711" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_54e3e641-4152-492f-948a-9b5e765284c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_870d96a4-a718-4e7e-acf8-94496e8b5fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7c1025e6-1119-41ff-aec2-12c3761e3711" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_870d96a4-a718-4e7e-acf8-94496e8b5fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_155f3cb7-2259-42b7-ba4a-a5f9bbc06133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce362177-d263-452b-b7fb-7214fb69d1d2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_155f3cb7-2259-42b7-ba4a-a5f9bbc06133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_fb7d8fe8-cf21-477b-8a4d-335b55e5d023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_155f3cb7-2259-42b7-ba4a-a5f9bbc06133" xlink:to="loc_us-gaap_ShareBasedCompensation_fb7d8fe8-cf21-477b-8a4d-335b55e5d023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="vtl-20220630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b9f85e91-6f1f-4b8d-b308-8a5d1469f278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_debbf76e-fde1-4f5a-99ce-fa3e42b07ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b9f85e91-6f1f-4b8d-b308-8a5d1469f278" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_debbf76e-fde1-4f5a-99ce-fa3e42b07ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_36c6b227-c777-4065-8ea1-2d668f47ef52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_36c6b227-c777-4065-8ea1-2d668f47ef52" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b522cf5d-3d6a-4440-bbf7-d2cb6a2d55e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b522cf5d-3d6a-4440-bbf7-d2cb6a2d55e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d690c9d1-e595-45aa-bdc8-5c684e71878e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b522cf5d-3d6a-4440-bbf7-d2cb6a2d55e0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d690c9d1-e595-45aa-bdc8-5c684e71878e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember_3b260766-65b7-46e3-b2c7-20f486dd6cfa" xlink:href="vtl-20220630.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d690c9d1-e595-45aa-bdc8-5c684e71878e" xlink:to="loc_vtl_ExecutiveChairmanAgreementMember_3b260766-65b7-46e3-b2c7-20f486dd6cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01722550-3a8a-48aa-8045-b71a936fa62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01722550-3a8a-48aa-8045-b71a936fa62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cb176a77-a79f-4e27-a17d-0549d48bb827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_01722550-3a8a-48aa-8045-b71a936fa62a" xlink:to="loc_us-gaap_RelatedPartyDomain_cb176a77-a79f-4e27-a17d-0549d48bb827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_be4edff3-4d20-472c-94e7-32060725e4ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cb176a77-a79f-4e27-a17d-0549d48bb827" xlink:to="loc_srt_AffiliatedEntityMember_be4edff3-4d20-472c-94e7-32060725e4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_93354bc8-becc-4d81-b8ba-37541978f8a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:to="loc_srt_CounterpartyNameAxis_93354bc8-becc-4d81-b8ba-37541978f8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45501ebd-402a-4abe-b1e0-441cc572ce8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_93354bc8-becc-4d81-b8ba-37541978f8a2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45501ebd-402a-4abe-b1e0-441cc572ce8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember_e316fddf-e8ff-4d3d-9622-d3bb32887330" xlink:href="vtl-20220630.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_45501ebd-402a-4abe-b1e0-441cc572ce8f" xlink:to="loc_vtl_DuaneNashMDJDMBAMember_e316fddf-e8ff-4d3d-9622-d3bb32887330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_8eef9e29-d764-433d-a663-35588b06cd8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:to="loc_srt_TitleOfIndividualAxis_8eef9e29-d764-433d-a663-35588b06cd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e532f279-e38f-4c65-ba0d-1349754fc1d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_8eef9e29-d764-433d-a663-35588b06cd8c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e532f279-e38f-4c65-ba0d-1349754fc1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_de782ace-e60a-44c3-bdd7-59b73a640e0b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e532f279-e38f-4c65-ba0d-1349754fc1d7" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_de782ace-e60a-44c3-bdd7-59b73a640e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9fd538d2-f79a-4c7e-8299-91fa2e8027fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:to="loc_srt_StatementScenarioAxis_9fd538d2-f79a-4c7e-8299-91fa2e8027fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_55afaa38-1f19-4097-af1d-027967aac9e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_9fd538d2-f79a-4c7e-8299-91fa2e8027fb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_55afaa38-1f19-4097-af1d-027967aac9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ec841f72-2613-4694-93b6-5aea8dc38940" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_55afaa38-1f19-4097-af1d-027967aac9e5" xlink:to="loc_srt_ScenarioForecastMember_ec841f72-2613-4694-93b6-5aea8dc38940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_81765962-3ed8-4d87-9fbb-aaf4936ff4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_97d0072b-3413-4297-90c2-b63331d8776d" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_81765962-3ed8-4d87-9fbb-aaf4936ff4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_123ae7c9-ed66-4718-8045-5f7d3edd7c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_81765962-3ed8-4d87-9fbb-aaf4936ff4d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_123ae7c9-ed66-4718-8045-5f7d3edd7c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary_8b6b3983-5c2c-4c07-b483-72bc1bef30b1" xlink:href="vtl-20220630.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_81765962-3ed8-4d87-9fbb-aaf4936ff4d2" xlink:to="loc_vtl_SalaryCostsMonthlyBaseSalary_8b6b3983-5c2c-4c07-b483-72bc1bef30b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SubsequentEvents" xlink:type="simple" xlink:href="vtl-20220630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_8cbb72ba-38f3-41db-8ed4-322bedfa4ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_5018899f-4b87-42fc-b03a-68596eced6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_8cbb72ba-38f3-41db-8ed4-322bedfa4ef9" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_5018899f-4b87-42fc-b03a-68596eced6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="vtl-20220630.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_03528e75-1370-4a08-8c17-38109e4c2ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_3eb67910-4831-4162-a339-1f5adc510c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_03528e75-1370-4a08-8c17-38109e4c2ff7" xlink:to="loc_us-gaap_SubsequentEventTable_3eb67910-4831-4162-a339-1f5adc510c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fcb2d880-e0e7-445a-8b19-9643b98641c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3eb67910-4831-4162-a339-1f5adc510c5d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fcb2d880-e0e7-445a-8b19-9643b98641c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7a58d7a1-96c3-4811-9601-76feaca830e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fcb2d880-e0e7-445a-8b19-9643b98641c6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7a58d7a1-96c3-4811-9601-76feaca830e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f61546f9-9cb6-4317-85d3-d64069c6fb55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7a58d7a1-96c3-4811-9601-76feaca830e7" xlink:to="loc_us-gaap_SubsequentEventMember_f61546f9-9cb6-4317-85d3-d64069c6fb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5c4cafea-8ed7-4da0-a6fd-bfb625d5368a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3eb67910-4831-4162-a339-1f5adc510c5d" xlink:to="loc_us-gaap_AwardTypeAxis_5c4cafea-8ed7-4da0-a6fd-bfb625d5368a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc74d13f-b6c7-4146-8bee-2353d89ac418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5c4cafea-8ed7-4da0-a6fd-bfb625d5368a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc74d13f-b6c7-4146-8bee-2353d89ac418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OptionsVestingInOneYearMember_06485432-f83c-4510-bc98-a5e5d89b355a" xlink:href="vtl-20220630.xsd#vtl_OptionsVestingInOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc74d13f-b6c7-4146-8bee-2353d89ac418" xlink:to="loc_vtl_OptionsVestingInOneYearMember_06485432-f83c-4510-bc98-a5e5d89b355a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OptionsVestingInThreeYearsMember_41272462-33e7-478d-a604-d4f43559cfa6" xlink:href="vtl-20220630.xsd#vtl_OptionsVestingInThreeYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc74d13f-b6c7-4146-8bee-2353d89ac418" xlink:to="loc_vtl_OptionsVestingInThreeYearsMember_41272462-33e7-478d-a604-d4f43559cfa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b7981788-135a-46be-a5bb-fcf24a051745" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3eb67910-4831-4162-a339-1f5adc510c5d" xlink:to="loc_srt_TitleOfIndividualAxis_b7981788-135a-46be-a5bb-fcf24a051745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85ba407e-7705-4c62-b422-fa59a37ddfe9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_b7981788-135a-46be-a5bb-fcf24a051745" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85ba407e-7705-4c62-b422-fa59a37ddfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_4854ae90-7477-4b57-8fdc-ac5f1acdfb70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_85ba407e-7705-4c62-b422-fa59a37ddfe9" xlink:to="loc_srt_DirectorMember_4854ae90-7477-4b57-8fdc-ac5f1acdfb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_d4648fc0-7fb2-4882-bdd9-f08b2a268fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3eb67910-4831-4162-a339-1f5adc510c5d" xlink:to="loc_us-gaap_SubsequentEventLineItems_d4648fc0-7fb2-4882-bdd9-f08b2a268fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c799df02-a326-4576-a93d-6a9adee4fc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d4648fc0-7fb2-4882-bdd9-f08b2a268fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c799df02-a326-4576-a93d-6a9adee4fc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eccf8bf6-4e8f-4384-9e53-d48d60d7c694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d4648fc0-7fb2-4882-bdd9-f08b2a268fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eccf8bf6-4e8f-4384-9e53-d48d60d7c694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c056671b-9d0d-4136-abd1-5344115df44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_d4648fc0-7fb2-4882-bdd9-f08b2a268fe2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c056671b-9d0d-4136-abd1-5344115df44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>vtl-20220630_g1.jpg
<TEXT>
begin 644 vtl-20220630_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[@ .061O8F4 9      "_^T +%!H;W1O
M<VAO<" S+C  .$))30/M       0 2P    !  $!+     $  ?_B__])0T-?
M4%)/1DE,10 !"0 (@'!!1$)% A   '!R=')#35E+3&%B( ?0  < &@ % "D
M-6%C<W!!4%!,     $%$0D4                       #VU@ !     -,M
M041"10
M        "F1E<V,   #\    =&-P<G0   %P    *W=T<'0   &<    %$$R
M0C    &P  "B!D$R0C(   &P  "B!D$R0C$  *.X  "B!D(R03   47   (X
MM$(R03$  WYT  (XM$(R03( !;<H  (XM&=A;70 !^_<  "0D61E<V,
M    &E4N4RX@5V5B($-O871E9" H4U=/4"D@=C(
M
M                        =&5X=     !#;W!Y<FEG:'0@,C P,"!!9&]B
M92!3>7-T96US+"!);F,N  !865H@        M5H  +QG  "2,&UF=#(
M! ,)   !                     0                    $   $   (
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M+IJ*J?Z)C8B]I>V(&G8QHC"&^V+DGKR&($Z?FZ:%CCC5F2R%2Q\NF*N&1@
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M$(SXLP^/YWP:KE*-^VJJJ<Z,8UA]I:N++459H?:*5S"5GQ.*+!=<GQR*L
MCSZ  )S5MT:::8QBLF&7IGM[K::5-&H&J223&%?MI/"1743AH3^0-3 ^GE*0
M*A<^GC:.N   CL2  )P[MK^B[HO9L=&?DGKZK0^<CVF+J(^9^%=YI%J7UD1]
MH)*6<"_XG9Z6I!<GG6>/J   CEZ  )O(MC:KH(MPL42GI7J8K(*D$VDOJ 2A
M!5<EH]2>ET0YH B=22_$G/"<)Q<5G*B/FP  C@J  )M*M=>TC(LBL-2OVWI7
MK .KJVCIIWFH,5;?HTNEL$/\GY6DGB^<G(:@,1<5G!>/FP  C<6  )K9M8:]
MZXK+L'2X@WH.JZ&SMFBLIQNOXU:RHN^MH$/?GSBJIR^1G"^@*1<?F[:/H@
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M3X"4O%N5M7"2MO"3=& +L;N1E4[HK-:0)CS#J)*/:2C7I6.0&Q $I>&*U
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M\W77REEX@V:NQ&]X6U<1OM9X?4:SN9-XVC4'M0AY6"#VLG=YK@?KLME[10
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M(750Q:2;&F8HOXZ8D%:#N:^6F48XM"^52S3CKUV52B&2K!B40 HTJQN&Y@
MBFB  (/^RRRESW5*Q.^B.68WOLR?.U:AN.F<_49<LVZ;N34.KIJ;K2'-JS*6
MVPJ1JA^')0  BG6  (/<RIJMIG5%Q%2I=F9*OBBF 5;"N#VCCD:$LL*BH34]
MK?B@Z2(*JH*7! KGJ4^'7P  BH"  (.^RA*UQ75%P\6PZF9DO9.L\E;RMZ.J
M9D;"LB6HWS6(K5:D,B)EJ=N700M'J+"'H   BHB  /*&>T9YBMKW>YQYI<+]
M>_9YT:I]?%AZ')%P?,-ZBG>[?3M[%ESV?<-[JC_6?GA\7!L6?]%]#_!<>9"$
M[]DZ>@>#Z,%Q>H"#!*D5>OZ"3I =>X6!R'9Y?!>!9%NZ?+*!"CZ7?6> U!EU
M?E^ V^YJ>":0=-=H>*R.4;_7>3>,4:>2><R*GXZ\>FF))74W>Q&'U5J1>[J&
ME3UV?&N%B1?V?.^%&.R8=OB<!M6?=X68T[X@>!J5T:8!>+R3#8U2>6^0IG/U
M>B>.:UEU>MN,33QL>X6*@A::>XB(W^KP=@6GH]0 =I.C;+R*=RV?;Z2%=]>;
MN8OO>)&81G*^>5J5+%AG>A>2.3MU>K>/U15D>E>,%.F"=4NS4M*9==6N(KLI
M=FRI**,U=QFD?HJ]=]J@(G&8>*><$U=L>6N89CJ6>@*5KA16>6>-P.A0=+F_
M'=%M=3VX]+G^=<ZR_Z(3=GJM9(FY=T.H+'"S>!:C3E:1>-B>ZSG6>6:<*A-R
M>*:-)N=7=$S+"]!Y=,K#ZKD&=5*] *$9=?FV=HC,=L2P:&_H=YZJX57G>&2F
M'#DS>..AT1*Y> B,J.:1= /7*<^X='G/#+@Z=/;',:!%=92_R(?_=ERX]V\O
M=SBRZ%5&> "N+3BF>'>F31(E=XN,1.'CA"YWY<PS@Z-X.[7R@RYXF)[^@M%Y
M#(=:@HMYG6[P@EUZ2U5@@D][ CDF@IE[TQ/?A)U\CN ?@J""O<KW@BF!][3=
M@<6!39W?@7F S(8C@4. =&VS@2F 0%0>@3" 'C?N@8. +!)X@R" IMZ$@4J-
MJ\E.@.&+WK-1@(>*+YQG@%&(PX34@#*'C&R&@"Z&@5,,@$"%CC;G@(V$XA$\
M@;*$<]SG@"J8E\>D?\65U;&J?W:3.IKJ?T:0U(-\?SR.PFM8?TB,WE((?V2+
M)#7Z?ZR)X1 K@'6'P=M@?SVCDL8D?MB?ZK R?I"<:YF!?FF9)((O?F&6%VHZ
M?GZ3:%$5?J.0\S4A?N*/2@] ?V6*4-H-?H6NK<3:?B"J)*[M?=6EO9A+?;&A
MCX$5?;"=J6DR?<N:&U X??F7"S1>?C*57PY[?H")RMCS??.YZL/(?8ZT@:W:
M?3ZO,9<\?1BJ(( C?1ZE;VAA?3^A)T]\?6>=C#.X?9F;9@W8?<.)7-@0?87%
M6<+K?1^_#JSR?,BXUY90?)FRXW]$?*"M;6>=?,NHE4[:?/>DV3,L?1N@6 U3
M?2B) M=D?371%\(\?-#)YZPP?&["QI6"?#2[]WZ$?#BUS6;W?&6PETY4?)>L
MEC*Z?+>B3 SH?*V(NM'!C5%VDKVUB^MW!JD#BJEW?I-^B8YX"7TQB)=XLF8%
MA\5Y>DV>ARAZ23(XAR5[,0S6B21\>= \B_& Q[Q\BIF /J?:B6-_SI)HB%5_
M?GP?AVY_5V3[AJY_44R4AAY_7#$UAAI_F OLAXN 6L[BBJF+&[LAB5^)G*:L
MB"N(-Y$OAS"'#7KRAEB&$V/BA:F%1DN/A2:$EC!$A2&$1 L>AB2#PLU^B8^5
M=;FQB$F3%Z4FAR60VH_-ABZ.SWFQA6R-"V+'A,R+=DJ<A%&*%2]NA$:)60IK
MA.R&M\PFB+"?VKA7AVR<JZ/.ADZ9GHZ!A5V6PGB$A)B4'F'"A B1T4G @Y./
MT"ZO@WZ.\0G2@^&&I,KVB "J:+<OAKVF:J*JA9ZBB(UHA+">VG>"@^^;;V#3
M@UB87DC[@NJ5XRX'@M"5#0E1@P"&3,GYAW*U&;8WAC&P3J&QA0^KEXQUA""G
M&G:G@V:B]V 7@M*?1TA5@EB<=2U[@CB:20CF@D:&!,DLAP.__[5MA<6Z9Z#?
MA)^TWHNA@ZFODG7>@N^JPE]G@F:FI$?'@>VC^2T$@;J>< B/@:Z%R<B1AJ[+
M/;3-A73$V* OA$F^>HKJ@TNX:'4U@HZS %[5@@:NM4=*@9.JUBR7@5Z>)@A*
M@36%F\('EKUUA*]9E(IV"YP-DH-VEX?PD*YW-G+XCP=W\UT&C91XRT6YC')Y
MIBL#C$YZC :IC/]\G,"\E7U_+*Y3DU!^RYL4D5-^?H<!CXA^4W()C>U^3UP<
MC(A^;43.BV]^F2HGBT-^^@8LBVR %[^.E%>(V*T8DC2'G9G[D#:&=87DCGB%
MB7#_C.J$QELHBY*$+T/QBH&#NBECBDV#N06^B@J#)KYODT&2IZODD2B0F9BY
MCS>.H83(C7",XV_KB_2+9EHPBJB*'$,9B9Z)$2BJB66(YP5?B->#H;U'DF><
MA:K/D$Z9LI>9CF&7 X.5C*J4A6[9BRB205E B>N04D)3B.2.QR@(B*".R@4-
MA]"#:KP\D;^FAJG%CZFB^):0C;R?AX*7C ><2FWPBH>945AMB4"6NT&GB#R4
MWR=\A_"4.P3(AO.#/+M;D3FPIZCICR6L7Y6TC36H+(' BWZD-&TLB@2@F%?&
MB+V=@T$9AZF;E2<+AU68O@2/ACR#%;JDD,^[ :@VCKVV )3YC,JQ#X$$BPZL
M7FQYB92H,%<HB%>DUT"=AT"BW":JAM::) 1@A::"]KH:D'S%NJ>GCFW  Y1;
MC'BZ4H!@BK:T\FOBB3>P3E:GA_NM$D MANRHQ"9(AH&9X@0[A2^"W;+#H'IT
MPZ%(G8AU3H\\FL=UXGQHF#UVC&BQE>EW4U/HD]IX,CVADD5Y#"-GDDEYU %*
MD%E\NK&PGV!]YJ!]G&M]F(Y\F:Q]8WNJER1]46?LE-A]9E,DDM)]G3S;D4!]
MX2*YD3-^5 $LCLQ_W;"[GD:'#I]YFUR%](V/F)N$^7JVEB"$,V<%D]V#G%)0
MD>&#,3P=D%."[B(>D#6#.P$1C6^ N:^\G5.0,9YHFFV.8(QNE[2,MGFWE3"+
M,V83DOJ)^E%^D06(\SMNCWB(.2&5CTJ(LP#ZC$" J:[5G'"9BIUVF9.7!(MR
MEN*4IWBSE&62<V4QDAN0@E"VD#..[CK*CJ>-W"$7CFV.+P#FBSV G*WSF\RC
M")RLF.Z?T8JIECB<OG?@D[R9Y61CD7V75T__CXJ5/3HXC?Z4$B"IC;>2X #6
MBF. D:TRFTVLH)OLF&^HP8GHE;>D_G<EDSJA?F.ZD/^>9D]NCPJ;\3G"C6J;
M B!5C1:5W #(B:Z AZR0FNNV:IM0F VQXXE(E5&M=7:%DLZI5F,@D).ERT[F
MCJ>C2CE9C0"A6R ,C)"5JP"]B1N @*P4FIS G9K3E[Z[;XB^E0"V5G7WDGBQ
MHF*?D#FMS4YZCDRK73C\C*ZF91^^C#Z5=@"TB*6 >J0)JI%T.9.?INQTO(*Q
MHWQU3W$%H$5U_%YSG4IVQ4J\FJAWHC57F+YX:QM F6MX[   C9Y_$:,PJ99\
MXY,+I>=\FX(DHG!\<W!VGS1\<%W:G#E\ETHBF9M\WC2_EZU]+1K0F#5]F
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M\H]GH@6E9WYWGHJB!FS(FT:>\UINF$Z<6T<JE;*:DS)BDYV:$!E0DZ*1'0
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M+(6,KL.#-'6PJI."963\IJF!V%-OHP>!?T"]G^"!6RPOG;2!9Q(_GS^""0
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M18,;JVRJ>',FIRRFXV)XHQ^CR5$=GVVAC3[.G#V@NBK:F<J<^1('FEV,,0
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MF'D!M_6)&VGGLR*'U%HLKH&&UTF4JD&&+3?/IIV%U2/RI%N&& L7I0>%40
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M/G? M/BO.6BWK_.K@UCUJR.HJ$B(IKVG.3<3HOVD#R/"H&"8+0OQH!V($P
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M96UEP7".@%[^O 2,Z% "ML*+I4!/L=^*SR]0K=R*K!O?J]"+, 6!J22#N0
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MCZQZ4#@9CI5ZS!X&CS5["P  B-E^DZ;OF%>!.Y;1E@F RH7ID]N 97/MD>6
M'&$%D!U_\4T!CIA_WS=CC8%_UAUWC?Y_\P  AW*  *7UES:*0)7"E.J)'X3&
MDL>(#7+VD,V'#V ;CQ.&04PYC9:%E3; C'Z%&QS\C-V%9@  ACN  *4+EBZ3
M<93.D^R1HX/+D="/XG'VC]R.,U]&CA:,LTM^C*6+?38JBXR*KAR/B]"*XP
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MA(L\H;IOKWM9GMUPTFI[G#AQ]%B5F<9S&T5NEZ]T/S!REF5U*!7_F$UU*
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MJX>7G+F7>G>7F=^55V;)ER^34U4OE+>1C4)[DIN00"X,D2>0#A22DA2-1@
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M07X&JGIVCF\ INUV\E\:HY5W;$XKH(-W^SOHG?1XC">$G)EXY TZGN)XT0
M@<6  (NZK0U^77USJ5A]_VY\I<)]NUZ+HFE]HDVGGU9]J#MYG,=]QB<SFU=]
MW@T_G39^.P  @2&  (LPJ^J&9WS/J#J%=VW#I*N$HEWKH4V#^4T1GD.#@3L
MF[2#-B;@FC6#+0T_F[6#$0  @).  (J;JOF.@WPTITV-#6T>H\&+M%U!H&**
M@4R)G4R)B3J-FL&([":4F3&(_PT_FER'/0  @!J  (H0JD&6Q'NNII:4S6R8
MHP62[%RZGZ&1.4P)G(6/T3HRF=V.]"9;F#^/6PU"F2>(]P  @ "  (FHJ9Z?
M('M I?B<JVPFHF2:1EQ(GOV8&$NAF]Z67#GCF2Z5AB8VEUZ4W U*F!&(_
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M_G%OLY]\G6-%KV=\7E0SJVA\5$0JI\)\:S*VI-5\EAZYH[5\H09RHS9]HP
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MY6_8KXZA4&&0JSV>S5*&IQN<J4*LHUR;<#&<H$J:XAYFGGR4C0=YG':%#@
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MVF6 O2:!^%?GN&J!0DFHL]* S#IFKZV EBF<K(J D!6OK#" S $AI?B Q
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M-F5#N5"EHE>[M$.C*$EKKW>A:SI%JRF@42G0I\J<11:HIH^/4@*ZG_.!V
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MVYK5AWM\^8G9AIA]"W>=A=I](61QA31]1E IA+A]=3I1A')]F2!5A/1]D
M@^9^BJG1AO:&6IFDA@^%MXB0A3Z% ':+A(:$4V-Y@^V#PT]<@WF#23FF@SB"
MXQ_&@YB"N   @F^  *BEA<./VYB8A.".BH>#A!>-(G5B@V>+MF)O@M:*9$YK
M@G6)2CCA@C*(;A\R@F:(>P  @2Z  *>KA->9?I>6@_J7?H:!@S"57'1O@H"3
M,V&,@?&1,$VJ@8:/>#A%@46.4AZU@5B-W0  @""  *;BA!RC,I;(@T6@B(6M
M@G:=K'.9@<*:RF#$@3>8)DT @,V5\C?'@':4NAY1@&R25P  @ "  *9*@X^M
M")8C@KZINH3X@>>F)G+A@2:BC& 2@)>?5DQ3@#F<V3<W?]^;M1WX?Z>41
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M*XS]CPN#LWSVC7Z#-6P)C!""N%GZBM:"6$;.B=.""3'EB3"!S1@1BA*!V0
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M5HF$BWNN\7E6B=RK.6A.B%*GD%:1AP:DE$/5A@2B]B^&A3B?'19KA4B/*
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MJ'_&EUF)N7"TE1V(QV"TDP>'WD_6D1R'##V;CZ"&>BEWCL&&/@^MD!:%>P
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M-W8\I?9IX&@5HQYK>%CBH'AL_DB+G@YN<C:RG#5OMR)>F^-P6@A8G:]P(
M@ "  (,2I_)P9W7>I-9Q1V>MH>=R+%B!GR=S%D@PG*MS_C9GFL-TRR(KFD=U
M'@B FW1U,0  @ "  (*6II9X:'4_HXAXHF<BH)-XY5?OG=)Y/4>PFU1YH#8
MF6=Y_B'KF,QZ%0B=F6=ZIP  @ "  (( I4* 4'20HCJ  &9?GTY_ME=.G(Q_
M@D<<FAA_:36+F"E_7R&AEW5_6 BNEXM_DP  @ "  (%DI"6(1W/PH22'>&6U
MGCR&K5:?FWF%\4:6F/J%7#4;EP^% B%:ED*%% B\E=^#T0  @ "  (#8HTN0
M7W-HH$Z/&64NG6&-RU85FIB,CT83F!*+B#3(E@>*\2$KE22+8@C,E&"%\P
M@ "  (!MHI"8AW+WGYF6SF2XG*B5 E6=F=J3346FEU&1\C1WE3R16R$5E!Z0
MZ CBDPZ& @  @ "  ( 4HA2@TW+#GQN>N61^G!><;551F2R:.$50EI68IC07
ME(Z882#&DV^5?PCHD@"&!@  @ "  '_1H;RI7')]GK>F[&0NFZ:D,E3ZF*VA
MI44"E@V@+3/9D_R>?""9DMB6"@CCD3N& @  @ "  ':TL\%G?VGUL#AI"%R
MK.5JC$X8J;QL CZ'IN)M7"T]I.MN:QBYI9=N; &)HJIP @  @ "  '9:LM!O
M4FG*KRAP'5Q7JZ9P^4WYJ%1QW3YPI5YRO"TZHTES:ACCHZ=S1@'^H#=U80
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M/6?FJ<&3REINIB.20TP8HJV0WCS4GYJ/[BPPG3N0!QC:G)6.60-6EVJ"0@
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M9%V=N-IU@%#5M,]UN$,FL.UV&311K9!V?".1JXAVK@\<K,AV)@  G(E\(@
M@ "  &FHNW)\:UUAMV9\'E"'LUU[Z4+RKW=[WC0MK!1[\".3J?)[^ ]GJN)[
MV   FVA_H0  @ "  &EZNC&#?UTUMB."VE!6LA6"2T*TKBN!US04JK>!FB.4
MJ(6!G@^IJ3"!K@  FFR     @ "  &E.N3R*NUT>M1R)R5!$L0"(W$*>K0V(
M$#/\J9&'DB.=ISJ'P _FIZN&N   F9"     @ "  &DIN'^1_ET4M$>0R% _
ML!B/@D*4K!N.;#/QJ)N-X2.GIC*.11 BIEF*Z0  F-^     @ "  &D-M_.9
M65T7LYZ7YE!$KUF654*2JTV5"#/DI\>4MB.<I5Z3S! _I5F*_   F$B
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M@Y*G@T5O"8* @NAP;7$U@I]QOE[#@FMS!$L7@EIT.S7 @GUU.!O(@V]U9@
M@ !ZN:"+@=EVU9%F@8AWBX%=@3MX*W 2@0-XP%W @-YY54HX@-=YY#4%@/-Z
M3QLW@9IZ+   @ !^.I]F@!F )9 S?]V (H 7?Z>  V\3?WE_WES;?V1_PDF
M?V9_K31X?WY_E!K*?^%_5P  @ "  )X[?K")?8\D?GV(SW\'?E"'_VWD?BN'
M'5O6?AZ&2DB1?C*%F3.R?D*%#1HY?EF%#   @ "  )U$?9"2[HXD?661E7X*
M?3J0#VSR?1F.=UKU?0Z,^$?7?1F+L3,<?22*W1G'?/N*9@  @ "  )Q]?*J<
M9XU9?(:::7T]?%>8+FPF?#25Y%HT?"Z3R4<T?#B2"C*E?"N1)AEQ>\>.V0
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M1X4<BDUV#G88B4AVQ&74B&1W<%1]AY]X&D'7AQ-XN2U)ANYY'Q,#B']XF@
M@ "  )(LB;A]^X0+B+)^)'3RA\%^-63JAN)^.U.IABY^1T$NA:E^52S+A79^
M5!*YAJ!^!@  @ "  )$PB$R&S(,/AU.&5W/\AFN%PV/UA9*%'5+UA-F$@4"<
MA%R$#"Q;A""#OQ)WA.B#A@  @ "  )!7ASN/OH)4ADJ.LG-#A6"-=V,BA(6,
M)U(D@\R*\#_R@T2* "O2@OV)GA(?@V>(.@  @ "  (^HAF*8M8&:A7B7%W*%
MA(F5.6)G@ZF31E%M@O*1BC]5@F600BMO@?N0'1'E@AZ,&0  @ "  (\@A;RA
MOH$)A-F?EG'I@^&=&V',@O2:BU#5@C>86CZY@;*6]"KP@3J61A&R@1&+]P
M@ "  (Z^A46J]X"7A&6H5W%C@V*E16$_@F*B(5!8@9>?F#Y6@0J>92J;@(Z;
M-1%Q@$6+RP  @ "  (=\F)UC%7IIEIAE66Q$E.-G>%SADV1I<DQ)D@]K33HV
MD2!L]279D3AN 0L\DY5M=   @ !]1H;5EOUKBGG/E1]M FN9DVEN9UQ%D=MO
MOTN\D'MQ!CF^CX%R)R5XCW9RR LND1AR10  @ "  (8@E4ASVWCNDXATI6K2
MD=EU9%M[D%%V'DL,CO5VU#DNC?IW="4.C=1WNPL<CLAW?0  @ "  (5(D[!\
M%G?^D?Q\3&G,D%U\<UJFCMI\ETI+C8Q\P#B1C)1\Y22<C%A\Y@L!C+Q]#
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MA'46C<ZD6V;+C!>AQU>1BF>?+T>$B/>=4C8\A^6<<"+NASF7G@J5AD:'*
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M[VN(FG*!N5X>F#6!=D_(EA.!+4!HE#2 ^"]DDN^ W!NUDO6 V 2.C_V G0
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MDV(#JEUCDE4ZI[=E@T=II3MG5SA-HQUH]R<VHA=J&Q(JI']IIP  F--N8@
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M\E_9HZ6&=U,EH,>%Y$6%G@N%4#;8FZN$Y29OFBB$U1*2FP.$N   D<:
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MVU7'M$]I DF2L15J.#QOK@MK9BWEJY]L9!SPJPILN@CQK EL:0  DA=W;@
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M%%2UK8V*?4B8JA^)O#N+IN&)""U=I#&(MATKHMZ)( IEHDJ&B   C3.
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MG)$X;UJ%.X$(<'6$MV_4<8.$'UVT<I2#D$I5<Y^#%S5\=$V"K1QJ<X6";P
M@ "  )]0;*^/5I @;>^./G_X;Q.,]V[-<"R+G5R]<46*54F-<DR)-C3;<O*(
M8QOO<<N(2P  @ "  )YM:X"9$X\\;,B71W\4;>Z5/VWP;PN3)UON<"Z1-$C<
M<3>/B#19<<6.<1N0<%V-6   @ "  )W$:I:BTXZ*:^.@5WY8;06=D6TU;AV:
MO%LV;T*8*T@P<%*6&3/1<-25'QLZ;S61>@  @ "  )U4:?&LEXX(:SVI<GW!
M;%2E\FR7;5^B:UJE;GV?34>U;XJ= S-6;_^;>!K$;D>2&0  @ "  )A0?Y=>
M6HI)?W!A1GL8?WAC^&J6?YYF=EC8?]=HU47&@"YK#3#E@+YLWA:U@CUM-
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M2X2I=B:+AW6$=I>*D658=P:)@U0Z=WZ(@T'@=_:'KBW&>#"'+12!=\:&I@
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MK7TZA:1HM6[LA2UJFE]SA,YL8DZZA(IN#SR/A'QOCRA A-]PCPW7ADEO]0
M@ !]6(E>A =O4WP=@Z1PHVWM@T)QVUYW@O-R^DW?@KMT"SO8@K%T^B>S@O=U
MAPV>@^=T[P  @ "  (A/@A1WZ'KZ@<5XEVRX@7AY*EV$@3)YJ$T @0UZ'CLC
M@0=Z@2<L@3)ZJPUF@=%Z70  @ "  (=*@%: BWG]@!N HVO"?]^ EER+?Z:
M;DQG?WN 23JH?WV +2;<?XZ $ U2?_Y_Z   @ "  (9H?P>)3WDV?MB(TVL"
M?IN((UO"?EZ'5DN-?C>&ESG]?BR&"291?B2%V0T-?GJ$HP  @ "  (6Q??.2
M$7AY?<R1!FI'?8V/MUL-?4Z.4$K<?2F-#SEF?1:,+"7U?..,.@SJ?3*(E@
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MT7 ZC,5O(V+DB[QP8E1.BM!QCD2+B@URHS,NB:ESAA\VBB-SS 9WB9]T*P
M@ "  'O)B^UUZ6]$BNYVJF'>B?EW5%.%B1-W\4/7B%UX>S*CA_9XYQ[=B$9X
M[09\AY)YOP  @ "  'KIBDI^!6YXB5A^1&$9B&M^9%*PAXY^:D-1ALM^;3(V
MAF=^=QZ=AHQ^8P:,A<9^KP  @ "  'HBB/J&1&VYB!:%^V!>ARJ%AU(+AD*$
M^$*ZA7R$<3'RA/>$(!YNA/F$.P:1A#R"VP  @ "  'F#A_2.C&TZAQJ-SE_C
MAB>,RE%WA3"+IT(9A&F*LC%@@]Z*,AXI@Z.*B0:+@O.$;   @ "  'D$ARJ6
MW6RYAE25L5]=A5F4)U#UA%62?$&:@X.1,3#4@OB0R!VX@IN/U@:)@>6$:P
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MXV/1E)9TK5<KDP=U94F-D8]V$CJ9D%MVJ"GEC\%W"17>D-EVK0"BC&MY1
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M#F%?CWV9^%2YC=287T<0C""6L3ARBK&5T2@YB<65)Q3\B<F., $GA@. R
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M\%?AG5-Y6$O>FSMYK3[CF3]Y[#"TEZEZ)R!-ERUZ,0R.F %Z*@  A]%_G
M@ "  &*0GBR 5E=QG!: 84MUF?B 2#Y\E_. &C!5EDY_^B EE:)_^ R5EAZ
M$0  AK2     @ "  &(FG2V'OU<9FQB'>4LDF/"&^#XHEMR&9B_ZE3*&#A_F
ME&V&1 RLE'2%#0  A<Z     @ "  &'5G%Z/*U;,FDJ.FTK3F!R-OCW8E?V,
MVR^NE$2,=A^+DWZ,KPR)DR6(>@  A2&     @ "  &&5F\N6S5:_F:Z6)$K%
MEVR4[SV]E2B3K"^KDTJ39Q^QDEN1[PR_D>R(GP  A)R     @ "  %DCL:U:
M9$X:KU)<C4)DK1E>JC6<JQA@GB<LJ>-B(Q63JV%B: -%J;9C6@  B.=Q_0
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M(TQ0IRI]2D#5I)U]3C1>HC=]/R:2H'1],Q8;H)=]%@3_G.]^%@  @UZ
M@ "  %:ZJ*"$+4PIIA*$%D"YHW6#QS1!H0*#;"9TGS2#1Q8=GRV#AP4^FR&"
M>@  @JV     @ "  %:%I]*+0TP3I3**_4"JHH.*9S0RG_Z)SR9=GB&)RA7_
MGA&)-@5-F:N#E@  @A:     @ "  %9BIS22?DP,I'J2(D"GH;J1530NGR.0
MI"9GG2^0F18FG/:-Y 5JF'"#J0  @8"     @ "  +4F85-9LJ/^8]%= Y(V
M9B]@-W^&:'%C3&O>:I]F1E<H;*YI)4$J;F)KSR?K;MIMW0:Y=*-NQ;,J7<YD
M8:)Q8)IFK)#48S9HYGY+9:YK$&JZ: UM*%8>:D!O+D U:_QQ!B<8;!)R7@9C
M=35S0;%.6K%O :"J7;-P2H]-8(-QC'S68R9RSFEN9:QT#53[9_YU0S\^:;MV
M5B91:65W"@87=;5X(J]T5^5Y@9[=6Q9YW(V,7@EZ.7M98-)ZEV@48W][ 5/4
M9>I[:SY.9ZA[Q"679MU[ZP75=B1\FJV^57B#\IU&6,Z#=8P$6^."]GG>7L6"
M>6;B88R""%+(9!&!KSUV9<J!6"3R9(2!$06==H. ;:Q24W:.9IOW5NF-&(K,
M6A2+P'BX70V*:F7.7^2)*%'G8G"("CR^9"6'&21B8G6&G05N=M.#IJLM4<^8
MU9KJ55B6MHG06)&4@W?*6YB2663O7H"05%$D812.A3PI8KB-#"/P8,B,H@5&
M=Q:#D:I04(2C-IH>5!N@0XD*5UJ=-W<,6F2:.V0W7527@%!X7_&5'CN<88J3
M5B..7VR1[ 4F=TR#>ZG!3YBM=9F24S2IH(AX5FREN79Y67"A^&.P7%Z>F5 $
M7OJ;Q3LH8'^:!2,B7D66'@4-=W>#:J@7:-M929AC:JE<KX?/;&M?YG8E;A]B
M\&-E;\IEW$]_<5]HISHB<J]K*B#H<O%LS %,?<]N\Z:!98AC=Y<T9Z5EY(:]
M:9IH,74M:W9J8V* ;4)L?4ZS;O%N?SET<#YP12!;< )Q3 $N?@%SQZ3>8HAM
MCI5_9-EO#H4W9OMP>'.X:/]QU&$X:N]S)DV6;+AT:3B!;?UU?!^=;2YU^0$4
M?BUX9:,T7]=WB)/58E!X,(.69)1XQW)?9KAY45_^:,UYW$R,:JIZ8S>K:^9Z
MSQ[Z:IUZX0#]?E1\9J&H77^!?9)@8!F!78(M8GR!)G#^9+B XE[H9N& I$N7
M:-2 =S;H:@. 2QYK:'2 '0#J?G5_U*!C6Y"+>Y$K7D**EH$)8+B)DF_I8PF(
M@UWF94"'@DK)9S6&HS9#:%B%^!WN9JN%V@#9?I& DY]?6?F5=) R7+R3S( :
M7SZ1^V\&89N0)%T18^*.;TH39=R,\S6_9N6+X1V/93.+C #,?JB BIZ=6+N?
M88]S6XB<]W]97@V:6VY*8&R7OUQ:8KB584EH9+F3:34W9;*2-QTZ9 20-@#!
M?KJ @IX=5]BI-H[J6J6F#'[#72.BIVVR7WN?3EO08<2<6$CU8\*:!S3#9**8
MY1S+8PV3> "X?LF ?)LV<+)8]XS5<<Q<8'UG<O%?D&R\=!MBC%KA=41E9$?!
M=F=H$S+R=VAJ8!E>=\UK6@  @ !R'9GA;8=BC8NC;NYE#WPQ<$%G:6NC<8QI
MH5GE<M%KOD;F= =MNC(X=/5O8!C2=,EOW   @ !VR)B%:J%L((H_;$!MQWL1
M;;UO56J%;R9PQECN<(-R*$88<<ES=#&9<J5T?!AC<B9TDP  @ !ZXI<$: 5U
MF8C!:<MV?GF#:V=W1FDZ;.QW^5>^;FQXHT46;\)Y03#'<(EYMQ?*;^QYC
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M\X0N8EVB9W3[9"F?A&399=:<G%/89WJ:%T'!:-F84RXB:1B78!7E:4R.S@
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MKGQ0;YE]%FX+<*E]5UZX<:5]>DY=<IY]FCR*<WU]NBC=<\9]PP^A=25]G@
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M7758@5A;EV?&@5I>H5CL@7UA=TC!@;AD&S<#@B=F<2+1@QUG^ CGA*1GWP
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MWG L=FN"WV+-=N&"K51?=T:"7$3E=ZR"$#/R> *!WR"?=^.!U0B#>A^!7
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MYVBSAYEB4UOHARYDGDWXAMEFQ3ZIAJMHN2V.AN)J2QE/B#!JNP(LAVQK^@
M@ !_@W-JA9%GYV>LA3YILUL+A.EK9DTCA*%L^3WXA'AN9"T'A*%O?1D A9EO
MH ).A1-Q-@  @ "  ')P@S]OWV:A@PAQ&5GV@L=R.$Q*@HQS/CTT@G!T(RQM
M@HYTRAB<@S9TL@)=@PIVS0  @ "  '%]@4)WX&6Y@1UXD5D.@.IY(DM=@+=Y
MF#R9@)-Y_"OH@*EZ0AA(@/]Z$P)N@41[P   @ "  '"F?Y!_\F3O?W^ (UA2
M?U6 )TJU?R& ##P'?OA_\"NS?NE_Y1@S?O-_Z *-?[U_^   @ "  &_V?CF(
M"V1A?CJ'QE?/?@V'/4HK?<J&E#MR?9N&"RLI?7V%U!?W?2J&'0*6?G:!P
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M-UQ CLQG_5!0C>=IK4,<C1MK/32-C)%LE2/BC,)M;@]>CH)LZ0  A%YSIP
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M15D-AN^+Y4TOAA^+)$ _A2R*.S(OA&>)L"(VA :* 0[E@Z"'\@  @ "
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M6E XEN=LGD31E9=MSCAJE&%NXRIJDY]OL1G=E#-OS@<NDK%P(P  @ ![90
M@ "  %H,EDQR@4^2E01S6T0PD[=T'#?&DGQTMRH"D:MU+1F4DAQU(0<QD"IU
MW@  @ !_+@  @ "  %ESE+=YR$\&DWUZ0T.QDBYZE3=1D.EZPRF8D 1ZWQEQ
MD"UZS <[C?A[T0  @ "     @ "  %CPDVN!$TZ6DCZ!.T-,D.J!(S;MCY>
M["DNCJ6 SAD@CJF ZP=0C!R X   @ "     @ "  %B(DER(8$XOD3J(.T+G
MC^:'Q#:0CH:'-BC<C7Z'!ABWC7.'1P<KBJ.$V0  @ "     @ "  %@WD8Z/
MY4X)D'*/HT+#CQ6.SC9OC9"-VRCBC%>-PACYC B,H0=RB52%"0  @ "
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M<40KH&MP3CDSGL5Q$2TKG4QQI!^,G*5Q]@[ G=EQC@ UE@!U"0  @ "
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M=(U>8+%@9'W:8R=C-6U"97YEYEN$9[=H=TB2:;9JY#07:P-M 1MG:DUN(
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M<X8_4P:-7W=#5D^,*V<_65J*\E9"7"N)U$0K7FZ(YC"I7Q2(4AC\8$V(20
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M((#=9')H27*/9HQJ5V+H:(%L0U(I:E9N%T 6:^MOQ2PY;*5Q%1,2;EUQ#P
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M@GLQ6.V3)VT16Y61CEWL7@*/ZDV_8#:.>SQ;8<Z-<2EO86Z-21&"9JJ*8@
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ML'1P:0QO-V< :K9PH5B5;$!Q\DB];:YS(C=];LQT*R07;N%TRPM.<UYTLP
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MDG R7ZB8(&+;8:662E2$8V24844I9.62UC1X9;Z2&R')9&*140IK;F2'"P
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M-VA+;K!U.ENB;]YV'4X%<.=VWC\\<=9WC"Z9<GMX$AM8<>YX(@2M>!EYLP
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M>V&"@LU5YU5(@O19+$?+@SE</3C6@Z%? 2?9A'AA+!+TAKMAE0  @SIEK@
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MQ5QP=7AZ8E"(=AYZU4.:=IU[)35_=O][9"5]=Q][DA'7=[E[8   @ !^"0
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M_E4KB1%;NTFJB-Y>53SUB,1@O"ZAB.YBQAW)B?EC^ FDBJAC_0  @ !N*0
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M/5#7?4]^DD69?6]^M#E'?61^MRN;?4]^NAO1?21^Q F-?=)_,P  @ "
M@ "  %JL>WF%RU!T>_F%SD5&?!N%>#D&>_&$_2MO>[:$PQN->UJ%&PE2?%R#
MWP  @ "     @ "  %H[>DJ-;% %>M>-*T39>O^,;3BG>LV+DBLG>G6+2!MB
M>=F+,@E,>RJ&20  @ "     @ "  %2EEMQ0/4J,E?%353^)E4]62C,FE0)8
M^B3/E7=;%A+OF%);J &"E*5=C0  @ !M%   @ "  %.>D_U7/TF\DT19X#[%
MDJ=<73*(DD1>FR1GDHA@3Q+8E.=@F0'4D0IB:0  @ !Q^   @ "  %++D0Q>
M/TC<D'E@9SX*C^QB;3'8CX=D.2/DCZ]EAQ*;D:1EC@(&C<MG9P  @ !VY
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MQ$6(AE*!\#K8A?:!UR\,A7"!IR&;A1&!IA$OA1B!PP)A@Q&!=0  @ "
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M.CR$F6]CW#'VF+QE5B9 F$=FBQA'F.UG!@B F$QG7P  B=YN?   @ !]@
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MQCHED,Z$]"_QD#*$LR29CUF$91=*CP6$APB%C%F#6   @G&     @ "
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M?21]B)5G/:F ?H=K0M2 ;'B;1XN 7&C#2]R 2U?O3\: /D7W4MZ 0S*14Z"
M6!NK5RF J &Z?12 Y90*.I:*<89*0 ^)B'>Q10:(IV@!28F'U%<[39.'%45<
M4*V&>S(N436&(1MG5<J&D@'"?0B!,)+U. :4/X5E/<"2=G;Y0NV0Q&=N1YB/
M-5:Y2[N-UD3<3M2,MC'#3QB,&QLQ5*^+RP'(?/V!-)(S-@^=M(2^._*;!W9Q
M04*8AF<$1@F62U9L2C^48T2E35F2XS&)35Z24!KW4\^/\ '-?/6!.).#6KY-
M[H5#76%2('9;7_U6.69]8HI:+U6!9/E=^T,]9Q=ACR]/:$!DL1:J:75F5
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M&WV$2;A^36]Z3<1^<F!F479^C%!.5+]^J3[T5QU^U"OU5L!_"12'7F1_6
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M&WE(7XM:=VMC8?Y=MEQ[9%%@TTQ99G)CPSK,:"EF=2=":(=HE Y#;A%H_P
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MM'*.3CR$>&5;4<J$&5<85/B#L$? 5Z6#63<962:#*22F6)&#1 T\::&#$P
M@ "  'X31_6-I7'23 J,PV2J3[:+LE9W4OB*G$<G5:J)N#:$5PJ)*R0W5L*)
M8@TE:<B'-@  @ "  'V"1B"69W%(2E.4\F0?3A&3-E7S45N1>D:Z5 N0%S8Q
M54^/42/?55"/9 SA:CR(M0  @ "  'R5:7-.$W &:PU1_&*Z;+=5TE1A;EA9
M@T3&;]U<^S./<2M@$Q_4<:QB.0<S=[9C$   @ !UAGJS9+)6D6Z<9K=9W&&#
M:*E="U-8:GU@%4/B;"%BZC+2;65E:!]$;4]G"@<?=.IGOP  @ !YK7D=8$5?
M*VT78J9AR6!)9-ID3E(W9MIFKT+Q:)EHY#(0:<IJSAZZ:4UK]P<-=!5LI0
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M.6>O4Z.)N5LV5IZ(^$VS62J()S\'6Q:'AB[>6WR'01R=7.2'Q0;3='B$G0
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M%V#X9L1H$E3B:)QI]T?>:C9KO3E&:X1M32CP;!%N@A5=;6YNJ0#S?F5QE@
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MQES%6@".,U#W7%Z--D0B7C*,(C8@7S^+:B9G7F&+B1.P9#B)\P$/?C6 N
M@ "  &3C>@Q-6EG<>KA0^$X'>XA4@D$#?&17W3)T?4Q:VR&4?H!=#0S,@*!=
M>   @ !EG0  @ ![M&-%=<)4WUBH=L%8 DS]=[I;!4 J>*1=V#'(>8)@4R$<
M>F=B$0RT?*QB/0  @ !J2   @ !^]&'Q<:=<@U==<NY?%TON=!)AD#\O=0]C
MUS#Z=>9ET""!=GAG'@Q\>4%G&@  @ !O5@  @ "  &"P;=5D,E8;;U%F-$JP
M<)=H'3XW<:QIWS ><GYK61_5<K-L/PPP=EAL(   @ !TT0  @ "  %^$:EQK
MZ%4#; 1M7TFD;6ENO#TL;HMO\R]X;T]P^1]+;QUQB O^<]!Q;@  @ !YL@
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M8$ZK@Y9/W4.$A 13/C<*A)I682B\A8!9 A=6AXE:7 1QA]5;H@  @ !I-0
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MJTE#<F]QNSZ$<V1RIC*A= 9S9R4W=#USZQ4%=(=STP1B>4-UWP  @ "
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ME$(XB>94BS>UBA=74"O%BG]9OAV9BYA;; PYC15;U@  ADY@WP  @ !QC@
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M73V5>BUU'3-<>LMUIR?F>P5V QIR>N=V$PK4?#9V;   @ ![1P  @ "
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M>#4ZDAE7X2L>DCY: A\ZDM=;H!"@E,-<'P+2D,]>+@  @ !I(P  @ !Y=
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M"C%=@\]W?"=VA&5WKAPNA)=WJ ZCA$EWD@)N@P)Z*P  @ "     @ "
M@ "  #H-@*I^)S#G@?9^3R<+@JQ^,1OC@LQ^ 0Z1@EQ^+@*)@8A^_P  @ "
M    @ "     @ "     __\  /__  #__P  ;69T,@     $ PD   $
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MVL3'Q;7&H\>1R'[);,I9RT3,+LT8S@'.Z\_5T+[1I]*0TWG48=5)UC'7&-@
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MVZS5K="NRZ_'L,2QPK+!L\&TPK7%MLBWS;C3N=NZX[OMO/B^!+\1P"#!,,)
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M2.2 KXXZ,KF P8?/Y-6#<[WXSOJ"A[=6N+6!O+#BHB^!)JJHBY^ Q*2*=1&
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M;W^IE3S!)H#8AM&[&'_Y>$6U%']<::ZO#W\'6Q6H\W[\3*:BIW\L/KV<$W^
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MBNF!*X!K=*"!"8 Y7G. _H 92'6!%8 ?,N"!6H!)WU&!08U!RL& V8MNM9:
M@HFXG\6 38@^B;* +H;P<Y2 *86^78^ -82*1[J 9(-8,E: OX('W;^ *)?%
MR25_QY3TM %_?))"GEQ_4(^YB'1_2XUN<H=_7(LQ7+=_?XCC1Q-_Q89T,=V
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MMGXE@0?%?WKY=)F_3WJG: 2Y!GJ>6V>RD7K;3MBKW'M>0HNDW'P=-N.=AWT
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M1X<[W%)N\[^ZQW9P&[E-LA%Q/K*VG%QR>:P9AJ1SX:6.<0-U<)[R6YIW&)@
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MLIF"](SDH"*"68L\C0R!W(FG>9^!?X@V9B>!.(;.4N*! X5>/]Z [H/8+9V
M]H(>PPZ"I)A L4Z!]I6^GN"!99,VB]N \I"P>)6 GHXV94N <8O34CN 48E2
M/VV 4X:@+6: <8.5P?6!VZ'UL#N!,IZ;G=* HILDBMN -)>D=[!_Z90I9(A_
MP)"N4:E_MXT;/PE_SHDZ+3=__X3DP1*!/:N;KUF F*=BG.V !*+VB?E_EYYQ
M=N=_5YGR8^5_.I5E42Y_,Y"M/K=_7HN=+1!_H(8)P&2 QK4JKJ: ); -G"U_
MBZJAB39_%J4)=C)^V9]X8T=^S)G74+A^TI0 /G!_ HW"+/!_48<$O^V =+ZA
MKAY_U;B8FXI_,;(:B(E^KZM?=99^;Z2O8LI^:9WR4%M^?9;\/C)^NX^=+-=_
M$H?5N7>0KG!&J1*.YG&2E_B-3'+0AAZ+U'01<]&*:75N85J)!W;R3QF'I7B;
M/0.&4'J/*Z:%!WSSN'Z/1'F5J"R-G'GJEP6,%'I#A3>*IWJN<O>)2GLV8)6'
M_'O=3FR&L'R:/(F%=7V(*WZ$0WZRMWJ-^8++IP2,8X(_E?N*X8&VA"R)A8%+
M<@N(.X#Y7\V'!("^3<R%T(",/!V$KH!J*UJ#DX!4MFB,Q8P I=N+.8J=E,.)
MR(DV@R:(<(?I<1J'/8:V7P:&&H6/332$_X1B.[N#^8,L*SJ"^8'7M4Z+S)4F
MI->*0Y+VD[N(V9#!@A*'CXZ/<"R&9(QH7CZ%6XI/3*"$4H@=.V&#7H7(*R""
M<X,VM%J+#9Y)H^")B9M-DLB(()@Y@2V&VY4<;V"%MI(!792$K8[A3"2#MXNI
M.Q6"V8@T*PF" (1MLY**=J=5HQB(]Z.'D?^'C)^,@&J&1IM\;K*%*9=J70F$
M*9-&2[^#,H[Z.MB"9HIH*O:!H85\LO:* K!(HG>(B*NDD52'&::Y?\"%S*&F
M;A2$L9R17("#P)=G2UV"TI(+.J*""(Q>*N>!4H9BLHB)KKDAH?J(.+.?D,*&
MPJVS?RF%;*>/;8Z$3J%J7!:#89LP2PF"@93$.FN!Q(X+*MJ!$X<?JUJ9P&^[
MG".7*W$*C$Z4QW)1>]*2@7.B:NN00W416=^. G:I21J+MGAF.)J)9'IS*0:'
M WSLJI.8?WB!FW&6 7CGBX^3IWE8>QJ197G>:CJ/+WJ$64&,_GM+2)2*PGPL
M.$B(A'U"*0>&-7Z9J<.70X$LFG^4V("^BK*2@H!>>CJ03X ::7*.*7_S6)F,
M"W_E2!*)XW_B-_Z'NG_Y*0B%?X GJ-66*XFTF8"3Q8B'B:61>H=E>5N/2(9/
M:*>--H595_>+*H1K1YZ)%H-]-[^' X*.*0F$WX&3I_:5*Y)+F)N2T)!=B+V0
MCXYQ>'2.9HR$9^^,3XJF5V"*68C51S6(6(;R-XB&783Y*0J$58+<IRJ4<IK?
ME^62&I@QB N/UY5P=[>-L)*I9SR+HX_D5M")K8T=1L^'O(I!-U&%U(<X*0J#
MX(/^IG^3X:-3ES:1CY_CAUJ/29Q)=PZ-()B=9J>+&93N5EB)*9$Q1GZ'-8U2
M-RB%7HD^*0N#?X3WI?>3=*NEEJJ1):=LAL>.VZ+R=GV,JYY49B"*IIFR5>6(
MP93\1B^&TI @-P6$_8L(*0N#+X7*I963([/>ECR0UZ[6ADF.AZEJ=?R,3J/*
M9:^*1)XG58V(8IAS1>N&@9*9-MN$N8R+*0N"[X9WG<VC"V];CZ6?M7"C@/F<
MBW'N<<*9<W-*8C264W3'4I&3(W9P0TJ/V'@^-&B,<7I?)J*(X7SDG3:A]'>C
MCR>>JG@.@'";?7B-<3R88'DG8;.50GGF4A^2''K+0N^.W7O,-$&+AGT&)LN(
M"'Z G)F@R7_$CFJ=CG]I?\>:8'\B<(Z73'\ 81F4.G[_4:*1)'\:0I6-]G]&
M-!V*LG^2)O"'2'_[F^*?LH?&C9V<?H:W?NJ96X6X;]6628348'.32(0.42"0
M0X-80CZ-)H*D,_N)]8'[)P^&H8%4FR*>SX^TC.&;GHWY?BR8@(Q(;Q25<XJC
M7]^2:XD$4*N/>(=X0?2,:87>,^")3(0Y)RJ&$8*)FH6>")>QC$*:XI5$?8V7
MQI+.;GZ4MY!47U>1LHW=4$B.N(MH0;6+NHCG,\F(M89()T"%F(.7F?R=>9^/
MB\R:5IQN?1:7,IDI;?^4')747MV1'I*#3^F.+H\I07R++(NX,[2(.8@C)U.%
M,X1^F8R=$:=$BUJ9[Z-I?)^6Q9]0;8N3IIL97G.0J);D3XZ-PI*B04&*Q8Y'
M,Z*'U(G$)V*$X85 F3B<Q*[:BO^9GZH\?#F6;J5 ;2232* 97AJ01IKU3TJ-
M897&01"*<9"",XN'CHLA)VZ$H(7?D.ZLCF\%@[>H?G!"=AZDC7&.:!N@FG+T
M6=J<BG1_2YB85W8Y/<J3^7@:,(./97I.)(&*F7S;D(6KFW;:@VRGB7=#=<JC
MAW?+9\F?A7AX68J;<7E02U>71'I2/9V2[WMR,(B.:GS0)-")L7YHD!NJ>7YY
M@N:F<GXI=56B:WWV9TV>;'WS61^:8'X52P6607Y:/6V1^GZR,(N-B'\S)16(
MYG_3CYJI8(7P@E"E7H3[=*^A7X0=9L2=88-D6*:998+/2JR55()-/3N1'8'5
M,(J,OX%Q)5&(-H$;CP^H=HU8@<*D>8O#=!N@?XH_9C&<@XC-6#>8@X=Q2EF4
M@X8E/0Z06834,(J,#H.&)82'GX(]CHZGPY2Y@4>CR9*#<Z2?RY!+9;V;S8X;
M5]"7S8OR2A:3PHG,/.R/IH>C,(R+<H5L):Z'(8,ZCBVG))O[@.*C,)D><SZ?
M,98K95N;,I,R5WR7-9 Z2=V3+8T\/->/!(HS,(^*YX<<)=*&N(01C=>FO:,9
M@*VBQY^1<P:>N)O291>:HI?[5S>6H)0N29V2K)!?/*^.E8R&,)"*?(B8)>Z&
M8X3%C9.F<JH2@&JB<J75<KZ>6:$_9,Z:/9R'5OJ6-Y??27&21),W/):..HZ*
M,(R*,8G4)@6&'X57A+NV1FZJ>&&Q@V_::\:LR'$F7NFG[W*64>NBWW0Q102=
MDW7_.*>8#'?U+/22.'H](J*,)WS2A(&U;G86>$JPF79X:ZNKOG<(7LVFS7?'
M4="ALWBX1/6<:WG9.*R6ZWL;+261)WR=(Q6+,'Y3A$RT37T[=_JO?7SQ:VBJ
MFGS.7H6EI7SH492@D'TO1-";57V>.*:5XGXF+4Z0,W[;(WB*6'^OA .S*(0N
M=YNN7(--:OFI?H*-7BVDBX'\44J?@X&81**:5H%-.)N4]($1+6^/6X#R(\V)
MGH#G@ZVR,(L1=T.M:(F>:IRHC8A&7<RCFH<&40B>D(7G1':9=(3>.)"4((/8
M+8R.GH+@)!:(_X'[@UFQ=9'L=O>LJX_F:E.GRHWE78:BU(OS4,N=RXH31%.8
MJ8A .(B39(9O+:2-^(2A)%*(>H+H@P^PY9B>=KJL%I8 :AJG*Y-074ZB+Y"B
M4)>=*HX#1#:8#8MH.(>2OXC,+;J-:88O)(2(#8.R@MZP:9\>=HRKF)OA:>NF
MIYA\72"AII4-4&Z<H)&J1!&7D(Y&.'J20HKF+<^,[X>')*V'M(19@JZP'*6"
M=H6K.Z&@:>"F-9UI70.A&YD94%B<"93K1 R6_9#*.(.1SXRU+>*,FXBF),V'
M;83A>1K ,&YE;7VZRV^ 8<ZU2G#'5@JO@'(]2D>I7'/F/KBBX77),\J<%W?4
M*:B4[7HQ(/J-D7S)>0Z_:75O;9>YY'7!8>>T,W915B*N1W<>2E^H%'@G/MNA
MFWEG- &:V'K+*@:3PGQQ(8V,B'X^>1"^/GP>;8&XN7O/8=:R_WNU5@RM"7OI
M2E6FV'Q2/N:@:GSL-"B9M7VC*E62N7Z+(@R+HW^.>0.] X*0;5RW@8&Y8:&Q
MR8$/5>>KUX"B2CREL8!M/N6?4H!8-$68L(!9*IB1SX!^(GF*WX"Y>.>[]8CM
M;3^V<X>588"PNH9A5;^JR8512BVDI81K/N:>68.F-&"7R8+J*M*1 H)((M:*
M.(&_>,:[)H]$;2VUF8UG872OV(N95;2IY8GC2B*CQ8A'/NR=>8;#-'J6_85+
M*P604H/E(R.)K(*@>*BZA95L;22TZ9,&87"O')"65;"I)8XR2B"C#8OE/O2<
MRHFF-).63H=Q*S*/O851(V*).H-=>(ZZ#9MA;2*T79AJ87.N@9505;&H@Y(V
M2ARB;H\T/O6<.XP_-*25R8E9*U:/0H:)(Y6(W8/Z>'NYM*$F;2>SZIV187RM
M_IG 5;:G^)7H2B2AXY(O/P6;N(Z)-+2568KW*VV.Z(>)([Z(DX1YVJ5Q\&TJ
MQJ9S46[$LBMTI'!7G2!UZG'IA[1W,'.)<B9XA75"7+5Y\W<51VU[E'DC,JU]
MBGN3V+9OVW@9Q1=Q:WB)L,9RXWD%F^1T3WF2AI1UOGHT<2)W/7KK6\QXU'NO
M1JUZGGR4,B5\N7VDUN]N&(,%PUMOOX)1KT1Q5(&NFGMRWH$UA5=T;X#7<!)V
M%("*6NIWT8 ]1?UYOW_T,:U[^W^=U31LCXW/P9UN18P-K9)O[(ICF0!QD8C6
MA ES0X=U;OMU"H8<6@]VZ82V15IX^(,X,41[48%ZTZ)K1YA]P!)M")7%K IN
MO9,;EXQP<I"%@LAR.XX%;>UT(8N<63]V'HD41,5X2H98,.EZO(,RTEAJ2:,8
MOL]L#Y]VJLAMR9O(EE1OB)@C@:MQ7Y2,;/1S5I#V6(!U;XU'1#]WM8E*,)QZ
M.X3!T5!I@:V7O<MK2:D-J;]M J18E4UNQ9^=@+YPJIKN;"URLI8R5]UTVI%#
M0\]W-HP$,%MYSX8BT(AH[[?LO09JMK)WJ.ML:*RYE'%N)Z;>?^EP%*$-:WAR
M*YLM5U5T9)4(0V]VSHY[,"=Y=8=3S_YHD,(#O'QJ4[N4J$AK][3$D[MMK:W'
M?SAOF*;-:MYQN)^_5M)S_9AG0P]V=I"B+_UY+(A3R\1Z&6PDN9=ZGFWRIKU[
M*&^HDRQ[MG%4?R)\3',,:NI\\73?5M9]JW;00NE^CWD +YI_MWN8RF!X+W:+
MN'UXX'<\I:UYB'?IDB=Z,'B=?BAZXGED:@9[J7I"5@Y\B7LR0DY]EWQ)+SE^
MYWV3R.AV@H#=MN5W28"!I#EX!X JD,=XS'_J?/9YGW^_:0-ZBW^F53I[C7^0
M0;)\O'^#+N-^*W]SQV1U#8L+M5-UX8F\HJMVL(APCW!WB8<P>\5X?880: 1Y
MAX3V5'1ZJ8/3029[^8*=+IA]A($UQ?ESTY4GL_!TL)+RH4MUCI"VCAYV=XY]
M>J9W>XQ/9Q1XI(HQ4[UYX8?W0*E[3860+EA\\H+2Q,YRW)\YLL=SOYPDH"9T
MH9CQC01UE)6V>:=VIY)^9CIWW8]#4QAY-8OP0#IZNHA5+B%\=81&P]UR&JDR
ML==S *4ZGS-SX:$+C!9TV)S'>-%U^)B$98EW/I0P4HYXHH^N/]YZ/HK@+?1\
M"X6-PR=QB;,%L1UR;ZXHGFMS2ZCXBTQT/Z.?>!!U9IY&9.5VO9C:4A1X,9,Q
M/X]YV(TJ+<Y[M(:FPJYQ*KREL)9R#+;9G<URW+"<BJ%SQJHG=V]T[:.N9%UV
M3)TA4:)WSI93/SUYA8\D+;%[;H>0O6"">VM2K-V"'FT_FXF!W&\+B5Z!KG#(
M=JV!C'*48\B!>'1_41&!<G:+/H>!C7C=++.!V'N;O$F MG4;J\F AW8 FF.
M7W;:B$N 1G>V=;* .WBB8NZ 1'FG4%N 77K!/@2 FGP$+'F!!GV NR9_%W[9
MJHQ_!G[&F5A^\7ZPAS9^[WZC=+E^^WZK8AQ_('[%3[1_6G[F/9!_O'\4+$:
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MA'TQAZ"D"GCR>VN@JGE%;LR=1'FK8:B9W7HR5%>69GK91Q>2WGNB.F"/.'R
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MA<F$#J+E=^^##9[W::6"$YJO6U.!3Y9D32. QY(4/X. 68VU,FV 'HDM)J:
M (2IC"B7 V2M@!Z4T&<@<UF2U&F#9=^0Z&OC6 2.ZVY72AF,X7#V/*"*S7/
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MPI7'?1]J^9+P;"QM89 66S=O_HTT2JQRRHHZ.H9UXX<3*WMY.X.HK-!C>*1
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M3$R!TG:Y0*J!I7@\-9J!B7G5*SV!CWN5(DV!KGUJ> >!(GB=;8Z ^GED8IN
MQWH65T6 DWJ]2]F ;'MM0%6 ;'PO-7* >'S^*T: IWWA(H: [G[,=T9_FW_T
M;-U_CX >8?M_<( A5KY_38 *2VU_/G_T0#-_4'_O-6E_A'_U*U5_W7_\(K6
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M*0N#3W)4(&.#U'=S<KY_DET<:0Q_RF!&7J^ !F-O4]F 0V:E2+* A&GV/92
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M03Z"3W*C-[*"*73P+LR"$G=9)J>"''GL']^"/7R(9<> QW$L7/& XW*@4\*
MX'0-2E> RG5Z0-^ OG< -W. RWB>+KN YGI.)L6!('P9("J!;'WA91-^]7?R
M7$U_-7C64S-_3WFC2=E_6'IF0'M_:GLW-U)_E'P?+K=_W'T5)N& 17X6(&F
MO'\-9'9]9'Y]6[M]RW[24K)^ 7[[26U^(7\10"1^4'\P-RA^F']?+M!^]'^?
M)P1_B7_<()V *X .8_M\*(3?6VI\M(2O4G%\^X0J23Y]'(-[0 A]58+A-P9]
MOX);+K1^/8'J)Q=^[X%K(,=_M8#E8YI[*HL%6P][RHI/4AU\(XD:2/E\48>L
M/]M\E895-O!]#H46+K%]IH/J)R1^>(*W(.A_5X&47N.3B%395IZ2%5B33@J0
MJEQF11V/)6!A/ 2-?F2.,Q2+R&CZ*LN*%FV8(TV(?W*%'2:'''>07@B0^UN#
M5?>/QEZW37>.=F(#1+&-!F5P.\B+>6D),PJ)ZFS8*O:(9'#2(ZJ&_G4,':^%
MRWE575B.9V(5546-9&3#3.N,/6>#1#J*[VIB.WV)C6UD,O"(+G"5*Q"&V7/G
M(_6%IW=L'B:$I7KR7+&+^VB25)N+(&JX3$.*'FSK0\B(^V\V.RN'R'&A,LR&
MFW0N*QV%>G;6)#"$>WFC'HV#J'QE7 V)VF\#5 *))G"B2[>(17)%0TN'07/Q
M.NN&-76^,JN%.'>G*R2$1GF@)&&#=WNP'N."T'VN6W6("W5A4WN'?G9\2T>&
MNG>(0N^%T'B5.J:$X'FV,I^#_WKV*S&#-WQ )(F"EWV0'RN"&W[,6O*&AWN-
M4PV&'WPG2NV%<WR80JF$FWS^.FZ#PWUW,H6"_GX(*T>"37ZG)+"!V'\\'V>!
MA7^_6H>%1H%P4J6$_8&!2H^$:(%40ER#HH$2.C2"W8#E,E""-X#**S^!DX#$
M)-N!,H"P'Y>!#("*6C.$2(=(4H&$)X;K2GF#IH8)0E^"SX3T.F*!^X0.,J"!
M6H--*WR WX*E)/V LH'J'[V K($O5-R<AE0C38N:6E?71?N8(%NO/A^5KE_
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M<%E#7JMQCUV44@YSSF'^165V/F:7.3QXWVMJ+:U[TG"O(WM^^'9[@&)G85D
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M5DYWF&X&3>-XP6_S149YW''J/*5[!G0 -!=\3G8V+$)]HWB!)3!_$7KJ'VN
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M(82!&7[Y'=J!+'^T2?N ?'ZE0Y>!4G[;/56!G7[F-S&!;'[Y,22!#W\P*U2
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M@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM.
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MHS4B_Z!"-_^F047_KSU0_K@[6?/$/&'FT4-DV=]#<\C<2H6WT%>5JL=EHJ#
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MQHJ.K,;_GS8:_YQ#+O^?1C[_I45*_ZM%5?RP1F'VMDEK\+Q.=.?"57O?R&&
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M?F11](!E4?2 95'T@&51](!E4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
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MJJ;-<+&HS6^YJ<MOP:G#<<&IO'+ JK=SP*JW<\"JMW/ JK=SP*JW<\"JMW/
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M<E#IE7-0Z95S4.F5<U#IE7-0Z95S4.F5<U#IE7-0Z95S4.F5<U#IE7/6O@<
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MVU-*J-596IS07VB0S&5SALEK?7W&<85UQ'>+;L-^D&G!AI1DP(^78,":FEW
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M4?]^;EK[>7=B]W6":?1QBF[Q;9)S[FN9=NQHGWGK9J1[ZF2J?>ECKW_H8K6
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MS)F4>LR9E'K,F91ZS)F4>LR9E'K,F91ZS)G_?B(&_X(R$/^2-Q?_G#T?_Z%
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M;D;MQVY&[<=N1NW';D;MQVY&[<=N1NW';D;MQV[_IP\ T[H' ,7'!P"ZU@D
MK?H3!J+Z(A*7^B\?C?LZ*X/\0S5Z_4P^<?U116C]5DMA_EM/7/YB4U?^:%94
M_6]84?MU6D[Z?%Q,^8-=2OB*7TCWD6!']IEA1O:@8D7UIV-$]+%D0_2U9$/T
MM61#]+5D0_2U9$/TM61#]+5D0_2U9$/TM636L@0 Q+X& +?,!@"LW D!H/\6
M")7_)12+_S(?@O\\*7G_13)O_THY9_]//U__54-:_UM'5?]A2E+_9TQ/_VQ.
M3?]R3TO_>%%)_WY21_^$4T7_BU1#_Y%50OZ85D']GE= _:980/RI6$#\J5A
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M7U2?L&5?EJQK:8ZH<G&&I7AX@*)_?GJ?AX-TG8^(;YN9BVR:I(UIFK".9YO
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M?%.\XGQ3O.)\4[SB?%.\XGQ3O.)\4[SB?%.\XGS_BA0!_Y\8 ?^P% '8PPH
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M2NR,34CLEDY%[:%00^VN44+NO%%![\Q20>_E4D#M\5% [?%10.WQ44#M\5%
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M;%J>[6Q:GNUL6I[M;%J>[6S_?! !_XX0 /:>#0#8K0D S;@) ,?$" "^RA0
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M84VW]6)-MO5B3;;U8DVV]6)-MO5B3;;U8DVV]6+_B0L X9P# -"J!0#%M04
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M=/LF!6S\, IE_#@07OU %5C^1QE3_DT=3_]4($O_6B)(_V$E1?]G)D+_;2A
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M8UR5]6)>D_5B7I/U8EZ3]6)>D_5B7I/U8EZ3]6+_=0X _X8- .N6" #5HP<
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M3D7"_TY%PO].1<+_3D7"_T[?D   S)\  +^J 0"SLP$ J;T" )_'!0"6T@D
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M)P-J[C((9.X[#5[N0Q-8[DL74^Y2&E#O61Y,[V @2>]G(T?O;R5$\'<G0?"
M*3_PBBH]\94L._&A+3GRKBXX\KXO-_/0+S?SYR\V\?,O-O'S+S;Q\R\V\?,O
M-O'S+S;Q\R^YIP  J[   )^[  "2Q@  AM ! 'O=!0!T]Q$ ;?<< 6;X)@-?
M^"\&6ODX"E3Y0 Y0^D<13/I.%$C[519%^UL80OMB&D#\:!P]_' =.OUX'SC]
M@B V_8TB-/Z8(S+^I"0Q_[$E,/^_)B__SR8N_^,F+O_C)B[_XR8N_^,F+O_C
M)B[_XR:MK0  G[<  )+"  "&S0  >=H  '#R" !H_Q$ 8?\: 5K_(P-4_RL$
M3_\S!DK_.PA&_T(+0_])#4#_3PX]_U40.O];$3C_81,U_V@4,_]O%3#_>!8N
M_X(7+/^-&2K_F1HI_Z0:*/^O&R?_NAPF_\<<)O_''";_QQPF_\<<)O_''";_
MQQRAM   D[\  (;*  !XU@  ;.(  &/\!P!<_P\ 5?\6 4__'@))_R8#1/\N
M!$#_- 4\_SL&.?]!!S;_1@@S_TP(,?]1"2[_5PHL_UT**O]D"RC_; PE_W4-
M(_]_#B'_B@\@_Y40'O^@$![_J!$=_[$1'?^Q$1W_L1$=_[$1'?^Q$1W_L1&5
MO   AL<  'G3  !KX   7NT  %;_ P!/_PP 2?\2 4/_&0$^_R ".?\G S7_
M+0,R_S,$+O\X!"O_/04H_T(%)O]'!23_3 8B_U$&(/]7!AW_7@<;_V4'&?]N
M"!?_> @5_X,($_^-"1/_E@D2_YX)$O^>"1+_G@D2_YX)$O^>"1+_G@G_0BT#
M_T(R!/](,@3_3#8&_TX\"/]01P[_4%(5_TY?&O]+:Q__2'<D_T6#)_]"CBK_
M09<L_S^@+O\_IR__/JXP_SVU,?\]O#+_/,4R_SS.,_\[WS/_.^HT_SOS-/\[
M^S3_//\S_CS_,_P]_S3V/_\U]3__-?4__S7U/_\U]3__-?4__S7_0RP#_T0P
M!/]*, 3_3C0&_U$Z"/]31@[_4E$5_U%=&O].:2#_2W0D_TB */]%BRO_0Y4M
M_T*=+_]!I3#_0*PQ_S^S,O\_NC/_/L(T_S[,-/\^W#7_/>@U_SWQ-?\^^C7]
M/O\U^S__-/@__S;R0?\W\$'_-_!!_S?P0?\W\$'_-_!!_S?_1"P#_T<N _]-
M+@3_43(%_U0Y"/]71 [_5D\5_U1:&_]19B#_3G(E_TM]*?](B"S_1I(N_T6;
M,/]$HC+_0ZDS_T*P-/]"MS7_0;\V_T')-O] US?_0.4W_4#P-_I ^#?W0?\V
M]D'_-_)!_SCL0_\YZD3_.>I$_SGJ1/\YZD3_.>I$_SG_12L#_TDL _]0+ 3_
M52\%_UDW"/]<0@[_6TT5_UA7&_]68R#_4F\E_T]Z*O],A2W_2H\P_TB8,O]'
MGS3_1J8U_T6M-O]%M#?_1+PX_D3&./Q$TCGY0^(Y]D3N.?-$]SGQ1/\Y[T3_
M.NM%_SOD1O\\XT;_/.-&_SSC1O\\XT;_/.-&_SS_1BL#_TTI _]4*03_62P%
M_UXU!_]A0 W_84H4_UY4&O]:7R#_5VLF_U1V*O]1@2[_3HLQ_DR4-/Q+G#7[
M2J,W^DFJ./A(L3GW2+DZ]D?"._5'S3OR1]\[[D?L.^M(]COI1_\]YT?_/N%(
M_S_:2O] V$K_0-A*_T#82O] V$K_0-A*_T#_1RH#_U G _]8)@/_7BH$_V,S
M!_]F/0W_9D<3_V11&O]@6R#_7&<F_5ER*_I6?2_X4X<S]E&0-?10F#?R3I\Y
M\4VF.^],K3SN3+4][$N^/>M+RC[I2]P^Y4SJ/>)+]3_?2_Y!W$K_0M1,_T/-
M3?]#RT[_0\M._T/+3O]#RT[_0\M._T/_2B@#_U0D _]<(P/_8R@$_V@P!O]L
M.PO_;$02_VI.&?YF6!_Y86(E]5YM*_);>##O6((T[%:+-^I4E#GH4YL[YE&C
M/>51JC[C4+(_X4^[0.!/QT#>3]A!V4_H0=1/]$/03OY%SD[_1LA0_T;"4?]'
MP%'_1\!1_T? 4?]'P%'_1\!1_T?_324"_U<A O]@( /_:"8#_VXN!?]R. K_
M<D$0_7!+%_=M5!WR:%XD[61I*NEA=##E7GXTXEN'..!9CSO=5Y<^VU6?0-A4
MID+54ZY#TE*W1-!2PD7.4M!&RU+E1LA2\DC%4OU)PE+_2KQ4_TJW5?]*ME7_
M2K95_TJV5?]*ME7_2K95_TK_4","_UL> O]D'@+_;20#_W,K!/]W-0C^>#X.
M]G='%/!T4!OJ;UHBY&ME*>!G;R_;8WDUUF"".M)=BC[/6Y)!S%F:0\I8H47(
M5ZE'QE:R2<16O$K"5<E+OU7?2[Q6[DRY5OI-MU;_3;)8_TVN6?]-K%G_3:Q9
M_TVL6?]-K%G_3:Q9_TW_4R "_UX< O]H' +_<2("_W@H _]\,0?X?CH+\'U#
M$>EZ3!CB=E<?W')A*-1M:R_/:70VRV5].\=BA4#$8(U#P5Z51K]=G$B\6Z1+
MNEJM3+A9MTZV6<-/M%G53[%:ZE"N6O=0K%K_4*A;_U"D7/]0I%W_3Z1=_T^D
M7?]/I%W_3Z1=_T__5AX"_V$9 O]L&@+_=2 "_WPE _V!+@7SA#<)ZH0_#N*!
M2!7;?5,=T7==)\MR9S#&;G WPFIX/+YG@$&Z98A%MV.02+1AF$NR7Y]-KUZH
M3ZU=LE&K7;Y2J5W.4Z9=Y5.D7O13HE[_4Y]?_U*<8/]2FV#_4IM@_U*;8/]2
MFV#_4IM@_U+_6!P"_V07 ?]P&0'_>1T!_X C OB&*@/MB3(&Y(H["MR(11+1
M@E <RGU:)L1X8R^^<VPWN6]T/;5L?$*R:H1&KF>,2JMEDTVH9)M/I6*D4J-A
MKE2A8;E5GV'(5IUAX5:;8O%5F6+]59=C_U259/]4E&3_4Y1D_U.49/]3E&3_
M4Y1D_U/_6AH"_V<5 ?]S%P'_?1L!_X0@ ?.*)@+HCBX$WY V!]2,01'+ATT;
MQ()7)KU]8"^W>&DVLG1Q/:YQ>$*J;H!'IFR(2J-JCTZ@:)A1G6>@4YIFJE68
M9;57E67$6)1EVUB29N]7D6;\5X]G_E:.9_Y5C6C^58UH_E6-:/Y5C6C^58UH
M_E7_7!@!_VD3 ?]V%@'_@!D!_8@= >^.(@'DDRD"VI0Q!LZ0/P_&BTL:OH95
M);>!7BZQ?68VK'EN/*=V=4*C<WU'GW"$2YQNC$Z8;)12E6N=5))JIU>0:;)9
MC6G 6HQIU5J*:NQ9BFKZ6(EK_5>':_U6AVO^5H=K_E:':_Y6AVO^5H=K_E;_
M7A<!_VP2 ?]X% '_@Q< ^8L: .N2'0'@F",!TY@O!<J4/0[!CTD9N8I3)+*&
M6RVL@60UIGYK/*%Z<D*==WI'F76!2Y5SB4^1<9%2CF^:58MNI%B(;:]:AFV]
M6X1MT%N#;NE:@V[X68)O_%B";_U7@F_]5X)O_5>";_U7@F_]5X)O_5?_8!4!
M_VX1 ?][$P#_AA0 ]H\6 .>6& #;G!P SYLM!,67.PV\DT<8M(Y1(ZV*62RG
MAF$TH8)I.YQ_<$&7?'=&DWE^2X]WAD^+=8Y2B'.7581RH5B"<:Q:?W&Z7'YQ
MS%Q]<N=;?7+V6GQR_%E\<OQ7?'+]5WQR_5=\<OU7?'+]5WQR_5?_8A0!_W$1
M ?]]$0#_B!( \I(2 ..:$@#5GQD RIXK!,&;.0RXET47L))/(JF.6"NBBE\S
MG(9G.I>#;D"2@'5%C7Y\2HE\A$Z%>HQ2@GB55GYWGUA[=JI;>76X7'=UREQW
M=N5<=W?U6G=V^UEW=OQ8=W;\5W=V_%=W=OQ7=W;\5W=V_%?_9!(!_W,0 /^
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M6FN ^UEL?OQ8;7[\6&U^_%AM?OQ8;7[\6&U^_%C_:1 !_W@. /^%# #BD@@
MU9L) ,ZC"0#'J!( O:@E K2F- FKHD 3HY]*'IN;4B>4F%HPCI5A-XB2:#V"
MD&]#?HYV2'F,?4QUBH50<8B.5&V'F5=JAJ199X6Q6V6%PEMEA=Q;987P6F:%
M^UEG@_Q89X/\5V>#_%=G@_Q79X/\5V>#_%?_; X _WL, /*)"0#9E08 SYX(
M ,FF" #!JQ  N*LB J^J,@BFISX2GJ1('):A426/GE@NB)M?-8*99CQ]EFU!
M>)1T1G.2>TMOD(-/:X^,4F>.EE5DC:)888RO65^,P%I?C-E97XSN65^,^UAA
MBOU788G]5V&)_5=AB?U788G]5V&)_5?_;PP _W\) -^- P#2F 8 RJ(& ,*I
M!@"ZKPX LK @ :FN+P:AK#P0F*E&&I&G3R.)I%8L@Z)=,WV?9#EWG6L_<IMQ
M1&Z:>4AIF(%,99>*4&&5E%->E:!56Y2M5UJ4O5A9E-17693L5UF3^59;D?Y5
M6Y#^55N0_E5;D/Y56Y#^55N0_E7_<PD ]80$ -B1 P#,G 4 PZ4% +NM! "S
MLPP J[4< :.T+ 6;LCD.DK!$%XJM32"#JU0I?:E<,'>G8C9QI6D\;*1O06BB
M=T5DH7])7Y^(3%R>DD]8GIY25IVK4U2=O%13G=%44YWK4U.<^%-4FO]35)G_
M4U29_U-4F?]35)G_4U29_U/_> 8 X8D  -"6 @#&H0, O*D# +.P 0"KN @
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M&"_ZH1DN^J\:+?N^&BS[SQLK^^<;*_OK&RO[ZQLK^^L;*_OK&RO[ZQNHJ@
MFK0  (V_  " R0  =-,  &?>  !>\@@ 6?X1 %/_&@%._R,"2?\K T7_,P1!
M_SH%/O]!!CO_1P<X_TX(-?]4"3/_6@DQ_V$*+_]I"RS_<@PJ_WT-*/^(#B;_
ME0\E_Z$0)/^N$2/_NA(B_\H2(O_0$B+_T!(B_] 2(O_0$B+_T!*<L@  CKP
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M3GEO_DUY;_],>6__2WEO_TMY;_]+>6__2WEO_TO_8 \ _VT- /]Y# #N@PL
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M2V2 _TMD@/]+9(#_2V2 _TO_:0@ ^W@$ -R$ 0#/CP0 QI<% +^=!0"WH0P
MKZ,< *>B+ 2?H#D+F)Y#%)&;3!R*F%0CA)9<*G^48C!ZDFDU=9!P.G&.=SYM
MC7]":8N(1F6*DDEBB9Y+7XBJ35Z(NDY<B,Y.78CI35V'^$Q=A_]+7H;_2UZ&
M_TM>AO]+7H;_2UZ&_TO_;04 ZGP  -6(  #*D@, P9H# +F@ P"QI@D J:<9
M **G*0.:I38)DJ-!$HNA2AJ$GU(A?IU:*'F;8"YTF6<S;Y=N.&N6=3QGE'U
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M*C_(L2L^R<0K/LGA*C['\BL]QOPM/,7_+CS%_RX\Q?\N/,7_+CS%_R[$DP
MMI\  *FF  "=K@  DK<  (:_  ![QP, <,\' &?6#0!DUQH 8-@J 5S8-@-8
MV$$&5-A*"E#84@U-V%H02M=B$T?7:19%UW(80M=\&D#8AQP]V),>/-BA'SK9
ML" YV<,@.=G?(#G7[R XU?DB-]3_(S?4_R,WU/\C-]3_(S?4_R.YG   JZ0
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M"1[_N@D=_\D)'/_="1S_W0D<_]T)'/_="1S_W0F8L   BKH  'S$  !OS0
M8M@  %7>  !)Y   1/L% #__#@ [_Q4 ./\< #3_) $Q_RL!+?\Q 2K_-@(G
M_SP")?]" B/_2 (@_TX#'O]5 QS_70,9_V<$%_]R!!7_?P04_XP%$_^:!1+_
MI@41_[(%$?^\!1'_O 41_[P%$?^\!1'_O 6,N   ?<(  &_,  !BV   5-\
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M0(E?_S^)8/\^B&#_/HA@_SV(8/\]B&#_/8A@_SW_5P\ _V(, /]L# #X= P
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M0'%P_T!Q</] <7#_0'%P_T#_7P@ _VL$ .%V  #4?P, RX8% ,6+!@"^C0T
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M.VE_D#YF?IM!8WZH0V%]MD1@?<E$7WWE0V!]]D)@??]!87W_0&%]_T!A??]
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M-TN>KSA*GL$X29[=.$F=\#A)G/PX29O_.4F;_SE)F_\Y29O_.4F;_SG;>@
MR(<  +R2  "QF@  IJ   )RF  "1K   A[$( (&R%@!\LR8!=K(S!'&R/0EK
ML4<.9K!/$V*O5AA>KET<6JUD(%>L:R-4K',F4*M\*4VJABQ*JI(O2*F?,$:I
MK3)%J;\R1*K:,D2H[S)#I_LS0Z;_,T.E_S1#I?\T0Z7_-$.E_S30@0  P8X
M +68  "IGP  GJ4  ).L  "(L@  ?+D" ':Z$0!RNR$ ;KLN FB[.@9DND,*
M7[I,#ENY4Q)7N%H65+AA&5&W:1Q.MW$?2[9Z(DBVA"5%MI G0[6=*4&UK"I
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M%S70[!8TS_<8,\[_&C/._QHSSO\:,\[_&C/._QJSF0  IJ$  )JI  ".L0
M@;D  '7   !JQP  7LT# %34" !,W0T 2MT8 $C>)@!&WC(!1-\\ D+?10,_
MWTT$/>!5!3O@708YX&8(-^!O"37A>@HSX88,,>&4#3#BHPXNXK,.+N/'#BWC
MXPXMX/(.+-_[#RS?_1 LW_T0+-_]$"S?_1"HH   G*<  (^P  "#N   =L$
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M @S_P@(,_\("#/_" @S_P@*'M@  >;\  &O)  !>TP  4-L  $/@   XY0
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M+I]/_RZ>3_\NG4__+IU0_RZ=4/\NG5#_+IU0_R[_3!  _U0- /]=#@#_8P\
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M-'Y@_S1^8/\T?F#_-'Y@_S3_50@ _V $ .AI  #:< , T'4% ,IX!P##>@\
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M-EE_KS=7?\ X5W_:-U=_\#=8?OTV6'[_-5A^_S58?O\U6'[_-5A^_S7I:
MU'0  ,9^  "[AP  LHT  *B1  ">E   EI8. )&7' "+ERL"A98W!7^400IY
MDTD0=))1%7"06!ELCU\=:(YF(66,;25ABW0H7HI]+%N)AR]8B)(Q58>?,U.'
MK352A[XU48?6-5&&[C52A?LT4H7_-%*%_S-2A?\S4H7_,U*%_S/C;   SGD
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M)T&CZB= HO@H0*'_*4"@_RE H/\I0*#_*4"@_RG)?@  NHL  *^4  "CF@
MF*   (VE  ""J@  =;   &RS# !IM!@ 9;0G 6&T,P)>M#T$6K1&!U:S3@I3
MLU4-4+-<$$VR8Q-*LFL61[%T&$6Q?AI"L(H=0+"7'CZPIB \L+<@/+#,(#RO
MZ" [KO<A.JW_(CJL_R,ZK/\C.JS_(SJL_R/ A@  LY(  *>9  "<GP  D*8
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M"";8_@DFV/X))MC^"2;8_@FDG0  F*4  (NM  !^M   <;P  &7#  !9R0
M3<T  $/3 0 ZV08 ->0- #/D%@ QY"  ,.4J "[F,P MYCP *^=$ "KG3 $H
MZ%0!)^A= 27I9P(CZ7,"(NJ! B#JD0,?ZZ$#'>NR QSLQP,<[.$#&^KQ QOI
M^0,;Z?D#&^GY QOI^0.:I   C:P  '^U  !RO0  9<4  %G+  !,T   0=4
M #C<   OX0( +?$- "OQ$P H\AP )O(D "3S*P B]#( (?0Y !_U00 =]4D
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M&;L\_QJZ//\;N3S_&[@\_QNX//\;N#S_&[@\_QO_/A0 _T00 /]*$0#_3Q0
M_U$; /M2(P#Q42T!Z4\X >)-10/<2U$%UDE<"-%'9@O.1G .RT5X$,A$@!+&
M0X<4Q$*.%<-"E1;!09P7OT&D&+U K!F\0+8:ND#"&KA TANU0>@;LD'V';!!
M_QZN0?\>K4'_'JQ!_QZL0?\>K$'_'JQ!_Q[_0A$ _T<- /]/#@#_4Q$ _U85
M /-7' #H5B4 X%4Q ==3/P+/4DP%RE!7"<9.80W#3&H0P$IR$KU)>A6[2((6
MN4>)&+='D!FU1I<;LT:?'+%%IQVP1;$>KD6\'ZQ%S!^J1>,@IT;S(:5&_R&C
M1O\BHD;_(:)&_R&B1O\AHD;_(:)&_R'_10X _TL* /]3# #_5PT ^5H0 .M;
M% #?6AP U%HK ,Q:.P+&6$@%P593";Q47 VY4F41M5!M%+-/=1>P3GP9KDV$
M&JQ,BQRJ2Y(>J$J:'Z9*HR&D2:PBHTFX(Z%)QB2?2MXDG4KP))M*_2692_\D
MF4O_))A+_R282_\DF$O_))A+_R3_2 P _T\( /]6" #U6PD Z5X* .1>#0#5
M7Q4 RV G ,1?-@*^7D,%N%M.";196 ZP5V$2K%5I%:I4<!BG4W@:I5)_'*)1
MAAZ@4(X@GD^6(IQ.GR.:3J@EF$ZS)I=.PB>53M8GDT[L)Y%/^R>03_\GD%#_
M)H]0_R:/4/\FCU#_)H]0_R;_2@D _U,% /A:! #B7P, VF(& -1C"0#-8Q(
MQ&4C +QE,@*V8T %L6%+":Q>5 ZH7%T2I5ME%J%9;!B?6',;G%9Z'II5@B"8
M5(HBE522))-3FR:14J4GCU*P*8U2OBJ,4M JBE/I*HE3^2F(5/\IAU3_*(=4
M_RB'5/\HAU3_*(=4_RC_3 4 _U8! .E=  #<8P( T6<% ,QH!P#&:!  O6H@
M +9I+P&P:#P$JF5'":5C40VA85H2G5]A%II>:1F77' <E5MW'I):?B&0688C
MC5B.)8M7ER>)5Z$IAE:M*X56NBR#5LPL@E?F+(%7]RN 6/\J@%C_*H!8_RF
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M+F9KKR]D:K\P8VO8,&-K[R]D:_PM9&O_+65K_RQE:_\L96O_+&5K_RST6P
MW68  ,MO  # =@  MWL  *]^  "F?@$ GW\0 )F 'P"3@"T"C7\Y!8A]0PF#
M>TL-?GI3$GIX6A9V=V$9<W5G''!T;A]M<W8B:G)_)FAQB2AE<)0K8G"@+6!O
MK2]?;[TO7F_4+UYO[2]?;_LM7V__+&!O_RQ@;_\L8&__+&!O_RSK7@  V&D
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M*TZ"Z"M.@?@J3X#_*D^ _RE/@/\I3X#_*4^ _RG;:@  QW4  +I_  "PAP
MIHP  )R/  "/D0  AI,% ("4$@![E2$ =Y4M 7*5. 1ME$(':9-*"V6240YB
MD5@27I!?%5N/9AA8CFT;58YV'E*-@"%/C(LC38N8)4N+I2=)B[4H2(O**$B*
MYR=)B?<H28C_)TF'_R=)A_\G28?_)TF'_R?1;P  P7L  +6$  "KC   H)
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M&3:F_QHVIO\:-J;_&C:F_QJZA   KH\  **6  "7FP  BZ$  '^F  !SJP
M9Z\  %JT  !3M@P 4;<7 $^W) !-N#  2K@Z 4BX0P)&N$L#1+A2!$&X6@8_
MN&('/;AK"3JX=0LXMX$,-K>.#C2WG0\SMZT/,K?!#S&WW@\QMO(0,+3\$3"S
M_Q(PL_\3,+/_$S"S_Q.RC@  I94  )J;  ".H@  @J@  '6M  !ILP  7K<
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M 1/C^@&6H@  B:D  'NQ  !NN0  8<   %3&  !(R@  /<\  #/3   JV0
M(MX" ![K"@ <[!  &^T7 !GM'P 7[B8 %>XM !3O-0 3\#T $?!& !#Q4  /
M\EL #O)I  WS>  ,](H "_6<  KUK@ )]L( "?;9  CU[0 (]>T "/7M  CU
M[0"+J0  ?;(  &^Z  !BP@  5<D  $?.   [T@  ,=@  "?=   ?X0  &>@
M !;X!@ 4^@T $OL2 !#\%P ._!T #?TC  S]*0 *_C  "/\X  ;_00 #_TP
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M!MXD_P?<)/\(VR3_"=HD_PG:)/\)VB3_"=HD_PG_+AL _S$7 /\R%@#_-1P
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M%J@\_Q:G//\6ISS_%J<\_Q;_/0T _T(( /]("@#_2PP ^DP/ .Q,% #A2AT
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M_R#_2@  Z50  -I<  #,80  PV0  +QD @"V8PH KV07 *EE)P"C9#0"GF-
M!)EA2@>57U(+D5Y:#HY=81&+6V@3B5IO%H99=AB$6'T:@5B&'']7CQY]5ID@
M>U:D(GE6L2-W5L$D=E;:)'57[R1U5_TC=5C_(G58_R%U6/\A=5C_(758_R'_
M30  Y5<  --?  #(9   OV<  +=H  "Q9P< J6@4 *-I) ">:#(!F6<]!)1E
M1P>09$\*C&)7#8AA7A"%7V43@UYL%H!=<QA]77H:>UR#'7E;C!]V6Y<A=%JB
M(W):KR1Q6K\E<%K5)6];[25O6_PC;UO_(F];_R)O6_\A;UO_(6];_R'Z3P
MX5H  ,]B  #$9P  NVL  +-L  "L:@0 I&L2 )YL(0"9;"\!E&LZ X]I1 :*
M:$T)AF95#8-E7!" 9&(3?6)I%7IB<!AX87@:=6" '7-?BA]P7Y0A;EZ@(VQ>
MK25K7KPF:E[1)FE>["5J7_LD:E__(VI?_R)J7_\B:E__(FI?_R+P4@  W5T
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M)EIKYR5;:_<D6VK_(UQJ_R)<:O\B7&K_(EQJ_R+C6P  SF8  ,!N  "V=
MK'D  *-[  "8>0  D'H+ (I[%@"%?"0 @7PQ 7Q[.P1W>D0&<WE,"G!X4PUL
M=UH0:79A$V=U:!9D=&\887-X&UYR@1U<<8P@6G&8(EAPIB16<+4E57#()55P
MY255</8D5F__(U9O_R)7;_\B5V__(E=O_R+?7P  RFD  +QR  "R>   J7T
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M'D6"_QY%@O\>18+_'D6"_Q[*;0  NG@  *^!  "EAP  FHL  (^-  "!C@
M=)$  &Z3"@!IE!4 9I4B &.5+@%@E3@"7)5!!%F42096E% (5)-7"E&37@Q.
MDF8/3))N$4F1>!1&D(,61)"0&$*/GAE CZT:/X_ &C^/W!H_C?$:/XS]&S^+
M_QL_B_\;/XO_&S^+_QO"<P  M7X  *J'  "?C   E)   (B3  ![E0  ;)D
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M"RJM_PNMBP  H)(  )68  ")G0  ?:,  '&H  !DK0  6;$  $VT  !"N
M.[H* #B[$P WO!X -;PI #2],@ SO3L ,KU$ #&^3  OOE4!+KY> 2R^: $J
MOG0"*;Z" B>_D0,FOZ(#)+^T R._RP,CON@#([SW!"*[_P4BN_\%(KO_!2*[
M_P6DD@  F)@  (R>  " I0  <ZL  &>P  !;M0  3[D  $2\   ZP   ,,0$
M "K'"P HR!, )\D= ";))P ER3  ),HY "/*0@ BRTL (<M5 "#,7P ?S&P
M'<UZ !S-B@ ;S9P &<ZN 1C.Q0 8S>0 &,ST 1C*_ $8RO\"&,K_ AC*_P*;
MF0  CY\  (*F  !UK0  :+,  %RY  !0O0  1,$  #G$   PR   *,P! "#0
M!@ 9U0L %M<0 !78&0 5V2( %-DK !/:-  3VCT $MM( !'<4P 1W5\ $-UM
M !#>?@ .WY$ #N"D  W@N  ,X-( "]_M  S>]P ,W?L #-W[  S=^P"2GP
MA:<  '>N  !JM0  7;P  %#!  !$Q0  .,D  "[-   ET0  'M4  !;: 0 1
MW@8 $.<-  [G$@ -Z!D #.@A  OI*0 *ZC$ ">H[  ?K10 %ZU$ !.M>  /K
M;@ !ZX   .J4  #JIP  Z[P  .O2  #KZ0  [.\  .SO  #L[P"'IP  >:\
M &NW  !>O@  4<4  $/)   WS0  +=$  "/6   ;VP  $]\   [C   ,[@(
M"O8*  ?V#@ %]A(  _88  #U'@  ]24  /4N  #U-P  ]D(  /9.  #V70
M]FX  /:!  #VE0  ]Z<  />W  #XQP  ^-   /C0  #XT ![KP  ;;@  &#
M  !2R   1,T  #?1   KUP  (=P  !C@   1Y   #.<   ?O   $^@   ?\#
M  #_"   _PT  /X0  #^%   _QH  /\A  #_*0  _S,  /\^  #_2P  _UL
M /]L  #_@   _Y(  /^A  #_K0  _[,  /^S  #_LP#_'"8 _QPD /\:)0#_
M%2< _Q$N /\0.@#_#D<!_PU3 ?\+7P'_"FL!_PIU ?\*?P'_"H<!_PJ. ?\*
ME0'_"IL!_PF@ ?\)I0#_":L _PFQ /\)N #_"<$ _@G, /P)W@#Y">L ]0GV
M /,)_P#R"O\ \0K_ ?$+_P'Q"_\!\0O_ ?$+_P'_'R, _Q\A /\>(0#_&20
M_Q<L /\5-P#_$T0 _Q%0 ?\07 '_#F<!_PYR ?\.>P'_#H0!_PZ+ ?\.D@'_
M#I@!_PZ= ?\.HP'^#J@!_ ZN ?L.M0#Z#KX ^ [) /4.VP#R#NH [@[U .P.
M_P'K#_\!Z@__ >H0_P'I$/\!Z1#_ >D0_P'_(A\ _R(< /\A' #_'R  _Q\I
M /\<- #_&D  _Q=, ?\56 '_%&,!_Q-N ?\3=P'^$X !_!.( ?H2C@'Y$I4!
M^!*: ?82H 'U$J8!]!*L ?,2LP'Q$KP!\!+' >T2V 'I$^@!YA/U >04_P'B
M%/\"X17_ N$5_P+@%?\"X!7_ N 5_P+_)1L _R87 /\D%@#_)1P _R8E /\D
M, #_(3L _Q]( /\=5 ']&U\!^1II ?<:<P'T&7P!\AF$ ?$9BP'O&9$![AF7
M >P9G0'K&:,!Z1FJ >@9L0'G&;H!Y1G% >,9U0'?&N@!W!OU M@;_P+5'/\#
MU!S_ ],<_P32'/\$TAS_!-(<_P3_*1< _RH3 /\I$@#_+!@ _RPA /\L*P#_
M*3< _2=# /<E3P'S(UH![R)D >PA;@'I(7<!YR%_ >4AA@'D(8T!XB"4 >$@
MF@'?(* !WB"G =PAKP':(;@"V"'# M4ATP+1(N<"S2+T \HC_P3((_\%QR/_
M!L8C_P;&(_\&QB/_!L8C_P;_+!( _RX/ /\P$ #_,Q0 _S,; /\R)0#Z,#
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M%X-)L1B"2< 8@4K6&7]*[1A^2_P8?DO_%WU+_Q=]2_\6?4O_%GU+_Q;_0P
MYDP  -93  #)6   P%D  +I8 0"T5@D K%<6 *98)0"A6#(!G5<^ IA62 25
M55$&DE18"(]27PJ,4F8,BE%M#HA0=!"%3WL2@T^$$X%.C15_3I<7?4ZA&'M-
MKAEZ3KT:>$[1&G=.ZQIW3_H9=D__&79/_QAV3_\7=D__%W9/_Q?X1@  XE
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M'65:Y!UE6O8<95K_&V5:_QIE6O\995K_&65:_QGH3P  TUD  ,1A  "Y9@
ML&@  *=I  ">90  EV8- )%G&0",:"< AV<R 8-F/0)_948$>V1-!GAC5 EU
M8EL+<F%A#7!A:0]M8' 2:U]Y%&E?@A9G7HT995Z8&F->I1QA7K0=8%[''6!>
MXQU@7O4<8%[_&V!>_QIA7O\:85[_&F%>_QKD4@  SUP  ,!D  "V:0  K&P
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M&E)J_QI2:O\94FK_&5)J_QG47   PV8  +9N  "L=   HG<  )9V  ")=0
M@78! 'IW#P!V>!L <GDG &]Y,@%K>#P":'A$!&5W3 9B=U,(7W9:"EUU80Q:
M=6@/6'1P$55S>1-3<X0647*0&$]RGAE-<:T:3'&_&TMQV1M,<? :3'#]&DUP
M_QE-;_\936__&4UO_QG.8   OFH  +)R  "H>   G7L  )!Z  "$>@  >GL
M '1\# !O?A< ;'XD &E_+P%F?SD"8G]" U]^205=?5 '6GU7"5=\7@M5?&4-
M4GMN#U!Z=Q).>H(42WF.%DEYG!=(>*L81GB]&49XU1E&=^\81W;\&$=V_QA'
M=?\71W7_%T=U_Q?)90  NF\  *YW  "D?0  F'\  (M_  !^?P  <X$  &R#
M"0!HA!, 984@ &*&+ !?AC8!7(8_ EF%1@-7A4X%5(55!U*$7 E/@V,+38-K
M#4N"= ](@G\11H&,$T2!FA5"@*D608"Z%D" TA9!?^T607[[%D%]_Q9!??\6
M07W_%D%]_Q;":@  M74  *I]  "?@@  DH,  (6$  !YA0  :HD  &2* P!@
MC!  78T; %N.)P!8CC( 58X[ 5..0P)0CDH#3HU2!4R-609)C& (1XQH"D6+
M<@Q"BWT.0(J)#SZ*F!$\BJ<2.XJX$CJ*SQ([B.L2.X?Z$SN&_Q,[AO\3.X;_
M$SN&_Q.\<0  KWL  *6#  "9AP  C(@  '^)  !SC   99   %R3  !7E0P
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M RJLC@,HK)X$)ZRP!":LQ00FJ^0#):GU!"6H_P4EI_\%):?_!26G_P6GB0
MFX\  )&4  "$F0  >)X  &NB  !?I@  4ZH  $BM   ]L   -+,# "^U#@ M
MM18 ++4@ "NV*0 JMC( *;<Z "BW0P GMTP )KA5 "2X7P CN&L (KAX 2"X
MB $?N)D!';FK 1RYP $<N-\!'+;R 1NU_ (;M/\"&[3_ ANT_P*?CP  E)4
M (B;  ![H0  ;J8  &*K  !6L   2K,  #^V   UN0  ++P  "2_!@ ?P@T
M'<(4 !S"'@ ;PR8 &L,O !G$.  8Q$$ %\1* !;%50 5Q6$ %,9O !/&?P 2
MQI$ $<>D !#'N0 /Q]0 $,;N !#$^@ 0P_\ $,/_ !##_P"7E@  BYP  'ZB
M  !QJ0  9*\  %BT  !+N   0+L  #6^   KP0  (\4  !O) 0 4S 8 $- +
M  [1$0 -T1D #=$A  S1*@ ,T30 "](^  K220 )TU4 "=-B  C3<@ &U(0
M!=28  34JP #U<   =7<  '5[0 !U?8  =7V  '5]@".G0  @*0  '.K  !F
ML0  6;@  $R]   _P   -,,  "K'   AR@  &<X  !+2   -U@$ "=L%  ;<
M#0 $W!$  ]T8  '>(   WB@  -\Q  #@/   X4<  .)4  #C8P  XW0  .2(
M  #DFP  Y:X  .7!  #EU0  YN<  .;G  #FYP"#I   =:P  &BS  !:NP
M3<$  $#$   SR   *,P  !_0   7U   $-D   O=   %X0   .0   #E!P
MY@T  .<1  #H%@  Z1T  .HE  #K+@  [3D  .]%  #P4P  \60  /%V  #R
MB@  \YP  /.M  #TNP  ],@  /3(  #TR !WK0  :K4  %R]  !/Q   0,D
M #/-   GT0  '=8  !3<   .X   ".,   'F    Z@   .X   #N    [P0
M / *  #Q#@  \Q(  /08  #V(   ^"H  /HU  #]0P  _E(  /]C  #_=@
M_XD  /^:  #_I@  _[   /^P  #_L #_%B, _Q4A /\1(0#_#20 _PDK /\&
M-P#_ T0 _P!1 /\ 70#_ &@ _P!R /\ >P#_ (, _P"* /\ D0#_ )8 _P"<
M /\ H0#] *8 ^P"L /D LP#W +L ]0#% /, T0#R .0 \0#Q .\ ^@#N /\
M[@#_ .T _P#M /\ [0#_ .T _P#_&2  _Q@= /\5'0#_$!\ _PXI /\,- #_
M"D$ _P=- /\%60#_!&0 _P1N /\#=P#_ X  _P.' /\#C0#] I, ^P*9 /D"
MG@#W J0 ]0*J /,!L #Q ;@ [P'" .T!SP#K >, Z@'O .@"^P#G!/\ Y@7_
M .8&_P#F!O\ Y@;_ .8&_P#_'!L _QL9 /\7& #_%1T _Q,E /\1, #_$#T
M_PY) /\,50#_"V  _PMJ /T+<P#["WP ^0J# /<*B@#U"I  ] J6 /,*FP#Q
M"J$ [PFG .T)K@#K";8 Z G  .8)S0#D">( X@KP -\+^P#>#/\ W W_ -P-
M_P#;#?\!VPW_ =L-_P'_'Q< _QX3 /\;$@#_'!D _QLB /\8+ #_%3@ _Q-$
M /X24 #Y$5L ]1!F /,0;P#P$'< [A!_ .P0A@#J$(P Z1"2 .@0F #F#YX
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M!+,C_P3_*0L _RH% /\N" #_+PP _RT0 /,K%P#H*"( X"8O -DF/0#2)TH
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M")PUM@B;-<4)F37="98V[PJ4-OT*DS?_"I(W_PJ2-_\*DC?_"I(W_PK_,P
M]CH  .0_  #80@  SD(! ,D^!@#$.P\ NSX= +4_+ "Q/SH K3]% :D_3P&F
M/E@"HSU? Z$]9P2?/&T%G3QT!IP[>P::.X('F#N*")8[DPF5.IP*DSJF"Y$Z
ML@N0.\ ,CCO5#(P\[ V*//L-B3S_#8D\_PR(//\,B#S_#(@\_PS_-P  ZC\
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M$W)*XQ-Q2O42<4K_$7%+_Q%Q2_\0<4O_$'%+_Q#L0P  V4P  ,A3  "]5P
MM%@  *Q7  "E4@$ GE,/ )A4' "35"D CU0U (M30 &(4T@"A5)0!()15P5_
M4%X&?5!D"'M/:PEY3W(+=TY[#75.A YS38X0<4V9$6]-I1-M3;,4;$W%%&M.
MX11K3O03:T[_$FM._Q)K3O\1:T[_$6M._Q'H1@  TU   ,16  "Y6@  L%P
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M%%Q9_Q-<6?\27%G_$EQ9_Q+<4   QUD  +I@  "O9   I&4  )ED  "08
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M$4AJ_Q''7@  N&<  *QN  "A<@  DW(  (=Q  !Z<0  <7(  &MT!P!F=1$
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M"#F%D0HXA* +-H2Q"S:$Q@LV@^0+-H+V"S:!_PPV@/\,-H#_##: _PRV;P
MJG@  )]_  "0?@  @W\  '>   !K@@  7H<  %6*  !.C 8 2HX0 $B/&@!'
MCR4 19 O $20. !"D$  0)!' 3^03P$]D%8".Y!? CF0: ,WCW,$-8^ !3./
MC@8QCYX',(ZO!R^.PP<OCN$'+XST""^+_P@OBO\(+XK_"2^*_PFP=@  I7\
M )B$  "*A   ?84  '"'  !EB@  6HX  $^2  !&E0  09@, #Z8%  ]F1\
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M !2RM@ 3LLX $['K !.O^0 3KO\!$Z[_ 1.N_P&:C0  D)(  (27  !UF@
M:)\  %NC  !0J   1:P  #NP   QL@  )[4  ""X   8N@< %+P. !.\%0 2
MO!X $;TF !&]+@ 0O3< $+Y!  Z^3  .OE< #;YE  R_=  +OX8 "KZ9  B^
MK  'OL( ![[?  B^\  (O?H "+W\  B]_ "3E   AYD  'J?  !LI0  8*H
M %.O  !'LP  /+8  #&X   GNP  '[X  !?!   1Q $ #,@(  C)#@ 'R10
M!LD<  7))  $RBP  \HV  +*0   RTP  ,M9  #+:   RWD  ,R,  #+GP
MR[,  ,O(  #,X@  S.\  ,SQ  #,\0"*F@  ?*$  &^G  !BK0  5;,  $BX
M   [NP  ,+X  ";!   =Q   %<@   _+   *S@  !-("  #3"@  TP\  -04
M  #5&@  UB(  -<J  #9-   VC\  -Q+  #<6@  W6H  -U]  #=D0  W:0
M -ZV  #>R   WMX  -[B  #>X@!_H@  <:D  &2P  !6MP  2;P  #S    O
MQ   ),<  !O+   3SP  #=(   ?6    VP   -X   #? P  X D  .$.  #B
M$@  XQ<  .4>  #F)P  Z#$  .H]  #L2P  [%H  .UL  #N@   [I0  .ZE
M  #NM   [L(  .[&  #NQ@!TJ@  9K(  %BY  !+P   /<4  "_)   DS0
M&=$  !'6   +VP   ]X   #A    Y0   .@   #I    Z@   .L&  #M"P
M[P\  / 3  #R&@  ]",  /<N  #Y.P  ^TH  /Q;  #];0  _8   /Z3  #^
MH@  _JT  /ZO  #^KP#_$!\ _PX= /\*'0#_ 2  _P H /\ -0#_ $$ _P!.
M /\ 6@#_ &4 _P!N /\ =P#_ '\ _@"& /P C #[ )( ^0"7 /@ G #W *(
M]@"G /4 K0#S +4 \@"] /$ R0#O -P [@#K .T ]P#L /\ ZP#_ .H _P#J
M /\ Z@#_ .H _P#_$QP _Q$9 /\-&0#_!AP _P,E /\ ,0#_ #X _P!* /\
M5@#_ &$ _P!K /T <P#Z 'L ]P"# /4 B0#T (\ \@"4 /$ F0#P )\ [@"D
M .T JP#L +( Z@"Z .@ Q@#G -8 Y0#H .0 ]0#C /X X@#_ .$ _P#A /\
MX0#_ .$ _P#_%1@ _Q,4 /\/% #_#1D _PLB /\(+0#_!#D _P%& /\ 40#^
M %P ^@!F /8 ;P#R '< [P!^ .T A0#K (L Z@"1 .@ E@#G )P Y@"A .0
MJ #C *\ X0"X -\ PP#= -$ VP#F -D \P#7 /T U0+_ -0"_P#4 _\ U /_
M -0#_P#_&!, _Q40 /\2#P#_$A4 _Q$= /\.* #_##0 _PI! /D(3 #U!E<
M\09A .T&:@#I!7( Y@5Z .0%@0#B!8< X :- -\&D@#=!I@ VP:> -D&I0#7
M!JT U :U -(&P #0!\\ S@CE ,P)] #*"_\ R S_ ,<,_P#'#/\ Q@S_ ,8,
M_P#_&PX _QD, /\8#0#_&!$ _Q<8 /\4(@#[$2X \Q Z .T.1@#H#5( Y0U<
M .$-90#>#6T VPUU -@-? #5#8( TPV) -$-CP#0#94 S@V< ,T.HP#+#JL
MR0ZT ,@.P #&#L\ PQ#F , 1]0"]$O\ O!+_ +L2_P"Z$O\!NA+_ ;H2_P'_
M'PH _QP$ /\?" #_'PT _QT2 /@:&P#N%B8 YA0S . 3/P#:$TL U!-6 - 3
M7P#.%&@ RQ1O ,D4=P#'%7T QA6$ ,05B@##%9$ P1:8 , 6GP"^%J< O!>P
M +L7O "Y%\L MQCB +,9\@&Q&O\!KQO_ :X;_P&N&_\!K1O_ :T;_P'_(@0
M_R(  /\E @#\) < ]R$, .P=$@#A&AP V!HJ - ;. #+'44 QQU0 ,,>6@#
M'F( OAYJ +P?<0"Z'W@ N1]^ +<?A0"V'XP M!^3 +,?F@&Q(*,!L""L :X@
MMP&L(<8!JR'= :<B[P*E(OT"HR/_ J(C_P*B(_\"H2/_ J$C_P+_)0  _R@
M /(J  #E*P  WR@% -PA"P#2(10 R20D ,,E,@"^)C\ NB=* +<G5 "T)UT
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M!X<VY0>%-O8'A#?_!X,W_P>#-_\'@C?_!X(W_P?T,@  XSL  -)!  #&1
MO4,  +<_  "Q.PD JCL4 *4\(@"@/3  G3T[ )D]10"6/4X!E#Q6 9(\70*0
M/&,"CCMJ XP[<02*.W@$B#J !8<ZB :%.I(&@SJ<!X$ZJ B .K4)?CO&"7T[
MX0E[//,)>SS_"7H\_PAZ//\(>CS_"'H\_PCN-P  W4$  ,M&  "_20  MDD
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M#&5*_PME2O\+94K_"V5*_PO@1   RTT  +U2  "R5@  IE4  )Q2  "53@
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M#%)8_PS-40  O%D  +!?  "C80  EF   (M?  "!6P  >5T  '-># !O7A4
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M"49HD@I$9Z$+0V>Q#$)GQ0Q"9^(,0F;U#$-F_PM#9?\+0V7_"T-E_PN_7
ML60  *9J  "6:0  B6D  'UI  !Q:0  9VH  &)L 0!=;0T 66X6 %=O(0!5
M<"L 4W U %%P/0!0<$4!3G!, 4QP4P)*<%H#2'!B!$9O:P5$;W4&0F^"!T!N
MCPD_;IX*/6ZO"CUNP@H\;N */6WT"CUL_PH]:_\*/FO_"CYK_PJZ8   K6D
M *!N  "1;0  A&T  'AM  !L;@  87   %MR  !6= H 4G42 %!V'0!.=R<
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M RF(N@,IB-0#*8;N RF%_ 0IA/\$*83_!"F$_P2J=   GGL  (YZ  " >@
M='L  &A^  !=@0  4H4  $F)  !!C   .9 % #61#P SDA< ,I(A #&2*0 P
MDS( +I,Z "V300 LDTH *Y12 "J47  HE&< )Y1S 264@@$DE),!(I.D 2&3
MMP$@D\\!(9+L 2"0^@(@C_\"((__ B"/_P*D?   EX   (=_  ![@   ;H(
M &*%  !7B0  38X  $*2   ZE@  ,ID  "J<"0 HG1$ )IT9 "6=(@ DGBH
M(YXR "*>.@ AGD( ()Y+ !^?50 >GV  ')]M !N??  :GXT &)^? !>?L@ 6
MG\D %I[H !:<]P 6F_\!%YO_ 1>;_P&=@P  CX8  (*&  !TAP  9XL  %N/
M  !0DP  1I@  #R<   SH   *Z,  ".F   <J L &JD1 !BI&  7J2$ %JHI
M !6J,0 4JCD $ZI# !.K30 2JU@ $:ME !"K=  .JX8 #JN9  VKK  ,J\$
M#*K?  RI\@ -J/P #:C_  VH_P"6B@  B8P  'J-  !LD0  8)4  %2:  !)
MGP  /Z,  #6G   KJ@  (ZX  !NP   4LP$ #[4*  VV$  ,MA8 "[8?  JV
M)P )MB\ "+8Y  >W0P &MT\ !+=;  .W:@ "MWL  +>.  "WH0  MK0  +;+
M  "VY0  M?$  +7W  "U]P"/D0  @90  '*7  !EG   6*$  $RF  !!JP
M-Z\  "RR   CM0  &K@  !.[   .O0  "< %  /!#0  P1$  ,$7  #"'@
MPB8  ,(O  ##.0  Q$0  ,10  #$7@  Q6\  ,6!  #%E0  Q:@  ,6\  #$
MT0  Q.8  ,3N  #$[@"&F   >9X  &NC  !=J0  4*X  $2S   WM@  ++D
M "*\   9OP  $<(   S%   &R    ,L   #,!P  S T  ,T1  #-%@  SAT
M ,\D  #0+0  TC@  -1$  #44@  U6$  -5S  #6AP  UIL  -:M  #7OP
MV,X  -C=  #8W0![H   ;J8  &"M  !3LP  1;@  #B\   KOP  (<(  !?&
M   0R0  "LP   +0    U    -<   #8    V@4  -L+  #<#@  WA,  -\9
M  #A(0  XRH  .4V  #G0P  YU,  .AD  #I=P  Z8P  .J?  #JK@  ZKH
M .K#  #JPP!PJ   8J\  %6V  !'O   .<   "S$   @R   %LP   [0   '
MU    -D   #=    X0   .,   #D    Y@   .<!  #I!P  ZPP  .P0  #N
M%0  \!T  /,G  #V,P  ]T,  /A4  #Y9@  ^7H  /J.  #ZG@  ^ZD  /NP
M  #[L #_"QL _P<9 /\ &0#_ !P _P E /\ ,@#_ #\ _P!+ /\ 5P#_ &(
M_P!K /\ <P#] 'L ^P"" /H B #X (T ]P"2 /8 F #U )T ] "B /, J0#Q
M +  [P"X .X PP#L -$ ZP#F .D \P#H /X Z #_ .@ _P#H /\ Z #_ .@
M_P#_#A@ _PH5 /\!% #_ !@ _P B /\ +@#_ #L _P!' /\ 4P#] %X ^@!G
M /< ;P#U '< \P!^ /( A #P (D [P"/ .X E #L )H ZP"? .D I0#H *P
MY@"T .0 OP#C ,P X0#B -\ \ #> /L W@#_ -T _P#= /\ W #_ -P _P#_
M$!, _PT1 /\&$ #_ A4 _P > /\ *0#_ #8 _P!" /H 3@#T %D \0!B .X
M:P#L '( Z@!Y .@ ?P#G (4 Y0"+ .0 D #B )8 X0"< -\ H@#= *D V@"Q
M -@ NP#5 ,@ T@#= -$ [0#0 /D SP#_ ,X _P#- /\ S0#_ ,T _P#_$0\
M_PX- /\,#0#_"Q( _P<9 /\") #_ #  ]@ \ .\ 20#J %, YP!= .0 9@#A
M &T WP!T -T >P#; ($ V0"& -8 C #4 )( T@"8 -  G@#. *8 S "N ,H
MN #( ,0 Q@#7 ,4 Z@## /< P@#_ ,$!_P#  O\ P +_ , "_P#_% L _Q &
M /\0"0#_$ X _PX4 /\*'@#U!BD ZP0V .,#0@#? TX VP17 -8$8 #3!&@
MT 1O ,X%=@#,!7P R@6" ,D%B #'!8X Q@64 ,0%FP#"!:, P :K +X&M0"]
M!L( NPC4 +H)Z0"W"_@ M0S_ +0,_P"T#/\ M S_ +0,_P#_%P0 _Q0  /\6
M P#_% D _Q$. /(.%0#H#"$ W@HN -8+.P#0#$< S Q1 ,D,6@#&#6( Q UJ
M ,(-<0# #7< OPU] +T.@P"\#HH N@Z1 +D.F "W#J  M@ZI +0/M "R#\$
ML1#4 *X1ZP"K$OH J1+_ *@3_P"G$_\ IQ/_ *<3_P#_&@  _QL  /D;  #K
M&0  Y10& .40#@#9#A< SQ$F ,@2- #$$T  OQ1+ +P45 "Y%5T MQ5D +45
M:P"T%7$ LA5X +$6?@"O%H4 KA:, *P6E "K%YP J1>F *<8L "F&+T I!C/
M *(:YP"?&O< G1O_ 9P;_P&<&_\!FQO_ 9L;_P'_'0  ]R$  .@D  #=)0
MU"$! ,\;" #*%Q$ PAH@ +P<+0"W'3H LQY% + >3P"M'E< JQY? *D?9@"H
M'VP IA]S *4?>0"C'X  HA^' * @CP"?()@ G2"B )L@K &:(;D!F"'* 98B
MY &4(_4!DB/_ 9$C_P&0(_\!D"/_ 9 C_P'_(@  ZRD  -TN  #/+P  QRT
M ,$G P"](@T MB,: + E* "L)C0 J"9  *4G20"B)U( H"=: )XG80"<)V<
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M!70W_P1T-_\$=#?_!'0W_P3G-0  TCT  ,-"  "X1   K$(  *0^  "?.0
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M!EI(_P;110  OTP  +)2  "C40  EU   (U.  "&2@  @$H! 'I+#@!V3!<
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M!D]4D0=.5* (3%2O"$Q4P@E+5-\)3%3S"$Q3_P=,4_\'35/_!DU3_P;%3@
MME8  *=:  "860  BU@  (%7  !W5   <%4  &I6!@!F5Q  8E<: &!8) !=
M6"X 6UDW %E9/P!7648 5EE- 5195 %365L"45EC D]8; -.6'8$3%B"!4I8
MCP9)6)X'2%BN"$=8P A'6-T(1UCR"$=7_P=(5_\'2%?_!DA7_P;!40  LED
M *-<  "46P  AUL  'U:  !R6   :UD  &5: P!@6PX 75P7 %I<(0!872L
M5ETT %1>/ !37D0 45Y+ 5!>4@%.7ED"3%YA DM=:@-)770$1UV !45=C09$
M79P'0UVL!T)=O@A"7=H(0ESQ!T)<_@=#6_\&0UO_!D-;_P:]50  KUT  )]?
M  "07@  @UX  'A=  !M7   95T  %]?  !:8 P 5V$4 %5B'@!28B@ 46,Q
M $]C.0!.8T$ 3&-( $MC3P%)8U8!1V-> D5C9P)$8W$#0F-]!$!BBP4_8IH&
M/F*J!CUBO <\8M8'/6'O!CUA_08^8/\&/F#_!CY@_P:Y60  JV$  )IA  "+
M80  ?V$  '1A  !I80  7V(  %ED  !49@D 46<1 $YG&@!,:"0 2VDM $EI
M-@!(:3X 1FI% $5J3 !#:E0!0FI< 4!I90(^:6\"/&E[ SMIB00Y:9@%.&BH
M!3=HN@4W:=,%-VCN!3=G_ 4X9O\%.&;_!3AF_P6T7@  IV4  )5E  "&9
M>F4  &]E  !D9@  66@  %)J  !-; 0 26X. $=N%@!%;R  1' I $)P,@!!
M<#H 0'%" #]Q20 ]<5$ /'%9 3IQ8@$X<6P"-G!X C5PA@,S<)4#,G"F!#%P
MN 0P<- $,6_L!#%N^P0Q;?\$,6S_!#%L_P2O9   H6D  (]H  "!:   =6D
M &MI  !@:P  56X  $UQ  !&<P  0G4+ #]V$@ ]=QP /'<E #IX+0 Y>#4
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M !F*]0 9B?\!&8C_ 1F(_P&==P  C'8  'UV  !R=P  97D  %I\  !0@
M1H0  #R)   TC   +9   "63 @ ?E0P '982 !R6&@ ;ER( &I<J !F7,@ 8
MF#H %YA# !:830 5F%@ %)AD !.8<P 1F(0 $)B6 !"8J0 .F+\ #I?=  ^6
M\@ 0E?P $)3_ !"4_P"5?0  A7P  'A\  !K?@  7X$  %2&  !*B@  0(\
M #:3   MEP  )IH  !Z=   7H , $J(, !"C$@ 0HQD #Z,A  ZD*0 .I#$
M#:0Z  RD10 +I%  "J1<  FD:@ 'I'L !J..  2CH0 "H[0  Z++  .BY@ #
MH?,  Z'[  .A^P"-@P  ?X(  '&$  !DAP  6(P  $V1  !"E@  .)H  "^>
M   FH@  'J4  !>H   1JP  #*X'  >O#0 #KQ(  J\9  &O(0  KRD  + R
M  "P/   L$<  +!3  "P80  L'$  +"#  "OEP  KZH  *^_  "NV0  KNL
M *[T  "N] "'B0  >(H  &J.  !=DP  49@  $6=   [H@  ,*8  ">J   >
MK@  %K$  !"T   +M@  !;D#  "Z"@  N@X  +H3  "[&0  NR$  +PH  "\
M,0  O3P  +Y(  "^5@  OF4  +YW  "^C   OI\  +VS  "^QP  OMX  +WK
M  "]ZP!_D@  <)4  &*:  !5GP  2:4  #VK   RKP  *+0  !ZV   5N0
M#KP   F_   "P@   ,0   #%!   Q@H  ,8.  #'$@  R!@  ,D?  #*)P
MS#   ,X\  #.20  SUD  ,]J  #/?@  SY,  ,^F  #/N   S\@  ,_;  #/
MVP!WG   :*$  %NG  !.K@  0;0  #2W   HN@  ';T  !/    -Q   !L<
M  #*    S@   -    #1    T@(  -,(  #5#   UA   -D5  #;'   W20
M . O  #B/   XTL  .1<  #D;P  Y8,  .68  #EJ0  Y;8  .7#  #EPP!L
MI0  7ZP  %&R  !$N0  -;P  "C    <Q   $L@   S+   #SP   -,   #8
M    W    -\   #?    X0   .,   #D P  Y@@  .@-  #I$0  [!@  .XB
M  #Q+@  \SP  /1-  #U7P  ]G,  />'  #WF0  ^*4  /BP  #XL #_ Q<
M_P 5 /\ %0#_ !@ _P C /\ +P#_ #P _P!( /\ 5 #_ %X _P!G /T ;P#[
M '8 ^0!] /@ @P#V (@ ]0". /0 DP#R )@ \0"> /  I #N *L [0"S .L
MO0#J ,L Z #A .< \0#F /T Y0#_ .0 _P#D /\ Y #_ .0 _P#_!Q, _P 1
M /\ $0#_ !4 _P ? /\ *P#_ #< _P!$ /X 3P#Z %H ]P!C /0 :P#R '(
M\ !Y .\ ?P#M (0 ZP"* .H CP#H )0 YP": .4 H #D *< X@"O .  N0#>
M ,8 W #: -H [ #8 /D U@#_ -8 _P#7 /\ V #_ -@ _P#_"A  _P,. /\
M#0#_ !( _P : /\ )@#\ #( ]P _ /0 2@#Q %4 [0!> .H 9@#H &X Y0!T
M ., >@#B (  X "% -X BP#< )  VP"6 -@ G #5 *, TP"K -$ M0#. ,$
MS #1 ,L YP#) /4 R #_ ,@ _P#( /\ R #_ ,@ _P#_# P _P8( /\""@#_
M  \ _P 5 /P ( #Q "P [  Y .D 10#E $\ X0!9 -X 80#; &@ UP!O -0
M=0#2 'L T "  ,X A@#, (P RP"2 ,D F #' *  Q0"H ,, L0#! +P OP#+
M +T XP"\ /( NP#] +L _P"Z /\ N@#_ +H _P#_#@4 _PD  /\)!0#_!@L
M_P$0 /  &0#F "4 X0 R -P /P#6 $D T0!3 ,X 6P#+ &, R !J ,8 < #%
M '8 PP![ ,$ @0#  (< O@". +P E "[ )P N0"D +< K@"U +D LP#( +$
MWP"P >\ KP'[ *X"_P"M _\ K0/_ *T#_P#_$   _PX  /\-  #V"P, \@<*
M .(!$0#; AT T@,K ,P#-P#(!$, Q 1- ,$$5@"^!5T O 5D +H%:P"X!7$
MMP5V +4%? "S!H, L@:) + &D0"O!YD K0>A *L'JP"I"+< J G& *8*W0"E
M"_  HPS] *(-_P"A#?\ H0W_ * -_P#_$0  _!(  .P3  #B$P  VP\# -8)
M"P#."!0 Q@HB , ,, "\#3P N U& +4-3P"R#E< L Y? *X.90"M#FL JPYQ
M *H.> "H#GX IP^% *4/C0"D#Y8 HA"? * 0J0"?$+4 G1'% )L1W@"9$O$
MEQ/_ )84_P"5%/\ E13_ )04_P#_%0  [1L  . ?  #2'P  R1L  ,04!0#!
M$ X NA(; +03*0"P%#4 K!5  *D520"F%5( I!99 *(68 "A%F8 GQ9L )X6
M<@"<%GD FQ>  )D7B "8%Y$ EAB; )08I@"3&;( D1G! ) :V "-&^X BQS]
M (H<_P"*'/\ B1S_ (D<_P#T'0  Y"4  -,I  #'*@  O"8  +8@  "T&0L
MKAH5 *@<(P"D'2\ H1XZ )X>1 ";'DP F1Y4 )<?6P"5'V$ E!]G )(?;0"1
M'W0 CR!\ (X@A ",((T BB"7 (DAH@"'(:X AB*] (4BT0&"(^L!@23[ 8 D
M_P%_)/\!?R3_ 7\D_P'L)0  VRT  ,DQ  "\,0  L2X  *LI  "G) 4 HR,1
M )XD'0":)2H EB8U ),F/P"1)D< CR9/ (TF5@"+)UP B2=B (@G:0"&)V\
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M F8V_P+8-P  Q#X  +5"  "F00  FS\  ),\  "-.   B#8' (0W$0" -QP
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M UA"D -70IX$5D.M!%5#OP140]H$5$/Q!%1#_@-40_\#5$/_ U1#_P/(0@
MN$D  *=+  "82@  C4D  (-'  !]0P  =D,  '%$"@!M1!( :D4= &=%)P!D
M13  8D4X &!%/P!?14< 745- %M%5 !:1EL!649C 5=&; %61G8"5$:! U-&
MC@-21YP$4$>K!%!'O01/1]8%3T?O!$]'_01/1_\#3T?_ U!'_P/$10  M4T
M *--  "53   B4L  ']*  !X1@  <4<  &Q'!P!H2!  9$@: &%)) !?22T
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M!$%3N 1!4\\$05/L!$%2^P-"4O\#0E+_ T)1_P.Z3P  JE0  )A4  ")5
M?5,  '-3  !I40  8E(  %Q3  !85 H 5%42 %)5&P!/5B0 3E8M $Q7-0!+
M5SP 2E=$ $A72P!'6%( 1EA: 4188P%#6&T!05AY D!8A@(^6)4#/5BE SQ8
MMP0\6,T$/%?J SQ7^@,]5O\#/5;_ SU6_P.V4P  I5<  )17  "%5@  >58
M &]6  !E50  7%8  %=8  !260< 3EH0 $Q:& !*6R$ 2%PJ $=<,@!%7#H
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M 2IH]@(K9_\"*V?_ BMG_P*I80  E6   (1@  !W8   ;&$  &)A  !88P
M3F8  $=H  ! :P  .FX% #9O#@ T<!4 ,W > #)Q)@ P<2X +W$U "YR/0 M
M<D4 +')- "MR5P J<F$ *7)M "=R>P F<HL )'*< 2-RK@$C<L,!(W'B 2-P
M] $C;_\!(V[_ 2-N_P&A90  CF0  ']D  !R9   :&4  %YF  !4:0  26P
M $)O   [<@  -'4  "YX"@ K>1$ *GD8 "EZ(0 G>B@ )GHP "5[.  D>T
M(WM( ")[4@ A>UP ('MH !]\=@ =?(8 ''N8 !M[J@ :>[\ &GO> !IY\@ ;
M>/X &W?_ 1MW_P&9:0  B&D  'EI  !M:0  8VH  %EL  !/;P  17,  #UW
M   U>@  +GT  ">! P B@PT ((02 !^$&@ =A"( '(4J !N%,0 :A3D &85"
M !B&3  7AE8 %H9C !6&<0 4AH$ $H:3 !&&I@ 1A;L $(76 !&#[P 1@OL
M$H+_ !*!_P"1;@  @6T  '1N  !I;@  77   %-S  !)=P  0'P  #>    O
M@P  )X<  "&*   :C08 %8\- !.0$P 2D!H $I B !&0*@ 0D3( $)$[  ^1
M1  .D4\ #9%<  R1:@ +D7H "I&-  B0GP 'D+, !X_)  >/Y@ 'CO0 "(W\
M  B-_P")<P  >W,  &]S  !C=0  5W@  $U]  !#@0  .88  #"*   HC@
M(9$  !J5   3EP  #IH(  N<#@ )G!, ")P:  ><(@ &G"H !)PS  .</0 "
MG4@  )U4  "=8@  G'(  )R$  "<EP  FZH  )N_  ":VP  FNP  )KU  "9
M^ "">0  =GD  &AZ  !<?@  48(  $:'   \C   ,I$  "F5   AF0  &9T
M !*@   .HP  ":8%  .G#   IQ   *<5  "H'   J",  *@K  "I-   J3\
M *E+  "I60  J6@  *EZ  "IC@  J:$  *BU  "HRP  I^0  *?O  "G\P!]
M@   ;X$  &&$  !5B0  28X  #Z4   TF0  *IX  "&B   9I@  $JD   VL
M   'KP   +(   "S!P  LPP  +,0  "T%0  M!L  +4B  "V*P  MS4  +=
M  "X3@  N%T  +AN  "X@@  N)<  +BJ  "WO@  M](  +?F  "WZ@!VB
M9XL  %J0  !.E@  0IP  #>B   LIP  (JL  !FO   1LP  "[8   2Y
MO    +X   "^    OP8  , +  #!#P  PA,  ,,9  #$(   Q2D  ,<T  #(
M0@  R5$  ,EB  #)=0  R8H  ,F?  #*L0  RL$  ,G1  #)V0!NDP  8)@
M %.>  !&I   .JL  "^P   DM0  &;@  !"\   *OP   <$   #$    R
M ,H   #*    S    ,T#  #."   T T  -$0  #3%@  UAX  -HH  #=-
MWD,  -]4  #?9P  X'P  ."1  #@I   X+(  ."^  #@PP!FGP  6:8  $RM
M   _M   ,K@  "2\   8OP  $,,   C'    R@   ,T   #1    U0   -@
M  #9    VP   -T   #?    X00  .,*  #E#@  YQ,  .H<  #M)P  \#4
M /%&  #R6   \VL  /.   #TE   ]*,  /2N  #TL@#_ !, _P 1 /\ $0#_
M !4 _P ? /\ + #_ #D _P!% /\ 4 #_ %H _@!C /L :P#Y '( ]P!X /4
M?@#T (0 \@") /$ C@#P ), [@"9 .T GP#L *8 Z@"N .@ N #F ,4 Y0#;
M ., [0#B /L X@#_ .$ _P#A /\ X0#_ .$ _P#_ !  _P . /\ #0#_ !(
M_P ; /\ * #_ #0 _@!! /L 3 #W %8 ] !? /$ 9@#O &T [ !T .H >@#I
M '\ YP"% .8 B@#E (\ XP"5 .$ FP#@ *( W@"J -L M #9 ,  U@#0 -,
MZ #2 /< T0#_ -$ _P#0 /\ T #_ -  _P#_  T _P ) /\ "@#_  \ _P 6
M /L (@#W "\ ]  [ /  1P#M %$ Z0!: .4 8@#B &D X !O -X =0#< 'H
MV@"  -@ A0#5 (L TP"1 -$ EP#/ )X S0"F ,L KP#) +H QP#) ,4 X@#$
M /( PP#^ ,( _P#! /\ P@#_ ,( _P#_ P8 _P ! /\ !@#_  P ^0 1 /$
M'0#K "D YP V ., 00#? $L VP!4 -4 7 #2 &, SP!J ,T < #+ '4 R0![
M ,@ @ #& (8 Q0", ,, DP#! )H OP"B +T JP"[ +8 N0#$ +< V@"V .T
MM #Z +0 _P"T /\ M #_ +0 _P#_!   _P   /\   #_  8 [  - .4 %@#>
M "( UP O -$ .P#- $4 R@!. ,8 5P#$ %X P0!D +\ :@"] '  O !U +H
M>P"Y ($ MP"' +4 C@"S )4 L@"> +  IP"N +( K "_ *H T0"H .@ J #W
M *< _P"G /\ I@#_ *8 _P#_!@  _P4  /$#  #H    X0 ' -4 $ #- !L
MQP G ,, ,P"_ #X O !( +D 40"V %@ M !? +( 90"P &H KP!P *T =@"L
M 'P J@"" *D B0"G )$ I0": *, I "A *X H "[ )X!S0"= N8 G 3T )L$
M_P":!?\ F@7_ )D%_P#_"@  \0X  .00  #9#P  S@L  ,@#"P#" !, O (?
M +<#+ "S!#< L 5" *T&2@"J!E( J =9 *8'7P"E!V4 HP=K *((<0"@"'<
MGPA^ )T(A0";"8X F@F7 )@*H0"6"JP E0NZ ),+S "2#.4 D WV (\._P".
M#O\ C@[_ (T._P#V$0  YA<  -8;  #'&0  OA4  +D0  "W"@T L0L7 *P-
M) "H#C  I0X[ *(.1 "?#TP G0]3 )L/6@":#V  F!!F )<0; "5$'( DQ!Y
M )(0@0"0$(H CQ&4 (T1GP"+$:H BA*X (@2RP"&$^8 A13W (,5_P"#%?\
M@A7_ ((5_P#M&@  W"$  ,HE  "[(@  L1\  *L:  "I% 8 I1(1 * 4'@"<
M%2H F14U )86/@"4%D< DA9. ) 650".%UL C!=A (L79P")%VT B!=T (88
M? "%&(8 @QF0 ($9FP" &J< ?AJU 'T;QP!\'.( >AWU 'D=_P!X'?\ >!W_
M '@=_P#E(@  T"D  +\L  "P*@  IR<  * C  "='P  FAH. )4<& "1'20
MCAXO (P>.0")'D$ AQ]) (4?4 "#'U8 @A]< ( ?8@!_'VD ?2!P 'P@> !Z
M(($ >2&, '<AEP!U(J0 ="*R ',CPP!R(]\ <"3S &\D_P!O)/\ ;B3_ &XD
M_P#=*0  R#   +<R  "H,   GBX  )<J  "3)P  D",* (PC$P"()!\ A"4J
M ((E- " )CT ?29$ 'PF2P!Z)E( >"98 '<F7@!U)F4 ="=L '(G= !Q)WT
M;RB( &XHE !L**$ :RFO 6HIP %I*ML!9RKQ 6<K_P%F*_\!9BK_ 68J_P'4
M+P  PC8  *\V  "A-0  EC0  ) P  "*+0  ARH& (,I$ !_*AH ?"LE 'DK
M+P!W+#@ =2Q  ',L1P!Q+$T <"Q4 &XL6@!M+&$ :RUH &HM< !H+7H 9RZ%
M &4ND0%D+IX!8B^L 6$OO0%A,-4!8##O 5\P_0%?,/\!7S#_ 5\P_P'--
MO#L  *DZ  ";.@  D#@  (DU  "#,@  ?S ! 'LO#@!W,!8 =# A '$Q*P!O
M,30 ;3$\ &LQ0P!J,4H :#)0 &<R5P!E,ET 9#)E &(R;0!A,W< 7S." 5XS
MC@%=-)P!6S2J 5HUNP%:-=(!637M 5DU_ %8-?\!6#7_ 5DU_P'(.   MSX
M *0^  "6/0  BSP  (,Z  !]-P  >#0  '0T"P!P-1, ;34= &HU)P!H-C
M9C8X &0V/P!C-D8 839- & V4P!>-UH 73=B %PW:@!:.'0!63A_ 5<XC %6
M.9D!53FH E0YN0)3.L\"4SKK E,Z^P%3.O\!4SG_ 5,Y_P'$/   LD$  *!
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M DE"M0))0LL"24+H DE"^0))0?\"24'_ 4E!_P&]0P  JD4  )A%  "*10
M?T4  '9#  !O0   :$   &-! 0!?00T 7$$4 %E"'0!70B8 54(N %-"-@!1
M0CT 3T)# $]#2P!.0U( 341: $Q$8P!*1&T!245X 4A%A0%'190!146C D5&
MM )$1LD"1$;G D1%^ )$1?\"147_ D5%_P&Z1@  ID@  )1(  "&2   >T<
M ')&  !J0@  8T,  %Y$  !:10L 5D42 %1&&P!11B, 3T8K $Y&,P!,1SH
M2T=! $I'20!)2%  2$A8 $=(80!&26L 1$EV 4-)@P%"29(!04FB D!)LP(_
M2L<"/TKE C])]P) 2?\"0$C_ D!(_P&V20  HDH  )%*  "#2@  =TH  &Y)
M  !E10  7D<  %E(  !520@ 44H0 $]*& !,2B$ 2DLI $E+,0!'2S@ 1DP_
M $5,1@!$3$X 0TU6 $)-7P!!36@ 0$UT 3Y-@0$]39 !/$V@ 3M.L0(Z3L8"
M.D[D CM-]@([3?\!.TS_ 3Q,_P&S30  GDP  (U,  !_3   =$P  &I,  !@
M2@  64L  %1,  !0304 3$X. $E/%0!'3QX 14\F $10+@!"4#4 05 ] $!1
M1  _44L /E%3 #U27  \4F8 .E)R #E2?P$X4HX!-U*> 392KP$U4L0!-5+B
M 392]0$V4?\!-E#_ 3=0_P&N3P  F4\  (E/  ![3P  <$\  &9/  !<3@
M5$\  $]1  !*4@$ 1E,, $-4$@!!5!L 0%4C #Y5*P ]5C( /%8Z #M600 Z
M5DD .5=1 #A76@ V5V, -5=O #17? $S5XP!,5>< 3!7K0$P5\(!,%?@ 3!6
M] $Q5O\!,57_ 3%5_P&H4@  E5(  (12  !W4@  ;%(  &)2  !84P  3U0
M $E6  !$5P  0%D( #U:$  [6A< .5L@ #A;)P W7"\ -EPV #5</@ T7$8
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M !QH_P"57   @UP  '5<  !I70  7UT  %9>  !,80  0V0  #QG   U:@
M+VT  "AP!  C<@T (7(2 "!S&@ ?<R$ 'G,H !UT,  <=#@ &W1  !IT2@ 9
M=%0 %W5@ !9U;@ 5=7X %'60 !-TH@ 2=+8 $73/ !)S[  2<OH $W'_ !-Q
M_P".8   ?6   &]A  !E80  6V(  %%D  !(9P  /FL  #=N   P<0  *74
M ")X   <>P< %WT. !9]$P 5?1L %'XB !-^*@ 2?C$ $7XZ !%^1  0?TX
M#W]:  Y_:  -?W@ #'^*  M^G0 *?K  "7W&  I]Y  *?/0 "WO]  MZ_P"&
M90  =V4  &IE  !A9@  5F@  $QK  !";P  .7,  #%W   J>@  (WX  !R!
M   5A   $(<(  V)#@ ,B10 #(D;  N)(P *B2L "8DS  B)/0 &B4@ !8E4
M  2)80 "B7$  8F#  ")E@  B*D  (>^  "'V@  ANP  (;U  "&^@!^:@
M<6H  &=K  !;;   4'   $9T   \>   ,WT  "J!   CA0  '(@  !6,   0
MCP  #)(&  :3#  "DQ$  )06  "4'0  E"0  )4L  "5-0  E4   )5,  "6
M60  EFD  )5Z  "5C@  E*$  )2U  "3S   DN8  )+R  "2]P!X<   ;7
M &!R  !4=0  27D  #]^   U@P  +(@  ".-   ;D0  %)0   ^7   *F@
M!)T#  ">"0  GPX  )\2  "@%P  H!T  *$E  "B+0  HC<  *-#  "C4
MHU\  *-Q  "CA   HID  **M  "AP@  H=P  *'K  "@\@!S=@  9G<  %E[
M  !-@   0H4  #B+   ND   ))4  !N:   4G@  #J$   FD   "IP   *H
M  "K!   JPH  *P-  "M$0  K18  *X<  "O)   L"T  +$Y  "Q1@  LE4
M +)F  "R>0  LHX  +&C  "RMP  L<H  +'@  "QZ0!L?@  7X(  %*'  !&
MC0  .Y,  #"9   FG@  '*,  !.G   -JP  !ZX   "R    M0   +<   "X
M    N0(  +D(  "Z#   NQ   +P4  "]&P  OR,  ,$M  #".@  PDD  ,-:
M  ##;   Q((  ,27  #$JP  Q+P  ,3+  #$V@!EB0  6(X  $N5   _FP
M,Z(  "BH   =K0  %+$   VV   &N0   +P   "_    PP   ,0   #%
MQ@   ,<   #)!   R@D  ,L-  #-$0  SQ@  -(A  #5+0  UCP  -A-  #9
M7P  VG,  -J*  #;G@  VZX  -NZ  #<PP!>E@  49P  $2C   XJ@  ++$
M ""W   5NP  #;X   3"    Q0   ,D   #-    T    -(   #2    U0
M -8   #9    VP   -X%  #@"@  X@\  .46  #H(   ["T  .T^  #M40
M[F4  .]Z  #OCP  \)\  /"K  #PLP#_ !  _P . /\ #@#_ !( _P = /\
M*0#_ #4 _P!! /\ 30#^ %8 ^P!? /@ 9@#V &T ] !T /( >0#Q '\ \ "$
M .X B0#M (\ ZP"5 .H FP#H *( Y@"J .4 LP#C ,  X0#2 .  Z@#? /D
MW0#_ -T _P#= /\ W@#_ -X _P#_  T _P * /\ "0#_  \ _P 8 /\ ) #^
M #$ ^P ] /@ 2 #T %( \ !: .T 8@#K &D Z0!O .< =0#E 'H XP!_ .(
MA0#@ (H W@"0 -P E@#: )T V "E -4 KP#2 +H T #* ,X XP#- /0 RP#_
M ,L _P#+ /\ RP#_ ,L _P#_  @ _P # /\ !0#_  P _  4 /< 'P#R "L
M[P W .L 0@#G $P Y !5 .  70#= &0 V@!J -@ < #5 '4 T@!Z -  @ #/
M (4 S0"+ ,L D@#) )D QP"A ,4 J@## +4 P0## +\ V@"^ .X O0#\ +P
M_P"\ /\ O #_ +P _P#_    _P   /\   #Y  < \0 0 .H &@#D "4 WP Q
M -L / #7 $< T@!0 ,X 5P#+ %X R0!E ,8 :@#% '  PP!U ,$ >@#  (
MO@"& +P C0"Z )0 N0"< +< I0"U +  LP"] +$ SP"O .@ K@#X *X _P"M
M /\ K0#_ *T _P#_    _P   /T   #N  $ XP , -H % #1 !\ S  K ,@
M-@#% $  P@!* +\ 4@"\ %D N@!? +@ 90"V &H M !O +, =0"Q 'H L "!
M *X B "M (\ JP"8 *D H0"G *L I0"X *, R "B .( H0#S *  _@"@ /\
MH #_ *  _P#_    ]@   .H   #@    TP & ,D #P#" !@ O0 D +D +P"V
M #H M !# +$ 3 "N %, K !9 *H 7P"I &0 IP!J *8 ;P"D '4 HP![ *$
M@@"@ (H G@"3 )P G0": *< F "T )8 PP"5 -P E #O ), ^P"3 /\ DP#_
M )( _P#Y!0  Z@L  -P-  #+"@  P@4  +P "@"V !$ L0 < *X * "J #,
MIP ] *0 10"B $T H !3 )X 60"< %\ FP!D )H :@"8 '  EP!V )4 ?@"3
M (8 D@&/ ) !F0". J0 C *Q (L#P ")!=8 B ;M (@'^@"'"/\ A@C_ (8(
M_P#O#P  WA0  ,H5  "\$@  LQ   *X,  "K!@T IP,5 *(%( "?!RP G @V
M )D(/P"7"4< E0E. ),)5 "1"EH D I? (X*90"-"FL BPIR (H+>0"("X(
MAPN, (4,EP"##*( @0VP ( -P !_#=@ ?0[O 'P/_0![#_\ >Q#_ 'L0_P#F
M%P  T1X  +T=  "O'   IAD  *$5  ">$ 0 G0T/ )@.&0"4#B4 D0\O (\0
M.0",$$$ BA!( (@03P"'$%4 A1!; (0180""$6< @!%N '\1=0!]$7X ?!*(
M 'H2E !X$J  =Q.N '43O@!T%-4 <Q7N '$6_0!Q%O\ <1;_ ' 6_P#<'P
MQB4  +,E  "E(P  G"$  )8>  "2&0  D10+ (T4% ")%1\ AA8I (,6,P"!
M%SP @!=# 'X72@!\%U  >A=6 'D87 !W&&( =AAI '08<0!S&7H <1F$ &\:
MD !N&IT ;!NK &L<NP!J'-  :1WL &@>^P!H'O\ 9Q[_ &<>_P#1)@  O2H
M *LJ  "=*@  DR@  (TE  "((@  AAT& (,;$ !_'!H ?!TD 'H=+@!W'C8
M=AX^ '0>10!R'TL <1]1 &\?6 !N'UX ;!]E &L@;0!I('8 :"&! &8AC0!E
M(IH 8R*H &(CN !A(\T 8"3I & D^@!?)/\ 7R3_ %\D_P#*+   MB\  *0O
M  "6+P  C"T  (4J  " *   ?20  'HB#0!V(Q4 <R,@ '$D*0!O)#( ;20Z
M &LE00!J)4< :"5- &8E5 !E)5H 9"9A &(F:0!A)G( 7R=] %XGB@!=*)<
M6RFE %HIM0!:*LH 62KG %@J^ !8*O\ 6"K_ %@J_P#%,0  KS,  )XS  "0
M,P  AC(  '\O  !Y+0  =2H  '(H"@!O*!( :RD; &DI)0!G*BT 92HU &,J
M/0!B*D, 8"I* %\K4 !>*U< 7"M> %LL9@!9+&\ 6"UZ %<MAP!6+I4 5"ZC
M %,OLP!3+\< 4B_E %(O]P!2+_\ 4B__ %(O_P#!-@  JC8  )DV  "+-@
M@34  'DS  !S,0  ;R\  &LN!@!H+1  9"X8 &(N(0!@+RH 7B\Q %PO.0!;
M+T  62]& %@O30!7,%, 5C!; %0Q8P!3,6P 4C)W %$RA !/,Y( 3C.A $TS
ML0!--,4!3#3C 4PT]@!,-/\ 3#3_ $PS_P"[.0  ICD  )4Y  "'.0  ?#D
M '0W  !N-   :3,  &4R @!A,@T 7C(4 %PS'@!:,R8 6#,N %8S-0!5-#P
M4S1# %(T2@!1-%  4#58 $XU8 !--FH 3#9U $LW@@!*-Y  23B? $@XL %'
M.,,!1SCA 4<X]0%'./\!1SC_ 4<X_P&W.P  HCP  )$\  "#/   >#P  ' Z
M  !J-P  9#8  & V  !<-@L 63<2 %8W&@!4-R, 4C<K % W,@!/.#D 33A
M $PX1P!+.$X 2CE5 $DY7@!(.F@ 1SIS $8[@ !%.XX 1#R> $,\K@%"/,(!
M0CW? 4(\\P%"//\!0CS_ 4([_P&S/0  GCX  (T^  !_/@  =3X  &P]  !F
M.@  8#D  %LZ  !7.@@ 4SL0 %$[& !..R  3#LH $L[+P!)/#8 1SP] $<\
M1 !&/4L 13U3 $0^7 !#/F8 0C]Q $$_?@! /XT /T"< #Y K0$]0, !/4#=
M 3U \@$]0/\!/C__ 3X__P&N0   FD   (E!  !\00  <4$  &A   !A/
M6ST  %8^  !2/@4 3C\. $P_%0!)/QT 1T E $9 + !$0#, 0T Z $)!0@!!
M04D 0$%1 #]"6@ ^0F, /4-O #Q#?  [0XL .D2; #E$JP$Y1+X!.$3; 3E$
M\0$Y0_X!.4/_ 3E#_P&J0@  ED,  (9#  !X0P  ;D,  &5#  !=0   5D
M %%"  !-0@( 24,, $9#$@!$1!H 0D0B $%$*@ _13$ /D4X #U%/P \1D<
M.T9/ #I&5P Y1V$ .$=L #='>@ V2(D -4B9 #1(J@ T2+T ,TC9 #1(\  T
M1_T -$?_ #5&_P"F1   DD4  ()&  !U1@  :D8  &%%  !91   440  $Q&
M  !(1P  1$<* $%($  _21@ /4D@ #Q))P Z2BX .4HV #A*/0 W2T0 -DM,
M #5+50 T3%\ ,TQJ #),=P Q3(8 ,$R7 "]-J  N3;L +DW5 "Y,[P O3/T
M+TO_ #!+_P"A1P  CD@  'Y(  !Q2   9DD  %U(  !52   3$D  $=*  !"
M2P  /TP& #M-#@ Y3A4 -TX= #9/)  U3RL ,T\S #)0.@ Q4$( ,%!* "]1
M4@ N45P +5%G "Q1=0 K480 *E*5 "E2I@ I4KD *%+2 "E1[@ I4/P *E#_
M "I/_P"<2@  B4H  'I+  !M2P  8TP  %I,  !13   2$T  $-/   ]4
M.5(" #53#  S5!( ,509 #!5(0 N52@ +54O "Q6-P K5CX *E9& "E63P H
M5UD )U=D "97<@ E5X$ )%>2 "-7I  B5[< (E?/ ")7[  C5OH (U7_ "15
M_P"630  A$X  '5.  !I3@  7T\  %9/  !-4   15(  #]3   Y5@  ,U@
M "]:"  K6P\ *EL5 "A<'0 G7"0 )EPK "5<,P D73H (UU# ")=3  A758
M(%YA !]>;@ >7GX '5Z/ !Q>H0 ;7K0 &EW, !M=Z0 ;7/D '%O_ !Q;_P"0
M40  ?E$  '!1  !D4@  6U(  %)3  !*5   05<  #M9   U6P  +EX  "A@
M P D8@P (F,1 "%C&  ?9"  'F0G !UD+@ <9#8 &V4^ !IE1P 995$ &&5=
M !=E:@ 697H %66+ !1EG@ 39;$ $F7( !)DYP 38_< %&+_ !1B_P")5
M>%4  &M5  !@5@  5U8  $]7  !&60  /5P  #9?   P8@  *60  "-G   =
M:@< &6P. !AL$P 6;1H %6TA !1M*0 4;3  $VTY !)N0@ 1;DP $&Y8  ]N
M90 .;G4 #6Z'  UNF@ ,;:T "VW"  MLX  ,:_, #6O]  UJ_P""60  <ED
M &99  !<6@  5%H  $I<  !!7P  .6,  #%F   J:0  )&P  !UO   7<@
M$G4)  ]W#P .=Q0 #G<;  UW(P ,=RH "W<S  IW/  )=T< "'=2  =W7P %
M=V\ !'>   -WE  !=J<  ':[  %UU0 !=.L  G3V  )T_ ![70  ;5T  &)>
M  !97@  3F   $5C   \9P  ,VL  "MN   D<@  'G4  !=Y   2?   #7\&
M  F!#  %@1$  X$6  *!'0 !@20  ($M  ""-@  @D   (),  ""60  @F@
M ()Y  ""C0  @:   ("T  " RP  ?^<  '[R  !^^0!T8@  :&(  %YB  !3
M9   26<  #]K   V<   +70  "5X   >?   %X   !&#   -A@  "(D$  *+
M"@  BPX  (L3  ",&   C!\  (TF  "-+P  CCD  (Y$  ".40  CF   (YQ
M  ".A0  CID  (VM  ",PP  C-\  (ON  "+]@!N:   9&<  %AI  !-;
M0G$  #AV   O>P  )G\  !Z$   6B   $(P   R/   &D@   )4   "6!P
MEPP  )</  "8$P  F1@  )H?  ";)@  FS   )P[  "<2   G%<  )QH  "<
M>P  G)   )NE  ";N@  FM   )KG  ":\0!J;0  7F\  %%R  !&=P  .WP
M #&"   GAP  'HP  !:1   0E0  "ID   2<    H    *(   "C 0  HP8
M *0+  "E#@  IA(  *<7  "H'@  JB8  *LQ  "K/@  K$T  *Q=  "L<
MK(4  *R;  "KKP  J\,  *O9  "JZ !D=0  5WD  $M^   _A   -(H  "F0
M   ?E@  %IL  !"?   )HP   :<   "J    K@   +    "P    L0   +(#
M  "T"   M0T  +80  "W%0  N1T  +LF  "\,P  O4$  +U2  "]9   OGD
M +Z0  "]I   O;<  +W&  "]UP!<?P  4(4  $2+   XD@  +)D  "&?   7
MI   $*D   FN    L@   +8   "Y    O0   +\   "_    P    ,$   ##
M    Q 4  ,8*  #'#@  R1,  ,L<  #.)@  T#4  -%%  #25P  TFL  -."
M  #3EP  TZD  -*X  #2Q !5C   29,  #V:   PH@  ):@  !JN   1M
M";D   "]    P0   ,0   #(    RP   ,T   #-    SP   -    #2
MU    -@   #:!@  W0P  . 1  #C&@  YB<  .<X  #H2@  Z5T  .IR  #K
MB   ZYL  .RH  #LL@#_  T _P + /\ "P#_ !  _P : /\ )@#_ #( _P ]
M /\ 2 #[ %( ^ !: /8 8@#S &D \0!O /  =0#N 'H [ !_ .L A #I (H
MZ "0 .8 E@#D )T X@"E .$ KP#? +L W0#+ -L Y@#9 /< V #_ -@ _P#7
M /\ UP#_ -0 _P#_  @ _P $ /\ ! #_  T _P 5 /X (0#Z "P ]P X /0
M0P#P $T [0!5 .H 70#G &0 Y !J .( < #@ '4 W@!Z -T ?P#; (4 V0"+
M -4 D0#3 )D T0"@ ,\ J@#- +4 RP#$ ,D W0#( /$ QP#_ ,8 _P#& /\
MQ@#_ ,< _P#_    _P   /\   #_  H ^  1 /$ ' #L "< Z0 R .8 /0#B
M $< W0!0 -D 6 #5 %\ T@!E -  :@#. '  S !U ,H >@#) '\ QP"% ,4
MC ## )0 P0"< +\ I0"] +  NP"] +H T "X .L MP#[ +8 _P"V /\ M@#_
M +8 _P#_    _P   /T   #S  4 Z0 . .$ %@#; "$ U0 M -$ -P#. $$
MR@!* ,< 4@#$ %D P@!? ,  90"^ &H O !O +L = "Y 'H MP"  +8 AP"T
M (X L@"7 +  H "N *H K0"W *L R "I ., J #U *< _P"G /\ IP#_ *8
M_P#_    _@   /$   #E    UP * ,T $0#' !P P@ F +\ ,0"\ #L N@!$
M +< 3 "T %, L@!9 +$ 7P"O &0 K0!I *P ;P"J '0 J0!Z *< @0"F (D
MI "1 *( FP"@ *4 G@"R )T P0"; -H F@#O )D _0"8 /\ F #_ )@ _P#]
M    \    .$   #1    Q@ $ +T #0"W !4 LP @ +  *P"M #4 JP ^ *@
M1@"F $T I !4 *, 60"A %\ H !D )X :0"= &X FP!U )H >P"8 (, E@",
M )4 E@"3 *$ D0"M (\ NP"- ,\ C #I (L ^ ", /\ C #_ (P _P#S @
MX@<  ,P'  "_!   MP   +$ " "K !  IP 9 *0 ) "@ "X G@ W )P 0 ":
M $< F !. )8 5 "5 %D DP!> )( 9 "0 &D CP!O (T =@"+ 'X B@"( (@
MD@"& )T A0"I (, N "! ,H @ #E (  ]0!_ /\ ?P#_ '\ _P#H#0  T!
M +X0  "Q#@  J T  *,(  "@ @P G  3 )@ '0"5 "< D@ Q )  .0". 4$
MC %( (H"3@") E0 AP)9 (8"7P"$ V0 @P-K ($#<@" !'H ?@2$ 'T%C@![
M!9H >0:G '@&M0!V!\@ =0CC '4)] !T"O\ <PK_ ',*_P#=%0  Q!<  +$7
M  "E%@  G!,  )81  "4#00 DP@- (X'%0"+"2  B DJ (4*,P"#"SL @0M"
M ( +20!^"T\ ?0Q4 'L,6@!Z#&  > QG '<,;@!U#78 = V  '(-C !P#9D
M;PZF &T.M0!L#LD :P_F &H0]P!I$/\ :1#_ &D0_P#0'0  N1X  *@>  ";
M'0  DAL  (L9  "(%0  AQ$' (4.$ "!#QH ?A D 'L0+0!Y$#8 =Q$] '81
M1 !T$4H <Q%0 '$15@!P$5P ;A)B &T2:@!K$G, :1-] &@3B0!F$Y8 912C
M &,5LP!B%<8 8A;C &$6]@!@%_\ 8!?_ & 7_P#'(@  L",  )\D  "2(P
MB2(  ((@  !^'0  ?!D  'H5#0!W%14 =!8? '$6* !O%S  ;A<X &P7/P!K
M%T4 :1A+ &@840!F&%@ 91A> &,99@!B&6\ 8!EY %\:A0!=&Y( 7!NA %L<
ML !:',, 61W@ %@>] !8'O\ 6![_ %@>_P"_)P  J2@  )DH  "+*   @B<
M 'LE  !V(P  <R   '$<"0!N'!$ :QP: &D=(P!G'2P 91TS &,>.@!B'D$
M8!Y' %\>30!>'E0 7!]; %L?8@!9(&L 6"!V %8A@@!5(9  5"*> %,BK@!2
M(\  42/= %$D\@!1)/\ 423_ %$C_P"Y*P  HRP  ),L  "&+0  ?"P  '0J
M  !O*   :R4  &DB!0!F(0X 8R(6 &$B'P!?(R< 72,O %PC-@!:(ST 621#
M %<D2@!6)%  5217 %,E7P!2)6@ 429S $\F?P!.)XT 32B< $PHK !+*;X
M2RG: $HI\0!**?\ 2RG_ $LI_P"S+@  GB\  (XP  "!,   =R\  &\N  !J
M*P  92H  &,G 0!?)PP 7"<3 %HG&P!8*"0 5B@K %4H,@!3*#D 4BE  % I
M1@!/*4T 3BE4 $TJ7 !,*F4 2BMP $DK? !(+(L 1RV: $8MJ@!%+KP 12[6
M $4N[P!%+OX 12[_ $4M_P"N,0  FC(  (DS  !\,P  <C,  &LQ  !E+P
M8"T  %TL  !9+ D 5BP0 %0L& !2+"  4"PH $XM+P!-+38 3"T\ $HM0P!)
M+4H 2"Y1 $<N60!&+V, 13!M $,P>@!",8D 03&8 $$RJ ! ,KL /S+3 #\R
M[@! ,OT 0#+_ $ R_P"J,P  EC4  (8U  !Y-@  ;C4  &8U  !A,@  7#
M %<P  !4, 8 43 . $XP%0!,,1T 2C$E $@Q+ !',3( 1C$Y $0Q0 !#,D<
M0C)/ $$S5P! ,V  /S1K #XU>  ]-8< /#:6 #LVIP [-KD .C;1 #HV[0 [
M-OP .S;_ #LV_P"F-@  DC<  ((X  !U.   :S@  &,W  !=-@  5S,  %,T
M  !/- , 2S0, $DT$@!&-1H 134B $,U*0!!-2\ 0#4V #\V/0 ^-D0 /3=,
M #PW50 [.%X .CAI #DY=@ X.84 -SJ5 #<ZI0 V.K@ -3K/ #8Z[  V.OL
M-CG_ #<Y_P"B.   CCD  'XZ  !R.P  :#L  %\Z  !9.0  4S8  $XW  !*
M.   1C@* $0Y$ !!.1< /SD? #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<[
M4P V/%P -3QG #0]=  S/8, ,SZ3 #(^I  Q/K8 ,3[- #$^Z@ Q/OH ,CW_
M #(]_P">.P  BSP  'L\  !N/0  9#T  %P]  !5/   3CH  $D[  !%/
M03T' #X]#@ \/14 .CX< #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 4  Q
M0%H ,$%E "]!<@ N0H$ +4*1 "U"H@ L0K4 *T++ "Q"Z0 L0OD +4'_ "U!
M_P"9/0  ASX  '<_  !K/P  84   %D_  !2/P  23X  $0_  ! 0   /$$$
M #E"#0 W0A( -4,9 #-#(0 R0R@ ,40O #!$-@ O1#T +D5% "U%3@ L15@
M*T9C "I&;P I1GX *$:/ "='H0 F1[, )D?) "9&YP G1O@ *$7_ "A%_P"5
M0   @D$  '-"  !G0@  7D(  %5"  !.0@  14(  #]$   [10  -T8  #1'
M"@ Q2!  +T@6 "Y)'@ L224 *TDL "I),P I2CH *$I" "=*2P F2U4 )4M@
M "1+;0 C2WP (DN- "%,GP A3+$ ($S' "!+Y@ A2_< (DK_ ")*_P"00P
M?D0  &]$  !D10  6D4  %)%  !*1@  04<  #Q(   W20  ,DL  "Y-!P K
M3@X *4X3 "=/&@ F3R$ )4\H "1/,  C4#< (E _ "%02  @4%( 'U%= !Y1
M:@ =47D '%&* !M1G  :4:\ &5'% !E1Y  :4/8 &T__ !Q/_P"*1@  >4<
M &M'  !@2   5D@  $Y(  !'20  /DL  #E,   S3@  +E   "A3 @ D5 L
M(E40 "!5%@ ?5AX 'E8D !U6+  <5C, &U<[ !I71  95TX &%=9 !=89@ 5
M6'4 %%B' !18F@ 35ZP $E?" !)7X0 35O0 %%7_ !15_P"$20  =$H  &9+
M  !<2P  4TL  $M,  !$30  /$\  #51   O5   *58  "19   >6P< &ET-
M !A=$@ 771D %EX@ !5>)P 47BX $UXW !)>0  17TH $5]5 !!?8@ /7W$
M#E^#  U?E@ -7ZD #%Z^  Q>V@ -7?  #5S\  Y<_P!^30  ;DX  &).  !8
M3P  3T\  $A0  ! 4@  .%0  #!7   J6@  )%T  !]?   98@$ $V4) !%F
M#P 09A0 #V8;  YG(@ -9RD #6<R  QG.P +9T4 "F=0  EG70 '9VP !F=]
M  5GD  $9J,  F:W  -ESP $9>D !&3U  1D_ !W40  :5(  %U2  !44@
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M  !Z4   >E\  'IP  !Z@P  >I@  'JL  !YP@  >-\  'CO  !W]P!J6P
M7UL  %9;  !,7   0F   #EC   P:   *&P  "!P   9=   $W<   Y[   )
M?@  !($"  """   @PT  (,0  "$%   A1D  (8@  "&*   AS$  (<\  "'
M20  AU<  (=H  "'>P  AY   (:E  "%N@  A=,  (3J  "$] !E8   7&
M %%A  !&9   /&D  #)M   I<@  (7<  !E[   2@   #8,   B'   "B@
M (T   ".!   C@D  (\-  "0$   D10  )(9  "3(   E"D  )4S  "50
MEDX  )9?  "5<@  E8@  )6=  "4L@  E,@  )/B  "3[@!A90  5F8  $IJ
M   _;@  -70  "MY   A?P  &80  !&)   ,C0  !I$   "4    F    )H
M  ";    G (  )T'  ">"P  GPX  *$2  "B&   HR   *4I  "F-@  ID0
M *95  "F:   IGT  *:4  "EJ0  I+T  *31  "DY !;;   3W   $-U   X
M>P  +8$  ".'   9C0  $9(   N7   $G    *    "C    I@   *@   "I
M    J@   *P   "M!   K@D  + -  "Q$0  LQ<  +4@  "V*P  MSH  +=+
M  "X7   N'$  +B(  "XG0  N+$  +?"  "WT !4=@  2'P  #R"   QB0
M)I   !N7   2G0  #*(   .G    JP   *X   "R    M@   +@   "X
MN@   +L   "]    O@   , %  #!"P  PQ   ,86  #)(   RBX  ,L^  #,
M4   S&0  ,UZ  #-D0  S:0  ,VT  #-P !-@P  08H  #61   IF0  'J
M !.F   ,K    [$   "V    N@   +X   #"    Q@   ,@   #(    R@
M ,L   #-    S@   -    #2 0  U0@  -D.  #=%0  X2$  .(Q  #D0P
MY58  .9K  #F@@  YY8  .>E  #FL #_  D _P % /\ !@#_  X _P 6 /\
M(0#_ "T _P X /T 0P#Y $T ]0!5 /( 70#P &, [@!I .P ;P#J '0 Z0!Z
M .< ?P#F (4 Y "+ ., D0#A )D WP"A -P J@#: +8 UP#& -4 X0#3 /0
MT@#_ -$ _P#1 /\ SP#_ ,H _P#_  $ _P   /\  0#_  P _P 2 /H '0#V
M "@ \P S /  /@#L $@ Z !0 .4 6 #B %X WP!D -T :@#; &\ V0!T -8
M>@#4 '\ T@"% -  C #. ), S "< ,D I0#' +  Q@"^ ,0 U #" .X P0#^
M ,  _P#  /\ OP#_ +X _P#_    _P   /\   #Z  < \0 / .L & #F ",
MX@ N .  . #; $( U0!+ -$ 4@#. %D RP!? ,D 90#' &H Q@!O ,0 = #"
M 'H P0"  +\ A@"] (X NP"6 +D H "W *H M@"W +0 R@"R .8 L0#X +
M_P"O /\ KP#_ +  _P#_    _P   /<   #J  ( X0 , -< $P#0 !T S  H
M ,D ,@#& #P P@!% +\ 30"\ %, N@!9 +@ 7P"W &0 M0!I +0 ;@"R '0
ML0!Z *\ @ "M (@ K "1 *H F@"H *4 I@"Q *0 P0"C -P H0#R *$ _P"@
M /\ H #_ *$ _P#_    ]P   .@   #9    RP ( ,, $ "] !@ N0 B +8
M+ "T #8 L@ _ *\ 1P"L $T JP!4 *D 60"G %X I@!C *4 : "C &X H@!T
M *  >@"> (( G "+ )L E0"9 )\ F "L )8 N@"4 ,\ DP#K )( ^P"2 /\
MD@#_ )$ _P#W    YP   -,   #&    NP " +, # "M !( J@ < *< )@"D
M #  HP X *  0 "> $< G !. )H 4P"9 %@ EP!= )8 8P"5 &@ DP!N )(
M= "0 'P CP"% (T CP"+ )H B@"G (@ M0"& ,< A0#D (0 ]0"$ /\ @P#_
M (, _P#L    TP   ,$!  "T    K    *8 !P"@  X G0 6 )H ( "7 "D
ME0 R ), .@"1 $$ CP!( (T 30", %, BP!8 (D 70"( &, AP!I (4 ;P"#
M '< @@"  (  B@!^ )8 ?0"C 'L L !Z ,( >0#= '@ \0!W /T > #_ '@
M_P#>"@  Q L  +(,  "F"P  G0@  )D$  "5  H D0 1 (X &0"+ ", B0 L
M (< - "% #L @P!" (( 2 "  $X ?P!3 'T 6 !\ %X >P!D 'D :@!X '(
M=@![ '0 A@!S )( <0"? '  K0!N +X ;0'6 &T"[0!L _H ; /_ &P#_P#.
M$   MQ$  *82  ":$0  D1   (L.  ")"P, AP4, (0!$P"! 1P ?@(E 'P#
M+@!Z S8 > 0\ '<$0P!U!4@ = 5. ',%5 !Q!5D < 9? &X&9@!M!FX :P=X
M &H'@P!H")  9PF= &4)K !D";P 8PK4 &,+[ !B#/H 8@S_ &(,_P##%@
MK1<  )T8  "0&   AQ8  ($4  !]$0  ? X& 'P*#@!X"A8 =0L? '(+* !P
M##  ;PPW &T,/@!L#$0 :PU* &D-3P!H#54 9PU< &4-8P!C#FL 8@YU & .
M@0!?#HX 70^< %P0JP!;$+T 6A#6 %D1\ !9$?T 61'_ %D1_P"Y&P  I1T
M )0>  "('@  ?AT  '@;  !T&   <14  '$1"0!O$!$ ;! 9 &D0(@!G$2H
M9A$R &01.0!C$3\ 8A%% & 22P!?$E$ 71)8 %P27P!:$V@ 61-R %<4?0!6
M%(L 5!69 %,5J0!2%KH 41;2 %$7[0!1%_T 41?_ %$7_P"R(   GB(  (XB
M  "!(P  =R(  ' A  !L'@  :1L  &<8! !F%0X 8Q85 &$6'@!?%B8 718M
M %P7- !:%SL 61=! %@81P!6&$T 51A4 %,87 !2&60 41EN $\:>@!.&X@
M31N7 $L<I@!*'+@ 2AW/ $D=ZP!)'?L 21W_ $H=_P"L)   F"4  (@F  ![
M)P  <28  &HE  !F(P  8B$  & >  !>' L 6QL2 %D<&@!7'"( 51PI %0<
M, !3'3< 41T] % =0P!/'4H 31Y1 $P>6 !+'V$ 21]K $@@=P!'((4 1B&4
M $0BI !$(K8 0R+, $,CZ0!#(_H 0R/_ $,B_P"F)P  DRD  (,J  !V*@
M;2H  &4I  !@)P  7"4  %DC  !7(0< 52$/ %(A%@!0(1X 3B$E $TB+ !,
M(C, 2B(Y $DB0 !((D8 1R-- $4C50!$)%X 0R1I $(E=0! )H, /R:2 #XG
MHP ^)[0 /2?* #THZ  ]*/D /2?_ #XG_P"B*@  CBL  '\M  !R+0  :"T
M &$L  !<*P  6"@  %0F  !1)@0 3B4- $PE$P!*)AH 2"8B $<F*0!%)B\
M1"8V $,G/ !!)T, 0"=+ #\H4P ^*5P /2EF #PJ<@ [*H$ .BN0 #DKH0 X
M++( -RS( #<LY@ X+/@ ."S_ #@L_P"=+   BBX  'LO  !O,   93   %TO
M  !8+@  4RL  % J  !,*@  22H+ $8J$0!$*A< 0BH? $$J)0 _*BP /BLS
M #TK.0 \*T  .RQ( #HL4  Y+5D ."YD #<N<  V+W\ -2^/ #0PGP S,+$
M,C#' #(PY0 S,/< ,S#_ #0O_P"9+P  AS$  '<R  !K,@  8C(  %HR  !4
M,0  3R\  $LM  !'+@  1"X( $$N#@ _+A0 /2X< #LN(@ Y+RD ."\O #<O
M-@ V,#X -3!& #4Q3@ T,5< ,S)B #(R;@ Q,WT ,#.- "\TG@ N-+  +33%
M "TTXP N-/8 +S/_ "\S_P"5,0  @S,  '0T  !H-0  7C4  %<T  !1-
M2S(  $8Q  !",@  /S(% #PR#0 Y,Q( .#,9 #8S(  T,R8 ,S,M #(T-  Q
M-#L ,#5# # U3  O-E4 +C9@ "TW;  L-WL *S>+ "HXG  I.*X *#C# "@X
MX@ I./4 *C?_ "HW_P"2-   ?S4  '$V  !E-P  6S<  %0W  !--@  1S8
M $(U   ]-@  .C8" #<W"P T-Q  ,C<6 #$X'0 O."0 +C@K "TY,@ L.3D
M*SE! "HZ20 J.E, *3M> "@[:@ G.WD )CR) "4\FP D/*T (SS" ",\X  D
M//0 )3O_ "4[_P"--@  ?#@  &TY  !B.0  6#H  %$Y  !*.0  1#D  #TY
M   Y.@  -3L  #(["  O/ X +3T4 "P]&@ J/2$ *3TH "@^+P G/C8 )CX^
M "4_1P D/U  (T!; ") :  A0'8 ($"' !]!F0 ?0:L 'D'  !Y!W@ ?0/,
M'T#^ " __P").0  >#H  &D[  !>/   53P  $T\  !'/   0#P  #@]   T
M/@  ,$   "U!!0 J0@P )T(1 "9#&  D0QX (T,E ")#+  A1#, ($0[ !]$
M1  >14X '459 !Q%90 ;170 &D6% !E&EP 91JD &$:^ !=%W  81?$ &43]
M !I$_P"$/   <ST  &8^  !;/P  4C\  $H_  !$/P  /4   #9!   Q0P
M+$0  "=& 0 D1PH (4@/ "!)%  >21L '4DB !Q)*0 ;2C  &DHX !E*00 8
M2DL %TM5 !9+8@ 52W$ %$N" !-+E  22Z< $DN\ !%+V0 22O  $TK\ !1)
M_P!_/P  ;T   &%!  !70@  3D(  $="  !!0@  .D,  #)%   M1P  *$D
M "-+   >308 &T\- !A0$0 74!< %E > !50)0 44"P $U$T !)1/0 144<
M$5%2 !!17P /4FT #E)^  U1D0 -4:0 #%&X  Q1T0 -4.P #5#Z  Y/_P!Y
M0P  :D0  %U$  !310  2T4  $1%   ^1@  -D@  "]*   I3   )$\  !]1
M   :4P  %%8) !%7#@ 06!, $%@9  ]8(  .6"@ #5@P  U8.0 ,6$, "UA.
M  I86@ (6&@ !UAY  98C  %6)\ !%BS  17R@ %5^8 !5?S  96_ !S1@
M9$<  %E(  !02   2$@  $%)   Z2@  ,DT  "M0   E4@  (%4  !I8   5
M6@  $%T&  Q@#  *8!  "6 5  A@'  '8", !6 K  1@-  #8#T  6!)  !@
M50  8&,  &!S  !@A@  7YH  %^N  !?Q   7N(  %[P  !>^ !L2@  7TL
M %5+  !,3   14P  #U.   U4   +E,  "=6   @60  &EP  !5?   08@
M#64$  AG"P #9PX  &@3  !H&   :!\  &DF  !I+@  :3@  &E#  !I3P
M:5T  &EM  !I@   :90  &BI  !HOP  9]P  &;N  !F]P!F3P  6D\  %%/
M  !*3P  05$  #A4   P5P  *%L  "%>   :8@  %&4  !!H   ,:P  !VX#
M  %P"0  < T  '$0  !Q%   <AH  ',A  !S*   <S$  ',\  !T2   <U8
M '-F  !S>0  <XX  '.C  !RN0  <=(  ''K  !P] !A4P  5E,  $]3  !%
M50  .U@  #)<   J8   (F0  !MH   4;   #V\   MR   &=@   'D   !Z
M!@  >@H  'L.  !\$0  ?14  'X;  !_(@  @"H  ( U  " 00  @$\  (!?
M  " <0  @(8  ("=  !_L@  ?LH  '[E  !]\0!<6   5%@  $E:   _70
M-6$  "QE   C:@  &V\  !1S   .=P  "7L   -_    @@   (0   "& 0
MA@8  (@*  ")#0  BA   (L5  ",&P  CB(  (\L  "/.   CT8  (]6  "/
M:   CWX  (^5  ".JP  C<$  (W<  ",ZP!970  3E\  $-B   X9@  +FP
M "1Q   <=P  %'P   Z!   (A0   (D   "-    D    )(   "3    E
M )8#  "7"   F P  )H/  ";$P  G1H  )\C  "@+@  H#P  *!,  "@7@
MH'0  )^,  "?H@  G[<  )[+  ">X !39   1V@  #QM   Q<P  )WD  !U_
M   4A0  #8L   :0    E    )@   "<    GP   *$   "B    I    *4
M  "G    J 0  *H)  "L#0  K1(  + 9  "R(P  LC$  +)"  "R5   LFD
M +*   "RF   L:P  +*_  "QS@!,;@  0',  #5Z   J@0  'X@  !6.   .
ME0  !IH   "?    I    *@   "L    KP   +$   "Q    LP   +4   "V
M    N    +H   "\!@  O@P  , 1  ##&0  Q28  ,4W  #&20  QET  ,=R
M  #'B@  R)\  ,BO  #(O !&>@  .8$  "Z)   BD   %Y@   ^?   'I0
M *H   "O    LP   +<   "\    OP   ,$   #"    Q    ,4   #'
MR0   ,L   #-    SP,  -(*  #6$   W!H  -TJ  #>/   WU   .!E  #A
M>P  X9$  .*B  #BK0#_  ( _P   /\  P#_  P _P 3 /\ '0#_ "@ _@ S
M /L /@#W $@ \P!0 /  5P#M %X ZP!D .@ :0#G &\ Y0!T ., >0#B '\
MX "% -X C #< ), V0"< -8 I@#3 +$ T0#  ,\ V@#. /$ S #_ ,L _P#+
M /\ Q@#_ ,$ _P#_    _P   /\   #_  @ ^P 0 /8 &0#R "0 [P N .T
M.0#H $( XP!+ .  4@#= %D V0!? -8 9 #3 &D T0!N ,\ = #. 'D S !_
M ,H A@#( (X Q@"6 ,0 H #" *L P "Y +X S0"\ .H NP#\ +H _P"Z /\
MN@#_ +8 _P#_    _P   /X   #T  0 ZP - .0 % #? !\ VP I -@ ,P#3
M #T S@!% ,H 30#' %, Q0!9 ,, 7P#! &0 OP!I +T ;@"[ ', N@!Y +@
M@ "V (@ M "0 +( F@"Q *4 KP"R *T Q "L .$ JP#V *H _P"J /\ J@#_
M *H _P#_    _0   .X   #B    U0 * ,T $0#' !D Q  C ,$ +0"_ #<
MNP _ +< 1P"U $X L@!3 +  60"O %X K0!C *P : "K &T J0!S *@ >@"F
M ($ I "* *, E "A )\ GP"L )X NP"< -( FP#N )H _P": /\ F0#_ )D
M_P#^    [@   -X   #+    P0 % +D #0"T !0 L0 > *X )P"K #  J@ Y
M *< 00"D $@ H@!- *$ 4P"? %@ G@!= )T 8@"; &< F@!M )@ <P"7 'L
ME0"$ )0 C@"2 )D D "F (X M "- ,@ C #F (L ^0"* /\ B@#_ (L _P#P
M    VP   ,<   "Z    L    *@ "@"D !  H  8 )T (0"; "H F@ S )@
M.P"6 $$ E !( )( 30"1 %( CP!7 (X 7 ", &$ BP!G (H ;@"( '4 AP!^
M (4 B "# )0 @@"@ (  KP!_ ,  ?@#= 'T \@!] /\ ?0#_ 'T _P#@
MQ@   +4   "J    H@   )L !0"5  T D@ 3 )  ' "- "0 BP M (H - "(
M #L A@!" (4 1P"# $T @@!2 ($ 5P!_ %P ?@!B 'T : ![ '  >@!Y '@
M@P!V (\ =0"< '0 J@!R +H <0#1 '  [ !P /L < #_ '  _P#-!   MP8
M *<'  ";!@  DP0  (X   "*  @ A@ / (0 %@"! !X ?P G 'T +@!\ #8
M>@ \ 'D 0@!W $< =@!, '4 4@!S %< <@!= '$ 8P!O &L ;@!T &P ?@!K
M (H :0"8 &@ I@!G +8 9@#+ &4 YP!E /< 90#_ &4 _P# #   JPT  )L.
M  "/#@  A@T  ($+  !^!P$ ? $+ 'D $0!W !@ =0 A ', *0!Q #  ;P V
M &X / !L $( :P!' &H 30!I %( : !8 &8 7P!E &< 8P!P &(!>@!@ 8<
M7P*5 %X"HP!< [, 7 /' %L$Y !;!?0 6P;^ %L&_P"U$   H1(  )$3  "%
M$P  ?!(  '81  !S#@  <@P$ '$'#0!N!!( ; 0; &D%(P!G!2H 9@8Q &0&
M-P!C!CT 8@=# &$'20!?!TX 7@A5 %T(7 !;"6, 6@EM %@*> !7"H4 5@N3
M %0+H@!3"[, 4@S' %(,Y !1#?4 40W_ %$-_P"M%0  F1<  (D8  !]&0
M=!@  &T7  !J%   9Q$  &<.!P!F# X 8PP5 &$,'0!?#"4 70TL %P-,P!;
M#3D 6@T_ %@-10!7#4L 5@Y1 %4.60!3#F$ 4@YK % /=@!.$(, 31"2 $P0
MH@!+$+( 2A'( $D1Y0!)$?< 21+_ $D1_P"E&0  DAP  (,=  !V'@  ;1T
M &8<  !B&@  7Q<  %X4 0!>$0H 6Q 1 %D1& !7$2  51$G %01+@!3$30
M41$[ % 200!/$D< 3A). $P250!+$UX 21-G $@4<P!&%(  116/ $05GP!#
M%K  0A;% $(7XP!"%_8 0A?_ $(7_P"?'0  C"   'TA  !Q(@  :"(  &$A
M  !<'P  61P  %<9  !5%@8 5!4. %$5% !/%AP 3A8C $P6*@!+%C  2A8W
M $D7/0!'%T, 1A=* $484@!#&%H 0AED $$9<  _&GT /AN- #T;G0 \'*X
M.QS# #L<X0 ['?4 .QS_ #P<_P":(0  AR,  '@D  !L)0  8R4  %PD  !7
M(P  4R   %$>  !/' ( 31L, $L:$0!(&Q@ 1QL@ $4;)@!$&RT 0QPS $(<
M.0! '$  /QU' #X=3P ]'E@ /!YB #H?;0 Y'WL .""+ #<AFP V(:T -2'!
M #4AWP U(?, -B'_ #8A_P"6(P  @R8  '0G  !H*   7R@  %@G  !3)@
M3R0  $PB  !)(   1R ) $0?#P!"'Q4 0" < #\@(P ^("D /" O #LA-@ Z
M(3T .2%$ #@B3  W(E4 -B-? #0C:P S)'D ,B6) #$EF@ P):L ,":_ "\F
MW  P)O( ,";_ #$E_P"1)@  ?R@  '$J  !E*@  7"H  %4J  !/*0  2R@
M $@E  !$)   020% #\D#0 ])!( .R09 #DD'P W)"8 -B0L #4E,P T)3H
M,R9! #(F2@ Q)U, ,"== "\H:0 N*7< +2F' "PIF  K*JH *BJ] "HJV@ K
M*O$ *RK^ "PI_P"-*   ?"H  &TL  !B+0  62T  %$M  !,+   1RL  $,H
M   _*   /"@" #DH"P W*!  -2@6 #,H'  R*", ,"@I "\I,  O*C< +BH_
M "TK1P L*U$ *RQ; "HL9P I+74 *"V% "<MEP F+J@ )2Z\ "4NV  F+O
M)B[] "<M_P"**P  >"T  &HN  !?+P  5B\  $XO  !(+@  0RT  #\L   [
M+   -RP  #0L"0 R+ X ,"T3 "XM&@ M+2  *RTG "HN+0 J+C4 *2\] "@O
M10 G,$X )C!9 "4Q90 D,7, (S&# "(RE0 A,J< (3*[ " RU  A,N\ (C'\
M "(Q_P"&+0  =2\  &<P  !<,0  4S$  $LQ  !%,0  0#   #LP   V,
M,S   # Q!@ M,0T *S$1 "DR%P H,AX )S(D "4S*P E,S( )#,Z ",T0P B
M-$P (357 " U8P ?-7$ 'C:! !TVDP <-J4 &S:Y !LVT@ <-NT '3;[ !TU
M_P"",   <3(  &,S  !9-   4#0  $DT  !",P  /3,  #<S   Q-   +C4
M "LU @ H-@L )3<0 "0W%0 B-QL (3@B " X*  ?.#  'C@W !TY0  <.4D
M&SI4 !HZ8  9.FX &#I_ !<[D0 7.Z0 %CNW !4[T  6.NP %SKZ !@Y_P!]
M,@  ;30  & U  !5-@  338  $8V  ! -@  .C8  #0V   N.   *CD  "8Z
M   C.P@ (#P. !X]$@ =/1@ '#T? !L^)0 :/BT &3XT !<^/0 6/T< %3]1
M !0_7@ 4/VP $T!\ !) CP 10*( $4"V !! S@ 1/^L $C_Y !(^_P!Y-0
M:3<  %PX  !2.0  2CD  $,Y   ].0  -SD  #$Z   K/   )ST  "(_   >
M000 &D(+ !A#$  70Q4 %40; !1$(@ 31"D $T0Q !)$.@ 114, $$5. !!%
M6P .16D #D5Y  U%C  -19\ #$6R  M%R0 ,1>4 #43V  U$_P!T.0  93H
M %@[  !/.P  1SP  $ \   Z/   -#P  "X^   H0   (T(  !]$   :1@
M%4@( !)*#0 12A( $$H8  ]+'@ .2R4 #4LM  U+-@ ,2T  "TM*  I+5@ )
M2V0 "$MT  =+AP %2YH !$NN  1*Q  %2N  !4KP  9)^@!N/   8#T  %0^
M  !+/@  1#X  #T^   W/P  ,4   "I"   D10  'T<  !I)   53   $4X%
M  Y1"P +41  "E$4  E1&P (42( !U$I  51,@ $4CL  U)&  %24@  4E\
M %)O  !2@0  498  %&I  !1OP  4-P  %#N  !0]P!H0   6T$  %!!  !(
M00  04$  #M"   T0P  +44  "9(   @2P  &TT  !90   14P  #E4$  I8
M"@ &6 X  E@2  !9%P  61T  %DE  !9+0  638  %E!  !930  6EH  %II
M  !9?   69   %FE  !8N@  6-4  %?L  !7]@!C1   5D4  $U%  !%10
M/T4  #='   O20  *$P  ")/   ;4@  %E4  !%8   -6@  "5T#  1?"0
M8 T  & 0  !A%   81D  &(@  !B)P  8C$  &([  !B1P  8E4  &-D  !B
M=@  8HL  &*@  !AM@  8<\  &#J  !@]0!=2   4DD  $I(  !#2   .DH
M #)-   J4   (U,  !Q7   66@  $5T   U@   (8P   V8!  !G!@  : L
M &D.  !J$0  :Q4  &P;  !M(@  ;2H  &TT  !M0   ;4X  &U=  !M;P
M;80  &R:  !LL   :\@  &OF  !J\P!830  3DT  $A,   ^3@  -5$  "Q4
M   D6   '5P  !9@   09   #&<   =K   !;@   '    !R P  <@<  ',+
M  !U#@  =A$  '<6  !X'   >2,  'HM  !Z.0  >D<  'I6  !Y:   >GP
M 'F4  !XJ@  >,$  '??  !W[P!440  3%$  $)2   X50  +UD  "9>   >
M8@  %F<  !!K   +;P  !7,   !W    >@   'P   !^    ?P(  ( &  "!
M"@  @PT  (01  "&%0  B!P  (DE  "*,   BCX  (E-  ")7P  B7,  (B+
M  "(H@  A[D  (?1  "&Z !25@  1U<  #Q:   R7P  *&0  !]I   6;P
M$'0   IY   "?0   ($   "%    B    (H   ",    C0   (\   "0!
MD@@  ),,  "5$   EQ4  )D=  ";)P  FS0  )M$  ":5@  FFH  )F"  ":
MF@  F+   )C'  "7W@!+7   0&   #5E   K:@  (7$  !=W   0?0  "8,
M  &(    C    )$   "5    F    )H   ";    G0   )\   "@    H@
M *0%  "F"@  J X  *H4  "M'0  K2H  *TY  "M2P  K5\  *UW  "LD
MJZ<  *NZ  "KRP!%9@  .6L  "YQ   C>   &7\  !"&   )C0   ),   "8
M    G0   *$   "E    J    *L   "K    K@   *\   "Q    LP   +4
M  "W 0  N0<  +P-  "_$P  PA\  ,(N  #"0   PE0  ,%K  #!@P  P)L
M ,&M  #!O  ^<@  ,G@  ">    <B   $I    J7    G0   *,   "H
MK0   +(   "V    N0   +L   "\    O@   ,    #"    Q    ,8   #(
M    RP   ,X%  #1#0  UA0  -<C  #8-0  V4D  -I>  #;=0  VXP  -R?
M  #<JP#_    _P   /\   #_  D _P 0 /\ &0#^ "0 _  O /D .0#T $,
M\ !+ .T 4@#J %D YP!? .0 9 #B &D X !N -X <P#< 'D V@!_ -< A@#4
M (X T0"6 ,\ H0#, *P R@"[ ,@ T@#& .X Q@#_ ,4 _P#% /\ OP#_ +H
M_P#_    _P   /\   #^  4 ]P . /( %0#N !\ ZP J .D - #C #T W@!%
M -D 30#4 %, T0!9 ,X 7@#, &, R@!H ,D ;0#' ', Q0!Y ,, @ #! (@
MOP"0 +T FP"[ *8 N0"T +< R "V .8 M0#[ +0 _P"T /\ LP#_ *X _P#_
M    _P   /@   #M    Y0 + -T $0#7 !H T@ D ,\ +@#+ #< QP!  ,,
M1P#  $X O@!3 +P 60"Z %X N !C +8 : "U &T LP!S +$ >0"O ($ K0"*
M *L E "I *  J "M *8 O@"E -L I #T *0 _P"C /\ HP#_ *( _P#_
M]@   .8   #7    RP & ,0 #@"^ !4 NP ? +D * "W #$ M  Z +  00"M
M $@ JP!. *D 4P"G %@ I@!< *0 80"C &< H0!L *  <P"> 'H G0"# )L
MC@"9 )D EP"F )8 M@"5 ,P E #K ), _0"3 /\ DP#_ ), _P#W    Y
M -    #!    MP " *\ "P"K !$ IP 9 *4 (@"C "L H@ S )\ .P"< $(
MFP!( )D 30"7 %( E@!7 )4 6P"3 &$ D@!F )  ;0"/ '0 C0!] (P AP"*
M ), B "@ (< KP"% ,( A0#B (0 ]P"$ /\ A #_ (0 _P#E    S0   +P
M  "O    I@   )X !P":  X E@ 4 )0 '0"2 "4 D0 M )  -0"- #P C !"
M (H 1P"( $P AP!1 (8 5@"$ %L @P!@ ($ 9P"  &X ?@!W 'T @0![ (T
M>@": '@ J0!W +H =@#3 '8 [P!V /X =0#_ '4 _P#0    NP   *L   "?
M    EP   )   @"+  L B  0 (8 %P"$ "  @@ G ($ +P!_ #4 ?0 \ 'P
M00![ $8 >0!+ '@ 4 !W %4 =@!; '0 80!S &D <0!Q '  >P!N (< ;0"5
M &L HP!J +0 :@#) &D Z !I /D :0#_ &D _P#     K    )P"  "0 @
MB    (,   !_  8 >P - 'D $@!W !H =@ B '0 *0!S #  <0 V '  / !O
M $$ ;0!& &P 2P!K %  :@!6 &@ 7 !G &0 90!L &0 =@!C (( 80"0 &
MGP!? *\ 7@## %X X0!> /0 70#_ %T _P"T!P  H D  ) +  "$"P  ? H
M '<'  !T!   <0 ) &\ #P!M !4 :P < &D (P!H "H 9P Q &4 -@!D #P
M8P!! &( 1@!@ $P 7P!2 %X 6 != %\ 6P!H %H <@!8 'X 5P", %8 FP!5
M *L 5 "^ %0 V@!3 .\ 5 #[ %0 _P"I#0  E@X  (<0  !Z$   <A   &P.
M  !I#   9PD# &8$"P!D !  8@ 7 &  '@!> "4 70 K %P ,0!: #< 60 \
M %@ 0@!7 4< 5@%. %4"5 !3 EP 4@-E %$#;P!/!'L 3@2* $T%F0!,!:D
M2P6\ $H&U !*!^T 2@?Y $H'_P"A$   CA(  'X4  !S%   :A0  &03  !@
M$0  7@\  %T-!0!="0T 6@82 %@'&0!6!R  50<G %,'+0!2"#, 40@X % (
M/@!/"40 3@E* $P)40!+"ED 2@IB $@+;0!'"WH 1@R( $0,F !##*D 0@V\
M $(-U0!"#>X 0@W[ $(-_P":%   AQ8  '@8  !L&0  8QD  %T8  !9%@
M5A,  %01  !4#@@ 4PT. %$-% !/#1L 30TB $P-* !+#2X 2@TT $D-.@!'
M#D$ 1@Y' $4.3P!$#E< 0@]A $$0;  _$'D /A"( #T1F  [$:D .Q&\ #H1
MU@ Z$?  .A+] #L1_P"3&   @1H  ',<  !G'0  7AT  %@<  !3&P  4!@
M $X6  !,$P, 3!$+ $H0$ !($1< 1A$> $41) !$$2H 0A$P $$1-P! $CT
M/Q)$ #T23  \$U0 .Q-> #D4:0 X%'8 -Q6% #85E@ T%J< -!:Z #,6TP S
M%NX -!;\ #06_P".&P  ?!T  &X?  !C(   6B   %,@  !.'@  2AT  $@:
M  !&&   118' $,5#@!!%1, /Q4: #X5(  ]%2< .Q4M #H6,P Y%CH .!9!
M #<720 U%U$ -!A; #,99@ R&7, ,!J# "\:E  N&Z4 +1NX "T;T  M&^P
M+AO[ "X;_P"*'@  >"   &HB  !?(P  5B,  $\B  !*(0  1B   $,>  !!
M&P  /QH# #T:#  [&1$ .1D6 #<:'0 V&B, -1HI #0:,  S&S8 ,1L^ # <
M1@ O'$\ +AU9 "T=9  L'G$ *Q^! "H?D@ I'Z0 *""W "<@S@ G(.L *"#Z
M "D?_P"&(   =",  &<D  !<)0  4R4  $PE  !')   0B,  #\A   ]'P
M.AX  #<>"0 U'@X ,QX3 #$>&@ P'B  +QXF "X?+0 M'S, +" [ "L@0P J
M(4P *2%6 "@B8@ F(F\ )2-_ "0CD  C(Z( (B2U "(DS  B).D (R3Y "0C
M_P""(P  <24  &,F  !9)P  4"@  $DG  !#)P  /R8  #LD   X(@  -2(
M #(B!@ P(@T +B(1 "PB%P J(AT *2(C "@C*@ G(S$ )B0X "4E00 D)4H
M(R94 "(F8  A)VT ("=] !\GCP >**$ 'BBT !THR@ =*.@ 'BCX !\G_P!^
M)0  ;B<  & I  !6*0  32H  $8J  !!*0  /"@  #<G   T)@  ,"8  "TF
M P K)PL *"<0 "<G%  E)QH )"<A ",H)P B*"X (2DV " I/@ ?*D@ 'BI2
M !TK7@ <*VL &RM[ !HLC0 9+)\ &"RR !@LR0 8+.< &2OW !HK_P!Z)P
M:BH  %TK  !3+   2BP  $,L   ^*P  .2L  #0J   P*@  *RH  "DK   F
M*P@ (RP. "(L$@ @+!@ 'RP> !XM)0 =+2P '"TS !LN/  :+D4 &2]0 !@O
M7  7+VD %C!Y !4PBP 4,)X %#"Q !,PQP 3,.4 %##V !4O_P!V*@  9RP
M %HM  !0+@  2"X  $$N   [+@  -BT  #$M   L+0  )R\  "0O   A, 4
M'S$, !PQ$  ;,A4 &C(< !DR(@ 8,BD %S,Q !8S.0 5,T, %#1- !,T60 2
M-&< $35W !$UB0 0-9P $#6P  XUQ@ /-.0 $#3U ! T_P!R+   8RX  %<P
M  !-,   13   #XP   X,   ,S   "\P   I,0  )#(  "$S   =-0( &C8)
M !<W#@ 5-Q, %#@9 !,X'P 2."8 $C@N !$Y-@ 0.4  $#E+  XY5P ..F0
M#3IT  PZA@ ,.ID "SFL  HYP0 *.=X "SGQ  PX_ !N+P  7S$  %,R  !*
M,P  0C,  #LS   V,P  ,3(  "PS   G-   (38  !TX   9.0  %3L& !(]
M#  0/A  $#X5  X^'  ./B, #3XJ  P^,P ,/CP "S]'  H_4@ (/V  !S]O
M  8_@0 %/Y0 !#^H  ,^O  $/M< !3[L  4^]P!I,P  6S0  % U  !'-0
M/S4  #DU   T-0  +C4  "DW   C.   'CL  !H\   6/P  $D$$  Y#"@ ,
M1 X "D03  E$&0 (1"  !T0G  9$+P %1#@  T5"  )%3@  15L  $5J  !%
M?   19   $2D  !$N0  1-$  $3J  !#]0!D-@  5S<  $PX  !#.   /#@
M #<X   Q.   *SD  "4[   @/0  &D   !9"   21   #D<$  M)"0 '2@T
M!$L1  %+%@  2QP  $LC  !+*P  2S0  $L^  !,20  3%<  $QF  !,=P
M2XP  $NA  !+M0  2LX  $KI  !*]0!?.@  4CL  $@[  ! .P  .CL  #0[
M   N/   )SX  ")!   <0P  %D8  !))   .2P  "TX#  =0"  "40P  %$0
M  !2$P  4Q@  %,?  !3)@  4R\  %,Y  !310  4U(  %-A  !3<@  4X<
M %*<  !2L0  4<H  %'G  !1] !9/@  3CX  $4^   ^/@  .#X  #!    I
M0@  (T0  !U'   72@  $DT   Y0   +4P  !E4"  !7!P  6 L  %D.  !:
M$0  6A4  %L:  !<(0  7"H  %PT  !</P  7$T  %Q;  !<;   7($  %N7
M  !;K0  6L4  %KD  !9\P!40@  2D(  $)"   \0@  -$,  "Q&   E20
M'DP  !=/   24P  #E8   I9   %6P   %X   !@!   80@  &(,  !C#@
M9!$  &46  !F'   9R,  &<M  !G.0  9T8  &=5  !G9@  9WH  &:1  !E
MJ   9<   &3>  !D\ !/1@  1T8  $!%   W1P  +TH  "9-   ?40  &%4
M !)9   -7   "&    )C    9@   &@   !J    :P0  &P(  !M#   ;PX
M ' 2  !R%P  <QT  '0F  !T,@  =#\  '1.  !S7P  ='(  '.*  !RH0
M<;@  ''4  !P[ !,2@  14H  #M+   R3@  *5(  "!6   86P  $E\   UD
M   ':    &L   !O    <@   '4   !V    =P   'D"  !Z!@  ? H  'X.
M  " $0  @A8  (0>  "$*0  A#8  (1%  "$5@  @VH  (.!  ""F0  @;$
M (#)  " Y0!*3@  /U   #53   K5P  (EP  !EB   29P  #&P   5Q
M=0   'D   !]    @0   (,   "%    A@   (@   ")    BP0  (T(  "/
M#0  DA   )06  "6(   EBP  )8[  "63   E6   )5V  "4D   DZ<  )*]
M  "2U0!$50  .5D  "]=   D8P  &FD  !)O   ,=0  !'L   "     A0
M (D   "-    D0   ),   "4    E@   )@   ":    G    )X   "@!@
MH@L  *40  "H%P  J2,  *DQ  "I0P  J58  *AM  "FAP  IYX  *:S  "E
MQP ^7@  ,F,  "=J   =<   $W@   Q_   #A0   (L   "1    E@   )L
M  "?    H@   *0   "E    IP   *D   "K    K0   +    "R    M0(
M +<)  "[$   OA@  +XF  "^.   ODL  +UA  "\>@  NY0  +JI  "ZN0 W
M:@  *W   "!X   6@   #8@   6/    E@   )P   "B    IP   *P   "P
M    LP   +8   "W    N0   +L   "]    OP   ,(   #%    R    ,H
M  #."   TA   -4;  #5+   U$   -17  #3;@  U(8  -2;  #3JP#_
M_P   /\   #_  4 _P . /\ %0#\ "  ^0 J /8 - #Q #T [0!& .D 30#F
M %, Y !9 .$ 7@#> &, W !H -D ;@#5 ', TP!Y -  @ #. (@ RP"1 ,D
MG #& *< Q "W ,( S #  .P OP#_ +X _P"] /\ MP#_ +( _P#_    _P
M /\   #Z  $ \P + .T $@#H !L Y0 E .0 +@#? #@ V !  -( 1P#. $X
MRP!4 ,@ 60#& %X Q !C ,( 9P#  &T OP!S +T >@"[ ($ N0"+ +8 E0"T
M *$ L@"O +  P@"N ., K@#Z *P _P"M /\ J0#_ *8 _P#_    _P   /(
M  #F    W0 ' -( #@#- !8 R@ @ ,@ *0#% #( P  Z +P 0@"Y $@ MP!.
M +4 4P"S %@ L0!= +  8@"N &< K !L *H <P"I 'L IP"$ *4 C@"C )H
MH0"H )\ N0"> -( G0#R )P _P"= /\ G #_ )D _P#\    [@   -T   #,
M    P0 " +H # "V !( L@ : +  (P"O "P K0 T *D / "F $( I !( *(
M30"@ %( G@!7 )T 6P"< &  F@!F )D ; "7 '0 E0!] ), AP"1 ), D "A
M (X L0"- ,8 C #H (L _0", /\ C #_ (P _P#M    V    ,4   "W
MK    *8 " "A  X GP 5 )T '@"; "8 F@ N )< -0"5 #P DP!" )$ 1P"0
M $P C@!1 (T 50"+ %H B@!@ (D 9@"' &T A0!V (0 @ "" (P @ ": '\
MJ0!] +P ? #< 'P ]0!\ /\ ? #_ 'P _P#9    P0   +$   "D    G
M )0  P"0  P C0 1 (L & ") "  B0 H (< +P"% #8 @P \ (( 00"  $8
M?P!+ 'T 3P!\ %0 >P!: 'D 8 !X &< =@!P '4 >@!S (8 <0"3 '  H@!O
M +0 ;@#, &X [0!N /X ;@#_ &X _P#$    KP   *    "4    C    (8
M  "!  @ ?@ . 'P % ![ !L >0 B '@ *0!W #  =0 V '0 .P!R $  <0!%
M '  2@!O $\ ;0!4 &P 6P!K &( :0!J &@ = !F (  90". &, G0!B *T
M80#" &$ Y !A /@ 80#_ &$ _P"T    H    )$   "&    ?@   'D   !U
M  , <0 + &\ $ !M !8 ;  = &L ) !K "H :0 P &@ -@!F #L 90!  &0
M10!C $H 80!/ &  5@!? %T 70!E %P ;P!: 'H 60"( %@ F !7 *@ 5@"[
M %8 V !6 /$ 5@#_ %8 _P"H 0  E 4  (4'  !Z!P  <@8  &P$  !I 0
M9P ' &0 #0!C !$ 80 8 &  'P!? "4 7@ K %T , !; #8 6@ [ %D 0 !8
M $4 5P!+ %8 40!5 %@ 4P!A %( :@!0 '8 3P"$ $X DP!- *0 3 "V $P
MS0!, .L 3 #Z $P _P"="0  BPL  'P-  !P#0  : T  &(,  !?"@  708!
M %P!"0!:  X 6  3 %< &0!6 "  50 F %, *P!2 #$ 40 V %  .P!/ $$
M3@!' $T 30!+ %4 2@!= $D 9P!' ', 1@"  $4 D !$ *$ 0P"R $, R !#
M .8 0P#U $, _P"5#0  @P\  '00  !I$0  8!$  %H0  !6#@  5 T  %,*
M! !3!@L 40,0 $\!%0!. 1L 3 $A $L!)P!* BP 20(R $@"-P!' ST 10-#
M $0#2@!#!%$ 0@1: $ %9  _!7  /@9^ #T&C@ \!Y\ .P>Q #H'Q@ Z!^,
M.@?S #H(_ ".$   ?!(  &X4  !B%0  6A4  %04  !0$P  31$  $L.  !+
M#08 2@H, $D($0!'"!8 10@= $0((P!"""@ 00DN $ ),P _"3D /@I  #T*
M1P \"D\ .@M8 #D+8P X#&\ -@Q^ #4,C@ T#9\ ,PVQ #(-QP R#>, ,@WT
M #(-_@"($P  =Q4  &D7  !>&   51@  $\8  !*%@  1Q4  $43  !#$ (
M0PX( $(-#@! #1( /PT8 #T-'P \#20 .PTJ #D-,  X#C< -PX] #8.10 U
M#DT ,P]7 #(/8@ Q$&X +Q!] "X0C@ M$:  +!&R "L1R  K$>8 *Q'V "P1
M_P"#%@  <AD  &0:  !9&P  41L  $L;  !&&@  0A@  #\7   ^%   /!($
M #L1"@ Z$!  .! 5 #<0&P U$2$ -!$G #,1+0 R$3, ,!$Z "\20@ N$DL
M+1-4 "L37P J%&P *11[ "@4C  G%9X )A6P "45Q@ E%>0 )17V "85_P!^
M&0  ;AL  & =  !6'@  31X  $<>  !"'0  /AP  #H:   X&   -Q8  #45
M!P T% T ,A02 # 4%P O%!T +10C "P5*@ K%3  *A4W "D6/P H%D@ )Q=2
M "8870 D&&H (QEY "(9B@ A&9P (!FO !\9Q  ?&>( (!GT " 9_P!Z&P
M:AX  %T?  !3(   2B   $0@   ^'P  .AX  #<=   T'   ,AD  # 9!  N
M& L +!@0 "H8%  I&!H )Q@@ "89)@ E&2T )!HU ",:/0 B&T8 (1M0 " <
M6P ?'6@ 'AUW !T=B  <'IL &QZM !H>PP :'N  &AWS !L=_P!W'0  9R
M %HA  !0(@  2"(  $$B   [(@  -R$  #,@   P'P  +1T  "L=   H'0@
M)AT. "4=$@ C'1< (1T= "$=)  @'BH 'QXR !X?.@ ='T, '"!- !LA60 :
M(68 &2%U !@BAP 7(ID %B*L !4BP0 5(M\ %2'R !8A_@!S(   9"(  %<C
M  !-)   124  #XD   Y)   -",  # B   L(@  *2$  "8A   D(08 (B$,
M " A$  >(14 '2(; !LB(0 ;(B@ &B,O !DC.  8)$$ %R1+ !8E5P 5)60
M%"9S !,FA0 2)I@ $2:K !$FP  0)MT $27Q !(E_0!P(@  820  %0F  !*
M)@  0B<  #PF   V)@  ,24  "TE   I)   )B0  "(E   ?)0, '28* !LF
M#@ 9)Q( &"<8 !<G'P 6)R4 %2@M !0H-0 3*3X $BE) !$I50 1*F( $"IQ
M  \J@P .*I8 #BJI  TJO0 -*M< #2KN  XI^P!L)   728  %$H  !(*
M0"D  #DH   T*   +R@  "LG   G)P  (B@  !XI   ;*@  &"L' !8K#0 4
M+!$ $RP6 !(L'  1+2, $"TJ ! M,@ /+CP #BY&  TN4@ -+E\ #"]N  LO
M?P *+Y( "2^E  DNN0 (+M  "2[I  HN]P!H)P  6BD  $XJ  !%*P  /2L
M #<K   Q*@  +2H  "DJ   D*@  ("L  !LM   8+@  %2\$ !(Q"@ 0,@X
M#S(3  XR&0 -,B  #3(G  PR+P +,S@ "C-"  DS3@ (,UL !C1J  4T>P $
M,XX  S.B  (SM@ ",\T  S/G  0R\P!D*@  5BP  $LM  !"+0  .BT  #0M
M   O+   *RP  "8L   B+0  '2\  !DQ   5,@  $C0#  \V"0 ,. T "C@1
M  DX%@ (.!T !S@D  8X+  $.#0  S@^  (Y2@  .5<  #EE   Y=P  .8L
M #B?   XLP  .,H  #CF   W\@!?+0  4BX  $@O   _,   ."\  #(O   M
M+P  *2\  "0P   ?,0  &C,  !4U   2-P  #SD#  P["  (/0T !3X0  ,^
M%   /AH  #XA   ^*   /C$  #\[   _1@  /U,  #]A   _<P  /X<  #Z<
M   ^L   /<<  #WD   ]\@!:,   3C(  $0R   \,@  -3(  # Q   K,0
M)C(  " T   ;-@  %C@  !([   //0  ##\#  A!"  $0PP  $,.  !$$@
M118  $4=  !%)   12T  $8V  !&0@  1DX  $9=  !&;@  18(  $68  !$
MK0  1,0  $/C  !#\@!5-   2C4  $$U   Y-0  ,S0  "XT   H-0  (C<
M !TZ   7/   $C\   ]!   ,1   "$8!  -(!@  20H  $H-  !+$   3!0
M $T9  !.(   3B@  $XR  !-/0  3DH  $Y8  !-:0  37T  $R4  !,J@
M2\$  $OA  !*\@!0.   1C@  #TX   W.   ,3<  "HY   D.P  'CT  !A
M   30P  #T8   M)   '2P   DX   !0!   40@  %(+  !3#@  5!$  %45
M  !6&P  5R,  %<L  !7.   5T0  %=2  !68P  5G<  %:.  !5I0  5+T
M %/=  !3\ !+/   0CP  #L[   U.P  +3P  "8_   ?0@  &44  !-(   .
M2P  "T\   51    5    %<   !8 0  6@4  %L(  !<#   70X  %\1  !@
M%@  8AT  &(F  !B,0  8CX  &%,  !A70  87   &"(  !@H   7[<  %[4
M  !=[@!'0   /S\  #H_   Q0   *4,  "%&   :2@  $TX   Y1   *50
M!%@   !;    7@   &$   !C    9 $  &4$  !G"   : L  &H.  !L$@
M;A<  &\@  !O*@  ;S8  &Y%  !N50  ;F@  &U_  !MF   ;+   &O*  !J
MZ !$1   /D,  #5$   K1P  (TL  !M/   35   #E@   A<   "8    &0
M  !G    :P   &T   !O    <    '(   !T @  =08  '<*  !Y#@  ?!(
M 'X8  !_(@  ?RX  '\]  !^30  ?6$  'UW  !\D   >Z@  'K   !YWP!#
M1P  .4D  "],   E4   '%4  !1;   .8   !V4   !J    ;@   '(   !V
M    >0   'P   !^    ?P   ($   "#    A0   (<#  "*"   C T  (\1
M  "2&0  DB4  )(S  "21   D5<  )!M  "/A@  CI\  (VU  ",S0 ]3@
M,E$  "A6   >7   %6(   YH   ';@   '0   !Y    ?@   ((   "&
MB0   (P   ".    D    )(   "4    E@   )@   ";    G@8  *$,  "D
M$0  IAL  *8I  "F.@  I4T  *5B  "D>P  HY0  *&K  "AOP V5P  +%P
M "%B   7:0  #W    =W    ?@   (0   "*    CP   )0   "8    FP
M )X   "?    H@   *0   "F    J    *L   "M    L    +,$  "W#
MNQ(  +L?  "[,   NT,  +I8  "Y<   MXL  +>A  "WLP P8@  )6D  !IP
M   0>   "8    "(    CP   )8   ";    H0   *8   "J    K@   +
M  "Q    M    +8   "X    NP   +T   #     PP   ,<   #+ P  SPP
M -,5  #2)0  TC@  -%.  #090  SWX  ,V6  #,J0#_    _P   /\   #_
M  , _P + /P $0#Y !L ]P E /, +P#N #@ Z0!  .8 2 #B $X WP!4 -P
M60#9 %X U0!C -, : #0 &T S@!S ,L >@#( (( Q@", ,, EP#  *, O@"R
M +P R "Z .H N0#_ +@ _P"Q /\ J@#_ *< _P#_    _P   /L   #V
M[0 ' .< #P#B !8 WP @ -X *0#9 #, T0 [ ,P 0@#( $@ Q0!. ,( 4P#
M %@ O@!= +P 8@"Z &< N0!M +< = "U 'L L@"% +  D "N )P K "J *D
MO0"G -X I@#Y *4 _P"C /\ G0#_ )L _P#]    ]@   .L   #?    T0 #
M ,H # #% !( PP ; ,  ) "^ "P N0 U +8 / "S $, L !( *X 3@"L %(
MJP!7 *D 7 "G &$ I@!G *0 ;0"B '0 H !] )X B "< )4 F@"C )@ M "6
M ,T E0#Q )0 _P"5 /\ D #_ (X _P#S    Y@   -$   #"    N    +$
M" "M  \ J@ 6 *@ '@"H "< I@ O *( -@"? #P G0!" )L 1P"9 $P EP!1
M )8 50"4 %H DP!@ )$ 9@"0 &X C@!V (P @0"* (T B "; (8 K "% ,$
MA #F (, _0"$ /\ @P#_ ($ _P#D    RP   +H   "L    H@   )P ! "8
M  P E@ 1 )0 &0"3 "$ D@ H (\ , "- #8 BP \ (D 00"( $8 A@!+ (4
M3P"$ %0 @@!: ($ 8 !_ &< ?@!O 'P >@!Z (8 > "4 '< I !U +< = #4
M ', ] !T /\ = #_ '0 _P#+    M@   *8   ":    D@   (H   "&  @
M@P . ($ % "! !L @  C '\ *@!] #  >P V 'H .P!X $  =P!% '4 20!T
M $X <P!4 '$ 6@!P &$ ;@!I &T <P!K '\ :0"- &@ G0!G *X 9@#' &4
MZ@!F /\ 9@#_ &< _P"X    I    )4   "*    @0   'P   !V  0 =  ,
M '( $ !Q !8 <  = '  ) !N "H ;0 P &L -0!J #H :0 _ &@ 1 !G $D
M90!. &0 5 !C %L 80!C &  ;0!> 'D 70"' %L E@!: *@ 60"] %D WP!9
M /@ 6@#_ %H _P"H    E0   (<   ![    <P   &X   !J  $ 9P ( &4
M#@!D !( 8P 8 &, 'P!B "4 80 J %\ , !> #4 70 Z %P /@!; $0 60!)
M %@ 3P!7 %8 5@!> %0 : !3 ', 40"! %  D0!/ *( 3@"U $X T !. /
M3@#_ $\ _P"<    B0   'L#  !P P  : ,  &(!  !?    70 $ %L "P!9
M  \ 6  4 %< &0!7 "  5@ E %4 *@!3 #  4@ T %$ .0!0 #\ 3P!$ $X
M2P!- %( 2P!: $H 8P!) &\ 1P!\ $8 C !% )T 10"P $0 QP!$ .@ 1 #Z
M $4 _P"2!   @ <  '$*  !F"@  7@H  %D)  !5!P  5 0  %( !P!0  P
M3P 0 $X %0!- !L 3  @ $L )@!* "L 20 P $@ -0!' #H 1@!  $4 1@!#
M $X 0@!6 $$ 7P!  &L /@!X #T B  \ )D / "K #P P0 [ .  .P#T #L
M_P")"@  > P  &H.  !?#@  5PX  %$.  !-#   2PL  $H( @!)! D 2  -
M $8 $0!% !8 1  < $, (0!" "8 00 K #\ ,0 ^ #8 /0 \ #P 0P [ $H
M.@!2 #D 7  X &@ -@!U #4 A0 T )8 - "H #, O  S -@ ,P#O #, ^P""
M#0  <0\  &00  !9$0  41$  $L1  !'$   1 X  $(-  !!"P4 00<+ #\%
M#@ ^ Q( / (8 #L"'0 Z R( .0,H #@#+0 W S( -@0Y #4$/P T!4< ,P50
M #$&6@ P!F8 +P=S "X'@P M!Y4 + >G "L'N@ K!]( *P?K "L']P!]$
M;!$  %\3  !4%   3!0  $84  !"$P  /A(  #P0   Z#@$ .@T& #H*#  X
M"1  -@@4 #4(&0 T"1\ ,@DD #$)*0 P"2\ +PHV "X*/0 M"D4 + M. "L+
M60 I#&4 * QS "<,@P F#94 )0VG "0-NP C#=( (PWK ",-]P!X$@  :!0
M %L6  !1%P  2!<  $(6   ]%@  .14  #<3   U$0  ,Q # #,."  R#0T
M, T1 "\-%@ M#1L + TA "L-)P J#2T *0XT "@..P G#D0 )0Y. "0/60 C
M$&4 (1!S " 0A  ?$)8 'A"I !T0O0 <$-@ '1#N !T0^0!S%   9!8  %<8
M  !-&0  11D  #\9   Z&   -1<  #(6   P%0  +A,  "T1!  L$ H *Q .
M "D0$@ H$!@ )A > "40)  D$"H (Q$Q "(1.0 A$4( (!)+ !X25@ =$V,
M'!-Q !H3@@ 9%)4 &!2G !<4NP 7$]0 %Q/N !@3^@!P%@  8!D  %0:  !*
M&P  0AP  #P;   V&P  ,AH  "\9   L&   *A8  "@4 0 F$P< )1,, ",3
M$  B$Q4 (!,: !\3(0 >%"< '10N !P5-@ ;%3\ &A9) !D65  8%V$ %A=P
M !48@0 4&), $QBF !(8N@ 2%]( $A?L !,7^@!L&0  71L  %$=  !''0
M/QX  #D=   T'0  +QP  "L;   H&@  )AD  "08   B%P0 (!<* !X7#@ <
M%Q( &A<7 !D8'@ 9&"0 &!DL !<9-  6&CT %1I' !0;4@ 3&U\ $AQN !$<
M?P 0')( $!RE  \<N0 .'-  #AOJ  \;^ !I&P  6AT  $X?  !%'P  /2
M #8?   Q'P  +1X  "D=   E'0  (QP  " ;   =&P$ &QL' !D<#0 7'!
M%AP5 !4<&P 4'2( $QTI !(>,0 1'CH $1]% ! ?4  /(%T #B!L  T@?  -
M((\ #""B  L@M0 +(,H "R#E  P?] !E'0  5Q\  $PA  !"(0  .B$  #0A
M   O(0  *B   "8?   C'P  (!X  !T>   9(   %B $ !0@"P 2(0X $2$3
M !$B&0 0(A\ #R(F  XC+P .(S< #2-!  PD30 +)%D "B1G  DD>  ()(L
M!R2>  <DL0 &),< !B/C  <C\0!B'P  5"$  $DC  ! (P  .",  #(C   L
M(P  *"(  "0A   A(0  'B$  !HA   6(P  $R0# !$E"  /)@T #B<1  TG
M%@ ,)QT "R<C  HG*P )*#0 ""@^  <H20 &*%4 !2ED  0I=  #*8<  BF;
M  $HKP  *,4  2CA  $G\ !>(@  420  $8E   ])0  -24  "\E   J)
M)B0  "(C   ?(P  &R0  !@E   4)@  $2@#  \I"  ,+ P "BP0  @L%  '
M+!H !BPA  4L*  #+3   BTZ  $M10  +5(  "Y@   N<0  +80  "V9   M
MK0  +,(  "S@   L\ !:)   328  $,G   Z)P  ,R<  "TG   H)@  )"8
M "$F   =)@  &2<  !4I   1*P  #RP#  TN!P ), P !C$.  ,Q$@ !,A<
M #(>   R)0  ,BT  #(V   S0@  ,TX  #-=   S;0  ,X$  #*6   RJP
M,<$  #'?   Q\ !6)P  2BD  #\J   W*@  ,"H  "LI   G*   (R@  !XI
M   :*@  %BP  !(N   /,   #3$"  HT!P %-0L  C8.   W$   .!0  #@:
M   X(@  ."H  #DS   Y/@  .4H  #E9   Y:0  .7T  #B3   XJ   -[\
M #?>   V\ !1*P  1BP  #PL   T+   +BP  "HK   E*P  ("P  !LM   7
M+P  $S$  ! S   --0  "3<"  4Z!@ !.PH  #P-   ]#P  /A(  #\7  !
M'@  0"4  $ O  ! .@  0$8  $!4  ! 90  /W@  #^/   ^I@  /KT  #W<
M   ]\ !-+@  0B\  #DO   R+P  +2X  "@N   B+P  '3   !@R   3-0
M$#<   PZ   )/   !3X   !!!   0@@  $,+  !$#0  1A   $<4  !(&0
M2"$  $@J  !(-0  2$$  $A/  !(8   1W,  $>*  !&H@  1;D  $79  !$
M\ !(,@  /C(  #8R   P,0  *S$  "4R   ?-   &38  !,Y   0/   ##\
M  A"   #1    $8   !( @  2@4  $L(  !,"P  3@X  $\1  !1%0  4AP
M %(E  !2,   4CP  %%*  !16@  46T  %"$  !/G0  3K4  $W2  !-[@!#
M-@  .S8  #0U   O-   )S4  "$X   :.P  %#X  !!!   ,1   !T<   )*
M    30   $\   !1    4P(  %0%  !5"   5PL  %D.  !;$0  71<  %T?
M  !=*@  738  %Q$  !<5   6V<  %M^  !:EP  6:\  %C+  !7Z@ _.0
M.#D  #,X   K.0  (SP  !P_   50P  $$<   M*   %3@   %$   !4
M5P   %H   !<    70   %\   !@!   8@<  &0+  !F#@  :!(  &L9  !K
M(P  :BX  &H\  !J30  :5\  &AU  !GCP  9J@  &7"  !DXP ]/0  -SP
M "X]   E0   '40  !9)   030  "E$   15    6@   %T   !@    8P
M &8   !H    :@   &L   !M    ;P(  '$&  !T"@  =@X  'D3  ![&P
M>R<  'HU  !Y10  >%D  'AM  !WA@  =I\  '6W  !TT@ \00  ,D(  "A%
M   @2@  %TX  !!4   *60   EX   !C    9P   &L   !O    <@   '4
M  !W    >0   'L   !]    ?P   ((   "$ P  APD  (H.  ".$P  CQX
M (XK  "..P  C4X  (MC  "*?   BI4  (BM  "'Q0 V1P  +$L  ")/   9
M50  $%L   IA   !9P   &T   !R    =P   'L   !_    @P   (8   "(
M    B@   (T   "/    D0   )0   "7    F@$  )T'  "A#0  I10  *0A
M  "D,0  HT0  *)9  "@<   GXL  )VB  "=MP P4   )54  !M;   28@
M"VD   %P    =P   'T   "#    B    (T   "1    E0   )@   ":
MG    )\   "A    HP   *8   "I    K    +    "T!P  N X  +H8  "Z
M)P  N3D  +A.  "W90  MGX  +66  "SJP I6P  'F(  !1I   ,<0   GD
M  "!    B0   (\   "6    FP   *    "D    J    *L   "L    KP
M +(   "T    M@   +D   "\    P    ,0   #(    S0<  -(0  #2'0
MT2\  -!$  #/6P  S7,  ,N-  #*H0#_    _P   /L   #Z    _  ( /@
M#P#U !< ]  @ /$ *@#K #, Y@ [ .( 0P#> $D V@!/ -8 5 #3 %D T !>
M ,X 8P#+ &@ R0!N ,8 =0## 'T P0"& +X D@"[ )X N0"N +8 PP"T .@
MLP#_ *\ _P"E /\ G@#_ )L _P#]    ]P   /(   #P    YP # .$ # #<
M !( V  ; -8 ) #2 "T S  V ,8 /0#" $, OP!) +P 3@"Z %, N !8 +8
M70"U &( LP!G +$ ;@"O '8 K !_ *H B@"H )< I0"F *, N0"A -D H #Y
M )X _P"8 /\ D@#_ (\ _P#S    [    .,   #3    R    ,$ "0"]  \
MNP 6 +D 'P"W "< LP O *\ -P"L #T J@!# *@ 2 "F $T I !2 *, 5@"A
M %L GP!A )X 9P"< &\ F@!X )< @P"5 )  DP"> )$ L "0 ,@ C@#P (T
M_P"* /\ A0#_ (( _P#G    W0   ,8   "X    K@   *@ ! "E  P H0 2
M *$ &0"@ "( GP I )L , "8 #< E@ ] ), 0@"2 $< D !+ (\ 4 "- %4
MC !: (H 80"( &@ AP!P (4 >P"# (@ @0"6 '\ IP!] +P ? #C 'P _0!\
M /\ > #_ '8 _P#6    P    *\   "C    F0   ),   "/  D C0 . (L
M% "* !P B@ C (@ *@"% #  @P V (( .P"  $  ?P!% 'X 2@!\ $\ >P!4
M 'H 6@!X &$ =@!I '4 <P!S (  <0". &\ GP!N +( ;0#/ &P ] !L /\
M:P#_ &D _P#     JP   )L   "/    AP   (    !\  0 >@ , '@ $0!X
M !< >  > '< ) !U "H <P P '$ -0!P #H ;@ _ &T 1 !L $D :P!. &H
M5 !H %L 9P!C &4 ;0!D '@ 8@"' &  EP!? *H 7@#" %X Z0!> /\ 7@#_
M %T _P"L    F0   (H   !_    =P   '$   !M    :@ ( &D #@!H !(
M9P 8 &< 'P!G "4 90 J &, +P!B #0 80 Y &  /@!? $, 7@!( %T 3@!;
M %4 6@!= %@ 9P!7 '( 50"! %0 D0!3 *, 4@"X %$ W !1 /D 4@#_ %(
M_P"=    BP   'P   !Q    :0   &0   !@    7@ % %P "P!;  \ 6P 4
M %H &0!: !\ 60 E %< *@!6 "\ 50 T %0 . !3 #T 4@!# %  20!/ %
M3@!8 $T 8@!+ &T 2@!Z $D BP!( )T 1P"Q $< S !& /  1P#_ $< _P"0
M    ?@   '    !F    7@   %D   !6    4P ! %( " !0  T 3P 0 $\
M%0!. !H 3@ @ $T )0!, "H 2@ N $D ,P!( #@ 1P ^ $8 1 !% $L 1 !3
M $, 70!! &@ 0 !U #\ A0 ^ )< /0"K #T PP ] .8 /0#[ #X _P"'
M=0,  &@&  !=!P  508  % &  !,!   2@$  $D ! !'  H 1@ . $4 $0!%
M !8 1  ; $, ( !" "4 00 J $  +P _ #0 /@ Z #T 0  [ $< .@!/ #D
M60 X &0 -P!Q #8 @0 U ), - "F #0 NP T -T - #U #4 _P!^!@  ;0D
M & +  !6#   3@P  $@+  !$"@  0@@  $ % 0 _ 0< /@ + #T #@ \ !(
M.P 7 #L '  Z "$ .0 E #< *@ V #  -0 U #0 /  S $, ,@!, #$ 50 P
M &  +P!M "X ?0 M (\ + "B "P M@ L -  + #N "P _ !W"@  9PP  %H.
M  !0#@  20X  $,.   ^#0  .PP  #D+   X"0, -P4( #8"#0 U 1  -  3
M #, &  R !T ,0 B #  )P O "P +@ R "T .  L $  *P!) "H 4@ I %T
M* !K "<!>@ F 8P )0"? "4 L@ E ,H )0#H "4 ]P!R#0  8@X  %80  !,
M$0  1!$  #X1   Y$   -@\  #,.   Q#0$ , L% # ("@ O!@T +@41 "P$
M%  K QD *@,> "D#(P H!"D )P0O "8%-0 E!3T ) 5& ",&4  B!EP (0=I
M " '>0 ?!XL '@>= !X'L  =!L8 '0;C !T%\P!M#@  7A$  %(2  !($P
M0!,  #H3   U$@  ,1$  "X0   L#P  *@X# "H-!P I"PL * D. "<)$0 E
M"!8 ) @; ",)(  B"28 (0DL " *,P ?"CL '@M$ !T+3P <#%L &PQI !H,
M>0 8#(L & R> !<,L  6#,4 %@SA !8+\ !I$   6A(  $X4  !%%0  /14
M #<5   Q%   +1,  "H2   H$0  )A ! "00!  C#@@ (PT, "(,#P @#!,
M'PP8 !X-'0 =#2, ' TJ !L-,@ :#CH & Y$ !<.4  6#UP %0]J !,0>P 2
M$(T $1"@ !$0LP 0#\D $ _D !$/\@!E$@  5Q0  $L6  !"%P  .A<  #07
M   O%@  *A4  "<4   D$P  (A,  " 2 P >$08 '1 ) !P0#0 ;#Q  &1 5
M !@0&P 7$"$ %A H !41,  4$3D $Q%# !(23@ 1$EH $!)I ! 3>0 .$XP
M#A.>  T3L0 -$L4 #!+A  T2\0!B%   5!8  $D8   _&0  -QD  #$9   L
M&   *!<  "06   A%@  'Q4  !P4 @ :$P0 &1(& !<2"P 5$@X %!(2 !,3
M&  2$Q\ $1,F !$4+0 0%#8 #Q5!  X53  .%E< #19E  P7=0 +%X< "A>:
M  D6K0 (%L$ "!;=  D5[@!?%@  41@  $8:   ]&@  -1L  "\:   J&@
M)1D  "(8   ?&   '!<  !D6 0 7%@, %18$ !,6"0 1%@T $!<1  \7%@ .
M%QP #A@C  T8*@ ,&3, #!D\  L:1P *&E, "1IA  <;<0 &&X, !1N7  0:
MJ@ #&K\  QG:  09[ !<&   3AH  $,<   Z'   ,QP  "P<   G'   (QL
M " :   =&0  &AD  !<8 0 5& ( $AD$ ! ;!P .&PP #1P0  P<$P +'!D
M"AP?  D=)P ('2\ !QXY  8>0P $'E   Q]>  (?;@ !'X   !^5   >J0
M'KT  !W8   =[ !8&@  2QP  $$>   X'@  ,!X  "H>   E'0  (1P  !X<
M   ;&P  &!L  !8; 0 3&P( $1P$  X>!P ,'PL "B .  @@$@ &(1< !2$=
M  0A)  "(BP  2(U   B0   (TT  "-:   C:P  (WX  ".3   BIP  (KP
M "'7   A[0!5'0  2!\  #X@   U(   +B   "@@   C'P  (!X  !T=   :
M'0  %AT  !,>   1'P( #B $  TB!P *) L !B4-  0E$  ")A0  "8:   F
M(0  )RD  "<R   G/0  )TD  "A7   H9P  )WL  ">0   GI0  )KL  ";6
M   E[0!1(   12$  #LB   R(@  +"(  "8A   B(0  'B   !L?   8(
M%"   !$B   /(P  #24#  HF!@ &* H  RD-   K#P  +!(  "P7   L'@
M+"8  "TO   M.0  +48  "U4   M9   +7<  "R-   LI   *[H  "O6   J
M[@!-(@  020  #@D   P)   *20  "0C   A(@  '2(  !DB   5(P  $B0
M  \F   -*   "BH"  8L!0 "+@D  "\+   P#@  ,A   #,5   S&P  ,R(
M #,K   S-@  ,T(  #-0   S8   ,W,  #**   RH0  ,;@  ##6   P[P!)
M)0  /B8  #0G   M)P  *"8  ",E   ?)   &R4  !8F   2*   $"H   TL
M   *+@  !C !  (R!   - <  #4*   W#   . X  #H2   Z%P  .A\  #HG
M   Z,@  .CX  #I,   Z7   .F\  #F&   XG@  .+8  #?4   V[P!$*0
M.BD  #$I   K*0  )B@  "(G   =*   &"D  !,K   0+@  #3    DR   %
M-0   3<    Y @  .P4  #P(   ^"P  /PT  $$0  !#%   0QL  $,C  !#
M+@  0SD  $-'  !"5P  0FH  $&!  ! F@  /[(  #[/   ^[P _+   -BP
M "\L   J*P  )2H  !\K   9+0  %"\  ! R   --0  "#@   0Z    /
M #\   !!    0P(  $4%  !&"   2 L  $H.  !,$0  318  $T>  !-*
M330  $Q"  !,40  2V0  $M[  !*E   2:T  $C*  !'[  [,   ,R\  "TO
M   H+0  (B\  !LQ   5-   $#<   TZ   (/0   D    !#    1@   $@
M  !*    3    $X!  !/!   40<  %,+  !5#@  6!(  %D9  !8(@  6"X
M %<\  !72P  5EX  %9S  !5C0  5*<  %+"  !2Y@ X,P  ,3(  "PQ   E
M,@  '34  !8X   1/   #$    =$    1P   $H   !-    4    %,   !5
M    5P   %D   !:    7 ,  %X'  !A"P  9 X  &83  !G'   9B<  &8T
M  !E1   9%<  &1K  !BA0  89\  &"Y  !>W  U-P  ,#4  "@W   @.@
M&#T  !%"   ,1@  !DH   !/    4P   %8   !9    7    %\   !A
M9    &4   !G    :0   &P!  !N!@  <0L  '0/  !W%0  =R   '8M  !V
M/0  =4\  '1C  !S>P  <I4  '"O  !OR0 U.@  *SL  "(_   :0P  $D@
M  Q-   %4@   %<   !<    8    &0   !H    :P   &X   !Q    <P
M '4   !W    >@   'P   !_    @@0  (8*  "*#P  C!<  (LD  "*,P
MB44  (=;  "&<@  A8L  (.E  ""O  O0   )40  !Q)   33@  #50   1:
M    80   &8   !K    ;P   '0   !Y    ?0   (    "#    A0   (<
M  "*    C    (\   "2    E@   )D"  ">"0  HA   *(:  "A*0  H#L
M )]0  "=9P  FH$  )J9  "9KP I20  'TX  !54   .6P  !6(   !I
M<    '<   !]    @@   (8   "+    CP   ),   "5    EP   )H   "=
M    H    *,   "F    J@   *X   "R    MPH  +L1  "Z'P  N3   +=%
M  "U7   M'0  +&.  "OI  B5   &%L  !!B   ':@   ',   ![    @@
M (D   "0    E0   )H   "?    HP   *8   "H    JP   *X   "P
MLP   +8   "Z    O0   ,(   #'    S $  -,+  #4%0  TR8  -$Z  #0
M40  S6@  ,N!  #*E@#\    ]@   /(   #Q    \P % /0 # #R !, \  <
M .T )0#H "X X@ V -X /@#9 $0 U !* -$ 3P#. %0 RP!9 ,D 7@#& &,
MQ !I ,$ < "^ '@ O "! +D C0"V )H LP"K +$ P "O .8 K@#_ *4 _P":
M /\ E #_ (\ _P#T    [    .@   #G    WP   -D "0#2 !  SP 7 ,\
M( #, "@ Q@ P ,  -P"\ #X N0!$ +< 20"U $X LP!3 +$ 5P"O %T K0!B
M *L :0"I '$ IP!Z *4 A0"B ), H "B )T M@"; -0 F0#Y )8 _P"- /\
MB #_ (0 _P#H    WP   -D   #)    OP   +@ ! "U  T LP 2 +$ &@"P
M "( K0 J *D ,0"F #@ I  ] *( 0P"@ $@ G@!, )P 40"; %8 F0!< )<
M8@"5 &D DP!R )$ ?0"/ (L C0": (L K ") ,4 B #N (8 _P!_ /\ >@#_
M '@ _P#9    S0   +L   "N    I0   )\   "<  D F0 / )D %0"9 !T
MF  D )0 *P"1 #$ C@ W (P / "+ $$ B0!& (@ 2P"& %  A0!5 (, 6P""
M &( @ !K 'X =0!\ (( >@"2 '@ HP!W +D =@#@ '4 _P!R /\ ;@#_ &P
M_P#'    M0   *4   "9    CP   (D   "%  0 A  , (( $0"" !< @@ >
M (  )0!^ "L ?  Q 'H -@!Y #L =P!  '8 1 !U $D <P!/ '( 50!P %P
M;P!D &T ;@!L 'H :@"* &@ FP!G *\ 9@#, &4 ]0!D /\ 80#_ &  _P"T
M    H    )    "%    ?0   '<   !S    <  ( &\ #@!O !( ;P 8 &\
M'P!M "4 :P J &D , !H #0 9P Y &8 /@!E $, 8P!( &( 3@!A %4 7P!>
M %X 9P!< ', 6P"" %D DP!8 *8 5P"_ %< Z@!7 /\ 5@#_ %0 _P"A
MC@   '\   !U    ;    &@   !D    80 $ &  "P!?  \ 7P 3 %\ &0!?
M !\ 70 E %P *@!; "\ 60 S %@ . !7 #T 5@!# %4 20!3 %  4@!8 %$
M80!0 &T 3@![ $T C !, )\ 2P"U $H W !* /H 2@#_ $H _P"2    @
M '(   !G    7P   %H   !7    50 ! %, !P!2  P 4@ 0 %( % !2 !H
M40 ? $\ ) !. "D 30 N $P ,P!+ #@ 2@ ] $D 0P!( $H 1@!2 $4 7 !$
M &< 0P!U $( A@!! )@ 0 "N $  RP _ /( 0 #_ $  _P"%    =    &<
M  !=    50   $\   !,    2@   $@ ! !'  H 1P - $8 $0!& !4 1@ :
M $4 'P!$ "0 0P I $( +0!! #, /P X #X /@ ] $4 / !. #L 5P Z &(
M.0!O #@ @  W ), -@"G #8 P  V .@ -@#^ #8 _P!\    :P   %X"  !4
M P  30,  $<#  !# 0  00   #\  0 ^  < /0 + #T #@ \ !$ /  6 #P
M&@ Z !\ .0 D #@ *0 W "X -@ S #4 .@ T $$ ,P!) #( 4P Q %X , !K
M "\ >P N (X +0"B "T N  M -T +0#X "X _P!S 0  9 4  %<'  !-"
M1@@  $ (   [!P  . 4  #<#   V  0 -0 ( #0 #  T  \ -  2 #, %@ R
M !L ,0 @ #  )  O "D +@ O "T -@ L #T *P!% "H 3P I %H * !G "<
M=P F (D )@"= "4 LP E ,\ )0#P "8 _P!M!@  7@D  %(+  !(#   0 P
M #H+   V"P  ,@H  # (   N!@( +@,& "T "@ L  T +  0 "L $P J !<
M*0 < "@ (  G "4 )@ K "4 ,@ D #D (P!" "( 2P B %< (0!D "  <P ?
M (4 'P"9 !X K@ > ,< '@#I !\ ^@!H"0  60P  $T-  !##@  / X  #8.
M   Q#0  +0T  "H,   H"P  )PD$ "8&"  F! L )0,. "0!$  D 10 (@$8
M "$!'0 A "( (  H !\ +@ > 38 '0$_ !P!20 ; 50 &@%A !H!<  9 8(
M& "6 !@ J@ 8 ,$ & #A !@ ] !C#   50X  $D/  ! $   .!   #(0   M
M#P  *0X  "8.   C#0  (@P# " +!@ @"0D 'P<, !X&#@ >!1$ ' 45 !L%
M&@ :!1\ &@4E !D%*P 8!3, %P8\ !8&1@ 6!E( %0=? !0';@ 3!X  $@>4
M !(&IP 2!;P $@39 !(#[P!?#@  40\  $80   \$0  -1$  "\1   J$0
M)A   "(0   @#P  '0X" !P-!0 :#0< &@L* !D*#0 8"1  %PD2 !8)%P 5
M"1P % DB !0**0 3"C$ $@HZ !(+10 1"U$ $ Q?  \,;@ .#(  #@R4  T+
MIP -"[H #0K2  T*Z@!<#P  3A$  $,2   Z$P  ,A,  "P3   G$@  (Q$
M !\1   <$   &A " !@/!  6#@< %0X) !0-"P 3# T $@P0 !(,%  1#!H
M$0T@ ! -*  /#3  #@X[  T.1@ -#E$ # ]>  L/;0 *#W\ "0^3  D/I@ (
M#KD " [0  <.Z !8$0  2Q(  $ 3   W%   ,!0  "D4   E%   (1,  !T2
M   :$@  %Q$" !41!0 3$ < $A ) !$/"@ 0#@P #@X.  X/$@ -$!@ #1 >
M  P0)0 ,$"T "Q$V  H100 )$4T "!):  <2:@ &$GP !1*0  02I  #$;@
M Q'/  (1Z !5$@  210  #X5   U%@  +18  "<6   B%0  'A0  !L4   8
M$P  %1(# !,2!0 2$0< $!$)  \1"@ -$0L #!(.  L2$0 *$A4 "1,;  D3
M(@ ($RH !Q0S  44/@ $%4H  Q58  (59P !%7H  !6.   5HP  %+<  !3/
M   3Z0!2%   1A8  #L7   R%P  *Q<  "47   A%@  '!8  !D5   6% $
M%!,$ !(3!@ 1$@@ #Q((  X3"0 ,% H "A4-  @6$  &%A, !189  07'P #
M%R<  A@P  $8.P  &4<  !E5   99   &7<  !F,   8H@  &+<  !?/   7
MZ@!/%@  0Q@  #D9   P&0  *1D  ",9   ?&   &Q<  !@6   5%0( $Q4%
M !$4!@ 0% 8 #A4'  P6"  *%PH !QD,  0:#@ "&Q(  1L6   ;'0  '"0
M !PM   <.   '40  !U2   =8@  '74  !V*   <H   '+8  !O0   :ZP!,
M&   0!H  #8;   M&P  )AL  "$:   =&0  &1D  !<8   4%P, $A8$ ! 7
M!  .%P0 #!D%  H:!P '' D  QT+   ?#0  (!   " 4   A&@  (2(  "$J
M   A-0  (D$  ")/   B7P  (G(  "&(   AGP  (+8  !_1   ?[0!(&@
M/1P  #,=   K'0  )!T  " <   <&P  &!H  !89 0 3&0$ $1D!  X: 0 ,
M' ( "AT#  <?!0 #(0@  "(*   D#   )@X  "82   F&   )Q\  "<G   G
M,@  )SX  "=+   G7   )VX  ":%   FG0  );0  "31   C[@!$'0  .1\
M # ?   H'P  (QX  !X=   ;'   &!L  !0<   1'   #AT   T?   *(0
M!B(!  ,D!   )@8  "@(   J"P  *PT  "T0   M%0  +1P  "TD   N+@
M+CH  "Y(   M6   +6H  "V!   LF@  *[(  "K0   I[P! (   -B$  "TA
M   F(0  (2   !T?   :'@  %AX  !(?   /(0  #2(   HD   &)@   B@
M   K @  +00  "\&   P"0  ,@P  #0.   U$@  -1@  #4@   U*@  -38
M #5#   U4P  -&8  #1\   SE@  ,J\  #'-   P[P \(P  ,B0  "HD   D
M(P  ("(  !PA   7(0  $R,  ! E   -)P  "2D   4K   !+@   #     R
M    - $  #8$   X!@  .@D  #P-   ^$   /A0  #X<   ^)@  /C$  #X_
M   ]3@  /6$  #QW   [D0  .JL  #G)   X[0 W)P  +R<  "@F   C)0
M'R0  !DE   4)@  $"@   TK   )+@  !3     S    -0   #@    Z
M/    #X!  !  P  0@<  $0*  !&#0  21$  $D7  !((0  2"P  $<Z  !'
M20  1EL  $5Q  !$BP  0Z4  $+#  !!Z  T*@  +"H  "<H   B)P  '"@
M !8J   1+0  #3    DS   #-@   #D    \    /@   $$   !#    1@
M $@   !*    3 ,  $X&  !0"@  4PX  %03  !4'   4R<  %,T  !30P
M4E4  %%J  !0@P  3YX  $VY  !,X  P+0  *RP  "8K   ?+   &"X  !(R
M   --0  "#D   (]    0    $,   !&    20   $P   !.    40   %,
M  !5    5P   %D!  !<!@  7PH  &(.  !C%0  8Q\  &(L  !A/   8$X
M %]B  !>>P  7)8  %NP  !9SP O,   *B\  "(P   :,P  $S<   X[   (
M/P   40   !(    3    $\   !2    50   %@   !;    70   &    !B
M    9    &8   !I    ;04  ' +  !T$   =!@  ',E  !R-   <D4  '!9
M  !O<0  ;8L  &NF  !JP  N,P  )34  !TX   4/   #D$   ='    3
M %$   !5    60   %T   !A    90   &@   !K    ;0   &\   !R
M=    '<   !Z    ?@   (($  "&"P  BA$  (D<  "(*P  ACT  (12  "#
M9P  @8$  '^;  !^L@ I.@  (#T  !9"   /2   "$X   !4    6@   &
M  !D    :0   &X   !R    =@   'H   !]    @    ((   "%    B
M (L   ".    D@   )8   "; P  H P  *(3  "@(0  GS,  )U'  ":7@
MF'<  )>/  "5IP C0P  &4@  !%.   )50   %P   !C    :@   '$   !V
M    >P   (    "&    B@   (X   "1    DP   )8   "9    G    *
M  "C    IP   *L   "P    M@0  +P-  "Z%P  N2@  +<\  "T4@  LFH
M *^%  "MG  <3@  $U0   M<   !9    &P   !T    ?    (,   ")
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M________________________________________________
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MV=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0
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MFHWAF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAU\P)&MK1"SC>T0Q?ULL+D<O
M*:S"N4VVO+-HOK>N>\:SJ8?,KZ:'T:JCAM6GH8?8I)^'VJ&>A]R>G8C=FIR)
MWI6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@
ME9N,X)6;C."5FXS@E9N,X)6;C."5FXS@ULP)&=G1"SC:TPQ?U,P+D<G *:W
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ML'ZDT;!^I-&P?J31_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MRML*;?[G
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MEJN#RI&JA,N.J83,BZF%S8BHALZ&J(?.@ZB)SH&GC,^ IXW/@*>-SX"GC<^
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MQX"LB\> K(O'@*R+QX"LB\> K(O'@*R+QX"LB\> K(O'U<8("=G,"B#ESPU
MV-4+7[W6"XBEQ#2FG+=:N)FU:[N7M'>]EK-_OI6RA<"1L87!CK&%P8NPAL*)
ML(?"B+"'PX:PB,.%KXG#@Z^*Q(*OB\2!KXO$@:^+Q(&OB\2!KXO$@:^+Q(&O
MB\2!KXO$@:^+Q(&OB\2!KXO$@:^+Q(&OB\2!KXO$TL@(!]//"AW5U L]PMD+
M8ZO>$(.;SC.9E,13II&^9Z^0NG2TD+=]N9&UA+R.LX:^C+*&OXJRA\"(LHC
MAK&(P86QB<&$L8K!@K&+P8&QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,*
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M"?^Q(Q[_KC$Z_ZD^6>VB2WG9FER7R)5RL,65?;7#EX6XP9>+N[^3C+V^CX[
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MH:F$S9NG@\^5IH/0CZ6$THJDAM.&HXC4@Z.,U(&CD=2 I)G3@*:AT8"FH=&
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M@)W0LG^DT:Q^I<^H?J?,I'^IR:& K,:A@*S&H8"LQJ& K,:A@*S&H8"LQJ&
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M?JO'HG^MQ)]_K\*=@+&_G8"QOYV L;^=@+&_G8"QOYV L;^=@+&_G8"QOYV
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MQ9>$K\*6A+# EH2PP):$L,"6A+# EH2PP):$L,"6A+# EH2PP):$L,"6A+#
M_Z88 O^G)0__I30E_Z%"/O^?3%7XHDQG[*5->>&F3HO5I%:<S*%AJL:A;+/#
MHG:WP** O;R@A\.WFHC*LI.*TJR+E-N@AY_8FH:DT9>&I\R5AJK(E(>LQ9.'
MKL.2A[# DH>PP)*'L,"2A[# DH>PP)*'L,"2A[# DH>PP)*'L,"2A[# _Z<8
M O^H) __IC,E_Z)"/O^@2E3YI$IF[:=*>.*I2XK6J%&:S:9;J<>E9;+$IW"V
MP*=ZO+RF@\.VHH?+KYV(UJ67E>:7CY[:DXVCTI&+I\V0BZK)D(JLQH^*KL./
MB;#!CXFPP8^)L,&/B;#!CXFPP8^)L,&/B;#!CXFPP8^)L,&/B;#!_Z<8 O^H
M) __IC,E_Z)!/O^B2%3YID=F[JI'=^.M1XC9K4N8SZQ4ILBL7J_&KVBSPK%S
MN;ZR?<"RJH?+I:*&U92<B]Z/FIW:C96BTXR2ILZ+D*G*BXZKQXN-K<2,C*_!
MC(ROP8R,K\&,C*_!C(ROP8R,K\&,C*_!C(ROP8R,K\&,C*_!_Z@8 O^I) __
MIS(E_Z-!/O^D1E/ZJ41D[ZU#=>2Q0H7;M$24TK5*H<NW4ZO*OE^MO;=NN+*P
M?,*IJH;+G*6$THV@A]B&H)?9AYZBTX>8I<^'E:C+AY.JR(B1K<6(D*_"B)"O
MPHB0K\*(D*_"B)"OPHB0K\*(D*_"B)"OPHB0K\*(D*_"_Z@8 O^I(P__IS(E
M_Z- /O^F0U+[JT%C\+$_<^>W/8+>OCN/UL0_FLS%2J:\O%VRL;5ONZJP?<.C
MJX3)EJ>#SHJDAM.!HY#5@:6?TH*AI<^"G*C,@YFJR826K,:%E*[#A92NPX64
MKL.%E*[#A92NPX64KL.%E*[#A92NPX64KL.%E*[#_ZD8 O^J(P__J#$E_Z0_
M/O^H0%'\KSQA\[8Y<.J_-WWCRC6'U-$WE;["2ZFPN6"UJ+1PO:.P?L*=K83'
MDJJ$RXBGALZ IHW0?:>8T'VHI,Y^I*C+?Y^JR8";J\:!F*W$@9BMQ(&8K<2!
MF*W$@9BMQ(&8K<2!F*W$@9BMQ(&8K<2!F*W$_ZH7 O^J(@__J# E_Z4^/O^K
M.T__M#==]KTS:NO*,77<VBF"Q,XXF;+!3ZNGN&.WH;1SO)ZQ?\&8KX3$CZR$
MR(>JA\J J8S,?*F3S'JJG,MYJZ;*>J>JR'RBJ\=]GJW$?9ZMQ'V>K<1]GJW$
M?9ZMQ'V>K<1]GJW$?9ZMQ'V>K<1]GJW$_ZH6 O^K(0[_J2XE_Z<\/O^P-DS\
MNC!9[\@L8M[9)VW+W":&MLP\FZC!5*N?N6:VF[5TO)FR?[^5L(3"C:^%Q(:M
MA\:!K(O(?:R0R'NLF,AYK9_'=ZVGQW>JK,9YI:W$>:6MQ'FEK<1YI:W$>:6M
MQ'FEK<1YI:W$>:6MQ'FEK<1YI:W$_ZL5 O^L( [_JRTD_ZLV._^V+TCSQ"A1
MX-8F5LSD(G&[VBB(JLQ!FY_#5ZF9O&FREK=VN92T@+V1LH7 B[&&P8:PB,.!
MKXO$?JZ/Q7NNE,5ZKYK$>*^@Q'6OI\1TK:[#=*VNPW2MKL-TK:[#=*VNPW2M
MKL-TK:[#=*VNPW2MKL-TK:[#_ZP4 O^M'P[_K"LD_[ O-_J_)4'DT2!%SN0=
M6[WI(G2MVBR)G\Y%F9?&6J23P&JMD;MVLY"X?[>-MH2[B;2&O86RB+^"L8O!
M?[&.P7RQDL)ZL9;!>;&;P7BRH<!TL:?!=+&GP72QI\%TL:?!=+&GP72QI\%T
ML:?!=+&GP72QI\%TL:?!_ZX2 ?^O'0W_KB@D_[@D,>K+&C70XA=#O_ =7J_H
M)76@VS&'EM%(E)#*7)Z-Q6JEB\%VJHF^?:^%O("R@KJ#M'ZYAK9\N(FW>;>,
MN'>WC[EVMI.Z=;:7NG2VG;ISMZ2Y<[>DN7.WI+ESMZ2Y<[>DN7.WI+ESMZ2Y
M<[>DN7.WI+ESMZ2Y_[ 0 ?^Q&@W_L24C\\07)]3?$"O![Q=(L/<@8*'J*W.5
MWSF"C==,C8C1796&S&J;A,ETH(#&>:1]Q'VF>L* J7?!@ZIUP(:L<[^*K7&_
MC:YOOI"O;KZ4KVR^F:]KOJ"O:[Z@KVN^H*]KOJ"O:[Z@KVN^H*]KOJ"O:[Z@
MKVN^H*]KOJ"O_[,. ?^T%@S\O!<:UM8+%L/M$#"R_!E*HODE7I;M,VZ,Y4%Z
MA=Y/@X'97HI_U6J/>M)PDW;/=9=SSGF9<<Q]FV_+@)UMRH2>:\F'GVG)BJ!H
MR(ZA9\>2HF7'EJ)DQYRC9,><HV3'G*-DQYRC9,><HV3'G*-DQYRC9,><HV3'
MG*-DQYRC]+8* ?^X$@O5S H+Q-L*&;+\$3.C_QU(EOPL6(SS.V6$[$EO?N=5
M=GKC8'QUWV>!<=UMA&W;<H=JV7:):-AZBV;7?8UDUH&.8]6$CV'4B)!@TXN1
M7]./DE[2E))<TIF37-*9DUS2F9-<TIF37-*9DUS2F9-<TIF37-*9DUS2F9-<
MTIF3W+L$ -C#!P3$T0@'L^@*'*/_%#&6_R1#C/\T4(3[0EI]]D]B>/%::''N
M7VUKZV1Q9^EI=&3G;G9BYG-X8.5W>5_D>GM=XWY\7.*!?5OBA7Y:X8A_6>"+
M@%?@D(!6WY6!5M^5@5;?E8%6WY6!5M^5@5;?E8%6WY6!5M^5@5;?E8%6WY6!
MU+T% ,3(!P"TV04*H_X-');_&BR+_RLZ@_\Z1'S_2$UU_U)3;OU76&?Z75QC
M]V)?8/9G8EWT:V1;\V]E6?)S9U?Q=VA6\7II5?!]:E3O@&M3[X1K4NZ';%#N
MBVU/[9!N3^V0;D_MD&Y/[9!N3^V0;D_MD&Y/[9!N3^V0;D_MD&Y/[9!NQL %
M +30! &CXP(*EO\0&(O_("2"_S O>O\_-W+_2#YJ_TY#9/]42%[_64Q;_U]/
M6/]D4E7_:513_VU54OYQ5U#]=%A/_'A93OM[6DW[?UM,^H-<2_F&74GYBUY(
M^)!?2/B07TCXD%](^)!?2/B07TCXD%](^)!?2/B07TCXD%](^)!?M<<" *3:
M  &6_P8'BO\4$8'_)!IY_S,B</\[*FC_0C%A_THV7/]1.U?_5S]3_UU"4/]B
M1$[_9T9,_VQ(2O]P24G_=$I(_W=+1O][3$7_?TU$_X-.0_^'3D+_BT]!_Y%0
M0?^14$'_D5!!_Y%00?^14$'_D5!!_Y%00?^14$'_D5!!_Y%0_Y$2 ?^5)PO_
ME3L<_Y-++_^/64/_C&14^XQK8_**<G'JB'Q]XX:$A]Z"BH_:?X^6UGV4F]-Z
MF)_1>)RBT'>?I,YUHJ;-=*:HS7*IJ<QQK:K,<+*KRW"VJ\MOO*O(<,"KQ''
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MX9Y^4>&E?U'AI7]1X:5_4>&E?U'AI7]1X:5_4>&E?U'AI7]1X:5_\;0( ,[
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M( ;_CS04_X]$)?^82C/_FTU _YU13O^=5UOXG%QH\)IC=.B7:G_BDW6*W(^
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M@J%JQ8ZE9L.;J&7#K*=APKVJ8[B_JV:POZQIJK^L;*6_JVVBP*IMHL"J;:+
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M>\:BEGO'H)1[R9Z4?,F=E'S)G91\R9V4?,F=E'S)G91\R9V4?,F=_X$1 ?^
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MUHM9MM:+_XX- /^7$@'_K14!V;\) ,S."0##ZPX$MO4>$:OU+"&A]#<PEO-
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MLV9$\L%G0_+49T7NYV=&Z^AG1NOH9T;KZ&=&Z^AG1NOH9T;KZ&=&Z^AG[J(
M ,VT @"\O@0 K\T$ *3>!P&:_Q4)D/\D%8?_,"!^_SLJ=/]",FO_2#EC_TX_
M7?]50UC_74=3_V1*4/]K34W_<D]*_WE11_^"4T7_BU1#_I160?V>5T#]J%@_
M_+-9/OR_6C[[T5H]^]M:/?O;6CW[VUH]^]M:/?O;6CW[VUH]^]M:TJT  +VX
M @"NQ0( H=4" );W"P*-_Q@(A/\F$7S_,1IQ_S@B:/\^*6#_12]:_TPS5/]3
M-U#_6CI,_V \2?]F/D;_;4!$_W1"0?][0S__@T4]_XQ&._^51SK_GDDY_Z=*
M./^Q2C?_ODLW_\)+-__"2S?_PDLW_\)+-__"2S?_PDLW_\)+O[,  *Z^  "@
MS0  DMX  (G_#0&!_QH%=_\C#&W_*A-D_S$97/\X'E7_0")0_T@F3/]/*4C_
M52M$_ULM0O]A+S__9S$]_VTR._]S,SG_>C4W_X(V-?^+-S/_E#@R_YPY,?^D
M.C#_KSLP_[([,/^R.S#_LCLP_[([,/^R.S#_LCLP_[([L+@  *#'  "1V
MA.\  'S_#0%O_Q$#9O\9!E[_(0I6_RD/4/\R$TO_.A9&_T$90O](&S__3AT\
M_U,>.?]9(#?_7B$U_V0B,_]I(S'_<"0O_W<E+?]^)BS_AR<J_X\H*?^7*2C_
MH"HH_Z,J*/^C*BC_HRHH_Z,J*/^C*BC_HRHH_Z,JH<(  )'1  ""X0  >/\
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M54#P]%5#Y_=40^?W5$/G]U1#Y_=40^?W5$/G]U1#Y_=4VZ$  ,6P  "UN@(
MJ,<" )W6! "3_ X!B_\=!H/_*P]Z_S47<?\\'VC_0B9@_TDL6?]/,5/_5C5.
M_UTX2?]E.T7_;3U!_W8_/O^ 03O_BT,Y_YA%./^D1C;_LD<U_\1(-?_=233_
M\$DW_OA)-_[X23?^^$DW_OA)-_[X23?^^$DW_OA)R:L  +:T  "HP0  F\\
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M:$^X\&E1LO!I4J_O:5*O[VE2K^]I4J_O:5*O[VE2K^]I_W\* .V6  #2I@$
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M.3/\_SDS_/\Y,_S_.3/\_SDS_/\YP:@  *^Q  "BO0  E,H  (?8  !]\P<
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M*_]*@R__2(XS_T:8-O]$H3C_0ZDZ_T*P//]"N#W_0<$^_T#+/_] W$#_/^E
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M:E^6\&EADO%H8X_Q9F./\69CC_%F8X_Q9F./\69CC_%F_VL0 ?]^"0#QD 0
MUIX# ,RJ!@#$M 8 OKX% +C($ "PR"0#I\8U#9W#0AN3P$PHBKU4,X&Z7#YY
MMV1&<;5K3FNS=%1DL7Y:7[")7UJOEF)6KJ5E4ZZY9E*OVV52J_)F5:3R9EB?
M\F9:F_-E7)?S9%R7\V1<E_-D7)?S9%R7\V1<E_-D_W - /^$! #=E@  SJ,#
M ,2N! "[MP0 M,(% *[-# "GSB "GLTQ"I7+/A:+R$DC@L92+GK#6CARP6)
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M4D>[_U)'N_]21[O_4D>[_U)'N_]2YHH  ,^;  "_IP  LK   *>[  "<Q@,
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M,_\O_S;_+_\Y_R_Y._\P]#W_,?$]_S'Q/?\Q\3W_,?$]_S'Q/?\Q_T8C O]
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M7?]0HEW_4*)=_U"B7?]0_T\> O]7&P+_8A<!_VP9 O]T( +_>2<#_WXR!_F
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M8&V ]UYO?_E<;WWZ6W!\^UIP?/M:<'S[6G!\^UIP?/M:_U\1 ?]O"@#_?@@
MXXP# -:7!0#/H < RJ@( ,2N$P"[K2<#LJLW#:FG1!F@I$XFF*!7,9&<7SJ*
MF6=#@Y9O2GV3=U!WD8!6<H^*6FV-EEYHBZ-A98NT8V.+S&-CB^YA98GW7V>&
M^%YIA/E<:H+Z6FN!^UIK@?M::X'[6FN!^UIK@?M:_V(0 /]R!P#X@@, VX\"
M ,^:!0#)HP8 PZP& +VR$ "ULB0"K+ U"Z.M0A>;JDPCDJ95+HJC73B#H&5
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M5EB5_E58E?Y56)7^55B5_E58E?Y5_V\$ .:"  #2D0  QIT  +NF 0"RK@
MJK<! *+"!0"<Q!@ E<,J!(W".0V%P$08?;Y.(76\5BINNEXR:+EF.&*W;CY=
MMGA#6+6"1U2TCTM0M)U.3;.N4$NTQ5!+L^I02K'_44RK_U).I?]24*'_4E&>
M_U%1GO]149[_45&>_U%1GO]1_W8  -V)  #*EP  OJ(  +.J  "ILP  H+P"
M )C&!@"1S!( B\PE H3+- E\R4 2=<A*&VW'4R-GQ5PJ8<1D,%S#;397PG8Z
M4\*!/T_!CD)+P9U%2,&N1D?!Q49'P>I&1+[_246Y_TI'L_]+2:W_3$JK_TQ*
MJ_],2JO_3$JK_TQ*J_],Z7\  -&0  #"G@  M:<  *JO  "@N   EL$" (S+
M!P"$U0T @-4> 7G5+@5RU#P,;--'%&724!M?T5DA6M%B)U70:RQ1T'4P3<^!
M-$G/CC=&SYTY1-"N.T+0QCM#T.HZ0,W]/C[+_T! P_]"0;W_0T*Y_T1"N?]$
M0KG_1$*Y_T1"N?]$W8@  ,>8  "XHP  JZL  *"T  "5O@  B\@# (#1!P!X
MX0T =.$= 6[A*P-HX#<(8>!"#ES@3117X%894^!?'4_@:2)+X',E1^!^*$3@
MBRM"X)HM/^&K+S[BP2\^XN4O/-_Z,3G>_S0YV?\V.M#_.#O,_SD[S/\Y.\S_
M.3O,_SD[S/\YS9(  +R@  "MJ   H;$  )6[  ")Q0  ?L\" '3:!@!NZQ$
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MB@@6_YL(%?^M"13_PPD3_^,)$__X"1/__PH3__\*$___"A/__PH3__\*FK$
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M;@H _7@) .B"" #<B0D V(\+ -"3%P#&DRL#OI [#+:,2!>NB%(AIX1<*Z&
M9#.<?&TZEWEU0))W?46.=89*BG*03H9QFU&";Z=4?V^V57UORU9\;^M4?'#_
M4GMP_U![;_].>V__37MN_TM[;O]+>V[_2WMN_TM[;O]+_U<1 /]C"@#_< <
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M36=^_TQG?O],9W[_3&=^_TQG?O],_V$* /]O  #@?@  T(D  ,:3 0"_FP,
MN*$" +&F"P"JJ!X!HZ<O!9NE/0^4HD@9C)]1(H6<62M_FF$R>9AI.725<3]O
MDWE$:I*#2&60CDQACYM/7HZJ4EN.O5):CMY26XWX4%R+_T]>B/].8(7_3&&#
M_TMA@_]+88/_2V&#_TMA@_]+_V0% /5T  #:@@  RXX  ,&7  "XG@$ L:4
M *FK!P"CK1H G*PL!)6K.@R-J$46AJ9/'W^D5RAYHE\O<Z!F-6V>;CMHG'=
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M1$V<_T1-G/]$ZG4  -*&  ##DP  MYT  *RD  "BJP  F+,  (Z[ 0"%P0P
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MKADRZ<89,NCJ&3'E_ADOY/\<+N3_'BWB_R MXO\@+>+_("WB_R MXO\@NIH
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M! __O04._^ %#O_V!0[__P4.__\%#O__!0[__P4.__\%E:\  (:Z  !WQ0
M:-   %K;  !,X0  0.<  #?S   R_P  +O\' "K_#@ F_Q, (_\: !__(  ;
M_R8 &/\K 17_,@$2_S@!$/]  0[_2 $,_U(!"?]= @;_:P($_WT" O^0 @'_
MHP( _[8" /_- P#_[ , _^P# /_L P#_[ , _^P#B+D  'C$  !IT   6]T
M $OC   ^Z0  ,NX  "O_   F_P  (?\  !W_"  :_PT %O\1 !/_%@ 0_QH
M#O\?  O_)  )_RH !O\P  +_-P$ _T ! /]* 0#_5@$ _V0! /]U 0#_B $
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M08Y?_T"+7_\^BE__/8A?_SR(7_\[B%__.XA?_SN(7_\[_TX1 /]8"@#_8P<
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M07)N_S]R;O\^<F[_/G)N_SYR;O\^_U8* /]B  #F;P  UWD  ,R! 0#%AP,
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M/EV _SY=@/\^_V(  .1Q  #/?@  PX@  +F1  "PEP  IYL  )ZA  "8HQ,
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MKBU!L\4N0;/I+4"P_B\_K_\Q/JW_,D"H_S)!IO\R0:;_,D&F_S)!IO\RU7P
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M#BW>^ \KW?\2*MS_%"G:_Q8HVO\6*-K_%BC:_Q8HVO\6LY@  *6@  "9IP
MB[   'ZX  !QP   9<@  %G.  !.TP  1-L$ #_I#0 ]Z1< .^HC #GJ+@ V
MZS@!-.M" 3'L2P(O[54#+>U? RKN:P0H[G@%)N^(!B7OF@<C\*X'(O'(!R+P
M[0<A[/\'(>O_""#K_PH?ZO\+'^K_"Q_J_PL?ZO\+J)\  )NF  "-KP  ?[@
M ''!  !DR@  6-   $S6  !!W0  ..0  #7V#  S]Q0 ,/<> "[X)P K^3
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M 0#_Z@$ __,! /_S 0#_\P$ __,!A+<  '3!  !ES   5M@  $??   YY0
M+>H  "/N   <_0  &/\  !7_   1_P0 #_\+  W_#@ )_Q$ !O\5  /_&@
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M4P/_&V$$_QEN!/\7>P3_%X<%_Q>1!?\7F@;_%Z$&_Q>I!_\7L ?_%[<(_Q?
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M+*9+_RRE3/\KHTS_*I]-_RJ=3?\IG4W_*9U-_RF=3?\I_T,1 /]+# #_4P@
M_UH+ /]>#0#Y8!  ZV$6 .%B(0#68C$!SF%!!<=?3@O"7%D1O5ID%[E8;1NV
M5G8?LU5^(K!3AR6N4H\HJU&8*JE0HBRG4*PMI4^Y+Z-/RR^@4.8OGE#Y,)Q0
M_R^:4?\NF%'_+992_RR44O\KE%+_*Y12_RN44O\K_T80 /]."0#_5@4 _EX&
M .]B!P#G90H Y&8. -9G&0#-:"T!Q6<]!;]E2@NY8U42M&!?%[!>:1RL7'$A
MJ5IZ)*99@BBD6(LKH5:4+9]5G2^<5:@QFE2T,YA4Q3.65.$TDU7V,Y)5_S*1
M5O\QCU;_,(U6_RZ,5_\MC%?_+8Q7_RV,5_\M_TD. /]1!0#_6@$ [F(  -]G
M P#8:@8 U6L* ,UM%0#%;BD!OFTY!+=K1PNQ:%(1K&9<&*AD91VD8FTBH6!U
M)IY>?BF;788MF%R/+Y5:F3*36:0TD%FP-HY9P#:,6=LWBEGS-HE:_S2(6_\S
MAUO_,89;_S"%6_\OA5O_+X5;_R^%6_\O_TL, /]4  #[7@  XF4  -AK 0#/
M;@4 S' ( ,9R$@"^<R8!MW,V!+%P1 JK;D\1IFM9&*%I81V=9VHBF65R)Y9C
M>BJ38H,ND&",,8U?E32*7J VAUZM.(5=O#F#7=0Y@E[P.(%?_S: 7_\T@%__
M,W]?_S%^7_\P?E__,'Y?_S!^7_\P_TT) /]6  #N80  W6D  -%O  #*<P,
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M,VEN_S-I;O\S_U8  .MB  #8;@  R78  +]]  "W@@  L(4  *B'!@"BB1<
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MJC5/C+TU3XS>-4^+]S1/BO\S4(G_,E&&_S%2A/\Q4H3_,5*$_S%2A/\QZF4
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M(CVK]2,\J?\E.Z?_)CNF_R8[I/\F.Z3_)CND_R8[I/\FS'H  +N(  "ND@
MHID  )>>  ",I   @*H  '6O  !IM   7KD& %NZ% !9NR0 5KLQ 5.[/0-0
MNT<%3;M0!TJZ60I'NF(-1+IL$$&Z=Q,^N805/+F3%SFYHQ@XN;<9-[K6&3>X
M]!HUMO\<-+3_'C.S_Q\SLO\@,[+_(#.R_R SLO\@P8,  +21  "FF   FYX
M (^E  ""JP  =K$  &NV  !?O   5,$# $S%#0!+Q1D 2<8H $C&-0!%QT !
M0\=* T#'4P0^QUT&.\=G"#G'<PHWQX ,-,>0#3+'H0XQR+4/,,C3#S#&]! N
MQ/\3+<+_%2S!_Q8KP/\7*\#_%RO _Q<KP/\7N(T  *J7  ">G@  D:4  (2L
M  !XL@  :[D  &"_  !4PP  2L@" $#-!P ZT@X .=(; #C3*  WTS4 -M1
M #352P$SU54!,=9@ B_6; ,MUWH$*]B+!2K8G04HV;$&)]K-!B?7[P8FU/\)
M)=+_"R31_PPCT/\-(]#_#2/0_PTCT/\-KI8  *"=  "4I   AJP  'FT  !L
MNP  8,(  %3&  !(RP  /M   #75!  MW0H +.$3 "OB'P IXRH *.0U "?D
M/P FY4H ).95 "/F80$AYVX!(.=^ A[HD (=Z:0"&^F\ AKJX@(:YOP"&>7_
M QGD_P08X_\%&./_!1CC_P48X_\%HYT  ):D  "(K   >K4  &R]  !?Q
M4\H  $?.   \TP  ,MH  "K?   E[@D (_ 1 "'Q&0 ?\2( '?(K !OS-  9
M]#X %_1( !7U4@ 3]E\ $O9N 1'W@ $0^)0!#_FJ 0[YQ@$.^>T!#?;_ 0WT
M_P$-\_\!#?/_ 0WS_P$-\_\!F:,  (NL  !\M0  ;;X  %_&  !2S0  1=(
M #G8   OW@  )N(  !_J   <^P8 &?\. !?_$P 4_QH $O\A !#_*  ._S
M#?\Y  O_0P )_TX !O]<  3_;  "_X   ?^6  #_K0  _\H  /_P  #__P
M__\  /__  #__P  __\ C:L  'VU  !NOP  8,@  %+0  !#UP  -]T  "OB
M   BY@  &>H  !7Y   2_P  $/\(  [_#@ ,_Q$ "?\6  ;_'  #_R(  /\J
M  #_,P  _ST  /])  #_5P  _VD  /]^  #_E0  _ZP  /_'  #_Z   __H
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M$L<T_Q/%-/\4PS3_%<,S_Q7 -/\5OS3_%+\T_Q2_-/\4_S85 /\[$ #_/@T
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M(Y-,_R*13?\AD4W_(9%-_R&13?\A_T(* /])  #_40  YE<  -U; 0#57 4
MTEL) ,M<% ##7B@ O%XX K9=1@:Q6U$*K5E;#ZE89!.F5FP7HU5T&J!4?1V>
M4X4?FU*.(IE1ER274*$FE5"M)Y)0O"B14- HCE#L*(U1_B>+4?\FBU'_)8I2
M_R2)4O\CB%+_(XA2_R.(4O\C_T4' /]+  #P50  WUL  --@  #,80, R&$&
M ,-A$0"[9"0 M60T J]C0@6J84X*I5]7#Z%=8!2>7&@8FUMP&YA9>!Z56($A
MDU>*))!6DR:.59XHBU6I*HE4MRN'5,LKA57I*X15_"J#5O\H@U;_)X)6_R6!
M5O\D@5;_)(%6_R2!5O\D_T<# /]/  #G6   V6   ,UD  #&9@$ P68$ +MF
M#@"T:2  KFDQ JAH/P6C9DH*GV54#YIC71278648DV!M')!>=1^.77TBBUR&
M)8A;D"B%6IHJ@UFF+(!9M"U_6<<N?5GF+7Q:^BQ[6O\J>UO_*'M;_R=[6O\F
M>EK_)7I:_R5Z6O\E_TD  /M2  #C7   TF,  ,=H  # :P  NFL" +5K#0"N
M;1T J&XN :-M/ 6=:T@*F6I1#Y1H6A209F(8C65J'(IC<B"'8GHCA&&#)H%@
MC"E^7Y<K>UZC+7E>L2]W7<0O=5[B+W5>^2UU7_\K=5__*75?_RAU7O\F=5[_
M)G5>_R9U7O\F_TL  /!5  #>7P  S6<  ,-L  "[;P  M7   *]O"@"H<1H
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MJ"]><;HP77'4,%UQ\BY><?\L7G#_*U]P_RE@;_\H8&[_*&!N_RA@;O\H\54
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M47[.+5%][RQ2??\K4GS_*5-[_RA4>O\G5'K_)U1Z_R=4>O\GZ%X  -!K  #
M=@  M'X  *N%  "AB0  EXL  (F-  "#CP@ ?I 7 'N1)P%VD30#<I _!FV/
M20MICE$/98U9$V*,8!=>BV@;6XIQ'E>)>R%4B(8D48>4)T^&HBE-AK0J2X;,
M*DN%[BE,A/\I3(/_*$R#_R=-@?\F3H'_)DZ!_R9.@?\FX6,  ,EP  "[>P
ML(0  *:*  ";C@  D9$  (23  !ZE0( =9<2 '*8(@!OF# ":I<[!&:710AB
MEDX,7Y56#UN471-8DV4759-N&E&2>!U.D80@2Y"1(TF0H21'D+(F19#*)D6/
M[25%C?\E18S_)4:+_R1&BO\D1HK_)$:*_R1&BO\DV&D  ,-V  "U@0  JXH
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M%"^M_Q4OK/\6+ZS_%B^L_Q8OK/\6NX$  *Z.  "AE0  EIH  (F@  !]I@
M<:L  &6O  !9M   3K<  $.\!0! O1$ /[T> #Z^*P \OC8 .[]! #F_2P$W
MOU0"-<!? C/ :@0QP'<%+\"&!BW EP<KP*H(*L'"""K YP<IO?T**+S_#">Z
M_PTGN?\.)[G_#B>Y_PXGN?\.LHP  *64  "9F@  C:$  '^G  !RK0  9K,
M %JX  !/NP  1+\  #K$ @ PR0@ +LH1 "W*'0 LRRD *\LU "O,0  JS4H
M*,U6 "?.80 FSF\!),Y_ 2//D0(ASZ4"(-"] B#/Y (?S?H#'LO_!![*_P4=
MR?\&'<G_!AW)_P8=R?\&J)0  )R:  "0H0  @J@  '2O  !GM@  6[P  $[
M  !#PP  .<<  "_,   GT 0 ']8* !O:$  ;VQH &MLF !K<,0 9W3P &-U(
M !C>50 7WV( %N!R !7@A0 4X9H $^*Q !+CSP 2X/0 $M[_ 1'=_P$1V_\"
M$=O_ A';_P(1V_\"GIH  )*A  "$J0  =K$  &BX  !;OP  3L0  $+(   W
MS   +=   "35   <VP  %=\% !3I#@ 2ZA0 $>L= !#K)@ .[#  #NTZ  WN
M1@ +[E, "N]B  GP=  (\8D !_*@  7RN@ $\>0  O']  +O_P #[?\  ^W_
M  /M_P #[?\ E:$  (:I  !XL@  :;H  %O"  !-R   0,P  #31   JU@
M(=L  !G@   2Y   #_ !  WY"@ +^@\ "?L5  ?['  $_"0  ?PL  #\-P
M_$(  /Q0  #\80  _74  /R,  #\I   _,$  /SK  #\_P  _?\  /W_  #]
M_P  _?\ B:D  'FR  !JNP  7,0  $[,   _T0  ,M<  "?=   =X0  %>4
M  [H   *\0  "/T   7_ P !_PD  /\.  #_$@  _Q<  /\?  #_)P  _S$
M /\^  #_30  _U\  /]U  #_C0  _Z8  /_"  #_YP  __P  /__  #__P
M__\ ?+,  &R\  !=Q@  3L\  #_6   QW0  )>(  !KF   1Z@  #.X   7R
M    _P   /\   #_    _P   /\%  #_"@  _PX  /\2  #_&   _R$  /\K
M  #_.0  _TH  /]=  #_<P  _XP  /^D  #_N0  _]0  /_>  #_W@  _]X
M_Q@L /\9*0#_&2@ _Q4K /\0, #_"S@!_P-$ ?\ 40'_ %X!_P!L ?\ > '_
M ((!_P", ?\ E '_ )P _P"B /\ J #_ *\ _P"V /\ O@#_ ,@ _P#7 /\
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M ?\*C0'_"I0!_PJ; ?\*H@'_"J@!_PJO ?\*MP'_"L  _PK, /\*X #["N\
M]PKZ /4+_P'U#/\!] W_ ?0-_P+T#?\"] W_ O0-_P+T#?\"_R(B /\D'0#_
M)!P _R(= /\>(@#_'"P _QDX /\610'_$U(!_Q)> ?\0:@'_$'4!_Q!_ ?\0
MB '_$) !_Q"7 ?\0G@'_$*4!_1"L ?P0LP'Z$+T!^1') ?41W0'Q$>T![A'Y
M >P2_P+K$_\"ZA/_ ^D3_P/I$_\#Z1/_ ^D3_P/I$_\#_R8= /\H& #_*!8
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M$*\T_Q"N-/\/KC3_#ZXT_P^N-/\/_S4. /\X!P#_/ ( _T & /]!"P#Z00\
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M&85,_QF%3/\9_T   /Q'  #E4   U58  ,I9  #"6@  O5@# +A7#@"Q61X
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MJ"5L7;@E:E[.)FE>[B1I7O\B:E[_(&I>_Q]J7O\>:E[_'6I>_QUJ7O\=^4H
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M)5ALZ"59;/TC66O_(5IK_Q];:_\>6VK_'EMJ_QY;:O\>ZU,  --@  #":0
MMG$  *QV  "C>0  F7D  (UW  "'>0L @WL8 ']\* ![?#4"=WM !7-Z20AO
M>5$,;'A9#VAW81-E=F@68G5P&5]T>AQ<=(4?6G.1(5=RH"-5<K D4W+%)%-R
MYR13<?PB5''_(%1P_Q]5</\>56__'55O_QU5;_\=Y5<  ,UD  "^;0  LG4
M *A[  "??@  DWT  (=]  " ?P< ?( 5 'B!) !U@C(!<8$]!&V 1@=I@$\*
M9G]6#6-^7A%@?68477QN%UI[=QI7>H(=5'J/'U%YG2%/>:XB3GG#(DUXY2)-
M=_LA3G?_'TYV_QY/=?\=3W7_'4]U_QU/=?\=WUP  ,AH  "Y<@  KGH  *6
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M&T&%_QM"A?\:0H3_&D*$_QI"A/\:S6<  +QT  "O?@  I88  )J*  ".C
M@HT  '60  !GE   894( %Z7% !<ER, 6I@O %>8.@%4F$0#4I=,!4^75 =,
MEUP)299E#$>6;PY$E7H1096($S^4EQ4]E*@6.Y2]%CN4WQ8ZDO@7.I#_%SJ/
M_Q<ZCO\7.H[_%SJ._Q<ZCO\7Q6X  +9[  "JA0  GHL  )2/  "(D@  >Y0
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M!R&R_P<ALO\'K8H  *"1  "5EP  B)T  'NC  !NJ   8:T  %6Q  !*M
M/[<  #2[   KO@, ),(, "+"%  BPQ\ (<,J "#$-  ?Q#\ 'L5* !W&5@ <
MQF, &\=S !K'A0 9QYD &,BN !?(RP 7QO$!%\3_ 1;#_P(6P?\#%L'_ Q;!
M_P,6P?\#HY$  )B8  "+G@  ?:4  '"K  !BL0  5K8  $JY   ^O0  -,
M "K$   BR   &<P$ !/0"@ 1TA$ $-(: !#3)0 /TS  #M0\  [42  -U58
M#=5E  S6>  ,UHT "]BD  K8O@ )V>8 "M;^  O4_P +TO\ "]+_ 0O2_P$+
MTO\!FI@  (Z?  " I@  <JT  &2T  !7N@  2;\  #W"   RQ@  *,D  !_-
M   7T0  $=8   S;!0 (W@L !M\1  7?&@ $X"0  N$N  'B.@  XT<  .16
M  #D9P  Y7L  .:2  #FJ@  Y\@  .?P  #H_P  Z/\  .C_  #H_P  Z/\
MD9\  (*G  !TKP  9;<  %>^  !)PP  /,<  ##+   ESP  '-0  !39   .
MW0  ">$   +E    Z08  .D-  #I$0  ZA@  .LA  #M*P  [S<  /%%  #R
M5@  \V@  /-^  #TEP  ];   /;0  #W\P  ]_\  /?_  #W_P  ]_\ A:<
M ':P  !FN   6,$  $K(   [S   +M$  "/6   9W   $>    SC   $YP
M .H   #U    ]    /4%  #U"P  ]@\  /84  #X'0  ^B<  /PT  #_0P
M_U4  /]I  #_@0  _YH  /^R  #_SP  _^T  /_Y  #_^0  __D >+   &BZ
M  !9PP  2\L  #O1   MV   (=T  !;B   .Y@  ".H   #M    \    /@
M  #_    _P   /\   #_    _P8  /\,  #_$   _Q@  /\B  #_,   _T
M /]3  #_:0  _X$  /^9  #_KP  _\,  /_5  #_U0  _]4 _Q,H /\3)0#_
M$24 _PTG /\&+0#_ #4 _P!! /\ 3P#_ %P _P!I /\ = #_ 'X _P"( /\
MD #_ )< _P"= /\ I #_ *H _P"P /\ MP#_ ,  _P#, /\ WP#_ .P _P#X
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _Q8E /\6(@#_%"$
M_Q C /\** #_ #  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"$ /\ C #_
M ), _P": /\ H #_ *8 _P"M /\ M #_ +P _@#( /T V0#[ .D ^@#V /D
M_P#X /\ ^ #_ /@ _P#X /\ ^0#_ /D _P#Y /\ _QHB /\:'@#_&!T _Q,>
M /\.(@#_"BP _P<Y /\#1@#_ %, _P!@ /\ :P#_ '8 _P!_ /\ B #_ (\
M_P"6 /\ G0#_ *, _@"I /P L #Z +D ]P#$ /4 T@#S .8 \@#T /$ _P#P
M /\ [P#_ .\ _P#O /\ \ #_ /  _P#P /\ _QX= /\>&0#_'!< _Q<8 /\3
M'@#_$2@ _PXT /\,00#_"DX _PA; /\'9@#_!G$ _P9Z /\&@P#^!HL _ :2
M /H&F0#X!I\ ]@:F /0&K0#R!K4 \ 7  .T%S@#K!>0 Z0;S .8(_P#E"O\
MY O_ .0+_P'D"_\!Y O_ >0+_P'D"_\!_R$8 /\A$P#_(!$ _QL2 /\<&@#_
M&B0 _Q8O /\3/ #_$4D _Q!5 /P.80#Y#FL ]@YU /0.?@#R#H8 \ Z. .X.
ME0#M#IL ZPZB .H.J@#H#K, Y@^] .4/S #A#^, W1#S -D1_P'6$O\!U!/_
M =,3_P+2$_\"TA/_ M(3_P+2$_\"_R43 /\E$ #_) T _R,. /\C% #_(AX
M_Q\I /\<-0#Y&4, ]!A/ .\76P#L%V8 Z1=P .87>0#D%X$ XA>) . 7D0#?
M%Y@ W1>? -L7IP#9&+$ UAB[ -09R@#0&N$!S!OS <D<_P+&'/\"Q!S_ \,<
M_P/#'/\#PQS_ \,<_P/#'/\#_R@0 /\I"P#_* 8 _RL+ /\K$ #_*1< _28B
M /0C+@#L(3L YB!) .(@50#>(&  VB%J -8A= #3(7P!T"&$ <\BC '-(I,!
MRR*; <DBHP'((ZP"QB.V L0CQ +")-L"OB7N [LE_@2X)?\%MB7_!;4E_P:U
M)?\&M27_!;4E_P6U)?\%_RP- /\M!0#_+@$ _S$% /\Q"P#]+Q  \2L8 .<I
M)0#?*#, V"A" -$J3P#-*UH R2ME <<K;@'$+'8"PBQ^ L LA@.^+(X#O2R6
M [LLG@2Y+*<$N"RQ!;8LOP6U+=$%L2WJ!JXN^P>K+O\(J2[_"*@N_PBH+?\(
MJ"W_"*@M_PBH+?\(_R\( /\Q  #_-0  ]C<  .HV @#G,P@ Y"\/ -DN&P#/
M,2P R3,\ ,0T20# -54!O#5? KHU: *W-7 #M31X!+,T@ 6Q-(@&L#20!JXT
MF0>L-*((JS2L":DTN0FG-,H*I37E"J$U^ N?-?\,G37_#)TU_PN<-?\+G#7_
M"YPU_PN<-?\+_S," /\U  #V.@  Y3X  -Q   #4/00 TC<) ,LX%0##.B8
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MJ1=\2[@8>TO-&'E,ZQAX3/X7=TS_%7=,_Q1W3/\3=TS_$G=,_Q)W3/\2_SX
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M'&19XQQD6?H:9%G_&&19_Q=E6?\595G_%&59_Q1E6?\4[T8  -I2  #&6P
MNF$  +!E  "F9@  G6,  )5A  "/8@X BV0< (=E*P"#93<!?V5" WQD2P9X
M8U,(=6-;"W-B8@YP86H0;6!R$VM@>Q5H7X879EZ1&6->GQMA7:X<8%W!'%]=
MX1Q?7?@:7UW_&%]=_Q=@7?\68%W_%6!=_Q5@7?\5ZTH  -16  ##7@  MF4
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M&$]K_Q=0:O\64&K_%5!J_Q50:O\5W54  ,5A  "W:@  K'$  *)U  "4=
MB70  'QS  !V=0  <7<0 &]X'0!L>2L :7DW 69Y0 -C>4D%8'A1!UUW6 E;
M=V ,6'9H#E5U<1%2=7P34'2(%DUTEQ=+<Z8827.Y&4ASU1E)<O,827'_%TIQ
M_Q9*</\52W#_%$MP_Q1+</\4U%H  ,!F  "S;P  J'8  )UY  "/>   A'@
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M#S:'_P\VA_\/OFT  +!Y  "E@@  F8<  (R(  !_B   <HH  &:-  !:D0
M4)4  $F7"0!'F!, 19@@ $29*P!#F38 09I  $":2 $^FE$"/)I: CJ:9 ,W
MFF\%-9E]!C.9C <QF9T(+YFP""Z9R@@NF.T(+I;_"BV4_PHMD_\++9+_"RV2
M_PLMDO\+MG4  *J!  ">B   DXT  (:.  !XCP  :Y(  %^5  !4F0  29T
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M>  0OXP $,"B  [ N@ .P.$ #[W[  ^\_P 0NO\!$+K_ 1"Z_P$0NO\!GX\
M )25  "'FP  >:$  &NG  !>K   4K$  $6T   ZM@  +[D  "6\   =OP
M%<,   _&!0 +R@T "<H4  C*'0 'RB< !\HR  ;+/@ %RTL !,Q:  /,:@ "
MS'X  <R4  #,JP  S<@  ,SM  #,_P  R_\  <K_  '*_P !RO\ EY8  (J<
M  !\HP  ;JH  &"P  !2M@  1;D  #F\   NOP  (\,  !O&   3R@  #<T
M  C1   !U D  -0.  #5%0  UAX  -@G  #9,0  VSX  -Q+  #=6P  WFX
M -Z$  #?FP  W[0  -[9  #?]P  W_\  -__  #?_P  W_\ C9T  '^E  !P
MK   8;,  %.Z  !%OP  .,(  "S&   AR0  &,T  !#1   +U0  !-H   #>
M    X $  .$)  #B#@  Y!,  .4;  #G)   Z2\  .L\  #M2P  [ET  .YQ
M  #OB0  \*(  /"\  #PXP  [_D  /#_  #P_P  \/\ @:4  '*M  !CM0
M5+T  $;$   WR   *LP  !_0   5U0  #MH   ?>    X@   .8   #I
MZ@   .P   #N!0  [PP  /$0  #S%P  ]2   /@K  #[.0  _4H  /Y>  #_
M=   _XT  /^F  #_P   _^$  /_U  #_]0  __4 =*X  &6W  !6P   1\@
M #C-   JT@  '=@  !/=   ,X@   ^8   #I    [    /    #S    ]
M /8   #X    ^@   /T'  #_#0  _Q(  /\;  #_*   _S<  /]*  #_7@
M_W8  /^/  #_I@  _[H  /_1  #_T0  _]$ _P\D /\.(@#_"R$ _P,D /\
M*0#_ #( _P ^ /\ 3 #_ %D _P!E /\ < #_ 'H _P"$ /\ C #_ )( _P"9
M /\ GP#_ *4 _P"K /\ L@#_ +H _P#% /\ TP#_ .< _P#T /\ _P#^ /\
M_P#_ /X _P#^ /\ _@#_ /X _P#^ /\ _Q$A /\0'@#_#1T _P<? /\ (P#_
M "T _P Z /\ 2 #_ %4 _P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"5 /\
MFP#_ *$ _P"G /X K@#] +8 _ #  /L S0#Y .( ^ #P /< _ #V /\ ]0#_
M /4 _P#U /\ ]0#_ /4 _P#U /\ _Q4= /\3&@#_$!D _PL9 /\ '0#_ "D
M_P V /\ 0P#_ %  _P!< /\ 9P#_ '$ _P!Z /X @P#\ (H ^@"1 /D EP#X
M )T ]P"C /4 J@#T +( \@"[ /$ R #O -P [@#L .T ^@#K /\ Z@#_ .H
M_P#J /\ Z@#_ .H _P#J /\ _Q@9 /\6%0#_$Q, _PX3 /\+&@#_!R0 _P(P
M /\ /@#_ $L _P!7 /\ 8@#\ &P ^ !U /4 ?@#R (4 \0", .\ DP#N )D
M[ "@ .L I@#I *X YP"W .8 PP#D -0 X@#I .$ ]P#? /\ W0#_ -T _P#=
M /\ W0#_ -T _P#= /\ _QL3 /\:$ #_%@X _Q(. /\2%0#_#Q\ _PPK /\)
M. #_!D4 ^P-1 /<"7 #R F8 [@)P .H"> #G H  Y@.' .0#C@#B Y4 X0.<
M -\$HP#=!*L VP2T -@%P #6!=  TP;G - (^ #."O\ S O_ ,L,_P#+#/\
MRPO_ ,L+_P#+"_\ _Q\0 /\>"P#_&@< _QD+ /\8$0#_%AD _Q(D /H0, #S
M#CX [@U* .D,5@#E#&$ X@QJ -X-<P#;#7L V0V# -8-B@#4#9$ T@V9 - .
MH #/#JD S0ZS ,L.OP#*#]  QA'I ,(2^0"_$_\ O1/_ ;P3_P&\$_\!O!/_
M ;L3_P&[$_\!_R(, /\A! #_(   _R$% /\?# #_'!$ ]A@< .P5* #E$S8
MWQ)# -D33P#3%%H T!5D ,T6;0#+%G4 R1=] ,<7A0#%&(P Q!B4 ,(9G #
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MK0>4-;L(DS70") U[ B.-OX(C#;_"(LV_PB+-O\'BC7_!XHU_P>*-?\'_R\
M /(T  #B/   TD$  ,="  # 0   NSH! +8V#@"P.1P JCLL *8\.@"C/48
MGSU0 9T]60*:/6$#F#UH!)8\< 64/'<&DCR !Y$\B >/.Y((C3N="8L[J0J)
M.[<+B#O*"X4\Z N#//L+@CS_"H$\_PJ!//\)@3S_"($\_PB!//\(_S,  .PZ
M  #:0P  RD<  +])  "W1P  L4(  *T^"@"F0!< HD(G )Y#-0":1$(!ET1,
M 91$50*10UT#CT-D!8U#:P:+0G,'B4)["(="A J%08X+@T&9#(%!I0U_0;,.
M?D'&#GQ!Y YZ0OD->4+_#'A"_PMX0O\+>$+_"GA!_PIX0?\*]C8  .9   #1
M2   PTT  +E.  "Q30  J4D  *1%!@"?1A, FD@C )9),@"22CX!CTI( HQ*
M40.*25D$ATE@!85): >#2&\(@4AW"G]'@ M]1XH->D>5#GA&H@]V1K 0=4;"
M$'-&X!!R1_</<4?_#G%'_PUQ1_\,<4?_"W%&_PMQ1O\+\SD  .!$  #,3
MOE$  +13  "J4@  HDX  )U* 0"72Q$ DTT@ (]/+@",3SH!B$]% H5/3@.#
M3U8$@$Y=!GY.9 =\36P)>4UT"W=,?0QU3(<.<TR2#W%+GQ%O2ZT2;4N_$FQ+
MW!)K3/41:DS_#VI,_PYJ2_\-:DO_#&I+_PQJ2_\,\#T  -M(  #'4   NE4
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M$5I8_Q!:6/\.6E?_#5I7_PU:5_\-XT@  ,M3  "[6P  L&$  *1B  "780
MCE\  (5<  !_7@< >U\3 'AA(0!U8BX <F(Y 6]B0P)L84L#:F%3!6=A6@=E
M8&()8V!J"V!?<PU>7GT/6UZ)$5E=EA)77:4355VV%%1=SA147>X35%W_$55<
M_Q!57/\.55O_#E9;_PU66_\-WDP  ,=6  "X7P  K60  *!E  "39   B6,
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M#45J_PU%:O\-RU@  +IC  "M;   H7$  ))P  "%;P  >F\  &YP  !E<P
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M@P,KDI0#*I*G RB2O00HDN$#)Y#Z!">._P4GC?\%)XS_!2>,_P4GC/\%L70
M *5^  "9A0  BH0  'V$  !OA0  8X@  %B+  !-CP  0Y,  #J7   RF@<
M+IL0 "V;&@ LG"0 *YPN "J=.  IG4$ *)U+ ">>50 FGF$ )9YN ".>?@$B
MGI !()ZC 1^>N0$>GMT!'ISX AZ:_P(>F?\#'I?_ QZ7_P,>E_\#JGT  )Z%
M  "3BP  A8H  '6+  !HC@  6Y$  %"5  !&F0  .YT  #*@   JHP  (J8)
M !^G$0 >IQH ':@D !RH+0 ;J#< &JE! !FI3  8J5@ %ZIF !:J=@ 5JHD
M%*J> !.KM  2J], $JCU !.G_P$3I?\!$Z7_ 1.D_P$3I/\!HX8  )>,  "-
MD0  ?9(  &V5  !@F   5)P  $B@   ^I   -*<  "JK   AK@  &;$  !*S
M!P /M1  #K47  ZU(0 -M2L #;4V  RV00 +MDX "K9<  FV;  (MG\ ![:4
M  :VJ@ %ML4 !K;J  >U_P (M/\ "+/_  FR_P )LO\ FHT  )"3  "$F
M=)P  &6@  !7I   2Z@  $"L   UL   *K,  "&U   8N   $;L   R^ @ &
MP L  L 1  '!&0  P2(  ,(K  #"-@  PT(  ,-0  #$7P  Q'$  ,2'  #$
MG0  Q+4  ,3:  #$]@  P_\  ,/_  ##_P  P_\ DY0  (>:  !XH   :J8
M %RL  !/L0  0;4  #6W   IN@  '[T  !;    0PP  "L8   /*    S 4
M ,P,  #-$0  SA@  ,XA  #0*@  T34  --#  #44@  U&,  -5X  #5CP
MU:<  -;"  #6Z0  UOT  -;_  #6_P  UO\ BIL  'NB  !LJ0  7K   %"V
M  !"N@  -+T  "C!   =Q   %,<   W+   &S@   -(   #7    V0   -H%
M  #<"P  W1   -\5  #A'0  XR<  .4S  #G0@  Z%0  .AG  #I?@  Z9<
M .JO  #JS@  Z^\  .O^  #K_P  Z_\ ?:,  &ZK  !?L@  4;H  $+    T
MPP  )\<  !O+   2SP  "],   +8    W0   .$   #D    Y0   .<   #I
M    ZP<  .T-  #O$0  \1D  /0D  #W,0  ^4$  /I5  #Z:@  ^X0  /N=
M  #\M@  _-(  /WM  #]]   _?0 <:P  &&U  !2O0  1,0  #3)   FS0
M&M(  !#8   (W0   .$   #E    Z    .P   #O    \0   /,   #U
M]P   /D!  #["   _@X  /\5  #_(0  _R\  /]!  #_5@  _VT  /^'  #_
MH   _[8  /_*  #_U   _]0 _PL@ /\''@#_ !T _P @ /\ )0#_ "X _P [
M /\ 20#_ %8 _P!B /\ ;0#_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#_ *
M_P"F /\ K0#_ +4 _P"^ /\ RP#_ .$ _P#P /X _0#] /\ _0#_ /T _P#]
M /\ _ #_ /D _P#Y /\ _PT= /\+&@#_!!D _P : /\ 'P#_ "H _P W /\
M10#_ %$ _P!> /\ : #_ '( _P!Z /\ @@#_ (D _P"0 /\ E@#_ )P _@"B
M /P J0#[ +  ^0"Y /@ Q@#V -D ]0#K /0 ^0#S /\ \@#_ /, _P#S /\
M\P#_ /, _P#S /\ _Q 9 /\.%0#_"!0 _P 4 /\ &0#_ "4 _P R /\ 0 #_
M $P _P!9 /\ 8P#^ &T _ !U /H ?0#Y (0 ]P"+ /8 D0#T )< \P"> /(
MI #P *P [@"T .T P #K ,\ Z0#F .@ ]0#F /\ YP#_ .8 _P#E /\ Y0#_
M .4 _P#E /\ _Q(4 /\0$ #_# \ _P,0 /\ %0#_ "  _P L /\ .@#_ $<
M^@!3 /< 7@#T &< \0!P .\ > #M '\ ZP"& .H C #H ), YP"9 .4 H #C
M *< X0"P -\ N@#= ,D VP#@ -@ \ #7 /X U0#_ -0 _P#3 /\ TP#_ -,
M_P#3 /\ _Q40 /\2# #_#@D _PL, /\)$@#_ QH _P F /T ,P#T $  [P!-
M .L 6 #H &$ Y0!J .( <@#@ 'H W@"  -P AP#: (X V "5 -0 G #2 *,
MT "L ,X M@#, ,0 R@#9 ,@ [0#' /L Q0#_ ,0!_P## ?\ Q '_ ,0!_P#$
M ?\ _Q@+ /\5!0#_$   _Q & /\/#0#_#!0 _ <? /$#*P#G #D X@!& -X!
M40#: EL U0)D -(#; #/ W0 S01[ ,L$@@#*!(D R 60 ,8%F #$!:  P@:I
M ,$&M "_!L$ O0C5 +L)[ "X"_T M@S_ +4-_P"T#?\ M W_ +0-_P"T#?\
M_QL% /\8  #_%P  _Q8  /L3!@#Z$ X [@P6 .,)(@#:"3  TPH^ ,X+2@#*
M#%4 QPU> ,4-9P#"#F\ P0YV +\.?@"]#X4 O ^- +H0E0"X$)T MQ"G +41
ML@"S$<  LA'5 *X3[@"K%/X J17_ *<5_P"G%?\ IA3_ :84_P&F%/\!_Q\
M /\<  #Z'@  ZQX  .,<  #?%04 W@X- -,.& #+$2@ Q1,W , 41 "\%D\
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M XHOX02'+_8$A2__!(0O_P.$+_\#@R__ X,O_P.#+_\#^RD  .LQ  #9.
MR3P  +\\  "V.0  L#(  *PM"P"G+Q< HC$F )XS- ":-$  F#5* )4U4P"3
M-5L!D35B 8\U:0*--7$"C#5Y XHU@@.(-8L$AC66!(0UH@6"-:\%@37 !G\V
MW 9]-O0&>S;_!7LV_P5Z-O\$>C;_!'HU_P1Z-?\$]2T  .0W  #0/P  PD,
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M"61&_PAD1O\'9$;_!F1%_P9D1?\&Z#L  -!&  "_30  LU$  *51  ":3@
MDDL  (U'  "'2 L @TH6 ']+) !]3#$ >DT\ '=-10%U34T"<TU5 G%-7 -O
M36,$;4QK!6M,<P=I2WT(9DN)"61+E@IB2Z0+84NT#%]+R@Q>2^H+7DO^"EY+
M_PE>2O\(7DK_!UY*_P=>2O\'XS\  ,M)  "\40  L%4  *%4  "64@  C5
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M"%!6_P=05O\'TTH  ,!4  "R7   HUX  )5=  ")7   ?UL  '99  !P6@
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MA@8\;Y4'.F^F"#AONP@X;]L'.&[V!SAM_P<X;/\&.6O_!CEJ_P8Y:O\&O5P
M *]F  "B;0  D6P  ()K  !W:P  ;&P  &%N  !7<   4',  $QU"@!)=A,
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M 2*+LP$AC,X!(8KQ 2"(_P(@AO\"((7_ B&%_P(AA?\"JW(  *%\  "/>P
M@'H  '-Z  !F?   6W\  %""  !&A@  /(H  #2-   LD0  )I,, "24$P C
ME!P (I4F "&5+P @E3@ 'Y9" !Z63  =EE@ ')9D !J7=  9EX8 &)>9 !>7
MK@ 5E\D %I7N !:3_P$6DO\!%I'_ 1:0_P$6D/\!I7L  )F#  ")@0  >X
M &R"  !?A   5(@  $F+   _D   -90  "V7   EF@  '9X! !:@#  4H1(
M%*$; !.A)0 2H2X $:(X !&B0P 0HD\ #Z)<  ZC:P -HWT #:.2  RCIP *
MHL  "Z+F  R@_@ -G_\ #9[_  V=_P -G?\ GH0  )*)  "#B   <X@  &6+
M  !8C@  3)(  $&7   WFP  +IX  "2B   <I0  %:@   ^K!  *K@P !ZT2
M  :M&P %K20 !*XN  *N.0 !KD4  *Y2  "N80  KG,  *Z'  "NG0  KK0
M *[5  "M]   K?\  *S_  "K_P  J_\ EHL  (R0  ![D   :Y(  %V6  !0
MF@  1)\  #FC   OIP  ):L  !RN   4L0  #K0   FW   !N D  +@.  "Y
M%   N1P  +HE  "Z+P  NSH  +Q'  "\5@  O&<  +Q[  "\D0  O*D  +S$
M  "\ZP  N_X  +O_  "[_P  N_\ D)(  (.8  !SFP  8Y\  %6C  !'J
M.ZT  #"Q   EM   &[<  !*Z   ,O0  !;\   ##    Q (  ,4*  #%#@
MQA0  ,<;  #()   RBX  ,PZ  #-20  S5D  ,UL  #.@P  SIL  ,VU  #.
MV@  SO8  ,W_  #-_P  S?\ AID  '>@  !II@  6JP  $RR   ^M@  ,+D
M "2\   9OP  $<(   K%   "R0   ,P   #0    T0   -(!  #3"   U0T
M -<1  #:&   W"$  -\L  #A.@  XDH  .-=  #D<@  Y(L  .6E  #EP
MY>8  .7X  #E_P  Y?\ >J$  &NI  !<KP  3;8  #^\   POP  (\,  !?'
M   /R@  !\X   #1    U@   -P   #?    X    .(   #D    Y@,  .@)
M  #I#@  [!4  .X>  #Q*P  ]#H  /5-  #V80  ]WD  /B3  #XK0  ^<8
M /GD  #Y\P  ^?, ;:H  %ZR  !/N@  0,$  #'%   BR0  %LX   W2   $
MV    -T   #A    Y    .@   #K    [0   .\   #Q    \P   /8   #X
M P  ^@L  /T1  #_&P  _RD  /\[  #_3P  _V8  /]_  #_F0  _Z\  /_#
M  #_U@  _]8 _P0< /\ &0#_ !D _P < /\ (@#_ "L _P X /\ 1@#_ %,
M_P!> /\ :0#_ '( _P!Z /\ @@#_ (D _P"/ /\ E0#_ )L _P"A /\ J #_
M *\ _P"Y /\ Q0#_ -D _@#L /T ^P#[ /\ ^P#_ /L _P#Z /\ ] #_ /
M_P#P /\ _P<8 /\!%0#_ !0 _P 6 /\ &P#_ "8 _P T /\ 0@#_ $X _P!:
M /\ 9 #_ &T _P!U /\ ?0#_ (0 _P"* /T D #\ )8 ^@"= /D HP#X *L
M]P"T /4 OP#T ,X \P#F /$ ]@#P /\ [P#_ .\ _P#N /\ [@#_ .H _P#J
M /\ _PL4 /\&$0#_ !  _P 0 /\ %@#_ "( _P N /\ / #_ $D _P!4 /X
M7P#[ &@ ^0!P /< > #U '\ \P"% /( BP#P )( [P"8 .T GP#L *8 Z@"N
M .@ N0#G ,< Y0#> ., \ #B /X X #_ .  _P#A /\ X0#_ .$ _P#A /\
M_PT0 /\)#0#_ 0P _P , /\ $@#_ !P _P H /P -@#Y $, ]@!. /( 60#O
M &( [ !K .H <@#H 'D Y@"  .0 A@#B (P X0"3 -\ F@#= *$ VP"J -@
MM #5 ,  T@#3 -  Z@#. /H S0#_ ,T _P#- /\ S #_ ,P _P#, /\ _Q ,
M /\,!P#_ P( _P ( /\ #@#_ !8 ]@ B /  +P#L #P Z0!( .4 4P#A %P
MW@!E -L ; #7 ', U !Z -( @ #0 (< S@". ,P E0#* )T R "E ,8 KP#$
M +L P@#+ ,  Y0"^ /4 O0#_ +P _P"\ /\ O #_ +P _P"\ /\ _Q$% /\.
M  #_"@  _P@! /\$"@#X !  Z0 : ., * #> #4 V0!! -, 3 #/ %8 RP!?
M ,D 9@#& &X Q !T ,( >P#! (( OP") +T D "\ )@ N@"A +@ JP"V +<
MM #' +( X "Q ?( KP+_ *X#_P"M!/\ K03_ *T$_P"M!/\ _Q0  /\0  #_
M#P  \@T  .H*  #I PD W0 2 -0 'P#- 2T R (Z ,0#10#  U  O019 +L%
M80"Y!6@ MP9O +4&=@"T!WT L@>$ +$(C "O")4 K0F> *L)J "J"K4 J K%
M *8+WP"D#?0 H@[_ * ._P"?#O\ GP[_ )\._P"?#O\ _Q<  /\3  #O&
MY!D  -L6  #2$ ( SPD+ ,@(%@#!"B0 O PR +<-/@"T#DD L0Y3 *\06P"M
M$&, JQ!J *D1<0"H$7@ IA&  *41B "C$I$ H1*; * 3I@">$[, G!/# )L4
MW@"7%O0 E1;_ )07_P"3%_\ DA?_ )(6_P"2%O\ _QH  /0=  #E(P  U24
M ,HD  #"'0  OA8$ +L0$ "T$QT KQ4K *L6. "G&$, I1E- *(95@"@&ET
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M G,P_P)S,/\"<R__ G,O_P)S+_\"\"H  -PU  #'.P  NC\  *P\  "B.
MG#,  )@O  "5+A  D# < (PR*0"),S4 AC0_ (0U20""-5$ @#58 'XU7P%]
M-68!>S9N 7DU=@)X-8 "=C6+ W0UEP-R-J0#<#:T!&\VR 1M-N<$;#;\ VLV
M_P-K-O\":C;_ FHU_P)J-?\"ZC   -,Z  #"00  LT,  *5!  ";/@  E3H
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M UA$_P-81/\#VCT  ,1'  "U3@  I$X  )9,  "+2P  @TD  'U%  !X1@(
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MA@5'5Y4&15>E!D17N 9#6-(&0U?R!D-6_P5#5?\$1%7_!$14_P-$5/\#QDP
M +56  "E6@  E%D  (98  ![6   <5<  &96  !A6   75D$ %E:$ !76QL
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M S-IL@,Q:<L#,6CM S%G_P,Q9O\#,F7_ S)D_P,R9/\#MUL  *ED  "69
MAF,  'AC  !M8P  9&0  %EE  !0:   26L  $-M! ! ;@X /F\8 #UO(@ \
M<"L .G T #EQ/0 X<44 -W%. #9Q5P T<6$!,G%M 3%Q>@$O<8H"+7&< BMQ
MKP(J<<@"*G#K BIO_P(J;?\"*FS_ BML_P(K;/\"L6$  *1I  "0:   @&<
M '1G  !I9P  7V@  %5K  !+;@  0W$  #QT   W=@H -'<2 #-X'  R>"4
M,7DN #!Y-P O>3\ +GE( "QZ4@ K>EP *GIH "AZ=@ F>H<!)7J9 2-ZK $B
M>L4!(GGI 2)W_P$B=O\!(G7_ B)T_P(C=/\"K&@  )UN  "*;0  >VP  &]L
M  !E;   6FX  %!Q  !%=0  /7@  #9\   N?P( *8$- ">"%  F@AX )8(G
M "2"+P C@S@ (H-" "&#2P @A%8 'X1B !Z$<0 <A(( &X25 !J$J0 8A,$
M&(/F !B!_0 9@/\!&7__ 1E^_P$9?O\!IG   )5S  "$<@  =G$  &MQ  !>
M<P  5'8  $EY   _?0  -X$  "^$   GB   ((L% !N-#@ :C14 &8T> !B.
M)P 7CC  %HXY !6.0P 4CT\ $X]; !*/:@ 1CWL $(^/  ^/I  .C[L #8_@
M  Z-^@ /B_\ $(K_ !")_P 0B?\ H7H  (YY  !^=P  <G<  &1X  !8>P
M37X  $*"   YA@  +XH  ">.   @D0  &)4  !*8!0 .F@X #9H4  R:'0 +
MFB8 "YHP  J:.P )FD8 ")I3  :;80 %FG( !)J&  *:FP  FK$  9G/  *9
M\  "F/\ !)?_  66_P %EO\ F8$  (=_  !Z?@  :WX  %V!  !0A0  18D
M #N-   QD@  *)8  !^9   8G0  $:    RC @ &I0H  :40  "E%@  IA\
M *8H  "F,@  IST  *=*  "G6   IV@  *=\  "GD0  IJ@  *;#  "EZ0
MI?P  *7_  "D_P  I/\ D8<  (*&  !RA@  8X@  %6,  !)D0  /98  #*:
M   HG@  'Z(  !>F   0J0  "ZP   2O    L08  +$,  "R$0  LA<  +,?
M  "S*   M#(  +4_  "U30  M5T  +5P  "UA@  M9T  +6V  "UW   M/<
M +3_  "T_P  M/\ BX\  'J.  !JD0  6Y4  $V:  ! GP  -:0  "JH   @
MK   %K    ^T   )MP   ;D   "]    O@   +X&  "_#   P!   ,$6  #"
M'0  PR<  ,4R  #&0   QE$  ,=C  #'>   QY$  ,>I  #'QP  Q^P  ,?^
M  #'_P  Q_\ @Y<  '&:  !AG@  4J,  $6I   XK@  ++,  ""W   6N@
M#KT   ;     PP   ,<   #)    R@   ,P   #- P  S@D  - .  #2$P
MU!L  -@E  #;,@  W4(  -U4  #>:0  WH$  -Z<  #?M0  W]D  -_S  #?
M_P  W_\ =Y\  &BF  !9K0  2K,  #NX   MNP  '[\  !3"   ,Q@   \D
M  #,    T    -4   #9    V@   -P   #>    X    .(%  #D"P  YQ
M .H8  #M)   \#(  /%$  #R6   \V\  /2*  #TI   ]+\  /3?  #T\P
M]/0 :J@  %NO  !,MP  /;T  "W!   ?Q@  $\H   O.    T@   -<   #<
M    X    .4   #G    Z0   .L   #M    [P   /$   #S    ]@<  /D.
M  #\%@  _R(  /\S  #_1P  _UT  /]V  #_D0  _ZD  /^^  #_V   _]L
M_P 8 /\ %@#_ !4 _P 8 /\ '@#_ "< _P V /\ 0P#_ $\ _P!: /\ 9 #_
M &T _P!U /\ ?0#_ (0 _P"* /\ D #_ )8 _P"< /\ HP#_ *L _P"T /X
MOP#] ,\ ^P#G /H ^ #Y /\ ^0#_ /D _P#U /\ [@#_ .D _P#G /\ _P 4
M /\ $0#_ !$ _P 2 /\ %P#_ ", _P Q /\ /@#_ $H _P!6 /\ 8 #_ &@
M_P!P /\ > #] 'X _ "% /H BP#Y )$ ^ "8 /< G@#U *8 ] "N /( N0#Q
M ,< [P#@ .X \@#L /\ [ #_ .P _P#K /\ Y0#_ .  _P#> /\ _P,0 /\
M#@#_  T _P - /\ $P#_ !X _P K /\ . #_ $4 _@!0 /L 6@#X &, ]0!K
M /, <@#Q 'D [P!_ .X A@#L (P Z@"2 .D F0#G *  Y@"I .0 LP#A ,
MX #3 -X ZP#< /L VP#_ -H _P#: /\ V0#_ -0 _P#2 /\ _P<- /\ "0#_
M  8 _P ) /\ #P#_ !@ ^P E /@ ,@#U #\ \@!* .T 5 #J %T YP!E .0
M; #B ', X !Z -X @ #< (8 V@"- -< E #4 )L T@"D ,\ K0#- +D RP#)
M ,D Y #( /8 Q@#_ ,4 _P#& /\ QP#_ ,< _P#' /\ _PH& /\!  #_
M_P $ /\ "P#T !( [P ? .H + #E #@ X@!# -T 3@#9 %< U !? -$ 9P#.
M &T S !T ,H >@#( (  Q@"' ,4 C@## )8 P0"> +\ J "] +, N@#" +D
MVP"W /  M0#_ +8 _P"U /\ M0#_ +4 _P"U /\ _PP  /\$  #_    _@
M /8  P#H  T X  7 -D ) #1 #$ S0 \ ,H 1P#& %$ PP!9 ,  8 "^ &<
MO !N +H = "Y 'L MP"" +4 B0"S )$ L@": +  I "N *\ K "] *H T "H
M .L IP#[ *8 _P"F /\ I0#_ *4 _P"E /\ _PT  /\'  #T"0  Z@D  .($
M  #:  < SP 1 ,@ ' #" "D O@ U +L 0 "W $H M !3 +( 6P"P &( K@!H
M *P ;P"K '4 J0!] *@ A "F (T I "6 *, H "A *L GP&Y )T#S "<!.@
MF@;Y )D'_P"8"/\ EPC_ )<(_P"7"/\ _Q   /<0  #H%   W!4  ,X1  #&
M#0  P@0+ +P % "W 2$ L@,N *X%.@"K!D0 J A- *8(50"D"5P H@IC * *
M:@"?"W$ G0MX )P+@ ":#(D F0R3 )<,G@"5#:H E VX )(-S "0#NH CA#\
M (P0_P"+$/\ BQ#_ (L0_P"*$/\ ^Q,  .T:  #=(   S"$  +\=  "W%P
MLQ$  +(+#0"K#1D IPXF *,/,P"?$#X G1%' )H14 "8$E< EA)> )4390"3
M$VP DA-S ) 4? "/%(4 C16/ (L5F@"*%:< B!:U (86R0"$%^< @AC[ ( 9
M_P!_&?\ ?QG_ '\8_P!_&/\ ]1H  .0C  #/*0  P"H  +,F  "J(@  I1P
M *05" "@%!, FQ8A )<8+0"4&3@ D1I" (\;2P"-'%( BQQ9 (D=8 "('6<
MAAYO (4>=P"#'X  @A^+ ( ?EP!^(*, ?2"R 'L@Q0!Y(>0 =R+Y '8B_P!U
M(O\ ="'_ '0A_P!T(?\ [R$  -LK  #',0  MC$  *DN  "@*@  FR8  )@A
M 0"5'A  D" ; (TA* ")(S, AR0] (4D1@"#)4X @295 '\F7 !^)F, ?"=K
M 'LG<P!Y)WP >"B' '8HDP!T** !<BBO 7$IP0%O*> !;2GW 6PI_P%K*?\!
M:RG_ 6LH_P%K*/\!Z"@  - R  # .   KC<  *$U  "8,@  DBT  (XI  "+
M)PP AR@7 (,J(P" *R\ ?BPY 'PL0@!Z+4H >"Y1 '<N6 !U+F  <R]G '(O
M;P!P+WD!;R^# 6TOD %K+YT!:2^L 6@PO@%G,-L!93#U 60P_P%C,/\!8R__
M 6,O_P%C+_\!XBX  ,HX  "Z/0  J#P  )HZ  "1-P  BC,  (8P  "#+@D
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M3$4 !@D"4#__ E$^_P%1/O\!SSL  +U%  "J1P  F48  (M%  "!1   >4(
M '0^  !O/P  :T , &=!%0!E0B$ 8T,K &%#-0!?1#X 7D1% %U%30!;150
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M D)*_P)"2O\"PD<  +-/  ">3P  C4X  (!.  !U30  ;$P  &-*  !>3
M6DT" %9.#@!43Q@ 4E B %%1+ !/434 3E(] $U210!,4DT 2E)4 $E270%'
M4F8!15)Q 4-2?@)!4HT"/U*= SY2KP,]4L8#/%+I CQ1_@(\4/\"/4__ CU/
M_P(]3O\"ODL  *Y3  ":4@  B5$  'Q1  !Q4   :%   %Y.  !840  5%(
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MME0  *19  "06   @%@  '-7  !I5P  8%@  %19  !.6P  2%T  $-?! !
M8 X /F$7 #UA(  [8BD .F(R #EB.@ X8T( -V-+ #9C5  T8UT ,V-H #%C
M=@$O8X4!+F.6 2QCJ0$K8[\!*F/C 2IB^P$J8/\!*U__ 2M?_P$K7O\!L5D
M )Y<  "+7   >UL  &];  !E6P  7%P  %%>  !)8   0V(  #QE   X9PH
M-6@2 #1H&P S:20 ,FDM #%I-0 O:CT +FI& "UJ3P L:ED *VME "EK<@ H
M:X( )FN3 "1KIP C:[T (FK@ "-I^0$C9_\!(V;_ 2-F_P$D9?\!K&   )A@
M  "%8   =E\  &I?  !A8   5V   $UC  !$9@  /6@  #9K   P;@0 +' .
M "IQ%0 I<1X *'$F "=R+P F<C< )7)  "1R2@ B<E0 (7-@ "!S;0 ><WT
M'7.0 !MSHP :<[D &7/< !IQ]P :</\ &V__ !MN_P$;;?\!IF8  )%E  !_
M9   <60  &9D  !=9   4F8  $AI   _;   -V\  #!S   I=@  (GD( !][
M$  >>Q< ''L? !M[*  :>S  &7PY !A\0P 7?$X %GQ: !5\9P 4?7@ $GV+
M !%]GP 0?;4 #WW5 !![]0 1>?\ $7C_ !)W_P 2=_\ GFL  (IJ  !Z:0
M;6D  &)I  !7:@  3&T  $-P   Y=   ,7@  "E[   B?P  &X(  !2%"0 1
MAA  $887 !"''P 0AR@ #H<Q  Z'.P -AT8 #(=3  N'80 *AW$ "8>$  >'
MF  &AJX !8;)  :%[  'A/\ "(/_  F"_P )@O\ E7$  (-O  !T;@  :6X
M %QO  !0<@  1G4  #QY   R?0  *H$  "*%   ;B0  %(P   ^/ P *D@L
M!I(1  22&  "DB   9(I  "2,P  DSX  )-+  "360  DVD  )-[  "2D
MDJ8  )&_  "1Y0  D/H  (__  "/_P  C_\ C7<  'UU  !P=   8G4  %5X
M  !)?   /X   #2$   KB0  (HT  !J1   3E   #I<   F;   !G0@  )T.
M  "=$P  GAH  )XB  "?*P  GS4  *!"  "@4   H%\  *!Q  "@AP  GYT
M )^U  ">V@  G?8  )W_  "<_P  G/\ AGT  'A\  !I?   6W\  $Z#  !!
MB   -HP  "R1   CE@  &IH  !*>   -H0  !J0   "G    J0,  *D*  "J
M#@  JQ,  *P9  "M(@  KBL  *\W  "O10  KU0  *]F  "O>P  KI0  *ZK
M  "NR0  KN\  *W_  "M_P  K?\ @80  '&$  !AAP  4XL  $:0   YE@
M+IL  ".@   :I   $J@   RL   $KP   +(   "V    MP   +<"  "X"
MN0T  +H2  "[&   O2$  +XK  # .   P$@  ,!:  #!;@  P88  ,&@  #!
MN@  P>,  ,#Y  # _P  P/\ >8T  &B0  !9E   2YH  #V@   QI0  ):L
M !JO   1LP  "[@   *[    O@   ,$   #$    Q0   ,8   #'    R 4
M ,H+  #,#P  SA4  - ?  #3*P  U3H  -5,  #68   V'<  -B2  #8K
MV<D  -GL  #9^P  V/\ <)D  &">  !1I   0ZH  #6P   HM@  '+H  !&^
M   )P0   ,4   #(    RP   ,\   #2    TP   -8   #8    VP   -T
M  #?!P  X@T  .43  #H'0  ["H  .T\  #M40  [F<  .^!  #OG   \+<
M /#3  #P[   \/0 9Z8  %BM  !)M   .KH  "J^   <P@  $,8   ?*
MS@   -(   #6    W    .    #C    Y    .8   #H    ZP   .T   #O
M    \@(  /4*  #X$0  _!P  /\L  #_/P  _U4  /]N  #_B@  _Z0  /^Z
M  #_T0  _^$ _P 4 /\ $@#_ !( _P 4 /\ &0#_ "4 _P R /\ /P#_ $L
M_P!6 /\ 8 #_ &@ _P!P /\ > #_ '\ _P"% /\ BP#_ )$ _P"8 /\ G@#^
M *8 _0"N /P N0#Z ,@ ^0#B /@ ] #W /\ ]@#_ /8 _P#O /\ YP#_ .(
M_P#> /\ _P 1 /\ #@#_  X _P / /\ % #_ "  _P M /\ .@#_ $8 _P!1
M /\ 6P#_ &, _@!K /P <P#Z 'D ^0"  /< A@#V (P ]0"2 /, F0#R *
M\ "I .X LP#M ,$ ZP#6 .H [@#I /X YP#_ .< _P#E /\ W0#_ -4 _P#1
M /\ _P - /\ "@#_  @ _P ) /\ $ #_ !L _P H /\ -0#_ $  ^@!+ /8
M50#S %X \0!F .X ;0#L '0 ZP!Z .D @ #G (8 Y@"- .0 DP#B )L X "C
M -X K0#< +D V@#* -< Y@#4 /@ T@#_ -( _P#2 /\ S@#_ ,D _P#& /\
M_P ( /\  P#_    _P # /\ #0#\ !8 ]P B /, +@#O #H [ !% .@ 3P#D
M %@ X0!@ -X 9P#; &T V0!T -4 >@#3 (  T0"' ,\ C@#- )4 RP"> ,D
MIP#' +, Q0#" ,, W #! /$ OP#_ +\ _P"^ /\ O@#_ +T _P"[ /\ _P
M /\   #_    _P   /8 " #N !$ YP ; .$ )P#= #, V0 ^ -, 20#/ %(
MRP!9 ,@ 80#& &< Q !M ,( <P#  'H OP"  +T B "[ )  N0"8 +@ H@"U
M *T LP"[ +$ S@"P .H KP#\ *T _P"M /\ K@#_ *X _P"N /\ _P(  /\
M  #]    \@   .@   #>  P TP 5 ,P (0#( "P Q  X ,$ 0@"] $L N@!3
M +@ 6@"V &$ M !G +( ;0"P '0 KP!Z *T @@"L (H J@"3 *@ G0"F *@
MI "U *( Q@"A ., GP#V )X _P"> /\ G@#_ )X _P"> /\ _P8  /L   #N
M!0  X@0  -4   #+  8 PP / +T &0"X "4 M  Q +$ .P"N $4 K !- *D
M50"G %L I0!B *0 : "B &X H0!U )\ ? "> (4 G ". )H F "8 *0 E@"P
M )4 P0"3 -P D@#R )$ _P"0 /\ D #_ (\ _P"/ /\ _0H  / .  #A$0
MSA   ,(-  "[!P  MP * +$ $@"L !X J  I *4 - "B #X GP!' )T 3P";
M %8 F0%< )<!8P"6 FD E )P ),#> "1 X  D 2* (X$E0",!:$ B@6N (D&
MO@"'"-@ A@GP (0*_P"#"_\ @PO_ (,+_P"#"_\ ]A   .87  #2'   P!H
M +,6  "L$@  J T  *8'#0"B!18 G0<B )D)+@"6"C@ E M! )(,2@"0#%$
MC@U8 (P-7@"+#64 B0UL (@.= "&#GT A0Z' (,.DP"!#Y\ @!"M 'X0O@!]
M$-L >A'T '@2_P!W$O\ =Q+_ '<2_P!W$O\ [Q<  -LA  #&)   M",  *@@
M  "@'   FQ<  )D1! "8#A  DQ ; (\1)P",$C( B1,\ (<31 "%%$P @Q13
M ($56@" %6  ?A9H 'T6;P![%G@ >1># '@7CP!V&)P =!BJ ',9NP!R&=0
M;QKQ &X;_P!M&_\ ;1K_ &T:_P!M&O\ YR   - I  "\*P  JRH  )XH  "6
M)   D"   (T<  ",%PP B!@6 (0:(@"!&RT ?APW 'P=0 !Z'4@ >1Y/ '<>
M50!V'UP =!]C ',?:P!Q('0 <"!_ &XABP!L(9@ :R&G &DBN !H(L\ 9B+N
M &4C_P!D(_\ 9"+_ &0B_P!D(?\ X"8  ,@O  "T,0  HS   )8N  "-*P
MAR@  (0D  ""( @ ?B 2 'LB'@!X(RD =20S ',E/ !Q)4, <"9+ &XF4@!M
M)UD :R=@ &HG: !I*'$ 9RA[ &4HB !D*94 8BFD & IM0!?*<L 7BKL %PJ
M_P!<*?\ 7"G_ %PI_P!<*/\ V"P  ,,U  "M-0  G30  ) S  "&,0  @"T
M 'PK  !Y* , =B<0 '(I&@!P*B4 ;2LO &LL. !J+$  :"U' &<M3@!E+E4
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M 4DX_P%*./\!QSH  +-   ">/P  CC\  ($^  !W/0  <#L  &HX  !F.
M8CD' %\Z$0!<.QL 6CLE %D\+@!7/3< 5CT^ %0^1@!3/DT 4CY5 %$^70!/
M/V8 33]P $P_?0%*/XL!2#^; 4<_K %%/\$!1#_C 40^^P%$/O\!1#W_ 40]
M_P%%//\!PSX  *]#  ":0@  BD(  'U!  !S0   :S\  &4\  !@/   7#X$
M %D^#P!7/Q@ 54 B %-!*P!2030 4$(\ $]"0P!.0DL 34-2 $M#6@!*0V0
M2$-N $=#>P%%0XD!0T.9 4)#JP% 0\ !/T/A 3]#^0$_0O\!/T'_ 4!!_P%
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M=@ [3(4!.4R5 3=,IP$V3+P!-4S= 35+]P$U2_\!-4K_ 39)_P$V2?\!N$D
M *)+  ".2@  ?DH  ')*  !H2@  7TD  %5(  !02@  3$L  $E,!P!&31
M1$X9 $)/(@!!3RL 0% S #]0.P ^4$, /%%* #M14P Z45P .%%G #=1<P U
M48( ,U&3 3)1I0$P4;H!+U': 2]0]@$O3_\!,$[_ 3!._P$P3?\!M$T  )U-
M  "*30  >DT  &Y-  !D30  6TT  %%-  !+3P  1E   $)2 P _4PT /505
M #Q4'@ Z52< .54O #A5-P W5C\ -E9' #564  S5ED ,E=D #!7<0 O5X
M+5>1 "M7HP J5[@ *5?6 "E6]0 I5?\ *E3_ 2I3_P$J4O\!KU$  )A1  "%
M40  =E   &I0  !@4   6%$  $Y2  !'4P  054  #M8   X60H -5H1 #1:
M&@ S6R( ,ELK #%;,P O7#L +EQ# "U<3  L7%8 *UU@ "E=;0 H77P )EV.
M "1=H0 C7;4 (EW2 ")<\P B6_\ (UK_ "-9_P D6/\ J%4  ))4  " 5
M<50  &94  !<5   5%4  $I6  !#6   /%L  #9=   P8 4 +6$. "MA%0 J
M8AT *6(E "AB+@ G8S8 )F,^ "5C1P C8U$ (F1< "%D:0 ?9'D 'F2* !QD
MG@ ;9+, &63. !IC\0 ;8?\ &V#_ !Q@_P <7_\ H5D  (Q8  ![6   ;5@
M &)8  !96   4%D  $=;   ^7@  -V   #%C   J9@  )&D) "%J$  @:A<
M'VH@ !YK*  =:S  '&LY !MK0@ :;$P &6Q8 !=L90 6;'0 %&R& !-LF@ 2
M;*\ $6S* !%K[P 2:?\ $VC_ !-H_P 39_\ F5T  (5=  !U7   :%P  %Y<
M  !57   2UX  $)A   Y9   ,F<  "MJ   D;0  'G ! !=S"P 5=!$ %'08
M !-T(0 2=2D $74R !%U.P 0=48 #W52  YU7P -=6X #'6!  MUE0 *=:H
M"'3#  ETYP *<_T "W'_  QQ_P ,</\ D6(  ']A  !P80  9&$  %IA  !/
M8@  164  #QH   S;   *V\  "1R   ==@  %WD  !%\!  -?PP "W\2  I_
M&0 )?R( "'\J  9_-  %?S\ !']+  )_6  !?V<  ']Y  !_C@  ?Z,  'Z[
M  !]X   ??<  'S_  ![_P  >_\ B6<  'AG  !K9@  868  %1G  !):0
M/VT  #5Q   L=0  )'D  !U\   6@   $(,   R& @ &B0H  8D/  ")%
MBAL  (HC  "++   BS<  (M#  "+4   BU\  (MQ  "+A@  BYP  (JS  ")
MTP  B/,  (C_  "'_P  A_\ @FT  '-L  !H;   6FT  $YO  !"<P  .'<
M "Y[   E@   '80  !6(   0C   "X\   22    E 8  )4,  "5$   EA4
M )<<  "8)   F"X  )DY  "91P  F58  )EH  "9?0  F90  )BK  "7R
MENX  );_  "5_P  E?\ >W0  &]S  !A<P  4W8  $9Z   [?P  ,(0  ":(
M   =C0  %)(   Z6   )F0   9P   "@    H0   *(&  "B#   I!   *44
M  "E'   IR0  *@O  "H/0  J4P  *E>  "I<@  J(D  *BB  "HO   I^4
M *;[  "F_P  I?\ =WL  &A[  !9?@  2X(  #Z'   RC0  )Y(  !V7   4
MG   #J    >D    J    *L   "N    KP   +    "Q!   LPH  +0.  "U
M$P  MAL  +@D  "Z,0  ND   +I2  "[90  NWT  +J7  "ZL0  NM(  +KS
M  "Y_P  N?\ ;X,  %^&  !1BP  0Y   #:7   JG0  'Z(  !6G   -K
M!;    "T    MP   +L   "^    OP   ,    #!    PP$  ,0'  #%#0
MQQ$  ,H9  #-)   SC,  ,]$  #06   T&X  -&(  #0I   T,$  -'F  #1
M^   T?\ 9X\  %>4  !)F@  .Z$  "ZG   AK0  %K,   ZX   &O    ,
M  ##    Q@   ,L   #-    S@   -    #1    U    -8   #: @  W D
M -\/  #C%P  YB0  .<V  #H20  Z5\  .IX  #KE   ZZ\  .O,  #LZ
M[/8 7YX  %"D  !"JP  -+(  ":Y   9O@  #L(   3%    R@   ,T   #1
M    V    -L   #?    X    .(   #D    Y@   .D   #K    [@   /$%
M  #U#0  ^18  /PE  #].0  _D\  /]G  #_@@  _YT  /^U  #_RP  _^0
M_P 1 /\ #P#_  \ _P 1 /\ %@#_ "( _P O /\ .P#_ $< _P!2 /\ 6P#_
M &0 _P!L /\ <P#_ 'H _P"  /\ A@#_ (P _@"3 /T F0#[ *$ ^@"I /@
MM #W ,( ]@#: /4 \0#T /\ \P#_ /, _P#I /\ X #_ -@ _P#3 /\ _P .
M /\ "P#_  H _P + /\ $0#_ !T _P J /\ -@#_ $$ _P!, /\ 5@#^ %\
M^P!F /D ;0#W '0 ]0!Z /0 @ #R (8 \ "- .\ E #M )L [ "D .H K@#I
M +H YP#- .4 Z0#D /L XP#_ .( _P#> /\ T0#_ ,P _P#( /\ _P ) /\
M! #_  $ _P $ /\ #@#_ !@ _P D /T , #[ #L ]P!& /, 4 #O %D [ !@
M .H 9P#G &X Y@!T .0 >@#B (  X "' -X C@#< )4 V@"> -8 J #4 +,
MT0## ,\ WP#. /0 S #_ ,L _P#+ /\ Q0#_ +\ _P"\ /\ _P " /\   #_
M    _P   /T "P#W !, \0 > .T *@#J #4 YP!  .( 2@#= %( V0!: -4
M80#2 &< T !M ,X <P#, 'H R@"  ,@ AP#& (\ Q "8 ,( H0#  *T O@"[
M +P T "Z .T N0#^ +@ _P"X /\ MP#_ +, _P"P /\ _P   /\   #_
M^0   .X !0#E  X W@ 8 -@ (P#2 "X SP Y ,L 0P#' $P Q !4 ,$ 6P"_
M &$ O !G +L ;0"Y ', MP!Z +4 @0"T (D L@"2 +  FP"O *< K "T *L
MQ@"I .0 IP#X *8 _P"F /\ I0#_ *4 _P"D /\ _P   /\   #U    Z@
M -X   #0  H R  2 ,( '0"^ "@ NP S +D /0"U $8 L@!- +  50"M %L
MK !A *H 9P"H &T IP!S *4 >@"D (( H@", *  E@"? *$ G0"N )L O@"9
M -@ EP#Q )8 _P"6 /\ EP#_ )< _P"7 /\ _P   /4   #G 0  U    ,D
M  #   0 N  . +, %@"O "$ JP L *@ -@"F #\ HP!' *$ 3P"? %4 G0!;
M )L 80": &< F !N )< =0"5 'T E "& )( D0"0 )P C@"I (P N "+ ,T
MB0#K (@ _0"( /\ B #_ (@ _P"( /\ ^08  .D,  #4#@  PPP  +<)  "P
M @  JP ) *8 $ "B !H G@ E )L , "8 #D E@!! )0 20"2 %  D !6 (X
M7 "- &( BP!I (H < "( '@ AP"! (4 C "$ )@ @@"E (  M !^ ,@ ?0'G
M 'P"^0![ _\ >P3_ 'L$_P![!/\ \0X  -X5  #%%0  M!0  *D1  "A#@
MG@H  )L## "7 !, DP > ) !*0"- C, B@,\ (@$0P"&!4L A091 (,&5P""
M!UX @ =D '\(; !]"'0 ? A^ 'H)B0!X"98 =PJC '4*LP!S"\< <@SF ' -
M^P!P#?\ ;PW_ &\-_P!O#?\ Z!8  - >  "Y'0  J1P  )T:  "5%@  D!,
M (\. P"."@X B0L7 (8,(P"##2T @ TV 'X./@!\#D8 >PY- 'D/4P!X$%H
M=A!A '40: !S$'$ <1%[ ' 1AP!N$90 ;!&B &L2L@!I$L< :!/G &83_0!E
M%/\ 913_ &43_P!E$_\ WQX  ,8D  "P)   H",  )0A  "+'P  AAL  (,7
M  ""$@@ ?Q$2 'P2'0!Y%"@ =A0Q '05.@!R%D$ <19( &\73P!N%U8 ;!==
M &L89 !I&&T :!EW &89@P!D&9  8QJ? &$:KP!@&L0 7AOD %T<^P!<'/\
M7!O_ %P;_P!<&_\ U24  +TJ  "H*0  F"D  (PH  "#)0  ?2(  'D?  !X
M&P, =AD/ '(:& !O'", ;1TM &L=-0!I'CT :!Y$ &8?2P!E'U( 8R!9 &(@
M80!A(&D 7R%S %TA?P!<(8T 6B*< %DBK !7(L  5B/A %4C^0!4(_\ 5"+_
M %0B_P!4(O\ S2L  +8N  "B+@  DBX  (4M  !\*P  =B@  '(F  !O(P
M;2$, &HB%0!G(Q\ 920I &,D,0!B)3D 8"9! %\F2 !=)D\ 7"=6 %LG70!9
M)V8 6"AP %8H? !4*(H 4RF9 %$IJ@!0*;X 3RG> $XI]P!-*?\ 32G_ $TH
M_P!.*/\ R#   + R  "<,@  C#(  ( Q  !V,   <"T  &LK  !H*0  9B@)
M &,H$0!@*1P 7BHE %PK+@!;*S8 62P] %@L1 !7+4P 52U3 %0M6P!3+6,
M42YN % N>@!.+H@ 3"^7 $LOJ !)+[L 2"_; $@O]@!'+_\ 1R[_ $<M_P!(
M+?\ Q#0  *LU  "7-0  AS4  'LU  !R-   :S(  &8O  !B+@  7RT% %PN
M$ !:+Q@ 6# B %8P*P!5,3, 4S$Z %(R0@!1,DD 4#)0 $XS6 !-,V$ 2S-K
M $HS=P!(-(4 1S25 $4TI@!#-+D 0C36 $(T] !"-/\ 0C/_ $(R_P!",O\
MP#@  *<X  "3.   @S@  '<X  !M-P  9C8  &$S  !=,@  63(" %<S#0!4
M-!4 4C4? %$U* !/-C  3C8X $PW/P!+-T8 2C=. $DX5@!'.%\ 1CAI $0X
M=0!#.(, 03F3 $ YI  ^.;@ /3G3 #PY\P \./\ /3?_ #TW_P ]-O\ NSL
M *([  "/.P  ?SL  ',[  !J.@  8CD  %TW  !8-@  5#<  %$X"P!/.1,
M33D< $LZ)0!*.BT 2#LU $<[/ !&/$0 13Q+ $0\4P!"/%P 03UG #\]<P ^
M/8$ /#V1 #H]HP Y/;8 .#W1 #<]\@ W//\ .#O_ #@[_P X.O\ MCT  )X^
M  "+/@  ?#X  &\^  !F/0  7CT  %@[  !3.@  3SL  $P\" !)/1$ 1SX9
M $8_(@!$/RH 0S\R $) .@!!0$$ 0$!) #Y!40 ]05H /$%D #I!<  X07\
M-T&/ #5"H0 T0K0 ,D+. #)!\  R0/\ ,T#_ #,__P T/O\ L4   )I   "'
M0   >$$  &Q!  !B0   6T   %0_  !./P  2D   $9!!0!$0@X 0D,6 $!#
M'P _1"< /D0O #Q$-P [13X .D5& #E%3@ X1E@ -D9B #5&;@ S1GP ,4:-
M #!&GP N1K, +4;, "U&[P M1?\ +D3_ "Y#_P N0_\ K$,  )9#  "#0P
M=$,  &A#  !?0P  5T,  %!#  !(0P  1$4  $%& 0 ^1PP /$@3 #I('  Y
M220 .$DL #9)-  U2CL -$I# #-*3  R2E4 ,$M? "]+:P M2WH +$N+ "I+
MG0 H2[$ )TO* "=+[0 G2O\ *$G_ "A(_P I1_\ IT8  )%&  !_1@  <$8
M &5&  !;1@  5$8  $Q'  !$2   /TH  #M+   W3 D -4T0 #-.&  R3B
M,4\H #!/,  O3S@ +D]  "Q02  K4%( *E!< "A0:  G4'< )5"( "10FP B
M4*\ (5#( "!0ZP A3_\ (D[_ ")-_P C3?\ H4D  (Q)  !Z20  ;$H  &%*
M  !82@  4$H  $E+  ! 3   .TX  #50   Q4@0 +5,- "Q4%  J5!P *54D
M "A5+  G53, )E4\ "5610 D5DX (E99 "%690 ?5G0 'E:% !Q6F  ;5JP
M&5;% !E6Z0 :5?\ &U3_ !M3_P <4O\ FTT  (9-  !U30  :$T  %U-  !4
M30  34X  $5/   \40  -E,  #%5   K6   )EH) "-;$  B6Q< (5P? "!<
M)P ?7"X '5PW !Q=0  ;74H &EU5 !A=80 777  %5V! !1=E0 37:H $5W"
M !%=YP 26_X $UK_ !-:_P 46?\ E%$  (!1  !P40  9%$  %E1  !140
M25(  $%3   X5@  ,ED  "M;   E7@  'V$# !IC#  89!$ %V09 !9D(0 5
M9"D %&4Q !-E.@ 2940 $650 !!E70 /96L #F5]  UED0 ,9:4 "F2\  ID
MX  +8_D #&+_  UA_P -8?\ C54  'I5  !K50  7U4  %95  !.50  1%<
M #Q9   T7   +%\  "9B   ?90  &6@  !-K!0 0;0T #FX2  UN&@ ,;B(
M#&XK  MN-  *;CX "&Y*  =N5P &;F4 !&YV  )NB@  ;9\  &VV  !LU@
M;/,  6O_  )J_P #:O\ A5H  '1:  !F6@  7%D  %-9  !(6@  /UT  #9@
M   N8P  )F<  !]J   9;0  $W$   YT P *=PH !7<0  %W%0  =QP  '<D
M  !X+0  >#<  'A#  !X4   >%X  'AO  !XA   >)D  '>P  !VS0  =?
M '7_  !T_P  =/\ ?E\  &Y?  !B7@  65X  $U?  !"8@  .64  #!H   G
M;   'W   !AT   2=P  #7L   A^   "@ @  ($-  "!$0  @A<  (,>  "#
M)@  A#   (0[  "$2   A%<  (1H  "$?   A),  (.J  ""Q0  @>L  ('^
M  " _P  @/\ =V4  &ED  !?8P  4F0  $=G   \:P  ,6\  "AS   @=P
M&'P  !%_   ,@P  !H<   "*    C ,  (P)  "-#@  CA$  (\7  "0'@
MD2<  )(R  "2/P  DDX  ))?  "2<P  DHL  )&B  "1O   D.4  (_\  ".
M_P  CO\ <6L  &9J  !8:P  2VT  #]Q   T=@  *GL  ""    7A0  $(D
M  N-   $D0   )4   "8    F0   )H#  ";"   G T  )X1  "?%@  H!X
M *(H  "B-0  HT0  *-5  "C:0  HH   **:  "ALP  H-@  *#V  "?_P
MG_\ ;G$  %]R  !1=0  1'D  #=^   LA   (8H  !>/   0E   "ID   &=
M    H    *0   "G    J    *D   "J    K 8  *T+  "O$   L!4  +(>
M  "T*0  M#D  +1*  "U70  M7,  +6.  "UJ   M,8  +/M  "R_P  LO\
M9GH  %=]  !)@@  /(<  "^.   CE   &)H  !"?   )I    *D   "M
ML    +0   "W    N    +D   "[    O    +X"  # "   P@X  ,04  #'
M'@  R"P  ,D]  #*4   RF8  ,I_  #*FP  RK@  ,K=  #*]0  RO\ 7H8
M $^+  !!D0  ,Y@  ">?   ;I0  $:L   FP    M0   +D   "]    P0
M ,8   #(    R0   ,L   #,    S@   -    #2    U 4  -D,  #=$@
MX1X  .(N  #C0@  Y%<  .5O  #FC   YJ@  .7%  #EYP  YO8 5I0  $B;
M   ZH@  +*D  !^P   3M@  "[P   #!    Q0   ,D   #-    T@   -8
M  #:    VP   -X   #@    X@   .0   #G    Z0   .T   #P"@  ]!$
M /@?  #Y,@  ^D@  /M?  #\>@  _9<  /VO  #]QP  _>0 _P . /\ #0#_
M  P _P . /\ $P#_ !X _P J /\ -@#_ $( _P!- /\ 5P#_ %\ _P!G /\
M;@#_ '0 _P!Z /\ @0#] (< _ "- /H E #Y )P ]P"E /4 KP#T +P \P#/
M /$ [ #P /X [P#_ .\ _P#C /\ UP#_ ,X _P#* /\ _P * /\ !@#_  0
M_P ( /\ $ #_ !D _P E /\ ,0#_ #T _P!' /X 40#[ %D ^0!A /8 : #T
M &X \P!T /$ >@#O ($ [@"' .P C@#J )8 Z "? .8 J0#C +4 X@#& .
MXP#? /@ W0#_ -T _P#4 /\ R0#_ ,( _P"^ /\ _P # /\   #_    _P !
M /\ #0#_ !0 _0 @ /H *P#W #8 \P!! .\ 2P#L %0 Z !; .8 8@#C &@
MX0!N -\ = #< 'H V@"! -@ B #4 )  T@"8 ,\ H@#- *X RP"\ ,D TP#'
M /  Q@#_ ,0 _P#$ /\ NP#_ +8 _P"S /\ _P   /\   #_    _P   /<
M" #P !  ZP : .< )0#D #  X0 [ -P 10#5 $T T0!5 ,X 6P#+ &( R0!G
M ,< ;0#% ', PP!Z ,$ @0"_ (D O0"2 +L G "Y *< MP"U +4 R "S .8
ML@#[ +$ _P"P /\ K@#_ *H _P"G /\ _P   /\   #^    \0   .4  @#<
M  T TP 4 ,T 'P#* "H QP T ,0 /@#  $< O !. +H 50"W %L M0!A +,
M9P"R &T L !S *X >@"L (( J@"+ *@ E0"G *  I0"M *, O@"A -L H #T
M )\ _P"> /\ GP#_ )T _P"; /\ _P   /P   #N    X    -    #%  @
MO@ 0 +D &0"U ", LP N +  -P"M $  J@!( *@ 3P"E %4 HP!; *( 8 "@
M &8 GP!L )T <P"; 'L F@"$ )@ C@"6 )H E0"G ), MP"1 ,P D #L (\
M_P". /\ C@#_ (X _P"/ /\ _    .\   #;    R0   +T   "U  ( K@ ,
M *D $P"E !T H@ G *  ,0"= #H F@!" )@ 20"6 $\ E !5 ), 6P"1 &
MD !G (X ;0"- '4 BP!^ (D B0"( )4 A@"B (4 L0"# ,0 @0#D (  ^0!_
M /\ @ #_ (  _P"  /\ ] (  . )  #'"   MP<  *P#  "F    H  ' )L
M#P"8 !< E0 A )( *@"/ #, C0 \ (L 0P") $D AP!0 (8 50"$ %L @P!A
M ($ : "  '  ?@!Y 'P A ![ )  >0"= '@ K !V +X =0#= ', ] !S /\
M<P#_ ', _P!S /\ Z0T  ,\0  "Y$   J1   )X.  "7"P  DP8  )  "P",
M !$ B0 : (8 ) "# "X @0 V '\ /@!] $0 ? !+ 'H 40!Y %< =P!= '8
M9 !T &P <P%U '$!@ !O HT ;@*: &P#J@!K [L :036 &@&\0!H!_\ 9P?_
M &<'_P!G!_\ WQ0  ,,7  "N%P  GA8  ),5  "+$@  AA   (0, @"#!@T
M@ ,4 'P%'@!Y!R@ =P@P '4(. !S"4  <@E& ' *3 !O"E, ;0M9 &P+80!J
M"VD :0QR &<,?@!F#(L 9 V9 &(-J0!A#;L 8 W8 %X.\P!=#O\ 70[_ %T.
M_P!=#O\ U!P  +D=  "D'@  E1T  (D<  "!&@  >Q<  '@3  !X$ 8 =PT/
M ',.& !P#B( ;@\K &P0,P!J$#L :1!" &<120!F$4\ 9!%6 &,270!A$F8
M8!)O %X2>P!<$X@ 6Q.7 %D3IP!7%+H 5A35 %45\P!4%?\ 5!7_ %05_P!4
M%/\ RB(  + B  "=(P  C2,  ($B  !Y(0  <QX  &\;  !N%P  ;1,, &H4
M% !G%1X 918G &,6+P!A%S< 8!<^ %X810!=&$L 7!E2 %H96@!9&6( 5QIL
M %8:=P!4&H4 4AN4 %$;I !/&[< 3AO0 $T<\0!,'/\ 3!S_ $T<_P!-&_\
MPR8  *HG  "6)P  AR@  'LG  !R)@  ;"0  &@A  !F'@  9!L( &(;$0!?
M'!H 71TC %L>*P!:'C, 6!\Z %<?00!6($@ 5"!/ %,@5P!1(5\ 4"%I $XA
M= !-(8( 2R*1 $DBH@!((K0 1R+- $8C[P!%(_\ 12+_ $8B_P!&(?\ O"H
M *0K  "1*P  @BP  '8K  !M*@  9BD  &(F  !?)   72($ %LA#@!8(A8
M5B,? %0D* !3)#  4B4W % E/@!/)D4 3B9, $PF5 !+)UP 22=F $@G<0!&
M)W\ 12B/ $,HH !!*+( 0"C+ #\H[0 _*/\ /RC_ $ G_P! )_\ MRT  )\N
M  ",+P  ?2\  '$O  !H+@  82T  %TK  !:*   5R<  %0G# !2*!, 4"D<
M $XI)0!-*BP 2RHT $HK.P!)*T( 2"Q) $8L40!%+%H 1"QD $(M;P! +7T
M/RV- #TMG@ \+;  .BW( #HMZP Z+?\ .BW_ #HL_P Z+/\ LC   )LQ  "(
M,@  >3(  &TR  !D,@  73$  %@O  !5+   42P  $\M"0!,+1$ 2BX9 $DO
M(@!'+RH 1C Q $4P. !#,#\ 0C%' $$Q3P! ,5< /C%A #TR;0 [,GL .3*+
M #@RG  V,J\ -3+' #0RZ0 T,O\ -3'_ #4Q_P U,/\ K3,  )8T  "$-0
M=34  &DU  !@-0  630  %0S  !0,   3#$  $DQ!@!',@\ 13,6 $,S'P!"
M-"< 0#0N #\U-@ ^-3T /35$ #PV3  Z-E4 .39? #<V:P V-G@ -#>) #(W
MF@ Q-ZT +S?% "\WZ  O-OX ,#7_ # U_P P-/\ J38  )(V  " -P  <C@
M &8X  !=-P  5C<  % V  !+-   1S4  $0V P!!-PT /S@4 #XX'  \.20
M.SDL #HY,P Y.CH .#I" #8Z2@ U.E, -#M= #([:  P.W8 +SN' "T[F0 L
M.ZP *CO# "D[Y@ J.OT *CK_ "LY_P L./\ I#@  (XY  !\.@  ;CH  &,Z
M  !:.@  4SH  $TZ  !&.   0CH  #\[   \/ L .CP1 #@]&0 W/2$ -CXI
M #0^,  S/C< ,C\_ #$_1P P/U  +C]: "U 9@ K0'0 *4"$ "A EP F0*H
M)4#! "1 Y0 D/_P )3[_ "8]_P F/?\ GSL  (H\  !X/0  :CT  %\]  !6
M/0  3ST  $D]  !"/0  /#X  #D_   V00@ -$$/ #)"%@ Q0AX +T,E "Y#
M+0 M0S0 +$0\ "M$1  J1$T *$18 "=%8P E17$ (T6" ")%E0 @1:@ 'T6_
M !Y$XP ?1/L 'T/_ "!"_P A0?\ FCX  (4_  !T0   9T   %Q   !30
M3$   $9    ^00  .$,  #1%   P1@, +4<- "M($@ J2!H *4@B "A)*0 G
M23$ )4DY "1)00 C2DH (DI5 "!*80 ?2F\ '4I_ !M*D@ :2J8 &$J] !=*
MX  82?H &4C_ !I'_P :1_\ E4(  (!"  !P0P  8T,  %A#  !00P  24,
M $)$   [10  -4<  #!)   K2P  )DT) "1.$  B3A8 (4\= "!/)0 ?3RP
M'D\U !U//0 <4$< &E!1 !E070 74&L %E!\ !10CP 34*0 $5"Z !%0W@ 1
M3_@ $D[_ !--_P 43?\ CT4  'M&  !K1@  7T<  %5'  !-1P  1D<  #]'
M   W2@  ,4P  "M.   F4   (%,# !Q5#  :5A$ &588 !=6(  65B< %58P
M !16.0 35T( $E=- !%760 05V@ #U=Y  Y7C  -5Z  "U>V  M6U  +5O0
M#%7_  U4_P .4_\ B$D  '9*  !G2@  6TH  %%*  !*2@  0TH  #M,   S
M3@  +%$  "94   A5@  &UD  !5<!P 17@T $%X3 !!>&@ .7B( #EXJ  U>
M,P ,7CT "UY(  I>5  (7F( !UYS  5>A@ #7IL  EZQ  )=S  "7>X  US_
M  1;_P %6_\ @4X  '!.  !B3@  5TX  $Y.  !'3@  /D\  #91   N5
M)U<  "%:   ;70  %6   !!C P ,9@L "&<0  9G%0 %9QP !&<D  )G+0 !
M9S<  &="  !G3@  9UP  &=M  !G@   9I4  &:L  !EQP  9>L  &3\  !D
M_P  8_\ >E(  &I3  !=4@  5%(  $M2  !"4P  .54  #!8   H6P  (5\
M !IB   490  $&@   QK 0 &;@D  &\.  !O$@  ;Q@  ' ?  !P)P  <3
M '$[  !Q2   <58  '%F  !Q>0  <8\  '"G  !OP0  ;^<  &[\  !M_P
M;?\ <U@  &57  !:5P  458  $97   \6@  ,ET  "IA   B9   &F@  !1L
M   .;P  "G(   1V    > 4  '@+  !Y#@  >A,  'L9  !\(   ?2D  'TS
M  !]0   ?4X  'U>  !]<@  ?8@  'RA  !\N@  >^(  'KZ  !Y_P  >/\
M;5T  &!<  !77   2UT  $!?   U8P  *V<  "-K   :;P  $W,   YW   (
M>P   GX   ""    @P$  (0&  "%"P  A@\  (@3  ")&0  BB$  (LK  "+
M-P  C$8  (M6  "+:0  BX   (N9  "*LP  B=@  (CW  "(_P  A_\ :&,
M %YB  !18@  1&4  #AI   N;@  )',  !IX   3?0  #8$   :%    B0
M (T   "0    D@   )(   "4!0  E0H  )<.  "8$@  FA@  )LA  "<+0
MG3P  )U,  "<7P  G'8  )N1  ";JP  FLD  )KP  "9_P  F/\ 96D  %=I
M  !);   /7$  #!V   E?   &X$  !*'   ,C   !)$   "5    F0   )T
M  "@    H0   *(   "D    I0$  *<'  "I#   JA$  *T8  "O(@  KS
M *]!  "O5   KVL  *Z%  "NH0  KKX  *WF  "L_   K/\ 7G$  $]T  !"
M>0  -7\  "B%   =C   $Y(   R8   #G0   *(   "F    J@   *X   "P
M    L0   +,   "T    M@   +@   "Z!   O H  +X0  #!%P  PR0  ,,U
M  #$20  Q%X  ,5W  #%DP  Q:\  ,71  ##\@  P_\ 5GP  $>"   ZB
M+(\  ""6   4G0  #:,   .I    K@   +(   "W    NP   +\   #"
MP@   ,4   #&    R    ,H   #-    SP   -((  #5#@  VQ@  -TG  #>
M.@  WU   .!H  #@A   X:$  .&]  #AX@  X/0 3HL  $"2   RF0  ):$
M !BH   .KP  !;4   "Z    OP   ,0   #(    S@   -$   #4    U0
M -@   #:    W0   -\   #B    Y    .<   #K!0  [PX  /09  #U*P
M]D$  /=8  #X<@  ^9   /FK  #XQ   ^.$ _P + /\ " #_  D _P , /\
M$@#_ !H _P F /\ ,@#_ #X _P!( /\ 4@#_ %H _P!B /\ :0#_ &\ _P!U
M /X >P#\ ($ ^P"( /D CP#W )< ]0"@ /, J@#R +< [P#) .T Y@#L /L
MZP#_ .L _P#= /\ S@#_ ,8 _P#" /\ _P $ /\   #_    _P % /\ #0#_
M !4 _P A /\ + #_ #@ _P!# /T 3 #Y %0 ]P!< /0 8P#R &D \ !O .X
M=0#L 'L Z@"" .@ B0#G )$ Y ": .( I #@ +  W0#  -H W #8 /0 U0#_
M -, _P#+ /\ P0#_ +L _P"W /\ _P   /\   #_    _P   /\ "@#] !$
M^0 ; /8 )P#T #( \  \ .P 1@#H $X Y !6 .$ 7 #> &, W !H -D ;@#5
M '0 T@![ -  @@#- (H RP"3 ,@ G0#& *@ Q "W ,$ S #  .L O@#_ +T
M_P"] /\ M #_ *X _P"K /\ _P   /\   #_    ^@   /( !0#J  X Y0 6
M .  (0#= "L VP V -, /P#. $@ R@!/ ,< 5@#$ %P P@!A ,  9P"^ &T
MO !S +H >@"X (( M@"+ +0 E@"R *$ L "O *X P0"M .  JP#W *H _P"I
M /\ I@#_ *$ _P"? /\ _P   /\   #W    Z    -P   #0  H R@ 1 ,4
M&P#" "4 OP O +P . "X $$ M0!( +( 3P"P %4 K@!; *P 80"J &8 J !L
M *< <P"E 'L HP"$ *$ C@"? )H G0"G )L N ": -  F0#O )@ _P"7 /\
ME@#_ )0 _P"2 /\ _P   /8   #D    T@   ,4   "[  4 M0 . +  %0"L
M !\ J@ I *@ ,@"E #H H@!" *  20"> $\ G !5 )H 6@"8 &  E@!F )4
M; "3 '0 D@!] )  AP". ), C "A (L L "* ,4 B #F (< ^P"& /\ AP#_
M (< _P"& /\ ^    .4   #-    O0   +,   "J    HP * )\ $0"; !D
MF0 C )< + "5 #0 D@ \ )  0P". $D C !/ (H 5 ") %H AP!@ (8 9@"$
M &X @P!W ($ @0!_ (T ?@"; 'P J@![ +P >@#; '@ ]0!X /\ > #_ '@
M_P!X /\ [0   -$"  "[ @  K $  *(   ";    E@ % )$ #0"- !0 BP =
M (@ )@"& "X A  V (( /0"  $, ?@!) 'T 3P!\ %4 >@!; 'D 80!W &D
M=0!Q '0 ? !R (@ <0"6 &\ I0!N +8 ;0#. &P [@!K /\ :P#_ &L _P!K
M /\ WPL  ,(,  "N#   G@P  ),+  ",!P  B (  (4 "0"! !  ?P 7 'P
M( !Z "@ >  P '8 . !T #X <P!$ '$ 2@!P %  ;@!6 &T 70!L &0 :@!M
M &@ =P!G (0 90"2 &0 H0!C +( 80#) &  Z0!@ /P 8 #_ &  _P!@ /\
MT!   +81  "B$@  DQ(  (@1  " #P  ? T  'D) 0!X PL =0 1 ', &@!P
M ", ;@$K &P!,P!J CD :0-  &<#1@!F!$P 9012 &,%60!B!6$ 8 5J %\&
M= !=!H$ 7 >/ %H'GP!9![  5P?& %8)YP!6"OL 50K_ %4*_P!6"O\ QA4
M *T7  "9&   BA@  '\7  !V%@  <1,  &X0  !M#04 ;0D- &H)% !G"AT
M90HF &,++@!B##4 8 P\ %\,0@!>#4@ 7 U/ %L-5@!9#5X 6 YH %8.<P!5
M#H  4PZ/ %$.GP!0#K$ 3@[( $T0Z@!-$/T 31#_ $T0_P!-$/\ O!L  *4<
M  "2'0  @QX  '<=  !O'   :1H  &87  !D%   9! ( &(/$ !?$!@ 71 A
M %L1*0!:$3$ 6!(X %<2/@!6$D4 5!), %,34P!1$UL 4!-E $X4< !,%'T
M2Q2, $D4G !'%:X 1A7% $45Z !%%OX 11;_ $45_P!%%?\ M1\  )XA  "+
M(@  ?"(  '$B  !H(0  8A\  %\=  !<&@  6Q<" %H5#0!7%A0 518= %07
M)0!2&"T 41@T $\8.P!.&4( 31E( $L:4 !*&E@ 2!IB $<:;0!%&WH 0QN)
M $(;F@! &ZP /QO" #X<Y0 ]'/P /AS_ #X;_P ^&_\ KR,  )@D  "&)0
M=R8  &PF  !C)0  720  %DB  !6'P  5!T  %,<"P!1'!( 3AT: $T=(@!+
M'BD 2AXQ $D?-P!''SX 1B!% $4@30!#(%4 0B!? $ A:@ _(7< /2&' #LA
MF  Y(:H ."+  #<BXP W(OL -R+_ #@A_P X(?\ JB8  )0G  "!*0  <RD
M &<I  !?*0  6"@  %0F  !1(P  3R(  $PB!P!*(A  2"(7 $<C'P!%)"8
M1"0N $(D- !!)3L 0"5# #\E2@ ])E, /"9< #HF9P Y)G4 -R>$ #4GE@ T
M)Z@ ,B>^ #$GX0 Q)_D ,B;_ #(F_P S)?\ I2D  (\J  !]+   ;RP  &0M
M  !;+   52L  % J  !,*   2B8  $<G! !$)PT 0B@4 $$H'  _*2, /BDK
M #TI,@ \*CD .RI  #DJ2  X*U  -BM: #4K90 S*W( ,2N" # LE  N+*<
M+"R\ "LLW@ L+/@ +"O_ "TJ_P M*O\ H2P  (LM  !Y+@  :R\  & O  !8
M+P  42X  $PN  !(+   12L  $$K   _+ L /2P1 #LM&0 Z+B$ .2XH #<N
M+P V+S8 -2\^ #0O10 S+TX ,3!8 # P8P N,'  +#"  "HPD@ I,*4 )S"Z
M "8PW  F,/< )R__ "@O_P H+O\ G"X  (<P  !V,0  :#(  %TR  !5,@
M3C$  $@Q  !$,   0"\  #PP   Z,0D -S$0 #8R%@ U,AX ,S,E #(S+  Q
M,S, ,#0[ "\T0P M-$P +#16 "HU80 I-6X )S5^ "4UD  C-:, (C6Y "$U
MV0 A-/8 (C3_ ",S_P C,O\ F#$  (,S  !R-   930  %HU  !1-0  2S0
M $4T  ! -   .C,  #<T   T-08 ,C8. # W$P O-QL +C<B "TX*0 K.#$
M*C@X "DY0  H.4D )CE3 "4Y7P C.6P (3I\ " ZC@ >.J( '#JW !LYU0 <
M.?4 '3C_ !TX_P >-_\ DS0  '\V  !N-P  83<  %<W  !.-P  2#<  $(W
M   \-P  -3@  #(Y   O.@( +#L+ "H\$0 I/!@ *#T? "8])@ E/2X )#TU
M ",^/0 B/D8 (#Y0 !\^7  =/VD &S]Y !H_C  8/Z  %C^U !4^T@ 6/O,
M%SW_ !@\_P 8//\ CC<  'HX  !J.0  7CH  %,Z  !+.@  13H  #\Z   Y
M.@  ,CP  "X^   I0   )D$( "1"#@ B0A0 (4(; "!#(P ?0RH 'D,R !Q#
M.@ ;1$, &D1- !A$60 71&< %41W !-$B@ 21)X $42S !!$T  00_( $4+_
M !)"_P 30?\ B3L  '8\  !F/0  6CT  % ]  !(/0  0CT  #P]   V/@
M+T   "I"   E1   (48# !U(#  ;21$ &4D7 !A)'@ 7228 %DDN !5*-@ 4
M2D  $TI* !%*5@ 02F0 #TIT  Y*AP -2IL #$JP  I*R@ +2>P #$C_  U'
M_P -1_\ @SX  '$_  !B0   5D   $U   !%0   /T   #E!   R0@  *T4
M "9'   A20  '$L  !9.!P 34 X $E 3 !%0&0 04"$ #U I  Y0,0 -4#L
M#5%&  M140 *45\ "5%O  =0@0 %4)8  U"K  )0Q0 #3^@  T_[  5._P &
M3?\ ?4(  &M#  !=1   4D0  $I$  !#0P  /$0  #5%   N1P  )TH  "%,
M   <3P  %U$  !)4 P .5PH "U@0  I8%0 (6!P !U@D  98+  %6#8  UA
M  %83   6%H  %AI  !8?   6)$  %>G  !7P   5N4  %;Y  !5_P  5?\
M=D<  &9'  !92   3T<  $='  ! 1P  .$@  #!*   I30  (E   !Q3   6
M50  $5@   U; @ )7@D !%\.  !?$@  7Q@  & ?  !@)P  8#   & [  !@
M1P  8%0  &!C  !@=@  8(L  %^B  !?NP  7^(  %[Y  !=_P  7?\ ;TL
M &%,  !53   3$L  $1+   [3   ,DX  "M1   C5   '%<  !9;   17@
M#6    AC   "9@<  &<,  !G#P  :!,  &D9  !J(0  :BD  &HT  !J0
M:DT  &I=  !J;P  :H4  &J=  !IM@  :-T  &CW  !G_P  9O\ :5$  %Q0
M  !24   2D\  #]0   U4P  +58  "19   =70  %F   !!D   ,9P  !FH
M  !N    ;P,  ' (  !Q#0  <A   '04  !U&P  =B,  '<L  !W.   =D8
M '96  !V:   =GX  ':7  !UL0  =-,  '/U  !S_P  <O\ 8U8  %A5  !0
M5   1%4  #E8   O6P  )E\  !UC   59P  $&P   IP   $<P   '8   !Z
M    ?    'P#  !^"   ?PP  ($0  ""%   A!L  (4D  "&+P  ACT  (9-
M  "%7P  A74  (6/  "$J0  @\D  (+Q  "!_P  @/\ 7UL  %9:  !)6P
M/5X  #)A   G9@  'FL  !5P   .=0  "7D   %^    @0   (4   "(
MB@   (L   "- 0  C@8  ) +  "1#P  DQ0  )4;  "7)@  ES0  )=$  "7
M5@  EFP  )6&  "5H@  E,$  )/J  "2_P  DO\ 76$  $]A  !"9   -FD
M "IN   ?=   %7D   Y_   'A    (D   ".    D@   )8   "8    F@
M )L   "=    GP   *$#  "C"   I0T  *<3  "I'   JB@  *HY  "J2P
MJF$  *EZ  "HF0  J+4  *?=  "G^   IO\ 5F@  $AL   Z<   +G8  ")]
M   7A   #HH   >0    E@   )H   "?    HP   *<   "J    JP   *T
M  "O    L0   +,   "U    N 4  +H,  "]$@  P!P  , M  # 0   OU4
M +]N  "^BP  OJ@  +[)  "][P  O/X 3G0  $!Y   R?P  )8<  !F.   0
ME0  !YP   "B    IP   *P   "P    M0   +D   "\    O0   +\   #!
M    PP   ,8   #(    R@   ,T"  #0"P  U1(  -8A  #7-   V$D  -E@
M  #:?   VIH  -NU  #;V0  V_( 1H(  #B)   KD   '9@  !*@   *IP
M *X   "T    N0   +X   #"    R    ,L   #.    SP   -(   #4
MU@   -H   #=    WP   .(   #F    Z@H  .\3  #P)0  \CH  /-1  #T
M:P  ](D  /6E  #UOP  ]=T _P & /\  P#_  4 _P + /\ $ #_ !< _P B
M /\ +0#_ #D _P!$ /\ 30#_ %4 _P!= /\ 9 #_ &H _P!P /T =@#[ 'P
M^0"# /< B@#U )( \P"; /  I@#N +, ZP#$ .D Y #G /D Y@#_ .4 _P#3
M /\ QP#_ +\ _P"[ /\ _P   /\   #_    _P " /\ "P#_ !( _P = /\
M* #_ #, _P ^ /P 1P#X $\ ] !7 /$ 70#N &, [ !I .H ;P#H '4 Y@!\
M .0 @P#B (L WP"5 -P GP#9 *L U0"[ -( U #/ /( S0#_ ,P _P#% /\
MN@#_ +0 _P"P /\ _P   /\   #_    _P   /\ !@#Y  \ ]0 7 /, (@#Q
M "T [0 W .< 0 #B $D WP!0 -L 5P#7 %T U !C -$ : #/ &X S !U ,H
M? #( (0 Q0"- ,( F #  *0 O0"R +L Q@"Y .@ N #] +< _P"V /\ K0#_
M *< _P"C /\ _P   /\   #_    ]0   .L  0#D  P W@ 3 -D ' #3 "8
MT0 P ,P .@#( $( Q !* ,  4 "] %8 NP!< +D 80"W &< M0!M +, = "Q
M 'P KP"% *T D "J )P J "J *8 NP"E -H HP#U *, _P"B /\ G@#_ )H
M_P"7 /\ _P   /X   #O    WP   -    #'  < P0 / +P %P"Y "  MP J
M +4 ,P"P #L K0!# *L 20"H $\ I@!5 *0 6@"C &  H0!F )\ ;0"= '0
MG !] )H B "8 )0 E@"B )0 L@"2 ,D D0#K )$ _P"0 /\ D #_ (P _P"*
M /\ _    .P   #9    QP   +H   "Q  ( JP , *< $@"D !L H0 D *
M+ "> #4 FP \ )@ 0P"6 $D E !/ )( 5 "0 %H CP!? (T 9@"+ &T B0!V
M (@ @ "& (P A ": (( J@"! +X @ #@ (  ^0!_ /\ ?P#_ '\ _P!^ /\
M\0   -@   #"    LP   *@   "@    F0 ' )4 #@"2 !4 D  > (X )@"-
M "X B@ V (< /0"% $, A !) (( 3@"! %0 ?P!9 'X 8 !\ &< >@!O 'D
M>@!W (8 =0"4 '0 HP!R +4 <@#/ '$ \0!P /\ < #_ '  _P!Q /\ X0
M ,0   "P    H@   )<   "1    BP " (8 "P"# !$ @0 8 '\ (0!] "D
M?  P 'D -P!X #T =@!# '0 20!S $X <@!4 '  6@!O &( ;0!J &L = !J
M (  : ". &< G0!E *\ 90#& &0 Z !D /T 8P#_ &, _P!D /\ SP4  +8'
M  "C"   E @  (D'  "" P  ?@   'L !@!W  X =0 3 '( &P!Q ", ;P K
M &T ,@!L #@ :@ ^ &D 1 !G $D 9@!/ &4 5@!C %T 8@!E &  ;P!? 'L
M70") %P F0!; *H 60"_ %D X0!8 /@ 6 #_ %@ _P!9 /\ P@P  *H-  "7
M#@  B0X  'T.  !V#0  <0H  &\&  !M  H :P 0 &D %@!G !X 90 F &,
M+0!A #, 8  Y %\ /P!= $4 7 !+ %L 4@!: %D 6 !B %< ; !5 '@ 4P"&
M %( E@!1 *< 4 "[ $\!VP!. O0 3@/_ $X$_P!. _\ N!   *$2  ".$P
M?Q,  '03  !L$@  9Q   &4.  !C"P, 8P8, &$$$0!> QD 7 0A %L%* !9
M!B\ 6 8U %8'.P!5!T( 5 =( %,(3P!1"%8 4 E? $X):0!-"78 2PJ$ $D*
ME !("J8 1PJZ $8*V !%"_, 10S_ $4,_P!%#/\ L!0  )D6  "'&   >!D
M &T8  !E%P  7Q8  %P3  !:$0  6@X& %H,#0!7#!0 50P< %,-) !2#2L
M4 TQ $\.. !.#CX 30Y% $L.30!*#E4 2 ]> $</: !%#W4 0Q"$ $$0E0!
M$*8 /A"[ #T0W  ]$?8 /1'_ #T0_P ^$/\ J1D  )(;  "!'   <AT  &<=
M  !?'   61L  %49  !3%@  4A,  %(1"@!0$!  3A$8 $P1( !*$B< 21(N
M $@3- !'$SL 11-" $0320!#%%( 011; #\490 ^%7( /!6! #H5D@ X%:0
M-Q6Y #45V  U%O4 -A;_ #86_P W%?\ HQP  (T>  ![(   ;2$  &(A  !:
M(0  5!\  % >  !-&P  3!D  $L6!@!)%@X 1Q<5 $47' !$&"0 0A@J $$8
M,0! &3@ /QD_ #T91@ \&D\ .AI8 #D:8P W&V\ -1M^ #,;D  R&Z( ,!NW
M "\;TP O'/, +QO_ # ;_P P&_\ G1\  (@B  !W(P  :20  %XD  !6)
M4",  $LB  !((   1AT  $4< @!#' P 01P2 #\=&0 ^'2$ /!XG #L>+@ Z
M'S4 .1\\ #<?1  V'TP -"!6 #,@8  Q(&T +R!\ "TAC@ L(:  *B&U "DA
MT  I(?( *2'_ "H@_P K(/\ F2(  (0E  !S)@  92<  %LG  !3)P  3"8
M $<E  !$)   0B$  #\A   ](0D .R$0 #DB%@ X(AX -B,E #4C*P T)#(
M,R0Y #(D00 P)$H +R53 "TE7@ K)6L *B5Z "@EC  F)9\ )"6S ",ES@ C
M)?  )"7_ "4D_P E)/\ E"4  ( G  !O*0  8BH  %<J  !/*@  22D  $0H
M  ! )P  /28  #HE   W)@8 -28. #0G%  R)QL ,2@B # H*0 O*#  +2DW
M "PI/P K*4< *2E1 "@J7  F*FD )"IX ",JB@ A*IT 'RJR !XJS  >*N\
M'RG_ " I_P A*/\ D"@  'PJ  !L*P  7RP  %0L  !,+   1BP  $$K   \
M*P  ."H  #4J   R*P, ,"L, "XL$0 M+!@ +"P? "HM)@ I+2T *"TT "<N
M/  F+D4 )"Y/ ",N6@ A+V< 'R]V !TOB  <+YL &B^P !@OR@ 8+NT &2[_
M !LM_P ;+?\ C"L  '@M  !H+@  6R\  %$O  !)+P  0R\  #XN   Y+@
M-"X  # N   M+P  *S * "DQ$  G,14 )C$< "4R(P D,BH (S(Q "$S.0 @
M,T( 'S-, !TS5P ;,V0 &C1T !@TA@ 6-)H %#.N !,SR  3,^P %#/_ !4R
M_P 6,?\ ARX  '0O  !E,0  6#$  $XR  !&,@  0#$  #LQ   V,0  ,3$
M "LS   H-   )34& ",V#0 A-A( (#<9 !\W(  >-R< '3@N !LX-@ :.#\
M&3A) !<Y50 5.6( %#EQ !(YA  1.9@ $#FM  XXQP ...L $#C_ ! W_P 1
M-O\ @S$  ' R  !A-   530  $LT  !$-   /30  #@T   S-   +34  "@W
M   D.0  (#H" !T["P ;/!  &3T5 !@]'  7/2, %CTK !4^,P 4/CP $CY&
M !$^4@ 0/E\ #SYO  X^@0 ,/I4 "SZI  H^P0 */>0 "SW[  P\_P -._\
M?30  &LV  !=-P  43<  $@W  !!-P  .S<  #4W   P-P  *CD  "4[   @
M/0  '#\  !=!!@ 40PT $D,2 !%#&  10Q\ $$0G  ]$+P .1#D #41#  Q$
M3@ +1%L "41J  =$?  &1)  !$.E  )#O0 #0^   T/V  1"_P &0?\ >#@
M &<Y  !9.@  3CH  $4Z   ^.@  .#H  #,Z   M.P  )ST  "%    <0@
M%T0  !-& P /20H #4H/  Q*%  +2AL "4HC  A**P '2C0 !4H^  1*20 "
M2E8  $IE  !*=P  2HL  $JA  !)N0  2=T  $GU  !(_P  2/\ <CP  &(]
M  !5/@  2CX  $(]   \/0  -CT  "\^   I0   (T(  !U%   71P  $TH
M  ], @ +3PD !U -  -1$0  41<  %$>  !1)@  42\  %$Y  !11   4E$
M %)@  !1<@  48<  %&=  !1M0  4-@  %#U  !/_P  3_\ ;$   %U!  !1
M00  1T$  $!    Y0   ,D$  "I#   D1@  'D@  !=+   23@  #E$   M3
M 0 &5@<  %<,  !8$   6!,  %D9  !:(0  6BD  %HS  !:/P  6DP  %I:
M  !:;   6H$  %F9  !9L0  6-$  %CT  !7_P  5_\ 944  %A%  !-10
M140  #Y$   U10  +4<  "5*   >30  &%   !)3   .5@  "ED   1<
M7@0  %\)  !@#0  81   &(5  !C&P  9",  &0M  !D.   9$4  &14  !D
M9@  9'L  &.3  !CK0  8LP  &'R  !A_P  8/\ 7TH  %-*  !*20  0T@
M #E)   O3   )T\  !]2   850  $ED   U=   (8    F,   !F    : $
M &D%  !J"@  :PT  &T1  !N%@  <!T  '$F  !Q,0  <#X  '!.  !P7P
M<',  &^-  !OIP  ;L8  &WO  !L_P  ;/\ 6D\  %!.  !(30  /4X  #-1
M   I5   (%@  !A<   18   #&0   9H    :P   &\   !R    =    '4
M  !W!   > D  'H-  !\$   ?18  '\>  " *   @#4  (!%  !_5@  ?VL
M '^$  !^H   ?;X  'SI  ![_P  >O\ 5E0  $Y3  !"5   -U8  "Q:   B
M7P  &&,  !%H   +;0   W(   !V    >@   'T   "     @P   (0   "&
M    AP(  (D'  "+#   C1   ) 6  "2'P  DBP  )([  "230  D6(  )%Z
M  "/EP  C[0  ([A  ",^P  C/\ 55D  $A:   [70  +V$  "1F   9;
M$7(   IW   "?0   ((   "&    BP   (X   "1    DP   )4   "7
MF0   )L   "=!   GPH  *(/  "D%@  IB$  *8Q  "F0P  I5<  *1P  "C
MC@  HZL  *'0  "@]0  G_\ 3F$  $!D   S:0  )VX  !MU   1?   "X,
M  ")    C@   ),   "8    G0   *$   "D    I0   *<   "I    JP
M *T   "P    L@   +4(  "X#@  O!8  +PE  "\-P  NTP  +ID  "Y@0
MMZ(  +?   "WZ@  M_P 1FL  #EP   K=P  'W\  !.&   +C@   94   ";
M    H0   *8   "K    L    +,   "W    MP   +H   "\    OP   ,$
M  #$    QP   ,H   #-!0  T0X  -09  #4*P  U$   --8  #3=   TY(
M -*P  #2TP  TO( /GD  #&    CB   %Y$   V9   #H    *<   "N
MLP   +@   "]    P@   ,8   #*    R@   ,T   #/    T@   -4   #9
M    W0   -\   #C    YP4  .L/  #L'P  [3,  .Y+  #O9   [X(  /"?
M  #QN0  \=@ _P   /\   #_  0 _P ) /\ #@#_ !4 _P > /\ *0#_ #0
M_P _ /\ 2 #_ %  _P!8 /\ 7@#_ &4 _0!K /L <0#Y '< ^ !^ /8 A0#S
M (T \0"7 .X H@#K *\ Z #  .8 X #C /@ X@#_ -L _P#+ /\ P0#_ +D
M_P"T /\ _P   /\   #_    _P   /\ "0#_ !  _P 9 /\ (P#_ "X _0 Y
M /D 0@#U $H \@!2 .X 6 #K %X Z0!D .8 :@#D '  X@!V -\ ?0#= (8
MV0"/ -4 F@#1 *< S@"V ,L S@#) /  QP#_ ,4 _P"[ /\ M #_ *T _P"I
M /\ _P   /\   #_    _P   /L  @#V  T \0 3 .T '@#L "@ Z0 R .,
M.P#= $0 V !+ -, 40#0 %@ S0!= ,L 8P#) &@ Q@!O ,0 =@#" 'X OP"'
M +P D@"Z )\ MP"M +4 P0"R .0 L0#] *\ _P"L /\ I0#_ *  _P"< /\
M_P   /\   #[    [@   .0   #<  @ TP 0 ,\ & #+ "( R0 K ,8 - #!
M #T O0!$ +H 2P"W %$ M0!6 +( 7 "P &$ K@!G *P ;@"J '8 J !_ *8
MB@"C )8 H0"E )\ M@"= -$ G #S )L _P"< /\ E@#_ ), _P"0 /\ _P
M /8   #G    TP   ,8   "]  , N  - +, $P"Q !P KP E *X +@"I #8
MI@ ] *, 1 "A $H GP!/ )T 50"; %H F@!@ )@ 9@"6 &X E !W )( @0"0
M (X C@"< (P K0"* ,, B0#H (@ _P") /\ AP#_ (4 _P"" /\ \P   .,
M  #,    O    +    "G    H0 ( )X #P"; !8 F0 ? )@ )P"6 "\ DP W
M )$ /0". $, C !) (L 3@") %0 AP!9 (4 8 "$ &< @@!O (  >@!^ (8
M? "4 'H I !Y +@ > #8 '< ]P!X /\ > #_ '< _P!U /\ Y@   ,L   "W
M    J    )X   "6    CP $ (L # "( !( AP 9 (4 (0"$ "D @@ P '\
M-P!] #T ? !# 'H 2 !Y $T =P!3 '8 60!T &$ <@!I '$ <P!O '\ ;0"-
M &P G0!J *\ :0#( &@ [0!I /\ :0#_ &D _P!I /\ T@   +@   "E
MEP   (T   "&    @0   'P " !Y  X =P 4 '8 ' !T ", <P K '$ ,0!O
M #< ;@ ] &P 0P!K $@ :@!. &@ 5 !G %L 90!C &, ;0!B '@ 8 "' %\
ME@!= *@ 70"^ %P Y !< /L 7 #_ %P _P!< /\ P@   *H!  "8 P  B00
M '\"  !X    =    '  ! !M  P :P 1 &D %P!H !X 9@ E &4 + !C #(
M8@ X &  /0!? $, 7@!) %P 3P!; %8 6@!> %@ : !7 ', 50"! %0 D0!2
M *, 40"W %$ U@!1 /4 40#_ %$ _P!2 /\ M@<  )\)  "-"P  ?@P  ',+
M  !L"@  : <  &4#  !C  < 80 - %\ $P!= !H 7  A %L )P!9 "T 6  S
M %8 .0!5 #\ 5 !% %, 2P!1 %( 4 !: $\ 9 !- &\ 3 !] $H C0!) )\
M2 "R $< S !' .\ 1@#_ $< _P!' /\ K P  )4.  "#$   =1   &L0  !C
M#P  7@X  %L,  !:"0( 600* %< #P!5 !4 4P < %( (P!1 "D 3P O $X
M-0!- 3L 3 %! $H"2 !) D\ 2 )7 $8#80!% VT 0P-Z $(#BP!  YP /P.O
M #X#R  ]!.H /07\ #T&_P ^!O\ I!   (X2  !\$P  ;A0  &04  !<$P
M5A(  %,1  !1#@  4 P% % )# !/!Q$ 30<7 $L('P!)""4 2 DK $<),0!&
M"3@ 1 H^ $,*10!""DT 0 M5 #\+7P ]"VL / MY #H,B@ X#)P -PRO #4,
MQP U#.D -0W] #4-_P V#/\ G1,  (<5  !V%P  :1@  %X8  !6&   4!<
M $T5  !*$P  21$  $D.!P!(#0X 1@T3 $0-&@!##B$ 0@XH $ .+@ _#C4
M/@\\ #T/0P [$$L .A!4 #@07@ V$&L -!!Y #(0B@ Q$)P +Q"P "T0R0 M
M$>P +1'_ "X1_P O$/\ EQ8  ((9  !Q&P  9!P  %D<  !1'   3!L  $<:
M  !$&   0Q4  $(3 @!!$@L 0!$0 #X2%P \$AX .Q,E #H3*P X$S( -Q,Y
M #840  T%$@ ,Q11 #$47  P%6@ +A5W "P5B  J%9H *!6N "<5QP F%>H
M)Q7_ "@5_P I%?\ D1H  'T<  !M'@  8!\  %8?  !.'P  2!X  $,=  !
M'   /AH  #T8   [%P< .18. #@7%  V%QL -1@B #,8*  R&"\ ,1DV # 9
M/0 N&48 +1I/ "L:60 J&F8 *!IT "8:A@ D&ID (AJM "$:Q0 @&N@ (1K^
M "(:_P C&O\ C1T  'D?  !I(0  7"(  %(B  !*(@  1"$  #\A   \(
M.1X  #@;   U' 0 -!P- #(<$@ P'1@ +QT? "X=)0 M'BP *QXS "H>.P I
M'T, )Q]- "8?5P D'V0 (A]R " ?A  ?'Y< '1^K !L?PP ;'^< &Q_] !T?
M_P >'O\ B2   '4B  !E(P  620  $\E  !')0  020  #PC   X(P  -2(
M #,@   P( $ +B$* "PA$  K(14 *B(< "@B(P G(BD )B,P "4C.  C(T$
M(B1* "$D50 ?)&$ '21P !LD@@ 9))4 %R2J !8DP0 5).4 %B3\ !<C_P 9
M(_\ A2(  '$D  !B)@  5B<  $PG  !$)P  /B<  #DF   U)@  ,24  "XD
M   K)0  *24' "<F#@ E)A, )"<9 ",G(  B)R< (2@N " H-@ >*#X '2A(
M !LI4P 9*5\ &"EN !8I@  4*90 $BFH !$IP  1*.0 $2C[ !,H_P 4)_\
M@"4  &XG  !?*   4RD  $DJ  !"*0  .RD  #8I   R*   +B@  "HH   F
M*0  )"H$ "(K#  @*Q$ 'RP6 !TL'0 <+"0 &RTK !HM,P 8+3P %RU% !8N
M4  4+ET $BYL !$N?@ 0+I( #BZG  TMO0 -+=\ #2WY  XL_P 0+/\ ?"@
M &HJ  !;*P  4"P  $8L   _+   .2P  #0K   O*P  *RL  "8L   B+@
M'R\  !PP"0 :,0X &3$3 !<Q&@ 6,B$ %3(H !0R,  3,CD $C-# !$S3@ 0
M,UL #C-I  TS>@ ,,XX "C.B  @RN0 (,MD "#+T  HQ_P +,?\ =RL  &8M
M  !8+@  32\  $,O   \+@  -BX  #$N   M+@  *2X  ",P   ?,@  &S,
M !<U!0 4-@P $C<1 !$W%@ 1-QT $#@D  \X+  ..#4 #3@_  PX2@ +.%<
M"3AE  <X=@ %.(H  SB?  $WM0 !-],  C?Q  ,V_P %-O\ <RX  &(P  !4
M,0  23$  $$Q   Y,0  -#$  "\P   K,   )3(  " S   ;-@  %S@  !,Z
M @ 0/ D #3T.  P]$P +/1D "CTA  D]*0 (/3$ !CX[  4^1@ #/E(  3YA
M   ^<@  /H8  #V<   ]L@  /=   #SP   \_P  //\ ;3(  %TS  !0-
M1C0  #XT   W-   ,C,  "TS   G-   (C8  !TX   8.@  %#T  ! _ @ -
M00@ "4,-  9$$0 #1!8  D0=  !$)   1"T  $0V  !$00  1$X  $1<  !$
M;0  1($  $28  !#KP  0\T  $+P  !"_P  0O\ :#8  %@W  !,.   0S@
M #LW   U-@  ,#8  "DW   C.0  'CL  !@]   30   $$(   U% 0 (1P<
M TD,  !)#P  2A,  $L9  !+(   2R@  $LR  !+/0  3$D  $Q7  !+:
M2WT  $N4  !*K   2LH  $GO  !)_P  2?\ 8CH  %0[  !).P  0#L  #DZ
M   S.0  +#H  "4\   ?/P  &4$  !-$   01P  #$D   A,   "3P4  % *
M  !0#0  41   %(5  !4&P  5",  %0L  !4-P  5$0  %12  !48P  5'<
M %2/  !3J   4L8  %+M  !1_P  4?\ 7#\  $\_  !%/P  /CX  #<]   O
M/@  )T   "!#   91@  $TD   ],   +3P  !E(   !4    5P(  %@'  !9
M"P  6@X  %L1  !=%@  7AT  %\F  !?,0  7CT  %Y,  !>70  7G$  %V)
M  !=HP  7,$  %OK  !:_P  6O\ 5D0  $M#  !#0@  /$$  #)"   I10
M(4@  !I+   33@  #E(   I5   #60   %L   !>    8    &("  !C!@
M90H  &8.  !H$0  :A<  &L?  !K*0  :S8  &M%  !K5@  :FH  &J"  !I
MG0  :+L  &?G  !F_P  9?\ 44@  $A(  !!1@  -T<  "Q*   C30  &U$
M !-5   .60  "%T   %A    9    &<   !J    ;    &X   !P    <@4
M ',)  !U#0  =Q$  'H8  ![(0  >RX  'H]  !Z3@  >6(  'EY  !XE@
M=[,  '7@  !T_   <_\ 3DT  $=,   [30  ,$\  "93   <6   $UP   UA
M   &9@   &H   !O    <@   '8   !Y    ?    'T   !_    @0   (,"
M  "&!P  B P  (L1  ".&   CB0  (XS  "-1   C%@  (MO  "*C   B:H
M (C/  "&]P  A?\ 35$  $%3   T50  *5H  !Y?   490  #6H   5P
M=@   'L   !_    @P   (<   "*    C0   (X   "1    DP   )4   "8
M    F@4  )T,  "@$0  HQH  *,H  "B.@  H4X  *!E  "@@0  GJ   )W!
M  ";[@  FO\ 1ED  #E<   M80  (6<  !9N   .=0  !7L   "!    AP
M (T   "2    E@   )H   "=    GP   *$   "D    I@   *@   "K
MK@   +$#  "T"P  N!$  +D>  "Y+P  N$,  +=:  "U=@  M)<  +2U  "Q
MX@  L/P /V0  #%I   E;P  &'<   ]_   &AP   (X   "4    F@   *
M  "E    J@   *X   "Q    L@   +4   "W    N@   +P   "_    PP
M ,8   #)    S@H  -(3  #2(P  T3<  -!/  #.:@  S8H  ,JK  #+RP
MR^\ -W$  "EX   =@   $8D   B1    F@   *$   "G    K0   +,   "Y
M    O@   ,(   #%    Q@   ,D   #,    S@   -(   #5    V@   -X
M  #A    Y0   .H+  #K%P  ZBL  .I#  #J7@  ZGH  .N9  #KM0  Z]4
M_P   /\   #_  $ _P ' /\ #0#_ !( _P ; /\ )0#_ "\ _P Z /\ 0P#_
M $L _P!3 /\ 6@#] &  ^P!F /H :P#X '( ]@!X /0 @ #Q (D [P"2 .P
MG0#I *H Y@"\ ., W #? /< W0#_ ,P _P"^ /\ M0#_ +  _P"M /\ _P
M /\   #_    _P   /\ !@#_  T _P 4 /\ 'P#_ "D ^P S /< /0#S $4
M[P!- .P 4P#H %D Y0!? ., 90#@ &H W0!Q -H > #6 (  T@"* ,\ E0#,
M *( R "R ,4 R0#" .T P #_ +L _P"P /\ J #_ *0 _P"A /\ _P   /\
M  #]    ^@   /@   #P  D [  1 .@ &0#G ", Y0 M -X -@#6 #X T0!&
M ,T 3 #* %( R !8 ,4 70## &, P !I +X < "\ '@ N0"! +< C0"T )H
ML0"I *X O "L .$ J@#\ *@ _P"@ /\ F0#_ )8 _P"4 /\ _P   /D   #R
M    YP   -L   #1  0 R@ - ,< % #$ !T P@ F +\ +P"[ #< MP _ +0
M10"Q $L K@!1 *P 5@"J %P J !A *8 : "C '  H0!Y )\ A "= )$ F@"@
M )@ L0"6 ,P E0#Q )0 _P"1 /\ BP#_ (@ _P"& /\ ]P   .P   #>
MR0   +P   "T    KP * *L $ "I !< J  @ *< * "B #  GP X )P /@":
M $0 F !* )8 3P"4 %4 DP!: )$ 80"/ &@ C0!Q (L >P") (@ AP"7 (4
MJ "# +X @0#D (  _P"  /\ ? #_ 'L _P!Y /\ Z0   -<   #!    L0
M *8   "=    EP % )0 #0"2 !( D  : (\ (@". "H BP Q (D . "' #X
MA0!# (, 2 "! $X ?P!4 'X 6@!\ &$ >@!I '@ <P!V '\ =0". ', GP!Q
M +, < #0 &\ ]@!O /\ ;P#_ &T _P!L /\ V@   +\   "L    G@   ),
M  ",    A0   (( "0!_  \ ?@ 5 'T ' !\ "0 >@ K '< ,0!U #< =  ]
M '( 0@!Q $@ ;P!- &X 4P!L %H :P!B &D ; !G '@ 9@"& &0 EP!B *H
M80#" &  ZP!A /\ 80#_ &$ _P!@ /\ Q0   *T   ";    C0   (,   !\
M    =P   '( !0!P  P ;@ 1 &P %P!L !X :P E &D + !G #$ 9@ W &0
M/0!C $( 8@!( &  3@!? %4 70!= %P 9@!: '( 60"  %< D !6 *, 50"Y
M %0 W@!4 /L 5 #_ %4 _P!5 /\ M@   )\   "-    ?P   '4   !N
M:0   &8  0!C  D 80 . &  $P!? !D 7@ @ %T )@!; "P 6@ R %@ -P!7
M #T 5@!# %4 20!3 %  4@!8 %$ 80!/ &P 3@!Z $P B@!+ )P 2@"Q $D
MS@!) /, 20#_ $D _P!* /\ J@$  )0%  ""!P  = @  &H(  !C!@  7@0
M %L   !9  4 5P , %8 $ !4 !4 4P ; %( (@!1 "@ 4  M $X ,P!- #@
M3  ^ $L 10!* $P 2 !4 $< 70!& &@ 1 !U $, A0!! )@ 0 "K $  Q0 _
M .H /P#_ $  _P!  /\ H @  (H+  !Y#0  ; T  &$-  !:#0  50L  %()
M  !0!@  3P(( $X #0!, !( 2P 7 $H '@!) ", 1P I $8 +P!% #0 1  Z
M $( 00!! $@ 0 !0 #X 6@ ] &0 / !R #H @@ Y )0 . "G #< O@ V .,
M-@#Y #8 _P W /\ F T  (,.  !R$   91$  %L1  !3$   3A   $H.  !(
M#0  1PH# $<'"@!%! X 1 (3 $("&@!! B  0 ,E #X#*P ]!#$ / 0W #L$
M/@ Z!44 .05. #<%5P V!6( - 9P #(&@  Q!I( , :E "\%NP N!=T +@;U
M "T'_P N!_\ D1   'T1  !L$P  7Q0  %44  !.%   2!,  $02  !!$
M0 X  $ -!@! "@P /@D0 #P)%@ ["AP .0HB #@**  W"RX -@LU #4+.P S
M"T, ,@Q, # ,5@ O#&$ +0QO "L,?P J#)( * RE "<,NP E#-T )0WU "8-
M_P G#?\ BQ(  '<4  !G%@  6Q<  %$8  !)%P  0Q<  #\5   \%   .A(
M #D1 0 Y#P@ . X- #<.$@ U#A@ - X? #(.)0 Q#RP , \R "\0.@ M$$(
M+!!+ "H050 H$&$ )A!O "00@  C$), (1"G !\0O0 >$.  'A'W !\0_P @
M$/\ AA0  ',7  !C&0  5QH  $T;  !%&@  0!H  #L9   X&   -18  #04
M   S$@0 ,A(+ #$2$  O$A4 +1(< "P3(@ K$RD *A,P "@3-P G%#\ )A1(
M "044P B%%\ (!5M !\5?@ =%9$ &Q6E !D5NP 8%=X &!7X !D4_P :%/\
M@A<  &\:  !?'   4QT  $H=  !"'0  /!T  #<<   T&P  ,1H  "\9   N
M%@  +!<( "L6#@ I%Q, *!<9 "<8(  E&"8 )!@M ",8-  B&3T (!E& !X9
M40 =&5T &QIK !D:?  7&H\ %1JC !09N@ 2&=L $QGV !09_P 5&/\ ?1H
M &L=  !<'P  4"   $<@   _(   .1\  #0?   Q'@  +1T  "L<   I&P
M)QL% "4;#  D'!$ (AP6 "$<'0 @'2, 'QTJ !X=,@ <'CH &QY$ !D>3@ 7
M'EL %AYI !0?>@ 2'HT $1ZB ! >N  .'M@ #Q[U ! =_P 1'?\ >AT  &<?
M  !9(0  32(  $0B   \(@  -B(  #(A   N(0  *B   "<@   D'P  (B "
M " @"@ >(0\ '2$4 !PA&@ ;(B$ &2(G !@B+P 7(C@ %2-! !0C3  2(U@
M$2-G ! C>  .(XL #2.?  PCM  +(]  "R+P  PB_P -(?\ =A\  &0B  !6
M(P  2R0  $$D   Z)   -"0  "\C   K(P  *",  "0C   @(P  '20  !LE
M!P 9)@T %R81 !8F%P 5)QX %"<E !,G+  2)S4 $2@_ ! H2@ .*%8 #2AD
M  PH=  **(< "2B;  <GL0 %)\P !B?L  <F_@ ()O\ <2(  & D  !3)@
M2"<  #\G   W)@  ,28  "TF   I)0  )24  "(E   =)P  &2@  !8J!  4
M*PL $BP0 !$L%  0+!L $"PB  XL*0 .+3( #2T[  LM1@ *+5( ""U@  8M
M<  $+8,  BV8   LK@  +,D  "SK  $K_  "*_\ ;24  %TG  !/*   12D
M #PI   U*0  +R@  "LH   G)P  (R<  !\H   ;*@  %RP  !,N @ 0, @
M#C$-  TQ$@ ,,1< "S$>  HQ)@ (,BX !S(W  4R0@ #,DX  3)<   R;
M,G\  #*5   QK   ,<<  ##J   P_   ,/\ :"D  %@J  !,*P  02P  #DL
M   R*P  +2L  "DJ   E*@  ("L  !PL   7+@  $S   ! R @ .- < "C<,
M  <W$  %-Q0  S<;  (W(@  -RH  #@S   X/@  .$H  #A8   X:   .'P
M #>2   WJ0  -L4  #;J   V_0  -?\ 8RP  %0N  !(+P  /B\  #8N   P
M+@  *RT  "<M   B+0  '2\  !@Q   4,P  $#4   XW 0 *.@< !CL+  (\
M#@  /1(  #X7   ^'@  /B8  #XO   ^.@  /D8  #Y4   ^9   /G<  #Z/
M   ]IP  /<,  #SI   \_0  ._\ 7C   % Q  !$,@  .S(  #0Q   N,
M*2\  "0P   >,@  &30  !0V   0.0  #3L   H]   %0 4  $$*  !"#0
M0Q   $04  !%&@  1B(  $8K  !&-0  1D$  $9/  !&7P  1G,  $6*  !%
MI   1,   $/H  !#_@  0O\ 6#0  $LU  !!-0  .34  #(T   M,P  )C0
M " U   :.   %#H  ! ]   -0   "4(   1%    1P,  $@'  !*"P  2PX
M $P1  !.%0  3QP  $\E  !/+P  3SP  $]*  !/6@  3FT  $Z%  !-H
M3+P  $OG  !+_@  2O\ 4SD  $<Y   ^.0  -S@  #$W   I-P  (3D  !L\
M   5/P  $$(   Q%   '2    DH   !-    3P   %$$  !2!P  5 L  %4.
M  !7$0  61<  %H?  !9*0  638  %E$  !95   6&<  %A_  !7F@  5K<
M %7C  !4_0  5/\ 3CT  $,]   \/   -3L  "P\   D/@  '$$  !5$   0
M2   "TL   5.    40   %0   !7    60   %L   != @  7@8  & +  !B
M#@  9!(  &<8  !G(@  9BX  &8\  !F30  96   &5W  !DDP  8[$  &'=
M  !@_   7_\ 24(  $%!   Z/P  ,$   "9#   >1@  %4H  !!.   *4@
M U8   !:    70   &    !C    90   &<   !I    :P$  &T%  !O"@
M<@X  '42  !W&P  =B8  '8U  !U1@  =%D  '1O  !SBP  <JD  '#-  !O
M]P  ;O\ 1D8  $!%   U1@  *D@  "!,   740  $%8   E:   !7P   &,
M  !H    :P   &\   !R    =0   '<   !Y    >P   'T   "  P  @P@
M (8-  ")$P  BAT  (HK  ")/   B$\  (9F  "%@0  A*   (+"  "!\
M?_\ 1DL  #I,   N3P  (U,  !A8   07@  "60   !I    ;P   '0   !X
M    ?    ($   "$    AP   (@   "+    C@   )    "3    E@   )D'
M  "=#0  H10  * A  "@,0  GD0  )U;  "<=@  F98  )FU  "6Y0  E?X
M/U(  #)5   F6@  &V   !%G   );0   '0   ![    @0   (8   "+
MD    )0   "7    F0   )P   "?    H0   *0   "G    J@   *T   "Q
M!@  M0T  +@6  "W)@  MCD  +50  "T:@  LHD  +"J  "NSP  K?4 -UP
M "MA   >:   $W    MX    @    (<   ".    E0   )H   "?    I
M *@   "L    K0   +    "S    M0   +@   "[    OP   ,,   #'
MRP4  -$.  #1&P  T"X  ,]%  #-7P  RWX  ,F>  #(O@  Q>D +VD  "-P
M   6>0  #8$   &+    DP   )L   "B    J    *X   "T    N    +T
M  #     P@   ,4   #(    RP   ,X   #1    U@   -L   #?    Y
M .@&  #K$0  ZB,  .HZ  #I5   YW(  .63  #CLP  X]0 _P   /\   #_
M    _P $ /\ "P#_ !  _P 7 /\ (0#_ "L _P U /\ /@#_ $< _P!. /\
M50#\ %L ^@!A /@ 9@#V &T ] !S /( >P#O (0 [0". .H F0#F *< XP"Y
M -\ U0#; /< U@#_ ,  _P"R /\ J@#_ *4 _P"B /\ _P   /\   #^
M_    /P  P#^  L _P 1 /\ &@#] "0 ^0 N /0 . #P $  [ !( .D 3@#F
M %0 X@!: -\ 7P#< &4 V !K -0 <@#0 'L S0"% ,H D0#' )X PP"N ,
MQ0"] .L NP#_ +  _P"D /\ G #_ )@ _P"5 /\ _P   /H   #T    \0
M /(   #J  4 YP . .( %0#A !X X0 H -@ ,0#0 #D RP!  ,@ 1P#% $T
MP@!3 +\ 6 "] %X NP!D +D :P"V ', M !\ +$ B "N )4 JP"D *@ N "F
M -P HP#[ )\ _P"5 /\ CP#_ (L _P") /\ ^0   .\   #G    WP   ,\
M  #(    P0 * +\ $0"\ !@ NP A +D *@"T #( L0 Z *X 0 "K $8 J !,
M *8 40"C %8 H0!< )\ 8P"= &H FP!S )D ?@"6 (P E "; )( K0"0 ,<
MC@#P (T _P"& /\ @ #_ 'T _P!\ /\ [0   .    #1    OP   +,   "J
M    I@ % *( #0"A !, H  ; )\ (P"; "L F  R )4 .0"3 #\ D0!$ (\
M2@". $\ C !5 (H 6P"( &, A@!K (0 =@"" (( @ "2 'X HP!\ +H >@#A
M 'D _P!W /\ <@#_ '  _P!O /\ W0   ,L   "V    IP   )T   "4
MC@ ! (L "@") !  B  5 (< '0"' "4 A  L (( ,@!_ #@ ?0 ] 'L 0P!Y
M $@ > !. '8 5 !U %L <P!C '$ ;@!O 'H ;0") &P F@!J *X :0#, &@
M]@!G /\ 90#_ &0 _P!C /\ R@   +0   "A    DP   (D   ""    >P
M '@ !0!V  P =0 1 '0 & !S !\ <@ E '  + !N #( ;  W &H / !I $(
M: !( &8 3@!E %4 8P!= &( 9@!@ '( 7@"  %T D@!; *4 6@"^ %D Z0!9
M /\ 60#_ %@ _P!8 /\ N0   *(   "0    @P   'D   !Q    ;0   &D
M 0!F  D 90 . &0 $P!C !D 8P @ &$ )@!@ "P 7@ Q %P -P!; #P 6@!"
M %@ 2 !7 $\ 5@!7 %0 8 !3 &P 40!Y %  B@!/ )X 3@"T $T V@!- /L
M30#_ $T _P!- /\ J@   )0   ""    =0   &L   !D    8    %T   !:
M  4 6  , %< $ !6 !4 5@ ; %4 (0!3 "< 4@ L %$ ,0!/ #< 3@ ] $T
M0P!, $H 2@!2 $D 6P!( &8 1@!S $4 A !$ )< 0P"L $( R0!" /$ 0@#_
M $, _P!# /\ G@   (D   !X P  :@0  &$$  !: P  50$  %(   !0  (
M3@ ) $T #0!, !$ 2P 7 $H ' !) "( 2  G $< +0!% #( 1  X $, /@!"
M $4 00!- #\ 5@ ^ &$ /0!N #L ?@ Z )$ .0"F #@ OP X .@ . #_ #D
M_P Y /\ E0,  ( '  !O"0  8@H  %@+  !1"@  3 @  $D&  !' P  1@ &
M $0 "P!#  \ 0@ 3 $$ & !! !X /P C #X *0 ] "X .P T #H .@ Y $$
M. !) #< 4@ V %T - !J #, >@ R (P ,0"A #  N  O -X +P#Y "\ _P P
M /\ C D  '@,  !H#0  7 X  %(.  !+#@  10T  $$,   _"@  /@@" #T$
M"  \ 0T .P 0 #H %0 Y !H .  @ #8 )0 U "L -  P #, -P R #X ,0!&
M "\ 4  N %H +0!G "L =P J (D *0"= "@ LP G -$ )P#R "< _P G /\
MA@P  '(.  !C$   5A$  $T1  !%$0  0!   #P/   Y#@  -PT  #8+!  V
M" H -08. #0%$@ R!!< ,04< # %(@ O!2@ +@8N "T&-  K!CP *@9$ "D'
M3@ G!UD )@=E "0'=0 C!X< (@>; " &L  @!LL 'P7M !\&_@ ?!_\ @ X
M &T1  !>$@  4A,  $@3  !!$P  .Q,  #<2   T$0  ,A   # / 0 P#08
M, L+ "\*$  M"A0 + L9 "H+'P I"R4 * PK "<,,@ F##H ) Q# ",,30 A
M#5@ ( UE !X-=0 <#8@ &@V< !D-L0 8#,H %PSK !<-_  8#/\ >Q$  &D3
M  !:%0  3A8  $46   ]%@  .!4  #,5   P%   +1,  "L2   J$ , *@\(
M "D.#0 H#A$ )@X6 "4/'0 D#R, (P\I "$0,0 @$#D 'A!" !T03  ;$%@
M&1!F !<0=@ 5$(D %!"> !(0LP 1$,X $1#N !(0_@ 2$/\ =Q,  &45  !7
M%P  2Q@  $(9   Z&0  -!@  # 7   L%P  *18  "<5   F% $ )1($ ",2
M"P B$@\ (1(4 " 2&@ >$R  '1,G !P3+@ :$S8 &11  !<42@ 6%%8 %!1D
M !(4=  1%(< $!2<  X4L0 -%,H #13K  X3_@ .$_\ <Q4  &$8  !3&@
M2!L  #\;   W&P  ,AH  "T:   I&0  )A@  "08   B%P  (!8! !X6"  =
M%@T &Q<2 !H7%P 9%QT &!@D !88*P 5&#0 %!@] !(92  1&50 $!EB  X9
M<@ -&80 #!F8  H9K0 )&,8 "1CG  D8^@ *%_\ ;Q@  %X:  !0'   11T
M #P=   U'0  +QT  "H<   F&P  (QL  "$:   >&@  '!H  !H;!0 8&PP
M%AP0 !4<%0 4'!L $QPB !(=*0 1'3$ $!T[  X=10 -'E$ #!Y>  H>;0 )
M'H  !QZ4  4=J@ #'<(  QWF  0<^  %'/\ :QH  %L=  !-'@  0A\  #H?
M   R'P  +1\  "@>   D'@  (1T  !X=   <'0  &!X  !4? @ 3( D $B$.
M ! A$@ 0(1@ #B$?  XB)@ -(BX #"(W  HB00 )(DT !R):  4B:0 #(GP
M 2*1   BJ   (<   "'E   @^   (/\ 9QT  %<?  !*(0  0"$  #<B   P
M(0  *B$  "8@   B(   'Q\  !P?   9(   %B$  !(C @ 0) < #B8,  PF
M$  +)A4 "B8<  DF(@ ()BH !B<S  0G/0 #)TD  2=6   G9@  )WD  ">/
M   FI@  )K\  "7D   E^0  )/\ 8R   %0B  !'(P  /20  #0D   N(P
M*",  "0B   A(@  'B$  !HB   7(P  $R0  ! F @ .* < "RH+  @K#@ &
M*Q, !"L8  (K'P !+"<  "PP   L.@  +$4  "Q3   L8P  +'8  "R,   K
MI   *[X  "KD   J^@  *?\ 7R,  % E  !$)@  .B8  #(F   K)@  )B4
M ",D   ?)   &R0  !<E   4)P  $2D   XK @ ++08 !R\+  0P#@  ,!$
M #$5   Q'   ,2,  #(L   R-@  ,D(  #)/   R7P  ,G(  #&)   QH@
M,+P  ##D   O^P  +_\ 6B<  $PH  ! *0  -RD  "\I   I*   )2<  "$F
M   <)P  &"@  !0J   1+   #BX   LP 0 ',@4  S0)   U#   -@\  #<2
M   X&   ."   #@H   X,@  .3T  #E+   Y6P  .&X  #B%   WGP  -[H
M #;D   U_   -?\ 52H  $@L   ]+   -"P  "TK   H*@  )"D  !XJ   9
M*P  %"T  !$O   -,0  "C0   <V   ". 0  #H'   ["@  /0T  #X0  !
M%   0!L  $ D  ! +@  0#D  $!'  ! 5@  0&D  $"    _FP  /K<  #WC
M   \_   //\ 4"\  $,O   Y+P  ,B\  "PM   G+   ("T  !HO   5,0
M$3,   TV   ).   !3L    ]    0 $  $$$  !#!P  10L  $8.  !($0
M2A8  $H>  !**   2C0  $E"  !)40  260  $A[  !(EP  1[0  $;@  !%
M_   1/\ 2C,  #\S   V,P  ,#$  "HP   C,0  '#,  !8U   1.   #3L
M  @^   #00   $,   !&    2    $H   !,!   3@<  $\+  !1#@  5!(
M %49  !5(@  5"X  %0\  !42P  4UX  %-T  !2D   4:X  %#7  !/^P
M3O\ 13<  #PW   U-@  +S0  "8U   >-P  %SH  !$]   ,00  !T0   !(
M    2@   $T   !0    4P   %4   !7    6 (  %L&  !="P  7PX  &(3
M  !B&P  8B<  &(T  !A10  8%<  &!M  !?B0  7:<  %S,  !:^   6?\
M03P  #H[   T.0  *CH  "$\   80   $4,   Q'   &2P   $\   !3
M5@   %D   !<    7P   &$   !C    90   &<!  !J!0  ;0H  ' .  !S
M%0  <B   '(M  !Q/0  <$\  &]E  !N@   ;9\  &O!  !I\0  :/\ /T
M #D^   N/P  )$(  !I&   22@  #$\   14    6    %T   !A    90
M &@   !K    ;@   '$   !S    =0   '@   ![    ?@,  ($*  "%#P
MAQ<  (8D  "%-   A$8  ()=  "!=@  ?Y8  'ZV  !\YP  >O\ /T0  #-%
M   H2   '4P  !-2   ,5P   UT   !C    :    &T   !Q    =@   'H
M  !^    @0   (,   "&    B0   (L   ".    D@   )4!  "9"0  GA
M )X:  "=*0  G#P  )I2  "8;   EHL  )2J  "2U   D/H .$L  "Q.   @
M4P  %5D   U@   #9P   &X   !T    >@   (    "$    B@   (X   "2
M    E0   )<   ":    G0   *    "C    IP   *L   "O    M D  +@0
M  "W'@  M3   +-&  "Q8   KWX  *R@  "KP0  J>X ,54  "1;   880
M#FD   5Q    >0   ($   "(    CP   )0   ":    GP   *0   "H
MJ0   *P   "O    LP   +4   "Y    O0   ,$   #&    RP   -$*  #3
M%   T24  - [  #-5   RG$  ,B2  #%LP  P]X *6(  !QI   1<0  !WL
M  "$    C0   )4   "=    HP   *D   "O    M    +D   "\    O@
M ,(   #%    R    ,P   #0    U    -H   #?    Y    .H   #N#
M[1H  .PO  #J20  Z&4  .:&  #DI0  XL8 _P   /\   #_    _  ! /P
M" #^  X _P 4 /\ '0#_ "8 _P P /\ .@#_ $( _P!) /X 4 #[ %8 ^0!<
M /8 8@#T &@ \@!O /  =@#M '\ Z@") .< E0#D *, X "U -L T #5 /8
MR@#_ +8 _P"H /\ GP#_ )H _P"6 /\ _P   /L   #V    \P   /,   #V
M  D ^@ . /T %@#[ "  ]P J /( ,P#M #L Z0!# .8 20#B $\ W@!5 -L
M6P#6 &  T@!G ,\ ;@#, '8 R0"  ,8 C #" )H OP"J +L P0"X .D M@#_
M *< _P": /\ D@#_ (T _P"* /\ ^@   /$   #J    YP   .<   #D  $
MX  + -L $0#: !H VP C -$ + #* #0 Q@ [ ,( 0@"_ $@ O !. +H 4P"X
M %D M@!? +, 9@"Q &X K@!W *P @P"I )$ I@"A *, M0"@ -@ G@#[ )4
M_P"+ /\ A0#_ (  _P!^ /\ [P   .,   #:    TP   ,8   "_    N0 &
M +< #@"T !0 M  = +, )0"N "T JP T *< .P"D $$ H0!& )\ 3 "= %$
MFP!7 )D 7@"7 &4 E0!N ), >0"0 (< C@"7 (P J0") ,0 B #O (4 _P!\
M /\ =@#_ ', _P!R /\ X    -    #&    M@   *D   "A    G0 ! )D
M"@"8 !  F  6 )< '@"4 "8 D0 M (\ - ", #H B@ _ (@ 10"' $H A0!0
M (, 5@"! %X @ !F 'X <0!\ 'T >0"- '< H !U +8 <P#? '( _P!N /\
M:0#_ &< _P!E /\ S    +X   "K    G0   ),   "*    A0   (( !0"
M  T ?P 1 '\ & "  "  ?0 F 'H +0!W #, =0 X '0 /@!R $, < !) &\
M3P!M %8 ; !> &H : !H '4 9P"$ &4 E@!D *L 8@#) &$ ]@!@ /\ 7 #_
M %L _P!: /\ O0   *D   "7    B0   'X   !X    <P   &\  0!M  D
M;  . &L $P!K !D :@ @ &@ )@!F "P 90 R &, -P!B #P 8 !" %\ 2 !=
M $\ 7 !7 %H 80!9 &T 5P![ %8 C@!5 *( 4P"[ %( Z0!2 /\ 4 #_ $\
M_P!/ /\ K0   )@   "&    >    &X   !G    8P   &    !=  4 7  +
M %L $ !; !4 6P ; %H (0!8 "8 5@ L %0 ,0!3 #8 4@ \ %$ 0@!/ $D
M3@!1 $T 6P!+ &8 2@!T $D A0!( )D 1P"Q $8 V !& /P 10#_ $4 _P!%
M /\ GP   (D   !X    ;    &(   !;    5@   %,   !1  ( 3P ( $\
M#0!. !$ 3@ 6 $T ' !, "$ 2@ F $D + !( #$ 1P W $4 /0!$ $0 0P!,
M $( 50!  &  /P!N #X ?@ ] )( / "I #L QP [ /, .P#_ #L _P \ /\
MDP   'X   !N    80   %@   !1    3    $D   !'    10 % $0 "P!#
M  X 0P 2 $, %P!" !T 0  B #\ )P ^ "P /0 R #L .  Z #\ .0!' #@
M4  W %L -0!H #0 >  S (P ,@"B #$ O  Q .< ,0#_ #( _P S /\ B0
M '8#  !F!0  60<  % '  !)!@  0P4  $ #   ^ 0  /  # #L "  Z  T
M.@ 0 #D %  Y !D -P > #8 (P U "@ -  N #, -  R #L , !# "\ 3  N
M %< +0!D "P <P K (< *@"< "D M0 I -P *0#[ "D _P J /\ @00  &X(
M  !?"@  4PL  $H+  !""P  /0H  #D)   V"   -04  #0"!@ S  H ,@ .
M #$ $0 Q !4 ,  : "\ 'P N "0 +  J "L ,  J #< *0 _ "@ 20 G %0
M)@!@ "0 ;P C (( (@"7 "$ K@ A ,P (0#S "$ _P B /\ >PD  &@,  !:
M#0  3@X  $4.   ]#@  . T  #,-   P#   +@L  "T) P M!@@ + 0, "L"
M#P J 1( *0$7 "@!'  G "$ )@ G "4 +0 D #0 (P$] "(!1@ A 5$ 'P%=
M !X!;  < 7\ &P"4 !H J@ : ,4 &@#K !D _P : /\ =0P  &0.  !5#P
M2A   $ 0   Y$   ,Q   "\/   L#@  *0X  "<- 0 G# 4 )PH* "8(#0 E
M!Q  ) 84 "(&&0 A!A\ ( <D !\'*P >!S( '0<Z !P(1  :"$\ &0A< !<(
M:P 6"'T %0>1 !0'IP 3!K\ $@7D !(%^@ 2!?\ <0X  %\0  !1$0  1A(
M #T2   V$@  ,!(  "L1   H$0  )1   ",0   B#@0 (0T' "$,"P @"PX
M'PL2 !T+%P <#!P &PPB !H,*0 9##$ & PY !8-0P 5#4\ $PU< !(-:P 0
M#7X #PV2  X-IP -#+X #0S@  T,]0 -#/\ ;1   %P1  !.$P  0Q0  #H4
M   R%   +10  "@3   E$P  (A(  " 1   >$0, '! % !P/"  ;#PP &@X0
M !D/%  7#QH %@\A !40*  4$#  $A Y !$01  0$%  #A!=  T0:P ,$'P
M"Q"0  D0I0 ($+P !Q#?  <0]  '#_\ :1$  %@4  !+%0  0!8  #<6   P
M%@  *A8  "85   B%0  'Q0  !T3   :$P( &1($ !<2!@ 6$@H %1(. !02
M$@ 2$A@ $1,> !$3)0 0$RX #A,W  T40  ,%$L "Q18  D49P '%'@ !A2-
M  04HP #$[L  A/=  $2]  "$O\ 91,  %46  !(%P  /1@  #08   M&
M*!@  ",7   @%P  '18  !H5   8%0( %A4$ !05!0 2%@@ $18- ! 7$  .
M%Q4 #A<;  T7(@ ,%RD "Q@R  D8/  '&$< !1A4  088P "&'4  1B+   7
MH0  %[D  !?=   6]0  %O\ 818  %(8  !%&@  .QH  #(:   K&@  )1H
M "$9   >&   &Q@  !@7   6%P( %!<# !(8!0 0&0< #AL+  P;#P +&Q,
M"AL8  @<'P ''"8 !1PO  0<.  "'$0  !U1   =8   '7(  !R(   <H
M&[D  !O>   :]@  &O\ 7A@  $\:  !"'   .!P  "\=   I'   (QP  !\;
M   <&@  &1D  !<9 0 4&0( $AH# ! ;!  .'0< #!X+  D?#@ &(!$ !2 6
M  ,@'  !(2,  "$K   A-0  (4   "%.   A70  (6\  "&&   @G@  (+@
M !_>   >^   'O\ 6AL  $L=   _'@  -1\  "T?   G'@  (AT  !X=   ;
M'   &!L  !4;   2'   $!T"  X?!  ,(08 "2(*  4C#0 ")!   "43   E
M&0  )B   "8H   F,@  )CT  "9*   F6@  )FP  ":#   EG   );<  "3?
M   C^0  (_\ 51X  $<@   \(0  ,B$  "LA   E(   (!\  !T>   :'0
M%AX  !,>   0(   #B$   PC @ ()04 !2<)   H"P  *@X  "L1   L%@
M+!T  "PE   L+@  +#H  "Q'   L5@  +&D  "R    KF@  *K4  "G?   I
M^P  */\ 42(  $0C   X)   +R0  "@C   C(@  'R$  !P@   7(   $R$
M ! C   .)   "R8   @H   $*@0  "P'   N"0  , P  #$/   S$P  ,QD
M #,A   S*@  ,S4  #-#   S4@  ,V4  #)[   REP  ,;,  ##>   O^P
M+O\ 3"4  #\F   U)P  +28  "<E   B)   'B,  !DC   4)   $28   XH
M   +*@  !RP   ,O    ,0(  #,$   U!P  -PH  #D-   Z$   .Q4  #L=
M   [)@  .S$  #L^   [3@  .V   #IW   YD@  .+   #?;   V_   -?\
M1RD  #LJ   R*@  *RD  "4G   A)@  &R<  !4H   1*@  #BP   HO   &
M,0   30    V    .    #L!   ]!   /P<  $$*  !##@  11$  $48  !%
M(0  12P  $0Y  !$2   1%L  $-Q  !"C0  0:L  $#2   _^@  /O\ 0BT
M #@N   O+0  *2L  "0J   =*@  %RP  !$N   -,0  "30   0W    .@
M #P    _    00   $0   !&    2 ,  $H'  !,"P  3@X  % 3  !0'
M4"<  $\T  !/0P  3U4  $YJ  !-A@  3*0  $K*  !)^   2/\ /C(  #4Q
M   N+P  *2X  " N   9,0  $C,   XW   ).@   CT   !     1    $<
M  !)    3    $\   !1    4P   %4!  !8!@  6@L  %T.  !?%0  7B
M %XL  !=/   7$X  %MC  !:?@  6)T  %?   !5\@  5/\ .C8  #,T   M
M,@  )#,  !LV   3.0  #CT   A!    10   $D   !,    4    %,   !6
M    60   %L   !=    8    &(   !E    : 4  &L+  !O$   ;Q@  &XE
M  !M-   ;48  &M;  !J=0  :)0  &:V  !DZ0  8O\ .#D  #(W   H.0
M'CL  !4_   .1   !TD   !-    4@   %8   !:    7@   &(   !E
M:    &L   !M    <    ',   !V    >0   'T$  "!"P  A1$  (0=  ""
M+   @#X  'Y4  !^:P  >XH  'JJ  !WU@  =?T .#T  "P^   B00  %T8
M  ]+   '40   %<   !<    8@   &8   !K    ;P   '0   !X    >P
M 'X   "     @P   (8   "*    C0   )$   "6 P  FPP  )T3  ";(0
MFC,  )=)  "48@  DW\  )"@  ".Q0  C/, ,40  "5(   :30  $%,   A:
M    80   &@   !N    =    'D   !_    A    (D   "-    D0   ),
M  "6    F0   )T   "@    I    *@   "L    L@,  +<-  "W%P  M2@
M +(^  "P5@  K',  *J4  "IM   I>4 *D\  !Y4   26P  "F(   !J
M<P   'L   ""    B0   (X   "4    F@   )\   "D    I@   *D   "M
M    L    +,   "W    NP   ,    #%    RP   -$$  #5#@  TQT  - R
M  #-2P  RF8  ,:'  #"J0  P<L (EL  !9B   ,:P   70   !]    AP
M )    "7    G@   *0   "K    L0   +8   "Z    O    ,    #$
MR    ,L   #/    U    -H   #@    Y@   .L   #Q!@  \!,  .XG  #L
M/P  ZEL  .=Z  #DFP  X+L _P   /L   #V    \P   /0 !0#V  P ^@ 1
M /\ &0#_ "( _P L /\ -0#_ #T _P!% /P 3 #Z %( ]P!8 /4 7@#S &0
M\0!J .X <@#L 'H Z0"% .4 D0#A *  W0"R -@ S@#2 /8 P0#_ *T _P">
M /\ E@#_ )  _P", /\ ^@   /(   #L    Z0   .D   #L  4 \@ , /@
M$@#W !L ]0 E /  +@#K #< Y@ ^ .( 10#= $L V !0 -, 5@#0 %P S0!B
M ,H :@#( '( Q0!\ ,( B "^ )8 N@"H +< OP"T .@ K@#_ )T _P"0 /\
MB #_ (, _P"  /\ \    .4   #>    V@   -L   #<    V  ' -$ #@#1
M !4 T@ > ,L )P#% "\ P  W +T /0"Z $0 MP!) +4 3P"R %4 L !; *X
M80"L &D J0!S *< ?P"D (T H0"> )X L@"; -4 F0#\ (P _P"" /\ >P#_
M '8 _P!T /\ X@   -,   #*    QP   +P   "V    L  ! *\ "P"L !$
MK0 8 *T ( "H "@ I  O *  -@"= #P FP!" )D 1P"7 $T E0!3 ), 60"1
M &$ CP!J (P =0"* (, B "4 (8 IP"# ,( @@#P 'P _P!S /\ ;0#_ &H
M_P!H /\ SP   ,$   "Y    K0   *    "8    E    )$ !@"0  T D  2
M (\ &0". "$ BP H (@ +P"& #4 A  Z (( 0 "  $4 ?@!+ 'P 4@!Z %D
M> !B '8 ; !T 'D <@") '$ G0!O +0 ;0#? &P _P!E /\ 8 #_ %X _P!<
M /\ O@   +$   "@    D@   (D   ""    ?    'H  0!X  D =P . '@
M% !W !H =  A '( )P!P "T ;@ S &P . !K #X :0!$ &@ 2@!F %$ 9 !:
M &, 9 !A '  7P!_ %X DP!= *D 7 #( %L ]P!7 /\ 5 #_ %( _P!1 /\
ML    )\   "-    ?P   '0   !N    :@   &8   !E  0 8P + &, $ !C
M !4 8P ; &$ (0!? "< 70 L %P ,@!: #< 60 ] %< 0P!6 $L 50!3 %,
M7 !2 &@ 4 !W $\ B0!. )\ 30"Z $P Z0!+ /\ 20#_ $< _P!' /\ H@
M (T   !\    ;@   &4   !>    60   %<   !5  $ 5  ' %, #0!3 !$
M5  6 %( &P!1 "$ 3P F $X *P!, #$ 2P W $H /0!) $0 1P!, $8 5@!$
M &$ 0P!P $( @0!! )< 0 "O #\ UP _ /\ /@#_ #T _P ^ /\ E    '\
M  !O    8P   %D   !1    30   $H   !(    1P $ $< "@!&  X 1@ 1
M $< %@!% !P 1  A $( )@!! "L 0  Q #X -P ] #X / !' #H 4  Y %L
M. !I #< >@ V (\ -0"G #4 Q@ T /4 - #_ #0 _P U /\ B    '0   !E
M    6    $\   !(    0P   #\    ]    /  " #P !P [  P .P / #L
M$@ Z !< .0 < #< (0 V "8 -0 L #0 ,@ S #D ,0!! #  2P O %8 +@!C
M "T <P L (@ + "@ "L NP K .H *P#_ "L _P L /\ ?P   &P   != 0
M40(  $@#  !  P  .P(  #<    T    ,P   #( !0 R  D ,@ - #$ $  Q
M !, ,  8 "\ '0 M "( +  H "L +@ J #4 *0 ] "@ 1@ G %$ )@!> "4
M;@ D (( (P"9 ", LP B -X (@#_ ", _P D /\ =P   &4$  !6!@  2P<
M $((   Z"   -0<  # &   M!0  + ,  "L  P J  < *0 + "D #@ I !$
M*  5 "< &0 F !X )0 D "0 *@ C #$ (@ Y "$ 0P @ $X 'P!: !X :0 =
M 'P ' "3 !L K  ; ,T &P#V !L _P < /\ < 4  %\(  !1"@  1@L  #T+
M   U"P  , L  "L*   H"0  )0@  "0' @ C! 8 (P() "(!#  B  \ (0 2
M "  %@ ? !L '@ @ !T )@ < "X &P V !H /P 9 $H & !7 !< 9@ 6 '@
M%0"/ !4 I@ 4 ,, % #N !0 _P 5 /\ :P@  %L+  !-#   0@T  #D-   Q
M#0  + T  "<-   C#   (0P  !\+ 0 >"@4 '0@( !T&"P <!0T ' 00 !L$
M%  9!!@ &00> !@$(P 7!"L %@0S !4$/  4!$< $P-4 !(#8P 1 W4 $ **
M ! !H@ / +P #P#E  \ _@ 0 /\ 9PL  %<-  !)#@  /@\  #4/   N#P
M* \  "0.   @#@  '0X  !L- 0 9#00 & P' !@+"0 7"0P %PD. !8)$@ 5
M"18 % D; !,)(0 2"2@ $@DP !$).@ 0"44 #PE2  X)80 -"7, # B(  L(
MGP *![< "@;;  H%]@ *!/\ 8PT  %,.  !&$   .Q$  #(1   K$0  )1
M "$0   =$   &@\  !@/ 0 6#@0 %0X' !0-"0 3#0L $PP- !(,$  1#!0
M$ P9 ! ,'P /#"< #@TO  T-.0 ,#44 "PU1  D-8  (#7$ !@V&  4-G0 $
M#+0  PS2  (,\0 ""_\ 7PX  % 0  !#$0  .!(  "\2   H$@  (Q(  !X1
M   ;$0  &!$  !40 @ 4$ 4 $A ' !$/"0 0#PH $ X,  X.#@ .#Q( #0\7
M  P0'0 ,$"0 "A L  D0-@ ($$$ !A!.  4070 #$&\  1"$   0G   #[0
M  [4   .\P  #O\ 7!   $T2  ! $P  -A0  "T4   F%   (1,  !P3   9
M$@  %A(  !01 P 2$08 $1$( ! 0"@ .$ L #1$+  P1#0 +$A$ "A(5  D2
M&@ ($B$ !A,I  43,P #$SX  A-+   36@  $VP  !."   2FP  $K0  !'7
M   1]0  $?\ 6!(  $D4   ]%0  ,Q8  "L6   D%0  'Q4  !H4   7%
M%!,! !,2!  1$@< $!()  X2"0 -$@D "Q,*  D4#0 '%0\ !A83  06&  #
M%A\  A8G   7,   %SL  !=(   76   %VH  !:    6F0  %;0  !79   4
M]P  $_\ 510  $86   Z%P  ,!@  "@8   B%P  '18  !D6   6%0  $Q0#
M !(3!@ 0$P< #Q,'  T4!P +%0@ "18)  88#  #&@X  1H1   :%@  &QP
M !LD   ;+0  &S@  !M&   <50  &V<  !M]   ;EP  &K,  !G;   8^0
M%_\ 418  $,8   W&0  +AH  "8:   @&0  &Q@  !@7   5%@$ $Q4% !$5
M!  /%00 #18$  L7!0 )&08 !AH(  (<"@  '@T  " 0   @$P  (!D  " A
M   A*@  (34  "%"   A4@  (&0  "!Z   ?E0  '[$  ![;   =^@  '/\
M31D  #\;   T'   *QP  "0<   >&P  &AH  !<8   4%P( $A<" ! 8 0 -
M&0$ "QH"  @< P %'00  A\&   A"   (PL  "4.   F$0  )A8  "8>   G
M)P  )S(  "<_   F3@  )F   "9W   ED@  )*\  "/:   B^P  (?\ 2!T
M #P>   Q'P  *!X  "(>   ='   &1L  !8:   2&@  $!L   T<   +'0
M"!\   0A   !(P(  "4$   G!@  *0D  "P,   N#P  +A,  "X:   N(P
M+BX  "X[   N2@  +5P  "UR   LC@  *ZP  "K4   I^P  */\ 1"   #@A
M   N(0  )B$  " @   <'@  &!T  !0=   0'@  #A\   LA   '(P   R4
M   G    *0   "P!   N P  , 8  #,*   U#0  -A$  #87   V'P  -BD
M #8V   V10  -5<  #5M   TB0  ,J@  #'/   P^@  +_\ /R0  #0D   K
M)   )",  !\A   ;(   %B   !$A   .(P  "B4   8H   "*@   "T    O
M    ,@   #0    W    .0,  #L&   ^"@  0 X  $$2  !!&@  0"4  $ Q
M  ! 0   /U(  #YG   ]@@  /*(  #K'   Y^   ./\ .B@  # H   I)P
M(R4  !\C   8)   $B4   XH   **@  !2T    P    ,P   #8    X
M.P   #X   !     0@   $4"  !'!@  2@H  $T.  !-%0  3!\  $PK  !+
M.@  2DP  $EA  !(?   1YL  $6_  !#\P  0O\ -BP  "TK   G*0  (R<
M !LH   4*@  #BT   HP   $,P   #<    Z    /0   $    !#    1@
M $@   !+    30   %    !3 0  5@8  %D+  !;$   6QD  %HE  !9-
M6$8  %=:  !5=   5),  %*U  !0Z@  3_\ ,S   "PN   G+   'BT  !8O
M   0,@  "C8   ,Z    /P   $(   !&    20   $P   !/    4@   %4
M  !8    6@   %T   !@    8P   &<&  !K#   ;!(  &L>  !K+   :3T
M &=2  !F:@  9(D  &&K  !?W   7?\ ,3,  "PQ   B,@  &34  !$Y   *
M/0   D(   !'    3    %    !4    6    %L   !?    8@   &4   !H
M    :P   &X   !Q    =0   'D   !]!@  @@T  ((6  " )   ?C4  'Q)
M  ![80  >'\  ':?  !SQ@  </< ,38  "8X   <.P  $D    M%   "2P
M %$   !6    6P   &    !E    :0   &X   !R    =@   'D   !\
M?@   ((   "%    B0   (X   "3    F 8  )P.  ";&@  F"L  )9   "2
M60  D7,  (V5  "+M0  B.@ *SX  "!!   51P  #4T   )4    6P   &$
M  !H    ;@   ',   !Y    ?@   (,   "(    C    (\   "2    E0
M )D   "=    H0   *4   "J    L    +<'  "X$0  M2$  +(U  "O30
MJFD  *B(  "FJ   HM$ (T@  !A.   .5   !%P   !D    ;0   '4   !\
M    @P   (D   "/    E0   )L   "@    HP   *8   "I    K0   +$
M  "U    N0   +X   #$    R@   -(   #:"@  UA8  -(I  #.00  REP
M ,5\  #"G0  P;T '%4  !%<   '90   &X   !W    ?P   (@   "0
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M_____________________________________________________P
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M=#$      P0A   !                     0                    $
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M<;M[LW&[>[-QNWNS<;M[L_^K) 7_JR\-_[HX$O/)01ODVDDHV.A,0,[S45?
M[UEKKN1A>J#<9X:4U&N0B\]NEX3,<)Q]R7.@>,9UHW/$>*9NPGRI;L)\J6["
M?*ENPGRI;L)\J6["?*ENPGRI;L)\J6["?*ENPGRI;L)\J6["?*ENPGRI;L)\
MJ6["?*ENPGRI;L)\J?^M) 7_L"\+^\ X#^K001?:XD8HS.Y,0</Y4%6U\UAF
MI>EA=)?A9WZ-VVN&A==OC'_4<I%ZT764=<]XEW'->YILS'Z<;,Q^G&S,?IQL
MS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,
M?IQLS'Z<;,Q^G/^O(P3_MBT)\<@V#-W</1/-ZD8JP?9+0+;_3U&J]UA@F^]A
M:X_H:'2%Y&U[?^!Q@'G>=(-UW'B&<MI[B6[8?HMKUH*-:]:"C6O6@HUKUH*-
M:]:"C6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HUK
MUH*-:]:"C?^Q(P3ZORP&X]0O!\[F.Q;!\T4KM/])/:C_3DR>_5=8D?9A88;Q
M:6E_[6]N>>IT<G7H=W5QYWIW;N5]>6OD@'MIXX1\:>.$?&GCA'QIXX1\:>.$
M?&GCA'QIXX1\:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\
M:>.$?/^U(@/KRR("T.,G!\+Q.AFT_D(JIO]&.9O_3462_U9/AOYB5G[Z:EQW
M]W!@<_5U8V_S>&5M\GQG:O%_:&CP@FIF[X5K9N^%:V;OA6MF[X5K9N^%:V;O
MA6MF[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%
M:_;"&P'4WQ$!PN\F"[7\.AJG_SXGF?]$,XW_2SV%_U5%?/]A2W7_:D]P_W!2
M;/]U5&K^>59H_7Q79OQ_6&3\@EIC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC
M^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6]3/
M"@#$[1("M?LF#:C_-AF9_SLCC/]!+(#_2C1X_U,Z<?]?/VS_:4-H_V]%9?]T
M1V/_=TAB_WM)8?]^2E__@4I>_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+
M7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$2U[_A$M>_X1+7O^$2_^?(@7_
MG2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3
MA+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,
M_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"
MC8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX
M%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BY
MOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H
M01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,
MO[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_
ML4DK_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#
MD<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK
M_[93//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W
M?Y?+M'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93
M//^X74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+
MM'V@SZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X
M74_[MF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@
MSZYYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[
MMF9C[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C
M[K1O=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N
M>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O
M=^*L=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31
MKGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N
M>:31KGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L
M=8G8I'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFD
MT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31
MKGFDT?^?(@7_G2T,_YXX%?^H01[_L4DK_[93//^X74_[MF9C[K1O=^*L=8G8
MI'N9SIM_ILB3A+'"C8BYOHB,O[J#D<6W?Y?+M'V@SZYYI-&N>:31KGFDT:YY
MI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFDT:YYI-&N>:31KGFD
MT?^?(@7_G2T,_Y\X%?^J0![_LTDK_[E2//^[7$_ZNF5D[;AM>.&P<XO5J'F<
MS)]]JL67@;6_D86^NHR)Q;:'C\RR@Y;2KX&@UJ=^HM.G?J+3IWZBTZ=^HM.G
M?J+3IWZBTZ=^HM.G?J+3IWZBTZ=^HM.G?J+3IWZBTZ=^HM.G?J+3IWZBT_^?
M(@7_GBT,_Z W%/^K0![_M$DK_[M2//^]6U#ZOF1D[+QL>>"U<HW3K7>>RJ1Z
MK<*<?KF\EH+#MY"'RK*+C-*NAY78IH.=VJ&"H=6A@J'5H8*AU:&"H=6A@J'5
MH8*AU:&"H=6A@J'5H8*AU:&"H=6A@J'5H8*AU:&"H=6A@J'5H8*AU?^@(@7_
MGBT,_Z$W%/^L0!W_MD@K_[U1//_ 6E#ZP6-E[,%J>MZY<(_2L76AR*AXL,"A
M>[RYFW_'M):$S["4C=6KD9?:H(F<W)J(H->:B*#7FHB@UYJ(H->:B*#7FHB@
MUYJ(H->:B*#7FHB@UYJ(H->:B*#7FHB@UYJ(H->:B*#7FHB@U_^@(@7_GBT,
M_Z(W%/^M0!W_MT@J_[]1//_"6E#YQ&)EZ\5I>]Z^;I#1MG.CQJYVL[ZG><"X
MHW_)M*&&SZR<C=6CEI3:FI&<W)6.G]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.
MG]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V/^@(@7_GRT,_Z,W
M%/^N0!W_N$@J_\%0//[%65#WR&!FZ\IG?-W#;9'/O'&EQ;1TM;VP><"VK'_(
MKJ>%SZ6ABM6<G)':E9F<W(^4G]B/E)_8CY2?V(^4G]B/E)_8CY2?V(^4G]B/
ME)_8CY2?V(^4G]B/E)_8CY2?V(^4G]B/E)_8CY2?V/^A(@7_GRT,_Z0W%/^P
M/QS_ND@J_\-0._O(6%#URU]FZ<]F?-S):Y+.PV^FP;IRM;:R=L"LK'O(I*A_
MSIRDA=24H(W8C9^9VXJ<G]B*G)_8BIR?V(J<G]B*G)_8BIR?V(J<G]B*G)_8
MBIR?V(J<G]B*G)_8BIR?V(J<G]B*G)_8BIR?V/^A(@7_H"T,_Z8V$_^Q/QS_
MNT@I_L9/._C+5U#RT%YFY]1D?=K/:9/(Q6VFNKMPM*VS<[^CK7;'FJAZS9*E
M?]**HH;7A*"1V82BG->$HIS7A**<UX2BG->$HIS7A**<UX2BG->$HIS7A**<
MUX2BG->$HIS7A**<UX2BG->$HIS7A**<U_^A(@7_H"T,_Z<V$_^S/QS_O4<I
M_,A.._7.5D_NU5UFY-IB?=/2:)+!QFRDL[QOL::U<KR<KW3$DZMWRHNG>\^#
MI('4?:*+UGNCE=5[HY75>Z.5U7NCE=5[HY75>Z.5U7NCE=5[HY75>Z.5U7NC
ME=5[HY75>Z.5U7NCE=5[HY75>Z.5U?^B(07_H"T,_Z@V$O^T/QO_OT<H^<M.
M.O+354_JW%MFX.!A?<S39Y&[R&NBK+YNKZ"W<+B5LG/ C:YVQ86J>LI^J'_.
M>*:'T76EC])UI8_2=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2=:6/TG6EC])U
MI8_2=:6/TG6EC])UI8_2=:6/TO^B(07_H2P+_ZHV$O^V/AO]PD<H]<U..>[9
M5$[FXUEEV.)@>\759H^TRFJ?I<%MJYFZ;[20M7*[B+%UP(&N>,5ZK'W)=*J$
MRW&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,
M<:F+S'&IB\QQJ8O,<:F+S/^C(07_HBP+_ZPU$?^Y/AKYQ4<G\-%-..G@4DSB
MZ5=DSN1?>KW79HRMS&J;G\1LIY.^;Z^*N7&U@[9TNGRS=[YVL7S"<:^"Q&ZN
MA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'
MQFZNA\9NKH?&;JZ'QO^D(07_HRP+_Z\U$/^\/ACTR48EZMA--N+G3TS<[U5C
MQN9?>+3:98FET&F6F,ALH8W#;ZB%OW&N?KMTLGBY=[9SMWNY;K6 O&NTA;YK
MM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNT
MA;YKM(6^:[2%OO^E(03_I"P+_[,U#_O!/A?MST8BX=]+--CK3TS/\U1BO.A>
M=*O>9(2=U&F0D<YMF8?);Z" Q7*E>L)TJ73 >*QPOGNO:[R LFB[A+-HNX2S
M:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-H
MNX2S:+N$L_^F(03_J"L*_[@T#?/'/13DV$4>UN9)-<OQ3DS$]U-?L>Q=<*'B
M9'V5VVF'BM5NCX+0<95[S72:=LMWG7')>:!MQWVB:<6!I6;$A:9FQ(6F9L2%
MIF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F
M9L2%IO^H( 3_KBH(_+\S"^G//!#7X4(>RNU)-;_X34JW^U);IO%=:9CI972,
MXFI]@]UOA'S:<XEWUW>,<]5ZCV_3?9%LT8"4:-"$EF7/AY=ESX>79<^'EV7/
MAY=ESX>79<^'EV7/AY=ESX>79<^'EV7/AY=ESX>79<^'EV7/AY=ESX>79<^'
ME_^J( /_M2D&\,@Q!]K=,PS+ZD(AOO9(-;+_3$:I_U%5F_==8([P96J%ZVQQ
M?>=Q=G?D=GISXGE];^%\?VS?@(%IWH.#9]V'A67<B89EW(F&9=R)AF7<B89E
MW(F&9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&9=R)AO^M
M'P/YOR4#W]8B LOH,@^^]$$BL/]%,Z3_2D&<_U%-C_Y=5H7Y9EY]]&YD=O)S
M:'+O>&MN[GQM;.U_;VKL@G!GZH5R9>J)<V/IC'1CZ8QT8^F,=&/IC'1CZ8QT
M8^F,=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=/^V' +H
MS10!S.8=!+[S,1*Q_SXBH_]"+Y;_2#J-_U!$A/]<2WO_9U%T_FY6;_QS66S[
M>%MI^7Q=9_A_7F;X@U]D]X9@8O:)86'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,
M8F'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8O/$#P#.V@L
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M_YLT$?^F/1G_KT4E_[=.-/^Z5T;_NV!9]+EI;>>V<8'<K':3T*1[H\B:?['
MDX2\NXR)Q;>(D,NTAIG.LH:DT:1\I-&??:G*GGVJR)Y]JLB>?:K(GGVJR)Y]
MJLB>?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJR/^;'P3_F2H*_YPT
M$?^G/!G_L44D_[E--/^\5T;^OE]9]+UG;N>Z;X+:L725SZAYIL6??;2^EX'
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MR9:/H<N0BZC,C(FLQ8R)L,",B;# C(FPP(R)L,",B;# C(FPP(R)L,",B;#
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MSVS#IL5GPZ; :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ'
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MC)J3OH>8F\"$EZ7"@):OPG^2L[R D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6
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M>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>/^B%0'_MQ4
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M>"8&_WHO"O^%,P[_C3L4_Y)$'/^63B?_E5HR_Y)E/O^.<4K_BGU5_H6(7OF
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M_Z% &O^G2"7_JE$R^:E;0?.F9%'LHFYAY9IV<-R1?G_2B8:+RX*-D\5]E9G
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MALZ7AX;.E_^"&0/_@",%_Y$E!O^>+ G_J#0-_[$\%?JX1!_POTLMY\51/=S
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M7_]P'@/_;"D&_VDS"?]R-PW_>3X2_WU'&?^ 42'_?E\I_WQM,O]Y>SG_=HA
M_W.31?]PG4K_;J9._VNM4?]IM%/_:+M5_V;#5_]CQUG[8<Q;]U_37/->W5WP
M7.->ZUOI7^=9[V#E6?%?Y5GQ7^59\5_E6?%?Y5GQ7^59\5_E6?%?Y5GQ7_]P
M'@/_;"D&_VDS"?]R-PW_>3X2_WU'&?^ 42'_?E\I_WQM,O]Y>SG_=HA _W.3
M1?]PG4K_;J9._VNM4?]IM%/_:+M5_V;#5_]CQUG[8<Q;]U_37/->W5WP7.->
MZUOI7^=9[V#E6?%?Y5GQ7^59\5_E6?%?Y5GQ7^59\5_E6?%?Y5GQ7_]P'@/_
M;"@&_VLQ"?]U-@W_>SP2_W]&&?^#4"'_@5XJ_WYK,_][>#O_>(9"_W622/]R
MFTW_<*11_VVL5/]KLE?_:;E:_V?!7/QEQU[X8LQ?]6#38?!>W6+L7.1CZ%OI
M9.):[V3@6O!BX%KP8N!:\&+@6O!BX%KP8N!:\&+@6O!BX%KP8O]Q'0/_;2@&
M_VXP"?]X- S_?SL2_X-$&?^'3B'_AELK_X-H-/]_=3W_?()%_WF.3/]VF5+_
M<J%6_V^I6OYML%[\:K=A^VB^8_EFQF7T8\QG\&'3:>M?WFOF7>5LX%OI;=E<
M[FC67.]GUESO9]9<[V?67.]GUESO9]9<[V?67.]GUESO9_]R'0/_;B@&_W$N
M"?][,@S_@SH1_X=#&/^*3"'_BEDK_X=E-?^#<C__?WY(_WR+4/]YEE;_=9]<
M_7*F8/INK63X;+1H]FF\:_1GQ6WP9,QPZV'3<N5?WW/>7.5TUESH<<]>[6S-
M7NYKS5[N:\U>[FO-7NYKS5[N:\U>[FO-7NYKS5[N:_]S' /_;R<&_W0M"/]^
M,0S_ACD1_XM"&/^.2R'_CE8K_XMC-O^';T'_@WM+_W^'4_Y\DEO\>)QA^72D
M9_9PJVOS;;)O\6JZ<^]HPW;K9<QXYF+5>MY?WWS37>-[S5_F=L=@ZG#&8.QN
MQF#L;L9@[&[&8.QNQF#L;L9@[&[&8.QNQF#L;O]T' /_<"<&_W8K"/^!+PO_
MB3@0_XY &/^222'_DU0L_Y!@-_^,;$/_AW=-^X.#5_A_CF#V>I=G\W:@;O!R
MJ'/M;J]XZVNX?.AHPG_F9LV"WV+8A-%?W(7*8.!_Q6'C>K]CZ'2^8^EROF/I
M<KYCZ7*^8^EROF/I<KYCZ7*^8^EROF/I<O]T' /_<"8&_WDJ"/^%+@O_C3<0
M_Y(_%_^62"#_EU(L_Y5>./Z1:43ZC'10]8=_6_*"B67N?9-NZG>;=>=RHWSD
M;JN!X6JSAMYGO8K:9<J-TF+4CLABV(K"8]R$O&7@?K=FY7BV9N9VMF;F=K9F
MYG:V9N9VMF;F=K9FYG:V9N9VMF;F=O]U&P/_<28&_WPH!_^(+0K_D#8/_Y8^
M%O^:1R#_G% K_YI;./F79D7TDG!2[XQ[7^J%A6KE?HUTX'B5?=MRG874;:2+
MT&JMCLUHMY#+:,.1R&?1DK]EU(^Y9]F)M&C=@K!IXGRN:N1YKFKD>:YJY'FN
M:N1YKFKD>:YJY'FN:N1YKFKD>?]V&P/_<B8%_W\G!_^*+ K_DS4._YD]%O^>
M1A__H4XK^Z!9./6<8T;OF&U4Z)!W8N*(?V_:@(=[TGJ/@\UUEXG)<9^-Q6ZH
MD<)LL9._:[R5O6O+E;9IT)2Q:]6-K&S;AJAMX'^G;>)\IVWB?*=MXGRG;>)\
MIVWB?*=MXGRG;>)\IVWB?/]V&P/_<R4%_X$F!_^-+ G_EC0._YT\%?^A1![^
MI4PJ]Z57./"B84?IG&I6X91R9=B,>W//A8-\R7^+A,-ZDXJ_=IN/NG.CD[=P
MK):T;[>7L6_$F*QMS9BI;].0I7#8B:%QWH*@<>!_H''@?Z!QX'^@<>!_H''@
M?Z!QX'^@<>!_H''@?_]W&P/_="4%_X,E!O^0*PG_F3,-_Z [%/^E0QW[J4LI
M\ZI4..RH7D?CH6=7VIEO9\^1>'/'BH!]P82(A;M_CXNU>I>0L7>?E*UTJ)>J
M<[*9IW*_FJ1RRYJA<]"3GG36C)MUW(2:==Z!FG7>@9IUWH&:==Z!FG7>@9IU
MWH&:==Z!FG7>@?]X&@/_=B0%_X8C!O^2*@C_FS(,_Z,Z$_^H0ASXK4HH\*]2
M-^>L7$?>I618T9UM9LB5=7/ CGQ]N8F$A;.#C(RM?Y.1J7N;E:5YI)FA=ZZ;
MGG:ZG)UWRIR9=\^6EWC4CI5XVX:4>-V#E'C=@Y1XW8.4>-V#E'C=@Y1XW8.4
M>-V#E'C=@_]X&@/_>",%_X@C!O^4*@C_GC$+_Z8Z$OZK0AOUL$DG[+50-N.P
M6D;8J6-7S*%K9L*:<G*ZDWI\LXV!A:R(B8RFA)"1H8"8EIU]H9J9>ZJ<EGNV
MG91[QIZ2>\V8D7S3D(]\V8B/?-R%CWS<A8]\W(6/?-R%CWS<A8]\W(6/?-R%
MCWS<A?]Y&@/_>B(%_XHB!?^6*0?_H#$+_Z@Y$?NO01KRM$@FZ;E/--^T6472
MK6%6QZ5I9;V><'*TEW=\K9%^A::,AHR@B(V1FH65EI:"GIJ2@*>=CW^SGHV
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M_X\>-/^7'C+_H!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'Z;
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M(C;_K2,U_[@C-?^Y(S7_N2,U_[DC-?^Y(S7_N2,U_[DC-?^Y(ZVV  "?Q
MDM(  (3A  !]_PT!<O\3 FC_&P1?_R,&6/\K"5'_,PM,_SH-1_]!#T/_2!%
M_TX2/?]4$SO_6A0Y_U\4-_]E%37_:Q8S_W(6,?]Z%R__@A<N_XL8+/^3&"O_
MG!DJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&:&_  "2S   A-P
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M0T7TWT-$]/!#1/+Z0D3R^D)$\OI"1/+Z0D3R^D)$\OI"1/+Z0M&B  # K@
MLK@! *?$ @"<T@0 DNT, (S[' ."^R@'>?LQ#'#\.1)I_$$78OQ)'%S\4"!7
M_%DC5/UB)E']:BA/_7,J3/Y[+$K^@RY(_HTO1O^8,43_HC)#_ZXS0?^[-$#_
MRS0__^,T/__O-3__[S4__^\U/__O-3__[S4__^\U/__O-<2J  "SLP  I[\
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M%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%)R^  "-RP  ?MH  '#F  !G_P
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M7DS ZEQ.O_E93[S^55"Z_E50NOY54+K^55"Z_E50NOY54+K^5?^% @#=F
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M*SK\]RLZ_/<K.OSW*SK\]RLZ_/<K.OSW*[VH  "NL   H;P  )7(  ")U
M?N@% '?_$@%O_QP"9_\F!6#_+PA9_S<+5/\_#D__1Q%+_TX31_]6%43_719"
M_V080/]L&3W_=1H[_WX;.?^)'#?_E!TV_Z >-?^L'S/_N1\S_\@?,O_B(#+_
MYR R_^<@,O_G(#+_YR R_^<@,O_G(+"M  "BMP  E<0  (?0  ![W0  <OT)
M &K_$0%A_QD"6O\B U3_*@5._S('2?\Z"47_00M!_T@,/O].#CO_50\X_UL0
M-O]B$33_:1$R_W(2+_][$RW_AA0K_Y(5*O^>%2G_J18H_[,6)__"%B?_QQ8G
M_\<6)__'%B?_QQ8G_\<6)__'%J2T  "6P   A\P  'K:  !MZP  9/\% %S_
M#@%4_Q0!3?\< DC_) 1"_RP%/O\S!CK_.0<V_T (,_]%"##_2PDN_U$**_]7
M"BG_70LG_V0+)/]L#"+_=@T@_X -'O^,#AW_EPX<_Z$.&_^L#QO_K@\;_ZX/
M&_^N#QO_K@\;_ZX/&_^N#Y>\  "(R0  >=8  &OC  !?]@  5O\  $[_"@!'
M_Q !0?\6 CS_'0(W_R0#,O\J R__, 0K_S8%)_\[!27_0 4B_T4&(/]*!A[_
M4 8;_U8'&?]<!Q?_9 @5_VT($_]W"!'_@0D0_XL)$/^5"0__F D/_Y@)#_^8
M"0__F D/_Y@)#_^8"?]))P+_1#$$_TLQ!/]0- ;_4CH(_U)#"_]13@__3UP3
M_TUK%O],>1G_2X<;_TF3'?](G1__2*8@_T>N(?]'M2+_1KTC_T;&(_]&T"3_
M1N D_T;J)?]&\R7_1OHE_T;_)?]&_R7_1O\E_T;_)/U&_R/]1O\C_4;_(_U&
M_R/]1O\C_4;_(_]))P+_1B\#_TTO!/]2,@;_53D(_U5""_]430__4ED3_U!H
M%_]/=QK_3H0=_TR1'_]+FR'_2J0B_TJL(_])LR3_2;LE_TC$)O](S2;_2-TG
M_TCH)_](\2C_2/DH_TC_*/](_RC^2/\H^TC_)_E(_R;Y2/\F^4C_)OE(_R;Y
M2/\F^4C_)O]*)P+_2"T#_U M!/]5, ;_6#8(_UE "_]82P__5583_U1F&/]2
M=!O_48$>_T^.(?].F"/_3:$E_TVI)O],L2?_2[@H_TO!*?]+RBK_2MDJ_TKF
M*_]*\"O_2O@L_TK_+/U*_RSZ2O\K]TK_*?5*_RCU2O\H]4K_*/5*_RCU2O\H
M]4K_*/]+)@+_2RL#_U(K!/]8+@7_6S0(_UT^"_]=20__6E04_UEB&/]7<1W_
M57X@_U.*(_]2E2;_49XH_U"F*O]/KBO_3K4L_TZ]+?]-QR[_3=,O_TSC,/],
M[3#\3/8Q^DS^,?=,_S'U3?\O\DW_+?!-_ROP3?\K\$W_*_!-_ROP3?\K\$W_
M*_]+)@+_3BD#_U8I!/]<*P7_8#$'_V(["_]B1@__8%$4_UY?&?]<;1[_6GHC
M_UB&)O]6D2G_59HL_U.B+O]2JC#_4;$Q_U&Y,_]0PS3^3\XU^T_?-OA.ZS?U
M3O4X\D[]./!/_S7N4/\SZU'_,>E1_R_I4?\OZ5'_+^E1_R_I4?\OZ5'_+_],
M)0+_42<#_UHF _]@* 7_92\'_V@Y"O]H0P__9TX5_V5:&O]B:"#_7W8E_UV!
M*O]:C"[^6)8Q_%>>-/M5IC;Y5*TX^%.U.O=2OCOU4<D]\U':/O!0Z#_L4/-
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MW6".2-E=ETS57)]/TEJG4<]9L%/-6+I4RUC&5<E7VE;%5^Q5PUOY3\)>_TK
M7_]&O6#_0KI@_T"Z8/] NF#_0+I@_T"Z8/] NF#_0/]2(0+_7AT"_VD: O]S
M'P/_>B8$_WXO!O^!. O[@4$2\X!+&NQ\5R/F=V,MX'%M.-IM=T#3:8!&SV6)
M2\MCD4_(8)E2Q5^A5<)=JE? 7+-9OER_6KQ;SENX6^5;MU[U5;=B_T^U8_]*
MLF3_1K!D_T.P9/]#L&3_0[!D_T.P9/]#L&3_0_]5'P+_81H"_VT8 O]W'0+_
M?B0#_X0L!?Z'-0GUB#X0[8=(&.6#5"+>?E\NU'AI.,YS<T#);GQ'Q&N$3,!H
MC%&]9914NF.<5[=BI5JT8*Y<LF"Y7K!?QUZM7]]?K&+Q6:QE_E.J9_].J&?_
M2J9G_T:F9_]&IF?_1J9G_T:F9_]&IF?_1O]7'0+_9!@"_W 6 O][' +_@R("
M_XDJ!/F,,@?OCCL-YXY$%MZ*42'4A%PMS'YF.,5X;T' ='=(NW" 3;=MB%*S
M:I!6L&B86:QFH%RJ9:E?IV2T8*5CPF&C8]5BHF7M7:)I^U>A:O]1GVO_3)YK
M_TF>:_])GFO_29YK_TF>:_])GFO_2?]9' +_9Q8!_W,5 ?]^&@'_AR "_XTG
M _22+P;JE#@+X91"$]:/3B#,B5DMQ8-C-[Y]:T"X>71(LW5\3JYRA%.J;XQ7
MIVV46Z-KG%Z@::5@GFBP8YMGO6299\YDF&GH89IM^5J9;O]4EV[_3Y9N_TN6
M;O]+EF[_2Y9N_TN6;O]+EF[_2_];&@+_:10!_W84 ?^!& '_BAT!_)$D O"7
M+ 3EFC0(W)H_$<^43!_&CE<LOHA@-[>":4"Q?G%(K'IY3J=W@%.C=(A8GW&0
M7)MOF%^8;:%BE6RL9)-LN6:1:\EFD&WD9)%Q]ER1<OY6D'+_49!R_TV0<O]-
MD'+_39!R_TV0<O]-D'+_3?]=& '_:Q,!_WD3 ?^$%@'_CAL!^)4A >N;* /A
MH# &U9X]$,J82A[!DE0KN8Q>-K&'9C^K@FY'IGYV3J%[?5.<>(58F':-7)1T
ME5^1<IYCCG&I98MPM6>)<,5GB'#@9HIT]%Z+=OQ8BG;_4HEV_TZ)=O].B7;_
M3HEV_TZ)=O].B7;_3O]?%P'_;A$!_WL2 ?^'% #_D1@!])D= >>@(P+=I2L$
MSZ$[#\6<2!V\EE,JM)!<-:R+9#^FAVQ'H(-S39N >E.6?8)7DGJ*7(YXDF"*
M=IQCAW6F9H1TLFB"=,)H@'3;:(-X\F"$>OM9A'G_5(1Y_T^$>?]/A'G_3X1Y
M_T^$>?]/A'G_3_]A%0'_<! !_WX1 /^*$@#_E!4 \)T9 ..E'@'7J"@#RZ4Y
M#L&?1ANWFE$IKY5:-*>08CZABVI&FX=Q3)6$>%*0@7]7C'^'7(A]D&"$>YEC
M@'JC9GUYL&A[>;]I>GG6:7Q\\&%^?OI:?GW^57Y]_U%^??]1?GW_47Y]_U%^
M??]1?GW_4?]C% '_<@\!_X$0 /^-$0#\F!( [*$3 -^J%@#1K"8#QZ@W#;RC
M1!JSGD\GJIE8,Z.48#V<D&A%EHQO3)")=E*+AGU7AH2%6X*"CE]^@)=C>G^A
M9G=^K6AU?KUI<W[2:7:![F)X@OI;>(+^5GF!_U%Y@?]1>8'_47F!_U%Y@?]1
M>8'_4?]E$P'_=0X _X,. /^0#@#UFPX Z*8. -FO#P#,KR0"PJLU#+BG0QFN
MHDXFIIU6,9Z97CN7E69$D)%M2XN.=%&&C'M6@8F#6WR'BU]XAI5B=(2?97&#
MJVAN@[II;8/.:6^&ZV-RA_E<<X;]5G.%_U)SA?]2<X7_4G.%_U)SA?]2<X7_
M4O]H$0'_> T _X8- /:3# #>H D UJD* -*R#0#'LB("O:\S"K.K01>JITPD
MH:)5,)F>73J2FF1"BY=K2864<E" DGE5>X^!6G:-B5YRC))B;HJ=96N)J6=H
MB;AH9XG+:&F+Z6-LC?E<;8S]5VV*_U)MBO]2;8K_4FV*_U)MBO]2;8K_4O]K
M$ '_>PL _XH* .*8!@#6HP@ T*P) ,NU"P#!MA\!N+0Q":ZP/Q:DK$HBG*A3
M+I2D6SB,H&) AIYI2(";<$YZF7=3=99^6'"4AUQLDY!@:)*;8V21IV5BD+9F
M8)')9F*2YV)EE/A<9Y+]5V>1_U)GD?]29Y'_4F>1_U)GD?]29Y'_4O]N#@#_
M?PD \8X% -F;!0#/I@< R:\' ,2Y" "[NAP!LK@O!ZBU/1.?L4@@EJY1*XZJ
M636&IV ^@*5G17JB;DMTH'51;YY\56J<A5EFFXY=8IJ98%Z9IF)<F;1C6IG'
M8UN:Y6!?F_=;8)K^5F&8_U)AF/]289C_4F&8_U)AF/]289C_4O]R"P#_@P4
MWY,! -&?! #)J@8 P;(% +N]! "TOQ@ J[XL!:*[.A&9N$4=D+5/*(>R5S*
MKUXZ>:UE0G.K;$ANJ7--::=Z462F@U9?I(U97*.87%BCI%Y6H[-?5:/&7U6D
MY%U8I/986J/_5%NA_U!;H?]06Z'_4%NA_U!;H?]06Z'_4/]W!P#PB0  UI@
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M0TC'_T)(Q_]"2,?_0DC'_T)(Q_]"2,?_0MZ-  #+G   O:<  +&P  "FN@
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M&"S_[Q@L_^\8+/_O&*NK  ">M0  D,$  (+,  !UV0  :>0  &'_"0!;_Q$
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M/_<>_S_^'?\__QW_/_\=_T#_'/Y _QO^0/\;_D#_&_Y _QO^0/\;_D#_&_]
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M8?\XL&'_.+!A_SBP8?\XL&'_./]2&P'_7A8!_V@4 ?]R&0'_>1\"_WXG _F
M, 7P@3D*YX!#$>!\4!K6=ULDSW)F+LEM;S7$:G@[P&>!0+QDB42Y8I%(MF"9
M2K-?H4VQ7:I/KERT4:Q<P5*J7-12J%WK4*A@^DFH8_]$J&3_0*9E_SRF9?\[
MIF7_.Z9E_SNF9?\[IF7_._]5&0'_810!_VP2 ?]V%P'_?1P!_X,C O2&+ 3J
MB#4'X8= #M:"3!G-?5@DQG=B+<!S:S6[;W0\MVQ\0;-IA$:O9XQ)K&643*EC
MG$^F8J51I&&O4Z)@O%6@8,U5GF#F5)YD]TV?9_]'GVG_0YYI_S^=:?\]G6G_
M/9UI_SV=:?\]G6G_/?]7%P'_8Q(!_V\1 ?]Y% '_@1D!^X<@ >^,)P+DCC %
MVHT]#,^'2AC'@E4COWU?+;EX:#6S=' \KW%X0JMN@$:G;(A*I&F03J!HF%&=
M9J%3FV6K59ADN%>69,A8E&3A6)5H]%"6:_]*EVS_199M_T&6;?] EFW_0)9M
M_T"6;?] EFW_0/]9%0'_9A !_W(0 /]]$@#_A18 ]HP; >J1(@'?E"L#TY$Z
M"\F,1Q? AU,BN8)<++)]936M>6T\J'5U0J-S?4>@<(1+G&Z,3IELE5*5:YY4
MDFFH5Y!IM%F.:,-9C&C<6HUL\E./;O],D'#_1X]Q_T./<?]!CW'_08]Q_T&/
M<?]!CW'_0?];% '_: \ _W4/ /^ $0#_B1, \I 7 .66' #9F28"S94X"L20
M11:[BU$ALX9:+*V"8S2G?FL[H7IR09UW>D:9=8%+E7.)3Y)QD5*.;YM5BVZE
M6(AML%J&;+];A&W56X9O[U6(<OU.B73_28ET_T2(=/]#B'3_0XAT_T.(=/]#
MB'3_0_]=$@'_:PX _W@. /^##P#]C!  [902 .":%0#3G"0"R)DV";^40Q6V
MCT\@KHI8*Z>&83.A@F@[G']P09=\=T:3>7Y+CW>&3XMUCU*(<YA6A'*B6(%Q
MKEI_<;Q<?7'07']S[%:!=OM/@WC_2H-X_T6">/]$@GC_1()X_T2">/]$@GC_
M1/]?$0'_;0P _WH- /^%#0#RCPT YY@- -N?#@#.GR(!Q)TT"+J80A2RDTT?
MJH]6*J.*7S*<AF8ZEX-M0)* =46-?GQ*B7R$3H5ZC%*">)56?G>@67MVJUMY
M=;I<=W;-7'AWZEA[>OI1?7S_2WU\_T9]?/]%?7S_17U\_T5]?/]%?7S_1?]A
M$ '_;PL _WT+ /6("@#?DP@ V)L* -.B# #)HQ\!OZ R![:<0!.METL>I9-4
M*)Z/73&8BV0YDHAK/XV%<D6(@WI*A("!3H!_BE)\?9-5>'R=6'5[J5MR>KA<
M<7K*7')\Z%AU?OE1=X#_3'> _T=W@/]&=X#_1G> _T9W@/]&=X#_1O]D#P#_
M<@D _W\( .6,!0#8E@< T9X) ,ZE"@#$IAT!NJ0O!K&@/A&HG$D=H)A3)YF4
M6S"3D&(XC8UI/HB*<$2#B'A)?H9_37J$B%%V@I%5<H&;6&^ IUIL?[5<:X#(
M7&N!Y5EN@_=2<83_37*$_TARA/]'<H3_1W*$_T=RA/]'<H3_1_]F#0#_=0<
M]H,% -R/ P#2F 8 S*$' ,BH" "_J1H M:@M!:RD/!"DH$<;G)U1)92962^.
MEF VB)-G/8*0;D-]CG9(>8Q]3'2*A5!PB(]4;(>95VF&I5EFAK-;98;%6V6&
MXUEHB/92:XK_36R*_TALB?]';(G_1VR)_T=LB?]';(G_1_]I"P#_> 0 Y8<
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M2EF@_T99G_]%69__15F?_T59G_]%69__1?]U  #@A@  SY,  ,2? 0"ZIP$
ML:X  *FV  "AO0T F[T@ 92\,0>+NCT0@[=(&GRU4")ULU@J;[)?,&JP9C9E
MKVT[8*UU/URL?D-8JX='5:J32E&JGTQ/JJY-3:K 34VJW$U.JO))4*K^1E*I
M_T-2J?]"4JG_0E*I_T)2J?]"4JG_0O)\  #7C   R)D  +VC  "RJP  J;(
M *"[ @"7Q D DL4; (O$+ 2#PCH,>\%$%72_3AUNO58D:+Q=*F.[9#!?NFPT
M6KET.5:X?#Q3MX<_3[>20DRVGT1*MJU&2+; 1DBWW45)MO)#2K7_04NU_SY+
MM/\]2[3_/4NT_SU+M/\]2[3_/>*#  #-D@  P9\  +2G  "JKP  H+@  );
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M+C_0_RX_T/\N/]#_+LJ4  "[H0  K:D  **Q  "6NP  B\0  (#- P!UV @
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MFV7_,_]5$P'_8 X _VL. /]T$ #_>Q( ]8$7 .B$'@#>AR<!T80W!\A_1A'
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M9P@ _W,( /-]" #>A@< V8P) -61"P#*DAX P9 P!;B-/PZPB$H8J814(:*
M72F=?64PF'IL-9-W<SJ/=7L^C'."0HARBT:%<)1)@F^>3']NJ4Y\;;=/>VW)
M4'INYDU\<?A&?G/_07]T_SV =?\Z@'7_.H!U_SJ =?\Z@'7_.O]=#@#_:@8
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M0VB&_S]JAO\\:H;_/&J&_SQJAO\\:H;_//]G! #V=@  W((  ,Z-  #%E0(
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M-T^D_S=/I/\W3Z3_-^1Z  #/B0  PI4  +:?  "LI0  HJP  )BS  ".NP(
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M&[F<  "JI   GJL  )*U  "%O@  ><<  &W/  !BU@, 6.$( %7J$P!1ZR
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M!1;_GP85_Z\&%/_ !A3_U@83_^D&$__I!A/_Z083_^D&$__I!I>O  "(N@
M>L4  &S/  !>V@  4.   $3F   \]0  -_\$ #/_#0 O_Q, *_\: "C_(0 E
M_R<!(?\M 1[_,@$;_S@!&?\_ 1;_1@(4_TT"$?]6 A#_8 (._VP"#/][ PO_
MBP,*_YH#"O^H PG_M0,(_\(#"/_" PC_P@,(_\(#"/_" XJX  ![PP  ;,X
M %[;  !/X@  0N<  #;L   Q_P  +/\  "?_!P C_PX (/\2 !S_&  8_QT
M%?\A !+_)@ 0_RP!#O\Q 0W_-P$*_SX!"/]& 07_3P$!_UD! /]F 0#_= $
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M3D8(_TM3"_](8 [_1FP1^T5X$_A$@A7V0XP7]$*4&/-!G!GQ0:,;[T"J&^Y
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M08Q>Z#^-8?DXC6+_,XYD_S".9/\LCF7_+(YE_RR.9?\LCF7_+/]5#@#_7P8
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M.75S_S5V=/\Q=G3_,79T_S%V=/\Q=G3_,?]=!@#_:0  XG0  -1]  #+A0(
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M,E^'_S)?A_\R7X?_,OUH  #@=@  S8(  ,*,  "YDP  L)D  *B=  "?H D
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M9K\S V&^/P==OD@+6;U1#U6]61-1O& 73KQH&DN[<1U(NWL?1;J'(D*ZE"1
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M$3';QQ$QVN<1,-CV$C#6_Q,OU/\3+]3_$R_4_Q,OU/\3+]3_$[.:  "FH0
MFJD  (VQ  " N@  =,$  &C)  !<SP  4M4# $C<" !%Y1( 0^4> $'F*@ ^
MYC4!.^<^ 3GG1P(WYU #-.A9!#+H8@4PZ&T&+NEY!RSIAP@KZI8)*>JG"BCJ
MN@HGZ]8*)^GP"B?G_0DFYO\*)N;_"B;F_PHFYO\*)N;_"JB@  "<IP  C[
M (*Y  !TP@  :,H  %O1  !/UP  1=T  #[N"0 \\A$ .?,; #;S)0 T]"X
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M 0#_M0$ _\8! /_* 0#_R@$ _\H! /_* 8:W  !WP0  :,P  %K7  !+W@
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M-?\-X37_#?\Y'@'_/QH!_T,8 ?]&&@'_22,!_TDM O](. /_140%_T-0!_]
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M+*9-[RJD3_TFI%#_(Z-1_R"C4O\>HE+_':)2_QVB4O\=HE+_'?]*#P#_4@H
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M+8)B_RF"8_\F@F3_)8)D_R6"9/\E@F3_)?]3!@#_70  YV<  -MO  #0= (
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M:_\I=VO_)W=K_R=W:_\G=VO_)_]7  #V8P  WVT  -%U  #(>P  P7\" +N
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M*&QS_RAL<_\H;'/_*/]<  #G:   U7,  ,E[  # @@  N(8  +&(  "IB0T
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M)4"HP"4_J-\E/Z;T(T"E_R) I?\A0*3_($"D_R! I/\@0*3_(,I^  "[BP
MKY4  *2;  "9H0  CJ8  (*L  !WL0  :K8  &.X#@!AN!T 7K@L 5JX. )7
MN$(%4[A+"%"W4PM-MUL.2K9C$$>V:Q-$M7460K6!&#^UCAH]M9P<.[6L'#JU
MP!TYM=\<.;/T'#FR_QPYL?\;.;#_&SFP_QLYL/\;.;#_&\&&  "TDP  IYH
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M!"#B^P0?X?\%'^#_!1_@_P4?X/\%'^#_!:2>  "8I0  BZX  'VV  !PO@
M8\8  %;+  !+T   0-4  #;<   OY0< +>T0 "ON&  I[B( )^\K "7O-  C
M\#P (?!% !_Q3@ =\E@!&_)D 1GS<0$8\X$!%_22 A7TI0(4];H"$_76 A/T
M[P(2\OP"$O#_ A+P_P(2\/\"$O#_ IJD  "-K0  ?[8  '&_  !CQP  5LX
M $G3   ]V@  ,]\  "KC   F] 4 )/L- "'\$P >_1L '/TB !G^*0 7_C$
M%?\Y !/_00 1_TH $/]5  [_80 ,_V\!#/^  0K_DP$)_Z8!"/^Z 0?_U $'
M_^L!!O_V 0;_]@$&__8!!O_V 8^L  " M@  <K\  &/)  !6T0  2-@  #O=
M   PX@  )N8  !_P   <_P  &?\) !;_#@ 4_Q, $?\9  __'@ -_R0 "_\K
M  G_,@ &_SL  _]$  #_3P  _UP  /]K  #_?0  _Y   /^C  #_M   _\8
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M$L<Y]Q+$.?\1PCK_$,$Z_P_ .O\.OSK_#K\Z_PZ_.O\.OSK_#O\]$P#_0@\
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M'Y10_QR44?\:E%'_&)11_QB44?\8E%'_&/])" #_4   ^U@  .5>  #=8@,
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M'G=B_QYW8O\>=V+_'O]2  #L7   W&8  ,YM  #$<@  O70  +=T 0"P= X
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M*DV$O"I-A-<J38/Q)T^#_R10@_\B4(/_'U"#_Q]0@_\?4(/_']YI  #)=0
MO(   +*(  "HC0  G9$  ).3  "%E@  ?I<+ 'F7&0!UER@!<9<U VR6/P9H
ME4@*9)10#6&35Q%=DEX56I%F&%>0;AM4CW<>48Z!($Z.C2-+C9HE28VI)DB-
MNR='C=0G1XSP)$B,_R))B_\@2HO_'DJ+_QY*B_\>2HO_'M5N  ##>P  MX4
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M%#2M_A0TK/\4-*O_%#2K_Q0TJ_\4-*O_%+N%  "OD   HY<  )B=  ",HP
M@*@  '2M  !HL@  7+8  %"Z 0!)O T 2+P9 $:])P!%O3, 0[T] 4&]1P$_
MO5 "/;U8 SJ]804XO6L&-KUW"#2]A DRO9,*,+VD"R^]MPPNOM ++KSN#"VZ
M_@TLN?\-++C_#BRX_PXLN/\.++C_#K./  "FEP  FYT  (^C  "#J@  =K
M &JU  !>N@  4KX  $?" 0 ]QP8 .,D0 #?)&P VRB< -<HS #3+/0 SRT<
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M  SK_P ,Z_\ #.O_ )>C  ")JP  >[0  &V\  !?Q   4LH  $7.   YTP
M+]@  "7=   =X0  &.P" !;W"P 4]Q$ $?@7 !#X'@ .^24 #?DM  OZ-0 )
M^S\ !_M*  3\5P #_68  OYW  #]BP  _9\  /RU  #\T0  _.T  /S\  #\
M_0  _/T  /S] (NK  !]M   ;KT  &#&  !2S0  1-(  #?8   LW0  (N$
M !GE   3Z@  $/H   [_!@ -_PP "O\0  ?_%  $_QH  ?\@  #_)P  _S
M /\Z  #_10  _U,  /]B  #_=0  _XH  /^?  #_LP  _\<  /_E  #_Y0
M_^4  /_E '^T  !PO0  8<<  %/0  !#U@  -MT  "KB   ?Y@  %NH  !#M
M   ,^@  "?\   ;_   "_P0  /\)  #_#0  _Q   /\4  #_&@  _R$  /\I
M  #_-   _T   /].  #_7@  _W(  /^'  #_F@  _ZH  /^Y  #_N0  _[D
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M NP;]P+I&_\"Z!O_ ^<<_P/F'/\#Y1S_ ^4;_P/E&_\#Y1O_ _\M&P#_,!<
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M#J\Z_PVN.O\,K3K_"ZTZ_PNM.O\+K3K_"_\\#0#_0 8 _T4$ /])"0#_2PT
M^4H1 .U)&@#C1B8 VD8V -%&10'+15$#QD1<!<)"9@B_0F\*O$%W"[I ?PVX
M/X8.MC^.$+0^E1&R/IT2L#ZF$Z\^L!2M/KT4JS[-%:D^YA6F/_<3I$#_$J-
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M%(91_Q2&4?\4AE'_%/]'  #X3P  Y%<  -5=  #,8   Q6 " ,%>!0"Z71$
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M)5IKNR99;-,F6FSO(UML_Q]<;?\<76W_&EUM_QE=;?\976W_&>A:  #29@
MPV\  +AV  "O>P  IGX  )U^  "1?   BGP/ (5]'@"!?2T!?'PY W=Z0P9S
M>4L)<'A3#&QW6A!I=F$39G5H%F-T;QAA<W@;7G*"'EMRC2!9<9HB5W&H)%5Q
MN254<= E5''N(E9Q_AY7<?\<5W'_&EAQ_QE8<?\96''_&>->  #-:0  OW,
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M'$2&^QI$AO\818;_%T6%_Q=%A?\7187_%\UM  "]>   L8(  *>*  "<C@
MDI   (:3  !YE0  ;)<  &:7#@!CF!L 89@I %Z8-0%:ESX#5Y='!5663P=2
MEE8)3Y5>#$R49@Y*E&\01Y-Y$T23A15"DI,70)*B&#Z2LQD]DLD9/9'I&#V0
M^A<^C_\6/H__%3Z/_Q4^C_\5/H__%<5S  "W?P  K(D  *&/  "6DP  BY8
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M"":R_P@FLO\()K+_"*^-  "BE   EYH  (N@  !^I@  <:L  &6P  !9M
M3;<  $*[   XO@$ +\() "W#$@ LPQX *\,I "K$,P IQ#T *,5' "?%40 F
MQ5P )<9H "/&=@$BQH8!(,:8 1_&JP$>Q\$!'L;D 1W$^ (<PO\#','_ QS!
M_P0<P?\$','_!*64  ":F@  CJ$  (&G  !SK@  9[0  %JY  !.O0  0L
M #C#   OQP  )LL$ ![0"@ ;T1$ &M(: !G2)0 8TR\ &-,Z !?41  6U%
M%=5= !35:P 3UGP $M>/ !'8I  0V;L $-G> !#5\P 0T_\ $-+_ 1#1_P$0
MT?\!$-'_ 9R:  "1H0  @Z@  '6P  !HMP  6[T  $[!  !"Q0  -\@  "W,
M   DT   '-4  !7:!0 0X@L $.,1  [D&@ .Y", #>4M  SE-P +YD( "N9/
M  GG70 (YVT !N:   7FE0 $YJL  N;$  'FY@  Y_D  .?_  #F_P  YO\
M .;_ ).A  "%J0  =[$  &FY  !;P   3L8  $'*   US@  *M(  "'6   9
MVP  $M\   WC   +\0@ "?,.  ?S$P $\AH  O(B  #R*@  \C0  /(_  #R
M3   \EP  /)M  #R@@  \I@  /.M  #SQ@  ].4  /3V  #T^P  ]/L  /3[
M (>I  !YL@  :KH  %S"  !.R0  0,X  #/3   HV   'MT  !7A   /Y
M"N@   7S   #_0$  /P(  #[#0  ^Q$  /L6  #\'@  _"8  /PP  #]/
M_DD  /Y:  #^;0  _X(  /^8  #_K   _\   /_8  #_Y   _^0  /_D 'NR
M  !LNP  7<0  $_-  ! T@  ,MD  ";>   ;X@  $N8   SJ   %[0   /0
M  #_    _P   /\   #_!   _PD  /\.  #_$@  _Q@  /\A  #_*P  _S<
M /]&  #_6   _VL  /^   #_E0  _Z8  /^S  #_NP  _[L  /^[ /\;)@#_
M'"0 _QHD /\5)P#_$"T _PHV /\%0P#_ 5 !_P!> ?\ :P'_ '8!_P"! /\
MB@#_ )( _P": /\ H #_ *8 _P"L /\ L@#_ +D _P#" /\ S0#_ -\ _P#L
M /\ ^ #_ /\ _0#_ /T _P#] /\ _0#_ /T _P#] /\ _0#_ /\?(P#_'R$
M_QXA /\9(P#_$RD _PXR /\,0 #_"4T!_P=: ?\$9P'_ W,!_P-] ?\#AP'_
M X\ _P*6 /\"G #_ J( _P*H /\"KP#_ ;8 _P&^ /\!R0#_ =L _P#J /P
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M M(;_P+1&_\"T!O_ M ;_P+0&_\"T!O_ O\M$@#_+@\ _RX- /\O$ #_+Q<
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M"9PZ_PF<.O\)G#K_"?\[ @#_/@  ]T0  .9'  #?2 $ VD8& -E "P#-0AD
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M  #C4P  T%L  ,1@  "Z8P  LV,  *QA  "D7@D G5\7 )A?)P"37S4!CEY
M XI=2@6&7%('@UM9"H!:8 Q]66<.>UAN$'A8=1)V5WX4=%:(%W)6DQAO5I\:
M;E6L&VQ5O1QK5M4=:U;P&FM7_Q=K6/\4;%C_$FQ8_Q%L6/\1;%C_$?%+  #?
M5@  S%X  ,!D  "W9P  KF@  *=F  "?8@8 F&,4 ))D) "-8S(!B6(] H1A
M1P2!8$\'?5]6"7I>70MW760-=5QK$'-<<Q)P6WL4;EN%%VQ:D!EJ6IP;:%FJ
M'&9:NAUE6M$=95KN&V5;_A=F6_\59ES_$V=<_Q)G7/\29US_$NU.  #:60
MR&$  +QG  "S:@  JVP  *)J  "99P( DF<1 (UG(0"(9R\!A&8[ G]E1 1[
M9$T&>&-4"75B6PMR86$-<&%I#VU@<!)K7WD4:5^#%V9>CAED7IH;8EZH'&%>
MN!U?7LX=7U[L&V!?_1AA7_\585__$V)?_Q)B7_\28E__$NI1  #47   Q&0
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M&U%L^AA1;/\54FS_%%)L_Q-2;/\34FS_$]Q<  #'9P  N6\  *]V  "E>P
MG'P  )%\  "">   >GD' '5Y% !R>B, ;GHO 6MY.@)H>4,#9'A+!6%W4@A?
M=UD*7'9@#%EU: ]7=' 15'1Z$U)SAA9/<Y,837*A&4QRL1I*<L8:2G+E&DMR
M^1=,<O\53'+_$TUR_Q)-<O\237+_$M1@  #":P  M70  *M[  "B?P  EX$
M (R!  !Z?@  <W\" &Y_$0!K@!X :( L &6 -P%B@$ #7W](!%Q^4 99?E<(
M5WU>"U1\9@U1?&X/3WMX$4Q[@Q1*>I$62'J?%T9ZKQA%>L081'KD&$5Y^!9&
M>?\41GC_$D=X_Q%'>/\11WC_$<UE  "]<   L7D  *>   "<A   DH8  (:&
M  !WA@  :X8  &:'#0!CAQD 8(@G %Z(,P%;B#P"6(=% U:'3013AE0&4(9;
M"$Z%8PI+A&P,281V#T:#@1%$@X\30H.=%$""KA4_@\(5/H+B%3^!]Q,_@?\2
M0(#_$4" _Q! @/\00(#_$,9K  "W=@  K'\  **%  "7B0  C(L  (&-  !S
MC@  98\  %V/"0!:D!0 6) A %:1+0!3D#@!49!! DZ020-,D% $2H]8!4>/
M8 =%CFD)0HYS"T"-?PT^C8T//(V<$#J-K!$YC<$1.(WA$#B+]A XBO\/.8G_
M#SF)_PXYB?\..8G_#K]R  "R?0  IX8  )R*  "1C@  AI$  'J3  !ME0
M7Y<  %29 0!/F0\ 3IH: $R:)P!*FC( 2)H\ 4::1 %$FDP"0II4 T"97 0^
MF68%.YEP!SF8? @WF(H*-9B:"S.8JPLRF+\,,IC?"S&6]0LQE?\+,93_"S&3
M_PLQD_\+,9/_"[AZ  "LA0  H8L  ):0  "+E   ?Y<  '*;  !FG0  6J
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M J&2  "6F   BIX  'VD  !OJ@  8J\  %:T  !*MP  /KH  #.]   JP
M(<0  !G'!0 3RPL $<P2 !',&P 0S"4 #\TO  [-.@ .S48 #<U2  W.8  ,
MSG  "\Z#  K.EP )SJP ",[&  C.Z  (S?L "<O_  G+_P )R_\ "<O_ )B8
M  "-G@  ?Z4  '&L  !DLP  5[D  $J]   ^P   ,L,  "C&   ?R@  %\T
M !'1   ,U@4 "-D,  ;9$@ %VAL !-HD  /;+@ !VSD  -Q%  #=4@  WF(
M -YS  #>B   WYT  -^S  #?S@  X.X  -_Z  #?_P  W_\  -__ (^?  "!
MI@  <ZX  &6U  !8O0  2L(  #W%   QR0  )LP  !W0   4U   #MD   G=
M   #X0   .,'  #C#0  Y!(  .49  #F(@  YRL  .DV  #K0P  [%(  .QB
M  #M=@  [HP  .ZA  #OMP  []$  ._K  #P]@  \/8  /#V (2G  !UKP
M9[<  %F_  !+Q@  /,H  "_.   DT@  &M@  !+<   ,X   !>,   #G
MZP   .L   #M!0  [@L  / 0  #Q%0  \QX  /0G  #W,P  ^4   /I1  #[
M8P  _'<  /V-  #]HP  _K8  /[)  #_WP  _]\  /_? '>P  !HN0  6L$
M $S*   \SP  +M0  "+:   7W@  $.(   GF    Z0   .P   #P    ]@
M /8   #W    ^    /H'  #[#0  _1$  /\9  #_(P  _R\  /\^  #_3P
M_V(  /]W  #_C0  _Y\  /^N  #_N@  _[H  /^Z /\6(P#_%2$ _Q(A /\.
M) #_!BH _P S /\ 00#_ $X _P!< /\ : #_ '0 _P!^ /\ AP#_ (\ _P"6
M /\ G #_ *( _P"H /\ K@#_ +4 _P"] /\ QP#_ -8 _P#G /X \P#^ /X
M_0#_ /P _P#[ /\ ^P#_ /L _P#[ /\ ^P#_ /\:( #_&1X _Q8> /\0( #_
M"B4 _P0P /\ /0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ @P#_ (L _P"2 /\
MF #_ )X _P"D /\ J@#_ +$ _0"Y /L PP#Z -  ^ #C /< \0#V /P ] #_
M /0 _P#S /\ \P#_ /, _P#S /\ \P#_ /\=' #_'!D _QD9 /\4&P#_#B$
M_PPL /\).0#_!48 _P)3 /\ 7P#_ &L _P!U /\ ?@#_ (8 _P". /\ E #^
M )L _ "A /H IP#X *X ]0"U /, OP#Q ,L \ #? .X [@#L /D ZP#_ .H
M_P#J ?\ Z0'_ .D!_P#I ?\ Z0'_ /\@%P#_'Q0 _QP3 /\7%0#_%AT _Q,H
M /\0- #_#4$ _PQ. /\)6@#_"&8 _PAP /X'>0#\!X$ ^@>) /@'D #V!I8
M\P:= /$&HP#O!JH [0:R .H&NP#H_^+__TE#0U]04D]&24Q%  @)!L@ Y@;<
M .0&[ #B"/H X K_ -X+_P#="_\ W0S_ -P,_P#<#/\ W S_ /\C$@#_(Q
M_R$. /\>$ #_'A@ _QPC /\8+P#_%#L _Q)) /P050#X#V  ] ]J /$/= #O
M#GP [0Z$ .L.BP#I#I( YPZ9 .8.H #D#J< X@ZO . .N #>#L4 W [: -80
M[ #2$?H SQ+_ ,T2_P',$O\!RQ/_ <H3_P'*$O\!RA+_ ?\G#P#_)PP _R4)
M /\F#0#_)1, _R,< /\@* #['#4 ]1I" .\83P#J%UH YA9E .,6;@#@%G<
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M!:0L_P2C+?\$HBW_!*(L_P2B+/\$HBS_!/\R  #_,P  ^3@  .DY  #B.0
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M"GI&_PEZ1O\)>D;_"?4^  #F2   TT\  ,=4  "]50  ME0  +!0  "I3 L
MHDT8 )U.* "83C8 E$Y! 9!-2P*-35,$BDQ:!8=+80:%2V@(@TIO"8!*=PM^
M27\,?$F)#GI(DP]X2)\0=TBL$G5(O!)T2=(3<TGN$7)*_P]R2O\-<DK_"W)*
M_PMR2O\*<DK_"O)"  #@3   SE,  ,%8  "X6@  L%D  *E6  "B4@< FU(5
M )93) "14S( C5,^ 8E21P*&45 $@U%7!8!07@9^3V4(>T]L"7E.<PMW3GL-
M=4V%#G--D!!Q39P2;TVI$VY-N11L3<X4;$WK$VQ._1!L3_\.;$__#&Q/_PML
M3_\+;$__"^Y%  #<4   R5<  +U<  "T7@  K%X  *1;  "<5@0 E582 )!7
M(0"+6"\ AU<[ 8-61 )_5DT#?%54!7I46P9W5&((=5-H"7-3< MQ4G@-;U*"
M#VU1C1%K49D2:5&F%&=1MA5F4<L595+I%&52^Q%F4_\/9E/_#693_PQF4_\,
M9E/_#.I)  #54P  Q5H  +I?  "P8@  J&(  )]?  "66@  CUH0 (I;'@"%
M6RP @5LX 7U;00)Z6DH#=UE1!'186 9Q6%\';U=F"6U7;0MK5G8-:59_#V=5
MBA%E59<38U6D%&%5M!5@5<@67U7G%6!6^A)@5O\/85?_#F%7_PUA5_\,85?_
M#.=,  #15@  P5X  +9C  "M9@  I&8  )MD  "07@  B5X. (1?&P" 7RD
M?%\U 7A?/P)T7D<#<5U/!&]<5@5L7%P':EMC"6A;:PMF6G,-9%I]#V):B!%?
M69037EFB%%Q9LA5;6<866EGE%5M:^1);6O\07%K_#EQ:_PU<6O\-7%K_#>-/
M  #-60  OF$  +-F  "I:0  H&H  )=H  "+8@  @V(, 'YC& !Z8R8 =F,R
M '-C/ %O8D4";&%,!&IA5 5G8%H'96!A"&-?:0IA7W$,7UY[#EU>AA%:7I,2
M6%V@%%==L!567L0655[C%59>]Q)67O\05U[_#E=>_PU77O\-5U[_#=Y3  #(
M70  NV0  +!J  "F;0  G6X  )-M  "%9P  ?F<) 'AG%0!T9R, <6@O &YG
M.0%K9T(":&9* V5F4@5C95@&8&5?"%YD9PI<9&\,6F-Y#EACA!!58I$24V*?
M$U)BKA518L(54&+A%5%B]A)18O\04F+_#E)B_PU28O\-4F+_#=E6  #$8
MMV@  *QN  "C<0  FG,  (]Q  !_:P  >&L% ')K$@!N;!\ :VPL &AL-P%F
M;$ "8VM( V!K3P1>:E8&7&I=!UEI90E7:6T+56EW#5-H@@]0:(\13F>=$TUG
MK!1+:, 42VC>%$MG]1),9_\/3&?_#DUG_PU-9_\-36?_#=):  # 9   LVP
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M?P  C($  (&!  !R@   97\  %U_" !9?Q, 5X @ %6 *P!3@38 48 ^ 4^
M1@)-@$X"2W]5 TE_705&?V8&1'YP"$)^>PD_?H@+/7V7##Q]IPTZ?;H..G[6
M#3I\\0TZ>_\,.GO_"SIZ_PLZ>O\+.GK_"\!I  "R=   IWP  )V!  "2A
MAX8  'N'  !NAP  8(<  %6' 0!0B X 3H@: $V))@!+B3  28DZ $B)0@%&
MB4H!1(E2 D*)6@- B&,$/8AM!3N(> 8YAX8(-X>5"36'I@HTA[D*,X?3"C.&
M\ DSA?\),X3_"3.#_PDS@_\),X/_";EP  "M>@  HH(  )>'  "-B@  @8P
M '6.  !HCP  6I   $^1  !'D@H 1)(3 $.3'P!!DRH 0),T #^3/0 ]DT4
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M ABF_P(8IO\"&*;_ J6)  "9CP  CY0  (.9  !UG@  :*(  %RF  !0J0
M1*P  #FN   OL   )K,  !ZU!@ 9MP\ &+<7 !>W(0 6MRH %;<T !2X/@ 3
MN$D $KA4 !*Y8@ 1N7$ $+F#  ^YEP .N:P #;G$  VXYP .MOL #K7_  ZT
M_P .M/\ #K3_ )R0  "2E0  AIL  'F@  !KI@  7JL  %*O  !&L@  .K4
M "^W   EN@  ';T  !7    0PP8 "\8.  K%%0 )Q1X ",4H  ?%,@ &QCT
M!<9)  7&5P #QF8  L9W  '&BP  QJ   ,6V  #&T@  Q>\  ,7\  #%_P
MQ?\  ,7_ )66  ")G   >Z,  &VI  !@KP  4[0  $:X   ZNP  +KX  "3!
M   ;Q   $\<   [*   (S@$  = *  #0$   T!8  -$>  #2)P  TS$  -0\
M  #520  UE@  -9I  #6?   UI(  -:G  #6OP  UN   -;S  #6_@  UO\
M -;_ (R=  !^I   ;ZL  &&R  !4N0  1KT  #G!   MQ   (L<  !G+   1
MS@  #-(   75    VP   -P#  #="@  W@\  -\4  #A'   XB0  .0N  #F
M.@  YTD  .A9  #H:P  Z8$  .F8  #IK0  Z<4  .GB  #I\@  Z?4  .GU
M ("E  !QK0  8[4  %6\  !'P@  .<8  "S*   @S@  %M(   _6   (VP
M -\   #C    Y0   .<   #H 0  Z@<  .L-  #M$0  [Q@  /$A  #S*P
M]C@  /=(  #X6@  ^6T  /J$  #ZFP  ^J\  /K"  #ZV@  ^M\  /K? '2N
M  !EM@  5KX  $C&   YRP  *]   !_4   4V@  #=\   7C    Y@   .D
M  #M    [P   /$   #S    ]0   /8"  #X"0  ^@X  /T3  #_'   _R@
M /\V  #_1P  _UH  /]N  #_A0  _YH  /^K  #_N0  _[P  /^\ /\1( #_
M$!X _PP> /\$(0#_ "< _P P /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\
M@P#_ (L _P"2 /\ F #_ )X _P"D /\ J@#_ +  _P"X /\ P@#_ ,X _P#B
M /X \ #] /L ^P#_ /L _P#[ /\ ^@#_ /H _P#Z /\ ^@#_ /\4' #_$AH
M_PX: /\(' #_ "$ _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_
M (< _P". /\ E #_ )H _@"@ /T I@#\ *P ^P"T /D O0#X ,D ]P#< /4
M[ #S /@ \P#_ /( _P#Q /\ \ #_ /  _P#P /\ \ #_ /\7& #_%18 _Q$5
M /\,%P#_!1T _P H /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#\ ((
M^@") /@ D #W )8 ]0"< /0 H@#S *@ \0"P /  N #N ,, [ #3 .H YP#I
M /4 YP#_ .8 _P#E /\ Y0#_ .4 _P#E /\ Y0#_ /\:$P#_&!$ _Q00 /\/
M$0#_#1D _PHD /\%, #_ 3X _P!+ /\ 5P#^ &( ^@!L /4 =0#R 'T \ "$
M .X BP#L )$ ZP"7 .D G@#G *0 Y@"L .0 M #B +\ X #- -X XP#< /(
MV@#] -@ _P#6 /\ U0'_ -4!_P#5 O\ U0+_ /\>$ #_' T _Q<+ /\5#@#_
M%!4 _Q$? /\.*@#_"S@ _0A% /@&40#T!%P [@1F .H$;P#F W< Y 1_ .($
MA@#@!(P W@23 -T%F@#;!:  V 6H -4%L0#2!;L T ;) ,X'X #,"/$ R0K_
M ,<+_P#&#/\ Q0S_ ,4,_P#%#/\ Q0S_ /\A# #_( 8 _QP# /\="@#_&Q
M_Q@8 /\4(P#V$3  [PX^ .H.2@#E#58 X0U@ -T-:0#9#7$ U0UY -,-@0#1
M#8@ SPV/ ,T.E@#+#IT R@ZE ,@.K@#&#[D Q!#( ,(0WP"^$?( NQ+_ +D3
M_P"W$_\!MA/_ ;83_P&V$_\!MA/_ ?\E!@#_(P  _R,  /\D P#_(0H _1T1
M /$:&P#H%B< X10U -H30P#3%$\ SA59 ,L58P#(%FL Q19S ,,7>P#!%X(
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M Y M_P.0+?\#D"W_ _\P  #R,P  Y#H  -8]  #,/   QSD  ,,Q!0"]+A$
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M._\%?#O_!?0W  #E0   TD<  ,5*  "\2P  M4D  *]#  "I/@L HC\7 )U
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M!^P_  #820  QU   +M4  "Q50  J50  *%0  "92@( DDD1 (U*'P")2RP
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M#5Q0K0Y;4< .6E'>#UI1]0Q:4O\*6U+_"5M1_PA;4?\(6U'_"-]*  #)4P
MNUH  +!?  "F80  G6$  )1>  "(5P  @%8* 'I7%0!V5R( <U@N '!7.0!M
M5T$!:E=) FA64 )F5E<#9%9>!&)5905@56T'7E5W"%Q5@@I:58X,656<#5=5
MJPY65;X/557;#U55\PU55?\+5E7_"595_PE65?\(5E7_"-M-  #%5P  N%X
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M#49C[PQ&8O\*1V+_"4=B_PE'8O\(1V+_",I8  "Z8@  KFD  *-N  ":<0
MD'(  (1Q  !T:P  :6D  &-I"P!?:14 7&HA %IJ+0!8:S8 5FL_ 55K1P%3
M:DX"46I5 T]J701-:F4%2FEN!DAI>0=&:88)1&F5"D-HI0M!:;<,0&G/#$!H
M[@M!:/\*06?_"4%G_PA"9_\(0F?_",5=  "V9@  JFT  *!S  "6=@  BW<
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M!2U]_P4M??\%+7W_!;-N  "H>   G7\  )*#  "(A@  ?8<  '"(  !CB0
M58H  $N*  !!B@( .XL. #F+%P XC"( -XPL #:,-0 TC#T ,XQ& #*-3P Q
MC5@ +XUB 2V,;@$KC'L!*HR+ BB,G (FC*\")8S& B6+Z (EBOL#)8C_ R6(
M_P,EA_\#)8?_ ZUV  "C@   EX4  (V)  ""C   =HX  &F0  !<D@  4),
M $24   ZE0  ,98( "V7$0 LEQH *Y<D "J7+0 IES8 *)@_ ">82  FF%(
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M )B.  "/DP  @I@  '6=  !GH@  6J<  $ZK  !!K0  -:\  "NQ   AM
M&+8  !&Y   -O , ![X,  .]$@ !O1D  +XB  "^*P  OC8  +Y!  "_3@
MOUP  +]M  "_@   OI4  +ZJ  "^P@  O>0  +WV  "]_P  O?\  +W_ )*4
M  "%F@  >*   &JF  !<JP  3[   $*S   UM@  *K@  ""[   7O@  $,$
M  O$   $QP   ,D'  #)#0  R1(  ,H9  #+(@  RRL  ,TU  #.00  SE
M ,]@  #/<@  SX<  ,^=  #/LP  S\X  ,_K  #.^   SOX  ,[^ (B;  !Z
MH@  ;*@  %ZO  !0M0  0KD  #6\   IOP  'L(  !7&   .R0  ",P   #0
M    TP   -4   #6!@  V P  -D1  #;%@  W!\  -XH  #@-   XD$  .)1
M  #C8P  XW<  .2.  #DI   Y+H  .74  #EZ@  Y?,  .7S 'RC  !NJ@
M8+(  %&Y  !#O@  -<(  "C&   <R0  $\T   S1   $U0   -H   #>
MX0   .(   #D    Y0,  .<)  #I#@  ZQ(  .T:  #O)   \C$  /1!  #T
M4P  ]68  /5\  #VDP  ]JD  />\  #WS@  ]]\  /?? '"L  !AM   4[L
M $7#   VQP  )\P  !O0   1U0  "ML   #?    X@   .4   #I    [
M .T   #P    \0   /,   #U!   ]PH  /H0  #\%@  _R$  /\N  #_0
M_U,  /]H  #_@   _Y8  /^H  #_M@  _[\  /^_ /\-' #_"AL _P(; /\
M'@#_ "0 _P N /\ / #_ $H _P!6 /\ 8P#_ &T _P!W /\ ?P#_ (< _P".
M /\ E #_ )H _P"@ /\ I@#_ *P _P"T /\ O0#_ ,D _@#= /T [0#\ /H
M^P#_ /H _P#Y /\ ^@#_ /H _P#Z /\ ^@#_ /\0&0#_#1< _P86 /\ & #_
M !X _P J /\ -P#_ $4 _P!2 /\ 7@#_ &D _P!R /\ >P#_ (( _P") /\
MD #^ )8 _0"< /P H0#[ *@ ^0"O /@ N #V ,, ] #2 /, YP#R /8 \ #_
M .\ _P#P /\ [P#_ .\ _P#N /\ [@#_ /\2% #_#Q( _PL2 /\ $@#_ !H
M_P E /\ ,P#_ $  _P!- /\ 60#_ &0 _0!M /L =@#Y 'T ]P"$ /4 BP#T
M )$ \P"7 /$ G0#P *, [@"J .P LP#J +T Z #+ .< X0#E /$ XP#] .,
M_P#B /\ X0#_ .$ _P#@ /\ X #_ /\4$ #_$0X _PT- /\'#P#_ A4 _P @
M /\ +0#_ #H _P!' /D 4P#U %X \@!H /  < #M '@ ZP!_ .D A0#H (P
MY@"2 .4 F #C )\ X0"F -\ K@#< +@ V@#% -8 V0#4 .P T@#Y -$ _P#/
M /\ S@#_ ,X _P#. /\ S@#_ /\7# #_% @ _P\% /\."P#_#!$ _P<: /\!
M)@#\ #0 ] !! .T 30#I %@ Y@!B ., :@#@ '( W@!Y -L @ #9 (8 U@"-
M -, DP#1 )H SP"A ,T J@#+ +, R0"_ ,8 T #% .@ PP#V ,$ _P#  O\
MOP/_ +\#_P"_ _\ OP/_ /\;!@#_%P  _Q0  /\3!0#_$0T _PX4 /D*'P#P
M!BP Y@,Y . #1@#< U$ U@1; -($9 #/!6P S 5S ,H%>@#(!8$ Q@6' ,4&
MC@##!I8 P0:= +\&I@"]!K  NP>\ +D(S0"X"N4 M0OW +,-_P"Q#?\ L W_
M + ._P"O#O\ KP[_ /\>  #_&P  _QL  /H:  #U%@4 ]A$- .L.%0#B"R(
MV LQ - ,/@#+#4H QPU5 ,0.7@#!#F8 OPYM +T.= "[#WL N0^" +<0B@"V
M$)$ M!": +(0HP"P$:T KQ&Z *T1R@"J$N4 IQ3W *45_P"C%?\ HA7_ *(5
M_P"B%?\ HA7_ /\B  #_(   \",  .8D  #@(0  W!D% -L0# #0$1D R!,I
M ,(5-P"]%D0 N1=. +475P"S&&  L!AG *X8;@"L&74 JQE\ *D9A "H&HP
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M O0N  #D-P  TCT  ,4_  "[/P  M#P  *\U  "I+PL HR\7 )XQ)@"9,C,
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M!FH^K@9I/\ '9S_>!V<_]09F0/\%9D#_!&9 _P1F/_\$9C__!.4]  #/1@
MOTP  +1/  "J4   HD\  )E*  "11   BD$- (1"&0" 0R8 ?40R 'I$/ !W
M1$0 =41, 7)$4P%P0UD!;T-@ FU#9P)K0V\#:4-Y!&A#@P5F0X\&9$.=!V-#
MJP=A0[T(8$39"&!$\P=@1/\&7T3_!5]$_P1@1/\$8$3_!.!!  #*2@  NU
M +!3  "G50  GE,  )5/  "+20  @T<+ 'U'%0!Y1R( =D@N '-(. !Q2$$
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M"4]0[0A04/\'4%#_!E!0_P504/\%4%#_!=!+  "_5   LEH  *=>  "=8
ME&   (E=  !\5P  <E0  &Q3#@!H5!D 950D &)4+P!@5#@ 7E1  %Q42 %:
M5$\!6516 5=470)55&4#5%1N!%)4>0505(8&3E24!TU4I A+5+4(2U3,"4I4
MZPA+5/X'2U3_!DM4_P5+5/\%2U3_!<Q.  "[5P  KEX  *1B  ":9   D60
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M!3MB_P4\8?\$/&'_!+Y;  "P8P  I6H  )MO  "1<@  AG(  'MQ  !L;0
M8&L  %5I  !/: T 36D7 $MI(0!):BL 2&HT $=J/0!%:T0 1&M, $)K5 %!
M:UP!/VIE CUJ< ([:GT#.6J,!#=JG 0V:JX%-6K$!35JY04U:?D$-6G_!#5H
M_P0U:/\$-6C_!+E@  "L:0  H7   )AU  "-=P  @G<  '=W  !I=   7',
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M :AT  ">?0  DX(  (F%  !^B   <8H  &6+  !8C   3(T  $".   VC@
M+(\  "60#  CD!, (I < "&0)0 @D2X 'Y$V !Z10  =D4D ')%4 !J18  9
MD6X &)%^ !:2D  5DJ0 %)&Y !.1V  3C_0 %([_ !2-_P 4C/\!%(S_ :-]
M  "8@P  CH@  (2,  !WCP  :9$  %V3  !0E0  19<  #F8   NF0  )9H
M !V; @ 6G0P %9T3 !2=&P 3G20 $ITM !&>-P 1GD$ $)Y,  ^>6  .GF<
M#9YW  R>B@ +G9X "IVR  F=S  )G.P "IO^  N:_P +F?\ "YG_ )R$  "1
MB@  B(X  'N2  !ME@  8)D  %2<  !(GP  /*   #"A   FHP  ':4  !6G
M   0J04 "ZL-  BJ$P 'JAL !JHD  6J+@ $JC@  JI$  &J4   JEX  *IN
M  "J@0  JI4  *FJ  "IP0  J.0  *CV  "G_P  I_\  *?_ )6+  ",D
M?Y4  '&:  !CG@  5J(  $JF   ]J   ,:H  ":K   =K0  %+    ZR   )
MM0$  K8*  "V#P  MA4  +<=  "W)0  MR\  +@Y  "X1@  N%0  +AD  "X
M=@  N(L  +>@  "WM@  M],  +;O  "V_   MO\  +;_ (^2  ""EP  =)T
M &:B  !8IP  2ZP  #ZO   QL0  )K,  !RV   3N   #;L   :^    P0
M ,($  #""P  PQ   ,05  #$'   Q20  ,8N  #(.@  R4<  ,E7  #):0
MR7T  ,F4  #(J@  R,,  ,CD  #(]   R/T  ,C] (69  !WGP  :*8  %JK
M  !-L0  /[4  #&X   EN@  &KT  !'    +PP   \<   #*    S0   ,X
M  #/ P  T D  -$.  #3$@  U1D  -<B  #:+0  W3D  -Y)  #>6@  WVX
M -^%  #?G   W[(  -[+  #>Y@  W_0  -_T 'FA  !KJ   7*\  $ZU  !
MNP  ,;X  "3!   9Q0  $,@   G,    SP   -,   #9    W    -T   #?
M    X0   .(%  #D"P  YA   .@6  #J(   [2L  / Z  #Q2P  \5X  /)S
M  #SBP  \Z(  /.V  #SR0  \^$  //A &VJ  !>L0  4+D  $&_   RQ
M),@  !?,   .T   !M4   #:    W@   .(   #F    Z0   .H   #L
M[@   /    #R    ] 8  /8,  #Y$@  _!P  /\I  #_.@  _TT  /]B  #_
M>   _Y   /^C  #_LP  _\$  /_! /\'&0#_ 1< _P 7 /\ &@#_ "$ _P K
M /\ .0#_ $< _P!4 /\ 7P#_ &H _P!S /\ >P#_ (, _P"* /\ D #_ )8
M_P"; /\ H0#_ *@ _P"O /\ N #_ ,0 _@#5 /P Z@#[ /@ ^@#_ /D _P#X
M /\ ^ #_ /8 _P#S /\ \0#_ /\+%0#_!1, _P 3 /\ % #_ !H _P G /\
M- #_ $( _P!/ /\ 6P#_ &4 _P!N /\ =@#_ 'X _P"% /X BP#] )$ ^P"7
M /H G0#X *, ]P"K /8 LP#T +X \P#, /$ XP#O /, [@#_ .T _P#L /\
MZP#_ .P _P#L /\ ZP#_ /\-$0#_"1  _P / /\ $ #_ !8 _P B /\ +P#_
M #T _P!* /\ 50#] &  ^@!I /@ <0#V 'D ] !_ /, A@#Q (P [P"2 .X
MF #L )\ ZP"F .D K@#G +@ Y0#% ., V@#A .T WP#[ -X _P#= /\ W0#_
M -T _P#= /\ W0#_ /\/#0#_# L _P,) /\ # #_ !( _P = /\ *0#[ #<
M^ !$ /4 4 #R %H [@!C .P :P#I ', YP!Z .4 @ #C (8 X0", -\ DP#=
M )D VP"A -D J0#5 +( T@"^ -  S@#. .8 S #V ,H _P#* /\ R0#_ ,@
M_P#( /\ R #_ /\1" #_#0( _P<  /\%" #_  X _P 6 /< (@#O #  ZP ]
M .@ 20#D %0 X != -T 90#9 &T U0!S -( >@#0 (  S@"' ,P C0#* )0
MR "; ,8 I #$ *T P@"X ,  QP"] -\ O #Q +L _@"Y /\ N #_ +@ _P"X
M /\ N #_ /\4  #_#P  _PT  /\,  #_!PD ^ $0 .@ &@#C "@ W0 V -@
M0@#2 $T S@!7 ,H 7P#' &8 Q0!M ,, = #! 'H OP"! +T B "[ (\ N0"7
M +< GP"U *@ LP"S +$ P@"O -@ K@+M *P#^P"K!?\ J@;_ *D&_P"I!O\
MJ0;_ /\6  #_$@  ]Q(  .P1  #F#@  Y08( -T#$@#4 R  S00M ,@$.@##
M!48 OP50 +P&6 "Y!F  MP=G +4';@"S!W4 L0A[ *\(@@"N"8H K F2 *H)
MFP"H"J4 I@JP *4+OP"C#-0 H0WM )\._@"=#O\ G __ )L/_P";#_\ FP__
M /\:  #W&0  ZAX  -\>  #5&@  T!," ,X,"P#'"Q8 P TE +H.,@"V#C\
ML@]) *\04@"L$%H JA!A *@1: "F$6\ I!%V *(1?0"A$84 GQ*. )T2EP"<
M$J( FA.M )@3O "7%-  E!7L )(6_0"0%_\ CQ?_ (X7_P".%_\ CA?_ /H=
M  #N(P  WR@  - J  #')P  P2$  +T9!0"Y$A  LA4> *T6+ "H%S@ I!A#
M *$93 "?&50 G!I< )H:8@"9&FD EQMP )4;=P"4&W\ DAR( ) <D@"/')T
MC1VI (L=MP"*'LH B!_G (8@^@"$(/\!@R#_ 8,@_P&"(/\!@B#_ ?4D  #E
M+   TS$  ,8S  "\,0  MBT  + E  "L'0P IAX8 *$@)@"<(3( F2(] )4B
M1P"3(T\ D2-6 (\C70"-)&0 BR1K (DD<@"()'H AB2# (0EC0"#)9@!@26D
M 8 FL@%^)L4!?2?B 7LG]P%Y*/\!>"C_ 7@H_P%X*/\!>"C_ >\K  #=,P
MRCD  +X[  "T.@  K38  *8O  "A* < FR<3 )8H( "1*2T CBHX (LK0@"(
M*TH ABM2 (0K6 ""+%\ @"QF '\L;0!]+'4 >RQ^ 7HLB %X+)0!=BV@ 74M
MK@)T+< "<B[= G$N] )P+_\";R__ F\O_P%N+_\!;B__ >@Q  #3.@  PS\
M +=!  "N00  ICX  )XX  "7,0$ D2X0 (PO' "(,"@ A#$S ($R/0!_,D8
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M!%H_[ 19/_X#63__ UD__P)9/_\"63[_ M8_  ##1P  M4P  *I0  "@4
MET\  (Y+  "$10  >D & '4_$0!Q0!P ;4 H &M!,@!I03L 9T%" &5!20!C
M05  84%7 &!!7@%>068!74)O EM">@):0H8#6$*4 U="HP150[,$5$/)!%1#
MZ0130_T#4T/_ U1#_P-40_\"5$/_ M!"  "_2@  LE   *=3  "=5   E%,
M (I0  !_2@  =44" &Y##@!K1!D 9T4D &5%+@!B13< 844_ %]%1@!=14T
M6T54 %I&6P%91F,!5T9L E9&=P)41H,#4T:1 U%&H0101[$$3T?'!$Y'YP1.
M1_L$3D?_ TY'_P-/1_\#3T?_ \Q&  "[3@  KU0  *17  ":6   D5<  (94
M  ![3@  <$H  &E(#0!E2!8 8DDA %])*P!=230 6TD\ %E)0P!724H 5DE2
M %5*60%42F$!4DIJ 5%*=0)/2H$#3DJ/ TQ+GP1+2[ $2DO%!$E+Y@1)2_H$
M24O_ TI+_P-*2_\#2DO_ \A)  "X40  K%<  *%;  "87   CEP  (-9  !V
M4P  :TX  &1-"@!?3!, 7$T> %I-* !833$ 5DTZ %1-00!33D@ 4DY/ %!.
M5P%/3E\!34YH 4Q.<P)*3W\"24^- T=/G01&3ZX$14_#!$10Y 1$3_D$14__
M T5/_P-%3O\#14[_ \1,  "U50  J5L  )]>  "58   BV   (!>  !R5P
M9U,  %Y1!P!941$ 5U$; %11)0!24B\ 45(W $]2/P!.4D8 35-- $Q350!*
M4UT!25-F 4=3< )%4WT"1%.+ T)3FP-!5*P$0%3!!#]4X@0_5/@#0%/_ T!3
M_P- 4_\#0%+_ \!0  "R6   IEX  )QB  "290  B&4  'UB  !N7   8UD
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M K->  "G9@  G&T  )-Q  "(<P  ?7,  ')R  !D<   6&X  $UL  !":@,
M/&D. #IJ%@ Y:B  .&HH #9K,0 U:SD -&M! #-L20 R;%( ,6Q< "]L9@ N
M;', +&R" 2ILDP$I;*4!*&RY 2=MU@$G:_(!)VK_ 2=J_P$H:?\"*&G_ JYD
M  "C;   F7,  (YV  "$>   >7D  &UX  !@=P  4W8  $AU   ^<P  -'(*
M #%S$0 P<QH +W,C "YS*P M=#0 +'0\ "MT1  I=$T *'57 "=U8P E=6\
M)'5_ ")UD  A=:( ('6W !]UT@ ?=/$ 'W/_ 1]R_P$@<?\!(''_ :EK  ">
M<P  E'D  (I\  " ?@  ='\  &=_  !:?P  37X  $-^   X?0  +WT" "A]
M#0 F?10 )'T< "-^)0 B?BT (7XV "%^/P ??T@ 'G]2 !U_7@ <?VL &G]Z
M !E_C  7?Y\ %G^S !5_S@ 5?N\ %GS_ !9[_P 6>_\ %WO_ *1R  ":>@
MCW\  (6"  ![A   ;88  &"'  !4AP  2(@  #R(   RB   *(@  ""(!0 :
MB0X &8D5 !B)'0 7BB8 %HHN !6*-P 4BD$ $XI, !*+6  1BV4 $(MU  ^+
MAP .BIL #8JO  R*R  ,B>H #8?\  Z'_P .AO\ #H;_ )][  "4@0  BH4
M ("(  !SBP  98T  %F/  !,D   09(  #22   JD@  (9,  !F4   2E@8
M#I<.  V7%0 ,EQT #)<F  N7+P *ESD "9=$  B74  &EUX !9=N  .6@  !
MEI0  )6H  "5O@  E.   )3T  "3_P !DO\  9+_ )B"  ".B   A8P  '>/
M  !JD@  794  %"8  !$F@  .)L  "R<   BG0  &9X  !*@   -H@( !Z,+
M  &C$   HQ<  *,?  "C)P  HS$  *0\  "D2   I%8  *1E  "C=P  HXL
M *.@  "BM@  H=(  *'P  "@^P  H/\  *#_ )&*  ")C@  >Y(  &V7  !@
MFP  4YX  $:A   YHP  +:0  ".F   9J   $:H   RL   %K@   *\'  "O
M#0  KQ$  + 8  "P(   L2@  +$R  "R/@  LDP  +);  "R;   LH$  +&7
M  "QK   L,8  +#H  "O]P  K_\  *__ (R0  !_E0  <9H  &.?  !5I
M1Z@  #JJ   MK   (JX  !BP   0LP  "K4   *X    NP   +L   "\!P
MO T  +T1  "^%@  OQX  , G  #!,@  PD   ,-/  ##8   PW0  ,.+  ##
MH0  P[@  ,+7  #"[P  POH  ,'^ (&7  !SG0  9:,  %>H  !)K0  .[$
M "VS   AM@  %KD   Z[   'O@   ,$   #%    QP   ,@   #)    R@4
M ,L+  #-#P  SA0  - <  #3)@  UC(  -A!  #84P  V68  -E\  #9E
MV:L  -G#  #9X0  V?   -GT ':?  !GI@  6:P  $NR   \MP  +KH  "&]
M   5P   #<0   7'    R@   ,X   #2    U0   -8   #9    VP   -T
M  #?!P  X0P  .,1  #F&0  Z20  .PR  #M0P  [E8  .]K  #OA   [YP
M .^R  #OQ@  []T  ._D &JH  !;KP  3+8  #Z\   OP   (,0  !3(   ,
MS    M    #4    V0   -X   #B    Y0   .8   #H    Z0   .P   #N
M    \ (  /()  #U#P  ^!<  /PC  #_,P  _T8  /]:  #_<0  _XD  /^?
M  #_L0  _\   /_& /\ %0#_ !0 _P 4 /\ %P#_ !T _P H /\ -P#_ $0
M_P!1 /\ 7 #_ &8 _P!O /\ =P#_ 'X _P"% /\ BP#_ )$ _P"7 /\ G0#_
M *0 _P"K /\ M #^ +\ _0#. /L Y@#Y /8 ^ #_ /< _P#W /\ ]P#_ /
M_P#L /\ Z0#_ /\#$@#_ !  _P 0 /\ $0#_ !< _P D /\ ,@#_ #\ _P!,
M /\ 5P#_ &$ _P!J /\ <@#_ 'D _0"  /P A@#Z (P ^0"2 /@ F #V )\
M]0"F /0 K@#R +D \ #& .X W@#M /  ZP#^ .H _P#I /\ Z0#_ .< _P#C
M /\ X #_ /\'#@#_  T _P + /\ # #_ !, _P ? /\ + #_ #H _P!& /X
M4@#[ %P ^ !E /4 ; #S '0 \0!Z .\ @0#N (< [ "- .H DP#I )H YP"A
M .8 J0#C +, X0"_ -\ T #= .D V@#Y -D _P#7 /\ U0#_ -4 _P#5 /\
MU #_ /\)"@#_ 04 _P # /\ "0#_ !  _P 9 /L )@#W #0 ] !  /( 3 #N
M %8 Z@!? .< 9P#D &X X@!T .  >P#> ($ W "' -H C0#6 )0 U "; -$
MHP#/ *T S "X ,H QP#( .  Q@#S ,4 _P## /\ PP#_ ,, _P## /\ PP#_
M /\+ 0#_ P  _P   /\  P#_  L \P 2 .X 'P#J "T Y@ Z .( 10#> $\
MV0!8 -0 8 #1 &@ S@!N ,P = #* 'L R "! ,8 AP#$ (X P@"6 ,  G@"^
M *< NP"R +D P "W -0 M0#L +, ^P"S /\ L@#_ +( _P"Q /\ L0#_ /\-
M  #_!@  _P,  /<   #T  , YP - .  & #: "4 TP R ,X /@#* $D Q@!2
M ,, 6@#  &$ O@!H +P ;@"Z '0 N ![ +8 @0"T (@ L@"0 +  F0"N *(
MK "M *H N@"H ,L I@#F *4 ]P"D /\ HP#_ *( _P"B /\ H@#_ /\0  #[
M#   [PX  .8-  #?"0  V@ & -  $0#) !T Q  J +\ -P"[ $( MP!+ +0
M5 "R %L KP!B *T : "K &X J0!U *@ >P"F (, I "+ *( E "@ )X G@&H
M )P"M0"; \8 F07B )@&] "6"/\ E0G_ )0)_P"4"?\ E G_ /P1  #Q%0
MXQD  -89  #,%0  QQ   ,0'"@"] Q0 MP0A +(&+@"N"#H J@E$ *<)30"D
M"E4 H@I< * *8@">"VD G MO )L+=@"9#'X EPR& )8,D "4#)H D@VF )$-
MLP"/#<4 C0[B (L0]@")$/\ B!'_ (<1_P"'$?\ AQ'_ /89  #G(   UB0
M ,@E  "_(@  N1P  +04 0"Q#0X J@X9 *4/)P"A$#, G1$^ )H11P"8$D\
ME1)6 ),27 "1$F, D!-I (X3< ",$W@ BQ.! (D4BP"'%)8 AA6B (05L "#
M%L$ @1?= '\8] !]&?\ ?!G_ 'P9_P![&?\ >QG_ .\A  #=*0  RBT  +XO
M  "U+   KB<  *@@  "C%P@ GA83 )D7(0"4&2T D1HX (X:00"+&TD B1M0
M (<;5P"%'%X A!QD ((<:P" '', ?QU\ 'T=A@!\'I$ >AZ> '@?JP!W'[P
M=B#4 '0A\ !R(?\ <2+_ '$A_P!Q(?\ <2'_ .@H  #2,   PC4  +<W  "M
M-0  I3$  )XK  "8(P( DAX0 (T@&P")(2< AB(R (,C/ "!(T0 ?B-+ 'PD
M4@![)%D >21? '<D9@!V)6X ="5W ',E@0!Q)HT ;R:9 &XFIP!M)[@ ;"?.
M 6HH[0%I*?\!:"G_ 6@I_P%H*/\!:"C_ >$N  #+-@  O#L  +$]  "G/0
MGSD  )<S  "/+0  B"<, (,G%@!_*"( ?"DM 'DJ-P!W*C\ =2I' ',K3@!Q
M*U0 <"M; &XK8@!L*VH :RQR &DL?0!H+(D 9BV6 64MI %D+K0!8R[* 6$O
MZ0%@+_T!8"__ 6 O_P%@+_\!8"[_ =HT  #%/   MT$  *Q#  "B0P  F4
M ) Z  "(-   @"X( 'HM$@!W+AX <R\I '$P,P!O,#L ;3!# &LQ2@!I,5$
M9S%7 &8Q7@!D,68 8S)O &$R>0!@,H4!7S*2 5TSH0%<,[$!6S3& 5HTY@%9
M-?L!637_ 5DT_P%9-/\!633_ =(X  # 0   LT4  *A(  ">2   E48  (M
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M 4T^_P%-/?\!33W_ <E   "X2   K$T  *%0  "740  CD\  (1+  !Y10
M;D   &8]"P!B/10 7ST> %P^* !:/C$ 6#XX %<^0 !5/T8 5#]- %,_50!2
M0%T 4$!F $] < %.0'P!3$&* 4M!F@)*0:L"24*^ DA"W@)(0O8"2$+_ DA"
M_P%(0?\!2$'_ <5$  "U2P  J5   )Y4  "55   BU,  (!0  !U2@  :D8
M &%"" !<01$ 64(; %=")0!50BX 4T(U %%"/0!/0D, 3T-+ $Y#4@!-1%H
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M ;I.  "L5@  H5L  )=?  "-80  @V$  'A>  !I6   7U8  %12  !,3PL
M24\2 $=0' !%4"4 0U M $)0-0!!43P 0%%$ #]13  ^4E0 /%)= #M29P Z
M4G, .%." 3=3D@$U4Z0!-%.W 3-4T0$S4_$!-%/_ 312_P$T4O\!-%+_ ;92
M  "I6@  GF   )1D  "+9@  @&4  '1C  !F7@  7%P  %%8  !'50< 0E40
M $!5&  _5B$ /58J #Q6,@ [5CD .E=! #E720 X5U$ -UA: #5890 T6'$
M,EB  3%8D $O6:(!+EFU 2U9SP$M6>\!+EC_ 2Y7_P$N5_\!+E;_ ;)7  "E
M7P  FV4  )%I  "':@  ?&H  '%H  !C90  6&(  $U?  !#70( /%L- #I<
M%  X7!T -UPF #5=+@ T738 ,UT^ #)=1@ Q7DX ,%Y7 "]>8@ M7FX +%]]
M "I?C@ I7Z  *%^S 2=?S  G7^T!)U[_ 2==_P$H7?\!*%S_ :U<  "B9
MF&H  (YN  "#;P  >6\  &YN  !@:P  5&D  $EG   _90  -6,) #)C$0 P
M8QD +V0A "YD*0 M9#$ +&0Y "ME0@ J94H *&54 "=E7P F9FL )&9Z "-F
MBP B9IT (&:Q !]FR0 ?9NL (&7^ "!D_P @8_\!(6/_ :EB  ">:@  E7
M (IS  " =0  =74  &ET  !<<@  3W$  $1O   Z;@  ,&T# "EL#0 G;!0
M)FP< "5M)  D;2P (VTT ")M/0 A;D8 (&Y0 !YN6P =;F< '&YV !INAP 9
M;YH &&^N !9OQ@ 6;ND %VW\ !AL_P 8:_\ &&O_ *1I  ":<0  D'8  (9Y
M  !\>P  <7L  &1[  !7>@  2GD  #]X   U>   *W<  ")V!P ==@\ ''<6
M !MW'@ :=R8 &7<N !AW-P 7>$  %7A* !1X5@ 3>&, $GAR !%X@P 0>)<
M#WBK  YXPP .=^8 #G;Z  ]U_P 0=?\ $'3_ )]Q  "5>   BWP  ()_  !W
M@0  :H(  %V"  !0@@  1((  #B"   N@@  )((  !R"   4@@D $8,0 !"#
M%@ 0@QX #H,G  Z#,  -@SD #8-$  R#4  +@UT "8-L  B#?@ &@Y$ !8*E
M  ."NP $@=L !('R  6 _P &?_\ !G__ )IY  "0?@  AH,  'V%  !OAP
M8HD  %6*  !)BP  /8P  #&,   FC   '8T  !6.   /CP, "I ,  :0$0 $
MCQ@  X\@  &/*0  CS(  ) ]  "020  CU8  (]E  "/=@  CXH  (Z?  ".
MM   C<\  (SN  ",^P  B_\  (O_ )2   "+A0  @HD  '2,  !FCP  69$
M $R3  ! E0  -)8  "B6   >EP  %9@   ^:   *FP   IP)  "<#@  G!,
M )P:  "<(@  G2L  )TU  "=0   G4X  )U<  "=;@  G($  )R7  "<K
MF\8  )KH  "9^0  F?\  )C_ (Z(  "&C   >)   &J4  !<EP  3YH  $*=
M   VG@  *9\  !^A   5H@  #J0   BF    J    *D$  "I"@  J0X  *D3
M  "J&@  JB(  *LK  "L-@  K$0  *Q3  "L8P  K'<  *N.  "KI   J[P
M *K>  "I]   J?T  *G_ (F.  ![DP  ;9<  %^<  !1H   1*0  #:F   J
MJ   'JD  !2K   -K@  !K    "R    M0   +4   "U P  M@D  +<.  "X
M$@  N!D  +HA  "[*P  O#@  +U'  "]6   O6L  +V!  "]F0  O;   +W,
M  "\Z@  O/<  +O^ 'Z5  !PFP  8J   %.E  !&J@  .*T  "JO   >L0
M$[0   RW   #N0   +P   "_    P@   ,(   ##    Q    ,8&  #'#
MR!   ,H6  #,(   SRL  - Z  #12P  T5X  -)S  #2BP  TJ0  -.[  #3
MV   T^T  -/V '.=  !DHP  5JD  $>O   YLP  *K8  !VY   2O   "K\
M  ##    Q@   ,D   #-    SP   -    #2    U    -8   #9 @  VP@
M -X.  #A$P  Y!T  .@J  #H/   Z4\  .ED  #J?   ZY4  .NL  #KP@
M[-4  .SE &:F  !8K   2;,  #NY   KO   '<   !'$   )R    ,P   #/
M    TP   -D   #=    X    .$   #C    Y0   .<   #J    [    .X$
M  #Q"P  ]1(  /@<  #[*P  _3X  /Y3  #^:@  _X,  /^;  #_K@  _[X
M /_* /\ $@#_ !  _P 1 /\ $P#_ !D _P F /\ - #_ $$ _P!- /\ 6 #_
M &( _P!K /\ <P#_ 'H _P"! /\ AP#_ (T _P"3 /\ F0#_ *  _P"G /X
MKP#\ +H ^@#) /D X0#X /, ]P#_ /8 _P#U /\ \0#_ .D _P#D /\ X0#_
M /\ #P#_  T _P - /\ #@#_ !0 _P A /\ +@#_ #P _P!( /\ 4P#_ %T
M_P!F /X ;0#\ '4 ^P![ /D @@#X (@ ]P". /8 E #T )L \P"B /$ J@#O
M +0 [0#! .L U0#J .P Z #\ .< _P#E /\ Y@#_ .  _P#9 /\ U #_ /\
M"P#_  @ _P & /\ "0#_ !  _P < /\ *0#_ #8 _P!" /L 3@#W %< ] !@
M /( : #O &\ [0!V .P ? #J (( Z "( .< C@#E )4 XP"< .$ I #? *X
MW0"Y -H R@#7 .0 U #V -$ _P#0 /\ T #_ ,\ _P#+ /\ QP#_ /\  P#_
M    _P   /\ ! #_  T ^@ 6 /8 (P#S #  \  \ .T 1P#I %$ Y0!: .(
M8@#? &D W0!O -H =@#8 'P U "" -( B #0 (\ S0"6 ,L G@#) *@ QP"S
M ,4 P0#" -@ P #O +\ _@"^ /\ O0#_ +P _P"\ /\ O #_ /\"  #_
M_P   /\   #T  < [0 1 .@ ' #C "D WP U -L 00#6 $L T0!4 ,T 7 #*
M &, R !I ,8 ;P## '4 P0![ +\ @@"^ (@ O "0 +H F "X *( M0"L +,
MN0"Q ,L KP#G *X ^ "L /\ JP#_ *P _P"L /\ JP#_ /\$  #_    ]@
M .X   #G    WP , -8 %0#/ "( R@ N ,< .@## $0 P !- +P 50"Y %P
MMP!C +4 :0"S &\ L0!U *\ >P"M (( JP"* *D D@"G )P I0"F *, LP"A
M ,, GP#> )X \@"= /\ G #_ )P _P"; /\ FP#_ /\'  #V"0  Z0L  -\*
M  #5!   S@ % ,8 $ #  !H NP G +< ,@"S #T L !& *T 3P"J %8 J !<
M *8 8P"D &@ H@!O *$ =0"? 'P G0"$ )L C0"9 )< EP"B )4 K@"3 +T
MD0#3 )  [0"/ /P C@#_ (T!_P"- ?\ C0'_ /D.  #J$@  W!4  ,T5  #$
M$0  O@P  +H""@"T !( K@ > *H *@"F #4 H@ _ *  2 "= 5  FP)6 )D"
M7 "7 V, E0-I ),#;P"1!'8 D 1_ (X%B ",!9( B@:> (@&J@"&![H A0C/
M (0*ZP"""_P @0S_ ( ,_P" #/\ @ S_ /$5  #@'0  S2   ,$A  "X'0
ML1<  *P0  "H"0T H@<6 )T)(P"9"BX E0LX ),,00"0#$D C@U0 (P-5P"*
M#5T B UC (<-:@"%#G$ @PYZ ((.A " #H\ ?@^; 'P/J ![$+@ >A#. '@1
M[ !V$O\ =1+_ '03_P!T$_\ =!/_ .@>  #3)@  PRH  +@J  "N*   IR,
M * <  ";$P, E@\0 ) 0&P",$2< B1(R (83.P"$$T, @A1+ ( 440!^%%<
M?!1> 'L590!Y%6P =Q5T '86?@!T%HH <A>6 '$7I !O&+0 ;AC) &T9Z !K
M&OP :AO_ &H;_P!J&_\ :AO_ . F  #*+0  O#$  + S  "G,0  GRP  )<F
M  "0'P  BA<, (48%@"!&2( ?AHL 'L;-@!Y&SX =QQ% '4<3 !S'%, <1U9
M ' =8 !N'6< ;1YP &L>>@!J'H4 :!^2 &<?H !E(+  9"'% &,AY !B(OH
M82+_ &$B_P!A(O\ 82+_ -<L  ##-   MC@  *HY  "A.   F#4  ) O  "(
M*   @"$( 'L@$@!W(1T ="(G '$B,0!O(SD ;2-! &LC2 !I(TX :"15 &8D
M6P!E)&, 8R5K &(E=0!A)8$ 7R:. %XFG0!=)ZT 6RC! %LHX !:*?< 62G_
M %DI_P!9*?\ 62C_ ,\R  "^.0  L3T  *8_  "</P  DSP  (HV  "!,
M>2H# '(F#P!N)QD :R@C &DH+ !F*34 92D\ &,I0P!A*DH 8"I1 %XJ5P!=
M*E\ 7"MH %HK<@!9+'T 6"R+ %8MF@!5+:H 5"Z] %,NW !2+_4 4B__ %(N
M_P!2+O\ 4B[_ ,HV  "Z/0  K4(  *)$  "81   CT$  (4\  ![-P  <C$
M &LL# !G+14 9"T? &$N* !?+C$ 72XY %PO0 !:+T8 6"]- %<O5 !6,%P
M53!D %,Q;@!2,7H 43&( % REP!.,J@ 33.[ $TTV !,-/, 3#3_ $PT_P!,
M,_\ 3#/_ ,8Z  "V0@  J48  )Y)  "520  BT<  (%"  !W/0  ;3<  &0R
M"0!@,A( 73(< %HR)0!8,RT 5C,U %4S/ !3-$, 4C1* %$T40!0-%D 3S5A
M $TU; !,-G< 2S:% $HWE0!(-Z8 1SBX 4<XTP%&./$!1CC_ 48X_P!&./\
M1C?_ ,$^  "R10  IDH  )Q-  "230  B$L  'Y'  !S0@  :3T  %\W!@!:
M-A  5S<8 %0W(@!2-RH 4#<R $\X.0!-.$  3#A' $LX3@!*.58 23E? $@Z
M:0!'.G4 13N# $0[DP!#/*0!0CRV 4$]T %!/? !03W_ 4$\_P%!//\!03S_
M +Y"  "O20  HTX  )E0  "/40  A5   'M,  !O1@  94(  %H] @!4.PX
M43L5 $\['P!-.R< 2SLO $D\-@!'/#T 1SQ$ $8]2P!%/50 1#Y< $,^9P!"
M/W, 0#^! #\_D0 ^0*( /4"U 3Q!S@$\0>X!/$'_ 3Q _P$\0/\!/3__ ;I%
M  "L3   H5$  )=4  "-50  @U0  'A1  !L2P  84<  %9"  !/0 P 3#\3
M $E ' !'0"0 1D L $1 ,P!#0#H 0D%" $%!20! 0E$ /T): #Y#90 ]0W$
M.T-_ #I$CP Y1*  .$6S 3=%RP$W1>P!-T7_ 3=$_P$X1/\!.$/_ +=)  "I
M4   GE4  )18  "+60  @%@  '96  !H4   74P  %-(  !*10D 1D01 $1$
M&0!"1"( 044I #]%,0 ^13@ /44_ #Q&1P [1D\ .D=8 #E'8@ X2&X -DA\
M #5(C0 T29X ,TFQ #))R0 Q2>L ,DG^ #)(_P R2/\ ,TC_ +1,  "G5
MG%D  ))<  "(70  ?ET  '-:  !E50  6U(  %!.  !&2@4 0$D. #Y)%@ ]
M21X .THF #I*+@ Y2C4 .$L] #=+1  V2TT -$Q6 #-,8  R3&P ,4UZ #!-
MBP N39P +4ZO "Q.QP L3ND +$W] "U-_P M3/\ +4S_ +!0  "D6   F5T
M (]A  "&8@  >V$  '!?  !B6P  6%@  $Y5  !#40$ .T\, #A/$P V3QL
M-4\C #10*P S4#( ,E Z #%00@ P44H +E%3 "U270 L4FD *U)X "E2B  H
M4YH )U.M "93Q0 F4^< )E/\ "=2_P G4?\ )U'_ *Q5  "@7   EF(  (UF
M  "#9P  >&8  &UE  !@80  55X  $I;   _6   -58( #%5$  P5A< +E8?
M "U6)P L5B\ *U<V "I7/@ I5T< *%=0 "986@ E6&< )%AU "-9A@ A69@
M(%FK !]9P@ ?6>4 'UCZ "!8_P @5_\ (5?_ *A:  "=8@  DV<  (IK  !_
M;   =6P  &IK  !=:   464  $9C   [8   ,5X# "I=#0 H71, )ET; "5>
M(P D7BH (UXR ")>.@ A7D, (%], !]?5P >7V, '&!Q !M@@@ 98)4 &&"I
M !=@P  68.( %U_Y !A>_P 97O\ &5W_ *1@  "9:   D&X  (9P  !\<@
M<G(  &9Q  !8;@  3&P  $%K   V:0  +6<  "-F"  ?9@\ '685 !QF'0 ;
M9B4 &F8M !EG-0 89SX %V=( !9G4P 5:%\ $VAN !)H?P 1:)( $&BF  ]H
MO0 .:.  $&?W !!F_P 19?\ $67_ )]G  "6;P  C',  ()V  !X>   ;7@
M &!W  !3=@  1G0  #MS   Q<@  )W$  !YQ   6< H $W 0 !-P%P 2<!\
M$7$G !!Q+P 0<3@ #G%"  YQ3@ -<5L #'%I  MQ>@ *<8T "'&A  9QM@ &
M<-( !W#O  AO_P );O\ "6[_ )MO  "1=0  AWD  'Y\  !T?@  9GX  %E^
M  !-?@  0'T  #5]   J?   (7P  !A\   1? 0 #'P,  I\$0 )?!D "'PA
M  =\*0 &?#( !'P]  -\2  !?%4  'QC  !\=   ?(<  'N<  ![L0  >LL
M 'GK  !Y^@  >?\  'C_ )9W  ",?   @X   'F#  !LA   7H4  %&&  !%
MAP  .8<  "V'   CAP  &H<  !*'   -B $ !HD*  &)#P  B10  (@;  "(
M(P  B2P  (DV  ")0@  B$X  (A=  "(;0  B($  (>5  "'JP  AL0  (7F
M  "$^   A/\  (3_ )!^  "'@P  ?H<  '&)  !CBP  5HT  $F/   \D0
M,)$  "21   :D@  $I,   V4   &E0   )8&  "6#   E1   )85  "6'0
MEB0  )8N  "6.0  ED8  )95  "690  EG@  )6.  "5I   E+P  )/?  "3
M]0  DO\  )+_ (N&  "#B@  =8T  &>0  !9E   3)<  #^9   RF@  )IL
M !N<   2G0  #)\   2@    H@   *,!  "C!P  HPP  *,0  "D%0  I!P
M *4E  "F+P  ICP  *9+  "F6P  IFX  *6$  "EFP  I+,  */0  "C[P
MHOP  *+_ (:-  !XD0  :I4  %R9  !.G0  0:   #.B   FHP  &Z4  !&G
M   *J0   :L   "M    KP   +    "P    L 4  +$+  "R#P  LQ0  +0;
M  "U)   MS   +<_  "W4   MV(  +=X  "WD   MJD  +;"  "VY   MO4
M +7^ 'N3  !MF   7YT  %"B  !"I@  -*D  ":K   :K0  $*\   FR
MM    +<   "Z    O    +T   "^    O@   , "  #!"   P@T  ,02  #&
M&0  R20  ,HR  #+0P  RU4  ,QJ  #,@P  S)P  ,NU  #,S@  S.D  ,SV
M '";  !AH0  4J8  $2K   VL   )[(  !JU   0N   ![L   "^    P0
M ,0   #(    RP   ,L   #-    S@   -    #2    U0,  -@*  #;$
MWA@  .(D  #C-0  Y$@  .5<  #F<P  YHT  .:E  #FO   YM,  .?G &.D
M  !5J@  1K   #BU   HN0  &KP   _    %Q    ,<   #+    SP   -0
M  #8    W    -T   #?    X0   .,   #E    Z    .H   #M!@  \0X
M /46  #X)0  ^3@  /E-  #Z8P  ^WP  /R5  #\J@  _+L  /W+ /\ #P#_
M  X _P . /\ $ #_ !8 _P C /\ , #_ #T _P!) /\ 5 #_ %X _P!F /\
M;@#_ '8 _P!\ /\ @@#_ (D _P"/ /\ E0#^ )L _0"C /L JP#Z +4 ^0##
M /< VP#V /  ] #_ /, _P#R /\ [ #_ .( _P#< /\ U@#_ /\ # #_  D
M_P ( /\ "@#_ !( _P > /\ *P#_ #@ _P!$ /\ 3P#_ %D _@!A /P :0#Z
M '  ^ !W /< ?0#V (, ] ") /( CP#Q )8 [P"= .T I0#L *\ Z@"\ .@
MS0#F .@ Y #Z ., _P#B /\ X #_ -4 _P#. /\ RP#_ /\ !@#_  $ _P
M /\ ! #_  X _P 9 /\ )0#] #( ^P ^ /< 20#S %, \ !< .X 8P#L &H
MZ@!Q .@ =P#F 'T Y "# .( B0#@ )  W@"7 -P GP#9 *D U@"T -, Q #0
M -X S@#S ,P _P#+ /\ R@#_ ,@ _P#" /\ O@#_ /\   #_    _P   /\
M  #[  L ]@ 3 /$ ( #M "P Z@ X .< 0P#C $T X !6 -P 70#9 &0 U0!K
M -( <0#0 '8 S@!\ ,P @P#* (D R "1 ,8 F0#$ *, P0"M +\ NP"] ,\
MNP#K +D _ "W /\ MP#_ +8 _P"T /\ L0#_ /\   #_    _P   /8   #N
M  4 YP / .$ &0#; "4 U0 Q -( / #. $8 R@!/ ,< 5P#$ %X P0!D +\
M:@"] '  NP!V +D ? "X (, M@"* +, DP"Q )P KP"G *T LP"K ,4 J0#A
M *< ]0"F /\ I0#_ *0 _P"D /\ I #_ /\   #\    \0   .@   #@
MU  + ,P $P#' !\ P@ J +\ -0"\ #\ N !( +4 4 "S %< L !> *X 9 "L
M &D JP!O *D =0"G 'P I0"$ *, C "A )8 GP"A )T K0": +P F #2 )<
M[@"5 /X E #_ )4 _P"5 /\ E0#_ /P!  #P!0  XP<  -4%  #,    Q0 $
M +X #@"X !< LP C *\ +@"K #@ J0!! *8 2@"C %$ H0!7 )\ 70"= &,
MFP!I )H ;P"8 '8 E@!] )0 A@"2 )  D "; (X IP", +8 B@#) (@ YP"'
M /D AP#_ (8 _P"& /\ A@#_ /0,  #D$   T1(  ,41  "]#@  M@@  +$
M" "K !$ I@ ; *$ )@"> #$ F@ Z )@ 0P"5 $H DP!1 )$ 5P"/ %T C@!C
M (P :0"* '  B !W (8 @ "$ (L @@"6 (  HP!^ +$ ?0#$ 'L"X0!Z _4
M>@7_ 'D%_P!X!O\ > ;_ .H3  #6&@  QAT  +H<  "Q&0  JA,  *0-  "?
M!0P F0 4 )4 'P"1 BD C0,S (L$/ "(!40 A@9+ (0&40""!U< @0== '\'
M8P!]"&H >PAR 'H(? !X"88 =@F2 '0*H !S"J\ <0O! ' ,WP!O#?8 ;@[_
M &T._P!M#O\ ;0[_ .$<  #+(P  O"8  +$F  "H)   H!X  )D8  "3$ (
MC@L. (@+%P"$#"( @0TL 'X--0!\#CT >@Y% '@.2P!W#E$ =0]8 ',/7@!Q
M$&4 <!!N &X0=P!L$(( :Q"/ &D1G0!H$:T 9A+  &42WP!D$_8 8Q3_ &,4
M_P!B%/\ 8A3_ -8D  ##*@  M2X  *HO  "@+0  F"@  ) B  ")&P  @A,(
M 'T1$@!Y$AP =A,G ',4, !Q%#@ ;Q4_ &T51@!L%4P :A93 &@660!G%F$
M919I &07<@!B%WX 81B+ %\8F0!>&:D 7!F\ %P:V !:&_, 6AS_ %D<_P!9
M'/\ 61S_ ,TJ  "],0  KS4  *0V  ";-   DC$  (DK  "!)0  >1T# ',8
M#@!O&1@ ;!HB &D;*P!G&S, 91P[ &0<00!B'4@ 8!U. %\=50!='5P 7!YD
M %L>;@!9'WD 6!^' %8@E@!5(*8 5"&X %,AT@!2(O$ 4B/_ %(C_P!2(O\
M4B+_ ,@O  "X-@  JSH  * \  "6.P  C3@  (,R  !Z+0  <B8  &H@# !F
M(!, 8R$= &$A)@!?(B\ 72(V %LB/0!:(T0 6"-* %<C40!5(U@ 5"1A %,D
M:@!1)78 4"6# $\FDP!.)Z, 3">U $PHS@!+*.X 2RG_ $LH_P!+*/\ 2RC_
M ,,T  "S.P  IS\  )Q!  "20   B3X  '\Y  !U,P  ;"T  &,G" !>)A$
M7"89 %DG(@!7)RL 52@R %0H.0!2*$  42A& % I30!.*54 32E= $PJ9P!+
M*G, 22N  $@KD !'+*$ 1BVS $4MRP!%+NP 1"[_ $0N_P!%+?\ 12W_ +XX
M  "P/P  I$,  )E%  "/10  A4,  'L^  !Q.0  9S0  %XN! !8*PX 52L6
M %(L'P!0+"< 3RPO $TM-@!,+3P 2BU# $DM2@!(+E( 1RY: $8O9 !%+W
M0S!^ $(PC0!!,9X 0#*Q #\RR  _,^H /S/^ #\R_P _,O\ /S+_ +L\  "M
M0P  H4<  )9)  ",20  @T@  'A$  !M/@  8SD  %HT  !2, P 3S 3 $PP
M' !*,"0 23$K $<Q,@!&,3D 1#%  $,R1P!",D\ 03-8 $ S8@ _-&T /C1[
M #TUBP \-IP .S:O #HWQ@ Y-^@ .3?\ #HW_P Z-O\ .C;_ +=   "J1@
MGDL  )1-  "*3@  @$P  '5(  !J0P  8#X  %8Y  !--0D 2301 $<U&0!%
M-2$ 0S4H $$U+P! -38 /S8] #XV10 ]-TT /#=5 #LX8  Z.&L .3EY #@Y
MB0 W.IL -3JM #4[Q  T.^8 -#O[ #4[_P U.O\ -3K_ +1#  "G2@  G$X
M ))1  "(4@  ?E   '--  !G2   7$0  %(_  !(.@8 1#D/ $$Y%@ _.1X
M/CDF #PY+0 [.C0 .CH[ #D[0@ X.TH -SQ3 #8\70 U/6D -#UW #,^AP Q
M/ID ,#^K "\_P@ O/^0 +S_Z # __P P/O\ ,#[_ +%'  "D30  F5(  (]5
M  "&5@  ?%4  '%2  !D3   64D  $]%  !%0 , /SX- #P^$P Z/AL .3XC
M #<^*@ V/S$ -3\X #0_0  S0$@ ,D!1 #%!6P P06< +D)U "U"A0 L0Y<
M*T.J "I#P  I1.( *D/Y "I#_P K0O\ *T+_ *Y*  "A40  EU8  (U9  "#
M6@  >5H  &Y7  !A4@  5TX  $U+  !#1P  .D,* #9#$0 T0Q@ ,T,@ #)$
M)P Q1"\ ,$0V "]%/0 M148 +$5/ "M&60 J1F0 *4=R "A'@P F1Y4 )4BH
M "1(O@ C2.  )$CW "5'_P E1_\ )D?_ *I/  "?50  E%H  (M>  "!7P
M=UX  &M<  !?6   554  $M1  ! 30  -4H' #!)#@ N214 +4D= "Q))  K
M2BL *DHS "A*.P G2T, )DM, "5+5@ D3&( (TQP "%,@  @39, 'TVF !Y-
MNP =3MT 'DWV !Y,_P ?3/\ ($O_ *=3  "<6@  DE\  (AC  !^9   =&,
M &EA  !<7@  4EL  $=8   \50  ,E(" "I0#  G3Q( )E 9 "50(  D4"@
M(U O ")1-P A44  (%%) !Y24P =4E\ '%)M !I3?0 94Y  &%.D !93N0 5
M4]D %E/T !=2_P 84?\ &5'_ *-9  "88   CV4  (5H  ![:0  <6D  &9G
M  !99   36$  $)?   X7   +EH  "58"  @5PX 'E<4 !U7'  <6", &U@K
M !I8,P 96#P &%A% !994  565L %%EI !-:>@ 26HT $5JA !!:MP .6M4
M$%GS !!9_P 16/\ $5C_ )]?  "59@  C&L  ()M  !X;@  ;F\  &)M  !5
M:@  2&@  #YF   S90  *6,  "!A 0 88 L %6 0 !1@%P 38!X $F F !)@
M+@ 183< $&%   ]A2P .85@ #6%F  QB=@ +8HD "F&=  EAL@ (8<L "&'K
M  E@_0 *7_\ "U__ )MF  "2;0  B'$  'YS  !U=0  :G0  %QS  !/<@
M0W   #AO   M;@  )&P  !MK   3:P0 #FH,  UJ$@ ,:AD "VHA  IJ*0 )
M:C( "&H\  =K1P %:U, !&MA  )K<0  :H0  &J8  !JK0  :<8  &GG  !I
M^   :/\  &C_ )=M  "-<P  A'<  'MZ  !P>P  8WL  %9Z  !)>@  /7D
M #%X   G=P  '78  !5V   /=@( "78*  1V#P  =A4  '8<  !V)   =2P
M '4V  !U00  =4X  '5<  !U;   =7X  '23  !TJ   <\   '/C  !R]P
M<O\  ''_ ))U  ")>@  @'X  ':   !I@0  6X(  $Z"  !!@@  -8,  "F"
M   ?@0  %H$  !""   *@@   H,'  ""#0  @A$  ((7  ""'@  @B8  ((O
M  "".P  @D<  ()5  "!90  @7@  (&-  " H@  ?[H  '_=  !^]   ??\
M 'W_ (U\  "$@0  >X0  &Z&  !@B   4HH  $6+   YC   +(P  "&,   7
MC   $(T   F.   "CP   ) #  "/"0  CPX  (\2  "0&   D!\  ) H  "0
M,@  D#\  )!-  "070  CW   (^%  ".G   CK,  (W0  ",\   B_X  (O_
M (B$  " B   <HL  &2-  !6D   2),  #N5   NE@  (I8  !>7   /F
M")D   ";    G0   )T   "= P  G0D  )T-  ">$0  GA<  )\?  "?*0
MH#4  *!#  "@5   H&8  )][  ">DP  GJL  )W&  "=Z0  G/D  )S_ (.+
M  !UC@  9Y(  %F6  !+F0  /9P  #">   CGP  %Z    ZB   'I    *8
M  "H    J@   *H   "J    JP$  *L'  "L#   K1   *X6  "O'@  L2D
M +$X  "Q2   L5H  +%O  "QB   L:   +"Z  "OW0  K_(  *_] 'B1  !J
ME@  7)H  $V?   _HP  ,:8  ".G   7J0  #JL   6N    L    +(   "U
M    MP   +<   "X    N0   +H   "\ P  O0D  +X.  # %   PQX  ,4K
M  #%/   QDX  ,9B  #&>@  QI0  ,:M  #&R   Q>4  ,7S &R9  !>G@
M3Z0  $&H   RK   )*\  !:Q   -M    [<   "Z    O0   ,    #$
MQ@   ,8   #(    R0   ,L   #,    S@   - &  #3#0  V!,  -P>  #>
M+0  WT   .!4  #A:P  X84  .&?  #AMP  X<\  .'F &"A  !2IP  0ZT
M #2R   EM0  %[D   V\   !OP   ,,   #'    R@   ,\   #3    U@
M -<   #:    W    -\   #A    XP   .8   #I 0  [ L  / 2  #S'P
M]#$  /9&  #W7   ^'0  /B/  #YI@  ^;@  /C) /\ #0#_  L _P + /\
M#@#_ !, _P ? /\ + #_ #D _P!% /\ 4 #_ %D _P!B /\ :@#_ '$ _P!W
M /\ ?@#_ (0 _@"* /T D #\ )< ^@"> /D IP#W +$ ]@"^ /4 T@#S .P
M\0#^ /  _P#P /\ Y@#_ -P _P#2 /\ S0#_ /\ !P#_  0 _P " /\ !@#_
M !  _P ; /\ )P#_ #, _P _ /\ 2@#^ %0 ^P!= /D 9 #W &L ]0!R /,
M> #R 'X \ "$ .\ B@#M )$ [ "9 .H H0#H *L Y@"V .0 QP#B ., X #W
M -X _P#= /\ V0#_ ,P _P#% /\ P0#_ /\   #_    _P   /\  0#_  T
M_P 6 /P (@#Y "X ]@ Y /, 10#O $X [ !7 .D 7@#F &4 Y !L .( <@#@
M '< WP!^ -T A #; (L V "2 -4 FP#2 *0 SP"O ,T O@#+ -4 R0#O ,<
M_P#% /\ Q #_ +X _P"X /\ M0#_ /\   #_    _P   /X   #W  D \0 1
M .L ' #G "@ Y  S .$ /@#= $@ V !1 -, 6 #0 %\ S@!E ,P :P#* '$
MR !W ,8 ?0#$ (0 P@", ,  E "^ )X NP"H +D M@"W ,@ M0#F +, ^@"Q
M /\ L #_ +  _P"L /\ J0#_ /\   #_    ^@   /$   #H  , X  - -@
M%@#1 "( S0 M ,H -P#& $$ P@!* +\ 4@"] %D N@!? +@ 90"W &H M0!P
M +, =@"Q 'T KP"% *T C0"K )< J0"A *< K@"E +X H@#8 *  \@"? /\
MG@#_ )X _P"> /\ G #_ /\   #W    ZP   .$   #6    RP ) ,4 $0"_
M !L NP F +< ,0"T #H L0!# *X 2P"K %( J0!8 *< 7@"F &0 I !I *(
M< "@ '8 G@!^ )P A@": )  F "; )8 IP"4 +8 D@#* )  Z0"/ /P C@#_
M (T _P", /\ C0#_ /@   #I @  VP,  ,P!  #$    O0 " +8 #0"P !4
MJP @ *< *@"D #0 H0 \ )X 1 "< $L F@!2 )@ 6 "6 %T E0!C ), :0"1
M '  CP!W (T @ "+ (H B0"5 (< H0"% *\ @P#! ($ X "  /4 ?P#_ '\
M_P!_ /\ ?P#_ .X*  #<#@  RA   +X.  "U"P  KP,  *D !P"C !  G@ 8
M )D (P"6 "P DP U )  /@". $4 C !+ (H 40"( %< A@!= (4 8P"# &H
M@0!Q '\ >@!] (0 >P"/ 'D G !W *H =0"[ '0 U !R /  <@#_ '( _P!Q
M /\ <0#_ .,1  #-%P  OQD  +,9  "J%0  HQ   )T*  "7 0H D0 2 (T
M&P") "4 A0 O (, -P"  #X ?@!% 'T 2P![ %$ >0!7 '@ 70!V &0 = %K
M '(!= !P G\ ;@*+ &P#F !K Z8 :02W &@%S@!G!^P 9@C] &8)_P!E"?\
M90G_ -8:  #$(   MB,  *LC  "A(   F1L  )(4  ",#@$ A@<- ( $% !\
M!AX >0<H '8(, !T"#@ <@D_ ' )10!O"DP ;0I2 &P*6 !J"U\ : MG &<+
M< !E#'H 8PR' &(,E0!@#:0 7PVV %X-S@!<#NT 7 __ %L0_P!;$/\ 6Q#_
M ,TA  "\*   KRL  *0K  ":*0  DB0  (D?  ""&   >Q$% '4-#P!Q#1<
M;@XA &L.*@!I#S( 9Q Y &400 !D$$8 8Q!- &$04P!?$5H 7A%B %P1:P!;
M$78 61*# %@2D@!6$Z( 51.T %03RP!3%.P 4A7_ %(6_P!2%?\ 4A7_ ,8H
M  "V+@  J3(  )\R  "5,0  C"T  (,G  !Z(0  <AH  &L3"P!G$Q, 9!0<
M &$4)0!?%2T 714T %P5.P!;%D( 619( %@63P!6%U8 51=> %,79P!2&'(
M4!A_ $\9C@!.&I\ 3!JP $L;QP!+&^D 2AS] $H<_P!*'/\ 2AS_ ,$M  "Q
M-   I3<  )HX  "0-P  AS0  'TO  !T*0  ;",  &0<!P!>&1  6QH8 %D;
M(0!7&RD 51LP %0<-P!2'#T 41Q$ $\=2P!.'5( 31U: $L>8P!*'FX 21]\
M $<?BP!&()P 12&N $0AQ !#(N8 0R+\ $,B_P!#(O\ 0R+_ +PR  "M.
MH3P  )<^  "-/0  @SH  'DU  !O,   9BH  %XD @!7( T 5" 4 %$@'0!/
M(24 3B$L $PA,P!+(CH 22)  $@B1P!'(DX 1B-7 $0C8 !#)&L 0B1Y $$E
MB  _)ID /B:K #TGP0 ])^, /2CZ #TH_P ])_\ /2?_ +@V  "J/0  GD
M )1"  "*0@  @#\  '8[  !L-@  8C   %DJ  !1)0L 3241 $LE&0!))2$
M1R8H $4F+P!$)C8 0R8] $(G1 !!)TL /RA4 #XH70 ]*6D /"EV #LJA@ Y
M*Y< ."NI #<LOP W+.  -RSX #<L_P W+/\ ."S_ +4Z  "G0   G$0  )%&
M  "'1@  ?40  '-   !H.P  7S8  %4Q  !,*P< 1RD/ $4J%@!#*AX 02HE
M #\J+  ^*S, /2LY #PK00 [+$@ .BQ1 #DM6P X+F8 -BYS #4O@P T+Y4
M,S"G #(PO0 Q,=X ,3'W #(Q_P R,/\ ,S#_ +$^  "D1   F4@  (]*  "%
M2@  >TD  '!%  !E0   6SL  %(V  !(,00 0BX- #\N$P ]+AL .RXB #DO
M*0 X+R\ -R\V #8P/@ U,$8 -#%/ #,Q60 R,F0 ,3)Q # S@0 O-), +C2F
M "PUNP L-=L +#7U "TU_P M-/\ +C3_ *Y!  "B2   ETP  (U.  "#3@
M>4T  &Y*  !B10  6$   $X\  !%-P  /3,+ #DS$0 W,Q@ -C,? #0S)@ S
M,RT ,C0T #$T/  P-40 +S5, "XV5@ M-F( +#=O "LW?P J.)$ *#BD "<Y
MN0 F.=@ )SGT "@Y_P H./\ *3C_ *M%  "?2P  E$\  (M2  "!4P  =U(
M &Q/  !?20  5D8  $Q"  !"/0  .#@( #0X#P R.!4 ,3@= "\X)  N."L
M+3DR "PY.0 K.D$ *CI* "D[5  H.U\ )SQM "4\?0 D/8\ (SVB "(]MP A
M/M0 (3[S "(]_P C/?\ (SS_ *A)  "=3P  DE,  (E6  !_5P  =58  &I3
M  !=3P  4TP  $I(  ! 1   -D % "\]#0 M/1, *ST: "H^(0 I/B@ *#XO
M "<^-P F/S\ )#]( "- 4@ B0%T (4%J "!!>@ >08T '4*@ !Q"M0 ;0M$
M&T+Q !Q"_P =0?\ 'D'_ *5-  ":4P  D%@  (9;  !]7   <EL  &=8  !;
M5   45(  $A.   ]2@  ,T<  "I#"P F0Q  )4,6 "1#'@ C1"4 (D0L "%$
M-  @13P 'D5% !U%3P <1EH &T9H !E&>  81XH %T>> !9'LP 42,X %4?O
M !9'_P 71O\ %T;_ *)2  "76   C5T  (1@  !Z80  <&   &5>  !96@
M3U@  $14   Y40  +TX  "9+!@ @2@X 'DH3 !U*&@ <2B$ &TLH !I+,  9
M2S@ %TM" !9,3  53%< %$QE !--=0 238@ $4V< !!-L0 .3LP #TWN !!-
M_P 13/\ $4S_ )Y7  "470  BV(  (%E  !W9@  ;68  &-D  !680  2EX
M #];   U6   *U8  ")4 0 :4@H %E(0 !52%@ 44AT $U(D !)2+  14C0
M$5(^ !!32  /4U0 #E-B  U4<@ ,5(0 "U28  E4K0 (5,4 "53G  I3^P +
M4O\ "U+_ )M=  "19   B&@  'YK  !T;   :VP  %]J  !29P  160  #IB
M   P8   )EX  !U=   56P4 $%H,  Y:$0 .6A@ #5L@  Q;)P +6S  "ELZ
M  E;10 '6U$ !EM>  1;;0 #6X   5N4  !;J   6\   %KB  !:]@ !6O\
M EG_ )=D  ".:P  A&X  'MP  !R<@  9W$  %EP  !,;@  0&P  #5K   J
M:0  (6<  !AF   19@$ #&4*  =E#P $910  V0;  )D(P  9"P  &0U  !D
M0   9$P  &1:  !D:0  9'L  &2/  !CI   8[L  &+=  !B]   8O\  &'_
M )-L  ")<0  @'4  'AW  !M>   8'<  %)V  !&=0  .70  "YT   C<@
M&G$  !)Q   -<0  !G$(  !P#0  <!(  ' 7  !O'P  ;R8  &\P  !O.P
M;T<  &]4  !O9   ;W4  &Z*  !MH   ;;8  &S6  !K\@  :_\  &O_ (YS
M  "%>   ?7L  '-]  !E?@  6'X  $M^   ^?@  ,GX  "9]   <?   $WP
M  U\   &?0   'T%  !\"P  ? \  'P3  !\&0  ?"$  'PI  !\-   >T
M 'M.  ![7@  >V\  'J$  !ZF@  >;$  'C.  !W[P  =OX  ';_ (EZ  "!
M?P  >((  &N#  !=A0  3X8  $*'   UB   *8<  !V'   4AP  #8@   :)
M    B@   (H   ")!@  B0P  (D/  ")$P  B1H  (HB  "*+   BC@  (I&
M  ")5@  B6@  (E\  "(E   AZL  (;&  "%Z@  A?L  (3_ (6"  !]A@
M;X@  &&+  !3C0  18\  #B1   KD0  'Y(  !22   -DP  !)0   "6
MEP   )@   "7    EP4  )<+  "8#@  F!,  )D:  "9(@  FBX  )H]  "9
M30  F5X  )ES  "8BP  F*,  )>\  "6X@  EO<  )7_ (")  !RC   9(\
M %:3  !(E@  .ID  "R:   ?FP  %)P   R>   #GP   *$   "C    I0
M *4   "E    I0   *8"  "G"   IPT  *@1  "I&0  JR,  *LQ  "K00
MK%,  *QG  "K@   JIH  *JS  "JT   J>\  *G[ '6/  !GE   69@  $J<
M   \GP  +:(  ""C   3I0  "Z<   &I    JP   *X   "Q    L@   +(
M  "S    M    +4   "V    N 0  +D+  "[$   O1@  +\D  "_-0  P$<
M ,!;  # <@  P(T  ,&F  # P0  O^,  +[S &J7  !;G   3:$  #ZE   O
MJ0  (:L  !.M   +L    +,   "U    N    +P   "_    P0   ,$   ##
M    Q    ,8   #'    R0   ,L   #."   T0\  -48  #8)P  V3D  -I-
M  #;9   VWX  -R9  #<L   W,D  -SC %V?  !/I0  0*H  #*O   BL@
M%+4   JX    NP   +\   ##    Q@   ,L   #.    T0   -$   #4
MU@   -D   #;    W@   .    #D    YP8  .L.  #O&0  \"H  /(_  #S
M50  ]&T  /2(  #TH0  ]+8  /3' /\ "0#_  8 _P ' /\ # #_ !$ _P <
M /\ * #_ #0 _P!! /\ 3 #_ %4 _P!= /\ 90#_ &P _P!R /X > #\ 'X
M^P"$ /H BP#Y )( ]P"9 /8 H@#T *P \P"Y /$ RP#P .@ [@#[ .T _P#L
M /\ X0#_ -( _P#) /\ Q #_ /\  0#_    _P   /\ ! #_  X _P 7 /\
M(P#_ "\ _P [ /T 1@#Z %  ]P!8 /0 7P#R &8 \ !L .\ <@#M '@ [ !^
M .H A0#I (P YP"3 .4 G #C *8 X0"Q -\ P0#= -T VP#T -D _P#6 /\
MSP#_ ,0 _P"] /\ N0#_ /\   #_    _P   /\   #_  L _  3 /< '@#T
M "H \@ U .X 0 #I $H Y@!2 ., 60#@ &  W@!F -P ; #: '( UP!X -0
M?@#2 (4 T "- ,X E0#, )\ R0"J ,< N #% ,T PP#K ,  _@"_ /\ O@#_
M +8 _P"P /\ K0#_ /\   #_    _P   /D   #R  8 ZP / .8 &0#A "0
MW@ O -H .0#3 $, SP!, ,P 4P#) %H QP!@ ,4 9@## &L P0!Q +\ =P"]
M 'X NP"& +D C@"W )@ M0"C +, L "Q ,( K@#@ *P ]P"K /\ J@#_ *@
M_P"C /\ H #_ /\   #_    ]0   .L   #A    U@ , ,\ $P#* !X Q@ I
M ,( ,P"_ #T NP!% +@ 30"V %0 LP!: +$ 7P"P &4 K@!J *P < "K '<
MJ0!_ *< AP"E )$ HP"< *  J0"> +@ G #. )H [@"9 /\ EP#_ )8 _P"6
M /\ DP#_ /T   #Q    Y0   -D   #-    Q  & +T #P"W !@ LP B +
M+ "M #8 J0 ^ *< 1@"D $T H@!3 *  60"? %X G0!D )L :@": '  F !W
M )8 @ "4 (H D0"5 (\ H@"- +  BP## (D XP"( /D A@#_ (8 _P"& /\
MA@#_ /,   #C    T0   ,4   "]    M@   *X "P"H !( I  < *  )@"<
M "\ F@ W )< /P"5 $8 D@!, )$ 4@"/ %@ C0!= (L 8P"* &H B !Q (8
M>0"$ (, @@"/ '\ FP!^ *D ? "[ 'H U0!X /( > #_ '< _P!W /\ =P#_
M .<'  #1#   PPT  +@,  "N"   J    *( !0";  X E@ 5 )( 'P". "@
MBP Q (@ .0"& $  A !& (( 3 "  %( ?P!7 'T 70![ &, >@!K '@ <P!V
M 'T = "( '$ E0!P *0 ;@"T &P R@!K .H :@#\ &H _P!J /\ :@#_ -H0
M  #&%   N!8  *T5  "D$@  G X  )8'  "0  D B@ 0 (4 & "! "$ ?@ J
M 'L ,@!Y #D =P!  '4 1@!S $P <@!1 '  5P!N %X ;0!E &L ;@!I '<
M9P"# &4 D0!C )\ 8@"O &  Q !? .0 7P'X %X"_P!> O\ 7@+_ ,X8  "]
M'0  L"   *4?  ";'   DQ<  (L1  "$#   ?@0+ 'D $@!U !L <@ C &\
M*P!M 3, :P$Z &D"0 !G T8 9@-, &0$4@!C!%D 801@ %\%:0!>!7, 7 9_
M %H&C0!9!YP 5PBM %8(P0!5">$ 5 OV %0+_P!4"_\ 5 O_ ,8?  "V)0
MJ2@  )XH  "4)0  BR$  (,;  ![%   = X# &X)#0!I"!0 9@D= &0*)0!B
M"BT 8 LT %X+.@!="T  6PQ' %H,30!8#%0 5PU< %4-9 !4#6\ 4@U[ % .
MB@!/#IH 3@ZL $P/P@!,$., 2Q#Y $L0_P!+$?\ 2Q#_ +\F  "P*P  I"\
M )DO  "/+0  ABD  'TD  !T'@  ;!<  &41!P!?#A  7 \7 %H0'P!8$"<
M5A N %00-0!3$#L 4A%" % 12 !/$5  3A%7 $P28 !+$FL 21)X $@3AP!&
M$Y< 112I $04O@!#%=\ 0Q;X $,6_P!#%O\ 0Q;_ +HK  "K,0  H#0  )4U
M  "+-   @3$  '@K  !O)@  9B   %X9 0!7% T 5!03 %$4&P!/%2, 3A4J
M $P5,0!+%C< 218^ $@61 !'%TP 11=4 $0770!#&&< 01AT $ 9@P _&I0
M/1JF #P;NP [&]L .QSV #P<_P \'/\ /!S_ +4P  "H-@  G#D  )$[  "'
M.@  ?C<  ',R  !J+0  82<  %DA  !1&PD 3!D0 $H:%P!(&A\ 1AHF $4;
M+0!#&S, 0ALZ $$<00! '$@ /AQ0 #T=60 \'F0 .QYQ #D?@  X'Y( -R"D
M #8@N  U(=8 -2'T #4B_P U(?\ -B'_ +(T  "D.@  F3X  (\_  "%/P
M>SP  ' X  !G,@  72T  %0H  !,(@4 1A\. $,?% !!'QL /Q\B #X@*0 ]
M(#  .R V #HA/0 Y(44 .")- #<B5P V(V( -"-N #,D?@ R)(\ ,26B "\E
MM@ O)M( +R;R "\F_P P)O\ ,";_ *\X  "B/@  ED(  (Q#  ""0P  >$$
M &X]  !C.   6C,  %$N  !(* $ 0"0, #TC$0 [)!@ .20? #@D)@ V)"P
M-24S #0E.@ S)D( ,B9* #$G5  P)U\ +RAL "XH>P L*8T *RJ@ "HJM  I
M*L\ *2OP "HK_P J*O\ *RK_ *P\  "?0@  E$8  (I'  " 1P  =D4  &Q"
M  !A/0  5S@  $XS  !$+@  /"D) #<H$  U*!4 ,R@< #(H(P P*"D +RDP
M "\J-P N*C\ +2M( "PK4@ K+%T *BQJ "@M>0 G+8L )BZ> "4NLP D+\T
M)"_N "4O_P E+_\ )B[_ *D_  "=10  DDD  (A+  !^3   =$H  &I'  !>
M0@  5#T  $LY  !!-   ."\& #(M#0 P+1, +BT9 "TM(  K+2< *BXN "DN
M-0 I+ST *"]& "<P3P E,%L )#%H ",Q=P B,HD (3*= !\SL0 >,\L 'C/M
M !\S_P @,_\ (3+_ *9#  ":20  D$T  (9/  !\4   <T\  &A,  !<1@
M4D,  $D_   _.P  -C8" "XR#  K,A$ *3(7 "@R'@ F,B0 )3,K "0S,@ C
M-#H (C1# "$U30 @-5@ 'S9E !XV=0 <-X< &S>; !HWKP 9.,@ &3CK !HX
M_P ;-_\ &S?_ *-'  "830  CE$  (13  ![5   <5,  &90  !:3   4$D
M $=%   ]00  ,ST  "HY"0 E-PX (S<4 "(X&P A."( (#@H !\X,  >.3@
M'3E! !PZ2P :.E8 &3MC !@[<@ 6.X4 %3R9 !0\K0 3/<8 $SWI !0\_0 5
M//\ %CO_ *!+  "540  BU4  ()8  !Y60  ;E@  &16  !840  3D\  $5+
M   Z1P  ,$,  "= !0 @/@T '3X1 !P^%P ;/AX &CXE !D^+0 8/S4 %C\^
M !4_2  40%, $T!@ !)!<  108( $$&7  ]!K  .0L0 #D+G  ]!_  00?\
M$$#_ )U0  "35@  B5H  (!=  !V7@  ;%T  &);  !65P  3%4  $%1   V
M3@  +$L  "-(   ;10D %T0/ !5$%  411L $T4B !)%*0 113$ $44[ !!&
M10 /1E  #D=>  U';0 ,1W\ "T>3  E'IP (1[X "$?@  E']@ *1O\ "T;_
M )I5  "06P  AV   'UB  !S8P  :F(  &!A  !37@  1UH  #Q7   R50
M*%(  !]0   73@0 $4P,  ],$0 .3!< #DP>  U-)0 ,32X "TTW  I-0@ )
M34T !TY:  9.:0 $3GL  DZ/  %.I   3;H  $W;  %-\@ !3?\  DS_ )9;
M  "-8@  A&8  'IH  !Q:0  :&D  %QG  !/9   0F$  #=?   M7   (UH
M !I8   25P$ #58)  E5#@ '51, !E4:  15(@ #52H  E4T  !5/@  54H
M %97  !690  57<  %6+  !5H   5;8  %34  !4\0  4_T  %/_ )-B  "*
M:   @&P  '=N  !O;P  8VX  %9L  !):@  /6@  #)F   G90  '6,  !5B
M   .80  "6 (  -@#0  7Q$  %\7  !?'@  7R8  %\O  !?.@  7T4  %]3
M  !?80  7G(  %Z'  !=G   7;(  %S/  !<[P  6_T  %O_ )!J  "&;P
M?7(  '5T  !J=0  770  $]S  !"<@  -G   "MO   @;@  %VT  !!L   *
M;    FL&  !K"P  :@\  &H4  !J&@  :B$  &DJ  !I-   :4   &E.  !I
M7   :6T  &B"  !HF   9ZX  &;*  !E[0  9?P  &3_ (MQ  ""=@  >GD
M '![  !B>P  57L  $AZ   [>@  +WH  "-Y   9>   $7<   IW   #=P
M '<"  !W"   =@T  '80  !V%0  =AL  '8C  !V+@  =3H  '5'  !U5@
M=6@  '1\  !TD@  <ZH  '+$  !QZ0  </L  '#_ (9Y  !_?0  =G\  &B!
M  !:@@  3((  #^#   RA   )8,  !J#   1@P  "H,   *#    A    (4
M  "$ P  @P@  (,-  "#$   @Q4  (0<  "$)@  A#(  (0_  "#3P  @V
M ()U  ""C   @:0  ("]  !_XP  ?OD  '[_ (*   !ZA   ;(8  %Z(  !0
MB@  0HL  #6-   GC0  &XT  !&.   *C@   (\   "1    D@   )(   "2
M    D@$  )('  "2#   DA   ),5  "3'0  E"@  )0V  "410  DU<  )-K
M  "3@@  DIP  )&V  "0V   C_,  (__ 'Z'  !PB@  88T  %.0  !%DP
M-Y4  "F6   <EP  $9@   F9    FP   )P   ">    H    *    "@
MH    *$   "A!   H@D  *,.  "D%   I1T  *8J  "F.@  IDP  *5@  "E
M>   I9(  *2L  "DR0  H^L  *+Z '..  !DD0  5I4  $>9   YG   *IX
M !V@   1H0  "*,   "E    IP   *D   "L    K@   *X   "N    KP
M +    "Q    L@   +,&  "U#0  MQ,  +D>  "Y+@  ND   +I4  "[:@
MNH4  +FA  "YNP  NMX  +GR &>5  !8F0  2IX  #NB   LI@  ':@  !&J
M   'K    *\   "Q    M    +@   "[    O    +P   "^    OP   ,
M  #"    Q    ,8   #( P  RPL  ,\2  #1(   T3(  -)&  #370  U'8
M -22  #5JP  U<0  -3B %N=  !,H@  /:<  "^L   ?KP  $;$   >U
MN    +L   "^    P@   ,<   #*    S    ,P   #.    T    -(   #5
M    V    -L   #?    X@   .8+  #K$P  ["0  .TX  #N3@  [V<  /""
M  #PG   \+(  /'% /\  P#_  $ _P $ /\ "0#_  \ _P 8 /\ ) #_ #
M_P \ /\ 1P#_ %$ _P!9 /\ 8 #] &< _ !M /H <P#Y 'D ^ !_ /8 A0#U
M (P \P"4 /( G0#P *< [@"S .P Q #K .$ Z@#X .D _P#G /\ V0#_ ,L
M_P#" /\ O0#_ /\   #_    _P   /\   #_  P _P 4 /\ ( #_ "L _@ W
M /H 0@#V $L \@!3 /  6P#N &$ [ !G .H ;0#H ', YP!Y .4 ?P#C (8
MX0". -\ E@#= *  VP"L -@ NP#4 -$ TP#P -  _P#. /\ R #_ +T _P"V
M /\ L@#_ /\   #_    _P   /\   #]  @ ]P 0 /, &@#O "8 [0 Q .@
M.P#C $4 X !- -P 50#9 %L U@!A -, 9P#1 &P SP!R ,T > #+ '\ R0"'
M ,< D #% )H PP"E ,  L@"^ ,4 O #E +H ^P"X /\ MP#_ +  _P"I /\
MI0#_ /\   #_    _@   /4   #L  , Y0 - -\ %0#: "  U  J -  -0#+
M #X R !' ,4 3@#" %4 P !; +X 80"\ &8 N@!L +@ <@"V '@ M0"  +,
MB "Q )( K@"> *P J@"I +L J #5 *8 \P"D /\ HP#_ *$ _P"; /\ F #_
M /\   #[    \    .4   #8    S@ ) ,< $0#" !H O@ D +L +@"W #@
MM !  +$ 2 "N $X K !4 *H 6@"I %\ IP!E *4 :P"D '$ H@!X *  @0">
M (L G "6 )D HP"7 +( E@#' ), Z "2 /X D0#_ )  _P"- /\ BP#_ /D
M  #K    W0   ,\   #&    O  $ +4 #0"P !4 K  > *@ * "E #$ H@ Y
M )\ 00"= $@ FP!. )D 4P"7 %D E@!> )0 9 "2 &H D !Q (X >@", (,
MB@"/ (@ G "& *H A "\ (( W "! /8 @ #_ '\ _P!_ /\ ?@#_ .P   #:
M    R0   +X   "V    K@   *< "0"A !  G  8 )@ (@"5 "H D@ R )
M.@"- $$ BP!' (D 30"' %( A@!8 (0 70"" &0 @0!K '\ <P!] 'T >P"(
M '@ E0!V *, =0"T ', S !Q .T < #_ '  _P!P /\ < #_ -\%  #*"@
MO L  +$)  "H!   H0   )L  P"4  P CP 3 (H &P"' "0 A  L ($ ,P!_
M #H ?0!! 'L 1P!Y $P =P!2 '8 5P!T %T <@!D '  ;0!O '8 ; "" &H
MCP!I )T 9P"N &4 PP!D .0 8P#Z &, _P!B /\ 8P#_ - .  "_$@  LA,
M *<2  "=$   E0L  (\#  ")  < @@ . 'X %0!Z !X =@ E '0 +0!Q #0
M;P Z &X 0 !L $8 :@!, &D 4@!G %@ 9@!? &0 9P!B '$ 8 !\ %X B0!<
M )@ 6P"I %D O !8 -P 6 #T %@ _P!7 /\ 5P#_ ,86  "V&@  JAT  )\<
M  "5&0  C10  (4/  !^"0  =P$* '( $ !N !< :@ ? &@ )P!E "X 9  T
M &( .P!@ $  7P!& %T 3 !< %, 6@!: %@ 8@!7 &P 50!W %, A0!2 )0
M4 &E $\!N !. M( 303P $T%_P!-!?\ 307_ +\=  "P(@  HR4  )DE  "/
M(@  A1T  'T8  !U$@  ;@T" &<&# !C Q$ 7P(9 %T#(0!;!"@ 600O %<%
M-0!6!3L 5 9! %,&1P!1!DX 4 =5 $X'7@!-"&< 2PAS $D)@0!("9( 1PJC
M $4*M@!$"]  1 SO $,-_P!##?\ 1 W_ +DD  "J*0  GBP  )0L  "**@
M@"8  '<A  !N&P  9A0  %\/!0!9"PT 50H3 %,+&P!1"R( 3PPI $T,+P!,
M##8 2PT\ $D-0@!(#4D 1@U1 $4.6@!$#F0 0@YP $ .?P _#Y  /A"B #P0
MM@ [$-$ .Q'Q #L1_P [$?\ /!'_ +0I  "F+P  FC(  ) R  "&,0  ?"T
M '(H  !I(P  81T  %D6  !1$0@ 3 \0 $H0%@!($!T 1A D $40*P!#$3$
M0A$W $$1/@! $44 /A)- #T25@ \$F$ .A-M #D3?  W%(T -A2? #45LP T
M%<T ,Q;N #06_P T%O\ -!;_ *\N  "B-   ES<  (PX  ""-@  >#0  &XN
M  !E*@  7"0  %0>  !,& 0 1A0- $(4$@! %!D /Q0@ #T5)P \%2T .Q4T
M #D6.@ X%D( -Q9* #874P U%UX ,QAJ #(9>0 P&8H +QJ= "X:L0 M&\H
M+1OL "T<_P N&_\ +AO_ *PR  "?.   E#L  (H\  " /   =CD  &LT  !B
M+P  62H  % E  !''P  0!H* #P9$  Z&18 .!D= #8:(P U&BD -!HP #,:
M-P R&SX ,1M' "\<4  N'5L +1UG "P>=@ J'H@ *1^; "@?K@ G(,< )B#J
M "<@_@ H(/\ *"#_ *DV  "=/   DC\  (=!  !]0   =#X  &DZ  !?-0
M5C   $TK  !$)0  .R ' #8>#@ S'A, ,AX9 # >(  O'B8 +A\M "T?-  L
M(#L *R!$ "HA3@ I(5@ )R)E "8B=  E(X4 (R.9 "(DK0 A),4 (27H "(E
M_0 B)/\ (R3_ *8Z  ":/P  CT,  (5%  ![1   <D,  &<_  !=.@  4S8
M $HQ  !!+   ."8# #$C#  N(A$ +"(6 "HB'0 I(B, *",J "<C,0 F)#D
M)25! "0E2P C)E8 (B9C "$G<@ ?)X, 'BB7 !THJP ;*<, &RGF !PI^P =
M*?\ 'BC_ *,^  "80P  C4<  (-)  !Z20  <$<  &9$  !:/P  43L  $<W
M   ^,@  -2T  "PH"0 H)P\ )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D_
M !\J20 >*E0 '2M@ !LK;P :+($ &2R5 !<MJ0 6+<$ %BWD !<M^@ 8+?\
M&2W_ *%!  "51P  BTL  ()-  !X30  ;DP  &1)  !81   3T   $8]   ]
M.   ,S0  "HO!@ D+ T (2P2 " L&  ?+1X 'BTE !TM+  <+C0 &RX\ !HO
M1@ 8+U$ %S!> !8P;0 5,7\ $S&3 !(QJ  1,K\ $3+B !(R^0 3,?\ $S'_
M )Y%  "32P  B4\  (!1  !V4@  ;5   &).  !620  348  $1#   [/P
M,3H  "<V P ?,@L '#(0 !LR%0 9,AL &#(B !<S*0 6,S$ %30Z !0T1  3
M-$\ $C5< !$U:P 0-GT #S:1  XVI@ --[P #3?=  TV]@ .-O\ #S;_ )M)
M  "13P  AU,  'Y6  !U5@  :E4  &!3  !53P  3$P  $))   X10  +D$
M "0]   <.@@ %C@. !4X$@ 4.!@ $SD? !(Y)@ 1.2X $#DW  \Z00 ..DP
M#3M9  T[:  +.WH "CN-  D\H@ '/+@ !SS5  @\\  )._\ "CO_ )A.  ".
M5   A5@  'Q;  !R6P  :%H  %Y8  !350  25(  #Y.   T2P  *D<  "%$
M   80@, $D + ! _$  ./Q4 #C\<  U (P ,0"L "T T  I /@ )04H !T%6
M  9!90 $078  T&*  %!GP  0;0  $'0  %![@ !0?P  D#_ )54  ",60
M@UX  'E@  !P8   9F   %U>  !16P  15<  #I4   O40  )4\  !Q,   4
M2@  #D@(  M'#@ (1Q( !T<9  9'(  %2"@  T@Q  )(.P  2$<  $A3  !(
M8@  2',  $B&  !(FP  2+$  $?,  !'[0  1_L  $?_ )):  ")8   @&,
M '=E  !N9@  968  %ED  !,8   0%T  #5;   J60  (%<  !=5   04P
M"U('  51#0 !4!$  % 6  !0'0  4"4  % N  !0.   4$,  %!0  !07@
M4&\  %"#  !/F   3ZX  $[)  !.ZP  3?L  $W_ (]A  "&9@  ?6D  '1L
M  !L;0  86L  %-I  !&9P  .F0  "]C   D80  &E\  !)>   ,7   !EP&
M  !;"P  6@\  %H3  !:&0  62$  %DI  !9,P  63\  %E,  !96@  66L
M %A^  !8E   5ZL  %?%  !6Z0  5?L  %7_ (QH  "";0  >G   ')R  !G
M<@  6G$  $QP   _;@  ,VT  "AK   =:@  %&@   UG   '9P   &8#  !F
M"0  90T  &41  !D%0  9!P  &0D  !D+@  9#H  &-'  !C50  8V8  &-Z
M  !BD   8:<  &#!  !?Y@  7_H  %[_ (=O  !_=   >'<  &YX  !@>
M4G<  $5W   X=@  *W8  "!T   6<P  #G,   =R    <@   '(   !Q!0
M<0H  '$.  !P$0  <!<  ' >  !P)P  <#,  &]   !O4   ;V   &YT  !N
MBP  ;:(  &R\  !KX@  :O@  &G_ (-W  !\>P  <WT  &5^  !7?P  27\
M #Q_   O@   (G\  !=^   /?@  !WX   !_    ?P   '\   !^    ?@4
M 'X*  !^#0  ?A$  'X7  !^(   ?BL  'TY  !]2   ?5D  'QM  !\A
M>YP  'JV  !YV@  >/4  '?_ (!_  !W@@  :8,  %N%  !-A@  /X@  #*)
M   DB0  &(D   ^)   'B@   (L   ",    C0   (T   ",    C    (P#
M  ","   C0T  (T1  "-%P  CB(  (XO  "./P  C5   (UD  ",>P  C)4
M (NN  "*S0  B>\  (G_ 'N%  !MB   7HH  %"-  !"CP  -)$  ":2   9
MDP  #I0   :5    E@   )@   ":    FP   )L   ";    FP   )L   "<
M    G04  )T+  ">$   GQ<  * D  "@-   H$8  *!9  "?<   GXH  )ZE
M  ">P@  G>@  )SY '",  !ACP  4Y(  $26   VF0  )YL  !F<   /G0
M!9\   "A    HP   *4   "H    J0   *D   "I    J@   *L   "L
MK0   *X!  "P"0  L@\  +,8  "T)P  M#D  +5-  "T9   M'X  +.:  "S
MM   L]4  +/P &23  !5EP  1YL  #B?   IH@  &J0   ZF   $J    *L
M  "M    L    +0   "V    N    +@   "Y    N@   +P   "]    OP
M ,    ##    Q0<  ,D/  #*&@  RRP  ,Q   #-5@  SF\  ,V+  #,J
MS,(  ,SB %B;  !)H   .J4  "RI   <JP  #ZX   2Q    M    +<   "Z
M    O@   ,,   #&    R    ,@   #*    RP   ,T   #/    T@   -4
M  #9    W0   .$%  #F#P  YQX  .@R  #I2   ZF   .M[  #KEP  [*X
M .S" /\   #_    _P   /\ !@#_  T _P 5 /\ (0#_ "P _P X /\ 0P#_
M $P _@!4 /L 6P#Z &( ^ !H /8 ;@#U '0 ] !Z /( @ #Q (< [P"/ .T
MEP#K *$ Z0"M .< O0#E -@ Y #S .( _P#@ /\ T #_ ,0 _P"\ /\ M@#_
M /\   #_    _P   /\   #_  D _P 1 /\ ' #] "< ^0 R /4 /0#Q $8
M[0!/ .L 5@#H %P Y@!B .0 : #C &X X0!S -\ >0#= (  V@"( -@ D0#4
M )L T@"F ,\ M #, ,D R0#I ,@ _P#' /\ P0#_ +< _P"O /\ JP#_ /\
M  #_    _P   /\   #X  4 \@ . .X %P#J "( Y@ L .$ -P#= $  V !)
M -, 4 #0 %8 S@!< ,P 8@#* &< R !M ,8 <P#$ 'D P@"! ,  B@"^ )0
MO "? +D K "V +X M #= +, ]P"Q /\ L #_ *@ _P"B /\ G@#_ /\   #_
M    ^0   .\   #F    WP + -8 $@#0 !P S  F ,@ , #$ #H P !" +T
M2@"[ %  N !6 +8 6P"U &$ LP!F +$ ; "P '( K@!Z *P @@"I (P IP"8
M *4 I0"C +0 H #+ )\ [@"= /\ G #_ )D _P"4 /\ D0#_ /\   #V
MZ@   -T   #/    QP & ,  #P"[ !< MP @ +, *@"P #, K0 [ *H 0P"G
M $D I0!/ *, 50"B %H H !? )X 90"= &L FP!R )D >P"7 (4 E "0 )(
MG0"0 *P C@"_ (P X@"+ /H B0#_ (D _P"& /\ @P#_ /0   #D    U
M ,@   "_    M0 ! *X "P"I !( I0 ; *$ (P"> "P FP T )@ / "6 $,
ME !) )( 3@"0 %, C@!9 (T 7@"+ &0 B0!K (< <P"% 'T @P"( ($ E0!_
M *0 ?0"U 'L SP!Y /$ > #_ '< _P!W /\ =0#_ .4   #1    PP   +@
M  "O    J    *  !@":  X E0 5 )$ '@". "8 BP M (@ -0"& #P A !"
M (( 1P"  $T ?P!2 'T 6 ![ %X >0!E '@ ;0!V '8 <P"! '$ C@!O )T
M;0"N &P Q !J .< :0#] &@ _P!H /\ :0#_ -4#  ##!P  M@@  *L&  "B
M    FP   )0   "-  H B  0 (, & !_ "  ?  G 'H +@!W #4 =0 [ '0
M00!R $< < !, &\ 4@!M %@ :P!? &D 9@!G '  90![ &, B !B )< 8 "G
M %X NP!= -P 7 #V %P _P!; /\ 6P#_ ,D-  "Y$   K!$  *$0  "7#0
MCP@  (@   ""  4 >P - '< $@!S !H ;P A &P * !J "\ :  U &< .P!E
M $$ 8P!& &( 3 !@ %( 7P!9 %T 80!; &H 60!U %< @@!5 )$ 5 "B %,
MM0!1 ,\ 4 #O %  _P!0 /\ 4 #_ +\4  "P&   I!H  )D9  "/%@  AQ$
M '\-  !W!@  <0 ( &L #@!G !0 9  ; &$ (@!> "D 70 O %L -0!9 #L
M6 !! %8 1@!5 $T 4P!4 %( 7 !0 &4 3@!P $P ?0!+ (T 20"> $@ L !'
M ,< 1@#I $8 ^P!& /\ 10#_ +@;  "J(   GB(  ),B  ")'P  @!H  '<5
M  !O$   : L  &$$"@!= !  60 6 %8 '0!4 ", 4@ J %  , !/ #4 3@ [
M $P 00!+ $@ 20!/ $<!5P!& 6$ 1 )L $,">0!! XD 0 .: #X$K0 ]!,0
M/ 7E #P'^  \!_\ / ?_ +(B  "E)P  F2D  (XI  "$)P  >R,  '$>  !I
M&   81(  %H- P!3" P 3P41 $P%%P!*!AX 2 8D $<&*@!%!S  1 <V $,(
M/0!!"$, 0 A+ #X)4P ]"5T .PIH #H*=@ X"X< -PN9 #4+K  T#,( ,PSD
M #,-^0 S#?\ - W_ *TG  "@+   E2\  (LO  " +@  =RH  &TE  !D(
M7!H  %04  !,#P8 1@P- $,,$@!!#!@ /PP? #X,)0 \#2L .PTR #H-.  X
M#3\ -PY' #8.4  T#EH ,PYF #$/=  P#X4 +A"8 "T0JP L$,, *Q'E "P1
M^@ L$?\ +1'_ *HL  "=,0  DC0  (<U  !]-   =#$  &HK  !@)P  6"$
M $\;  !'%@  0!$) #L0#P Y$!0 -Q ; #80(0 T$"< ,Q$M #(1-  Q$3L
M,!%# "X230 M$E< +!)C "H3<0 I$X( )Q25 "84J0 E%<  )!7C "46^@ F
M%O\ )A7_ *8Q  ":-@  CSD  (4Z  ![.0  <38  &<Q  !=+0  5"@  $PB
M  !#'0  .Q<% #44#0 R$Q$ ,107 "\4'0 N%"0 +!0J "L5,0 J%3@ *19
M "@62@ G%U0 )A=@ "08;P C&(  (1F3 " 9IP ?&;X 'AK@ !\:^  @&O\
M(!K_ *,T  "8.@  C3T  (,^  !Y/0  ;SL  &4W  !;,@  4BT  $DH  !
M(P  .!X! # 9"@ L& \ *A@4 "D8&@ G&"  )ADG "49+0 D&C4 (QH^ "(;
M1P A&U( (!Q> !\=;  ='7X '!V1 !H>I0 9'KP &!_= !D?]@ :'_\ &Q[_
M *$X  "5/0  BT$  (%"  !W0@  ;4   &,\  !9-P  3S,  $8N   ]*0
M-20  "T@!P G'0T )1T2 ",=%P A'1T (1TD " >*P ?'C( 'A\[ !T?10 <
M($\ &B%< !DA:@ 8(GL %B*/ !4BHP 4([H $R/: !0C]0 5(_\ %B/_ )X\
M  "300  B40  ']&  !U1@  ;$0  &)!  !7/   33@  $0T   \,   ,RL
M "HF P C(@L ("$0 !XA%0 <(AL &R(A !HB*  :(S  &2,X !@D0@ 6)4T
M%259 !0F:  3)GD $B:- !$GH@ 0)[@ #B?6 ! H]  1)_\ $2?_ )Q   "1
M10  AT@  'U*  !T2@  :DD  &!&  !500  3#X  $,Z   Z-@  ,3(  "@M
M   @*0D &R<. !DG$@ 8)Q@ %B<? !4H)0 4*"T $R@V !(I0  2*4L $2I7
M ! J9@ .*W< #BN+  TLGP ,++4 "RS/  PL[P -+/\ #2O_ )E$  "/20
MA4P  'Q.  !S3P  :4X  %Y+  !31P  2D0  $)    Y/0  +S@  "4T   =
M, 4 %BT, !0L$  3+14 $BT< !$M(P 0+2H #RXS  XN/0 -+T@ #2]5  PP
M8P *,'0 "3"(  @QG  &,;$ !C'+  8QZP ',/P "##_ )=(  "-30  @U$
M 'I3  !Q5   9U(  %U0  !23   24H  $!&   U0@  *SX  "(Z   :-P$
M$C0)  \S#@ .,Q, #3,9  TS(  ,-"@ "S0Q  HU.P (-48 !S52  4V8  $
M-G$  C:$   VF0  -J\  #;(   VZ   -OD  37_ )1-  "*4@  @58  'A8
M  !O60  95@  %M5  !14@  1T\  #Q,   Q2   )T0  !Y!   6/P  $#P'
M  LZ#0 ).A$ "#L7  8['@ %.R8 !#LN  ([.  !/$,  #Q/   \7@  /&X
M #R!   \EP  /*P  #O%   [YP  ._@  #O_ )%2  "(6   ?UP  '9=  !M
M7@  8UT  %I<  !.6   0E0  #=1   M3@  (TL  !I)   21@  #40&  =#
M#  #0Q   $,5  !#&P  0R,  $,K  !#-0  0T   $--  !#6P  0VL  $-^
M  !#E   0JH  $+#  !!Y@  0?D  $'_ (Y8  "&7@  ?6$  '-C  !K9
M8F,  %=A  !)70  /5H  #)8   G50  'E,  !51   .3P  "4T%  )-"P
M3 X  $P3  !+&   2Q\  $LH  !+,@  2ST  $M)  !+5P  2V<  $I[  !*
MD   2:<  $G   !(Y   2/@  $?_ (M?  "#9   >F<  '%I  !I:@  7FD
M %!F  !#9   -V$  "Q?   A70  &%L  !!9   *6    U<#  !7"0  5@T
M %40  !5%0  5!L  %0C  !4+0  5#D  %1%  !44P  5&0  %-W  !3C0
M4J0  %&]  !0X@  4/@  $__ (AG  !_:P  =VX  &]P  !E<   5VX  $IL
M   ]:P  ,&D  "5H   :9@  $60   MC   $8@   &(!  !A!@  8 L  & .
M  !?$@  7Q<  %\>  !>*   7C,  %Y   !>3P  7E\  %UR  !=B   7*
M %NY  !:WP  6?<  %C_ (1N  !\<@  =74  &MV  !==0  3W0  $)S   U
M<P  *'(  !UP   3;P  #&X   1N    ;@   &X   !L @  ; <  &L+  !K
M#@  :Q(  &H9  !J(@  :BT  &HZ  !I20  :5H  &EL  !H@P  9YL  &:U
M  !EV   9/4  &3_ (!U  !Z>0  <'L  &)[  !4?   1GP  #E\   L?
M'WL  !1Z   ->@  !'H   !Z    >@   'H   !Y    >0$  '@&  !X"P
M> X  '@3  !X&@  >"4  '@R  !W00  =U(  '=E  !V?   =94  '2O  !S
MS@  <O$  ''_ 'Y]  !U@   9X$  %B"  !*@P  /(0  "Z%   AA0  %84
M  V%   #A0   (8   "'    B    (@   "'    AP   (<   "'!   APD
M (<.  "($P  B!P  (@I  "(.   ATH  (==  "&<P  AHT  (6G  "$Q0
M@^P  (+^ 'B$  !JA@  7(@  $V*   _C   ,8X  "./   6CP  #9    *1
M    D@   ),   "5    E@   )8   "6    E@   )8   "7    EP   )<'
M  "8#0  F1,  )H?  ":+0  FC\  )I2  "::   F8,  )F?  "8N@  E^(
M );X &V*  !?C0  4)   $&3   SE@  ))<  !:8   -F0   9L   "=
MGP   *$   "D    I0   *0   "E    I0   *8   "G    J    *D   "J
M!   K P  *X3  "N(0  KC,  *Y'  "N70  KG8  *Z3  "NK@  K<T  *SO
M &&1  !3E0  1)@  #6<   FGP  %Z$   VC    I0   *<   "J    K
M +    "R    M    +,   "T    M0   +<   "X    N0   +L   "]
MOP$  ,,+  #%%0  Q24  ,8Y  #'3P  QV@  ,:%  #&H@  QKP  ,;> %69
M  !'G0  .*(  "FF   9J   #:L   "M    L0   +0   "W    N@   +\
M  #!    Q    ,,   #%    Q@   ,@   #*    S0   ,\   #2    U@
M -L   #@#   X1@  .,K  #D00  Y5H  .9T  #FD0  Y:P  .7$ /\   #_
M    _P   /\  0#_  H _P 2 /\ '0#_ "@ _P T /\ /@#] $@ ^@!0 /<
M5P#U %T ] !C /( :0#P &\ [P!T .T >P#K ($ Z0") .@ D@#F )P Y "H
M .( MP#? ,T W #N -D _P#9 /\ R@#_ +X _P"U /\ L #_ /\   #_
M_P   /\   #_  8 _P / /P & #X ", ]  N /  . #K $( Z !* .4 40#B
M %@ X != -X 8P#< &@ V0!N -8 = #4 'L T0"" ,\ BP#- )4 R@"A ,@
MKP#% ,$ P@#C ,  ^P#  /\ NP#_ +  _P"H /\ I #_ /\   #_    _P
M /L   #S  $ [0 , .@ $P#C !X X  H -H ,@#3 #P SP!$ ,P 2P#) %$
MQ@!7 ,0 70#" &( P0!G +\ ;0"] '0 NP![ +D A "W (X M "9 +( IP"O
M +< K0#0 *L \@"J /\ J0#_ *$ _P"; /\ EP#_ /\   #_    ]    .D
M  #@    U0 ( ,X $ #) !@ Q0 B ,$ *P"\ #4 N0 ] +8 10"S $L L0!1
M *\ 5@"N %L K !A *H 9@"I &T I@!T *0 ? "B (8 H "2 )X GP"< *X
MF0## )< YP"6 /\ E0#_ )( _P"- /\ B@#_ /P   #P    XP   -0   #(
M    OP # +D #0"S !, KP < *P )0"I "X I0 V *, /@"@ $0 G@!* )T
M4 "; %4 F0!: )< 7P"6 &8 E !L )( =0"0 'X C@"* (L EP") *8 AP"X
M (4 U@"$ /8 @@#_ ($ _P!^ /\ ? #_ .T   #=    S    ,$   "X
MK@   *< "0"B !  G@ 7 )H 'P"7 "< E  O )$ -P"/ #T C0!# (L 20")
M $X B !3 (8 60"$ %\ @@!E (  ;0!^ '< ? "" 'H CP!X )X =0"O ',
MQP!R .P <0#_ '  _P!P /\ ;@#_ -T   #)    O    +$   "I    H0
M )D  P"3  P C@ 2 (H &0"' "$ A  I ($ , !_ #< ?0 ] 'L 0@!Y $@
M> !- '8 4@!T %@ <@!? '$ 9P!O '  ; ![ &H B !H )< 9@"H &4 O !C
M .$ 8@#Z &$ _P!A /\ 80#_ ,T!  "\!0  KP4  *4"  "<    E    (T
M  "&  @ @0 . 'P % !X !L =0 C '( *0!P #  ;@ V &T / !K $$ :0!'
M &@ 3 !F %( 9 !9 &, 8 !A &D 7P!T %T @0!; )  60"A %< M !6 -
M50#R %4 _P!4 /\ 50#_ ,$,  "R#@  I@\  )L.  "2"P  B04  ((   ![
M  ( =0 + '  $ !L !8 :  = &8 (P!C "H 80 P &  -@!> #L 70!! %L
M1@!: $P 6 !3 %8 6P!4 &0 4@!N %$ >P!/ (H 30"; $P K@!+ ,8 2@#J
M $D _@!) /\ 20#_ +D2  "J%@  GA<  )06  "*$P  @1   'D+  !Q P
M:P & &4 #0!A !$ 70 8 %H '@!8 "0 5@ J %0 , !3 #8 40 [ %  00!.
M $< 30!. $L 5@!) %\ 1P!I $8 =@!$ (4 0P"7 $$ J0!  +\ /P#B #\
M^  ^ /\ /P#_ +(9  "D'@  F!\  (X?  "$'   >A@  '(2  !J#@  8@@
M %P!" !7  X 4P 3 %  &0!. !\ 3  E $H *P!( #  1P V $8 / !$ $(
M0P!) $$ 40 _ %H /@!E #P <@ Z ($ .0"3 #@ I0 V +H -@#; #4 ]  U
M /\ -0#_ *P@  "?)   E"8  (DF  !_)   =2   &P;  !D%0  7!   %0,
M 0!.!@H 2@(/ $< % !$ !H 0@ @ $  )0 _ "L /@$Q #P!-P [ CX .0)%
M #@#30 V U8 -01A #,$;@ Q!7X , 60 "\%HP M!K@ + ;4 "P'\  L"/\
M+ C_ *@E  ";*@  D"P  (8M  ![*P  <B<  &@B  !?'0  5Q<  $\2  !(
M#@0 00H+ #X'$  [!A4 .0<; #@'(0 V""8 -0@L #,(,@ R"3D ,0E! "\)
M20 N"E, + I> "L+;  I"WP * R/ "8,H@ E#+< ) S3 ",-\  D#?\ )0W_
M *0J  "8+P  C3(  (,R  !Y,0  ;RX  &4I  !<)   4Q\  $L9  !#$P
M/! & #4-#  S#!$ ,0P6 "\,'  N#2( +0TH "L-+@ J#34 *0T] "<.1@ F
M#E  ) Y< ",/:@ B#WL (!". !\0H@ =$+< '!#4 !T1\@ =$?\ 'A'_ *$O
M  "5,P  BC8  ( W  !V-@  ;3,  &,O  !9*@  4"4  $@@   _&@  .!4
M # 1"  L$ X *A 2 "@0&  G$!X )1 D "00*@ C$3( (A$Z "$10P @$DX
M'A): !T3:  ;$W@ &A.+ !@4H  7%+4 %A31 !85\0 7%?\ &!3_ )XS  "3
M-P  B#H  'X[  !T.P  :S@  &$T  !7+P  3BL  $4F   ](0  -!P  "T7
M!0 F$PP (Q,0 "(3%0 @$QH 'Q,A !X4)P =%"\ '!4W !L500 :%DL &197
M !<790 6%W8 %!B) !,8G@ 2&+, $1G. !$9[P 2&?\ $QG_ )PV  "1.P
MACX  'P_  !S/P  :3T  %\Y  !5-0  3#   $,L   Z)P  ,B(  "H> 0 B
M&0D 'A<. !P7$@ :%Q< &1@> !D8)  8&2P %QDT !8:/@ 5&DD $QM5 !(;
M8P 1''0 $!R'  \=G  .';$ #1W+  T=[  .'?\ #QW_ )DZ  "//P  A$(
M 'M$  !Q0P  :$(  %X^  !3.@  2C8  $$R   Y+0  ,2D  "@E   @( 8
M&AT, !<<$  5'!4 %!T; !0=(@ 3'2D $AXR !$?/  0'T8 $"!3  X@80 -
M(7$ #"&%  LBF0 *(JX "2+'  DBYP *(OL "R'_ )<^  ",0P  @T8  'E(
M  !P2   9T8  %Q$  !2/P  23L  $ X   X-   +S   "<L   >)P, %B,*
M !(A#@ 1(1, $"(9 ! B(  /(B< #B,O  TD.0 ,)$0 "R50  HE7@ ))F\
M!R:"  8FE@ $)JP  R;$  0FY0 $)O< !B;_ )5"  "*1P  @4H  'A,  !O
M3   94L  %M(  !01   1T$  #\^   W.P  +38  "0Q   ;+0  $RH'  \H
M#0 -)Q$ #2@6  PH'0 +*"4 "BDM  DI-P '*D( !BI.  0K7  #*VP  2M_
M   KE   *ZD  "O!   KXP  *_8  "K_ ))&  "(2P  ?T\  '91  !M40
M8U   %I-  !/2@  1T<  #Y$   S0   *3P  " X   7-   $3$%  PO#  )
M+A  !RX5  8O&P %+R,  R\K  (P-0  ,#\  #!,   Q60  ,6D  #%\   Q
MD0  ,:<  #"_   PX0  ,/4  "__ )!+  "&4   ?50  '56  !K5@  8E4
M %A3  !.4   14T  #I)   O10  )4(  !P^   4.P  #CD%  DW"P $-@\
M 383   V&0  -B   #8I   V,@  -ST  #=)   W5P  -V<  #=Y   WCP
M-J4  #:]   VX   -?4  #7_ (U0  "$5@  ?%H  ');  !I6P  8%L  %=9
M  !,5@  0%(  #5.   J2P  ($@  !=&   00P  "T$$  1 "@  /PX  #X1
M   ^%@  /AT  #XF   ^+P  /CH  #Y&   ^5   /F0  #YV   ]C   /:,
M #R[   \W@  ._4  #O_ (I7  ""7   >5\  '!A  !H80  7V$  %1>  !'
M6P  .E<  "]5   E4@  &U   !)-   ,2P  !DH#  !)"0  2 T  $<0  !'
M%   1AH  $8B  !&+   1C<  $9#  !&40  1F   $5S  !%B0  1*   $2X
M  !#W   0O4  $+_ (A=  !_8@  =V4  &YG  !G:   6V8  $YC  !!80
M-%X  "E<   ?6@  %5<   Y6   '5    %,!  !2!@  40L  %$.  !0$0
M3Q8  $\>  !/)P  3S(  $\_  !/30  3ET  $YO  !.A0  39T  $RU  !+
MV   2O4  $K_ (5E  !\:0  =&P  &UN  !B;0  5&L  $=I   Z9P  +64
M ")D   88@  $&    E?    7@   %X   != P  7 @  %L,  !:#P  6A,
M %D9  !9(@  62T  %DZ  !92   6%@  %AK  !7@0  5YD  %:R  !5T@
M5/0  %/_ (%L  !Y<   <W,  &AS  !:<@  3'$  #]P   R;P  )6X  !IL
M   1:P  "6H   !J    :0   &D   !H    9P,  &8(  !F#   9@\  &44
M  !E'   92<  &0T  !D0P  9%,  &1E  !C>P  8I0  &&M  !@S0  7_$
M %[_ 'UT  !W=P  ;GD  %]Y  !1>0  0WD  #9X   I>   ''<  !%V   *
M=0   '4   !U    =@   '4   !T    =    ',"  !S!P  <PP  '(0  !R
M%0  <B   '(L  !R.P  <4P  '%?  !Q=   <(X  &^H  !NQ@  ;.T  &O_
M 'M[  !R?@  9'X  %5_  !'@   .8$  "N"   >@0  $H$   J!    @0
M ((   "#    @P   (,   ""    @@   ((   ""    @@4  ((*  ""#P
M@A<  ((C  "",@  @D,  (%6  "!;   @(8  '^A  !^O0  ?>8  'S\ ':"
M  !H@P  684  $N'   \B0  +HH  ""+   3BP  "HL   ",    C0   (\
M  "1    D@   )$   "1    D0   )$   "1    D@   )("  "3"0  E \
M )09  "4)P  E#@  )1,  "38@  DWP  ).8  "2LP  D=@  )#V &J(  !<
MB@  38T  #^0   PD@  (90  !25   *E@   )<   "9    FP   )T   "?
M    H    *    "@    H    *$   "B    HP   *0   "E    I@<  *@0
M  "H'   J"T  *E   "I5@  J6\  *F+  "HJ   I\<  *;L %^/  !0D@
M098  #.9   CG   %)T   J?    H0   *,   "F    J    *P   "N
MKP   *\   "P    L    +(   "S    M    +8   "W    N@   +T'  "_
M$   OQ\  , S  # 20  P&(  ,!^  # FP  P+<  +_8 %.7  !$FP  -9\
M ":C   6I0  "Z<   "J    K0   +    "S    M@   +L   "]    P
M +\   #!    P@   ,0   #&    R    ,H   #,    SP   -,   #:!P
MVQ,  -TE  #>.P  WU,  .!N  #?C   W:D  -W" /\   #_    _P   /\
M  #_  < _P 0 /\ &0#_ "0 _P O /P .@#Y $, ]0!+ /, 4@#Q %D [P!>
M .T 9 #K &D Z0!O .< =0#F 'P Y "$ .( C0#@ )< W0"B -H L0#5 ,4
MT@#H -  _P#/ /\ Q #_ +@ _P"O /\ J0#_ /\   #_    _P   /\   #_
M  ( ^P - /< %0#S !\ [P I .H - #F #T X@!% -X 3 #; %, V !8 -0
M7@#2 &, T !I ,X ;@#, '4 R@!] ,@ A0#& )  P@"; ,  J0"^ +H NP#9
M +D ]P"X /\ M #_ *D _P"B /\ G0#_ /\   #_    _P   /8   #N
MYP * .$ $0#< !H UP C -  +@#+ #< QP _ ,0 1@#! $T OP!2 +T 6 "[
M %T N0!B +@ : "V &X M !U +$ ?@"O (@ K0"3 *H H0"H +$ I@#( *0
M[0"B /\ H@#_ )L _P"5 /\ D0#_ /\   #\    [@   .,   #8    S0 %
M ,8 #@#! !4 O0 > +D )P"U #  L@ X *\ 0 "L $8 J@!, *@ 40"G %8
MI0!; *, 80"A &< GP!N )X =@"; (  F0", )< F0"4 *@ D@"\ )  WP".
M /L C@#_ (L _P"& /\ @P#_ /@   #I    W    ,P   #!    N    +(
M"@"L !$ J  8 *4 (0"B "D G@ R )P .0"9 #\ EP!% )4 2@"4 %  D@!5
M )  6@"/ &  C0!G (L ;P") '@ A@"$ (0 D0"" *  @ "R 'T S !\ /$
M>P#_ 'H _P!W /\ =0#_ .8   #3    Q@   +L   "Q    IP   *$ !0";
M  T EP 3 ), &P"0 ", C  K (H ,@"( #@ A@ ^ (0 1 "" $D @0!. '\
M4P!] %D >P!@ 'D : !W '$ =0!\ ', B0!P )@ ;P"I &T OP!K .8 :@#_
M &D _P!I /\ 9P#_ -,   ##    M0   *L   "C    FP   )(   ",  H
MAP 0 (, %@!_ !T ?0 D 'H *P!X #( =@ X '0 /0!R $( <0!( &\ 30!M
M %, ; !9 &H 80!H &H 9@!T &0 @0!A )$ 7P"B %X M@!< -4 6P#W %L
M_P!: /\ 6@#_ ,4   "V @  J0(  )\   "6    C@   (<   "   4 >@ ,
M '4 $0!Q !@ ;@ > &L )0!I "L 9P Q &8 -P!D #P 8P!! &$ 1P!? $T
M7@!3 %P 6P!: &0 6 !N %8 >P!4 (H 4@"; %$ K@!0 ,@ 3P#N $X _P!.
M /\ 30#_ +L*  "L#0  H T  )4,  ","   @P(  'P   !U    ;@ ( &D
M#@!E !, 8@ 9 %\ 'P!= "4 6P K %D ,0!8 #8 5@ [ %4 00!3 $< 40!.
M %  50!. %X 3 !H $H =0!( (0 1P"5 $4 J !$ +\ 0P#D $( _ !" /\
M0@#_ +(1  "E%   F14  (X3  "$$0  >PT  ',(  !L    90 # %\ "P!;
M  \ 5P 4 %0 &@!1 !\ 3P E $X *P!, #  2P V $D / !( $( 1@!( $4
M4 !# %D 00!C #\ ;P ^ 'X / "0 #L HP Z +@ .0#9 #@ ]0 X /\ . #_
M *P7  "?&P  DQT  (D<  !_&0  =14  &P0  !D#   708  %8 !@!1  P
M30 0 $H %0!' !H 10 @ $0 )@!" "L 00 Q #\ -@ ^ #T / !$ #L 2P Y
M %0 -P!? #8 :P T 'H ,@", #$ G@ P +, +P#. "\ [P N /\ +@#_ *<>
M  ":(@  CR0  (0D  !Z(0  <1T  &<8  !?$P  5PX  % *  !) P@ 10 -
M $$ $0 ^ !8 /  ; #H (0 Y "8 -P L #8 ,@ T #@ ,P _ #$ 1P P %
M+@!; "T 9P K '8 *@"( "@ G  G +  )@#) "4 Z@ E ?L )0'_ *(C  "6
M*   BRH  ($J  !W*   ;24  &0@  !;&P  4A4  $L0  !## ( /0<) #D#
M#@ V 1( ,P$7 #$!'  P 2( +P(G "T"+0 L S0 *@,[ "D$0P H!$T )@58
M "4%90 C!G0 (@:& " &F@ ?!ZX '@?& !T'YP ="/@ '0G_ )\H  "3+0
MB"\  'XO  !T+@  :BL  &$F  !8(0  3QP  $<7   _$@  . X$ #$+"@ N
M" X *P<2 "D'%P H"!T )P@C "4(*0 D"3  (PDW "$*0  @"DH 'PM5 !T+
M8@ ;#'( &@R% !@,F0 7#*T %@S& !4-Y@ 5#?D %@W_ )PM  "0,0  AC0
M 'PT  !R,P  :#$  %\L  !5)P  3",  $0=   \&   -!,  "T0!@ F#0L
M) P/ "(,$P A#!D 'PP? !X-)0 =#2P &PTT !H./0 9#D< %PY3 !8.80 4
M#W$ $Q"$ !(0F  1$*X $!#& ! 0Z  0$/L $1#_ )DQ  ".-0  A#@  'HY
M  !P.   9S8  %TR  !3+0  2B@  $(D   Y'P  ,1H  "H5 0 C$0< '1 -
M !L/$  9#Q4 &! ; !<0(0 6$"D %1 Q !01.@ 3$44 $A)1 !$27P 0$F\
M#A."  X3E@ -$ZL "Q/"  L4XP ,%/H #1/_ )<U  ",.0  @CP  '@]  !O
M/0  93H  %LW  !2,@  22X  $ J   W)0  +R$  "@<   @& , &10* !42
M#@ 4$A( $Q,8 !(3'P 1%"8 $10N ! 4.  /%4( #A9/  T67  ,%VP "Q=_
M  D8DP (&*@ !AB_  <8X  '&/4 "1C_ )4X  "*/0  @$   '=!  !M00
M9#\  %H\  !0.   1S,  #XP   V*P  +B<  "<C   ?'P  %QH( !(7#0 0
M%Q$ #Q<6  X8'  .&", #1DL  P:-0 +&D  "AM,  D;6@ ''&D !1Q\  0=
MD0 "':8  1V\  (<W0 "'/(  QS_ ),\  "(00  ?T0  '5%  !L10  8T0
M %E!  !//0  1CD  #XV   U,@  +BX  "4J   =)0  %"$$  \="P -'1
M#!T4  L=&@ *'B( "!XJ  <?,P &(#X !"!*  ,A5P !(6<  "%Y   AC@
M(:0  "&Z   AVP  (?(  "#^ )!   "&10  ?4@  '1*  !K2@  8DD  %A&
M  !.0@  13\  #T\   U.0  *S0  "(O   9*P  $B@$  TD"@ )(PX !B,2
M  4C&0 $)"   B0H  $E,0  )3P  "5(   F50  )F4  "9W   FC   )J(
M ":Y   FV0  )?(  "7^ (Y%  "$20  >TT  '-/  !J3P  8$X  %=+  !-
M2   1$4  #Q"   Q/0  )SD  !XU   5,@  #RX#  HL"@ %*PX  2H1   J
M%@  *AX  "HF   K+P  *SD  "M%   L4P  +&(  "QU   LB@  *Z   "NW
M   KU@  *O(  "K_ (Q)  ""3@  >E(  '%4  !H5   7U,  %91  !,3@
M0TL  #='   M0P  (S\  !H\   2.   ##8#  8S"0  ,@T  #(0   Q%
M,1L  #$C   Q+   ,C<  #)#   R4   ,F   #)R   RAP  ,9X  #&U   P
MU   ,/(  "__ (E/  " 5   >%<  &]9  !F60  7ED  %57  !)4P  /D\
M #),   H2   'D4  !5"   .0   "#T"  $\"   .PP  #H/   Y$@  .1@
M #D@   Y*0  .30  #E    Y3@  .5T  #EO   XA0  .)P  #>S   WT@
M-O(  #7_ (=5  !_6@  =ET  &U?  !E7P  75\  %)<  !$6   .%4  "U2
M   B3P  &$P  !!*   *2    T8!  !%!@  1 H  $,-  !"$   014  $$=
M  !!)@  03$  $$]  !!2@  05H  $%L  ! @0  /YD  #^Q   ^T   /?(
M #S_ (1<  !\8   <V,  &QE  !D9@  660  $MA   ^7@  ,EL  "99   <
M5@  $E0   Q2   $40   $\   !. P  30@  $P,  !+#@  2Q(  $H9  !*
M(@  2BP  $HY  !*1P  2E8  $EH  !)?@  2)8  $>O  !&S0  1?$  $3_
M (%C  !Y9P  <FH  &ML  !@:P  4FD  $1F   W9   *F(  !]@   57@
M#5T   9;    6@   %D   !8    5P0  %8(  !6#   51   %04  !4'0
M5"<  %0T  !40@  4U(  %-D  !2>0  4I(  %&K  !0R@  3^\  $[_ 'YJ
M  !W;@  <'$  &9Q  !8<   2F\  #QM   O;   (FH  !=I   .9P  !F8
M  !E    90   &4   !C    8@   &($  !A"   80T  & 0  !@%P  8"$
M %\N  !?/   7TT  %Y>  !>=   78T  %RG  !;Q0  6NT  %G_ 'MR  !U
M=@  :W<  %UV  !/=@  074  #-U   F=   &7,  !!R   '<0   '$   !Q
M    <0   '$   !O    ;P   &X   !N @  ;@@  &T,  !M$0  ;1H  &TF
M  !L-0  ;$8  &M8  !K;0  :H8  &FA  !HO@  9^@  &;^ 'EZ  !P?
M87P  %-]  !$?0  -GX  "A^   ;?0  $'T   =]    ?0   'T   !^
M?P   'X   !]    ?0   'P   !\    ?    'P&  !\#   ?!(  'P=  !\
M+   ?#P  'Q/  ![90  >WX  'J:  !YM@  >-\  '?Z '.   !E@0  5H,
M $B$   YA@  *X<  !V'   1AP  !X@   "(    B0   (H   ",    C0
M (T   ",    C    (P   ",    C    (T   "-!   C@P  (X3  "/(0
MCC(  (Y&  ".6P  C70  (V0  ",K0  B\X  (KS &B&  !:B   2XL  #R-
M   MCP  'I   !&1   'D@   ),   "5    EP   )D   ";    G    )L
M  ";    G    )P   "=    G@   )X   "?    H0,  *(,  "B%@  HR8
M *,Z  "C3P  HV@  **&  "BH@  HL   *'H %R-  !-D   /Y,  #"6   A
MF0  $IH   >;    G0   *    "B    I    *@   "J    JP   *H   "K
M    K    *T   "N    KP   +$   "R    M    +<!  "Y#0  N1H  +HM
M  "Z0P  NEL  +IW  "[E   N[$  +G2 %"5  !!F   ,IP  ".@   3H@
M"*0   "G    J@   *P   "O    L@   +<   "Y    NP   +H   "\
MO0   +\   #     P@   ,0   #&    R0   ,T   #2 0  U \  -4?  #7
M-0  V$T  -AI  #7A@  UZ,  -:] /\   #_    _P   /\   #_  , _P -
M /\ %0#_ "  _  K /@ -0#T #\ \ !' .X 3@#K %0 Z0!: .< 7P#E &0
MXP!J .$ < #? '8 W0!^ -L AP#8 )$ TP"= ,\ JP#- +T RP#@ ,D ^P#'
M /\ O0#_ +$ _P"I /\ HP#_ /\   #_    _P   /\   #\    ]@ + /$
M$0#M !L Z0 E .0 , #? #D V@!! -4 2 #1 $X SP!4 ,T 60#+ %X R0!C
M ,< :0#% &\ PP!W ,  ?P"^ (H NP"5 +@ HP"V +0 M #- +( \@"P /\
MK #_ *, _P"< /\ EP#_ /\   #_    ^@   /$   #H    X  & -D #@#2
M !8 S@ ? ,@ *0#$ #( P  Z +T 00"Z $@ N !- +8 4P"T %@ L@!= +
M8@"N &D K !O *H > "H (( I@". *0 FP"A *L GP#  )T Y@"; /\ F@#_
M )0 _P". /\ B@#_ /\   #V    Z    -P   #.    Q@ ! +\ "P"Z !$
MM@ : +( (@"N "L J@ T *@ .P"E $$ HP!' *$ 3 "? %$ G@!6 )P 7 ":
M &( F0!H )< < "5 'H D@"& )  DP"- *( BP"U (D TP"' /< A@#_ (0
M_P!_ /\ ? #_ /(   #C    T@   ,4   "Z    L0   *L !P"E  X H0 4
M )X ' ": "4 EP M )0 - "2 #H D !  (X 10"- $H BP!0 (D 50"( %L
MA@!A (0 :0"" '( ?P!] 'T BP![ )H > "K '8 Q !T .L <P#_ ', _P!P
M /\ ;@#_ -\   #,    OP   +0   "K    H0   )H  @"4  L D  0 (P
M%P"( !X A0 F (, +0"! #, ?P Y 'T /P![ $0 >0!) '@ 3@!V %0 = !:
M ', 8@!P &L ;@!U &P @P!J )( : "C &8 N !D -X 8P#[ &( _P!B /\
M8 #_ ,P   "\    KP   *4   "=    E    (P   "&  < @0 - 'P $@!X
M !D =0 ? ', )@!Q "T ;P R &T . !K #T :@!" &@ 2 !G $X 90!4 &,
M6P!A &0 7P!N %T >P!; (H 60"; %< KP!6 ,L 50#R %0 _P!4 /\ 5 #_
M +X   "P    I    )D   "0    B    ($   !Y  ( <P * &\ #P!K !0
M9P : &4 ( !C "8 80 L %\ ,@!> #< 7  \ %L 0@!9 $< 5P!. %8 50!4
M %X 4@!H %  = !. (, 3 "5 $H J !) ,  2 #H $< _P!' /\ 1P#_ +0)
M  "F"P  FPP  ) *  "&!0  ?@   '8   !O    :  % &, # !? !  6P 5
M %@ &@!6 "$ 5  F %, + !1 #$ 4  V $X / !- $( 2P!( $D 4 !( %@
M1@!B $0 ;@!" 'T 0 ". #\ H@ ] +@ /0#= #P ^  \ /\ / #_ *P0  "?
M$@  E!(  (D1  !_#P  =@P  &X%  !F    8  ! %D " !5  T 40 1 $X
M%@!+ !L 20 A $@ )@!& "L 10 Q $, -@!" #P 0 !# #X 2P ] %, .P!=
M #D :0 W '@ -@") #0 G  S +$ ,@#. #( \0 Q /\ ,0#_ *86  ":&0
MCAH  (0:  !Z%@  <!(  &@.  !?"@  6 ,  %$ ! !,  H 2  . $0 $@!!
M !8 /P ; #T (0 \ "8 .@ L #D ,0 W #< -@ ^ #0 1@ S $\ ,0!9 "\
M90 N ', + "% "L F  J *T *0#& "@ Z@ H /X * #_ *$<  "5(   BB$
M '\A  !U'P  ;!H  &,6  !:$0  4@T  $L'  !$  8 0  + #P #P X !(
M-@ 7 #0 '  S "$ ,0 G #  +  N #, +0 Z "L 0@ J $L * !5 "8 80 E
M '  ) "! "( E0 A *D ( #! "  Y  ? /D 'P#_ )TB  "1)@  AB@  'PG
M  !R)0  :2(  %\=  !7&   3A,  $8.   _"P  . 4' #0 #  Q !  +@ 3
M "P &  J !T *0 B "< *  F "X )  V ", /@ B $< ( !2 !\ 7@ = &T
M' !^ !H D@ 9 *< & "] !< WP 7 ?4 %P+_ )HG  ".*P  A"T  'DM  !P
M*P  9B@  %TD  !4'P  2QH  $,4   [$   - T" "T)"0 I!0T )@,0 "0!
M$P B AD (0(> " ")  > RH '0,R !L$.@ :!40 &05/ !<&7  6!FH % =\
M !,'D  2!Z4 $0>[ ! 'VP 0"/( $ G_ )<K  ",+P  @3$  '<R  !N,0
M9"X  %LJ  !1)0  22   $ ;   X%@  ,1(  "D.!  C# D 'PD- !T'$  ;
M!Q4 &0@: !@((  7"2< %@DN !4*-P 3"D$ $@M- !$+6@ 0"VD #@Q[  X,
MD  -#*4 # V[  L-V0 +#?$ # W_ )4O  "*,P  ?S8  '8V  !L-0  8S,
M %DO  !0*P  1R8  #XA   V'0  +A@  "<3   @$ 4 &0X* !4,#@ 4#!$
M$PP6 !(,'  1#2, $ TK  \--  .#C\ #0Y*  P/6  +#V< "A!Y  @0C0 '
M$*( !A"X  40U  %$.\ !A#_ )(S  "(-P  ?CH  '0[  !K.@  83@  %@U
M  !.,   12P  #TG   U(P  +1\  "8:   >%@$ %Q,& !$0"P .#@X #@\3
M  T0&0 -$"  #! H  L1,@ *$3P "!)(  <250 &$V4 !!-V  ,3BP !%*
M !.V   3T0  $^X  !/[ ) V  "&.P  ?#X  ',_  !J/P  8#T  %<Y  !-
M-@  1#$  #PN   T*@  +"8  "4B   >'@  %AH" ! 5"0 ,$PX "A,2  D4
M%P (%!\ !Q4F  85+P $%CH  Q9&  $74P  %V(  !AT   8B0  &)\  !BU
M   7T   %^T  !?[ (XZ  "$/P  >T(  ')#  !H0P  7T(  %8_  !,.P
M0S<  #LT   S,   +"P  "0I   ;)   $Q\"  T;"0 )&0T !AD1  09%@ "
M&1T  1HD   :+0  &S@  !M$   <40  '&   !UR   =AP  ')T  !RS   <
MS@  &^T  !O\ (P^  ""0P  >48  '!(  !H2   7D8  %5$  !+0   0ST
M #LZ   S-P  *C(  " M   7*0  $"4"  LB"0 %( T  1\0   ?%   'QL
M " B   @*P  (38  "%!   A3P  (5X  ")P   BA0  (9L  "&R   AS0
M(.T  !_\ (I#  " 2   >$L  &],  !F30  74L  %1)  !*1@  0D,  #I
M   O.P  )3<  !PS   3+P  #2P"  <I"  !)PP  "8.   E$@  )AD  "8A
M   F*0  )C,  "<_   G30  )UP  "=M   G@@  )YD  ":P   ES   )>X
M "3] (A(  !_3   =E   &Y1  !E4@  7%$  %-/  !*3   04D  #5$   K
M0   (3P  !<Y   0-@  "C(!  ,P!P  +PL  "X.   M$0  +18  "T>   M
M)P  +3$  "T]   M2@  +5D  "UK   M@   +)<  "RO   KRP  *NX  "K^
M (5-  !]4@  =54  &Q7  !C5P  6U8  %-5  !'40  .TT  #!)   E1@
M'$,  !,_   -/0  !CH    X!0  -PD  #8-   U#P  -!0  #0;   T)
M-"X  #0Z   T1P  -%<  #1H   T?0  ,Y4  #*M   QR@  ,>X  ##_ (-3
M  ![6   <UL  &I=  !B70  6UT  $]:  !"5@  -E(  "I/   @3   %DD
M  Y'   (1    $(   !! P  /P<  #X+   ]#@  /1$  #P8   \(0  /"L
M #PW   \1   /%,  #QE   [>@  .I(  #JK   YR   ..T  #?_ (%:  !Y
M7@  <6$  &EC  !B9   5V(  $E>   \6P  +U@  "15   94P  $%$   I/
M   !30   $P   !*    200  $@(  !'#   1@\  $84  !%'   12<  $4S
M  !%0   15   $1A  !$=@  0X\  $*H  !!Q@  0.P  #__ 'YA  !V90
M;V@  &AJ  !=:0  3V8  $)D   T80  *%\  !U=   26P  "UD   )8
M5@   %8   !4    4P   %($  !1"0  4 T  % 0  !/&   3R(  $\N  !/
M/   3TL  $Y=  !.<@  38L  $RE  !+P@  2>H  $C_ 'MI  !T;   ;F\
M &1O  !5;0  1VP  #EJ   L:0  (&<  !1E   -9    V(   !B    80
M &    !?    7@   %T   !<!   7 D  %L-  !;$@  6QP  %HH  !:-@
M6D8  %E8  !9;0  6(4  %>@  !6O0  5>@  %/^ 'EP  !S=   :74  %MT
M  !,<P  /G,  #!R   C<0  %F\   UN   $;0   &T   !M    ;0   &P
M  !K    :@   &D   !I    :0,  &@)  !H#@  :!4  &<A  !G+P  9S\
M &92  !F9@  97\  &2:  !CMP  8N$  &'\ '=X  !M>@  7WH  %!Z  !"
M>@  ,WL  "5[   8>@  #GD   1Y    >0   'D   !Z    >@   'H   !X
M    >    '<   !W    =P   '<!  !W"   =PX  '<8  !W)@  =C8  '9)
M  !U7P  =7<  '23  !SKP  <M,  ''W '%^  !C?P  5(   $6"   V@P
M*(0  !J$   .@P  !(0   "$    A0   (8   "(    B0   (@   "'
MAP   (<   "'    AP   (@   "(    B <  (D0  ")'   B2P  (@_  "(
M50  B&T  (>)  "&IP  A<<  (3O &:$  !7A@  2(@  #F*   JC   &XT
M  ^-   $C@   )    "1    DP   )4   "7    F    )8   "7    EP
M )<   "8    F    )D   ":    FP   )T'  "=$0  G2$  )TS  "=20
MG&(  )Q_  "<G   G+D  )OB %J+  !+C@  /)$  "V3   >E0  $)8   28
M    F@   )P   ">    H0   *0   "F    IP   *8   "G    IP   *@
M  "I    J@   *P   "M    KP   +$   "S"0  LQ4  +0G  "T/0  M54
M +5P  "TC@  M*P  +3, $V2   _E@  +YH  ""=   1GP  !:$   "C
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M^_S^______________________________________________________\
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M________________________________________
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M_O]M9G0Q      ,!(0   0                    $
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M____________K%,0       7;=;____________________________[@#$
M       )8<S____________________________26@(         7<S_____
M______________________^H-0          7-/_____________________
M______]]#0          5-;__________________________^Y]10
M    1-3___________________________RJ9"\"   $(C=)6,[_________
M___________________II&M!*#]C?Y6GNMK_________________________
M_____]6RK++,Y/K_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^6[EW=BR/__
M_______________________________;GF<V"@ "C/__________________
M_____________\A_/P4     7L______________________________V8$Y
M        /*K_____________________________GDP         (Y#_____
M_______________________<;QH         $'WY____________________
M______^O2            &_N__________________________^$$P
M     &3F_________________________^Q1             %?>________
M_________________[@5             $C6________________________
M_W04             #C/________________________^:):$P
M "/%_________________________]^;7"P           VZ____________
M_______________OL7U5.2(1!P$"$2*R____________________________
M___?OZ69F)J@K+W:____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________COIV ?/O________________________________R
MMX17, X ':S______________________________]**3!4      '+S____
M________________________UG\V         $O)____________________
M_______ZD3X          "^K___________________________ 6@
M     !J5__________________________^-)             B$________
M_________________^=>              !W________________________
M_[0E              !J_________________________WT
M  !;]/_______________________2L               !,Z___________
M____________I0                 \X?______________________, P
M               MV?____________________^9BF$G               G
MU_______________________[;Z)52<            EW/______________
M___________^RIUV74H\,BTL,#E'WO______________________________
M_>;=UM+0T]GD________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^_4N];_____
M____________________________Y[B/:DLO%6______________________
M_________^2A9S0'     #S)____________________________UH([
M     !*7___________________________MA3$           !O________
M__________________^F0@            !0X?______________________
M_^QI               WR?_______________________[,O
M   BMO_______________________WD                0I___________
M____________\C0                 F?______________________J0
M                C/______________________1@
M?______________________?                    =/______________
M______^7                    :O_____________________.
M            8_______________________*2(!                8?__
M____________________N:. 5S<7            :/__________________
M________^M.NE(9\=7%P<G>!E/__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________;
MNIV":6G3_______________________________(DV4]&0   !V>________
M____________________VXY,$P        !N________________________
M___;?"P           !%U_________________________^+*@
M   BM/_______________________\)$               #E___________
M_____________WT!                ?_______________________YS8
M                :O______________________G0
M6/______________________1@                  1_C_____________
M_______I                    ->G___________________^6
M            )=O___________________^\                    &,[_
M___________________K                    #\+_________________
M____                    "KG_____________________)P
M        "K7_____________________<                   #;G_____
M________________X)R,<%5",R8;% \-#A(:)K______________________
M_______YY-C2SLS+S,_6X/S_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________KT[SC________________________
M________TJF%94@L$@&%____________________________\:MQ/ \
M  !/X/_________________________5?S4            ?LO__________
M_____________^-U'0              B?_______________________Y C
M                9_______________________U4,
M2/;_____________________B@                  +MW_____________
M________.                   %\C___________________^^
M            !+;___________________^<                     *7_
M__________________^Z                     )/_________________
M___<                     (+_____________________
M         '3_____________________$P                   &C_____
M________________0@                   &#_____________________
M>@                   %W_____________________T0
M     &'______________________R0                  &;_________
M_____________\FLF8E]=G%L:6=F9VMP>HS_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________BQ:J1>6%W____________
M_________________]VF=U L#      QQ/_________________________@
MDDX3            C________________________])P'0
M8/______________________[F\/                -^+_____________
M________EAP                 %,#_____________________0
M             */___________________^N                     (G_
M__________________^>                     '+_________________
M__^\                     %_____________________:
M         $W____________________Z                     #O_____
M________________#@                   "KY____________________
M,P                   !OI____________________7@
M      _;____________________CP                    ;0________
M____________T                     #*_____________________RL
M                  #(_____________________X
M  #+______________________<6 04% P$       $&#1C+____________
M___________\Z^'8S\S-S]#2U-?<XNK_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________\=K&_______________________________QQJ.$:$TR&  5
MJ___________________________N7Q&&           <?______________
M_________]=\+P              .^/_____________________WV0)
M            #+7_____________________= ,                  (W_
M___________________%%0                   &K_________________
M__^9                     $O___________________^V
M         ##]___________________7                     !GG____
M_______________V                      73____________________
M#@                    #!____________________+P
M      "O____________________4@                    ">________
M____________>0                    ".____________________I0
M                  " ____________________V
M  !T_____________________S8                   !M____________
M_________WP                   !I_____________________]<-
M              !H______________________]P                  !A
M________________________4#Q&3E1976%D:&QP=GZ)________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________OU;NCBW-:E?__________________________^+^.
M9$$A!0      4OS_______________________>=5A@             %\'_
M____________________Y6P6                 (W_________________
M____8P                   %[___________________^=
M         #7\__________________^A                     !'9____
M_______________*                      "[___________________N
M                      "A____________________#
M      "*____________________+0                    !V________
M____________30                    !D____________________;P
M                  !2____________________E
M  ! ____________________O                      P____________
M________Z@X                    B_____________________T0
M               5_____________________X$                    +
M]?___________________\@+                   "[/______________
M______]>                    Y?_____________________)'
M            VO______________________G0$             !PX7Q?__
M_____________________]6YO,''SM7;X>;M]/O_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________C?S___
M___________________________LQJ6(;50[(0< ,M[_________________
M_______7DEDI             *#______________________XDV
M         &?_____________________9@                   #+V____
M______________^5                      /(__________________^G
M                      "@___________________7
M      !\____________________                      !>________
M____________)0                    !#____________________2
M                   L____________________:@
M   8____________________BP                     %\___________
M________KP                      X?__________________U0
M                S____________________R0
MOO___________________U0                     KO______________
M_____XL                     G____________________\L.
M            DO____________________]7                    AO__
M__________________^J"@                  >?__________________
M____;0                  9O______________________]U4
M        1?________________________]J(RLU/TI58&IU?H>1G/______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
MZ,^VG8-I3KG_________________________[+*#7#H= @       'O_____
M_________________\5M*0               $#_____________________
M@QL                   ?+__________________^2
M      "8__________________^D                      !J________
M___________=                      !!____________________#@
M                   =____________________.0
M    Z/__________________8                       SO__________
M________A0                      M___________________J
M                H___________________RP
MD/__________________[Q8                     ??______________
M_____SX                     ;/___________________VD
M            6O___________________YD                     2?__
M_________________](6                    .?__________________
M__]8                    *?____________________^B
M        &?_____________________U5@                  !/______
M________________NR\                  /C_____________________
M_ZLI                 ,_________________________)1P     '$R N
M/E)HA.W_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________TU<G_____________________
M_______ZTK"2=UU"* P  $K________________________%?447
M     !'8____________________Q%                    "?________
M__________^B#                     !H__________________^4
M                   V___________________:
M   '[/__________________%0                      Q/__________
M________2                       HO__________________=0
M                @___________________G0
M:?__________________PP                      4O______________
M____YP\                     /O___________________S,
M            *____________________U@                     &/__
M_________________X$                     !?__________________
M_ZP                      /___________________]XB
M         /+___________________]<                     -______
M______________^?                     ,S____________________H
M2@                   +?_____________________H!8
M     )S______________________WH"                 '?_________
M______________]Z"P              !4S_________________________
MHE=H=("-G*N\T.?_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________[>/_________
M_________________]*C>E@Z*2,<%@X&  "?_____________________ZQ2
M#@                !I___________________D0P
M   T__________________]Y                        X___________
M_______-                        LO__________________$P
M                A?__________________3P
M7?__________________@P                      .O______________
M____L@                      '/__________________VP,
M             O___________________RH                      /O_
M_________________T\                      .?_________________
M_W0                      -3__________________YL
M         ,#__________________\0'                     *W_____
M______________ S                     )K___________________]G
M                     (;___________________^C
M     '+____________________C1                    %S_________
M____________D08                  $'_____________________ZU\
M                 !W______________________\I+
M  #________________________+5P  #!@D,3].8'2+I\?_____________
M_____________]?G\O__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________^O4S<?"OKJWL["MJ:BE____________
M________W7Y3/S C&1$) @          V_________________]V
M                I_________________^Z
M=?__________________!P                      1O______________
M____3@                      &O__________________C
M             /W_________________P0                       -O_
M________________\1D                      +[_________________
M_T0                      *3__________________VL
M         (W__________________Y$                      'G_____
M_____________[<                      &;__________________]XA
M                     %/___________________]*
M     #____________________]W                     "O_________
M__________^L"@                   !;____________________G10
M                  #_____________________B@
M  #_____________________UDT                   #]____________
M_________Z<N                  #5______________________^8*@
M        !A@M16#@________________________J&-T@8^<J[O-XOK_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^?+MZF=E8Z)A(!\>'1P;&AED/______________
M__^\:D@M&0H                 ,?__________________
M             ___________________0@                       -S_
M________________C@                       ++_________________
MS@                       (W__________________RD
M         &O__________________UH                      $[_____
M_____________X8                      #3__________________ZX
M                     ![__________________]07
M      K___________________H]                      #_________
M__________]E                      #___________________^.
M                  #___________________^\&0
M  #O___________________Q3@                    #8____________
M________BP                    "_____________________S$,
M              "A_____________________Y$9                  !Z
M______________________)T"@               !%?________________
M_______H=!,?+#A%4V)RA9NTTO7__________________________]?H]/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________^_?S\>[LZ^OL\?__
M________________V;*9AWEM9%U644M&03PX,BTH(\3_________________
M2R4+                     )+_________________B
M         &;_________________UP                       #W_____
M_____________S,                      !C__________________VP
M                      #__________________YT
M      #__________________\D,                      #V________
M__________$U                      #?__________________];
M                  #+__________________^"
M  "W__________________^I!@                    "C____________
M_______3+P                    "-____________________7@
M              !W____________________DP<                   !>
M____________________S4,                   ! ________________
M_____X<0                   <_____________________]A>
M            ______________________^_3@      #APL/E)JAJ7(____
M____________________PGR,FJ>VQ=;H_?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________[N'7S\G#OKJVL:VIIZ:FIZ[_____
M____________OH9M6TQ -R\H(AP6$ L$     !3_________________UP4
M                      #__________________S0
M      #V_________________W8                       #2________
M_________[                        "R_________________^$D
M                  "6__________________]1
M  !\__________________]Y                      !F____________
M______^@                      !1___________________'(P
M               \___________________N2P                     G
M____________________=                      0________________
M____HQ8                     ____________________V$P
M            _____________________X@/                    ____
M_________________\M3                    ____________________
M__^E.           "1TT3FN,________________________F3E#45]N?8Z@
MM<OE_____________________________^OY________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________^O,N:RAF9&+AH%\>'1P:VAF9FCQ________
M_________V%%,B,8#@8               ">_________________WX
M                  !U_________________\,
M  !2__________________LW                       R____________
M______]J                       6__________________^6
M                __________________^_&P
M___________________F0@                      ________________
M____:0                      ____________________D (
M            ____________________N2P                     ]/__
M________________Z%P                     V?__________________
M_Y$8                    O/___________________\I3
M        G?____________________^8+@             0*49FQ/______
M_______________N?QT,&B@W1E=I?I6OS.[_________________________
MYZ"JN<C8Z?S_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________]]?#KYN+?V]C4TM'0
MTM?@_________________\Z>BGQQ:6%;5E%,2$,^.C8R+RXQ____________
M_____](E$0,                     __________________]"
M                __________________]]
M__________________^P"P                      ]O______________
M___=.0                      W/__________________8@
M            Q?__________________B0                      K___
M________________KR(                     F?__________________
MUD@                     @O___________________W(
M        :?___________________Z$H                    3O______
M_____________]-<                    ,_____________________^6
M+@              %3)2=______________________@<A,   $/'R]"6'"+
MJ,CL________________________RF]N?HZ>L,/8[___________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________YX-+(P+JUL*RHI:*?G9N;G*"G
M__________________^"9%9+0SPV,"LG(AT8$PX)!   U/______________
M__^2                        K?_________________,'@
M            B__________________[4@                      ;?__
M________________@                       4?__________________
MJ1L                     .O__________________T$(
M        (___________________]6@                     #/______
M_____________X\4                     /___________________[@^
M                     /___________________^5M P
M     /____________________^?-P              $"]0=/__________
M___________=<A0     !A<J05IUE+;:________________________O%A$
M5&1UAIJOR./______________________________]+-X?'_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__S[^OO]_______________________NN:B=EH^*AH)_>WAV=')S=7A_D/__
M_______________K3SHP*"$;%1 +!P(         (___________________
M:0                       /__________________FPH
M         /__________________R#D                      /______
M____________\&,                      /___________________XH.
M                     /___________________[ T
M     /___________________]5;                     /__________
M__________^%&@                   ^S___________________^Q20
M            &#E=@?_____________________E>QX       PA.%)OC[/9
M________________________NU@I.4E:;("7L,WM____________________
M_________[.>M,77Z___________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________KOY^'<V=;4TM#0
MT-'3V>#K]___________________N(I^=W%L:&1A7EM96%=765YE<?______
M____________OS$?%A *!0               /__________________[58
M                     .C__________________X($
M     ,S__________________ZLO                     +/_________
M_________])7                     )O___________________=\$
M                 (7___________________^B-P                 %
M*Y3____________________+80(            ,+%!VGM'_____________
M_______UC3        TC.U=VF;[E________________________PV,8*CM,
M7W2-I\;G_____________________________ZA_EJB[T.?_____________
M_______________________]____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________]W.Q;^\N;:TL[&RLK6Y
MP,G5X____________________Y=L9%Y955%/3$I(1T9(2U!99J'_________
M_________Z<F#@<"                 %;__________________\Y0
M                 #K___________________1Y"P
M "'___________________^?,@                    [_____________
M_______$6                 @Q6H3____________________I?Q\
M      8G2W&:PNG_____________________ITD      A<O2FB*KM7\____
M____________________TW4>)CA*7G6/J\OO________________________
M_____ZYRA9BLPMOV___________________________________?[_______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________^_LJJFHZ&@GY^AHZ:LM,#-
MW>S___________________^*6E-/2TA&1$-"04)#1TY9:7W_____________
M______^>+@8                   #____________________#5@
M            %4'____________________G>QH             "31@B[3_
M____________________GS\         !"5*<9G"Z___________________
M____QF8/    $RI$8H.GS?7_________________________ZXXU*SY1:(&=
MO-[______________________________[YV?Y2IP=SY________________
M___________________2V//_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________;R\._O
M[_'S^/W____________________________XL)^:EY:6EIB;GZ2LML+1X>[_
M___________________^CE!*1T5$1$1%1D=+45IH@ZG_________________
M____ID$!           '-F./NN'_____________________QF4*       $
M)TQSG,3L________________________Y8@O   3*D1B@J;,]/__________
M_________________ZM0-DIA>Y:TUOK_____________________________
M_]*'?)BQR^G____________________________________4SNW_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^WEX^/DYNCM
M\?G______________________________;&4DI*5F9VCJ;*\T.W_________
M_________________YU31TE-459@<XJOUOS_________________________
M_[)6 !HU4&V+KM+W_____________________________\UO/E][F;?7^?__
M_____________________________^Z?@Z;"X?______________________
M_______________CSNO_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________\
M
M
M /__________________________________________________________
M____________________________________________________________
M____________________________________________________    _]L
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MM,(D0X.$HA@E8V?P)B=FP\3AXN.F\49DHT3_Q  ; 0$  P$! 0$
M     P0% @8!!__$ $81 0 ! P$""@D#! (! P0 !P ! @,$$045$A,A,5%2
MD:&QT10605-A<8'!\#,TX08B,O$U<D(C)()B8\+2DJ(E0U2R\O_:  X$ 0 "
M$0,1!   /P#Y4 ^J0
M
M
M
M
M
M
M
M
M
M
M                                           ,T& Z*U5:J)AJUG-5
M6B2BW-<:P@:BUR]&V%H+6LLS6J!*4^D5F9IS&3DHY7X,>N3K:BXZL-:X%_:;
M^4TYXR'?$3TMUW'OLWFLCS2)U1VF_E-'&0<1/2=Q[[-YK(\TB=4=IOY31QD'
M$3TG<>^S>:R/-(G5':;^4T<9!Q$])W'OLWFLCS2)U1VF_E-'&0<1/2=Q[[-Y
MK(\TB=4=IOY31QD'$3TG<>^S>:R/-(G5':;^4T<9!Q$])W'OLWFLCS2)U1VF
M_E-'&0<1/2=Q[[-YK(\TB=4=IOY31QD'$3TG<>^S>:R/-(G5':;^4T<9!Q$]
M)W'OLWFLCS2)U1VF_E-'&0<1/2=Q[[-YK(\TB=4=IOY31QD'$3TG<>^S>:R/
M-(G5':;^4T<9!Q$])W'OLWFLCS2)U1VF_E-'&0<1/2=Q[[-YK(\TB=4=IOY3
M1QD'$3TG<>^S>:R/-(G5':;^4T<9!Q$])W'OLWFLCS2)U1VF_E-'&0<1/2=Q
M[[-YK(\TB=4=IOY31QD'$3TG<>^S>:R/-(G5':;^4T<9!Q$])W'OLWFLCS2)
MU1VF_E-'&0<1/2=Q[[-YK(\TB=4=IOY31QD'$3TG<>^S>:R/-(G5':;^4T<9
M!Q$])W'OLWFLCS2)U1VF_E-'&0<1/2=Q[[-YK(\TB=4=IOY31QD'$3TG<>^S
M>:R/-(G5':;^4T<9!Q$])W'OLWFLCS2)U1VF_E-'&0<1/2=Q[[-YK(\TB=4=
MIOY31QD'$3TG<>^S>:R/-(G5':;^4T<9!Q$])W'OLWFLCS2)U1VF_E-'&0<1
M/2=Q[[-YK(\TB=4=IOY31QD'$3TG<>^S>:R/-(G5':;^4T<9!Q$])W'OLWFL
MCS2)U1VF_E-'&0<1/2=Q[[-YK(\TB=4=IOY31QD'$3TG<>^S>:R/-(G5':;^
M4T<9!Q$])W'OLWFLCS2)U2UDNYSGM14Q;M.IKTC5S3:F9F.AREE:]>[:.T]J
M*')U^SD.9H$6%"F'Q9-R,>L1'89&"*N'@+M1-I=VF_E-.>,AUQ$]+J^X]]F\
MUD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3
M?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>
MD[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'
MFD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\I
MHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X
M]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$
MZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,
M@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9
MO-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.
MTW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(
MGI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S6
M1YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_
M*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3
MN/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:
M1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFC
MC(.(GI.X]]F\UD>:1.J6OEW,R<53PEP/L5Q+FJU-.CF;9UF]^RDQ9^#/U^S<
M5U9J4*F05@R;E1D2(N"*[%$\'S8KY"[M-_*:?.,AUQ$]+INX]]F\UD>:1.J.
MTW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(
MGI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S6
M1YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_
M*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3
MN/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:
M1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFC
MC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CW
MV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3J
MCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#
MB)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\
MUD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3
M?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>
MD[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'
MFD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\I
MHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X
M]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$
MZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,
M@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9
MO-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.
MTW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(
MGI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S6
M1YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J6PI=T1F4BIAY3[-<1.CFFU-4:PYF[
MFLWOV[LI+5^EV@LW E9A[V-9,R;D>F2Y6KCDHJ;4XR[M-_*:?.,AUQ$]+INX
M]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$
MZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,
M@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9
MO-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.
MTW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(
MGI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S6
M1YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_
M*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3
MN/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:
M1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFC
MC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CW
MV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3J
MCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#
MB)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\
MUD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3
M?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>
MD[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'
MFD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\I
MHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X
M]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$
MZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,
M@XB>D[CWV;S61YI$ZI2)+.8Q7*J8)Q'V*XF='RJS-,:RT5N)Z^&QUEJA7ZE:
M"S,:3DFM?$AR\FY8CD5R-\'*1$X>%2J2CU3'*;K/G&0^Q8F6TILE?3/T^5G(
M5I;)MAS$)L5J.E'XHCD141?!\H[3?RFCC(.(GI>GN/?9O-9'FD3JCM-_*:.,
M@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9
MO-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.
MTW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(
MGI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S6
M1YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_
M*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3
MN/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:
M1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFC
MC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CW
MV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3J
MCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#
MB)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\
MUD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3
M?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>
MD[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'
MFD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\I
MHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X
M]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$
MZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,
M@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9
MO-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J6
MLEW.<YJ*G@K@?9KB',6IF9AS5F*S>]:*O6CI,G7[-PYBA1V2\P^+)NR'N<BJ
MBLP15PP3AP+NTW\II\XR'7$3TNE[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD
M>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?R
MFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[
MCWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD
M3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHX
MR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]
MF\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH
M[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@X
MB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-
M9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW
M\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI
M.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61Y
MI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:
M.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/
M?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.
MJ.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(
M.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;
MS61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM
M-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)
MZ3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD
M>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?R
MFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JEL27<S)Q5-:X:C
MJ*]7-5J:7*6\KU[MC.XG=&OV<C=U9^'3X68DW+DO?C@KL43P=7!BI=VF_E-.
M>,AUQ$]+J^X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D
M[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'F
MD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IH
MXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]
M]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$Z
MH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@
MXB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O
M-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.T
MW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(G
MI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61
MYI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*
M:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N
M/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1
M.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC
M(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV
M;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JC
MM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B
M)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\U
MD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?
MRFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D
M[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'F
MD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IH
MXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]
M]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$Z
MH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@
MXB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O
M-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.T
MW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(G
MI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61
MYI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*
M:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N
M/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1
M.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC
M(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV
M;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JC
MM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B
M)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\U
MD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?
MRFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D
M[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'F
MD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IH
MXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]
M]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$Z
MH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@
MXB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O
M-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.T
MW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(G
MI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61
MYI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*
M:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N
M/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC(.(GI.X]]F\UD>:1
M.J.TW\IHXR#B)Z3N/?9O-9'FD3JCM-_*:.,@XB>D[CWV;S61YI$ZH[3?RFCC
M(.(GI.X]]F\UD>:1.J.TW\IHXR#B)Z3N/?9O-9'FD3JED: Z$B*Y47'B.J:N
M$XKMS1SM1/UV\ZR=K;(REJ*S09R1K-29)N9)2JHY$54QUN1,-2\&)A.D:=@
M/=(>UN\Y%<YUJQS2B#L?/RK>A\+9W[QZ2-.E\
M                                P0/;H_G0[JYH16_\JD*W*^[)?'^V
MR?V1C.<)4U
M          &&9VPO[Z'5/M17.>/FB#L@ORK=?\+9+[RF8Y2I?
M
M              ,,G[0AU7SHK/\ @B#L3?<2I'^-,?SG&8Y2I?
M
M             #%->T/.J.=Q=_PE&O9)>XE:K_!A_P YA>SV#?,?)=4\SM;)
M?FK1OV*#]QI<?'UM0
M                                        P0/;8WG0ZJYH16_\JD07
M,^Z?>W^\Y?[CS.<I4O@
M                                         !@FO^[_ +Z'='M17?9\
MT*]DS_9Y\)I7_4SG"5-0
M
M
M                                              'EG_8-\Y);YT%_
MFA$%^GYY75?"!GV(>(E54O@ >Z0]K=YR*YSK5CFE$'8^?E6]#X6SOWCTD:=+
MX                                                      !@@>W
M1_.AW5S0BM_Y5(5N5]V2^/\ ;9/[(QG.$J:@
M                                   ##,[87]]#JGVHKG/'S1!V07Y5
MNO\ A;)?>4S'*5+X
M                                        !AD_:$.J^=%9_P $0=B;
M[B5(_P :8_G.,QRE2^
M                                         &*:]H>=4<[B[_A*->R2
M]Q*U7^##_G,+V>P;YCY+JGF=K9+\U:-^Q0?N-+CX^MJ
M
M      &"![;&\Z'57-"*W_E4B"YGW3[V_P!YR_W'F<Y2I?
M
M         #!-?]W_ 'T.Z/:BN^SYH5[)G^SSX32O^IG.$J:@
M
M
M
M              /+/^P;YR2WSH+_ #0B"_3\\KJOA S[$/$2JJ7P /=(>UN\
MY%<YUJQS2B#L?/RK>A\+9W[QZ2-.E\
M                         P0/;H_G0[JYH16_\JD*W*^[)?'^VR?V1C.<
M)4U
M   &&9VPO[Z'5/M17.>/FB#L@ORK=?\ "V2^\IF.4J7P
M
M        ##)^T(=5\Z*S_@B#L3?<2I'^-,?SG&8Y2I?
M
M      #%->T/.J.=Q=_PE&O9)>XE:K_!A_SF%[/8-\Q\EU3S.ULE^:M&_8H/
MW&EQ\?6U
M                               #! ]MC>=#JKFA%;_RJ1!<S[I][?[S
ME_N/,YRE2^
M                                 &":_P"[_OH=T>U%=]GS0KV3/]GG
MPFE?]3.<)4U
M
M
M                                      >6?]@WSDEOG07^:$07Z?GE
M=5\(&?8AXB552^ ![I#VMWG(KG.M6.:40=CY^5;T/A;._>/21ITOE\O!B3$>
M'!@L5\6(Y&,:FU55<$0^5513$S/,^Q&LZ0<!V6BRV/B?^*@]<SM[X?7[I\EG
MT.]U>^%F=9ROH-96[%6BHD!T>I4F/"@-3%T1N$1K4\JM543XR:SGX]^>#;KC
M7L\4=>/<MQK5"K7M=L4YTN(5P
M             8('MT?SH=U<T(K?^52%;E?=DOC_ &V3^R,9SA*FHWUG+(5R
MTD"-&HLBLS#@N1CW9UC,%77AX3DQ*N1FV,:8B[5IK\)^R:W8N78UHA:Y[6^R
M7 V^BRV/B?\ BH/7*^]\/K]T^23T.]U>^%,ZSE?0-%EL?$_\5!ZXWOA]?NGR
M/0[W5[X,ZSE?0<[:"@U*ST\V3K$LLM,.AI$1F6UV+5541<6JJ;47T%O'R+>1
M3P[4ZP@N6ZK<Z5QRKFN1R8MUH:PG<*@
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M#5@Y>7BCEVY28;/+M,_.VAZ'533P=>%\5G'QN.B9UTT61(F0J)ACB<6:2JO
M                   -S9VS%8M&^*VBR$29S?LW(J-:WR*YRHF/DQQ*U_+L
MXT1-VK35+;LUW?\ "-5'.1OLEP-9.RL:2G)B5FF+#F($1T*(S%%R7-7!4U:M
MJ$]%<5TQ73S2CFF:9F)51<414V&$Z?                          Q37M
M#SJCG<7?\)1KV27N)6J_P8?\YA>SV#?,?)=4\SM;)?FK1OV*#]QI<?'UM0
M                     ]5*I\U5:A D:?"6--1G9,-B*B8KYUU)\9'<N4VJ
M)KKG2(=44S7/!IYQ51$55V'5Z++8^)_XJ#URCO?#Z_=/DL>AWNKWPLSK.5]!
MI:]92N4%N75J;'EX>.3G,$<S'BRFXI])9L9EC(Y+=43^="*NS<M_Y0N:]KMB
MFG@0UBQH<-%P5[D;CYU+$SI$RCB-9T5.NO'L2MC)B1A]T$G4F6.=CF<WDY*H
MFS*7':9^S\_TV*IX.FGQU\EC(Q^(F(UUU60GY:+JPP..-%67@
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M>[V*O;X+O,Y-2_$6;.1:OQK;JU15VZ[<Z51HJUR.V+B:TF<*@
M             &":_P"[_OH=T>U%=]GS0KV3/]GGPFE?]3.<)4U
M
M   ;N>LK69"A2]9FY)8=-CY.;C9QBY64F*>"BXIBB<*%:C,LW+LV::O[H]G*
MEJLUTT\.8Y%$<U7*U%UH:1$QU)K52RB5-]6K(5RB4R#4*K(.EI2,Y&L<Z(Q5
MQ5%5$5J+BFI%VH5;.;8OUS;MU:S'S35V+E%/"JCD6M>URJB+BIH2TA7
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M77X:\VB:<;2SQNJU(F,168?&<4:2JO
M
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MY<552!K<?GI:#]X3'\QQZK"_;V_^L>#)O_J5?.7HA^P;YD-(642H
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M!,M7.:J_'DX^=5+FQ;U5W&TJ_P#&=$&=1%-WD]JZ JK#U\&HCPUU-D
M                   ,$#VV-YT.JN:$5O\ RJ1!<S[I][?[SE_N/,YRE2^
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MA*FH
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ML,1T^
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ML@                &"![='\Z'=7-"*W_E4A6Y7W9+X_P!MD_LC&<X2IJ
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M8_F.-3"_;V_^L>"K?_4J^<LD/V#?,AI"RB5
M,4U[0\ZHYW%W_"4:]DE[B5JO\&'_ #F%[/8-\Q\EU3S.ULE^:M&_8H/W&EQ\
M?6U                       #LKGO='HW]Z)_*>9VUOVE?T\86</\ 6I61
MO:G'9WKV%M%7;8QYZE4[/RKH4-J/S\-NM$P74YR*9NR]H8]C'BBY5I/+[)\E
MK*QKERY-5,<BR#$:UF"KK-U=E8YUA9:?KUI9B! B9E69*.RDA,Q15Q78KE5$
MP1,?IP*VT<[TZ:;%B->7ME)C6/1XFY<E;$?G,&M3$AJKU1:U:Z8J*M5J3,WG
M&M7:C5=J3XDP/1VK/$6(M]$,VNOAW)JZ99VIDLP\A]"7DVBI%EEE*G.2;)RK
MHUS)-B_U4U93L>!-FO;P)PGDMG8M[*UMTSI1[?LV,F[19TJF-9]CS0FN?BB+
M@G"<O8&]6:K]H85*K,C*,AS>+(;X*.3!<%5$<CE7''9P%W.V/3CVINVJIUCI
M08^;-RO@5QSKXD)&MQ15U$<7K467H5MIZ6DF-ARL1&QH<-NQB.36B>3''#R8
M&SLN_5?QJ:J^?F4LJW%N[,1S,D%V4Q%7:;*R%YLS9>S;:7(TR7B1$B/B+&BO
M7!5=LQ:F&SSZ_(09>R:<J]QM=4_)W9S)M4<&(4?"1SL54Z2R]\=4G:[)2E4D
M)%9>8BM@JZ71['-5RX8ZW*B[=A3R=AVJ+55=NJ=8C7ET\H3VL^NJJ(JB.5:Z
M"B-545?C.>ORHTK2;8-B24)L*'.0$CO8Q,$1^4Y%5$X,<$7SJI<V+?JO8^E<
MZ\&=/H@SK<47.3VKH#E5FO@.YLC$[U;HH=9H5.9.S\9N<C.P557PU157#6J-
M1-B<2KQF7E1Z7GS9O5:4QS=GW6[,\3C\.B-98W^'&5'+@AR<2^6K34C.2M0I
ME/B0YB"^$F9RV*W*:J8KBKL=J:M1?C85JBJ*J*IY)UY=/X5_3ZYB8JB%^91%
M14530W368A6GM2V#.HKI&69GXS=F6B*B(S'RJOH12UM3+G%L:T_Y3R0AQ+,7
M:])YH7179+-6U3MK57NQ:34XM-LU3I))24<L'+C-7)<K5P7):U6X)CL,W%V+
M%VB+E^J=9Y>3^=5J[G315P;<1I"QD'%,7*N*FTH-8E+V+/5&F562@R]3EF9<
M**S6C7+C@]N.M-:8*F*XIAKXH+]BO9-VFY;JUIGG\I26ZXS*)IJCEA146"Y%
M1=2D"1&.AQ'0XB*U[55JHO J'JHG6-89.FC.6GU\  )1N(L[$FZ\^NS#<B2D
M&N1KW;'1%;A]"*J^@P]MY446N(I_RJ\%_!M:U\9/-#%'=@W)X5.;O2M##M';
M":FI9V5*PD27@.Y36XZ_,JJJ^94+FS,:<;'BFKGGEE!E78NW)F.9=";DLP7:
M<D:"NO                         ,$#VV-YT.JN:$5O\ RJ1!<S[I][?[
MSE_N/,YRE2^                         3Y9.G355N'61I\+.S49D5L-F
M4C<I<\J[55$/*95VFUM/AUSI$:>#7LTS7B\&GG_EYW*B1\5V'"4JZ.U$U.,A
MSLK"D8"KX4:)&8_!.'!&*JJO_P!8FK=VUBT4S-$\*>C2?NJ48-V9TF-&18S4
M34N)U5]U5DJ99NFV4D'HZ)"2&L1$7%60V-P:CO*JX+\7E*&QK-=V]5E5^W7M
MGG6,VNFBB+-*V BJY7J7]CNC'4JT+8JX0U=#1R\29+\3YM_6*[>GQ^QL[_&I
M28VM/#5+VH5&BMIUC:5)LI<NN0U\9KOZ1.-$14PQXUQ5=JDMK8TWHXS*KGA3
MT.:LZ*/[;4<D*M@Y6MZKBIN[919*W=U#J\DLR#/2K5>WA6&K78/;CPM5-?HX
MBMB17@9W$:ZQ/Y$I;TTY%CC-.6%&8PXN3P*1)8:TBV5KJ5-LHV;<V$^&UCGY
M."N3#''!3?S<7TJUQ6NC.L7>)KX6FK*]N4W#' [2)?;7EC*L*GTML+5@US(C
ME\NO+3[#-C8%C3EJG7Z>2SO"Y[(A9F&\:G16WCREMKI4M%$E&P)Z6P<U=JM5
M(F0YJ+MR5QQP\Q3PZ:\+.]'B=8GRUCZI[TQ?Q^,TY86LQ9&R<=2G*7"4N2J%
MJYF+.PV18DK+YV"QZ8HCLI$RL/)_KYB_MR[7;L1%')K/+Y*^!135<F9]B^.J
MHS5PJ;JT=[EH*3:";DG4F2@PH,56I#CM>L16HNW*RD36FM%PP\Y6Q]BX]VU%
M?#F9F/9IIX?=+<SKE%<TZ+6P6JW'%5(YMA7HEK;1NJ"2C8$:.V'#S3'96+D1
M&XXX)M4V,3'C$L\7KK$:J5ZY-ZOA:,C&Y#<,27JI4*?=)9N1DI"3A359FVJZ
M)$=J1RIAE.<NW)Q7!&ZOMQ\_:M7-KWJJZYTHC\_W+1JJIPZ(IIC6J6%$6*Y5
M5<&H:BS%\4W4*M D:_3I)9.:>D%SX#7)DY6K%R.5R.37K35JQVEC)V'1;HFN
MS5.L<O+_ !HCM9\U5<&N(TE<Z"B(JM5<4.0O>LW LW:Q\.19FY*:AI'A,38S
M%51S4\F*8^94-#9655DV-:^>.16R[46KG)S2O@NRF:]J'$&FJKRZ$C71&->[
M):JHBNXDXSY/)'(^P$WR%W]W:S,/)M(DTJ_]RM1@^%\E$7T*>9KVEM#2?_3T
M^/!G[M2G%QM?\M?K# L2)A['#XCT7QRU;DK+MD*+(R\"S,%K4B++O58F2FM,
MIN"8-QXLK':JIK0XV179KO<9=JF;D]/-]/R/@^YD5TT<&B/[2"K5=BY5RB!C
MU3)9P                        #!-?]W_ 'T.Z/:BN^SYH5[)G^SSX32O
M^IG.$J:@
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MI'L:QQ6-%4\]7+Y.LVYP[LQT*0&X,QXS@355&0F/L</]NKO^'"^UQYW^H/\
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M6=5*_?F],3,:,L-F0BHBXG+%Y77
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M*DU%14_SJ;./RVJ?E"C<_P Y^;(WV*>8UQ,X5
M         PS.V%_?0ZI]J*YSQ\T0=D%^5;K_ (6R7WE,QRE2^
M         29V/GY[S'[#$^^PQ=N_MH^<>$KVS_U9^3',>P^,RVXO$M33+6U:
M2D:IFI:!'<R&SM>$[)1/*K<3G"V9BW;%%=='+,=,^;[?RKM%R:8GD^BD.&U6
M(JIKP(^K%9J59CI&JL],3<1J8-6*]51OF38GQ&O9L6[,:6Z8A3KN55SK5.K(
MUJ-V)@;*[K\^J%^V0_O$&?\ MKGREWC_ *M/S4B>UN\QT]_WY],_8X?WG%+8
M7[:?G/V3Y_ZOT6R_M?QF*X:,R';Z&QZIE19:(QF/'J7[$4ZVW3,XLS'LF'S
MG2Z1_:U._M?>Q%LW:&;I<:@+%6 J9,59O(RVJF*.1,A>/C,G$V-&3:B[%S37
MX?RN7LV;5<T33W_PQLA9347*^@T^G7_\._QW_P##+'J]_P#<[OY1[R_^GO\
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MJ3(                    89/VA#JOG16?\$0=B;[B5(_QIC^<XS'*5+X
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M-=ROTO)_RGFC[^4>Q8R,BFFGB;7,LA,55RW[2)S>9[*
M         !@@>VQO.AU5S0BM_P"52(+F?=/O;_><O]QYG.4J7P
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MU
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M
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M5#.V1BW<:U53=C29G[?!9S+M%VN)HE9 :K6JCN,CXUE-D
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M#F\5N[<QJHFJ/\I^:QC8B*B+J:A#)Z-F,P
M     &&9VPO[Z'5/M17.>/FB#L@ORK=?\+9+[RF8Y2I?
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M                    PR?M"'5?.BL_X(@[$WW$J1_C3'\YQF.4J7P
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MP]BFM?,3V*-JV^#1_P",:1_X\WBXKJQ*M9]OU7-2*F"<'Q$*'I66S
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MU%=]GS0KV3/]GGPFE?\ 4SG"5-0
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M-2:D1$3@U\9I;-V?Z'3,USK5/.JY61QTQ$<T+X3,A%Q7%5.'--57@
M
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M7]]#JGVHKG/'S1!V07Y5NO\ A;)?>4S'*5+X
M
M!AD_:$.J^=%9_P $0=B;[B5(_P :8_G.,QRE2^
M
M &*:]H>=4<[B[_A*->R2]Q*U7^##_G,+V>P;YCY+JGF=K9+\U:-^Q0?N-+CX
M^MJ
M                          &"![;&\Z'57-"*W_E4B"YGW3[V_P!YR_W'
MF<Y2I?
M                             #!-?]W_ 'T.Z/:BN^SYH5[)G^SSX32O
M^IG.$J:@
M                             .TNFGJ)2K3]T;0S68ART-5@(L)[\J(N
MK'P478F/QX&;M2W?NV>+L1KKS\W-]5K$JHHKX5<\RR*CE9@U-IK;P*_WRVKG
MJ@Q5[75V;@(J880VZDU>7;YU4FP,;T:Q3;GG]OS1Y%WC;DU*PVY+$0YTN(5P
M
M                                                           !
MY9_V#?.26^=!?YH1!?I^>5U7P@9]B'B)55+X 'ND/:W><BN<ZU8YI1!V/GY5
MO0^%L[]X])&G2^
M         8('MT?SH=U<T(K?^52%;E?=DOC_ &V3^R,9SA*FH
M                                                 PS.V%_?0ZI]
MJ*YSQ\T0=D%^5;K_ (6R7WE,QRE2^
M                                                      89/VA#
MJOG16?\ !$'8F^XE2/\ &F/YSC,<I4O@
M                                                      !BFO:'
MG5'.XN_X2C7LDO<2M5_@P_YS"]GL&^8^2ZIYG:V2_-6C?L4'[C2X^/K:@
M
M                   !@@>VQO.AU5S0BM_Y5(@N9]T^]O\ ><O]QYG.4J7P
M
M                       P37_=_P!]#NCVHKOL^:%>R9_L\^$TK_J9SA*F
MH
M
M
M                           #RS_L&^<DM\Z"_P T(@OT_/*ZKX0,^Q#Q
M$JJE\ #W2'M;O.17.=:L<TH@['S\JWH?"V=^\>DC3I?
M                                      ,$#VZ/YT.ZN:$5O_*I"MRO
MNR7Q_MLG]D8SG"5-0
M                !AF=L+^^AU3[45SGCYH@[(+\JW7_  MDOO*9CE*E\
M
M                      PR?M"'5?.BL_X(@[$WW$J1_C3'\YQF.4J7P
M
M                    Q37M#SJCG<7?\)1KV27N)6J_P8?\YA>SV#?,?)=4
M\SM;)?FK1OV*#]QI<?'UM0
M                                             P0/;8WG0ZJYH16_
M\JD07,^Z?>W^\Y?[CS.<I4O@
M                                              !@FO\ N_[Z'='M
M17?9\T*]DS_9Y\)I7_4SG"5-0
M
M
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M2:")'?N\#YW;^&,X_EN](T@X4])H(D=^[P/G=OX8SC^6[TC2#A3TF@B1W[O
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M2:")'?N\#YW;^&,X_EN](T@X4])H(D=^[P/G=OX8SC^6[TC2#A3TF@B1W[O
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M$"T-I*LLQ78;%959U([68*BXM3)3!2T/CZ6   1!V/GY5O0^%L[]X 2^
M                                                    (5N5]V2^
M/]MD_LC ":@
M           !$'9!?E6Z_P"%LE]Y0!+X
M
M
M
M
M
M                   "%>R9_L\^$TK_ *@":@
M
M
M
M     $07Z?GE=5\(&?8@ E\  !$'8^?E6]#X6SOW@!+X
M                                        A6Y7W9+X_P!MD_LC ":@
M
M!$'9!?E6Z_X6R7WE $O@
M
M
M
M
M
M       (5[)G^SSX32O^H FH
M
M
M                                                   !$%^GYY75
M?"!GV( )?   1!V/GY5O0^%L[]X 2^
M                          (5N5]V2^/]MD_LC ":@
M                                             !$'9!?E6Z_X6R7W
ME $O@
M
M
M
M
M                                                    (5[)G^SS
MX32O^H FH
M
M
M                                    !$%^GYY75?"!GV( )?   1!V
M/GY5O0^%L[]X 2^
M           (5N5]V2^/]MD_LC ":@
M                              !$'9!?E6Z_X6R7WE $O@
M
M
M
M
M
M                                     (5[)G^SSX32O^H FH   -S*
M67K\Y+0YB3H=4F)>(F+(L*4B/:Y.-%1,%*]>9CT3--5R(GYPFIQ[M4:TTS,?
M*5,IJ;7)Z3+WG6FW<K/,8O5.?3L;WE/;'F^^BWNI/9)EMY2>DU4_(S=.F72U
M0E8\K,-1%="CPU8],=:8HJ8D]NY1<IX5$Q,?!%5151.E4:2JBHJ:EQ0\QVY
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M2.Z K)MC6O1S415U-<Y,/"3A '5@
M                           B"_3\\KJOA S[$ $O@  (@['S\JWH?"V=
M^\ )?
M $*W*^[)?'^VR?V1@!-0
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M++MB9<.,S%/#8O\ F;QXHY%1=N "G9->X=:C^Y _YB& +Z54JM1NQVHU3L[
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M/"]BJ[.'  ?-UGM(_P#[25I^U.]#OK[DL[:SO;/:69_[/AD8>'E^U[=7LO(
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M6SOW@!+X
M    A6Y7W9+X_P!MD_LC ":@
M                       #?6!_/JSG[REOYK2KG?MKG_6?"4^+^M1\X\4/
M=D-^4KL?A9)_:I]G'YN]BE0
M
M
M
M
M
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M-"?;:\"UUY<XQW:\>*M-I*/3V,!F&+D3@541GQJ_R@##-?[Y$G^Y5^X\ 3^
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M #* )^ 'S]V0,E+0[Y;GYR' AMFH]36'%BHGA/:R+ 5J*O#AENP\Z@#Z!
M<7;2\VS%D)^%3JI.Q(U5BIE,D)."Z/'5,,<<ENS4F.O  1A>Y>@VMW:VBIS[
M!V[DTF)5S>V)ZCYN!"7%%1SW9:X(BIMP $@]CX]S[F;)JY<5[4P^)'.1/H0
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M#(R[ER696+GQ'<36IBKE\R #B=-$M%\.1L+>!/2R^PF):B*L.)Y457HODV<
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M"_3\\KJOA S[$ $O@  (@['S\JWH?"V=^\ )?
M                                 $*W*^[)?'^VR?V1@!-0
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M3$SP8L.-"9%@O;$A/:CFO8N*.1=:*B\*',Q-,S$\[[$Q,:PIL+CX^@
M  8)V;EI&5?,STQ!EI=GLHL9Z,8W7AK5=2'5%%5RK@T1K/P<U54TQK5.D")C
MJ1,5,5+JM/JL-\2ES\I.PV+DN=+1FQ$:O$JM5<%.KEFY:G2Y3,?.-'RBY1<Y
M:)B?DJJ*FU%0]A&[4,4W,P).6B3$Y'A2\O#3%\6*]&-:G&JKJ0ZHHJKG@TQK
M+Y55%,:U3I B8K@A@I=5IU5AO?2Y^4G6,7)>Z6C-B(U>)5:JX'5RS<M3I<IF
M/G&CFBY1<Y:)B?DJJ*FU%0]A&[4   #F:';6FUFU53H$K"FVSM/1RQ7Q&-2&
M[)<C5R51RKM5-J(7;V!<LV*<BJ8TJYNE6MY5%RY5:C76%RL5&(Y=BG3%)96@
M >.6JE/FIZ/)2T_*1IR![; AQFNB0]?]9J+BGQDE5FY33%=5,Q$\TZ<CBFY1
M55-,3&L*JBHF*HN!["-VH   ',NMK36VY;9584WW1<S+SF0W->PR\,<K''!.
M(NQ@7/1O2M8X/?SZ?G*K>E4<=Q'+KW+LA<C*U8'3%)96@    %'.1K5<Y41J
M)BJKL1!'*<P:IEIJ"^:[696Z6Z9Q5,TDW#5^*;4PQQ+$XE^*>%-$Z?*449%J
M9X/"C7YPKDNPQP7#S&V*Z50   .9KUM:;1+34NA3<*;=-U%6I"=#8U6-RG9*
M92JY%V\2*7;&!<OV:[],QI3S]/2K7<JBU<IM5:ZRN:Q7-5R88(=,4EE:
M           >.6JE/FIZ/)2T_*1IR![; AQFNB0]?]9J+BGQDE5FY33%=5,Q
M$\TZ<CBFY155-,3&L*JBHF*HN!["-VH     <Y+6PI\U;*8LU+PYF+.R\+.Q
M8K&-6$Q,$U*N5CCX2<&U2Y5@W*<>,FJ8X,SI'2KQDT579LQSQV+LA<C*U8&Y
MJ52D:7 2/4YV6DX*NR4B3$5L-JNXL7*B8ZE*UNU7=G@VZ9F?A&J6NY31&M<Z
M?-1$5=B*IK66OLT]R-9:&CN<JX(B3L)55?E$_H.3'+-NKLE'&39Z\=L*Y#N2
MOH-U"B,BPVQ(3VO8Y,6N:N**GD4JS$Q.DIHG7EA:>.J5BF4E(:U6HR<DD3'(
M[9CMAY6&W#*5,26U8NW=>+IF?E&KFN[1;_SF(^:J(J[$53TRDS G):',2D:'
M'@1$RF1(3D<UR<:*FI4.*J*J)FFJ-)=4U15&L<RF&"X*93E]#Q5.K4ZE,8^J
M3\I),>N#'3,9L-'+Q)E*F)):LW+TS%NF9^4:N*[E%O\ SF(^:J(J[$53T2DS
M G):',2D:%'@1$RF183T<UR<:*FI3FJBJB9IJC275-451K3.L*8:\%,=0J$G
M3H&>J$Y+RD'EQXC8;?2JH?;=JNY.E$3,_#E?*JZ:(UJG01%78F)BIE8IE51R
MTRHR<ZC?9=KQVQ,//DJO&GI.KEB[:_4IF/G&CFB[1<_PF)^2JHJ;45#76TM5
M)V1ID*?J4O-Q99\5(*NEV-=D*J+@KL7)JU$V'AUYE<V[<Q$Z:\J/(R*<>GA5
M1.GP58U7K@F&)O)>-#F($.- >D2%$:CV/38YJIBBI\15JIFF9IGGA/$Q,:PM
M+SX^@      'EJ52D:7 2/4YV6DX*NR4B3$5L-JNXL7*B8ZE.[=JN[/!MTS,
M_"-7%=RFB-:YT^:J(J[$536=^-F=XZ-SZ%UB?T')]W5V3Y(_2K/7CMA7(=R5
M]![Z76*;5FQ%I51DYU(>"/66CMB9..S')5<-A%<L7+/ZE,QKTQHDHNT7/\)B
M?DHJ*FU%0LBURDP:BE/C520ASZJB)+.F&)%55V)DXXZS[&/=JHXR*)X/3I.G
M:^3>MQ5P)JC7HU,E<,<%P-B0I%#R3-4D)6=@2<S/2L&;C^U0(D9K7Q/[K57%
M?B)*;-RJF:Z:9F(YYTY(<3<HIF*9F-951%PQ1%P/61NU#4Q;2T*#-=JQJU3(
M<SBC<TZ;AH_%=B88XXEB,2_53PHHG3ITE%-^U$\&:HU^<*Y+L-B^@VK'->QK
MV.1S7)BCD7%%0KS&G)*6.50\<*K4Z+48E/A3\H^?AIB^6;&:L5J:M:MQQ3:G
MI0DFS<BCC)IG@].G)VN(N435P(F->A7!<,<%PXSVD;M0\<>JTZ7J$*0F)^4A
M3T9,8<N^,UL1Z:]:-5<5V+LXE)*;-RJB;E-,S3'MTY.UQ-RB*N#,QKT*HBX*
MN&HRSTY+2$J^9GIB#+2[/918ST8QN*X:U74AS115<JX-$:S\'VJJFB-:ITA1
M$5=B8FI[\;,[QT;GT+K%CT')]W5V3Y(O2K/7CMA=D.Y*^@W,M,09J"V++1H<
M:$[8^&Y'-7XT*U5-5$Z51I*:F8JC6%NS:63TY+2$J^9GIB#+2[/918ST8QN*
MX:U74A]HHJN5<&B-9^#Y5531&M4Z0(BKL3$U/?C9G>.C<^A=8L>@Y/NZNR?)
M%Z59Z\=L+LAW)7T'LIE>I%5C/A4NJR$[%8W*<R7F&1'(W'#%4:JZM:$=S&O6
MHUN43$?&)AW1>MW)THJB?E*BM5-J*AL2%(H:B;M10).9B2\Y7*7 F(:X/A19
MN&US5XE15Q0L48>17'"IMS,?*4-61:IG2JN(GYPJC7*FIJ^@P]^-F=XZ-SZ%
MUCKT')]W5V3Y/GI5GKQVPKD.Y*^@]$A:6AU":9+2%:IDU,OQR84&:AO>[!,5
MP1%Q74BJ<5XE^W3PJZ)B/C$NJ;]JN>#35$S\X45KD36BX>8VI E4,4W-2\E+
M1)B<CPI>7AIB^+%>C&M3C55U(=4455SP:8UE\JJBF-:IT@1,=2%)*;EYZ5AS
M,E,0IB7B)BR+!>CV.3'@5-2BNBJW5P:XTF.E\IJBJ-:9U@P5-2[3,<N@ #16
MTM1)61HZ5*I0YB) 6*V$C8#4<[%<5X51,-2\):P\.O,N<7;TUY^5!D9%./1P
MZ^9<QJO7!#:4R=A5&FRD] 1R09F"R,Q'I@N2Y$5,?+@I!<MS;KFBKGB=.Q+1
M5%=,51[5%3!53B/2<.E
M
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MZ'PMG?O "7P
M      !"MRONR7Q_MLG]D8 34
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MR'!FF/<OQ(N)-7BW[<<*NB8CXQ*.F_:KG2FJ)^JJM5$UHJ?$:J\>A4.O4*'
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MXT5>)1<LW+4Z7*9CYQH47**XUHG7Y"HJ;45"(+T_=GL3_>@?SU/0[,_XZ_\
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M5&IT19?7MR-K/H7#_*7]NX_%94U1S5<OFJ[+N\99X,\\<BZ.W!_G)(,9HL8
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ML2#$9$ANV.8N*+\9#,33.DI(F)Y84+SX^@
M
M
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MU\3+B*B(KO#5<-B:DP0 ;"NTB2KU'G*75H';$A-PUA1H64YN6U=J8M5%3XE
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M[3;,2J3+%1S'3$2),(U4V*B1'.1%3CP^P 2$   ^?[9ICV8]A$76G<6)]R=
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M"_3\\KJOA S[$ $O@  (@['S\JWH?"V=^\ )?
M                                 $*W*^[)?'^VR?V1@!-0
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M792IE+CAC@FH\[E9->5<XRYSM>Q8IL4<"CF87.5RXKM-P5TR@
M
M
M                         $/]DQ^:E+_;?^AYZ'^G/UZ_E]X9&V/TJ?G]
MD-=DA[*[WX32O^I\YGL7GDY
M                                                T%;L=0JY7Z36
MJM(),U*E.5\E%=%>B07*J+BC$7)5<41<51=B<0 WX              -!.6/
MH4[;"0M3,R"/KTC!67EYK.O3(AJCT5,E%R5]L?M15U@#?@
M                                              #06CL?0K1U2C5&
MM2"3,Y1X_;$C$SKV9F)E-=C@U41VMC%P=BFH ;\  !J[46?IEJ*%-4:O2J3=
M-F<E(L%7N9E9+D<FMJHJ8*U%U+P #U4FGRM)I<G3J?"S,E)P62\"'E*[(AL:
MC6IBN*K@B)MU@#U                                   B"_3\\KJOA
M S[$ $O@  (@['S\JWH?"V=^\ )?
M                        $*W*^[)?'^VR?V1@!-0
M                                          !OK _GU9S]Y2W\UI5S
MOVUS_K/A*?%_6H^<>*'NR&_*5V/PLD_M4^SC\W>Q2H !"=K_ />(L]_@P_\
M\P]+B?\ $W/G/V8M_P#?T?G2S,_V=Q)=X% 9:6R-1IJM1T9\-7P%7@BMUM^G
M5YE4Q<#)G&OTW/9[?E[6EE6>.M31^:L<-V2Y%(ZN>J,2T=V=;LU$?_VV6@Q9
M9C7K@N;B-<C<<>)RN3R)@;.UK48V91DQ_C,Q/UB6?@5S>QJK,\\:QVLD5,F(
MCN YNYJSMD*Y*SE.M+)L6NP)A41D68B0G/9@B8(U'(BJCD<BIMV%S:^5F6*H
MN8]7]DQT1/VZ%;9]C'NQ-%V/[HGIE=%<]NMJ^"2+4+M;O*=#SE0D):5AK_6C
MS\5B>E8GE3TF/;VKM&Y.E%4S\J8G[-&K Q*(UJC3ZSYL:1(B[%Q^(]U[4"%*
MW5UB7@,1D&% APV-3^JU'M1$]!%LJJ:LZBJKGF9\)=YT13C51'0I"UQ4\YKK
MN)N/(7'P)R4;E3,O)346$W#'%S71%1,/.B$VT**;FTIHJYIFF/!'B531AQ53
MSQ$_=6(F,947A5#B;H;(4.VLG/5>TTQ&J=4='5(D%\PYJM;@F#ER51RXXKKQ
MPU8<"FGM7-OX-5-G'C@TZ<^GY"E@8UK)B;EV=9UZ5\5SF*B-3!#7UN0LQ3+W
M++2ED4A)#AS4%)G-1GQ6I$SJ:LIRKKPPV+])-8N9-W NUY/MB=.2(Y-/@CN4
M6:,JBFSTQKVJM5RPGJ_BU'?=D9[G[/VV']UYD_T_^[^D_9?VM^A]8^ZR7]L^
M(Z&ZZT5,K5D:9"D)ICH\I*PX,>"JHCV.8U&JJMXL=B["GM/%NV,BN:XY)F9B
M?9RK&%?HNVJ8IGEB%L1JH]<4VJ1S:F=A6LORL]+4B(V8@TQT-T6+#7%N+'K$
M?KXDP1/.;.+;G$V9<JN\DU:Z?6-(\V=>KC(S:*:.7@_;E9&)D0'8\)*]9FK.
MU.>=9VLODXTR]C8J2DPFMR*JHBMQVKJ79K0P+-&1:I](M:Q'-K'YXM6Y59KJ
MXFO37HEB:CD3*3'#C(9O-H$G=M/TZK6/J,:2G(L7!TDL57HK4Q7'!=:MQ1$5
M'8XXH>DV;DU[3HJM95.L1'/I^<OR8^99IPJHN6*M)Z&6$Y8B*CTQ3C.O[()[
MXMVTM$BL6&]TU!<YB_U55KL4,_8,1&9,1T3XK>U)UQXF>F%LO[8OF.FE_<CA
M_N-/^7*-7[^?^_\ ^2S'[7_X_9:OMO\ F.:[&[\PIG]OB?<AEW^H?W4?]8\9
M5MD?H3\_)=,>S^(U/9.?DBA_X\3[J%C^F_U+GRA%MC_"E66VN.B[("?CR5WT
M6' @MB,FH[($5SFY6;;K=CY\6HF/!CQX%/8-NFO+B9GFC6%C:E<TV)B(YY6P
M$QB>8XF3LI1&R,.!3+U4DZ7$:CGR:S36XX^RQ;G&HF/E;Y\33KS+\U35<Q-:
MH]NG\3XJ5./;X.E%_2.C7^8\%ZN=CKA8KQX$L7?6=HMFZ)VM0(S9F&]V5%F4
MB(]8KL.%4U;,,$3C\N)@9^5>R;G"O1I/LCH:N+8MV:-+?+\6)[E<N+CIBDLK
M2..R ]S>:_QX7WC8V#^\CY2SMJ?MY^<,D#VPW5@Y2#/W8T>3FFY<"8IS(41O
M&US,%3T*5\ZN;>;773SQ5KWIL6F*\:FF>:84>N$153C(![NU&RE"M-8A6Q'Q
MXTVD*&]J?U57!^"?\:(S!/*IZOT>WEW;6=[(C7R[.5@\=78HKQO;,_[[6?)1
MRM?Y#Z,L'06V;LG3J8B)G(4-%BJG#$=K<OI5?BP/'YV3.3?JN]/-\O8]%BV>
M)M10\[W93E4CCL>/]OMC^U0_MBFQM_\ PL_*?LSME?Y7/GYLD?8SS'EK$U!H
MG9&2\W47I EIF"U$BO7!J94%6(N/%E-P)+-%5_9$T4<LQ/WU<7*HM;0BJKFG
MRT$3*E\$VH2)>5:*F42RE12H33&19F6B0H,)JHKXBN:J)@G%KV[$,?9V+=OW
MZ>!')$Q,S[(T:&7?HM6IX4\\,<-JJY,.!3E^QN_,*9_;XGW(9>_J']U'_6/&
M5;9'Z$_/R7S'L_B-3=G[N5L_[L;^<PL;1_XRS]/"46'^\N?7QA6)[0PO[(UR
M08UE)AZ+F84S$5SN+7#7[$7T'S^GHUB]3'/,1]S:W)-N?CY$OL>GD)BA3,"*
MD)84:&](K<N'DN1<MO&G&FM/2>=FBJ-=8YFQ%43S,.&TABR'^\1:+_!B?_EG
MH\O_ (FW\X^[&Q_W]?YT,SO]G:>:^J?@TJ].RD_-97:\LR%&B9*8KDMC*JX)
M\1)L:W5=P;UNGGG6.YSM"N+>3;KGFC3Q5@IC">B;28X%>I4>CK5850EG4Y&Y
M:S"1$R&IY5X%\BZSSDXUVFYQ4TSPNAL1>MS1QD3R=+#DKC@J+B1'<LY]<O(M
M7:2$QR241'PV*J88Y<1'-3SHUB8^<]#MB(L8=K&GGC3NC^63L[6[D7+T<WG+
M+&\&&UO"9(G^\S"_P/\ ],IS'_#3\_\ \GV?^1^GV$_V9?\ ZX3R7]T^!!MM
M9NK5> Z-1GM;+3*-54\%L17.3%-:+DO7##B4DV'<JJQKMJU.E?/'9_#C:=$1
M>HN5Q_;S3VJP%\!R)M.RI]V5W]1E63,A384S+O3%L2%.QG-7XT>9M>UMH6ZI
MIKJTGY1Y+E&!B5QPJ:=8^<^:Q8D1-JX?$;>QEF[)46=G'V6ARS9K(:R/FIIT
M9S6KK:BHKER<</)C@5\S*R[],1D:Z>SDT^T)L>Q8M3,V>?V\NJCW.5$RL</,
M=84%I8:F-:6C2]:=29BHR\&H(Q(F9BNR%5JXX8*NI5U+J1<2Q3B7JK?&TTS-
M/2BF_;BOBYJY54:N3CAJ/'>!/4N2LE5.[<2"DM$EWM2'$5,8BX+@C4X5QPPP
MV+K),"W=KOT\5SQ,?1QE5T4VJN,YM%8:*KDR=I&%R-'G)V[&U$%$<UE1;%@2
M^.I%<L)6JJ>3%43XC<VS?HHS;4]729[=69LZU55C7(Z==.QDC*B1&^0]_8Z5
MR42@S="F(K8-2@3+HC8,1<ESVJB;$7:J*BXIP:B'^H,>OC8OTQK3,<Z39-ZG
M@3:GGB5([=>5P8$H3%>I<O5Y6E19Z"E1F55(4NBY3UP:KEQ1/8I@BZUP,.G&
MNU6YNQ3_ &Q[6G-ZBFN*)GEGV,:-7!5PU<9$]Z?NSV)_O0/YZF_LS_CK_P!?
M!E9O[NU]/%EA>TO,O9*TZ+&I%%J38:Q($G&?#BHB[$B9.&/$G@88^5#G^G+L
M1<KMZ\LQ&GTU\WW:]$S337[(^Y++K<G"IN:!=_=S7Z;"G:538<>#$:CO!G(R
MJS'@<F7J7R*5K^T]HX]<T7*M)^4>2:UA8=VGA44Z_6?-:Z)$:N"K]!N;-60L
M91*_ET*!+0ZM"AN\!LX^)$8W')<N0YZX)CJQPX2OD9V;?M:7IG@S\(B.W1-9
MQL:U7K;C^[Y_RHYSU;X6.'F.(O3]V>Q/]Z!_/4T]F?\ '7_KX*6;^[M?3Q7P
MO:7DU*B.:J+L5,#S4-EA((N*J$&S-HK06:K$5DM,NBM2%G5R4>YBN14QXU14
M5./6>JVW:JRK-O)M1K&G+]6%LVN+%RNS7R2SQDRFHY-:$H7C6BD;/66J$6<C
MPVQHD!\.!!5WA1'N141$3;ACM7@3$P]GXMS(OTQ1')$\L]#3R[]-FU,U3RL4
M-JN<F!Q]QDNVSEVTU5:NY9>7C17S:N<BKA!1K41V")C_ %57S8&AMJKTG,BU
M:Y9B(CZJFS:>)QYKKY(GE^B^-X43!-NPW-?L58VVLG$JC>UT=$17+/R45&Z\
M,55W]55V8Y28^8K6,_,P:N*Y?E/V]O8FNXN/DQP^^%&O>Q</H4YVX&KS\>8K
M]'C3KZC3J?$:DM,N55U93FZEU^"J-143'5K+NW;%NF+=Z*>#55SQ^="OLN[5
M,UVYG6(YI5CHB(BX8*O >6[/W<K9_P!V-_.8=[1_XRS]/"7.'^\N?7QA6)[0
MPD2JI9:U<U-4*I=ISLW*NP?+Q/!BPU5J+BQ=3MF&MJF/:]*Q*8OV]8B?;[/K
M[.UH5\1?F;5>DS'L_/LQMRF)E)BB$25BGLNXO'H<O9.HQXD.?BM;,4]T3+P1
M7(W!43;BBKABF*8;3T%FY.TL.Y5DTQ_;')5^=[)N4>AY%,6:N?GAE:N<ANRT
MV<)] GDF^P'%7SRJS=VE;8U,7,8R+\38C7+]"*:6QZ^!F43\X[8E2VA3PL>K
M\]J^"N$1"RY*:;-7:4=45%="2)"<G$J1'8?1AZ3K;-' S*_CI/<^;.JX6/3^
M>TC)A$4Y?LF/S5I7[;_T.+O].?KU_+[PK;8_2I^:^6]D[S$I4R&R-0Y2%%:C
MX;Y9C7-<F*.16HBHIAW)FF[,QTM.B(FB(GH8EVKYR&KK8CK&WI5NR<=ZME)I
MRNELI=JHF4STL5<?*B'H]IQ&;A49=//'/X3WLC"GT;)JL3S3S?;N98GAPD=Q
M&>^_W0;$_P",W^:PYV+^TO\ R^TONT?U[7Y[2![6\[J]VS_?#86H0(;<J9ET
M[:@:L5RF(JJB>=N4GQF5LG)]'RJ:IYIY)^J]GV>.LS'MCE60G9+T\NHA2F5:
M;O#?8VRD1(F9D\>VW\MK<41?BAIACQN4]-<LT;.X_+CGJYOK_/<QJ+E69Q=C
MHY_SY,RHD/+=Q[";;V6-AW:5QC&HUC9=$1$V(B.0\SLJ9G,MS/2V<Z-,>J/@
MPPO;$\YY;FHK(-U='BQ79,-D.*YR\2)%?BIWM>)JSJXCX>$.=GSIC4S/Q\9(
MOMJG34&T%)K\LV/1ZA+S;%3%48[PF_WFKK:NM-2HA2OXUW'G@W:9A9M7K=V-
M:)U6N:K=J8$.=D=,TZ>F*-(R2PYBM-B.8YL+!SVM7!$8[#A5VQ//QZ_1_P!/
M47+<5UU\E'Q\>QD;6JHJFFFGEJ9I=%3*5=A-M+A1)>ERD*8=C&AP6-B+CM<C
M413S%V8JKF:>:9;5$3%,1+"NU2'>Q\8LY7[751NN%%BM1KN5E/>Y?]/2>CV]
M/ M6;7MB/M$,?97]URY7^>UECZFM0FP\RVF$      "'^R8_-6E?MO\ T./0
M_P!.?KU_+[PR-L?I4_-FEO9.\Q*M&_)$C_@,^ZAA7OU*OG+4M_X1\F)=JGK(
MW:A"]E_]XNT/[.[[L(])D_\ $6_GYL:S^_K^7DS._P!G:=M>Q91+5V2F($%B
M+4);&/*KPJY$UM_S)BGGP7@,S9>9Z)?BJ?\ &>2?/Z+N=C<?:F(YXYED)V2[
M'@X2#:!:*-7[;6%9.-?VW3WPI2(YVU^3$56KY\%1%\J>4]1?Q:<?&R)IYJM9
M[F):OS=O6N%SQI'>S.;DL?AL76?1]3M%2*74I60J50@2LU,M5T%L9<E'(BX>
MR75CBNQ5Q7@/&VL6]=HFY;IF8CGT>BKOV[=44U3I,O.C55%5$Q/14YZGRE,B
MS-2F)>'(*SPWQ7)D.:J;->I<4X.$XM6[E=<4VXGA?#G=5UT4TZUSR"(JK@FT
MA?L<I9SZW:2>E(;X=,=DPX:.X\I5:GG1OVH>E_J"K2W:HJG^YC;)IUKKJIYF
M:8V-1=I2MS++$W\=U*DBLIE2AZHRHN#4<U&JOQ.;K\BBS1.=LOBK?^5/L^OD
M7*HQLWAU\U0WPX&";4)M;/RCI%)ULU+K)JW*2.D1,WAQY6.&!YGBZXJX&DZ]
M'M;7#IX/"UY&#!<<,-9"DK,P[<7[R\]2ESM.I,-$=,(G@N1F5K3SO=@G&B8G
MI:J)P=ES1<Y*J_9\_P"(8M-496;%5'-3^>+/AD0%1=JG8W]^YI4/\6#_ #$,
M[87[RGY3X+FT_P!O/T\5D#VQ#=76>YY0/V1A6VG^[N?--A?H4?);$]L=YR,I
M?"P-^CH+?Z*E5I-2;&IG%U>35$3#R(IMU?\ ]0V9KSU4?;^&;'_M,W3_ ,:O
MO_++[9!\K3L[^_<TJ'^+!_F(9NPOWE/RGP7-I_MY^GBL@>V(;JZSW/*!^R,*
MVT_W=SYIL+]"CY+8GMCO.=245I:   $(TK_>6J7^$O\ (8>FN_\ #T_G_E+%
MH_Y&?SV,R_[,A+-K?S5K7[%&^XXP,3]>CYQXM6_^E5\I8F>R3SG =C=^84S^
MWQ/N0S6_J']U'_6/&5#9'Z$_/R9)CV?Q'0WR>YI7?\)G\QI4V1^\M_GLE8S_
M -O7^>U;!]L::J[B;CR%Q\"<E&Y4S+R4U%A-PQQ<UT143#SHA/M"BFYM*:*N
M:9ICP18E4T8<54\\1/W5B)C&5%X50XFZ&R%#MK)SU7M-,1JG5'1U2)!?,.:K
M6X)@Y<E4<N.*Z\<-6' II[5S;^#539QXX-.G/I^0I8&-:R8FY=G6=>E?%<YB
MHC4P0U];D+,4R]RRTI9%(20X<U!29S49\5J1,ZFK*<JZ\,-B_236+F3=P+M>
M3[8G3DB.33X([E%FC*HIL],:]JK5<L)ZOXM1WW9&>Y^S]MA_=>9/]/\ [OZ3
M]E_:WZ'UC[K)?VSXCJ:'5I&BW?T.=JLPV6E6R4JQ8CD5417,:B8X>5=I1O6:
M[^7<HMQK.M7C*U:N4VK%-5<Z1I"QR*L1R(F.LYFV=WED*O2IBLRT2!3'I#6*
MV>E8B)"54UY2HG@KKXL%\I=P]IYEFN+-6M7LTGG\U;(PL>Y3-R.3XQS+F1'H
MN&WR*5N!KE2K5D9A*K%B3"RLPL&%'B*JN<W)1<E5X53';Q*A\V[CV[&1'%QI
MK&LP;+O5W;4\/ETDCM1KM7"A)ABM)C
M
M
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MQHST:UJ>55 '&6;OBL':2MPJ11K0PIBH1E5L.$LO&AH]4X&N>Q&JOF76 ._
M   !H;9VOH5BZ7"J-IY])&2BQFR[(BPGQ,8BHY43!B*NQKEQV:@!O@
M
M         !H9JUU#E+825EIB>1E>G("S,"5S3URX:9>+LI$R4]K?J5<=0 WP
M
M                      "(+]/SRNJ^$#/L0 2^   B#L?/RK>A\+9W[P E
M\                                                        0K<
MK[LE\?[;)_9& $U
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MDO-,R'NA*B.1,<=2JBI]!5Q[]6/<B[1SPGNVHNT315S2M:N2J*ACLU0I2S]
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MX,-GTJJKK5?*NLQKUZN_7-RY.LRT+=NFU3P:(TAC555555Q4]I&[4
M
M
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MJ-1SX:.5$Q55PQ7C $+]FO[EE*_?4+^1' $_@
M       "-+_;?5.[RR5.JE&EY.8F)FI0Y-[9MKG-1CF1'*J9+FKCBQ.'CU "
M2P                                          $#6L_P!\.QG[BB?9
M-@">0
M                           $07Z?GE=5\(&?8@ E\  !$'8^?E6]#X6S
MOW@!+X
M  A6Y7W9+X_VV3^R, )J
M                    -]8'\^K.?O*6_FM*N=^VN?\ 6?"4^+^M1\X\4/=D
M-^4KL?A9)_:I]G'YN]BE0                #66BH%-M'3NT:U+=LRN6D3(
MRW,\),<%Q:J+PJ3X^3<QJ^':G2?SI17;-%ZG@W(UA5KE:N**>Z3EH,E)P)65
M9FX$!C84-F*KDM:F")K\B$5=<UU355SRDIIBF(ICFA1=:ZS*<OH
M >>H2,K492)*S\O"F9:(F#H<5B.:OQ*=V[E=NKA43I+FJBFN.#5&L"+@NI=9
MQ\:ZBQ<6*Z(^AL1SEQ5&S$9J?$B/P0T(VSFQ&D7.Z/)4G9V-,Z\'OGS7YU_*
M.HHM%IE$EG0*1(R\G"<N4Y(3$;E+QJNU?C*-Z_=OSPKM4S/Q6;=JBU&E$:+5
M<J[5Q-@1)%                    #352R]'JE9D:M/R:1JA)*BR\7./;D8
M+E)J141=>O6BEFUEWK5NJU15I35S\R&O'MW*XN51RQS+D<J-5$74IN2LF6@
M                                           &H;9JDLM(ZOLDT;5G
M,S;HZ1')E-PPUMQR5U(FO#'46/2[LV>(F?[>CD_VAXBW%SC=/[E<I<G)QU&W
M*Z90               U-H[.4NTDK"EJW*]M0(41(K&+$>Q,I$5,5R53'4J[
M>,L8^5=QJIJM3I,\GL^Z*[8HO1I<C6%6N5N*HN!M6-:QC6,:C6M3!$1,$1"O
M,Z\LI8Y%"H
M
M
M                                               "'^R8_-2E_MO_
M $//0_TY^O7\OO#(VQ^E3\_LAKLD/97>_":5_P!3YS/8O/)R
M ?*U3J=H*?V6%LH-D*?"G*Q/T^!*0GQU5(,JBPI5SHT3#:UJ,V<*JFW8H"2Y
MRZBTLQ)/F]*%JN^)4RDB-C-AR2OXNUVI@C?C^( >SL?K>U*V=G:C*VE8QMH:
M+-+)SJL1&I$5,<'Y*:D7%'(J)JQ:JIAC@@#I+<TJUM8CR<I9JNRE"IKFN[<F
MDE\]-*NK!L)'> U%3*Q<NM%PPV #CZG=%6F2D28HMYMM&5A$5['3D_G99S\%
MU+"1J(C57SX<2@#V]CW;RHVXLC-K:%C6UNES3I.;<QJ-2(J(BH[!-2+M1435
MBG!C@ .7MK_O>W?_ +IC_P N; '57X6-[MV;K=8[Y+24[M*DQ_\ L4A/9F5C
MY+'N_I8>2N5CCDKK3%$1 !'5P5VG=^ZF@U3OUMM3,]G_ /LE.JN9EX>3'B-\
M%F0N&.3BNO6JJH ^DVI@U$Q5<.%0!4 05#M+:F]FV%9I5CZNZSUD:/%[7F*G
M AH^8FXO"V&J^Q35M37A@JXY6" -G5KJK2TR4B3EC+R+6.JT-JK#@UF=2;@1
M5145&JU6HC<<,,<%V^?$!NKC;PXUO;/SC*M+,D[04F/VK4(#-B/UX/1.!%5K
MDPX%:H AB^RP'<:W-VTKWVVNG^ZE62#GIZI9V)*?TL%,N [)3(=X6..O6UO$
M )ZL58#O6JD6=[[+6UG+@K"S%7J7;$)N*HN4C<E,':L,>)5 ':@" .REL;C8
M2TUIN^.TFKM;_P!U=O?^[_;84/VG)_S;?9:P!L[O+JNV+)69J/?Y;V%G)&6F
M.U858R8#<8;79#69&IB;$3'9J &L[-?W+*5^^H7\B. -_3;.VSO$@=UK46AK
M%DJ;'\.3H]&BI CPV<#HT;!55RIABW#!/(N* #2TBM6DNSO:H]D;05R:M!9N
MO,5)&;GL%F($5-62Y^U^O)1<>6BI@N** F:U-<D[-6=J-:J;U;)R,%T:)AM5
M$V(GE5<$3RJ@ AJQ5,MG>U3DM+:&U%5LS0YIRNI]-H<5($7-HJHCWQ<%5<?*
MBXIKU(J ##;"):RY5\G785HZG:BQ[H[8$_*55Z19F CE7"(V+@BKQ<"8X(J+
MJ5 $\R<S!G)2!-2L1(DO'8V)#>FQS53%%]"@#, (?O3MS7HMMJ;=]=^^#!KT
MY#S\Y4(K,MLC!P5<439E8)CKXVIM=B@"^+=%6FRKH\M>A;-*S@KDBQ9M'2N6
MN/\ W&&&3Y,H >FY6W=7K<]7K*VR;!;:F@Q$9&BP6Y+)J&JX)%1$U)P;,$P<
MU<$UH@#GK/5RL66[).KV:KE4G9JCU^ LY3&3,=SV07ZW9#$<JHQ-45N"8;&>
M0 3JJX(JKL $*7$5JK6UMK;>UD>I3K[/+,]H4R4=&<L!&MP57HS')1<E(>M$
MQ\-P \<.T=I[V[:5JE61K,2S]D*/$[7F*E+,19B;BZT5(;E]BFI=::T3!5QR
MD1 'LM-=]:ZR=*F*S8:WEI:A/2;%COD*Y,I.0YEK4558F*)DJJ8^=>%-2H [
MVZBVL"W]B)"O0(:08L5%AS$!%QS45JX.;CQ;%3R*@ A:MVQMM+=DA:NS]E71
MZ@^8E($&5EYJ.]920QA0'OF%9LU8NV88J_AQP4!W$W=/:6/)/F]*%JN^)4RD
MB-C)#DE?AL[7:F"-^/X@![>Q^M[4K9V=J,K:5C&VAHLTLG.JQ$:D14QP?DIJ
M1<4<BHFK%JJF&." (L[*^QG<JSTO6N^2TL[V]7&IVC.3V<E9?+9&=C"AY*9.
M3ADMUK@BJ@ E^@W6=R*Q*5#O[MY/=KQ$B=K3M7SL&+A_5>W(3%/( .?O7M3:
M">O-L]=W92H]QXE0@+.3E1:Q'Q&0DRUR6(NQ<(;M?E36FL >Q]V-IJ(D.<LC
M>+:*8J$-45TO:"9[<E8__"J9**Q%UZTQ79Q8@"6@  $17GVZKT2VU.N_N_6!
M#KTW"[8FZA&9ELD8/'DKJ5V"8Z]6MJ88NU +]$%4= 2,^\^W"U5%1V=;.HV7
MRD7]!AAD_P##E8?8 /#=?;BT5-O F[NKPHT&;JL.$L>G5*&U&=N0D3'!S4_K
M9**N/_"Y%QPQ4!TE]=X$:PU E&TB5;.6AJTPDG399VQT1<$REXT3%NK'6KD
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M0YA[8S>)'(_@X479L0!]5
M                                            (@OT_/*ZKX0,^Q !
M+X  "(.Q\_*MZ'PMG?O "7P
M                  !"MRONR7Q_MLG]D8 34
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M)PW;($S$FXD1GG<SP5^( <?V(O;&<O [>S7;?=9,]F<<C+\/*R<=>&..&.O
M >RVO^][=_\ NF/_ "YL 2K>;[F]K/W3-_R7@#CNQ:]PJS/_ )K_ )J* )5
M&OM$^)"L_4XD!SFQ62L5S%;M1R,7#  0_P!AU"@LN@1T'#.1*A'=%_O8-1/_
M $HT 3@ /GVY9N:[(B]1DLF$JKT>]&[,XK\=?EQ5_P!( ]/9&^Z1<W^_4_G2
MX GD  !%792>X5:?_P K_P U" '8W9>YO9/]TRG\EH B3LU_<LI7[ZA?R(X
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M ?0  ^6:,MKX_9,V_BV/[@.JC(+6/6M9[(2 F:1,C-:\=3-NK  2C_\ ??\
M_+;^. 'ANXN_MA3[VZU;:V$U0$B5&125= I*QE:KDS2(N$1J8:H7&NM>! !I
M*Q_3=F-0TFD14@T5W:^/]V-BJ>EX GX 0-:S_?#L9^XHGV38 GD
M
M             !$%^GYY75?"!GV( )?   1!V/GY5O0^%L[]X 2^
M                                                (5N5]V2^/]MD
M_LC ":@
M       !$'9!?E6Z_P"%LE]Y0!+X
M
M
M
M
M
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MJEM(,*4G9^GQXT"1ANRTDH"0X[6PE=PNQ17+Y7\&Q 'U&
M
M        B"_3\\KJOA S[$ $O@  (@['S\JWH?"V=^\ )?
M                                          $*W*^[)?'^VR?V1@!-
M0
M  B#L@ORK=?\+9+[R@"7P
M
M
M
M
M
M        $*]DS_9Y\)I7_4 34
M
M
M                                                     B"_3\\K
MJOA S[$ $O@  (@['S\JWH?"V=^\ )?
M                           $*W*^[)?'^VR?V1@!-0
M                                               B#L@ORK=?\+9+
M[R@"7P
M
M
M
M
M                                                     $*]DS_9
MY\)I7_4 34
M
M
M                                      B"_3\\KJOA S[$ $O@  (@
M['S\JWH?"V=^\ )?
M            $*W*^[)?'^VR?V1@!-0
M                                B#L@ORK=?\+9+[R@"7P
M
M
M
M
M
M                                      $*]DS_ &>?":5_U $U
M
M
M
M                        (@OT_/*ZKX0,^Q !+X  "(>Q^P[JWGY*JO\
M]K)S'%,->4 )>
M         $+7*X:8KXL%7*[=D\4PU)JC ":0
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M.L '=B^S=FR/.XG6 #NQ?9NS9'G<3K !W8OLW9LCSN)U@ [L7V;LV1YW$ZP
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M=8 .[%]F[-D>=Q.L '=B^S=FR/.XG6 #NQ?9NS9'G<3K !W8OLW9LCSN)U@
M[L7V;LV1YW$ZP =V+[-V;(\[B=8 .[%]F[-D>=Q.L '=B^S=FR/.XG6 #NQ?
M9NS9'G<3K !W8OLW9LCSN)U@ [L7V;LV1YW$ZP +6+Z\$PLS9+'A_P"UOZP
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M6 $?7L3MOINH6';;JDT21DVU^66 ^0CN>]T7'8J*JZL,>+S@#Z@
M
M
M
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MQL7%^3A\9%9NLME                   !"MRONR7Q_MLG]D8 34
M                                                      (@[(+\
MJW7_  MDOO* )?
M
M
M
M
M
M  0KV3/]GGPFE?\ 4 34
M
M
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MX5/)'3*CHC6[=OD)#NQN^KMD+PY6+4X,.)*.@16I,R[LN'E9.Q<4147SHF/
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MXNV^:6?=M56JYHKYX7M5')BFPUI,C5   0K<K[LE\?[;)_9& $U
M                                                    "(.R"_*M
MU_PMDOO* )?
M
M
M
M
M                                                           0
MKV3/]GGPFE?]0!-0
M
M
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MD8 34
M      (@[(+\JW7_  MDOO* )?
M
M
M
M
M
M              0KV3/]GGPFE?\ 4 34
M
M
M
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M>#= V0@3$-LP^4;+1<?^[C,1,,I$V(JM1?,IFWHJV=G\9,<FNOSB5RUIEXG
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M&M_3]-<8O]W-K.GR_P!J&U9IF_R<^G*R2^.;U\>HBXW&8R   (5N5]V2^/\
M;9/[(P FH
M          1!V07Y5NO^%LE]Y0!+X
M
M
M
M
M
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M,K#.>!CAQ_: -K8SNSWJ4GOH6'W<[69VYF\G#.X>%['P?1JQV:@!N0
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M/$KMO" -_8JTLG:^R]/KU,9'AR<ZQ7PV1VHUZ(CE:N*(JIM1=BJ -V
M     (!MDYR=F-81J.7)6C1=6.KV$YT( )^        0/V9SE;=3)*U51>ZT
M'6B__#B@"> !\[R-+@WPWRVTDK51IJ8LU9IS)27IL..^%"=$57-5[\E455QA
MO7;Q<"8 "8;"6'HUAI2:D[.LF8,E'B9U)>+,.BLA+PY&4JJB+PZU '3@
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MYRXJJKM55XS2B(B-(4YG7EE>6    $*W*^[)?'^VR?V1@!-0
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MRC0=:K])3/7NZH]8,7HGL_DW3?\ @9YOE&@ZU7Z2F>O=U1ZP8O1/9_)NF_\
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MY1H.M5^DIGKW=4>L&+T3V?R;IO\ P,\WRC0=:K])3/7NZH]8,7HGL_DW3?\
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MS?*-!UJOTE,]>[JCU@Q>B>S^3=-_X&>;Y1H.M5^DIGKW=4>L&+T3V?R;IO\
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MJHFO61N;+.9
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M*C=KS\B]V5D.UIE-7B56N3!=:*BIKU*H#A^S0]R>2_>T'^5& '>WVVHKMC;
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M%E8Y.'!AB /FVYK2/I"O.[W.]#NGW19W4[?[9S.=SD?#,9'A9..7[+7AD^4
M?3=EN[G<.6[Z^YO=GPL_W-R^U_9+DY.7X7L<,<>'$ ;4 1M>#><M#M'+65LM
M2(MH+63+,XDHR(D.'+L7^O%>OL4X<.+:J8IB U<U4KZY"6[=B4:Q50A-17ND
M9.-,,F,,%7!'/7(Q35LQQX., =+=3>/3;PZ5,QI2!&D*E)/S4]3YCVR7?KU+
MJ3%-2Z\$V*BHB@"$^RU[]^]-_=SO;[V>ZS>T^T\_VY[&+D9S*\#V...'#A@
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M$U+J3SJB:T 2G9BNR%IJ!(UFCQL_(3D-(D)^&"X;%14X%145%3C10!LP
M1!?I^>5U7P@9]B "7P  $0=CY^5;T/A;._> $O@
M                                  "%;E?=DOC_ &V3^R, )J
M                                                      -]8'\^
MK.?O*6_FM*N=^VN?]9\)3XOZU'SCQ0]V0WY2NQ^%DG]JGV<?F[V*5
M
M
M
M
M            T5OOS%M'^[9G^4XM8/[FW_VCQ097Z-?RGP70_9M\Z'Q@?I#Q
MSU@
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MV?$H \/8G4RM4>[:;D:_39ZGN94HKI:%.P70HF:5D-<<ER(N&5E:_. )H
M !$%^GYY75?"!GV( )?   1!V/GY5O0^%L[]X 2^
M                                    (5N5]V2^/]MD_LC ":@
M                                                      #?6!_/
MJSG[REOYK2KG?MKG_6?"4^+^M1\X\4/=D-^4KL?A9)_:I]G'YN]BE0
M
M
M
M
M            -%;[\Q;1_NV9_E.+6#^YM_\ :/%!E?HU_*?!=#]FWSH?&!^D
M/'/6
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M-#W)Y+][0?Y48 3R /G>\V<AW77^T>VD7*AT.O2KY.HJU,<(C$1$=J\T)?\
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MDLB0I>.F#T@HLNV&YR<"N8C7?Y@!], #!/I'=(3*2BHDRL-R0E78C\%P^G
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MW M'?U>!6)*%'ARDY+,BP4CLR'.8KF9+L.!')@Y/(J #==FA[D\E^]H/\J,
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M)Y=/F\[G+GL,5PQ0^=3V#SST  >NE=K+4Y/M_'M3/,SV'(RDROHQ.+O"X%7
MY].3YNJ-.%'"YA<<%PVDR7R]XR62ETLYW%[HYYN;[0R,O(P7*R\C@V>RX3S>
MR/3N/GC^%P=/;KW:_9L;0]&XJ.*TU^##!R\I<K*P\I"!Z=BLP
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MQ4;'5&QLO38$I%96:O"D)A9AKE5L-RHBJS!R8.U[5Q3R "1
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M:QR:QXL?L7Z]>"G&7(VBG:E2ZC1ZW'B1JM2H[H41\5ZN>YJJNU5UJJ.1R>;
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MHX$S#++M15=BB*2X>?:S$
M                          :*WWYBVC_=LS_*<6L']S;_ .T>*#*_1K^4
M^"Z'[-OG0^,#](>.>L
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M%XVKM:OE144 <O9RYJP%G9]D[2K-2K9ICD<Q\>)$F,A4QP5J1'.1%U[4\G$
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M-8 WH T-GK(T.SU5K52H\BDM.UB,D>>B9U[\\]%<J+@Y51NM[M341-8 WP
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MF*JV'K\KN, >Z_'W8;F_V^:__( $W "$>R2_+EU_PD@?>: )N
M                   -]8'\^K.?O*6_FM*N=^VN?]9\)3XOZU'SCQ0]V0WY
M2NQ^%DG]JGV<?F[V*5  (/M5_O%T/_#A_=>>GQ?^(N?7[,2]^_I^C,S_ &=Q
M+EJIJ3D[-U./4G,;*-EWI$R]BHK53)\N..&'#B>?Q:*Z[U--OGUAK7ZJ:;=4
MU<VC$Q%5R8;<2+>QEEXS*#68[VN27B3#&PU78JM:N5AZ6F[_ %'53-VBF.>(
M9FQZ9X%4^S5EF?9(8:3>_6*BR9D).CP)VO1)ET*4@0&N:Q(:)K?$57:_B5$V
MXX</5W8EFWI<JKF*-.69Y]>B.3S<V]IW*]:*:=:M>3^1834UJN#>$D&Q57M%
M'I]0BVUITM2XLLJ*CH3O <S)Q5V.4Y-7G,C,L8]-=,8E4U1/;KV0T,>Y>FF9
MOTZ:?GQ8WHW%,A57$XQ;S+16CGYB#=_9UD[+0'9*S4VJHUVW@RFHW'@178X<
M!I;IQ\:F*LVYI,^R/]3X*?I]Z]5,8U&L1[9_(7YMK4_I'8+Q(725Z%9HE:EZ
M=>#0X=-287!LU 5<AJ8X8X8N1435BJ.U<1\KV19OVYN85SA:>R>?[>!3M"Y:
MKBC)ITU]HL-'-58;L<. D6U-H).S= F:M/N58$)J8-9K6(Y=36M\J_\ [3'Q
M<:O)NQ:HYY:%Z]39HFY5S,;6JYV";2,Y>W%XU7D5JE#LG)=RWHKH6>571'-X
MT3.-5WG1NO@-J=G[.LU<5>O3POAS>$Z=K-C+S+E/#MVXX/Y\89,B&BX.<N)D
MNUM];&UE9:R)2Z4E,@1,B<B0\61(.*+AX+HBKM3DKPGS:.S</$MZQ7/"GFZ)
M[(^[[AYF1D5\M,:1S_FI$8QC=JX\!ZK67I1K-6ZGJ5-RD&+3X$NU\)(;79Z+
M%<U%1N..")BO%L3A(\78\96+3=IG2J9^D1^?%W?VA-B]-NJ.2(^NHR%E,147
M7B;:QE=MQ4*U"9:.SLM(4J/#<]D5B^&Q4V(Y,M<%\Z(09F-@V[<S8N355'9X
M?>4N/>R:Z]+M&E,_G2HYK$:N2Y54\EK;QYN!:)]G;'TKNO5X:+G7.5<W"7B7
M##'#%,5Q1$V8X[),395%5GTC*KX-'LZ9_/9SN+^=5%SB;%/"J&0TR<IZX(:J
M)>-:VS,S =;NS4&7I\9R-[8DG8Y&W;X;D5=6S%%)XV7B95,QAW=:H]D_ZC[H
MISLBS,>D4:1\/]RKFV.1<AVORDF5*NR-/L[&K<6+ET]D!)A'L3'+:J8MP\^*
M8><Q;>/7<O18B/[M=&E7>IHMS=GFTU8T:JNPX=A&,G;F\*O2_=&S=E9):6Y5
MS;IB)B]R(JZTQB,Q^)-N)MU[.V?CSQ=^[/"^'^I\6;3EY=V.':MQP?C_ +AD
MR(;=3G+B2'9:M3D]9Q:A7Z>ZDS$-8F>@OQ\%K57PM:;,$Q,?)L46[W%V:N%$
MZ:3\VA8NU56^'<C@RL<B([!JXH1]+7A6SM-$CQ[$69EHU,A/6&D:<?@K_2]B
M8\:)CABAKU;,P\6(IR[LQ5/LC_4_9GTYN1?F9QZ.3X_[A?FV-]F[7Y#N;!UB
MMU>0F>^2CK2YV!$2'DICD14R47*;CCJQQV*OG,O.L6+-4<17PHGN7L6[=N4S
MQM/!F%CT:B^"N*&DLA;:H5F\:T%GYF!*,DZ>CUA/AM<D1<E[6^$JN5%V\"(6
MLO9]NSAV\BF9UJTUZ.:90V,JNYD5VIB-(7.8B0VN3'%3'9FW-2F;RJM9:MR\
MI!S66LH^"US7/1/";E8N7%58N5J1-BGW(V=;IPZ,JS,SKSZ_ZZ7-G+KJR*K%
MR(^'Y\AS$S:.:J^4[&U-7AT&SM1JD7!6RL%T1&K_ %G?U4^-<$^,SL6Q.1>I
MM1[97+UV+5NJN?8L:F4Y$XSFK"VQFY^P4:TMJFRDG :Y[FK 8Y$S3<$QP555
M55R.1,-NHNYN#1;RHQL?69Y.?I[O8K8V5578F]>TB/LN>Q$?DMQ4YF4O MO:
M5'S5C;+2[J:CE:V+./UOPXE5[$X\<,>+'47:MFX.-_9E79X7P_U*M3F9-_\
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M%G^G.>[\H^Z':_-1\Y72VUQ-1YILL(
M                                  !HK??F+:/]VS/\IQ:P?W-O_M'B
M@ROT:_E/@NA^S;YT/C _2'CGK
M                                                   $*]DS_9Y\
M)I7_ % $U
M                                  T#['4*);*':N)((^OPH':\.:=%
M>N1#P5,$9CDIJ5=:)CK7C &_              !H).Q]"D[8SUJI:01E>GH"
M2\Q-9UZY<-,A$3)5<E/:V:T3'4 -^
M
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MO*'_ "HI#_3O[FK_ *SXPDVO^C'S^TJ2WLU\Q[+(>X$O[KFO_P PCRO^4_\
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M?Q\U^( (VO:NTLG8:T]W$S9:D]HQYFT$O#BN[9BQ<IJ/:J)@]RHFOB 'T\
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MK9;:XFH\TV6$
M                 T5OOS%M'^[9G^4XM8/[FW_VCQ097Z-?RGP70_9M\Z'Q
M@?I#QSU@
M                                 "%>R9_L\^$TK_J )J
M
M   :*QUKJ);*FQY^S4\D[*08[I:)$2$^'DQ&HBJW!Z(NQS=>S6 -Z
M         -#-6NH<I;"2LM,3R,KTY 69@2N:>N7#3+Q=E(F2GM;]2KCJ &^
M                                :"<MA0I*V$A969GT97IZ"LQ+RN:>
MN7#1'JJY2)DI[6_:J+J &_              !H+8VRL_8V19-VFJLO3X,152
M'EXN>]4VY+&HKG8>1 !X[#WAV6MRLRVRU7ASSY;!8K,U$A.:B[%R7M1</*FH
M =6
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M>E;&:JOQ1%74?/D94=&B*FM%<JIZ3UU/,P)YV=#&?7P
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MOV[,W.,JB-8CGG3I6-J6J[D4<")E;+JB*[%40EP\^UF(
M                                                 T5OOS%M'^[9
MG^4XM8/[FW_VCQ097Z-?RGP70_9M\Z'Q@?I#QSU@
M
M     "%>R9_L\^$TK_J )J                       1C>Q>#4['VTN^I%
M.EI*-+6AJ"RDTZ.URO8W.068L5'(B+A%7:B[$ $G "-ZW=?W4O@I-NN[D>#V
MA!2%VBD+%'X(]-3\KP47+UIDKCAMU@"2           !&ET]OJG:^UMOJ74I
M>3A2] J2R<LZ UR.>S.16XOQ<J*N$--B(FM=0 DL
M           0-V&?N;US]^Q_Y,  3R    "-+T[?5.R5MKOZ-3I>3BRUH)YT
MM-/CM<KV-1\%N+%1R(B_TB[478@ DL         $#6L_WP[&?N*)]DV )Y
M 1)%NFG;4UBH3MY%HIVJ2<2._M6D2<9\O*0X.5X".1N"N=DX8KJ\[MH Y&\^
M[=MV% C6QNLG)VC1Z:K8DU(=L/C2\S"5R([*:]55<-2KBJI@FK!410!-MAK0
M0[560H]<@P\TV?EF1EA\ARIX3?B7% !O%7!%5=@ ^,[^JE.7DR]I+32T:(VR
M5FHL.GT_)]C-3#XC4B1/*F"^C(XU 'U=8!RNL)9QSE57+399555UJN:: -\
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MGY5O0^%L[]X 2^
M          (5N5]V2^/]MD_LC ":@
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MJXD>9M"S&/Z+B4S%/MF76/B7)N\??GE]FBCWIDY+$U$G&(TV,
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M$._,E?8P
M
M            #16^_,6T?[MF?Y3BU@_N;?\ VCQ097Z-?RGP70_9M\Z'Q@?I
M#QSU@
M                              "%>R9_L\^$TK_J )J
M?--<MM;&2[(FUUGK+I,5*9FI>7@R,M,QWK)R*K!@O?'<S'!$3PMB:U=PXX*
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MCG9N8P3#!&X(L-JIBF.( F&\^V<I8*QD_7IUF=S*(R# 1<%C17+@UN/!QJO
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M)LQU@#S7#6SKU2JEI[(6RC,FZU9Z.D-)QK$;VQ"Q5J*J)PZD7'#6CDQUHJJ
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M)2,Z$]S,U&<K55JHN"JU-7D 'II5G+:7ARZ5BU=H:O9.GQ_#DZ/1(R0(\)G
MZ-&5%57*FUN&">1<40!J*16K279WM4>R-H*Y-6@LW7F*DC-SV"S$"*FK)<_:
M_7DHN/+14P7%% =-?S8WNS92T%:[X[22':5&F/\ L$C/9J4F,B'$?_2P\E<K
M*QR5UIBU$0 <'<7=EW>NJH-2[][<4W/LBKVK3JMF9>'A&>WP&9"X8X8KKVJH
M ^BI&7[5DX$OG8L;-0VP\[&=E/?@F&4Y>%5VJO& ,P                B"
M_3\\KJOA S[$ $O@  (@['S\JWH?"V=^\ )?
M                                $*W*^[)?'^VR?V1@!-0
M                                                  !OK _GU9S]
MY2W\UI5SOVUS_K/A*?%_6H^<>*'NR&_*5V/PLD_M4^SC\W>Q2H
M
M
M
M
M        &BM]^8MH_P!VS/\ *<6L']S;_P"T>*#*_1K^4^"Z'[-OG0^,#](>
M.>L
M                             0KV3/\ 9Y\)I7_4 34
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M?\U% #LI/<*M/_Y7_FH0 ZNZ;7=;8U5V]QI/^0P 1AV./ND7R_OU?YTR )Y
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M/[(P FH
M       ]%/FX]/GI:<E(F;F9>(V-"?@BY+FKBBX+J76B;3FNBFY3-%7-/)+J
MBJ:*HJIYX0_V0:8U2[!%V=]DE]Y3L]+=MO'?\) ZAF;EPNIWSYKF\LGK=T>2
M7<TSD_2-+=MO'?\ "0.H-RX74[Y\S>63UNZ/(S3.3](TMVV\=_PD#J#<N%U.
M^?,WED];NCR,TSD_2-+=MO'?\) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W;;QW_"
M0.H-RX74[Y\S>63UNZ/(S3.3](TMVV\=_P ) Z@W+A=3OGS-Y9/6[H\C-,Y/
MTC2W;;QW_"0.H-RX74[Y\S>63UNZ/(S3.3](TMVV\=_PD#J#<N%U.^?,WED]
M;NCR,TSD_2-+=MO'?\) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W;;QW_  D#J#<N
M%U.^?,WED];NCR,TSD_2-+=MO'?\) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W;;Q
MW_"0.H-RX74[Y\S>63UNZ/(S3.3](TMVV\=_PD#J#<N%U.^?,WED];NCR,TS
MD_2-+=MO'?\ "0.H-RX74[Y\S>63UNZ/(S3.3](TMVV\=_PD#J#<N%U.^?,W
MED];NCR,TSD_2-+=MO'?\) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W;;QW_"0.H-
MRX74[Y\S>63UNZ/(S3.3](TMVV\=_P ) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W
M;;QW_"0.H-RX74[Y\S>63UNZ/(S3.3](TMVV\=_PD#J#<N%U.^?,WED];NCR
M,TSD_2-+=MO'?\) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W;;QW_  D#J#<N%U.^
M?,WED];NCR,TSD_2-+=MO'?\) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W;;QW_"0
M.H-RX74[Y\S>63UNZ/(S3.3](TMVV\=_PD#J#<N%U.^?,WED];NCR,TSD_2-
M+=MO'?\ "0.H-RX74[Y\S>63UNZ/(S3.3](TMVV\=_PD#J#<N%U.^?,WED];
MNCR,TSD_2-+=MO'?\) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W;;QW_"0.H-RX74
M[Y\S>63UNZ/(S3.3](TMVV\=_P ) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W;;QW
M_"0.H-RX74[Y\S>63UNZ/(S3.3](TMVV\=_PD#J#<N%U.^?,WED];NCR,TSD
M_2-+=MO'?\) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W;;QW_  D#J#<N%U.^?,WE
MD];NCR,TSD_2-+=MO'?\) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W;;QW_"0.H-R
MX74[Y\S>63UNZ/(S3.3](TMVV\=_PD#J#<N%U.^?,WED];NCR,TSD_2-+=MO
M'?\ "0.H-RX74[Y\S>63UNZ/(S3.3](TMVV\=_PD#J#<N%U.^?,WED];NCR,
MTSD_2-+=MO'?\) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W;;QW_"0.H-RX74[Y\S
M>63UNZ/(S3.3](TMVV\=_P ) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W;;QW_"0.
MH-RX74[Y\S>63UNZ/(S3.3](TMVV\=_PD#J#<N%U.^?,WED];NCR,TSD_2-+
M=MO'?\) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W;;QW_  D#J#<N%U.^?,WED];N
MCR,TSD_2-+=MO'?\) Z@W+A=3OGS-Y9/6[H\C-,Y/TC2W;;QW_"0.H-RX74[
MY\S>63UNZ/(S3.3](TMVV\=_PD#J#<N%U.^?,WED];NCR,TSD_2-+=MO'?\
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M\S>63UNZ/(S3.3](TMVV\=_PD#J#<N%U.^?,WED];NCR,TSD_2-+=MO'?\)
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MB+BB;/*<4:2FO
M                                       $*]DS_9Y\)I7_ % $U
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MN78X(OY=8G_JA@">0! ,RU?_ &QY1<%P2BJN.'_"X =3V4GN%6G_ /*_\U"
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M /D"P]*J<_>!2+J9Z&Y]+H5H)BHQG.74^$Q$R45.)<EV"\.>X !]LJF**B[
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MYN=FHD-8D3"3B,9 1$QP>YR(B+M1,,<5 ' ]D<U5O2N75$542M+KP_\ CRH
MGX 0W?A8^MK:6SMX%C)5)VN4)<B-)(N#IJ755Q:U>-$<],-JH]<-:8* ]4KV
M0-A6PD97)NH4.H)@D21GJ?'SK%\N0UR?3P; !T-BK>S%KZS$ATZS%8E:'#A.
M<M4J$/M=(D1'(B,APU\)R>RQ=JP5N&  XCLA*-5Y6U-BK<4BF1ZM+T&.Y9R4
M@-RHB0U5JY;4X<$1VO@U+LQ5 &TB7_V/F9566?95JU653P*5*R$5(V7LP<JM
MR41%5$545=NI% '%W")6G7\V]CVGDX4E58\G!CQY>$[*;!SF0]K,>%4:J(OE
M10!V79368J-IKKG)1H$29G*=.0Y](,)N4][6M>QV2G"J(]78>0 >VR5]]D[2
M3=+ILI$GN[LVYL.+(=I1$=+/V.RW*F2B(NU450!R79JM5UUE+R45<*S"V)_\
M&. )^ $#7FHJ]D[=GJ7_ &>-]D0 3R (!NG:J=DQ><N"X)"AZ\.-6 #=7X6/
MK:VEL[>!8R52=KE"7(C22+@Z:EU5<6M7C1'/3#:J/7#6F"@/5*]D#85L)&5R
M;J%#J"8)$D9ZGQ\ZQ?+D-<GT\&P =#8JWLQ:^LQ(=.LQ6)6APX3G+5*A#[72
M)$1R(C(<-?"<GLL7:L%;A@ (Z[-5JNNLI>2BKA686Q/_ (,< 3\ (![(YJK>
ME<NJ(JHE:77A_P#'E0!,]L:4^NV2KE(AN1CY^1CRK7+L18D-S47Z0! MS%ZE
M$L!866LC;ED_2J_2XD6$V5?)1'NF$=%>YJLR45%UN5NM41<-6.T ?15/FFSL
MC+34-D1C(\-L5K8C<ES4<F."IP+KV #.                (@OT_/*ZKX0,
M^Q !+X  "(.Q\_*MZ'PMG?O "7S?6$I"5VV%(IKTRH<>8;G$XV)X3O\ THI5
MS;_$8]=R.>([_8GQK?&W::.F5'KDL528>R9JBPJ=1J3#5$;%B/F(C4U:FIDM
M^+PG>@\[_3EG6NN[/LY.UK[8N:4TVX^;#+)K<OQ&U[&G\Q9_]Y/_ )4(@_J+
M]S3_ -8\92[(_1GY_:%)CV:>8AZGZ[XY9%\?M_Y@]%<_X^?^G_XLBC]W'_;[
MLR^TK_=/JJ;J<.5J]/D8N".G6Q<VN.US$1</DY2_$>#HM37;JKC_ ,=.]ZBJ
MY%-<4S[7E1,45>(^6KY*"E MY/PX3$;+3>$W!1$P1$?CBGQ.1R>; ]ULC)](
MQ:9GGCDGZ?P\QGV>*OS$<T\KTP793$\FHZ3L<[/I/VFF:O'9C!I\/)AJJ:LZ
M_%$]#4=Z4*7]09/%V8LQSU>$?RL[)L\.Y-R?9XK9AV#<.,F^8J<*L6,JTW P
M6$L.;A-5-:.2&Z)#Q^/)Q^,\S3:FSD443S_VSVZ3]VU-R+EFJJ/CW:PPHF#T
M3S$&]C3^?4_^[7_S81Z?^HOVU/\ VCPEB;(_6GY?>&:8]@GG//V1GN@,_8H?
MWGG?]/\ [3ZS]G.UOU_I'W5E_:_C-3<9[J-$_P#'_D1"?;7[*Y]/&$6S?W-/
MU\)5C>U..S[)[_;[/_X4;[6F=_3?^%SYQ]US;'^5'U62VQQ")Z9BLQTEW5'E
MZ];6DTV=7_LT:+C$3'#*:U%<K<?+DX?&4]H7ZL?&KN4<\1_"QB6HNWJ:*N:5
ML1<EBJA/-ZUN9B[^!29&A4V3R8S'9.=8J0V-;@F2UK53CX]6KC/*[+V?3M":
MZ[U4\G;R_/5NYN7.)%--NF&"$Q(F*N53:61J4"\J[^(^N2,%C8JO@16HF+4<
MG]=F.M,,<4UZE3:5\JU5LS*TLU<VDQY2EL7(S;'_ *D?G2HY,V_P5(#NTM33
MK'U.?GIVGK4)G-9$K@C41K\K6N4N.3JX415/6;1P[F913;HJX,:\OY[6#AY%
M&/5-54:S[&>(U7HB(N"<)(5CKZ:I5;52-/J-.DFRDY'; :L!'H]BN7!JJJN5
M%UJG AD9>P;5FQ5<HJG6F->733D:&/M6NY=BBJ(TGD6.@HC%5%7%#V]DG19+
MN)(UEL)C)])ELLZ(B8+$8K'+@O'ADZO.I%_3N17QE5G7^W37OCS=[7M4\"+G
MMUT4EU7%6\!XNQML_(QY>H5N8A,BSD*,DO!5R8YK!J.5R<2KE(F/D\Y+_4.3
M73--BF=(F-9^+C9%FF8F[//S*S#EU)P";OJJD"V46G]RI3N?#FUEE8N7GU1'
M9....&/#AD^3RBC8-JK'BYPYX6FOLTYM?SE*MJUQ>X'!C373XB04R,<5QP/=
MV2='DNX4A5TAL9/MF4EU>B(BQ&*URX+QX*U,.+%>,B_IV_7QM5G7^W37ZZN]
MKVJ>!%SVZZ*2ZKE*G 5[&RHI-V<J](CX/;+QDB(UR8HK(C<%3S8L7TC^HK7
MO47H]L>'^WW9%?"MU6Y]GW)A,'(J$'VKI:T6TE3IJZTEIA\-J\;474OHP/3X
MM[C[--SIAB7[?%7*J.B69BXM134DZ)4              $*W*^[)?'^VR?V1
M@!-0
M     B#L@ORK=?\ "V2^\H E\
M
M
M
M
M
M            !"O9,_V>?":5_P!0!-0            " ;&M5.S&MVJHN"T6
M%@N'_!)@"?@
M !%?91HJW%6G1$55_P"S+J_:80 ZJZ9,+K;&HNWN-)_R& #J@
M
M
M      $07Z?GE=5\(&?8@ E\  !$'8^?E6]#X6SOW@!+Y)/8^P6Q;QI=[ML*
M7BO;Y\G)^QRF-MZJ8PYCIF&CLN-<B/E+'']K4V/9*1E?;:1A?U8<@Q?C6)$Z
M$(?Z=ITQJI_^K[0DVO/_ *T1\/O*DM[!?.=UV-/YBS_[R?\ RH1E_P!1?N:?
M^L>,KVR/T9^?VA9,>S3S$/4[W9);]_M_Y@]#<_X^?^G_ .+(H_=Q_P!ONS+[
M2O\ =)COUJKZ'-62J<+%72L\Z(J<IJ(F*?&F*?&>=V)9B_3>M3[8:^TKG%3;
MKCV2PP$RD>G&AX^R(H\.IV5D*]*(C^U7HCGMX8,38ORLGY2DG]/WYM7ZK%7M
M\8<[5M17:B[3[/"277!RM7A/59MFC^Y*-//3-S\>"LSKU+G8N"0T^),C5Y%.
M,B=X;2BB/\8G3Z1S_=U9CT3#FKVSR_6>8=_21L.#8>R[+7<9"5?U2<_F12+:
M7_)S\Z?"'>'^R^D^,J1/;OC0CCL:?SZG_P!VO_FPC9_J+]M3_P!H\)9VR/UI
M^7WADF/8)YSS]D9[H#/V*']YYW_3_P"T^L_9SM;]?Z1]U9?VOXS4W&>ZC1/_
M !_Y$0GVU^RN?3QA%LW]S3]?"58WM3CL^R>_V^S_ /A1OM:9W]-_X7/G'W7-
ML?Y4?59+;''%0+J+:1H+(L.BJK'M1S569@HN"ZTU*_%#3G;.%3,Q-?=/DI1L
M[)F-8I[X\U^=9Q_0:N9HMHK&6EIS8\I$EJLCF1Y9C'-BJY<I43#)547%45,.
MDFIOX^;9JTG6GFGV>*.;5[&N1K&E7L516O:N"XIPGTQ.2LE:"R$LZ\*GR4BY
MV"OAQ8Z(D)ZZD5K\4R57B1?)K/%45UX^1/H54S].>/E[7I*J:;UJ/28B/J\Z
M*K7KFU535WER58IU@G2-AY279(LA*R*V"JYQL%47'-IPXZ\5Q5=>K7K)]G7+
M-S*X>7,ZZ\FO-K\?S1%F4W*+'!QXY/M\%8:HK\7JN)\V65DI&H6BD)2K3/:L
MA&BHV-&RVLR&\>4[4GG4]IE7*[=FJNW&M41R0\Y8IIKN137.D/0Y51JJFM3Z
M%L%8:PM.K;)RB5=E6GH/A0VNG84;-KK\)&L1->W;B>0SMHYURW-%VC@TS\)C
M7M>@Q<3%HKX5NKA3\XGP8'O>K<')@GF.1[(EMI(L66?.2T%E A/7,O@/5^+U
MU(L3%$P7#8FQ,53%30_I^<:(F*9_]2>?7[?GT5-J\=,QPH_M_.==+Y.O!?"-
M-<#4Z]*V@C2E(DNW*?'R5FT<[(;!PQP?E<"[=6O'XL4L[=LV*[45W:M*HYOC
M\/SF0[+N7:;DTT1K$\ZZ.C5;BJX+P$Y1;/66C6O9/OEI!UH(34B8(],YY'JS
M'6NK4Y4Q\IY>,G*IQ^+B9XN>SY:_9MS9L3=X>D<+\Y=&!'.R,,5R2%.R#6T;
MZU 6KPH;*.U5226 JN8JKMRE77E^=$U)JX5/3;!]&BW/%3_?[=>?_7Y+%VIQ
MW#CA_P"/L_.EFE\G)7#;PF?L9HJMM15H/ ^3R_0]J?\ 4<?U'3_Z%%7Q^TNM
MCS_ZE4? F?8IYSGK^)=(-Y=2<W_O60HBIY<VU/\ 0N;#JX6'3\-?%7VG&F15
M]/!= ]K0CXUE!>              "%;E?=DOC_;9/[(P FH
M                                                1!V07Y5NO^%L
ME]Y0!+X
M
M
M
M
M                                                      "%>R9_
ML\^$TK_J )J
M
M
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M:' FJHKP              0K<K[LE\?[;)_9& $U
M                                         "(.R"_*MU_PMDOO* )?
M
M
M
M
M
M                                                0KV3/]GGPFE?
M]0!-0
M
M
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M;E?=DOC_ &V3^R, )J
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MP TCV(WRLW\Z0.N &D>Q&^5F_G2!UP TCV(WRLW\Z0.N &D>Q&^5F_G2!UP
MTCV(WRLW\Z0.N &D>Q&^5F_G2!UP TCV(WRLW\Z0.N &D>Q&^5F_G2!UP TC
MV(WRLW\Z0.N &D>Q&^5F_G2!UP TCV(WRLW\Z0.N &D>Q&^5F_G2!UP TCV(
MWRLW\Z0.N &D>Q&^5F_G2!UP TCV(WRLW\Z0.N &D>Q&^5F_G2!UP TCV(WR
MLW\Z0.N &D>Q&^5F_G2!UP TCV(WRLW\Z0.N &D>Q&^5F_G2!UP TCV(WRLW
M\Z0.N &D>Q&^5F_G2!UP TCV(WRLW\Z0.N &D>Q&^5F_G2!UP TCV(WRLW\Z
M0.N &D>Q&^5F_G2!UP TCV(WRLW\Z0.N &D>Q&^5F_G2!UP TCV(WRLW\Z0.
MN &D>Q&^5F_G2!UP TCV(WRLW\Z0.N &D>Q&^5F_G2!UP TCV(WRLW\Z0.N
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M]M79ZNQ[ 0*'7J34HT.TDJ]\.3G(<9S6XJF4J-<JHF*IK 'T(
M
M
M
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M $U
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M*)S1G0 &BFP6Z%$YHSH #138+="B<T9T !HIL%NA1.:,Z  T4V"W0HG-&=
M:*;!;H43FC.@ -%-@MT*)S1G0 &BFP6Z%$YHSH #138+="B<T9T !HIL%NA1
M.:,Z  T4V"W0HG-&=  :*;!;H43FC.@ -%-@MT*)S1G0 &BFP6Z%$YHSH #1
M38+="B<T9T !HIL%NA1.:,Z  T4V"W0HG-&=  :*;!;H43FC.@ -%-@MT*)S
M1G0 &BFP6Z%$YHSH #138+="B<T9T !HIL%NA1.:,Z  T4V"W0HG-&=  :*;
M!;H43FC.@ -%-@MT*)S1G0 &BFP6Z%$YHSH #138+="B<T9T !HIL%NA1.:,
MZ  T4V"W0HG-&=  :*;!;H43FC.@ -%-@MT*)S1G0 &BFP6Z%$YHSH #138+
M="B<T9T !HIL%NA1.:,Z  T4V"W0HG-&=  :*;!;H43FC.@ -%-@MT*)S1G0
M &BFP6Z%$YHSH #138+="B<T9T !HIL%NA1.:,Z  2ZFP:+BED:*BIL5)1G0
M &BFP6Z%$YHSH #138+="B<T9T !HIL%NA1.:,Z  T4V"W0HG-&=  :*;!;H
M43FC.@ -%-@MT*)S1G0 &BFP6Z%$YHSH #138+="B<T9T !HIL%NA1.:,Z
MT4V"W0HG-&=  :*;!;H43FC.@ -%-@MT*)S1G0 &BFP6Z%$YHSH #138+="B
M<T9T !HIL%NA1.:,Z  T4V"W0HG-&=  :*;!;H43FC.@ -%-@MT*)S1G0 &B
MFP6Z%$YHSH #138+="B<T9T !HIL%NA1.:,Z  T4V"W0HG-&=  :*;!;H43F
MC.@ -%-@MT*)S1G0 &BFP6Z%$YHSH #138+="B<T9T !HIL%NA1.:,Z  T4V
M"W0HG-&=  :*;!;H43FC.@ -%-@MT*)S1G0 &BFP6Z%$YHSH #138+="B<T9
MT !HIL%NA1.:,Z  T4V"W0HG-&=  :*;!;H43FC.@ -%-@MT*)S1G0 &BFP6
MZ%$YHSH #138+="B<T9T !HIL%NA1.:,Z  T4V"W0HG-&=  :*;!;H43FC.@
M -%-@MT*)S1G0 &BFP6Z%$YHSH #138+="B<T9T !HIL%NA1.:,Z  T4V"W0
MHG-&=  :*;!;H43FC.@ -%-@MT*)S1G0 &BFP6Z%$YHSH #138+="B<T9T !
MHIL%NA1.:,Z  T4V"W0HG-&=  :*;!KMLC15PV?]D9J^@ -%-@MT*)S1G0 &
MBFP6Z%$YHSH #138+="B<T9T !HIL%NA1.:,Z  T4V"W0HG-&=  :*;!;H43
MFC.@ -%-@MT*)S1G0 &BFP6Z%$YHSH #138+="B<T9T !HIL%NA1.:,Z  T4
MV"W0HG-&=  :*;!;H43FC.@ -%-@MT*)S1G0 &BFP6Z%$YHSH #138+="B<T
M9T !HIL%NA1.:,Z  T4V"W0HG-&=  :*;!;H43FC.@ -%-@MT*)S1G0 &BFP
M6Z%$YHSH #138+="B<T9T !HIL%NA1.:,Z  T4V"W0HG-&=  :*;!;H43FC.
M@ -%-@MT*)S1G0 &BFP6Z%$YHSH #138+="B<T9T !HIL%NA1.:,Z  T4V"W
M0HG-&=  :*;!;H43FC.@ -%-@MT*)S1G0 &BFP6Z%$YHSH #138+="B<T9T
M!HIL%NA1.:,Z  T4V"W0HG-&=  :*;!;H43FC.@ -%-@MT*)S1G0 &BFP6Z%
M$YHSH #138+="B<T9T !HIL%NA1.:,Z  T4V"W0HG-&=  :*;!;H43FC.@ -
M%-@MT*)S1G0 &BFP6Z%$YHSH #138+="B<T9T !HIL%NA1.:,Z  T4V"W0HG
M-&=  :*;!;H43FC.@ -%-@MT*)S1G0 &BFP6Z%$YHSH #138+="B<T9T "*K
M]K%V;LW,V!F*!0Z?3H\6T<K#?$EH+8;G-Q5<%5.#%$ 'T4
M
M
M
M              A^_5$6V5U6*)^<#/\ 0 3    B#L?/RK>A\+9W[P E\
M                                                     0K<K[LE
M\?[;)_9& $U
M            "(.R"_*MU_PMDOO* )?
M
M
M
M
M
M                   0KV3/]GGPFE?]0!-0
M
M
M
M   "(+]/SRNJ^$#/L0 2^   B#L?/RK>A\+9W[P E\
M                                      0K<K[LE\?[;)_9& $U
M                                                         "(.
MR"_*MU_PMDOO* )?
M
M
M
M
M
M    0KV3/]GGPFE?]0!-0
M
M
M                                                "(+]/SRNJ^$#
M/L0 2^   B#L?/RK>A\+9W[P E\
M                       0K<K[LE\?[;)_9& $U
M                                          "(.R"_*MU_PMDOO* )
M?
M
M
M
M
M                                                 0KV3/\ 9Y\)
MI7_4 34
M
M
M                                   B"_3\\KJOA S[$ $O@  (@['S
M\JWH?"V=^\ )?
M         $*W*^[)?'^VR?V1@!-0
M                             B#L@ORK=?\ "V2^\H E\
M
M
M
M
M
M                                    !"O9,_V>?":5_P!0!-0
M
M
M
M                      "(+]/SRNJ^$#/L0 2^   B#L?/RK>A\+9W[P E
M\                                                        0K<
MK[LE\?[;)_9& $U
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M.;IGYHKVS+-%NJN-=8B56Q7*Y$7#6I\[GKWGV<
M
M    0KV3/]GGPFE?]0!-0
M
M
M                                                "(+]/SRNJ^$#
M/L0 2^   B#L?/RK>A\+9W[P E\
M                       0K<K[LE\?[;)_9& $U
M                                         &^L#^?5G/WE+?S6E7._
M;7/^L^$I\7]:CYQXH>[(;\I78_"R3^U3[./S=[%*@
M
M
M
M                                                           :
M*WWYBVC_ ';,_P IQ:P?W-O_ +1XH,K]&OY3X+H?LV^=#XP/TAXYZP
M
M                   !"O9,_P!GGPFE?]0!-0
M
M
M
M     "(+]/SRNJ^$#/L0 2^   B#L?/RK>A\+9W[P E\
M                                        0K<K[LE\?[;)_9& $U
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M)TT5<7*C(UB8TF/8O>S(PUXHO"=<9ZVL
M
M                                   #16^_,6T?[MF?Y3BU@_N;?_:/
M%!E?HU_*?!=#]FWSH?&!^D/'/6
M                                                    (5[)G^SS
MX32O^H FH
M
M
M                                    !$%^GYY75?"!GV( )?   1!V
M/GY5O0^%L[]X 2^
M           (5N5]V2^/]MD_LC ":@
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M,?/G&?\ J4V(CTK97+ST3X?Q+/F>(SOA5^>,,B>%+^5"9SS;980
M
M                                                      T5OOS%
MM'^[9G^4XM8/[FW_ -H\4&5^C7\I\%T/V;?.A\8'Z0\<]8
M
M            A7LF?[//A-*_Z@":@
M
M
M                                                        $07Z
M?GE=5\(&?8@ E\  !$'8^?E6]#X6SOW@!+X
M                               A6Y7W9+X_VV3^R, )J
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MC7?64BT]9-:!3VPE;DY;(2-B)Y<Y[+'RXF+&T\N*^'QDZ_/D[.9I3A6)IX/
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M6TP@
M
M      !HK??F+:/]VS/\IQ:P?W-O_M'B@ROT:_E/@NA^S;YT/C _2'CGK
M
M                       $*]DS_9Y\)I7_ % $U
M
M
M
M         (@OT_/*ZKX0,^Q !+X  "(.Q\_*MZ'PMG?O "7P
M                                           !"MRONR7Q_MLG]D8
M34
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M+]M5]/%; ]L0VUUGN>4#]D85]I_N[GS2X7Z%'R6Q/;'><CZ>_P!YFG_X"_\
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M7_TL539V5/%8%Z[/Q\/Y9V=_ZF5;HC\Y?X9(6J$]2;#S+:80
M
M                                                   T5OOS%M'^
M[9G^4XM8/[FW_P!H\4&5^C7\I\%T/V;?.A\8'Z0\<]8
M
M         A7LF?[//A-*_P"H FH
M
M
M                                                      !$%^GY
MY75?"!GV( )?   1!V/GY5O0^%L[]X 2^
M                             (5N5]V2^/\ ;9/[(P FH
M                                                 WU@?SZLY^\I
M;^:TJYW[:Y_UGPE/B_K4?./%#W9#?E*['X62?VJ?9Q^;O8I4  TDU96C35HX
M%>F))'U6 B-AQ\X],E$Q1/!1<E=J[4+-&9>HLS8IJ_MGV<G^T-6/;JN1=F/[
MH51RHW)QU&[*R90 #36<LO1[..FW463266;<CXV$1[\M4QP]DJX;5V<99R,N
M]DZ<;5KIS<R&SCV[.O%QIJJYRNVKC@;2:EX4U*QI>89EP8S%AO;CAE-5,%3T
M%>BJ:*HJIYX2S$51,2HFH\%F[/TRS=/=)465[6EE>L169;GXN5$15Q<JKP(3
M9&3=R:^'=G6?SH1V;-%FG@VXTA5SE<N*KB8J;9>CTVN3M8D9-(51G$5(\;./
M7+Q5%74JX)K1-B(=7,N]=M4V:ZM::>:.1\HQ[=%<W*8Y955RJB(JZD/57:/(
MUZEQJ=5H';$G%5JOAY;FXX*BIK:J+M1.$CL7[F/7%RW.DPZN6J;M,T5QK"C5
M5JXIM,M+D):ET^7D9"%FI678D.&S%5R6IP8KK7XSFY<JNUS77.LRZHHIHIBF
MGFA155555/ ^R]'B6EAV@?)HM7AMR&S&<?J3)5OL<<G8JIL)HR[T69QXJ_LZ
M.3Y_-'Z/;FYQNG]RN4N3DXZCTURBTVNR2RE7DH,W QQ1L1N.2O&B[47RH1V,
MBYCU<.U5I+JY:HNQP:XU@:JM7%%P-+1+O;*T6968IU&@,C\#XCWQ5;Y6Y:K@
MOE0LWMIY5^.#77R?2/!#;PK%N=::>7\Z55B.5-:FULW9^F6;D'25%E>UI5T1
M8JLSCGXN5$15Q<JKL1"#(R;N37P[LZS^="6S9HLT\&W&D*.<KEQ768Z;9>CT
MVN3M8D9-(51G$5(\;./7+Q5%74JX)K1-B(=7,N]=M4V:ZM::>:.1\HQ[=%<W
M*8Y955RJB(JZD-R5DRTB[LAJK+REBFTZ)#;%F9^,UL)J[6HQ4<KT^A/\QN;
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MM6V,RN-)N=T1X0KT[/QZ9UBCQ79UZ_UCL8,*'+P6PH,-D*$Q,&L8B-:U/(G
M9TS-4ZSSK<1$1I"PAR[UG?;>W7K4>RD9'&7E7<#EPR$5/\J.7_.AZ+/GT3 M
MXO\ Y5<L^/CX,C%CTC*KO^R.2&9_@0FMX5VDS'G&PP@
M
M                                             !HK??F+:/\ =LS_
M "G%K!_<V_\ M'B@ROT:_E/@NA^S;YT/C _2'CGK
M
M      $*]DS_ &>?":5_U $U
M
M
M                                                    (@OT_/*Z
MKX0,^Q !+X  "(.Q\_*MZ'PMG?O "7P
M                          !"MRONR7Q_MLG]D8 34
M                                             ;ZP/Y]6<_>4M_-:
M5<[]M<_ZSX2GQ?UJ/G'BA[LAORE=C\+)/[5/LX_-WL4J
M           >*>I%-J$>!'GZ?)S4: N,*)&@M>Z&N./@JJ8IK1-A)1?N6XFF
MBJ8B>?27%5NBN8FJ(G15%5$U*J'M(W:@
M      !;%A,C0W0XS&Q(;DP5KDQ1?B/M,S3.L/DQ$\DAIVV2LZV,D5M I"14
M=E(])*'E(N....3M+'IN1,:<95I\Y1>C6==>!'9"N4[E+Z3<PV-APVLAM1K&
MHB-:U,$1$X$*TS,SK*:(TY(4*@                         "CFHYJM<B
M.:J8*B[%01R ::-9*SL:*Z)&H%(B1'+BYSY*&JJOE7)+,9N13&D7*NV4,XUF
M9UFB.R%<IW*7TFW@08<"$D*!#9#AMV-8U$1/B0KS5-4ZREB(B-(4+SX^@
M        'DJ%,D*DD)*C)2LVD)V7#S\)L3(=QIBFI22W=N6M>!5,:]$Z.*K=
M-?\ E&JJ*J;%5#UD;M0           "CFM>US7M1S53!45,45!$Z<L&@>:FT
MZ2IDNL"FR<M)P%=E9N7A-AMQ7:N"(B8ZCNY=KNSPKE4S/QY7-%%-$:41I"JJ
MJ[5Q/4<.E
M
M             T5OOS%M'^[9G^4XM8/[FW_VCQ097Z-?RGP70_9M\Z'Q@?I#
MQSU@
M                             "%>R9_L\^$TK_J )J
M
M
M
M              1!?I^>5U7P@9]B "7P  $0=CY^5;T/A;._> $O@
M                                                "%;E?=DOC_;9
M/[(P FH
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M-R,FW,TS_E'L^*')N439KB)CFGP5AHN6W4NU#X]/T-Y%ZP
M
M           !"O9,_P!GGPFE?]0!-0
M
M
M                                                         "(+
M]/SRNJ^$#/L0 2^   B#L?/RK>A\+9W[P E\
M                                0K<K[LE\?[;)_9& $U
M                                                   "(.R"_*MU
M_P +9+[R@"7P
M
M
M
M
M                                                           $
M*]DS_9Y\)I7_ % $U
M
M
M                                             (@OT_/*ZKX0,^Q
M!+X  "(.Q\_*MZ'PMG?O "7P
M                   !"MRONR7Q_MLG]D8 34
M                                       (@[(+\JW7_"V2^\H E\
M
M
M
M
M
M                                             !"O9,_V>?":5_U
M$U
M
M
M                              (@OT_/*ZKX0,^Q !+X  "(.Q\_*MZ'
MPMG?O "7P
M    !"MRONR7Q_MLG]D8 34
M                        (@[(+\JW7_"V2^\H E\
M
M
M
M
M
M                              !"O9,_V>?":5_U $U
M
M
M
M               (@OT_/*ZKX0,^Q !+X  "(.Q\_*MZ'PMG?O "7P
M                                                 !"MRONR7Q_M
MLG]D8 34
M         (@[(+\JW7_"V2^\H E\
M
M
M
M
M
M               !"O9,_P!GGPFE?]0!-0
M
M
M
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M)U0 [CWV;S61YI$ZH =Q[[-YK(\TB=4 .X]]F\UD>:1.J '<>^S>:R/-(G5
M#N/?9O-9'FD3J@!W'OLWFLCS2)U0 [CWV;S61YI$ZH =Q[[-YK(\TB=4 .X]
M]F\UD>:1.J '<>^S>:R/-(G5 #N/?9O-9'FD3J@!W'OLWFLCS2)U0 [CWV;S
M61YI$ZH =Q[[-YK(\TB=4 .X]]F\UD>:1.J '<>^S>:R/-(G5 #N/?9O-9'F
MD3J@!W'OLWFLCS2)U0 [CWV;S61YI$ZH =Q[[-YK(\TB=4 .X]]F\UD>:1.J
M *)1[[<-=IK)<TB=4 5[CWV;S61YI$ZH =Q[[-YK(\TB=4 .X]]F\UD>:1.J
M '<>^S>:R/-(G5 #N/?9O-9'FD3J@!W'OLWFLCS2)U0 [CWV;S61YI$ZH =Q
M[[-YK(\TB=4 .X]]F\UD>:1.J '<>^S>:R/-(G5 #N/?9O-9'FD3J@!W'OLW
MFLCS2)U0 [CWV;S61YI$ZH =Q[[-YK(\TB=4 .X]]F\UD>:1.J '<>^S>:R/
M-(G5 #N/?9O-9'FD3J@!W'OLWFLCS2)U0 [CWV;S61YI$ZH =Q[[-YK(\TB=
M4 .X]]F\UD>:1.J '<>^S>:R/-(G5 #N/?9O-9'FD3J@!W'OLWFLCS2)U0 [
MCWV;S61YI$ZH =Q[[-YK(\TB=4 .X]]F\UD>:1.J '<>^S>:R/-(G5 #N/?9
MO-9'FD3J@!W'OLWFLCS2)U0 [CWV;S61YI$ZH =Q[[-YK(\TB=4 .X]]F\UD
M>:1.J '<>^S>:R/-(G5 #N/?9O-9'FD3J@!W'OLWFLCS2)U0 [CWV;S61YI$
MZH =Q[[-YK(\TB=4 .X]]F\UD>:1.J '<>^S>:R/-(G5 #N/?9O-9'FD3J@!
MW'OLWFLCS2)U0 [CWV;S61YI$ZH =Q[[-YK(\TB=4 .X]]F\UD>:1.J '<>^
MS>:R/-(G5 #N/?9O-9'FD3J@!W'OLWFLCS2)U0 [CWV;S61YI$ZH =Q[[-YK
M(\TB=4 .X]]F\UD>:1.J "4>^O%,JTUDL.'"4B=4 .X]]F\UD>:1.J '<>^S
M>:R/-(G5 #N/?9O-9'FD3J@!W'OLWFLCS2)U0 [CWV;S61YI$ZH =Q[[-YK(
M\TB=4 .X]]F\UD>:1.J '<>^S>:R/-(G5 #N/?9O-9'FD3J@!W'OLWFLCS2)
MU0 [CWV;S61YI$ZH =Q[[-YK(\TB=4 .X]]F\UD>:1.J '<>^S>:R/-(G5 #
MN/?9O-9'FD3J@!W'OLWFLCS2)U0 [CWV;S61YI$ZH =Q[[-YK(\TB=4 .X]]
MF\UD>:1.J '<>^S>:R/-(G5 #N/?9O-9'FD3J@!W'OLWFLCS2)U0 [CWV;S6
M1YI$ZH =Q[[-YK(\TB=4 .X]]F\UD>:1.J '<>^S>:R/-(G5 #N/?9O-9'FD
M3J@!W'OLWFLCS2)U0 [CWV;S61YI$ZH =Q[[-YK(\TB=4 .X]]F\UD>:1.J
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M3J@!W'OLWFLCS2)U0 [CWV;S61YI$ZH =Q[[-YK(\TB=4 .X]]F\UD>:1.J
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M3J@!W'OLWFLCS2)U0 [CWV;S61YI$ZH =Q[[-YK(\TB=4 .X]]F\UD>:1.J
M'<>^S>:R/-(G5 #N/?9O-9'FD3J@!W'OLWFLCS2)U0 [CWV;S61YI$ZH =Q[
M[-YK(\TB=4 .X]]F\UD>:1.J '<>^S>:R/-(G5 '%VSDK=REN[MUMW5:+/R[
MJY#27;(0',<U^*8JY51-6'G 'TF   B#L?/RK>A\+9W[P E\
M                                            0K<K[LE\?[;)_9&
M$U
M   "(.R"_*MU_P +9+[R@"7P
M
M
M
M
M
M           $*]DS_9Y\)I7_ % $U
M
M
M                                                         (@O
MT_/*ZKX0,^Q !+X  "(.Q\_*MZ'PMG?O "7P
M                               !"MRONR7Q_MLG]D8 34
M                                                   (@[(+\JW7
M_"V2^\H E\
M
M
M
M
M                                                         !"O
M9,_V>?":5_U $U
M
M
M                                          (@OT_/*ZKX0,^Q !+X
M  "(.Q\_*MZ'PMG?O "7P
M                !"MRONR7Q_MLG]D8 34
M                                    (@[(+\JW7_"V2^\H E\
M
M
M
M
M
M                                          !"O9,_V>?":5_U $U
M
M
M
M                           (@OT_/*ZKX0,^Q !+X  "(.Q\_*MZ'PMG
M?O "7P
M !"MRONR7Q_MLG]D8 34
M                     (@[(+\JW7_"V2^\H E\
M
M
M
M
M
M                           !"O9,_P!GGPFE?]0!-0
M
M
M
M             "(+]/SRNJ^$#/L0 2^   B#L?/RK>A\+9W[P E\
M                                                0K<K[LE\?[;)
M_9& $U
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M.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/
MSK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U
M/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^
M1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C
M=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ
M\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[
MSQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^
M'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#
M>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/
MK#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;U
ML/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4
M;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO
M$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%U
MLO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-
M%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.
M4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ S
MK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/
M SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1
MU/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=
M^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\
MC=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[S
MQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'
M[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>
M^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K
M#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL
M/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;
MUL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$
M4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%UL
MO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%
MULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4
M-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK
M.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/
MSK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U
M/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^
M1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C=^1U/ SK.4-%ULO$4;UL/K#>^'[SQ\C
M=^1U/ SK.4:NT-CZ]9V6AS%:IT25@Q'YMCG/:N+L%7#4J\"*3X^=8R:IIM5:
MS"*[C7;,:W(T5:]KEP:N)SY;0+@
M
M
M                   $*]DS_9Y\)I7_ % $U
M
M
M
M     (@OT_/*ZKX0,^Q !+X  "(.Q\_*MZ'PMG?O "7P
M                                       !"MRONR7Q_MLG]D8 34
M                                                          ;Z
MP/Y]6<_>4M_-:5<[]M<_ZSX2GQ?UJ/G'BA[LAORE=C\+)/[5/LX_-WL4J
M
M
M                                                 0_V3'YJ4O\
M;?\ H>>A_IS]>OY?>&1MC]*GYLLM[)?,?.9[%YYZ
M
M
M                                 $*]DS_9Y\)I7_4 34
M
M
M
M                  B"_3\\KJOA S[$ $O@  (@['S\JWH?"V=^\ )?
M                                                    $*W*^[)?
M'^VR?V1@!-0
M          !OK _GU9S]Y2W\UI5SOVUS_K/A*?%_6H^<>*'NR&_*5V/PLD_M
M4^SC\W>Q2H
M
M
M !#_ &3'YJ4O]M_Z'GH?Z<_7K^7WAD;8_2I^;++>R7S'SF>Q>>>@
M
M
M                                            !"O9,_V>?":5_P!0
M!-0                          Q3,>%*RT:8F'MAP(3%B/>[8UJ)BJK\2
M #FKMK<4Z\"SSJS1I>=@2:1WR[>VV-8YZMPQ<B-<[P=>&W'4NH =4
M                                     #',QX,K+Q9B9BPX,"$Q7Q(D
M1R-:QJ)BKE5=2(B<( PTNHR55D84[2YR7G9.+BL./+16Q(;\%5%P<U51=:*G
MQ #U                                           /!4*Q3*;-2<K4
M:C)RDS.OS<K"CQVPWQW)AX+&JN+EUIJ3':@ ]X
M                             \-8K%,HLLR8K-1DZ? ?$2$R)-QVPFN>
MJ*J-17*B*JHBZO(H ]P                               B"_3\\KJOA
M S[$ $O@  (@['S\JWH?"V=^\ )?
M                        $*W*^[)?'^VR?V1@!-0
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M,G'P-AU906EH
M
M                               !#_9,?FI2_P!M_P"AYZ'^G/UZ_E]X
M9&V/TJ?FRRWLE\Q\YGL7GGH
M
M
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M;BG"B>3A &VL93ZC2K*4F1KD]W0JDO+,AS,UBKL[$1-:XKK7SKK7:H W(
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MB;0!TX       "!NS+]S>B?OV!_)C@">0
M   !$%^GYY75?"!GV( )?   1!V/GY5O0^%L[]X 2^
M                                      (5N5]V2^/]MD_LC ":@
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M^D]$Q^?98_(P\#%/(IV)G+BP
M
M                                        "'^R8_-2E_MO_0\]#_3G
MZ]?R^\,C;'Z5/S99;V2^8^<SV+SST
M
M
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MR5E8<]5[7=U*-'K*=K4ON9"@=K8PXRM7.M7*?DM16Z]N..U !*O>1>=[[O\
M_+4KU@!QUKZI>)8*W-@9&HV]2N25=JC)6/"6C2\MA#2)":Y,6XKK2(NQ4PP
M'T''<YD&(Z'#6(]K55K$5$5R\"8KJ3$ 1:VFWLVC;VQ,U^CV,A.UPY24DFU&
M,U.3$?$5&*NO:S5J3C4 <_$MG;6[>W-"HUOZA)5^@UN-VO+U2%+)+1843*P3
M+8WP?ZS<4UZM:+J5% 2C>;[F]K/W3-_R7@#CNQ:]PJS/_FO^:B@"50!$W9*6
MRK%B+&4FI4&>22C1:M!EXT18+(F,%8<5SDP<B\A-::]0 \M,J]X5Y3%J5FIV
M7L99AZXR4Q,239N<G&<$18;ER&L75AP\.*I@H \DO;>UMWMMZ59^\B:E*Q1J
MO$S,C7($!)=S8F."-BL3P4VMV;$7'%<%P 25>-:N7L38NJ6AFX3HT.3AHK83
M5P6(]SD:QN/!BYR:^!,5 $<V:DKV+6T.4M#$MI3K/I.PFS,O2X%)AS#$8[PF
M(^(]<I%5%3'#'!/* )'L'%M-$HT2';66D854@1W0DC23\J%-0T1%;%1%UMQQ
M5%:O"W'4BH .)MO>+6IFW/>+=S)2DU7F0DBST].*JR\BQ<-J)K<[!S?C5$P7
M7@ QS5EKW)26[;DKQJ?4)MJ*[M"9HL*# <N"^#G&XNU+A@N">7B &TN<O)B6
MV94Z96Z?W*M12(F:GY+'P=JIELQ55PQ39KPU:U144 :WLF;95JQ%AZ;4K.SJ
M2<S%JL*7B1%@LB8PEAQ7*F#D5-K&Z\,0!XZ7/7B7DP(M<LW78%C[.ORDIL.)
M3V34><8BX)%B9>IC7<&'!P+J50&^O7K5H;(W)U*J0ZC"[XY.7@(Z<A0&Y"Q%
MBL:YR,<BI@J*NI4X0!U5WM1FJO8*S52J$3.SDY3):8CQ,E&Y41\)KG+@F")B
MJKJ34 .0GI:]*T4]-)+5"D6-I;(KF0'-@)4)N(U%U/<BKFT1R(F";4REQUH@
M Y"UUI[PKHYBGU.U-9D[6V7F)ELO,14D6RDQ+Y28XHUFK^J[#'''8N&*8 )K
MJ]9DZ59V=K<P]72$K*OFWN9K58;6JY</B34 (=L7/7F7GTAMI)&T\C9"CS#W
MI)2L&FPYV(]C79.4]T14PUM79MXDU "1KOEME"2H25N6TZ8=+N8LI49%<E)I
MKLK*1T-=;'-P3R+E:MBJH#D[Z;85RS=MKM*?19U)>4K%626GF9IC\[#SD%N3
MBY%5NI[M;<%U@#MKQK5R]B;%U2T,W"=&AR<-%;":N"Q'N<C6-QX,7.37P)BH
M CFS4E>Q:VAREH8EM*=9])V$V9EZ7 I,.88C'>$Q'Q'KE(JHJ8X8X)Y0!(]@
MXMIHE&B0[:RTC"JD".Z$D:2?E0IJ&B(K8J(NMN.*HK5X6XZD5 !T8 XR]JWL
MI=Y9*)5IF"Z:FHD1)>4E&K@L>,['!,>!$1%55\G&J #D:?0[X*O3X=4G+9TR
MASD1$B-H\*DPXT)B*N*,?%<N6BX+@N&.&&I>$ 15;6U5=K-[UU]%MC2&TZOT
M>KIGHD!<9>:9$BP<B+"QUX+FW8IP>?%$ ?5%<F9V4H\Y,4J1[H3\.$YT"5SK
M86>?P-RW:FXKPJ (X2@7L5E.V9VVM(LT]=:2=-I39QK47@<^,J*JI@FS5BJ\
M&  U-DK=6KLY>?*V#O%B24^^H0,]3ZM*PLUG51%\%[4P1,<AVQ$P7#:BI@ V
M]_-$M-.V4M!/4BUW<NC0*-,=M4SN;"C]M9+(CG_TKERF93<&ZMF&.T <'<79
M6WE0NJH,U0[Q^X]-B,BYJ1[AP)C-81GHO](Y<78JBKKX\.  3C:&8K],LNU:
M')0JY7&MAPD2-$;+0WNU(Z*[B1-;LE-? @ X>+9>]B?A.F(]XE+I4RK5PDY"
MB0XT!%VX)$BKEX8KACAL1%VX@#!=9>!7X]NZQ8.WL&3[O2$/MB!.2B*V'-0M
M2XX+L7!S53##5BBHBIK 2\   ABJ6_M/;.VU3LM=@V2EI>E+FZC7)QF<9#B:
MTR(;-BKBBIKQ15:NQ$Q4!9:.!>S8BFQJY!M/(6QDY1N=FI"8I;).)FFHJN6&
ML)=:X:]?%L78H#O+/6C;>!=VVKV5G74^8GI=Z08SF-B.E8R8I@YJHJ+DN3BU
MIKX4 ''W$7A56NQZQ92W#F,MC1HKDC>"UG;,+'V:(U$34JHFI$145J\*@#%>
MA;FNSEO*38"[J;9 K<54F*E/+";%;)0$UZT<BMQ5%QUIPM1-;M0#H;]:_5;)
M71UJKT2<6#5)1LND.8=#8]<71X;'*K516ZT<O!P@#C[*6NM[>;2Y1UD8TM0:
M1!@PX<S7IV52-%FIA&HD3,05P;DH[*UKMX,,%0 8Z_:RW5TM1D)JVU3EK562
MFXR0(M0A23968E'JFI58SP5;J5>''#:BX(H"<F1X3Y=LPR*Q8#F9:1$7P5;A
MCCCQ8 "$Z9;6V=Z=7J,.[J8DZ#9:1C=KK6YF728BS#TP5<U#=X.&"XX+P*FM
M%7! %+45:\NZ^5;7*Q5Y.VEG(3T2>1)%DG,P&*J)E,1G@JB+QX[=>K6@"8Z%
M592N4:2JE-BI&DIR"V/!>G"UR8ICQ+QIP* (FF+<6JM[;&J4"[:))TVDTE^9
MGJ]-0<^N=UIDP8?L7*BHNW4N&.I,,H!EJ4&]JQD/NE#J\E;R0AX.F9%:>V2F
MLG'7F<WBCEPX\5XFJ /5?A2;3U2QE;J=)M4^CT>'0X[YND/ID*,Z8PAQ'/18
MKERF*YJHS5LPQ36 .'N+LK;RH754&:H=X_<>FQ&1<U(]PX$QFL(ST7^D<N+L
M515U\>'  )NM3:.5L18N8K%H9IT:'(P&YV(UB-='B:FHC6[$5SN#8F/$@ C:
MS;[U;P:=!KC*](6*I<TW.R<K"I[)V.^&N&2Z(L141,4UIAAYD %9*W%K;!VT
MI5G;RXLE4J75WYF0KDK"S"YW4F3&9[%,55-FS''%4QR0$F6ZM1(6,LI4:]55
M=VM*0\K(;[*(Y5P:QOE551/C $96<AWL6ZI$.O=\TA8^5FVYV3I\&F,FWK"5
M/!6(Z)L54P75Q[$V( BGLBK3VJ2@T^R5NZ= 2HPJI"G96J22*DO.06LB,74N
MMKT6(W%/H34J@/L$                               1!?I^>5U7P@9]
MB "7P  $0=CY^5;T/A;._> $O@
M                     "%;E?=DOC_;9/[(P FH
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MYM78TJA2)#1$RFKBU20S':#&
M
M                                        !#_9,?FI2_VW_H>>A_IS
M]>OY?>&1MC]*GYLLM[)?,?.9[%YYZ
M
M
M                      $*]DS_ &>?":5_U $U   !]?W2^YS0?V?_ %4_
M/-J?N[GS>MP?V]'R>6+[8[SG6E!;6'RM?W[I=0_PH/\ +0]WL+]G3]?%Y?:?
M[B?IX/5 ]K0CPUV>O   ?._8T)W-O.O8I$5$2*VHI$8G&UL6.F/H<WT@#Z(
M!5P1578 /GGL3_\ M];O+KL/7+5"JMS;DV+@Z,_[(K0!Y%M79ZWM^#Y^T%?I
M,A9BR3LB0@3LW#@]MS>.N*C7JBJC5;J7_A9QJ .XO?MY9&?NOM5*2-JJ!,S4
M:GQF0H,&HP7O>Y6K@C6H[%5\B #R]CA:JSS;K;*T=U>I*5?-O9VBLY#S^5G'
MJB9O*RL<->&  E.T-6EZ#0:C5IYR-EI&7?,1%QPU-:JX)Y5PP $0=BK29B+9
MFM6RJK/_ 'G::?B3*N5/^Z:YR)AQ)EK$^+  3> .?MW:ZE6)LU-5JN1LW+04
MP:Q,,N,]?8L8G"Y?HUJNI%4 1C<=9:K5FT,_>=;6"D*KU1F33I1<?^R2RIJU
M+L56X(G#ABJZW+@ Z#LF9=TS<?:B&Q%54AP8FKB;'AN7Z$4 ;ZYN89,W3V/B
M0_8I29:'\;8;6K]** .O54:BJY41$UJJ@"!.P[8L>Q]I:EDX,G*S$5BX*F*(
MQB_]0 G>:F(,I+19B:BPX,O!8KXD2(Y&M8U$Q555=2(B #Y[I\./?M>3+U>)
M">R[RSL9>U4B-5.Z$PF&+L%_JXX;?ZN";7+@ ^B0  $"7PV@GKQ+1)=?8B*B
MHYR.KM0;KARL)%3&'BFU>-./!O*P 319FB25FZ!(4>E0LU)24)L&$WAP3A7C
M55Q55X550!LP    0-V1OND7-_OU/YTN )/O9]RRV7[EG/Y#P!R?8LM1+B[-
M*B(BN695<$V_]IBH '92M1;B[2JJ(JM665,4V?\ :82 #K;J7.?=?8]SU57.
MHTFJJO"N88 (O['GW5[Z/WM#_FS0 P]FO[EE*_?4+^1' $_@"!NR-]TBYO\
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MI%Q\F&I=N"@"+^R+M-;:J793<M:.[WN'3UF(+G3O=J!-9+D=J3(8F*X[,>
M3U2:9 KMV<E2Y_*=+3](AR\;!?"5KX*-7!>/!0!#=GG7C7)R#Z5&H7??8^7>
MYT"8D7*DS 8YRJN+-:X:U54P5$U^%@ )=NXO$L_>%3HLU9Z9B+$@*C9B5CLR
M(T!5QP1S<537@NM%5-2Z]2@"-.R-]TBYO]^I_.EP!*UXME):VUC*I9Z<BN@P
MYR&B-BM3%8;VN1S'8<.#FIJU8IB@ ARBVMO NDI,O2[<69BUZSLBU(,*KTIV
M6^'!;J3+:O B(B8NR.#6J@"9[#VOHMMJ&RK6<G&S4HKE8],%:^$],%5CVKK1
M=:>E%3%%Q &_ $!7]_\ ;KY;IJ9,XK)=NNCJQ?8O<CX>&/'['Z5XP!/H @3L
MA6-2]NYEZ-;EK57M5V&M42++8)]*^D 3A5:C)TBFS-0J<Q#EI*68L2+&B+@U
MC4VJH B^3O:K-HX3IBP%W]6KE/1RHV<FYJ%3X45$U*K%B8Y28X<7#Q* (UMA
M6;25:_J[.):BRW>W&AQU;"8E1AS>>:KDQ7%B)DX;,%VX@">[V?<LME^Y9S^0
M\ <UV,GN'67_ +D?_F(@ [BU=HZ792A3-7KTVR5D9=,7/=K5578UJ)K55X$0
M 1Y*WGVLKDNR<LC=A59^FQ$RF3%0J$&06(U=CFM?BJHNO7Q8<8 CZR]2K53[
M*^4F+1T'N!/NI+FNDTG&37@HQV#LMB(FOBX, !]-@#Q5J9B2=&GYF#AG8,O$
MB,Q3'6C55/L 'R]V-->MA2;"S;K-V![X(,U/Q(L:?6LP)9SGY+4R58]%75AC
MC_Q* )7B6TO,B0W,?= CF.3!46TLK@J?) &/L9;(V@L98.=IMJ)-LE,/J,2/
M!@9YD56PU9#3V3%5-K7<.( X_LHX$.R=9LW;Z@3D.3M5"F$E6P,G'MV'@N**
MU-:X(N2O&CT3'') '0=BO2)%UBIBU3I]*G7ZY'?$J$R[6Z&]'+_1>3#'*7CR
MN+  ;;LI/<*M/_Y7_FH0 ZFZ-C675V-1C6M3N/)K@B8:U@L55^-<0!SW9*RD
M&;N4M,V/A_1PH<5BKP.;%8J8?9\8 T\S5)N%V**3K7N[:6S;&9?#@L)&8^?!
M<<0!R=QEH;<4:ZZB2MGKLVU2GY,2(R>2O2\#/JZ(Y5<K')BFO5@O$ .GM;7;
MR[167J]&BW3)"94)2+*K$6T4J[(RVJW*PP3'#''#%-FT ;ZZ>DUNQUQ\I(5R
M&V7J\A*S+U8CVQ,WX<1[$56JJ+@BIL4 <]V'\O#A70MCM1,[,S\>+%=M5SD5
M&XK\34 $V@#E;V?<LME^Y9S^0\ <UV,GN'67_N1_^8B #B^S,F(W>A9R0AM6
M)!FJHU8D-'9&6K6.P;E<&.4OV\  ZR#;*\N#"9#A70-9#8B-:UMI)5$1$V(G
M@@#A;XI"\V\JS\C2TNW2D1I6=9-LFUKLM&R<&N;ADIDK_61<=>S8 -IV7T2)
M%L?9BG155L"<K$)L?(54141CM7F\+'XO( )[A,9"AMAPVHUC$1K6HF"(B<
M@;LS&-6[JA/5K<MM<@HCL-:(L&-BGT)Z !/8
M       B"_3\\KJOA S[$ $O@  (@['S\JWH?"V=^\ )?
M                                         $*W*^[)?'^VR?V1@!-0
M                                                           !
MOK _GU9S]Y2W\UI5SOVUS_K/A*?%_6H^<>*'NR&_*5V/PLD_M4^SC\W>Q2H
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MC6[$)+,5I,8
M
M                           $/]DQ^:E+_;?^AYZ'^G/UZ_E]X9&V/TJ?
MFRRWLE\Q\YGL7GGH
M
M
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MO0^%L[]X 2^
M       (5N5]V2^/]MD_LC ":@
M                         #?6!_/JSG[REOYK2KG?MKG_ %GPE/B_K4?.
M/%#W9#?E*['X62?VJ?9Q^;O8I4
M
M
M                  A_LF/S4I?[;_T//0_TY^O7\OO#(VQ^E3\V66]DOF/G
M,]B\\]
M
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MDJ5(PI*ER<O)2<+%(<"6A-APV8JJK@UJ(B:U5?C 'J $ =FO[EE*_?4+^1'
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M##'*R<=@ V;Z53GU:'5'R$HZIPX699.+!:L9L/%5R$?AE(W%57#'#6 /:
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M]<H=+J3V>Q=.2D.,K?,KD4 >FCT:ET676!1J;)4^!^CE(#83=JKL:B)PKZ5
M'O &CJED+-5>=[<JMG://3:8)GYF2A17ZMGA.:J@#V5*B4JIR,*2J5,D9R2A
M.:Z' F)=D2&Q6ZFJC5141439Q #8                               "
M(+]/SRNJ^$#/L0 2^   B#L?/RK>A\+9W[P E\
M                                  0K<K[LE\?[;)_9& $U
M                                                    &^L#^?5G
M/WE+?S6E7._;7/\ K/A*?%_6H^<>*'NR&_*5V/PLD_M4^SC\W>Q2H
M
M
M                                            !#_9,?FI2_VW_H>>
MA_IS]>OY?>&1MC]*GYLLM[)?,?.9[%YYZ
M
M
M                          $*]DS_ &>?":5_U $U
M
M    \%9HU,KDJV5K5-DJC+->D1L*;@-C,1R8HCD:Y%3'6NORJ />
M                                                          /+
M4Z=)561BR54DY>=DXN"1($S";$AOP7%,6N1476B+\0 RRDO!E)6#+2D&' EH
M+$APH4)J-9#:B8(UJ)J1$1$1$0 90
M                        !$%^GYY75?"!GV( )?   1!V/GY5O0^%L[]X
M 2^                                                        (
M5N5]V2^/]MD_LC ":@
M                 #V4B?BTNK250EVL=&E(S([&O15:KF.1R(N"IJQ0CNVX
MNVZK=7-,3':[MUS;JBN/9RH?[(-,:G=@G':R2^\I)NG>TWZC1O4Q?Q#$]7<;
MK5=L>32WO>Z([_-+>8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U
M=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]
MIOU&C>IB_B#U=QNM5VQY&][W1'?YF8;QJ-.]IOU&C>IB_B#U=QNM5VQY&][W
M1'?YF8;QJ<W;F\>KVRI\O)U27D(4*#%SK5EV/:JK@J:\IRZM9=PME6<*N:[<
MS,S&G+IY0K9.=<R:8IKB.3H_VN9#1BXHJG%&DIKP
M
M
M                                $*]DS_9Y\)I7_4 34
M
M
M
M                 B"_3\\KJOA S[$ $O@  (@['S\JWH?"V=^\ )?
M                                                   $*W*^[)?'
M^VR?V1@!-0
M           B#L@ORK=?\+9+[R@"7P
M
M
M
M
M
M                 $*]DS_9Y\)I7_4 34
M
M
M
M  B"_3\\KJOA S[$ $O@  (@['S\JWH?"V=^\ )?
M                                    $*W*^[)?'^VR?V1@!-0
M                                                        B#L@
MORK=?\+9+[R@"7P
M
M
M
M
M
M  $*]DS_ &>?":5_U $U
M
M
M                                                (@OT_/*ZKX0,
M^Q !+X  "(.Q\_*MZ'PMG?O "7S>V(L^ZU%IY&CMF$EEF5?_ $JLR\E&L<Y=
M6*8^QXRKFY/HMFJ]IKI[/KHGQK/'W(MZZ:K7NR6JN&.!NKSK!NL--2$):BD\
MV:8YR.S.:5JM5,4PREXT*VS=H^GTU3P>#I\=?M";,P_19B-==5(3\M%U88'7
M6;N/B5B@4^I1:^V7=.0&1TA-E,XC4<F*)E9:8K@J<!GY']019NU6XMZ\&=.?
M3F^BW9V3-RB*YKTUC7F_E:Z-@Y4R=GE.!O LA-6,KG<^:BMCL>Q(L&.UN2CV
MJJILX%Q1=6*FM@9U&;:XRF-/9,*&5C58U? F=5\-^6W%#G(,-\:*R%":KXCW
M(UK4VJJZD0N3,4Q,RKQ&LZ0N)LDK@8\25A/G+0,@S#FHKX;)3+:U>)'9:8^A
M#S-?]24Q5,4V]8^>GV;5.QIF/[J^7Y?RPK'U^Q^DB*T=)B4.O3],C1&Q7RL9
MT)7M3!'8+M/0X]Z+]JF[')K&K(NVYM5S1/L96KE-1>,D"WMT;[)V9BU=:RV;
M6$]C70>ULW[)<-3LI>%>(R,';49=Z+/ TUUY==?LT,G9OH]OC.%K]/Y60XN6
M[###XR+#=9;(2G&NC?"L EI5K+5<LBV=[6[6U8*U'9.7E;<%XC#IVU$Y7HW
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M56JN#DQ3%-NM ![0          !$'9!?E6Z_X6R7WE $O@
M
M
M
M
M
M                                 (5[)G^SSX32O^H FH
M
M
M
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MHC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U
MTZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO
M3+>HC=0 42_6[;>F6]1&Z@ KIUNVWIEO41NH &G6[;>F6]1&Z@ :=;MMZ9;U
M$;J !IUNVWIEO41NH &G6[;>F6]1&Z@ :=;MMZ9;U$;J !IUNVWIEO41NH &
MG6[;>F6]1&Z@ :=;MMZ9;U$;J !IUNVWIEO41NH &G6[;>F6]1&Z@ :=;MMZ
M9;U$;J !IUNVWIEO41NH &G6[;>F6]1&Z@ :=;MMZ9;U$;J !IUNVWIEO41N
MH &G6[;>F6]1&Z@ :=;MMZ9;U$;J !IUNVWIEO41NH &G6[;>F6]1&Z@ :=;
MMMZ9;U$;J !IUNVWIEO41NH &G6[;>F6]1&Z@ :=;MMZ9;U$;J !IUNVWIEO
M41NH &G6[;>F6]1&Z@ :=;MMZ9;U$;J !IUNVWIEO41NH &G6[;>F6]1&Z@
M:=;MMZ9;U$;J !IUNVWIEO41NH &G6[;>F6]1&Z@ :=;MMZ9;U$;J !IUNVW
MIEO41NH &G6[;>F6]1&Z@ :=;MMZ9;U$;J !IUNVWIEO41NH &G6[;>F6]1&
MZ@ :=;MMZ9;U$;J !IUNVWIEO41NH &G6[;>F6]1&Z@ :=;MMZ9;U$;J !IU
MNVWIEO41NH &G6[;>F6]1&Z@ :=;MMZ9;U$;J !IUNVWIEO41NH &G6[;>F6
M]1&Z@ :=;MMZ9;U$;J !IUNVWIEO41NH &G6[;>F6]1&Z@ :=;MMZ9;U$;J
M V_.[=RHC;4RRJJX(F8C=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>H
MC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  T
MZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3
M+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U
M  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=
MMO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZ
MB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #
M3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV]
M,MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W
M4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.M
MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRW
MJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0
M-.MVV],MZB-U  6_.[=$15M3+:TQ3^@C=0 -.MVV],MZB-U  TZW;;TRWJ(W
M4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.M
MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRW
MJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0
M-.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;
MTRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC
M=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZ
MW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+
M>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U
M TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=M
MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB
M-U  TZW;;TRWJ(W4 #3K=MO3+>HC=0 -.MVV],MZB-U  TZW;;TRWJ(W4 #3
MK=MO3+>HC=0 1I?/>'96V<[824LS68,_,R]H9:-$8UCV*C,53'PD3'6J:DU@
M#Z5
M
M
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MU-YJSH #O;H?B:F\U9T !WMT/Q-3>:LZ  [VZ'XFIO-6=  =[=#\34WFK.@
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M)J;S5G0 '>W0_$U-YJSH #O;H?B:F\U9T !WMT/Q-3>:LZ  [VZ'XFIO-6=
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M34WFK.@ .]NA^)J;S5G0 '>W0_$U-YJSH #O;H?B:F\U9T !WMT/Q-3>:LZ
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MFIO-6=  =[=#\34WFK.@ .]NA^)J;S5G0 '>W0_$U-YJSH #O;H?B:F\U9T
M!WMT/Q-3>:LZ  [VZ'XFIO-6=  =[=#\34WFK.@ .]NA^)J;S5G0 '>W0_$U
M-YJSH $/]D33)"G/L ^GR,K*O?:258]T"$UBN;KU+@FM !.H
M
M
M
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M>DWXTC77E]LI,S+MVK7$VIUG33Y00F.<_*<GE/G0]@\\S@
M      "%;E?=DOC_ &V3^R, )J '*WL)C=;;)$V]QIS^0\ :;L>45+F+*8_J
MJ_?< (Q[]:!83LF;?3EJYYU/EIN3E&0'K B1,M4@P<<,AJKP+KV:@!WK>R"N
MR<J(EIM:ZO\ 8)K\, 2H   X.UM[UA[(UN+2+0USM2HPFM<^%VI'B8(Y,4UL
M8J;%XP!!]R]Z]C+.6MO(G:U6>UI:KUA\U)/[5C/SL)8D54=@UBJW4YNIV"ZP
M!]-V>K4A:&BRE6HTQVS3YIF7!BY#F93<<,<'(BIL7:@ B"^#*MU>A96[R"BO
MITNY*S6.)83%5&,75PZT_P [>( 3@B8)@FP  !H;>6B@V3L;6*[,9*MD99T5
MK5_KOPP8WXW*U/C '&=CA9V-1+M96=J&+JK6XCJI-O<GA.6+K;C_ )<E<.-5
M $H@  (,L0U4[+"\151<%IDK@N'_ ,.7 $IW@V;@VNL76*%,9.$[+NAL<[8R
M)M8[XG(U?B '$=C1:.8K5V\*G5-',JU!C.I<RQZ^$F;]CC_EP;YVJ .5DI>L
MW(6PJ[Y>D3M7N_K,QVTBR$-8D6G1G+@N+$_J[$QX41NO%,% =2WL@KOXT%.Y
M]0GY^=<W*;(RU.CNC.7#%6HBM1N*?WL/* /%8:SU=ME>*V\&V=.B4F6DH*R]
M$I,?VV$UV.5%BI_5>N*ZEUZ_^%%4!X>R]:KK!6>R45<+02VQ/_A1@!.8 @BF
M(Z[_ +):<DLE8=%MI+]L0M?@MFV8J[XU7*]:T =[?I14KUTEJ9)6Y3VR3YB&
MG#EPOZ1N'QLP^, 1!<Y+U6]F>LM5Z_ ?#LQ9.5A09=D37V]/-8B+%5.%&X(O
MG1.-R( ^F0!\V76VUI%T4S:ZS%NNW*=,/K$:>DHJRL2(V;AO1K4R%8U>0BZ\
M$\+#:B@#Z*I<[#J5,E)Z V*R%-061F-BL5CT:YJ*B.:NM%UZTX !Z0
M   1!V07Y5NO^%LE]Y0!+X
M
M
M
M
M
M         "%>R9_L\^$TK_J )J
M
M
M                                                      1!?I^>
M5U7P@9]B "7P  $0=CY^5;T/A;._> $O@
M                            "%;E?=DOC_;9/[(P FH
M        1A?M9:N6VD+/V>I<OC1YFHLBU>8SK6K"EV:\$1517*JJJIDHNMJ8
MX "384-D&$R'":C(;$1K6M3!$1-B( +@                 'DJ\NDY29V6
M5,4C0'PU3CQ:J?Z@"-.QAIU3I-T5.D:U(3<A-08\=,Q-070HB-6(KD56N1%U
MXJ )6              !$'9!?E6Z_P"%LE]Y0!+X
M
M
M
M
M
M                           "%>R9_L\^$TK_ *@":@
M
M
M
M             $07Z?GE=5\(&?8@ E\  !$'8^?E6]#X6SOW@!+X
M                                                A6Y7W9+X_P!M
MD_LC ":@
M        !$'9!?E6Z_X6R7WE $O@
M
M
M
M
M
M               (5[)G^SSX32O^H FH
M
M
M                                                           !
M$%^GYY75?"!GV( )?   1!V/GY5O0^%L[]X 2^
M                                  (5N5]V2^/]MD_LC ":@
M                                                     !$'9!?E
M6Z_X6R7WE $O@
M
M
M
M
M
M(5[)G^SSX32O^H FH
M
M
M                                            !$%^GYY75?"!GV(
M)?   1!V/GY5O0^%L[]X 2^
M                   (5N5]V2^/]MD_LC ":@
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MKJQXCYD/;/-/0
M                                       (5[)G^SSX32O^H FH
M
M
M
M                       !$%^GYY75?"!GV( )?   1!V/GY5O0^%L[]X
M2^                                                        (5
MN5]V2^/]MD_LC ":@
M                #?6!_/JSG[REOYK2KG?MKG_6?"4^+^M1\X\4/=D-^4KL
M?A9)_:I]G'YN]BE0
M
M
M
M                                  -%;[\Q;1_NV9_E.+6#^YM_]H\4
M&5^C7\I\%T/V;?.A\8'Z0\<]8
M                                                   A7LF?[//A
M-*_Z@":@
M
M
M                                   $07Z?GE=5\(&?8@ E\  !$'8^
M?E6]#X6SOW@!+X
M          A6Y7W9+X_VV3^R, )J
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M#N3E896&3CAKPQQ+7H5_B?2.#_9T]WS0>DV^,XK7^[H79*Y.5AJXS>%5.M
M                "CW-8QSWJC6M3%578B"(UY(-= X9;V[$HJIW;3FL?J&I
MN7-ZG?'FH[RQNMW3Y+\T_D_2;NSML;/VB?FZ-59>8C896:ULB*B;5R'(BX?%
MQ%;(P<C&C6[1,1W=L)[65:O<E%6JCF.;M0WY43K0
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M6
M                                    &BM]^8MH_P!VS/\ *<6L']S;
M_P"T>*#*_1K^4^"Z'[-OG0^,#](>.>L
M                                                         0KV
M3/\ 9Y\)I7_4 34
M
M
M                                           B"_3\\KJOA S[$ $O
M@  (@['S\JWH?"V=^\ )?
M                 $*W*^[)?'^VR?V1@!-0
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M&N?_ '\,'?2BF9EV>(OUV^B?]+N/<XVU37TPQN3)<J&X*Z90
M
M                     -%;[\Q;1_NV9_E.+6#^YM_]H\4&5^C7\I\%T/V;
M?.A\8'Z0\<]8
M                                      A7LF?[//A-*_Z@":@
M
M
M
M                      $07Z?GE=5\(&?8@ E\  !$'8^?E6]#X6SOW@!+
MX                                                        A6Y
M7W9+X_VV3^R, )J
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M1S3,*>S+-NNQK53$SKT+H[E1^I535QGO[(I$;=]#1J(B).PD1$X/!>0_T_\
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MKY8,[.L6L?T/$Y8]L_G2DQ<6[7>](O\ /[(4>]J,R&>DU%]'A7LV09&UR_\
M08HNSV]<?HP+&Q^3 O3'/R^"+:'[JWKS<GBN@^U/)U/+-Q@  Y:]*$D:[RT#
M7;$E'N^--:?87MF3IEV_FJYL:V*_DNA>V-\YI+@HSHMVTDURXI"C16-\V6J_
MZJ6MNTQ&95/3$>"'9<ZX\?5=']L4D0QV@Q@
M
M       !HK??F+:/]VS/\IQ:P?W-O_M'B@ROT:_E/@NA^S;YT/C _2'CGK
M
M                        $*]DS_9Y\)I7_4 34
M
M
M
M         B"_3\\KJOA S[$ $O@  (@['S\JWH?"V=^\ )?
M                                           $*W*^[)?'^VR?V1@!
M-0
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M;1P<>GXD9<8BG=&6O+
M                                                    T5OOS%M'
M^[9G^4XM8/[FW_VCQ097Z-?RGP70_9M\Z'Q@?I#QSU@
M
M        "%>R9_L\^$TK_J )J
M
M
M                                                     1!?I^>5
MU7P@9]B "7P  $0=CY^5;T/A;._> $O@
M                           "%;E?=DOC_;9/[(P FH
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M$M";!8G_  M3!/H0PKER;E<UU<\SJU**8HIBF.:&-5Q55/0<.E
M
M                        T5OOS%M'^[9G^4XM8/[FW_VCQ097Z-?RGP70
M_9M\Z'Q@?I#QSU@
M                                        "%>R9_L\^$TK_J )J
M
M
M
M                         1!?I^>5U7P@9]B "7P  $0=CY^5;T/A;._>
M $O@                                                       "
M%;E?=DOC_;9/[(P FH
M                  WU@?SZLY^\I;^:TJYW[:Y_UGPE/B_K4?./%#W9#?E*
M['X62?VJ?9Q^;O8I4
M
M                                   #S5"0DZE+++U&4EYN75458<>&
MV(U538N"HJ'=NY7:GA43,3\.1S5137&E4:P(JHNI</,9X4-D*&R'"8UD-B(U
MK6I@C438B)Q'$S,SK+[$:<D!<'T                 \CJ9(.J3:@Z2E5GV
MMR&S*PFYU&\2/PQPUKZ22+MR*.+X4\'HUY.QQQ=/"X>G+T^U7%<,,5P/61NU
M
M                                   #16^_,6T?[MF?Y3BU@_N;?_:/
M%!E?HU_*?!=#]FWSH?&!^D/'/6
M                                                    (5[)G^SS
MX32O^H FH
M
M
M                                    !$%^GYY75?"!GV( )?   1!V
M/GY5O0^%L[]X 2^
M           (5N5]V2^/]MD_LC ":@
M                             #=6+F(4K;"A3$S$;"@09^!$B1'K@C6I
M$:JJJ\2(A7S*9KQ[E-/+,TSX2FQYBF[3,\VL>*'NR%3&I78X;V27WE/J[O\
M+*[PTSG#>D\%N[*]W/8]3Z98Z\=J5LAW)7T#O\LKO#3.<-Z1N[*]W/8>F6.O
M':9#N2OH'?Y97>&F<X;TC=V5[N>P],L=>.TR'<E?0._RRN\-,YPWI&[LKW<]
MAZ98Z\=ID.Y*^@=_EE=X:9SAO2-W97NY[#TRQUX[3(=R5] [_+*[PTSG#>D;
MNRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\ +*[P
MTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#
MO\LKO#3.<-Z1N[*]W/8>F6.O':9#N2OH'?Y97>&F<X;TC=V5[N>P],L=>.TR
M'<E?0._RRN\-,YPWI&[LKW<]AZ98Z\=ID.Y*^@=_EE=X:9SAO2-W97NY[#TR
MQUX[3(=R5] [_+*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>
M[GL/3+'7CM,AW)7T#O\ +*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.
M&](W=E>[GL/3+'7CM,AW)7T#O\LKO#3.<-Z1N[*]W/8>F6.O':9#N2OH'?Y9
M7>&F<X;TC=V5[N>P],L=>.TR'<E?0._RRN\-,YPWI&[LKW<]AZ98Z\=ID.Y*
M^@=_EE=X:9SAO2-W97NY[#TRQUX[3(=R5] [_+*[PTSG#>D;NRO=SV'IECKQ
MVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\ +*[PTSG#>D;NRO=S
MV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\LKO#3.<-Z1
MN[*]W/8>F6.O':9#N2OH'?Y97>&F<X;TC=V5[N>P],L=>.TR'<E?0._RRN\-
M,YPWI&[LKW<]AZ98Z\=ID.Y*^@=_EE=X:9SAO2-W97NY[#TRQUX[3(=R5] [
M_+*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,A
MW)7T#O\ +*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3
M+'7CM,AW)7T#O\LKO#3.<-Z1N[*]W/8>F6.O':9#N2OH'?Y97>&F<X;TC=V5
M[N>P],L=>.TR'<E?0._RRN\-,YPWI&[LKW<]AZ98Z\=ID.Y*^@=_EE=X:9SA
MO2-W97NY[#TRQUX[3(=R5] [_+*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65
MWAIG.&](W=E>[GL/3+'7CM,AW)7T#O\ +*[PTSG#>D;NRO=SV'IECKQVF0[D
MKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\LKO#3.<-Z1N[*]W/8>F6.O
M':9#N2OH'?Y97>&F<X;TC=V5[N>P],L=>.TR'<E?0._RRN\-,YPWI&[LKW<]
MAZ98Z\=ID.Y*^@=_EE=X:9SAO2-W97NY[#TRQUX[3(=R5] [_+*[PTSG#>D;
MNRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\ +*[P
MTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#
MO\LKO#3.<-Z1N[*]W/8>F6.O':9#N2OH'?Y97>&F<X;TC=V5[N>P],L=>.TR
M'<E?0._RRN\-,YPWI&[LKW<]AZ98Z\=ID.Y*^@=_EE=X:9SAO2-W97NY[#TR
MQUX[3(=R5] [_+*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>
M[GL/3+'7CM,AW)7T#O\ +*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.
M&](W=E>[GL/3+'7CM,AW)7T#O\LKO#3.<-Z1N[*]W/8>F6.O':9#N2OH'?Y9
M7>&F<X;TC=V5[N>P],L=>.TR'<E?0._RRN\-,YPWI&[LKW<]AZ98Z\=ID.Y*
M^@=_EE=X:9SAO2-W97NY[#TRQUX[3(=R5] [_+*[PTSG#>D;NRO=SV'IECKQ
MVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\ +*[PTSG#>D;NRO=S
MV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\LKO#3.<-Z1
MN[*]W/8>F6.O':9#N2OH'?Y97>&F<X;TC=V5[N>P],L=>.TR'<E?0._RRN\-
M,YPWI&[LKW<]AZ98Z\=ID.Y*^@=_EE=X:9SAO2-W97NY[#TRQUX[3(=R5] [
M_+*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,A
MW)7T#O\ +*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3
M+'7CM,AW)7T#O\LKO#3.<-Z1N[*]W/8>F6.O':9#N2OH'?Y97>&F<X;TC=V5
M[N>P],L=>.TR'<E?0._RRN\-,YPWI&[LKW<]AZ98Z\=ID.Y*^@=_EE=X:9SA
MO2-W97NY[#TRQUX[3(=R5] [_+*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65
MWAIG.&](W=E>[GL/3+'7CM,AW)7T#O\ +*[PTSG#>D;NRO=SV'IECKQVF0[D
MKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\LKO#3.<-Z1N[*]W/8>F6.O
M':9#N2OH'?Y97>&F<X;TC=V5[N>P],L=>.TR'<E?0._RRN\-,YPWI&[LKW<]
MAZ98Z\=ID.Y*^@=_EE=X:9SAO2-W97NY[#TRQUX[3(=R5] [_+*[PTSG#>D;
MNRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\ +*[P
MTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#
MO\LKO#3.<-Z1N[*]W/8>F6.O':9#N2OH'?Y97>&F<X;TC=V5[N>P],L=>.TR
M'<E?0._RRN\-,YPWI&[LKW<]AZ98Z\=ID.Y*^@=_EE=X:9SAO2-W97NY[#TR
MQUX[3(=R5] [_+*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>
M[GL/3+'7CM,AW)7T#O\ +*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.
M&](W=E>[GL/3+'7CM,AW)7T#O\LKO#3.<-Z1N[*]W/8>F6.O':9#N2OH'?Y9
M7>&F<X;TC=V5[N>P],L=>.TR'<E?0._RRN\-,YPWI&[LKW<]AZ98Z\=ID.Y*
M^@=_EE=X:9SAO2-W97NY[#TRQUX[3(=R5] [_+*[PTSG#>D;NRO=SV'IECKQ
MVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\ +*[PTSG#>D;NRO=S
MV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\LKO#3.<-Z1
MN[*]W/8>F6.O':9#N2OH'?Y97>&F<X;TC=V5[N>P],L=>.TR'<E?0._RRN\-
M,YPWI&[LKW<]AZ98Z\=ID.Y*^@=_EE=X:9SAO2-W97NY[#TRQUX[3(=R5] [
M_+*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,A
MW)7T#O\ +*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3
M+'7CM,AW)7T#O\LKO#3.<-Z1N[*]W/8>F6.O':9#N2OH'?Y97>&F<X;TC=V5
M[N>P],L=>.TR'<E?0._RRN\-,YPWI&[LKW<]AZ98Z\=ID.Y*^@=_EE=X:9SA
MO2-W97NY[#TRQUX[3(=R5] [_+*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65
MWAIG.&](W=E>[GL/3+'7CM,AW)7T#O\ +*[PTSG#>D;NRO=SV'IECKQVF0[D
MKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\LKO#3.<-Z1N[*]W/8>F6.O
M':9#N2OH'?Y97>&F<X;TC=V5[N>P],L=>.TR'<E?0._RRN\-,YPWI&[LKW<]
MAZ98Z\=ID.Y*^@=_EE=X:9SAO2-W97NY[#TRQUX[3(=R5] [_+*[PTSG#>D;
MNRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\ +*[P
MTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#
MO\LKO#3.<-Z1N[*]W/8>F6.O':9#N2OH'?Y97>&F<X;TC=V5[N>P],L=>.TR
M'<E?0._RRN\-,YPWI&[LKW<]AZ98Z\=ID.Y*^@=_EE=X:9SAO2-W97NY[#TR
MQUX[3(=R5] [_+*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>
M[GL/3+'7CM,AW)7T#O\ +*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.
M&](W=E>[GL/3+'7CM,AW)7T#O\LKO#3.<-Z1N[*]W/8>F6.O':9#N2OH'?Y9
M7>&F<X;TC=V5[N>P],L=>.TR'<E?0._RRN\-,YPWI&[LKW<]AZ98Z\=ID.Y*
M^@=_EE=X:9SAO2-W97NY[#TRQUX[3(=R5] [_+*[PTSG#>D;NRO=SV'IECKQ
MVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\ +*[PTSG#>D;NRO=S
MV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,AW)7T#O\LKO#3.<-Z1
MN[*]W/8>F6.O':9#N2OH'?Y97>&F<X;TC=V5[N>P],L=>.TR'<E?0._RRN\-
M,YPWI&[LKW<]AZ98Z\=ID.Y*^@=_EE=X:9SAO2-W97NY[#TRQUX[3(=R5] [
M_+*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3+'7CM,A
MW)7T#O\ +*[PTSG#>D;NRO=SV'IECKQVF0[DKZ!W^65WAIG.&](W=E>[GL/3
M+'7CM,AW)7T#O\LKO#3.<-Z1N[*]W/8>F6.O':9#N2OH'?Y97>&F<X;TC=V5
M[N>P],L=>.TR'<E?0._RRN\-,YPWI&[LKW<]AZ98Z\=ID.Y*^@TUM+:6:FK'
MUZ7EJ[3HL>-(1X<.&R.U5<Y8;D1$3C52QAX&31D6ZJK<Q$51[/BAR,JS5:KB
M*XUTGP58QR/3P5VGR@>]>6>H
M                                                  0KV3/]GGPF
ME?\ 4 34
M
M
M                                    B"_3\\KJOA S[$ $O@  (@['
MS\JWH?"V=^\ )?
M          $*W*^[)?'^VR?V1@!-0
M                              B#L@ORK=?\+9+[R@"7P
M
M
M
M
M
M                                    $*]DS_9Y\)I7_4 34
M
M
M
M                     B"_3\\KJOA S[$ $O@  (@['S\JWH?"V=^\ )?
M                                                       $*W*^
M[)?'^VR?V1@!-0
M               B#L@ORK=?\+9+[R@"7P
M
M
M
M
M
M                     $*]DS_9Y\)I7_4 34
M
M
M
M      B"_3\\KJOA S[$ $O@  (@['S\JWH?"V=^\ )?
M                                        $*W*^[)?'^VR?V1@!-0
M
MB#L@ORK=?\+9+[R@"7P
M
M
M
M
M
M      $*]DS_ &>?":5_U $U
M
M
M                                                    (@OT_/*Z
MKX0,^Q !+X  "(.Q\_*MZ'PMG?O "7P
M                          !"MRONR7Q_MLG]D8 34
M                                              (@[(+\JW7_  MD
MOO* )?
M
M
M
M
M                                                      0KV3/]
MGGPFE?\ 4 34
M
M
M                                        B"_3\\KJOA S[$ $O@
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M'MZWOL?54/I #1[>M[['U5#Z0 T>WK>^Q]50^D <;:^S5L:';Z[:):VV/?#
MB5R&V#"[4; S3D5%5V*;=6K  ?3@  "(.Q\_*MZ'PMG?O "7P
M                                            !"MRONR7Q_MLG]D8
M 34
M    (@[(+\JW7_"V2^\H E\
M
M
M
M
M
M          !"O9,_V>?":5_U $U
M
M
M                                                       (@OT_
M/*ZKX0,^Q !+X  "(.Q\_*MZ'PMG?O "7P
M                             !"MRONR7Q_MLG]D8 34
M                     \-=J\E0:/.52K1^UY"4AK%C1<ESLAJ;5P:BJOQ(
M +J/4I2L4F3J5-C9^2G(+(\")DJW+8Y$5JX*B*FI4U*F( ]@
M            (@[(+\JW7_"V2^\H E\
M
M
M
M
M
M                  !"O9,_V>?":5_U $U
M
M
M
M   (@OT_/*ZKX0,^Q !+X  "(.Q\_*MZ'PMG?O "7P
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MGL=^Z97^4T =@                        "(.R"_*MU_PMDOO* )?
M
M
M
M
M
M                                            0KV3/]GGPFE?]0!-
M0
M
M
M                            "(+]/SRNJ^$#/L0 2^   B#L?/RK>A\+
M9W[P E\
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M3!6HH B>_.[.R4I;RQ$67I.1$M#7LBIKVS&7MA'O:KDUN\'%7.]CAM $B?\
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M@#L                         1!V07Y5NO^%LE]Y0!+X
M
M
M
M
M
M                                  "%>R9_L\^$TK_J )J
M
M
M
M                   1!?I^>5U7P@9]B "7P  $0=CY^5;T/A;._> $O@
M                                                     "%;E?=D
MOC_;9/[(P FH <K>S[EELOW+.?R'@#2]CQ[B]E/V5?ON ',7/>[E>]_CR?W8
M@ [:^WW([7_NR/\ =4 8;A_<>LE^P0P!QG8FHK;'VJ:[4Y+236*+M3^C@@#6
M]EK(RT6'82>K$%8M!EZND*H-RE:BPGY*JBJBXIBUCTQ3C '4P^Q^NOB0VOAV
M;:YCD16N;4)E45.-/Z0 ;^QMU%B[&5=:I9JBI)SZPW0<ZLS&B^"JIBF#WJG
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MXJ<V7%=<
M
M
M A7LF?[//A-*_P"H FH
M
M
M                                              !$%^GYY75?"!GV
M( )?   1!V/GY5O0^%L[]X 2^
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MOK _GU9S]Y2W\UI5SOVUS_K/A*?%_6H^<>*'NR&_*5V/PLD_M4^SC\W>Q2H
M
M
M                                                  !&W9!^YS'_
M &F%]JFSL']W'REG;4_;S\X9)?VSXCY</<O,/2
M
M
M                               A7LF?[//A-*_Z@":@
M
M
M
M               $07Z?GE=5\(&?8@ E\  !$'8^?E6]#X6SOW@!+X
M                                                  A6Y7W9+X_V
MV3^R, )J
M        -]8'\^K.?O*6_FM*N=^VN?\ 6?"4^+^M1\X\4/=D-^4KL?A9)_:I
M]G'YN]BE0
M
M
M"-NR#]SF/^TPOM4V=@_NX^4L[:G[>?G#)+^V?$?+A[EYAZ0
M
M
M                                       $*]DS_9Y\)I7_ % $U
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M1>!47A1474J+K3A &Q ''7P6I;8V[BN5E'HR8A0%ARVO6L9_@LPX\'*B^9%
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M+%9AP)CJ1?1K $K4^=EJC(P)R0F(4S*1V)$A1H3D<Q[5UHJ*FU !Z
M    !%=\%N*U2;06<LA8ULJVT-=>["9F6Y3):$W:_)X5U.X]35U+B@ W%CJ!
M;RD5QL2T5M):T-*?"5'PG4N'*1(;^!6K#U*G'B .\    !X:=6*94YB<EZ;4
M9.;CR43-3,.!';$= ?BJ9+T155JXHNI<-B\0 ]P           B6Y:V%<M);
M:\NGUJ=28E*/5EEI%F:8S-0\Y&;DXM1%=J8W6[%=0 EH    '@J%8IE-FI.5
MJ-1DY29G7YN5A1X[8;X[DP\%C57%RZTU)CM0 >\
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M\$PQS?@[<?*6MH^B\9'HG^.GQY_KRH,3C^!_[CG^GV5B9./@;#JR@M+0
M
M
M            (V[(/W.8_P"TPOM4V=@_NX^4L[:G[>?G#)+^V?$?+A[EYAZ0
M
M
M                                                    $*]DS_9Y
M\)I7_4 34             ^=I:"V]+LDJFRIHDQ9ZQS,B#+.\*&^8QP57)L]
MFCE\N;:G& /HD <[>#9.1MK9*HT.IPV.9,0US3U37!BHBY$1J\"HOT8IL50!
M''8I6FG*Q=_,4>K*YT_0)E9%5>N*YO:Q%\WA-\S4 $Q,DY5D[%G&2T%LY$8V
M&^.D-$B.8U55&J[:J(JK@G!BH NG,QVI'[;S?:V0[.YS#)R,->./!AB (([#
M9L5+!UQ8><2FNJ\191'XXY.0S'_3X\0!/@ @'L@'+;*\>P]W,#%\O&CI4JBC
M5V0FY2(B\7@MB[>%6^0 3O,R4K-2423FI:#&E(C,V^!$AHZ&YF&&2K5U*F'
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M4I84+'%$VHY5X<=2 "4J?.RU1D8$[(1X<Q*3#$B0HT-V4U[53%%14VHH ]
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M@S=GV)L>EXDZT^V.A+C9=R+O$9$?W>R5'L3)RF+J)0,-IL0
M
M                                           $;=D'[G,?]IA?:IL[
M!_=Q\I9VU/V\_.&27]L^(^7#W+S#T@
M
M
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M%T]#J,>5EEG(#',9,OAMSD-B^R1'KK1%PUIB -#4;<V*9GY*HVILXU5:L.+
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M6#FLK+<JX(W*=AAYP!PG8MHG<JW"X)BMI9I,?\K !-@
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MYT0IEL1BM:BIB3$>=:[$
M
M                !&W9!^YS'_:87VJ;.P?W<?*6=M3]O/SADE_;/B/EP]R\
MP](
M
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M41M0GY*DV5D\MTU(14AQ63"JU<6/5%R792L3'#'^B7S@#O=#7_S'O)^?/_W
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M"@NOBOKM?7W5BLTNFT-6TZ0FJ5,) BJJ935R7JB^"N$1RHF'MB?& DC0U_\
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MUSLE,434B8 #:REE:RSLB9VU#Y/"AQ*&DFV9SK-<7.,7)R,<K8BZ\,/* )0
M$7REE:RSLB9VU#Y/"AQ*&DFV9SK-<7.,7)R,<K8BZ\,/* )0 $7W;V5K%&O5
MO&K-2E$@TZK199TE%SK'9U&M?E>"BJK<,4]DB;=0 \=N; VADKP&V\NYF)-M
M6BP6R]1ITXJMA3K$P1%RDV.P1O%[%%QVHH#(EIKVJE [6E;OJ71IIS4_[;/U
MEDQ!:NQ?Z.$F7PX[5U(NT 2/9R7J,I1).!7)YD_4V0T28F8<)(38C^'!J;$X
M/B ' 7"65K-E:=:F'7I/M6).UR8G(#<ZQ^7!<C,EW@JN&."ZEU^0 2@
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ML:U5>R9_(\%BQZ757$W=(IZ/S5:[-HU<G%5XR0C(:#&
M
M                                       !&W9!^YS'_:87VJ;.P?W<
M?*6=M3]O/SADE_;/B/EP]R\P](
M
M
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M,K4B8_\ #EX^3$ ;RX"R3['W84J3FF*VH32+.SF5[+.Q,%P7RM;DM7^Z )$
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MJ8)J3!$PX$ '67>7>4NQ2STU F)VI5BH*CIVI3\7.1XZIL3'8C4X$3R8JN"
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M1,0X$E-4^'(0J9#E\EL!&YOPLO*\+'-XKBF.+E554 2,
M       B"_3\\KJOA S[$ $O@  (@['S\JWH?"V=^\ )?
M                                         $*W*^[)?'^VR?V1@!-0
M                                                           !
MOK _GU9S]Y2W\UI5SOVUS_K/A*?%_6H^<>*'NR&_*5V/PLD_M4^SC\W>Q2H
M
M
M                                                  !&W9!^YS'_
M &F%]JFSL']W'REG;4_;S\X9)?VSXCY</<O,/2
M
M
M                               A7LF?[//A-*_Z@":@
M            <C92P%)LU:JT5H92+.1ZG6XB1)A\R]KDAIBJY$/!J8-UIM55
M\%->H =<                                            #D;*6 I-
MFK56BM#*19R/4ZW$2),/F7M<D-,57(AX-3!NM-JJO@IKU #K@
M                                  !']Y-W"6\KMFIBH55T*D4B8[9B
MTY(&4DT_%,,I^4F"(B8;%U*[C $@
M   X"C7=)3;XZ[;Q*HL1:I)-DUD<QAF\$@IE9S*U^TIJR4]EMU #OP
M                                           1!?I^>5U7P@9]B "7
MP  $0=CY^5;T/A;._> $O@
M                 "%;E?=DOC_;9/[(P FH :RU-7;0+,U>LQ(3H[*=)QIM
MT)JX*](;%?DHO!CDX "++.WHV^M%192K4:ZKMFGS3,N#%[XI=F4W%4QP<Q%3
M6B[4 '86*M%;&K56)+VGL)WO238*O;-=UX,WE/Q:B,R&(BIBBN7'9X/E ';
M            /%4*K3Z=&E(-0GY25BS<1(,LR/&:QT9Z[&L15\)WD36 /: .
M L3>-WSV_M99CN/%E.X+VL[:=%RDC8JJ:VY*9..&*:UQ3'9@ ._
M                          -]8'\^K.?O*6_FM*N=^VN?]9\)3XOZU'SC
MQ0]V0WY2NQ^%DG]JGV<?F[V*5
M
M
M                 (V[(/W.8_[3"^U39V#^[CY2SMJ?MY^<,DO[9\1\N'N7
MF'I
M
M                                                        0KV3
M/]GGPFE?]0!-0
M
M
M                                        "(+]/SRNJ^$#/L0 2^
M B#L?/RK>A\+9W[P E\
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M^UL2WEB&S%B<PR1KV-,?W5@N[I*CVHU,$3^ARD1J^%CAE>0 2)W[WG>]%_\
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M16>95QVX(JZ@!+\"+#CP8<: ]L2%$:CV/:N*.1=:*B\0 O
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MC:%S(HX%41I^?%<R$C%Q15.!-517@
M
M
M                     (5[)G^SSX32O^H FH
M
M
M
M     !$%^GYY75?"!GV( )?   1!V/GY5O0^%L[]X 2^
M                                        (5N5]V2^/]MD_LC ":@!
MRM[/N66R_<LY_(> (AN:NN[M78V?J/?S;JG]L2^7VK(5?-0(?A.3!C,A<$U<
M8 EFP]A^].:FHW?1:FMY]B,R*S4.V60\%QQ8F2F"^4 <!>-_O+W8?LTW_+B
M";@!"G8R?VA_"69_T 'FNED)6-V0-ZL[%EX;YN6B2S(,5S<70VO:[*1%X,<E
MOH '<W[2\*9N?M<R.Q'L2GQ(B(O*;X35^)41?B &MN]J<Q*]CQ2ZC#>O;,K0
M%B0W+P+#A+D_=0 >7L7*?!DKF:+&A(BQYY\::F(G"]ZQ7-Q5>%<EK4^( 2N
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M
M
M
M
M
M                                               "%>R9_L\^$TK_
M *@":@
M
M
M                                 $07Z?GE=5\(&?8@ E\  !$'8^?E
M6]#X6SOW@!+X
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M[4U@#F+GT73E>\O!GY/[L0 =M?8BK=':_#Q9'^XH PW$(J7/V2Q\7PP!W8
M                        B#L@ORK=?\+9+[R@"7P
M
M
M
M
M
M                              $*]DS_ &>?":5_U $U
M
M
M
M                (@OT_/*ZKX0,^Q !+X  "(.Q\_*MZ'PMG?O "7P
M                                                  !"MRONR7Q_
MMLG]D8 34
M          (@[(+\JW7_  MDOO* )?
M
M
M
M
M
M                  0KV3/]GGPFE?\ 4 34
M
M
M
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MG3?DKT@!H9N\W3IOR5Z0 T,W>;ITWY*]( :&;O-TZ;\E>D -#-WFZ=-^2O2
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M3IOR5Z0 T,W>;ITWY*]( :&;O-TZ;\E>D -#-WFZ=-^2O2 &AF[S=.F_)7I
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MG3?DKT@!H9N\W3IOR5Z0 T,W>;ITWY*]( :&;O-TZ;\E>D -#-WFZ=-^2O2
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M&*QJY3'(N**FL =L
M
M
M
M
M
M
M
M
M
M
C                                          !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351963581248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immunic, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2358443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1200 Avenue of the Americas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-9818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMUX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001280776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351965401024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 88,078<span></span>
</td>
<td class="nump">$ 86,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">16,683<span></span>
</td>
<td class="nump">18,125<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">104,761<span></span>
</td>
<td class="nump">104,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">32,970<span></span>
</td>
<td class="nump">32,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">138,657<span></span>
</td>
<td class="nump">139,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,117<span></span>
</td>
<td class="nump">3,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,741<span></span>
</td>
<td class="nump">7,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">544<span></span>
</td>
<td class="nump">585<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,402<span></span>
</td>
<td class="nump">11,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,809<span></span>
</td>
<td class="nump">11,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of June 30, 2022 and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 130,000,000 shares authorized and 30,564,995 and 26,335,418 shares issued and outstanding as of June 30, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">368,087<span></span>
</td>
<td class="nump">324,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(660)<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(239,582)<span></span>
</td>
<td class="num">(196,873)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">127,848<span></span>
</td>
<td class="nump">127,115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 138,657<span></span>
</td>
<td class="nump">$ 139,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351963680560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">30,564,995<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">30,564,995<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351965351920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 16,538<span></span>
</td>
<td class="nump">$ 15,738<span></span>
</td>
<td class="nump">$ 33,983<span></span>
</td>
<td class="nump">$ 27,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,072<span></span>
</td>
<td class="nump">3,432<span></span>
</td>
<td class="nump">8,062<span></span>
</td>
<td class="nump">7,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_RoyaltySettlementAgreementSalesNet', window );">4SC royalty settlement (see Note 4)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">20,610<span></span>
</td>
<td class="nump">19,170<span></span>
</td>
<td class="nump">42,045<span></span>
</td>
<td class="nump">51,557<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(20,610)<span></span>
</td>
<td class="num">(19,170)<span></span>
</td>
<td class="num">(42,045)<span></span>
</td>
<td class="num">(51,557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(1,397)<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
<td class="num">(777)<span></span>
</td>
<td class="num">(952)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(1,291)<span></span>
</td>
<td class="nump">1,236<span></span>
</td>
<td class="num">(664)<span></span>
</td>
<td class="num">(911)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (21,901)<span></span>
</td>
<td class="num">$ (17,934)<span></span>
</td>
<td class="num">$ (42,709)<span></span>
</td>
<td class="num">$ (52,468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in USD per share)</a></td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
<td class="num">$ (1.49)<span></span>
</td>
<td class="num">$ (2.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in USD per share)</a></td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
<td class="num">$ (1.49)<span></span>
</td>
<td class="num">$ (2.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">30,248,767<span></span>
</td>
<td class="nump">21,749,439<span></span>
</td>
<td class="nump">28,686,910<span></span>
</td>
<td class="nump">21,463,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">30,248,767<span></span>
</td>
<td class="nump">21,749,439<span></span>
</td>
<td class="nump">28,686,910<span></span>
</td>
<td class="nump">21,463,656<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_RoyaltySettlementAgreementSalesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Settlement Agreement, Sales Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_RoyaltySettlementAgreementSalesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351963401344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (21,901)<span></span>
</td>
<td class="num">$ (17,934)<span></span>
</td>
<td class="num">$ (42,709)<span></span>
</td>
<td class="num">$ (52,468)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="num">(350)<span></span>
</td>
<td class="num">(277)<span></span>
</td>
<td class="num">(408)<span></span>
</td>
<td class="nump">2,714<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (22,251)<span></span>
</td>
<td class="num">$ (18,211)<span></span>
</td>
<td class="num">$ (43,117)<span></span>
</td>
<td class="num">$ (49,754)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351959551184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Public Offering</div></th>
<th class="th"><div>4SC Royalty Settlement</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Public Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>4SC Royalty Settlement</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Public Offering</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>4SC Royalty Settlement</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,168,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 158,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,112)<span></span>
</td>
<td class="num">$ (103,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(34,534)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="nump">2,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">581,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,749,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">137,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,121)<span></span>
</td>
<td class="num">(138,462)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,168,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">158,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,112)<span></span>
</td>
<td class="num">(103,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(52,468)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,749,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">120,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,398)<span></span>
</td>
<td class="num">(156,396)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,749,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">137,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,121)<span></span>
</td>
<td class="num">(138,462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,934)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,934)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,749,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">120,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,398)<span></span>
</td>
<td class="num">(156,396)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">127,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="num">(196,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="nump">2,904,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">$ 29,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">$ 29,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,240,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">137,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="num">(217,681)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">127,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="num">(196,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(42,709)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">127,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(660)<span></span>
</td>
<td class="num">(239,582)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,240,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">137,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="num">(217,681)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,612<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">$ 9,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">$ 9,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 127,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (660)<span></span>
</td>
<td class="num">$ (239,582)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351966055088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">$ 918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351959482416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (42,709)<span></span>
</td>
<td class="num">$ (52,468)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency loss</a></td>
<td class="nump">2,103<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,131<span></span>
</td>
<td class="nump">3,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Common Stock issued in connection with the 4SC royalty settlement (see Note 4)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">139<span></span>
</td>
<td class="num">(8,683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Accrued expenses</a></td>
<td class="num">(861)<span></span>
</td>
<td class="nump">2,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Other liabilities</a></td>
<td class="num">(114)<span></span>
</td>
<td class="nump">3,059<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(36,444)<span></span>
</td>
<td class="num">(41,953)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued in connection with the Company's employee stock purchase plan</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">39,719<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(2,020)<span></span>
</td>
<td class="nump">1,704<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">1,215<span></span>
</td>
<td class="num">(40,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">86,863<span></span>
</td>
<td class="nump">127,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">88,078<span></span>
</td>
<td class="nump">87,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common Stock issued in connection with the 4SC royalty settlement (see Note 4)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of use asset obtained in exchange for lease obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 39,584<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351963578272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Financial Statements</a></td>
<td class="text">Description of Business and Basis of Financial Statements<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic, Inc. ("Immunic" or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#228;felfing near Munich, Germany.  The Company currently has approximately 60 employees.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is currently pursuing three development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;); the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (&#8220;ROR&#947;t&#8221;), an immune cell-specific isoform of ROR&#947;; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. These product candidates are being developed to address diseases such as multiple sclerosis ("MS"), psoriasis and gastrointestinal diseases. In addition to these large markets, these products are also being developed to address certain rare diseases with high unmet medical needs, such as primary sclerosing cholangitis (&#8220;PSC&#8221;), as well as metastatic castration-resistant prostate cancer (&#8220;mCRPC&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and the inability to obtain on acceptable terms, if at all, additional funding to complete the development and commercialization of the Company's three development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $239.6 million as of June 30, 2022 and $196.9 million as of December 31, 2021.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the preclinical and clinical development of its product candidates and adds personnel necessary to advance its clinical pipeline of product candidates.  Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through June 30, 2022, Immunic has raised net cash of approximately $299.1 million from private and public offerings of preferred and common stock. As of June 30, 2022, the Company had cash and cash equivalents of approximately $88.1 million.  With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Research GmbH (which both began operations in 2016) and Immunic Australia Pty Ltd. (which began operations in 2018).  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. </span></div>Unaudited Interim Financial InformationImmunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed on February 24, 2022. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351968764400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG and Immunic Research GmbH&#8217;s operations are located in Germany with the Euro being their functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDU2MA_257586a5-1545-4cd3-af1d-02cb0660d644">three</span> to thirteen years. Depreciation expense was $20,000 and $15,000 for the three months ended June 30, 2022 and 2021, respectively. Depreciation expense was $41,000 and $29,000 for the six months ended June 30, 2022 and 2021, respectively</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the three and six months ended June 30, 2022 and 2021.</span></div><div style="margin-top:12pt;padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">When conducting the Company&#8217;s interim goodwill impairment assessment, we considered the Company&#8217;s history of reported losses and negative cash flows from operating activities, along with the downturn in macroeconomic conditions and the broader mid-cap and micro-cap equity markets in 2022. Given the relatively short period of time between the commencement of the downturn in macroeconomic and general equity market conditions as of June 30, 2022, management believes that the recent reduction in prices of our common stock, consistent with the broader market, is not other-than-temporary and not indicative of any fundamental change in the value or prospects of the underlying business as of the measurement date.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As another data point, the Company also performed a quantitative goodwill impairment analysis comparing the estimated fair value of the Company&#8217;s reporting unit to its carrying or book value as of the current period presented herein. In performing the quantitative analysis, the Company compared the fair value of the reporting unit to its carrying or book value to determine if the fair value of the reporting unit exceeded its carrying value as of the testing date, in which case the standard indicates that goodwill would not be impaired, and no further testing is required. The fair value of a reporting unit refers to the price that would be received to sell the reporting unit as a whole in an orderly transaction between market participants at the measurement date. Quoted market prices in active markets are considered to be the best evidence of fair value and should be used as the basis for fair value measurement, if available. When using quoted market prices to estimate the fair value of a reporting unit, we consider all available evidence. In certain circumstances, such as a distressed market, it may be appropriate to consider recent trends in the Company&#8217;s stock price, instead of a single day&#8217;s stock price in evaluating fair value. In these circumstances, averages over relatively short periods of time are used to determine representative market values.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the qualitative analysis and other data points described above,  the Company concluded that goodwill was not &#8220;more likely than not&#8221; impaired as of June 30, 2022.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described above, we have significant goodwill recorded on our consolidated balance sheets. We will continue to evaluate the recoverability of the carrying amount of goodwill on an ongoing basis. There can be no assurance that the outcome of such reviews in the future will not result in substantial impairment charges. Impairment assessment inherently involves judgment as to assumptions about expected future cash flows and the impact of market conditions on those assumptions. Future events and changing market conditions may impact our assumptions as to prices, costs, holding periods or other factors that may result in changes in our estimates of future cash flows. Although we believe the assumptions we used in testing for impairment are reasonable, significant changes in any one of our assumptions could produce a significantly different result. The  closing stock prices for our common stock subsequent to June 30, 2022, consistent with the broader market, have continued to trend downward. If the decline in our stock price persists throughout the three month period ending September 30, 2022, we will perform an interim goodwill impairment assessment as of September 30, 2022, consistent with the methodology and approach described above.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC, COVID-19, and PSC.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of June 30, 2022 and 2021, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:73.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351968648960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text">Balance Sheet Details<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets and Prepaid Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:74.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.255%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,745&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfMjE5OTAyMzI1NjI5MA_3d8ceb1b-3c21-469b-880e-2ea581b8f112"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfMjE5OTAyMzI1NjI5MA_f85fe492-0c02-4937-8946-c1829a42d290">Other Current Liabilities</span></span></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.740%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351968700224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on April 30, 2023 for the New York City office and on June 30, 2025 for the Gr&#228;felfing, Germany office.  These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease has renewal options, but they were not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a five year lease for its facility in Gr&#228;felfing, Germany. On March 1, 2021, the Company added additional lease space at the Gr&#228;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease.  There were net additions to right of use assets of $435,000 as a result of signing for additional lease space at the Gr&#228;felfing, Germany office in March 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6%, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $136,000 and 145,000 for the three months ended June 30, 2022 and 2021, respectively and $266,000 and $239,000 for the six months ended June 30, 2022 and 2021, respectively.  Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of June 30, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"/><td style="width:85.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.945%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company has non-cancelable contractual obligations under certain agreements related to its development programs for vidofludimus calcium, IMU-935 and IMU-856 totaling approximately $2.6&#160;million, all of which is expected to be paid in the next twelve months.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, the Company entered into a purchase agreement (the &#8220;Agreement&#8221;) with 4SC AG, whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to 4.4% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing 120,070 shares of the Company&#8217;s common stock, immediately following the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transaction, to 4SC AG while keeping Tranche III in effect. Approximately $1.5 million of expense was recorded as a result of the issuance of these shares on April 12, 2019. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, Immunic AG and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.25&#160;million (Tranche III of the Agreement). The payment was made 50% in cash and 50% in shares of Immunic&#8217;s common stock (the &#8220;Shares&#8221;). Pursuant to the Agreement, the Company filed a resale shelf registration statement on Form S-3 covering the resale of the Shares. With the execution of the Agreement, no further payment obligations remain between Immunic AG and 4SC AG.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351968678448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:50.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,241&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,241&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:50.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds, which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div>The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351967755920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common Stock<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of July 31, 2022, there is $75.0&#160;million remaining on this shelf registration statement </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 31, 2022, $8.4&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 31, 2022, $80.0&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company has agreed to pay SVB Leerink a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended June 30, 2022, the Company raised gross proceeds of $10.3&#160;million pursuant to the December 2020 ATM through the sale of 1,300,000 shares of common stock at a weighted average price of $7.90 per share. The net proceeds from the December 2020 ATM were $10.0&#160;million after deducting underwriter commissions of $0.3&#160;million.  In the six months ended June 30, 2022, the Company raised gross proceeds of $40.9&#160;million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6&#160;million after deducting underwriter commissions of $1.2&#160;million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any ATM activity during the three or six months ended June 30, 2021.</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Common Stock</span></div><div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001 per share. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through June 30, 2022, no cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20 million shares of $0.0001 par value preferred stock, having rights and preferences to be set by the Board of Directors. No preferred shares were outstanding as of June 30, 2022.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at June 30, 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;2021 Employee Stock Purchase Plan    </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,232,534&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351967675584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Plans</a></td>
<td class="text">Stock-Based Compensation Plans<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#8217;s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">     </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued  24,612 shares under the ESPP for the three and six months ended June 30, 2022 and 37,370 shares life to date.   The Company recognized $25,000 and $53,000 of expense related to the ESPP during the three and six months ended June 30, 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#8217;s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to 4% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2022 by a total of 2,481,195 shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI1Mzg0_7a7a7119-e170-4cdf-8081-4d8911387b29">three</span> or four years. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the six months ended June 30, 2022 and 2021, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:52.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,702,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,873)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,248&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127,085&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:52.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064,839&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,022&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the six months ended June 30, 2022 and 2021 was $7.25 and $11.36, respectively. The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six  Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.94</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.391%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>&#160;Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,263,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,131,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,086,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, there was $19.4 million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 3.06 years.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital Therapies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital&#8217;s 2012 Stock Option Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain 43,311 shares available for grant under the 2014 Plan as of June 30, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Vital&#8217;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense was recorded for the plans assumed from Vital during the three and six months ended June 30, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351970305520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the current Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020, which was subsequently extended to April 15, 2021. On April 15, 2021, the Company and Dr. Nash entered into an addendum (the &#8220;Addendum&#8221;) to extend the term of the Executive Chairman Agreement to April 15, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 90,000 shares of Company common stock, which vests monthly commencing on May 15, 2021, and to increase Dr. Nash&#8217;s monthly base salary to $27,960 from $25,417. Effective March 15, 2022, the Company extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $29,358 per month (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). In connection with this extension, the Company made a one-time award to Dr. Nash of an option to purchase 75,000 shares of the Company&#8217;s common stock, which vests monthly commencing on April 10, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other terms of the Executive Chairman Agreement remain the same.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351963458944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Board of Directors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2022, the Company announced the appointment of Monika Maria T&#246;rns&#233;n as a member of the Board of Directors of the Company, effective as of July 5, 2022. As a Class III director, Ms. T&#246;rns&#233;n&#8217;s term lasts until the Company&#8217;s 2023 annual meeting of stockholders.  Ms. T&#246;rns&#233;n is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Ms. T&#246;rns&#233;n and any other persons pursuant to which she was selected as a director.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with her appointment as director, Ms. T&#246;rns&#233;n was granted a long-term equity incentive grant in the form of an option to purchase a total of 30,000 shares of the Company&#8217;s common stock, with an exercise price of $4.30 per share, which is equal to the closing price of the Company's common stock on The Nasdaq Stock Market on the date of grant, July 8, 2022. The option to purchase 10,000 shares vests in monthly increments over a period of one year from the grant date, and the option to purchase 20,000 shares vests in monthly increments over a period of three years from the grant date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Ms. T&#246;rns&#233;n and the Company entered into the Company&#8217;s standard form of indemnification agreement for directors and executive officers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently, the Company also announced that current Class III director, Jan Van den Bossche, resigned from the Board. The Board accepted Mr. Van den Bossche&#8217;s resignation effective July 5, 2022. Mr. Van den Bossche&#8217;s decision to resign did not result from any disagreement with the Company on any matter relating to Company operations, policies or practices.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351963538304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Research GmbH (which both began operations in 2016) and Immunic Australia Pty Ltd. (which began operations in 2018).  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. </span></div>Unaudited Interim Financial InformationImmunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed on February 24, 2022. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG and Immunic Research GmbH&#8217;s operations are located in Germany with the Euro being their functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</span></div>Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDU2MA_257586a5-1545-4cd3-af1d-02cb0660d644">three</span> to thirteen years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">When conducting the Company&#8217;s interim goodwill impairment assessment, we considered the Company&#8217;s history of reported losses and negative cash flows from operating activities, along with the downturn in macroeconomic conditions and the broader mid-cap and micro-cap equity markets in 2022. Given the relatively short period of time between the commencement of the downturn in macroeconomic and general equity market conditions as of June 30, 2022, management believes that the recent reduction in prices of our common stock, consistent with the broader market, is not other-than-temporary and not indicative of any fundamental change in the value or prospects of the underlying business as of the measurement date.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As another data point, the Company also performed a quantitative goodwill impairment analysis comparing the estimated fair value of the Company&#8217;s reporting unit to its carrying or book value as of the current period presented herein. In performing the quantitative analysis, the Company compared the fair value of the reporting unit to its carrying or book value to determine if the fair value of the reporting unit exceeded its carrying value as of the testing date, in which case the standard indicates that goodwill would not be impaired, and no further testing is required. The fair value of a reporting unit refers to the price that would be received to sell the reporting unit as a whole in an orderly transaction between market participants at the measurement date. Quoted market prices in active markets are considered to be the best evidence of fair value and should be used as the basis for fair value measurement, if available. When using quoted market prices to estimate the fair value of a reporting unit, we consider all available evidence. In certain circumstances, such as a distressed market, it may be appropriate to consider recent trends in the Company&#8217;s stock price, instead of a single day&#8217;s stock price in evaluating fair value. In these circumstances, averages over relatively short periods of time are used to determine representative market values.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the qualitative analysis and other data points described above,  the Company concluded that goodwill was not &#8220;more likely than not&#8221; impaired as of June 30, 2022.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described above, we have significant goodwill recorded on our consolidated balance sheets. We will continue to evaluate the recoverability of the carrying amount of goodwill on an ongoing basis. There can be no assurance that the outcome of such reviews in the future will not result in substantial impairment charges. Impairment assessment inherently involves judgment as to assumptions about expected future cash flows and the impact of market conditions on those assumptions. Future events and changing market conditions may impact our assumptions as to prices, costs, holding periods or other factors that may result in changes in our estimates of future cash flows. Although we believe the assumptions we used in testing for impairment are reasonable, significant changes in any one of our assumptions could produce a significantly different result. The  closing stock prices for our common stock subsequent to June 30, 2022, consistent with the broader market, have continued to trend downward. If the decline in our stock price persists throughout the three month period ending September 30, 2022, we will perform an interim goodwill impairment assessment as of September 30, 2022, consistent with the methodology and approach described above.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC, COVID-19, and PSC.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Arrangements</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of June 30, 2022 and 2021, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and/or Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351967756736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:73.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351963546208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets and Prepaid Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:74.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.255%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,745&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,741&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.740%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351967702144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Obligation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of June 30, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"/><td style="width:85.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.945%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351963398704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:50.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,241&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,241&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:50.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,630&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351967663568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Shares Reserved for Future Issuance</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at June 30, 2022 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;2021 Employee Stock Purchase Plan    </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,232,534&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351963493936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the six months ended June 30, 2022 and 2021, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:52.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,702,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,873)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,248&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127,085&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:52.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">961,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,064,839&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,022&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions Used</a></td>
<td class="text">The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six  Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.94</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.391%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>&#160;Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,263,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,131,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,086,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351964623056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">98 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>employee </div>
<div>program</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_NumberOfDevelopmentProgramsPursued', window );">Number of development programs | program</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 239,582<span></span>
</td>
<td class="nump">$ 196,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">299,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 88,078<span></span>
</td>
<td class="nump">$ 86,863<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfDevelopmentProgramsPursued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Development Programs Pursued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfDevelopmentProgramsPursued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351959458016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_LesseeOperatingLeasesNumberOfExistingLeases', window );">Number of existing leases | lease</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeasesNumberOfExistingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Leases, Number Of Existing Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeasesNumberOfExistingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351965332384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock ( in shares)</a></td>
<td class="nump">3,713,248<span></span>
</td>
<td class="nump">2,064,839<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351958834752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_PrepaidClinicalAndRelatedCostsCurrent', window );">Prepaid clinical and related costs</a></td>
<td class="nump">$ 11,895<span></span>
</td>
<td class="nump">$ 14,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT receivable</a></td>
<td class="nump">397<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_ResearchAndDevelopmentTaxIncentiveCurrent', window );">Australian research and development tax incentive</a></td>
<td class="nump">2,875<span></span>
</td>
<td class="nump">1,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">1,516<span></span>
</td>
<td class="nump">1,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 16,683<span></span>
</td>
<td class="nump">$ 18,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_PrepaidClinicalAndRelatedCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical And Related Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_PrepaidClinicalAndRelatedCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ResearchAndDevelopmentTaxIncentiveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Incentive, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ResearchAndDevelopmentTaxIncentiveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351963633072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accounts Payable (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_ClinicalCostsPayableCurrent', window );">Clinical costs</a></td>
<td class="nump">$ 3,807<span></span>
</td>
<td class="nump">$ 3,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_LegalAndAuditCostsPayableCurrent', window );">Legal and audit costs</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total</a></td>
<td class="nump">$ 4,117<span></span>
</td>
<td class="nump">$ 3,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ClinicalCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ClinicalCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LegalAndAuditCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal And Audit Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LegalAndAuditCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351965250560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_AccruedClinicalCostsCurrent', window );">Accrued clinical and related costs</a></td>
<td class="nump">$ 4,974<span></span>
</td>
<td class="nump">$ 6,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_AccruedLegalAndAuditCostsCurrent', window );">Accrued legal and audit costs</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">608<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 5,741<span></span>
</td>
<td class="nump">$ 7,071<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedClinicalCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedClinicalCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Compensation, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedLegalAndAuditCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal And Audit Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedLegalAndAuditCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351959443840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">$ 366<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 544<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease, liability, current, statement of financial position</a></td>
<td class="text">Total<span></span>
</td>
<td class="text">Total<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351959050240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 07, 2020</div></th>
<th class="th"><div>Apr. 12, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_OperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate on operating leases (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_OperatingAndVariableLeasesCost', window );">Operating and variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales', window );">Asset purchase agreement, royalties as percent of aggregated net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_RoyaltySettlementAgreementSalesNet', window );">4SC royalty settlement (see Note 4)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 17,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=vtl_ImmunicAGMember', window );">Immunic AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales', window );">Asset purchase agreement, royalties as percent of aggregated net sales (as a percent)</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_RoyaltySettlementAgreementSalesNet', window );">4SC royalty settlement (see Note 4)</a></td>
<td class="nump">$ 17,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_RoyaltySettlementAgreementCashPaymentPercent', window );">Royalty settlement agreement, cash payment (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_RoyaltySettlementAgreementSharesPaymentPercent', window );">Royalty settlement agreement, shares payment (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember', window );">Grafelfing, Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Additions to right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_NewYorkCityMember', window );">New York City</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_LesseeOperatingLeaseRentHolidayPeriod', window );">Rent holiday period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeaseRentHolidayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Rent Holiday Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeaseRentHolidayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_OperatingAndVariableLeasesCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Variable Leases, Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_OperatingAndVariableLeasesCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_OperatingLeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_OperatingLeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_RoyaltySettlementAgreementCashPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Settlement Agreement, Cash Payment, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_RoyaltySettlementAgreementCashPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_RoyaltySettlementAgreementSalesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Settlement Agreement, Sales Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_RoyaltySettlementAgreementSalesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_RoyaltySettlementAgreementSharesPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Settlement Agreement, Shares Payment, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_RoyaltySettlementAgreementSharesPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=vtl_ImmunicAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=vtl_ImmunicAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_NewYorkCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_NewYorkCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351963453920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">PV of obligation</a></td>
<td class="nump">$ 767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351965296080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 63,241<span></span>
</td>
<td class="nump">$ 31,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">63,241<span></span>
</td>
<td class="nump">31,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">63,241<span></span>
</td>
<td class="nump">31,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">63,241<span></span>
</td>
<td class="nump">31,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351959208272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Shelf Registration Statement (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 05, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of securities under shelf registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock', window );">Commission, percent of gross proceeds from sale of common stock (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_ShelfRegistrationStatementAmountRemaining', window );">Shelf registration statement, amount remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember', window );">December 2020 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of securities under shelf registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice', window );">Shelf registration, termination, prior written notice | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,204,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_SharesIssuedWeightedAverageSharePricePerShare', window );">Issuance of stock (in USD per share) | $ / shares</a></td>
<td class="nump">$ 7.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Underwriter commissions</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember', window );">December 2020 ATM | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_SaleOfStockRemainingCapacity', window );">Sale of stock, remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember', window );">May 2022 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of securities under shelf registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice', window );">Shelf registration, termination, prior written notice | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_SaleOfStockRemainingCapacity', window );">Sale of stock, remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Aggregate Offering Price Of Securities Under Shelf Registration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SaleOfStockRemainingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SaleOfStockRemainingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SharesIssuedWeightedAverageSharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Weighted Average Share Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SharesIssuedWeightedAverageSharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationStatementAmountRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Statement, Amount Remaining</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationStatementAmountRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration, Termination, Prior Written Notice</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationTerminationPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351958935328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, cash dividends declared (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, cash dividends paid (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351965224304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351965495424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Shares Reserved for Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">4,232,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">3,713,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan | Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">162,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan | Common stock options available for future grant:</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">43,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember', window );">2017 Inducement Equity Incentive Plan | Common stock options available for future grant:</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Common stock options available for future grant:</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">267,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351958336688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">14 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2021</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which compensation cost will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Purchase price of the stock, at discount from market price at purchase date (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember', window );">2019 Omnibus Equity Incentive Plan, Evergreen Provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent', window );">Additional shares authorized (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,481,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember', window );">2017 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtl_IncentiveEmployeeStockOptionMember', window );">Incentive stock options | 2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Non-statutory options | 2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Non-statutory options | 2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_IncentiveEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_IncentiveEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_NonStatutoryEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_NonStatutoryEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351965414400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Summary of Stock Option Activity (Details) - 2019 Omnibus Equity Incentive Plan - Outstanding stock options - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">2,157,460<span></span>
</td>
<td class="nump">1,117,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,702,513<span></span>
</td>
<td class="nump">961,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(852)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(145,873)<span></span>
</td>
<td class="num">(13,380)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">3,713,248<span></span>
</td>
<td class="nump">2,064,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest, Ending balance (in shares)</a></td>
<td class="nump">3,713,248<span></span>
</td>
<td class="nump">2,064,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, Ending balance (in shares)</a></td>
<td class="nump">1,127,085<span></span>
</td>
<td class="nump">462,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (usd per share)</a></td>
<td class="nump">$ 13.54<span></span>
</td>
<td class="nump">$ 12.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="nump">9.29<span></span>
</td>
<td class="nump">15.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="nump">5.67<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (usd per share)</a></td>
<td class="nump">11.88<span></span>
</td>
<td class="nump">12.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (usd per share)</a></td>
<td class="nump">11.66<span></span>
</td>
<td class="nump">14.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest, Weighted-Average Exercise Price, Ending balance (usd per share)</a></td>
<td class="nump">11.66<span></span>
</td>
<td class="nump">14.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, Weighted-Average Exercise Price, Ending balance (usd per share)</a></td>
<td class="nump">$ 13.83<span></span>
</td>
<td class="nump">$ 13.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">8 years 10 months 9 days<span></span>
</td>
<td class="text">9 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">8 years 10 months 9 days<span></span>
</td>
<td class="text">9 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">8 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 23,870<span></span>
</td>
<td class="nump">$ 411,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">23,870<span></span>
</td>
<td class="nump">411,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 227,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351958927280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted in period, weighted-average grant date fair value (in USD per share)</a></td>
<td class="nump">$ 7.25<span></span>
</td>
<td class="nump">$ 11.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">97.90%<span></span>
</td>
<td class="nump">92.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351963661488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,131<span></span>
</td>
<td class="nump">$ 3,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,062,000<span></span>
</td>
<td class="nump">$ 1,507,000<span></span>
</td>
<td class="nump">4,131,000<span></span>
</td>
<td class="nump">3,086,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">765,000<span></span>
</td>
<td class="nump">492,000<span></span>
</td>
<td class="nump">1,561,000<span></span>
</td>
<td class="nump">823,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees | General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,297,000<span></span>
</td>
<td class="nump">$ 1,015,000<span></span>
</td>
<td class="nump">$ 2,570,000<span></span>
</td>
<td class="nump">$ 2,263,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vtl_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351959178016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - Executive Chairman Agreement - Affiliated Entity - Duane Nash, MD, JD, MBA - Board of Directors Chairman - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 15, 2022</div></th>
<th class="th"><div>Apr. 15, 2021</div></th>
<th class="th"><div>May 14, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_SalaryCostsMonthlyBaseSalary', window );">Monthly base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,417<span></span>
</td>
<td class="nump">$ 27,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=vtl_ExecutiveChairmanAgreementMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vtl_SalaryCostsMonthlyBaseSalary', window );">Monthly base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SalaryCostsMonthlyBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Salary Costs, Monthly Base Salary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SalaryCostsMonthlyBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=vtl_ExecutiveChairmanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=vtl_ExecutiveChairmanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140351958642528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event - Director<br> shares in Thousands</strong></div></th>
<th class="th">
<div>Jul. 06, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted in period, weighted-average grant date fair value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 4.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Options Vesting In One Year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Options Vesting In Three Years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_OptionsVestingInOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_OptionsVestingInOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_OptionsVestingInThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_OptionsVestingInThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>vtl-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vtl="http://vitaltherapies.com/20220630"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vtl-20220630.xsd" xlink:type="simple"/>
    <context id="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id01675085b9d47cfa6a56a99e63d5f56_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0947672575364c46afe56198033d6c85_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic4fb55fd2ef8427d80a634661f1773b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e90af7dc9ef4a6c9069acdbb42eae07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i383623f0307f4b9d96b57d1489b5600c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a7559d9f82448c8987eae81fa4ec3ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic96897f104fb48d78ee6473de6c83c97_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9608caccfcbc4563859345eaa9991b07_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i076950ee40df42d89a5d26ba9bf6795d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i465c366ef51f4b189565cac81dffddbe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i75532eaec46d443bbf4be7aca9794114_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i495588de7e354f81b29f181b399ebdba_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf34bda03a394ba8a77214d6b3305235_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i121e4a3cffdb4f6fbed73a792bf1b69e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i961bd468dc6e4b2085750c3208bb55f3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2f74c7f405464d128cc5abb31ca4304c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7a5095123e1441ce8ab5b195e2a7381e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i290eaed6709c4900870088935dc57a9c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia63039ccf15b40d4b5364ae7c9bf408a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i02e09f06bafe421b9a79431f6587dd3f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9aa74dec5d9242b787918ed1421800d6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i85c7a5aa8a4246d0b7f7f081825bb773_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iba1820fc164b4f9bac61e09fc44afa8b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5159f770ea0f4a9497673433e3e78293_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie3074803226e47ebb7c58a8d15c07885_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i10c1446033584b39a0f7674b22567b72_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i24615a42f1564951b37f6e0d11cdb4d2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iac6c3453adbd4c6dafb2f21387665bff_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie3b20273750b4a70831e7df55a20101e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7bbd2fff93de403e844b1b5d38504e4c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i640e715a3f0c4def9b0d868c1d6092b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d857c13ffa547129b4b709b775b0c0c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3b3eff571ab4389b83a686f38bf0009_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2320639dc1b945fb806ec94ec779e328_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a4772f1271c40e191e770ac6d61d1dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72df3680356349e7bfa91bda10e3f3f7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib2fb388e8881440ea3a00a25cd305aca_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id83cbae3a80f4486b48792aefcc6aa84_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i819b55b7eb0b41cb872b2a55a28511a4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i302f3eed4b894be3bfb581b012217fa7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:A4SCRoyaltySettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia25252f765c54d26893666d4b8a4b6d1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:A4SCRoyaltySettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7cff2d4dae0141d7a9400429428808cb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:A4SCRoyaltySettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i06b0939acbbd4016a2017d08bbc14611_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id40c3cee4b0a4933a0d3743284b8b9bb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if6038f471ebd492dacb91545b0bd1204_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib888b4c6dea340ddac2a5f3d0444fb01_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7e6c3ba533a04a6d9765af14c3539988_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie94d2d5ea505442cbfb5b9f4af2174cb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i273c8f6ffe2d4bae939069532f577216_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaf514b4446b646f2969c39b9e0c88824_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2addead69d9548889d3828a4cf706290_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4d825e45e7c948c9b4d93eb5be9afd4c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie7d44abdaa9d4db2a3c8a5442cead68d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0f57bfb4d140406a809324570a0730bb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5539c23cb2e040f787397c935b00dc96_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2d116a4fcc3e4f2aab94d415e3453a5a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id2540362a6b449a9988c08de956ec7c7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id28377b56621409b831d879cd0e930a4_D20140417-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2014-04-17</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifd8c52afb34d445d83af15ec3dbddf0b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3ad392238f03492fb9409e9edf57a05e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9e8992acd92c4178a465c433d46d5797_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8745b84aae60434e9b96daf94cfac93a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i58796c8360524abb862423e11c8db6ad_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idcfd1b5059be473ca463b8dfc127debf_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8851c67679bf4084b6bf5354695ad9d2_I20200407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-07</instant>
        </period>
    </context>
    <context id="idfa9e23428124c2486f4015b0a2d6c95_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0900a41bd91a4900bd798f3276eb85bb_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic0596eac93474ba595e10a41ccb463c3_D20160501-20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="ic822612a93bf4322a15f67ee66c0e1ea_I20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2019-04-12</instant>
        </period>
    </context>
    <context id="i0ac3802756644803be0171f1cae2cca5_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtl:ImmunicAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6e183777c2784361bb1f6d43969d764e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">vtl:ImmunicAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if619c407624b4922b1afa2e57a9ff01a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie0e026c775ec49f9861b7f0d7ef051f1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaf678ced37ba47f7910be49d8d28b9e7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3bf2a21a1b3143b9a9bb2e50c90d5ad2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i01049530b3a04055a71bdcbd2ddb098f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i91585558cbe34e778b4f5fbf7b1c8daa_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia8722bc2bc004244be18e6327d5c0084_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i848040a12f93446e94b293d803e3ba3e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i900fc28b42424c17b00cd3ca859d30a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd253af90c7049ba9afdf7bd8778d934_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee4d595729674eff99b3ca2ca86c0b7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e62c8bbfe554143bcfccd623eef0f68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee62d52d680b41dba637ae523465d27e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fcb0abe6f0749babe8150c967988400_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9a91903ca2a4ad0b30d85fb1a845075_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8557ddef2d144928039c8fb2320084e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib934db459d0f41d6983debfc2a9bb490_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i655d008592954266b8c505297b7e326a_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="if084565ea6544630b40bf38bc6aa362c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5357132f62b84045b8592c18e2fa2958_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i84614fc2f3a34f45abbfe8caa4cc2f8c_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="iaab1b036d9dc44e98547c47688f3775e_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i2b29f09bbaba4becbebde67f5b01a643_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i31e27d1c40d042c8a3fc68107417bf24_I20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="i77bff47627ab4656a7df6dfe32e589aa_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0f1bda4b5eb14655844a6f52d4e19aeb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i42f6581040da46739944cde97b521f6f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibc9159032004498fb16925e81f722e24_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia5fb46bdccd14b0bb258e8b0caf6b17a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if73baf845ed84292a90be900622c8546_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3a7be395eedf4ec7b90be1d1cc54a7f4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7a36d78c3a1d41aabc3bc530c7149510_D20210425-20210425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-25</startDate>
            <endDate>2021-04-25</endDate>
        </period>
    </context>
    <context id="id4759bb9bc5548028846f27721d451dd_I20210425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-25</instant>
        </period>
    </context>
    <context id="ic41959aa4a854ce99c1ae76d7e539c7b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie3846e4b177145349132e464e8ead06e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7a60641c12434b9d9746366fd13f9c6a_D20210425-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-25</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i331baf434b944eed8f84aac672fd3fba_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i4743858c51494178bb0a0087929cf1ca_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i78621ec446654b619edd9f1c7ddbbfdb_D20200101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i241a45995e6d46d2b52b33a2b6d06c7f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9f6c4820198d4fcbbd17c0e25cf2af03_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4afb1db82db3489ca373a267e6b8630c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1175a630abb249cba6da4df17900b2f3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic25815c038244077a908eacfe7cdb746_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9c548edb791d48468aecdf5a3211e335_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib0e20fcc653c40a39665c834b098509d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93a9137d93f44392b7470a9982635184_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaa2a1c898f234b2da41f85403f50c9d6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie44b429d3b05430ea58a4793c8c7b0ed_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5d31dbd295f24c42bfabd2db4c4c9f38_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibc512c7aab944fc485311bf9c02ff970_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3a4ddd497fd542b9b3fd027648d47f75_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8e71423082664f22b47833b74742032b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic2bea17fde984023989bd83f8d7409d3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i647b4b4c351941fe967436ca5d55ac90_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8d7bda77d8e54df095211d496fde1e19_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i780a02233b614aad8fc86df96172eeb7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6be40b2c9d674c08af4179c7ed347d3e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibbabe7452d5d43f6b73995f3e391e6b8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i26a9bf6e1992474bbccdbdce509a8df2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2dd13b02f4a346ca9385ff8f54ab0d4c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i23ce68a8dc964e0992d506ff2d9b8074_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib42e39df400b422a95c9c1d1cd93fae5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i12cdbd33c3434c698ad8b49490ad01ef_I20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="i679e236a84ee4593a0aed89cb7edadf1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic40354f16dc842a1a88ac97efa9f06d6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibb4ae9a6beec4eae8fa5eb08ddd32a03_D20210415-20210415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-15</startDate>
            <endDate>2021-04-15</endDate>
        </period>
    </context>
    <context id="if42ab5585116465fbf465ea6f59165fe_D20210515-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-15</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaabe57dcd0314a53bb5425c2259aeed2_D20210101-20210514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-05-14</endDate>
        </period>
    </context>
    <context id="i9a5888f9828e4ffcb2ca6bbe78a31e05_D20220315-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-15</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie57caaa75a5a464083b4f824217dc1e7_D20220315-20220315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-15</startDate>
            <endDate>2022-03-15</endDate>
        </period>
    </context>
    <context id="ifdfa66f7711347ab96273868fd75f343_D20220706-20220706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-06</startDate>
            <endDate>2022-07-06</endDate>
        </period>
    </context>
    <context id="i8de1a675bd3646b6b25adee3e85cab4c_D20220706-20220706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:OptionsVestingInOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-06</startDate>
            <endDate>2022-07-06</endDate>
        </period>
    </context>
    <context id="ib73002cd7def4d70a33e0dbcb20c34ff_D20220706-20220706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:OptionsVestingInThreeYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-06</startDate>
            <endDate>2022-07-06</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>vtl:employee</measure>
    </unit>
    <unit id="program">
        <measure>vtl:program</measure>
    </unit>
    <unit id="lease">
        <measure>vtl:lease</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80L2ZyYWc6ODJhOWQwZTkyYjM5NDFjMTkzYmMzNTZiMDE5MTBkY2UvdGFibGU6Njg4ODAwMDFlNDMzNGU1NTg2Mzc4YmZlOTM2ZDMxNDUvdGFibGVyYW5nZTo2ODg4MDAwMWU0MzM0ZTU1ODYzNzhiZmU5MzZkMzE0NV8yLTEtMS0xLTI2ODkx_40aa48bf-a443-47e9-9185-e39b088b5df8">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80L2ZyYWc6ODJhOWQwZTkyYjM5NDFjMTkzYmMzNTZiMDE5MTBkY2UvdGFibGU6Njg4ODAwMDFlNDMzNGU1NTg2Mzc4YmZlOTM2ZDMxNDUvdGFibGVyYW5nZTo2ODg4MDAwMWU0MzM0ZTU1ODYzNzhiZmU5MzZkMzE0NV8zLTEtMS0xLTI2ODkx_9853189f-4a07-4242-9e16-11c0db11382e">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80L2ZyYWc6ODJhOWQwZTkyYjM5NDFjMTkzYmMzNTZiMDE5MTBkY2UvdGFibGU6Njg4ODAwMDFlNDMzNGU1NTg2Mzc4YmZlOTM2ZDMxNDUvdGFibGVyYW5nZTo2ODg4MDAwMWU0MzM0ZTU1ODYzNzhiZmU5MzZkMzE0NV80LTEtMS0xLTI2ODkx_12830e5b-1fbd-4005-9339-4e2ea2754006">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80L2ZyYWc6ODJhOWQwZTkyYjM5NDFjMTkzYmMzNTZiMDE5MTBkY2UvdGV4dHJlZ2lvbjo4MmE5ZDBlOTJiMzk0MWMxOTNiYzM1NmIwMTkxMGRjZV8zOA_3aa42a89-3535-4e0c-bec7-ba9546a8974a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80L2ZyYWc6ODJhOWQwZTkyYjM5NDFjMTkzYmMzNTZiMDE5MTBkY2UvdGV4dHJlZ2lvbjo4MmE5ZDBlOTJiMzk0MWMxOTNiYzM1NmIwMTkxMGRjZV82Nw_bf772137-75e4-4275-ad47-489e3abcace7">0001280776</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ifd8c52afb34d445d83af15ec3dbddf0b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDU2MA_257586a5-1545-4cd3-af1d-02cb0660d644">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfMjE5OTAyMzI1NjI5MA_3d8ceb1b-3c21-469b-880e-2ea581b8f112">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfMjE5OTAyMzI1NjI5MA_f85fe492-0c02-4937-8946-c1829a42d290">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4afb1db82db3489ca373a267e6b8630c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI1Mzg0_7a7a7119-e170-4cdf-8081-4d8911387b29">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF84Mw_b9b9078b-f4de-45b3-9aee-6cc34686e302">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MWZkNzUwNDhlNTE5NDg5N2JiM2U1MzJmZmMyZGQxZmUvdGFibGVyYW5nZToxZmQ3NTA0OGU1MTk0ODk3YmIzZTUzMmZmYzJkZDFmZV8wLTAtMS0xLTI2ODkx_f7bb5ad4-7e87-471d-a653-e7c9c42c4bcd">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8xMzI_5dbaa63e-e0ac-4e68-be24-bc8c7bf2475e">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6YWJjYjIwNzE1YzJjNGY4NmExNzA2MDg0ODU0YTI2NmQvdGFibGVyYW5nZTphYmNiMjA3MTVjMmM0Zjg2YTE3MDYwODQ4NTRhMjY2ZF8wLTAtMS0xLTI2ODkx_684bfa34-1ca4-40f6-8c1f-5431700ba44a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8yNDA_4c77572d-6d5b-4d71-b78d-94bc598cd7a7">001-36201</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8yNDU_682b2489-097a-4019-bacb-7644eca81649">Immunic, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MzQ2M2E1M2FjYjY3NGJkYjllZmJkYTNhNDgzOWVhOGUvdGFibGVyYW5nZTozNDYzYTUzYWNiNjc0YmRiOWVmYmRhM2E0ODM5ZWE4ZV8wLTAtMS0xLTI2ODkx_d88aff92-0561-4694-884d-31d5e38c2a52">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MzQ2M2E1M2FjYjY3NGJkYjllZmJkYTNhNDgzOWVhOGUvdGFibGVyYW5nZTozNDYzYTUzYWNiNjc0YmRiOWVmYmRhM2E0ODM5ZWE4ZV8wLTItMS0xLTI2ODkx_225e6e45-b3d9-46a4-9953-4911967d8334">56-2358443</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MzQ2M2E1M2FjYjY3NGJkYjllZmJkYTNhNDgzOWVhOGUvdGFibGVyYW5nZTozNDYzYTUzYWNiNjc0YmRiOWVmYmRhM2E0ODM5ZWE4ZV8zLTAtMS0xLTI2ODkx_05fcf09a-f103-4b34-b845-48da1d7bf025">1200 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MzQ2M2E1M2FjYjY3NGJkYjllZmJkYTNhNDgzOWVhOGUvdGFibGVyYW5nZTozNDYzYTUzYWNiNjc0YmRiOWVmYmRhM2E0ODM5ZWE4ZV80LTAtMS0xLTI2ODkx_892217c4-556d-4d26-a006-382ae57693c1">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MzQ2M2E1M2FjYjY3NGJkYjllZmJkYTNhNDgzOWVhOGUvdGFibGVyYW5nZTozNDYzYTUzYWNiNjc0YmRiOWVmYmRhM2E0ODM5ZWE4ZV81LTAtMS0xLTI2ODkx_b1a5c2c3-ecb4-430c-b460-7fe33409a0bc">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MzQ2M2E1M2FjYjY3NGJkYjllZmJkYTNhNDgzOWVhOGUvdGFibGVyYW5nZTozNDYzYTUzYWNiNjc0YmRiOWVmYmRhM2E0ODM5ZWE4ZV81LTEtMS0xLTI2ODkx_47b8e44f-0a24-4229-ac3c-78425d6e0943">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6MzQ2M2E1M2FjYjY3NGJkYjllZmJkYTNhNDgzOWVhOGUvdGFibGVyYW5nZTozNDYzYTUzYWNiNjc0YmRiOWVmYmRhM2E0ODM5ZWE4ZV81LTItMS0xLTI2ODkx_6b5a56f7-a79f-44a0-94d7-57af845a0a1f">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8xOTY0_f73a0be9-faaf-45c4-8e6b-bee81a2c7997">332</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8xOTY1_7bb51ab7-37cc-4b21-a436-c042251ad2c7">255-9818</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6NThkNTMyOWE2OTVlNGRjNGIzYjVlYTQ0MTQxZTRkNjcvdGFibGVyYW5nZTo1OGQ1MzI5YTY5NWU0ZGM0YjNiNWVhNDQxNDFlNGQ2N18xLTAtMS0xLTI2ODkx_e3363439-1c6c-4d48-bc93-636d6327ba80">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6NThkNTMyOWE2OTVlNGRjNGIzYjVlYTQ0MTQxZTRkNjcvdGFibGVyYW5nZTo1OGQ1MzI5YTY5NWU0ZGM0YjNiNWVhNDQxNDFlNGQ2N18xLTEtMS0xLTI2ODkx_ca7424f3-4cc9-4947-959a-400bff7a363b">IMUX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6NThkNTMyOWE2OTVlNGRjNGIzYjVlYTQ0MTQxZTRkNjcvdGFibGVyYW5nZTo1OGQ1MzI5YTY5NWU0ZGM0YjNiNWVhNDQxNDFlNGQ2N18xLTItMS0xLTI2ODkx_f8a88980-b1af-4171-abde-5e9814f3bd37">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF83ODk_cd406666-cb51-4ca7-a6e1-d0522d6b19ae">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8xMTI2_080f5b96-a1c6-4443-bdb7-a2f009a55666">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6NGU1MTBmZTcwNzczNDRjZWFiYjgwNTc0YjRjN2YzYTgvdGFibGVyYW5nZTo0ZTUxMGZlNzA3NzM0NGNlYWJiODA1NzRiNGM3ZjNhOF8yLTAtMS0xLTI2ODkx_49fef7e4-7510-4254-bb23-7dca25e74ae9">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6NGU1MTBmZTcwNzczNDRjZWFiYjgwNTc0YjRjN2YzYTgvdGFibGVyYW5nZTo0ZTUxMGZlNzA3NzM0NGNlYWJiODA1NzRiNGM3ZjNhOF8yLTMtMS0xLTI2ODkx_ce9a1484-d27b-42ce-adc2-7e36d54f7b25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGFibGU6NGU1MTBmZTcwNzczNDRjZWFiYjgwNTc0YjRjN2YzYTgvdGFibGVyYW5nZTo0ZTUxMGZlNzA3NzM0NGNlYWJiODA1NzRiNGM3ZjNhOF80LTMtMS0xLTI2ODkx_0e1cce1a-06b2-4342-b227-421a720f1ef9">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8xODcw_671a65e7-f18d-4ab6-bc58-c69318b5e030">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id01675085b9d47cfa6a56a99e63d5f56_I20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xL2ZyYWc6MDEyNGIxZDZlNDEyNDczMmE5NDk5NWUzMWFlODllMzQvdGV4dHJlZ2lvbjowMTI0YjFkNmU0MTI0NzMyYTk0OTk1ZTMxYWU4OWUzNF8xOTAw_4ef60ff0-2c9c-46a2-aa2f-52777848254d"
      unitRef="shares">30564995</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNC0xLTEtMS0yNjg5MQ_bd879333-9035-43cd-8287-4af5297a2b08"
      unitRef="usd">88078000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNC0zLTEtMS0yNjg5MQ_ca27a4d6-f1a5-4859-822c-91be1577f595"
      unitRef="usd">86863000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNS0xLTEtMS0yNjg5MQ_c7bf18e2-201a-445f-952e-722c5a691664"
      unitRef="usd">16683000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNS0zLTEtMS0yNjg5MQ_912e30a1-9ecd-41dc-99d0-464d30569ea9"
      unitRef="usd">18125000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNi0xLTEtMS0yNjg5MQ_d4573743-295b-4d80-a0cf-4a700aaf3d7a"
      unitRef="usd">104761000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNi0zLTEtMS0yNjg5MQ_edf659e2-7d8d-4add-b18e-c85e44aa0eba"
      unitRef="usd">104988000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNy0xLTEtMS0yNjg5MQ_a2f9d841-3863-4053-afad-beffa76cfa3e"
      unitRef="usd">139000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfNy0zLTEtMS0yNjg5MQ_eb840058-e6b7-4919-912d-b270e81195f0"
      unitRef="usd">152000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfOC0xLTEtMS0yNjg5MQ_fbb13026-855a-4372-9057-4d83c64f8a81"
      unitRef="usd">32970000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfOC0zLTEtMS0yNjg5MQ_a20534d1-5f7f-4d86-84ff-1fb99cfa322f"
      unitRef="usd">32970000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfOS0xLTEtMS0yNjg5MQ_c273cb5d-7389-4ca5-a840-a617b6c88f1d"
      unitRef="usd">745000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfOS0zLTEtMS0yNjg5MQ_ea5c98a7-f018-476e-8669-4b4b2537643f"
      unitRef="usd">948000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTAtMS0xLTEtMjY4OTE_8a7998ee-e79a-4618-9a7b-f8e61af0b484"
      unitRef="usd">42000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTAtMy0xLTEtMjY4OTE_98a7d291-228c-4165-ba48-4dd44fc4255e"
      unitRef="usd">42000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTEtMS0xLTEtMjY4OTE_270ca0bc-b3b7-4198-b63d-ca0c62748c01"
      unitRef="usd">138657000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTEtMy0xLTEtMjY4OTE_f384b8c3-fd83-465a-94d3-6ae59113b2b2"
      unitRef="usd">139100000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTQtMS0xLTEtMjY4OTE_543f72cc-1977-471f-b608-68605287becd"
      unitRef="usd">4117000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTQtMy0xLTEtMjY4OTE_53ca381d-8eea-485b-b826-23fc097aa2cb"
      unitRef="usd">3745000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTUtMS0xLTEtMjY4OTE_2314997f-a00a-48b4-a746-5e24699e3e08"
      unitRef="usd">5741000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTUtMy0xLTEtMjY4OTE_c196e74f-b4dc-45d2-ac32-7c48d3757588"
      unitRef="usd">7071000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTYtMS0xLTEtMjY4OTE_4b6a2579-5188-49b7-b7b5-f67f05c7fd08"
      unitRef="usd">544000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTYtMy0xLTEtMjY4OTE_e5b58f54-bf07-49e4-9b67-2dcf1e41ab53"
      unitRef="usd">585000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTctMS0xLTEtMjY4OTE_9b21b5b6-3995-4fc5-b415-45cbc20e9993"
      unitRef="usd">10402000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTctMy0xLTEtMjY4OTE_d2a1c57a-b2bb-41de-a24a-206f10b6d5c5"
      unitRef="usd">11401000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTktMS0xLTEtMjY4OTE_43a30272-5559-4b1e-ae75-0419f7a4d358"
      unitRef="usd">407000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMTktMy0xLTEtMjY4OTE_1d1c3fa0-caaa-469d-b8d8-db53233ad9e8"
      unitRef="usd">584000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjAtMS0xLTEtMjY4OTE_dabcf1de-3e76-416a-9b64-0f0fa501cc5d"
      unitRef="usd">407000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjAtMy0xLTEtMjY4OTE_fd2c344e-7883-458f-91fc-9f96db291e64"
      unitRef="usd">584000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjEtMS0xLTEtMjY4OTE_6d758824-5c0b-43b5-b321-3d15007ffec8"
      unitRef="usd">10809000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjEtMy0xLTEtMjY4OTE_aadf5e52-e9b3-4895-9836-7a6a782551a2"
      unitRef="usd">11985000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjItMS0xLTEtMjY4OTE_3f2f2460-b623-42db-b639-bd7743caf685"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjItMy0xLTEtMjY4OTE_918d878b-8e4f-47a0-92eb-82b0525db712"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzEx_20bce812-22ca-4ce1-bc5f-5582fc293970"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzEx_ec28c54e-8b0a-49b8-b94e-fbf06885a171"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzAx_0d1a0723-f818-4d96-b263-a3a5310145c8"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzAx_3ee5b529-538c-46f8-b1d9-17883cea98ec"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzE2_0eea3ce3-3947-49dc-ad20-6898c5d853dd"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzE2_15eb8202-6e79-4a62-83a9-e5673ea9248b"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzE2_4d4efef0-51ea-4d03-960a-ec8d43380969"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjo5YjZkY2JlMWI4NTA0M2YyYjFlYWUyMWExYzZlYmU2OV8yMTk5MDIzMjU1NzE2_7ef31782-feb5-4e19-a1e0-63f9d4a98849"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMS0xLTEtMjY4OTE_32205f7d-9163-4738-b95f-3608f388cae3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjQtMy0xLTEtMjY4OTE_bfc29858-8de9-44cd-95f7-8b087d394ea8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1NzQx_4f8f7905-c31a-49f3-9666-77079730d68c"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1NzQx_fba6a383-0ed6-4e0a-b2a0-53fba0e87694"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1NzU1_5a5a147e-7a28-4930-860f-14e2173d537f"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1NzU1_7f8ff03c-d2bf-424b-8954-f1c14a47eedc"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1NzY4_4063f0c7-692d-4f4d-a680-7cbbbeb87800"
      unitRef="shares">30564995</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1NzY4_8fa408a7-8c06-4a20-b2cd-20bfb0590190"
      unitRef="shares">30564995</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1Nzgx_0d33ae19-d5dc-412e-ae98-08ec305fc4b6"
      unitRef="shares">26335418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMC0xLTEtMjY4OTEvdGV4dHJlZ2lvbjowZjIyMDk0MTYzOGE0NzlmOWMzZjdiZjk1MmQyOTQyZV8yMTk5MDIzMjU1Nzgx_3e1a864d-f080-428a-90cd-7d646932bb1a"
      unitRef="shares">26335418</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMS0xLTEtMjY4OTE_a6ab8f48-1e7e-46bb-a779-86323a4c9f4c"
      unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjUtMy0xLTEtMjY4OTE_cb085ce4-4ea4-4210-95eb-dde15ac7fb99"
      unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjYtMS0xLTEtMjY4OTE_07f431de-52ed-4809-9912-9f822409bb94"
      unitRef="usd">368087000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjYtMy0xLTEtMjY4OTE_0787ef0c-0404-4ffb-a1a5-bac438c20b3d"
      unitRef="usd">324237000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjctMS0xLTEtMjY4OTE_7f45fc2f-f715-47f9-b475-9b1808d592fa"
      unitRef="usd">-660000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjctMy0xLTEtMjY4OTE_e2383212-c631-4037-a57d-df4042a6a4e9"
      unitRef="usd">-252000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjgtMS0xLTEtMjY4OTE_d33fd4d6-fd59-45d0-ab54-f0a17ba4b461"
      unitRef="usd">-239582000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjgtMy0xLTEtMjY4OTE_fc4cb686-134b-42d3-b839-484afbd87b62"
      unitRef="usd">-196873000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjktMS0xLTEtMjY4OTE_897aed52-c7f6-4d29-b945-71be980dd7c9"
      unitRef="usd">127848000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMjktMy0xLTEtMjY4OTE_071242b8-800a-4da8-a0d4-131c184b2e18"
      unitRef="usd">127115000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMzAtMS0xLTEtMjY4OTE_cc1da695-89d3-45a0-88dd-b304b7f0e02c"
      unitRef="usd">138657000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMC9mcmFnOjY4NjgyNDZiNjlkMzRhODY5OWZlMDI4YzA4MmJiNzE5L3RhYmxlOjdhYTI0NzRkYjQ1ZDRhMWZiYjAyMGI0ZGJmMmUxYzhlL3RhYmxlcmFuZ2U6N2FhMjQ3NGRiNDVkNGExZmJiMDIwYjRkYmYyZTFjOGVfMzAtMy0xLTEtMjY4OTE_baafb126-e355-4f6c-bbfb-8b18fc50a904"
      unitRef="usd">139100000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMy01LTEtMS0yNjg5MQ_0aa69ffc-002c-4153-8a5f-cd12754a0c3b"
      unitRef="usd">16538000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMy03LTEtMS0yNjg5MQ_96f9b648-c4d8-4558-aaca-cf8764a22dc6"
      unitRef="usd">15738000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMy05LTEtMS0yNjg5MQ_ba6a8ca9-1e3b-49e6-a5be-100e92dbffff"
      unitRef="usd">33983000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMy0xMS0xLTEtMjY4OTE_8af10435-9faf-4804-a158-0a307a32ebd4"
      unitRef="usd">27257000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNC01LTEtMS0yNjg5MQ_defaf8a9-0623-42f8-bb33-07013cce4105"
      unitRef="usd">4072000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNC03LTEtMS0yNjg5MQ_6ded3e4f-d958-4a08-b820-79cd1ac38768"
      unitRef="usd">3432000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNC05LTEtMS0yNjg5MQ_cb852271-750d-4b36-8e60-f9b7427e0612"
      unitRef="usd">8062000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNC0xMS0xLTEtMjY4OTE_6132896a-ba1c-47ba-bbdc-6015a3900832"
      unitRef="usd">7050000</us-gaap:GeneralAndAdministrativeExpense>
    <vtl:RoyaltySettlementAgreementSalesNet
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNS01LTEtMS0yNjg5MQ_7471402d-809d-463d-8c9f-0c78c29eabdb"
      unitRef="usd">0</vtl:RoyaltySettlementAgreementSalesNet>
    <vtl:RoyaltySettlementAgreementSalesNet
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNS03LTEtMS0yNjg5MQ_fb6eaecd-0b81-4502-b12e-20348ad1d1f3"
      unitRef="usd">0</vtl:RoyaltySettlementAgreementSalesNet>
    <vtl:RoyaltySettlementAgreementSalesNet
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNS05LTEtMS0yNjg5MQ_f4ac1ebf-3945-4453-8c8a-49a6c3b1fc54"
      unitRef="usd">0</vtl:RoyaltySettlementAgreementSalesNet>
    <vtl:RoyaltySettlementAgreementSalesNet
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNS0xMS0xLTEtMjY4OTE_828ad43c-951a-4b1e-bc89-8207d371d501"
      unitRef="usd">17250000</vtl:RoyaltySettlementAgreementSalesNet>
    <us-gaap:OperatingExpenses
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNi01LTEtMS0yNjg5MQ_0db05a11-1285-46da-828d-3335ccd19d72"
      unitRef="usd">20610000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNi03LTEtMS0yNjg5MQ_d2efae9e-2cae-43d7-930c-ff3aff5c4cf1"
      unitRef="usd">19170000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNi05LTEtMS0yNjg5MQ_b4b37645-7bf3-45a0-bb38-4adab347d6ab"
      unitRef="usd">42045000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNi0xMS0xLTEtMjY4OTE_c0215ee0-6c61-48e2-b922-c4be9930ea6d"
      unitRef="usd">51557000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNy01LTEtMS0yNjg5MQ_c6a2d3a8-b66f-4b09-80ca-bd44b825a6a2"
      unitRef="usd">-20610000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNy03LTEtMS0yNjg5MQ_42fe0b1f-be4c-4ddb-9792-ab8e18c4a477"
      unitRef="usd">-19170000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNy05LTEtMS0yNjg5MQ_0941012d-49dd-4b24-b262-638e4b9c33d4"
      unitRef="usd">-42045000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfNy0xMS0xLTEtMjY4OTE_fdc51c0b-7360-4274-b996-6dea7a9cd216"
      unitRef="usd">-51557000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfOS01LTEtMS0yNjg5MQ_b4c24d22-1317-464e-a24b-00047ecf954f"
      unitRef="usd">106000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfOS03LTEtMS0yNjg5MQ_f402a81b-72c9-4a14-9e61-0f088b3d34e6"
      unitRef="usd">13000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfOS05LTEtMS0yNjg5MQ_38429236-abc4-4853-bbd8-b191acd39cc4"
      unitRef="usd">113000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfOS0xMS0xLTEtMjY4OTE_c6f7bfca-963c-4896-977c-fb83a585824d"
      unitRef="usd">41000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTAtNS0xLTEtMjY4OTE_11294bb8-aa5e-4955-a950-f93c04e7197d"
      unitRef="usd">-1397000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTAtNy0xLTEtMjY4OTE_be97899e-1754-40f9-8b92-9fcf231f8220"
      unitRef="usd">1223000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTAtOS0xLTEtMjY4OTE_60d138db-dd70-45d8-ac4d-eedffedec71c"
      unitRef="usd">-777000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTAtMTEtMS0xLTI2ODkx_e9935ce6-68f7-4ced-974b-6d5d0e0177d5"
      unitRef="usd">-952000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTEtNS0xLTEtMjY4OTE_b2fdefe1-ff2c-43e0-8513-9d34fd5abd7a"
      unitRef="usd">-1291000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTEtNy0xLTEtMjY4OTE_6e338c71-011b-4a97-99e1-99d65201585b"
      unitRef="usd">1236000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTEtOS0xLTEtMjY4OTE_4575d626-d4b0-44d1-82e3-9e4debde9929"
      unitRef="usd">-664000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTEtMTEtMS0xLTI2ODkx_5bd93d92-07d7-425f-bf74-bb0c870086a8"
      unitRef="usd">-911000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTItNS0xLTEtMjY4OTE_50493c7f-721a-46a0-82c5-1667ef067e93"
      unitRef="usd">-21901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTItNy0xLTEtMjY4OTE_86df4c1f-637a-4814-bba5-a2559c7b088c"
      unitRef="usd">-17934000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTItOS0xLTEtMjY4OTE_63fbca6a-13bc-4cd9-8dd3-93bcb4a14925"
      unitRef="usd">-42709000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTItMTEtMS0xLTI2ODkx_f6853c51-63c9-4149-824d-32ee2010972a"
      unitRef="usd">-52468000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtNS0xLTEtMjY4OTE_63b07437-8fa1-4afd-b85a-ad767be69549"
      unitRef="usdPerShare">-0.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtNS0xLTEtMjY4OTE_6eb7bb64-2a12-4de2-a2a6-a01bd917647c"
      unitRef="usdPerShare">-0.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtNy0xLTEtMjY4OTE_6c323fc5-5677-4ac4-85a1-9925b9f5431e"
      unitRef="usdPerShare">-0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtNy0xLTEtMjY4OTE_f552c187-5d93-4638-a411-81b1d89bab9d"
      unitRef="usdPerShare">-0.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtOS0xLTEtMjY4OTE_dec0d4ec-e4ae-4e92-8f08-f093b2a7b4fe"
      unitRef="usdPerShare">-1.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtOS0xLTEtMjY4OTE_fcda81a0-1c7c-4e47-b63c-17240954c0b5"
      unitRef="usdPerShare">-1.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtMTEtMS0xLTI2ODkx_1591700f-2cc5-4eab-8324-a6bac1097b02"
      unitRef="usdPerShare">-2.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTQtMTEtMS0xLTI2ODkx_168f3726-ec6f-42c8-be8c-d09704871803"
      unitRef="usdPerShare">-2.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtNS0xLTEtMjY4OTE_a6f0d533-b7e3-44f6-963d-0feae7428a2a"
      unitRef="shares">30248767</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtNS0xLTEtMjY4OTE_c7497a37-72f2-4223-8900-cf5c5bb55405"
      unitRef="shares">30248767</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtNy0xLTEtMjY4OTE_3eb704bc-efde-4fb3-b958-0192f9ff24a2"
      unitRef="shares">21749439</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtNy0xLTEtMjY4OTE_e4f3b232-31e8-4912-9512-7290c0b75aec"
      unitRef="shares">21749439</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtOS0xLTEtMjY4OTE_10e5c688-845a-487e-85b7-ac791f99e551"
      unitRef="shares">28686910</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtOS0xLTEtMjY4OTE_3d27df15-ddee-4bf3-97a4-8338d6bfc5c1"
      unitRef="shares">28686910</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtMTEtMS0xLTI2ODkx_19d8eff1-a120-450e-ac32-4bfa39544bb2"
      unitRef="shares">21463656</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xMy9mcmFnOmRhM2ViMGM5ZmJjYTQyMjk5ZmRmOTkyZWY0ZjRiNDA2L3RhYmxlOmNiNDcyZjEzMmU5OTQ3ODY5MzAxOTgzY2UyMzgzMjFkL3RhYmxlcmFuZ2U6Y2I0NzJmMTMyZTk5NDc4NjkzMDE5ODNjZTIzODMyMWRfMTYtMTEtMS0xLTI2ODkx_8ea30a61-8d1b-4dda-bf51-e8bd18b29f23"
      unitRef="shares">21463656</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfMi01LTEtMS0yNjg5MQ_74231f36-fd54-44e9-9fe6-30fb95d83618"
      unitRef="usd">-21901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfMi03LTEtMS0yNjg5MQ_3c3b9785-2ecb-4dc2-bcee-1c1f5fe13dc1"
      unitRef="usd">-17934000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfMi05LTEtMS0yNjg5MQ_63fbca6a-13bc-4cd9-8dd3-93bcb4a14925"
      unitRef="usd">-42709000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfMi0xMS0xLTEtMjY4OTE_f6853c51-63c9-4149-824d-32ee2010972a"
      unitRef="usd">-52468000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNC01LTEtMS0yNjg5MQ_2979ba31-8cd2-454d-adbc-622be6ed24a6"
      unitRef="usd">-350000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNC03LTEtMS0yNjg5MQ_f01ed116-277f-43c6-9b55-90368c3de4f1"
      unitRef="usd">-277000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNC05LTEtMS0yNjg5MQ_f3f979ea-4a3a-4ef6-bf6a-38e0c711c340"
      unitRef="usd">-408000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNC0xMS0xLTEtMjY4OTE_3963de4d-68ad-4288-9257-e426942bfe60"
      unitRef="usd">2714000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNi01LTEtMS0yNjg5MQ_a4322b0c-8a9e-46b1-ba7f-d13f4ae75153"
      unitRef="usd">-22251000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNi03LTEtMS0yNjg5MQ_03971c50-9f5a-4b87-bfd3-cb6140180570"
      unitRef="usd">-18211000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNi05LTEtMS0yNjg5MQ_c79d4f63-472a-4bfd-8020-4abe4cbcebde"
      unitRef="usd">-43117000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xNi9mcmFnOmZjMmJmNzgyMmY3ZDRhNzBiYmQ0Njk2MGQ4MzU1OTI4L3RhYmxlOjExMjE5YTRiNTdhMTRlMTVhZTg0NDM3ZWY5NzYzZjc2L3RhYmxlcmFuZ2U6MTEyMTlhNGI1N2ExNGUxNWFlODQ0MzdlZjk3NjNmNzZfNi0xMS0xLTEtMjY4OTE_e7503f6b-65dc-4645-b373-0d110d14fd17"
      unitRef="usd">-49754000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ic4fb55fd2ef8427d80a634661f1773b2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMy0xLTEtMS0yNjg5MQ_15930644-8c6b-4377-9b01-d51f21651c13"
      unitRef="shares">26335418</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic4fb55fd2ef8427d80a634661f1773b2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMy0zLTEtMS0yNjg5MQ_e63a752f-77fb-4be6-b501-dafc7834ae1e"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8e90af7dc9ef4a6c9069acdbb42eae07_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMy01LTEtMS0yNjg5MQ_4fe6e0e5-7950-4cb5-8712-5b7267309c8a"
      unitRef="usd">324237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i383623f0307f4b9d96b57d1489b5600c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMy03LTEtMS0yNjg5MQ_619e13f0-3410-4e0f-ac36-5fec0a60e7bd"
      unitRef="usd">-252000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0a7559d9f82448c8987eae81fa4ec3ac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMy05LTEtMS0yNjg5MQ_6956c5aa-98be-4cd2-8180-b29ade32350d"
      unitRef="usd">-196873000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMy0xMS0xLTEtMjY4OTE_e0356510-92b4-4048-b3ad-cc9bbe4bb3f8"
      unitRef="usd">127115000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic96897f104fb48d78ee6473de6c83c97_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNC05LTEtMS0yNjg5MQ_a3653cd7-b099-4bfb-8420-082e80126f50"
      unitRef="usd">-20808000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9608caccfcbc4563859345eaa9991b07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNC0xMS0xLTEtMjY4OTE_4d41b4cf-1a5f-40c5-b50c-fbe8532a9043"
      unitRef="usd">-20808000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i076950ee40df42d89a5d26ba9bf6795d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNS01LTEtMS0yNjg5MQ_20d28773-c5d5-4d7f-97ee-d02542380fb9"
      unitRef="usd">2069000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9608caccfcbc4563859345eaa9991b07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNS0xMS0xLTEtMjY4OTE_693a7d01-cb74-44a2-800e-e5ecfdcdec33"
      unitRef="usd">2069000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i465c366ef51f4b189565cac81dffddbe_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNi03LTEtMS0yNjg5MQ_08799999-2061-4547-9df0-1282ac4ddc04"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9608caccfcbc4563859345eaa9991b07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNi0xMS0xLTEtMjY4OTE_08e32058-f0af-49f3-bb08-1b29497d9e38"
      unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i75532eaec46d443bbf4be7aca9794114_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNy0xLTEtMS0yNjg5MQ_5f02fb9c-09eb-47b8-bbc0-30135e1ab7fb"
      unitRef="shares">852</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i076950ee40df42d89a5d26ba9bf6795d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNy01LTEtMS0yNjg5MQ_deeb3450-bea0-4a52-81d6-1c364c792556"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9608caccfcbc4563859345eaa9991b07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfNy0xMS0xLTEtMjY4OTE_cd03095d-0844-4b4d-a2d2-5c14f301e809"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i9608caccfcbc4563859345eaa9991b07_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOC0wLTEtMS0yNzUxMy90ZXh0cmVnaW9uOjJjYzczNmY0Mzk1YjQzNjQ4MDA3OGFhYTRhYmUyOWE5XzIxOTkwMjMyNTU2NDY_4618ace1-4b76-437b-907d-f23097216e73"
      unitRef="usd">918000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i495588de7e354f81b29f181b399ebdba_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOC0xLTEtMS0yNjg5MQ_22df07db-b466-4ed7-a646-4d571e4aebc7"
      unitRef="shares">2904113</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iaf34bda03a394ba8a77214d6b3305235_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOC01LTEtMS0yNjg5MQ_4f299f8b-76c7-4b3f-9c68-b54f9e9814a2"
      unitRef="usd">29638000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i121e4a3cffdb4f6fbed73a792bf1b69e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOC0xMS0xLTEtMjY4OTE_40f1b5d4-1a22-4322-850c-454aeaba80f1"
      unitRef="usd">29638000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i961bd468dc6e4b2085750c3208bb55f3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOS0xLTEtMS0yNjg5MQ_bd5939a1-2baa-48c9-96ff-15e838893694"
      unitRef="shares">29240383</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i961bd468dc6e4b2085750c3208bb55f3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOS0zLTEtMS0yNjg5MQ_e4fff4dc-9de1-40a3-90ae-988e7ca865dd"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f74c7f405464d128cc5abb31ca4304c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOS01LTEtMS0yNjg5MQ_5d584515-926e-4d27-890b-2fbbd5b3fe27"
      unitRef="usd">355949000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a5095123e1441ce8ab5b195e2a7381e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOS03LTEtMS0yNjg5MQ_c3d49943-cabe-4ade-90ce-4ea69548b3dc"
      unitRef="usd">-310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i290eaed6709c4900870088935dc57a9c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOS05LTEtMS0yNjg5MQ_880b1c6a-eb19-4037-8055-0b85b4cea2bd"
      unitRef="usd">-217681000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia63039ccf15b40d4b5364ae7c9bf408a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfOS0xMS0xLTEtMjY4OTE_bf548ee5-7c72-4068-afad-9671c296faa9"
      unitRef="usd">137961000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i02e09f06bafe421b9a79431f6587dd3f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTAtOS0xLTEtMjY4OTE_8c23aef7-b3d8-4312-88eb-8ce9d7b26e25"
      unitRef="usd">-21901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTAtMTEtMS0xLTI2ODkx_9aee1a3f-48ae-4150-8814-9fc8a9c89755"
      unitRef="usd">-21901000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9aa74dec5d9242b787918ed1421800d6_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTEtNS0xLTEtMjY4OTE_91d6268c-ad32-49e2-a2d4-c36097ee11f4"
      unitRef="usd">2062000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTEtMTEtMS0xLTI2ODkx_f173240a-1148-4cd0-ad40-25d064700f05"
      unitRef="usd">2062000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i85c7a5aa8a4246d0b7f7f081825bb773_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTItNy0xLTEtMjY4OTE_914308bf-a52a-4af4-ac7c-000bfe389974"
      unitRef="usd">-350000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTItMTEtMS0xLTI2ODkx_a177e7d3-a22e-4435-b055-ef8bb19c9429"
      unitRef="usd">-350000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iba1820fc164b4f9bac61e09fc44afa8b_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtMS0xLTEtMjgxNDY_c7173d65-78cf-47e1-82e8-bf69ea15a116"
      unitRef="shares">24612</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9aa74dec5d9242b787918ed1421800d6_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtNS0xLTEtMjgxNTM_97470b8c-ac5b-4649-a391-fcdbb392f235"
      unitRef="usd">130000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtMTEtMS0xLTI3NTE4_4a9dd3f8-1ea2-487e-814f-ee2cd6159fba"
      unitRef="usd">130000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTQtMC0xLTEtMjc1MTgvdGV4dHJlZ2lvbjphM2EzN2QyNjEyYTM0M2UyOWQxMDAxOGEzMGJiODI1M18yMTk5MDIzMjU1NjQ2_3680df10-010f-4024-aa63-64c8d8d02a9b"
      unitRef="usd">308000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5159f770ea0f4a9497673433e3e78293_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTQtMS0xLTEtMjc1MTg_331a4f47-9ae3-4bdd-97a8-4e1a2b1f05c8"
      unitRef="shares">1300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie3074803226e47ebb7c58a8d15c07885_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTQtNS0xLTEtMjc1MTg_245028eb-cfd9-4218-8f55-2cfefeba861f"
      unitRef="usd">9946000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i10c1446033584b39a0f7674b22567b72_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTQtMTEtMS0xLTI3NTE4_23fb185e-4e4b-41b3-a427-0659e88d097f"
      unitRef="usd">9946000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i24615a42f1564951b37f6e0d11cdb4d2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtMS0xLTEtMjY4OTE_22476513-75b1-4c75-a891-6b7af10907ec"
      unitRef="shares">30564995</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i24615a42f1564951b37f6e0d11cdb4d2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtMy0xLTEtMjY4OTE_c61fac6a-0814-499c-959c-a2ff8b64e5d3"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac6c3453adbd4c6dafb2f21387665bff_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtNS0xLTEtMjY4OTE_c305d945-7284-47ed-a3dd-7cb57e169a56"
      unitRef="usd">368087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie3b20273750b4a70831e7df55a20101e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtNy0xLTEtMjY4OTE_da8f4c05-1f48-4144-9a20-8321bca6bc31"
      unitRef="usd">-660000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7bbd2fff93de403e844b1b5d38504e4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtOS0xLTEtMjY4OTE_6f227bfc-2681-4801-84e0-638bac14ed2f"
      unitRef="usd">-239582000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOmNmNmU0N2JjOTFlOTQzODA4YThhYzRlZGZmMDNiYTg2L3RhYmxlcmFuZ2U6Y2Y2ZTQ3YmM5MWU5NDM4MDhhOGFjNGVkZmYwM2JhODZfMTMtMTEtMS0xLTI2ODkx_15cc3c05-2f48-43fc-9113-cd9e4f9c9337"
      unitRef="usd">127848000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i640e715a3f0c4def9b0d868c1d6092b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMy0xLTEtMS0yNjg5MQ_fe3f06af-bcca-4c8c-aa41-2aa1937f56df"
      unitRef="shares">21168240</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i640e715a3f0c4def9b0d868c1d6092b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMy0zLTEtMS0yNjg5MQ_939c280c-6a1d-456b-bc81-54824f566094"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d857c13ffa547129b4b709b775b0c0c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMy01LTEtMS0yNjg5MQ_3c2ec1cf-e675-4c3f-9d50-1be670318f48"
      unitRef="usd">266823000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic3b3eff571ab4389b83a686f38bf0009_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMy03LTEtMS0yNjg5MQ_41f88346-83f5-457d-ad22-12fbf5f5ec00"
      unitRef="usd">-4112000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2320639dc1b945fb806ec94ec779e328_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMy05LTEtMS0yNjg5MQ_6cae2d52-9e52-4b51-8a5a-1f1c4492dc8a"
      unitRef="usd">-103928000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1a4772f1271c40e191e770ac6d61d1dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMy0xMS0xLTEtMjY4OTE_320cd7fd-a80b-40bc-8489-d6a879f926fb"
      unitRef="usd">158785000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i72df3680356349e7bfa91bda10e3f3f7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNC05LTEtMS0yNjg5MQ_188ee169-1ff2-4623-81fc-d6aabece0fec"
      unitRef="usd">-34534000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib2fb388e8881440ea3a00a25cd305aca_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNC0xMS0xLTEtMjY4OTE_d471e966-544b-4a1c-8738-fd3d2c9805dd"
      unitRef="usd">-34534000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id83cbae3a80f4486b48792aefcc6aa84_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNS01LTEtMS0yNjg5MQ_8ab77705-8ec8-45d8-b92c-69116735e8a5"
      unitRef="usd">1579000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib2fb388e8881440ea3a00a25cd305aca_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNS0xMS0xLTEtMjY4OTE_539baacf-0135-44d9-948c-11cbf6799614"
      unitRef="usd">1579000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i819b55b7eb0b41cb872b2a55a28511a4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNi03LTEtMS0yNjg5MQ_3d865b0a-d50b-4271-b3dd-07dc424f8366"
      unitRef="usd">2991000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib2fb388e8881440ea3a00a25cd305aca_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNi0xMS0xLTEtMjY4OTE_5369b198-9823-4d95-9b10-e14f3ef7b584"
      unitRef="usd">2991000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i302f3eed4b894be3bfb581b012217fa7_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNy0xLTEtMS0yNjg5MQ_a1fb32d5-8aa5-4221-b32e-b176c33b4b0c"
      unitRef="shares">581199</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia25252f765c54d26893666d4b8a4b6d1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNy01LTEtMS0yNjg5MQ_12e0b5f1-a51e-4636-8462-f2becdcbe48c"
      unitRef="usd">8625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7cff2d4dae0141d7a9400429428808cb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfNy0xMS0xLTEtMjY4OTE_d6c5deea-0a99-4f5e-b789-7772f94238b5"
      unitRef="usd">8625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i06b0939acbbd4016a2017d08bbc14611_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOC0xLTEtMS0yNjg5MQ_4de025d3-cc90-42bd-8f0c-d218f8b48c2b"
      unitRef="shares">21749439</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i06b0939acbbd4016a2017d08bbc14611_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOC0zLTEtMS0yNjg5MQ_d59a638e-a9d9-434f-8fd0-4331dee7518f"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id40c3cee4b0a4933a0d3743284b8b9bb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOC01LTEtMS0yNjg5MQ_cbb2255d-a0b1-461c-b8f4-547598f18de9"
      unitRef="usd">277027000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6038f471ebd492dacb91545b0bd1204_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOC03LTEtMS0yNjg5MQ_ec23a61f-2ec8-4928-9914-9db59a093a47"
      unitRef="usd">-1121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib888b4c6dea340ddac2a5f3d0444fb01_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOC05LTEtMS0yNjg5MQ_a970d7a7-4018-49d0-b616-545f2d09e4e1"
      unitRef="usd">-138462000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e6c3ba533a04a6d9765af14c3539988_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOC0xMS0xLTEtMjY4OTE_19e5284e-ecf6-4b31-bedf-db5c11b14ffd"
      unitRef="usd">137446000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie94d2d5ea505442cbfb5b9f4af2174cb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOS05LTEtMS0yNjg5MQ_ace902bd-f1ce-43b8-a787-2698d1eee2cd"
      unitRef="usd">-17934000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfOS0xMS0xLTEtMjY4OTE_1dc28fcd-a15a-4f49-b7e0-c158b8f14f80"
      unitRef="usd">-17934000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i273c8f6ffe2d4bae939069532f577216_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTAtNS0xLTEtMjY4OTE_cbacb169-eafd-4688-b523-d8dd590940e7"
      unitRef="usd">1507000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTAtMTEtMS0xLTI2ODkx_5c783625-63bd-41b0-923b-a28e7b2e7369"
      unitRef="usd">1507000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaf514b4446b646f2969c39b9e0c88824_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTEtNy0xLTEtMjY4OTE_867bec99-922f-4fce-a08a-c31ca40b6d6f"
      unitRef="usd">-277000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTEtMTEtMS0xLTI2ODkx_b322d121-6bc8-4b9e-8855-cf128f429b2e"
      unitRef="usd">-277000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i2addead69d9548889d3828a4cf706290_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTUtMS0xLTEtMjY4OTE_1196cadb-bf5f-4f01-a015-c00bd4824fa3"
      unitRef="shares">21749439</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2addead69d9548889d3828a4cf706290_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTUtMy0xLTEtMjY4OTE_2270fd7f-92ab-46de-8161-b267764daf4e"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4d825e45e7c948c9b4d93eb5be9afd4c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTUtNS0xLTEtMjY4OTE_b393b33c-3953-43eb-893a-37f093a3f65b"
      unitRef="usd">278534000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie7d44abdaa9d4db2a3c8a5442cead68d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTUtNy0xLTEtMjY4OTE_475d7231-e9e8-4625-971c-f95bc245a2d1"
      unitRef="usd">-1398000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0f57bfb4d140406a809324570a0730bb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTUtOS0xLTEtMjY4OTE_92ae5415-45d9-4d6f-b4c6-4a0c191a890f"
      unitRef="usd">-156396000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5539c23cb2e040f787397c935b00dc96_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8xOS9mcmFnOjU0YjUwZmJkN2UzZjQwMWE5OTNmMGNlNWIwMDI1MjY5L3RhYmxlOjA4YjE4NDExNzdmMTQ0ODdiZmRmNTYxZjI4N2MzZGZlL3RhYmxlcmFuZ2U6MDhiMTg0MTE3N2YxNDQ4N2JmZGY1NjFmMjg3YzNkZmVfMTUtMTEtMS0xLTI2ODkx_528dd36d-16d8-4f16-ac38-9e3c1793fb11"
      unitRef="usd">120742000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMy0xLTEtMS0yNjg5MQ_cebea2fd-346d-4c21-85ca-b34056d523de"
      unitRef="usd">-42709000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMy0zLTEtMS0yNjg5MQ_ef3a85e0-44b7-4129-a6cd-6ad783e66690"
      unitRef="usd">-52468000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfNS0xLTEtMS0yNjg5MQ_b2d16554-b497-47dd-ac7f-9049e588f5dc"
      unitRef="usd">41000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfNS0zLTEtMS0yNjg5MQ_71417ca8-4ae0-4df0-bbbe-b61875c4bb5d"
      unitRef="usd">29000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfNi0xLTEtMS0yNjg5MQ_c34deac2-93d1-4179-90b8-76360ef5060e"
      unitRef="usd">-2103000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfNi0zLTEtMS0yNjg5MQ_23bdfc14-347c-4c59-a6ce-8a5faacd6a40"
      unitRef="usd">-1905000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ShareBasedCompensation
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfOC0xLTEtMS0yNjg5MQ_cc8d0aa7-1053-498f-9bfd-2d7aad797abf"
      unitRef="usd">4131000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfOC0zLTEtMS0yNjg5MQ_3fd42570-67a3-43b8-b31f-5a6e795cb3b7"
      unitRef="usd">3086000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfOS0xLTEtMS0yNjg5MQ_365fb296-8a1d-484f-9136-434f58b26799"
      unitRef="usd">0</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfOS0zLTEtMS0yNjg5MQ_c7d65fb7-1a99-4328-bfc9-93a11dd99ca0"
      unitRef="usd">-8625000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTEtMS0xLTEtMjY4OTE_f95de18e-189a-4981-a373-b9eb7f24eb19"
      unitRef="usd">-139000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTEtMy0xLTEtMjY4OTE_d26f32f0-a483-4dd2-ae83-4f6810bdc0b1"
      unitRef="usd">8683000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTItMS0xLTEtMjY4OTE_a73ea7bb-9c74-471c-9cbc-33bdb9937ee2"
      unitRef="usd">826000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTItMy0xLTEtMjY4OTE_7a0103e6-d4f2-4602-8f6e-79085320cac1"
      unitRef="usd">483000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTMtMS0xLTEtMjY4OTE_ca82c266-7f2d-4691-8fa7-845c03547ffb"
      unitRef="usd">-861000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTMtMy0xLTEtMjY4OTE_e5d68902-b07e-403a-b64c-adeb0c7c5f30"
      unitRef="usd">2011000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTQtMS0xLTEtMjY4OTE_1527a637-8af5-465a-8a99-2a0a68408867"
      unitRef="usd">-114000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTQtMy0xLTEtMjY4OTE_10fa1cc3-12ac-4143-86b1-d9bdaebcc37b"
      unitRef="usd">3059000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTUtMS0xLTEtMjY4OTE_38170463-1a6e-4b00-b4b0-2b13fb8b06ed"
      unitRef="usd">-36444000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMTUtMy0xLTEtMjY4OTE_4ca87b94-2f99-40a3-8de7-271bbf9fac50"
      unitRef="usd">-41953000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjAtMS0xLTEtMjY4OTE_5b51b9ed-d82b-4395-ae9e-a0cc13a482cd"
      unitRef="usd">40000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjAtMy0xLTEtMjY4OTE_b0ea85ff-00ed-4519-812d-62495891c2bc"
      unitRef="usd">28000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjItMS0xLTEtMjY4OTE_c7280b28-aacd-4244-b6ed-c15ac39382ac"
      unitRef="usd">-40000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjItMy0xLTEtMjY4OTE_424d7d99-0044-4e4f-bdde-f75eb0023c4a"
      unitRef="usd">-28000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2d116a4fcc3e4f2aab94d415e3453a5a_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjUtMS0xLTEtMjY4OTE_8e2064cc-efc1-4251-a1e2-252e96190f67"
      unitRef="usd">39584000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id2540362a6b449a9988c08de956ec7c7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjUtMy0xLTEtMjY4OTE_db883da0-6462-4e16-8153-2be1c78f009b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjYtMS0xLTEtMjY4OTE_25f13236-9c81-4dd0-ac48-3afea52a202c"
      unitRef="usd">5000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjYtMy0xLTEtMjY4OTE_ef45393b-a6c6-44b8-b71c-d9c1e600d9b2"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjctMS0xLTEtMjY4OTE_69f75e2e-548b-479d-824f-b7b3a532360b"
      unitRef="usd">130000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjctMy0xLTEtMjY4OTE_88d4266d-98ec-44fc-9ad9-6481186a1009"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjgtMS0xLTEtMjY4OTE_ea62d408-a9ea-4d58-a2a4-d492a0ee6966"
      unitRef="usd">39719000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjgtMy0xLTEtMjY4OTE_c2ecbea4-26dc-47ae-8a50-e578deef0a55"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjktMS0xLTEtMjY4OTE_34d576bc-db2e-4290-8a39-0095130c2692"
      unitRef="usd">-2020000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMjktMy0xLTEtMjY4OTE_274bb238-4687-4af0-b877-30e702ab83a4"
      unitRef="usd">1704000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzAtMS0xLTEtMjY4OTE_324ce4a6-4b68-465f-a7e4-7e7bbb50946a"
      unitRef="usd">1215000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzAtMy0xLTEtMjY4OTE_e40901c9-3644-48b2-b960-4e15a3b04919"
      unitRef="usd">-40277000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzEtMS0xLTEtMjY4OTE_534db2ca-60dc-4a42-83cd-5c1be8180570"
      unitRef="usd">86863000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1a4772f1271c40e191e770ac6d61d1dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzEtMy0xLTEtMjY4OTE_b156185a-ebda-4564-90a4-cc5c1040353f"
      unitRef="usd">127452000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzItMS0xLTEtMjY4OTE_5879065b-bed3-4247-8f8a-80c5c0a4ba29"
      unitRef="usd">88078000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5539c23cb2e040f787397c935b00dc96_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzItMy0xLTEtMjY4OTE_26e0ff28-c851-4108-8c4d-4e9ddb86ef01"
      unitRef="usd">87175000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzctMS0xLTEtMjY4OTE_85afcadd-3618-4a77-8b87-9be56ead524a"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzctMy0xLTEtMjY4OTE_3151f312-0142-435e-b2a2-87a7744039ec"
      unitRef="usd">8625000</us-gaap:StockIssued1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzgtMS0xLTEtMjY4OTE_85ff23eb-c965-427b-98fe-06533e90b7ab"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8yNS9mcmFnOjA1MzBiN2I5ZTgwODQ3OTJhYjc0NjcxMWY4MzU5NjA0L3RhYmxlOmY0NGU1NjI0MzUyYjRkOWRhODg1NTM1NWM4MGU2YTQ2L3RhYmxlcmFuZ2U6ZjQ0ZTU2MjQzNTJiNGQ5ZGE4ODU1MzU1YzgwZTZhNDZfMzgtMy0xLTEtMjY4OTE_eebec66e-bd2e-4109-8f1b-7f854a1a6972"
      unitRef="usd">435000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfNTQ5OQ_962abe5c-bef1-4aaf-bee6-2169133e6d16">Description of Business and Basis of Financial Statements&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Immunic, Inc. ("Immunic" or the "Company") is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#xe4;felfing near Munich, Germany.  The Company currently has approximately 60 employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is currently pursuing three development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (&#x201c;DHODH&#x201d;); the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (&#x201c;ROR&#x3b3;t&#x201d;), an immune cell-specific isoform of ROR&#x3b3;; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. These product candidates are being developed to address diseases such as multiple sclerosis ("MS"), psoriasis and gastrointestinal diseases. In addition to these large markets, these products are also being developed to address certain rare diseases with high unmet medical needs, such as primary sclerosing cholangitis (&#x201c;PSC&#x201d;), as well as metastatic castration-resistant prostate cancer (&#x201c;mCRPC&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and the inability to obtain on acceptable terms, if at all, additional funding to complete the development and commercialization of the Company's three development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Financial Condition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $239.6 million as of June 30, 2022 and $196.9 million as of December 31, 2021.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the preclinical and clinical development of its product candidates and adds personnel necessary to advance its clinical pipeline of product candidates.  Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From inception through June 30, 2022, Immunic has raised net cash of approximately $299.1 million from private and public offerings of preferred and common stock. As of June 30, 2022, the Company had cash and cash equivalents of approximately $88.1 million.  With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Research GmbH (which both began operations in 2016) and Immunic Australia Pty Ltd. (which began operations in 2018).  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. &lt;/span&gt;&lt;/div&gt;Unaudited Interim Financial InformationImmunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#x201c;US GAAP&#x201d;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#x2019;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#x2019; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#x2019;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed on February 24, 2022. The nature of Immunic&#x2019;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityNumberOfEmployees
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-1"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfMjE5OTAyMzI3MjI3NQ_6e9f8a80-f46a-41c5-a726-c455679393a6"
      unitRef="employee">60</dei:EntityNumberOfEmployees>
    <vtl:NumberOfDevelopmentProgramsPursued
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfNTQ5NzU1ODIzMTQ1_821d71f4-5c0f-4e7c-a1a7-1ef25b072ea6"
      unitRef="program">3</vtl:NumberOfDevelopmentProgramsPursued>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfNTQ5NzU1ODMwNjM3_4f039848-a8dd-4180-a0ad-d0de2fb811d9"
      unitRef="usd">-239600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfNTQ5NzU1ODI0Nzc0_78b8267b-36f6-4f0d-a18e-3b30a453a601"
      unitRef="usd">-196900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="id28377b56621409b831d879cd0e930a4_D20140417-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfNTQ5NzU1ODMwNDcx_c3fec4cf-bc97-4071-94a7-3f6e77efeae7"
      unitRef="usd">299100000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfNTQ5NzU1ODMwNjE3_bbfb9f63-0f4c-41bc-915c-ece7121e061c"
      unitRef="usd">88100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zMS9mcmFnOmNhYjY3OThhMTI4ZDQ5MDg5NzcwMTgxNjFmNWQ1ZmRkL3RleHRyZWdpb246Y2FiNjc5OGExMjhkNDkwODk3NzAxODE2MWY1ZDVmZGRfNTUwMw_00f03956-d8e9-4208-bc8e-e7fd692ee583">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Research GmbH (which both began operations in 2016) and Immunic Australia Pty Ltd. (which began operations in 2018).  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. &lt;/span&gt;&lt;/div&gt;Unaudited Interim Financial InformationImmunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#x201c;US GAAP&#x201d;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#x2019;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#x2019; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#x2019;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2021 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K filed on February 24, 2022. The nature of Immunic&#x2019;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDE_1f3e53ce-079e-4ed3-ad5e-61a3a9f8d3b4">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. Immunic AG and Immunic Research GmbH&#x2019;s operations are located in Germany with the Euro being their functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDU2MA_257586a5-1545-4cd3-af1d-02cb0660d644"&gt;three&lt;/span&gt; to thirteen years. Depreciation expense was $20,000 and $15,000 for the three months ended June 30, 2022 and 2021, respectively. Depreciation expense was $41,000 and $29,000 for the six months ended June 30, 2022 and 2021, respectively&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the three and six months ended June 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;When conducting the Company&#x2019;s interim goodwill impairment assessment, we considered the Company&#x2019;s history of reported losses and negative cash flows from operating activities, along with the downturn in macroeconomic conditions and the broader mid-cap and micro-cap equity markets in 2022. Given the relatively short period of time between the commencement of the downturn in macroeconomic and general equity market conditions as of June 30, 2022, management believes that the recent reduction in prices of our common stock, consistent with the broader market, is not other-than-temporary and not indicative of any fundamental change in the value or prospects of the underlying business as of the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As another data point, the Company also performed a quantitative goodwill impairment analysis comparing the estimated fair value of the Company&#x2019;s reporting unit to its carrying or book value as of the current period presented herein. In performing the quantitative analysis, the Company compared the fair value of the reporting unit to its carrying or book value to determine if the fair value of the reporting unit exceeded its carrying value as of the testing date, in which case the standard indicates that goodwill would not be impaired, and no further testing is required. The fair value of a reporting unit refers to the price that would be received to sell the reporting unit as a whole in an orderly transaction between market participants at the measurement date. Quoted market prices in active markets are considered to be the best evidence of fair value and should be used as the basis for fair value measurement, if available. When using quoted market prices to estimate the fair value of a reporting unit, we consider all available evidence. In certain circumstances, such as a distressed market, it may be appropriate to consider recent trends in the Company&#x2019;s stock price, instead of a single day&#x2019;s stock price in evaluating fair value. In these circumstances, averages over relatively short periods of time are used to determine representative market values.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Based on the qualitative analysis and other data points described above,  the Company concluded that goodwill was not &#x201c;more likely than not&#x201d; impaired as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As described above, we have significant goodwill recorded on our consolidated balance sheets. We will continue to evaluate the recoverability of the carrying amount of goodwill on an ongoing basis. There can be no assurance that the outcome of such reviews in the future will not result in substantial impairment charges. Impairment assessment inherently involves judgment as to assumptions about expected future cash flows and the impact of market conditions on those assumptions. Future events and changing market conditions may impact our assumptions as to prices, costs, holding periods or other factors that may result in changes in our estimates of future cash flows. Although we believe the assumptions we used in testing for impairment are reasonable, significant changes in any one of our assumptions could produce a significantly different result. The  closing stock prices for our common stock subsequent to June 30, 2022, consistent with the broader market, have continued to trend downward. If the decline in our stock price persists throughout the three month period ending September 30, 2022, we will perform an interim goodwill impairment assessment as of September 30, 2022, consistent with the methodology and approach described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC, COVID-19, and PSC.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of June 30, 2022 and 2021, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,064,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and/or Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MjA_afbde2c7-1188-4aea-9f23-012e74a1da49">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDM_ac3ea99a-d3f2-4d5c-b852-e8da8b320f24">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. Immunic AG and Immunic Research GmbH&#x2019;s operations are located in Germany with the Euro being their functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDQ_4fd27a2b-0aa2-4a48-8c1f-8b0c477a8af4">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.&lt;/span&gt;&lt;/div&gt;Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S., Germany and Australia. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions and believes that the Company is not exposed to any significant credit risk. The Company currently deposits its cash and cash equivalents with two large financial institutions.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTM_4bb33025-46b7-434f-8735-ceda152215b3">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014; Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDI_d309e193-b673-4b7f-ad90-7496e1f8852d">Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDU2MA_257586a5-1545-4cd3-af1d-02cb0660d644"&gt;three&lt;/span&gt; to thirteen years.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3ad392238f03492fb9409e9edf57a05e_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDU2Ng_f9e52995-18da-40b7-90e2-456c96a1570f">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDU5NQ_7948bb51-6bac-4126-8005-2d0ec1b3d67e"
      unitRef="usd">20000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDYwMg_d8ad37fa-1bf1-4392-8824-e168085c19db"
      unitRef="usd">15000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDY5NQ_c8fc5053-4eb5-487d-a447-b5f130a3bf81"
      unitRef="usd">41000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNDcwMg_670f98c8-63e5-43d4-a7b8-143822bbb9e5"
      unitRef="usd">29000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTY_c5b96dad-3287-46c5-9b04-a412390af8c0">Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTExMg_58a0132b-78e1-489f-b7f2-b4a4bbc7ab1c"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTExMg_803476e9-f223-4a65-ae56-998644e45b36"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTExMg_b197de6b-6824-4cb0-9376-fbbe59584cbe"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTExMg_d988873f-6345-4d65-b3e3-87eaf22197db"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDU_229e8a65-3fea-45ee-8158-8be814747f82">&lt;div style="margin-top:12pt;padding-left:20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;When conducting the Company&#x2019;s interim goodwill impairment assessment, we considered the Company&#x2019;s history of reported losses and negative cash flows from operating activities, along with the downturn in macroeconomic conditions and the broader mid-cap and micro-cap equity markets in 2022. Given the relatively short period of time between the commencement of the downturn in macroeconomic and general equity market conditions as of June 30, 2022, management believes that the recent reduction in prices of our common stock, consistent with the broader market, is not other-than-temporary and not indicative of any fundamental change in the value or prospects of the underlying business as of the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As another data point, the Company also performed a quantitative goodwill impairment analysis comparing the estimated fair value of the Company&#x2019;s reporting unit to its carrying or book value as of the current period presented herein. In performing the quantitative analysis, the Company compared the fair value of the reporting unit to its carrying or book value to determine if the fair value of the reporting unit exceeded its carrying value as of the testing date, in which case the standard indicates that goodwill would not be impaired, and no further testing is required. The fair value of a reporting unit refers to the price that would be received to sell the reporting unit as a whole in an orderly transaction between market participants at the measurement date. Quoted market prices in active markets are considered to be the best evidence of fair value and should be used as the basis for fair value measurement, if available. When using quoted market prices to estimate the fair value of a reporting unit, we consider all available evidence. In certain circumstances, such as a distressed market, it may be appropriate to consider recent trends in the Company&#x2019;s stock price, instead of a single day&#x2019;s stock price in evaluating fair value. In these circumstances, averages over relatively short periods of time are used to determine representative market values.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Based on the qualitative analysis and other data points described above,  the Company concluded that goodwill was not &#x201c;more likely than not&#x201d; impaired as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As described above, we have significant goodwill recorded on our consolidated balance sheets. We will continue to evaluate the recoverability of the carrying amount of goodwill on an ongoing basis. There can be no assurance that the outcome of such reviews in the future will not result in substantial impairment charges. Impairment assessment inherently involves judgment as to assumptions about expected future cash flows and the impact of market conditions on those assumptions. Future events and changing market conditions may impact our assumptions as to prices, costs, holding periods or other factors that may result in changes in our estimates of future cash flows. Although we believe the assumptions we used in testing for impairment are reasonable, significant changes in any one of our assumptions could produce a significantly different result. The  closing stock prices for our common stock subsequent to June 30, 2022, consistent with the broader market, have continued to trend downward. If the decline in our stock price persists throughout the three month period ending September 30, 2022, we will perform an interim goodwill impairment assessment as of September 30, 2022, consistent with the methodology and approach described above.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTQ_57004986-499f-4aa5-a881-0e35c4adafb0">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, IMU-935 and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in RRMS, UC, COVID-19, and PSC.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDg_d921faac-ba05-4f4c-86e7-e3894de82617">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc0OTk_3edc16d1-f6c8-43db-aab6-176c38303d27">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDk_1249641e-1964-4b59-9863-e524c62e8698">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTA_6a8338cc-7710-421f-9b31-d3029c9369d3">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's two leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i9e8992acd92c4178a465c433d46d5797_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTQ5NzU1ODU1ODA1_89919aae-2535-445e-a8ea-c412cbd5d19b">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i8745b84aae60434e9b96daf94cfac93a_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTQ5NzU1ODU1ODE5_33426e25-5854-45ad-a6fa-84fa8693880f">P60M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <vtl:LesseeOperatingLeasesNumberOfExistingLeases
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTQ5NzU1ODU1OTgy_60d39a03-8f8b-4109-b907-33a38e46d704"
      unitRef="lease">2</vtl:LesseeOperatingLeasesNumberOfExistingLeases>
    <vtl:LesseeOperatingLeasesNumberOfExistingLeases
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfNTQ5NzU1ODU2MjQy_60d39a03-8f8b-4109-b907-33a38e46d704"
      unitRef="lease">2</vtl:LesseeOperatingLeasesNumberOfExistingLeases>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTc_e1c724e7-b021-4e31-b080-c95129154fb4">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MDA_6d167f63-97c5-44c1-9544-6f0c7c255de5">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of June 30, 2022 and 2021, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2021 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTg_68b75c04-543e-42f7-bd7d-02033f9a25c6">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTE_e7187c53-85de-48dd-9659-6f15e0ee5ae6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.955%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,064,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i58796c8360524abb862423e11c8db6ad_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RhYmxlOjM3ZWY4MjM5OThjMzRlZDM5ZjI5ZWVmMDNjMWY2NmZlL3RhYmxlcmFuZ2U6MzdlZjgyMzk5OGMzNGVkMzlmMjllZWYwM2MxZjY2ZmVfMi0xLTEtMS0yNjg5MQ_6835d07b-052a-4b3c-9a89-7d221d096c08"
      unitRef="shares">3713248</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idcfd1b5059be473ca463b8dfc127debf_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RhYmxlOjM3ZWY4MjM5OThjMzRlZDM5ZjI5ZWVmMDNjMWY2NmZlL3RhYmxlcmFuZ2U6MzdlZjgyMzk5OGMzNGVkMzlmMjllZWYwM2MxZjY2ZmVfMi0zLTEtMS0yNjg5MQ_c758d0f6-ddb7-40f9-bb53-1c193bd73895"
      unitRef="shares">2064839</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNC9mcmFnOmNiMGUxNWZlMDZhNzQ5MjNhODkyMDY0ZDY1YWRkYmVlL3RleHRyZWdpb246Y2IwZTE1ZmUwNmE3NDkyM2E4OTIwNjRkNjVhZGRiZWVfMTc1MTI_f5e43c53-69a0-4541-b55a-64eeab6768e1">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and/or Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfNTM4_3318b1fe-a08a-473c-867f-2ea34a5c7fc9">Balance Sheet Details&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Assets and Prepaid Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Assets and Prepaid Expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.419%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfMjE5OTAyMzI1NjI5MA_3d8ceb1b-3c21-469b-880e-2ea581b8f112"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfMjE5OTAyMzI1NjI5MA_f85fe492-0c02-4937-8946-c1829a42d290"&gt;Other Current Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfNTMw_d72b4075-a7fa-493c-8554-fa89e120f250">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Assets and Prepaid Expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.419%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <vtl:PrepaidClinicalAndRelatedCostsCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfMi0xLTEtMS0yNjg5MQ_ca2518fb-b037-4d11-97bc-d7e707777bd4"
      unitRef="usd">11895000</vtl:PrepaidClinicalAndRelatedCostsCurrent>
    <vtl:PrepaidClinicalAndRelatedCostsCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfMi0zLTEtMS0yNjg5MQ_45da4d32-fd3c-433a-aecb-25722617dcd5"
      unitRef="usd">14853000</vtl:PrepaidClinicalAndRelatedCostsCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfMy0xLTEtMS0yNjg5MQ_f98a2192-35bb-4a8a-b448-31d91f0516b5"
      unitRef="usd">397000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfMy0zLTEtMS0yNjg5MQ_f83e8d65-97a8-442c-935c-e80b34db7b8f"
      unitRef="usd">279000</us-gaap:ValueAddedTaxReceivableCurrent>
    <vtl:ResearchAndDevelopmentTaxIncentiveCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfNC0xLTEtMS0yNjg5MQ_fcdd4bce-b141-4e8b-bb0b-972abc299741"
      unitRef="usd">2875000</vtl:ResearchAndDevelopmentTaxIncentiveCurrent>
    <vtl:ResearchAndDevelopmentTaxIncentiveCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfNC0zLTEtMS0yNjg5MQ_c6cc20fb-404d-4cda-92f7-f59dd0969a1b"
      unitRef="usd">1871000</vtl:ResearchAndDevelopmentTaxIncentiveCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfNS0xLTEtMS0yNjg5MQ_eafde641-6d2f-4c4f-83c0-bbd2209ee8ec"
      unitRef="usd">1516000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfNS0zLTEtMS0yNjg5MQ_761d7ffa-2ef7-40dd-be95-577487f4eb91"
      unitRef="usd">1122000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfNi0xLTEtMS0yNjg5MQ_9305e114-db05-40b0-8b54-91908c73f26b"
      unitRef="usd">16683000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmViZjQ4Njg5MDIzZDQ1NDI4OGRhY2Q1MzIyZjhhMzVhL3RhYmxlcmFuZ2U6ZWJmNDg2ODkwMjNkNDU0Mjg4ZGFjZDUzMjJmOGEzNWFfNi0zLTEtMS0yNjg5MQ_b65abbd9-87f5-4d28-8609-82d1f0637522"
      unitRef="usd">18125000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfNTM2_cf85d761-54c1-4919-8c74-5a8c7cabde5c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.474%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <vtl:ClinicalCostsPayableCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfMi0xLTEtMS0yNjg5MQ_ef0e4d76-a41f-42a9-b278-8b0a53960d5d"
      unitRef="usd">3807000</vtl:ClinicalCostsPayableCurrent>
    <vtl:ClinicalCostsPayableCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfMi0zLTEtMS0yNjg5MQ_ea8fd2a8-f4ec-4abd-b644-f5b78c21f651"
      unitRef="usd">3427000</vtl:ClinicalCostsPayableCurrent>
    <vtl:LegalAndAuditCostsPayableCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfMy0xLTEtMS0yNjg5MQ_de2d15d1-3515-47dd-ae1d-79aed2ee893c"
      unitRef="usd">102000</vtl:LegalAndAuditCostsPayableCurrent>
    <vtl:LegalAndAuditCostsPayableCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfMy0zLTEtMS0yNjg5MQ_e8e24719-bf38-4ed7-94d2-ab258617be05"
      unitRef="usd">72000</vtl:LegalAndAuditCostsPayableCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfNS0xLTEtMS0yNjg5MQ_9aedb22c-d30b-4261-8cab-b600a4dfe4a1"
      unitRef="usd">208000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfNS0zLTEtMS0yNjg5MQ_27634cdb-1d7e-418f-8d93-b887ce186583"
      unitRef="usd">246000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfNi0xLTEtMS0yNjg5MQ_d30e3b43-9fa8-4ccc-b171-8190a31e93f6"
      unitRef="usd">4117000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOmFjOWQzOTM5NGQ3NjRkOTU4ZThlM2NhZWI4OTlkNjNlL3RhYmxlcmFuZ2U6YWM5ZDM5Mzk0ZDc2NGQ5NThlOGUzY2FlYjg5OWQ2M2VfNi0zLTEtMS0yNjg5MQ_3adf575e-399b-4ac3-990c-5e44dd664ad0"
      unitRef="usd">3745000</us-gaap:AccountsPayableCurrent>
    <vtl:AccruedClinicalCostsCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfMi0xLTEtMS0yNjg5MQ_41c4f2db-4b8e-49f4-a8bf-99db385166a4"
      unitRef="usd">4974000</vtl:AccruedClinicalCostsCurrent>
    <vtl:AccruedClinicalCostsCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfMi0zLTEtMS0yNjg5MQ_29f28932-129f-45d7-ab9d-91794ad24abb"
      unitRef="usd">6214000</vtl:AccruedClinicalCostsCurrent>
    <vtl:AccruedLegalAndAuditCostsCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfMy0xLTEtMS0yNjg5MQ_89a3c795-867d-472e-83a0-d1a0ff1cffe3"
      unitRef="usd">69000</vtl:AccruedLegalAndAuditCostsCurrent>
    <vtl:AccruedLegalAndAuditCostsCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfMy0zLTEtMS0yNjg5MQ_04a479f8-1feb-422d-94c6-8a0d2cd5e063"
      unitRef="usd">96000</vtl:AccruedLegalAndAuditCostsCurrent>
    <vtl:AccruedCompensationCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfNC0xLTEtMS0yNjg5MQ_9fd86827-dd64-4e7e-a8ae-214eaee11ab1"
      unitRef="usd">608000</vtl:AccruedCompensationCurrent>
    <vtl:AccruedCompensationCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfNC0zLTEtMS0yNjg5MQ_4c4d8ac5-c196-421d-a8ad-b661cec0d63a"
      unitRef="usd">674000</vtl:AccruedCompensationCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfNS0xLTEtMS0yNjg5MQ_d155158f-7741-4746-8d15-f0d398c4b926"
      unitRef="usd">90000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfNS0zLTEtMS0yNjg5MQ_b1322f93-b0b9-4f15-8e17-b9df90efbd8c"
      unitRef="usd">87000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfNi0xLTEtMS0yNjg5MQ_60241f9a-eb7a-4c72-b50c-b50d09170f3f"
      unitRef="usd">5741000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjA5ZGNiZWZmNWM3MDQwNTRiYjlhN2Q4NmYyMGZmY2Q2L3RhYmxlcmFuZ2U6MDlkY2JlZmY1YzcwNDA1NGJiOWE3ZDg2ZjIwZmZjZDZfNi0zLTEtMS0yNjg5MQ_f029f953-29ca-4e92-bc71-8b550fee7fa3"
      unitRef="usd">7071000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RleHRyZWdpb246MzUyMzdmZGQzNzBjNDY5YWE1ODQ4MTE0ZWQ5N2M2YmJfNTMx_50b91b42-7122-49d3-9461-335064082d3c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.912%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjc0YTM1YjBiYTFmODQ3MDRiZDkyYTQ0ZDY1MWI2NWM1L3RhYmxlcmFuZ2U6NzRhMzViMGJhMWY4NDcwNGJkOTJhNDRkNjUxYjY1YzVfMi0xLTEtMS0yNjg5MQ_9e735579-b915-4062-8364-61adf8434ce4"
      unitRef="usd">366000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjc0YTM1YjBiYTFmODQ3MDRiZDkyYTQ0ZDY1MWI2NWM1L3RhYmxlcmFuZ2U6NzRhMzViMGJhMWY4NDcwNGJkOTJhNDRkNjUxYjY1YzVfMi0zLTEtMS0yNjg5MQ_f102a985-4940-44d7-ba23-4ad521a06276"
      unitRef="usd">408000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjc0YTM1YjBiYTFmODQ3MDRiZDkyYTQ0ZDY1MWI2NWM1L3RhYmxlcmFuZ2U6NzRhMzViMGJhMWY4NDcwNGJkOTJhNDRkNjUxYjY1YzVfNC0xLTEtMS0yNjg5MQ_212ab774-774c-4eb9-8a35-8dbde4cbfc4f"
      unitRef="usd">178000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjc0YTM1YjBiYTFmODQ3MDRiZDkyYTQ0ZDY1MWI2NWM1L3RhYmxlcmFuZ2U6NzRhMzViMGJhMWY4NDcwNGJkOTJhNDRkNjUxYjY1YzVfNC0zLTEtMS0yNjg5MQ_9c497109-d22a-4045-8af0-e89473750786"
      unitRef="usd">177000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjc0YTM1YjBiYTFmODQ3MDRiZDkyYTQ0ZDY1MWI2NWM1L3RhYmxlcmFuZ2U6NzRhMzViMGJhMWY4NDcwNGJkOTJhNDRkNjUxYjY1YzVfNS0xLTEtMS0yNjg5MQ_79ee9b5d-989a-492a-8f48-8e13c59b83a6"
      unitRef="usd">544000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id9a0bfa4b5414f6b93e79d1b3c38222f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl8zNy9mcmFnOjM1MjM3ZmRkMzcwYzQ2OWFhNTg0ODExNGVkOTdjNmJiL3RhYmxlOjc0YTM1YjBiYTFmODQ3MDRiZDkyYTQ0ZDY1MWI2NWM1L3RhYmxlcmFuZ2U6NzRhMzViMGJhMWY4NDcwNGJkOTJhNDRkNjUxYjY1YzVfNS0zLTEtMS0yNjg5MQ_4d1c92a3-66fa-4d9b-af42-810aa30ea8ca"
      unitRef="usd">585000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTEyOQ_04a5f7a4-63f6-4ddc-ab10-af535e6215a1">Commitments and Contingencies&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain office space under non-cancelable operating leases. The leases terminate on April 30, 2023 for the New York City office and on June 30, 2025 for the Gr&#xe4;felfing, Germany office.  These leases include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease has renewal options, but they were not included in calculating the right of use asset and liabilities.  On April 7, 2020, the Company signed a five year lease for its facility in Gr&#xe4;felfing, Germany. On March 1, 2021, the Company added additional lease space at the Gr&#xe4;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease.  There were net additions to right of use assets of $435,000 as a result of signing for additional lease space at the Gr&#xe4;felfing, Germany office in March 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6%, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Immunic&#x2019;s operating lease costs and variable lease costs were $136,000 and 145,000 for the three months ended June 30, 2022 and 2021, respectively and $266,000 and $239,000 for the six months ended June 30, 2022 and 2021, respectively.  Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the operating lease obligation are as follows as of June 30, 2022 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PV of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022, the Company has non-cancelable contractual obligations under certain agreements related to its development programs for vidofludimus calcium, IMU-935 and IMU-856 totaling approximately $2.6&#160;million, all of which is expected to be paid in the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments and Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2016, the Company entered into a purchase agreement (the &#x201c;Agreement&#x201d;) with 4SC AG, whereby the Company acquired certain assets, including the rights to patents and patent applications, trademarks and know-how. This transaction has been accounted for as an asset acquisition under Accounting Standards Update 2017-01 - Business Combinations (Topic 805): Clarifying the Definition of a Business. The Agreement included payments (Tranches III and IV) that were contingent upon the occurrence of certain events and required the Company to pay royalties equal to 4.4% of the aggregated net sales for a certain period as defined in the Agreement (Tranche III) upon commercialization of the acquired assets. Effective April 12, 2019, the parties agreed to settle Tranche IV by issuing 120,070 shares of the Company&#x2019;s common stock, immediately following the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;transaction, to 4SC AG while keeping Tranche III in effect. Approximately $1.5 million of expense was recorded as a result of the issuance of these shares on April 12, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, Immunic AG and 4SC AG entered into a Settlement Agreement, pursuant to which Immunic AG settled its remaining obligation of the 4.4% royalty on net sales for $17.25&#160;million (Tranche III of the Agreement). The payment was made 50% in cash and 50% in shares of Immunic&#x2019;s common stock (the &#x201c;Shares&#x201d;). Pursuant to the Agreement, the Company filed a resale shelf registration statement on Form S-3 covering the resale of the Shares. With the execution of the Agreement, no further payment obligations remain between Immunic AG and 4SC AG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Daiichi Sankyo Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i8851c67679bf4084b6bf5354695ad9d2_I20200407"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfMjE5OTAyMzI3MDExOA_606ba24b-e6b9-4e81-82af-a43a6d566db3">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <vtl:LesseeOperatingLeaseRentHolidayPeriod
      contextRef="idfa9e23428124c2486f4015b0a2d6c95_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfMjE5OTAyMzI3MDExOQ_7a75b61e-284f-42ec-8aa7-09a47a650a47">P6M</vtl:LesseeOperatingLeaseRentHolidayPeriod>
    <vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i0900a41bd91a4900bd798f3276eb85bb_D20210301-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODIyNDc5_1a252324-a339-4f26-90e0-91c8f8d39b0d"
      unitRef="usd">435000</vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <vtl:OperatingLeaseIncrementalBorrowingRate
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODIyODIz_7524421f-4310-45ba-a4e3-b28262d458c9"
      unitRef="number">0.06</vtl:OperatingLeaseIncrementalBorrowingRate>
    <vtl:OperatingAndVariableLeasesCost
      contextRef="i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfMjMwOA_b28d10c7-3e13-4e13-a7fd-8ff4b19cd784"
      unitRef="usd">136000</vtl:OperatingAndVariableLeasesCost>
    <vtl:OperatingAndVariableLeasesCost
      contextRef="i0947672575364c46afe56198033d6c85_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfMjMxNQ_f418b2d8-14c8-40f7-87d1-4163745538dd"
      unitRef="usd">145000</vtl:OperatingAndVariableLeasesCost>
    <vtl:OperatingAndVariableLeasesCost
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfMjM4Ng_4248006b-73e9-4ec2-9b93-9c7895ca0457"
      unitRef="usd">266000</vtl:OperatingAndVariableLeasesCost>
    <vtl:OperatingAndVariableLeasesCost
      contextRef="ibc6c9478c7804911bd280e98042f959a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfMjM5Mw_2cd57965-c27d-46b6-9fd3-f9384d5794ad"
      unitRef="usd">239000</vtl:OperatingAndVariableLeasesCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTEzNQ_9196074b-b41a-4722-96f3-275d02fd39bc">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the operating lease obligation are as follows as of June 30, 2022 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PV of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfMC0yLTEtMS0yNjg5MQ_0347d81f-0b46-407f-a240-47336fff56e1"
      unitRef="usd">219000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfMS0yLTEtMS0yNjg5MQ_93c48846-18e2-454b-86d8-9739163cf0c0"
      unitRef="usd">289000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfMi0yLTEtMS0yNjg5MQ_43abf3fc-067c-4305-b9d7-8dc49766a1b7"
      unitRef="usd">214000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfMy0yLTEtMS0yNjg5MQ_535f8281-2497-40a7-a181-290251f43ce4"
      unitRef="usd">107000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfNC0yLTEtMS0yNjg5MQ_3ac8aff5-390c-453e-b981-9687edbb7984"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfNS0yLTEtMS0yNjg5MQ_57926198-8930-4097-9540-2b27c4201b77"
      unitRef="usd">829000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfNi0yLTEtMS0yNjg5MQ_bc100f58-8b14-49e5-a8d6-af87dc0c9d6d"
      unitRef="usd">62000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RhYmxlOjdmZDVkNmFiZmQxMTQ5NGRiY2NlYWNlMmRjZjY3OWVjL3RhYmxlcmFuZ2U6N2ZkNWQ2YWJmZDExNDk0ZGJjY2VhY2UyZGNmNjc5ZWNfNy0yLTEtMS0yNjg5MQ_5f2d3dac-75bc-4826-83a3-54894ea40b12"
      unitRef="usd">767000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ContractualObligation
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfMjE5OTAyMzI3MDU4Ng_35082021-1370-49ba-9e74-051a07611085"
      unitRef="usd">2600000</us-gaap:ContractualObligation>
    <vtl:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales
      contextRef="ic0596eac93474ba595e10a41ccb463c3_D20160501-20160531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODI1NzM2_df758eeb-f257-4f54-a28b-53fdf3574eb8"
      unitRef="number">0.044</vtl:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic822612a93bf4322a15f67ee66c0e1ea_I20190412"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODI1OTU1_ebb51acc-279b-4487-b30b-601853d0b0e0"
      unitRef="shares">120070</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ic822612a93bf4322a15f67ee66c0e1ea_I20190412"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODI2MDk3_926eeb1f-e706-4b2b-ab30-211e5fb80f3b"
      unitRef="usd">1500000</us-gaap:CommonStockValue>
    <vtl:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales
      contextRef="i0ac3802756644803be0171f1cae2cca5_D20210331-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODI2MzM2_fbd9f822-42fe-4745-a6f9-68231232f31b"
      unitRef="number">0.044</vtl:AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales>
    <vtl:RoyaltySettlementAgreementSalesNet
      contextRef="i0ac3802756644803be0171f1cae2cca5_D20210331-20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODI2MzY1_374df1f8-f1ba-41e5-bf74-efab675dac41"
      unitRef="usd">17250000</vtl:RoyaltySettlementAgreementSalesNet>
    <vtl:RoyaltySettlementAgreementCashPaymentPercent
      contextRef="i6e183777c2784361bb1f6d43969d764e_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODI2NDIy_bb2e26b2-b24c-4fd7-8f61-be842e44d3eb"
      unitRef="number">0.50</vtl:RoyaltySettlementAgreementCashPaymentPercent>
    <vtl:RoyaltySettlementAgreementSharesPaymentPercent
      contextRef="i6e183777c2784361bb1f6d43969d764e_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80MC9mcmFnOmIyNDE1MzM2ZjAzZDQwN2ZiM2RiMzVlODVmZWEzYWJkL3RleHRyZWdpb246YjI0MTUzMzZmMDNkNDA3ZmIzZGIzNWU4NWZlYTNhYmRfNTQ5NzU1ODI2NDM4_48dd3d90-9496-4aee-a5ea-dbc59fb48633"
      unitRef="number">0.50</vtl:RoyaltySettlementAgreementSharesPaymentPercent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RleHRyZWdpb246NTQyZDBiODBhMGMyNGU2Yjk0MGNjMWZhNWJjYzU2MGJfODY2_89da85dd-ba8e-4c97-8615-6f4bf33cee93">Fair Value&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy tables present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Company&#x2019;s money market funds, which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RleHRyZWdpb246NTQyZDBiODBhMGMyNGU2Yjk0MGNjMWZhNWJjYzU2MGJfODY1_46211e67-c1d3-4933-b287-84714b8a672f">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy tables present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.240%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if619c407624b4922b1afa2e57a9ff01a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfMy0xLTEtMS0yNjg5MQ_f286d260-279b-452a-9404-a44c7a21732c"
      unitRef="usd">63241000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie0e026c775ec49f9861b7f0d7ef051f1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfMy0zLTEtMS0yNjg5MQ_76703a2d-ead2-4dc7-904a-bae615050ffc"
      unitRef="usd">63241000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaf678ced37ba47f7910be49d8d28b9e7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfMy01LTEtMS0yNjg5MQ_78c22210-bf2f-440a-ac0d-5c4b9937e2fa"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3bf2a21a1b3143b9a9bb2e50c90d5ad2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfMy03LTEtMS0yNjg5MQ_cd5e0772-ebe4-412f-90d5-850ee1e494f0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i01049530b3a04055a71bdcbd2ddb098f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfNC0xLTEtMS0yNjg5MQ_448a2e37-f9cf-4f57-a77d-7f1f7011454d"
      unitRef="usd">63241000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i91585558cbe34e778b4f5fbf7b1c8daa_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfNC0zLTEtMS0yNjg5MQ_c62f459b-8edb-4c41-a457-105f3691561d"
      unitRef="usd">63241000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia8722bc2bc004244be18e6327d5c0084_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfNC01LTEtMS0yNjg5MQ_dbaf61aa-7120-45c9-9d80-cbc781ce0186"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i848040a12f93446e94b293d803e3ba3e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOmQ5NWJiNWZhZjBlYzQ4ZGI5NWFkNjNlZDc1M2YyNGQzL3RhYmxlcmFuZ2U6ZDk1YmI1ZmFmMGVjNDhkYjk1YWQ2M2VkNzUzZjI0ZDNfNC03LTEtMS0yNjg5MQ_4461615e-0e39-475c-bf27-509c13566eb5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i900fc28b42424c17b00cd3ca859d30a1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfMy0xLTEtMS0yNjg5MQ_3b7f7b42-5ce7-43e9-8657-67b24dc3c249"
      unitRef="usd">31630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibd253af90c7049ba9afdf7bd8778d934_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfMy0zLTEtMS0yNjg5MQ_be8e9fcd-ecdc-45c3-8a77-ffeeb3f1decb"
      unitRef="usd">31630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iee4d595729674eff99b3ca2ca86c0b7e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfMy01LTEtMS0yNjg5MQ_cf8b7835-7198-4914-9c4d-65225adca713"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0e62c8bbfe554143bcfccd623eef0f68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfMy03LTEtMS0yNjg5MQ_4677d250-ec12-4269-92d3-526f9c5d7f0d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iee62d52d680b41dba637ae523465d27e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfNC0xLTEtMS0yNjg5MQ_0caa509b-0e01-4b65-a9a6-354484fe9614"
      unitRef="usd">31630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7fcb0abe6f0749babe8150c967988400_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfNC0zLTEtMS0yNjg5MQ_31dc69b2-1393-4afe-9bb1-4f0e16f0fde1"
      unitRef="usd">31630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if9a91903ca2a4ad0b30d85fb1a845075_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfNC01LTEtMS0yNjg5MQ_bb3995c1-33e8-40ed-866f-7c6695c67d98"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie8557ddef2d144928039c8fb2320084e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80My9mcmFnOjU0MmQwYjgwYTBjMjRlNmI5NDBjYzFmYTViY2M1NjBiL3RhYmxlOjEyZDZjNmMyZDc1ZTQ4ZWVhMThmMTc3YzJhZGI4ZDMwL3RhYmxlcmFuZ2U6MTJkNmM2YzJkNzVlNDhlZWExOGYxNzdjMmFkYjhkMzBfNC03LTEtMS0yNjg5MQ_223ecc1d-3551-44fb-9f59-8bcb3b3ac0f3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNjc3Mw_7c896d89-1324-49df-a5e6-840fd05feba9">Common Stock&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shelf Registration Statement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of July 31, 2022, there is $75.0&#160;million remaining on this shelf registration statement &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("December 2020 ATM") with SVB Leerink as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of July 31, 2022, $8.4&#160;million in capacity remains under the December 2020 ATM.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by SVB Leerink at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of July 31, 2022, $80.0&#160;million in capacity remains under the May 2022 ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company has agreed to pay SVB Leerink a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Leerink with customary indemnification and contribution rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the three months ended June 30, 2022, the Company raised gross proceeds of $10.3&#160;million pursuant to the December 2020 ATM through the sale of 1,300,000 shares of common stock at a weighted average price of $7.90 per share. The net proceeds from the December 2020 ATM were $10.0&#160;million after deducting underwriter commissions of $0.3&#160;million.  In the six months ended June 30, 2022, the Company raised gross proceeds of $40.9&#160;million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6&#160;million after deducting underwriter commissions of $1.2&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any ATM activity during the three or six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022, the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001 per share. The voting, dividend and liquidation rights of the holders of the Company&#x2019;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through June 30, 2022, no cash dividends had been declared or paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20 million shares of $0.0001 par value preferred stock, having rights and preferences to be set by the Board of Directors. No preferred shares were outstanding as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance at June 30, 2022 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;2021 Employee Stock Purchase Plan    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,232,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="ib934db459d0f41d6983debfc2a9bb490_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTQ5NzU1ODI0Mzgy_a2f120db-804b-4eec-bb4e-bc4bcc02782f"
      unitRef="usd">250000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationStatementAmountRemaining
      contextRef="i655d008592954266b8c505297b7e326a_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTQ5NzU1ODI0NTU1_77d257b6-1afc-41df-8a44-ffbfbe831db5"
      unitRef="usd">75000000</vtl:ShelfRegistrationStatementAmountRemaining>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="if084565ea6544630b40bf38bc6aa362c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTQ5NzU1ODI0NzUx_454e223d-e8f9-4b1e-944b-095092d539c6"
      unitRef="usd">50000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationTerminationPriorWrittenNotice
      contextRef="i5357132f62b84045b8592c18e2fa2958_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NTcyNQ_b42a3b6b-5114-4103-93bf-55f531b750a1"
      unitRef="d">10</vtl:ShelfRegistrationTerminationPriorWrittenNotice>
    <vtl:SaleOfStockRemainingCapacity
      contextRef="i84614fc2f3a34f45abbfe8caa4cc2f8c_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTQ5NzU1ODI1Njg0_e0cee319-e3db-4747-9229-849a77e229c2"
      unitRef="usd">8400000</vtl:SaleOfStockRemainingCapacity>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="iaab1b036d9dc44e98547c47688f3775e_I20220510"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTQ5NzU1ODI1ODc4_80880fa4-8602-4ab7-97e7-48d71d055217"
      unitRef="usd">80000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationTerminationPriorWrittenNotice
      contextRef="i2b29f09bbaba4becbebde67f5b01a643_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NTc0NA_21020bd6-b18a-4d4c-838c-c70c7c608c3f"
      unitRef="d">10</vtl:ShelfRegistrationTerminationPriorWrittenNotice>
    <vtl:SaleOfStockRemainingCapacity
      contextRef="i31e27d1c40d042c8a3fc68107417bf24_I20220505"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTQ5NzU1ODI2Nzg2_66ad3d43-cecb-4863-97df-b4b010244a3e"
      unitRef="usd">80000000</vtl:SaleOfStockRemainingCapacity>
    <vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTQ5NzU1ODI2OTAw_2a1985bb-7b9a-4717-a816-e2acd04dc897"
      unitRef="number">0.030</vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i77bff47627ab4656a7df6dfe32e589aa_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDU1NQ_146214a2-8c59-4831-96f9-380fe11dc9dd"
      unitRef="usd">10300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i77bff47627ab4656a7df6dfe32e589aa_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDU3MA_755d1206-f316-4c08-b2f1-2bb12d44a394"
      unitRef="shares">1300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vtl:SharesIssuedWeightedAverageSharePricePerShare
      contextRef="i77bff47627ab4656a7df6dfe32e589aa_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDU4MQ_561a61b4-0828-447a-a339-47fb3c9714c7"
      unitRef="usdPerShare">7.90</vtl:SharesIssuedWeightedAverageSharePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i77bff47627ab4656a7df6dfe32e589aa_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDU4OA_fae2400c-09ae-4e07-b3a8-e211722d30d8"
      unitRef="usd">10000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions
      contextRef="i77bff47627ab4656a7df6dfe32e589aa_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDYwMw_11205a78-cf95-4fed-a80d-015a01ffaa2c"
      unitRef="usd">300000</us-gaap:PaymentsForCommissions>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0f1bda4b5eb14655844a6f52d4e19aeb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDYxNw_6996505d-125c-475a-82da-ec08aa0f8553"
      unitRef="usd">40900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0f1bda4b5eb14655844a6f52d4e19aeb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDYzMg_24b71785-ae60-4e29-a4dd-82c45c9e1fba"
      unitRef="shares">4204113</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vtl:SharesIssuedWeightedAverageSharePricePerShare
      contextRef="i0f1bda4b5eb14655844a6f52d4e19aeb_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDY0Mw_5fdf3af4-fc7a-4dca-a9b4-119243ad8eaa"
      unitRef="usdPerShare">9.72</vtl:SharesIssuedWeightedAverageSharePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0f1bda4b5eb14655844a6f52d4e19aeb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDY1MA_d32db5f2-20da-4d63-b0ba-0809abed05ff"
      unitRef="usd">39600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions
      contextRef="i0f1bda4b5eb14655844a6f52d4e19aeb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfMjE5OTAyMzI3NDY2NQ_44a21f95-82f1-4868-8e32-658b5041f973"
      unitRef="usd">1200000</us-gaap:PaymentsForCommissions>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTg1NA_5062a8c3-a5c6-483c-a41f-ed17dff783dc"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNTg5NA_1978b503-4ab5-4256-9549-5546ad053006"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNjM1Ng_25f0efe1-6058-4b2d-82cc-d82ca99d534c"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNjM1Ng_9e3aac0a-3c39-4172-ad5b-ad88bc819aaf"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNjUxOA_a6e94bc1-c0e7-4d52-8fe8-b948c3a04651"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNjUzMQ_e902a588-ac98-4706-bfe4-aa05a379f7a4"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNjYyMQ_096d6cf3-3f57-408f-b1d3-bd7e2b1ca6bc"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RleHRyZWdpb246ZjUxNjY0MmIxYTI3NGUwZjhmZTc4NWIwN2ZjZTc0OTJfNjc4MQ_5cfc076f-af8a-448c-b97a-a71f19c04809">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance at June 30, 2022 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;2021 Employee Stock Purchase Plan    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,232,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i42f6581040da46739944cde97b521f6f_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RhYmxlOmEyNDE4ZWRmNzM3NjRjNzliNzU3MzY3NTAyN2QxZmEyL3RhYmxlcmFuZ2U6YTI0MThlZGY3Mzc2NGM3OWI3NTczNjc1MDI3ZDFmYTJfMi0xLTEtMS0yNjg5MQ_ae17a6db-faeb-4ca9-a39d-33a3027a01a9"
      unitRef="shares">162630</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ibc9159032004498fb16925e81f722e24_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RhYmxlOmEyNDE4ZWRmNzM3NjRjNzliNzU3MzY3NTAyN2QxZmEyL3RhYmxlcmFuZ2U6YTI0MThlZGY3Mzc2NGM3OWI3NTczNjc1MDI3ZDFmYTJfMy0xLTEtMS0yNjg5MQ_1685c470-b0fa-4dd3-adc1-358d587e5a7b"
      unitRef="shares">3713248</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia5fb46bdccd14b0bb258e8b0caf6b17a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RhYmxlOmEyNDE4ZWRmNzM3NjRjNzliNzU3MzY3NTAyN2QxZmEyL3RhYmxlcmFuZ2U6YTI0MThlZGY3Mzc2NGM3OWI3NTczNjc1MDI3ZDFmYTJfNS0xLTEtMS0yNjg5MQ_5d6f8c14-c864-45da-9d2b-6c7d8fb81ee2"
      unitRef="shares">43311</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if73baf845ed84292a90be900622c8546_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RhYmxlOmEyNDE4ZWRmNzM3NjRjNzliNzU3MzY3NTAyN2QxZmEyL3RhYmxlcmFuZ2U6YTI0MThlZGY3Mzc2NGM3OWI3NTczNjc1MDI3ZDFmYTJfNi0xLTEtMS0yNjg5MQ_281c0510-aa10-4e80-9e13-4885b2501041"
      unitRef="shares">46250</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3a7be395eedf4ec7b90be1d1cc54a7f4_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RhYmxlOmEyNDE4ZWRmNzM3NjRjNzliNzU3MzY3NTAyN2QxZmEyL3RhYmxlcmFuZ2U6YTI0MThlZGY3Mzc2NGM3OWI3NTczNjc1MDI3ZDFmYTJfNy0xLTEtMS0yNjg5MQ_6bf91979-8e55-4928-88b5-772fe3167141"
      unitRef="shares">267095</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80Ni9mcmFnOmY1MTY2NDJiMWEyNzRlMGY4ZmU3ODViMDdmY2U3NDkyL3RhYmxlOmEyNDE4ZWRmNzM3NjRjNzliNzU3MzY3NTAyN2QxZmEyL3RhYmxlcmFuZ2U6YTI0MThlZGY3Mzc2NGM3OWI3NTczNjc1MDI3ZDFmYTJfOC0xLTEtMS0yNjg5MQ_9852e8ad-afd6-4991-b25b-3b6d69c40572"
      unitRef="shares">4232534</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTk5NQ_3ac3509b-b39e-4ed8-8370-9d9809724bb3">Stock-Based Compensation Plans&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#x2019;s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;     &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issued  24,612 shares under the ESPP for the three and six months ended June 30, 2022 and 37,370 shares life to date.   The Company recognized $25,000 and $53,000 of expense related to the ESPP during the three and six months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company&#x2019;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) which was adopted by the Board with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#x2019;s common stock were available for grant under the 2019 Plan. The 2019 Plan includes an evergreen provision that allows for the annual addition of up to 4% of the Company&#x2019;s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2022 by a total of 2,481,195 shares. The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI1Mzg0_7a7a7119-e170-4cdf-8081-4d8911387b29"&gt;three&lt;/span&gt; or four years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Movements during the year &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the six months ended June 30, 2022 and 2021, respectively, for the 2019 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,702,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,064,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,064,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock options granted under the 2019 Plan during the six months ended June 30, 2022 and 2021 was $7.25 and $11.36, respectively. The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six  Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;&#160;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months&lt;br/&gt;&#160;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,570,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,263,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,131,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,086,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022, there was $19.4 million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 3.06 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Equity Incentive Plans Assumed from Vital Therapies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital&#x2019;s 2012 Stock Option Plan (the &#x201c;2012 Plan&#x201d;), Vital&#x2019;s 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) and Vital&#x2019;s 2017 Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There remain 43,311 shares available for grant under the 2014 Plan as of June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, Vital&#x2019;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#x2019;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expense was recorded for the plans assumed from Vital during the three and six months ended June 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i7a36d78c3a1d41aabc3bc530c7149510_D20210425-20210425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODIxNjU0_f50bf778-6448-4c1a-b36d-3f6c8f7d28d5"
      unitRef="number">0.15</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="i7a36d78c3a1d41aabc3bc530c7149510_D20210425-20210425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODIxODY3_ee108844-fc69-438e-9808-2ddcf71cf378"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="id4759bb9bc5548028846f27721d451dd_I20210425"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODIyMDc3_92991f44-08b6-41b4-98d2-e58ab683a668"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic41959aa4a854ce99c1ae76d7e539c7b_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfMzI5ODUzNDkwNzQ2OA_396b25c6-5426-43e2-b6c4-7f55010115a0"
      unitRef="shares">24612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie3846e4b177145349132e464e8ead06e_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfMzI5ODUzNDkwNzQ2OA_642d8a3a-8c5e-4f9a-bdf0-c1f756bb664c"
      unitRef="shares">24612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7a60641c12434b9d9746366fd13f9c6a_D20210425-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfMzI5ODUzNDkwNzQ3Ng_54221b62-4642-4b08-b9e6-2f52c1f58e84"
      unitRef="shares">37370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie3846e4b177145349132e464e8ead06e_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfMzI5ODUzNDkwNzQ4NA_ee072828-5251-44d1-afbb-d908bfa684b7"
      unitRef="usd">25000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic41959aa4a854ce99c1ae76d7e539c7b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfMzI5ODUzNDkwNzQ5Mw_ca91d6ae-375d-418f-b368-409e8ac78b9c"
      unitRef="usd">53000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i331baf434b944eed8f84aac672fd3fba_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI0MzA5_1d788d4e-462e-4f99-9b7b-bffa293e33b3"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
      contextRef="i4743858c51494178bb0a0087929cf1ca_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI0NDg2_f313fca1-c32b-4d27-8757-2f55f0d22658"
      unitRef="number">0.04</vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i4743858c51494178bb0a0087929cf1ca_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI0NTc3_725f8c8e-53df-41ce-b489-5e3087a7978c"
      unitRef="shares">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i78621ec446654b619edd9f1c7ddbbfdb_D20200101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI0NzM2_5229a578-ff8c-4c9e-8966-2d59961b546e"
      unitRef="shares">2481195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i241a45995e6d46d2b52b33a2b6d06c7f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI1MTcy_a7e9e3fd-5506-4be4-a212-6c3627dbc9d1">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9f6c4820198d4fcbbd17c0e25cf2af03_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI1MjQy_fad3faf4-d502-4c7e-9fbf-971939cfe43d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1175a630abb249cba6da4df17900b2f3_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODI1Mzkx_b53d43fe-8fb8-4fcc-8105-b7529bffaf2a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTk5Ng_f9427e69-27b8-435b-804a-69880631eb22">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the six months ended June 30, 2022 and 2021, respectively, for the 2019 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,702,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;961,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,064,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,064,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic25815c038244077a908eacfe7cdb746_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfMS0xLTEtMS0yNjg5MQ_1fd14178-b2b5-4aab-8c72-539b80fd78fb"
      unitRef="shares">2157460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic25815c038244077a908eacfe7cdb746_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfMS0zLTEtMS0yNjg5MQ_e8886b0d-a2ed-45da-8794-3f3c457018f1"
      unitRef="usdPerShare">13.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfMi0xLTEtMS0yNjg5MQ_06a57ade-4dfc-43ab-a8f7-4fe152a3da90"
      unitRef="shares">1702513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfMi0zLTEtMS0yNjg5MQ_554d3806-60c2-40cf-8beb-5129530b1d31"
      unitRef="usdPerShare">9.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfMy0xLTEtMS0yNjg5MQ_e2536700-5958-436c-9611-176ddec6b222"
      unitRef="shares">852</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfMy0zLTEtMS0yNjg5MQ_d5e5007b-6cbe-4d8e-8029-aac8464cd1c3"
      unitRef="usdPerShare">5.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNC0xLTEtMS0yNjg5MQ_e475887b-b6bf-4e82-8d42-51723aeda02f"
      unitRef="shares">145873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNC0zLTEtMS0yNjg5MQ_54ff622f-455e-42db-864d-84fbecfa8ecd"
      unitRef="usdPerShare">11.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNS0xLTEtMS0yNjg5MQ_f9afa761-5cbc-4f7a-a843-ac14750f1a2f"
      unitRef="shares">3713248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNS0zLTEtMS0yNjg5MQ_c714d448-2c2b-44d9-8546-ec0035eab9d5"
      unitRef="usdPerShare">11.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNS01LTEtMS0yNjg5MQ_43c2da5f-fee7-4014-9082-b2635d9bccba">P8Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNS03LTEtMS0yNjg5MQ_6a3b9b70-9ba4-437d-ad43-69080572d258"
      unitRef="usd">23870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNi0xLTEtMS0yNjg5MQ_32439ec1-add8-42c0-a13d-c271f4366a5c"
      unitRef="shares">3713248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNi0zLTEtMS0yNjg5MQ_45f4a336-7759-4e1c-93b0-02a198fd296d"
      unitRef="usdPerShare">11.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNi01LTEtMS0yNjg5MQ_48473d87-1977-4c86-8dc0-cc5006f00845">P8Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNi03LTEtMS0yNjg5MQ_4429ae96-c487-4cf8-8a10-a83f04133f93"
      unitRef="usd">23870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNy0xLTEtMS0yNjg5MQ_8b9c34ae-f015-4de4-ac05-8c4dbf3f0aa6"
      unitRef="shares">1127085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNy0zLTEtMS0yNjg5MQ_1cf6af1f-402a-47e2-a3a5-07f3d17dc162"
      unitRef="usdPerShare">13.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i96f5b4651d63447eab9b912df9ace6ff_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNy01LTEtMS0yNjg5MQ_2706486f-23c8-4c66-a779-204afa16089d">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i9c548edb791d48468aecdf5a3211e335_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmY1YzU2ZjQwZmI1NzRhNzRhNWUyMWIxODYzNTEyZmYyL3RhYmxlcmFuZ2U6ZjVjNTZmNDBmYjU3NGE3NGE1ZTIxYjE4NjM1MTJmZjJfNy03LTEtMS0yNjg5MQ_57e3f7c1-fd2f-4b86-a38b-c3d49859d073"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib0e20fcc653c40a39665c834b098509d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfMS0xLTEtMS0yNjg5MQ_c1d1ed41-c805-4c52-b9c0-91e28454c2e9"
      unitRef="shares">1117160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib0e20fcc653c40a39665c834b098509d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfMS0zLTEtMS0yNjg5MQ_7af22a58-d533-4975-b65a-b6d5879d0b1b"
      unitRef="usdPerShare">12.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfMi0xLTEtMS0yNjg5MQ_d92918a1-13a9-4be1-891c-ab43b97ed6cf"
      unitRef="shares">961059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfMi0zLTEtMS0yNjg5MQ_55890bd4-bd7a-4276-b9c2-938357143d3f"
      unitRef="usdPerShare">15.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfMy0xLTEtMS0yNjg5MQ_f3ac54fd-3650-46a7-ad6f-544fe6a70123"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfMy0zLTEtMS0yNjg5MQ_c9f98428-81d6-4996-8d20-6b4b2a8dfb5d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNC0xLTEtMS0yNjg5MQ_5f5706a4-d7fe-4e26-ad9e-72e820b21ded"
      unitRef="shares">13380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNC0zLTEtMS0yNjg5MQ_e290fa04-0548-471d-b7b5-83ef2e2c18cd"
      unitRef="usdPerShare">12.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNS0xLTEtMS0yNjg5MQ_d8621fd6-0dd8-41cc-9bb1-108f112c086d"
      unitRef="shares">2064839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNS0zLTEtMS0yNjg5MQ_f04cce76-2ff2-4e7a-b2a6-8418af1bdd67"
      unitRef="usdPerShare">14.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNS01LTEtMS0yNjg5MQ_b471dc66-9e06-4218-85fd-168efac32485">P9Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNS03LTEtMS0yNjg5MQ_c786deb4-4ebe-4a7e-9d7b-e3f2b12fe579"
      unitRef="usd">411563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNi0xLTEtMS0yNjg5MQ_1437df00-5195-411e-a6e2-8ea2e62005f5"
      unitRef="shares">2064839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNi0zLTEtMS0yNjg5MQ_04ad025f-3c34-4902-83ef-211175e5b219"
      unitRef="usdPerShare">14.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNi01LTEtMS0yNjg5MQ_2494949e-9223-487f-ab2c-667d68081ec4">P9Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNi03LTEtMS0yNjg5MQ_b1157d22-9462-4ebc-b799-396e1da863a2"
      unitRef="usd">411563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNy0xLTEtMS0yNjg5MQ_80505e88-b139-4151-bd19-6ecc0fa0e902"
      unitRef="shares">462022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNy0zLTEtMS0yNjg5MQ_86453c9b-4e20-45d2-ab5c-62f3bd6e3fc8"
      unitRef="usdPerShare">13.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i93a9137d93f44392b7470a9982635184_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNy01LTEtMS0yNjg5MQ_2704e05c-dd30-43bf-ab40-bc3661457359">P8Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="iaa2a1c898f234b2da41f85403f50c9d6_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOjA0NTYzOTdjYjE2MzQwN2JhOGY1YjBhZTZlNjRmZjgyL3RhYmxlcmFuZ2U6MDQ1NjM5N2NiMTYzNDA3YmE4ZjViMGFlNmU2NGZmODJfNy03LTEtMS0yNjg5MQ_a1bd3c3f-4c41-45f6-9cb5-3681b25027a6"
      unitRef="usd">227848</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODM0MDE5_4f3f2eeb-a824-4d69-ba31-7936fffbe9e4"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie44b429d3b05430ea58a4793c8c7b0ed_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfMzI5ODUzNDkwNzQ1Mw_42130e7d-0a65-4072-9c4b-b08996660562"
      unitRef="usdPerShare">7.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5d31dbd295f24c42bfabd2db4c4c9f38_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfMzI5ODUzNDkwNzQ2MA_079e339c-dc71-441c-8f9d-3f1f18d07e8c"
      unitRef="usdPerShare">11.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTk5Nw_43f27d30-a0e6-4637-8a8d-dcbd9cf71d3e">The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six  Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie44b429d3b05430ea58a4793c8c7b0ed_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfMi0xLTEtMS0yNjg5MQ_285acef3-bc35-4fe2-ae26-437a2889943a"
      unitRef="number">0.0195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5d31dbd295f24c42bfabd2db4c4c9f38_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfMi0yLTEtMS0yNjg5MQ_82948537-291f-4eb5-a080-e6a17d46e680"
      unitRef="number">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie44b429d3b05430ea58a4793c8c7b0ed_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfMy0xLTEtMS0yNjg5MQ_db63fc10-afb0-4187-af49-8472bdb6c1a6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5d31dbd295f24c42bfabd2db4c4c9f38_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfMy0yLTEtMS0yNjg5MQ_f939c8f8-b715-412c-a11b-cf41e02b0ec5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie44b429d3b05430ea58a4793c8c7b0ed_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfNC0xLTEtMS0yNjg5MQ_ad750ffa-1015-4e97-9488-1b9bbc517baf"
      unitRef="number">0.979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5d31dbd295f24c42bfabd2db4c4c9f38_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfNC0yLTEtMS0yNjg5MQ_bfd009fb-6fac-4107-8bea-08a543f0666c"
      unitRef="number">0.923</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie44b429d3b05430ea58a4793c8c7b0ed_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfNS0xLTEtMS0yNjg5MQ_964de7d3-37ad-4af7-999b-307010d0fc8a">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5d31dbd295f24c42bfabd2db4c4c9f38_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmNiMjVjOTc4YjI4NjQ1Yzc5ZTdlMmVlMWEyNzEzMjg5L3RhYmxlcmFuZ2U6Y2IyNWM5NzhiMjg2NDVjNzllN2UyZWUxYTI3MTMyODlfNS0yLTEtMS0yNjg5MQ_84b9aa46-bb36-4ee9-8dc8-fec3e3c93541">P5Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTk5OA_085e6cc2-b383-428c-bcda-6093e7755868">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;&#160;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months&lt;br/&gt;&#160;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,570,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,263,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,507,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,131,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,086,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="ibc512c7aab944fc485311bf9c02ff970_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMi01LTEtMS0yNjg5MQ_d79e5b34-251c-48a7-8d3f-b271ae1f80f8"
      unitRef="usd">765000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3a4ddd497fd542b9b3fd027648d47f75_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMi03LTEtMS0yNjg5MQ_67f444f7-c515-418a-8841-be641efbb4f4"
      unitRef="usd">492000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8e71423082664f22b47833b74742032b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMi05LTEtMS0yNjg5MQ_ed4a80f2-eade-4891-bcb7-2b34b55dcc67"
      unitRef="usd">1561000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic2bea17fde984023989bd83f8d7409d3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMi0xMS0xLTEtMjY4OTE_d13d1d29-42b1-431a-b9ab-43456afc6806"
      unitRef="usd">823000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i647b4b4c351941fe967436ca5d55ac90_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMy01LTEtMS0yNjg5MQ_f94233a2-96be-49be-9bdf-f600620a55dd"
      unitRef="usd">1297000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8d7bda77d8e54df095211d496fde1e19_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMy03LTEtMS0yNjg5MQ_5ddda92b-2577-4460-ae5f-69791b2d5fcc"
      unitRef="usd">1015000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i780a02233b614aad8fc86df96172eeb7_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMy05LTEtMS0yNjg5MQ_21577fa0-fc30-4fb6-be73-38088c4725d0"
      unitRef="usd">2570000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6be40b2c9d674c08af4179c7ed347d3e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfMy0xMS0xLTEtMjY4OTE_89836af6-06af-4a96-b363-47d9ecbe6031"
      unitRef="usd">2263000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibbabe7452d5d43f6b73995f3e391e6b8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfNC01LTEtMS0yNjg5MQ_51baa32b-021e-4188-8853-e4238ef1d79e"
      unitRef="usd">2062000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i26a9bf6e1992474bbccdbdce509a8df2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfNC03LTEtMS0yNjg5MQ_969b5866-4b04-4b86-b94d-1c3d54c38070"
      unitRef="usd">1507000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2dd13b02f4a346ca9385ff8f54ab0d4c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfNC05LTEtMS0yNjg5MQ_fed53e81-fdca-44c6-9418-c825af4620b2"
      unitRef="usd">4131000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i23ce68a8dc964e0992d506ff2d9b8074_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RhYmxlOmE5ZDBjOTNmM2Y1OTQ5YjliNDVmNjBhODFlMTc2ZGUwL3RhYmxlcmFuZ2U6YTlkMGM5M2YzZjU5NDliOWI0NWY2MGE4MWUxNzZkZTBfNC0xMS0xLTEtMjY4OTE_6a8eb5df-33b0-40ef-9e63-bac83e4efb41"
      unitRef="usd">3086000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i7dc0d5e8a345477e98262fa6c4169a4c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNDgwNA_bc39d115-ab44-4a7c-ae2b-11b7a86231d8"
      unitRef="usd">19400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNDkyNw_cfc0cbb8-ac86-4c34-9046-df7179c0f8f0">P3Y21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ib42e39df400b422a95c9c1d1cd93fae5_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODM2NDI4_14f072f0-77ce-49d5-b357-68624b89267b"
      unitRef="shares">43311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i12cdbd33c3434c698ad8b49490ad01ef_I20170930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODM2NjUy_3e0fc136-1a65-4c50-bd4d-b6096518b363"
      unitRef="shares">46250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i679e236a84ee4593a0aed89cb7edadf1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODM2OTQy_9ffcc378-de89-49a6-9b12-7cde7987d08c"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic40354f16dc842a1a88ac97efa9f06d6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl80OS9mcmFnOmI5OWE5OGQ1N2Q2ZDQ4MzlhNjg0MTk2M2ZiNDBhMzE2L3RleHRyZWdpb246Yjk5YTk4ZDU3ZDZkNDgzOWE2ODQxOTYzZmI0MGEzMTZfNTQ5NzU1ODM2OTQy_e1f54d93-7966-49df-8afc-8d45d4c688a7"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81NS9mcmFnOmFmODAzNzI1YWZiZDQ4ZWFhODVjZjNjMTBlY2M0OWQyL3RleHRyZWdpb246YWY4MDM3MjVhZmJkNDhlYWE4NWNmM2MxMGVjYzQ5ZDJfMTEyMg_0362fff9-8ec8-4a03-a6fa-2b88d99428c5">Related Party Transactions&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Executive Chairman Agreement with Duane Nash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the current Chairman of the Board, Duane Nash, MD, JD, MBA (the &#x201c;Executive Chairman Agreement&#x201d;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#x201c;at will&#x201d; employment relationship pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020, which was subsequently extended to April 15, 2021. On April 15, 2021, the Company and Dr. Nash entered into an addendum (the &#x201c;Addendum&#x201d;) to extend the term of the Executive Chairman Agreement to April 15, 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Addendum, the Company made a one-time award to Dr. Nash of an option to purchase 90,000 shares of Company common stock, which vests monthly commencing on May 15, 2021, and to increase Dr. Nash&#x2019;s monthly base salary to $27,960 from $25,417. Effective March 15, 2022, the Company extended the term of employment from April 15, 2022 to December 31, 2022 with a base salary of $29,358 per month (which includes the cash retainer payable for serving on the Company&#x2019;s Board or for acting as the Chairman of the Board). In connection with this extension, the Company made a one-time award to Dr. Nash of an option to purchase 75,000 shares of the Company&#x2019;s common stock, which vests monthly commencing on April 10, 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other terms of the Executive Chairman Agreement remain the same.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibb4ae9a6beec4eae8fa5eb08ddd32a03_D20210415-20210415"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81NS9mcmFnOmFmODAzNzI1YWZiZDQ4ZWFhODVjZjNjMTBlY2M0OWQyL3RleHRyZWdpb246YWY4MDM3MjVhZmJkNDhlYWE4NWNmM2MxMGVjYzQ5ZDJfMzI5ODUzNDg5MDMyNQ_6b8a895f-6632-4779-80da-88e391f7bc8f"
      unitRef="shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <vtl:SalaryCostsMonthlyBaseSalary
      contextRef="if42ab5585116465fbf465ea6f59165fe_D20210515-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81NS9mcmFnOmFmODAzNzI1YWZiZDQ4ZWFhODVjZjNjMTBlY2M0OWQyL3RleHRyZWdpb246YWY4MDM3MjVhZmJkNDhlYWE4NWNmM2MxMGVjYzQ5ZDJfMzI5ODUzNDg5MDM1MA_73689642-084b-409a-af8b-0d64351cdcf5"
      unitRef="usd">27960</vtl:SalaryCostsMonthlyBaseSalary>
    <vtl:SalaryCostsMonthlyBaseSalary
      contextRef="iaabe57dcd0314a53bb5425c2259aeed2_D20210101-20210514"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81NS9mcmFnOmFmODAzNzI1YWZiZDQ4ZWFhODVjZjNjMTBlY2M0OWQyL3RleHRyZWdpb246YWY4MDM3MjVhZmJkNDhlYWE4NWNmM2MxMGVjYzQ5ZDJfMzI5ODUzNDg5MDM1OQ_4fb8f9d2-931c-429b-8bee-347aec89e2ac"
      unitRef="usd">25417</vtl:SalaryCostsMonthlyBaseSalary>
    <vtl:SalaryCostsMonthlyBaseSalary
      contextRef="i9a5888f9828e4ffcb2ca6bbe78a31e05_D20220315-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81NS9mcmFnOmFmODAzNzI1YWZiZDQ4ZWFhODVjZjNjMTBlY2M0OWQyL3RleHRyZWdpb246YWY4MDM3MjVhZmJkNDhlYWE4NWNmM2MxMGVjYzQ5ZDJfMzI5ODUzNDg5MDMzMw_08387a5f-0727-487b-abff-cb9e811ccaa4"
      unitRef="usd">29358</vtl:SalaryCostsMonthlyBaseSalary>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie57caaa75a5a464083b4f824217dc1e7_D20220315-20220315"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81NS9mcmFnOmFmODAzNzI1YWZiZDQ4ZWFhODVjZjNjMTBlY2M0OWQyL3RleHRyZWdpb246YWY4MDM3MjVhZmJkNDhlYWE4NWNmM2MxMGVjYzQ5ZDJfMzI5ODUzNDg5MDM0Mg_12bcee7f-4a39-4e82-ba08-3dbe7923eaed"
      unitRef="shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81OC9mcmFnOmI0ZmMwYjVhNzdkZjQyYmVhNTk4MGZiMDFjZThlMzUzL3RleHRyZWdpb246YjRmYzBiNWE3N2RmNDJiZWE1OTgwZmIwMWNlOGUzNTNfODc2_02060a9e-d65b-4c6f-8fd1-aa45ea06b48f">Subsequent Events &lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Changes in Board of Directors&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 6, 2022, the Company announced the appointment of Monika Maria T&#xf6;rns&#xe9;n as a member of the Board of Directors of the Company, effective as of July 5, 2022. As a Class III director, Ms. T&#xf6;rns&#xe9;n&#x2019;s term lasts until the Company&#x2019;s 2023 annual meeting of stockholders.  Ms. T&#xf6;rns&#xe9;n is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K. There are no arrangements or understandings between Ms. T&#xf6;rns&#xe9;n and any other persons pursuant to which she was selected as a director.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with her appointment as director, Ms. T&#xf6;rns&#xe9;n was granted a long-term equity incentive grant in the form of an option to purchase a total of 30,000 shares of the Company&#x2019;s common stock, with an exercise price of $4.30 per share, which is equal to the closing price of the Company's common stock on The Nasdaq Stock Market on the date of grant, July 8, 2022. The option to purchase 10,000 shares vests in monthly increments over a period of one year from the grant date, and the option to purchase 20,000 shares vests in monthly increments over a period of three years from the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, Ms. T&#xf6;rns&#xe9;n and the Company entered into the Company&#x2019;s standard form of indemnification agreement for directors and executive officers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently, the Company also announced that current Class III director, Jan Van den Bossche, resigned from the Board. The Board accepted Mr. Van den Bossche&#x2019;s resignation effective July 5, 2022. Mr. Van den Bossche&#x2019;s decision to resign did not result from any disagreement with the Company on any matter relating to Company operations, policies or practices.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ifdfa66f7711347ab96273868fd75f343_D20220706-20220706"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81OC9mcmFnOmI0ZmMwYjVhNzdkZjQyYmVhNTk4MGZiMDFjZThlMzUzL3RleHRyZWdpb246YjRmYzBiNWE3N2RmNDJiZWE1OTgwZmIwMWNlOGUzNTNfMzI5ODUzNDg5OTM5MQ_2c81e3d1-1ae7-45a8-92a1-1204174c96fd"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifdfa66f7711347ab96273868fd75f343_D20220706-20220706"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81OC9mcmFnOmI0ZmMwYjVhNzdkZjQyYmVhNTk4MGZiMDFjZThlMzUzL3RleHRyZWdpb246YjRmYzBiNWE3N2RmNDJiZWE1OTgwZmIwMWNlOGUzNTNfMzI5ODUzNDg5OTM5OQ_2ead954c-fbf5-49f2-be54-c62b85bb5ad5"
      unitRef="usdPerShare">4.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8de1a675bd3646b6b25adee3e85cab4c_D20220706-20220706"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81OC9mcmFnOmI0ZmMwYjVhNzdkZjQyYmVhNTk4MGZiMDFjZThlMzUzL3RleHRyZWdpb246YjRmYzBiNWE3N2RmNDJiZWE1OTgwZmIwMWNlOGUzNTNfMzI5ODUzNDg5OTQwNg_e4c9180d-0f4f-4c76-a11c-66440db5843d"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8de1a675bd3646b6b25adee3e85cab4c_D20220706-20220706"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81OC9mcmFnOmI0ZmMwYjVhNzdkZjQyYmVhNTk4MGZiMDFjZThlMzUzL3RleHRyZWdpb246YjRmYzBiNWE3N2RmNDJiZWE1OTgwZmIwMWNlOGUzNTNfMjE5OTAyMzI3MTY2NQ_4daf3a2a-5844-480c-9047-486314e2de6f">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ib73002cd7def4d70a33e0dbcb20c34ff_D20220706-20220706"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81OC9mcmFnOmI0ZmMwYjVhNzdkZjQyYmVhNTk4MGZiMDFjZThlMzUzL3RleHRyZWdpb246YjRmYzBiNWE3N2RmNDJiZWE1OTgwZmIwMWNlOGUzNTNfMzI5ODUzNDg5OTQxNA_8393dafc-e4bf-4c7a-861c-401b80b64ade"
      unitRef="shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib73002cd7def4d70a33e0dbcb20c34ff_D20220706-20220706"
      id="id3VybDovL2RvY3MudjEvZG9jOjEzMmEzNmI4NGFlMTQzNjM4ODlhN2NhYmU1N2E4ZDZmL3NlYzoxMzJhMzZiODRhZTE0MzYzODg5YTdjYWJlNTdhOGQ2Zl81OC9mcmFnOmI0ZmMwYjVhNzdkZjQyYmVhNTk4MGZiMDFjZThlMzUzL3RleHRyZWdpb246YjRmYzBiNWE3N2RmNDJiZWE1OTgwZmIwMWNlOGUzNTNfMjE5OTAyMzI3MTY4Mw_bdaa3d93-4ad5-4677-9b4f-56e5528fa313">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M(8&7@;'Q<*=BW%4./%3?D/.BX+RHV3,E@^](]AFH;D?<:\'"Q-B0J*PA8+\
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MGN,XL$7K;8]'PUKJ^XWZ_GGJJ^)$N-"ID/0/3!@7U6BG_(H_V-(%K\+R]\+
M"8$M"T%C(7B5!:I4<5Q^L*/JI>Y#$2W!82,X?)5@^%HHC7E"^>J8ZO"HZD,1
M+=6#1O7@H.JIR#(XU:\L\L%I17XTK"5]V$@?GB'][ H?[J32];M+_)3(EH-1
MXV!TOH/3"GRTH\EW@K _&@4OQ.\&>J'O!WUWV*W==?Y]*YWSU9]1[37]"1XZ
M(O>8L+>^_>;B]17+%>4*,;($J-,; (>L[C)51XN\O XLA(;+1=E,X?Y'I F
M^:40^KEC;AC-C3+Z"U!+ P04    "  W. 152]\?^?D$  !>%0  &    'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;*U8:V_;-A3]*X16# F01")%O3+;0!.[
M6X>U"Y)V_:Q8M"U4$CV1MI-_/U)29%N\4KW-7VP]SCWD.9<B+SG:\?*[6#$F
MT4N>%6)LK:1<W]JVF*]8'HL;OF:%>K/@91Y+=5LN;;$N69Q407EF$\?Q[3Q.
M"VLRJIX]E),1W\@L+=A#B<0FS^/R]8YE?#>VL/7VX#%=KJ1^8$]&ZWC)GIC\
MNGXHU9W=LB1IS@J1\@*5;#&VWN/;&0YT0(7X*V4[<7"-M)1GSK_KFX_)V')T
MCUC&YE)3Q.IOR^Y9EFDFU8^_&U*K;5,''EZ_L7^HQ"LQS[%@]SS[EB9R-;9"
M"R5L$6\R^<AWO[%&D*?YYCP3U2_:U=C M=!\(R3/FV#5@SPMZO_XI3'B($#Q
MP &D"2#= -H3X#8![JDMT": GMJ"UP14TNU:>V7<-);Q9%3R'2HU6K'IB\K]
M*EKYE19ZH#S)4KU-59R<W/,B46EG"5)7@F=I$DMU\R35GQH/4B"^0'^N61GK
MO ITC;X^3='%NTOT#J4%^K+B&Q$7B1C94O5&<]KSIN6[NF72T[*+/O%"K@2:
MJ1XD0/QT.-X?B+>5"ZT5Y,V*.S)(^/NFN$&N<X6(0PC0G_O3PS$DY_^U/OO/
MK1^9X;;CPJWXW!Z^)N7%$K&7M1X@XA9*<4U"81(]R=V*=3QG8TO-8H*56V9-
M?OX)^\XOD+_G))N>DVQV)K*C3- V$W2(??*H&.-ROD+J,U-3X%;-[6O]94+I
MJ)G\BDDO$=L)]CTW'-G;0Y\!E!=T45,3Y;I1Z!ZC9B:*!,0+6M219*^5[ U*
M_I45:O1EE>(X4;->*J0>C5L&B:ZYO(,N4"<@'<TFR*5N!S0U0:'C=T S$Q0X
MG@,+]EO!_J!@^G2/2OX:9_(5"29E5LV]Z$(PACYSR1"]A)3[1E><CNP?(J8_
M1,Q,!%8I[E$<M(J#0<5?N%0)YL8L \D,C X0Q\==J28*1SCHRC51E#C4ZT@V
M41[V^D9UV$H.!R7_P85 BY+G;[+5>@K)#8W&KR&]  P2#, @Q0!L0'+42HZ&
M5Q&Y8J6J$^8\9^BBR?$EN))$YUQ)SDDV/2?9[$QD1]G SK[8<P:'X,=",L4K
MFY2 19MC?D>.WQE[$*BS,DPA3!<T T 4PV,.'Y2T>% E/.JN4,' 1;-A._Z2
MW"CH:C9AF!!#-4 6!$%7-H"*/-(CG.R%DU,F55 ^J)P RDF$N\I-&":NWU4.
MD/D^[2H'4!'N2_F^6L6#)=CDL]I29VI^!56Z1HUR37#D&#(!' XBEW:% CA*
M B?J2@5P'J%^V"-V7Q#BX8KP32Q2RP@2J[AD5WJSG,[1A=J2Z?U9^P).>TT?
M'G;,N3%*)A@6=HLF"(9OJ.$& ",WE/:8L2\5\7"M")F1I-E&[V)/M,,[S0X0
M9MH!P" [ -B '?M"$@]7DM^JDQ&67,=;56,L&5*S0,Z+6K[:S&^DD*JL5B77
MX9BIW\+NF.6?ZQ :!KXQ09I(@@,:43?J>@0@0S_THVZ1,P,YJ>_ZGM_CU+X
MQ<,5Z+]QZG! #7EEUHU]7@$U;8]7 ++'*X@3],H^."_*6;FL#NJ$,F!3R/J(
MH'W:'@:^KX[ .L_O\.T]!IY/]>%A=3ZUIZ]/'C_%Y3(M!,K80C6E/C/5W;(^
MS*MO)%]7IU7/7$J>5Y<K%B>LU #U?L'5?JBYT0VT1ZJ3?P!02P,$%     @
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M[<'T]OH/'FQXCAF\5D)0ECPC^#=@LB"Z$# =2:T6;-K#"YR.(PT@'(8=/QI
MOG/6<>-+$ Y=W^S%L TYW!OR'5>DZ'AQUQ4,#5<0XZ![!0TP]PR['5AL@/F>
MZW8R,S;!SL.@&[:]43B45,RJBDU"8 NFZC>B'6V+PHNJ%NJ,7[K]D6L8CZ&(
MK&N^O_)U!7I-Q"QG$A5T"DLYIR&<D*BKNKJC^+PJ6QZX@B*H:F90"%.A 3 _
MY5RM.WJ!MK2._@!02P,$%     @ -S@$56Z>R&UH#0  9[(  !@   !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6R]G>]SFT8>QO\51NWTFIESQ?X 06M[IK&
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M+65-CLJ:&)55GT'FR[N-E?\Y6V2;N]RJMMFF7&6?T@'S_S^4U8GMH->3[I:
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M:]$X-4=!G2%0FH#28B@M@=(DE):B:&VA-C828O:1:'<HSXO3[YE(@[I%H+2
M=&T-G6D*ZA:!TH2F"_2)-*@5!$J3FC9H$VFZ8H9$&FV<'M3^BCN4%&K\@-*F
M4%H I8506@2E"2@MAM(2*$U":2F*UA9V8PZA9G.(:8>2ZO+R$[]S 9LYQ& !
M0ET@4%H(I450FH#28B@M@=(DE):>'^5M:37F$VHVGPRYF(UVS1?$L2>JT+#W
M#<'>. 1)"Z&T"$H3O?HJAL9,H#0)I:4H6EMFC76$FJTC+[BRC6HR^O7:0%4=
MU#T"I0506@BE15":@-)B*"V!TF2O49FB8K95UUA6J#%S_M+$FID^> 4(]:A
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M<F//KQ2R7S/*DX[Z:7U&=F-/AEK/;_'EHCSI:M24!V\?J 1N5%"!:U 9O)E
M\<CR+*N\T:*PQT$KH;7([.66T81)(P#_7PMH1M6->4%]HCC_'U!+ P04
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M=0D?(&T]ZEK1N2TN^"4Z(<O2$V-TE8:9 G8@S9$C43=(AP#G>D<L=##X_#"
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MC*[FGW1G5IXVX/W<N=@MZ(#^V^75?P%02P,$%     @ -S@$55WG)2#0'
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M8\XY_LUPG03H[BSI'+YFRC!7].5D<62=>_A\?F3"/^3X$^7XYQD9)W7'6!)
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M$,9$#D>F,3V+D!%@XW9*#OX4!@['2@4P/D_\J*I(I\H^[9;C*4-44M8Q:D?
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M_]ANP,44C_.)'5*:1)', &?LA,0#?[A.=1BAF:VUB:-CODX"ZP>U4D$5#3A
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M+.?#Y6.Q3(;CWOMC%S[C3N%<S*BHF0Z7$W'O"/I5F.:\YWZS'SII?UD[]*%
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;*U6;6_;-A#^*P>U*%K
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M_12]T$\'O<='AY$10E*@%MWK9I\7^IYQ!M_J\"TZ)$+2%0+STOIN7KS4P&3
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M&R1*&AOT3"I=V+F ,'L+V  $57"W+BD#*>S/[2KL(LY#I1YD.<HDX8]46@P
M#(;&A5UB+V.S #H2M5M1(X%CJ*ZWBY_$0DV-.<6!/)E/20?T10I4>V30#F;,
MSE+&[.Q@VBOVY>!4+S%\MYP-EK+Y='+T;XZ)0H3.#)4-]P@VVY!%X8*/O@:V
M8AVXRMX=-(\1X_$)W%K;MCIK+@NU!][=? C@X\JI!O0;D()=8@*IZ1&?UJ7I
MFUGQ]OWGXY_N/^"^)?C\Z,'#U%&TAEV$T*45-*:^V%"A1HSK\B7G<\(/((XE
M9WNGI\T<X[]\42-:F*":UC5LJ"/5_O3I_>6L^'PQ*RX^_/;VY?'I3PR /UY>
MS(M/^\B*W!()I*Z<U/Y!80G9G;T+R^-UQNUA^T9$DI13[W8:3 H!^)O@M,;4
M8.'01FW4KN'*CP>WZXQL>>@;@3BTMCN-1K/52]-1NB!D3\$\L\=ET4K(!%2>
M]R$6(?QMN$/8F3PBF9YA]VU@T[ ^AN&;DT8DM0(1S'H<;C+"NI5JS9\R:.BL
MN_CTP<?..O).%K'MN)\RK(2= E@N>*BG?B@0,1V*9/8+Q=L+(.U:ESV'0NEA
M/*G!,0DF  &TM%P-4,5[!9;)@=WBHLVYH]H,,2@0^O[R/-#)7( O8K;68N$(
M!LMG""M!BCGI1: Z1,&R]4QY^*/?V)ANV=0Z](#=D)Q1H5*&QRX;,L4W.FS2
M;-2D1"*-'&'9B4J V*ZELK]"\C<8=V!5$5-^RR26H]ZI/(+(6^+)S1PTW>F8
MQ.G!<PW/+[##;6&E_SG;GFF;_;V#%1<AE!H\PKGM$A>=RSDA+3$$D<&H.BX4
M]=(.(1II=4P'AXHT]30"LQX#8FV/(0K'M!(&>)@_PLB8<LO9]_T&AFZEQX I
M6FKL:\QT>C;(L;85Y^X<]0_>M#U/PB<2U$:U/0(_;BGQ_6:#$98HWY- $R66
M64(1DYEFT3L?4X-[[2A)&S=+.KM3-1<B6LK7@P%D_"C+"CBM&XEZ%/#M6I.Y
MHU @6!LV8VB 1#9]"5*,P[Z.+919:\^E9%U\\<)B\N7.Z_/+%W>GG_B\P0 I
MFH/SR\_1;)V=G/YP?/)3".7 V )2[Z6T>Q%)([MX08>KT#Z$Z [9 :,5O]@Y
M'; X/GTTBT-ELGHUL$O!:.)Q$WQ;WCS"XQGI3W ZZ%>6)N238J-_G9H!R\$<
M*M<'1LP4"B^I:730K<F&/BYHS/+SRXOBX<E#"ND_0"R!>!#I&L;'Y$1"1S"=
M.-FO<\4=?//HI3+@A$UQJ=JO.UN<AY^/[C))H]\O['PF1UM&K^(+Y,\!=5 J
M,B>,@ENJM6#_9B %'K7]AMG6;"QV)<T0KD(HD8K+N;@&>#7C7,S&(@1&.6SU
M%O2(/)Q6'2L/KQT5<04>R6%Z@8(A!(C&8V7$Q[Q."9&4*L/W,ZKZJ:9AM5_8
MK:ZSWQP@.#(@_(/?M97#6)KXA8>,W%JK#$0LX!NC4^=Y[N0")?/B96H %=+9
MZ ]W.,M/XTY5[.5N@;:($0*X.DJ81%M#C![M,VP+BA!WVO6-S'9,LU&-:UY<
M<MX@-U@\;*H,2I63.FI#6H(K986J.,CF4Q;[0' VN$_Y@%!"QR12D-=Y\:$M
M?@:+B[6&!Q0HG8R4XQKMMI?LLO 87<R"M+CC>FG=4X<V@(\:8K,J$]MD^05X
MT:FS@/?/L[(N6LR5Y-9EGC Y:X?/CSM$W2"'-]R'F._#2AWN)_@0JI[0IL>.
MZ!1U4.VNE?.R,38<$3$2*6R&4NA2CRG;%]PBJRDE#[2^2=J\^!P[&?89D=GX
M%^I9\!8/L*T,JA ,*]GPD.PXY'S9L4UA?H59#TSK^LP=3G#H$()*1S=/#Y_=
M?)/UPI\/>^$/AK]_>]3BS2VZ\$-HE@)D3/)-Q42,6-$PI'C8M 'O8^Z3#TM0
MC5N*; /K$DT<@AO,' <3!_:,N^EO=VS@&X5T2LI,G/FB-+ED-B4#!T!GB6<5
MR; @FJ/E4:5]E@-J2B"JZSRB!*KY<,4L,F@B+@3J@0$'Y2B=;CP]?#CQDM;%
MF?*+;%V3PO-]0PWPGI1;O$1%$KZ'P)C+7^UQ_"+&B;%>1<(A)5KD:S@ LR54
M-^C>(SMW3##O9MF/7B!/L6KYI$LZ$,RMWBP;Q1USEU+<HW9!+B;%!A8JSWD0
ME]@I*&DYSNE0#IA)W-(?5ZFRQS236U/Q[9@!YI3('2-4M'1<N9;6-^E9Q#EN
M-7I^=C:; 87>MO4N% PQBX49<VJLY#ZC.DO<3X["&<8%)0'!,>]1%QP0&9KJ
MTS(F[1)6%7#/AMM(*TMGX-).9ML/L!@T#G!Q%1@1N;;D<QFC&B3K9#QN<.-]
M.ANTU*8C81T?TTD-PJGV"]^!F2LA]!YE5=+9SQLU0D[U6LEGI\[4%[4"]EV6
M6'OUQ^\!Y-N I(\Q,4RE EN!K;QS].+R_='=V(.:GPJ6OK1A+YKO%U^DUVY/
M6QJ# ?_U>(E92,I78KG54:E[NH:>M4(,.S98F@0S4>(&,^ [H^MJ7SO"@0&N
M+%8)\[I4;$S\]DBA7A-'H^-;\BKS=B[9W?Q,,56*8O$(5BHA5Q<\F:1,(B:B
M0M#>'D)*^H=2C)@QPIRQ6C&H\$C5<S:YOGT^*9JN,E3!L_/"::)!G>V@-TEG
MA$\/G^)]1X'$I.^XS8L#O:GY*[M<XA;3=1+2@$E?Q.9OUK9, NG%/+%#A1C^
M%O><TQ*Q0?CT+!S1HJ./%'0\/)'O\$P#D<$X-KR=W@G'NA3R$^^1H.!* (0)
MI6)A=6H98VH8U^-QH-"]S"L</1;-U/@X ZQ@"T#VVOCTM%2S,JY!8) 31^7\
M$8^&:#S6UU-6!OU.C-ICU=VGD5IIO<^ZRC16?D83$?KFE$\E]<M@>D5]V/DF
M%F#VC7,]884#+OR+>2!+3]=3Y ;=CSDJ>=YV>D..[?)XN"$33R;7D>;,"_%3
M^CJHQ<.N#*<33M&D&8<G.[9"/-A+NU$F_3Q J"0EJ8^VBK^R"PA_0A 7)Z.>
M)]A#P_F+<)U$>BTEGL%#Q$/ \?=Y\6G/DJ2B$6=-/E7@E^" @021HQY@@7!:
M('H?<.F*>[]'!$9DEEA O153_!2AJ"QI;4CT8Y6T0;MN<N>7:Q\W%[49F@$U
M8Y !D&-AG:-L,)^S':S#M'P5%DE\; /:RP.P']6HS?T&)X;K9R79*V!BF7P1
M+6WB7*,J<JPH0G9(#)VZN;[Q*AJ7%B&%3)M)76@"$!:1R'"0?6/6E'T/@ CK
M%PA%*SE'TG$C7#R#'+*?$9F&S2$L&O,=]'/P\!]&BAQ\I324BS1^&_"G-<X"
MIJ)T%;8(I>Z%3.$&K>$,0D03'(2&+D*O7%Y_ S4CR> O.02,"4.&-Z!'*@L.
M-^&$%(26@EQEB=6P\I<[-FH(,)3&C*AHJQ'XC-V<>+:QJ1N:MD-8(AWY/OW&
M0>W!=07A2/P[O*Y@$F!\]VC%\+?!Q0@31YU3>[#$'G)L7L6(+][Z$!+K*4F1
M]_P,.OGI)0Q]\;(H5TCEG0XNW_X:!S)*XHJR>Q,PJJ3+AO3PBH@#]TF$4F!^
M1<[@_H$7LN&7U%<F9:F6>U6P:VCR8H5PG4OUI0\'Z.]@L0C%35W?/2@WZ13\
MZ>'CZ[*WOZ+X3PK*[5\?P"T\8YCT',0?F\J[N .8R:G5-F2W*&<8[ME"5N+-
M'K-X-PPEV,*5+7.<;?".5+P(07T!\?*5*2.RS*A@5P(J"Q+1#:X8B7G'?63Q
MWQ0M#EJO8DN<":>SLN!F"$![C,7^E& SH:4$C20]P;>1A+075_P#SPACWHA<
MQ1*'!578SNQD-7ONB0F(9]RQAZ^@9%(KEYPL$"TDOY#@VQBM*PB'.47YS9NI
M7@8",V'8=Y\-Y9<%8(^.FX;8#,G,#VM,3!JSAXMPK=Z>^3BIH%M5!G%PX;8L
MN?8C<&ZGE1ND,P;T!$=22C;;:3K_(X>\>"2LHF6^+\Z%9_5NL85#%VS&M]5E
M21?:N8AA:-MQ@5F'^<MLOIC P3Y!Z1!))]"Q!6=+M@Q!QBS%:N 1Q^'\3##(
M5'<OV&S8>>KXQM=$&D'F:</'JT]]K7P=&-VV0P!UW!%,;((/I[/LG&2]&Z)1
M!,%RYDJ!Y,/04PL,W2*YQYY6KWGQM@M72XW1\@9OMMSES3U\IC2B,1AE8_WH
M<%,P2#&?1& %MHWK)%F:<B)[DG4D KTQ*&4%X&:JO=O"IP;2F32:0U^K1@[(
M4HD7%]Z#L7(3UP9$F?3[B ]']2VWJ^+U25&,,Q+]Q#5-F<$0F#8_X'7H>JBE
MKC!1/2M^T=OB?ZW[.BLNL*!O76O4K/@5UN:#IQDZFG9@>&\[$=TQT8U<W6$&
MLDTAIX8'RO 2OEI7 TOC0:9/[A-]\#4EX[.;"JC?/'P/;/KEPSO/;C*\>_HP
M],22<HP](QEOI&R:#P<W7(Z026M7O9-B[VC)U%, P^3^^> ]/J?I"H73PW<?
M_ +V :%I\1&;V/"VP4D@\U<'P0,1IJ3V'(2+:$SY+D,(/#MG%CVW%$C09X<7
MCM$="JHN!8LN=IS.#5%+'%0:)K9TD;&NCL.E4VU/#<3<:$&#X\R>VANQ*2=
M@V3E9P2#L.,Y'&)1L9UBT*F=WZ-4O#0U7?/P-U89;HKXKZT1ED=GBRJDC8J:
M^^@_P(X<-:1* 3:;^-[MCGFH<(;_M>4C1C=N,2&WX33+>.;@@]M+2Q#:PZ&;
MN/>$.$I)6C.O)[8RT^6Q_T@[(T[BD-*<I9LRS@[?:_&)#CB!MK[UON<3[/>
M"^>5I<M]IYK IK3JOS_+L.G$A0&,#)#>\/&-[*P>X=/A,>YP'"2UEG(B]-M
M=8K1][)KOQOM5G2Y.;6*M1W? !Z_C1>HG_.UX>EQOGW]O7(KO#.OUDMX]63^
MXX,C3D&%/SJ[H4O$%[;K;$,?UQH/3> #\/O2VB[\@1/$:^6?_P=02P,$%
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M<*D==70P"QJA:/P!VE]I[78+'Z =RNE?4$L#!!0    ( #<X!%59%!HN] (
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M)$X1"L/CLKC H*0F0B'&*L>8'^@OR=A?DL/]!6_^JD?UJ/LS:WIW(2P5%O_
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M!E&[ -I?*NIP[<0=T#VLZ6]02P,$%     @ -S@$58BE$^ $ P  ]@<  !D
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M*.N ZTLIS<O$-L3N_4O^ %!+ P04    "  W. 15@_EB"=0"  #+!P  &0
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M'D@[P8POA-!O'5N(V_]H]AM02P,$%     @ -S@$5195,_7A P  \!8  !D
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M@C ;]/J<<[69F'M5=2T._P!02P,$%     @ -S@$5?GILYG-"@  9HT  !D
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M(S&*Q!PDQC;828U5QTAWL]'9\&XW/\CN.!+SD)@/PI3\3+;YF6CS\\^L*,?
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M;&_N&LSO-'EC?\?4DE,H$EP095!O4XE7>:^<#XS,7+LYDX::5W>[HN\+5-:
MGB^D-/N!7:#\8AG\#5!+ P04    "  W. 15_*>[.@@$   3%@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T,BYX;6S-6-^/XC80_E>L]%3=27>;7Q!@"TA
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M];@'G "5 /%^2PA_',@%ZC[P_#]02P,$%     @ -S@$54-C:Q6% P  G1
M !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULM9AM;ZLV&(;_BL6FJ4=J
MRTN I%V"E!38.IT>5>W.]F':!Q>>!.L SK&=IOWWLPVE24LXC>1]2&+#<U]^
MN8W-D^F6LF^\ !#HJ2IK/K,*(=:7MLVS BK,S^D::GEG25F%A:RRE<W7#'"N
M155I>XX3VA4FM15-];5;%DWI1I2DAEN&^*:J,'M>0$FW,\NU7B[<D54AU 4[
MFJ[Q"NY!?%W?,EFS.TI.*J@YH35BL)Q9<_<RG:AX'? 7@2W?*2,UD@=*OZG*
M=3ZS'-4A*"$3BH#ESR-<05DJD.S&]Y9I=4TJX6[YA9[JL<NQ/& .5[3\F^2B
MF%D3"^6PQ)M2W-'M[]".)U"\C)9<?Z-M&^M8*-MP0:M6+'M0D;KYQ4_M/.P(
M7/^ P&L%WD<%HU8P>BL(#@C\5N!_5!"T@N"M(#P@"%M!J.>^F2P]TS$6.)HR
MND5,14N:*FB[M%I.,*G5PKH73-XE4B>B.RBQ@!S=8B:>T9\,UQQKSSDZ0_,\
M)ZJ,2W1=-XM8K8:3& 0F)?\D0Y(GR#9J<:"K A,94:/YB@'(M2<48;DD)=$M
M)+4@LHDS%&]P#>@+YL4INHE/T1_R<[.8RSL+BEF.Z!+%A,F51QE_I9ZAK_<Q
M.OGYT]06<MRJ]W;6CC%NQN@=&*./;F@M"BZ[D$/>HT^&]9,?Z=-AO>L, &QI
M6.>:]^+:PALDWF!VCMS@%'F.Y_5TZ&I8/E^_RMV^^?Q1Z\_(]0^JDV%U#-DY
M&KD'Y>G'Y=[ 5(ZZ!V"D>:-C'P#TSV<9BJX%5/S?GGXN&J[?SU4'PB5?XPQF
MEMSQ.;!'L*)??G)#Y]<^PTS"8I.PQ"0L-03;<]KOG/:'Z-%OTEOE] FI$2^P
M;*!O+UDTD$!#U+'\&(T#QW&F]N.N7^^C+IQW4?%@AXXUPB0L-03;,R+HC @&
MC=";8?FLWP@0QZ5\H>DS8A!R[/-E$A8WL'#'?"_PW?&^^4E/U/@B?+-$4D,=
MVS,B[(P(!XV0[V:082[Z9G]0>>SLFX3%)F&)25AJ"+;GY;CS<OP_G6-CDTZ;
MA,4F88E)6&H(MN?TI'-Z8F+['(0<:ZM)6&P2EIB$I9/W6_;%*)AT6W;CE[V3
M;E7 5CHQYBBCFUHTF5=WM<N]YSKEM%_#F\1=OLBOB,RU2EA*J7,^EL<!:Y+A
MIB+H6B=O#U3(5% 7"\ Y,!4@[R\I%2\5U4#WCT3T'U!+ P04    "  W. 15
M+=,Q2N("  #Z"0  &0   'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6RU5FM/
MVS 4_2M6-DT@0?/H$]9&&G33F#:!*#!-TSZXS6UCD<3!=E*0]N-W[:0AV](,
M4/<EB1_WW'-\CV./UUS<RA! D?LX2N3$"I5*CVU;+D*(J>SP%!(<67(14X5-
ML;)E*H &)BB.;,]Q!G9,66+Y8]-W(?PQSU3$$K@01&9Q3,7#"41\/;%<:]-Q
MR5:ATAVV/T[I"F:@KM,+@2V[0@E8#(ED/"$"EA/KG7M\XGHZP,RX8;"6M6^B
MI<PYO]6-LV!B.9H11+!0&H+B*X=3B"*-A#SN2E"KRJD#Z]\;] ]&/(J94PFG
M//K* A5.K)%% EC2+%*7?/T12D%]C;?@D31/LB[G.A999%+QN Q&!C%+BC>]
M+Q>B%M#UM@1X98!9"+M(9%A.J:+^6/ U$7HVHND/(]5$(SF6Z*K,E,!1AG'*
MGV5S"7<9)(J\S_$IR=X4%&61W">'Y,]1[)HR@0O*L; A%2 )2\A5R#-)DT".
M;864-+"]*-.?%.F]+>D_95&'.(,#XCF>1UX3>P-;O'X'M%%;)="K!'HF0_>)
M LGWSSB#G"F(Y8\FP@5<KQE.;Y)CF=(%3"S<!1)$#I;_YI4[<-ZVD.U69+MM
MZ/YYJJTJR4K01$% ]G!UBY78;Z):@/4-F-Y^N=]UQG;>0*!7$>@]BP#F3T$P
M'AR0M3$X!(<T!X$;MIA# JJ +"D3)*=1!H;R]6RJPPKJ^^1GK;!-,@I*HYJ,
M7J?;K*-?Z>@_2<<-2,62%3E+R#E6_1M0T<2@%>R%-1]45 >[->C@/Y =5F2'
MNS3H\"^#NEL,.JH(C%H); I:N-+D?\"B-J=OAW)-9,NB'%6<CIYKMJM00&&W
M1L>WXKVPA*[S^,MW=NNX$F_'?&M'E+M+TY5H===Y6USG/IXB;NM__WF^^P=6
MMPAM6AN[=I+K6]$7*E8,I4>P1"BG,T15HKAH% W%4W.XS[G"JX+Y#/%R!D)/
MP/$EYVK3T/>%ZKKG_P)02P,$%     @ -S@$5> #-X4O P  \!(   T   !X
M;"]S='EL97,N>&ULW5A=:]LP%/TK1EU'"Z-.XL6-UR2P!0J#;13:A[T5)983
M@2QYLM(E^_73E1SGH[JEZ\.6SB&U=(_.N4?2=2TRK,U:L-L%8R9:E4+6([(P
MIOH0Q_5LP4I:7ZB*28L42I?4V*Z>QW6E&<UK()4B[G4Z:5Q2+LEX*)?E=6GJ
M:*:6THQ(OPU%_O8Y'Y%N^IY$7FZB<C8B]V=O?RR5N7H3^?O)NY.3SOWYU6'\
MS 'G) Z*]I\A>M&Q%ZKL4$P^?9[\4^*8].6^M!M^:H4\\12C#0(TFV7+A(XC
MQ\VVC(>%DMO=28@/6'5:LNB!BA&94,&GF@.KH"47:Q_N06"FA-*1L65ATW4A
M4O_R<-?WH&(:G9)+I5UNG\'_G3;##X!-#PQR(5J#/>(#XV%%C6%:7MN.&^R"
MCZ"H:=^M*^MPKNFZV^N3+<'=;)*ITCG3;9HNV83&0\$*L*/Y? %WHZH80&-4
M:1LYIW,EJ?.P830-*SMC0MS"X_2]V-->%3O[UH%=DVW3&FJ:7L9W0']7S6OO
MRO9>I!M5_$&93TL['>GZ4*#L1K."KUQ_5;0&,/4NKDZK2JP_"CZ7)?.3?W;"
M\9!N>-%":?[+9H-2F=D TR1Z8-KPV6[DIZ;5'5N933FM"MQS[Q5Z_KOK/&>2
M:2IV3=O:/^95?K'CY/)?67;_50X-!STV[\AC-]E_#2;3UV#R5=3DX/A-)ME1
M>HR;]_?.(6'OB-!&(SB*C<@W.-B);=)HNN3"<-GT%CS/F7QT4K#RAD[M<7Y/
MWX[/64&7PMRUX(ALVU]9SI=EUHZZ@85H1FW;7V!ZW;0]!]I<7.9LQ?))T]7S
MJ6M&MF&S-A<0#I%K=X41C..Q, (8E@=S@'$\"\OS/\UG@,['8YBW01 9H)P!
MRO&L$#)Q'RQ/F)/9*SS3+$N2-,56=#().IA@ZY:F\ VK8=Z @>6!3'^VUOAN
MXQ7R=!U@>_I4A6 SQ2L1FRF^UH"$UPT861;>;2P/,+!=P&H'\H?S0$V%.4D"
MNXIYPYY@',DR#(%:#-=HFB*KD\(GO#_84Y(D619&  L[2!(,@:<11S 'X %#
MDL2]!P_>1_'F/15O?^,:_P902P,$%     @ -S@$59>*NQS     $P(   L
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M?"8#>AA,K6 $R:DF3^R::ZF<N)6Z'PF:\TJ>7"Q=ATMC'6Q]1YDXC>2)/3+
MG.'J'$)+AR/YH9-8X?,WNI><1_+$(KF)C4BXDBX\B"\.T>2P>1T1<A+)$UMD
MW6\\?.VQD_CC$!<&!>/$D2<V!QOO1AN%G%-'GM@=/";=*N2<//+$]G@R+(L7
MF)]H\"_I)IN31Y%8'FQ\%B\H)J>1(K%&'B/TDS/(YBG)$Y7'4/TD'.>1(K%'
M^)@]2O4XM12)U<)N!T>1I^#<4B1V"Q]YZ/Z_X 13)!<,ATDS@(+339%8-T\'
MR#.QQK&;7E-,3C=%8MVPF.-GD]--,8EN3IC4BB7GFW**9.4G)EU")>>;<LJT
M19Q13,X]Y?_@GF<QQT4RMDJ6V$+$WC^7-\3P=*T,/@T4D[-0F;Q01DQ^%A]1
MW8H;V"H?G!SE^R5GH3)YJ6R$.=Y_+&D*6W(6*I,7RT:8*P<M.#=4HF(+Q>0L
M5"8OE_URTZ7#%7X#'MP!82DF9Z$R==+#;>3&*YVS4)FZ9,9B4@M5G(6JQ!;B
M,:F%*LY"56(+\9AT(U=Q%JH26^CYD@LNJ/<-Q>0L5*7.A7ZMN\1H.>P_:+I6
ML6]J!@/-3J\,&V@Q3VG^QN$]MM=2URLGXL>QI%F=QPI$VVO]$=O^,9^M;$YO
M($]O3]_] %!+ P04    "  W. 151QQ@N:0!  ";&@  &@   'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QSS=F[;L) $(7A5T%^ ):966X14*6AC7@!"Y:+
M,-CR;A1X^R HX%@ITJ ]E;6V//X+ZY.UGGV%JDR'^ASWAR;V+J?J'.?%/J7F
MP[FXWH=3&?MU$\ZW*]NZ/97IMFQWKBG7QW(7G X&(]>^SB@6L]>9O=6U"?^9
M6&^WAW7XK-??IW!.?PQV/W5[C/L04M%;E>TNI'GA+M7S='3W@_1ODXO><C,O
MVN5&"I<[2"%(\P<9!%G^( ]!/G_0$(*&^8-&$#3*'S2&H''^H D$3?('32%H
MFC](!BCC@""I@S6!UH)<"X'7@F +@=B"9 N!V8)H"X':@FP+@=N"< N!W()T
M"X'=@G@+@=Z*>BN!WHIZ*X'>VOG8)M!;46\ET%M1;R706U%O)=!;46\ET%M1
M;R706U%O)=!;46\ET-M0;R/0VU!O(]#;4&\CT-LZFR4$>AOJ;01Z&^IM!'H;
MZFT$>AOJ;01Z&^IM!'H;ZFT$>GO4VQ/H[5%O3Z"W1[T]@=X>]?8$>OO.9O<[
M]8[I6H7X['FL\?GOI#K=[@W/Q]^7CY.=M_>.LX-_48M?4$L#!!0    ( #<X
M!%4NTOC K@$  ,H:   3    6T-O;G1E;G1?5'EP97-=+GAM;,V9S6[",!"$
M7P7EBHBQG=(? 9>VUY9#7\!--B0BB2W;4'C[.N%':D6C(BIU+K$2[\Z,O=)W
MR?1M9\@-MG75N%E4>&\>&'-I0;5RL3;4A)U<VUKY\&J7S*ATI9;$Q'@\8:EN
M/#5^Y%N-:#Y]HERM*S]XWH;/KM3-++)4N6CPN"]LO6:1,J8J4^7#/MLTV3>7
MT<$A#IU=C2M*XX:A(&)G'=J=GPT.?:\;LK;,:+!0UK^H.E2Q;<6<WU7DXGZ)
M,QEUGI<I93I=UZ$E=L:2REQ!Y.LJWHL.^YU]N&':/_G5_IU,GV&H7%AM7)B8
MI<OMCB-INT<F")'U9?\13XY!^NKS43OMC+)?>H?K_=!VU<W#L6ZY_HZ_SOBD
M?V$. 9)#@N1(0'+<@.28@.2X!<EQ!Y+C'B0''Z,$02$J1T$J1V$J1X$J1Z$J
M1\$J1^$J1P$K1R&K0"&K0"&K0"&K0"&K0"&K0"&K0"&K0"&K0"&K0"&K1"&K
M1"&K1"&K1"&K1"&K1"&K1"&K1"&K1"&K1"%K@D+6!(6L"0I9$Q2R)O])UG>M
M5W_]=Z5=XUJ5S=&?=;^PYI]02P$"% ,4    "  W. 15!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M #<X!%4ID$<C[0   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( #<X!%697)PC$ 8  )PG   3
M  "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ -S@$53O>
MW%SD!0  LA\  !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( #<X!%4)9/P#KP4  ,L7   8
M  " @28.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  W
M. 15Y.*/S@ #  !="@  &               @($+%   >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ -S@$54O?'_GY!   7A4  !@
M         ("!01<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( #<X!%5%07IN-@,  &8+   8              " @7 <  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  W. 15;I[(;6@-  !GL@
M&               @('<'P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ -S@$5?$P^"QY @  VP4  !@              ("!>BT  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( #<X!%50.2=^<08
M %T<   8              " @2DP  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    "  W. 15/J[<7N (  #'%   &               @('0
M-@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ -S@$55WG
M)2#0'   O58  !D              ("!YC\  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    "  W. 15SRS,J7P#  ":"   &0
M    @('M7   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M #<X!%5CF\##W H  - :   9              " @:!@  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ -S@$5:IP +=[ P  > @  !D
M             ("!LVL  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    "  W. 155AQQBAP(   7&0  &0              @(%E;P  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #<X!%4P^$*LL P
M !TB   9              " @;AW  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ -S@$5;2[CU5J!   7@L  !D              ("!
MGX0  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  W. 15
M%Y</4/,$  "S"P  &0              @(% B0  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( #<X!%7F3D[JG!T  &)>   9
M      " @6J.  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ -S@$5;AM(AG+ @  (P8  !D              ("!/:P  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  W. 15)CQ1M:<#  "Q"0
M&0              @($_KP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( #<X!%59[#8<A@(  * %   9              " @1VS  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ -S@$55D4&B[T
M @  8P<  !D              ("!VK4  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    "  W. 153AUW7\P"  !7!@  &0
M@($%N0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( #<X
M!%5#\$HJ.P4  /T,   9              " @0B\  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ -S@$551L^:0F P   0D  !D
M         ("!>L$  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    "  W. 15OZD1X0D$  !D%@  &0              @('7Q   >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( #<X!%7,LWJRV (  &0'
M   9              " @1?)  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ -S@$58BE$^ $ P  ]@<  !D              ("!)LP
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  W. 15D031
MA[0"   +!P  &0              @(%ASP  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( #<X!%6#^6()U (  ,L'   9
M  " @4S2  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M-S@$58A0?J_) @  :0<  !D              ("!5]4  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    "  W. 15;6;]\)X'   N3   &0
M            @(%7V   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( #<X!%59ZY)8G0(  %,'   9              " @2S@  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ -S@$5195,_7A P
M\!8  !D              ("! .,  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    "  W. 159Y:E#50'  !"2   &0              @($8
MYP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( #<X!%4/
M!_=ALP(  "8(   9              " @:/N  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ -S@$575)9TYL @  AP8  !D
M     ("!C?$  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #<X!%7\I[LZ" 0  !,6   9              "
M@4L, 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ -S@$
M54-C:Q6% P  G1   !D              ("!BA ! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    "  W. 15+=,Q2N("  #Z"0  &0
M        @(%&% $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( #<X!%7@ S>%+P,  / 2   -              "  5\7 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ -S@$59>*NQS     $P(   L
M ( !N1H! %]R96QS+RYR96QS4$L! A0#%     @ -S@$553Y#I[, P  P1T
M  \              ( !HAL! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M #<X!%5''&"YI $  )L:   :              "  9L? 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #<X!%4NTOC K@$  ,H:   3
M              "  7<A 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     T
- #0 (PX  %8C 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>151</ContextCount>
  <ElementCount>222</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows</Role>
      <ShortName>Condensed Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business and Basis of Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements</Role>
      <ShortName>Description of Business and Basis of Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2127107 - Disclosure - Stock-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlans</Role>
      <ShortName>Stock-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2133108 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/BalanceSheetDetails</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/CommitmentsandContingencies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/FairValue</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/CommonStock</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Stock-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansTables</Role>
      <ShortName>Stock-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/StockBasedCompensationPlans</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business and Basis of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails</Role>
      <ShortName>Description of Business and Basis of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accounts Payable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails</Role>
      <ShortName>Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Common Stock - Shelf Registration Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails</Role>
      <ShortName>Common Stock - Shelf Registration Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Common Stock - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockCommonStockDetails</Role>
      <ShortName>Common Stock - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Common Stock - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockPreferredStockDetails</Role>
      <ShortName>Common Stock - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail</Role>
      <ShortName>Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vtl-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SubsequentEvents</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="vtl-20220630.htm">vtl-20220630.htm</File>
    <File>exhibit4211111.htm</File>
    <File>imux-063022xexhibit311.htm</File>
    <File>imux-063022xexhibit312.htm</File>
    <File>imux-063022xexhibit321.htm</File>
    <File>imux-063022xexhibit322.htm</File>
    <File>vtl-20220630.xsd</File>
    <File>vtl-20220630_cal.xml</File>
    <File>vtl-20220630_def.xml</File>
    <File>vtl-20220630_lab.xml</File>
    <File>vtl-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vtl-20220630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="459">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vtl-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "contextCount": 151,
   "dts": {
    "calculationLink": {
     "local": [
      "vtl-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vtl-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vtl-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vtl-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vtl-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vtl-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 353,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 4,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 9
   },
   "keyCustom": 26,
   "keyStandard": 196,
   "memberCustom": 21,
   "memberStandard": 20,
   "nsprefix": "vtl",
   "nsuri": "http://vitaltherapies.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://vitaltherapies.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Balance Sheet Details",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Commitments and Contingencies",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - Fair Value",
     "role": "http://vitaltherapies.com/role/FairValue",
     "shortName": "Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Common Stock",
     "role": "http://vitaltherapies.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127107 - Disclosure - Stock-Based Compensation Plans",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlans",
     "shortName": "Stock-Based Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133108 - Disclosure - Related Party Transactions",
     "role": "http://vitaltherapies.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Subsequent Events",
     "role": "http://vitaltherapies.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Balance Sheet Details (Tables)",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Fair Value (Tables)",
     "role": "http://vitaltherapies.com/role/FairValueTables",
     "shortName": "Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Common Stock (Tables)",
     "role": "http://vitaltherapies.com/role/CommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Stock-Based Compensation Plans (Tables)",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansTables",
     "shortName": "Stock-Based Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "-1",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityNumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business and Basis of Financial Statements (Details)",
     "role": "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
     "shortName": "Description of Business and Basis of Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "-1",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityNumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i58796c8360524abb862423e11c8db6ad_D20220101-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i58796c8360524abb862423e11c8db6ad_D20220101-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:PrepaidClinicalAndRelatedCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail",
     "shortName": "Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:PrepaidClinicalAndRelatedCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:ClinicalCostsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail",
     "shortName": "Balance Sheet Details - Schedule of Accounts Payable (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:ClinicalCostsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:AccruedClinicalCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail",
     "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:AccruedClinicalCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Details - Schedule of Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "vtl:OperatingLeaseIncrementalBorrowingRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "vtl:OperatingAndVariableLeasesCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails",
     "shortName": "Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i01049530b3a04055a71bdcbd2ddb098f_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i01049530b3a04055a71bdcbd2ddb098f_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "ib934db459d0f41d6983debfc2a9bb490_I20201130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Common Stock - Shelf Registration Statement (Details)",
     "role": "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
     "shortName": "Common Stock - Shelf Registration Statement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "ib934db459d0f41d6983debfc2a9bb490_I20201130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Common Stock - Common Stock (Details)",
     "role": "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
     "shortName": "Common Stock - Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Common Stock - Preferred Stock (Details)",
     "role": "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
     "shortName": "Common Stock - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)",
     "role": "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
     "shortName": "Common Stock - Shares Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i7dc0d5e8a345477e98262fa6c4169a4c_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "ic25815c038244077a908eacfe7cdb746_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "ic25815c038244077a908eacfe7cdb746_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
     "shortName": "Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "ie44b429d3b05430ea58a4793c8c7b0ed_D20220101-20220630",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails",
     "shortName": "Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "ibbabe7452d5d43f6b73995f3e391e6b8_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "ie57caaa75a5a464083b4f824217dc1e7_D20220315-20220315",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "ie57caaa75a5a464083b4f824217dc1e7_D20220315-20220315",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "ifdfa66f7711347ab96273868fd75f343_D20220706-20220706",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Subsequent Events (Details)",
     "role": "http://vitaltherapies.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "ifdfa66f7711347ab96273868fd75f343_D20220706-20220706",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i640e715a3f0c4def9b0d868c1d6092b8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i72df3680356349e7bfa91bda10e3f3f7_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i4c93de53cc26410982e5107a63a6e7f4_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statement of Cash Flows",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
     "shortName": "Condensed Consolidated Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business and Basis of Financial Statements",
     "role": "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements",
     "shortName": "Description of Business and Basis of Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20220630.htm",
      "contextRef": "i554ead0342cb4d22a02e724522bd3a3c_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 41,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of persons employed by the Entity",
        "label": "Entity Number of Employees",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "EntityNumberOfEmployees",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r219",
      "r335",
      "r336",
      "r339",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Directors Chairman"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r35",
      "r37",
      "r81",
      "r82",
      "r177",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r156",
      "r158",
      "r159",
      "r160",
      "r176",
      "r186",
      "r221",
      "r223",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r392",
      "r394",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r156",
      "r158",
      "r159",
      "r160",
      "r176",
      "r186",
      "r221",
      "r223",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r392",
      "r394",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r148",
      "r156",
      "r158",
      "r159",
      "r160",
      "r176",
      "r186",
      "r211",
      "r221",
      "r223",
      "r256",
      "r257",
      "r258",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r392",
      "r394",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r148",
      "r156",
      "r158",
      "r159",
      "r160",
      "r176",
      "r186",
      "r211",
      "r221",
      "r223",
      "r256",
      "r257",
      "r258",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r392",
      "r394",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r36",
      "r37",
      "r81",
      "r82",
      "r177",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r92",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r92",
      "r97",
      "r154",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r130",
      "r131",
      "r209",
      "r210",
      "r393",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r130",
      "r131",
      "r209",
      "r210",
      "r393",
      "r416",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r92",
      "r97",
      "r154",
      "r222",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r132",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r28",
      "r344"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r40",
      "r41",
      "r42",
      "r383",
      "r399",
      "r400"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r39",
      "r42",
      "r50",
      "r51",
      "r52",
      "r84",
      "r85",
      "r86",
      "r295",
      "r332",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20",
      "r344"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r268",
      "r269",
      "r270",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r225",
      "r273",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r200",
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Options to purchase common stock ( in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "auth_ref": [
      "r286",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "negatedTerseLabel": "Common Stock issued in connection with the 4SC royalty settlement (see Note 4)"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r13",
      "r80",
      "r122",
      "r124",
      "r128",
      "r134",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r292",
      "r296",
      "r311",
      "r342",
      "r344",
      "r374",
      "r382"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r27",
      "r80",
      "r134",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r292",
      "r296",
      "r311",
      "r342",
      "r344"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r3",
      "r83",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Basis of Financial Statements"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r10",
      "r71"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r65",
      "r71",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r65",
      "r314"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r32",
      "r376",
      "r387"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 4)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r161",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total common shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Common stock, cash dividends paid (in USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, cash dividends declared (in USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r84",
      "r85",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r344"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock issued",
        "verboseLabel": "Common stock, $0.0001 par value; 130,000,000 shares authorized and 30,564,995 and 26,335,418 shares issued and outstanding as of June 30, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r45",
      "r47",
      "r48",
      "r56",
      "r379",
      "r390"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum annual contributions per employee (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r69",
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r69",
      "r121"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r227",
      "r228",
      "r262",
      "r263",
      "r265",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r57",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r98",
      "r100",
      "r102",
      "r103",
      "r104",
      "r107",
      "r108",
      "r300",
      "r301",
      "r380",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r57",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r100",
      "r102",
      "r103",
      "r104",
      "r107",
      "r108",
      "r300",
      "r301",
      "r380",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period over which compensation cost will be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r50",
      "r51",
      "r52",
      "r84",
      "r85",
      "r86",
      "r88",
      "r94",
      "r96",
      "r109",
      "r135",
      "r200",
      "r207",
      "r268",
      "r269",
      "r270",
      "r284",
      "r285",
      "r299",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r332",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r302",
      "r303",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r303",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r178",
      "r212",
      "r213",
      "r218",
      "r220",
      "r303",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r212",
      "r213",
      "r218",
      "r220",
      "r303",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r303",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r306",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r70",
      "r312",
      "r313"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedTerseLabel": "Unrealized foreign currency loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation and Presentation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r11",
      "r136",
      "r137",
      "r138",
      "r140",
      "r344",
      "r373"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r139",
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r142",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r146",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other current assets and prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r60",
      "r120"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Obligation"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29",
      "r80",
      "r125",
      "r134",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r293",
      "r296",
      "r297",
      "r311",
      "r342",
      "r343"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r80",
      "r134",
      "r311",
      "r344",
      "r375",
      "r385"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r31",
      "r80",
      "r134",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r293",
      "r296",
      "r297",
      "r311",
      "r342",
      "r343",
      "r344"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r14",
      "r15",
      "r80",
      "r134",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r293",
      "r296",
      "r297",
      "r311",
      "r342",
      "r343"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r162",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r65",
      "r67",
      "r70"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r43",
      "r46",
      "r52",
      "r54",
      "r70",
      "r80",
      "r87",
      "r89",
      "r90",
      "r91",
      "r92",
      "r95",
      "r96",
      "r101",
      "r122",
      "r123",
      "r126",
      "r127",
      "r129",
      "r134",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r301",
      "r311",
      "r377",
      "r388"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued and/or Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r122",
      "r123",
      "r126",
      "r127",
      "r129"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "PV of obligation"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease, liability, current, statement of financial position"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r26",
      "r344"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r290",
      "r291",
      "r294"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r47",
      "r50",
      "r51",
      "r53",
      "r55",
      "r200",
      "r315",
      "r320",
      "r321",
      "r378",
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Foreign exchange translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r344"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r164"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForCommissions": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for commissions during the current period.",
        "label": "Payments for Commissions",
        "terseLabel": "Underwriter commissions"
       }
      }
     },
     "localname": "PaymentsForCommissions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r344"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of June 30, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Other current assets and prepaid expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from issuance of private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r64",
      "r267"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from shares issued in connection with the Company's employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r64",
      "r267"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r144",
      "r344",
      "r381",
      "r386"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r144",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r219",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r219",
      "r335",
      "r336",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r219",
      "r335",
      "r339",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r333",
      "r334",
      "r336",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r277",
      "r359",
      "r432"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r207",
      "r344",
      "r384",
      "r398",
      "r400"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r84",
      "r85",
      "r86",
      "r88",
      "r94",
      "r96",
      "r135",
      "r268",
      "r269",
      "r270",
      "r284",
      "r285",
      "r299",
      "r395",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r329",
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of use asset obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r260",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense for Stock Awards Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets and Prepaid Expenses"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r224",
      "r226",
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r232",
      "r247",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r78",
      "r110",
      "r111",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r193",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Purchase price of the stock, at discount from market price at purchase date (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Other Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, Ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, Weighted-Average Exercise Price, Ending balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options granted in period, weighted-average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value, Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (usd per share)",
        "periodStartLabel": "Outstanding, beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest, Ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest, Weighted-Average Exercise Price, Ending balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r251",
      "r252",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r231",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r271",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, Aggregate Intrinsic Value, Ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Weighted-Average Remaining Contractual Term, Ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r77",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r34",
      "r50",
      "r51",
      "r52",
      "r84",
      "r85",
      "r86",
      "r88",
      "r94",
      "r96",
      "r109",
      "r135",
      "r200",
      "r207",
      "r268",
      "r269",
      "r270",
      "r284",
      "r285",
      "r299",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r332",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r109",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Common Stock issued in connection with the 4SC royalty settlement (see Note 4)"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r200",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r200",
      "r207",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r200",
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r23",
      "r24",
      "r80",
      "r133",
      "r134",
      "r311",
      "r344"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r185",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r207",
      "r208",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r322",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r322",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r322",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r322",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r1",
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "VAT receivable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r99",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r98",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "vtl_A2017InducementEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Inducement Equity Incentive Plan [Member]",
        "label": "2017 Inducement Equity Incentive Plan [Member]",
        "terseLabel": "2017 Inducement Equity Incentive Plan"
       }
      }
     },
     "localname": "A2017InducementEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_A2019OmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Omnibus Equity Incentive Plan [Member]",
        "label": "2019 Omnibus Equity Incentive Plan [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan"
       }
      }
     },
     "localname": "A2019OmnibusEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_A2021EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Employee Stock Purchase Plan",
        "label": "2021 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2021EmployeeStockPurchasePlanMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_A4SCRoyaltySettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4SC Royalty Settlement",
        "label": "4SC Royalty Settlement [Member]",
        "terseLabel": "4SC Royalty Settlement"
       }
      }
     },
     "localname": "A4SCRoyaltySettlementMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_AccruedClinicalCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Costs, Current",
        "label": "Accrued Clinical Costs, Current",
        "terseLabel": "Accrued clinical and related costs"
       }
      }
     },
     "localname": "AccruedClinicalCostsCurrent",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_AccruedCompensationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Compensation, Current",
        "label": "Accrued Compensation, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedCompensationCurrent",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_AccruedLegalAndAuditCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Legal And Audit Costs, Current",
        "label": "Accrued Legal And Audit Costs, Current",
        "terseLabel": "Accrued legal and audit costs"
       }
      }
     },
     "localname": "AccruedLegalAndAuditCostsCurrent",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales",
        "label": "Asset Purchase Agreement, Royalties As Percent Of Aggregated Net Sales",
        "terseLabel": "Asset purchase agreement, royalties as percent of aggregated net sales (as a percent)"
       }
      }
     },
     "localname": "AssetPurchaseAgreementRoyaltiesAsPercentOfAggregatedNetSales",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_ClinicalCostsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Costs Payable, Current",
        "label": "Clinical Costs Payable, Current",
        "terseLabel": "Clinical costs"
       }
      }
     },
     "localname": "ClinicalCostsPayableCurrent",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_December2020ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2020 ATM",
        "label": "December 2020 ATM [Member]",
        "terseLabel": "December 2020 ATM"
       }
      }
     },
     "localname": "December2020ATMMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_DuaneNashMDJDMBAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duane Nash, MD, JD, MBA",
        "label": "Duane Nash, MD, JD, MBA [Member]",
        "terseLabel": "Duane Nash, MD, JD, MBA"
       }
      }
     },
     "localname": "DuaneNashMDJDMBAMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_EmployeeStockOptionsforFutureGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options for Future Grant [Member]",
        "label": "Employee Stock Options for Future Grant [Member]",
        "terseLabel": "Common stock options available for future grant:"
       }
      }
     },
     "localname": "EmployeeStockOptionsforFutureGrantMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_ExecutiveChairmanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Chairman Agreement",
        "label": "Executive Chairman Agreement [Member]",
        "terseLabel": "Executive Chairman Agreement"
       }
      }
     },
     "localname": "ExecutiveChairmanAgreementMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_GrafelfingGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grafelfing, Germany",
        "label": "Grafelfing, Germany [Member]",
        "terseLabel": "Grafelfing, Germany"
       }
      }
     },
     "localname": "GrafelfingGermanyMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_ImmunicAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunic AG [Member]",
        "label": "Immunic AG [Member]",
        "terseLabel": "Immunic AG"
       }
      }
     },
     "localname": "ImmunicAGMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_IncentiveEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Employee Stock Option [Member]",
        "label": "Incentive Employee Stock Option [Member]",
        "terseLabel": "Incentive stock options"
       }
      }
     },
     "localname": "IncentiveEmployeeStockOptionMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "terseLabel": "Additions to right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_LegalAndAuditCostsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal And Audit Costs Payable, Current",
        "label": "Legal And Audit Costs Payable, Current",
        "terseLabel": "Legal and audit costs"
       }
      }
     },
     "localname": "LegalAndAuditCostsPayableCurrent",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_LesseeOperatingLeaseRentHolidayPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Rent Holiday Period",
        "label": "Lessee, Operating Lease, Rent Holiday Period",
        "terseLabel": "Rent holiday period (in months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentHolidayPeriod",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vtl_LesseeOperatingLeasesNumberOfExistingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Leases, Number Of Existing Leases",
        "label": "Lessee, Operating Leases, Number Of Existing Leases",
        "terseLabel": "Number of existing leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesNumberOfExistingLeases",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration",
        "label": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration",
        "terseLabel": "Maximum aggregate offering price of securities under shelf registration"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_May2022ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2022 ATM",
        "label": "May 2022 ATM [Member]",
        "terseLabel": "May 2022 ATM"
       }
      }
     },
     "localname": "May2022ATMMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_NewYorkCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York City",
        "label": "New York City [Member]",
        "terseLabel": "New York City"
       }
      }
     },
     "localname": "NewYorkCityMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_NonStatutoryEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Statutory Employee Stock Option [Member]",
        "label": "Non-Statutory Employee Stock Option [Member]",
        "terseLabel": "Non-statutory options"
       }
      }
     },
     "localname": "NonStatutoryEmployeeStockOptionMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_NumberOfDevelopmentProgramsPursued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Development Programs Pursued",
        "label": "Number Of Development Programs Pursued",
        "terseLabel": "Number of development programs"
       }
      }
     },
     "localname": "NumberOfDevelopmentProgramsPursued",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_OperatingAndVariableLeasesCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Variable Leases, Cost",
        "label": "Operating And Variable Leases, Cost",
        "terseLabel": "Operating and variable lease costs"
       }
      }
     },
     "localname": "OperatingAndVariableLeasesCost",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_OperatingLeaseIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Incremental Borrowing Rate",
        "label": "Operating Lease, Incremental Borrowing Rate",
        "terseLabel": "Incremental borrowing rate on operating leases (as a percent)"
       }
      }
     },
     "localname": "OperatingLeaseIncrementalBorrowingRate",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_OptionsVestingInOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Vesting In One Year",
        "label": "Options Vesting In One Year [Member]",
        "terseLabel": "Options Vesting In One Year"
       }
      }
     },
     "localname": "OptionsVestingInOneYearMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_OptionsVestingInThreeYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Vesting In Three Years",
        "label": "Options Vesting In Three Years [Member]",
        "terseLabel": "Options Vesting In Three Years"
       }
      }
     },
     "localname": "OptionsVestingInThreeYearsMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_PrepaidClinicalAndRelatedCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Clinical And Related Costs, Current",
        "label": "Prepaid Clinical And Related Costs, Current",
        "terseLabel": "Prepaid clinical and related costs"
       }
      }
     },
     "localname": "PrepaidClinicalAndRelatedCostsCurrent",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_ResearchAndDevelopmentTaxIncentiveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Incentive, Current",
        "label": "Research And Development Tax Incentive, Current",
        "terseLabel": "Australian research and development tax incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxIncentiveCurrent",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_RoyaltySettlementAgreementCashPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Settlement Agreement, Cash Payment, Percent",
        "label": "Royalty Settlement Agreement, Cash Payment, Percent",
        "terseLabel": "Royalty settlement agreement, cash payment (as a percent)"
       }
      }
     },
     "localname": "RoyaltySettlementAgreementCashPaymentPercent",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_RoyaltySettlementAgreementSalesNet": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Settlement Agreement, Sales Net",
        "label": "Royalty Settlement Agreement, Sales Net",
        "terseLabel": "4SC royalty settlement (see Note 4)"
       }
      }
     },
     "localname": "RoyaltySettlementAgreementSalesNet",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_RoyaltySettlementAgreementSharesPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Settlement Agreement, Shares Payment, Percent",
        "label": "Royalty Settlement Agreement, Shares Payment, Percent",
        "terseLabel": "Royalty settlement agreement, shares payment (as a percent)"
       }
      }
     },
     "localname": "RoyaltySettlementAgreementSharesPaymentPercent",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_SalaryCostsMonthlyBaseSalary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salary Costs, Monthly Base Salary",
        "label": "Salary Costs, Monthly Base Salary",
        "terseLabel": "Monthly base salary"
       }
      }
     },
     "localname": "SalaryCostsMonthlyBaseSalary",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_SaleOfStockRemainingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Remaining Capacity",
        "label": "Sale Of Stock, Remaining Capacity",
        "terseLabel": "Sale of stock, remaining capacity"
       }
      }
     },
     "localname": "SaleOfStockRemainingCapacity",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent",
        "label": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent",
        "terseLabel": "Additional shares authorized (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_SharesIssuedWeightedAverageSharePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Weighted Average Share Price Per Share",
        "label": "Shares Issued, Weighted Average Share Price Per Share",
        "terseLabel": "Issuance of stock (in USD per share)"
       }
      }
     },
     "localname": "SharesIssuedWeightedAverageSharePricePerShare",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "label": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "terseLabel": "Commission, percent of gross proceeds from sale of common stock (as a percent)"
       }
      }
     },
     "localname": "ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_ShelfRegistrationStatementAmountRemaining": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Statement, Amount Remaining",
        "label": "Shelf Registration Statement, Amount Remaining",
        "terseLabel": "Shelf registration statement, amount remaining"
       }
      }
     },
     "localname": "ShelfRegistrationStatementAmountRemaining",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_ShelfRegistrationTerminationPriorWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration, Termination, Prior Written Notice",
        "label": "Shelf Registration, Termination, Prior Written Notice",
        "terseLabel": "Shelf registration, termination, prior written notice"
       }
      }
     },
     "localname": "ShelfRegistrationTerminationPriorWrittenNotice",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_TwoThousandFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "label": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan, Evergreen Provision"
       }
      }
     },
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20220630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r433": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r434": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r435": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r436": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r437": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r438": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0001280776-22-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001280776-22-000017-xbrl.zip
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M5?QW VC<>\26[5I<A+=-EKO!QMUE)BZ*8Z6050*B"A;_0-5X( [-<^6U</J
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M\_BF?Q[?LFQ[K/>ZV>MT]PZWF]'>L2^I/6^VV[VOK[7?C/K[IZZK;7D@ AB
MVQ0T?UL[KRTF%)2Y(\&@4SR1:/,1ON3)-N*J^._'HW^+<H>0\P6!W)23$E6O
M6_=O>Y:DKX XYCV^FV^6O/^!+;TZZ2*)^<^-UQP;>SR0HVVWU=I!N!P@6N4B
MWRH6P,4]("$+0(X&W^\+TZ.![385/"'OET7T8VBY_X_@P0B>?@J/:@#>%HQG
MVSBV?$G?ZDUVO!%?ZPV?O50O5/A5P2 \^9SRK=?LJ]CV+4-[-86.$>"EW3]E
MW[OKO>_LJ\_P"P+_6X;K?P%02P,$%     @ -S@$5?TABN"M!   J!(  !H
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M[\%]/#D)%NTRKM)_ONG,\#K&AC&[+ R+99%K\*M3YZ'H-T2\9(QOUX_/D?\
MI,,#O]O/S>>CH_H1QF?6J%-";3R+EV>H;O8B<[ZDR(L2G$)-R(OA]_OB],70
MMF=._)_!9S-X=)5QY"Y%\K[06/-XO$ND;<[TG>'D*S<16S/@D\N,5%6W.;V,
M"1R![MC.]<:7YC8S@_/%A"RPPPN]WV3?3]6]=R6;S^KFQMPAG?\!4$L#!!0
M   ( #<X!%5C,HFF5I,! &\J$  0    =G1L+3(P,C(P-C,P+FAT;>R]:5=;
MR9(N_/W^"KUTW[Y5:Y$XYX&JPUV4P1Q\+6%CL!N^>.4( @VT!AOX]6_DEH09
M;3!"D[?/*5O2GG)G1#SY1&1DY-__][S9J'R-G6Z]W?K7$EG!2Y7_N_;W_X?0
M?_^S^ZZRT?;]9FSU*J\[T?9BJ'RK]XXKGT/LGE92I]VL?&YW3NM?+4+%-:_;
M9Q>=^M%QKT(QI;<.=E:UXH8Y)1$ASB#N340Z.8624<Q''852?OEH-6JKM(#3
MK/("3L,6F>0I4CHDBPTC@83EL$H8M4PZS6TDG$FFM8$+K(/;6!UDRH\][L';
MP1NVNJO]7N=?2\>]WMGJJU??OGU;.7>=QDJ[<_2*8FQ>P=&EX8DAUJ].+$[J
M1K]RU/[Z"@Z\RN\U.K%^WKO_CO56H]Z*N0-?]3JVU4WM3M/VH(/SY1AABLC5
M3<[AU-,;M_G&BIL08\RKXNCHU&[G^_.2[;KB-/CQ5J,>>DO"KC5L>/K##\X]
M=]5&N$FXU2G#GI.O!@='I_:[Z,C:L[OM'!ZXT=9\:?U!H>3F=GNVY>/5NW7;
MG!+UHRL&9UR3$ +IW;A@),T?"8D(A#5B9'2?.S*Z^=1\V-GN53N_]AI79W^M
M]VRC=QP[]JP>NRN^W2RZ $N&K[JA6[]/#G!K\NJ_J^\^^N/8M.A&9ZPV;.OH
M7TNQA?8_+H&:1QO6_F[&GJWD^Z#X/_WZUW\MO6ZW>F"\:._B#"[S@V__6NK%
M\]ZK0KZOUO[7__I??_?JO49<@T:C4<O^?C7X[>]7@SN[=KA8^SO4OU:ZO8M&
M_-=2J'?/&O9BM=5N17A^_7PUGQ@[@X_U$&*K^ C':P @G;H?//Z\MQO3OY;J
M0G X'S-.O>.!4HMI5)0+2EU@EODO&T53"";H>V^U;#,_.M971[#TIM[UMG$0
M;><-_-)=JM0#W#RP3Q=NH_WU'=W]>L"J_7"R^?5PRYSLG&Q>5IN;E[7F-J]M
MO6E4]SY<UDZJ?&>C<5RCM>.#YCZIT4U^N''8?,=JC8/+]GGU\NUQ]?*POK.Q
M>WRXMXFKEP>7.QM'XF OG!Q\?MNH[87CG:T/]+"A\3MZ>''PV<N=C;?'.Y\_
M?#O<.[TX.*F*VL:;D^K>Z>5!LWI9VSNL5S<V177OG],#NO\U;+VINZU]63LY
M@G:L?ZMNO&G4-N"\+6C+WA&M7GI^T#QL[.Q5Z>%&];RV,;KF$SQ+M [WVA3:
MPZOYVL_[T+XJ/MS;)SL;!Y>UR^/Z87-?0/M/JY>;N/9)7[S;V^Q5/^+S=WO;
M<-WI^1>.K>7:)60Y9XBK:) A6J#(C,-:.Q&27EK+0OC[U0V!3DZ^[^'^[5!*
M^%$2OKPC8:,%(]HDQ"U6B%-.D8DD#\(>!T<(TQ1L^,,DY;L.P@V%@!OV:*DR
M@%ZX[7EO-=7/8T#)-C*<EL+^L;#Q'6$3JAF.PB&27$ <8X$,8T"V(HV6*@&_
MR*6U-^OO/FY.4-ZO^YW.#;C>;(4-X)-S*>%///S[;>.0-KZZDS:']HG#C7]
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M=(QA09DHM:AD%$_3*$))Y)9YX ^.)YE<#(I99:A+Q$DS5XQBC!HUE[(TDKC
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M7K?BCXN@T9\S-(]]_VO='$/+>;/?8]YLLG(6;$6*7Y(SERN8Z;&';N0*?8&
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MX5G?#D[@?LV#B\.]-R<[6Y]2[77>8W S[S5X 6T4U0]?7-#*,,:0P4P@SGQ
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M0/56Q=NS>L\VRBV_7GPKT:N^?P]=O]UZ/>CXLG#)^,#H[GY@6"7.<LU$06-
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M"8RG(*P+RE8FCYEW&"]?:FI!@Y7V?10,>!@,F'%[R,@8,&:",!!FQ*U1R!B
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M&XLCS9@.TB4O/&P7JIM2RZ8AN&BJN^46%#VV.#UVQP!L@:7E@:7Y4*T)&F2
M($MH;H^$(V@P(-2 4)89P;ES-S:Y'FB_%-[S*#M&1\NPE03ID$O#AV"12X*@
MJ%T@VE&3:%W4CTO6E&*^/OSZ:+(JYOB/H87[PK^A_6WKG_!C,O(CV]]O=^L*
M#O2B1O QM[9^>/"G51N?@]BPWO>.X+M/80H:W=X0[@Y2U(#!M&%D^WW;:1S;
M_K#12XWA01Q$D'@["FT0MRSJ(9=?KGZKRE+8_')J=VW7M^%"D,-AS%V\!YO3
M-9V=F_& .-U4 @9]W!NT\U9XUH\=.VQ_B\]/VF%X,-%6YRX<+S<^N\0Z& 0
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M5G!%J''<*6R<4L)AC_U=Y'GM Z8/)^QD1MB9I]$3GU"42H 69PF9(# B#E[
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MI)E8TH@<4=(SYKC#?F,+UKE)S#+Y_4HPH(1LUF25;M)QCPKX?U)2>,$#E=J
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MP]=B=^_%:>O'-FL=;K.==U]D-$E;C5'BTB).O$!648D\%T(JPPRS<F-+SE=
MF_:7^(EE<1/1OXSHWO)6#XTB,S)W)@7'H_Y@E&7GRLT/$@(&WM%"]O[VSA^3
MS?]MV'DVV?:OXK?8Z1UG/?BV_K;!VSRNF<XZ\/ ^9QR<]/H!.,V3E9%,9W9^
M?"2[K[9_P+.0+YJ2H$CB2'B<$(_*(TNL0B0F*AQ6-&8)&1[T8YP7DG V^8WQ
M6M<@/<BUJ'*]D%@IFF_MT$NY>LC1"#:0[?CVZ*CQVW;K(P(6\OODTF;CY #@
M-V^R\YH"KC__/:!K*@V3%W?4&0,ZO&@; ]@HG<91#Q31J),'<-!V;= G8]="
M(W9_G!YE;7)P&OJ]7K^7"13<N_IS/W9SB/VW'/.B^/FK_]E]]3_5[^3Y[\^K
MR_-P#1,_'VWEUO@6^SFDOP^*;5 -N!]!U_5 RUG?#O"7C\<P+E2Y(/)U?="S
MW49WY#M9"TW>;^QGA0BJ<M3UU><F@WN_^_Z__X_AZOEP,L)F]<6UMO2Q QK\
M& 0G9;TZZ.69RJ.87O:\4K"39])"SCU3]UNO\RV;B_.3;QNA/]IO#($'Q4J#
MY\^ H0 #MA,6E3T[.;L;ELG9?K\=^XT$#U&]G;^Z'V&ZX]GG7>\D=AKQ&/0U
M$(K1T60/P;#"R.?B^=U0F:FU[\C%_+WC<<&\@%%K0^AGKCRA"HW!")X#U#3L
MD6'[&+;# ":WW\LL^K>-UH<-F++C0:_?KGAU'M.^'0S[O7,C/V,=V]U\_\H'
ME+^K=E-U\@0 L\@=F@?-\8OC 8]=7)U![V=C];&?0S2-?O[P=. 5:3D _ 48
M/8K#QE$,%??JYCX<S>ES'?<!%X$J31ZKHE*]CNWNPS@'TZWR]L/+<WL$[@Z;
MHYJ6.+39>Y9-ROS@U5+ AH39&-I:FBOG6IYZ&.?T?D<OW[^=WO%63I"ETF_B
MHGZK M[J^:#AQF9 <\(:87IA<F OP4MG_L?LH&Q/=_5^OW<RK)H\9.D;;X+!
MR!WF&LBP[KE64Y;)/+_]]N!KO>]&W?$^R(<>FF/8G,A5LNW.^.1$YK$3@@Z8
M %]?>7..(NP1^&B[GT]L'^<-G(<XO@X^4.<499'+:%FQZ\Q<O\%=)B@ SU/'
M <]]/C^3SSB4/<X-(-A'>7 @_D/8UYWF5" R$H^Z]8![E8'0B<,X!QS5&?/>
MT5'N>@?[X,=4]"]V]:KTS.5J957VV@WMSW^W_S-JASSW>8K.K/N7DZVU*L_]
M4X?TV/*L#*=N[QQ,5ELQ^_1!W9WMC\8 R%DU(?4%P\987\ G,PWMPP;ICF+=
M.&ZB)/(U&:R']47PD3Z@;^SF#Z1VO8\GMP0IRS0VG!/O3F^0X3=GWEF V-.L
MB0$$?,5D8NT@@#<I)G+&+JRLP4I<1A4C@=N&"'+>KO7E!3OQO^[_1+VXLBK<
M^UBG!+RV_5R':O#B;,2OZ@%?+T-7/EG2W#J!YV!?>,+,:*Z1U2& 60D&IL4V
MH(!#I,EI0H+9V*+,;,IYT@SBU:E41D5;_\R4C>%F(Z]EM3]OLD5N62:K;)%[
MM*LPW!M_4=J!N"J'F$P2P88)8%?IB)ACV'+!K,Q'@XF1F_/-:V:VR"NP![*Q
MVV"DVB8$\.?#R%5$#< 24"7;/?#!,<J"'IV#M9J\9*"M^WGG]FSQ' Y><E M
M$XX< +!]7]>(N4PMU\<W\SUKA*Y)A0U'[6S[]*L(*]QYD+%^,.@!N.=!3.]_
MYI-;&?U^+3V7)SCK-Z!$U11?X'[3V<]3U:[+;%9E 6<7+8W]M/ OK$.L-%@:
M#3.QRSIL"!<#1:C-HHI?U1[[VFP[!C-R0A>K=R=_S-AS>1DNL[.J90R#7 !H
MD'=&MD \4.)L=%1&S#=;*<?SM/2\0WC^GK!MY^;G /CDN8UP]NPG( *-U($[
MC+(9<F[^8+]7&V[L^(6-@<:_5H/.BCN_5BGP,*HX\+!]-*Z[>.DLK!S'_.D>
MS+T:SW$6H-2]$5B3%Q1-LW&>D?5M[D0-ZSMN4W<GUA*H9DHY(24E'!NG&0E:
M&1]P-!GZ<E 2WN!$79X_+J[7@_)MO_T-!O>V8WT5!"MJZ9?,Y97__L6S%#WW
M"3EO%.)8$62X58@E&8%BIFBC N9BS":Y6BV-:7>U )7,'8\<6#NP;Q)L66 -
MM?S#W2K=,K']>ED4>O[K9N/%//5IGK<$85>&JRO9/Q:KGB_+\J([6V_EQ?"E
M[?=SKM-?MC.*95?^FD^_9E^<2\XDR1!.W .?=AX9(CP"A:,()1%+DH^NZ9]L
M2E N?X^/UP]BY9(8-.?53?;'-6J/1J_ZT P+@;=/>]DK<A([0%Q@RPX/QOW)
M*X]&WO!CIT5[#$63OR_DN=T^<^V>TSWJQ Y@];U1)@O[;V%L_K3^^713/#Z>
MM$Z^8)RM.B%1T-$@3K$&D 3&'E4*TM 8A6:S:1'14&<"HT&#LE-46F=%LE0Q
M@F%%HIY-\5C1)(EI]LGYC* *F\]2R-;%5367L_I+"09M]2U.7$WQV)[94QG\
MIXD('[M54FN5MC.8F$O9>*O<K%E/3J4R*U?XEN-.]@C_MO%Q\\-FX\V+%V\W
M?I_8#-/0VOBBP3G[K_X,O'1RT(,O0+V3?*1T !9C.[1MOW(S3S[ZXDWUZ<F?
M[R?VWILC]S^-W^IHD.O!Z%W<M[,Y%-D7]ON%ZU^,LM'7:=O&6WCL?P_#YO0F
MEU^O?P?@?@%4/P=>^I/\DNE#51[J/JQFC?;GIQH,#2#UU:+4DWVV#S>GXX'=
M8'.CP1F4SPZ[[-S;[^30U7&O7WL'!W&_L@<F=M?QJ'_<R\9()AS9*JG,-+A-
MI=0S]N?Q'=FO%ZVWK-X'E4W;F,ELG4W3FDG-NB SXY,:*!_\>D9YE45[O62"
MU;IR)D_X2>1GFZOSLQ\WU?HGR_CX6NCR3,9?9B;.9C)*H2-FP3.9>.(,+B%&
M1"NHX(%'=M7W_%K57_P>YR66+BFJ5>!<1@._1PM&<(@1\P3?,\U=;FSGO=@^
M.A?^V>[6AD.E5>=@XI)7UD#S7K&^MURO7\__>1?(5''/4?GV>&UN=2PEJZ9\
MMWZHU,7=>, X!/_Q0\4%SL+Z65U-1GDVB/;9#JK4U+3X6+L+.GHTUJ=@!OV1
MTT,(1N^JC[VOX\3YJ@_H?R?&S8?7+\%JKQXD:\W3REH_;81>%9R;\)&Q&[K^
MDHO?GGJ]87WXIY\M^3S3[K0Q)3:3^%\=/+[43)JF%=UE.?HQY335:J0V9 FH
M7\]7MNMZA%610AAZ)^?AC/K]NBJA[X]RP+WB,CE(7SUD[[C='8>Q:Z*1;]:L
MPOX7?*7'-6O.4?D^+/1XWTV3#:X8]D2M-2]^8)R&4.5!31G-S&>F3UQEYF:?
M"S#!$/N#\7=6WI1QR/G"A96K)75Z)V?.Y[H _-@A/)BL;^TD'C]8#!<R<Z</
MEMK9P5&'4B,8Y#FIX%PPH[[HBN5SME.)S. @)SA<$0AIG, ;\%SM;Y/(QKE-
M\8NMX$;Y9&P<S.W@LX*55VS6R5:\R<8;'/1&G9"]#Z#0)XSU<)(3-95-VP4,
MZUSC?I/4C5JF<HIUK&,-^3'"9(.>)5:\J&_\OB*[>1TF4O__X/Z=.G?MC^A@
ME\.6I;SVR=4+!!Q[G((RNW$G63(Y!Z[*2ZK<^>-\L,DFK=)&QT);[R40EM-J
MUET6YYS=5.>-IPN7UKZ:VG,S3A"HD_B&L"#5GMJ\CF9LW/I<$/_5N2#Z:.>"
MZ+V?"_IP%F^9<1:!^;@LCJ*=EU-'4;OUYN/WG;\_=UJO/A_L_'@G6H<[![NO
MOIZV7GW"GU]](I_^?O_UT]%?G7E'T?8)? _Y?/3Q9.?H-=O)U\"8=O>V3W8.
MWW_=.?SKX/.;]^W/?_^56GN>M%Z]_D(2BX+YB+ R$?%<#-\&$9$DEEF3=&".
MS])!&CA\)"A%J>+!"$.<HBP0+4PDSII93]&'T5&5WP=2<6XM&F>+T9BLQBU.
M__QZ,!<';YV60*(8C_!/Q-H$K8CCQ/CDO1%BX[[]EA\'<3>]!@6='?Z#I[CM
M#E]\L<F%2+U"A.A<<S):9!)E"!.83VY)L'QN&ZVHP_'CH-('TQ5?"_MFKX[*
M@YTQS7Z\RF:8\QU.B?*8D0PNA,MR'JC]&J<9Q7$R;V/6-A@='8_Y?M;0MNK:
M.=:VF1!DH^-HZD:L:M$!I>R,R\-4#L,+20L5 [Q0U[O&B_TJU;.ZO/K<N3O,
M4))?D=\9XM\XZ@V&%Y,HIH]XQ8VOI$V7%"2H$_&K!-8+&;87GWIP ,P>.5LS
MOJ/\SMC=V)JR?^ LG7;\-G8YG@VR9C,YTZ/7K7R-(]B0-:/Q[;X?'>5L'I]S
M)%[DC(?.E ;YBC>&=@ZM-O*]^G7*SS@FU0-!N7*U-W_N?KQ?R :""9N_^[(Z
M+N1/]\YY<5]T0_7G^/3&<D6?'H=4M+Y8SZ(UQJ+ $D6@GSUR6E 4=;#:,8H3
MY3=&]Y5)@Q[OEL9DNS3.;9!J6Y^//*V--IC%K!J-JZ#39![ M+KH,)JZ@4 E
M3'Q 8,AV.K8_V+Q67&?Z=><C(@#C('R3<,KX .R98?IZU)^<9:D/&TS.\V1K
M=3S6S9^$@<Y@>?ZZ_(SY.Z97=<?/LUE%AB:::8SSE^+Z23: Z[<OOW\V-_/;
ME2*M[UX]\W"\S:K'!I ^__[YE!,[/"O(VJ^Q-KM(.ME5\FQA^U$]QF[4>3=6
M.TD^OTIYP^.?[<W:BD>Y06 U%<]O?:SU\9^WW05-'L\YS,Y"C_#[-Y"/_3B[
M\A-7Q.R,5,?J5G@N,J?I=2<95A,7X;!QT,Z'^RI65$W >J1)O@&B/-[HXVS;
MBE&=4SMCA]05'/TB6-0(VH_90UY#Z,_<KE6QA<EL5Y3[W-F17O;F56_WXP%P
MS.P;&V_3W_)0?]\$.,]GJ,:I=:-N?_+G_NPSU2PR;]'JZ=)8RTZ1\4)L'=:D
M=SZD7G\HBW\]I&$^I'H5QM:/7WG78^4H_DD^^+GT\S%U/V<#G)4UR1.S>Y8@
MWOCC)Z._[-'KZ81UZO2Z^R@?8;N89=#IV:E%!*,_MJ<5,Y_HF4N2KF>6>+>:
MENWQVKRNG^KWB2_\RF>JFJ[^43G93[+:FL:>W&EC-)@<_;L4?*KC2;7U%D;]
ML].W%X%H?(IW:FV<GD^7K'7M649T98),W?Z/:C)<GE)9S(/6JW=?> I46>H0
MMI;F;NFYU1Q)2#OLN5)6VS3G<W2$:4MYHEC@RC\$!@:&B1<6:\-R39)U-2>F
M?8VK7\YMIK5071>*TN3(9=8Q5>PJGQL'<>]4ATK'3=;&#+DJV0-*K=_>KXZW
M'^6P3M9&%0;D8[?C;->JW<!@XK*83;[^!4"LZ(Q>D4+P*_FYNG_V)*)<^<:J
M,Q7=QD&E"JN#5%5LM])_SG:_#LZ;7A,K95J%J+ID:AM=K(&4"QL-*\UW5;;\
M)) ZI]XKBRY?<('%5-ODR![")CB?2@#+-1Q-\_:FAE2^?#+*NF5%WCB3$'']
ME(V<IU<]:_855DHNO[O? _W6S7OS@ONL5F"9:W:J8[[M>%(K+ _7PLVRFRR<
M::Y!O&J8>6A37]PT+GFNCDVV"(&(] ;CH@SPZGG_XOC[\CG]S2NJ0)TMX_#J
M^1]/Z?"D-ZX8<?EX+XEE7I(\>&6RX%-,HB-XJ;+H+D607P;.9@-M6E$?C:/P
M.:!36 =/J>:2R\ <\>3> VU_V':_.KFRFZ;):-M5PM#1&1=[BA1LK_6%.\<8
MI@)QZ12"107VI9A /@9+8)*)<&Q]*57>&8UJ:S1:8%@ EN<=L19\JGJT;]6C
MM0=5[89N;</6YVC;/M8:Y.0LA\?'*N<H5W6I*NIT)QV<<LT),"7;U7N5@9H#
M-W;J3:L49<7#@+1U+MJP+@Y/<FI[752H*HO=]FV8D.%@4@GKZ&SJJQRLS?,9
M ?M ^JJD*6!]8/:U!P?9=5>EG8T?[_]G[TV7X\:9->%;J="<,],=(>@E2( $
MN^=SA-JR/>KH*GF1VR']46"52JY%IQ;+\M5_F0#)8BW:[+)5DGAFWK:D*I(@
MD'AR0>:39UUP*D?Z["J\4'68" .RGDTP'"6"IPC3YQ\X#2>Q0P5S^Z7PCR^F
M18@0O?K%;TX'R]^]/,.W\D/WL8AJ0$&U>J4N1V@8(1FGLB413 ^+=,>!4<K?
MR(\:TX>4?YX)##A^2FIW75] ]B&E\A]\^= >@A:=>-Y-AVB]>9$L<DM]0*5@
MH0J9H#CR4/4=8KEHS\]"N3LM?]\6+3\N#%4,/#ET >Q5*7^^B&XI#W!USI^O
MV!P,JYO7@\?7W^&IK5-<K%-K/XAK+6Y6VQ3_,[>*Y>Q4^%$AQ7;+=OT-#.Q1
MC1:G3_0M?_NS,(#+W,7EVXYA<_J#CE6"L$)\<$LOWV4F4'>Y97FO*JR&=G9X
MS@T"$U]SP^<C.DDA.A]7P&?@G//8%FS+OIV<#4U)KUM,=-U[*:ZH:XLRFCU3
M!E6JQQ)$7+M.R?-<)Y^G7-1USR;O6I=ONXSA!U>Q?JCF8[U@')0A\.W9@5,1
M?]X.V>9V[CL#LW#+N<.Y>G"WMKXE^05JV#-,^RVBPR@),#M!U8<@T/=%=<1F
M)Y']9%?I[0C/SR=7;WN8)#LP&&4,/+1-P'IO_\0D46YIGA"59@EA*G-$FCPB
M&<M32YT0/#:+[B]7D;$RR3-C-4MRJJSC6D<I<R(2+N.+WE6Y!'Z#5/-_<T+L
M(X6@U?&%6R=L?HIL.44^8W\2^/0FGI]II[5GD3*H6]Q][$\@I_B-V9D4QB!]
MUUI/\A.T4"LDQ!7^29F+9EJHQ-!SZG6_V"HF6*86%@=4H;\MGDS.S2F2-9/N
M5W+6-3#Q?SR;K=/9^QBW=T]BGG&12DXH9YPPC>GECAH2 59%:1J9E+&*DMF+
M-D+Y36B72)/D<9P(!XB7QT[E##9G;HWCF8RX_1&T^SBV;MK[I^OL,N&VF8XJ
MPNUG!8*XDIW3$Y=;'N<YK*0PDK!(922/;$P83W6>2LJSR.%*=D<3]/NQJ&4I
MG7]59'ANJQ9F@J^%N@\1#M-Y8K".0<<I=BP4L>4TRF2:R-1FCA5"P>[<Z+<^
MJKL1WSPT^_H#B 7OO#O)<B:4XI2D2B+=39P2$46<Q":RFJK$I!DHMSC:!I6R
M3'AS7X[(*&=9FB&H)"G3+)7.\I3F(DK@05KPHM$HNW.CT6:=;U_GH\OVZ8D1
M@+N9DX0J;!H$$$R$B!FQ- 7US#7-C=IZ0?GJ=2Y]JKG#63O W)-ETE!<N6U,
M][D(75AZ5SOK08FUMP-OI.<.TH,HH873/.)@.UL%9H#(#)&,941Q1Y-()LH)
MNO6"T?6@Q-K;$3?K?/LZ:T2)%(R 7&A!TL3".B>&$9DI02A##E^E%!@12,EW
M,TJ,NU_OCQ%W\HR>MY>_W[^0W1$:N@>CO>[X8CB6O0/WSW!P^@^> /E6VTV*
M&FT?'IUHKO+42$.26&2$I9J37$4@S6#A)'DDG=#1"C:6+$H555%"F4U26"8N
M-<".2W(&6G/1XY\M![J4N S$KT,K+,1/<_U_-A7.]Q&CW#QU<WEB(6]UW.K.
M)K!(E(7[^039GI_'(E;I#]?FFZ;Y0[RB7G\X"J=RLYO)D,@Z+IL]^!/! 18)
M8G1SGEIB%B0(.68S<G^?'(0U;67(%,M2?#):F7L</B@3JJN@;"@2P0H4'-'L
M/60H"QG,\G9EU2ZC&D7M/'*%LW7H:TM\INZOLYMJW:Y*)#K$WBZJ9[VDS_;!
MRS-,*QH_BFY7OUS#'K[Z"AJ6"QG1)%8D$Q;L<)$[HC(7$\4D4TIG4B&]Z*\S
MEIK%7>/B@A\+_JW-B8MCL)5ERHD$!Y?DN4@9LXRK)+W7XOY@7*19W#4NKJ(8
MVDX52=%O9EI%)$^RE#BE+,^Y@+_8>RWN#P9#FL5=X^*:7 B1)0X<'XQS&]BY
M*K$)$9F5L)EQZ=76B\%PR>GYCC^LL'MJ!30AQ.)K_._F1OU2TN8WPZ'!=@B[
M [,_F-3%;5Q^]'SS,O<^GL1Q;@7B?N*L)(Q;2P3E@@AE!649RYR(E_P.F6)K
M2Q-G*2AM%2E*.?R8<*.3V-GL/GF<\Z29T4Z\(>YQQK#,L9"0)W$(6K5$U\.^
MPE*&JG:]R*(HB,)FY!I2_\^T&S+;B_/*D-TR&4Z08F\ZTF=R7"9Y>K:RN4NZ
MOJRF*,XH<BG\S7N!&]*G1KFN3]89V$EUOED_$^V.:C&7E5['N$:L5W]Z2/#<
MLUBZV!W4>@(N9_#XR\IF"W/)(4@'XFD#BU3/&5-A59-_/C6G59>^H9MX/Z_6
M ;3([%Q-O[+ .5+O8%@GGO%5$,4\!/)]7U+IO4+L_8U^H7_\=.)_V<:N+&KV
M'OC\J=:^)V/I589RY.UR"'82#INWT1O$$A&?,=.=6&Q*NWO'>9JK\;S15RSR
MI.:+7A8EZDLAAZN7O;AH)CFS\77'M6&,6Z?%-GX:^50E*'GF!SLNMVT]G%"G
M)T)90ILNY ,7)(F]JUFE[G0$PE4T =K&W+3^$!."4>9#J8Z/76#3P)"Z%BIJ
M ]-2G7VG#&_86<50D*L^#M[S%1;QA9W6JZ\2Z4I+R3RKWW[AGCX_<]LS3I89
MD;XHRF/*MJ<BG^TL:4+[X*+J%X;8LZ<A^;+B6]0]+TRXUPP6AE4INU5#4K\K
MJGO5FW_JP"DZANM\IS>T;K%2V%9%ZZ7L(HYBBS%,09^4G$>3;J \>NQRZ%N;
M?T*QP#E#.MP"7A<Y64KNRM-*9FM2ZDGA ^OKI:UJ,0L:X<4[!1Z%J] 0NJ#=
M*FQ11*,!+'-HEU8C8<7<F!FSO,^C+0BY) ;M9@0M9G@Y $0=A!Q</1H">&"]
MGZ[)1!684Z.A1 W9[QH"5DZ1RP\7^=\*EH(RD]<3]2,9Z!L8W*#8EJ&L#';6
MRLS"LI#!%^YA5\^!GDM"O7ZPOH]NP1PP-XZYUUC5/JB_@H.KQD>*I6KPCPG$
MQ_C@(L49BQNFH[D&1=M54CQ<4\UP-6E^/-ME#:'7,@3CDP0T#2PKLC;Z]?2\
MLG5Z4XS#8E*]Q%$B>4*UQ<OT7K_K9@V$B^FJ61P5!,PLAJ62D.]H.M P]5]7
M9$@?09'A;46#"[Y/HC437*6:BXBE3N3.V%@*:?+49%QDUQXXW.8SW8OOYB%Q
M?Q>A,)B'L&-DR[?-GN] YINW%ZT^T 1#\P(KI,)F7JD,!K)W-2X2)V456UAE
M^2TTOE[!_^7-'61T]J7%Q2$'F@##X>?B'C,$*)/""Q2NDN];>'+1'?@&]L6K
ME*.:>YMRY/,S$%ZCT&7+8[_76.%34[@Q%KN(W^F6:%E;3[52O_'BRZ/]Z+NN
M% 91D5NJT:*9U(O+2MNN4 O5$H:JOI*/NK#OM@L(![P>A2*>XC'=&2EXL/\7
MW+'%E_!=\*H2CCL5$ZZ8"L\8A.U\['>6#Q9Z<+E\L"@I*Z^YKK(,[=:Z>>//
M[;Q6A'D!TQ<]X>!!U^8CD&:6[^F/%(NB2N4;2J'-7_MZ;7"AU?P7V>VA:[W3
M\H9:R$/^GU4#AO&4^VR5C[PPG7/&6N@%4#ZJ>A6_:4H^U3F#?CN8^WY)#)(:
M@3JN!K2-;5F+ D5?EP$#+*E%RP<6Q@A<B/5UU]"7UBSQ;<\4@+3Q_EV*OD5&
MKORRYV$H*H462BWW!T7%V,+K%$Q#X^"M7F/;C2OC#D6AK+V<;>J1O:@8&BNY
M*1WE)9/B1GOC3L;()JN7O^H9\8"TO46@K17TS/3/N"I_A6VB8"VV6PMX7++[
M+^"7#(9HP0OI7=]>]S,NH#\UA\\*GL@*W599T/=<I,>P#KLKIA1VON\A5G>Y
MJZFL(B[(_N:=@NLZ4HP!DVQH4EP:5QZ$PLZSI=.!.ZJL^ZZXMN92%O#/U?.'
M =L'IT-OZR-([A3Y!S!0Q!302!BI&OF15.[-<#KQ'&1E**(D3BD#)"'6YA^!
MDA)8X;R_/VLC7C=E=#B\*M,I%GQ=N!"'Y ,K59QP%D/T:%P/_<',3R>U3@ZU
MR-\L[H?CQ!'H26BGLNCS^=U49(94_,:MU^%>1>C%U^*A3X6SMWP+A.7R$=/1
M_!#'H4]+UP.B[U>^W4+ROAFIFH_LA#WKX!:8 5-5H\\FM!99PF?,PJ2H&1=?
M'/E-X:6P._.E+;W6,NHTBYS:*ANG-$(6@V6C.K7T]CR/S6Q ""+#T)Q[\?T#
MRW1HV6WG U)(=./9IX,#C2\:#)\6TG_C:&K:)^CT17_:BUF(Q>$T+SCN=_&U
M_9:MO)A K8#\HQA(N 3C#B2U)!W2OC:IF/^Z8L1&YMVQ+TWV';%1*!?RJTL+
MV@:.H0_8CRDTG*E&>UGLH\*>QOUZMPA1@;FK[KEJ!NHEOCZ^C<:$A+V]@&@K
MO/UY[_[GGDV6Q,*[ [,WZZA>4"$^WU/)PW<G/(LBEHN4L#QWA$G)B12"DL@F
M7#-II%/1TV6+J0BG479KDM$J1./1$_%Y ^.PZ .%J (@ T/O>IT8"!E@E':$
M5'NF]OYS'04\<N W$)N&@X&M=1R8+_^HWP* X'0D^Z"AP%<9.CQLZT_10^[I
M[K2_W=IO?R1YP@,!./PL>#JCYL9F=^,+C\2(,LCT5A@G7=\?K;9L]6?"!X"G
M.J2+KGYLS5;]/^-6#_V5%:,.G=[FNBQXY?3^??O#=NOCR^W6RX-_]_<(S8,+
M_O;#RYW6HS]M6-X3*V6B1AI8X\CUX1VO_Z]=GOK!0(A_E$*X,-5>V4PP*V9V
MLZ)2%S\K_%UX>; TT%:XD%?]0&DP!O-WU"T$MR37M?V+WO#*HO$RL*X[\><2
MY7DYF$G!\@T;9.;S@.8-TE15"8]W6K?/CH]!>,O46P#S_7S+:7H:!Z3US&T?
M_BX8I^4I@$&-T'-Y,8>C4SGH?BLFIFP6\/+]P;AJ%N MW2'&.1;;G92K4;24
MA,GKFJDGOH;-;DL&B^&Y/YQ0,+2O5D]#6&SVY<OAZ'.(3XT+EL>0V"U;;0E&
MS@A,H% 9OCOR!>!^D<N!MC_LEN,,5B;\H<HQ&&(Y$=RL_H3R37#$X9AS5#1N
M]*!3B&\8>?G+]&)8G4UAQ\F"['M)^A>84(K;(YVRM^J6J)1G3_-LU'Y;AG9^
MXTEM(Z.?Z,DP84HN?%EUV6 R' T66VN!)+L>3:IW"/46Z\/2-B-WJ!H&<N_:
MHBXTCGN6AN >ICG&U$FIB9(1)\PQ341J,V(3D3-C19S2;(FYV44RBF@*WY;,
M9DQH&FF;9DJF$=61NZOAN.&U6S7)@2U8$YU';QZ&URO#QW.O&3*/M*_&K>&Y
MCTX42KL"$E1SH[+7TPR)T(,?V"K1I:1V\NU(8+O]T8+=3D;6GS5C4!L/E?$T
MH&#5K?X^O8!;#PK6L3 B9^WXS[K^W9[+'O$-8_N (Y[!=ME.^+/\R0,RS. 4
M@R4ATW8\O;C J'*A9/XLQ]2J]_X=V6Y?34?C*E_@6IO'H^J?P1P97LE>2!,;
M^&PJ,%9"S*5XK3*V,5F ] K(+\^L-TU\^*S4JL'D0$5;8/!8 UKC;6>-NFOT
MBQ^*DZ9QZZ\A'CC]]GKWPU^_K_[&QPL,*E9J;_?#QTH] ]@R$N5E/+?<";]Z
MQUYGPWZQ&.OT(OFRFB=OC+R$_3<$T1C_Y"'?., RU.U)LS]\;'6&.SBC@E"Q
MO9E3.J<^YT"P>)?MAYS/UF];.(W%%&Z!55;[%3P&= I<MSQ4K1H0]F;M+O3<
M^\G:^Q5A1W]"XGQ;E+E^),'"+86JM;@'=S^\;*51^C0,_OU!ZT!/AA@7Q+F=
M/XGW'D#9H0H/""ZN5R2MW_#*K3W9!2^PV_H@!Y^OAJW=\N.MW\.T+GS^<KBS
M[?MTP7+/?X07>(<2G'>?4U ?F#_E\*F1V&6E' I\=3B]"$O?OQ@BB^@VABUA
MXF=%GG4,+J,4V^%0]6*(H5 $UP%,[G#DW1,K)T$CA'='[7(*[L0(3\Y\5%SZ
MSMV8R#BN#FBU[76E+O^^[1.-9;\?=)D:7MI>[;/1J#OQ6C%\,+X:F!$>JOCY
M,ET0W#,K:UZL@K]T[:P36MU#*4>RT]J;59D40P\6^_P*UQ)-<*5,<%'NX.[[
MB2@\_HD_"JP4J)_H<C&_(R?L6:=]Q9N?]G5K&M<BN9XU5"OJ!,TS1KF52I@\
M88E5PK'(ZFN[8-SFB]P3=!]H20ND V!"$ TDU]-^L=^(WV\^*7NG]2$<H=;M
MT+"Q9NGX16F![_Q4GM"&U.X6%@,5S;%NB*;6;CZ>'8V6=2N8(5 B]M/0;P>#
MUM_@#&!N+/?'7M&"BON*+L6X2/8JD!*]'^7MB4DHM.A-?3>TR^&H9RXQZE,I
MGYE34L2^4/U4P>_=6CT(&O.G1:I;\9SRX4''C>M--"L-YWVQ>=58I=]@>CRB
M,K@W/MO70W?5?6P6@O>YY@,;M$5UTK<PB 7%@&2Q$KT]XI-O2H\M*%M_%FSM
M\M!V6A^K$JCK3('MQ4]\L=-X",9;UY<8XFV+Y+3R[/HFOS#X7*M"QQ(/L3'+
M:ESSU%;,T,,>97Z (<*$O@G9Y[L#LSO7M:X\N'KV7"_1P>'GD\0:35-#B4NU
M0-(B1:14*:%9JA.11(F)[UQ#N>%!JC>U1H;S(O%D#C.7WO.ZAHWE =7LL!-3
MCE:=#(68-UJGL[--WR+*GQA@)E9HA.3KHHJ:ACD3M[*S,6R$>8BEG0U&=6B\
M>+<.D[<47_D,D15-W;=#PRJ?9U7D UV,A@Z&&70[QLG\Z_GJK.UZ2-ZG,\FO
M]7,U&'7HP[E=3="*TS$8/4S @\;R/V"/>Y^_^+(V&0=>1?GZ<S3+88:1!O89
M=P/:^WQ"8Y:GC%I"X1_"%,])+M*$6!XSG<96I+EX(@CXP>^1D-5:%XO0N>!)
M@%\]*%SDH1=]YX;%>7QYTAWJ @:D^D-U:%HE\H=6>*&X"R&B;/M[Z4._<WS9
MWN(D/A:\7 _A+_!^Q^D@]/<-B-<++81GI)Z_=7_WN:,+!-TAR[ZJ0?9U"^")
M5T,NT]U"JHE/K@Q#O/2_?)F5/(0Q>R=)5E=7J94A4^.W;C$*+![0ME=0>A4L
MX?B,.]V]"(44P%L] ?%[..A=E944F%R#J:B>RCR4BO=J&;$K[Q(R]Y1/K@,W
M[QKDQQOBA,X*=XI[^E7"=%U<L_EE]&\VZW$_6\G:\NN>!.7ANGC#,!'5K+G0
MD7.A.".HEZIOU-+UOB.RL]V)%];%YL23JAW'K"@&_@8:6^OIZ&EXE7-I$E6J
M[7(!2$@#'1;)KC,^^[]Z$D3@@\;"FC%IV]%D6$97"2:-^CSBH0'3Y;>MOSZT
MMWZOF.M+-H4:/<(\)<)XJLX+RH=KV!&":SG^3!PF>/E4,*RE&?DZIM4%4K5"
MT/EZU; CBBB"S\3 [-BKKNV9ZVK-;KC!ER%&]NI)ZQ4_QNUW*I.YJ[OYQMO%
MI6%N?<1D;&LS5J215YGE\*;%4<*D-"R+'(C*P_99XM=26?B$X#)/NX!B'X6I
M4IGGTK^+DI;ME>]WG8E8P:\N2YSP94;AE'7VH+DD_ <U[O[!LT[[CX],/WLW
MEK8/=T]2*9)$:$VRC$:$Q=217"64F"2*<YTG:6[NW-)QR8C[V9RA][3BPKK?
MC_)W\W"_S+NM<+\7CGR&SB%$P6BT+7AL_!^JEB?AX+^&H/[">@:&+S((?T7,
M"OD#%?GH37LSMR+/8ZE-'FM&,R%9RC5+$L-2P[,\.]F_>4L>E P/?HT.X>$'
MKCQ<7]E5PU<K/+,]VSE\QSO?/M*#/?S?+CV!.:>YE);$/.&$,6Z)%%826 +
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MG8ONAO4H0[L[K;<URV4.3N9#R*[;\YST<*U$@I(SVW/PRVEW/!D%(V8\ :O
M(P_\\AKT0NL#26 <7V;TEL7%!7"%D>RT/F%T&?\0^@C4#*+:6 ;#E@NDWA7
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M;GZCNG$__7HVI"UUWP-U?SX0[T(A4A7&"2N R)G,4\.2-(J8T&&:1CP+961
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M'!NJK=,/4&FOYK.F$0&U0B(S5 O^T;DP&F$C@K4UOJSN<=M>NM_;=[5^=P]
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MH4I?%44O9JW^/JWJ>HNC[TU K!: ]R,5QDH;)G61,QD CE9)$3-9&!X*%6C
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MJ-@@9$&6IW]2>ZVG7]![;UU#QINU2'1@8NW(W[Q5F!^*.[8*\\7E?[Y[2RL
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M 59[.][W#WZ'=1R_+0Z/_PH//[_B1WL'_L'>\_"=+()"&),QE0C)I(Y2EJF
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M+$M5!C_),%)%'B5^M/,T$<&&,:=["I!^ /:_W\W$3%W58:7'Y:2L9U,J5_L
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MH3":^B/7W<48J7, ?[]=/A+ZX(!\WJ/7#Z8*P S#V+QI67^PUPJ!"GV&XPU
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MLFX%![$V@B4SQ+U=K--HQ-K@E8&K%'U96,LYE>Y1^2E&LAU6K3!0VD::-O6
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M8$A,,><A]@'&L/'%4"#0_)3&RL<W/JQ;E@_9 !9%EOMGG2'EUTI--47ZP.W
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MZ:Y01Z7?K:.)2@_LOQ+"GY_S'<YJHWEMU"AG2JU01V=PC*&FB\-PI5Q(]IN
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MHNA/4U"YV=:H?6A3F'=G&GR<XZH_AO%->L_U;#OM;0P2+KXAUR-Q83K!M7A
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M3D#EG6*;<"?"Y%I1=_X2WS#VP,MFRRC0*[IG4T=T3VTAO.!W>!Q(8NA%/Y5
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M[2=<@\;J!7F3@R'.,;LE%-%5QBD?13!3$< "BU.N'HA F% >P5;[\"'.M^;
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MON%<G=L=R?DKJ*9;=S[\F@1#C#K>'^IF6ZF+__.7BW<7/RZ?7( VUR+7<KO
MYP7Z 6JO-]CHWA3I9U#O])J/#O33J'=:R]]Y7Z"?3JO>;NW+9+OU;KN_)W/M
MU%M[LZ]NM]X9=!\#[6DG>K?VU^S#7M6+=,6:EK9-/O+ENYUUUB\AW+:R PO*
M3K;4'L4)QJ,S3JCZ+LA9,!*E37DB@G]\G;K>HJ5M\M0*?KW)?,G1@3[GQ'IJ
M1MP]0I1GXOP(LE \KD!:VARYL=@?>;<W"=O#K=-5?)T%']7&S7.\W;L-B"Z@
MSM3O045LHA0VV0#J2MYC5_\=R@/&VU+[]E;=W0VYM'Q;5NFP\?C)]H8GYV/T
MF!Q$;ZCF"'\%<_(J/1>"&?+MUB?H3!(Q_O.+29;-WKQ^?7-S4X=IUJ_BZ]=G
MR6@27(OTM?"OO.0U)KF\=IO]1J_7?0W3==U!J]_HN /XN]ONOA9=M]_I]/XI
M?K5.W?HD VX]FW)I"P8:O@OJQ^@[9WAN,B916%^<V.#-![.V89!OC\/ZIW][
M# YK5JY\?9"(K8J8E>@0]P-SX/4\.2WMV%Y2BS^WAVDI[N !MYD]T4WK0#,_
MM<RPZF<WU$^3U<^/29" OJE20N]NL0+):ARK<:S&L1KG/HMM/_9MR&J</=(X
M_5:/-$ZWTP2-TU8:!PG?^3J-@F&>JH0KN.-@>OZU<+Z%GKWD_'9YVC]NE=.V
M*N?QB$G,,D[ ;S8>K'=VEV>87E2?K.9_6\VSQYI'SJ?==/$_K#C>$Q;03-5F
M?:?\W<2+LO]*C33/H]<=1W]= >:WNN.1]K)H1M"EVJW&0:H.MV$O*GNM+A[3
M->8V5&B&RT+.%!Q&S>&*O](5OJ91*BZFTSP*1C6\S-3)DW;Y]W?.)P$KCGXZ
MGSZ=5UQK5E<I6;UU5'H+I9!57#OF9]M=?@%RV6X\9ZT4/:NWGE%O20_;UYEN
M3?,I&"%FPJ(2,YP"S"3]!4WFG/U.8[SW@@#FY%QZT<_;&)&+X:AO:\ZGS+>>
M.JNU&O:Z9;76)N32LEK+:BU#:[5D(ASBUCC?<AC)J])8GSU@C1:Q1G>IKFI?
MGL.?5BU9M01RQJHEJY;6)Y?V_[$N0*N4E%)JLU+"8AI.PO;%E!OFT-U*:R>K
M:JRJ =EA58U5->N32\>J&JMJM*KIL*KY,)V%\2VU>]/:15]SWB=UY[T7!2)T
M_AYDW,&\N/I8)625$$@5JX2L$EJ?7+K;54+6#[=E/=0;R/3L5CGKX<SW1>3G
M4^RO>XD(E"-1H9#F8T1E_605DE5(-IOA*5*X.X>ME'KV9G2\&FGA9M1=\V;T
MV8O&V,?Y]R06LQGH('L]LMIHP=ZUVLA>C]8GE[[51,>KB1;N1LT'WHWF-915
M258EV<0Y>T':F&0&5BT=I5IJXM3;@P&JI4&GVRZII<H+$F?-G<V2()3&&I9_
M+Z]6>I][D7"^>.G$*B>KG Y/.3U->]0U]Y/9D/LO'' 1;<-JI^/43C ^7)U:
MH)V:H*5:Y3):!'T%363<G58HK*^C+$8[SNWLH\K:JI!Y)*VUIR+V68OX=V_Y
MTM ;,,3NP6H8VZ?A.!5,@Q2,O/[TNB4%\RWT1D(J$Q&-;A=KAZ3YU;I;I7R/
MLXES[LT0Y]SYYB59))*TANT;K(:Q&L9JF!5WF-<$(??;(HC?<V)=5T(?/C]J
MX!( [-ZN 6#_9L$"+5B@!0L\++# [5KH%F3 6NC:0F^6RR@--/;EA?[K&^O9
M1#A!!%/+XB1U9F"MW^)GB<ABZQ"RYOIS-LC:O>4?2<AAN]UDK+K9IKKI]OND
M;KJ#WH8.H;_FD7#<QFH5HW4,.86L,\AJ%^L,*G* D8&:!ZY<VE:Y6.4RZ-W_
M+K.6GKGC*F-UC=4U1WV3.0Y=T[&ZYFAUS:#7(5W3;[NH:]0]Y@]\RPTJF>BJ
MPD^67^5IYK2U<KDE3?(0/ *K6(Y+LKI'?8>1#.0>NHNL:S7+L6H6MSGH4E(N
MW&=*+K*/0>1%(^&<P_QPV;7Y]-O!RCM+;;[(\4.>Q#,!QWM!EQAROKWSHI]6
MQQR]CCEN1YEBJ(,/Q/2LEK%:IE$=]_\]]Q"H4ZRHEM]0K]C+BU4LQ^T5.QK%
M\BA0Z%:Q[+9B(2U265;8:#1)M[C]M= YWXN1Q#63-YCU'6)6I5B5<M1WE;]Z
M$8$]MP^\B'!@-<KA:Y0E5Y5VL\-7E7ZCW/88E(A/UXM/(LM$HO3)E_B:]8GK
M*CO+:@FK)8YX^05'M [[YC&W,JLGCD5/X+6CW7:YFTFK.]?-),M"46Y=4D!4
MPOA.BQ6%NR<@E5:16$6RG>67V>5@M8AKFV(=@1I9[L!:UA=+-\3Z$M>=YAUM
ML61['VZ*Y:[5$\OJ%ZM?CEJ_E'GF8/5+T^J7H]8O_6Z#]$NOT;ZK[^)]\;RL
M*K&JY*A5B5G'=;B:I&4UB=4DIB9I5FJ2JN)&=V/U<A;YB?!2YW,N)J%(K(JQ
M*N:H\[F.0\6TK8JQ*L94,:WE$";5>F:%Z\MJ%:M5*H3.\[6(VKWE'X=6Z5BM
M8K6*J57:CZ=5?@]%%#G_F'BAN+7JQ*J3^O,UA=J]Y1^'.NE:=7+,ZL1MM#EB
MW^=RQO7:L3 J=D?G?MW5C>5;,!.)<PE_PCW%^4]O.GOKG-MF7U;#''F@Q>"B
M@U4P/:M@CEK!M#M4A.*"JBF%[%?=5W1GEO:2]&)3MWA9$HQ^.O_P0IL'9E7*
MD0?OYSGG8-5*?[MJ11^RU2Q;T2S42K))5Q<7_BYIEA^3(*F(X,N"7[:WFC6;
M(V;5C%4S#ZR>E^ZQYL&JF8%5,U;-S*F9YI.J&1O5MZK&YHH=GZII-:RJL:IF
M3M6TGE35_$6$H>?\+9Z$DWAL%8U5-,>=/G8LBF;+1?I6T6Q?T70:;5(T[4Y_
M>9U^:UF=?KD'C*OUCZW4MVK&NL[6Z@2CF.9@E<SS75FMCMFQEF*H8'HNM11S
MN_.%^N5.QE*1>"EVSO_LW3K->5V"?8L-^,E/G\Y)H914C-4I5J<<N4[1G'.0
M"J7UG(F"5I\\B3X)IOFOTT:W!33Z2\ZMY4JM<(Z[/8;]QD=1%7Q+@F@4S+S0
M^? +A'\&6L?Y.H9?B,29Y4D*UXD,;R??\U X;LL[==LGWBLG3N0G'5]],B:X
M84.#?/@UFGC1E7#.1AE^#4JK74,-Y/GQ#)61.3X\1U."6>NAO&0(EYGT].NO
M4-RJ44#G-9]<#^WM3TD.O<Z\82C4SL#_J$<D&;6;]5X'2&T6IP&14")"#T_^
M[4W@9Q,I"LP'F2O?-(I'O&$:AWFV_)$2BZ3Y=.HEMR;SC\ H$<GSB[DFB;G^
M'/48_SM)BAV^$J?#1'@_3[TQ3/:-%]YXM^F+UZ6%3H/H=&YCY_>$%_G;_QTF
MK^?)5AT1G#(>6K'A"7#U*>Q'Z,U2\4;]\=8/TEGHW;X)(EH5/?06]O8*9B%/
M"6<PKU!PW_GK8G+U!D]0JBWY9OEUG;Y2Y%?Z;E#O])I+OP7[X)[?=5K+W[GJ
MR55S[;3J[=:^3+9;[[;[>S+73KVU-_OJ=NN=07>M80_(CK-^@4.TXYIWVG$,
MPAK 7]:.V]N?'HP<:M;=_[:"Z/ $4?.A%TJW[_Q1OZR?U[7(<%N=QIUR9=#H
M6KEBY0K(E::5*X<H5QYJX%BY8N7*_>7*8%"WR!I[+53N'4UU!QA-'?1>BZ[;
M[[80%W8P6*>3X*4 J4+8950*Z@Y6YN<L%A[L2E1U>USW2"'59N7*&\ZZD<6M
MBIW6?_Z'VVV\G=^'ZJ.D)3767-!VPK3;V\R"'SO,CP<9J062V3)&A[6 =TU9
M-<NYI2L4U -KY:S*LBH+Y(]5659E;6CE6)5E59:ILMI/IK)*-7=685F%-:BW
MK<*R"FM#DK$*ZS@45F/-/O#%-6L= *O#*!6W6LM>LPZD@.,8>LV[]8LOESL2
M'=_&#OS/N^^?G(LHS;P(I.[[>)2CT*T_S8;L[4\/B=XOS_]R[/3^P_L51_'T
MUOGP*Q-1BCD-EZ.)F'J6 8Z  <[//ED&6&" <R\<Y2&G$'T*HI]#+[7ZX!C8
MX?V'CY8=%MCAO1@'43#'#7#WQ3\L-QPN-WPZ>V>Y88$;/GE#$5JU<$R,\.W[
M!\L("XSP+1$I$+XUDXZ,']I'S OG,<S&^>9="><"^Q!X(RI40FO(^1B$PA+]
M!FTE9/L!H.4W;I,>XLU;;'>P_*&EK2&6#//;,_=+& SJ_4[K/NT2VO5>9[WB
M\TU&';3JC7;[J&K:-XG$[OQB+B(?BYM@0,^!P4 046!P! ^B,,+"[%$\G8&*
M]K(XN76 B"/\T$L2K,5>U,R'<LJ;**6=7\Q%Y'BC$<@FBD3<!-G$N<C$E -Z
MW89[,GQUTFJ^.@D"*KS_+JZ4N^KR]&\4$K[\< X?AP)-LB]QG9]LM4[[S5:?
M?M!JG[9[@WZW1G5Q(97SOW$^:Y+ZS__H-]W>VQ1&F<5)ECHP.*D\_/$YDEL<
M.E]1&Q9U=?Q3V&%ZPT(IWOL@'85QFB?"":)R>X!OL$\Q4+9Z6XTJZD;F"*DS
MSI,H2"?"Y\<I72!UL%2<5]2L-YV)2$06 [D+Q\>@N8^!=-S+*1SC+8P:I,['
M.)DZ;D/NU$T0ADX48W!=/8)K;\+Y@D+WZ6_WK3..J5YP%J>">B'* D#>6+>O
MB@#-5=6=RWPTF5]%Q?M@BD/<$SCQ&>8CP$?#6R<18U@,$D 0X2)@^C CV-W4
MH62%^7X+9\S^\[.H.>+72,RH:A&_$VC P[\F7D;_3L15D(+P@,_2F1C13,/P
MUIQ.Z@19:485(F1!R]]'FZ]G MAV5*H=U6 NR:/<&\H)_#^_"-Q6TVMUA_VV
M)]QVJ]OJ]P=>;^0-1:?G]?WN^)]NH_7BMZTVL5*C/?^^]BKW]?+B]R]G/_[X
M_N%R,S,T +:,8"<&]8ZFY>>FB6]&D3*S][_S("&1GJ[=I&5.+DR\U/$1"WGD
MY2G**Y2B"4EJ*;M2.#/X N0\BN2AF'CA&"4&#D3"2OX@0_F<HSBC\;P\F\0)
MK,ZO/WRG[Y :YG/-?O\9#JB:N"X^?_[CR\5YS;GX<KZXZHV7LE5B@WLO& UG
M^56>9JP)&=54IAX]__^^NWWC.([:N.??DE5YCZ_3UR9$I7/7?W:(DJM/7\]T
MV6F4 #GW?3'GDT",*YK3$,1U(M( E[#[RWQR.?NH\MI(!]SXJ77<0=LP*7?%
M>FPWEEN/KX>Q?PO_-\FFX6__'U!+ P04    "  W. 15#-D'KRP.   #B@
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M13@D]UB,[Z[^<W5WT;\CP9#PO*YQ;V-55[6N8K\5)Z_+ DS#]8H4J@">=58
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MV)!B[>UQ<2/<:JZ39N"G#."(_/^O7X_JVA01V9GTJZP7&17Y_@"*6<H(6%!
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M[H*>%BK9T+6>O5]_1!KKY^_^ U!+ P04    "  W. 15/IF\!H [  #GF (
M%    '9T;"TR,#(R,#8S,%]D968N>&UL[7U9DULWDN[[_ I=W]>;;>Q+Q_1,
MR)+ET0U;<DAR]\P3 TNBQ-M5/!J2):OFU]\$R=JWPR(.R2I51+N:FPYR^0!D
M KG\Z[]_.SI\\16GLW$W^=L/_"_LAQ<X25T>3P[^]L,?G]Z ^^'?_^U?_N5?
M_Q? ?_[TX=<7K[MT?(23^8M74PQSS"_^',\_O_A'QMD_7Y1I=_3B']WTG^.O
M >#?%O_H5??E9#H^^#Q_(9@05[^=_M59Y66T!CB/'E3R"*Y$"\5;F="AMC;]
MGX._H@O6:?I9L$G3SU@ 7Y( ZW()S$N>>5X\]' \^>=?ZY\89OB"F)O,%F__
M]L/G^?S+7W_\\<\___S+MS@]_$LW/?A1,"9_//WU#ZN??[OV^S_EXM?<>__C
MXMNSG\[&-_V0'LM__,_??OV8/N-1@/%D-@^3=#X #9_G9__P(C7ZQ^67]-/9
M^*^SQ;__M4MAOE#/O2R\N/47]1V<_@SJ1\ %2/Z7;[/\P[_]RXL72\F%:9IV
MA_@!RXO5RS\^O+U.Z7@R_S&/CWY<_>;'<'A(%"^>,#_Y@G_[838^^G*(IY]]
MGF*YE?I3EBM1NI+SO^O3?MR8IL]$R#0=1P3Z%"<5X UIO.GIF]-\]BS(6,+Q
MX;PAQ=>?W93>[BB,6PKXVJ,;4+MX$!SA4<1I2U(O/?<"G:=$7J7PZW@>#N>?
M<1J^C''VE]0=_;@@\%4WR<0T9GHQZP['N:ZP'^?TMRZYLZY\G'?IGY^[PTP+
M]L__?3R>G]S/QM?Y(=2UEQG)%N0^9)0+3!%ZQI-Q79!^I;>KH2KYP[.'W^9(
MC\@_O!CGO_TP5B)QY&B,%5[9[%S2*A85I# 8:9\8/63 RN@IJX==NC3^85V)
MNS/H'(:(AXM/1\<S. CAR^CLX20;?$LO9Z.LLV7H-822:(<K24$0+H.F#2WP
M*&5$?QUXLU,@ES"+"^BMAOBQZO)'/)S/3C]9:'>AV=NI6"KPX7R]G23:[V?X
M&I?__W9R770?NL/#-]WTSS#-(\V*3%XQL+)(4 H->!:(:>VL2RJ9I&5CIM<D
M\;)$SD']<GHJF]6R\<!UI1I#3;$Q[[:GDB4LB+\?7G13>MS??F";(NCCYS#%
MV?OC>;6%JGDY2HHL/!(\T:(XJ)@2^& <N.!S8HH7YG+KB7&5B.VC8%"U=2UE
M?AT$?&,07&-UI*5DSF>RY[,5H!S+X+!PT,5[:5E(@=^P+V^X/-Z\OSU9&&PF
M]>LX$)OBX!W.20#=$?[:S6@5#)XSR3@D[A4H&31X5!*,3%)DY53!UIO%)0*>
MMO8?+NOKBI>;*OYE_G_'L_G"^OK4O<QY(>=P^'L8Y[>35V0ODN6X6+6JFTIF
MV]$7LM\6WN\')*G,QG/\B-.OXX2_XW3<Y0^8NH.EMOX>#H]QY&5**;( (3 &
M"IF#&',$4;B-W& PT3;&TM \/6UX[A4BKB->;8KX]]41JF1/\7-U:+_B^6RD
MJ?F^? K?1DX&9W5@0"\LV8'.0;"E0-(B62&0958:H[8/74\;><TU<QT]NHG!
M]'8V.\;\^GA*%MP2Y$O#[AW^N?AJ-G+*:92R #+M0#&>R*)+&B)'R:WBPD<]
MA!%U+V5/&T$#:.<ZALQ &%JLCN=$2G0EF9 @H"6@2RD@>(5@34ZV<"F3:VV$
M]2+LNT30!KJY#B#;WG67)10C) -:%",11&ZD2SP"9LEY*J[$O&77O8DO:IC@
MUFE/FA3D%1EFP>5072/)3%$V:@Q;]D4W.(+\%.(ACJP-CD=!!G\NA!W-.83H
MZ^V/Y\;:F(5O[U]?I*#A!+YPS33X\=H&8KSIX.3%\M+@K^FP(S/V;S_,I\=X
M_F$WF>.W^<^'BP'_]L,,#^J+9DA8 JN:.MVD&MHOOXUGHZ)"D3P:2$D:6K8<
MV3@LTAS&K*-20NO0WF:X@Z"&.+GCZN\.W#Q T;=A9F.!#W#V=H6FUXO-L!=1
MHRN7D8W0<"-!+;?[VRY3[\# YHKKAI+Z]B A+$=F+*2B-*B<(@3ER>2(A8G$
MBPB,/UXH7+JGW@,DK"'L 1! Y!QU2_OVMX59/$JE1!:=!J$S6;->D#7KE8$H
M542>>'*JM;UPC8CMV_P-E-.UE.P %W"WG*VMB',R&\=HG[/)U3@L%LGT10X<
M12ZQ9"99;'YN>@=!3P$"[20^P,Q_F=+QT?%AC8BX[2#L%+?:!4:F-&11B%"K
M+7AA33T"0V\29T6U=O9Z$_<D8#*()@:XM?N <^(5\\]A.B$'?+:BRI2HO(\2
M8M2FWBD[",$&D,YR+K@BW[FU(W$S)4\!# UD/,"UW<?C.!OG<9B>? R'^'X9
M-[6PB 1Y2PF5AR 3$:9= J\<>4]%B!B5L$DU]R)O(^8I>)!-!#W W+] SKMP
M1"\_3<-D%E*5[PKV?2@<R)6\G[H=^95MU'D5),/H8HAXGQZ4:H="88920G6I
M=#UNY1**E-%H)YC-Z8F@Y3[7<V=@64,%#4'R=7XX^OTX'H[3^U*P7GZL-CLM
M:8-$)8!AS0EAB4%TH@"/"EF0/L=RY0#B6HSS;<_>0=1G8_EW#877T,NL]+Q4
M'U]]Z$["X?SD(\[GR]/L%5E,1JU2X62QE$"F*^'8&UWW2"$(Q1:-BCUT>L<0
M3TJUK41YZW3]UQ^OB.E7>CM4YD)77H79YS>'W9^SYOD*%Y^]A2R%6UFYDIM@
MLN!:RB 4\XH'YEGAI'$A>5(IL?MR$RX.TSPC093 I>0:HJHG#QP-.&?IE1+%
M&*,MZM8Q<NTS$M[AO(KH]VGW=4QB_^GD#Y+EV\E[LMO#G);#ES0-2<6D6A(P
M?7!,GZV^)(&_C+/YE&;J2(=D74E('EJJE_=:@T_D4EOCH\LYREA:1UZUH7PO
M\A?60=(-<:G;5N  IZJ7HVM3]?M-#*!+$>3Y>UKNA;> *>=L<RG9ML[UV7$D
M\RZT>&> \SHJ&.)8]3R<]5TW222:Q4SYU-6XU$D:'^(E<C]U/:5W)BF?M5;6
M1XC&T$039%%X%Q!HN_18BB[:MSYP&9JG[Q*U>P64 0Z,7N.7*:;Q0F+T^A 7
M&IWDET?==#[^G\7G(^]<-MQE,)F,8B6<JXZM@\"=DN3FJHBM+9$^=&T?D/N%
MAFY@50ZP[K[IIC@^F+PZGDYQDDXN>&*_D/RKS/Z83#$<CO\'\X@(Y:8$"Y8I
MI'E;Q6+IK62I1)?06F2-8;<.?<_PVXYJAS@FKU&J/UW-5!E9%,'[DB!);LAE
MST@N>ZF!B 6Y9;*@:!Y<?2,ES]!JK:XADN1F,YR_3,OL)J*GGA"0-);6QP+^
M!6DNY.7MX]O)'*<XFR^CR&E9KB\6%U%>)>&LBI ,CZ!T]!"$(,M8$E]!*2=E
MZW#F1J0_PW3G@!@@%>YZ8L69P%:A,>>6M9 1-7EQI=@ RI@"7I,7QZS5210C
M4QJ^?L1MU#VC<QMJ'2";[CJEOT_Q2QCGU[B:0-_J)H T9Q:1.(MY-QN%2#8L
MRS1C@DF@O+/@N4X0=>16E1BD:1T;]S!*]R%7JHWN[X58<\4-X)-<I_IE2MTQ
M3>+?P\EB00[HDXM&TPK,B$!N%#B="D2GN349DPBM@VWO)>H[ M$FZAC >;A!
M#HMXP(7C,_]U'.+X<+%LCZ2-LGA;0*(F+X<+!AZMAI*LX"+(;+49?GN\F;CO
M"#\MU#. _W CT*=D"UZD,2B&D=,^CZ;FQCFO("KT8(26QDC)L;0^ ^E#UW>$
MG@V5,H"!WO]8?)11>YD%![<H),4(YU'Y1)0Z+J1!GE/KL*W^U'V7%PH#*6^
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M9#USO8(UZ*D7 $3OSL%S:<"=G>\/HLIN4Y$VM$W/B%@=(O4A8YVC_#X:;G]
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M_>BA@VX82-7-9I?&.O>(G)?%YN3K47, 94TF)&L%DKF"6K(2<NNHV]NIV4+
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M<0[7!7"^(V>E@O/]T60<CV=W8-3$D@IJD-D)(I=%<*Y8T+7CG1'%H>QSB?F
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M0WZG,!F@>N;9G19.OXX3WLSONV[1W@>7$WGVJ9O78]/S[U]UL_F[;OY?./^
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M:YFNP=<"HA*T"P;M@[0Y%^S50_PQ &?M](5MX68=)33&RVGT_.D61S900,_
M*DM;7-067,D)0M*%AY1+M"V"%2^/NM_I"6LIIVLBV75#%E<?US^U>>R__<O_
M!U!+ P04    "  W. 15#9(%^'!Z"0#&/PX $P   '9T;"TR,#(R,#8S,%]G
M,2YJ<&>4V@=0$UWX,/JH*"IB01$516PHB@("BE@ 0114I"B(*$CO/;UN>N^5
M= @D(?3>BQ0;B!4+]MY[[U_>__O>.]_,_>;>N2>;V2>S^>V><_;L[GDF^7O]
M[SW0[)"@X"#0!'-QF> " OU] YKIGYR7F )*!IG+Q+^O02YAZ7G@O*+TO'Q'
MCPUN(.^=P?LGO?YG(VCV/P(TP:S_6_]]\/=O<$! ?%C$@:#@?;M $Z:!I@+Y
M_H$[=TV<#0+E%X(+ _;'[-V7D.AH>0%D"5H$F@QR!GDE)!7E^X>%[?MGE_]\
M%_3_*%^NFO=N+I?7_Y^W_[^6Z<DI14GF]2_S&YQDKH2YJOGF>!T,G/]/K#3'
M\_PW[G0SQW4@4.D4<[SQ?XO=02!=VS_QSHW^;J )N_I $[V;S+$[:!(6_%^\
M$32Y=<T_<5I"#AAD^?86",3C_W?<?\JB0QLB-SA&IR0Z!N0E@%.2'==$1A\(
M<W:$;OS_V9C_KP).@8/_60?DY2,*,]+2P8X;W=S<'/_GE#I&(HK *3E%+H[!
MN4D;0*##,4<<_U7-1T"@KC002."6DPK^GRI93)H&^K?/_[?R?_AL7B::EY46
M2R:/6V9,O3%]DQ5YQBGKO[/<9\?-8=JTSGU@:S5_HUWT L1"V:)F^TN+WSJL
M6AKC2%W6L'Q\Q=]5*YP"5Z>NH3@;UIY:]VS]U UK7/>X9;C3-^H]^CWO>/W<
MO,#;:TNX3\Y6^K;R[?T[[OA^\Y^STSE@9^#179 @[NZ*/0/!MT.^[K/9[Q(:
M<" F+"^<$J&,;#AXYM#=J"^'K6-6'/&)#3^:>@P>QXA7'*].Z$D\GW0O^7WJ
MQ#2;]!49'ID[LR*RXW+2<@ORD/G$ E:AJ$@)UD%,T'I8*[P;,8 \C3J''L6<
MPX[@AH$S^%.$(6(_J9?<26FE-M)JZ!6,,J::)6/S.10NBI?/3Q8<%NX3^8D]
M)$[2A;(9LK_%'^2/%%>5IU6=ZFJ-1LLI09=FZJ++=I5[Z!T-,PV_C"\JKIF&
M*ANK2JJY-9C:K+J8^MT-FQI7-MDT@YI?MXRWGFYK;M=U\#JQ75G=,3V[>[WZ
MEI^8?>)/_ZN!\<%30\TG=:?XI[%GLL_&# >.;#BW8'3"Z,OS8Q=Z+AHN\2XC
MKB2,!5]UO[;@.NCZDQOGQAMNRFYA;B?>V7W7Y=[L>Y_N7W_0^5#]"/4X^HG'
MTYE/GST[\5S^HN#EGE=+7KU[/?!&\A;Z[M![CP^S/KSX./!)^;GH2_!7AZ\?
MOYW\+OZ1\-/YY\M?AM]'_UC]:?I[Y.]?\RAX-LDPV64*R;)WZM/I%E;S9RRV
M=IBY>-;"V79SYMG,GFLUSV+>+]N/\Y_875\PLO#JHCOV]Q??7W+7X>;2JXX7
MEPTO'US1L[)M5:-3S6K3&KUSZ5KM.K6+:KU\@]B5[\8VCP:*!]$3[X7;A-N,
M\P:V$'QP6[';T-O1.]"^&#^</V$G.8 >R-XE")+MEN]1!*M"-'MU^_3[3:&U
M!YK".L+[(DY%CAX<.W0MZD;TS<-W8NX=>1C[].B+8Z_CWL=_/OXMX5<2*'E2
MRH24OZF_TGZD?\OXG/DQZUWVFYR7N<_R'N??+[A3.%YT%7P.,@!MA]7"RQ$*
M) ]%1B,Q>=ADW&%@/]Z?X$5T)BTFSR;_H;RFWJ2=I;<Q]$PQB\@NX!SGAO*V
M\UT$]L+IPA^BY^(;DC/2#IFA6"@'%#G*(ZH]ZDV:5=IY)18EGTN?Z*Z7G2WO
MUM<;]$9%!=]$K<15P:KS:M)JC]<=J3_8<*!Q7U-P<U#+KM; MEWM01U[.D.Z
M0KLC>J)[C_4EG<CL+QQ #9*&&"=YIR2G56?*SU8/MXSTGCL]>NG\K0M/+KZ_
M]//*E#&;JP[7UE[??"-P//QFW*VLVX@[E+NB>\K[I0^,#ZL?-3QN>=+QM/M9
MW_.!%U=>/G[U^8W%6YMWCN]=/GA_#/@4^CGF2]+7S&^YW_-^9/],_A7U._"/
MZU^[?\[_Q,F3KD].GW)RZI1I&Z='6*7,*+2&ST3.0LY&SD'80.;FSTNWC9L?
M8;=KP>:%SHL\[;<O]EOBZ^"SU-/19=F*Y0M7S%IIL?+[JC=.#U=?7S/B?&)M
MR[I*%\UZX0:J*]HMWSUY8XS'?D]_KTV;UFU>YCU_BY4/R.?+UM?;'FZ_N>.R
M[[#?H'_WSM: AL"J7?J@DMW*/=)@40AO+V<?<S\CE'Z %D8+IT?0(FD':8=H
M4?1HQF%F#/L(-Y9_5'A,$B<SWQ=4"9I$;5))LBZE+%6?9D@W9E1DFK),V94Y
ME;F5>97Y%07&PO(B'5@+44&+86(X'\%"4E$$-!H#Q>;A,H $_!%".'$/:0?9
MB[*.NHQF1Y_!F,CXRGS->L"^SCG''>"U\VL%Y4*E2""F2P I7)9?G"E/4L0I
M8U2'U!&:,.V!D@.E8;J(LD/E,?IX0ZHQMP)N(E1RJI35E36=M2-U=^L_-DYK
M<FSV;@EOS6ZCMI=U]'?>[Y[0LZPWH"_E!+7?-# Z^/ZD[:DMI^/.$,[JA\^.
MO!Z=?7[CA8,7P9=$EQNNG!][>6W*=8<;F\;WW4RX!;Y-O2.[:[C7>+_GP:F'
MYQY=?'SIR86G(\\&GW>\J'JI>$5]G??F\-NC[V+?1WW8]W'[I[6?;3Y_^7+U
M:^,W]O?$'ZX_/OVL_Y7Z>\[OQC_[_]S_6_ _U_^-2>S)TZ8<M,1-E4PKF5YF
MI9DAM";,S)\5/WO?G,TVR^9.F_MNWE7;SOD:.^("_$+,(K!]ZN)#2_P=7);:
M.8(<7RR[O+Q[A7XE;Q72*7EUZ)HMSJO6SE[[>]T+EVOK!S?4NZK=6.Z(C6D>
MASP#O39N6KYYCO<$[_=;'OA<WCJXK7F[?H?,E^&'\<_;F1AP*#!XU[8@M]TK
M]M@%6P7_#?FX]]F^6_LOA X=: ^K#B^)$)O' ?)03E1\=/CA@!BO(TZQ"XY.
M._KCV,NX6_$CQ[L3JA(52?1D>$IJZL&TG>EN&0Z95IG?LAYG7\KIR37E2?()
M!=F%445^8&>(#>0G]!'L'+P%H4924+GH*,P.["J<->X3<!/?3S 2V:1"<C1E
M*]61-IGV@GZ>T<B4L3#L1,YN[GJ>#>\;_XY@4&@2\<5PR7'I;IEK\0+Y!/D+
MQ15EK\JDEFB(VH*2^-(#.M\RM_+E>EO#5,-OX\>*%Z8'E3>KQJHOU S7GJH;
MK.]O.-%XHJF_>:CE=.NYMLOM-SL>=K[N^M9CT3NGS_&$6[_?0,1@ZA#R)/>4
M_G3/F:MGWX_,.+=V=/?YI O 1<VEWLOWQB9=77UMW_6B&XKQP9MO;R^Z$W2W
MZ%[)_?,/)S[:_[CXR=-GFYY37EQ_M>XU\.;:._?WO ]O/^W_;/IJ\>W(]\H?
M7W[Y_$;]Z?QK'@" ^?6X"7<.=W#$%U>.'6A@X438#!D.I\;NPSS$G< F)?KC
M_F %@0D #C=Y:3+^#[#X5QL6S$0\FH6-IC><O8D]0)M7OP-[E-(D=<42R JT
M$-M#ZCC^'#>+^"D A),0X4M*@4?$NS]TF%72J0_V8!:+W,\<QJSB(VM',7NY
M#N*K& K;&A6*N<;<%M^$W4RG^P]C^VCK%UO@SM/F?.M%VY76W2.@[=1G3C6@
MURGFU>Q"QTIUHB)TI4B/G(F9P7\2)\; N ?\6C!_V>L7L;"#S#-?IZ%VUT#N
MC*,"*Y G[5''R@:K+J$DVE3A;-0+Y1'X.#I6UGF,ACXOWN_;CHD0,!=NPYSD
MO/M,1IHZCMV.06J:]@P:D(TUS$HT\EW%=OX#U+ZR4%@#JD_3<92)WJ[@[KB,
M[I)!%]BA;_*"/WDC74\6WK)&VO=N'4A$KFXK,NU')C=LXMU%GJDJ@%Y"!1IF
MQ]:@^DK==LQ ;]7,LEN,MN1J/RY!7+QT>OP]HNEL0G\PHJV?7>&+>->9P'V*
MC&D:A4Y!WJXY&3L%%5=!W9Z$NE!V>7XP*H([Y\-:!.LNZ<9O1.K8Y1.'$,='
MWABC$*+!!]RYB#_= LA>)*75\D@&:D;]K6WC*&3%*ELU\C1']?HU?2YVW54L
M#82I[SE'G8R)UC=3W# >G$5D$F8/^ +I%X9U)(NDP#S;SB%IL,P%3 H2F/#R
M#+6&/G4,1-%1,=UL<CME63F6](T\B76!E$Q:6X0A?B+28F81C43+;5N(;81[
M\[^38:1)SW]2\H7?+D>287Q(UVR2DKNP;![Q,WLNDTZ$,*,*#Q'MZ&/1?PG7
M:>BM+H275)$MC82B&I]%D(O4WRXVD(@*? >.V"#;6EI"G"GV87@3M(*2 F="
M&"\@ZBO!GK/8QY.P@269YTVD,\X\.4TRF19<V$CL+*]NGT)X7T(H\24<4I71
MWN ?RFWRK? ZR=.HB7B(\.^62#Q%,&.N+4'.>OHXB32C.7'T*G%)W:369D*$
MZ85V,KY=OX$ZA@\M.9G[&S]-U75H*?!0[N%-!S[*O&V6XKM8_H]<B<R^\7-5
M!&4'H46 'VU"JC_A-]7<I3P#+E?4Y;H#PK+7!X\"*=KKFV\#8/7A.0?QDYBM
M#YV)*T?$([6$34-;FV7XE)X ]23@;.LP91J047\[!P9X5+$C3P)3C5&;]P/3
M=4=GUP#9S-T/0@D7KG<.C^.?7 AM&L3//9V@\@+ )^:10P&;#F3V&.YNT[G(
M;;B.NCV;+N*ZRF?/7HO[Q'AS>YL@ 2T[E<5#H@/JHS@-Z-GR4^Q%Z#E$*;,5
M'9RE9A#0]1$0.@VS<1.'OAH[8<Y&YE7<G9M!_/64X9.3N3O)I+JU;"(IK[B!
M^8O((Q 9U80/F2PZFT +CZ/I"'Y>2%HPX?AL"X:,2+G1R /Q5PZJ.,LYKVM^
MLY)8=V4 XSW3"7^(WDAOR,BDZ6GHL!#J,!7J":4BJ)-G_J!'43JO[^9.50@&
M-K WRE#5>"9%+)4Z,.8*?@-VM&>\GO1(ZA-.UX%8ZES67P\5I9^U9.8\VAHZ
MZ>IS3HC>]L1%%KS4J6HEXXJZ2'R)GJZ8CGU"VRA]D;:7ND.\/A1#R1.,;+Q!
M6<P_81U*747[.V9@U]>=ZE,P'U2!3%\8.PPP41/MJLX?\X!:ICF:>IAB4(SO
M;R;?EGW?Z$)F2#_,,%+VTKA7>&R/SO)> 3.M97+%!WI_G5[80XNM+,-,I[H9
MIJ:H*9M*G^Z?08[7U+JKR%8JWQD.9"G-_;*.-7SR5$\C<U)?<,5\>ES'/,%3
MZJ>F8/1.RDBM1?(7\BT3;!^5/-F0XKZ25%KB8U5#MJ ^N72/57@INOLGH^[L
M>^,QNO7 ?8$[5=<=B5)1D*WHY PRL^'4/FM2=TV:6ROIJ/:=U2$2AUHQ\E/Q
M 17;)BS>C5JF^R)I0TWCW!$=1SDA; 6[4/#$#%X*ZGM((6<<+71-XGAAL-.Q
MO*6XOF$?^0/2[]94V0KB4]T$<3'A%_N'<#]A+WP=/P!_/0'-A>#EP5CV5SQ^
M X(=C7\X[3Q'09QZYG+Q74YURV+I*E9_R6.1C/&-=5\02Z?#EO'B: >/$SEJ
M:MP>&7LM1;O>P&)15-.\V+O)STX;94]EG*:'DNWB4:U!V"WT9';R"WFOH9.X
M%,[?>!S[$CMB=STKE?G3Y0YSA'EN:BUK*?GN*;3,I932>%),4O_0H(16BBH&
MB7=)9@*_XMP0?XKCLMV%VJ WS"'^H,M6YFI^S]1MS&5D_LEXJ:*JO*%!]-D8
MH\X68,M"Z"1>B)8-GL")5*TXUL92R5<'^3,]I5_7U3!$TJV6-QG[R&%#J5*G
MEE?U9T1 _1T573"U>B;-Q!TSRHO\V(_+N,?FLMQ*YNZJ9S2I+Z_S8=@H3ELR
MZ0KRHD&!9. $O-Y2Y-!9KCS#-[3,I[[A%M:]*>2RR56'CF*8X\;B73L81_7^
M:V_0C<KOEB%T*]*;@0>2W!%$79KP[-!UY1I^5"^9&LI=T=Y8\(>]J<ET=!*3
M73\W<(RQJ&KG6C0]0]EA.9]63!KN]BV_@$2:%I>F(_=++FH6(W<1YRFG(@MS
M5<7>R"LQ+I(&5/+.2%$I>OKJC\*/Z-\6)B$.I^]L+'M %%6L+3E"4$ILU=/Q
M%PC'Y;_Q.W)NRGR EX>3Q/W J#]!V 7<7.TIM,)#+-(%DPCR#IKN):O?:*=-
M9TX0KU39TG/Q67([FG/V>^DQZNIHAN@M)=6O2_"&_,R)(_"FQ%JX\IH(5]K1
M.GOQ9_UOC4Z(%/Y5QO"W /'%H5R/K,\2%9L?52WR9+G[311X,K>L^LZ',6],
M^LT5$!K:)*6'-.GZZ>KG2@_!'X6IV!<7)=-+F%D6XNNB#8=N"-$"7]\(/I;W
M:E4NKY<?->DRIY@@:=65G*Z86.ZE/E1N*]B@F%.2A27(YJ@79FX11RF6'UHN
M>"FKVC' >R7U736!MUIB-:F6?9J :1DNB6[H+LM1W:]QX&?+514G,6>EVO*+
M&1+1R]*(@Q(!H"'N.,#+5A]<6<75RD8F\=F+"!DML[1_NEIT)U6$U@3>6?GV
MAJ,8%ZEO]4C&!!&GXMY!.\%Z@_7VMSR;LH&5*5PWF6(2@L4FQ#07:&M/N>BV
MJ=:?L./Y%[_HC$>72]ZU^*;31'X--I&-_'NUN\W3ADL5QI5+.9]DV9-26$L(
M^VH<:O\@'BF=*^\@6ABS#7<0#3!&F1WB2?)NK0P9=N"[J@CYQ&>I_ N*[>@L
MEZ$+0"#Q9=S9JM':-02B(MWT"%],Q^K'@7O0G[JY0%*24:, G Y$*G' BBU@
M^61@W]*28@G>#@02<0!0Y=V:[<P-<D;%'SJ;UEW^FK8(ZE[J1OF9^$C=17$,
MU2CT9([W6+$+>>_2#;)*2A (),PW*YOJ3.'38E/%9KZ<.E+NQB5!PDK2V=V)
M-JI?K/#]S^3/F-[>_K),1JG#6>DU9B,()( #()-_U5EEDVS<*"ONIWPL$TGM
MP!#M>5%?PG[57D'=_IWR[?PUFWNE;;PL!XAT'B\!9,47 )85O"J7\A&9J^%7
MJ3MEC^Z[^D'16:V7XNUQD[*A^.B^VF*N-&OS?NETR6.'-9)XT6&0/6\0L#$^
MJ&ROG20M-6!,;>1^7:%^H,A/4Z4+..ZLW*0]L,^_>+%ZZZ8O$D"%6?)1?%KD
M!UK#6PC8&W=6)K2!I0L-]HTH<H#.NN9IX6G-'M.C^$[%54/%WONRH?*'F^HD
M*TI?+AD1'Q Y@3RX7&"YH;W2MC].HM</=E62KI:VM!84)JJ_-/R(3U)0:COV
M*F60ZJ6;4.+;95>7&,331-:@;5Q'8(VFKH.$ '/&FBL1/IB+=;\0&[.3JYB(
MM"/>QF3$E:"W937(3/>7)4]0EG;O2@M1/2 0?PT 4NO;6_!EG)U-_4 W)K%N
M,F"=];&2A5/'M!F2<85!V;H:'-$]6WL'=\*NKF0KT $"\7(!D.IKVS!]C"UO
MO$,+1I^O741YDW7(I"._CG'0(\F>N^Z7GB2-N/W0O"(-VN&UBRD6(!!WV*S2
M6S\*9K.^-<[B/D4OJHE@_\PT58RRD@YCRBN9ZW?%E'QA1+N)-7,9+G9'-8L9
M=6:U P IQUJ#Y!FLQ(8$J1Z%JM:+/3.G5*P4+HA^7?:.?RSP?HDOS\MMASJ"
MM]9NAWH3IPT$X@R:U=:6WM(WS!OU%S4"Y(_J64IN!M/(+?X6C2@[(KT:B-$*
M)/FNWU1J29G=:E4:UVA6<0!(<;IE4Z66F5\?:"A'RJH(97,S7(T6)9.C5^FN
MJ*6!6[135<&N@\IWRM5VMDHC5V%6T\TJI/E:$XNYO.Y*[4UD=-6DRLKTYP:$
MT3WJKFYO>5W +XVX3.VJ5%*T[F9E]X]B#P$@^8UF2O=+QG =N(V(G%E9TMB2
M7F6PKWT8U5#ZMEH;<%?C;3*X\I6N6F>[I8H6;JE9F:\O_L>A),0"PM+>2_#A
MPOD=:'A[@JXY _XBK*#.@(C<8555A'CDK*^0(#-GI5;&H*S,*L"L-@\R@2?X
MEIZ/N&\%_>T\7$A"2%,.]D&8=:T:.[B]NC(>^]CYF#$5MW$6N6( " 2!6'\
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MS]>%1O'AU]4OMUQ%I"K7SBV$Z]E.3Z/!^X:M+B# 9P=>M$^!1'2#2A9"OK=
M:2/0P;KTO&<PM>G^H:?P9/WB+1[PAR47;=KA4UG&)WSPI&O.Y]O B/,SVGS
M7TZY:W=!1+VGJ7^A1]N^YKG"O!N>'0J"@VK6>^OA,/U^FU4P)BOP_D/2!MCC
M$0^B#KZU^0-Q URF_D.XB)A!/4)@(E2Y[PC'D'L/'2<<0$W<XD0H1EV>>Y>D
M0G/N+25H"=UGOQ*<\5^;;N.'\/M5=_$(8(2R A\ @',:\<Z WT$'O!O@L/D-
MG@BXV,")CH#^#@D?PJX\$PK<9]YI# >H#%=E&A!.&R!= 3926=D48 ,%'SD#
M\"-S-CT%V*0'<[;A&TA%MYX":V724V6X(?%8O0D'%?K(7^"">%>(:-PV3G_6
M8=P>UIV(J;ADYDJO'[@J^OW9ZP (]<3-X[CM.L')E=CKFA=U&[$\958Q'IM1
MO)+@BDV0V&7Z8+'"]'!;K([WT6L9]@$W9)8?+H41-FZ-)==4#XYC'4TK:UYC
MQLJ[97LQ]25<O"VF3E61L1$S++</\\9\EUIYQF$WBN-GHK  _>SUCYB/[2\&
M3F,X3?CJ<<R.6G?I-LP"DR.P N-0GI>>@/$M67T C4E3L3S:,,6*5.OKF 'Z
MT>NS,>2AF/Z7F*6],ZL^H$^W79.$H8L;'N("T=KJG#05>M@H#AU'?RV[X>&"
ML=<>MH[$K*%/O):,\;IHU[\-?>',TRHW=&[_23$![=GY%4M">S>?2_V*3JF3
MAAY$2ZLD&SO0K:7[9CQ#5],Z+IY@AT,%W<W,E[ I%9,8%3"L$$OGP*=AW&E2
M>$/J9.H0 KE?35V##-[H35V%<I]QE;X2C;BPC?D>.-6%9A0#.PSC]"3<J""=
M=@B'12^EYN*BDW]2:G#A^T04!]Q1=R_*(IS,ZA65"1P9?<"H8-IW+J/'TY7Z
M*MHZVF:^*]6-:HW\0#E,F9OT@%Q!#MK+)3N1)&Z!Y&6D0"L'RDIB_SDLG2N&
MM-?3@H5VY4[45;QQ[CG*!LYY1#TYFVV5>(HTPH2&*$GA#%O77%(0/69Z%ND5
MI77$B5:G&6^+IF8K*W6CE-!B-0=//B;IAY-(,I%#0C]I*O]B<!]1R+VPH9:(
MY;R?=HEXGU)V]@L-9$IO=:5TZS-+361U*8V=3JI3C\,(Q+>*O..7B8=E<7M^
M$EZ('VZP)%P06T\+)X(H^\Y\IQ8V+VS93'&O"RVI)\^JE+(@)$?#(JB!F%KZ
M];@=X9)F]YY#A,-*R'H4P5L>//4)(8AB<<:%.JGW;W,.>:@C37N7I&FZPRPA
M5M0*('<(;TW]\6F$5'W9[E/XU[KOZRWP'>K\J5Q\#?G,:3ZE9GA[TSDR>/"Z
MUI44W(-DO"#N;4N'>!$XC:"X,<*4FN;=(7BAZ:J+%!^G=IH:@O<B*_HM)=T0
M4FV,B &U4EH+B% I]1VO!K:I\!O7$O;QV!2V"#Z\JYU5B-"OF\0*1;*F5+#^
MHI5]76(,SJ4F4AB&'5;,XT=BL=0)7!HVLG :^S7VP-'%+!HV)W"4F8<M7KN:
M&8#],<6%F0W8]7)$T;3KU0L$GE15\4_>)@J$_(@#)]/S_[)>D$[&KF$*2*X!
M[QEX8H=S$F,_L7UR#V,ZT:DG3^@O,%0^XJ_A%<O:N9LY):33['S6P[R7S$_,
MU"-N#"-C<<!"NIH^9XV)GD)[.CF>=HU8TKU;D*8DF\[S0HL;I,6<!.DDHIAE
M$I%S;S#7"/QC_.@O>1$[(VF/.*?63*5I.6<G6U,O$#.[MO%[]92*(6Y%Z3<)
MC]VEH1*D+$ME2,X[!K4X_' .W4_2Z6^@;1/=78VFOA-MM3A-^4C<UAG+WU)G
M,#[GKJJ*%S>QO8PN^#XFMLPSQX5AH95%GZ1UJXC^"ZD5"O%J*^HA68\%E[*-
M:-M1QCO?.<&XB=/= A)]9YVMGX6W8,ZLBLM&T$5&M^@UM.BR:WXJJE_I+2<3
MY:I\I<5QLI[PI6,1#SW483!P<OHFB6)9\(X(X#BCI>E#U@/ZYKK0* /U9[6-
MWWK**^.@TQX*OOB!Q5:R*^%VPX 6"1XHV:.B04*YV^2G( _0Z;+M4%9ZO?@Y
M+#+RF7 <OG%[B6 78L:*-$$PXLJ$$%X,NJ.^3G,<\T2+469A9!QT<14F"662
MKL2$I[T27<>D1JX47,*HMMWD^V'N+V_G>V /3G#AC.!NUW6J@Z@S-0C%4?(G
M-E>F('U'MD@<21YIDX6WB<J(,/Y]HONV);Q(PIOE#CPOXM8)<]AY0'MMERJ2
MYZY.E^=PCK-RI4VL%D2KV(WID3I7\(/^(QS+GTS[N#67"Z=M62;FAM :03]8
M?D!%S9@ROYBA@A8+I1;,0LD#D0'>*$H1%*6X"^QYA+ 6G@?GC<]9CH%]:YD=
M)X?C"GK"W XHJS\J1G13E56R-YJ+C J)M[('=D_85?PX.8F/D48?^,MEB+?[
M>+/_B&P<*]BM@GN@JXPD@%^]4;&_2JMX)<LSGJ _$[>6_8&M$OJ48),Z>'_5
MJ0=RN=,5[[?TLS,5$QT/L>>+;X%.TVL :A5/_K(E4Q$FLZY_2-\C#J^&0,F"
MT8JH)$>>L'PX] G'H O9$L,&E<0ZSF#QQ)6@;KH] %3-DRO[5/++TI[./%J/
M&-02!?DJ@->7)FIX6ZK/A2(Y^RJ/>?]BU>A3EO:P=HBAH"9:.8 LFV;B@[<(
M-?I7X"Y"O0X-.5 PV?P\_Q57I J!#H5TR8VP4J]H60\\R]ZO. O^RIQ)J7%S
M=&X5$O1#H57Y4[2"L+(T'UV4#]5XHO./C2NWH*4ARXL5Z#N>O=)JS/I%%V1>
M&)DY=\@&0*5%1@:9)O M>T0BX[-+4HEE>0UJ=\*?8TL5VPBT8(1,1PCT=)$T
M$-8MRI$N))PT9P'' 5!)G4',<>4GZ;ZPB !&"S#^Y-Y4!=(;CAZ2Q] J]PQ+
MAZCW/4K$%ZGP17,EBVC>YEDE# !I'^JO2)[PI#HOD1Q7H>D7X'(G*FD\3:RR
MF,[YLL=%\IO=Z^$DGLAV77A:O)[UVIP[U)J5CWZYY@[W=2E=^1'[2S-?[I43
MI1B7MASY)AL74W9K)5N$CS=VBK8*Z0M)HBC>"[.R!$ :57F)\0,WK71R>1H6
MIF:43LD^K0A2?SR2*PM5QNY>*VZ0"S<F"E7RV0O#A*7\)2 0#6U6\\L#&CPY
M3TK*:F9C/JE7F&RS]\C']<B8S])[.E%0CWA?Z<R-<X0;-."%3L+9_ EF906
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M!ZLMN&3HYM//8<^@VUJBX7SHH](RQ'H8D?T*,0A?#M^)/ 8_FU"+_(M !M]
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M&"(@BRLCN1(8OF8M\B:B&9):N!"U ;Y@10"F&GG&_RGF;_0-QQVD=LRA+0'
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M,A?Z7'TG?S+<H&(G74*\4Q8LGHE$*/I=&Y&^\B/VE'VS*J1>+MI<$VMK)6O
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M/>.SJZBK]O.'09Z1#@)_"'[>6:$7])/30U$']-;OJ@B1=X(S5'F'!.,<KZF
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MH[]^"\"_?L3C(-PL+OI\*:X%>WY@$5>*152HX>JQ:21_W DL!4S!_<0>"YG
MI^(<;5<0-N$W?I_!HEF6#P]C4QG9YYRQ";1S_6787&IZV3Q61G$C;L,ND(-
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M\_@-+9<;!O(3ZWNKSP,FJQK+OH44E)9)55W'Q.&"59:/N*]9B[KEC!CJA:J
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MWF9-N^XA!M,1QN\(5\@GSL71QEM P_Y49(-UXP EJF:MH(.<4OX*@R!)2NZ
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MHSH6"MF)JSOR %)3N+677!P"!':H0VTB*YIPL'#O%S5=\';[L3(94M_$5'P
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M_"GX)-P1#X*\UF+8?JC%]BH6#R_MP82MP@FU*\A=9);"EGA - (F8C'^K-2
MT_"@5 *[A76&;<:2L4EK5Z-?T&+;8V@'LKD[EX25?VH<B"J%3NZ$GY5/$,CQ
MV5):22_&%]].V8^-%"6&6: &<H_'4S2<&&6[$YV-+>QB$[7&#]5K\0/Z [)U
MV&=M!K\?"U3?*7Z.;E8FIRQ'?667UF]!7DA\/%J0;4**;1]BPC,[M^$O&XY7
ML?%9M6>E FQ]E93W%C4:YQ6O12=KFY--2+MZ^?H49(,<]Z @'N(FVU;$F>!T
M6N%YG8CY%J9OW2&YC!YNE/+6H^-J%Q;5([BI*WDBLE*W(O1_\ N5T,,?OB@U
MVM;!M\C\CB/XF,$YYCS,NQ>4!*-9'8G<+8BIZ7;18F1R;4Y2![S/>">T Y9H
MW#RFP[@\T-8$&X2VC4]T,TNBM>\T(\K6D8YJQXJYK!HEF_(ZWR@_2+N26"X;
MQW@:;)!$LA>O&2<R<MMLV.0+077C:DT58[C65SW$'$OD*]^R)C#O*SS9\_)>
MRA2<=1MN2IYRR> E8A_>T]7'A?4"R$9,C@53&LHJ;04*39@J2W 4%RJ:!7^8
MPV5_@>"\%=(\H'F#M_@*.#>H2Q0$UJR6DP<@;QLCX0=]K>>K;N'O*M<KY^%T
MC"FOP-XR+*47L9+</$DL^C.A570=-00%"C-1M]4IQ%?DBDT+7HG0Z_3*K?)D
M=;K\K\P"E<DR);?H?I+S8C)G2!PK6I,P3_B!_%_@8[*2:%GM0 3B@38#V _T
M1.U9Q4W=?E6'?*7F$G)3JE3OI9&284IESFB13)X>KQ8Z2^T"2>*QZ*7;;[R'
MQ&QV87SL<ZVMPJEVA/*73%J5ACA*GAOIU+OB%%U.-E7XNC(R?CYI5MH'>A-1
MTH]NMW![D<3F$#85_U;3*>]O7:ADR:8V;H-K)46UGZCQHG_-W[/>" OTG^/:
MR.65#P->X_<4V]SV80<E"38GT)W$I9H8>4+O#.5$Z?:.U["%Y)\6?\H547Y]
M9!9*?JJ*BTL@MNK# GIQ1&WM9L(8TJLV9U$&*=(]JK4L_BVZ5;6I]#'?T7BB
M?'_I-7T@I6[34LT@S1"=J)[*V+'N@R*-/=SEN]3,K;:R%YT4&'6)U7?HJT3)
M9F>&#\]LJ&%&ET;IIK.HZ2V5.+L_ZIWR#7?ZNC9Y"$_C\E!B%$1:90MO@<':
M[54HWT.H-[[B8]RW^C3^I9(&S6V!5_I4=9I@7Q2@N &DKTN5A8(37<Z(^\%[
M5FKA>.B"YJ?9$YM#'C'TH4/<23I'-*'X5>40\C>-J@I'#D2-E-]!*M=-DF8C
M12Y#HOM(I-5.<@/BH?$T.4CND^/T;>*;G'BMH^A4L8-ZKW!;ZG-E+-D6:9)]
M)]I\STHJ\3J7%M$*3&5UB]B.\BJKC.LKMQ"%N@OJD>S-FA2E6Y%)]4(>FYJK
M0*6ED?XR&['4URR^+&QRT0N%1)/5=V(5IJV<96@TY^*?=<[&">QUE8,Z9M%"
ME6?ESI07\AO*WQ$/I3*YCV^AV$-"<1&2?X2(]33\&$ZHNPTV#4]QH79'[3W6
MJ4JW*J"P2SEH>)R"R..UX1&$=*JJW==6=$3VQ85'JL7+K2WQ,B)&O4E_KF,=
M[J3-:!&R"M7_-D04ABB#JT^GV,GN&\,B@B2-FH,^/T6Y2D>77-)/@EB[X5;$
M)S'25E;<#L0U?2M%*<WUK>6;<M@U8930Q-&F4[384+W>ED%Z-E86L!ZN]%+
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MJFD+;[Q7=,U=OHM+KN&B@+TB4ZT'GB^])LV!RFG_; L$SA=$;J8 36F\GC3
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M4$(O\[EN%GD6FR^93I5PQLGMC"F\AMR_6?L$$3&WN.M%,WV-!4\E?]I5201
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MI#:C865<U2:L09:OFI"5(@M0FL5/D(4JHH-OR)ARL6>";#,Z8I\'N2-WS6Y
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MZ;A>X;G<!<3EXEFQ?M13DD+?AZQ;TJOVMP3>H*8G+%D(AM4?3[\#,M0'<\S
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MW. -Q@W(3%B7YZZ(4<>D(0IKU?,XL;Q7]5=8,7I:\<$/AWQ7S';K0/+DB?8
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MFH%MF"W=FUD[5P]+][1MD.]O7J\X6/?;H_*WAWZM\IAZ0'7BGS+>[_D?A\'
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M4\:'G-W&M]D&/SEE%'SBT?*TT5>F])Y;#O*&<Y'5E<?S6\L.4GOT^_@#NMW
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MV[LQTJXNE*J[$Z[OZ8#5]C;"++T6N*5G.8!T^TH@MC4(?9Z]^_<!2K_(^ZK
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M6=E$E85.-Q@IW!HU45*OP*N;I+B:9A'6:JW$69MY^-9&+KZU82D YUG#GB^
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MH=+$>A);4847:618E5Z,-AL%Z!83']UCXF)ZC!QLKYZ-[7NIYPU46X-@WU=
MON\GH+'?!(S.NQ[7N-O?JO-UO]04XG?*&ALZ7Y></*;/*NQ1%F"M(CBMEHOC
MZID4L8K*5$C(E9I*@D+/Q1N,+'R3B8GO-C%*>XSEI;T&&_W+ *JM@69K$.[]
M"BCWVK;W_@W [+CC89W;OIM-/LX7VH(]3[3'!,TT)B4/FC,+VM5YV#I9"=4@
M0'-4'*)(S"Q7\.D\#:M,JB\GZTQ4<KV90NZVZ3%12#T&"JE7_S+/&^C;/P'B
M/5\"U;/MO>]G4..P[7ZCJ]VU-F_[LSTA+@O=48'CUL2DGMKT@F9]+L:L*J*J
M)4B.1% JXG&I"B:+K:$R;)>E7&TJI=>:<>6=9CR]VU1*[3&44GM?"M!L#0Q;
M@\3N2U"UV[:]]ZP#=?LWWVEQWG&YV\ON]'#P_KF^B(#AMOC$]H;4?$MU-EJG
M*RB3*>%LOA0K9(HH\K+*"C6!*]!C."HCDEUM@K/;S A6CPG%[#6@&;WZEP%T
M6P-SV\= NNL+H-EEV]Z[USQNW+OAUP['+1<&O;:=& _8-S44[M_7%9?0W)("
M,=5EH93F?(I 5\*JJ$(+RA1$&5Y:7H42\W4E0KFA2& T%@BMID)!CQ'*[364
M</KT+_.\@;7U8R#?\3G0[?@6U.[\\6&+W=KK?0[KSTUZK3L\X[MG=#34KZ,_
M)L[2D92KL68@Q?40$KNZF$DU(/EX;:D$J:8IBU4<3;Y2JLM5Z W9BB:;7CU$
MW*?+%[X<*%_U%N!N^3=0;OL4&+=]#1JV?7^W:^</ET?WKUH\Y/[C@7D?N_ZI
M$)_FD:A88U]BMKPS#<YMR2'0&@O+2^O@7&0-3E1DIL@@)I8JTR!6IQFTVA1#
M@S;%V*])5P]H,I4O!QBVAF=G**NVK 35F[]XVK+IJYN#6[\Z,[?OL\,GG%>-
M'?7>U3D7Y&69BHRN&HW/% RD0LM[LG"$SOPR9%M)15$+AI_;3!9E-%5(DQM%
MBH0&C3*^L4X5U]2G3*@=4B697@Y4V!K$&S\ VHV?@+KU*^]WK5MY86KC)PLG
M=OYW\HS3CWV+WCN:C@9ZZ.?#(R0SL6D5$\D%I-%,%&HHCU@T *7E]*,KTGM)
MW*0>9F5<CT@4W:,11_;4B2-Z>\61'6.2:.N8]&4 R]8@__E?P+C.MO]__/>U
MD54?'#GVT[L39[=]WGM^__KF,VY[C8L^7K+C(>'L(]')E$.)N>B#&27%LQ!,
MS@R4F#:-*4N<(I?'3E541$Z*V.&3&D[H5#TG9+J/$S(^PPT=G.:]#.#8&JK6
MO@LLJ]Z[V_/E.R?G/WUC\NP/'_9>V?)MT^4]FPT7G!VDYSS]6&<"HDBGPU*0
MB[$YA2=3BK).9,-33A1AXH^C\-''2,2(HTQ*V(* &G)820LZ;+:QT@,/C]("
M#QUZ*5#YW5O L.H?3UL^>^O\U+_^/G7FDS=[KJ_ZI/'FIA_UUW?OD%QS=&%=
M]0P@70V(0EX)3RJX$I.9<3D)DGPQJRC^?&%)S%DD(O)T*2I\D88).<G&!9\0
ME0:>4)4&'#<2_(\WVW2_%)!__3JP?/KW2X/OO#JS\/8K/=?_\\^&>ZL^T]W=
MN%9\=_>NBKM.KL2[7O[(NX$1!7?#XS)OQZ8DWTS)B+^6G1U]I1 2<1E>$'81
M5QAR@5P<=+Z\)/ <%^9_5@SW.ZM$^)XQ(GW.6%X*Z#][Y4K'/_\V.?'6BM[%
M?[Y6_]M_W]<\_N$KT9--ZYE/]NPF/G5V1@!OGWP0%)SY*"(BZ4%<;-R]U(2H
M.]G)X;?R4T-_+4D/OHG."+Q1FN5_O2S;[QHSQ^<J-]?[B@CB=469YWE9F_\R
M]QO>63'1_^:*[@-OKJB[\>[K:O#IAT+PT]<,L&4] >S;B0"N]GG QRT#!/DD
M@HB F*=Q(1&/4\)"'V5%!/^6%Q7XL#C&_P$\UO<^)L[G'B'>ZVY9@N==1J+'
M'6Z2^VU1LMMM6<K+3+;_?47G\.LKZ@Z_\;<J\/Z; O#E1^5@[5>E8/L:.+#?
M @&NN]. MWT\"'*. A'N82#6,Q@D>P> #%\_D./O _(#O  TT!,@@MP!)MCM
M*2'$]2DEU.5)>:C3$TZ8TV-^^,MT=K^VPC+UV@K5XNNO5((/WZ2#;SXL!>L_
MAX$=W^> O>M2@/.F6."U/1P$[ X&87O]0?1^7Y#@X 52'#U AI,[R'%V!?DN
M+J#8U1G W1P!VLT!X-WM <EV4TKSW >8+U4[],H*U:%75O#O_^,5&OCX#3SX
M[CTH6/=)%MC\12+8]5T4</@Q!+BO]0>^/_N X(V>(&*S&XC9Z@(2MCF!E.V.
M('V'/<C:L1] =NX#!;OV NBN/0"QVPZ@[7:!4AO2GI<!1=^]#HJWO@^@CI\!
MK,</@!BP&9#"]P)BG!O I04 9&[$8R@LX7Y!:=J=7'K.KUF<_!L9HJ)KJ8J2
MJ\D:^)4D(_)R0BWJ4GP3^F)<.^9B;#_V0NPX[GS,/&XQ[BCNEX03N(.))U_H
MKX;?&XIM#5!; \SA,]M7Z0= ]M\$*&%[ #G6#92F^ -T3L0C&#3A?A$^_4X>
M->?7;';!]4QA\=4T.>Q*BAIQ.<F(NI18B[F8T(2]$-^!NQ W@#\?.X4_$_M+
MZ;'XHZ6SB<=+IY->#$!M#26V!J3]9X#H]@.@^FX"]) ]@!;M"LA)_@"?%?$(
M69APOP23?KN0DGL34E%X+:NRY$J&#'$I58V^F&+$7DBRX,\G-)>>B^\BG(L;
M)IZ+FR,>3U@@SB4=(TXD'R6-O@0H^;T!O?]30'%=!<I]-@)FL!U@1+H 6H(?
M(*6'/\;F)=Q'(-)O%Q,A-_(915=S>+#+F1+4Q?0J[(44 _Y<LH5P-M%*/)O0
M0SX3/TX^F3!/GD\Z0IY,7J ,I2Z4#:0>?B$ ^_9U -OR/L#N^Q1075:!"N\-
MS\_%L"*< 3/.%U!3PQ\3<N+OHTO2;\'PD!N%M.(K$ [B4K88<R%#A3^7:B"<
M3;:0SB2U4DXG])>=3IBA'DXZ3)U*.4P=3OV%UI-VB-Z5_F+/&^"VAM*]GX)R
MY^\!Q^OGYV=2N*%.@!WM QC)88\IF?'W\87IMY 8R'4HI?A* 0MY,5>(/9^I
M))Q-,Y!/I]25G4IJIRTF#M./)1ZD3Z<<H@^GS9?WI!]DM&4<9+1DOAB VQH0
MM@;BGI6 Z?0=X'NL!Y4^.T!ED /@17@!=GS(8T9Z[#TR).T6#@ZYAB!"+Q<S
MD.?S*G%GLN6DQ0Q]V?%4"_U(2GOYH>1AQH&4@\SAM#EF=\9<16OF+*LA:Y95
MG_UB &%K0&[Y%Z#8K01LQ^^ P&T=$'EM!Z( >R ,\WA<&1MTCY,2?;,\)^4*
M&9I['HLK/H6@H8X5<4I_R9.09W/4M.E,,V,BO8DUFM;#'DZ;YG1G'N"T9,UP
MZK-GN-6Y,QQ3[H$7 DA; \K60-W]7\"U_Q:(7-8"B>=6(/7;!Z0A;@_$T?Z_
M"A(CKW RD\Z6%V6?(*&+#F/)R -P9NE$<679<+Z\?"!7Q^K)MG"ZLMIY[9DC
M_.;L:;XE=XIO@DSSM7G3/$W^B_W10-_U7U"Y_QL@>78&P7T+4/C8/5(&.=]1
M1/A<E<:'G1.FQY_@%&3,TQ&%4\12U B&1NB#<ZA=Q6)F6T$5ISG/Q&_(;1;4
MY?8)JB&3 GW^I$!=,"E0%$Y5RE\"H&P-F,W_ HR=_P'"9_O?\2>@=-T$JKQV
M/= $.-Y4AWE>K(H-.B5/B_Y% $F;8I44#E&QJ!X"A=B&8=*:$)45=5 YM[I(
M5VDLJ!/J"CK%FH)QL:)H7"0MGA")H)-"(712\"( _<WK +OI?5"QXS] ;-O_
M"H<?@=IEPU.MYXX[>K_]5PVAKF<-T7['-"D1,]*<M&%>44$W X5J+2,0&TKI
M]&H,AV5 BGEJF%JHA%:+9=!6B00Z(A&6C$DJ8>-B'GQ"Q(5/"%_D>0/>UL!^
MMGMMVUNY_P>@=5K_R."^]5>SK]VEFF#'4[71GO/ZI/!Q969JG["@H)4#1]67
MXXAF2AE=2ZA@*;$"OA2E$ F11@D?T2SE(@9D;.28E(4:DS!1XV(F:D+T(@!C
M:R!L?!]PMGT"9'9?@*I]WP.]P]H'U:Z;;EB\=YYO#-IWO"'2?<:<$#ZDSDCI
MD.;E-U9"D686FJBED^@*2CE+1.3Q^7B9B(W529F8>EDYME=&QX[*:-@Q*14[
M+GZ9YPW$#>\!GFU[RW=_#C1[O@,F^]5W+<X_7VWRVG*F+6CG86NXVWAM?%BO
M/BW%JLS-KQ47(74\)$'!*J6)RFDL+I7#9Y+%(AI1(Z40+'(2H4M.)([*B(11
M*9$P)B$2QL4O K"V!O+/[X%*V_96[/H,Z.R^>5J][X?;#4YK+[5Y;CC5';!U
MKBW,=;@A-K3#G))<K\G.,\@+$$H1G"#BXVA<-H7%8%;PR^A"$8&JDN*HU7(,
MM5V.IH[(,&6C4BQE3(*EC(M?!.!L#67KWP/"K?\&JAV? L.NKQY9]GQWL\7A
MQ_/='JN/]_MNF>H,<>EKC@FQ6I*3J@V9$+4Z#RZ1EY1RQ6@JHY)40>$Q>'@V
M7XBN4$C@3).LA-DBAU:,RF",,2F</BY&O,3S!MJZ=X%XRT= O?V_P+SCBP>-
MN[Z^UKG_V[-#[M_^,NRU>;0WV+FS+2JXOC$Q45^3GBLWY,+XFF(\0XDL(TM+
MF3@QC8L4< 702JFX@*^7YO&;9!#^D#2?.R8I9(^+BUCCHA<!>%M#^=IW@'3+
MAT"[Y3^@=NNG=UJV?W:I?^]GBY/.7QX8]]PT,!CDV-(=&5C=&A^O:DS+%M;F
M0"M,A5B*#D[&J7'E"%49NTC!XD-D8F&V5"O.D#9(TF7]DDS)N#A',"'*K9P0
MO@@HM6V]BC7O (7M_Y1AT[^?-&S\Y&;7ED_.C>_^]Y&#^SX?GW;?T#4:X% _
M$.ZOZXZ+E;2E9+*;LXK*ZO/1N-H2(MR,H14:R16Y>B8G0R?DIVK5@B1MG3!1
MURM,TDP*4A63@C3Y9.6+ (*M@?/3VT!E^]NH7O_!@Y:U'UP9^OG]Q?D=;\\>
MV?/9X$&W]2W3?OO-8V&^BL&8:%YO4AJM,R._M T"1UB+<85-*'). Y&65L]@
M)M4)V/&6*FZ,Q<*+KNNVF>'&&6>X\?H7 R1;0^6/_P!:V_6H^_'=6SVK_GEF
MYL<W#I[<]/;HR;W_[3SJNK;ND.\>]8$0+^%D5#AC-"&9,)26@QC(+2[L+4)F
M]R#Q:5T$4F)G>5EL1R4]LD/%".^H989U=C%"NPXRPIOGF!&-<Q4O BBV!LD/
M;P+C#_]XW/+U6Y?&/OW[_(FO7AL]M^&]KC-[/F\\Y;)6?\)GE^1(L!OK4&0P
M:2X^#CF3FEXXE0/)GBPJ3AU'(A+&">B8L7)\Q%@E(72LBA0\5DL*&N\B!4[,
MDX(&%BC!O0ME+P+*/_\[4'UOV_]?_OU6WT>O+AQ]]V^CY[]ZH_/BSQ_57]CU
MC>Z<XT;Q&8^]%:?\/$@G0X.0)V*B"X\G)V4=S<I(.5J8&W\$61"U0"@.7V#
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M&39&4&!K")5V>Z'1W@ Z'?3AR!^=."2-])R41AJNR2#%C^60;%@FG01;%*-
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MX&^_$82X'>!/U0(?]E[@"<R '6X#C 1'<,]R!DH1'DA51'!K)(%K.P4(^ZF
M[Z,![H3[+Y<+'C]=;M!_.(_2OSJ_I$^[O*6_P[^G3Q ^T,>)4[_U_V5@&2P
M7],5(+3;"($N.T!(T0(_S[W ]S,#3J@-,.,QX)'I M0B I KW<"M@0S$-BJX
M[J<!H<_]%W[08P9W@?[3Y1;CN_-3QF>7EXP/N'>,UX1)QC/B!\83MZG? B::
M@89FX.@O (')<A#;;(0@Y^T@)FE" ',O^'B; 2_8%CSC,,!(QX%[@2M0*DA
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M0?Q$..@VC1\@3>$OD-_C[E#>X)Y37N*GR$\(GZA_$S_3KKM]<;](_NI^X3>
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M@.V8(]@]QH#]; "[709PNV3_.Y5@JBL []\3(LOEX.VT#GAN6X'%W D>?II
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MCUNQ\4/7:M-[A";S._@NBYNX/LMAW&FK:[AAZ\NX9]87<5.VYW S=J=Q8#]
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M_P9$]/J9:-_S17MG$)HG<IO,3)R:W'3"GCFO$DP6/HVS7?XP"K_^1HB[RN5
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MELX7VR<Z'VW?:;]G?==^RT*=-[:H^]H6]5[8HOY<R-*GH8LV#;VTZ>BGQ\!
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MP/$J@/D- +T[ !JO -2^\X R"H$B2H <RH$TJH D:H$X&H HFH,(LD (G4$
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M<GDM3?G77<1%FM*E)S2EB^_IBA>0\;,1DM]+\IO6_^]W4#L!XO>1?)+M>1S
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M(S?P(C_)$R)Y8B1/BOQW% A50H<P(5B$.Q%"D%\,D/Q2@(T$^>!#\M#CUG]
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M=FV2#7:="NOLEDK[[-9*5]MNE:VR.ZBXPNZ2XC*[.TI+[)\I]]ASRHN)[O_
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M=4INL=4-N2[K1_(+K=_*+[#AY#O^P^"Q[G/2ONU(GL\%N.S"X-QD(4[:*>+
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M%#.;3:J8?I,Z9J-),[/>9"ZSSJ2+[3-9QJXV7<^N,MW!KC ]QBXWO<;VCGS
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MT:3R7K%-V6;BJ-BZ[*;8IO2)V*;DG=BFF/N'78-G804T'HJH+Q*U1 GI9I8
ML>7DO<FJ^5<+X%VC",]:+7C4&<.];C1<ZZW@4N\ YWIW.-;[,@[UH8Q]?2QK
M6Y?&3JPKX%G73>-/J&OECZOK$8RMW2BTK#U$?"^TK/E3:%G]EN"$EE,_L)4L
MT)HRFI>)9J**=/,KR'N3=@19M(#IY#T; 9=F!3BVJ,)AYE#8SS2!W2Q+V,Z:
MB(FSG& SRQ/6LP(P858D,WY6$C-V5BYC,:N2'3.KA1T]:Q'/;.8ZWLB9^XFK
MO)'-#WDCF][P1S9R_["QE.:E:IJ7IP+U1"G=9]8"<:0=W$3>;Q;@3)9U4KL
M5O,5,;Y#$^,Z##&V8R0L%XR#^0);C%G@C-$+O#%J83#,%L;"=&$&3!:6,,,7
M-C##%BY@C!:L80P7[&$,%EQA##L>, ;MKUB#>=P_K)D&+"(+UE('5-,UOX'Z
M(6E'D+;?7,J_ [#M L:1-S?KE8/I4F6,6*J-X4N-,&R9&8R7C8/1,EL8+G.!
MP3(?Z"\/@][R1.@NS\.0Y=.@L[P-6LN70W/Y=F@L/P>-9?>@T?L"&DLX1O,C
M2V?0O-A,XY$H;:&Q,)OZX3P@D&RA1S?YWUY@_ I@U&K >"V@NUX"G0W*T-J@
M!<T-AM#8.!+J&\=";>,DJ&YTA6J_'U3Z(Z'<GP:E_E+(^IN)Q9#V;X)"_S$H
M;+P%A0U/(%W_AN#>T]5*XY%J/;6-Q@+9\\1.ZH<]U ;+ 4?2M5I'^N2+C;>0
M!R=OKK:#@>(N>4AW*T%AMP8DN_4AO]L$<KLM(-X]":(]KA#N"0!_3PQX>[+!
M#OXAICU4T#TK:5$BO[V;C/QN,LZ['A,OWC/X-WFFDR4O7@2D4<Z1]*.^E*]S
M/V!#MG@T>7+C78#.7D#U " [!,@=%8!W3$J;#F6"//]Q\OS'1Q 6M !. D[2
MAN#DX'\4H07H% VZ4]2Y3E%RI]83!^GK9.A/WB$>OJ>9ZETU^!X.Y1RW@=J
M\G7;0?J[27\?8$2_HGT$4#X.*)P"A&?)[U,JN"@B*(Y+%,<E#=H0#Z7-T##:
MF-,F^:N)P%6*XRIM1*[1A'^-!OHWU-#?+"'(\_^/'OCM9>+&>ZI7?'@/)Y&^
M%4+:[I3O1-(=13]F2+J:IP&E<X#\18#]@K2O$O\COB6^%P _2&A3+@-NJI(Y
MT09^,J1-\J!9L0;NT@;Y[N ?+*.)^#<:\+]1H_].C?P[)?K[?N+$>PJI/,E4
M\S#*>PII3SI*^9\$#"A?#=*5D:YH4/<[XL;'<Y!?/KZ/,OA>R%V&GDTUN:\
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M9&,#$]CHP Q>5& A/R)PJB LL%D8&KA %!RX4AP4N$TN,/ D\1/QE#YSHJ"
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M7&,<5QC'9<RP_?5L=RLNX Z<8R[.\-DI?OH$6SK.43N&[W"4(WV4JK?0Z?\
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MKD4<.1ZO+\57)' <6 IWD@8^K^)[)8RC@/&H^9G,>#-DR,50RAV1(O=$LCP
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MT6*=@F9K%1IM<M%@HT&=325J;1I0;=N)*MMA5-@M1[G=1I3:[T.)_3D4.SP
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M]H2H.V2\X<)A\J,DPDXSS7>G=)//X#&?P+?_!H_Y"[S?=%+H%/CR='D(&WH
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M$3P;QB>'RG.\FD/$S,>ZM7A*[2@Z!AX0T:R7C%/U.U5U3&4KF-Z+66IF@N?
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MR<*6E@$.DA:@E90 5VD1X"-) 4&2&! A"8'Q$A^8(G%!K20V*$]B@KM+=/!
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MPEG\6NC$-]E=?)+]Q#LY1+R2H\4SI85XI&2*>TJ>N*7V$-?4(6)('2_ZM)=
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MS??[0KK1QG:@52O3O6CQ/(^@S8&XT1O*[MK97/_I!0?L@^[^@#"3P21:0TG
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M$C??ON+J.TH,?E-$[S=7='Y+P&9Q\3LD6K]KHO7]1%Q\OS>>A3,4?3U)MSJ
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M-]8]R.] #.]%84^D@[5$V-I+A+63A%MI)<Q"!]PDQ,)+@BW\T1."GBAD)DB
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MK*;J6G2+0D=LGWB#P*_!=[/^>7]04ET\\?:@KTA%A?X\1C]:Q>E#50N//DW
M\>I4X'QG%G#,60ZLWX3>,'\'/^7]J+2C^1.UU;G5HK7&N%6F'&^5 =TLK26T
M"G3X=HZ6T,'4/+H_>/3^@-Q3I*;T8-7T7K2ZK =9PWNJ'KA>F?K /?.#OUT?
M_0#JOPB]Y9F;.S[X2K&CZ4N-QK';IK#&N:6FW,;*.HROPO#/#8+^GS<(_]P?
M$+7DA[<'6"VM$ZUE=B*UK*?J%\]++_S1\,;[]QL^6/; .2_T<N^;B>VC,TKT
MS=]7R^PA=K$UT55A?GB#X"W_7S<(Q?Z2VN*6XEI2"Z'V?^X/6C%Z1AM*7_I4
MC7NG/?^K[]7W?O.]O?1F^\P]/2=?BK>.O4J6=RR5"AM"C/SZ9 ?7FO_/#0+A
MX0T"_>$-0G$3N>[1#0+!6.*;N$' &:G-6 .]&6U@/E6COJG/7VB;\>[/[:\M
M[A^;L<EY]95$U>EWB\K[EW'+VO?)F+ZX&D9#=BW=C3#1G#AKB;VHGF0GV(GU
M1 ?>5NPLLI&@_TIV8:TE+K25XD99:&ZDA>YYFH;\4Y\;[IH^<W!HQF>><R]M
MJ[G[5IS@TKQ"QLGEQ>2AW:7%1Z/XA.XT$;XC3XII*Y2C6A$*> M*!?-CJPN:
M<>I\'[XFST?0Y#85:Q_>(GA+=%F-5/W3=+1UZC-]/=/?\(Y._UIW[]6M%?<_
M#&/^O#"E^/+Z?.RY/6CTJ4@B8C2)4G LG9D[F,/*ZB_@9/;!>>E'4?RT7HP@
MM0<G2.G!"Y.[B15)W2118E>).*&3]E1UMD^;XAN8^F;MI>G?B,',=67@\SVD
M^\O#<'>VQB-_VI]><"4B+^M"'#SM; HZ>3P3EW@ZCQ!_LI 8=P)!.C*&)L>,
MX4JB1_&4J%$B)6J$1(T8H= BANGTI\G?.?79NK'G9DK RY^SP.QE)>#;#45@
M]2[D7SL.%/P>$IEQ)SPN\59,<NQ/2>G1US.R(J_FY(1?*<@+NXS(/WP)71!Z
M"5MXZ"(>=O B$7[P AE^X (5$7*>@7R:@&;6\T#SV3N@>ND"(-^X_;YX;]PU
M?B3Z)#N=?915J&QE%5G\K!);<QG#WL0H=7HI+'<CB>-I(/ :&XH$7@^VHLF#
MKFQRHV0^-T+A<\/5S6Z8OMD.,_@FVW\-_S7\WS-\\(]AR0)0-6$(BKO*CT"?
MX*1QCK(*5"TLG,7/)MN:671[$Y/I]%++W(UD=D,#D=?H*2IO<F,K?&YTI0\R
M-+L0"K\+7N-WPO1^*ZRV>;(!+630SG\'J!<O (H-V_^HW!-WM3P<,\9-XO9P
M<M4M'+3%SRVV^;@T1U,9P]5(+_4TE+ :/<6<)C>>W^S""?U.M+C%B9*U.A'*
M5@=<TVJ%ZUKKX'K_9 /:]R'#O'= S81A_?8_)+OCKPC"L&.\>%XW-ZNFA8NT
M^'GX>A^?ZO2R:>X&)J/10RUM<I/8S4X"K\6!$[0Z,.(V.TK6;D>J.JQP38<1
MH6W3(?0MDPWHWGL>Z.:^#6H6+0#*=?\8#N-&RX_PNGD9FA8>S-+,Q]4WE9<X
M&[E43T,9W>NF,WU.,JO%0>2VV8O*.^HQXDX;2MYE0ZJ[C(B:3AU2TZY&Z5HF
MV_\8--]/&';\(=V5<%EX"#<JB.9W\=.T+?P"2[, 4]\D)+D:^90&#_OA/LCO
MH)2VV8O9';:B\BXK1MQC05?UUB%5O3J4NDN-TG0HT;K6R?;0H/_TD4&U=L?O
MTIT)ET4'<*/""'Y7>;*N19!K:1:BZILJB*X&04FCFTOQ.4MI+78:L]U&8G59
M\/Q>,U;<9\(H^G5HY5$UNKI;@:GID&%UK9,-Z-]]9- NA QK'AG$P;A141B_
M4Y"H:Q%F6YI%<+M7A'<UB$H:7?R29@>;VE;/H'=-W,28"+S^.IQX4(>5#U9C
ME7T*;'6/%%?368G3MDZV1X8YCPS5D$$6F'"Y<A]N5'R(WUD1IVL195B:Q85V
M;R7.[:DD>UU"LG_B+L9:2NTQ49G]QF+NL5I"Y?'J(ME059&B7U)4W2/"UW0*
M\=JVR0;T[SP/:B<,WT&&'R'#CL3+DB#<J"2$WRF*T;6(4RW-DCR[5XIV>Z2D
M)J?XX1NE+C.[Y*B101_2EW!&U<7BL?_L8"J(JEX!L::33]2V3390^\YS#PVZ
M?PSR'8E79+MQH])]_,[*2%VK),G2+,NV>^5(MT=.:')(26T/W^;PR0.U;.J(
MAL$>EU-%)T4ETF$!N6J 3U;U<LDUG1RRMFVR/3)\ AD6+ #JU9!A>^(5^4[L
MJ'P/OTL:!GW3Q)F;%>GU7F6AVZTL\MD5I':+E-1K%)./:0644Q,[D(JRBE,\
MIO0XAUXUR**ICI91U5VE%&W[9 .U;S\'#)!!/V%8M>.>?%OB%<5V[*AB)Z]+
M?E#;JH@V^ZN3Z[TUN6YW#=IG5Y/:S2K249V<=%P!S?U"(?TL5UAQNHPK&6&R
MY8.,4F4?@ZGNIC,T'9,-&/YC^'8!J($,5=N2KJBV8L:JMW*[E?LT;>HPDU\7
M:VNJ37=Y#(5>FX[045M-ZE-5%1\32XM'V0_W#QPHR0A5(!NB\A1]%'9U#Z6L
MIF.R </,YX#QX[=![81AY8Y[BBU)5]4;T2>T&S@]-8$U[?K]QE9SF-E7'^^H
M-Q;XC-"L65-=?%0&S?Y\.6&8(26-DB7,,9),.$*2RH9(%8I^4KFJE\2MZ9QL
MP/C0,!/4?K, :%;L^%VU,?&:=BWJI&$5ZZAAO:K3NDW?ZMY;Y[ FN(S&PF8M
M]'500/._")K]V9"#"GT]B'+:<)&<,XQ7B(?P<D4_OE+52Q"JNR8;,+[U'*C[
M:"8P?/TMT"[?\7O-VH3KAI6(T[9%S 'G8EFW;[G&Y0RV&BW)'HT1UERM)[1)
M-(2N<C6^I[2:T%>B+!X@*"B#6$7I($;)'\"HI'T8I:H7*U5W3390]^9SP/3A
M3&#\ZEN@6Q9X7[<R[B?KXL)SC5^4C'1_7-[0N+K6:#]DKS&G-BB-<)\<FKLK
M)N9_:/:?N#^8N#W 5Y<\O"% 5[./(M7"7F2-O =9K>Z:;,#TQG/ /'LFJ/OB
M6Z!?&OB@;DG,+YXOLR_U?(1M[_ZDHLZ]R:2NCW!4F3,:I'6(IDIH_N?7$EK+
M=(2VB?L#DH;T\.X JZ%UHVI*NY$:;A=<(^J$:163#IA??PY8/G@+F.=_"PR+
M O]R?!5^O?.CI('QUS&.[L]$U9[ .FE]C$-LR?)4F)"-0FC^YQ@)S=#\__#^
MH%A/:L/K2B9N"-K1.D8[4L=J1^CX[3!]9=MD ];7G@6V]]X"UKG? ,O7VVZW
M?+1_^-0;,4WC;^)T/=\*)=[=6J$]KIYOS7;Q+$@/UX1OG+A!@.;_B?N#YF(#
MN1EO*'EX0X"II;>@:DM;$+6<%KA!X)]LH/Z59X'][3=!_<??_-'XT;J3HZ]O
M]%]_([YN_%V<M&\1E]^ZIXKM/:(O<V69R^P(>ZFMR,6P$#U4<W$CV43R%IM*
MO/^Y/<#6T9O0=4P?LH[E0]1QFR;;7>>,9_]RO?'&WZX/OK[8]^KW[5=?W6ZY
M/3-!?FX.BC>\C,[LW5U.:X^64OSI*DI3H8;4B-(3&K!&G+NH#N,BF%$NH@7A
M)%GACA(KS$&U%3CHMGP[LS[7SIYT)QM>>.9W[RNOWVQ_94[7B1G?VGY_/5#Y
MZ^PC_"M?Y]''5^-((WNH^,$H5M'15#ZF)Z<"V54@AG7 I07M*%E>&Z8JI[5(
MD=U"4&:V%"LS_&15NI]2G=9,KTYI+E5/MN/>%Z:<:)WV2M?@BS/M5U[Z7@5F
M;B^_/S^,?FM9$O'JYES,A7T(Y'@4KO!D(C%W+*TD<R2+FCZ<1T\]5LA,'D*4
M)@VBRQ(&L:SX 3P[;H#(B>TG<8[T4;@Q?0S>9.OWO3"EIVOZ\\ZQJ>^I_WYE
MH0#,WL  "X*(]]>$H>_NC(7=.IB<<R,R(^W:D9RDRTGY"1?387$7LA%'SN>C
M8L[!T%%GD9C(,VALQ#@.%SZ.+PH[78P_?*J$$'J*3IQL7?X7 ES]+TRMN?S"
M^T+PYE<,,'<Y$2S=B 8;=\) 4'#6GP<.I]P+CXJ[&Q,;<SLQ(?)66G+XSUFI
MAW_*2PO]J3#CT U$YL'KZ*P#UW#9(=<(V<%723G[KU)R]UUAY$TV=\?S =H3
M4Z8)P8RWF>"]3XG@JV_08/FR0K!Y;2;8M24)[-\9 T+W1OP='1+Z(/[0P3]3
M#@?_D1F^__?<B+WW"B.#[B&B]OR&CM[]*RYF]Z^$([ONDF)WWJ7&!=XIC9]L
M0/KNLT#^]6M NG(>$&U;!?@']OW.BDVX49H*.\?,*QEEH/G]=)*\FT;7M%'*
MZOQDCJV9R+/[\ *'#U?A:,)4.IM0,E<30N'RPJM=7IC&[2VL=7L++"YWX>3Z
MK^&_AO]ED$&&JJ\@PPK(L!4RA.S[G7TD\08K"7ZV+(<RPD26]S$(BDX&3=]*
M+[7X*>SZYF*NW4<H=S3A*IQ-&+'+BY*ZO0B%&S)XO#"=QUMH]'@*S6[[)'MD
M^/(U(%L^#XBWK@;EP?OO<:*3KG/B$6=8&;3ALD)A;VF1JIU98O0SF;9F:EF]
MC\QQ-!'X3F^1T.W%B#V-*&E#(T+1T !7-S84ZAL]A74-]D)3@P5F]DPF((<,
MBB\@PP^08<MJ(( ,O(BDZ]PCB#.<5/HQ5IZHIPRC;BLCF?QE#%LSO=3>5,)V
M>HMY[L8B@:<1(VIH0$D;/0BEUP/3>#V%1J\=9O1:8'6-!KC),YE U3\&.62H
MW P9]@??XX<E7>='(<=Y2?1C[&QQ-PNI:6$1+7X6S>9C,AU-5);+2^)Z&O#E
MC1ZLR.M!29O<"*7/#=/Z'#"#SP(S-!GA1J\.86J83)#A&:#\'#(LFP<DD$&X
M+_B>(#3INB ".<Z/8PQQ,\1=')BVA5UD\7,H];XRAL-+*WVXD_(0^-Z)?90+
M)6UV(51^)US?8H'7^@UP@T^','K5R+K&R004_QBJED*&38\,P@-)URL.(\<%
M,8PA?DIE%S=?U\+!6IJYY/HF-MWI93 G=E)>-Y'KF]A'.5#25@="W6:!:]L,
M"'V+%E';7(TT-"E0=8V3Z:%!]=DC@W3C:E"Q-^2>*#CINN@@<KPB@C$D2*CL
MY.?H6GA(2S.?6-_$H[H:R^@-$SLI5S''/W$75(^6=MB0-9VU"$V[!JEK5:'T
M_BJTH4F*KFN<3$ Y89C_*E L>600!87<J]R7=+TR&#%>&4H?JHBM[!1DZ%K*
M899F0='#&Z$&#JW1S6 T.\BLMOJ)71!:UF- 5O?4H&HZE6AMFQRC]TLP!I\8
M6]<XF8 *,E3_Q[#A1R#>$WQ/$I1X7;H/<49Z@#Y4&5G969&B:ZG(LS17H.W>
M"I+;PZ=XG66TEGI*::>%P#]JPE8-J#'*HU58=9<4JVT3X_0M%3B#3U!4USB9
M'AGFO0J4B^<!&62HW!7\NVQ7X@WY'OB9JKVT8[+#XJ[*>%VK.,O27 FW>RL)
M;G<%V>?@4MJL='JOL9@W5%,D'985*?K$1>HN(5[3+L#K6_@$@X]','HGT_\V
MK/\12 *#?Y<')MQ0[H2=5>VB'E.$B+IET9I66:JY69Y?[Y5C/6XIJ;E>2.XT
ML2D#.BKGA)0D&1$6*_KYQ=7=W&)-.X>D:V&3:IM9)*-W,H%JR*">^RI0+9H'
MY)!!NGW_'XKM\3]5;R\\5[.#,JP.$O:H#M>T*>-,_NI,F[<:[G:K\,TV.:G+
M("8/*_G<2WQFY1B;7C501JWN*:5J.DHINE8FI;89^J>U:3+];\.Z'X%\Z_X_
M5%OB;VJV%)S7;R&/ZG>4']7M5[7K(@RMAD2SKR['T6!">4T:4I=27GR,(Z*>
M9@K%8W2N?)#&4O522VLZJ0QM&Y6N]]-HAJ;)!-20H08R5'\_#U1!!L7F??=K
M-L;^K-^0=Z%N/?&$92-GP+I=UE6_3]O9$*GWU*?;34:D;^)W(8@F?N^@E#12
M+.6/DBKE@Z1RY5$25]U%8FO:R67Z%G*IP3>9'AD^_<>P]D>@VK#W3^VZ([?J
MUN1<KE]==+IA)7/8OT;8W;)=Y7:'F^JL&2Z-$=5<I25T\*KQO1.W![B)-P]*
MR4"13'FT2*3NQ@LT'02>KI7(J6V>3* &,F@@@WKA/*!8\R-0KPUZ8%@5?<>V
M//-:XS+4^<XEI*'^9=P&WXX:HR/*JK9D>JJ,:)]83VAC:0A=Y.KB7JR*WH>J
M+N]#J16]:(6Z"R/1=& KM*VX<KU_,@'-.Y!A#F3X;AY0_O@CT*[<#2S+PG_S
M+$J^WKDP[^38%T7^WA\$IJ;=VFK[D7J9)<==68=I*C<0_!/O#R9F?VP-K1M9
MP^Z&9OXNF%;5":_6M"/EVC94I=X_F8#F[6> ]I-70,VW\T#UJA^!<6G@ ^=W
MAWYN_SKF].AG:5TGYQ?;NE=5J)OV:R6.>%N%-=<]\7L(N$:"CVX@^J'9OQ4'
MS?TH72DT\Y=#,[^DK4!?W5:@T;7"E'K_9 +:F<\ W<>O .TW<X%VZ4I@6[#U
MCO_SH#/#\T.Z+\S)<HU]3M9TKZN0-!^H$;B33+SZ? ?'@O64F8A>:EUQT\2[
M@XFY'UW+_&?F%_H+#5)_GJ':GZNO;9Y,0/?6,T#_T2M ]]5<8%RP['[CO'47
M^C_>U'MA]F'/U3FY^K&O2R2]FP3\UE %VYNL+W/EFTOMF'JZC> JL11[B"9R
MX\3<CZEC-$W,_/ Z7A.LKJ*IT"3SYM95-TTF4/O&%&"8_3*H_7PNL,]=>*WK
M_25]Y][9T'AK=H3ARKP\Z8F%)%[_5DYI9U@EO25926W*UY0TH Q$-]94Y,1;
MT(YB&])>4@^KI]D+ZIF.?!O;F6?C.W-M8F=.O<(QF8#QM2F@[OV70=V\3^_X
MW_EL:/RUKYI^?F>K\=['4;)K7^5PQY<7T8\'TLG]X=SB[N0*0D>N%-L*4Z#\
M*!7<AZTI:,)K\KS%NIQ&BCZKD5Z;T5!J2&_@&%(;!(:4!NFD N97I@#+VR\]
M<+_S_O#PC+>;?WKM.].#][;+_Y@7P?MI43KMXCHX\?1N/&XT@H(YELR$#V2R
M\X_F\7-Z88*L;E1%1A=6G-9)J$SI($F2.BC2Q':&+*&-)8]KX\ECVT15D^FN
M[<4IP/[&C&/=+\[PGWCQ/=.#UQ=5@=E;>0^^/DB[LS*.<&-;!OIR<#[\?!0R
M;SP!EW4JC9!V(IN4/)I?DC@"I\8?1]%CAW&,(\<(S.@A<FG4(+4L<I#)BAC@
ML,(&!.S)=-+U7,!(\]3G_/W3IIJOO#BK"KRUD ?F;J"!Q7L(?ZX/1?VV.Z;P
ME]#$K)N1:2G78[,2KB;EQEY.SX^YE%,8=;$ %GD!C@@_CT:&G<.A#I\CHD//
MDC&'SE"Q!\Z48D/&N;C)-.1Y/L#?/C7 ,OK\BU5_OSR+!][_F@J^6H$'*S8B
MP=:=>6#OOO2_#AQ,N!\>=N1>3&34;PDQX7=38@_?R8@[=#LGX< O!8DAO\"3
M@F^ADO?_C$W9]S,A9>]-4NJ>F]2TW3^5ID^F5N_S 9:^YZ94G7_F11YX[5TJ
M^'AN$?AN 1RL698-MOZ8#'9MB 7[MT: 0X&'0>3N@R!V;S!(VK\/I 7O_3OK
MP)Z_<@_N?E!X:->?B-"=?V(.!]['A^WXHSA\VQ_4B*V_ET9.)FO;,P&*L8 I
M//#"5 IXZW4<F/L^#"R:DPE6?ID(UB^,!MN7AH&@E0? @37[0/CZ/2!FXRZ0
ML#D0I&[=#C*W;0.YV[>"@AV; 2)P$\#LW CPNS8 TJ[U@+I['2C;,YE &?3O
M _>S&8"[<A9@[U@ F(<V %KL_C]I*4=N4[*SKI&1J//%!-+I(@IS#,/D#:,X
M%8/P<DE_H4C>5R!1].;)53VY*G5/=DU-=Y9>TYUITG9EVK1=&6YM>Z97Z\_R
M:I[4?PW_APPLR,#[[$7 @PR<'=^!4LC /++_/B,I]A=Z9O95*AQ]KJ2HY"2Q
MA#52Q! ,8=B5_2B^_"BB0M4#JU1W%\@U7?E*76=NC;XC1U_;D6TR=&35&]JS
MW 9?CJ>V(==C>%* #1GXD*$<,G A0]FAC: L*OA^:7SL+69:SA5Z ?8L#4L]
M029QCA'IHH&B,ME1#$_5C1+4="'$N@Z8K+:]0&ELRZ^I:\W3FUIS3>;6'(?9
ME^<TNZ'L^4\.<%Z? LHA@P R\" #"S*P(H+OLV+C;I4EYUYFYN#.,%"T42J1
M-T2F5O812Q4]19R:3DRYOATE,K8AI";H1YBEI5!M]>?7VOQY%EM3?KW-75!O
MJX<R%SXYP(4,@G\,_.W? ?;!C8 3%GR?$QUWBYV0>[DLLVB<"6>,T/'E U2*
MM)?$K.XBL'7M.+ZQ%5-A]J,DUF:$HMX'JW'X"@P.7[[5X2ZTV>U0YD);O1%6
M_\0 #S(((8/PH6$AX 1O!+Q#P?=Y$7&WN+&YE]FI1:?+\ADC3(R@GTZ6]U 8
M-1TD5FTK@6?VXX0V'UKB\"$4SB:8QME44.?T%%J=]856AQEF=1A@-KL.;JM_
M4H /&2KFOP@J($/YMH6 MV\C*#\0?+_\<-PM?G3N95YBT6EV-G.X#"'L8Q*J
MNN@T[</]7#'7UHP7V!_NY29V<C"MN['@X8[+98)97+4PJU,+MSK4")O]2?V/
M0;3BD:$\:",0[M]_O^)@["UA>.[E\B-%IWEIS&%V@;"O#*OH9);H6NE,<W,)
MI]Y'*'=Z,97N1H2RH1%6V^ H-#688":/'FYVUR L3A7"ZE @;?8G!<HA@VC"
ML'P6$&Q=" 2[-P+1WOU_BH./_"(.S;E<$8D[+4AB#O.RA4?92&5G&5'?4DJW
M-%-9]B8BS]6(%3=X$,HF%\S09'JX@ZIK4"/,'B72XI*CK XIRF9_4D  &<20
M03QAV+(05.S< "IW[_M3LO?(+]*0["N2P]AQ<2SCN#!-V,<O4'1R</H6%L7J
M8Y0Z&DE<CP<K:G(AJOUFN-ZO11A\*F1=8Q7*Y)&B+:Y*C-4APMCL3^JAH7+"
M\,,L((0,HAWK@73GW@?R/3&WJ_9E7:TZ@#DCBZ"-5":4]U5D5766(_0M7*+%
MQZ([&RBL1B>NHJ4>6=.A16K;%*C:9BG:Z!5C3)X*K-DEP%F=Y3B;_4D!X3^&
MR@G#YN]!Y;;U0+X]Z"_%SJ@[JCT9UZKWH\ZJ#E+&%#&\ 5F*K$N<IVT58LV^
M<HK3S6#Z;'A!EPZEZI5C-!UBK-XOQ!F]Y46F!C[>[.;BK4X.WF9_4@\-D@G#
MLEF@ C)(MJP#BJU[_J[>'GFW)C#MNG8/XKQN/^FD-HP]5!,G[E5E5+=7P8W-
M$H+=Q:/ZC31!KQ2OZ!<0:CIYT+<*AVAH8A/K&EA$L[N,:'&6$:V.)P4J_C%(
M)@R;O@>R36N!:O-NH-D2_IM^6\I/QL#"2^;=^'%+,&/4&LD?M"9)>ZWYU4U:
MI,TH(?IE7%8OAU$U4$I5=S$INE8&Q>!CE-0U,DI,'@;9XF*0K8XG]= @G3 L
MG05$&Q>"J@UK@'K#+J#?>/CWNDV)MVQ;<Z^Z M'GO4&D\=;#C.'V%$ZK)TME
M-1=:E6I<,T="[RD1R0=(G.IN<IFVK819VUS",'I+Z*8&"LWLIE MSB<%1-",
M(X,,4LA0N7XA4*Z%9N^U@:!N[:'[]>MB[W@V9MQLV59PL7<O\M1P#*:[-Y'E
M;DE7:%WY%B$T?U,TE"Y,M?@H5J+N+A)HV_!<O9_ -C01R^H:BYEF#XEA<3TI
M((8,\@G#DEE NN8[4+UZ-:A=M1U85P7?]ZR.NM6Z/N%2__;4TZ=WY?>,'2 U
M],7P:EO2E3(WS,2UX#W%>G(K0L/I+-2J.Q#0O(\6Z?U8@<&'XQF]11Q3 YYE
M=C\I4/F/0;9X%I"O^A9H5JP$IA^V/' M"[K=LN+@I?YU82=.KT_J.;<9V7 \
MB%;;'5DA:TY3ET.&,BO!1:PK\2%KRUH*:R4M>7I=2Z&RU@^7&GQ(D=&+%M0U
M8'@FSY-Z:*B:-QW((8-R^3>@=LD/P+YH_=WF1=LO]_VP:_3T\M"N2ZO3&\ZL
MQ]8.[2F5=46*RR%#F0=61[7C[7@+V8.J*X5F;6%37IVR*=M@\.6I#4T%548O
M3%+7B!"9/$\*2"&#8NYT4/7]+*!>_!4P+UC\1^,WJZ[V+%@[>GK!]L[+BR,]
MUU;D&$ZOP\L&@\KX75'B4G^ZBM8(UQ>[<&:,G62'V^BN BO7G6>5N+,M:D^Z
MV=20I3,UY%:;&O*K3)XG!6200?GI=*!8. OHO_T,.+Y8<+-]_J*QD_.7=5[^
M>K?G]O='#%>6Y\E.K2?PAO:5,GMBA)2V3'EQ,UR-;<3J$1YB7;Z+:LEQL*Q9
M#J$MTU%E37-H;<EVBSW%9+.GZYX<J((,U7.F ^6"#X#YLSEW?9_,/S4R>V[7
MY4]7>6Y_N<]PY_MXV>65^=S3F_'TX1 ZJ2^61^C*$F':"V7P%K1RXMU!=E.)
M-J.1J4]MY-6F-(AKDQM5M8F-M;5Q'KLQSN%Z8D )&=0?3P.Z^>\\<,U^_WS_
MF^]U7WSO"\_M.>L,?WT9++NS.)YW=4TN[>P.#/'$(3+V6#P3V9_!*>C-%^1T
M(469'3A)6CM)EMQ&JTIL92GB6P3*V!8IE%IYI-6DB/*[5$\*J%\+ )H/IP'S
M[-=O=+SR:N_Y5V8VW'[W&\/?<S;(P#?!O+O+8VDW-F40+@;!T&?"L+"3"<6Y
MH^F4S.%<1NH@K"QI ,-.Z"-P8X]2^#&]S/*H'JX@LD<DC.B15X3W:"O">BS"
M)P6TKP8 _?M3;WM?GM8[^.(+#;=>>=_P]WO?R:#YGPN^WTO]?4T$_I<=B:@;
M(9D%5R+S)]Y!I)Y-12>-9^/B3Q42CIQ$%4>?*")'CI%*PD=IU,,C+-JAX^7T
M@\.5] /#2D;(,=T3 X:7 R9N8GHZIDUI&)D^O?:OUV;)P*P%7/#%&BI8%ECT
M]Z80Y!][(O+N'HI-_R4R*?%F;%KL]>3,Z&N9.9%7\O+"+\,+#E_"%!ZZ2( =
MO%#R\-U#\#DV:O^Y<O3>LY7HH+-*S)/ZQ3(MH-?[0H"G=^J4VC-39TC!&[,X
MX..O*&#!#SBP>@,<;-N1 _8&I?Y]X$#<G^&'H_\X$A%Q+S'J\*]I,0?O9L>&
MW"F(#[Z-2-CW"S8QZ!8A:<^MDN3=/S-2=MUDIP;>%*3M^$F2_J3Z'<\&N%N>
M#] //SM%\ON,&6SP]KLE8.Y<+%B\  ;6+<L$6W],!+LWQ(#@+>$@=,<A$+4S
M!,3MV0>2@X) ^K[=('O_+I ?'/@W(F3'7Y@#V_XB'-SZ@'QHRY_TT,U_L@]O
MNE\>]J0\GF<#]#U3 BK' Z:PP,O32."]-]#@BP_RP))/4\&J+V/!A@418/OB
M@V#/LOT@9$40.+QJ%XCZ<0>(7;L=)*[;"E+7;P:9&S:!W(T;0>&F]0"U>1W
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MS"14])'I55TXGK8-(:MKR3=:G07U-@.LWJ:&VVU52+M%BG28*U%.DPCMJJM
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MZSET20.#6M=(*S&[:256!XU<;Z.1[58:R6&AD9QF*-/C>F3XZ 7 @0RBU9^
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MT0O6@OB%/X*4[U>!S$4K0-[BY0"^9!G +ET*BI<M ;0?%@$.5/GRQU7='!#
M'PH((%\(",""%Z=D@U>>20!O/A\)9D\_ .:_' 06O!X(ELW< GY\9P/8]-Y:
ML..#U6#/[)4@^,/EX-!'RT#$)TM S)S%(.'3[T'JW(4@>]X"4##_6X#Z[!M
M^/PK0/WB*U#VV$#^S&= SL?/@>R%+X&L#>^!K#WS0=ZA12 O9@W(2=X&,G/W
M@73TX0<II.@_DI@)OR7P4N[&B=)O'Y%E_1*CRODY6IMW,\J8?S/"6O!3A*OP
M1G@S[$98%_SZX1'XI?#3\/&(L["1J/.P8X_I_X[AH^= [L*70?;Z]T#N[L]
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MJHO/QQO(YV+K*6>/-%'/QO121V*'J3WQP]36A&&:-W&8YDH:ICD?$T"\.07
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MR8_U7./O.SR-OA_V,AJZXF4X=.>/KFXFY. >)ND^R23M-YBDZ<LH9B6F219
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M!X3DND)0SH5_O<\/OQ7\(5Y[P*#W^J!O7MTA7SU[0K]P#X1]]C@5_LG]2L0
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MH2KP2M2">ZX^7"N-X=QL#L<.2SALM(%=CRUL#]O#Y@)]I8_HJWKC^-WFF].
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MP99V38O%(G"4$P%;7A0>BF+PU)*$C]E8>#M-!M=S%CA!\^$:)P?G+$4XE*G
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M[1"Q<:Y+R(9>]Z -JSP#-NSV\M]XU=-O_6LOWW4XR7\53@H<Q$F3E_VWAR4
M5V@O'ET L+,?8'0EP(KU7_)?YUX&&@\+0]T1%:@\8L(N.>PHD'?(6V+FP1#Y
ME -35!/V)VK%[,O0C]I;8!*VM])\\IYFZX ]"^U\]ZQR\-ZSRW'2GE\<O':]
M=O+<@2Z>8^@Z:2.Z>J_];S=G YRF'NSM ]A(:S \GC\I_W7N!F@XS(+RTWQ0
M?%8:\L_I,EEG;;BI9]T%D\X$BL>=B92=<CI>,?QTJEKPJ3RMP%,5NKZGF@PF
MG>HQ]CRUTM3]U"XSM]._F+F=?&WN<@RMG(ZBC?,!M'79A7;?NTP].+008.L
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MISZ)=3@IJ08]I\]&C^1*=$NI^!8F #S(H;U(ZW"*>G"@G7(7Y=^-BP!6+^7
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M<#3N"4>CB="'^A\L0/WGPN<$'CQ-YH/[J8)P)TT4?DY7@/,9)LSQ=!?NP=0
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MH3U&7D/7#+T&7AMY]J.1YS(T]ER*QI,6H=%$OQ32^5A+/6@'6$?U!ZA^SW*
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M^\\&N0+-69#7Z+:_H'?^C?])?_$K-*=#_KH'1-<6DF"MW7NP(7:CGEO" A)
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MHL_L_YY0OT_#<FHULJYE\LD<OH]AG0,:>0W0)CMWT']3=T(/8-U/_37TX(.
MDO89F[@8WFQ$N!C<0J^]E0N>;5QP;.-$.\Q)>%C>A&>G'F8RASLU_R3R-IKY
MK33/6[XBU-^LH:.)8S,U\TDB<QW2SNNPB]< =1VH.V$M8$5-DRWTX/3H JM#
M.P<NI#FX,8Y]C.. ?$K%2O/78H<9QQ$NBHYPXCM*WW^4'>LH&_+(*K*/7.?O
M?,C!F:OY0]+H*97%K&L925_*?KB<UT$?^R!U9U!WPE;J4].$FKKR_LL1PJIP
MD<^)CIR13ZG0$)SGXOP"%^<7Z?DOL5TN,XZK7)A<Y>1WE8/,-7:N:\S%519X
M]2RAD;_*]K@BC5++]LUE<\4/<"Q8__^Q=1[@<197VWXL69)5O>J]]]Z[M.J]
M6UVVW.7>>\4V!IMJ>K,I!M,_0@L=0@@E$ ($TGY2(:&WT%LH^]^S^PJ<?-_%
M];"KU>J<,V?.S)SG>&9>Y@&^EG65:U=,Z$V2_VV2A]%UCU5[F:Z%F),ZCUDU
MD2=F2$]"")XB&7\:DO!LI.OH^@LD'[]A 7R1P?XBO/\E'/LBC7F1/WKI3? 5
M<&@Y_3M*5W4<I0_P;QYZ$W]"_!$^ 0](GH]8NIZPZBZF#O*\59>8/JGS>ZL^
M\6=(VU^]I5>(U==(S-_$CK=(DMYF\7F'^'QWA_0>RM[#B>\])[T/JWO_"RVX
MFOD(TQKQ<<G=Q,"#4B3M#'B<V#/UEV<MG2^=5'/Y7R=T].-.D7^972+F*3;X
MY&O(RK>I$$EB]'MS0H9!YZ##'3C:<2^@08[7K?K#; OF_?2ID'RY;@EI W.L
M^H/9'6)N*MTLURF9_>"0S*VIW\/FOM,5\,9K]6_8X%=TWI<PXB]@_Y_#N<UI
MF.G;.,R.$+,CXV59MU(X:Q^^5@W"U[+#W%AB;@DQ.U3,4VNZG;48U^F49?H:
MGOLE//=S[/@,.S[!CH]TKC[4Q?H %O@^/-.<3GD'AOP63GR#=Z_SEZ^=5'LQ
MM0]S(N09IPVF[F%V0LRP7HU-9J=,"NTJX"^KT=>*_?WH&$?^0N0O1_8ZNF +
MLG<A=S_M.HSL(S#;2VCYU83'S83)3]'UA'Y#Y[V M4;GKRT\9=4BG*="Y/8?
M]0=F<G0&X[TXVI2%OE+TU:.G4W^C3_X$[_\#O/^WV/$B_GB!?GD..Y[%CF>P
MXY<PZ2=AW(_3)X_I)PRAA]'S(A[Y0 _BR0?08F">[_-3N9[U<[+^KYTAY8'O
M FA3!/V5C*X\VE&)[4UZFCYY4D,,Q[FT81&REZ-A+;(W(W.7[M4!HN!,W0W+
MOY,^N4,WP=OO84KYI7//S$U$R7_ORKC^)!O,!3CORK4)ZT5BXQEX_^/$Q:/*
M0$\Q>FK1T8K\'N0/T\*YR%^D6['C9NRX"3MNP([K=:JN(T:/ZU)=@R^N(BZ.
M(>4*6G09WC7[F@PN.PG3^M^:X1KFOW).!S/Q5P"^"J,MB;0C!SUEV%^G$XR3
M:]6'_&'DST7^(AW%CLN)C\NTE6C82V0>PA,7Z'QG->06+'I 9Q.;9S)XSZ"W
MS7.'3L;7YL%8?J[+J9_@]7ZFF#O=S)3LC4X;;8HBPE+158">2MK0@(X.=/2C
M8P0=\Q@1B]&Q4F=I S)W$!4'=#J:3^,O3L4[^^F/4_#LWAEO:8_;U]KMSCHU
M\T=\C.Z_L^P]!>YAV;F%J?9:/KN:)>"8NQ]M"V;DQ^G\&9DZUZU89[G7Z(R9
M33KDT:73/0=TT'-4IWK-UWZOI=HW:XWVSMJB/;-.T2[O,[7#^U)M]SFAK3X_
MU6;?I[7)[TUM\/\&L$:<A+>9REZ,8^F(13_+WE51+*=\=C[+SWD![CKB$Z S
M?<-UR"]9!_USM=^_3*<$V+4GH%6[ WJT<_:@=M@FM,VV2%MM*[39ME$; W=K
M0^!AK0N\6&L"K]/JH+NU,NAIK0A^2\N"O]-4B,.%8!=>B7/58.X$QTE#+DXD
MW8B'<['\'63*/S5HEO8%!FE/4*QVAF1H6TBAMH16:5-8@S:&M6M]>)_6A8]H
M3?BD5D<LU<J(M5H1N5W+(@]J:>3Y6A)UC19%W:&%44]J?O3KFHSY1O-B')H7
M_2/,Z:2?9;$L9Y)B@',RT,UG>Y/@?=BR(]I=VR)G:U-4A-;')&MM;*Y6QY9J
M95RM5L0U:UE\EZ;BYVA)PK@6)RS2HH256I"X69.)^S0O\5Q-)%VI\:3;-)KT
MF$:2_Z'AY*\UE.S04-*/>#Z;)9_4YSIP(3C=JGULPY9-:>0W^&9MHI]6)85J
M>7*\IE(RM22E4(M3*[4PK4$+TMHUF=:G>>DCFIL^J?'T91K+V*"1C#T:RCA+
M@YE7:"#S5O5G/JJ^S+^K-_-+]60Z7,APJ!<\4^"ZF>5*< [83^JQC<\V8,MJ
M;%F!;Y9E>&M)1J 69L9H?E:JYF7G:6YVF<9S:C66TZS1W&X-YPYJ*'>N!G.7
M:"!OG?KS=JDW[PQUYU^FKOR;U9'_L-KS_P*^4%L^*V$>R'6H'3Q9PC@L)<T#
MA\%NL(G/5F//,E(R*(P6Y'IH7IY-$_D1&BM(TDA!MH8+BS586*4Y18T:*.I0
M?U&_>HO'U%.\2%W%J]59O%WM):>KK>02M93<J*:2!]58\D?P&7"HL1@4N6#^
MV>DF<!$X"+:#M:3&RT@]%I$&36++>)&;1HO]-502JCFE\1HHS5!?68%ZRRK4
M75ZGKO)6=9;WJJ-B1&T5"]1:L5+-%5O55'%0#947J;[R>MDK'U!MY>]44_FI
M:BH<JBVW4.;0P]7$ C@/[ .;3?VERM1>T(\M8]@RQ.M A:_Z*H/54QFCKJI4
M=5;EJKVZ5&W5-6JM:59+39>::P;56#-/#;7+55>[6?;: ZJIO4!5M2=467N?
M*FI?4GGM)RJO<:BBVD*50_>1_EYM=@>!/6;_"UC&9_/!&/8,8D\?K]TUL]11
M&Z@V>Z1:ZY+47)>EIKHB-=97J:&^0?7U';(W#*BV84(U#4M5U;!!%0W[5-YP
MGDH;KU5)XSTJ:GQ!10T?J:C>H6*#.H=*[ [=1>I[%!P&.QJD-6 Q[^>"H3KX
M!NCD?6N#AYH; ]38%*;ZIGC5-:?+WIROFN9R5;?85=72JLJ67E6TCJFL=;%*
M6]>IN'6/"EO/54'K-<IK_:ER6Y\#'RJWQ:&\9M#DPFU0HDO!0; %K  +P"CH
M!^V@N07^WSI#]C8_U;0'JZH]1I4=*:KHR%%91XE*.ZM5TMFDXLYN%74.JZ!K
M@?*[5BNW:Y=RNLY65M=5RNBZ2^E=SX(/E-[I4$8':'<HL\VAFUJE"\ ^L %,
MF1H0& +=4*7F=GA?)SEW%_R[VUNE/385]T:HJ#=!A7T9*N@K4'Y?A?+ZZI73
MWZ[L_CG*ZI^GC/X52N_?KM3^,Y32?TQ)_:S _<\HH?\])?:1L?:"'H>2P;6D
MW>> 76 -NA:!L4Y7#:@#O?50I>I>N"?TL7#.3.4.^BMG*$190S'*'$Y1QG".
MTH>+E39<H]21%J6,]"II9%R)(U.*']FBN)'3%3-RN:)';E/DR%/@'44-.Q0]
M! 8=BIGCT+$>UH8>UUZ@%6 2#($>]+:0CM<,P'L&T3\,_X:JI$UX*WFN34ES
MPY4X+UX)\](5/R]/L?/*%3-9K^C)3D5-#BMB<I'")S<H=/* 0B8O4?#DK0J<
M?!R\I:"YWRMXPN%$R+A#%Z-C/]@ EH)Q,  ZH&@-Z&;(JV@<_7/AOU#'^$7N
MBEKBIXBE@0I?&JFPI8D*79JID*E"!4]5*6BJ68%3_;)-36KVU&H%3.V5_]0%
M\INZ03Y+'P&ORG?)U_);[)#_(A?.I7V[P&JP (R 7M \B@_073(/_@]%2EN,
M?FAC)#0Z>+6';&O]%; N2/[KHN2W+@EDRW==B7S6V35K7:>\UHW*<]V49J[;
M)K=U9S'Q70/NH\,A9&L^U8S59-.K''('IT\P'L R, ^=@Z"=]W63],%"N-\2
M]$./XE>A?RWZ-\+!MKC+9[N//+;;-&,[R<]V$H_M+/X[6&1V,*'M8##M((!V
MX+@=ZP$D?H>Y]@'BN@W2MO4C0!:YQ853:.,ZL)BOCX,>WC?2YDK:7$";T]>@
M?X,4L44*V@X'AJ.3)LEM_RSI 'SN (G7J20:!TE$#K+0GL:"=QJ3VFGMKJN0
M3D/(:7O 1?S^5KX+@3P *3SP/4'@<&([NE::&WIH[QQ>VVASS6IB$/,S-DL)
MZ(U 1. ^R0^.[GF8I!?7ZAQW0/)Y+HG?$>PX#SO.QXX+TDD"S-94)K<+S?58
M-.I"!%T(L;\ ,G\!)/K\-_C^M_R=PXF-Z%MF;N@QI[/P=1V^+MD&_Z>]"?NE
M\-,EVYF2[[EPX O0?0FX'.!:'<6.8_CC2OQQ-79<0Q)X'#NN(_FXC@7X!+S_
M!,%UPCPJ#&'70>ZOA= ?ASP?_X+O.YQ8A\X%FQ@+6XG#G<Q#^#F'[DNDK>'G
MH1^J[F/J+U=9]9?IO2BF'G(+P+VZC>3\)[[2'3:2$>+C;NRXA\3C'A:^>SJM
MDSKXXMXC@#^\YY?23S_@>PXGENUB7M[+6(22U^#G?+Z6C-X(3+81RM[76[I^
M8M5=IFLA#X 'K9J(J5$\"B%X#)\\3M\\:6XMP8YG<B L+'[/$I_/+@-TZ+/'
M '_\[-\ S.99A^8?8ETT-Q3CYV)\G([>Z!OH__]!O]%YKZ7K9U;-Q=1!GK'(
MD*F'/'=2/<3LU?B]A_0GB,K?@J1_8(?91OQ:H_0Z\?D&0?;F.0!?O$%LOO$6
M[[_0"&UN/V:>T$0?T-YX] 8SC'T?L70^9>E[7C_N!_FS50OYX72.50N9/C7C
M?+(N!.4S8N0K$N.OB=%_,TZ^(3Z_Q?'?70;N $^#U_7CB1 _Z_WTJ9#I^H.Y
MH:-'KB>4+)#K22GKY'IZKJF#'("]'=:WL*U_P\"^AM]]";?Z');X&9WT*8SY
M8[WOO"MU^G8.4X?X?W+M@7C6R3=-[</3JCV8O1!F#\;T?A1S0J;668OY7@/Z
M1N/H6*0OM +YZY"_!?F[D'L OGX834?@S9?J;=BH.9WR&AWY3SKO5=Z] N>>
M?B**.9%B]E\\+M<^B!_W7\BJ@QB?A-"V!-J539O*T-6 GBYT#"%_+O(7(W6%
M_H$=KV#'7['CS]CQ,FSS][#0WS)X?P-3?1[._6M\\2O]3D_C";/GXTD+9N_%
M?58-XK_W8'R)+S["%^_!==_"%Z_#=?^A:O2TZ _TR4OP[1>PX]?8\2OZY6EX
M_U/P_B>PXQ?8X;HAXT)T7$DHW\00NI?_GD'7F[H;3]YEU3W,W@OSO..;3K+!
MG$HQAZ[>D!OZ_+$\A';$TU]9Z"G!=KL>HT\>4:\>PH[[L>->^N6G/^S#V(S<
M7;H-IGTK+/QF)K.;F%!N8%"?P./F[I+C]*!YSI#9=V%>S?.&CUDV?&N5]%ZU
MAMA3^.)1?/$@<7&ODM&3AXYRI-4COQWY?<@>1O9</+X0V<N0N0:9FY&Y6T>=
MK/\(D7'4:<E%6'P!@_A\>M/LN3AR$LS/1O^'UE#[E34-W(LO;F><W,(8N4&Q
MZ$E'3R$ZJI#:B/P.Y/<Q"H:1/Q?Y"Y&_')EK&1U;\<(I],B91,<E.L1?GTX/
M',23!^C9_42UV5FU_R1\QO3V*DO/TTQQ]WLQ[;($W.B<EKUHTVSTA2,ID1[.
MPN9B=-2@HPD-'8R$?G0,T^JYZ%B$CA7(W( %.[6'3W=CV4XLWT$/;<.S6QD5
MF^D/4]T\&>;AY+]AFG\0W *N9JJ]C*G_(I: \^6K<Q2(OBATI: G#SUEM,.N
MO6I&3Q<1,(">46W7)'J6,DK6:/.,K=HX8[_6NYVK=6Y'M<;]5JUV?U@K9_Y1
M*SP_U@HO9IF3\ I3^Q,LN[>#JUGV+F+).9MI]A#VG.;GIH.>_MKO'J(]'G':
MZ96A[;,*M'56A39[UVN3=ZLV^'1KO<^@UOJ.:XWO(JWR7:F5?INTW.\4+?,[
M6TO]K]!B_UNTR/]A+?1_6?,#/M5D@.,_\/L85PWF>J;V2W@]DY\/1,%]L6E'
M,+!Y:KO_;&T.B-"&@"2MFYVM-;9BK;)5:Z6M4<L#.[0LL$]+ T>T)&A2BX*6
M:6'0>LT/VJUYP6=H;O!E&@^^2:,A#VDDY \:#OU40Z&.'Q'"7)GDNA7EJF32
M$7# U#X2X9W8M#Z:' M;U@;[:55(B):'QFDJ+%U+PO*U*+Q<"\/MFA_1HLF(
M+LV+G*.)R F-1R[6:-0:C41MUU#4Z9H3?;$&HJ]77_3]ZHU^43TQ'ZL[QN%$
MCT&T0T^8DTFD/I>FN_:?[$YWU3[6D!ZNP)9EV+(T>I861P=J04R4)F.3-3<N
M6Q-QQ1J+K])H?(-&$MHUE-"GP811#20N4'_B2O4F;E%/XJGJ2KI '4G7J3WI
M'K4E/:_6Y _5DNQ02Y)#K0:)#CV213]DDV*!4UGNM_&ZEL^6D8(LQI8%V#*9
M-%-S$P,TEA2FD>1X#:5D:#"E0'-2R]6?:E=?6HMZT[K5G3:DKO1YZDA?IO;T
MC6I-WZ>6C//4E'%<#1EWJS[CUZK+^  XG*A/=^%^4N%K6.+/R9?V@HU@!3\O
MXO-)[)G -Z/X9BC=3W,R@M6?&:/>S%3U9.6H*ZM$G=G5ZLAN5'M.AUIS!M22
M,Z'FG*5JS%VO^MR]JLL]5[6Y5ZLF]TY5Y3X#W@,.%W)<N)LT^%BA= 9+_$ZP
M%BP%DWPVACU0.0V OEQO=><&JC,O4AWY26K+SU)K0:%:"BK45%"GQL(V-13V
MJ;YP5/;"1:HM6JOJHMVJ+#I;%457JJSH#I46,>L7O0,<*BVT4.#03XJ)A1+&
M(2GH5K 2+ 3C?#;$[_JQL1M[.@H]U58T6RW%86HJCE=C2;KJ2_)45UHF>VFM
M:DN;55/6K:JR8566+5!YV6J5E>U02?F9*BH_JL+RGRB__"GPMO++OE=!J<.%
M$H=N*2/M!ONA)INL_2^F_C("^OF\"UO:L*FYS%T-Y?ZJJPB1O2)&-94IJJ[,
M455EL2JKJE11U:BRJDZ55@VJI'I21=4K5%"]3?G5AY5;?85RJF]35O43RJQ^
M4UE5WP&'LBL=RJEPZ'IT'B']W5/%. 1+P$25J_[2 UKY?2.O=="6FAI?5=4$
MJJ(V4N6UB2JS9ZK$7J!B>[F*ZNI46->F@KI^Y=5-*+=^F;+KMRBS_C1EU%^F
MM/I;E5K_"Z74OZ&4NF^5:G<HK=:%:Y!]5@US$>GO*K  C( ^T $:08T=W@5E
M*6N8I9*&V2IJ#%-A8YSRFU*5UY2KW*82Y337*+NY65G-/<IH'E-ZRQ*EMFQ4
M<LNI2FJY1 DM-RN^Y>>*:WY-\<W?*+[)H81&AQ(;'#J*_-.1OZ5>6@[F@4'0
M;>H_P-X ]X8^EK3 _5K=E=OFK^SV(&6U1RFS/4D9'9E*[RA4:D>E4CH:E-S9
MJ:3.825T+E)\YWK%=NY3=.>%BNJ\41&=/U-XYZN*Z/BW(ML=BFISX1+2[OU@
M WJ6@#&K!M0!&J%)U>@N;4-_!_R_"_[;XZV47IN2>L.4V!>KA+Y4Q??E**ZO
M5+$X+Z:_35'] XKLGU1X_VJ%]>]12/]Y"NZ_7H']#X&_*[#O*P7UDCWWD#6"
M\]"QNQ7N#Q:@:QCT@%9 ]ZH<FE38C7ZH8QI4)6'073'#?HH:"53D2(3"1Q(4
M-I*NT)$"A8Q4*GBT44&C/0H<'9=M=(5FC^Y4P.@Y\A\]+M_1^^0[\GOPF?R&
MR5R'R.0''3J#]FU#SW(P%PP W*DF4X-"=S&ZF7K$%*C$$?C/N!0ZSTN!\_UE
MFQ\,HA0P/PEDR7]^L?SFU\IW?KM\Y@]IUOS%\IJ_61X0*??YQ^0V_RZY33X'
M_B7W>63R<QWR  ?0L0$L!J.@%[0!>Q\QB.X\=*=#D1(GT ]M#%T(!USB+K]E
MOIJUW";/Y:'R6!ZCF<M3Y+8\5S.6E[LV>"U'R/)Y "*]'+Z[#+*\[#9I"EXS
M!?=?2@:WE$QR"2QE#N-AD#EACNLL6!=HY.=*Z'+!&/Q_+OJA1U&+I9 I]*^0
M_%;/D.<ZDJ_U)#SK23;61] 0^-0&)O6-3&H;&6P;X54;<=Q&>.9&R/1&"/0&
MR/)ZR-MZ"-DZ;%CK<&(S>J9HYP08X$]:30V(-A?1YJQ%4M)2]*,W9(T4 %WT
M@://W$:RMP->N8.$:R=V["+1V!W)))/ HL-BMY<)=B^#:B^^V#L?\$=[S^#W
MUX*'^"[D<->_^5MLV.'06G0MQ&6C9A\.[^MI<^D28G Y_'LU^M$;#&T/V"[-
MVBVYG8)^.+H.SF"")^$['3L.S6;!P8XSL>,L\P]!V:X]*>>8PY@T[.R5@/XX
M^PIK/\K+?/_+'_:CK$ ?H:,!T&S.@?'UO'52"GJC=J!_K^1_0/(\';UG@G-E
M$DTF> L7XX]+X+>7X8_+Z9>C],LQ[+B2A?<J)K^K".PKS?5 ..\8Y/X8A/XH
M&?S1CZ0KL.%RAZ;,62C0@:]K-Q(#?#5U#_&'WJ##]/TY)]5?3.UENA;BW(MB
MU41NP"<WD93? N>_%:[]$^RX@X3L#F+CC@;K7(YY7#8-N9T_O/U1OO,F2?RW
MSEMCYZ.W;PMQ2-B4[B,&^5HL>H-IH]_EDOM5EJX;K9K+[58MY"[P4ZLF<I]5
M$WEHIO0(/GG4W%I"$OA$BFNSKKE&_DGBXBDZ]*F+ +S_J9?XW2?.)^:,T.8V
M^K>*D,DA=!,N)?[0ZW\"_;=8.N_6C_M0S!Z4QRU,G\DQ-9'IO1K.LS+F]E;Z
MYB_XXV^,E;^SZ+W"!/<JP?WJ:=(_\,4_8%/_(#9?_4R]9Q.'M+D(/Z?RJXB;
MB3_,]##UEX<LG4]:>J9O;#7_*&TVYK]LU4.<9W'^JQ;RGGF2+W9\1IQ^3HQ^
M09]\R2#\BC'R-0'U-7'Q%8*_,F=A?/7C^8_IFSE=3P;Y\:FYYHFU9B^(N2G$
M/#7&W)BZ7N:VD.]A4]_"?+Z!V7T-$_M2E^ES N93.NX3G/<A#/(#./?[?,/<
MRO&>58,P]8]?6C4(5^UCFOM[6/4'<V-)HEQ/23$W=#3I.W6C8P@=\V!K2Y"_
M4A]AQ[^PXWWL>)<!^S8#YRW8Y^NPTG\2K*\2.'^#K?\9)O\R?V7.OIB])V8/
MQB^L&L3]_T?]P=1EOH/??:UH?0'7_0Q?? 3'?%^MZ.A%_HAU2^@2)*_0G[0.
MV5OT6^QX$3N>UUGHN(BNNXIVWDPWWH^^YYS/C9D^>V)PCU6#^)__LL$\!/D3
M?/&N O2&PFA'(NW(AI.787\=_FLG]/KT-'8\B1V/PW,?@V\_"M]^!/;Z$.SS
M >RX#U9\#\S\;@;PG;H#7;_03Y!F[I$U=8];Y-J'<:U5A_BQ_N(Z@_)7N?9@
M/(LOGL(7CRN5L,Q'1P7R&W0O=MR-'68?QNT_[,-81HO76/LP=NL$G/M:'4'^
M4;QQ$_S] =Z]R/3RH?,$E=EW8?9AF.<.76C9\(45SK^UAMO#^.)>?'$G<7&;
MXM&1B8XBY%<Q5302<1VZ&CNNQ(ZCQ.GE6HC,94QC:^B%+<C=RU1Z&"LN@K=?
MBU?NI(>>(FK?Y--OG+N9#ELP[[^2ZT*>YZWZQT^MJ>@$OK@&7QQ3)/8G8WL.
M.DJ07X/\)N1W(+\/V4-$X@3R%B)O&1Y8IX/:SD@YH'U,[*<@80\2=^/)7?2J
MN6_7G# [&::<^9(;;0>WS7!-B<? I?CB L;(N0JA';&T(0T=>>@HH\=KM1\[
M3L&.O=BQ!W_LHE]VTB_;&2];M1%O[-$F_FHCDM;CP75$B=E%M(:1M!J])^,5
MEKW'F>9O!U>#B_CY'*;^,[#I=.:, [+1GG D)J G [L+M(W8V,*\L5G-Z.C4
M!O6C8P0=D^A8JE6\6X$UR[%X"L\MI3^6$$6+F"L6ZAWPK?/DW31>9&J_CV7F
M.I:\B\ 9O-_/4KS'G^7=>X9VN/O2KD#T1:$K6>MF9&O-C&*M<JO42O=Z+7=O
MU;*9W9J:.4=+/,:UV&.1%GJLT@+/+9KT/*!Y7N=IPNL:C7O=J5&O7VK$^RV-
M^'RC81^'$R/@EZ$L8>;L#5/[66 ?[[>%D?:0#JS#OK7^'EKK[:]5WB%:[A.K
M*9\T+?'-TV*_4BWTJ]$"OT;-]V_7//\^S?4?T;C_?(T%K-!(P&8-!^S78,!Y
M&@BX1OT!=ZDWX!GUV-X%WP''#W@DVK7]\\)8US\';>=U/3^OC"+]PYZE(< V
M2XMGV[3 %J%)6Z+F!F9J(K!08T$5&@VR:R2H14-!W1H,'M1 \%SU!T^I-V2#
MND/VJBOD''6$7*FVT-O5&OJ46D+?5DO8]\#!>Q?N)0V\VJ0^+/=[P,8D5^UC
M,9\OP)YYV#(WW$T3H?X:#0O1<%BLAL)3-2<B5P,1)>J+J%9O9*-Z(MO5%=6O
MSJ@QM9-\MD6M54OT+C5%GZG&Z*.JC[Y-==&/RQ[SAFICON65E2C:A3N275MQ
M#Z7B U-_ 4MX/\EGX]@S@BU#V#(8XZN!F"#UQD:I)S9)77&9ZHPK5$=\N=KB
M[6I-:%%+0H^:$H;5F+! ]8FK5)>X7;6)AU6=>+DJ$V]51=)C*D]Z#7P#6(D2
M7;@5G1>SQ!\@%=T,EH,%8"P#W?QN !O[L*4[R4N=23:U)X6K+3E>+2EI:D[)
M4V-*B1I2JU6?VJ2ZU$[5I@VJ)FV>JM*6JS)MJ\K33U-I^J4J26>62W]4A>G_
M %^K*,WA1'&J0S>@[[PLTMX<X@ L)0V<R^LP2WX_GW=C2R>VM*7/5'.ZOQHS
M0M20$:.ZS&39,[-5FUFDFJQ*56?5JS*K7179_2K+GE!I]I2*LS>I,/M4%>1<
MK+R<FY23\XBR<_[.ZU?*R78H-\N%:\VV;/3NS(/OY9-CY[OJ+P/\W W:^7T+
M]C2 NAQ?U>8$JCHW4E5YB:K,RU!Y7K[*\LM4FF]727Z+BO-[50@Q*2A8HKR"
M#<HIV*^L@@N567"#T@L>4EK!7\&72L]W*,,@SZ$KT7.8U'-;(;%8Y-K_,@QZ
M^;D=-/.[>FRJX;6JT%OEA3:5%86IM"A.Q<6I*BK.46%QL0I*JI5?TJ3<DF[E
ME(PHJW21,DO7*;WT%*66GJ_DTA-**GU0B:5_4F+)%THJ<2BY&!0Y=#EZ#A:[
M]@)-@0E2T(%25_VE!=2#*GY?SFM)J:>*R@)44!ZL_/)HY94G*;<B4]D5A<JJ
MJ%!F9;TR*CN45CFHU,H%2JY<H\0J9MBJ(XJKNDXQ5?<KNO(/BJG\7+$5#B?B
MRAVZJ,1U0\XZ*,DB, IZ03MH!#6@M()\LU+*KW)33K6OLFH"E5D3H8S:>*75
MIBFU-D\IM:5*MM<JR=ZJ!'N_XNWS%%NW4M%U.Q55=XXBZHXKK.Y>A=I_JS#[
MIPJO=2BBQH4CZ-B%CE7HF&_5@+I BZG_@$I0!%7)LTN9T+>TAEE*:0Q04F.(
M$ANCE="4K/BF+,4U%2FFJ4K1S4V*:NY11/.XPIN7*[1YNX*;SU)0\]4*;/ZI
M;,TORM;TB0(;R5Q!<(-#9T)/M]6X]@)-@'[0/ET# F7HSD=W%E0ZM1G^V^JN
MV'8_17<$*K(C7!$=<0KO2%-81YY".\L4TEFOX,Y.!7:.R-:Y5+,[MRB@\[#\
M.X_)K_-.^70^*]^.]^773N;:YL)!=&RL<^T%&@$]H 74@4K2\2)T9[?0_C;T
M0U5BNJ2P7B\%]P<HJ#]8@?V1LO4G:G9_I@+Z"^7?7RW_@5;Y#@S(9V"!O ?6
MRZO_@#SZ+Y5[___(K?\IN?>]#;Z11Z]#GCT.[47'ZB;& VV< SI!$S_7\%J*
M[CQTIW>B']H8TR>%#\ !A]P5,.HCWS&;?,9"-6LL1EYC*?(<RY''6)G<Q^HU
M8XP_&(/ CZTTC_P%$,91N/_H8S26K&GD:P:@PPES)FP9&&]G/N2U#=2#"GXN
M0'=F#_P?BA0S2/N'I4!HBO]<-WG/]];,!7"8!2SX"UAP%S*I+V3"7<@@7D@'
M+T3(0GCF0DCU0DCL0LC4 C*D!9"U!9"A^=@PZ7!B/;Y=A,G#W:ZS8,U=KAI0
M42]]0)N3$1,SBOZYZ(<R^B^49B'6;1F)SG*2GN4D&RM8Z%?"IU:QV*UBXEW%
M8%M%9ZZB :O,8YC6 XCL*DCD2LCI"HC9"K+HY=BP#,:$GGFT<P[HQ-=UO);2
MYMP1^/\X_!<18:;^LQ0.O%SR7$6BMPZL=Y<VP"LWDNQL(M'8PB*_E41@&PO,
M]AS7YK]MK>9Q6 ">N<T\CO@RO@-9WO([%J?/ 39L<F@)7QG#Q_VTMYG72GR=
M3YO3%J"?]H:BU[9&\MD@S=R,;E.#V07V&&#'*=BQ#W\<P(Y3L>,T[#C=+,1,
MKH=J71N?3E_@>B30Z9#JTR#2!W_%=S_F;UQ[41:@;X30Z>"U%E\7+2(&ETEQ
MJ]&/W@#^U'NG-,/47P[())DD?'+M1SG;U$1(A(^8?X C$;V ?KD(.R[!CLM8
MZ"ZC3RXCN"^CH9?2D$L. 6+BXE_PO7=)G!Q.3)JS4* 17Y<1PEGX.7X+^M$;
ML$_R.LVJOQRQZBZ7RK47Y:B5@)OZQ#6F)H)/3N"3&^B;FX)=FY1O9=&]E<GO
M5H+L5I3<@@-OAN#?#*F_B9BXZ2OGF9P1NJH=$ZMH<YZY!V<OXP^] ;33ZWQ+
MYU%+SPFY]J$8 F+.Y9B](7><5 \Q]8('X/P/T3<_8[P\9@ZNLR@_1GS^G([^
M.0U\%.<]>C.@/W[VH?3(]^JES?7F+AK:G'I8BJ2]MDO0?Z55?S$Z;[-J+]-[
M0AZQ")&I33C/X_QW+01B\")]\P?L^"-CY?_1)R\SP?V)X/XS@?1G&O47A/WE
M3^ 3M9[*7("OLVES+#X..D[\W6357^ZQ=#YJU5VF[R5Y03_>3?+#69S_JH68
M\S'FT18?TB\?D1Q^PL+S*8/P,P+M,Q1^?@.@$9^;:H2GM0?"PZJ'F#T8YI92
M<Q[&W,=1"9KEV@LR#";E.A.S2N9ND.\8*-\P2+Z&X7U)H+KNY#BFCV#6YCZ.
M]V#HYA3*6WQC^@FQI@9A;N3\N?ZO.RC<+#M,+<:<AS'W<10[:S'?J@UNVJ?/
M-*J/L>-?,*?WX77OPN3>A@6]B1VO8\<_&2ROP$S_2@#]B:#Y UI^B[-^HT]^
M>#**.8/RD%6#^.\S("YX8O%LVA-.>Y+0EPLG+;?.HG0@OQ_F.JK_AQV_QXZ7
M8'6_8=)Z#CN>Q8YGX'=/P5(?9_ \INL)F[NQXI=TZ=MZ *^9NHO9_V'NPC#[
M+T[\EPWF',9[FD%[_/1W!=..&/R6AIX"=%0AOQ'/=B*[']DCR)Z'[$7(74ZX
MKL7S6Q@B>Q@JIZ/C?(;/E;J9_]_(-V\@8$Z@P>B\3JY]&$?UXQD0LP?D0RN<
MS!Z,I^5%N,\F_,/1D8".+'04X[=J9#?AX0[G/HP;B8_KX?TG8*[7.O=AK&6Z
MV(+FO<@_ T]<S-"^CO^;TS&_@L>_]Q_W8)PCU[V[9@^&>3#TG^2Z^N<AYW!W
M0X\?O@I"1S3R4W1<.=A>2K35(+L)V1W([D/V$/(F=)X6T /+B(:U3&G;L&"_
M#CG/@1QU[DXYP. RIY>F]V!,XQ1@]L"\; T],\V8;7 ,3UV!+RY1 #I"T1''
M-)F&CCSL+M-AU>+M)N1W(+\7^4/(&T?>0GIB.<O)>NWD_]NQ8BN6;L%3F_#D
M)B)GH_/9QXX?L%$.YP.BGK2F(#,EL;+I N=2X(8$7R(]$!T1Z$C$PYGH*$!^
MN79@QS;LV((=F[%C$W9LP!_KM1A/K-)J?K.*5J_ ^N7TT!11,D5L+B4VEQ*;
M2^1PPHSRWS"UWN?EFNHO!F?R_E2S'&+';L;(=GRQE?C<1)]L5#(ZLM%1I#6J
M0(>=T=F,C@YZH0\=(\B=Q(HI/+*>WMG-3V<2N5=H+OTQSHPP3JO'&.5CZ#8P
MSZ<V-9A;_5VE_S/!7K"-GS<RQ:UG.5PK']ID0U<8NN*0GH:>7$9#,7HJT5.'
MGA;T=*%G#IX81_9B1N\:(G:'!O'F'*)G@.CJ9WSTS?B+>MT^4Z^[0[TS'<[7
M!UCVKV5:/\*4N@]L 6OX>3F?3V'/$E]W+?'TTZ*9@9KO'JEY,Q,UUR-#XY[Y
M&O,LU8A7M8:]&C7DU:[!67T:F#6B?N\%ZO5>J1[O;>KR(6I\+E:[SXUJ\WE(
MK3XOJ\7W4[7X.7[ G2SW5X3!]T@)=Y".K>5U*IR4C\_F8<]$( CPU(2?OT;]
M0C3L%Z-!_Q3-\<]6OW^A^@(JU!M@5T] B[H">M09,*SVV?/5-GN%6F9O59/M
M-#6P"-;;;I3=]K!J;7]5;> 7P,%[9F!P"WHO).4XP#*[*9;V@P6\'^>S87XW
MB"USL&5.H(_Z;3;U!D:H.S!!G4'IZ@C*4WMPB=J"J]42W*CFX XUA<Q10\A<
MU85,R1ZZ236A!U05>J$J0J]7>>B#*@U]6:5AGZLLS.%$>2AS)?K.C2/^$LRY
M&W@&F !#I,G]?-Z#+=W8TA7FJ8ZP +6%AZHE/$;-$2EJC,A20T2AZB,K5!=9
MI]K(5M5$]:DJ:DR544M4'KU>I=&GJ#CZ?!5%7Z>"Z/N5'_T[Y<=\RJN#GUVX
M"EUG))&"DHJN) V<#T9 /S]W\7D[MK7BFY88-S7%^*DA)DAUL9&RQR:J)BY=
MU7%YJHHO565\C<KCFU46WZV2A!$5)RQ48<):Y2?L46[B$>4D'E=6XKW*3'P1
M? (<RDIP*!M<@9[36-XWD_Y-00_F@D'0;>H>?-Z,/8WXI0[4)GJK.M&FRJ0P
M523%J2PY5:7)V2I)*5)Q2J6*4AI4D-*I_-1!Y:;.5W;J:F6E[E)&ZCE*2[U&
M*:D_57+J"^ CWCN4FN+"Q>C9C\[U9@].%C0(]($.?FXF':SG=U!K5?&]\C1/
ME:8%J"0]1$7IT2K,2%)!1J;R,PJ4FUFNG,PZ96>V*3-S0!E9\Y26M5(I63N4
MG'66$K.N4GS6W8K+>@Y\J/A,AQ) 8@9K!WKVH'---K$(+1@"W: UQU5[J0$5
M_+X4%&6[JR#;3WDY@<K-B5!.3KRR<M.4F9NKC-P2I>?5*"VO12EY?4K.FU!B
M_G+%YV]3;/X9BLD_IJC\.Q61_ZPB\CY09)Y#T;DNG)/MVB9O]@+--34@T &:
M@)W/*D$)* "Y?)9=X*/,0IO2"T.55ABCU*)DI11E*;FH4(G%E4HH;E1\<;=B
MBT<57;Q4425;%%%R2&$E1Q52?+N"BY\![_/>H= BA\(*'3J,["W(GC+[@$!O
M$3X ];RO!F6@$&072QFDIJFEGDHN\U=B69 2RB,57YZ@N/)TQ5;D*;JB3%$5
M=8JLZ%!XY;!"*Q<KI'*C@BI/4V#EY;)5_D0!%4^#]V2K(&LL=RBP#.Z/_ WH
M7(3\X1)7#:@9U((*4 QR2]%?#O>#*B14N2FVVE?1-39%UH8JHC9&X;7)"JO-
M5JB]6"'V&@796Q5HGR.;?8%FV]<KP'Y ?O9+Y&N_13[V7\BG]G7YUGXCOQJ'
M_*OA_N9,6IEK+]" 50-J -6F!@0*0!:Z4Z'2"5"WF#KX1X.G0IK\%=04I,"F
M"! O6W.Z9C?G*Z"Y4O[-3?)K[I5O\UQY-Z^25_,>>3:?KYE--\BMZ6=R;WH5
M?*&9C62.#0[M@)HN1\<XJ7>O50.R@PI0#'+1G8[N1&A*3"/ZH6[!K>Z:W>$C
M_\[9\NL,D6]GM+P[DS6K,UM>G27RZ+1K9F>'W,R%(IU3P#SN%F[3>2W!!EGH
M@ 1TD#FV.YS85,.81,>PG:_83ZH!@7RK!I6,[M@6]+>AOU.:W>TFWSYO>?7[
MRWV !66 !6: 274@S174 S1JP!15!LSC?GAO#A5 H 8@A@-PFWZRIGYLZ',X
ML08=DPW\"K2!>E,# D6\SVHB!J#O<>WHAS(&]<(!$>L[.$.>(R0:HRS\8RRP
M8RPHXY&N27Z"B66" )Z@TR;,1<,0Z@ESP06$>1RN.0XQ''L)?,;?.YR8HGUC
MH >T8+K=J@'ETN94VAP'=8_H1_\@^G&MS[@T<QX)SOR93"C>TD*2C478L3B4
MA9[%96FRJ^"\E$Y>VN*Z\'<I1'[I;GY_$8"D+GZ.O_D$8,-"N#]Z!LT^'.A@
M$^VMY#4?\]/[X-]ST ]5#4*O_Z0T"[>Z+4$_(K4"SK^2)&P5R<YJ[%A+GZQC
MD=W XK*1/MEH!IS=M=EFPP*PF<GX7 "17 <Y74LFO\;AQ 2Z^OE:.^VMY;48
M7V=B>L(8^FEO('K]EDJ>\',2*F0 NI=T421Y+';X8P?^V(4=>_#'7NS81VSL
M9P+>SZ#>CR_VX<!]_/$^"/TI9,Q[(;![WG'=B[(+[H^^7OS<R&LY7\VA^Y(P
M.X+V!J+7=ZWDONFD^LM>L!\<!*8V<0@<=G,EHF<3'^=BQ_G8<2$+\H5,^!<R
ML"ZD@>82F L0<!Y9\WF0Z2-DT^=\ V"QUEFH:GR=OX@8Q,^1A% @>GT84FY&
MYZF6KK.M6HA)O.E:Y]Z0R^3:'^*LA^"3:^B;ZV9+UYLGZ1"C-](G-YK'Z(WR
MV0:29P2<^!\22-C4\<^=YW%ZT5N/KXM7$@/KI.BMY@X:VF_:.5U_,?I,[<74
M7,P>%.?^$ZLV<<M)]1!#$,Q^C7MGN9XH_ AV/,*"^P@3W<,$V4,H>I#Q<3\L
MXO['P+O@6[723968ETV;X_<Q_FFO+WIG7&*US>B\T=)SIT6$[K=@2-DC)]5"
MGK3(FK,.0KR^A!V_9\S^GH7Q]PSXWQ%DOR.0?G>A]%N$_?9WX!/9=[(FT;_)
M9S 'X&-__.I^W&KC[99.L]?E9Q89^Z6EXS_VGNC'I]A,UT',O:EO8<=[],O[
MQ,8'S!G_8I+Y$%]\2.=^=(WT,7/FQR^?Q+O-7@RS%\2<AS%[,,QYF$RYGEAK
M[D8U>T'Z+69BGIX[!5M:K6]@/E_#A+Z"%7T! _P41O@Q0?(O6-M[<*NW8>EO
M.D^B?.6\A\,\)65Z#\:#5@WB?]<?IN\D->=AS!-C\M!5B9Y&F'NG/H&Q_ L[
MWL..=V!J;\*V7H?E_9.!\PJ#YF\$[Y]@P'^ Z[Z$,U_0?>A\ =;]D;/V\I15
M>[G'JD'<\G_8\ T\\POYTY9@?8 OWE<&NHIH1S7RF^''7?H=K.E%['@>AO5K
M6->O8)6_9.)X$CL>QQ\_AQ4_ EM^2-<0-C^![?Z"4'T=/O^=\YG"M\EU!\9Q
MN9ZS\Z-NUSD0LP_BKYJ%'AM='8&.)'1DHZ,$2;6$13.RNY ]@.P19,\C5!<1
M.LN1O0Y6N0WNOH\P/@NV?2DA?0.6W,>0>@E]GSK/G1B]9@_&158=8GH/AME.
M]#LKY%CA"4-_PC$8VV.P/14=>?C-W(51B^QF9'<BNP_9P\B=P/,+&;[+D+T.
MMK\=+QQ _A'^NU+GX(NS] 1#_6WGO1?FN<MF_X6Y8=<\A_E3*X2?LX;9G=:0
MN!9?7*W9R ]C"HI'?CKR\[&]G"FJ%ME-R.Y@VNI%YA RQY&YD*ES.7+7,Y7N
MHE<.:0\6F5M"=M*J'?3D=N=SCUU[+[;+]2PD4T;\M37<3?WC:KE*L^<Q3LZ6
M'W8'(3\2^8G(ST1^ 9XN)_IJD=^$_';D]R!OD%X89QE9Q'*RDM&R&4OV.4_'
MF),ZJ_#F2CU#Y'S@W%UU,GYK#?\;K&GW7&M:-N7Q/?AB)V-UNT*0'X/\9"1G
M([\0^>5XO1;Y38S0=G3T(G\(+\QEU"[AO[5:3&L7TH(%M&J2%D[J4:+G=? -
M</P ,^W<RC)\N3M3,]/]/I:?'=:RN %?K,47JQ6(O>'HB*/'4]&1@XXB=%2@
MHQ8=38S4#N3U8<$(T3&?4;-"HU@\[*P47<"(/D$4FTC^(_C<>0.R@=E]9FHP
MUYCCJ+XLJRQ[FWE=P[*S@L^GL&N)O/"N/WJ":4<4>A+1DX[7<]%3C,9*]-2A
MIX7>Z$+N'&:R":Q92@^M5S>]UHEW.XA@LZNIC<AKTX?.FYC;+-QFK@1C6C_(
MDKL5K 9+F%[G\]E<?C?A[:;QF3ZT:3:Z0M$3@Y9D=&6B)Y\>*%7/C&IUSVA0
MIUN[.MSZU.XVJE;W16IQ7ZLF]UUJ=#];]>Y7JL[]#MG=GU'MS'=5Z_&M:CT=
ML@-S%=B1(/K>[#T)<>W[,+6/$3X;-.DJMO3[>:C?VT]]7H'J\0I7UZQX=<Q*
M5;MWMMJ\"]7J7:%F'[N:?%K4Z-.C>E\\X[M M;ZK5>.[4U5^9ZG"[TJ5^]VA
M4K^GP3LJ]?\..%3FYW!>#7^85' ;J?'*"-H/1D _/_?P>2>_[\"6C@ OM?L'
MJ-4_6,W^46H*2%1C0(;J _)4%U J^^P:U<YN4K6M2U6V(578YJO,MEHEMITJ
MLIVE0MN5RK?=J5S;KY0;^#Y@%0#Y-H<N8XD_E>5UHTE'3?T%#(!N?FZ+@G-A
M3Q.V- :[J2'(5_6!-MF#PE43%*?JX%15!6>K(KA(Y<&5*@NI5TE(NXI#!E08
M,D\%H2N4%[I=.:%G*"OTJ#)";U=ZZ--*"WV75P<_LRJ""]"S%YUKXUS_1&GV
MGO2"=GYN(CVMYW=VOE.++=7A7JH,"U!%>(C*PJ-5&I&DXH@,%47DJS"R3 61
MM<J+;%5N5)^RH\:5%;5,&5%;E!9U2"E15R@IZB=*C'I*"5%O\_H]/[,J@G-C
M7?? K"3MFI<$)0&=H-FJ>]0DD.-@3P5^*8V9J9(8?Q7%!*D@-D+YL?'*BTU5
M;ER.LN.*E157K<SX)J7']R@M?E0I\4N5%+])"?&G*3[^,L7&_X^BXY\ ;X'O
M^)D,(8ZY&QU;T3D%+1A/@?:DNNHO#;ROX;,*4,KOB_E>0<(,Y27Z*"?1INS$
M4&4EQ2@C*5GI29E*2RY0:G*%DI,;E)32J<248<6G+%)LR@9%IYRJR)1+%)YR
MJ\)2?J'0E#=X_5;AR60(X'2S'RG%=0YJQ-2  /15=E#)9Z6@$)OR^$XVKYFI
M7DI/"U!J6K!2TB.5G)Z@I/1T)6;D*2&C3'$9=L5FM"LZ<U"1F0L4D;E.89G[
M%9)YL8(R;U9@YF,*S'@=?*/@#(="TAW:C]QUZ%L '1B$IG5D$7^\5H,R4,3G
M>2 +I/%S2M9,)67[*2$[4/$Y88K-B55,3HJB<[,5E5NLB-P:A>>V*"RO7R%Y
MDPK*6Z/ O%-DR[M0 7DWR3_W9^ 5\+4"<LB6P!YDKT+O7+,/R*H!U8%*4,)G
M^2 ;I/%S4AYY+Y0VIL!;484!BBP,5GAAE,**$A6*L2%%!0HNJE10<9,"BWME
M*YZK !)V_^)=\BL^(I_BZS2KZ$'P)_"9? H=\@7;D;\,>CB&_!ZK!E3#^S)0
M:.H_(!/0W8HO(O<G-0TO]5!(F9^"R@,56!X&8F6K2-'LBAP%5)3*OZ).?A6=
M\JT8E7?%E+PJMLFCXBRY5URC&>7W@M_)K?QCN9<YY $V(W\Q\H><9["(15 )
M2D!^@:D_P7W1G8#NZ#+T0V6#J]QDJ_&6?VV _&J#Y5L;*9_:1'G79FI6;:$\
M[=7RL+?*W3Y',^P0&#N$R<YJ7'LE@(#4PF]J/@(.)\RYM$ES%JR$?@#V$M<>
MH"(^HWN5SOLD=,>B.Z)*"JF5;'5N\F^8)>\F?WDV!\J].4QNS;&N8F9SKCG,
M!1H !+89TMH,86PF&VB&*#7= 2 %C=C0Z'!B!5\?@P9UHZ.IPJH!\5D!R.1]
M<B7\'\H8@>Y@:(JM$0[2,D.SVKSDWL&BUC';-:%WF8(R [B+ .NB85W\03<D
MOAN.UP5Q[8(T=EW,=V\#D),.>'>'PXG%M&T('1V@OMJU#Z@8O3F\IM80 W7P
M3YH4W(S^-C@X8F=!V]SZX"_]+/+]\.T!%KXY3.A#3&1#R:XBI[ED:*C9=;AE
M" (]!)$;.H_!1[8VAZQUS@?\G<.)>>CH RW ;J<?K!I0.FU.@*HR]2JXP]1_
MX(!]DB<B21:D49*=,9*,<5_SCPL,+!:V21:?^:;P;PY=%KHN'3(/?9H/H38'
M'"8AL),GF) AAG/?X^\<3HQ@:A>ZFO!QC;4/*+-%2FR7HJ!FP:;^@UZ?83@@
M')T$!GE@(5B,'4L\F63QQS+L6($=JUAP5S/YK\YT%?Q6(VSU")^O G"\E1#G
M%0]+R]]R[D/1%/D4NMK;S7U ^ !?YW02 SV,@0'THS< O;-HQ@S"F]2(OP5F
M/\H:N?:DP)>UB7[93#*VE7[9CAV[6.!VL]CL9M#MPA>[:,C.Q0!RNX.,>3LD
M=NNK)(S?.O>C]**OS=S'PVL!ODX;9 Z"'@<3SO[H]5QFZ9RNOYA:R$ZY]J*8
MVL0^*P$^B$\.F0W)Q.G9V'$$.XXP3HXPN,YM=ET&?#9"SCJ'Q/56O@=9/O2E
M=+I#/0.N^W!*:'/F!&-@@>L,E#]Z/398.G=;NDQ-8OI>%). _W<]Q+D_!)]<
MA1W'L>,$B_X)<S\) 7XMOCB.X.,8?#7$_BIBXAC,[JA#K?BZDC;GTN9$_!RV
MSK4'QF.WU;[#EK[I?2AF3\@/^T_DJH?<J/^\L_4NDN%[B-4'L.-!<X$>D^\#
M!-W]-/)>&G4/+.*>>_G>/R%5WZJ./BY<R3C$31$,G]G[K#M@3!LOMG0>MPC(
M]'D<L_?$66_1_ZZ%3.\),9<'O.#C>HKO;QFO+S%67Z2S7\#!S^/(9S'XU["K
M7W^H<H9,)H0B=K\4R-"9=8&E]UJ+])D:CZF#G+P?Y*F3]$S?23)=!S'[0<P]
M(>8?D,U&_G?QQWN,E7=9F-[%%^\RJ-[=Q6=7 !KQWA].XOWF#@PON<ZAF#T8
MYIDHYCX.<S>J>3:+>7*N>4;,H,R9F.\8G.9NTG_#@+XB6+^ &9F[23^&?7Y(
MQ[U/A[V#X][$0:_!Y%^!9YI=)V8/ACD+8IZ*>J=5@_B_]F!,W\?A@.N:6LPW
M<)DOX5.?PF,^A+F\CQUOPW+>@/F\!NMZE8'S-QC@G['CC]CQ6X+V-P3I<[H.
MAGDW;OL5[OM CUGU#Z/[9KGNX+SV)!O,LTC,.11S%N(C>:,G$#V1>@L^\P:<
MZN_P_C_*KI=@2,_#GIZ%Z3P#TWH*]O4$;.PQV."C3!:/8,>#!//]!/(]=.I=
MNH40>D2WT3FWZENG;E/[N$(_G@,Q^LT]I.99**8&8>ZB> F>^2R^>!I?/*E8
MVI#F/(OR,#SW?GC=/?CC+OKE=MC6;;"]6V& -\,(;X1CGL".:YE KH&E7\7
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MR@\*56Y0C'*"DY0=G*FLX )E!)<K/:1.:2'M2@D95%+( B6$KE5\Z"F*#;U
MT:$W*#+T846$_AU\I<@0AZ* N2)O?91K'\X@:7DG: 0UH)S/2K )6JM\[,G#
MEISP6<H."U!F>+ RPB.5'I&@U(@TI43D*CFB1$F1M4J $,1%#B@V<E+14:L5
M&;5'X5'G*33JA$(B'U)0Y%\4'/D%[QT*C7!H+_)7FS-09@]. O$'ZD E/Y>
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MA(@&$1<Q)F(B;F2$2!01%<DG(L)MP&W@'4")*<K68'X>A2N\EEG[ LQC<B_
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MR>PAO#(ZA%O&EG#)P)>5QHPH#6=,^@:"J'< )5K,.3@R[)_+54:S<T S@,F
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M1H[B)2, $2E>(B0]C C*\A&^T0*$6PZ#R#@8]@0TZ@0)]LT3$$_(3^?D8M8
M")0FZ +P8\?' O 6QH'#6'B2S#.\9=GKD>;+L?=@30+&X?UH<)$&#TEI;B(.
MB,EP$1%9+B(TFIL(R/&086-Y"?=X#*3R&& FHH-/AG$K0A>*3$)O''LCSQ3X
M\E,PZR@BUE0\"F!4G@PO95(Y[H'GJ !O6IZ2C<QZ)-PRE[,.2 $8"QZRX"$%
M'C S(H;7(K@FA.\*X'N\J";71$PHDS'(3P&/:1A,E839 \LL";9"F44ULQ!
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MY!%^*<H_Y4QP2%Z_3V1YMUM\;:=C2G.;779[BTUQ5XUYV?$RJ^J68NNZAJ&
MQLJQ.<2"0P8X%*X93RLVSZ0U>Y;3FB/;OE7K'WU5;F'UH-#!^UJZ6_3Y>._,
M@;# DFZ_L-H.CYC6%N>DXTU.V3WUCL5])=8EO?FVE>VY]K5-0P&+0S0XQ,T=
M03.7C*)%X%"U68FU%J3^\+8O=<>T7M:8V=POM?7[/<<Y;C#9([<ORK>R,RBX
MN=4_IJ/9-[6[SBNGK\*MZ$2N?=&)3,>*SG2GZI:AX"\.\>"0#0XEX% ##HW@
MT*2Q[6.3KO:?#2:V]ZJL ZX4.B:>3G<K[$GPJ6F/#FEI"(WNK Y,["GSRSQ1
MY%/8G^Y2>#+9M:PKT:VJ=2B@<1P."7-$:0XXE*X>1VLW*3%K0;ZU'MKVOE5'
M^T6KL=W=.LO 2V7VR0.Y+D5=J=XUC7&!+561$9TE(7&]^8&I)[+]\TXF>A0,
MQ'F6=<=Z5K8-!2P.,5,$:2(XY"Z1I&7@4+^)M1;D:[OZMK>=VMK/.@WM[S1;
M!)^OM$GM*W N:LGPK*E)\F\IB0GMRHN(Z<T(3>Y/"<X9B/4K&(CT+>V)\*UL
M'PHX' 1H$K,?9K$DK5@]EC: 0_O.99^[#FY[W:VE\[C'P/Y&FVG(Z1KKU*YB
MQZ+Z'+>:LE2?EKR$H,Z,F,C>I,B$_KCPS(&(X()3(8$E/2&!%1U# 8T'AUAP
M2&;VPX!#)3@T@4/7#I6/O0>VO3RAJ?/@A)[#E4[CT/YZR]36<OO"JGR7ZL),
MK^;,E(#.I(3PWIBXN/Z(F/2!X,B"4_YA);W^H16=0P&-'\/#XI Z6X06+I:@
MU:O&TI:-T[_V;%=YW[]_V_/31W3N#N@ZG.\V"NEN-D]IJ+(M+"UVKL[.\VA.
MSO3KC$D-[0E+CCD1E)AZTB^Q8, KNJ37*ZJ\<RCXBT,:.!2!0^TJ.=JV<=JG
M$]N6OCF];^N3"QK:-P>U'4[W&02WMYDE5]5;%^17.%:E%;LUQ>;[=(1E!W<'
M9$;U>:<G]7MDY)]T32KI=4TH[QP*: (XQ(%#!CB4+!*G]:O&?.O<./7]P+8E
M?U[8L^7![^K:5RYJV?<-Z <U'C=)*FVQRL^LLZ],J'1M""_U:@LH"CSN51#1
MZYJ?>,(I/[??/JNDQR&]HG,H8'&(5Q2@6;.%:1DX-*X<_:E[PY179[8N?G)M
MM]KM6P>/GKVJ:==Y]EA@=;]Q8EZ716YRJVUY9(-S74"M1XMGE5^'<T7H<;NR
MN![KLLQ>J]+2;JO"BHZA@":"0P(XY,P2HI4+1WYO72G[]L2&R4\O;EWXQ[T=
MFWZ_MU^S_]81FZ;?=/U*!@WC4OM,LR,[+$O\FFVKW>J=&NUKW%NMJGS;32M#
M.XTJXKL,*W,[36JJ6H<"F@0.B>"0/W,XK5TXXE/G2ND79]9/O']]R[P;#[=O
M&GRT[TC'_<-653=UO;(O&D;&#IBF!/98Y+IW6)?8M]A76C2ZU!K7>S;HU_DW
MZ=1&-&O5)K?HU.<U#@4T&1R2)_/3XIF"M'&!R.N^%:/^N+1^_-5[FY0'GV[;
MU/M\S^'Z)QIF!7=U7)-^-PP*.V\:XW/*,MGYA&WFCST@AAV>)<?:_,NT6\,J
M-%OC*X^TI T)-&4T#\V8Q$<KE 0^=<P7>CRX7.SJK35CSSS>I-S]:MO&YM>[
MU$M?'C),>ZAC%W7;T-/_JGF@VT7K"/MS]K&69YP334ZYIQB<]$[3[0_(T.H+
MRSK2&YNCT9L\)- T<,B=.(S63Q_V\L0\_NO7%@B?>;AF?->KC?,;/FU97_YA
MY]ZL=X>T8Y_KF@8]-+;SN&OAZGC3ULOZFI._V>]N0<:_>87H7_(+T[T8'*%U
M(2+JR+FX&(USR;%# <V4Y::E\CP?VQ5Y[EZ<S'/F#^4172_7R-=]WJ!<_%UM
M3=;W'=OCOQQ2#WYW3,?KI8F1TS,K"YO'#C;F#UWL3?[P=#*XY^.B=S? 5>=.
MB/O1VY&>1V[%>6G<3/(>"F@V.-2-Y7I\2IIK\-XXGJZ7RN*UGU<I%"+V3Z6;
MEL?2'1N#Z:$=7M^.[7?Z9'K8YKVUEOE;1UWCUV[Z!J^\#/5>^AGI_AEDHOTB
MS/3H\RBSP\_B+32>)EL.!;1D%->;XV+DW%4ATOGG>+Z:+\H2!739A&2Z1BF"
M;ESH3[>O=*?JZQWH,35+:KK=A%KO,J2.>_6^N^W7_>9U0/NKWT&M+T'JFI_#
M#AWY'*6A\2G^\*&/R4>&@L^-HN3T@"#I>"#"5?5U@D ^599(HDO&AM*5BEYT
M_2PGNFV!-3VPU)3JK#2D)FN.4:MUVM1^_5'JLD&3>FX\3'TW:=" S8=HB)HZ
MC=AR@,9NW4\3AX33G7RD[2P_J7PORIU+Y043Z2SQ$#I?UH.J3+"C:Z>8TBU*
M>G3/'&UZ5/D(-5R@0<T7J5.;Q0>IXY(#U'7I?NJALH_ZJ.RE_LOVT.#ENVG$
M\ETT>L50T-HSC%3\-HQD4S&>1*H@&$RGC7"C<T99T\6C#>FJ\=ITT\1#=*?B
M?JH^=2_5GKZ+&L[82<V5=E#KF=NI_:QMU EPG;V5>LS>0GWFJ-$ ('A(H,'P
M'P*F"E"?^:(T?*DDC5\C1]/4IM"T_?-IJO8:FFBZG48[:'P,]=)_'1!L^<PK
MVO&12Z+'?8<TOSLVV4&W+ O";IB715XSK8ZY:M(8=\6X*^&2X:FD4\<&DG\6
M___B0.]2NFGM6LT=N[:OW[1%E? +_F]@]8O#_R<< L'!5UF41B#B2.!P2-\W
MGZ9IK:%)ICMHK/WA#^&>!J\"@ZV>>D<Y/W1-\+KGD!IPVR8[Y(950<0U\]+H
MJV;5<5=,FA(N&W<EGS,\F7)2[^=!0^1X:" \S(!YHC0:WG[R:CF:M7D*S=DS
MGV9IKJ7I1CN_)=EHOHMQ,WD>%N#PT#_<\ZY';- -YZ2(J_89<9=M\I(N6I:D
MG3>ORCQKVI@]:'(\KT?_>%Z'85_FSX*&@D,0. 3-%:%QBR1HVJHQ-'?3%)J_
M>S[-/[R6YACL_IIAI?TZR<7B28ROZ[W@X( ;/E&15]P2$BXXI:6?M<W).6U5
M5#!@7E'<;]I0UF784M%BW%%4;]J=^[.@H?"L@L$A9(X(30"'#'#(WZA(BW?-
MI\4:ZVBAWI[/N1:Z+],=K1\F>'G>"@\(_3T@//Z\9VS&&>?D_)-VF:5]U@65
M/1;EM9VF]?6-Q@VUU6:M9146G04_"QK&<("'&08.20O%:=;*T;1P(WN%2MFA
M=;1$=^^G(K-C?^;:V_V1ZNY[/<8WZF)(2.H9GZC\?H0+W0YIM5VV^8V=-I7-
M#1;5S97F=0TEELV5A=;MQ3\+%H<0<(A Q)$,#CG@4+Q!D58R*U0.KOM:H;/W
M?9F)_O,B6X=[F2X!OR=XQYV+",P^Z1]>VN,57]/EGM'0YE+0W.Q4T5II4]5:
M:%73G&?36)UMUU;ZLZ#A+ [\-'*6,$T%A[P5HVGI!LX*E0/K/M=H[7M3963P
MK-S:Z4Z>4_#E5(^DTS%^^;VAH>7M_C&U35XIC;7N.2U5KB5MQ8Z5[=EV5:T9
M#@VU:8ZMY3\+%H=0<(@&A[0%(VG!"EE:OGXRK=NF_+U^_[H/]4?WO:PS,'Q4
M;>%\L\@^]&RZ2VI?O'=^>T10>4-P9%V57T)3J7=&:Z%G87NN6T5'"G@D.=?7
M)[@V5_PL:,1H-H<89H<,.!2"0^7Z2;1AJ_+7YGWKWC5K[GO>K&]XK];,]7*)
M=?C);*?4SF2/_(88_XK*\+"ZXJ#8YCS_U+8LW]R.=)_RSCBWBLX8][J&:(_F
MJI\%BT,8.,0R.V3 H7BY#*T&AZ:MRI_;]JY[TWYXWY/V8T:W&HS=SI9;AO?D
M.:0TI[OE5R7XEA='!]?EAD4WIP<GM24'9G4F!)1T17B5=X5[US:&^S15_RS8
M'!#UQ"D)T:P%8K0$'&I5)]*6+?,^=NY9^_*XQKZ'QW6,KC8;NIVJL@CO*+)+
MJ<MRR2]-\2K/C0^L2XN.:$X,3VB+"<WHC PI[ H.*.L*"JAI"@IHK/E9T$AP
M" >'!'#(F2]&R\"A7I6U,N-]S^ZU+TX<VG>O5\OH8KN!6U^=65ASJ4U*99Y3
M7GZ&1WEZLE]M0GQ8<W1L;%M85&IG4%1^EU]869=/:$VS;TACS<_B+PZ)X) W
M?P2M6,9:%?&U4VWNV_Y=:YZ>/KCW5O]1H\$N/=>N1I/0NDJKY.)BA[RL7+>R
MQ R?VJC4X*:0I.@V_X3D#I_XW"Z/N/(N]ZCJ%H_(AMJ?!8T"APAP2%8:3O/!
MH6J9%&U>)_^I1VW.JS,[5S\\?V#/U3-'#$_V'G-I;34.J:BS2,JML,M-*7(I
MC<[SJ@G)#FSTRXAH]4Q+;'=-R^IT3BOO=$RL;G&*;ZC]6= H63:'U!G#:1'F
MSMIEH[ZVKYOP]L3F6<\O[%AY[\J^W1?.'S;H.:GC7-]E&%S4;)Z07F>3'5OI
M5!):ZE'E6^1?[YX?UNR4%]]FGY?1;I-7VFZ=6=-LD]90^[.@T> 0.8F?IL\0
MI"7*(K1!1?+C\;7C_CR]6>GAU>W+;]S<N_/TE4/Z;8/:3A4G] -SNDSC$UNL
M,L,;' K]:MTJW*M\:QTK0AILRF.;+<K36\S*2UI,BVL;S?(;:WX6- 8<HL A
M:[H K9@G_+UEJ?CKOC5RCRYLFG;GSA:5B_=V[^R]H7ZL_M)1A\)!/?_4?N.8
MR!Z+-/].NSSW-I<2AQ:?2JNFX!K3QN@ZHX:4!OWZ?*"^SJ"JN?)G06-E>&CL
M1#Z:.XV?ULP=_K%SJ=C3,VMD;M_8,/G2'VHJ P]W[FB]=U"G_*:F3=:58]YQ
M%XS"@\Z8)[J?L,ZT[7;(-^MT+39L\RD[UAI<J=427:79D@J45&JWMY7^+&@<
M."3*#Z-%4_EHXQR!ER>851&K)"[>4U4\^51-I?/9]NW5C_8?S?M#TSSIKIY+
MV'43/Y]+EN%.9VUCK4\[)9N<=$_7[_/)TND-RM'LCLS3Z$[,5S^>DZ_>7?'3
MH G2W#1M B\M5QSVL6,6WX.SR@*7[BR3['^B.K7]]6:5VE?;MA3^N>]0ZG--
M@Z@G^M;^]TQ=W&Y:>=E==0BP^,TUQ/BB5X3>>?\HG7,AL9J#47$:9Q(3#I[)
M2CQPNCCI9T&3P"%W' ^MG\CSO%^1Y_+-:7S]CU6DV]ZLFU;]<=/2@@];-Z:_
MW[LWYIWFT<!7!@8>S\PM'![9VEK]X>1H>M?=U?"VC\>Q6X%>VC?"?#2O1_L=
MOI;HKWXU,_# [P4_#9HBQ4U+QW"_[QS+=>VJ!%?_HVF"K6]49*N^K9V:]WW#
MPI1O6]9&?]N[->B;YC[/3X:''=]9:%N_MM,W>^EB9/3"TU3_F9^Y[M-@2ZTG
MX5::CV-L#C]*M%5_F&%_X$&>P\^"9HWBHO6CR)5!(7+RH01WRYMI0I7?5&1S
MZ"K%1*HZ+YRJ+?.G>]:Y4TTU!VJXPY):[#'Y9G? \(N+NMYG3PV=CWY'M#X$
M:VJ^C] Z\CY66^-=DH[ZVPS= V]RC_TL:*D8N7Q<@)RX,)PTOQW%4TZGBV33
M13+Q=+E",%VKY$DWSW>BNY9:TR,KS:C!6D-JOD&/VF[2H<YJ6M1SBR;UW7:8
M!FW7H.$[U&GTSH,T8==^FK9['\W>\[/XO6D8Z>GC)XV_"Y 2*CTLB\X0B:7*
M4H%TR3@WNFJR+=TXPY3NF*-/U>?KT&.+CE+3)4>HM8H&=5BN3EU7'*!>*_=3
MOU7[:/"JO31\]1X:LV8W35J[DZ;_-'K;AI'ZT\-(T7T!KG0JRQ=#IPK[TUD2
MSG2!K"5=/LZ0JD[4IEL5#]%]TPY03:5]U&#F'FHV>S>UGK.+.LS=25WF[J >
M\[93'^5M-$!Y*PV9OX5&S5>C<0M^%O7=/*3P(C=)^23$'4W'#/.E$X<[TFDC
MS.A<R6-TB<QANGK,?KIYW&ZZ:\(.>E!A*STZ48WJ3=I,C2=OHN:3-U)KQ0W4
M7G$]=9ZB2MT KZGKJ/_4M31XVL^">B/&\9C"3YTQ5_@M'DG#5LG2Z$T*-';O
M3!JMM81&F*K28(?MU,_GX%>O,*T/KG$&;QU2S5[99%N_L"RT?V96YO3$I-KU
ML5&C^T.##L\'^GW>]XX-^M[0N>)WX>A5_Y_!+PZ_./P?.;C.$Z8!BT;2B)4R
M-!8<XO?,I'&:2VBTL2H-L]]) [P.??8)T7WG'F/\RBG9ZH5=EOU3JWSGQ^:E
M[@]-JKS^,&KPN6_8[G_7H"_PMMY@T&6=RR&#VE>"?@;4!W&6)SAXS!6FP0M'
MTN@5,C1Q@P)-V363)AU>2A,,-]!HF]W?P]PT/P0$&K[RBK1Z[IK@^-@AW?T/
MFQR?>Q9% ;=-*T)N&M>'WS!JC[QF>"+ZDMY@[(#NN>C>8Q?#?@;4%QR\$.-X
MS1&F88@OXN#;IZR7IQD[9M+T0RHT16\C3;#<]R7:1?MMJ)_I"_\P^T<>L1[W
MG5+\;]MF,7F8R*OFY;%73.L3+QEWI)PW[$_K/]:?UJ5_.J'-\%STSX#Z@8,W
M./C.%J(1B"\2ETO3='#(WCZ39JNKT S=3335_,#G!,=CKZ*\+9\$A[C<]X[R
MN^6:&';5(2/VLDU^T@6+LO1SIG79@\8=N7UZ7?D=!KU9S48#R?4F9^)^!G]Q
M\)\E1*/!(1GQ1:;J!)J_=2;-.Z!"<[0W?\TT.?@AQ<[@SS@/VX?A@9ZW_2-"
MKGK$Q5YR2DL]9YN;?=JBI&# M+:DS[BMM-6@O:3!^'A>M>F)] KS4XD_ ^J/
M^,('OGW@3"$:JSR"IB*^R%DW@19MF4F+]JM\+SBJ]C'72/U-IHW1\Q0WQ_O1
M?G[7@T.C+GG'I RZ).<.V&<7]=D4EW9;UY:W6[14U!JW5%28=1:66/1F%5J=
M3/D9_,4A&#%./#BDJTC1O'7C:8F:$BW;J_*E1%/M79&!QHL\2Y.'&4XNM^*]
M@BZ%!22<]@W/[/.(S^]R3BMI=<@O;[*KJ*RW;:HJM6BJ*K1L+\FUZ<[)MNU/
M^QG0 '#P!8<0Q#@)\T1IILHH6KAV/"T'A\H]*A\K#ZN]*M?3>%)L;G8GV\[]
M4J)K^*E(G\2>H)"L-I_H@D;WI-(:E^R*"J?BZE+'NIH\F\::+-O6\G3[XWFI
MCGT9/X._.(0QNW3 (7OI*%J\9ARMW#SC6^UNE?>U&FHOJG4/_U%F8GXMU]KS
M3*I3>$^L9V);6$!6?4!$8:5/?%F)1WIE@5M!3:YK56VZ4T-=LF-S9:)S9T&"
M2V_6SX &@H/?9#X:P>R0F2M"<Y=*TE)PJ-D\XTO#KJ5O&M75GC1H'[E3:61Q
MH=#"\T2&?7A[HEMB?91O5D5(2&%10$Q9KD]*58973FVJ9UE=HGM]?8QK4W6T
M>T=1E'M/]L^ !B+.\IO$1R.G"=)4<,A?(DG+UXRE=9NF?VS9L?1EZT&UARU:
M1Z[7ZEN>*3'W/)YC&]:8XI)8&>>551095)@=$EF6%IA8E>B761OG6UP?[5M7
M'^;96!/FW5X<ZMV=^S-@<? 'AVAP2 >'PB42M'*U'&W<-.U]Q_8ES[OV;[[?
MKGGX<J.>17^%J4=;@75838938G&21U9.K']A:F1867Q87%54<'IM>%!A?4A0
M34. 7T-M@'];28#_\;R? 0WB<(@!ATR,E<5+Q&G-:KFOS1NGOCV^;?'3OGV;
M;Q\_<OA<RS'S[FICC\9BR]#R'/N$O#2WS+0DGX+XN)"RR.B8JI#(E-J \+QZ
MW_#*!J^0^CJOD+92[Y#C>3\#%H< <(B;*D"SP:%TL3BM6S7F<]O&*:_ZMBUZ
M>&KOQNM]&AJGVG7,V^L-W6LJ+$(*"VWC,[*=,Q+2O0HBDP-+@Q*CJGSCDFH]
M8W/JW6++ZYVCZNM<(UO+7".Z\G\&-!@< L$A 1QR,5Y78/YN7"7[L6N#XHN!
MK0ONG]VS_M+ H4-]Q[7-FIH-W,IJS(*SRZSCD@J=TJ-R/?*",OU+?-+#*]U2
M$VJ<4C+K'))+ZFR3ZNOL$UK+'.*Z\G\&- 0Q;Q#B[B3,G?FSA]/J12.^MJZ4
M>=.[?N*3LUOFW;ZT2W5P\*!ZYXFC)C4=>BX%329!J356L3$5#FG!)6ZYW@6^
M1:YY(>4..;%5-MGI-9;91;7F.8TU%AEMI5:I7?D_ Q:'$ 4^F@H.1;,$:=U"
MT0^=*Z2>GUH_X?X5M5F_7]^QKO_B@0/-IX\8E_4><\KJ, J(;[:("JVW3?:I
M=LERK?0N^'_8>Z^X)K8^4'NHBKVW;>^](8)2I$GOG1 20DA((R0D@0"!0.B$
M&GKOO1>EB"""H@(6+-L&%L2*B@6[_K]QO^?BN]C@OCP7Y^+Y>;D>9ZV96<\X
M$[WKHJO9-4EU'C4Y#;2:BD9J34L#K:*KFE[:4_I?@-@5TA"_7@[RM\I#[9Z9
M/T\IS7G7I[YX[+KNZN&'!GNN/C+7/GO/SJ[YNC.E;)#(S[Q "8OO8<:'G>&F
M!YSVR_5N#RYFM465TULEE>XMV=6DUO(:8NO)&K<3W16D^G/%_P6(0[L[:9TL
M%&^1@Z;=\I^[%16>7U:;?W]$<^75,8.]?6.FVFT/;6VJ[SF1\FX2N)*KY."(
M088X\))7DO<%WPS/\\&YM'-1A:1SDF+7WIQ2?&]9F7-O<QFNI[<8?_I"_G\!
M$E"']#6R4+%)%MIVR+ZY<$!^^.ZA65>?:/UU_I7^WHZ7)EKU3ZVMBD8QA+2'
M!&;,,,57=(\I\KO#B_*Z*8BG#XF22%<BTUP&XS.Q VG9F/[\'(?^JAS[_O8<
MQX&!C/\"2-#VST'WE'7KI3^=V2+]^/IFF:NC!^><&]=<T_Y.?U_]6^-C):\M
MS3)?83#Q+UU)8<]IS(!G7CS>*-_?\V%@$'4X--3M7G2$RYW$*.?;Z6+,K?Q8
MAUOE<78WF^-L;G;_)R!YJ304KY2&EM52+_J725U[M$;ZW/B!>>V3FFMK/Q_?
M6S1II);YT<(@X0/&.OP#T2GP/</5YQV'PG[CY\%X%<1R?Q'.(3Z+\79Y*N$[
M/TGWPXSF^CN,E@38/:X+M'G4^I^ ],524+-$ZD//?&3H]FRD=WRM;.NG PMK
M?FJL+?RILROMAX%RW ]SK; ?CH8!/X@6/C\\[%C?N1CZ5S\<Y7,PP6TR@DCX
M$$O"OT]R=WZ70<%,Y%(=WI;0[=[6,&S>-'O\%Z!H ?*N;0YR^:("TOM@-G+R
M\SKY:CBX*!]4UR2#UK9HT#\0#&9'_,#A& =<CS.!84@%C@D9_,R)$&3I N'6
M.(BQP8+$%O,KW=[Q9XZ#_8]B1]OO51B;[PU._X6)NIG(8-<,Y,S@3*3YS3SI
M"M@P,P\.+)2 \JH(T-@8 ,=W\,!T/Q-LE:C@<H0$-#4"L#7PX*.)A4!M#(3J
M.$*4KCW$'[>#9#U;R-2WAGP#*R@SM(0:H__"E599I+-'#FF\(8^4_EH@DPV;
M9B; GOFAH+C,%U17LT!G(Q6,MKF"U4YGP.[! &F_ W@<L ..H@WX'K*&0"4K
M"#UL 5'*YA"G8@9)*J:0<<0$\H\:0^E_HJM#!JF_)(,4W9>1RH!%,O&P<:8(
MML_UAGV+/$!Y.0F._84#_;4.8+;!!NPW60)^BQF0MIH"8YLQL+<;@?<.0_#?
M:0!!._4A;)<>1.U"PVRW+B3OUH',/?^%AK-22-$0@J2\DI&*@<4R0;!:G@N;
M9E%AYSP7=%TXPM&EUJ"]W P,5QJ#Y2H#<%BM!\YK=(&X1@?<UVH!8YTFL-8=
M ^YZ#>"O5P?!>C4(WJ *$2@Q&_\+X+=&!KRWRX.7XFP0*,^'T&-+(=)@#8BM
MMT&4RP$(]U %D:\N!(:;@'^B-?AD.@"WT/D'NYSPC5GK]H7>[/Z9VDZ=I'33
M/Y O>+PE#GJ.$ZZSGN&'V8^=QSC#3D__R/]S^+_) ;U7^&R3!^[!V2 \/!_"
MU9>"6'\-Q%EN@QC< 8BBJT&8CQX$AYA!0+P=^*9C?_#R"5^]2DF?/6NHDXPF
MQ@=:F^=[RAGV!/D"9]QMD/><<,-[%#_B<\]YU/>F\YCWGP#__^/@LW\6B)3F
M0;3:4HC76P,2\VV0B#T(<11UB.8:0'B0%02+,3\"4@A?^#GND]QBC_?L2O8$
MLY[[AG[29YS:Z??2O2_@&>FR\+'KK: [^.'@J_B'@0,NH_Y_ @2H Q_=O_BA
M^[C?[X+$JBX!B>YJ2#7;!BF8@R A:4 <VPBB VQ_A47BO@9)W#_Z9S(GO LX
MK[W*^"\]:P.>,YJ#GE([0IZXGP]_A-[([[C^'7V%<"?R@NNPJ)?X4/@G( !M
M?U_40;!WUC_O@B2@G96BLQHR3;9!AH,BI!*/@81I G%^]C^BPEPG0^/I$X%I
MG''?7+_GW)*@,595V&-&4]1#VJF8$<KY^+OD:Y++KM<D?6XW8[I)]\)/DX=%
M?^(?!S_408AVMQAMG*2CB_]Y)R;'>"ODV"E"%D$3TABFWR7>F,^QP>3WD3&L
M<5&R[S/_K.!17F'D W9%W'V/!LD=^JG4OZD7,@;<^K/.D2ZGG7$?2FRGW(X^
M2;T7_B<@$'7P1QV"=RE +.J0@G96EO9?D&^T%0IL%"$/K_4]FVK^*8WC_$X2
M2!N/B>0]"TL,>AR8'C7,ST^\[566-N11EW.%T98W0#^7W^/>E]]!Z<]JH5U-
M;F3<C*UCW(GZ$Q"(-J\_VKPA.Q4@'FV<=+1Q<K7^@B+#K5!JI?BSV%GK<X&[
MQ;ML-OY5FK_'6'R(WTB$./QFH"3Q"C\C[1*W(+N/79G7X]E4T,WL*FJGGRMJ
MHE_(J_,83*_R'$JL8-V*^1,@1!T$J$/XCID@V3<'LE"' LU54&:P!2HM#WZM
M<-+Z4.IF.5[()(QE>K/N)P8*AZ+"Q?VBV*1S 2D99_@YN1V\DH(V3FWQ2:^V
MDD963VF5Y_G"<G9_5C'G:E(A]T;<GX"@_^/P^SVM9+2S<I070O&QE5"IO_EG
MK?G!3S6.6F^K7*V>E=)=1W*].$,I?L&78D7BGHCHI-/!B9DM 1EY3;X%174^
ME:75WLUEE=[=Y46<GI)\WL7<7)\KJ=D^0XE_XA^' -3A]_M)J7MG0][A!5!V
M; 74Z&_ZWFAVX$.CO=:K!A>KQY44MUN%+.Y AD]PCT0H[A"')Y\(C\NL"T[)
MKPS,*2[U+RTK\JNO*/#MJ,CRZ2[/\.W+3_<;3$_SOY;T)R 8=0A$>_/W.S'I
MZ/E9B#I4:*R .KU-7TZ8[I]HL=-\=@)G-5Q+=KM:PN2<S^$%G4X5B$\DA"37
M1HNSRL,E^46BS)(\85%Y5F!-97I 6U6R_YG*I(#SA9+ @8Q$X=7D/P'!*__G
M\/M]E,P]LZ!8:3Y4JR__U7A\XZ=6D_VO.VPTG[0Z6_[=Z$;LKV!PSA1P@EHR
M_<1UR4%)Y?&16871\?G9$6DE::'YY<FBBLI$T8FJV. NE'/%,:+^K!C1E90_
M 2+408@Z_'X'(GN/ I2BU^M:]64_3AS?\*'#>._+;JMC#SN<+*^=(!+/U]"\
M3I6PA8VY/M$5Z8%)A4EAF5GQL?FI,2DEB5$YY;$19571$8W5$1%=U>'AO241
MX9>R(\(OI_V)?QR"-LE!(KHF<G<K0/FAN="@MO1;J^ZZB2[C/<_.6:K?/X.Q
M&&PEN';74]@G*SP#JPMY4<4Y DEVNB@S)3DZ/SY14A(=ATY+;$E52$Q]=7!L
M9W60N*<T6'PQ)U@\F/XG( 1U$&V4@R3T6.3OG@E5BG.A66W)YPZ=M6]ZC78]
MN6BI>K/7P?Q"APNAH]F=U5#C$5!6QHG*+?25I.8$9<1G1N9%I244AR2GEPN3
M"BL%DIHJ/\FI:K_$GE+_A(NY@OC!]#\!(6AWAVZ0@Q34H7#73*A1G/VK1771
MQS/:JU]>--S^<-#\R-4^>[.>,SB7EE:29U4C75!0S8Y(+^,G)!2A%\O\L%Q1
M3FQ10%9J&3\COX*7457)R6BMXJ3WE/)2+^9ZIPQF_ D(11TBT/9/0^>C9.<,
M:#@XZ_NIHPO>G=-:^>R*P99[0Z8J_?VV)J=[G7$-G41F22O-/ZO1,UQ2ZQT?
M52E(%96%9/L7BPN\"Y-+V 4Y9<S\B@I&P<D*CX*>4L^<B[FL[,'T/P%AJ$/T
M6EG(W"@+Y3ODX<3^F9_.J,Q[U:^Y]-%MO?77;QL?/G?5QKCEHA.VJL>5D==)
MX2>W,4/$)S@Q(8U^2?YUP1F\FJA<SRI)(;TRNYA2659"KFPN)5>=*Z:47LJF
M%@^F_0D(1]L_=K4LY&Z0A>IM<C_;]\F_[3L\:_2&QH+;#W36]8\8'>J\9650
M?Q6#*;[D0DT_3_:.[68$A79Z1?F?XB=PVX0IS):(3.K)A!S2B:Q\U^;2 I<3
M307XD^?R"0T#F:ZU5U+^!$2@#K_?3RI<+P.-6V0FS^R2?7KE@/SM$97Y V,Z
MZWL>&RJ>'+'4J[CM8)\]A",E7';S"N^G"0076*'<\S[1S-[ >$I/1#+Q;$(:
MOCLK ]M=FNETMBD+TW,NTZGS2@JV?2CQ3T#4,FE(1=N_?(WTK]8-TN,7-TK?
M&=XB.S"FO/#L2YV-+<\,%*N?F.OF/[2S3AYV=HF\2Z0'WJ+Q>#=8 <PAGQ#W
M:\)(UZL18MS5Q#C,U>P$AZMEB7973TALA_H2[09OQ-E=N"7^$R!>*@TYRZ6@
M;J74Q^X54L.W%R(#8UOENM\H+S[Y5GM3U6O]@P6O3#137]B:BI\Y.XB>D@B^
M3QA4KR=<3\:H@.O^.)3O^CC6'_<X)=#I86Z0PX,RD>U(0XCU2&>(U<A0B.6=
M^Z(_ ?&+I:%XL=2OUD7(K8'9R,"3A5)GWFZ=<6)296GE1\V->1_T]J>\-U:+
M>6>C)YIP-O>;(-MQ)YA8YEMO O5MH!OI;3B%\#:.AGN3ZN'T.M?3X54)R^Y5
M+=OF9:N7U<L^CN6+FW\$TA=(0>T\Y$:W G+QB@+2.;%(NNGKMED5WU66YG[7
MV)#T77=WU#<CI>!OUAJ^WYR/>WTC&WE\\S2C?/.V<OL6:$OX%FZ/_QZ'P7Y+
M=<)\S7&V_U*"L_U<[6+]^03!ZE,WP>+3)=<_ 46SD5NM\LCYWAG(J1L*2/V/
M)3*EL&-V-B@M30#5M>&@O34 #/?RP/*0)S@=I0))@P1,+5?@Z>)!H(>%$ ,,
MB T=(,G8#K),;*'0U!HJS"RAP=P"3EF80X_EG[A;)XV<[Y!#VB[*(37W9B)%
ML%PV$W;-CH,#BT) 994O:*YG@?Y6*ICO(H+#/CRX'L0"_1 &O X[ %_%#H1'
M;"!<U0IBU2PA1=T<LC7,H$C#%"J/&4.3IA&T:?V)"R>DD=9N6:3JJ@R2]TI!
M*A56R8EAZRPA[)G/0X\% ]17D4!W+0Y,-CJ S19;<-YF!:0=%L#8:0:<7:;@
MN]L$A'N,(&RO(<3L,P#)?GW(V'\<\@_H0L5!':C](ZWMTDCE!03)N8,@$I@C
M'06K9 -@PTPOV#Z' OL7N(#*$@QH+K<!@U7F8+[:!.S7&(+S6GT@KC\.U/6Z
MX+E!&[@;M<!OHR9Z SX&X9LU(&:S.DBVJ$'&%E7(W?HGJKK1\:\B2/PC! F'
M>=)^L%2&":OEW6"3 A9VS;$%Q?GFH+K0$+07ZX'A$FTP7Z8)MLLT +-<#? K
M5,%MQ1&@K%0!CY7*X+7J,/BL4@+!JD,0_)<B1/YU$&+_"+#6R@ #O4]0%17
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M!RZM!H#K-@+G?F/ WC7]AADUFW1\:3YA_\[BE=TGRV?VW\V>.(#Q(T<PG K
MH_LW#.I 0O?3'FC?<)3F@(_&0N ;+ =?JW7@X[(-N,R]P/)7 H\(5:!)M, ]
MZSB0B@U_$:M-?A*:S;Z[=%A^PYVW_NI\PW;2:=3N+>:EPPN']XYCCI_M'F*^
M6]]S O._G<!T*L %=7#^_2QHASRP?S\'^?U]DMH""-!;#H$6ZR# >3OXTO8#
MSUL%V*)C/SQBCW^CI1E_<<\S_T0JL_[H6F?WP:75\1V^&SOA/(A[C7WH\APS
M3GB$>>]RU^F3TW7L-_LKSC^M!W!@.15 6"<#+MMDT<NN'/#0[A8<F 7!1Q=
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M\1M@OH >5@KJ8,L*+>Q=J8F;5VK@7B%U/"NDA@^(MTN:G 382,Z@]1A Y06
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MPXGT"&YT2.'[85_ _\VN4O"+;>/*3S8=0A^M^X3?6P^+OK6:$'UC-2WVVO*
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M%:U"V7]8)')^,\]91DJ!^Z-I'<][TU;>MR;=?*]-^I>_,A[E?V$\Q?_<>(_
M4^-C D^,+PD^-/Y+\*[Q>\';)C\%_C!!_M]-<?DUXC=3Y"-X_PG-1<G\%8!T
M 4#7E13T6/B9#')'/'2IZ&;)],/9F>6SHS_[>X<8KM=VZ=S/;0OYGMJLYG]D
MW2#PT*I]Q7W+WI7W+(>$[EA,"-^VV"GRA\4AD1L6YT1_L[@G>LGBK>AYRQ\B
MLU8H=,8*5YZV1L%3UBAP<A&T)JWO2)K?E32W-UF'GRB@OQP%_32HWWR-:>^]
M[%E>>GBS/W$+XWK@DLA[QRF'_R:]=,7O#C5"O]DWBURQ[Q*[9+=!_(+=)HES
MMELES]KND3IM>T+ZE.TUZ6.VSZ4/VWV5/&B/XC,.*+K?$87W.:(0L?*?T([,
M=2'SO4AW^B\\AR![$BH!<Z%*E+?!NM2G@99,]_W=V&[Y!BZ[YAVS_))GVHIS
M[OG"9US+Q4ZYU$D<=VZ5.NJ\3OJP4[_L0?J8W Q]N_P^^D&%O?3SBKL<_U*<
M=OHHO]T99:9<4'+*%<6WNJ+H5C<4^2=T)',]2//[D>X,(>N(6 Z_HH3@7;0T
M/(E2H]R-,*%=#Z.S7@SV778F()S_A%_BRB.^6:('O8LD]GM52N_Q7".[RZ--
M?MJ]1W&[VY#2E-NDRA;7/:H3KB?5QEUOJXVZO549\?BE,.*)LL->*#7LC1)#
MWBC^3^A,VM^;M'\0:?\(TIZQW/ YG@^>)0C!G7@Y^"U.GWHNQH[U1*3GLD-A
MP?S[0V*$=@>EBNT(R)6:\B^5W<*HDM_LVZ@TYM.ALLE[@]JP]ZCZH-<.S7ZO
MPUH;O*YJ]7J]T%SO\UUE/0,5>OQ0EI#N\4?)?T(WL@<,TGNAS/ CAA7>)K+#
M\V0N>)#""]=2)6 V19MZ/,F*]4"\Z[+=,?[\VR,CA+>$)XJ/AV9*;PHID!L*
M*E<<"*Q5V1#0JM;KWZW1XS>DU<78HM/!V*_;SCBGV\9XK-OF_U6]+1"5VX)0
MOBT890GI?T(/\K'[4TG_4^%% @7NIC+!'QEL\'L&)YS/$H7CF1K4F71SEETI
M3LNF$GWY-\>'"H_$Q(H/1J5*;XC,D5\?7J+4';9:M3.T07UM<(=6:_!&G::@
M<;V&P-WZ:P)/&]0%/C"H"_FD51>*JO5AJ%0?CO*$[#^A%SF#((#/I+?ND^[\
M3R8-KN2PP,5<=CB9MQ(.YJE0=N68,$]E.G"-I7DM'TH.$MJ8&"6^/CY1NBLV
M4[X]ID"I-:I<M2FR3J,AHDV[+GR];DW8)OW58=.&E6''#<O#_C0J#_^@6Q&)
MZI51J%P9C0J5,2C_3^BS< ZD_>,!;I/NO))#A7,%S'"ZD!4.%PG"GB(ERK8"
M0^;Q/#O.H6SWY7T9_D+=J>'B'<GQTJU):?)-";E*:^)+56MCJS6J8IJU*Z+7
MZ:V*&C(HB=IF5!1UV+@PZG?CPNBW>D6Q\YK%<:A:$H]*A,(_(8-&[B+ 7TD
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M<3^=1YX@GY#/_Z4>]4M&>F## .$8N]<9 /L+ %-0VPBU-5%;\2Z S$, X0<
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MP+IH>)]USO U^XP189]"3B _(<>-"&LT9!+J6Z#WMD3?;RW$)85CLL%<3#.
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M&<LT_3/6:OMF[-+QR3B'/-7TR_BBYI]!5!"E@ RB^(/;>.0\@^M@/]9@6R%
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M@O#R'N0:""^^!.$O!(07""4\_S<=J+\(]2LQ]SD8>SS&'8S:[@=1_RC E)\
MC$\#:*,G5[D(('>%"<);DB"\+0+!'25$"_AWC8%W=PI(WIL!$O=F _?^'.#<
M3P'6O7)@WEL"C'O]0+MW!*A[:.3OOT?0O-_[FQ;4KUKW[3FD!(P]&.-V/X;U
M/PDPZ2R P04 C4L BK\#2%\'X-\&D'S. >Y+ ;!?R@#CA1+07F@"O#! T/._
ML$'P4/("-^,7N/!?X*)_@1/]Y08$W_C57>0-\O&_U*!^ <ZYQ-VX!@^A_@D
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MK=LM<UAW3F:_[K;,?O1SF?W:W^7VJT4%5BEPANU^B'6?H 1:3\ZA=?3!!OJ
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MA&UVAX0M=N>%3?8WA8WV;PL;'.X)ZQQ%V2BQEEBC@"#A-V=.>_.!][GDO10
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M?2 V/(3?N-Q\:TM^)W+/ YYUY')@#5PW4\450WT\,LL"9XQ=<=PD (=-HW'
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MF]4^NECA:X*E?G98Y.^! ?] ] 5$84% (KH",M 9D(_V@#*T!M0*+0&M0E-
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M5;D'FI6/0*/R#O$5-"O^@%:Y"&UB%\O?),GS3K9#MV(?2I/R/I3T+O;%#OJ
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M?#EC!#1]#J^3^#QV,;'(=R7HETE1\=@HG/N#T,MOIJ\\9I+XC##(CS"PC3#
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M<]6<Y/H $?0*WOO$L>O-G()L7I^B"_D>P\RMP=*UO%Y-UW;0R\Q_P/OD#FX
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MFW0&>:K)/T -/E;5>H>KVB=653[)JO#-4+EOGDI]2U3B5ZUBOR85^HU5@?^
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M9SN1 "(>?^II$0" Z2^W#K#/ B8O9!8 1   UD$ 4 X 3@*S'/, X%@5L)$
M@+0$"+ #@$(@< L?.$KP"2-QCV_!) 78Z*F.'24_0<=60>"I;6U,]'6VM32W
MM/>,?"4*[.H_3O-=Y>,[V3K1GJ;RYT[L\21J7<ZT%SOVZX!2'2%BQ[K_GCT$
MG2:RKQY'GOII3/H2 D^8?QZTYH1?((4WJN4)"K%^^,.>9Q@(".,#-,!DS2O
MU",!QBAQ  "4"@!*@4 H !@" A[ 1@(!@A"$$@ 0Q >2 . &$' ! 'I H ,
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M@I0X3@OY#W5%3_WCC.1= G.M+<?//Q7PIK?UD![_QSX(V+&& $<D* H?2"$
M #N080+@"J -!+N#4P! A. C9O"!&P0 H(+A20 4XP,9!  @T=),   .K+VG
M!@+W -V0  (V , 2".@  (+-W%4 T ELA @ V-(" !Q   4 :(' )TU\@ 0(
M;)4!MG/ BM765B;>J"1827%JE-LV'*3\A4="W>+1#J>+=_63/F*)GZ'XTODL
MY+:>Y%FR[3]=3:#:>S)_5.U!%'T <\TUP'!(Q+>C"&)[P):6(.X&">$#!-E%
MT$% T M,<8! @%0M07@ 0N$#2 +@(3Y L$T";MVK"0# !F/Z&!"0 +@2F.($
M<0$ X-0D"&* VP?0?@"01=!* /"6"0BL  A=(/ . "0" >"Q_!D%  !8:K>V
MG@)6*<+XP&4O'D D>>_R\TYIOQ(AL(6"6SC>#XC++'_SIT\_[^IW+1*MLG8F
MNVB)<C S4),?( Q(M[+4\6_?@'DS@5__Q$D0'R#(VX% ^*UH)00 A5I@;1$$
M A2#50D 0/'P(0$@B@_D$P ,^,#@/B"P%^ H3H*/ .RL"5L)&+>.! #@<958
M @!03JHY" 2R\8$/!(M4#* ;YD  N,%(!@+ >M,X,$VB"P"V@@_@ \" <6O>
M !\ !HQ;6TV*^ 0!L-6,VRF1G63ANZ1RP]$_G>@S4KW3P-5Q5_\%S7>WUE>]
M*BTN>):-S@ >/AAV@UXZSTQ+<?CW%1^_L.=$,*9!^&<L"4XO@$!(_*\@&/0@
M67Q A0"@PP<>$WX'?I&DDA# [\8R+0$ R X 9P4(E((/6!, @&QP, $ V-L7
M$P" O?W;,T  B@]L >_MH$L X#80 $8Y68#\ X@: $S+ #\"  #/S! "/<!\
M\3<@D<Z##V"!P%;4[POV@9/<,C>(G![*,'9\$!276=8ZMOM8WW^CIIN+T?'A
M@;Z/[KO><;QE8V&*OS$OMY+GIL4?<WSX'P <32#0/GP >#8))_PG* () ?P8
M!7C &D0P>3D( &M\0(< 4,$'O @ 0*A%<%0$Q(@/=-,  5)\X(LXP4?@ UNF
M?P40N@H E!.LE._Q@66"Y1JX:25(HU8 @!9@5 JL6&T% UKA @16'/'&%(4!
M$-B:<:0\?4Y8!FJ$\(Q]WDGT)2Z],W_U=KA=_?NT^7EU>6EA?GYA&?]Z?WZT
MM[.MB9ZFFJ+L%3%A?NZSS/@)"$560-D.F)?W(1CT@#LO81$%)([?"(+ ')@=
ML"'\"'R ,,<! !H)<CD@_&K1,H0 >(?_$=<) $ ^V8,  &0'T >  " 1VT5P
M5@18% >62 G2!Z' B!!8D&H%K@\$>7/OX_@  Q#H [8""&Q5_+J.D3.<DU"W
M\DHE\A!VE>OCF/2BVIX9@O!E5_]A6AKM;6^L?E5:E)>-3D]+2\>O_+WRLKVN
M=/D"[UDF!NKC1TBVAP45'M"[GV#>  :4("& /WF);*0Z\8!GA !^$#-*4. $
M1> W0HT  -2"";,]@!W(4P) #1^H9P8"8@!/*P(!=GR ,(]R'  D$Y1R $"?
MTE\ 6S[ =# 0:(;^!;"5^OO)_\.G!%6LB1Q&CQ:14C.PNQ?XM+!YA_<;S>^^
MV.C_AN9;2K*2HH/]O1YL;X*L+<S,+/"C&$,9?N:3Y'@W5_PCE&X$,P^01R$L
M@0!J()L7" !^_%82'-, ;OZ!CZH1S(L*^K\ I@@W:P!7$519@<"3O7\!E)P#
M H P?H:@B@)\9C_X)  H!P!-P/4A'@!L1?V4PCC.(6M&\/S"DOLI,KJS%V3A
MEF[AN2W$7HXR_113TM WN_N@W*ZV]>W3A_FIL7>#?=V='6\Z>_%37FT)?J[V
MEH;7-=64Y*4D1(7X>7GP\RB=K!0$11#\SR>21\$'[OT5\(Q@HP6(<H8)SXH
M7G9A1   #D#Z$@" P^BY!$54P$/]/00%:> #<P@@ #PIGG06  "2/5M=P"5&
M  !L1?R<X@3SJQ,444<0E"#0GF.G>26U;OEG-!!YC63333NWP(1GU7WO"6V[
MVM7?T\9(9\/KTL)G61FIJ,3XV-BXIX"W97B8:"I*B0F=YV)G.G62DOPP";#"
M27@:#5# ;&$D /SQ@$V"!TF 3W'<)P  .Q T00@"*!:_(5CGF/&!3Q9 @ S@
MJB J( $ 7A <)@, D[; Q1@ ;"7^'*X=Y[U&\+C+,.)'*P[0<%[10885$7FK
M6+F6M(8)TBLFMV&GY[,[6T>7=S#M:E?_97W=_+))F!5;*LF(CPCR\_)POWO'
MR1'A@+SCCE\,FE<5/7_V##WX^)&#OP7Y@+E)N#L 3)Q88/T2"#00AB#XP ?@
M0SL$<]./X$@L 'A&D.X! %B"3"S05YYT^/9]P/M_WM6?K"=%]!X /V'R[J^K
M+=D98?6;005$WKY<IL4A<E7'YG[DL]8=3G 6)#RO[=WYY?.[VM6_5U_>3X\.
M]?=T=[YY\Z:CJW]D'O#N]!=^;K?M;2Q,#/6O:VO!X=KZIH#'?BOX3E,?)\7+
MU^(#BX#STR""X^P>)$  <,8RDZ &4H /= (? P'%X@.?70$%#."9N2T4?C9G
M/Q?PC5W-AG_D2<C.77-* /XAJT\!YW\8CS)?A#M%$WL%>[7Q2<Z+2@:. >EU
M.YS1S'"/R"C[TP.<N[617?U':;BMMJ*\I.AY05Y^?F')ZT8L,':.M#'1UX:I
MJ2HIR,O)RBM>TS8#'$](9R,_B)^CU,0'VH"G]H%;E(_.P$3*&4 C$OD! #D
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M_[,ZOGMI]]+NI;\3*N3KM3G$^"60CMR+&6.H14='.6@:%=SM\7MI,<N/W+Q
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M.MP:@R$XOW$L@RWZ7CSO2E43$!=M[^?6[C5#^G9873%B>UX3C(%07^>*C,W
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M.N>*#5:> ]98%1S'+;<;E5RQ)?U"_SC0W9HFV7I0]2UZ8^7K(;?2$<+(#FG
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M#/;6YI8&I-0"8^[0R5*AH9QP?#@,LTT7R38=:HKF!O#50, B=Y[B[G9!5W9
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M]P+!V6*7,&X UP.,,5+,E)XD)=W_?,-(!OSJUBTJ*P3 $]5<5)3#(9"5%Z&
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M]0$T/Q+/ V^X7I)/[-PV821(X3 DTZJG\ 6-$?NKO4!75]!LOEK019_[_XS
M_Q>ZVD#S;DN-HO^+O?<.A//;]L8?(H40489H$:/%"**,3AJBC-%F#*+$:#%*
M] @B4D0+HG<2=<PP,AB]E^A$=$)TP1 M$E'R2\ZYYYSOO>]]SWMSS_N[[<WZ
M<YC/_CQ[K[7VVFO6L[:9JD"XD'11_E7'$RU/DGVLYZ%Z?OPP5@O&C42C"E3A
M$LH'>S0VDA S,57O=0@R"@7?OW\NL8T/Z9:;J502EU1U'&V2=>&SXQW1-EI/
MI1H1"_"K(O]6-I;%2;]W^<[S$SA(3E3/3:B>!N5GAUV3(7U^"&(OZ#KAAAII
M@^5TOVGK^(@";9PAH55U[FNQEZVT(7]'N>E#.SCQ:,]PBS!>"T/J[(DW.20N
MJ.[R.]+-:VCH5C_"++ XIX9W/-M!7SDQ%Z&57*W'BM[ S"K;.5:M5K?-]<:=
MV_,8T&'U@C[F@Z)LQ%T,W/:J,P.68,T!4>C,N60U& Y"^'!\BI[^FOG%\:&'
MCKU1/P*MPYP9RS:QY$2U'W[WV..:,!T>>PCC@[87:VS4LEHT3*!"9UF"<FM5
M<OH-E-VLZ9M,[W$2S@X)"QN<3)Q6BSH] S4)"YW%Z:]@-B_NSJ8P!'^1L#S$
M,Q3 D#W^V4/SIG%?GPT068FXD%VW767T2$,UTPXX]_+(._7#%U!OM]@D"%^9
M%I<D@ZT5-#_H<6B%U>$2I"@M5[F)"'V/.S3O53_8$UT:R1%W5JHI<%L.Q2<\
MT3M^_E5L+\"([#3Q44U.P2N3I(I[(L^PWS"=^!"+);2-9FZ^"BL3%YT?4#$)
M]QC)6J\-] DS4)2S>C[D)J!I]8A+6PD,>Q/<AU["QW3C' W8#<[F*!:WIU#C
M/HE)QVD116(*8'*"\\F+UX)2W)9,DD<3,R&"@N8<]#(9Q<Z3'3/CD6OI#X-T
M4G2X)4)%[$VWFJG4-8M:I85.]_6\R4A/3$GR,O7>Y *MS[D1(#X*'JI5Z-#[
MKY*0!HCN+GD!ZL<NC$HT@_T+SL]R5"*E"_-;4?/7?OAS(N*'/^^8&\]5(BL,
MV0WX\.Y;P<UU=JN=/S-$2L&VB'*AQ*A1C"R>34E,F^21--:VN/ 25LQW<QH?
M/6CF\-C!0$MT$G4)I:JXS5CX3V?;R'__V38E.1"7]:8R"<,L1S+!@RIU)76&
MGB+O%3<+VL46W3VSXT1=+WY8JYC&E8^I59E3_;'EQ6%;^X1?#[KLZM?+V.+=
M/@MQLO IP:W*E/ D_)+4%A';42Z]NHLSJ9;&S=S@'8_ 9$:_'RJH#C,,3RIU
M@R>D-DK$;<SRQAD8LKF0*IFZYB\+-8_+9DR@"ZV69T38ZL-]X^?=CCPN9X$E
M#5#,BI+#=8UCW_S><PAI&FV[6LHS\2Z^3Y)3KQ\)F9DI0@O4*+;$6MK-(YFB
MS*.8"!DM;K*X(Z6*1!)G?9HB+@LL9R#BR0D='Z=YD%:D%FD4:YS/%G)/2P4-
MY7XLG%PQ3\C955#,S>U_4QF#$2+)P^!UD(H1^W)#DMKK#@;<XHHI*Z?&Z?+U
M\/,Q^9>&(LDE<MBO5JTQY"MO.V9WR[\Z= P4*BNNIEZZLC70=B@^PV'9:AY8
MX41(C0_DI]C:&5-!/&V;CO AC$ $L@>#@U/9O_:(I)0<GDE*7C+)2T,)\T8D
M!B\&;B2]^&E4SJ+QDP87/3K&15XY5%^W7-EM41,>3U(/=S<=''F<*=!BSE@V
M./;E[HCVZI4%[JA,4UBRTX 4JD<8W8R"R%7K;IKS#06NPX1\N43QTA^7&?FL
M'1%J)2?!Y=^T?=T\P;>U'JG=8X/:Z BDOL^P8V.R>I*#7?AV./0L2GQC1*^X
M>K\S)NK5/9HAS2I,^C">IT6-]^#,C?%J@Y"'1]ER$Y"J]<VOVSD6J:]CN$63
M[6?7U5YGJVL2.M'3N<MQ"CEY;XR7C;W>)&(6^*2><'5$R*XX'%"6CH^/\#Y"
M+'/+[KMEAVX*I3,_&)YA,SAN\*P&?__\J/:-0!JFG/P7K!!F05%1]S*;ZB><
MTH(G2G3L'%=<EI.2AO-W]R#S\SW+[^22>&ZH";+G5U:=1MXL&<21V6O&NUH2
MU6QCI+XL3(\(?M9S&4]Q&4?](042_9=?0<J$.1><J5\_IR.=T-<IB<=%"GK$
MF5SJ'B_.8T,O3B^F5QH;6<Z +=M(,-ASA:&E_C__[AAS6#11JRJ[K=(GS)2(
M9^,,P48L@]A"M35-_%7WF"0^J3_W&FR5/7A6.X&8S'0:Z8$@D%)(T$T%\']N
MGCF(^K:38B#[8*^.H?6P+=R+65W/,DMO3T['@=AAIIE^AILM/RW$[7-PYI")
MMKR.'3A7:>5.)13%&?U3U<%0%X1"[X<J*1]X=HGAE>+NQ:R92!:=U]^!&V)A
MXQ]FB@3AI5^W"S=^?-"EP[U3<FKB#&1'I-G)8[Y4Z")]0FXG.%O@"I7[D%>E
M'E0@6T5E>N2-O>-DQD>/[A'Y(<652F-.CY:;4C\KM4U1((,@J2%4P+]G-_]W
M-OF>_@.$R.A$<Z9\5V/);MVU_IQIL#2GBJTK;M#,*%<V,X_]')NOQ(%YZG-,
M:=(W*<<%O8;9]39>IIEJ(=/684?)+]?$#B]=-!XI-Y$4L!\]@ \M\TRO^50*
M>'P'OOKW?FZ.L(!>R;4X>K$H!MZX@%K>N#@H!(W):D28@K!#_N=;&?+S"^%B
MTMVG)Z[8#D4BIFH-27U+0R?@"-.(XPS9HH'T_$C3BHJ('D^!J_^[&?B[%VG^
M[5M4*?=8'\&S=>=T13AC<H6(G L.R8/^I]8*W5$8JR+F.7&O9SV5/F0+HF&<
MF)6-@:JB6?L\.H0..:9M9KNOY+Y2N8#F'6EN[TB>**=5BFQ]G=\X?O#AJ'Y-
MNL+O"/-0^SLP?"+^O3F_/+I/OL^8[7A,7GUC"(/1\]:*6>QP'OL:<KCJZ^:E
M&<>NV,F=Y\FD?- !SC9"=-">IOE9I;&.*2(LO/6$[M]=Z5]ZY^R7Y1>;%OZ*
MH)-W@]+T>F<_?=6$DJ._,)(LIIN/W$^/D3D6E;5P]],*HP^&LOQ;3ZY+57S]
M-A[P#XU%\?ADV9OM5T-_;NP<+&HWJ;S[';C?==B6U*N?\P]>LOQ_O^O+7V1-
M--DG1+/TL+]4TCC8[>W0;7"3[U:F:($?LUE(9-NC%)+(AVJ[,"+[:E]/SV>3
M%ERH\ Q*L0N<%9<(E4Z>:"CZTH59PM$BUSR]G"DAED^E5[3-S>H\]1UI[ZH1
MM2N7=@_ZY\WFG+4UFYVU&,YX5 2Z_&,3\7?D_X(_^C\,\']HW?T+\MNB_@WR
MW]2B_G^58UU7R!Q+?.6]C[\#4N#3.P=;545/:??/;C+B?LS(%W7?6S7S*+GA
M G?-"V2_ [P/]VD[_\UE7OB_[(O]=T;XMVUJ_P8YP9;VNKXN"+&O9[H4F7R!
M_/@ [_D=.&U=MY44\0^O'T KX?\V"+F=67)TZ@E1YKUFU)%4VW;JO]("_%?E
M'WS![)?D5[.BOR*WD[\#U4??N/K75.^-;5^OC;DRMM1D;_'YE]?Q/U9.QC\<
ME>G5N)MV_.B."NORWH*GQ2FV79Y9?J36-(6;7,\H+MV&7;FEVUW9KAI?F5!F
MF+PER#NNH*WIP:&C<)Q'/R^:2D; A& 095)1;7YN$TP[M^>\DR$5-,6\4YU&
MI?YI<MIO_4,S6]O6Y#+[M:;TF&N,"E^\N17*-]ZX'I3[J+UPR<M^JQ)Q.'6R
M=^U //6AR%14-J?0LA0#;_V]1]O5#VGMN+ON9=N?I/'1_@WV&^S? =8DUX[#
M+HR4&W]1]YO1E*A6(,07F*O.#7!C1*SQ0@82;R?$A775U!([U:OF%'C<AB0\
M,3!QO9_#Q2R^V&]*CTUY&<*U7T.?-O'52O;H5BVONJS!NSO@F_Z?CBUY'9WK
MO1+_2?W=&>:=Y%-1'ZH;]B;KGTE&+E2_DWH2J"3PF._>^H;RO;LSSW]:1?B%
M&1V-WV"_P?Y#P2Q-%YI9(0=VDSS;@1=7OCCC#)]<L7S53#*L\H1(/S;1Z$W#
M9JL&1%HX!DX+P%2FO6IDG_TT/YWD&Y]H?/1%_WL^]&^PWV"_P?X-8 SK*HV<
MV'15]AOSR,O;!M7G[Y2.&789% 96Q,9C<&7,-"D\1! *U,C(<NS/@ ]F=+0&
M_N<\_V^PWV#_;X.!UA$(%"0OU9X^5<@RA>R?#>^J,_<9G4C*MYM).*&D'6FU
M8>IB6* ($A>.7S?X)P_ )QR8U_1LU&6MM<Z*/7B81++-! NTJ/3$_G4 PG^U
M<\!OL-]@O\'^?6"GO@@H,ZYN97@$]=@L)9!],[O4(MD-1R:\&7)!7.?Y(#'L
M'SL3IXL0@6$)YD-_&EG9GKY&:-GGO^GS_@;[#?8;[%\FTBJ[2)T5]W6J;BR6
M7.S<)U29]-[+2":Q%#\LQ[OP<TU\I@I+NFDUT[S!Q+_<4/7F#TD$Y_]J,<]O
ML-]@O\%^@_T&^PWV&^PWV']GL$#W-%)GG:?RQSU)R=Y9$=*4UNB$KU?,61&Z
M;/RE5B\.4)SQ8,3P;6P%2<+@N A]9$[ SRJEO3W#'666WL-IJKI_>ZT SZVX
M+]9U5R:LC]H;J+&_5&9 \<>BJZN,_VC)U?\(H021DX[ZE)DTOP-8RO_UM=O_
M0O*WPI +E!8 P/"W!F<!O[*4?ZSA P1>_A(%JFMCQ_<,5X]8.AXL /]HK<[_
M##F%*K;;5_RJ+7ST\A>M\3]6*/[6+"^ VN^'-OWM\J1?64G*/UP* R0'_!(%
MAI/6K NWBK[>XO\22_&O=?3_?T]X_EJ#&?"+IO@?*U1_NX<+X-_XN9'\M9SX
M5U;RE.'"@S&QR-VQ*\67?]79JG"]L(ASKI]Q3)C2_97]\G^P!/H*/"SI>_JN
M?N5/IOB^T]CG8+Y4+D2>2Q]M#D:WO\X!*Q'@4@@8<Y&YK1*3U) ;V-\E.=67
MI%8Z(,DM9""43^I8EOB29E_N5M*-_@Q_H, Q93!Q_FY=F&^^4K1->6QZ#/(*
MKPP\R8-TW5"QH%D/]#:KV5!)?#@Q,Y=O=UW/+1W$Q,1-A=1#,N7H9>-"0Y,3
MF!7;G*\"%%2W?&\ZKJ"VQ= %0WE.E*H[\TF]_/*T[Q; <BAF'ZLB*FW-]-LG
M%OV[I]8DS+81^,:\$5N>3)QZG][+SF*Q&%%V7&;1B5(X5/LE74^GN<'=,V$*
M$]'V.@0#\&[-03H$V^;0V!%1P\K?\7A5%9-;BSMV;4S<L9 KZI6N[[MTZ^=K
MUQ_PIX'>&C,9:DXG*A%48"XCSR[0!5E-UF)O:4DJB=B#0NPO;L-CTU70XF;E
M_"N#@Z&X",S,8W3K*! 'L'?IF,25E/GD&&$5! S5CLVUS"$PD.ETY&@Z$O!;
M=;OWRGF-:V5@7D21++J F$?W78NV+I7.EO8V/B?'D7!H9H2;#2N@V &12HNE
MKW<A\$/(>QB-Z[URA<U"JQ%T:*NF)0CX/H*"90PUE3.C?P$U<6?^DI.\4^68
MG#KS,+S%C[^9O\\H#,\\G&@9H<"$!E8*GBNTYYA<E&!)5P+77@]NLT(DV#G
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MQ_92S:1;EO2('/B2RB-AT9#'5BR0C=56]N0AAJN<#^#Y#Q!CZG''LXPJ][S
M+1[/4XTCQCH:453N<><(.@)35,/ JG/N!W5SD=@@X[PFOY()AMLPS18WN;=H
M 9K"5NE<FM P/+-9<,7+8^EUPMV1]W:36[7D^(PU\#>?CS]MZ3(G/*$Y[]!D
MJQ5C3N\UZ"4K\/)DQ/4Q<VAIX.1I:CML:2<3J:O'1#9*GV_"^_RH"XG(^H33
M5=M[%? A'U_2T3'Y."PQ^8Y-E00+2GO\PB)!3+9%%>D!-;//![FT>H)_1%D
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M&9]4TD%1>+.'N.UJ&D*>^D(@;4/9,\Y2:B8]HL&82-4T<S!2&5Z2(4YP#L%
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MC/*!IHY4":!5PYN."T[JXEH<= UZ$)(9E*ZZ5K/I/F6,1.PDW]*=%QRXUG\
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M^U))KI9(J0\DI/O80]%668+Q:E\<V0_X3M/UR\X C&IJ9P#ACC- _(^0EV<
M1^O3:GW+(\2B$B;>H4 X_8_.YWF+B[R[=A97+1/2ZI[59I%+GC%'Q]G,&7TH
M 9'\D;S.!Z?>BN,(@KFKD2*Z3^W2'_<-:XRXY6Z]'263M%$ZBE0]GU8][9[O
M9H7,O,I2Y6J[V7JA0S.;..Q WHN.F9*@>=OI39\9C0;%,X"B:"H[3]3B^W<S
M:\"9072EXYT=IP61C<[$V)&\\=+^SJ$.RU"& Q#V0V2NW%2D8U0 6/\R:BDN
M3@V]T5T'AOLY^D8L&DJA-&V>4S[_(^#-2JJ_?U]9<2#*)*5C7.#5K6'<0HJB
M46::3+[<T%,,DG:!OT"N<0XH;\T7I+_FD-G&P"1?'H=OB_!V6>BX/2T)%W$5
MZ24.&%V6<A)EMYF/S$@.CH4A8A@#2^]51NOZTSQ1RZ?*-1Q;R8FO3ZKF3%=.
M@\>D.)A9;:?S:7JTI,[LQ#AGD2TVL:1;DI'[)<\7R9RDQ1IY=L090.L)\F,=
MZMANI$,:S/-NF,;!@D"Y#W0W%QN':J_S6U24O_G&9IN'$H^:[:%MI5SG\(E8
ME+T'0YA+W!WLA$"@>MQ>]_=C[>FC!';VQ$2S%#U>94?8U\;.+N!8A085D?1-
MA-U:ZZUY#6CHLDQWU).\"38X;QD'*RLIS7:A198D03,>S)1+1_@UK.V#J('\
MQ2'U ]>&]T/J$+8+[W15HM% 9 OT0S!!,#"4OB]\]$DM!_^J^U\*%;SG9.J_
M%*J0,+8<U O'A?R5LI2+"]K\'WMQ\^3;.']3R?,'NC!_L"&^J9G OSN"D8T,
M#L'NYT!-BEMDMF'%?TT20)1F&1D+5C_#W31/%*T62?]!_6&63,I3%M0-N#N"
M>Q)%9;&6$*P;.](C)\HMIQ'R7AS_4145SK)B:2 ]4+)=8\W,HVNL#WZU*CSQ
M9WU@3 H!SF7X=ZMM2W(0?[X&K3UB73NC[ ,RZM40Q*BXT!US;Z6S1O-R]7R.
MKBK?2B]CL ED%%_LL@\T G$J&%WQ3)-L2.SWD.IYD-_:K=_ZU^@]V[E7#W.!
M/6V\C'5Z^V+]MYXZSJ-A>M3=&&NY:+@""Y1[A\_WB4VFGQ+31J^E93:NY4VF
M_=TM4D*)%EGNH+=5X !N$:MWJX1-U4A4P-7>.I*8_CE]?D"_PXI*I8^GD<\
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MZK7FG*J]4 SO.NW^H\SA!<CA"4'M>Z2HF+)95+H7\=EIPA,^"]M2'=GW2.D
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MCY,"9;9:BUUP$F> U!\O%"!!A>6[ZF%TX8DVUR59@J$ L!N^^8"3Z1K@QAG
M?.BN8/4%#U:)&'[:::;O8R#Z,X"&)(4,0,F?9+-<PR&B&TO^ UO'ON?</=_
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M#2 _[)6>Y7S5B^WE:A6ZHF4>:5=$O]17GF='(@#7DS"[ E>X[>TS /FO:Q>
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M,E0UK2/'GSY2H16Q#(-5YOG+H/-.C[0*S@#MJ0"=]Y<IVXB0,I9I+'JVW,!
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M\8,@38B. JJ* YM!;=9HQ"+9HT1M!BX-4V3^3<4]Y[Z/0((N:)'D,A$D+_^
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M[K^DGXD>OY)VQE7*]*='=3F$21C*G&^7OG%5.>L,L+P CO0N@#J/KYLE8Q?
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MN^R&.(97F*0#TQN>OZEF^ZI4X,G9;HETX]*L7S;^Z,^)]04@= $LW9L9,KT
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MWS\LY^3_A4"3J?UWHN-_L_S_(]&Q QRC%S&WB]G&Y7+4^ QZ'BER%GS],IF
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M-'W60+EYMK>^QDD;\$SJ?)73+63&&>4/(^0ZR(R@&:0M9L5RL>5E9:!C;?%
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M(% B/PI7UN=JE&*SC'%!#0/'?]PQ>:&1M)UU^) &CUM45)YB4_ /U7P#L8&
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M ,%=/RF?I/N+>Z;U&1< 6. OMBS&XHV3.$/^R?+T3@_2I V+0\JR"V R_ *
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MX4K@D2,&,+Z^MLU)XH@9OP&E#\09A"JIZ<2-6#YJF<^$= 5P136.=+RE 9D
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M\GVW$OA1=POZ*6(LO-GYV!F0K?_X4[B2:-":H@N)*^"8?YQ%*3@GL#@<^B=
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M;0"@>J34IBC!; ;7\G7"]Y#>)_370C=O;* A+8QN:>]X#*>$7ODS\GK^6KH
M^.)4IDJ&?M/WI][OM]*6VWSMK*(6M;<)ROG,"^6IIZE)/)1BQ5KNH@5:R'9
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MHQPB)NLB>?G0)4WQ*^[WI:2 [\RO9L2T( PT7G9VO/G]",>+0XQ7XT.B[I-
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MOHX#36F*:F3-J;!67*FB?*U1EWT&71P=*S-J=YE$-=>-NPRT%Z^-<!(?>NK
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MK$SJ#W],%<U02K ^D3DAJ2FXY09>7+YVKNV=1 80@Z?L!6TF'H3L3P+JZ9@
M]L4R\&YSPBE@KENC;72;M+Y=NH;DBZ1* [D/]?Q/\F(=_*9_XW*/0X>EFMB\
M#22MROYHY9P"SIT"? R5'7\*';9!5@X,N]&-S]&-;*J/$-PU=9L\+2>:OT>"
M/M+*XW_[!%$=@I/\XU7MVMOQ:WOFLGANHP$%/K.,KPFC#RVA.B25(*6(T.%W
M8.9QZS\*OJ0I9F!K4:ZS6)RXU7GWH(>PGNGI*XQR!7[Z*79ZJ"6!*RW:UG8@
M9M>KN!SG.8$!=(P6>F71^&:=^.5K9F&W>GHL?U:^LZU4A#"Q9>6NOYC)\96
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M=8JX1K6>83<,6S1BPH/WD7G 'SK"AN[:*ER:^Q1>$<V\VE&C6C"&:TC8PYB
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M:M+D,Q8[6T)Z,.9HK]%HJ+VN245V"K .A:QS;IP"V"Y/4_#NDF_+H:QR>Z>
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MEKST].-D5XV)16>-PA9?;B,MS=&<D,,YN6# 2M3JU]=7[SROJ?C@DF,EY+P
M3RV?!3V1@0.#E:_\7FZM(,R;6H)SGAB6_A.*9"^-JHU!'';A0JL(%[[ZAP]?
MW14;-1%+%EA/3H7$\QEA8AGPCVXY=\7!<"0//=@C^#R^SF:C-KM,OBA*4B0#
M)E]]"C#>-0,M(D"FSNCTE?&3MF%FMM=\*<#H\V4U8LUW])^F%YJX- M5;N\@
ML^FD&#9,21Q14<041H@GVT%5Y;8;>5)\M"SH+ T>=?M5;(UU'55S5LT68<M
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M9"D<1[DY !%.<P908*'1_GY0R/5>9Q(ZL5UO7:]2]4K"SH?6YU3Y\BQ:6J#
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MW;TJ%]!1OG(QIN$[+MGDZR,8/IS9_2OB_T6YKRL^S:IM=/VY&;C\X>^;=@&
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M&F_ S1>,>6O3ZQFQ5>.!&@6ZW>V)E4P#B:E^'K7F'3GSU:Q 94:V7^"I\#+
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MC)AW@HG9XN$D%GR%R4^P<6K1H+W&>$O"*RP$) 3XR_P[Z]!G2V!B\'N<F&'
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MGR0C1S(VJ*-N_"6 ([/+PMTW^<\6TU'YARO+YW;[;SKX!72G!;)V_CQ'U7B
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M:*P,=>'#C1$(<YZUE7^!/:L&81.1V83]JLG,%172I813@*5.E:MT9%=XPE8
MJY+R(4#@^<GQ&?@Y_':Z -6N/_:'-:G05U4Q&9HPV94/"68PQ);MA+;;(R &
M_%Z+Y(;BL-)S,W-!"UU&''YI.;V:A4@@H^L-YJ- ^^0PDH'4>2'1$O/1T7<,
M'EP_]A%&DRDFT-#<5A>^W.*'&!MYF^T--ZG+W:0@YG.M:"GW,\SU\M\Y"'$_
M-LLHF[KI'5&4[WNUF>ZJ]!1@^L#Z.&WH7L"'$XC367U?W ']Z16U:'H?R*?T
M]\1<G1IV1@U^3$E=^W_8>^^PIIMM;3CV!Q04(2!%5#I!0$J 4%5"$0A(24(+
M2 L0>BC2!!L*H4GO\$@)D! 0,/0BG5"E=Z77H#01I+T^IUSO_L[WG7WV\Y[]
M[?><<WG_R75QKWLF\UNS9F;-&@?5 ZZG_+^?/>/18T"-K]GEPQ?(8/(76M)
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MQ2%_)HB %WS%+M8$_'!*&'64$%\<+QMW-]JW.8CWXBU+T*-B3D*AW[NM2GC
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MPXR3DX3W:OA]+\L=06R-UZH5>[2'ZT8K<R0G(E,NE3A@#U5'BG.WF0._QYP
MXGY[\2/TN^0?#UK;B+0?L>X?O7T0B4ZWY,Q=JX-8F]\H/WZT@U2:6SK..+Z-
M4WI\8_>@5/1]T7<= G[5=0&SLW^M@CO7A$6J8MV=@>5R3&P]P_0R&3Q!J/C9
MK]K?\PCS^J;ZBB-QC$SP647C.@W:A\+SAS):JIVP&>ES#'>@:G,X?VTU_I0S
M4XYA&>HM>-MT"/_*H7SKDW308;.[CM# N3$M';ZL;*I[Z8J2/1ZS.1;&YB^?
MB,DGRA[J*M"I^3[,.;H7TS(6*M:+?!DH),?72S\_F6&+&WO]:%*&4F>92UML
M!1IPO6.H2>_," =G1;-G*K?-4=KFY+NE\#TJ3#I*N[W.,=^=8.V5:$+6W%3!
MG<Q'.SIBYW<ECY_H'*\';EMP9OP(W1W\XXXM;TB)DG& N3<Z<9=F2?XH*GWY
MTA'NQB>?SSLG@'7%TEUW<KWYR@U/FZ.B.; TZY<LZ,\N.(;>?T(^$,K0N:92
M&NBN,]((#U_7EE.D?-T]4#IF<B'C'^]\WC/=;YMR=PR,NP&/GN"XSX^W++W.
M.Z6[L#8\' -+,S^0M*MHUG+M<- U);5UQKQNU1]G66UK+5S@V+S1V,J;5^V;
M#%J,*V;AQ>7I2).<T2+'Y_A4@V QE+ VZR7#?+IP9YKH8;)^9"2B4**#6INA
M_3%YK=9@RVOK\)OSXD(/CSZLRN(YXU4^T(*^O37FH2CHZZQB)?>Y<%S1,V!>
M(IDC8P0M.W#)#>8;)Q6W18*7BK\O14K%<.K%M[1W%Y\ \F^D@2 2+AL&3[_T
M#PX4/-$.\/5*)].D#D,+?QM4K1<R7A"!R%;H G6,WKM^0>O"JD#3K37UZ</T
MG"K7OL'@JJ54V^ A7RZNZ52>(*LB?#Z<K"?Y(USV04E,U,0IXBG.2,M*5PR!
M&,=BG'N:E=7O_% *T#0S?SAQ) $&8;MV@*A.L,1E2J:K1#P/;C& MUQVL4YC
MUJR(!L<W6O'WVY3T!(<\;[8L[GR^.1-#[,DV'Z@$;L89C1QXC-3)3ZW[&6QP
M+96CF!+@+28?O*O9'0_#?'R#G"T9N7KNAT5OP"D1#N>SXBC-Q-B0R)@>S2/E
M&)0$#&>KGC@<("*EDHSFHVYO"]U9&$P][?R#\$8XUC@0FR.70>]D$Q>:D&&@
M9CT7(6/5]$HGID-@5(K0%IH*F;$O*M5V"H1HE)'<_)XUA(,'9GF8VMN ;6>F
MQOC5HK\P!:%N%<>L)SWP_-DES9;DG[JG25HRQ6;BHBL3WS;)_Z1\C5A;A$D_
M:[J[EAF]6JF1>LZ/'20H;0O:"=Y3*-F,Y@)3<$)<TN=TI&Z;JQ]GDC_4JBSO
MMKT^>#(&W" -.3_)P%K<P8*N/"'FD)C[#5:()%[\#3IBZR!*<_G#SEYYQ8'D
MY,HKW@-_>$?><CQ:1%@%S+,<]Q?.ZWZYT!>*?V 9Y2CJ*>-#P)_!S[CT^2'1
M\P1PT;INZRGOQG_\'__S\>_L&9T^54PRH+:68_(JA)F9+[X^O/J(9N]O8V0P
M_X_6NJM/__]IR[_%7ZT.,A\S>G"NV(4-]66"UDQH8HE".># 2WTB6-%;X2VR
M2N9,@_<U.0(=]*W&!%G-G;(M A$<+UCF#*-DK[S^X94F1L@X+GK/,[Y] B Q
M;!QT1']J\%_R'!W8#U4ZH)P .E[:G !T Q8S?K2%%3E&]F5DC#-K^4EN7_DF
M-Q5M\OT@</&RLONQXA_/5<VV9WUW.P&X5(L?:)P /!*_#A-^< Q%YS>VH(3D
MEW&I^$P^P4V\X&;Z8TNCT)U/9,51AW6A5(.)0H7HIE/B42NMKR-+N"+I<VVL
MA?J#(]>1F9#UF1>,EH<%&;'9&0/?%X=^%,#7-U_+(0:1&)$!ZD8TRA5+]M:!
MIZ COVA(;@](*W'2=JT-5HY6\$CNQ7 CH[3%^;V=!#*56OEULMV/IHPBH4W)
MM:6=W](M/O>K-KVPH%8+/V:E07Y[T+NHPC5NON6^G=MX?>:X<T51/%O'>>]C
MA!Q;H&+N"<"K?O]=>,:JZ(3^"<!N(]ZK_<A^_\E,M-4H?^KVKJK?[Q*[ H$^
M2X$#)X#W/WK'>H:/ K.?#"7LUH<-3MI6A?^,EV[L,]#LCE +G\A;,'<?=2N9
MTR"DR3+4 _[Z">H)8$^W;CCI\T#@C/O2#<_NXF.#)PA-1[>6NU6A]FP7N9HR
M"<7K:F $FE;D(@DLM*FL[=4#E! #?]>)CG6D)H5;IN]MFZ?9WOB(6;0KP[4:
M&[M;=4#CB=Q)G$9A[I;$!$'=.Q2X2HNN/GTTQF5N<8SX8#C=?M<[*P597*A:
MG&/6HFN\6W@1YYJAI:U!,;YXZ_9:8RY%O7)4:*8E(OA->E64\:$^+S*$A5*P
M:8 T4X3^ .HK:7OO^YE%$^QK,0I\7(I%LB#R6@I<'^F#A>,\GWN$OXY-L Z]
M)<151EOH]@[.PC'N.E<$;$&:D7PINYZ=TN(5/NZR:Y0BJ?H;W0QH?6PH!X?W
M_($_\%5>4<MJ18:4D9$@6U#FFUBBUF[!2[N\T;Z2\:Y7FPMR>CZ#NTE(H7(T
M8;V5#,4J]QCBD[^H@'O>[$#@;(3DP1_,#88.%[5))=@0I(VQ[^4@NL*T(':I
MJD,>!P;P^D3(O$19A&>GN\JXC&1OHY79R.\MS2V9=<"J"OWMD(U'?I](#93G
M/A%J);QET;>-;'LT[]F<9AP1W[N,G/TV&,K(I,5"%U(L9M "N[RRWQJ<B _\
MQI]A7K[4IX_9'!!KC%P_7$*)QA2=VP@'?QA<ZR][+IG#I5DNN+F%<.*@OFIH
MXK@1]Z':TZ%MMN7V^H24$!DX1=3(2IG;.%Q4+OF"PL\/0!T8>ZIDP2:XPHL?
MM'4=O\6'.XPI[MM?,/X-II[(/0"9]RV][D#4CQ/;2C<3Q^:WS<[:AJ;WQM>C
M)\>*I;U]U2YN)ZB>=2^YTX)5UR^A<V)?>\A<1,LNL Y_P/N4L @JG,Q!^01X
MP!X0@W1@[YZP"?<"E3ZOCV0<!6BR8-PF97X&\)&EVSG)YOR\KA.-ME0TCD0&
MVLE?CNG<4<C_Z0+:OEU7^L$$WSS0)$4J_8A3^Y"T*[@$6=M+4)=.T',/_&I$
MRY6;(/4SP+N_V$0,>JW39 Y\DLMF#=_90)T9_Q@9;G-N^G_[L_]$XN)/W_?&
M/,ZY?L8QX=/#LW5_5S?[WQ7_WQ5F_NN!X=R/ !\4LO'\DV! P@? V7NC^_N(
M'47FGJ/ILW7J(Z?NC+)$";0Y19Z^+;D]OQ#8;[4^CBZ I(>\BN@D:@5'I!G.
M'1BG!%",/&V*<[L"$;=#33;+N#=_< 0%KG20VPCI(0?W447:"98!G!A-OW/;
M:?56.HNW3P!?^4\ ((:D(Y6#Y, U3O'J$B75@$ [(S'J0)?RX%>O!RZ?UT\
MB0ITO7O[)X"?_CZ4*W*J[:B.VKDN=-2O0TT]C%(^ 7#R3RDS_G#Y)N+_-K=,
MJ3%>T*E0]F)62@)YQ+3#Z8%$]],1]39,(1GC8'L<Y_)[/MF.>%G*V61^)%[Q
M:&4#%!;F?"Z@1Z58GXOOYU?C3,&,B].!7IP:Y9H#L^83SVH9-Q\<OQ0-U+9:
M W_.B/7N'4,Z3/4+DF\H\6Y1R)V+LG[%WR^^..!9VN:*]4HX3#U<V0@J4!I[
MPM^*@.Y^#?\M>L;ABJ#4,2T,ZBCC_LY<(,*K&4LT'=P;RLM@799:P!59]EXX
M ;".;)-C2D5:J@_K/JD:KH2!FUX837Q>#R;",25#!/D"HV&>L\_8F)@Z_. $
M0H0JGJRB9D$,[4 ["K_%#%66>GDL#//Y)'BE\W;&J71PP]]P!N.&3.E0K:,:
M@V3B"V.B>MN;^%BK+?8[+5:S"MT(B^BJ#2C<U+_YP,%NC- \5FX E\B5;DI(
M8^YNJH1]$J_HY\XQ[,44Z[)PZ%RPMD&?NS_4H:ZI4/3%'^CX<\:ZRIT =&D.
M_JSS)N&';PN""NNHWTK7B949'[&L+H;Z 1.TKA%J^)5.?UO/OG8[B/Y]7BN8
M;=#(#E3!ESU<T*(94_R.D)245><_-&<WWVP/?*P631V0J8O)K$I1@=A_U4N3
MML>G@,&TQCR0QPIA:-I@0G#P(+3MW./8W/>;=BT-A##O?CXKL\#Z/JOS1\@M
M2V)IP4I[F9#NNSBVQ%MUU)=OC65)EAE7TW@A"IK6EV)?WVZ#MH?&4G,0Y<#A
M)-F.E#/<;$-5F569R>3=+6P )@-C5(NM2+9$*UX7LAG*"\5E"HZ:>@1ADBR'
MZ=Y:VUU3=<^9T<+XRQCRY:@,#[8)Z5$ERH8ZI;&>Q9V4SMPRI)03BT!ISN=<
MBJ.-2N#S>^$E\(OFB/<#PV:7!+9*!B+<'V7U%7I(UZX..<LFG'7AE+O3_(TS
MQ85^BB#._R!Q::]9F;&/V$ZH*F@M9IPC2NF)L46,Y]VN?4TN?(^%)60;6&?=
M#QOQZC(4>=GN+6=2,L3 ,HOROS"9]C:D>:BQD(\/0AXQ?VO+R!T6+IBX%^$G
MCFQ4X4_93(N+K<:E0LB8.ELN)F:1$25A%F02 W)6'M]2#O>)[5;L1@<8!RB[
MVR-A,M^@!X8W^7="YL%/(M83^@Z&36[Q,6/X?/2=$32OE)C/'@1@=HJ^+/9+
MJI6\GX5 OJ%N3( WKZP5I%4Y%1A28(3')F7B!V[7J&$U3^(?C\XLM)WI4W6^
MS- PHW9!VV4N+7)YS-2YAG7&H?>P9$&"'V/1#'O\C>VL4&G2:YG%VUV&[TPN
M=#)PX @9"VJ<#A8#!HO0OFZVM:T3@*]466JS51>\M[WIS 3848:^U<C3,ZM
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M2_8OV;]D_Y+]2_8OV;]D_Y+]2_8OV;]D_Y+]2_9?R*:SR:N< &N5@GWV[>*
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MSLNE%/VL]MYL^7'8W=<WN#FPV.2()DX.,="G\A93PF=HEQ=?N3E],!'/9-
MEXFT8"?_[P;2\>:0/4PDQJ<F,ZR+' G9/ A(!_5.VVCF=/* \>KM.8M/'2,A
MN2C("8#W'#742W*.'X8$$ZA8?4:O(34PD( +)0%E-"8IPT__A7 TL?##A5L&
M-<1;6DD>-(3YJA;,=/ZYR+#@&HT"%>7[PQV=U1P@NS1%6;4(7-R259\LS#SP
MW K=6C'=POF/>@X;U]G"'R:D6+EVJ#MOI"PY#^Y]) 6R?9%?\4IZ.5QD4LW6
M)TMRA__LKG3/*M5/5HZ1[B,LRIWK-=_IG<Q?J>K$T.54C(W/_#"_N)+;IOWD
MH:_Y\5S?SH\C,"KJB--,B6&<E1CZ3S+I1;I-LDD3N*$T#=\&8ZR"GY5"7"K%
M5WIT'L_N/=C?/C:I"F;E$/8VZX94@I>&M'O,V7V)LH&19+^D%PRCZW+*8+='
M_]J'YR.(#@*QR8-I?%F*[6":FM0N7JL$(<$Q05SFHT2"!>DAV8'V:,W="^>)
MARR<\Y$BC3"OIAN9AL,Q!+YLZ2"#M;MGU!#D6 T5M':<;H8US?Z_80 Y& @;
M-];[3DZ5:[]ODZ7=<C(I%!Z2+ZED(^#RDM]\ NJ3_I Q+QQ'UE0RS>Q;X$&\
M?9@/I:@_8)=.0<O8%.8,1<B;M< NR5]6)Z-6"=,#.DTHN+AX1?)*.4-!QZZ$
M8"'<E($^/4M.5/M-8EHZ[DW.[S^_L. \0CC& 3Y4D.,\A03A!,+1"(=" 3R&
MF,R<"2K\S2W9I%A1[OBJTL.^R<I:[;UM_4^&4\XK6ZCD0/X564T%^[QA''N&
M2KYF]WRF4&+;H]W,#2+RG$XXK<^UA.)<S?== 5ZWC=O+_796AQR2%]>UZ%X>
M4LF*>CR#A\V"/M[VH;,M6#!I;_#55%4AO"$3'!N'A#$T$CQ^?M]#[^>3?!%B
MVZC"N'9(%US,4)<AN7X.,7_$]Y+JWYX;U/*][545H?5CVXCV#1QU8)_?0ECL
M/.8,=Z?*:[:+ X)1MRHY1OC90!A]60(Z*1D3SNN<A,LR-"JU?T[4C\K6D,7D
M2I_60U7%\]AFZ7/RM&'VZ=>-"K^9LKL5''*,8%/<&@L]@G2!2#U+;/_W+"NK
MKD56U//(MDOFM-SL6ZF#+OUF1*M%?0[!\L^<;*LD=F5.VW^2L;'+;T$OP=W)
M8X]L"FLK![$G'QH?"]M'% FF279+-!"CG/D-AYE]>A!?G;*$'65C94HT=?+4
M5;O:XCQ,9\LQ5A$TC1&PU'.'AS1-TUWP1GS>,#\,Z(;-XC9,[+<:K:6V-YD)
MU/";VI(*_LR4\&=Q1L6E7LSIQI>QC 49\HN#E,#=2"96\RSS#G\6Y5VG[;>;
MSWXHMRD\^@]Y_@/<,J-D4+=G)(M^//V3=]3^L3A[+R C'0G?>)9A^<=9T:DK
M7HH!\-K+0:7UWG],\7\K_A-%4Z2'+VRO]@1LQ1\[:%1^+JL\ 1AMQ.[5D]1Z
MY!]^MY9>$"K>,^+?S=]UVZ\>S;D+>$XJ**CY:@WD-,.>%0SQ?C.3-:-BJ5"H
ME;"N,IB;WUA(D()[ZLOJB(Z]CM*"IVG!V=JX)5AH'H.N'Q565X/U?^]1#GH0
M%9WHR"_+Y&,G_'(1PL@$IT!;P([Z_(SV\^/56MWN8D6WM=9FZP-INSVT5,08
M-^8-VR/4^,@&6ZGU5DX(M'/WH#6:2Y:'5:"[:T$$(NP+(NI3<*!#FZ^K[))]
MOLDK2P1( &Z":P%NDFP[6F7!P!':^OB*TT)RJ%9JGA2)AF>!"VT%]>.<O$&!
M&K1T'@WJBWAY:2%A=1=N;[5)2T^L5K/&HY.*@B@7Q:_C^-@&JS3ZQCJ1=_.A
M\2G6"^(<TB4NS J)8L:5AIF9(EU>-X1:*,W5/]L)IRZ> %2DJ9\S\T.&,^Q(
M[J:)^(L?+*J]QCS>JGB&J.9 K*J%=;DLB^]HN?5XFXC[O_:[CZT8W:G?&ICI
MWIGW;YZ5N?&#X[-Y):.04-.XWZ/Q52:CCFPBYF$*6]+Q2*J:V#OR#*D'JC)"
MU,MGFC''V1-?4)#2;2L]7\2=M(9T+A[Z=+U^%/IJZE5=FO>N1M;#!X+&D^<2
MD=9@SK;B0E/7!HYYU4*ATG/#,'<;FXFLUW#&W'Y_B&Y?6B3*]!HQ#OYJ7@N>
M6]=O_(,N&2%5KO]"F&$EU&)ZJ9Y>/CZSD-/T-[<-E_GC.-ECCP[-,:F"XQQC
M@6'(IQ8Q!2FO/CTG#N*B0,Q'_(R8[HT8'(10+?9SRMY\VZHJ/(FID+;O1QG7
M.^\X.'OJ=B/6M2ZC]')X-6+\I[0QEPI*I9K#=C!6+46O*8UJF*''F&F3<-OI
MU:J5<@[0DCH#$'E62QL!7#%L+T45CL_S!( F4>>YC8C'O,[:G*::V\7;7.DL
M+'^X22*[,IOMOWAKJ_.W93:2F"^I0E_N9B7OB@C,HW"XE(<]B<EH2Y\1+DLK
M0T.[,4<[^F1")TF#D:M_X&?W.B2^(<]0XQA8S$@:.?D-[?_2O2V7;(R'\V8"
M(V6IKQ\EEU'E!XE/T(3^TFVF'YFJ0=PT5EV@>\&X5KZ11Z06?>1Y_L=>SC!"
M/K[*(SE7?2$B8(0);53)*#G4W=MS6YKO&G[ P=9A<$)->WWU=K]6QT*!_'NK
ME!<QF$?S*C,Z#\RYV;Z _2\69^>0?4,'-T@][[*22:8L>J'**/S8.+87@=8S
MAG.$=2(@HY5>?'0J9O2W(L/=^>I$!AU$RUUTT>E ]VPZ3*4KQD$A=K\"2,/J
M0U%;XL7?*KO-3X17PK"6H<_78)J-:BB@"<&.F ZYKFN U(+K2.;E/R>(GFKX
M/'@X&/Y):S=ELF<TK)W!=$KS3<5L!N=OZ3;@LNM5SC9M%\<8E>#7<U$&ANF7
MR=&GN9I'/EA4'5RWL1KU->W0F^>?[?K@,-<:25.,2C782,%ESD]7X&E>-7WI
M[^G(Y:OR=M>";D&U4]/;NFX[,**3IIO7SJI5"^L#E?-*=F6CT/P8"29#,=Y^
M/V[(!6%X.&+A$4EE.'%!E)[#D GK7F2C#Y.V-:.OJ?MDOE-JRSP50G#:PI![
MD5Q6'YQ6/5EE#6(65_4?VM@D43-5?,&,E#\&%)*,J2:["K>6;FBB/"8B?G:/
M0#"A@J\T(:[F@%U",GIC[1T[ _*2I7((78J/,T9Z111>(B&8&R2U5.67"<\?
MO_9-.\K\YX@:,'O0NPN%%%6WZUA%=7G,\ZIQS>*21(=-CS/"Q1?Y,P/:I8J$
M(PM$$G9[@[\XZBPZ7=BE"5QXW]EUU-)[H!-6.!<0IR2P87@"0'^%S+UG_M)M
MM!^40(1/WTO48OB8'!&\N]\73,BX$1,6W=I#:8\ 5O%9E;:T3%9+V6JL+K"U
M0<"WJ*7QF:'VMVIW-,)8:UZV=#D+^^F'&\^K0/>"M^Y\M=).L!_8SDV:2@U]
M7*_MR3'D4J)U:1A7#RN-_?*)I+7[OM!8N;/=_9"W[6Q#'O%#KLS>B+C#M'&X
M[7;.[L^1.-!8*7L__.? @:$)9!=J"[.\ !A4(Z";6<P%#FZKU262@&,"E3*9
M&],ZMN@%\Q#"%%NS?]WA<B':D"P+UR.]6E!IH*-V:VL@TB:V]5UO4JRSMC<Y
MPYTUJ*;(,"*,L%84B@>GO]S&)MO/=&W]\1-P.4 ,:C6OE4)>%BIW=E!:'K6H
MSAU14^]LS3WS<U]<:9P]F/L97SY^)57E6H-$9U!D]R'Y/F-V[N)N,UJ:S5I&
MS(Q]W5BW3'R.Q%HF 93L$,Z+3<[,&TX:9@:!G,8Q3KRDMT;9MEZK#VW,=CH<
MP2U?#=HN88UQ%3ZNMZUFS"E'(,_#O:U;M3&8WE5XYF)QSR@.+R3MY/@M.VQ9
MTCA5,'%=!=N$J(QLN-."-0TF)']<XS[#S2:#M.N7\[]Q>\&H5M:$:,31)HUA
MJ^YX;047+"RGL]QS=B14<JT/Q6;T;?A=KPHI\U@,]+!\XE.W7#)WX^ )]TKO
M+H+3K"8R;!4T)"@K+"+_[3Y(DZ))!GZEP%7Q,GS9*F9,HT'L"&*]J4DF.,FX
ML,I)'PRG7"$SP%UA^$S?*:-\6@.2JC/I-%/!P%6><XAJ$6ZW)B8TJZ&_2K*4
M%ZQC<4K20:SW>+_ZXU "&F=919C/Z+'1C8 ;0%%J^&[CJNLYCBJ9!A8P63;+
M12XASL&V2_!"J*E\!<.\Q>?6(XS'X9YL:0SF^TK/3Z>SJ^ZTB+[9T=D<"6;F
MN'9E0'"3"\(VG,M&6(4*#6B-R+-9&<' *F(%V\(P/WH1\-IHA2Z*[ENK4'(%
MJ,Q,(F;6 $UKK]K:G3@L_+TM.76=PRY-!C4P7R]YS&UE*[R>\MZ3OB_+(!KM
M<,ORYT0NT0 CAB:'-"I'E9:XY<U,Y:KOMXWK&765^A;2 1V4X!QM8#$#66QT
M1__U>O9["F!]O&$'CXIURSV3"7K,# XR)FQ9=!H#-^?CN)8>:CFGJP)$HQ9S
M4U9Z%;7"<WP)A%S.S_+;)0T8+J&I#YZ[F'7';N84>M1._H.]Y<&>+EB#(U)A
M$A1,U<V?USD!V&=$D4M<1L J[EH>T.5RV]/=51[3S;TM#ID0) =<OJ7DL?L#
MO/$8:)W.7-N?Q\^J\WX;^'HA!G_-:GJZ0H1D7&95<& V6.O5@A -]*H9D-]<
MW->FJQ)IF?#/H(^R!!4;KP?HAT0LEI881?I%%3A6$0B%OX6,=Q8,X,&C PP#
M)X#Y7/D4Y95=LPQJYPE@A&:J;MO1G;]:UZ%D;!*+C2HR]#X!!(?$O$Y@!$EI
M6P\TS2[IX&M3U^HR(AD;9H[]]^/1GU]!^%&TW%Q-UNHZ#C.U#-WN2":L2(O*
MK 2>C_^!2<A(/#-;Q]';;*,]&K;2A\\$VBQ)ZA$;::\FX_'DO3?IK<+4D/XA
M"8$OG\O1X$(/. GIJ 43%MDJ"-*VX5UP>'-5*.&L>I<_$WQ6Q4_WHK07PH;@
M#=>5]9?,H'O8EQ%IN@)\4H.\+8T?E-U6<+*@G<JHCBL]IKHLW=FI5CL6[QUH
M-!P-K*G\MOG*+OUCHS%I>"468IU([-6D-&*GAW [6CFST/%ZAB7JW%2]/+M!
M5V\#$;O.G&6\I,I'1A6+058]EPQ_O.RT65A[H\==9FO1_#*TZ++U;J;K9H*(
M8UBGQP8A*V8F>T^CEG7O6T\4,DS$4 <ZZB5($H.]PLXVI<64#6.Q&1"%\\13
MO+P_HT 57,2K\$"6ER&X_6(19.F67:% ,L0V7J&.=F=AC)!$ ,T'=;1Q95J0
M=!3H-PK(6)\2C_'F:S$BIJQT5']>WTUI84;@UJVA]:0XR_3K'1#%F.G%3TZA
M9%<[8JRA,\8RSU/$W7 $\D65G(_[^4,'ZP:/1#.3C=UB$K*LK!=OG 9C&=.'
M&A!, E$FFQ"2@7D(#"2E:./6&/IDDU,\%_&Q#>^1?(C,YB]LEM#]RM6!P#P4
MW%DM]'66G6]Z/;YI$EMA1>Z&3L]!:DM*J'W2(KK9:JWRGYV6#"L-=&&FI1M1
M%I6,0)A:^M#]8@<G@4X[5CJG,T,AO#B5D1<C_!P99\:LJ!&;MM)]:[.!.@EF
MSA%F 6;.KZ6SV"-RPTX HK9*/]@3WE SK!H=7.+'VONHWU3C1/5#!<U":#G4
MZ9Y'L1TR<UGF[6@QZLD%T92IGGM<..!% &?R>8YH1T0T^RF#4KP6@XD:M:E'
M"J &2V(47,R^Z%UY+GKA=ISX.=]*X)#4_4;9EA=LW"7%J$**J:=%(RRE>,NA
M'HYP.@&XE,9S5QMX3]SOELH4079^@V^D%IK&KTITC3N4OO>*3X&(2="CB^BY
M;W4J/-*2:.QHR:NC!?OS'I>SMLBDZ+!U&^BSZ<JN=>J,3!19Y=<'^2Z M=:0
MI:FJS0YPJ5L\O3V=^MFSW3I:]Q/B7R;IA +;A\GRJY83Y?".3!RW47PX?  *
M@VN_:0W!K8YC78LT6E62NJ2J:6[@\")!#*2A$\#5<OX527ZK115Y$=$Z>?"0
MGM0K^9Y4)>!8[@Q5NSO"83S"*JH;:XD+Q8%8J^PI0L5"M$]OI5S=(;-,F1=
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MB[SFM;RAB]>WL<;SS"I#/6HDT2:F\YBL=[LFNFXH7YP)B^*1CSRJ Y^7YG.
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M<Q27AHE/OF9_F?+E#-A/94M73I[-&OTF,ZY<89+=VMH,I22\O&)A)G!NJ3T
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MUV80%-3+**RD].Q_WCB- +%[[R*CL[CYI2)3XZ\JGR>+L3<EX+-OEV%I!1Y
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M;%1)U-'.:4@K8HY"@?0GR@0C"<7!HH(W6@MY;QF_=(5-MM5?.W,PY7R&>]*
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M,<M\YE<\G5;X<C*?I1?7F(FZEQ%7(EZDH9:J'#B[I_,U![7<Y@*Y<+-MA)P
M;72PW3J]8OIT/"$VO8094U"PW*1&*7G)#O@=L03"45O!W2D-S([2<;R22:KA
MD[@AJ?N90A9LED31(L@?O<40)F__M*ERQ&; -*REO%Z7W U++S>7$NWV3*&=
M(O/CY^%< NX=XZ;>XS3/7Z%^(?KM!#!5D&PKY1L&@T7JD=<=I[@,(WK!% L;
M,G\K_V5F[0'49DA079.A-??H."^$6VYI:*K4V5+)NOP)1MBDBZ.]27R+[-'P
M^#P'P+UY6+-@)VV@AYF#K9#A25FQST#C5VZH(- 6&YD$JS=T-N7(2'Z5@D4\
M-=8IT#S-LQ-4?5L]PYV%JQVQ%*^V>QMXLIXZ.?,^Q[Z0>:=$>$T%9:#J0?9V
ML1,%#6G)P8>OWWL<P1C/^+J<S.&KRT[A\!AL/D9,27($:;J[7M%B#6+53_*7
MXR9&IW2YAI?%],8O!%/RS\4_A:=46A014Z;+>8VQC([MP;Z4?KQC5ZO[Z_RS
MF>AY%"G$$Y/"6!\M9EHTZI"16V5Z[4WE/913>^26;5E92X ,]X:)0IAS^;4V
M$L^%YEL;>X@]/4'FC$14B%-)C=]4QO#'>%NU77O1/X;> _8L<U@UH3E'=$([
MP3#R>OQQ\_7U9X4:CF?]^+]9_1%OR<RR81NY;N4PM9"8FOJ]YP$P'J+ IR/!
M+)9$?TNMSD?RF1V*[QX683]NP3D"=I=> UEDTT)"-:<,NMK-)8>7/Y;^,UHY
M:LHPNKPLSKL+J?D8[=@5=G9V^.6!#WT.?>/ MZ?XXF%533%)AMS^Z2\1C4[-
MH"X8I%NYA#OH&96UI)^'IT!=L?7<8(R(9?'$AXQGE<8=0S+W+)UZ7*M-X%"7
M(;]N*/\S5N=F"BNGP@#,8P)^S\/X^D"?3TW4BBUOSS$<SO8),$!@!;9LB!"-
MH]!13FV$5].,1BBOH^C[%X2K'%%K61Q0NHG>:I7+9TMKP&.S1?EC6X264EWC
M/^I/8@95E 2^.7+- R0?(%/?QBGD9_Y<&1QV0OOO^#DL=#\>!-DA.^CO1_V5
MLD%[;?KX&/%-FW/DU^)?)SC^H[AB0SAR>JDSYW3:]_K</W>PXH/5I3<D]9,!
MFV,R^/.#V<^_7#N@'T\IE]1VKR\\^Y!2V;ODE#=;.M.[^@5-^./T; X7#DY]
MZ<BYF1V*N#G4_J2WF;5 G>V,3#$,MOA1RWOX%4)[F+A]=5?Q\+8+*J8I4=]V
MK/"J"*(=;D935S)/2$E.-ZI.?:X1';ZZ*B1J?AI!>9"LLOIAL%(I3FA%T%^R
MSI/$/E);<1K**>4*]KVR '.#'?^@Q4C=P'660IYF#.M!T/*M/&J>G0AZ>&M,
MZD[W6MY.] 2.I(3T]AK"2AF"9:X*PYG?S+6TI$758[WI,-&,W#GE'+E\4'XD
M_?:QS&3CAFJI&(W;F]-64XXW#?M?+B%LK0<Z$WY)+$'?#J;TY?8K(&._[.Q,
MZ];?I<M+"Z_9O_C^1>$U_VJ#5^<#9!G LG-=3I\7)Y[>BR$&1*]$.W0-Q&:%
MBB^GJM9>F?9EF7(TIBSL-:M(:E??<>5X/WCAPB^_WH\J.F64>+#0SZ '0[\2
M?@.YK3_S<#<2-G99%\J'CFJ1V]G9O1C]P8&9Y&>-Z=RSN^.^00<)G.1MM6;*
MZJA5QE;RB,&O. D6*>=K=O'NK@N)"8)>Z;^!Y[6_]$N+H&/M)X.:CIM=;]YL
M]<MOC0UYG/#SOI^EQ+<KU+Y-YE=>BM5SV+BT2[ET[D1MAO](.R_ 146)0/99
M)7L<BG_PZV$6VWRWG\!9_!L8):U(F1S>^*S&W/-E2")O[N/]/I>&@PL[A:?5
MG\!\0M_$/B__N<"ID!W#'.K$#YF;^L*W6'B]IK+/>B9%']X=H(D">[0C:3&+
M68'G2EV7%N=**OHSB/<3CX\,>8)XX,-J/R"&]? ^1Q:%7;@]K=KF3.F<A)I2
MI UO7>Q/+D.LKF<+"[$7TXT\Z[78&3LZ@_3=S/S%&5UR=V7JUT!N  ][]]7[
M%CJR!XQ+DES\3V!B+<XN*])P:G2:=I4'Z/8JQ+4FXMOT\J=]/W"N^05PZ\UJ
M7,2A/M[GG1+L=:^D'9XE%-)PY'$E)5&$-!D,9\. M=F5?@/CX\=&4=Z&^5X:
M;76VN?UY%\ZENIYN,N12Y(^/1_H7(?:<C5]LW$3(^K/F$T69J]?CA 0$F.:L
MEAT3AQT42MZSOQ[XAJGVEZ XU#AV!\M"'PIZ0[>CK9.36=@&_+7B/J1#=1JZ
M3IX-OAK7:4[XT1M+\DQXFY>7M)[@NLL-OA?D)G7@C:V^1U'SM72>\7,2*@W?
M#ES$-Q:4@!L=PPMDQEI"S"^)SEL/%]JIE^A</37SZ&AQ:6J*0^J\,(KSMP")
M]7C+K'X81H+W4QCUS8WOX^#$S\J-RQ (K-?R4_BF_FQ9.9GAY+K+._2\0S62
M(=HT.@,^NSHQ/5IF*:P$&<!\G!!6%,CO^:=TQ?\R:'5FY(_+;_YJ.(W,C?SA
M?[!Y?'\IL5['."]+JJ'&07X_8\L^:.W_S%?YG^#?)M]0'?P:/<E^^]#U-P#7
MN3J;U]*T'SQ_:>[=7A#ZQ+'U,^J6C54H^>&#]8 +7_-_ ](7[KUXY6H^U;UR
MF+<CMKYXH'M8)]1IE]L* *%?IM_F#+=N3A?I0XS(944&8GPVG!J.:_[W+U\H
M .AL6> X0#MHR_PWT##Y1:;E@BU%CS@_EXQ>7'MS JJC6K9!NI*WOVL_>(M<
M5^!$]VN"]&BWYM6T&E3C&\NFB.!">'/:*:=?&4UCVTF0D^O.RPECHUDB[= X
M)M1%[S%](=V7$ (I7+EL"QX:!>P=JJ%(5^?(-77WD.42R.&VG(+:9_O'UKU$
M41])R3\J(XP:6J?L'LQ$7XC(Q?XQ3^SV6;CXE96)C6($W]=4%W'@41?03.9$
M#;'V-Q TZ_X]&;QB?E+2U)?N)XKJ^OX",%UD?K PNP&/KH7"B<N>\W7L[14F
M"I^T[L=P9\LX%*(JB^" @:J ,W$BZ[I.T.0D@QYI@B?9+,7VX5;20"9%IANQ
M&-T9 6Z>;P36-$6=%Q3]#@OX6."6_-R9C5F"?&EK^H!/I?>=9%5SQX_7#R5N
MI$;NUO.A7AF+TU3!#0I(!!8V%#'LLEEGO53()7>,M9H"MI;%JA&,CNJ1_:5[
M[CT&?;ZHSCJZ[,7B8#OZI;!1O $E#M(-AP> 0(!V2&EGPH.I9%ED]+FMED%-
MGA X2!G:S'8N0J;](2F>[R$IW N[2+/V#*"B=F#*SVV]"4ES0(,*"K/C*\?Y
M*ODKA&$]@A*4P+$$^KT75$K6F<*$K'PCB_5;M9:6M[+HV0)]S3@^P6WAR*=P
M73ZY/Q*GNY#X<IU+]>1 )T<&2/[B.E\S\V E^_3Z:_X\]*"%C,PP& 1J<H'[
MFKXZ3"\#<)84SH_;8"*(A+"&LL_\!MR?A#'7;]A^7KB?X#\!'RF\021^K;P3
M=O95]><%^Q\Z(==//=_27'!YU>0L>30NNVP(F"^>Y:M170"M_@8>E.X7OV9K
MM8I]?&[74:LBH@NIOF/+4I8%1SX"6*[+AFL%N[@PS<\P%)=%ROP<*U6L2";X
M)V-4I$R;6[-MW0"\YF4O.C))I4]AW*KRZ'('2?ZM8S'B_&S7/3%ZD&2 1Q?5
M-^?5DZS9-PN*#_L#:>*W4$<,M3K'5<=E^>=@5 #.XR35\M5]O5.(+^T)4UPD
M4T7$Y)__P8!2'@X2HP8NCPP%G@^8'##]E"@O"7O,RCAF64"RCPG_&?A3]QQX
M=B9*Y?"+RUH =V4XX1Q.)H#<?:=+WY R[;NX;&HK@0= QM+D5L:BHL'1[>Z,
M&/O:&FDC.>*W4N>7_)P;)O55U" 0>BN>"9-_+K=S]H=T_?,:LJL8G[)X)4)+
M#O&2;8P.H44B<Z&"+:#LMKH7C]!S(;BW]G![Y^/^8WQS9T@:1EF !<HLW/U!
MSP_0#@-"CX5'/A\ZF15E.JD\2"0HQ$VO]'E_B.<#>#25?PU*.+Q\_A"D1AV2
M^H@!8<_>VJK2\?A<5)\G^G8<1O1L5+91V-FQ&H]YC?&'V#,_N^3.W+S[?B55
M]4@J;8\;6 7?:Z-'MVCJOY@,+L9L*'@D"NQ5>DI8F?>>3S/$%=F&IF/L&L6I
M9;=BZB9GRW%0[&3\EY!(<^LHF;M?</FF3DT"Y0K<Z96:\HN .2S3B6%[IM_R
M\UZ.M(Y1I"P?W5="57B<+5<"'7 =%S05A\5>*#9X?N^#X\K[S[KIB=BB(7KU
M 5*,<B7O!%P.9OJ $SB'VY%E??.>0T-J(C<CJOHR6 6-T%00TH7WTOK[P:;^
M;#JP\>8#<6JEK;@CHZ97'\I_KOO2D@/K+5%S5@/%N=GX-;G/5PI4)*$<$8=-
M_+UW.A]G9E+0Z?G4_ 6S<Z^;C4W:9.:MTRF;FJ#QQPQ5QCB;I7;OHD',5Q!(
M5*9O<9((9&QI517,8?C DUB_6DO\BN,8G<?2'Z_)<;;Y74!I,8>\?A?5*T 7
M>?0;\'YI4U)B\K'&KGEMH_M0%JLMR+U[<JDX\#7;&C7MUE-'R\,=Y[7)/Q[<
M-O(.V0(T>#O/^(<NVU-$H9A1R= XV/_B2E%Q>C6H)ZI1.<Z4F'_VI=DA226>
MK42*[L,$*>4;MM!5=/4Y=$D?,D[LCHZW=(SDNL :)F1SQ[J.X/&C12VU8/!>
M R]_@*>HB '_^R#B<K<?6M2,3^Z/&R[6,G,D5>_0Y*KS[.L9Y>G^'0'GWT#3
MI5/T99I&"BX^S5D<JAS\;4[$R7F,2VMV HY3+LN<0#ZZ2"5H_/Y^1>7-&FS?
MPE/$@RP6A0SY6V77GEG%V<5[.."),FVA5GYA0INREF38B>2*J+3 F4:VG:*F
MRN0;/::!XKVWM^I!HB]ES@.73,.NPLO3D^ZZ'Z>KN=X>[(H:@@JX3<!.@$NR
M.*4I\E/1CN'FX6G![Y>'S;MB>.][R(ED?UZF*, 3].VL'!-^&@.$CS8WAZ*9
MANZ_%4I?;K?PDJIDR!.F2JA.[9MEY+G]V;V^P+0&>J&L*X&>/B@1_F+BV=B,
M/%R%,J\6IG8ZH'9Q*\=E>&Z#=EE=$\YP1\2&1DQP(3+\(WY\LA&T7,6KQ<:/
MU14X@VX#Z4^"T1,:]\$!/Y;O=969M-@\;^-_]2Y(KE<B<*_Q!>#5(J'50=8Y
M19YB+M*4-ZLHIR$=+>(\H(U['N&BO).,',A/MKK\1TX513PM*77#"9'??)]W
MHZMHLCCPZ??SN&G,%6%93Z<+DLDA+>Z><SQIG>$=!HZ?V_VZJ/KGG9\WL'M4
M%AC/;-9Z6>8ELPJ));7)TFA71JT@)?G32]JL9"_2E%(H<X-U"/LJ@YB[_><(
MYXQJ2"Q>[*0:A5GR0"=M[WF_3O:9.JJ7S<&FWKVVH45/L7S.&WNLM;((H3DV
MU:6N$!8XL:P15-(-^"]$[GU=LF-TI+!I*NH(2B&]D.H<?/B?IKJTL\"*SS_L
M"E..8HT!::?+#X^CPIAE:Q70JL&<6#T^A# /L1 AK(0S0/TQ_9MLN5=DYUX#
MFY?G) <?GWNV9$=CS105YV'C+F+!PH86"P>6?/!Z^S[@-WVCH]NCB;R(@&3/
M+-16G6<V[^I24H;D+R?;@*UI8!;G (GF[)W!WX4C7F=7Z'F&/H7I0QPI0:U2
M#V0O4X<\Z=&+F/:=C7-DX9TLN!T5_1IXU*+(/=%"9)L@#WIA&81>3$:]<$3G
MZ04#;-/_CLGUGY]%_$\UDZ2U=J@)R&A9*T86K[",ETFA(0DY:">B4")4!"F!
M*^E:4O5TF2ET1:++3]</W74N%,KL* _4K+>P_'HQ, 6ZAOA4D3(D6LA25)^R
MD6/YQN3F+==)O2)B;WL<O@ ]!5HD9C-&\'$-67>V8":FB0=7P?=?/ ;A-QOD
MO>\2AF"&@3?P+,O6I(48\(^0\KJ2%>4[%3^THKY\N9,6H;/\/2ZJT$G?UI7A
M@>U+AX!S)&W'1^T)><N_TI88^?T<Y*?LO.*^R+S1,%/"]68GL&D);/6*<-%"
M//P6(::D!HY]GA-SS3'OKQ^5HI:?5D@Y&#2T9TPZ>QJNM C2/*NTDC1T)=L.
MY[=\_\HA2AB)$^*Q*".2\ 6.BR1X:%EY?*%>SVAO7S7W<?75[+%+>=N6JP*;
MJBX[2OLG7,K;_@IH7]]T3-W@2#UVI 1Q><PMY3-1V%4O&-SEPUG:AAS&@WZ8
MD>UGTJ$]LQF552ZO-K2_$.:&^^/I@J&7\GC@)*;,,2X)L1ECVN+,Y\:CRRS^
M<C;DG4-S["92E@#K&NBO F\M5.6B<%)CZ*B"/$>V[$HL,5MK8 ;5G1GGAJ"(
M)ZTK\_+E+W$D#$*0'U\R5 KVJV2&."J,P&P^EMJ! CY_%]_:"DEU>:F@-'7L
MP-.WE<UUY\,LCUMM"D-V10NVT) 0PQ37>]ZV @;I'2DQT_+3G\60,D6O(G?&
ME"W@\MM/X\:7U1F3:R<TE9T<;R"*6U#.^S[XV!'E4P9*5$P,'/J#Z+:=3;)6
M_=@"K7!G^31:7ELQY3(^AE7*0?9@U:<+OO(_>9K4P$E?K5VO0$LP2U/Y6?14
M8"U#/'UY!=1$PCM&B!-C.I??5JF><;,I'2UQ)VKHC!.A<<G1MKLL;&S'7VVK
M'&<S @N>+]4C1+]*0R10<7;.GX;J%80U/%L-*$E;,+A_M?\+>#>+LF3:8%G:
M!3?/G]99.$K4V,_27-?]Y4]";."?^@'[WPRK$=I\< LMX?) ]MF?OQ2L#RT+
M9L"Q=4XQCZ?H#;P9\+T8F%WC8GE$)5,))]U\2,"0TQA9D3?TI;0)46;*Q$^Q
MJ)-=&0->$17WA1O=([F5ORL;JYN%Q=9U^ENX9+$T-K5P\0NN3&:;?N.M+W5V
M1'*5$8DEZF@=T%689.SF^'!S>53TX:G)=P51=Q(>3-P5H/#V']'O%+X5_C#'
MQBC)@S_XZI]H'_]I.KU2T%'AT*?(N4<_-+$"I[?=ZBTIZ 4=U##WK";5%#C+
M\E0TQ:C#:NL57/1J:2BB'TTA4>-&<<&%\%B(+8J891%XX_ EO"([J@D3$!6U
MFYL2HMV-\QSFZ$DFKE4:ZK!/IO.JG0OAO!\C(DN=XQ"V<&O5L<ND54T>'L*!
M?).078M8[SO]4>*6&_4;@!Y>$\SS.$&#RM9_IB-_B'E,?KA2TQ+#ADRJJSTL
MF#2Y%HW,PE2_N%TI'1$308%-Q#-!("8!OL2M2#<O1N694BY>G1JMFF0VUA55
MT5_KI^N60N]0<=Y=PK4<17^[YO^ _]$UUYI&X6ES'A4,CB EL/L7%V]_MW!9
MJAZV15H65(H'VA5')MK#!\H;%-FT6 ^XK3G+JTW@,,C/I=6H*<F%Q\@+\N/W
M/KG<BX][\SP K_TX>6=C*T\DS[AV*G[:YMF.\8\+F5\J@RT+ Q7'E([+V"QW
M(L^Q2IV-.I0Y#[%S+SO,XEW [4J4-*;GVC\P]QCQXEVO_#FL6('5NFAA*5BG
M=MU"/Q  PGPTHJU;YMY%!M6C\WA+33.?SAXTB3/U@!1I]:/&S<YS=^^I-Q^
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MS$-])592X'"[V\PET:CB*6<!Y>OE-V#%F0<1:Z-^,SQ1RQ XIHE8'L\0$TD
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MWS#&%J!?;([WM3'[L_&38T5<.6L8M0W&4_>3R/>4\6YJWDF@CIE+QOG4'&Y
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M!W4GOF^)(2>#"UY37A5AAUFCVV\?8_38YHSFYO<ZOE#7/FLE-?C6-^TLNOR
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M.%JJ1ESS3N1!DNW(/8234C^<E541:E3))ENHKM^N6<7G3U\>&[=,>WRUX<P
MI.W:?0S8N\<=JIZB&9^49>:#^1#Y4!]G^*X3ZY]]#"L4Q86R80NAA<"KL;*Z
MN8\5?H)=JI/2$I*ZNB65I*O@,46$G67(LFU9UJ+BDEHQ 5$X=,[]_:2&?V\#
MIRA6N&YCL:15#IW(C)0G,95" , L>B8[B0-FA6W5DW=OAEO7\O35D5$Y9M2
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MH+(XJC=E&0QYIS]KOZ>QN4C\A".G<HX-(J8N,<:,9?I)6G/G>]3)]0XM/OQ
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MG7NK V9=7R#XQX8Q0IBWIXRW0">=*$'&JL"(68#!AMQX@*%E^R'+U&7*;_B
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MB)K4I@%NY[GRWRQ^L_C-XC>+WRQ^L_C-XC>+WRQ^L_C-XC>+WRQ^L_B765"
MRRMB4:C6X:P%;/FWDCD%^0#*.ZPX6(^6C8R,*EBCA>F*RFVZ%<Q$LZSZVL''
MMHXR&&:6*\0I[;)6*^M HUY.Q]4Z=[-_]QS>):Y1@9-4+[:8,\#S2X/_7FW_
M-Q'X:&"W8Z7^IL#:DTOU   +96MO1^7'K0K7S5]S(_]:D)!-%-4\W#X=9]^7
M Z@\^:LLN/:VE'RG8/B8)_*HXZ_9TOS?&+\WI_^KP4+9]JBC\L56A?(FQX47
M?]V]_TWQM"Y*>G3IL\6+[W_M4/S[XIKOB;1$(7;FHE3SK[</%^ZM>1UC/9C)
MS;RW_II_\F9!QU'I"^;UTM?&+__:6!LH?J\!-/GZ\^BCV@]_S=?:_OOB]X?W
M_O4X]UC?8ZSS&8#<N'['YZ](E_^-\5^V\I$R*!8R'!WFD9UK+84/U!W*Z5@,
MR;P9LPY)]M8IA'.5::0;S -<$B7K;%^%83[N^3#\EOY&$JME12E\PV7;EEHC
MRE;\:0:[ ._H87V?T9%S1P2_7F1]Z_6[9=& 2"=/CZDC9MBS98#@;^GO(LE7
MEAGS?!?S:!:JM#W*/L0<EY,*N[R]OY_O_.**4)%)5/,'4G+YRH+-DN]0J?"+
MOZ7_P=)EZDU;W1O.KS$S/EP9XT,_1GYBF!5(?DO_XZ0+!36K1'F6ZN^E$?0Z
MKKP,1ML^G/_A1OV6_C-(%["NPUA? X\1D+7^0M/P D#S/SQL_9;^XZ1+UJ^$
MY";[C_HV3FHW*JW@'_XX[QF*2YDM6Y .ABO[6O: !RE,4Y7UK<3G/Y]0_)9^
M2[^EW])_,XG1NJ@,WA)@6SCVL*!"<NM3$-)_Y'&->K& JJPLPC#)&?6)9&_Z
M]\3Z?P[\GEC_)W"Q20_;_MQ\-T:IW'LX/-J_Q$BVW;&4(0EQ)1USK "H#M.(
MSM<P7H&.C!YRMG&'76!3JN0)E8$7D@7FY6EJ9-^[\?(O=?[VO;_ _VS?6[#5
M@U7J6L5@<O/DDJ'0Z=,WTQ3"1AV8"4)TZW?8T09 X>7Y3:$;3R>@U@L7<)+P
M-YP7N&-T!-\)QEHF$OU;FJ"P#H<#?8:Y$K 50,'G3Y;^W%TOD.L8NW/COMH;
M3FJ@0^XH9X"\94R7(58=%B_ZV-6O">T.H+YVT:=$V'&*T("+3:NA,CVJW6_
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MQM<(0&T"NW##FZHE=*D9 @]-J>/+GF?=E]?B5 ]=,@A?8B/+\X>3AGVGI_A
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MAMI62Y/J'DBYXW-@L"^N+RV/GM'M,3$/2C+KO*NB_;,\,V5!:WF5ZXKU895
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MN!3?XHP_T!-\EDDM\=D$O0^4@2244RH_-==D&Z+*[//4DGSQJ9,I5BU/E<R
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M:?Z,P\8_LTD.DUHBBZU3C:U#_Y=&_O]N_WYSX.1*4&75CW,])W7PV6^'EL3
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MY_?NLQQY0#;$[![$XAOA<ONUNU:E)L]!,91>G*1M;M@]5J&Q)DTY6!2F?)L
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M/^7+.>:[0#M+"<0SES(8+FM$2/0W&I)R,&)+;/<S5>SS*?Q[2O1NZ]#YWN5
MIS_-C_&S*[#5RIT0QZI)3>D9_IT)A3]Z-AJ\ABGOOQ0?HJ-^1TRLU_>;0).D
M2EK)I5YZU]((LLTBZ(_@%3TA@^J?SQ\BT9CNPC!P2F<,>Z)3OFHWH>(4 DNQ
M<X]GA_TRXG^7I>WVS5B7QAP42IPKT=6UMZ=9#64^TPHYSZP<)XP1LQ>]C(>[
M/N<D>%:6=IOTUKNRM3REFI:.N)F;S;1O'G UH)>D U!-W!G%BCE^!T\7[1>5
M"5VU';WP58$OVBDR&)JCMC"(\X1CH^%E"<_K:RGXV&]/\++]-_$8%V=U]%SV
M]:8SV>,'N[.VL\-\;3NM#K+<V9DJ"EURO:WL*_0.]X]&J/7%Z=OAJW<X[.M@
MV"0A#\H8#.,-;F"U</@.7F5&51@KG1[*F!-[4%$P?K"=E__J<W=KPJ'#1DE1
M(E]G;D>SO0@S9)<;45Z3=:]$LS\E,_,E#XA1=YY])9+0$2]T6;"5IN2+J770
M@.VWDDML;=N+ZY\4.[58A.)U+.Q*(S+[!RMTI4]D7<IP?_!I04B:?6C-THA>
MR20DY7YJY/4F?-8Y3.?!Q*019[%J?XX!1^)*9-<^KCY0>R8NY $IC=MLCMG!
MJ9@:6D--&TFPJV9&6TQT-KVKYY8.\02A1('"-![K\L\*F7MI(%[F6$>^4]CP
M\*0,H;6+N*OLQ>0L689)I+6A::6$*#E!O_+_G]/_;SC]U=]%/U7?' T<$4.>
MT+0?^R[MOM.N+5C8IN]U/.FO?E-3>6!]=#BT(C1[Z\A:\+MC2']>14S/NO:4
MR7#SRO/U!WKA#9H! ,!!=\25=)=Q.;LT4IUHZ4A=#D52_A!NN;)6!O(7#Z?P
M'[E6<%0*Z8:JQG31MI4$.QB2?F=C,<WAA!/\Z;8/NF->MQD+H#[A*P G7ZY9
M5R6GA7Q'6V#6@B"(KK#<R-%B#BSHAJM$>_WTT7W66FEU205!UPO5O6<'BW)?
MSU<)P'S?JIJ"@)VY=&\+6Y[G-P5#S_2/GN,0H/^V?[5[&7C]R=1$/=\SW:\]
M0!37C)T[T,];O1NP\5MDW;R,S&#F&S;9:-Z#E?3<K]_.1\=;;!< 5_#>^0#E
M6FT7&R>ON0A=I(B8\$W]9#5:F=N^24?"&4A)QC\L8Z%7U5NJ:9+#U5L;V\WP
M,CZ+*XB5'B@EMN/4"[K1NU6=T5D9"4+IXCU.Z21J2H^$V\)7ANJCYR*0WK1:
M3%V [>(LKIQV[W3^WE<Y3^B$M0&<RGVMMRUK1PHV\C5N<RR//S,2L!1TV?,"
MV_J@Z5NYKU2+]K)7;1I^%,OW'%K^SA4ED2R3-@UZTLYK8=:UZL"R"'&6 8QJ
M<-9F<YP)I(%U_Z/ &7133H+;1OS=G;)'JM&%;@R!4<^N0&@98H<2][@=\..+
M] +<:C^IQK[S]MW?GHBC>.N3-W"&T&??[;,XD9#(>AJDO'#D)-9WU%?V?BG%
M3H&_=IW]UOBOU%O[I *8'8:!&$V*)M5:$XGE4_^<"0$LRLI,FY4?]>F2D$(I
MWQUEI3K L(RHC^W' .*F6.694X^0@B1DA=96!:CT]QVE+X=?P N;$I]4@$!_
M]5-V-N8@!+W?%F $N,B.KC#*OULV[?I6W"2U6]>M>+Z&4SX=[:)J*@<(G-&)
M$+R@\@DL?XTW3H^RAI.T_8^*6PA %O!D<;E(S-6U:''IC0X^%2>O(0;34^-,
M!78FP&RMB='1^$W(OPIS#W8HQP"HW-/:$E68;M&Y82FTE.)1W!;N2W3M<[^"
M4=3)Y%B6F1JN4?L.9VM3_GMY287C5AJU1OHZ^CY6-XA,>H*%;;J+)*> W%'4
MTQF.GW<<_G0TYN5I'WYDM0E&@M%K)1Y][XM'R2"<IMJ3U\7<%2K)LAZB=%.R
MOP$$^E2)^*RCN8SE1["9%^OAZ^SLE,A$E^)K#MR<PT[XKYC2#WP0 #CW_^7[
MQX'K$>P#D4NT./B_6L-&9D, !WM==;5OQ]GEL->2U5T]>C^X&\!7._$)L]B'
M?."FU81+<@'W6";]]29*K&P()%AZ8$W@FRB3M&:_11A=@+"H*\*\,0L#//0*
MZ:YIGZ9SQ);IPF^')HKY82T'-O,2!#D0)O)73[ZI?I;%-!E''](!,+N(W/G>
MP_?:AU?91;_//T8MNZPO"'W]YN=LX&EJ;N8M9OZA)VGA7YK%1KW4P],'TD8S
MNNVB,IFDNX60DA>EN5WK^ZFH8\#EF_SV/7D^3XX!$T5'^R>,_AO*_\S ([;S
M%=&_UH.#F=%],EEWD,.%8@3S<R<@1!<HSK[T/=LLL#LJHD:\_83^I]%C@-QW
M\>6!8X W"^]$]XFIZ6W+WP;=?6B",4ES"'J.6-VB%XV?^7+N*P.!@5HO&(6,
MO+_/.AAR-#_2L'<V]**R4\>[II3#U)#?H5>F#0*1&<)RFO?P8=+B,O0H;D64
M,RW.B$@$O-B004*IC:LV3ZC_"''DR#>]->@'Y[_GQUE7P';D",N^R:$L6J$
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M"Q97T<X8C[]ZS<;D_AH(W&VQY&2%A4J?MC8#+\_IWX+'\KV#U-G$J\Q6"/@
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MG),==#1-L_[1G\2UWBQ_%5OG;^5Y?DX4NW #I^>M-MVQ-.NQ$?$%>XJHJYC
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MTE%U43D8(RKT)%;"!2NU%I5#NYC<$G$I/,DSHY]J:SO/(RXB0(ZLWVSM!J0
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MWO52A+Q"&LE?:[D=.5)EQF_/A&$@Q=HC>]<;5'S:?O/KL<5B:Z3U3BLN?,O
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M4<;J-8PW5^-=GKIHU3+7KOZ#$JK':)_=K#WM"XA8MW8%\<NFY;;=#"^?SQ'
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MFJ \^=/&E5"N=PDON.0.$3&SBATUN;B'3*[?^P^./7UWA7RC_!=02P,$%
M  @ -S@$57>@#,;*H0  '=(& !0   !V=&PM,C R,C V,S!?;&%B+GAM;-R]
M>W/<.)8O^/]\"FS/QAU7A-!%D" )]#QNJ&RYKS?<EL-V==_>BHT,/*6<2F6J
MDYDJJS_] GQD4OD$F"#%NA/3+ELBB7-^('\X.#B/__B?WQ]FX$DMB^EB_I]_
M0'^,_@#47"SD='[WGW_X^=M[2/[P/__K7_[E/_XO"/_W3U\^@G<+L7Y0\Q5X
MNU1LI23X;;JZ!W^3JO@5Z.7B ?QML?QU^L0@_*_RIK>+Q^?E].Y^!>(HCG=_
MN_P3R3%->)Y!A#B%6% %B>8YU#1/A"(JS7-Q=?<G15A.4G,9RT5J+HL8I%K$
M,"=2LX@F2")9/G0VG?_Z)_L'9X4"1KEY4?[S/_]POUH]_NG''W_[[;<_?N?+
MV1\7R[L?XRA*?FRN_D-]^?>]ZW]+RJL1I?3'\K>;2XOIH0O-8]&/__LO'[^*
M>_7 X'1>K-A<V &*Z9^*\H<?%X*M2LS/R@6.7F'_!9O+H/T11#%,T!^_%_(/
M__4O %1P+!<S]45I8/_[\Y</1X>D/]HK?IRK.SNSG]5RNI!?5VRY^LBXFAGI
MRZ>MGA_5?_ZAF#X\SE3SL_NETH<?.ULN7SS52DFME"BS4O[KL<%^O$#\0/*N
M]F4-(%RI[J=0,I["]%,P<;\9?E#]"]P:YF*1JQ?J9BZ'>G<W0UTL>O\2AWHM
M%BLV&^"UV [3$GEF?_#1_*T>QC[H!)F6X]34W1)5?5^IN5056[YX-)C*__R#
M^=MD7< [QAXG'^;"+'F%>J>J_WZ8?UTMQ*_WBYDT[^W-/];3U?.7Q6SV?K'\
MC2WE!(L4(4891"J.(4XDAIRE*4Q5G,4L89A3-5EM7OF)FL.?OS;2E2)<-/X?
M/'!9'?F^EZI8K)=BNS(^S XM=V:ELVLC^7'.'E3QR.H;C!+6B*CT^J]&?/"F
M4> ',)V#M@[_!BHMP"]6#U K\O_]QX];2,)/T^RUP9_][G!?B!?2SJPILUCN
MHK<0EZ*W98["*%Y"IUG!2]WK1_]HK<H?U6Q5-#^!]B<E?70=_<>]E^QZV6C,
MEN+,G-97_"@6QN)[7,$7TVLMY"#0K!9!WL]J HW(?P"+I;G2[  .J+_WC7U4
M1:'4[:-:&AMV?O?1COAQROAT9H;YS)[M!J%XMU83$3.6)9S G+$(8HXEI#3&
M,.<R)\18\9G6D]6&W\]^AJX#>Y'?D54LY$=8+F%^/.:,L1N!]8%<S\Q5B7P%
M-D*#4NHKL)'["JP6@"OPF4UE.+;RA2H033D/.R@_^8*Q2TS>]W=C),-K:GHW
M?[M>+M5</'];LGG!A-U@%]=S6?YS5NZWB\^+V=1<8 R_GXR>OTXXB6-%9 I1
M*G*():&0I(I!G E"$(Z84IF/F=99DK$9;+4BH-$$M&0';"[!9S.:F;WR!W[<
MUGVVW,AND#GHF?T.PU]K4>+?U@-4BH!?ZO]:C4"I4D S[F)8 S%E=SD&I<Z+
MX=KETLL?V(U<OZA9Z>=@R]7+07FQ6IJ_3WAFC+R,9U!D)(58IQ%D2"(8);'.
MD))II(D/AYX;<&Q46<L+2H%??JB_-#)[;F//8N[&A"&1[)GP+@/1F\Q<D0G$
M66>'&Y2:7)7?92#G^_R(IEBN)E_5G;4%_ZP6=TOV>#\5;/9N\<"F\PF.>:YT
M;C:1L23&+HL9)"+AD+*8Y2S1.<JT"[N<'&5LE-*6$/Q2R>A((:?1/,T;P3#J
MF2S\X'$F!R?U3S&">4"+#<R_MDQP^MF#?/Y.ZC7?O-O%W2R*S\N%V1&:#:"9
MU)6Q7:R#ZM&.M&OOIS06.48*9I&6$!L[ K(L1Y#&))=F;Y8@/\O"=>"QT4$C
M=VGX;X3V,RF<07<S+?J LF?6:$2^ J70+\&\&F0/Y8M:(//#>=A!S1!?,';-
M$>_[N[*5TLKLN63I4S?&S^WRZ\K:07]EL[7ZK)9?[]E239!F2M!(0!W+Q-@I
MB39VBF4M%),(\RBCDOIQE<NPXV.J6FI06+&OP"-;@B<K,7@SG8.?O[X#9LY
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M>I!Q;"14BF@V'W9G5^[H"L\M71_S&*LLU4I3&"74S"-)<L@R)B#.$XDE4[E
M>O*DEGSQ.YG)MJS]S64M*[@;XYRZ+4:O/$\]+V2EZ+"4';3U RT% 7\&[>MJ
M)4&II37)2SVO0*6I#02N=+4_,=J&6Q![G(I BVD?$@ZZ$/<(\>XBWN=0?@:
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MW+;QKS4*9[1T1"Z0&>,[^J"&34=H=DV=KH\)$=.V_STEB5 I%@2BS)ZJ2IY
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MF[10$^]&CD/.XX"AI:"ETA5XH11H:775F(*-8DV:L77M-;H%#DX-!W;(L-8
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M2O4'9)<..SRA<Y27C;\VCRP+/=B<ER8Q*TZS/.8Y@8P(8NQSRB!-8@H)2[7
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M27":"^*WU3NEL4NCIWT5G!_64KOYLKM3[08,VP'9N 3LR]4N,M;7FK^V)^"
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MC;WU!JL?$0W!ZT8_ 4&;F'1:2P]XS9-"Z8A0(-(9:FU6JG%T_27!N-X6LE:
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M(8DB03*!$R]U.8<VEQ8VM297\Y:.T7XLX *V&RL$AG!BECB'7IN-/L%Y10^
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MT[_^M_8WYE\V?^]?_]O_!U!+ P04    "  W. 15E'S]V[UA   V;P0 %
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M/NZY,_MZL;S(/7M;W-WS),FS"74A.@VI;#E6!OYP$HR.!(2SS"83E*[]_'H
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MC/],;"@SHTV0G$KTRT)M-[<6[:V\3S[W,WX_,#S_37!T4B*4B;>!9B<]B<D
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M\(766;=;%S-RSFT+''RU*S5A_'2,QPGM-[<\:2!3,F3=R58D,:F%0ZN!2\M
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MHO*1T7^J>(=/3MM\4+_4@:K__5__#U!+ 0(4 Q0    ( #<X!%65@LOW2Q
M +!$   2              "  0    !E>&AI8FET-#(Q,3$Q,2YH=&U02P$"
M% ,4    "  W. 15:FD=IJ\'   Q(0  &@              @ %[$   :6UU
M>"TP-C,P,C)X97AH:6)I=#,Q,2YH=&U02P$"% ,4    "  W. 158G>S&*('
M   F(0  &@              @ %B&   :6UU>"TP-C,P,C)X97AH:6)I=#,Q
M,BYH=&U02P$"% ,4    "  W. 15_2&*X*T$  "H$@  &@
M@ $\(   :6UU>"TP-C,P,C)X97AH:6)I=#,R,2YH=&U02P$"% ,4    "  W
M. 15L41 BZ0$  ">$@  &@              @ $A)0  :6UU>"TP-C,P,C)X
M97AH:6)I=#,R,BYH=&U02P$"% ,4    "  W. 158S*)IE:3 0!O*A  $
M            @ ']*0  =G1L+3(P,C(P-C,P+FAT;5!+ 0(4 Q0    ( #<X
M!%4,V0>O+ X   .*   0              "  8&] 0!V=&PM,C R,C V,S N
M>'-D4$L! A0#%     @ -S@$5>E397="%   ][H  !0              ( !
MV\L! '9T;"TR,#(R,#8S,%]C86PN>&UL4$L! A0#%     @ -S@$53Z9O :
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G+3(P,C(P-C,P7W!R92YX;6Q02P4&      P #  E P  C9H,

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
